<SEC-DOCUMENT>0000875045-21-000044.txt : 20210722
<SEC-HEADER>0000875045-21-000044.hdr.sgml : 20210722
<ACCEPTANCE-DATETIME>20210722161610
ACCESSION NUMBER:		0000875045-21-000044
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210722
DATE AS OF CHANGE:		20210722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		211107796

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:00d4ab53-132a-461c-a04e-3900c9e9172a,g:268dc15b-49f4-4ca1-9cf5-eeb8cc02f2b7,d:904ca67b48e9438aa45cc860a3e98146--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:biib="http://www.biogenidec.com/20210630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl8xLTEtMS0xLTA_470615df-e9f9-4833-98be-fcf9e49f446d">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl8yLTEtMS0xLTA_cce4702a-db22-4856-b999-1de9ef355ffa">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl8zLTEtMS0xLTA_742b5cb8-5c67-4222-820a-2f96c69e998a">2021</ix:nonNumeric><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl80LTEtMS0xLTA_49357a99-9043-4f51-9e05-53d36c615d6a">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl81LTEtMS0xLTA_3b2f5a2d-2a91-4222-8276-6da0ec3557a5">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="ib889c2d4156d4791a136cd35997ec490_I20210721" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl82LTItMS0xLTA_9e74c52b-44e8-4c46-a48c-b8c0a14b4abc">149,033,443</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMS0xLTEtMS0w_7a289f25-7de9-4ee7-9679-48f110fd0bb1">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMS0zLTEtMS0w_4dd40ee9-efd2-46b5-a8d1-fed76ecef980">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMi0xLTEtMS0w_e1b06504-9f19-4049-afca-16a2a08d6b51">0.0005</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMi0zLTEtMS0w_408cf44a-2e70-4392-a04e-47f334eced16">0.0005</ix:nonFraction><ix:nonNumeric contextRef="i09027731e61a42988fe6ef2a4a7fd42c_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfMS0xLTEtMS0w_8b95d170-0d44-4dde-b270-80fa0b961bb8">13</ix:nonNumeric><ix:nonNumeric contextRef="i23be9c67c76d4186b731732ff57d13fb_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfMi0xLTEtMS0w_a9256ab5-6779-4874-851b-dd7a6e5544cf">23</ix:nonNumeric><ix:nonNumeric contextRef="i9c307d55279b419ea2386fe0de0cb1b2_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfMy0xLTEtMS0w_6eb46d1b-0be0-4b32-bf95-d7b9b5f60da5">15</ix:nonNumeric><ix:nonNumeric contextRef="ie349b92369f646b9b58c66a22bfd7298_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNC0xLTEtMS0w_e6578637-4476-41c0-9107-a3cace72dfa4">28</ix:nonNumeric><ix:nonNumeric contextRef="id9e4ef37dfe9481b8471820d3e30119f_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNS0xLTEtMS0w_3f211575-9ddf-4901-bc3c-8f54c6743af4">4</ix:nonNumeric><ix:nonNumeric contextRef="i06bfb17addc54ed589cce69a74b3cb7a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNi0xLTEtMS0w_690e65b9-ddde-480f-8fbb-62efb561bcc0">18</ix:nonNumeric><ix:nonNumeric contextRef="id615384c43134264bf0013bc467194b5_D20210101-20210630" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNy0xLTEtMS0w_2250fa2f-6cd7-4808-8f62-e8d8c48d43f0">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="i07d3862fcf4b48ee9108d423b5ba2d58_D20210101-20210630" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfOC0xLTEtMS0w_d67c0d00-1312-45d8-bcf6-116442489e56">Indefinite</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RleHRyZWdpb246YzhiMTAyYWM4M2U1NDhmNWIwNWM0MDg4YTgwYmZkMWNfMzk_aea3b2e2-3ef7-4413-8bd8-2869d86a78d0">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RleHRyZWdpb246YzhiMTAyYWM4M2U1NDhmNWIwNWM0MDg4YTgwYmZkMWNfNTI_1d6c27dd-2380-4183-977f-a4c4ad30177a">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RleHRyZWdpb246YzhiMTAyYWM4M2U1NDhmNWIwNWM0MDg4YTgwYmZkMWNfNTU_4f6dfafc-599f-46a7-8c48-4d04e4b2a47c">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfNS0xLTEtMS0w_b1a08774-d147-4efe-8af6-854e715324e7">2.900</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfNi0xLTEtMS0w_f8028dcc-031f-4204-9f10-cd63cc6210f0">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i37f011c57e3b436783a11ba0e28c19ed_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfNy0xLTEtMS0w_e58df55d-fb94-42e7-82da-d865395f7686">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfOC0xLTEtMS0w_a4661480-63fc-4abc-9808-1f1bf4524dd8">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfOS0xLTEtMS0w_ad0c6608-07ba-4318-a522-9b14fd5b01fc">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i630a522bf9a74f1f95a783e75d21daf3_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfMTAtMS0xLTEtMA_020cafba-dfb7-4c2d-b71d-940b1fe1babf">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfMTEtMS0xLTEtMA_385b2256-fa28-4311-a231-244b2c63b6be">3.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i703ad29a631c4d6a98bdf0bded3bfc94_I20210630" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmY2ZGU2MDUwNjBiNjQ2MGRhNGY5ZGFkMGM4Mzk0ZGEwL3RhYmxlcmFuZ2U6ZjZkZTYwNTA2MGI2NDYwZGE0ZjlkYWQwYzgzOTRkYTBfNS00LTEtMS0w_e9abd1ee-9f43-4196-99e5-b40051dbe2ca">0.83</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iea767474fca14a4e9823a37eee15721d_I20210630" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmY2ZGU2MDUwNjBiNjQ2MGRhNGY5ZGFkMGM4Mzk0ZGEwL3RhYmxlcmFuZ2U6ZjZkZTYwNTA2MGI2NDYwZGE0ZjlkYWQwYzgzOTRkYTBfNi00LTEtMS0w_75d92c1e-4bac-42c7-a4ba-5afaf751adc1">1.18</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RleHRyZWdpb246OTVjYzNkMWRhNTk3NDM4MGE0MDk3YTRiN2M2NGQyMGVfMTI_d2087288-ab8d-4a0c-9ed8-d3626b7a77e4">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib889c2d4156d4791a136cd35997ec490_I20210721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie7cf54c2c77a4e6c9dbf0332cbd0f00c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b5d4606fd747a98fc6804633f0b093_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948d754496294f759ddb105ceeca7aa1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf3aacf570724f99badb8ea0d3a29373_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e165fd1993b481c8583fa0659f62931_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a7b47c3caa498fbd7d5570bba5dfb5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i597ac0475acb4b008433332ad02431ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaebd3ec3de74756a298f2a7c57d8b32_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id563dc7eefa34305b99b4e811541cfce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22951db8734f44ec9b10b05a829c8cb7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892ed7dcf1654ee7a0c75a99e9a162b8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92244e16cec54d629634c4fa97c7505d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b121f8efd14872a1e30df2ef86c797_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcac24a08e5e42818462bbc94b13c07f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6833d5d8e1488588e71a36bbe9c769_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i025174d34d0e4fed9880bf522bf39caf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1c8cc7d1984bd2986f1829be158a77_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc82ffb87eb341eb9922b2fe03938ef1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i881e688a79754d32bd4eaef661200a43_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c3490a5f63c46eca7c3d7b457bc76b1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b15e57dd5eb4ecda365d4f991fa27a8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8812efb9d84361a4d49aff1088e74b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a59ef186277439e93b9cb5d517c2f8e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i890d1bfbc3404c338c8adf2e20d53e18_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c7280649ce4b709f5ceef9dca96ca8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4231dfa8299436094f9cbd4382d29bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8169d797254002b81948999f73a837_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dfbafcd38f34defb5d883855aba00e1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd3814086244d508377429d979db225_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74292aa380dd4293a8ab78259fb0e8fd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62788c451f3146bbb9013bf26f1e565a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib434b673b42b4084b62db622b022d71f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd1fb2ad6d46412c862aa18af17395f5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94926bf743db49f1aa339479ffa0244e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee3f5cdf6da46f3bbd994edd429f1d6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3240d0cbbf2494d9586ee74965f1b85_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide200ffdc85b47c8a5734609c9cd5e17_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6c47b7744b4c20842a09b8f4244db0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514061955b07437c95410fb7d8491901_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8001088915642409667fe820a47d9b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94de1f81562452191bd4f557a5d4d18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5721ea124d3a4b198cd7d7caa427c5ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b80cd19565047b394b037487d83b697_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e2df370b96408ba273c05e55e0cef7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0829016ca6b341a59a77978d812303fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba68db7328d4088b2362283392e5a4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433038a0a2e04b4a9718b3a120978075_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d83325fe697454bacf1a67ada1d4e30_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829fb96209e04376a983019df1ad41d5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d3cbd78d4e4e8a828d2ff80ce13faa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc688f4fb4ba4c3e9b5aba00112dcd1b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50339615ca3c47dc93e748d4d2d021e0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55c7e84188d4fc58a512a4f573231f5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b2ecb22ef74586961d6a6a7339b061_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee86344392cc4815b2010b4698cb5995_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732c024e790641aaabfd3fb6981c4767_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f73c932ef614e2b809c4c6773f7b46f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a136827ea89494eb44b4f53d790b6f4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0888859ea81d4a4b9b7e7be25c61e121_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3300c292f1f6481daedcd2a3fd9d0d4c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i072ed2cc59e146fabce4bf0c8984c641_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b1a00011ea462489b26d05daea35c5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8633c1b979664edba4ec90abfc549bf1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f72654aca994523940646887601ba08_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66fd684614f472ab9ae858337e37137_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d7b9a6dc614f7dbb3208265a4d8bb3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib552a12f17ae45c9bd51081076579744_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4529d1da0b4585a765bc987c30b140_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4edbd823d74be5afee6c24f030f8c4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia746808beaea4283b2a877a9fbf80dae_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia379321841ec4c9b893de5b4c3c0049a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecf6373de814aeaa2667c45b15358df_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d526c2292440b7a5a31fc1b5888e03_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i570dc5bd6835411ea0f2c6404bf2707d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c053e7c564a44a0bafea18992724f4f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a510bf622c4fa8919b08f823833b36_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0a20b044aa4874a09f45a93c3dec1f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fba909ac97644db8c749b15a7d893ad_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeccde350a794ad3a057220538aae69a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c2c7cddf4e4e6fa048863f067c096f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc71f78bf134170821013d4e0e24571_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc925cb31f04e6eb50fc1c74378baa1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ee4e438b174ae69ecb16ee0621c73b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75cc8f1ab2514617bcec62bafc7b0a4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedb54914b4a4be1bb1f89fa85924372_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb7cbe5c0ee40cf910d38587c7169eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703486666e174b76b44043f8976ce92e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03fe4f4d72bc4079969e2e9ed876d281_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a6be740b88408b97794cbc0105f101_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948a3706ba984935b4f52d3af4515a54_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa7cd1f56a4406b8baf99c16459364c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912a36fc12da4b8493cc611846c2ffb2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bce9f6487694050a70f9480c769461e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id653e67025f441eca2b7a99e95e1a140_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide90025ae7d14057a14eaf2dffb72595_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d4db9869c24b76826c44a5bad5b4d9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff71a4c7590448a39c9de6e0fc71bedb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c71f71a23d4cc3a2b3597fe3bfca81_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5972e118118f4152ad8f8978769af8e0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843c3b0a19d643c98f098c2cbdda56c8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454fe0c0d5134bb092b7b31a87c40846_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c40ac7856a4709b06d820f5782887c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia41f1626c54d4651b01a960a763e25d1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44acf878e9a40e293c35b91d422db18_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1ec14a0b4c5428e96dc682fe53e2adb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaaded065ec24455a1510514fd2e792d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde9c2714ad74d01aea890f100a512e3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ad626e97a14a56ab100e2a98cd07db_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de49699ab2b4ef2950e4d9cf8d55bd7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f953a78b614e29b9d12ce31c18106a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib847f37c0de04daf96e1223d256cd610_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3bd6129bb04c41922bebfc2cfdb7dd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice992f8d6bde4f81ba988f03ad04702d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913530b0c7a04680a81480a377dc75e9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f26c5f8f7b644c1a6ae043ec51ab4c2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf57f3df80b47afbcf37febeca4a0ea_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353e33f7e0a94012bc4281ed787c9554_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ac4b25470f4639aaafda04d93ef98e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8841bf5e9b84dc9ae7268750ef2bb0f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c0c612c5734c7fb188c1543fa11185_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb5970ca1764f70aa1f12bc6e44c3e2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644dc9ce5a6049f0bb8a6913c237d0e8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74762eae8227417c92bc8b0acd73d688_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23feca6c7c1644d1801a7f85831cd895_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc3f2e402ed45da9a6e36c3ef2bfb5e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99acb96aa164c78bdba482e516c404d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia755e6ceac1747b180c2cc6df3ef4066_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e782c4b0e049938858ca5e31f73ec7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b65b40d820457fb4b9fa1f07a65f61_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83dafc6720834c76a63a5163e4f532eb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4a9f31dff843009dabe3a4e826ee4f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af0c1582a2a408baa70b8e99def7c62_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7281dae8894892967238587445989c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231ad3d6d41645d3945da088fec9f599_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf8bb8c3fe841d0ba7abd41f7fb1ee4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17628a71886641909400cb4619218426_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9a9b26fba3467cba137763a14e9be3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide17051dcca44f5ea4cc198403e62293_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f0293658e6748dfa458ae395ab995a5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d15291982e4ca994818b360dcda3ad_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24d10cad1d34675a3fc968bdbb574a2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab460f1c1bc4867a271a58701f0e028_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7301eef41d9640ed921b3e6efe6127c0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e99a1a7e774a0e815fa6a725ad326b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a34315115c4b8589338e15d7ea6439_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664fb5d936da45f59b4e592bfb74ac94_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6e9d15df534c6caeb9f68534bdb18f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347194d919304c0c812e6741db0e657f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2598e479464106bcdb82c4a4df0181_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8798ca731041d684373855710bb939_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed6f9bb6cf4494cbb6951ffc4427cff_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a873d0cc0244a8b91d944434d46b46_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1d133f9df644b8b0d7cd4410031d4c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3369c80db6c4ee5a519938ac9f89bcb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4585d796bb774ac1bea9b1ff5af52ba1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d5ada70f524874932a465b9b730154_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31f861e6a524cd19f95e0d648eb24ca_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb689c657f6b45ccb27299e839af1320_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18dbf21007504156bc2266d82193def3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia538789f89324807b17b67af0a111518_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765e12ebae8140ec80846e0ec971b64a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fedca069ca4c35895923673877e4ac_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbc0ef98c72c43c0a4299bf74ba8c183_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if442ac7b0d344adc8562bfde02e57543_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if619b64750344bd396a36966f4e1d8db_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id888d7b35a7049cc9a61406634e23db2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23586c6cb02341758cd17f3eda3f41ea_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cd0486507d4bb9b3535aa6a9703959_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id76ba5beae9b4ebcb9b0d537208ce555_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ffa6986e434982a6f8ec10fd4f5706_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549472d5a38946e59e5b1caa96706fe7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dd3b810e859443a898e81c46682f449_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6084fcf81a7a4f17a2138fa073f7d226_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f337b2eb414f3fa41dc8811176125d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271aab5d507d493c86b6444f888c9ad3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9512deae649d4c98b378b690ec4b9532_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f99b0163013464e974cb8cb0fc170e9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a00992695e4dd1be1075fc2e7e7f10_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb24c52b894b4b7b83524d55b0ce82ba_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3255c22b11a4fda8d05a99d09fef6ac_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f3957759bb4881946620abdea1906e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0e61991f2f4369b1013159e84567ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21d03e014ce4af4a87f80e4d2f06f89_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3038a0c2bf415589f4da253eeb15a5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e951773a30439e95ed2c070c0d26f7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69bc97b92384fe9b8b1109cb7b609ea_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d698ae847c34141bd30186c02516ab9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if352a0720bb54a1f95411b27afbe2fdd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc18c39667846fbb99cfe5795bb832b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fdc86037324795b46c202ca0d00be3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e95d1f892c4f938eea104fc6553abf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe219fd14a84e3980655fdb9727e9c2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8273fa766cef4c98862e9f44eb96455b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22959fc6b46c4630bfb1d8629dd63f34_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f8875d0f60402ba93a3ddeb81920eb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76548eed129741f499223726cdcc1f1f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f82ef87090045aab2b1cb5b17aeea9b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba409194c834bf3a16a2de8f61db0ed_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida1adad387b4453c8301620505216a13_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38367c3fd9fe456cafc14d56b87cb674_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132d903ffcdf44229d51ea6ed57f6217_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653b99dd16f24c3e8a3cb8ab81b27bda_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc05073dde7472d85556d435dfeaf18_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e757557007b47cda6f71a9ebaa17530_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac584f59af64735be732faa98be7b4c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0370bfbe4664865b37fa1b911566c9f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952aaf5b1c50480eba24ec10039104f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ec420238dde4d4b9a44da7620294099_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a50f8d869747819b54ebbf6d2af672_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722f82ed215948ea88263cf586031bef_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdaa47b325f24a16bea0eec2bea1a4a2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a76f1d5912f4b52aeb510ca5da3346c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907f1e7563f14378b1ecd1b5ef055a57_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3345cb93fc40480f8456095f9d4fc38f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2bc0914169f4c2cb3ffcf46eff93a7e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8adae560f142bb811699bb9d9628d7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3232a5cc744549b80ca58b6a95c533_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a40b518b8b4d188979f3929210955d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74bb1c58883a4dc99af1b4e416cf52b4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f1e6f6cea24d9e98d7885cab1433a5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e96adf1d0b34fd48f31726b6ff44a4c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2cc9787466b46abbef67317ed6f0fa0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fad1ddd69340d38bd387385c2d5c25_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db8c7cca1d041038bed1f6b7d4ab6b2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08947c7925794460a22599c198525943_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387134594a0c4e6cad32daab163ac56a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa741e73d69423689689570e4a4b68e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ce3cc5ca544c28aad1d97c409db5fc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i592a4b594aed46f581483bbad038153f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3892d49afb415e99c3cba37acf71fc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d64b2e8b964e8d8aa87f143c540622_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id21894b409b844989e613f38670ae21a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cb9c645dd194a048e1a08eff82cb7f3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fdda44309f8410d9f5d04e02ea87a60_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be3e03b30c944c68f2524da9d3dd097_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098fb6e6a3044546a3431b4d1b2a365e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0e971c4d3c436ba2b2b28e78c71d81_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0d22abebca4da6a32bd29921ecf3dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83e0421e29db4f0ca253c4ef2ea6cad5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d2503001f7463ba388d1b6a4c3cf5e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01d8f96012745ff89b701ea923ba757_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf07a847be8e4948957569950fc2b185_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab5abd3f3f9f445291db02d0de25095f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409b88462b9b4206b6f0ad945e5c7a09_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243da6c48d9248179768b97ac1550b9b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d74bd6f2b1d4e72a7d2229724e592c2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720052044b584f03b3810ec2f322ddf2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ed419e0f084f27aea90bd9a24d8bd1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635500abf5b347d6a57cfe76e6ceb55d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d301e27c3914f82885e217461346e41_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if458daa2b72f4bda93915b366f415c9a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="ib22f26cdb1e1424a8f3ca3d681e15ffc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a60f7b09c98409e9ddc3f0e238fdfc8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec1e52281e643248c39bb68e766f607_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ee71674694843249ecd53f5a7dbe42b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a55a2a9bc94211851b88701a3d8e7d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia613a30223bf4bf883786f9f016d0237_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8965948dfbe425a85da6fca9e06c6da_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1d6b7809484ea6979801fe0bebf01f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e542e2b2e7467bb76adfbda503ec69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48dc4d3a85fb44099d30fed3e469b5f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e902f930d64955b720bc0e0fd5de58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0214f5546f034d149788dc3f904a7419_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dda4e5979a3455ba24bfb6dccd4adcd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98775b1b10a41a392536907027ba668_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad52dd82f08d441e93f786ded8f4be36_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702781d7d4d143c985f549228c64fa29_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bba8977699149f58c07fbe9bcb19689_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf361b51f5534b34939b0f745631d54d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad6c76d74374942bcbb4934411ede69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee771fa2648044888a8356de8f0d5e38_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47ae3a613a94bfbaea1fea5774148fc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c38ac27d6b4276ba03f7c2e9d29e86_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5645d9467cc4e1c9a27bfe42553e646_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907bc0d2ec594c419d577f002f5b337b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i340b682e29fc4f8595ff4caf9fd4f83e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5698b182a7d4143989d02e2a19043a0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbcba6dffaf3400cb18c2f40d6b7d5fd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5df461441ec4e59bcc1bb4b499e5d18_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6292523b5a4b84be8b5aa038a4e8c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4937d91a9de34cd3a68c76b9f4988ba5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49dbdd6ccc5c4f4e8c800f8f4c3db2ed_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0174dd54e1428da6b9c96728976e62_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ffe2c761d3548bbae62483d2028c1e7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab0fad6e18f47efaf41fe8fc095a1f6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78be0a546c174fa2a2cdab944955d487_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720dbccd07034f98942db90af7a7d38a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7236fcab1a8f44a8b21addbfbcd77b5e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d874a874e60463fb1b3910e76852f6c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd2696c492034bfeaae4a745a688853c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564232db534949ec8f4d4776b844bc62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425b64c01d0a489ebae1f721822fbfd3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf72f9358a9449ea227a870a11d948e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292c5e4fd4e242e9875eefba463479ee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4c60f1930e46e492d95823df89a04a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915928be88b2414c93eeb0775ef69931_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3471ca51d841a8bc1d6e8d9212942e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5dd5cac2c4b4ef88f7c9af0cdbe95aa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe3131e1f0f4d2f96592abae7ae34ff_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc71ae0114074c328965f93fa714853d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if424d27a99a040a8a69fe6179239ad68_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic861662623824bafa546d7da7df31404_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib26ab77751224af3bdafebf334667bf5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b7babcbee94700b48f10861f4efe40_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c1c6a24b94432396492121d59bce8b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3589e2b3b4439795b2b25630eaee3e_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09027731e61a42988fe6ef2a4a7fd42c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23be9c67c76d4186b731732ff57d13fb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c307d55279b419ea2386fe0de0cb1b2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie349b92369f646b9b58c66a22bfd7298_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e4ef37dfe9481b8471820d3e30119f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06bfb17addc54ed589cce69a74b3cb7a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id615384c43134264bf0013bc467194b5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d3862fcf4b48ee9108d423b5ba2d58_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919f06b975ef48769887372c1ad1d83c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbd029fbc344b46a9e18552f63b771d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bfd21709274d769bdfe5ee0c2a4f9d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id690c3d268444a479ccd8676d8f87382_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee42b4171fd43f7b3d5a343e610ffc2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5278f4a26a6e47f587f7ca52b525d078_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd88e5dc8c048bbad2674a4096e3603_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4bfc66e80d34cdda3587ae96c181943_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b59ff6648844150b9a65bfbd8584495_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36ef803d07a43c9b37becf139ada10c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie818c37f85794462a4a3bb25a7063d68_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e27733c20de4673aa52d098a7ee84bb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2010fabf284a188f6f32e901e8f4dd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597e26ec891640fba08ea16a165c80d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a34184f549249be8306e9d072ccd958_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8d5194bfdc4c11856e1dd30d419809_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96bbdd06b85242b4acd39c16f2de4f68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17a07be4c334ab5bf381339cd0805c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db3718d80134232900c7bf04328d7ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbea1376e99b45eea49529b1a794cfb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1497c2e19e48d4a054f3ddaa892b41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6febac69f96c45f0b01a347765248601_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e243522dafd43409ff7994995b9d578_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74fec6d1e18f43c6aaa04084519b0b4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f8c8feb0384cc4b6dd32e68d1156d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e051c5c511343dd9a80f274f5cbc761_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb3c6b56f5242c9ba547dfeab34e697_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4035f415b24c6cbd58d80693db5b18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7d9660d3bf4a90965d36747d39593f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260a3e69565e4b828bff65115e0af19f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c4677be3fb47c7b1f75c1d21d7e655_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc509257f5be4a76b94830882324d568_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e963ce175141e289e8f4ab954e3f94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f9390e677c4071a7ae6a84252c90f2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i773881e5f2394e0ebf447f4efbf9d486_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56f856147db941a0804cfc73b59b772a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0576235f4f574413b5c8e270830d6b36_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i937eaac40dc143619d61ac7e212f0a77_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id89cf8bc140442ae872b864148ab6939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f011c57e3b436783a11ba0e28c19ed_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc580ad737ef4e489c1ba3d69c8dfe89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca50968196b4b61ac6745902e8f15f7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61e30f1dc0024078af380776f8c704ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb9fb78022c43f0a0b87550768dcfd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630a522bf9a74f1f95a783e75d21daf3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fba93be0fea4ade8ac439ac8b9db515_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1fb36c730ba45d4ab09be804637ed64_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a894a26a474d8a8a4ca98884aa9ca5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie394eb8420ae465f88327d5264884868_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c9a173f74b432699e417cff17cf882_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ab760d5bc14df3ab137b467a13aa03_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie454762cebb348ce9e3d9253487d13f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5bed7f18604646be99d5feb31fc4b3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8dcc2572e864232810d889863e8b6a1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703ad29a631c4d6a98bdf0bded3bfc94_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea767474fca14a4e9823a37eee15721d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c698cd4a9e4be08876c788f019876a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ce0d61306a499d84402c0d7b2ac015_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7937d5eea9143a480379f4cf9a45fc4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47869cfa31654403b8a137ce71cddf41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i341192473b2c4e86ba0b46d1823dc869_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0765b5a9983479983cc32b7829fb9a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24972f1aece34e51acc03fa88f074792_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f336c946104c0db5fe50289af1e486_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcd05b4880a4540810666063e3fa5c4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025802fa7e3847d4ae2eef093ae4c52e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea966d9152224b339632f5f1382ae44a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d314e63f4cd44538653c170af449268_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a12db724d6a4e459f2d028b6a9183ac_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9cfa41b71984268a5cb3226a08be9b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da4427e9e314137b7a5b4ca1ca37219_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2345724701914330b955cf8be98888d9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddda160e4f824f399742551361ab9a2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd259f1cd1d64891b5247097034ba0e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046a19b35a87471dbbfd93c7cac2007f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc1544fae3a46a4beeec639311e70a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84100fb99b304864bdd82f94e09a5f4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccdddbc872c141098bb571cc14541a6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa604084a4f426cb962e44bba729d00_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b531a1cb354dadb1d4b04d6c9d7dde_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc4527faa29483d89169d9c64e45fc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c93ea4397fb4f4cacf7e9b9766c5d11_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82cf1cd794bc4e22b1558829c36fdbe6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3fe0fbe0a3c4dec98ff2998e5d84527_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512790f7d615460ab79e03a4291d683a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46d4c476a5740f3a1de4a18cc7dd358_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f0d11ff3fc4f448b2f08227bf61ec8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4176720cd9a4369ad4b4aafcdcf8e71_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3365b3ac299340f1817dd1c53085ac56_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e1c79ee9d842c499a267151200ea06_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25afa94ed8e9481ab9840103fd7abdae_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c4856250984299a9cced80dcf2d079_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50f69c368cc9469e8e39f044f00e3e4f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbd5e05042b4036a8d14b4e5ebca682_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011039cdd7d14a4cb9f0e79057e4cc60_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361c2d5b5f9a40ca84ea9fc27a68ea9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a45a9c2ad44e1fa1cf0df1ef188ea0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2288b6bd35ab44fc89e7711afcecb9b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041267955427406394b3d10cc3f1a76e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c013d5be0e0491980d059486bae596e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a47da70628b45368fa3c768152f89ab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34356bbd90064319b545c3acc5fab084_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b264cff07c440eac3e823fa20d8f64_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d5e77b1f3d4a9fa12b15878cb707cf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89bfefbfa10f41fab03c1114e9b9886d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idefcc8d10a5a4365aafafd0f6a18ada6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic773015e74094678bef62859130a7966_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf78e07bf74c48a797d7b1e5be1d1a78_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8644901576fc48e89f7637ea72cd9a14_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc16ed7a14e24bfa91d7bef98db547da_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0fa9272fb14f3d92662a3cf36c6a91_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd7e5ea5d2434fdb8b011b6c00426a56_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7a2205485b42a29e91f52900709717_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d9977b79f94870b4d88a3efdae4b18_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eaabdea048846fe96c2e448be0650d7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ff03e21ceb4d898ce5d84c9f83373b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7296f2fd8d4fcb8a228339d858558a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be0b892adfa46da854229dbdc2b29e2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2404b4e4cf7047b6a33ade2b330db9ad_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a7aca0e9644a159e0edce9ec0ffa8e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fa629226d049e2a9ffe5ae168ceb55_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if078c4e7fa004892b58a2d85cb5816aa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35fa105818345dcb7a4da4701cf3007_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac95fd0cd294483986cafbab07cd5d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02aaf8bc41e445329bc5a2dee146c97a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb95e23801654e2bba2506940e05081b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab366cb8c1584b168540336d12773aaf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74eeb72d9da54664aaeffbd41250c0b4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08317e7cb534a3289414130d2f13dff_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8b068d3ff24daca734cfd11aacfa1c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if261c4da0ab44775b42f4cccccfe73ec_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3cd384eb084efab9ae4e2d17d5a9c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0281011ecb3d433e9e4a910b3c2764cb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4592ebbd81f14b13b42251b139794fe1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b01c7943bb4de2afd50de4b1bd1d85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4431cd1978604f468b85792244a703c3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33dd48f244f4225b552ee2004b13a84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b29717f14d4bcdb08b0e8f526654cf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db5325f2f3e41fdbbd2d84f4bae2316_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d7d7619dfe248fb92239ddd3b9eb83a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffdc90f0b7184b6f826b98475df4665c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7819501654a14b97b346551b244f99e9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1250cef8ffc24c32aa61879bf6b514d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54aba4f031f44f21b6560820384f079e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4743c680e7440da17e364ec93d7b53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1bf393f58e4ed0abf1efa1dd592205_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433d1dcae59d4e858da20f98b3db0590_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b29bd51ce34a84a747af8d0b76aa9f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7354b1363641bda1fe4879d47cd10c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf0486182bcb4de1b50c1c4e665beb58_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b7ae3032894fbdbbde3fe9f817db9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic7f7ccbfa9ed411e963f8ab905c572e1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2998a0b67c1c4fdcad0435d7a30e8285_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81df80dd2e3a491087572c5e78a6d533_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib044e39931fe4842989f0f875a50f3ba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7fbc25be7d405ab815f3b0802c4430_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifead4a76cf1c4aedb1f743dff60ab9c5_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327c113b77e945e794ed2983beca310e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5605847573354f9fbd73ba2055256fbc_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d713ade1b14480a777502c5e1bf27b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78d6dabfa0b4866b6108e9a2c352b12_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49528d2d9baf4068bd97b947293b14ac_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4010afcb4574fb5a96678335abc87c3_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f180f950ceb4167854fd3cd90ea9c70_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0aa046537b415fa3f8df9b5a030319_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53079fa10c74963b5f0f9ba19d3c804_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43e9a82c06fb46bab58a5f1115cdafbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd5030b156d448aa845809d96101ccf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3c7e0b91104fac8e090638fd4b76a4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377f7b2b4b52412c99af798994cc4777_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5853a7e3ef491bae7a65e1700e49f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36720c0b63744ff81262ab66ab00c7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca5708d24544f20a4280b1a87d305ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f97bf2a176745928cd1dcd5ea7396f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92db432fc134e3e94c64ac21f29c319_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60fdc6283c6461ab18da2fc1f5f4f7c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0beb22829148494f946ca0c797b83a17_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c400ae85bb449a972a93be398be207_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22b6d24018d47dc812ff8762a4fa3cd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b30ac7e13f4d9c97c0e658be456894_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e22cb23d684bd2bfc1ab92393bf68e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350abaf377694487bce4d1569f7c6563_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b9bf78269b4fb284993468c59edd91_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a327327cab48738dd4d95d812889ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6ecb6a9ead4700bd2dc91367ec36e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8cc4cd6af248d9bfe66ed30639196d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a59246306f44bb4b8c54ec6ff864503_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f6ec19f64e41568b2068e96298f003_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id99da815ae3f44649e4b32bb305c0670_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia94afab659f248cba857933e77ec8718_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f12d27ddfb1404aaf145062a7713f57_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92055b26fdd84bf0b0f9ed93e463988b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd9eee9380f42788da909d05cfb8fd7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a22cdb164d4ec1b3e8b6f30d33a058_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f51c78567604483a89db091767965c6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2867d1e4c35544c591c011e82114911d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i550626667d504f049e3f27be6c6e87d1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc844f221fc242d7ac07b31786e87e81_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec6ff2fc5d644a894df350de003ed08_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d7f325ae73459e825690036a3d6239_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida11029c7cd140e7b425e00d05e00a01_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85699448040462d8f5baad3e1537a64_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85035a7642e240e7bf1eb74af9286dba_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c79aa09732f4485b81ca20d090dc9d2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic607ef111a0b40c98d2bb3abadd70ac3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2282dfbca39426985c7b4c02362b0f6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eec312c192244b58a5937395a9f32ca_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f60cc29d37f4bb39e05aacb97220a95_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida800d3221da45ab8bb24399a9800a50_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743269d62e29412c951e960acc6995bf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cfcde33ee94b2091ef4e9994affc0a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69456628ebe4d798414fbd24865b055_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca6ce9dd1204c9d8ee47ed61c9d49e3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24286416527948f3a36f9903ba223e92_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5868596776a48bcb3288f10554ae486_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7711bdabafa4868acf0cef411512b10_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea5a899ef244aa7ad5b55e212db3c75_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic508730c80624e0a9bd030c7f4a89e07_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b1713d5c5845d3ac44180eebc6f115_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33eb872c6b4401cbc20e2f4180db8ea_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic438578392a5405689d4d33d4518f669_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c7482558954653832964511911a842_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed6e6d0ef254bcab5ae8ea84750ae16_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d163820b4b429c8ac869eca01a9a0b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812c1ff8e80b47b58ab63fcf9ec1c7fa_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1023665010a54e788e30ff06159d6b65_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d84900139e040b39413a2c034c9a0a5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81326f8c0faf4c82934916df0e7ba73b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48408b16cb17457fa4d16374fac38f5f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af3d4e0eb01491fbe2b12666856a203_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55281e38b4084b1a87f417de6e85d628_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice3a443da8f344bfbcc4b77135174e59_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3bf599004a64372aa741876daef053b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cf1f40f75d4c3eb9de865f64ecbbe5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i627f7085dbc94df5a856a6ef66dae68a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f184261bc64a1c87dca1dc5e5dcb5c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327ede04c0d64a02a183dcb72ead44b0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63915734eeed4a7fa8f44b93a5f9dad2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if414343ed3b64a0ebf09d1a0ac51b4ed_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4be0f188a48449bb2c0674eb366a190_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16260595953d496b8eddf5ebe0653440_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a4ab76f4f554cc692c968485d75b3ad_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e972a3b7174d6f895bab11575fb911_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd08f32f2a474aaf85876113c161d15f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034140dcf36b473790fbcfecad31c0f5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15391fb757e741998e7ea0be726a8c97_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5126740cc446437cac3cd23b16210a6b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5def17fd84945bea951f1f209f4a742_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc2ebe6040c4f58b354ab2338b8717a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i177c8a1d0d754674a0c18fab88e27143_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6bd17fd1a848c39c8365d388aeb423_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c191952c6e484ba3dd03915045e4df_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5386b3cc1f54a49bc7493b4ef834955_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc7874f6e244472f9ef1586998fa6bd7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dddb0afc8b342b58b72feb818dfc513_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f242af2dd048a2bc766c9493467dc0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5336835708cc4dc48247e0e9ad7969f9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5082dfd8d8a4569a216ee449ace1886_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf8d368179dc4c9290de72ce73993e6c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cce66e5d593473eb28168ab00d42bbe_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9d0511d58d472bb7e1f483ef7f6e88_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33fdfdf2e5d4d1b9eed0a03f5eb93d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="ie30cba3e2edd4bc08f2a74408c366d3b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080d328364f74b708ca4d19448cd3c44_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60376f76b3314e2bbb38c6fa9587253b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b682df909084551b169517453ffa2c0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f83a2e2c6a4460c9814ca56bd7798e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683dd88ba1804d5d81e60a6e361b15e2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf76ad095d44d08b376319fd02096b7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a1d8eb24644ccdb1958fc8538a767b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e917d9b36df462b8f02b672a61e80a6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940aec5d7103466d9529cc5b08d8e33a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d0e998a1764fefaa1b533582262643_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e9f1b5c6644324895da8c763579ea1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657a17d9e3ef4c86b23042aa118c1b39_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa87cc62218145ad8330f96b7227e231_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2cbebcfd92341b9a4800299106bcc4f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a1617e837c46c9af07f92da67420a5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb715e3d5a940248b7d9789bde6f8cd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd89562ebcc4af9ab88aabef74b9794_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14520938d40f4be7b3788532f0a39e36_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9789f6e0bd394724b1766f169596f0eb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b30bd6c2b6a47a09c2ee57818fe9437_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68eaa385cc39449cbea95fc77f8b73e5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia53f50175e4b428ba3381dc4cbbabff9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c297982d9641fcb3a085dda0c1bd2f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3b63d2e34c47ca90c46007d640803a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9cc66426f84e3e828a71db655b5ca5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d35c0b653e746d894c5a5ff25f40d74_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2fcfe4886749c19597e9ee5c80f50d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9327f22b43043478937934e403bdec8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70318dd2805c4be293874a85d342f3a0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6801ccc665a4e8db08e33134390d9c6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b163de37ced4db78033769ec4cfd792_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658f7b7a80934324a5fde431814f9cd9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1ff74fe0d44db0b1983d0c557a90b0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0eff84f0a64614b8a69a4c069072af_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c24d776c67459baefa074ef5ce43e8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0531061801234f06bd21a3e0b235a6a9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26e88285d5d8470a8b499ee193fb4bbf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1453070338d24ee3b7ee1fb21644243d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525a88b3fbd24d928dea67537541252d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a1f935392743a6b8a9a61a8026ab24_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24ae1e5faa24314a3a0baafdb89a376_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bbf4a5ff6c4f5085293b4809ad89df_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11863a558bbf46bca75ffd9f7fafbba7_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f071a5198246d4a5303f52da35079c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee4b7c75b03465cb35c3c8b87a54189_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187bf0ed97484588819f3c772481972a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4faa3349fe88498e9d027f1467d57c95_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia27d340d112941fc9280b61618209c41_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcfeec350bdb466ab3c2f0500fc633e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11706266e0b64d6b838208836874f7c9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b0165e2b7d4f55925670a51aac39ab_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22390c69ed8c484a87e99931785d60cd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85191396f14a48159b6ea71eb3da36ae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc20aceecce4ad98ad607135283cd1f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d184845c0fd4540af43215a509def5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id238c93aacac4f80a409e4c0cd6eb474_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05bc48381d6b4149b19415bd7d37bd95_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d03ddf77e1f433eaa830646366273e1_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa100d41aa7e425a9482c71b0293c71e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a247039a04a4250a57179e383ed799e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43ae0706b95445a8789a5fcbf8ac563_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361307437209490a864b62473d1cedf7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f888c4ff5e0416ba053664107506cc4_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a38fb832714a92860b173e6a8b3564_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i904ca67b48e9438aa45cc860a3e98146_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDA5_94fe6d78-41fe-4cbd-96e9-5605d3afd51b">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6NTZkZjVkZDY3Yzg5NGNkM2EzYjYxZjk3ZDhhYmNkZTkvdGFibGVyYW5nZTo1NmRmNWRkNjdjODk0Y2QzYTNiNjFmOTdkOGFiY2RlOV8wLTAtMS0xLTA_7aad80d5-87ba-4bad-b464-f28417100a77">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18xMjQ_e831f6e0-1e38-44fa-b116-b55dfc179f6c">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6MGM2NjFkN2VmZWMxNGQ0YWEwNzg3ZGRlNjE1YmU1MWUvdGFibGVyYW5nZTowYzY2MWQ3ZWZlYzE0ZDRhYTA3ODdkZGU2MTViZTUxZV8wLTAtMS0xLTA_374d0e11-c342-4f87-b060-eae8787bed4f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEw_c0905868-5033-400f-b798-33c0847763b2">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20210630_g1.jpg" alt="biib-20210630_g1.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE2_eb719ae6-7a53-4a0f-bde8-efd85515fb7a">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6YTQ4NTg4NDVmZDg0NDYxNDgxNjQ1NWM4NmU4MWYzNzUvdGFibGVyYW5nZTphNDg1ODg0NWZkODQ0NjE0ODE2NDU1Yzg2ZTgxZjM3NV8wLTAtMS0xLTA_2f784d92-eed3-4022-a709-62f36794357f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6YTQ4NTg4NDVmZDg0NDYxNDgxNjQ1NWM4NmU4MWYzNzUvdGFibGVyYW5nZTphNDg1ODg0NWZkODQ0NjE0ODE2NDU1Yzg2ZTgxZjM3NV8wLTItMS0xLTA_83a7cd76-d4fd-498a-96d3-4689d4e652c3">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEx_60bbfbcf-a387-4399-90c6-4d23ae1ff329">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEy_d16a0b46-de49-49b3-a7a7-9bb656f8a5b9">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE3_e30d116c-8de6-4aa7-8ceb-fdd87a5a0124">MA</ix:nonNumeric> <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE4_c3d1cc67-8db8-4615-b74f-7ca17a4631d1">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEz_e3bb91b0-0304-4b46-8638-f3e79436d701">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE0_30182bf4-ed3b-4567-b6ab-e8d5312a5bdd">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZmJiMzAzYWJmMGM1NDhhZjljZWViNjU0MGIzNmI1YzgvdGFibGVyYW5nZTpmYmIzMDNhYmYwYzU0OGFmOWNlZWI2NTQwYjM2YjVjOF8xLTAtMS0xLTA_65efd2c7-7ed7-4269-8478-d54ff6fa0c88">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZmJiMzAzYWJmMGM1NDhhZjljZWViNjU0MGIzNmI1YzgvdGFibGVyYW5nZTpmYmIzMDNhYmYwYzU0OGFmOWNlZWI2NTQwYjM2YjVjOF8xLTItMS0xLTA_14431537-9cca-4723-8163-4f18635cca48">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZmJiMzAzYWJmMGM1NDhhZjljZWViNjU0MGIzNmI1YzgvdGFibGVyYW5nZTpmYmIzMDNhYmYwYzU0OGFmOWNlZWI2NTQwYjM2YjVjOF8xLTQtMS0xLTA_f7a0f1ea-01ed-4ab8-be36-79303843d45a">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE1_f0c6a423-6347-40f3-a3d5-902ef3c29f7f">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE5_b216a551-e6b7-4d33-8daf-78a8bcec7de7">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZjY1M2VkNjRkOTI4NDNkYTliMGZkMDhjNTgyYWM1MTgvdGFibGVyYW5nZTpmNjUzZWQ2NGQ5Mjg0M2RhOWIwZmQwOGM1ODJhYzUxOF8wLTAtMS0xLTA_f45b272d-471a-48cd-9f7a-57f33847075b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZjY1M2VkNjRkOTI4NDNkYTliMGZkMDhjNTgyYWM1MTgvdGFibGVyYW5nZTpmNjUzZWQ2NGQ5Mjg0M2RhOWIwZmQwOGM1ODJhYzUxOF8xLTQtMS0xLTA_fea6bee6-ff3b-402e-8c32-dfeb8a1d0d25">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZjY1M2VkNjRkOTI4NDNkYTliMGZkMDhjNTgyYWM1MTgvdGFibGVyYW5nZTpmNjUzZWQ2NGQ5Mjg0M2RhOWIwZmQwOGM1ODJhYzUxOF8yLTQtMS0xLTA_1824e267-d1ce-4892-9df6-0364b6302378">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDA4_861b8488-462d-4547-8faa-5962effcf200">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of July&#160;21, 2021, was <ix:nonFraction unitRef="shares" contextRef="ib889c2d4156d4791a136cd35997ec490_I20210721" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18xOTk2_9e74c52b-44e8-4c46-a48c-b8c0a14b4abc">149,033,443</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended June 30, 2021 </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Six Months Ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Six Months Ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of June 30, 2021 and December&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_1">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Six Months Ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_34">Condensed Consolidated Statements of Equity &#8212; For the Three and Six Months Ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_37">13</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_133">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_133">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_214">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_214">72</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_217">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_217">74</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_220">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_223">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_223">75</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_226">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_226">75</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_229">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_229">90</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_232">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_232">91</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_238">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_238">92</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our core and emerging growth areas as well as implementation of our corporate strategy;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park, North Carolina to be operational;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#8482;, BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482; and IMRALDI&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_16"></div><div style="text-align:center"><span><br/></span></div><div id="i904ca67b48e9438aa45cc860a3e98146_19"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7cf54c2c77a4e6c9dbf0332cbd0f00c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy0xLTEtMS0w_3562d9f9-be38-401e-8a43-8bdb263e98bd">2,236.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b5d4606fd747a98fc6804633f0b093_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy0zLTEtMS0w_e9227720-3125-4f1f-b0ff-085ec1098ae2">2,795.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d754496294f759ddb105ceeca7aa1_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy01LTEtMS0w_155c3bc8-e45e-42a2-a3ef-b4162eca3158">4,447.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3aacf570724f99badb8ea0d3a29373_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy03LTEtMS0w_ff90e24c-742b-4ec7-8af3-05b8079a724d">5,700.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e165fd1993b481c8583fa0659f62931_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC0xLTEtMS0w_4cae9e0c-9df6-4943-a558-59a8f277f4d0">440.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a7b47c3caa498fbd7d5570bba5dfb5_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC0zLTEtMS0w_b0dcdb73-7d3d-45f0-8343-52db2aa1bde4">478.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597ac0475acb4b008433332ad02431ea_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC01LTEtMS0w_177018e9-cab1-4506-ab48-30c51c64f84f">829.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaebd3ec3de74756a298f2a7c57d8b32_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC03LTEtMS0w_daf5801d-bb7a-45c1-93dd-de6f2cfa494c">998.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id563dc7eefa34305b99b4e811541cfce_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS0xLTEtMS0w_3a5d2b36-22fe-49db-b438-032f648b32e1">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22951db8734f44ec9b10b05a829c8cb7_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS0zLTEtMS0w_088b3d37-fc3e-4f66-bf27-4f0a2d99f96e">407.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892ed7dcf1654ee7a0c75a99e9a162b8_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS01LTEtMS0w_c639dbc5-65ac-4371-8527-2dc325929779">192.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92244e16cec54d629634c4fa97c7505d_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS03LTEtMS0w_7326a4ae-57d7-4ee8-ab1a-39f5954ef0f8">516.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi0xLTEtMS0w_6bd5d17b-da7d-492f-b6e1-5d8dbdfecdd3">2,775.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi0zLTEtMS0w_e9126d98-7d00-4876-8f8c-49ba66b0f281">3,681.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi01LTEtMS0w_a2f12fe2-4efd-4c85-8f16-ff964316048f">5,469.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi03LTEtMS0w_cd094cd9-f922-453a-ad40-543d6dcad31d">7,215.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC0xLTEtMS0w_dfa45bde-4cb2-4075-8c20-8e1395c57441">459.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC0zLTEtMS0w_c6b574b0-a1b3-4b1e-8f92-bb131bca2125">411.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC01LTEtMS0w_29382302-58cf-4d35-812c-9f1fca96d1ab">937.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC03LTEtMS0w_80b14a5f-49c2-455e-acb4-f55a86abd4b7">865.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS0xLTEtMS0w_175df58b-fbc7-4143-a11a-8c44807a0833">585.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS0zLTEtMS0w_16183e02-b0b8-4677-a70c-cb813b5fde08">647.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS01LTEtMS0w_9f90a31e-ee89-4fe2-9fe7-9b390c004743">1,099.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS03LTEtMS0w_ce6e4aee-32b8-41ec-bd61-e7993d73132e">1,123.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtMS0xLTEtMA_8659759b-d0c7-498c-ba75-e7e7eb205a67">637.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtMy0xLTEtMA_1624a187-9666-495a-8df2-de9fab71e65a">555.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtNS0xLTEtMA_e06a745d-10db-4ed1-9e28-77e7f348c148">1,232.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtNy0xLTEtMA_eec190bf-86a5-4be1-b488-ebc3058bde67">1,125.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtMS0xLTEtMA_05ed352f-8fad-4657-82b2-bea1ded51171">604.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtMy0xLTEtMA_a613122d-380f-442a-a766-b64cfbc964f3">61.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtNS0xLTEtMA_174045cf-24c3-407c-82a7-206992ebbc4b">702.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtNy0xLTEtMA_628a6666-b904-453f-98bd-c7939e11a732">133.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItMS0xLTEtMA_aa9a570e-016f-4ff1-8b5a-a091500dae4c">15.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItMy0xLTEtMA_9afb2d9e-ca28-40b6-aaac-7f6fd399d8b6">21.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItNS0xLTEtMA_07e9a2cd-fe4e-45ab-b946-ed2bfd44f450">53.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItNy0xLTEtMA_4dab44fd-1ddd-4f1e-996f-980761ee6577">93.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtMS0xLTEtMA_2f589e08-a765-4a48-9c01-feb7e14125af">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtMy0xLTEtMA_89c7c5f4-611a-4578-b22e-698908d6ab59">10.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtNS0xLTEtMA_022d71eb-e8c7-4b19-b41b-311bf129103f">33.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtNy0xLTEtMA_74fa092a-0602-4b84-9cdd-677931db093c">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtMS0xLTEtMA_f593a0fd-1833-4b56-9209-f0480b51df8c">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtMy0xLTEtMA_722bc253-e056-484f-92da-8c4b943557d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtNS0xLTEtMA_7a3820ee-ebeb-402c-a42d-120f2ea30106">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtNy0xLTEtMA_b20d8ff4-10aa-42c9-9a3e-b5685f6da809">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctMS0xLTEtMA_19f8cd13-9818-4581-a830-923fbd9e4c33">2,289.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctMy0xLTEtMA_3a48bc97-c8a2-42b5-9957-e4c3e6c94147">1,707.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctNS0xLTEtMA_ec657286-6ba6-4d17-943a-180355753c41">4,009.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctNy0xLTEtMA_9eaf6028-9648-49c7-b16c-d55c29d434dd">3,421.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtMS0xLTEtMA_f379c4e6-d7a7-42c2-8439-a5e22bec7040">485.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtMy0xLTEtMA_740bba8d-2dcb-4261-a755-a26414d3b3a9">1,974.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtNS0xLTEtMA_4135cf8d-0186-4cc7-b937-e15091a8a3c1">1,459.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtNy0xLTEtMA_9a575974-1deb-43e9-9647-d645381857a4">3,794.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktMS0xLTEtMA_3f899a08-ccfc-4ab0-92b5-20469b2ca6cd">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktMy0xLTEtMA_f862d5ec-938d-4096-90ea-8c714fa1a6bd">63.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktNS0xLTEtMA_2b93320d-f5ab-4a20-af77-da0c9c578aab">410.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktNy0xLTEtMA_ce502122-5e73-4e33-bf32-8c786c75aeb6">57.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtMS0xLTEtMA_5f788a40-9517-40b4-ae3e-87e9d3b54443">582.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtMy0xLTEtMA_4f477735-ca35-41b2-8397-8b9ce5923047">2,037.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtNS0xLTEtMA_cafc8ea0-c505-4552-b370-b76d719a99c0">1,049.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtNy0xLTEtMA_e9a9f138-81b7-4b23-86fb-f8eb9d482750">3,736.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtMS0xLTEtMA_0868dbec-1ffb-4bc5-860d-ce601af9c3b4">409.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtMy0xLTEtMA_43541e35-29ad-4b8a-af2b-af1246621b05">446.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtNS0xLTEtMA_15900a21-3113-4294-a6cd-836daeea3354">364.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtNy0xLTEtMA_1a568997-ff14-49b2-9e26-1639789bc250">738.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItMS0xLTEtMA_41f494b6-a642-4f76-a105-cb11ebdf1e19">34.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItMy0xLTEtMA_4ef59bf6-b83e-41b8-9a59-b6410c39ba14">15.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItNS0xLTEtMA_451eb6b2-78f5-46d5-b982-751fb8cee191">16.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItNy0xLTEtMA_be9a0663-67f8-4a9f-804a-6dfb017aa944">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtMS0xLTEtMA_640015b0-22c5-4bf4-961c-6177e55fbad9">1,025.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtMy0xLTEtMA_586eba6d-fba3-43ac-be7b-f2c43b29a9be">1,606.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtNS0xLTEtMA_34efbcc5-c4fb-4380-b737-90cb48312ba4">1,430.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtNy0xLTEtMA_3621b3fa-7cfe-4ef9-818a-ed642c079836">2,999.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtMS0xLTEtMA_128db8f4-ba0f-4877-a019-575374ff75b2">577.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtMy0xLTEtMA_fca574b8-f6cf-440b-a582-02b6eeada7ff">64.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtNS0xLTEtMA_8afcaa9a-f910-4fa4-8b38-c078ce7417ba">571.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtNy0xLTEtMA_f732c0c8-701f-4268-b1cb-aaf380c0c65e">57.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtMS0xLTEtMA_232b2dec-5eac-418e-a975-d86f811acc67">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtMy0xLTEtMA_5da21e50-2f68-4347-a7de-168585439c27">1,542.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtNS0xLTEtMA_411c5714-04d4-4582-b1f9-7ac52c2b65df">858.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtNy0xLTEtMA_8a5fdb7e-78ea-4753-a029-675acc765d3a">2,941.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtMS0xLTEtMA_ce293d3b-fefe-45e2-a61b-6f4ef64d4a7d">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtMy0xLTEtMA_ad6eab33-e00d-4e8c-9bc7-0d2938b28d5b">9.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtNS0xLTEtMA_d991a889-cd63-41df-80f8-b15e642a20ac">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtNy0xLTEtMA_35c6ea5e-5379-4386-b839-bec81fa042c4">17.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktMS0xLTEtMA_e2936ca9-146d-4571-bab5-ec4f77aaf248">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktMy0xLTEtMA_a9d6a07a-17ba-41de-8f2f-47e2a6c8255e">9.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktNS0xLTEtMA_2e0d2c36-b70d-4213-9381-ce2b4c0a2317">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktNy0xLTEtMA_f8c1b31e-bd77-4723-a0fa-7c514cf72cd7">17.61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItMS0xLTEtMA_c662533d-f319-4e52-bac1-bc0463bce3d8">149.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItMy0xLTEtMA_466c2f5b-839d-482b-a165-f9896d7bd740">160.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItNS0xLTEtMA_432e4fad-6eb2-4682-a018-3ec5dcdec1c4">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItNy0xLTEtMA_8f174852-9928-486d-b1c8-d449f97eab29">166.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtMS0xLTEtMA_c47dfcc3-86f0-4920-af5f-7d50a171963e">150.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtMy0xLTEtMA_0980a725-b0ff-4322-be4d-1dc0e2cfc6d7">160.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtNS0xLTEtMA_9b0b5082-3204-407c-a1b9-a3496464e141">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtNy0xLTEtMA_04cccabc-d2e2-4433-a2f5-db0560645a95">167.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi0xLTEtMS0w_4fadf593-cf16-4490-af6b-614c5bbfe18a">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi0zLTEtMS0w_daa4664b-03de-430d-8c00-be10b4260ed4">1,542.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi01LTEtMS0w_4b569c81-89d3-44a8-b7b0-37d5c49c13e2">858.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi03LTEtMS0w_769bb5b6-e2b5-4f51-a77c-9469d114a02b">2,941.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC0xLTEtMS0w_dae99992-d5b9-492c-a2bc-8b40c94767eb">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC0zLTEtMS0w_45d1bced-74d7-4f83-9622-84dfea2939bf">8.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC01LTEtMS0w_fbe29517-0fbd-4411-bcef-920b2c24312c">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC03LTEtMS0w_9c96e18f-a0da-4d6e-94df-ccf08a0dc30c">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS0xLTEtMS0w_38a3d801-3639-4757-8494-d18a737bdfa6">11.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS0zLTEtMS0w_b6291bea-1f9e-478d-b40f-6868ae6ba814">51.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS01LTEtMS0w_18369ab9-1763-4461-8639-c705b8d461bc">138.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS03LTEtMS0w_25eb0e28-66dc-42e4-b1e7-7cf7b0f49539">17.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi0xLTEtMS0w_5062eab5-610f-48b1-b7c5-2b39410f5759">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi0zLTEtMS0w_693392c5-8360-40fa-9c6f-815be5442e44">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi01LTEtMS0w_ec041a72-2313-46f5-8788-c7b78b31cfa9">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi03LTEtMS0w_2a64449c-4802-4061-8e63-3c2ede91a22b">16.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy0xLTEtMS0w_60a4d7eb-a06d-489e-8789-276982149852">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy0zLTEtMS0w_99292259-50e2-4937-8169-f7a832fc956c">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy01LTEtMS0w_268a7aba-5b7d-4995-8267-8aec204187d6">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy03LTEtMS0w_3a507cf1-01b3-4e7e-a4a5-16c16509a074">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC0xLTEtMS0w_eaf08ae3-f8ee-4f26-9c8a-162322565f15">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC0zLTEtMS0w_e0d56da3-a62a-417c-b90a-28e392650a64">16.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC01LTEtMS0w_caaf026e-b574-4bdf-8ab6-13590a7c1b25">32.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC03LTEtMS0w_e660cb57-0b61-4972-8984-d2ba1433d48e">47.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS0xLTEtMS0w_07274664-e5f8-4bd1-bcf2-1d766c1a10a1">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS0zLTEtMS0w_4f42ca16-81d6-43cd-a28b-d468c74e267a">31.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS01LTEtMS0w_7a39e0c4-13ee-4d5b-bc65-654de4434ced">127.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS03LTEtMS0w_9235dc31-c618-4ddf-ad78-7361f42f6118">45.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtMS0xLTEtMA_8733dd15-7aef-4cd6-8bcc-7428c151b52e">451.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtMy0xLTEtMA_c7de6e8d-a7cd-4a1e-9773-5d38e7232253">1,510.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtNS0xLTEtMA_a002981d-588c-405b-9f07-a8823c20c34e">985.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtNy0xLTEtMA_ebbc1a1e-9c5b-4cd9-8969-0f33066e2bc0">2,895.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtMS0xLTEtMA_2fb5c42e-a81b-457e-8e24-e2d9b24904a7">576.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtMy0xLTEtMA_1910e9ea-a6e2-4844-82ff-749cb560d188">65.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtNS0xLTEtMA_690d9818-4eb6-487e-9174-305be1eec00b">572.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtNy0xLTEtMA_8c2351b1-9c67-4539-b18b-c4764b50fd48">59.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItMS0xLTEtMA_6b4218bf-161e-486e-8125-982f3901b12f">1,027.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItMy0xLTEtMA_57fcab83-98fe-4c05-9150-b7d8213dfff9">1,575.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItNS0xLTEtMA_b121ac2b-bc14-4ade-a7d1-758a5a98cb49">1,557.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItNy0xLTEtMA_030d8b06-d074-4b74-918d-81280058b0cf">2,955.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMy0xLTEtMS0w_07ddfd8b-3e53-47c0-b30a-b5723cebcd45">1,742.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMy0zLTEtMS0w_44e611b9-94b6-4772-9a46-c6632a8d96c7">1,331.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNC0xLTEtMS0w_62c6d8ac-81b2-45f1-b705-d75072b24dbd">1,308.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNC0zLTEtMS0w_07c7009b-785d-453c-8afe-588d10920361">1,278.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNS0xLTEtMS0w_c935efd3-5a8b-4124-82fd-c93bf4b78e01">1,688.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNS0zLTEtMS0w_d0cfe4b1-bac2-44d9-8e64-4cea333db679">1,913.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNi0xLTEtMS0w_b79a0da5-38ed-457a-8e4f-9d631c96decc">422.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNi0zLTEtMS0w_dba94cc7-8a44-41a4-b1e0-2e26ee2e9bd0">413.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNy0xLTEtMS0w_eaca3d1f-a161-43a4-8e8b-275e8c8ea0d7">1,254.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNy0zLTEtMS0w_a5fdc7f0-a77c-4599-8a52-a9919fe7544b">1,068.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOC0xLTEtMS0w_67570ed0-a052-4c71-9a84-8466e968f00a">767.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOC0zLTEtMS0w_77f43b76-e909-470c-acf2-b813e8612be0">881.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOS0xLTEtMS0w_62f53eab-e648-41eb-8bd3-e0da4ea9e863">7,183.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOS0zLTEtMS0w_df35afe2-10dd-4a32-9065-4d6b184703f6">6,887.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTAtMS0xLTEtMA_7e906172-e9ec-44fc-8a13-f1bcdc91f226">915.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTAtMy0xLTEtMA_2581fdc3-9981-4052-abf3-3130090e52b9">772.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTEtMS0xLTEtMA_df98682f-2ee9-458d-a745-ef53aa9e39dc">3,442.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTEtMy0xLTEtMA_4b0182ff-6694-4f5c-813c-25fea53e51f8">3,411.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTItMS0xLTEtMA_c0f8ce02-1e02-458c-a802-6bd46969e757">402.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTItMy0xLTEtMA_a87ac96f-e852-4e2b-8afc-199bef46ed03">433.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTMtMS0xLTEtMA_af67ade8-e95e-437f-bdaf-8e4cb99ef46b">2,385.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTMtMy0xLTEtMA_6a54222b-6f75-4eae-836e-bf90c081e178">3,084.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTQtMS0xLTEtMA_650c41fb-388a-4c98-b8fd-17b3580973aa">5,763.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTQtMy0xLTEtMA_1b48a7e2-8878-4d2a-9e62-6629e7b844d0">5,762.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTUtMS0xLTEtMA_dbbba736-c70b-4c64-978c-a18d4be6a717">1,849.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTUtMy0xLTEtMA_ab727692-d5cb-4148-8708-8bd452c3fd56">1,369.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTYtMS0xLTEtMA_88697db4-1ffd-4991-8634-499b8c397ac8">2,528.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTYtMy0xLTEtMA_2f9edeff-599f-4656-be8a-7063a21e67a2">2,899.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTctMS0xLTEtMA_7fc20db1-b10b-4037-95a9-9369eb71ecff">24,470.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTctMy0xLTEtMA_ee1e76eb-0888-4c8b-a1ee-1161926bd482">24,618.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjEtMS0xLTEtMA_c6c02439-2cbe-4eaa-a32f-5f102bd89d42">230.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjEtMy0xLTEtMA_cd188abe-b064-479b-8fd9-19e70f4cf593">142.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjItMS0xLTEtMA_a5522864-f782-40a7-b732-be466d14e566">375.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjItMy0xLTEtMA_fba3dd32-d5d2-4430-a6a9-dfa9f1a43df5">454.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjMtMS0xLTEtMA_c490cfe9-b37f-4d4d-89ff-8c9a40a3aec8">2,741.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjMtMy0xLTEtMA_7e9cc0d6-7c9e-4157-8073-cb90e418e257">3,145.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjQtMS0xLTEtMA_d6f246cc-d00e-410f-917c-ed9cfd293785">3,347.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjQtMy0xLTEtMA_cd0e007d-70a0-4e24-8a82-a3bd7e1ca4f0">3,742.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjUtMS0xLTEtMA_62e2470c-29a9-4335-a9a2-3950ea356989">7,269.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjUtMy0xLTEtMA_e232f5ba-2c7e-49bd-9195-bc152cb5dee6">7,426.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjYtMS0xLTEtMA_ad84c76b-3ed4-4e48-b239-927baba25186">918.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjYtMy0xLTEtMA_7afeb487-f9cc-4d86-afa6-42c1041ff6e4">1,032.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjctMS0xLTEtMA_85bbc8bc-56f0-46b2-8ebf-653f9dfd19cc">363.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjctMy0xLTEtMA_5c5f97fa-b985-4afb-961f-877796d02960">402.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjgtMS0xLTEtMA_26413be5-1d01-45b7-8e2e-b8203daa0155">1,356.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjgtMy0xLTEtMA_1c45e206-c774-4c27-8f7c-af45b946d416">1,329.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjktMS0xLTEtMA_97d492fb-0c1c-4db6-baa8-6a2785ab2cd2">13,255.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjktMy0xLTEtMA_941bb4f5-554d-4d72-a7a0-473ddabdc0fc">13,932.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzAtMS0xLTEtMA_01ffb28c-ccee-42c9-ae95-1ced9a36097f"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzAtMy0xLTEtMA_a92bfe99-d795-4239-a80b-d94b2e848f40"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzMtMS0xLTEtMA_9e54d8bc-453e-4221-9c4c-e4d43b0fcebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzMtMy0xLTEtMA_5cb5a422-f0cb-4170-8f89-e3dcb12b963f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzQtMS0xLTEtMA_e3129235-2df9-4c47-8b11-05dcd4e875a7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzQtMy0xLTEtMA_8e85da44-b70d-42d1-8e3e-4b2182283908">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzUtMS0xLTEtMA_721095e5-d054-4cf2-a1cb-f1413f8df385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzUtMy0xLTEtMA_24c3cf85-97b8-4b52-8c80-0c0a0dbd44e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzYtMS0xLTEtMA_b7fa0550-dd9e-44d3-9edf-81fa36418b43">171.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzYtMy0xLTEtMA_6dd23ba1-81c8-4f67-aae4-a7cc356330b5">299.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzctMS0xLTEtMA_d73a1acb-1b00-40c8-b2e5-798438056bba">13,900.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzctMy0xLTEtMA_b9d2817b-69c2-465e-a00d-d903cf89cc69">13,976.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzgtMS0xLTEtMA_ffecaf23-a487-4ab0-9422-974f08a19cf9">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzgtMy0xLTEtMA_0aae3c69-7251-4e3a-9cf3-cd404afffe52">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzktMS0xLTEtMA_1d5a21ce-d09b-448b-b8e3-8963cad9a420">10,751.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzktMy0xLTEtMA_fe4ed7ad-e97e-4584-97ee-db7e211cd756">10,700.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDAtMS0xLTEtMA_cae0e03f-dcae-4327-993b-a86f320335c2">462.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDAtMy0xLTEtMA_5acbff93-63a1-4bd6-bf5c-e67306a65da6">14.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDEtMS0xLTEtMA_4f0fd602-c9fb-4413-8ddf-864e3c6ae3b7">11,214.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDEtMy0xLTEtMA_e23bb792-0480-497d-ad97-072ea6558697">10,686.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDItMS0xLTEtMA_a0f0a004-cd1f-41e0-ae59-d9992b7e0f13">24,470.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDItMy0xLTEtMA_2842555f-8687-4a59-8be7-d06acdb760c4">24,618.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMy0xLTEtMS0w_70d64d0e-7bc7-4fab-9ee8-3c4c7c2491a6">1,430.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMy0zLTEtMS0w_8d90b8e3-bc19-4c63-9b42-796dfcd6736c">2,999.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNS0xLTEtMS0w_1319130e-ed2f-47e1-be69-6cc3023f145f">219.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNS0zLTEtMS0w_65cc93bf-3986-4733-a78c-a0ec46fc632c">232.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0xLTEtMS0xMjAxNw_83c049fa-b5e1-4b5e-89cc-d2cfd5122196">585.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0zLTEtMS0xMjAyNQ_9690b687-7aeb-4df8-a7e8-9b79fad4067a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0xLTEtMS0w_3a0f5be4-6d4e-4e43-9564-abcdce653f9d">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0zLTEtMS0w_f0e37791-376b-4555-abe7-1f51d0154298">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNy0xLTEtMS0w_a05ec578-c496-44ad-8da7-f3a72fbd9ce4">124.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNy0zLTEtMS0w_0f828d58-6470-4dc1-ac9f-2d43d7663f0b">115.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Gain on interest rate swap</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOC0xLTEtMS0w_66448f47-fb1d-4167-af82-2b017e5e88f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOC0zLTEtMS0w_c3c637ff-e644-4adf-92f5-132a99926e1d">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOS0xLTEtMS0w_b48d0be6-9db3-4e7c-a53a-cdd38b7679a7">33.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOS0zLTEtMS0w_6b45227a-9060-4e34-adc0-17ae3859d5d8">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTAtMS0xLTEtMA_a1f4665c-f86f-4d25-8713-c117d259b742">622.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTAtMy0xLTEtMA_7055f28f-96a4-4ab9-9c16-7be2252ccf90">180.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTEtMS0xLTEtMA_4c5069d5-c5ac-4a07-a3da-fbc5db93735d">283.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTEtMy0xLTEtMA_8706fd7e-cd38-422f-99b4-be70749149ed">39.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTItMS0xLTEtMA_8b387b0d-f152-4c20-80b4-65ef2abf4ca4">16.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTItMy0xLTEtMA_362f7df0-4865-4095-84ac-1822c42bfadd">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTMtMS0xLTEtMA_d171ef40-71df-4e05-bf11-fdc48cad5bde">112.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTMtMy0xLTEtMA_0dfc8d8e-e8b6-4823-b402-36ca48b1f8d8">83.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTUtMS0xLTEtMA_3ed4986b-563a-4bc4-a48a-3f2d9d4df37e">211.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTUtMy0xLTEtMA_657f3289-0f11-4842-b25e-7d5d0cf010c8">268.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTYtMS0xLTEtMA_2b458593-9b8f-4575-a339-6004ade32ad4">8.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTYtMy0xLTEtMA_9ac2bfb8-03de-481d-b522-b13794995167">149.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTctMS0xLTEtMA_49d305e8-9e4e-4396-838d-dee59dd1e822">193.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTctMy0xLTEtMA_564f01c1-f2f7-40b7-9efd-cfd16617fcce">188.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTgtMS0xLTEtMA_91cc8268-89ae-446a-8c09-b09b6647a813">188.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTgtMy0xLTEtMA_72dab038-5aeb-4538-957f-21ec42479028">441.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTktMS0xLTEtMA_b7b07b50-22d8-4cdc-966b-c94d272fc87a">171.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTktMy0xLTEtMA_836981ba-753d-4e1b-b3f3-8d6ca7d16bef">504.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjAtMS0xLTEtMA_365b445b-4f05-4e50-a6e2-56fa080efc1b">97.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjAtMy0xLTEtMA_cabb5bc8-4002-4e5b-a91f-ef35d05b966c">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow provided by operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjEtMS0xLTEtMA_f6adad02-b594-4944-a842-1b283ceb821b">1,996.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjEtMy0xLTEtMA_731eb423-545d-496a-b2ab-c6ea72a5ba87">3,415.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjMtMS0xLTEtMA_64722401-130c-42a5-8cfe-53e571391e31">1,452.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjMtMy0xLTEtMA_3db655e8-eeae-46a1-989e-08d89de395ad">3,879.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjQtMS0xLTEtMA_0405b816-d901-433e-880e-245eb6e6aba6">1,626.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjQtMy0xLTEtMA_44eacdb5-8048-4ef4-afe3-d24e6c4cd636">3,753.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchase of Sangamo Therapeutics, Inc. stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcac24a08e5e42818462bbc94b13c07f_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjUtMS0xLTEtMA_d81083f9-0c6a-4dd9-8057-7f1103eac746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief6833d5d8e1488588e71a36bbe9c769_D20200101-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjUtMy0xLTEtMA_332bce7a-c5d1-4d02-87d9-cff99c963b8b">141.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjctMS0xLTEtMA_de9c51a9-6fc8-46a0-8aa7-e6579536f9e2">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjctMy0xLTEtMA_068b200c-3ddb-4f28-9ab7-932fec8b9718">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjgtMS0xLTEtMA_ed937573-69c5-4230-928f-cbaa03805b56">164.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjgtMy0xLTEtMA_57a02346-f19c-42c0-8489-48a86b5c9396">254.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjktMS0xLTEtMA_aa2a8e36-0eb9-42d2-bd14-44869ade4bf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjktMy0xLTEtMA_60d619b1-46e5-4fe5-a5f6-1d404e8a2ec4">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzAtMS0xLTEtMA_b86dd859-6e5b-47c6-a516-2e853d2a01bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzAtMy0xLTEtMA_f6696b9c-21fb-4a58-91c3-cbb06f596f51">37.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzMtMS0xLTEtMA_d6cc8f15-9d22-4cfb-b4c1-1fd54f506f05">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzMtMy0xLTEtMA_8ff2d11f-dca1-4588-b2d0-be0d1689d9de">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzQtMS0xLTEtMA_ce5b3ed6-4764-47c4-a12e-4dbbfe5746a9">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzQtMy0xLTEtMA_49f42dd5-a7a4-4672-b468-b0a498cb549b">7.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow used in investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzUtMS0xLTEtMA_14534638-e04a-4e34-9ae2-864b6ec107fb">217.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzUtMy0xLTEtMA_640cfeec-60e8-4df2-9394-43b01c4fd79c">389.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzctMS0xLTEtMA_15403116-7061-4c62-93f1-4e02668f3c86">1,050.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzctMy0xLTEtMA_ee3a7a83-19a4-45cb-bc83-892d45e6de9d">5,029.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzgtMS0xLTEtMA_4965cebb-4495-47cd-9be0-17eae045f85e">14.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzgtMy0xLTEtMA_20096a9f-c3d0-466b-82bb-f2e14a39e240">19.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid on debt exchange</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzktMS0xLTEtMA_46e9931d-c5ca-4a2d-afef-5e605665dac9">170.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzktMy0xLTEtMA_d3d5a86e-5997-4874-82db-37178c41fe95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Proceeds from borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDAtMS0xLTEtMA_e5189de3-a86c-43cb-ab7f-9a753d664db9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDAtMy0xLTEtMA_29e8897d-c2e6-45ff-a9f9-f6b646ab5092">2,967.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Repayment of borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDEtMS0xLTEtMA_fcecf31e-73bb-4664-ad1d-50abc8ddbefd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDEtMy0xLTEtMA_61299b32-a8f7-4c50-9f5e-996c3f5ef155">1,500.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash proceeds from settlement of swap</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDItMS0xLTEtMA_68b3534f-4017-4c0c-b0b1-416123b0edd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDItMy0xLTEtMA_87ec7c11-b107-4bde-a96e-5ce2e3650e03">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDMtMS0xLTEtMA_83741579-4f69-450a-bf5d-3ecae3c795d5">94.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDMtMy0xLTEtMA_5b58835e-46cd-4cc6-a84e-bc0b5e26f01e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDQtMS0xLTEtMA_6cf618c6-a3b2-400e-bb04-09c700087924">20.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDQtMy0xLTEtMA_b592d58f-5ab9-4b12-88e3-dbfc7e2687ee">19.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net cash flow used in financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDUtMS0xLTEtMA_d1adb37f-1868-4184-a55e-99af29be425c">1,349.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDUtMy0xLTEtMA_c8a09484-fceb-4bda-bc72-cee67a8eb87f">3,558.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDYtMS0xLTEtMA_4a7bc2c3-ce5f-4f23-b6fa-7faa3ee3c033">429.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDYtMy0xLTEtMA_e8719a0c-bacb-48be-a9a6-0c011687140b">532.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDctMS0xLTEtMA_f129e717-7cc0-4a75-afc4-0a7d22a609c8">18.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDctMy0xLTEtMA_044079c5-9816-48ff-bff2-eef9e767c992">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDgtMS0xLTEtMA_5c100f6a-83b7-4f9e-b667-a49101c1cf3b">1,331.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025174d34d0e4fed9880bf522bf39caf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDgtMy0xLTEtMA_d575ed43-564f-4656-a65e-101ef1418ff0">2,913.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDktMS0xLTEtMA_df0f3266-d0bb-48fb-b89b-f37fa0111a0b">1,742.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDktMy0xLTEtMA_f0b063f1-c585-4cae-b818-cbd56dac47fb">2,384.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc82ffb87eb341eb9922b2fe03938ef1_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xLTEtMS0w_0427b195-521f-41ed-b8c2-96da95d605ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc82ffb87eb341eb9922b2fe03938ef1_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0zLTEtMS0w_fb25fa1d-dd69-4d0f-9941-69a08612679c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i881e688a79754d32bd4eaef661200a43_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi01LTEtMS0w_c8e2ab17-960a-459c-a423-3e0cf9725be2">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881e688a79754d32bd4eaef661200a43_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi03LTEtMS0w_f435b5cf-d0a3-49cc-8173-2d42262c756a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c3490a5f63c46eca7c3d7b457bc76b1_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi05LTEtMS0w_e9a39824-fb6a-4d90-bbd6-7c97479f27ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b15e57dd5eb4ecda365d4f991fa27a8_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xMS0xLTEtMA_cae4a16b-59e4-4c2f-81e3-8db3f06eca89">174.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8812efb9d84361a4d49aff1088e74b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xMy0xLTEtMA_38a84680-9caf-441b-894f-71408c7a245a">13,833.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a59ef186277439e93b9cb5d517c2f8e_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xNS0xLTEtMA_852631fa-cd46-4777-b6f7-c4dded838823">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a59ef186277439e93b9cb5d517c2f8e_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xNy0xLTEtMA_a255f77e-b3ec-4e78-9c77-6b161eaa1ecc">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890d1bfbc3404c338c8adf2e20d53e18_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xOS0xLTEtMA_9148f492-ecec-42c5-9ff3-10791508aa26">10,682.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c7280649ce4b709f5ceef9dca96ca8_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0yMS0xLTEtMA_a29ac7f3-72be-4bea-931f-bb0bfbd68e5e">19.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4231dfa8299436094f9cbd4382d29bb_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0yMy0xLTEtMA_3db9cef2-5be3-489f-82df-013ceb656171">10,663.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0xMy0xLTEtMA_d746eb2e-3fbe-463b-93c9-0185165648ab">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0xOS0xLTEtMA_c13ec420-2ff7-443c-aa79-36d091d29c8d">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0yMS0xLTEtMA_0fafad19-bc39-4c14-9428-1ed4e68153e1">577.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0yMy0xLTEtMA_0c61e225-f358-4ce4-8818-3ee89014cb92">1,025.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8169d797254002b81948999f73a837_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0xMS0xLTEtMA_34fe993a-cd04-48e6-9f4c-46184b69b9dc">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0xOS0xLTEtMA_257540d1-7caa-4c3d-9501-6bc4dfcd61fe">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0yMS0xLTEtMA_5b90a32d-0f22-4026-a523-51e9dd84e678">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0yMy0xLTEtMA_7be1ef21-9596-4284-ac12-39d631a27b0d">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNS0xOS0xLTEtMA_8e89ca84-6ea0-4afb-a07e-39a75ffd5354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNS0yMS0xLTEtMA_713a0ae3-6914-40ca-8ce5-6a0181da914c">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNS0yMy0xLTEtMA_a30c5c6d-91cb-4b34-bf96-58b1344372b1">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0yMS0xLTEtMTEyNA_975ddf7c-13fe-462a-8d9b-e34e4d263092">100.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0yMy0xLTEtMTEyNA_d288d293-5cbe-4b9b-8c53-91a037caa9b8">100.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi01LTEtMS0w_141b080c-91d0-4f20-bdad-f18266ec38cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0xNS0xLTEtMA_8fdfe3bb-1764-4f72-994a-84c8e4191fc9">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0xNy0xLTEtMA_65af8bdb-f255-4132-8d9f-019ca72e9ed8">450.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dfbafcd38f34defb5d883855aba00e1_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0xOS0xLTEtMA_c863881f-ab91-44fb-ab11-4b2feea2915a">450.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0yMy0xLTEtMA_af41a241-d55d-4784-85eb-a51044c6a3be">450.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1cd3814086244d508377429d979db225_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy01LTEtMS0w_186189b2-88ae-444f-a010-712a9e5eb9d0">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd3814086244d508377429d979db225_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy03LTEtMS0w_e01c6e4b-f1db-474d-9e65-fae79101f96e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74292aa380dd4293a8ab78259fb0e8fd_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy05LTEtMS0w_a592ddd0-1bd3-4098-aa83-34dc71166746">69.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62788c451f3146bbb9013bf26f1e565a_D20210401-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xMy0xLTEtMA_657a687a-92f7-4c2e-9023-ee2121ca6ae8">380.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xNS0xLTEtMA_c264c2f7-c04f-49ec-87e7-7671321f9af2">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xNy0xLTEtMA_a580c54a-12c4-4027-b43f-2609f6e922ed">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dfbafcd38f34defb5d883855aba00e1_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xOS0xLTEtMA_fbd72695-fc0e-4033-bbdb-69f2f09b1b46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0yMy0xLTEtMA_09f69e04-016b-437f-8e7b-d98d3e5dd269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC01LTEtMS0w_cdc7dcc3-873c-4742-b821-90b75c61c00d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC03LTEtMS0w_39c50454-81f3-4b55-8a3e-fee8b98f8f97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC05LTEtMS0w_62571719-ece4-4452-9750-5098063322fe">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC0xOS0xLTEtMA_3e3708e7-801e-4b86-ac04-264172e82edd">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC0yMy0xLTEtMA_cb17d0ac-d189-4948-93f7-56f5c7cb8e53">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS01LTEtMS0w_3e5aa27e-ad94-4be2-8f22-4169d2faf8b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS03LTEtMS0w_71b8da7b-9a54-4572-b881-9759c5548b6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS05LTEtMS0w_92eb3e76-f4b7-411b-b846-0940b4e5faea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS0xMy0xLTEtMA_c424044e-a4cf-4dc6-abee-fbb28f043172">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS0xOS0xLTEtMA_199730bc-e006-4d4f-950f-ac7fb8e10276">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS0yMy0xLTEtMA_7ebda0b0-dafd-4041-90a4-700abecb0134">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTAtOS0xLTEtMA_bafb4a4e-1ff0-4a99-a4db-ef1564255cc9">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTAtMTktMS0xLTA_f6461e21-c128-4df5-a5e6-c757d05867c3">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTAtMjMtMS0xLTA_1524286f-f58a-4e97-a52d-84745c61de3c">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtOS0xLTEtMA_6337bb70-373a-42f8-8cc6-1bf8aac316f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtMTMtMS0xLTA_e80aeb9e-63ae-4fc9-8030-51b7961aa514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtMTktMS0xLTA_05851c9f-a9db-4193-8f41-04f1c1209b91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtMjMtMS0xLTA_da485bef-d0d5-4c41-a4d4-4119f339a65f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMS0xLTEtMA_907b0041-4009-4ced-b339-38bc27ea0280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMy0xLTEtMA_55fae5ae-73c4-4990-8b80-b9a19065e109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItNS0xLTEtMA_d8035cb3-8af9-43c0-868a-2f136e989429">172.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItNy0xLTEtMA_ca076932-3a3f-4149-ab04-7ca2f52b530c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94926bf743db49f1aa339479ffa0244e_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItOS0xLTEtMA_76f50d41-773a-4acd-ad14-c0ba220d1cc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ee3f5cdf6da46f3bbd994edd429f1d6_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTEtMS0xLTA_cbceed07-2998-4ee0-ac58-38c8d7b95992">171.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3240d0cbbf2494d9586ee74965f1b85_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTMtMS0xLTA_18e84a42-891e-4e2b-8dc7-5d47ce9929c3">13,900.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTUtMS0xLTA_d2fddc27-9a45-4b7f-8fba-9797f894913f">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTctMS0xLTA_6a51891a-08be-431b-9cb3-393f8e5314d6">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6c47b7744b4c20842a09b8f4244db0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTktMS0xLTA_65e9704f-5682-406e-928e-c9934d1202ad">10,751.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514061955b07437c95410fb7d8491901_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMjEtMS0xLTA_9040b3ad-6f2f-42a5-bee5-2a4cbfbb91c5">462.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMjMtMS0xLTA_8a4a8620-312f-4ae6-a2b3-412bb42e8168">11,214.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8001088915642409667fe820a47d9b2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xLTEtMS02MDg_828becd4-6430-4d63-b4e9-305cad536380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8001088915642409667fe820a47d9b2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0zLTEtMS02NTQ_9e51bfd7-76cc-4ba6-a1ce-3acde7c481e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib94de1f81562452191bd4f557a5d4d18_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi01LTEtMS02MDQ_f6851356-6a20-4667-8d32-130f079fde14">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94de1f81562452191bd4f557a5d4d18_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi03LTEtMS02NTQ_f2db5244-9f6e-435b-a44b-4b4644ae4f48">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5721ea124d3a4b198cd7d7caa427c5ef_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi05LTEtMS02NTQ_0c78e4a4-c871-46a9-8701-4dc94ae90f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b80cd19565047b394b037487d83b697_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xMS0xLTEtNjU0_84a3bd99-68ac-4d7d-a2ef-e424bdd1cd4a">299.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e2df370b96408ba273c05e55e0cef7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xMy0xLTEtNjU0_9c3a2ed7-2cb8-4314-a939-bfc42d934793">13,976.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0829016ca6b341a59a77978d812303fb_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xNS0xLTEtNjU0_72e7107a-fb09-4591-bccf-4ff96b82ad84">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0829016ca6b341a59a77978d812303fb_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xNy0xLTEtNjU0_7ec7d171-2851-4784-b256-5b6e3244b24e">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba68db7328d4088b2362283392e5a4a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xOS0xLTEtNjU0_c5b061c0-4582-4870-a61f-451a5b7262d5">10,700.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i433038a0a2e04b4a9718b3a120978075_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0yMS0xLTEtNjU0_6eb6dc17-80d6-49f0-8529-36ccf10a20b9">14.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0yMy0xLTEtNjU0_ecec2867-bb38-4c08-b6c0-a03e21884328">10,686.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0xMy0xLTEtNjU0_abc60d36-3737-4826-a148-475df80e58d4">858.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0xOS0xLTEtNjU0_9c3f85ca-45d3-4728-9a7c-834efd7018a1">858.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0yMS0xLTEtNjU0_3326f9f0-4406-42ea-89fe-45e58b8441dd">571.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0yMy0xLTEtNjU0_a9bc9a9e-d5b7-4414-b03f-5b89cc201fd8">1,430.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d83325fe697454bacf1a67ada1d4e30_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0xMS0xLTEtNjU0_ffc874cf-ea3d-4640-ab24-4ab065ea9892">127.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0xOS0xLTEtNjU0_e0e00d29-ff1e-4450-a35e-8115a4a5f1cc">127.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0yMS0xLTEtNjU0_8abd2c07-a94b-4289-9c79-9548cc75eebc">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0yMy0xLTEtNjU0_1cafe643-5031-42e6-b935-5e2a0f58ad27">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNS0yMS0xLTEtNjU0_7ee7c371-f971-415f-87f4-0e401e61b87c">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNS0yMy0xLTEtNjU0_26fa441b-a914-4c06-b66b-49801b1abf48">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNi0yMS0xLTEtNjU0_b752bf1f-83e2-4333-b2ae-0c90c53e9b7a">100.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNi0yMy0xLTEtNjU0_b821b936-d280-4beb-8bc7-41ca73df7418">100.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0xNS0xLTEtNjU0_07e87a9a-3fdd-4269-8685-e7c5ef3374e1">3.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0xNy0xLTEtNjU0_fc18578c-dbfa-44bb-aa9c-dacc50c54d96">1,050.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i829fb96209e04376a983019df1ad41d5_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0xOS0xLTEtNjU0_2916bb94-1c93-4765-9f6d-6e6585b787aa">1,050.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d3cbd78d4e4e8a828d2ff80ce13faa_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0yMy0xLTEtNjU0_7f118563-35d3-417e-9e13-d1078669ab4f">1,050.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icc688f4fb4ba4c3e9b5aba00112dcd1b_D20210101-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC01LTEtMS02NTQ_38a42788-f636-4ed2-ac8e-745388cb1acc">3.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50339615ca3c47dc93e748d4d2d021e0_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC05LTEtMS02NTQ_62f0e6ce-02b0-4bd5-93d3-1af7f0b0d2f4">163.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if55c7e84188d4fc58a512a4f573231f5_D20210101-20210630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0xMy0xLTEtNjU0_7be51b14-e8a4-4925-b045-919e3752042f">886.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0xNS0xLTEtNjU0_08ce3f4e-de02-423d-a7c7-b0854d965336">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0xNy0xLTEtNjU0_53e790a1-5541-4758-bd3a-d6af45b92ac1">1,050.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d3cbd78d4e4e8a828d2ff80ce13faa_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0yMy0xLTEtNjU0_83323a9b-8158-4dcd-aec4-38d453847b28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS01LTEtMS02NTQ_bcb4d07a-f581-4b07-953d-b3e3d4d212e9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS03LTEtMS02NTQ_86b8ed38-cb04-4836-8d81-31a590b914f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS05LTEtMS02NTQ_5c25a626-7e2d-4fd7-8086-9799b4e3e75e">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS0xOS0xLTEtNjU0_5851fa15-110d-4d95-88de-43145f40051a">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS0yMy0xLTEtNjU0_f5b6a592-205e-4b0b-92e9-50d591341ab4">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtNS0xLTEtNjU0_64015daf-599e-4956-81c3-c99a57192dc6">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtNy0xLTEtNjU0_d0361e5f-2efa-4c78-bb80-4d12d1032c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtOS0xLTEtNjU0_c5f06f80-0f93-44a9-9d4f-523927c38b1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtMTMtMS0xLTY1NA_4bb33bd2-20d4-4388-85a6-875337230ec1">47.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtMTktMS0xLTY1NA_013f1c64-3554-486f-a5af-ff5d5281a04c">47.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtMjMtMS0xLTY1NA_4a518741-ea9c-41fd-986a-3340a98ff9e1">47.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTEtOS0xLTEtNjU0_96131207-8d5e-4bed-82b2-0a23f9f78b41">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTEtMTktMS0xLTY1NA_e75dade7-dcfb-4f24-b41b-6b1761c75adf">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTEtMjMtMS0xLTY1NA_11a540ae-e530-4f37-a978-ebd6433c016b">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItOS0xLTEtNjU0_ddc4816e-6eed-4df2-9ae2-ac1d4b994572">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMTMtMS0xLTY1NA_8031ef62-297e-46e9-8151-de1480c10948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMTktMS0xLTY1NA_999951ef-6c68-4eba-bfa0-b45d96fdd6a9">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMjMtMS0xLTY1NA_a4ee935b-c1cc-4994-ab3a-7c4e92fe3aa4">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMS0xLTEtNjA4_439387f6-f1ee-4f9f-b1f4-b9558348aaf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMy0xLTEtNjU4_5644a621-c75a-4fcb-85ab-733040b8810b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtNS0xLTEtMTI5ODg_9d300bc9-0f1f-42c2-bcd6-734e7956b99c">172.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtNy0xLTEtMTI5ODg_20ca0039-8e15-4e18-88b9-db5786490e99">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94926bf743db49f1aa339479ffa0244e_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtOS0xLTEtMTI5ODg_e62b3059-b49a-43a4-85f4-a4dddd8a2131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ee3f5cdf6da46f3bbd994edd429f1d6_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTEtMS0xLTEyOTg4_08941624-03a5-4562-b450-94885c79afe1">171.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3240d0cbbf2494d9586ee74965f1b85_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTMtMS0xLTEyOTg4_45115c0e-7b27-4657-bd33-f475362f936c">13,900.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTUtMS0xLTEyOTg4_c69bd047-ab37-4087-ae97-0f730f5898d4">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTctMS0xLTEyOTg4_85a2e827-2fc3-46ad-9298-90fec94f5b7c">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6c47b7744b4c20842a09b8f4244db0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTktMS0xLTEyOTg4_c0898852-1759-4792-bc3e-7582bb398406">10,751.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514061955b07437c95410fb7d8491901_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMjEtMS0xLTEyOTg4_30434753-74b3-434b-8018-14a8aa747859">462.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMjMtMS0xLTEyOTg4_4b581e7b-fe31-4262-8786-4bcedc1838be">11,214.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78b2ecb22ef74586961d6a6a7339b061_I20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xLTEtMS0w_6a08589a-e06c-4103-99d5-bb780d3272bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b2ecb22ef74586961d6a6a7339b061_I20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0zLTEtMS0w_e81d9657-bb27-4c0f-846f-1233d7ed0c74">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee86344392cc4815b2010b4698cb5995_I20200331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi01LTEtMS0w_dbfc2920-c4fa-4ea8-bbd6-7298a05c8ac6">191.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee86344392cc4815b2010b4698cb5995_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi03LTEtMS0w_5d216f0b-e4c9-4d2b-a793-7edb4920aef7">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732c024e790641aaabfd3fb6981c4767_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi05LTEtMS0w_940a93ba-53cd-4435-a533-b9517ea76a1d">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f73c932ef614e2b809c4c6773f7b46f_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xMS0xLTEtMA_3bc65571-70bc-4823-a3e0-2cbf0ff0c7d2">149.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a136827ea89494eb44b4f53d790b6f4_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xMy0xLTEtMA_00a4f1f8-4eca-4816-815f-6f88b92b345b">15,673.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0888859ea81d4a4b9b7e7be25c61e121_I20200331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xNS0xLTEtMA_27cb767b-a20b-4be3-87d7-0e576bd71ca8">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0888859ea81d4a4b9b7e7be25c61e121_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xNy0xLTEtMA_970b7c39-c632-4fe0-99a1-e9a17dc18337">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3300c292f1f6481daedcd2a3fd9d0d4c_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xOS0xLTEtMA_1796d3d5-30ee-4a87-ab19-12fd2f73ba3a">12,546.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i072ed2cc59e146fabce4bf0c8984c641_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0yMS0xLTEtMA_d06d8439-1cf5-43d2-8431-da1a3b912acd">10.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b1a00011ea462489b26d05daea35c5_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0yMy0xLTEtMA_4486422f-e660-4373-9af9-a9dc6bca76e7">12,536.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0xMy0xLTEtMA_0aa132db-858c-4b87-a0fd-1fe77b01b64d">1,542.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0xOS0xLTEtMA_d77c4ade-80a4-4712-853c-e3ec3f2b08b6">1,542.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8633c1b979664edba4ec90abfc549bf1_D20200401-20200630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0yMS0xLTEtMA_83f49a7d-ba36-4443-ae9c-1c085b72b661">64.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0yMy0xLTEtMA_8d50240a-1e4d-4372-a25b-439abb5fd8bf">1,606.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f72654aca994523940646887601ba08_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0xMS0xLTEtMA_53b99094-c1eb-4d3f-a0b3-523c9285c9dd">31.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0xOS0xLTEtMA_3fc913ab-2573-4cab-8062-b54beebf7480">31.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8633c1b979664edba4ec90abfc549bf1_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0yMS0xLTEtMA_8df09587-e429-4309-866c-33d2d5299aa4">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0yMy0xLTEtMA_916420e2-b796-45fd-9411-d536b764e60b">30.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNi0yMS0xLTEtMTEzOQ_4b220544-2de7-40e6-8969-6431675e70e9">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNi0yMy0xLTEtMTEzOQ_d041e5a8-149e-4dad-9f21-de94c6f4d0ae">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0xNS0xLTEtMA_2b062139-e06f-4d9d-812b-258de0fbb503">9.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0xNy0xLTEtMA_ad10aa8f-b00c-4ef0-beed-1c66f340a92d">2,808.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08d7b9a6dc614f7dbb3208265a4d8bb3_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0xOS0xLTEtMA_9daa51f9-3cef-4d90-95da-2b8588d3f7e2">2,808.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib552a12f17ae45c9bd51081076579744_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0yMy0xLTEtMA_8fa73612-d3a4-4ad4-b5ff-44ca37a663c8">2,808.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icb4529d1da0b4585a765bc987c30b140_D20200401-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS01LTEtMS0w_1b002dd2-700a-402f-9824-81667620f9d6">9.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4529d1da0b4585a765bc987c30b140_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS03LTEtMS0w_07412792-783e-44e6-8162-1f5d7e2e8775">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b4edbd823d74be5afee6c24f030f8c4_D20200401-20200630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS05LTEtMS0w_05ca400d-236b-4ae5-9594-a825a16f3cb3">60.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia746808beaea4283b2a877a9fbf80dae_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xMy0xLTEtMA_0d7bf7dd-0439-408a-89fb-f3daf17b97e3">2,748.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xNS0xLTEtMA_96a12913-a8ee-4ec4-9f77-156f9d69b05d">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xNy0xLTEtMA_87bf45ab-a9b9-4fab-af0e-ba777862a004">2,808.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d7b9a6dc614f7dbb3208265a4d8bb3_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xOS0xLTEtMA_1277226b-ec65-4db6-aa14-6b7c9deafe13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib552a12f17ae45c9bd51081076579744_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0yMy0xLTEtMA_6b7c6c38-42ec-4ba7-bb16-696edb986b5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtNS0xLTEtMA_62f1411c-4b85-43e7-acc0-2347e1c04d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtNy0xLTEtMA_73a9a088-0ba7-48c2-aca7-34748491d353">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtOS0xLTEtMA_1e0c3697-4e14-49cd-8791-bbb8b491c51a">11.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtMTktMS0xLTA_32dd4335-7898-4cb9-ba88-3d3411e6ad0f">11.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtMjMtMS0xLTA_73b48699-98ce-4c8a-961f-d146be4a15b2">11.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtNS0xLTEtMA_910e59f7-5b42-4cac-90d3-1d0770d09d32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtNy0xLTEtMA_c8d083a1-4927-4927-9514-66cf35db209e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtOS0xLTEtMA_28dd93ca-3bd0-4f48-8128-9174a6a24b16">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtMTMtMS0xLTA_2d5edfd3-92f8-4d3c-84b6-6b22405232a0">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtMTktMS0xLTA_74341c84-5f9f-4cec-9113-19f85f5ffba2">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtMjMtMS0xLTA_35cca2b0-54a6-4984-be58-40c0f3c7aa5c">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItOS0xLTEtMA_acade68e-a79f-49e2-a01c-55032850ad18">49.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItMTMtMS0xLTA_02c59bfb-b663-4df8-80e6-31e17e40f689">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItMTktMS0xLTA_f1e91b4f-d695-41a4-bf65-647d1f45176a">49.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItMjMtMS0xLTA_b6085845-2cf1-4d4e-ac78-53a42be46bc7">49.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMS0xLTEtMA_53428a09-5d78-4ef0-89dc-e519a7915fc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMy0xLTEtMA_976a56af-a015-4c5f-af68-32c0e26d9076">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtNS0xLTEtMA_d6e8df4b-e4e2-4841-ae97-faa23297418f">182.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtNy0xLTEtMA_8855f89e-c439-4ba0-a8b8-5f98c1f6a09b">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d526c2292440b7a5a31fc1b5888e03_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtOS0xLTEtMA_4d8a9c60-d749-4bf9-8a3a-95f4251b2f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570dc5bd6835411ea0f2c6404bf2707d_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTEtMS0xLTA_9461628f-529d-4f7c-8fe5-754475d6e39c">181.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c053e7c564a44a0bafea18992724f4f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTMtMS0xLTA_0791c539-ddeb-4e0b-9c48-8952d3da8bf2">14,466.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTUtMS0xLTA_0241c67a-45a0-493a-969a-daba487bed3f">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTctMS0xLTA_887dc502-ac37-48c4-b032-6f75d6de70dd">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0a20b044aa4874a09f45a93c3dec1f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTktMS0xLTA_a0b60fe9-b8ee-4fc8-8b76-8569bec05d5b">11,308.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fba909ac97644db8c749b15a7d893ad_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMjEtMS0xLTA_51c489de-c3a1-4f8e-ace8-e7b49993a21c">19.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMjMtMS0xLTA_01cd8407-1e50-41a0-8efa-bb79fb3c7dd4">11,289.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibeccde350a794ad3a057220538aae69a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xLTEtMS0xMTUz_f51548dd-cce9-4784-98d2-c6fcda986f3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeccde350a794ad3a057220538aae69a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0zLTEtMS0xMTUz_05c2e115-f54f-4aa3-bb16-13d716f4966f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6c2c7cddf4e4e6fa048863f067c096f_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi01LTEtMS0xMTUz_d98a2360-919f-4837-a21a-2aeb1b685f77">198.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c2c7cddf4e4e6fa048863f067c096f_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi03LTEtMS0xMTUz_73f48a42-9233-4e0d-a7f8-b9f213c2e834">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc71f78bf134170821013d4e0e24571_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi05LTEtMS0xMTUz_dbb9aa1f-5734-4985-afa7-c4dc25dde851">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc925cb31f04e6eb50fc1c74378baa1_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xMS0xLTEtMTE1Mw_158cacd1-3b00-445f-82cf-c9802c0a5835">135.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ee4e438b174ae69ecb16ee0621c73b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xMy0xLTEtMTE1Mw_2f9448b5-38a5-4b66-8d92-8a211d14ec42">16,455.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i75cc8f1ab2514617bcec62bafc7b0a4b_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xNS0xLTEtMTE1Mw_f23408a8-4236-474a-8c15-716b09c399d0">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75cc8f1ab2514617bcec62bafc7b0a4b_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xNy0xLTEtMTE1Mw_904d84c1-e1ac-4bea-b026-b8c139b520c9">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedb54914b4a4be1bb1f89fa85924372_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xOS0xLTEtMTE1Mw_0e9c1707-dfc4-47f9-a4f8-0d6e9ba5ac30">13,343.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ideb7cbe5c0ee40cf910d38587c7169eb_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0yMS0xLTEtMTE1Mw_7952b06a-a1f6-4e44-aac0-87ccc0c2e868">4.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025174d34d0e4fed9880bf522bf39caf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0yMy0xLTEtMTE1Mw_bdf759d0-5be9-4d3c-a1a4-705d59995845">13,339.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0xMy0xLTEtMTE1Mw_8869c191-c9e5-4114-99de-b877f71f38d3">2,941.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0xOS0xLTEtMTE1Mw_221de883-e671-4b78-ad9c-7c93a6396a33">2,941.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0yMS0xLTEtMTE1Mw_d0874572-8e1e-4480-a06c-7f911cdc75c9">57.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0yMy0xLTEtMTE1Mw_f2f93a28-9cea-4ff4-99be-e69281b78388">2,999.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03fe4f4d72bc4079969e2e9ed876d281_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0xMS0xLTEtMTE1Mw_7f09bf34-2cef-491a-94ab-43ebf30cb000">45.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0xOS0xLTEtMTE1Mw_47f49b02-e84e-4301-bbb3-1a62fdc2ba29">45.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0yMS0xLTEtMTE1Mw_ad5db68e-938d-4dc7-bf22-2ea1e1d1f7f1">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0yMy0xLTEtMTE1Mw_b892af7e-50da-4e8f-b444-3c71972885c5">44.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNi0yMS0xLTEtMTE1Mw_9469a4f6-7ad7-4765-ab63-6a1a981fa778">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="biib:NoncontrollingInterestIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNi0yMy0xLTEtMTE1Mw_6fefa83e-b754-4016-9b47-92276b91124f">75.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0xNS0xLTEtMTE1Mw_bb055e56-ffbc-4446-9dc1-8c4abf71262f">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0xNy0xLTEtMTE1Mw_4caaccae-9170-4c78-8ee6-9c954cc2dec5">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i948a3706ba984935b4f52d3af4515a54_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0xOS0xLTEtMTE1Mw_fea9da9d-42fe-4e3a-9a0e-9e7c0325851c">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aa7cd1f56a4406b8baf99c16459364c_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0yMy0xLTEtMTE1Mw_427a18b4-ce62-4af0-bfcf-5c02c1dd043c">1,279.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i912a36fc12da4b8493cc611846c2ffb2_D20200101-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC01LTEtMS0xMTUz_91bc407c-942f-49ec-be3b-1474424629ed">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bce9f6487694050a70f9480c769461e_D20200101-20200630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC05LTEtMS0xMTUz_69293f4a-f2bf-41b3-b601-cfebe25e516f">71.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id653e67025f441eca2b7a99e95e1a140_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC0xMy0xLTEtMTE1Mw_9daecfc0-31e4-4295-afe7-30ce0924aa1c">1,208.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC0xNS0xLTEtMTE1Mw_f7aa7b74-5f9b-4126-a117-01bef742edda">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC0xNy0xLTEtMTE1Mw_21990b8c-08c2-4c29-9f6a-398ec40d7a6b">1,279.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0xNS0xLTEtMTE1Mw_b8bb8cde-0679-4995-a18e-14911eac755d">12.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0xNy0xLTEtMTE1Mw_a5e6437e-1917-46f8-b40e-831269fe562b">3,750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide90025ae7d14057a14eaf2dffb72595_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0xOS0xLTEtMTE1Mw_d62adb20-1b3f-4882-9b61-54204676bffd">3,750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8d4db9869c24b76826c44a5bad5b4d9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0yMy0xLTEtMTE1Mw_154be291-4e1e-4f0f-aefd-aba6ac0d4fea">3,750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff71a4c7590448a39c9de6e0fc71bedb_D20200101-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtNS0xLTEtMTE1Mw_29c92412-193c-4844-85d9-44fc672f6f36">12.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff71a4c7590448a39c9de6e0fc71bedb_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtNy0xLTEtMTE1Mw_0b3a6b2d-426f-4919-a017-64723d030b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44c71f71a23d4cc3a2b3597fe3bfca81_D20200101-20200630" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtOS0xLTEtMTE1Mw_8887d08a-64a4-4605-8ec5-4a52fa39a5d2">76.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5972e118118f4152ad8f8978769af8e0_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTMtMS0xLTExNTM_b7aa7627-e4ee-4488-944f-ee9a926f1933">3,673.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTUtMS0xLTExNTM_ba094629-2bfe-471e-8768-f9320ab4c7dd">12.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTctMS0xLTExNTM_e60c2f69-2407-42a8-9947-ba5c2dd76f7b">3,750.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide90025ae7d14057a14eaf2dffb72595_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTktMS0xLTExNTM_438c5f9a-778c-4d20-ae7c-7b1d61ab0372">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d4db9869c24b76826c44a5bad5b4d9_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMjMtMS0xLTExNTM_c9d5d7da-d153-46a8-a4e7-51e0aa81f4ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtNS0xLTEtMTE1Mw_dfe0b17e-9764-49c8-8f3b-e0095030dc58">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtNy0xLTEtMTE1Mw_8e36ea44-10ff-4d9a-9c0c-9832b622eb29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtOS0xLTEtMTE1Mw_c7ef9655-2f14-4a74-bad0-11c7a2489d56">29.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtMTktMS0xLTExNTM_b084d240-d576-4832-a379-8d40cf36cdc8">29.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtMjMtMS0xLTExNTM_2939ed26-6d98-406b-be4e-527d57c43084">29.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItNS0xLTEtMTE1Mw_a1b1364d-4732-4926-b4c9-b93f5fee8414">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItNy0xLTEtMTE1Mw_a7623301-ace6-47c2-be44-6074be6209ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItOS0xLTEtMTE1Mw_3d5f853d-630d-4633-a0b8-8bfccb9b4dbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItMTMtMS0xLTExNTM_07b512db-8d2b-46d1-b4c4-1141fc8dff6a">48.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItMTktMS0xLTExNTM_baf80d43-6683-48d8-b22c-bba31625ad08">48.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItMjMtMS0xLTExNTM_9daf68aa-9e46-4f76-ba88-474a706fbb26">48.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtOS0xLTEtMTE1Mw_70772dcb-880c-438c-8e95-030510e976e6">118.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtMTMtMS0xLTExNTM_61e0b8d9-bf96-4095-b968-05a83529f31f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtMTktMS0xLTExNTM_18a64295-1eb4-4375-8166-dcc7bb2a0704">118.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtMjMtMS0xLTExNTM_f81ef52a-b964-41c0-8a40-d53f702f3fb0">118.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTQtOS0xLTEtMTE1Mw_a29e3f8f-e799-41f4-8244-d940edbd4db2">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTQtMTktMS0xLTExNTM_877486cc-f85e-4ef1-b94c-277b10816105">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTQtMjMtMS0xLTExNTM_b2633add-16bf-4e83-8a1d-c6a9e896dfea">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMS0xLTEtMTI5OTY_ae4e2f60-f6f8-4970-944c-6d93ea8c8ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMy0xLTEtMTI5OTY_8469ef2d-e5c8-4745-b635-3b25b07be6cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtNS0xLTEtMTI5OTY_eb70a97c-164f-4895-be6e-5efa3de5679f">182.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtNy0xLTEtMTI5OTY_6b101eae-4292-4417-bf80-eecfd9e74a94">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d526c2292440b7a5a31fc1b5888e03_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtOS0xLTEtMTI5OTY_759113af-2f26-456d-9ed1-c4757a159a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i570dc5bd6835411ea0f2c6404bf2707d_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTEtMS0xLTEyOTk2_00990e37-7ffe-4c4d-a3cd-6f4b9def84cc">181.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c053e7c564a44a0bafea18992724f4f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTMtMS0xLTEyOTk2_8fdd8c40-c71e-48f1-b199-6b0c56babce3">14,466.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTUtMS0xLTEyOTk2_65f37f63-e4e4-4432-b749-c895d542683a">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTctMS0xLTEyOTk2_6e19718c-1d4b-4fb7-9b65-b54471712e9a">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0a20b044aa4874a09f45a93c3dec1f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTktMS0xLTEyOTk2_ce011ed5-87e3-4a71-8d47-11e0fdfd65ab">11,308.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fba909ac97644db8c749b15a7d893ad_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMjEtMS0xLTEyOTk2_1bed5132-8622-48a8-be6e-ec92db3374e1">19.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMjMtMS0xLTEyOTk2_ba7a7484-59fe-451a-bde0-67ae01f48685">11,289.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i904ca67b48e9438aa45cc860a3e98146_40"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQxNA_e77d2a6d-e520-4929-9210-7ad6edf61c20" continuedAt="ia949d043b549485c893cefd4b5660891" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQyMQ_ef0d294e-384e-46cc-a899-085c86a87ce4" continuedAt="i6b944c0bbdbb430bbf53553f0de8811b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i6b944c0bbdbb430bbf53553f0de8811b" continuedAt="i117cd3d64ef14258ba3c996e3873a477"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i117cd3d64ef14258ba3c996e3873a477"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQ1Mg_a1823ab1-2cdd-4405-af88-38cf91882b1c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfNDM5OQ_af45dc6f-f821-4252-a21e-2c41dcd088aa">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia949d043b549485c893cefd4b5660891"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQwNA_8ee70f9a-3e11-4792-b0c6-0647cd738647" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfNDkwOQ_0a9d0cb2-c32d-4dbf-aa6c-25c015eaf49a">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQ0MQ_5a07394e-b4df-45d3-a76d-a13e94145259" continuedAt="i949856c5b4094809a559501ae2b30e10" escape="true">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i949856c5b4094809a559501ae2b30e10">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQyNA_59e01dab-80bd-4dff-9cc3-ff5c8523284e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i904ca67b48e9438aa45cc860a3e98146_43"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Acquisitions </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80My9mcmFnOjUyNmJlYmIyMDg5ZTRjZmU5YWYxODY0ZjQwNTVlZTkzL3RleHRyZWdpb246NTI2YmViYjIwODllNGNmZTlhZjE4NjRmNDA1NWVlOTNfOTQw_d77671a5-fd9d-4ac1-afa1-449ba9b8cd66" continuedAt="i811eb2f31aff4b34a8cce3dc69a4216d" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80My9mcmFnOjUyNmJlYmIyMDg5ZTRjZmU5YWYxODY0ZjQwNTVlZTkzL3RleHRyZWdpb246NTI2YmViYjIwODllNGNmZTlhZjE4NjRmNDA1NWVlOTNfNTIz_3388234f-f302-401b-ac2e-d48c3396ee1f">75.0</ix:nonFraction> million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i811eb2f31aff4b34a8cce3dc69a4216d">condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80My9mcmFnOjUyNmJlYmIyMDg5ZTRjZmU5YWYxODY0ZjQwNTVlZTkzL3RleHRyZWdpb246NTI2YmViYjIwODllNGNmZTlhZjE4NjRmNDA1NWVlOTNfNzky_fd722fc4-f77e-4043-8d65-a4cb254c61e8">635.0</ix:nonFraction> million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</ix:continuation></span></div><div id="i904ca67b48e9438aa45cc860a3e98146_52"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Revenue </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMzMQ_f55b1f0c-f9c9-4d9d-94b1-c3a5ba7d6525" continuedAt="i3e18a42d71a3462da06dabafbdd9c97e" escape="true"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMxOA_cf8835b8-9090-49af-90c0-f83c4ef7f6dd" continuedAt="ib8c1f47586474fad9d564549ecf09bbe" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843c3b0a19d643c98f098c2cbdda56c8_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC0yLTEtMS0w_fa459e66-41dc-4293-a528-e82296d2e1f4">269.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454fe0c0d5134bb092b7b31a87c40846_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC00LTEtMS0w_0ddadb26-dd57-4a82-a6d0-de34a2470f2d">309.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c40ac7856a4709b06d820f5782887c_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC02LTEtMS0w_43950abe-bf05-4db0-a37a-076540d7eee1">578.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41f1626c54d4651b01a960a763e25d1_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC04LTEtMS0w_28cea7be-a359-49ef-ba3e-3720762a3531">921.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44acf878e9a40e293c35b91d422db18_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC0xMC0xLTEtMA_e68b45a9-4ac0-4228-bf33-f40b246dda57">268.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1ec14a0b4c5428e96dc682fe53e2adb_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC0xMi0xLTEtMA_cf6c9f88-fa1a-4d30-9281-0e82e8e165fd">1,190.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaaded065ec24455a1510514fd2e792d_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS0yLTEtMS0w_06e07ae8-1226-41d3-aa3c-d1438a508b78">257.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde9c2714ad74d01aea890f100a512e3_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS00LTEtMS0w_a21e73ac-8362-4f04-8cb8-1c1edda883ac">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ad626e97a14a56ab100e2a98cd07db_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS02LTEtMS0w_e09f35ec-492a-4770-9e8d-27b005f0c55b">400.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de49699ab2b4ef2950e4d9cf8d55bd7_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS04LTEtMS0w_4ad96ef6-82fd-4813-af1b-b1b8cbd8996d">345.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f953a78b614e29b9d12ce31c18106a_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS0xMC0xLTEtMA_3c8a9c61-9ffe-4a0d-920c-cf5cde954589">135.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib847f37c0de04daf96e1223d256cd610_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS0xMi0xLTEtMA_85d1f5fb-4704-446c-bc28-3082aaca1f2b">481.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3bd6129bb04c41922bebfc2cfdb7dd_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi0yLTEtMS0w_59352008-0cab-4347-9226-19c789d6f6f0">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice992f8d6bde4f81ba988f03ad04702d_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi00LTEtMS0w_78ca4148-7ed0-4cb5-875a-393f651fcad9">224.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913530b0c7a04680a81480a377dc75e9_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi02LTEtMS0w_a889adf5-9926-4ae8-ba15-dda8e553333e">524.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f26c5f8f7b644c1a6ae043ec51ab4c2_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi04LTEtMS0w_bf7ebf79-bf69-4438-9a94-c159bc3103ff">244.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf57f3df80b47afbcf37febeca4a0ea_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi0xMC0xLTEtMA_ac83b998-2208-472f-8e95-0fa1c61aff1a">187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353e33f7e0a94012bc4281ed787c9554_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi0xMi0xLTEtMA_f860a078-6c90-49f1-9bab-218ffaa271de">432.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ac4b25470f4639aaafda04d93ef98e_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy0yLTEtMS0w_c4ffb340-8916-4f0c-a406-61e6870546cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8841bf5e9b84dc9ae7268750ef2bb0f_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy00LTEtMS0w_33e181b7-d9cc-45f7-a1a6-e41b87737df7">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c0c612c5734c7fb188c1543fa11185_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy02LTEtMS0w_e1808e30-809b-44df-8293-48e4c14330ee">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb5970ca1764f70aa1f12bc6e44c3e2_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy04LTEtMS0w_20cee530-7e14-4e4b-b49e-1e40db2df012">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644dc9ce5a6049f0bb8a6913c237d0e8_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy0xMC0xLTEtMA_4b9c4026-11c0-4e75-af6e-7157155e751b">23.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74762eae8227417c92bc8b0acd73d688_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy0xMi0xLTEtMA_51e0de48-62ec-4d59-84cf-3b6dde5fe18d">23.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23feca6c7c1644d1801a7f85831cd895_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC0yLTEtMS0w_f32a5279-d6ee-4a60-ac2d-c786dc604a83">826.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc3f2e402ed45da9a6e36c3ef2bfb5e_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC00LTEtMS0w_88b8def6-48a3-4ded-80f4-d7c148fe1067">702.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99acb96aa164c78bdba482e516c404d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC02LTEtMS0w_15ac7205-75ba-4ab1-9429-5323e9314339">1,529.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia755e6ceac1747b180c2cc6df3ef4066_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC04LTEtMS0w_afee9e70-80f9-44e4-adeb-9aaf2211d986">1,511.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85e782c4b0e049938858ca5e31f73ec7_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC0xMC0xLTEtMA_39d3fdd7-de4b-4f85-aed4-fc3ade2a4063">615.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b65b40d820457fb4b9fa1f07a65f61_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC0xMi0xLTEtMA_f03a1320-a4e8-4f4f-95a8-59acc15447e1">2,126.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83dafc6720834c76a63a5163e4f532eb_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtMi0xLTEtMA_0292d581-d332-4661-bf66-e67432b6505d">149.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4a9f31dff843009dabe3a4e826ee4f_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtNC0xLTEtMA_10303c01-5733-4275-b18b-a51c1f96a35e">350.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af0c1582a2a408baa70b8e99def7c62_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtNi0xLTEtMA_83fb9205-9625-4383-bc2e-40bd08df0079">499.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b7281dae8894892967238587445989c_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtOC0xLTEtMA_58fd33a5-e043-42ef-a91c-333dde242946">210.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231ad3d6d41645d3945da088fec9f599_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtMTAtMS0xLTA_76dde262-3668-44d1-87bc-b4ab83019a56">284.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf8bb8c3fe841d0ba7abd41f7fb1ee4_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtMTItMS0xLTA_03155d5f-59cb-4a33-9f7d-ae43cb8e7320">494.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17628a71886641909400cb4619218426_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMi0xLTEtNDUyOQ_f46ebc1d-cd9e-4e73-9d39-57c61203f750">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9a9b26fba3467cba137763a14e9be3_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNC0xLTEtNDUyOQ_8015a109-527c-4957-8885-f1a3d152add0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide17051dcca44f5ea4cc198403e62293_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNi0xLTEtMTMwMDE_b8ee15ab-27ae-435d-983b-03324a80f302">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0293658e6748dfa458ae395ab995a5_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtOC0xLTEtNDUzNA_bac1be2b-644d-486a-b29d-6901cce22ae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d15291982e4ca994818b360dcda3ad_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTAtMS0xLTQ1MzQ_749bb2c8-7997-4798-919e-267e2d84735c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24d10cad1d34675a3fc968bdbb574a2_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTItMS0xLTEzMDAx_bb43634e-02cd-44e9-a4a2-9e06dab04bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab460f1c1bc4867a271a58701f0e028_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMi0xLTEtMA_9ff2f81d-5c17-43b1-92aa-1aabeec8db4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7301eef41d9640ed921b3e6efe6127c0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNC0xLTEtMA_68721ee6-4d9f-4ce1-acd7-1b2f590e5ada">121.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e99a1a7e774a0e815fa6a725ad326b_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNi0xLTEtMA_ec62fe08-f553-4ddc-b396-410a6948986e">121.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a34315115c4b8589338e15d7ea6439_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtOC0xLTEtMA_58d1589d-2036-4aac-931e-915b751d9afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i664fb5d936da45f59b4e592bfb74ac94_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTAtMS0xLTA_d26fdcd1-5c06-47cc-96b6-c45ec0cc7f6c">106.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6e9d15df534c6caeb9f68534bdb18f_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTItMS0xLTA_936e54b7-d10b-4f12-b43a-486728c09db2">106.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347194d919304c0c812e6741db0e657f_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtMi0xLTEtMA_72a6c860-f401-483c-818e-dcf714c284c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2598e479464106bcdb82c4a4df0181_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtNC0xLTEtMA_12804f53-abdb-45b3-ad6d-41bc931067d9">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8798ca731041d684373855710bb939_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtNi0xLTEtMA_f3ba960c-77ee-4b02-b7cf-fac2ecbd2e65">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed6f9bb6cf4494cbb6951ffc4427cff_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtOC0xLTEtMA_480d81e3-18d7-48cd-bd22-6a7b3045733b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a873d0cc0244a8b91d944434d46b46_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtMTAtMS0xLTA_bf7605ef-31c5-4b69-ba68-29a86fc10145">44.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1d133f9df644b8b0d7cd4410031d4c_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtMTItMS0xLTA_951d17a7-0b24-4591-b11c-90181fa2a17c">44.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3369c80db6c4ee5a519938ac9f89bcb_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtMi0xLTEtMA_9cd69082-0af0-4609-bad3-069c281bee20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4585d796bb774ac1bea9b1ff5af52ba1_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtNC0xLTEtMA_7e96ebed-61be-4421-92c3-e90397446e4b">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d5ada70f524874932a465b9b730154_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtNi0xLTEtMA_3051b7e1-c411-41db-92fa-165c5f89c2a4">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31f861e6a524cd19f95e0d648eb24ca_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtOC0xLTEtMA_0a84b9a6-5458-4034-b2c3-a38ca0d98874">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb689c657f6b45ccb27299e839af1320_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtMTAtMS0xLTA_af58121b-5f4c-4a67-8a2b-6958ef11a916">20.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18dbf21007504156bc2266d82193def3_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtMTItMS0xLTA_76d2a2be-5039-493a-b526-5db880160b9c">20.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia538789f89324807b17b67af0a111518_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctMi0xLTEtMA_fd588f95-257d-447a-8ec1-61c86a8737d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e12ebae8140ec80846e0ec971b64a_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctNC0xLTEtMA_c49b6a6b-f8ee-43cf-a67c-a09f1a8c526a">202.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fedca069ca4c35895923673877e4ac_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctNi0xLTEtMA_6bc4c247-57c5-4c24-8116-0372b5398733">202.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbc0ef98c72c43c0a4299bf74ba8c183_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctOC0xLTEtMA_d8450593-091a-4c6d-8c3e-5bce7f0959cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if442ac7b0d344adc8562bfde02e57543_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctMTAtMS0xLTA_18e6a4c7-7e2c-41b0-85f6-47f13534b6eb">171.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if619b64750344bd396a36966f4e1d8db_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctMTItMS0xLTA_e99575e5-0233-43a5-b951-a34665ee7ec2">171.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id888d7b35a7049cc9a61406634e23db2_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtMi0xLTEtMA_54d79f3b-3d1f-45a8-8717-f9880ae7d0dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23586c6cb02341758cd17f3eda3f41ea_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtNC0xLTEtMA_1492a3a5-e069-4371-82be-119afd6a14dd">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05cd0486507d4bb9b3535aa6a9703959_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtNi0xLTEtMA_3b66b0da-43e9-4fa4-b274-ef4572902091">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76ba5beae9b4ebcb9b0d537208ce555_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtOC0xLTEtMA_54f6def3-87c5-4fd6-a10e-7f49f14b0c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ffa6986e434982a6f8ec10fd4f5706_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtMTAtMS0xLTA_38d37970-2581-4b3a-8b3d-3fc2027702d7">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549472d5a38946e59e5b1caa96706fe7_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtMTItMS0xLTA_e0d9712b-0e91-4cfb-b781-8b482e52d944">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd3b810e859443a898e81c46682f449_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtMi0xLTEtMA_0a8eaea8-c0df-4cdd-997b-aed9cb5502e1">977.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084fcf81a7a4f17a2138fa073f7d226_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtNC0xLTEtMA_070ce11d-1eb1-46a3-aff4-7c6baa5c79ad">1,258.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7cf54c2c77a4e6c9dbf0332cbd0f00c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtNi0xLTEtMA_2630ac93-c1d3-4124-9dfa-59c9b93a50f3">2,236.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f337b2eb414f3fa41dc8811176125d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtOC0xLTEtMA_ee66638b-310f-4859-a7db-c6542ab02df3">1,721.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271aab5d507d493c86b6444f888c9ad3_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtMTAtMS0xLTA_1bd8e1fa-5a41-4557-bc9b-8e4f3c89144a">1,074.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b5d4606fd747a98fc6804633f0b093_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtMTItMS0xLTA_045d0326-87a2-4c4c-938b-64386709b536">2,795.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*** </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the United States (U.S.) during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i3e18a42d71a3462da06dabafbdd9c97e" continuedAt="i72a057982f534acab7d9b37d2789971a"><ix:continuation id="ib8c1f47586474fad9d564549ecf09bbe"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9512deae649d4c98b378b690ec4b9532_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC0yLTEtMS0yOTA3_068d2be6-780e-4614-9489-71497ee32ecd">505.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f99b0163013464e974cb8cb0fc170e9_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC00LTEtMS0yOTA3_3f3a1794-4f77-458a-920d-311beca8fd88">626.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8a00992695e4dd1be1075fc2e7e7f10_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC02LTEtMS0xMzAwOA_d59947c9-3b58-4d48-afa9-b85cc05b52c5">1,131.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb24c52b894b4b7b83524d55b0ce82ba_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC04LTEtMS0yODk4_f6baed7b-af97-4403-84ee-4dbaf73b0a44">1,699.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3255c22b11a4fda8d05a99d09fef6ac_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC0xMC0xLTEtMjg5OA_708b3c0d-786c-4e2d-8612-b43511fb017e">591.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f3957759bb4881946620abdea1906e_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC0xMi0xLTEtMTMwMTA_31a0d6f9-73ef-4ffd-9903-515ee493e221">2,291.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0e61991f2f4369b1013159e84567ea_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS0yLTEtMS0yOTA3_b2237410-3afc-4fba-8d11-91727b7d7a66">499.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21d03e014ce4af4a87f80e4d2f06f89_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS00LTEtMS0yOTA3_56f80f17-d36a-4eef-94e2-65ab10ab1a6c">301.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3038a0c2bf415589f4da253eeb15a5_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS02LTEtMS0xMzAwOA_ef8a9c97-c488-4a0c-9950-d4202461759a">800.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e951773a30439e95ed2c070c0d26f7_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS04LTEtMS0yODk4_1dd4a17a-c25c-4bb4-aae3-242570c6f5b1">638.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69bc97b92384fe9b8b1109cb7b609ea_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS0xMC0xLTEtMjg5OA_7eabe062-e20e-4359-a749-4dc52a8b37bb">309.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d698ae847c34141bd30186c02516ab9_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS0xMi0xLTEtMTMwMTA_9da47317-464c-43bf-a477-d793b0647441">947.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if352a0720bb54a1f95411b27afbe2fdd_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi0yLTEtMS0yOTA3_0dbbceed-af18-419e-affa-1e10449be66a">573.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc18c39667846fbb99cfe5795bb832b_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi00LTEtMS0yOTA3_ccf6de82-3b48-40c8-8c06-c9295502c92a">454.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdc86037324795b46c202ca0d00be3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi02LTEtMS0xMzAwOA_8450b277-e5af-4503-943e-ce95f414be3c">1,027.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e95d1f892c4f938eea104fc6553abf_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi04LTEtMS0yODk4_185c08a1-d429-472f-bb98-18249634a846">521.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe219fd14a84e3980655fdb9727e9c2_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi0xMC0xLTEtMjg5OA_6e7ff099-65e8-459a-9523-afb473b874ff">432.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8273fa766cef4c98862e9f44eb96455b_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi0xMi0xLTEtMTMwMTA_3c5c2b63-6ab8-4425-98d5-4e7aceab6427">954.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22959fc6b46c4630bfb1d8629dd63f34_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy0yLTEtMS0yOTA3_ba2524ff-2f3f-4689-96c1-a3b616ca3c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f8875d0f60402ba93a3ddeb81920eb_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy00LTEtMS0yOTA3_22d76915-7e42-4715-8211-c96fa1093e95">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76548eed129741f499223726cdcc1f1f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy02LTEtMS0xMzAwOA_34d9a302-2f23-4ce8-97ad-79711dddd1be">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f82ef87090045aab2b1cb5b17aeea9b_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy04LTEtMS0yODk4_7f47cdaf-6f3a-4705-ae04-f2e443bbb6ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba409194c834bf3a16a2de8f61db0ed_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy0xMC0xLTEtMjg5OA_01ce224e-aa1c-47ca-abde-89f1bcaff6a8">51.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida1adad387b4453c8301620505216a13_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy0xMi0xLTEtMTMwMTA_35307ae1-4559-4c41-86ce-55e1848444d5">51.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38367c3fd9fe456cafc14d56b87cb674_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC0yLTEtMS0xMzAxNA_0b927bed-924d-4e1f-a03a-67572efb1868">1,577.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132d903ffcdf44229d51ea6ed57f6217_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC00LTEtMS0xMzAxNA_68a2613b-ca7e-4de5-b565-a096729ca448">1,435.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653b99dd16f24c3e8a3cb8ab81b27bda_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC02LTEtMS0xMzAxNA_17805dee-dd81-4273-8376-0d525d3a13dd">3,012.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc05073dde7472d85556d435dfeaf18_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC04LTEtMS0xMzAxMg_4a0afd72-059f-42de-9424-2a51895131f9">2,859.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e757557007b47cda6f71a9ebaa17530_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC0xMC0xLTEtMTMwMTI_b172c349-1d66-46b3-a9e7-c354ec4c7e43">1,385.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac584f59af64735be732faa98be7b4c_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC0xMi0xLTEtMTMwMTA_ceaa418c-175e-401a-804d-f00dbf1d757b">4,244.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0370bfbe4664865b37fa1b911566c9f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtMi0xLTEtMjkwOQ_836fdb58-a8e4-48c0-ba73-a88065b7998e">298.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952aaf5b1c50480eba24ec10039104f0_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtNC0xLTEtMjkwOQ_24c71c8a-4b64-4d0f-8e67-6eee1dff9eca">722.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec420238dde4d4b9a44da7620294099_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtNi0xLTEtNDU0NQ_57bee566-f117-452b-a803-35ec3e0666fb">1,020.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a50f8d869747819b54ebbf6d2af672_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtOC0xLTEtMjkwMA_ae1af200-c79a-43b9-a7f3-cdba99da88e0">445.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722f82ed215948ea88263cf586031bef_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtMTAtMS0xLTI5MDA_a4bc1ff4-6a07-4d00-847b-3b5435e4e787">613.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdaa47b325f24a16bea0eec2bea1a4a2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtMTItMS0xLTQ1NTI_c3cd80ae-59e6-4afb-a91f-d796c5d420d4">1,059.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a76f1d5912f4b52aeb510ca5da3346c_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMi0xLTEtNDU2MA_7502c5aa-0426-4471-9e9b-c91ac1eb67f5">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907f1e7563f14378b1ecd1b5ef055a57_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtNC0xLTEtNDU2MA_e3ee6c10-e378-4fd3-aa7e-858423ee086c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3345cb93fc40480f8456095f9d4fc38f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtNi0xLTEtNDU0Ng_631df5d3-6f90-4fef-948c-74f67fea9bc8">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2bc0914169f4c2cb3ffcf46eff93a7e_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtOC0xLTEtNDU2NA_19baf4d9-4d35-4559-ae33-77ce7a5ec4aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8adae560f142bb811699bb9d9628d7_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMTAtMS0xLTQ1NjQ_5adc3803-06ac-433c-a54d-0c43413b27ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3232a5cc744549b80ca58b6a95c533_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMTItMS0xLTQ1NTM_e1c8263e-a150-49f0-89d2-aaef52399236">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a40b518b8b4d188979f3929210955d_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMi0xLTEtMjkxMQ_419edfc3-2c5d-4f55-b783-bc9ff0a47cee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74bb1c58883a4dc99af1b4e416cf52b4_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtNC0xLTEtMjkxMQ_f6b2cbc9-8f11-4202-b7da-5a3582ec9114">243.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f1e6f6cea24d9e98d7885cab1433a5_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTctNi0xLTEtMTMwMjQ_584c3fae-d367-480f-b9d5-d009f058cd8b">243.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e96adf1d0b34fd48f31726b6ff44a4c_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtOC0xLTEtMjkwMg_76dba587-fe3b-409d-b059-2fcee8f564c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc9787466b46abbef67317ed6f0fa0_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMTAtMS0xLTI5MDI_78849921-d848-4205-ab25-74ea80154bbc">239.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28fad1ddd69340d38bd387385c2d5c25_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTctMTItMS0xLTEzMDI2_9e89dc9c-e699-4698-8987-6de458ccff80">239.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db8c7cca1d041038bed1f6b7d4ab6b2_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtMi0xLTEtMjkxMQ_dd3c26da-a209-4803-a3c9-88b493367f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08947c7925794460a22599c198525943_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtNC0xLTEtMjkxMQ_11a6665d-da2e-4801-8a3b-81174e8b45eb">113.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387134594a0c4e6cad32daab163ac56a_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTgtNi0xLTEtMTMwMjQ_86bd8611-5d89-481c-b095-6cb3635839eb">113.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa741e73d69423689689570e4a4b68e_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtOC0xLTEtMjkwMg_1ebaf71b-5e3b-4e62-848d-28a71349484b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ce3cc5ca544c28aad1d97c409db5fc_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtMTAtMS0xLTI5MDI_e142abf3-6bf2-4e8d-b408-33e96bbaec07">106.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592a4b594aed46f581483bbad038153f_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTgtMTItMS0xLTEzMDI2_10038b9c-3aed-42bb-ab44-aa465c047402">106.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3892d49afb415e99c3cba37acf71fc_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtMi0xLTEtMjkxMQ_7a29c69f-9a8d-4e8c-abe8-b52bfbfdcefa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d64b2e8b964e8d8aa87f143c540622_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtNC0xLTEtMjkxMQ_0f28741a-112f-42d2-91ba-604dfa7d141e">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21894b409b844989e613f38670ae21a_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTktNi0xLTEtMTMwMjQ_eceaded1-959e-432e-aad5-cc0fe7699aa2">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb9c645dd194a048e1a08eff82cb7f3_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtOC0xLTEtMjkwMg_d9e628bc-db94-4e75-9086-7d6d82e1e45b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fdda44309f8410d9f5d04e02ea87a60_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtMTAtMS0xLTI5MDI_8aa770b2-bac5-434d-877a-b274619fd59b">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be3e03b30c944c68f2524da9d3dd097_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTktMTItMS0xLTEzMDI2_903378ab-8903-45c0-a558-e03458906f88">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098fb6e6a3044546a3431b4d1b2a365e_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMi0xLTEtMTMwMjA_479a8cbe-ff4a-4adc-b261-20d625d96750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0e971c4d3c436ba2b2b28e78c71d81_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtNC0xLTEtMTMwMjI_a454ce91-5a70-416d-9d2d-44f164a031c2">407.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0d22abebca4da6a32bd29921ecf3dd_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtNi0xLTEtMTMwMjQ_c1788150-4320-4e62-b6b5-481264982d2b">407.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e0421e29db4f0ca253c4ef2ea6cad5_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtOC0xLTEtMTMwMjg_0cdeb258-969b-4ce5-a5ba-e9371c613a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d2503001f7463ba388d1b6a4c3cf5e_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMTAtMS0xLTEzMDI4_99193ffa-54c5-4371-8138-96bfd379003c">390.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01d8f96012745ff89b701ea923ba757_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMTItMS0xLTEzMDI2_6a9e286f-c89c-4d40-84d3-25b355b6f3a4">390.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf07a847be8e4948957569950fc2b185_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMi0xLTEtMjkxMw_d82842cd-99c5-4adf-b2ac-a1ca7a50ee56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5abd3f3f9f445291db02d0de25095f_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtNC0xLTEtMjkxMw_4f3b33b9-6bc8-44a3-84bc-0b1cfd952ccb">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409b88462b9b4206b6f0ad945e5c7a09_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjMtNi0xLTEtMTMwNDA_3164af13-440a-4c84-a53d-97bbedae1d64">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243da6c48d9248179768b97ac1550b9b_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtOC0xLTEtMjkwNA_cdc98183-1ea1-40ff-8743-592c84071c8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d74bd6f2b1d4e72a7d2229724e592c2_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMTAtMS0xLTI5MDQ_f712222e-f2d2-4603-9b91-83cea6ecabac">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i720052044b584f03b3810ec2f322ddf2_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjMtMTItMS0xLTEzMDM2_fcff3779-f08c-449e-881f-8141b70f124d">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ed419e0f084f27aea90bd9a24d8bd1_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtMi0xLTEtMTMwMzg_84627a99-97c0-417d-b865-3d3072ac894d">1,877.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635500abf5b347d6a57cfe76e6ceb55d_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtNC0xLTEtMTMwMzQ_2b6817e8-d4c2-4aa8-b54d-d34479c86e16">2,570.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d754496294f759ddb105ceeca7aa1_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtNi0xLTEtMTMwMzQ_bed6c78d-2a11-49c7-bca0-413159ce48a8">4,447.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d301e27c3914f82885e217461346e41_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtOC0xLTEtMTMwMzY_8f7e8767-7ace-4f56-9428-56b5ac77304c">3,304.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if458daa2b72f4bda93915b366f415c9a_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtMTAtMS0xLTEzMDM2_55f62f59-b323-49c9-98eb-96b0ce437ec2">2,395.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3aacf570724f99badb8ea0d3a29373_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtMTItMS0xLTEzMDM2_457e44d6-e65e-4347-856a-60eab504938a">5,700.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*** </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjYx_04a194bd-fe4a-4141-9757-a33c9e46cb35"><ix:nonFraction unitRef="wholesaler" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjYx_0beded98-04e7-4358-a350-c3de37a17627">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="ib22f26cdb1e1424a8f3ca3d681e15ffc_D20210401-20210630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjkx_c0b6aaaa-bbd1-46ee-bad2-32583aeeaf0b">30.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3a60f7b09c98409e9ddc3f0e238fdfc8_D20210401-20210630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjk4_cacd4d7d-c993-4419-9a01-7fc4c6997f75">9.9</ix:nonFraction>% of gross product revenue for the three months ended June 30, 2021, and <ix:nonFraction unitRef="number" contextRef="i8ec1e52281e643248c39bb68e766f607_D20210101-20210630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NDkxOQ_943fe824-616e-4ee7-80b0-282566e2e723">30.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2ee71674694843249ecd53f5a7dbe42b_D20210101-20210630" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NDkyOQ_9e043b75-80cf-4cad-8fd8-1cf9228e21d1">9.6</ix:nonFraction>% of gross product revenue for the six months ended June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTA1NA_04a194bd-fe4a-4141-9757-a33c9e46cb35"><ix:nonFraction unitRef="wholesaler" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTA1NA_0beded98-04e7-4358-a350-c3de37a17627">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="ia2a55a2a9bc94211851b88701a3d8e7d_D20200401-20200630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzU4_689dcabb-3e42-4c78-9264-0807aa47f8a9">31.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia613a30223bf4bf883786f9f016d0237_D20200401-20200630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzY1_47f0698a-f9e3-49eb-9fbd-7d81fed7a5f2">17.9</ix:nonFraction>% of gross product revenue for the three months ended June 30, 2020, and <ix:nonFraction unitRef="number" contextRef="ia8965948dfbe425a85da6fca9e06c6da_D20200101-20200630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTIxMw_f7680288-cb35-47bc-9ce1-f83294ae6bc6">30.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7c1d6b7809484ea6979801fe0bebf01f_D20200101-20200630" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTIyMQ_aa9c5488-267b-447e-a94d-1942ebd72dd0">16.2</ix:nonFraction>% of gross product revenue for the six months ended June 30, 2020.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMyOQ_36541e5c-b663-489c-8545-9cd8a87f97a5" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e542e2b2e7467bb76adfbda503ec69_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS0yLTEtMS0w_1c59ae7a-4724-4c5f-bc03-fccd25889d34">141.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48dc4d3a85fb44099d30fed3e469b5f7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS00LTEtMS0w_1cd0c382-d866-4d96-b256-b27acb6b7c0c">1,093.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e902f930d64955b720bc0e0fd5de58_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS02LTEtMS0w_fe3350ae-43b1-4198-9e79-22b623363eeb">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS04LTEtMS0w_b13aa9d3-5298-4966-8471-6477ecec13c8">1,276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi0yLTEtMS0w_68e57eb8-dc50-43cf-8621-9bfded0ee8cc">375.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi00LTEtMS0w_39a148d5-bc96-41d7-8d05-7712b71a1426">1,577.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi02LTEtMS0w_afe839fa-6d06-4180-b68b-74fb271847eb">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi04LTEtMS0w_646e5610-bb5c-4a04-ac2f-1adfe816c29a">1,960.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy0yLTEtMS0w_5e02f365-e865-4c59-ac31-e2a00a11c54f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy00LTEtMS0w_c4f3ff33-921c-49bd-9633-303f39a5cfc2">51.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy02LTEtMS0w_dc052e47-ea5d-4b60-a75f-0356add874c0">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy04LTEtMS0w_b742e0a1-1ff2-4e6e-ba0e-f60b9888369c">48.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC0yLTEtMS0w_ece2fe62-d726-46a3-8512-e3aa4a129b9c">275.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC00LTEtMS0w_1c8323fd-9c85-41c4-8e80-f8c25674ac06">906.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC02LTEtMS0w_e3e282a8-eca0-4a99-9623-4339a1ed0a0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC04LTEtMS0w_e5787705-6b87-4342-80a3-d1837a73b28e">1,182.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS0yLTEtMS0w_35670fca-f256-49cd-93f8-364e3c9c7274">119.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS00LTEtMS0w_42451646-9d2f-4ac5-9e50-9eb89d046069">676.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS02LTEtMS0w_6b3190ef-2ce4-48b1-9fde-47c3db263d33">6.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS04LTEtMS0w_d157377a-cfc5-4695-90d9-2ece0120a02c">802.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dda4e5979a3455ba24bfb6dccd4adcd_I20210630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi0yLTEtMS0w_4cd2b23b-1ce2-412c-9502-f8808a815e41">123.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98775b1b10a41a392536907027ba668_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi00LTEtMS0w_96d55c63-6abb-45c6-99b9-ca93ed9ef2ae">1,035.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad52dd82f08d441e93f786ded8f4be36_I20210630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi02LTEtMS0w_ee7a8d33-2846-4ac4-af1c-d356232d63b6">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi04LTEtMS0w_8b2eea61-2ba4-4de3-bac3-d2d6b623cfad">1,202.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i72a057982f534acab7d9b37d2789971a"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMzMw_bdf007c0-56ee-46a7-94f6-1b356637cc61" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702781d7d4d143c985f549228c64fa29_I20210630" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMS0yLTEtMS0w_92abc7f5-fbfd-4625-b807-b8158e7219db">160.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bba8977699149f58c07fbe9bcb19689_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMS00LTEtMS0w_e9fee869-ed83-477d-9a09-3fca864a6f09">195.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf361b51f5534b34939b0f745631d54d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMi0yLTEtMS0w_d2676922-ce75-4852-8e31-6305cc93cea2">1,042.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad6c76d74374942bcbb4934411ede69_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMi00LTEtMS0w_b2369f00-2a75-4096-8aeb-19083b786cdb">1,080.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMy0yLTEtMS0w_acb5c7c9-09b8-47fa-acf8-536ead6f7958">1,202.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMy00LTEtMS0w_efce314d-0d3c-4bf9-a0fc-6539345829c7">1,276.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMwOQ_f3e076e5-3335-4543-9d04-f64a158105dc" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi0yLTEtMS0w_fb23f6fc-48c0-412c-a76c-f5688584b651">178.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee771fa2648044888a8356de8f0d5e38_D20200401-20200630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi00LTEtMS0w_8e907471-f667-4501-a9d4-c387aff86882">257.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47ae3a613a94bfbaea1fea5774148fc_D20210101-20210630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi02LTEtMS0w_0dc1600a-8a39-41c7-94a8-ad90776f15bc">352.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c38ac27d6b4276ba03f7c2e9d29e86_D20200101-20200630" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi04LTEtMS0w_1eb3872b-36c2-462e-a480-3c2eee1d0c46">598.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy0yLTEtMS0w_568fbb05-f932-4a60-81b2-e119fd35676b">261.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee771fa2648044888a8356de8f0d5e38_D20200401-20200630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy00LTEtMS0w_e4949e3b-c526-4c34-a9bd-1b223551df95">220.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47ae3a613a94bfbaea1fea5774148fc_D20210101-20210630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy02LTEtMS0w_dcd05803-8183-4a24-b5bb-7864cef1e6e3">476.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c38ac27d6b4276ba03f7c2e9d29e86_D20200101-20200630" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy04LTEtMS0w_7a007d5c-2077-4b25-ab7a-a513bcfa7d09">399.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e165fd1993b481c8583fa0659f62931_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC0yLTEtMS0w_49f74083-60d1-44e2-aab7-f354e5b688a6">440.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a7b47c3caa498fbd7d5570bba5dfb5_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC00LTEtMS0w_90ed6d74-ebb6-4d87-99eb-ee8fe7b585e6">478.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597ac0475acb4b008433332ad02431ea_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC02LTEtMS0w_63ace6aa-0ae1-4f89-8f23-10f4dfd1ff03">829.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaebd3ec3de74756a298f2a7c57d8b32_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC04LTEtMS0w_276f0cf0-8c11-4588-9ab2-c3cece9232dc">998.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMwMw_c98c96f3-db56-490f-adba-c3c3d5dfceb0" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5645d9467cc4e1c9a27bfe42553e646_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy0yLTEtMS0w_167ea8cd-f965-4cbf-8620-c6d0c7e99224">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907bc0d2ec594c419d577f002f5b337b_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy00LTEtMS0w_56f78a9d-93bb-4621-baa1-e438420ec295">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340b682e29fc4f8595ff4caf9fd4f83e_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy02LTEtMS0w_703d322b-fe04-406f-bbc6-af79da2c4b62">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5698b182a7d4143989d02e2a19043a0_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy04LTEtMS0w_859b75c7-359a-4297-adc5-dc063495cf6f">8.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbcba6dffaf3400cb18c2f40d6b7d5fd_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC0yLTEtMS0w_11afad26-bd39-4e3a-b3f8-58ea32556293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5df461441ec4e59bcc1bb4b499e5d18_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC00LTEtMS0w_620273b8-56e0-4d9d-ae88-c64008e9ded3">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6292523b5a4b84be8b5aa038a4e8c9_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC02LTEtMS0w_72a53df5-18b6-46d5-bea9-c32eda56733f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4937d91a9de34cd3a68c76b9f4988ba5_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC04LTEtMS0w_4c330210-a563-43fd-a7e2-bd7266780c32">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49dbdd6ccc5c4f4e8c800f8f4c3db2ed_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi0yLTEtMS0w_3b68932e-9f9e-4537-aa85-14d69fd43139">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0174dd54e1428da6b9c96728976e62_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi00LTEtMS0w_3add91c4-5b08-44c2-ad25-0a3b1fb7e7ed">7.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffe2c761d3548bbae62483d2028c1e7_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi02LTEtMS0w_28851d80-adeb-4d73-b96a-7798e3d899df">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab0fad6e18f47efaf41fe8fc095a1f6_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi04LTEtMS0w_0e72aaf3-16ef-4b14-b091-9992a23de0e6">18.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78be0a546c174fa2a2cdab944955d487_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy0yLTEtMS0w_37f449ac-0e94-4db7-a104-268a9aa74170">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i720dbccd07034f98942db90af7a7d38a_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy00LTEtMS0w_cf776424-93e4-4691-9a1e-b307f0c12ea7">395.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7236fcab1a8f44a8b21addbfbcd77b5e_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy02LTEtMS0w_8b274511-ba1b-4c27-88b6-1db502620198">170.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d874a874e60463fb1b3910e76852f6c_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy04LTEtMS0w_684a8bb7-e972-443d-b770-fe70a077d970">489.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id563dc7eefa34305b99b4e811541cfce_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC0yLTEtMS0w_1a938aad-7507-4075-9b3f-de088a3ea520">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22951db8734f44ec9b10b05a829c8cb7_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC00LTEtMS0w_20829678-0b91-426a-b929-bd2c8bf59ce5">407.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892ed7dcf1654ee7a0c75a99e9a162b8_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC02LTEtMS0w_0d2a37ae-e5b2-4d46-b7af-40cec56a76bd">192.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92244e16cec54d629634c4fa97c7505d_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC04LTEtMS0w_c221beba-b140-4586-8b0b-b0141527d455">516.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_58"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Inventory </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RleHRyZWdpb246NDAxZDAyMzA3MzlkNGM4MjhmYTJjYjRmNjc3N2VhNmZfODE_c4f8ae0f-cb29-4e18-8046-8450e54ada82" escape="true"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RleHRyZWdpb246NDAxZDAyMzA3MzlkNGM4MjhmYTJjYjRmNjc3N2VhNmZfODQ_527af207-29da-48f8-8c90-121c57650241" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:58.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMS0yLTEtMS0w_55a6c992-6ced-48c0-a596-c8ab25e96d5a">328.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMS00LTEtMS0w_929ae83f-26c6-4fae-a596-e7b337238e9c">314.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMi0yLTEtMS0w_37ea9b9f-b0b0-4b31-a65c-d4cc6beca1ad">723.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMi00LTEtMS0w_2b601b75-1a47-4972-9670-a8966573f72b">544.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMy0yLTEtMS0w_1298a831-e8c6-4153-a9fd-d26ba2da8153">203.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMy00LTEtMS0w_20ad11fd-686d-4806-a065-b5799936626d">209.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfNC0yLTEtMS0w_7387933c-23ae-4415-b292-11140f354464">1,254.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfNC00LTEtMS0w_87860d02-b501-45c8-a522-ea559a63007c">1,068.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM3Mg_2ba79867-113a-478d-b1f1-9afafdeab412" continuedAt="i24a8c9ec7294416f95c6c5217be2c1f0" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM3NA_49716e16-a23d-44e0-8de0-b92c126ca033" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2696c492034bfeaae4a745a688853c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi0zLTEtMS0w_5888b240-41ee-4a38-b9a3-e325e2aba973">7,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd2696c492034bfeaae4a745a688853c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi01LTEtMS0w_adde1eee-ee81-4ed8-9643-aa3111e36a15">5,252.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2696c492034bfeaae4a745a688853c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi03LTEtMS0w_208ed058-96bb-444c-84e3-89d8626b0bfe">2,141.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564232db534949ec8f4d4776b844bc62_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi05LTEtMS0w_dd7b7bf2-80e5-4b50-9e51-75c4722bd6c8">7,394.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i564232db534949ec8f4d4776b844bc62_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi0xMS0xLTEtMA_276350fd-4369-4b08-acf0-ed2a2ba96365">5,136.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564232db534949ec8f4d4776b844bc62_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi0xMy0xLTEtMA_115fcf8f-1b5f-484a-92eb-a3c9295fa318">2,257.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425b64c01d0a489ebae1f721822fbfd3_I20210630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy0zLTEtMS0w_7d6e52ad-4685-4538-9f78-654403ec4570">179.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425b64c01d0a489ebae1f721822fbfd3_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy01LTEtMS0w_e3cfd676-6f4e-4f71-9075-81d2806c0b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425b64c01d0a489ebae1f721822fbfd3_I20210630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy03LTEtMS0w_97e4775d-ef5d-41d8-bacc-ab919b164907">179.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf72f9358a9449ea227a870a11d948e_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy05LTEtMS0w_5ec48280-16af-4a26-aa01-aca457c74c02">762.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf72f9358a9449ea227a870a11d948e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy0xMS0xLTEtMA_25257413-4e2e-48e1-bffb-0d5699d219f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf72f9358a9449ea227a870a11d948e_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy0xMy0xLTEtMA_3f1ebfc4-e596-40b9-92f4-9b7edabbe358">762.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292c5e4fd4e242e9875eefba463479ee_I20210630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC0zLTEtMS0w_f90de67d-969a-4e67-a924-66a774d93caa">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292c5e4fd4e242e9875eefba463479ee_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC01LTEtMS0w_3b01ab14-e04d-4aff-9f70-296301fd2fb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292c5e4fd4e242e9875eefba463479ee_I20210630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC03LTEtMS0w_20e50b5a-4fe4-43dc-b0b6-9cbb5793ad18">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4c60f1930e46e492d95823df89a04a_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC05LTEtMS0w_aa06722e-d81c-43c4-b0a7-268164303cc2">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4c60f1930e46e492d95823df89a04a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC0xMS0xLTEtMA_e86f9b16-4cf2-4c67-af7d-2a04e1fc64dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4c60f1930e46e492d95823df89a04a_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC0xMy0xLTEtMA_890d3319-21f6-4ba6-9bb9-6bfdcbb9c538">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS0zLTEtMS0w_ed7f7440-2033-42fa-9b47-aebc092014b0">7,637.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS01LTEtMS0w_22cbf57a-8709-4f88-b741-bb9ea2571825">5,252.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS03LTEtMS0w_395a2ee4-1c97-4a21-939c-5f07793cafa2">2,385.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS05LTEtMS0w_89a3728d-51b0-4474-aced-44bac3ccc1b6">8,220.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS0xMS0xLTEtMA_b16d63ff-4a56-4143-bb45-15944479d0a7">5,136.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS0xMy0xLTEtMA_6a54222b-6f75-4eae-836e-bf90c081e178">3,084.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjQx_05ed352f-8fad-4657-82b2-bea1ded51171">604.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMzI5ODUzNDg4Nzc1NQ_174045cf-24c3-407c-82a7-206992ebbc4b">702.2</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjU3_a613122d-380f-442a-a766-b64cfbc964f3">61.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMzI5ODUzNDg4NzgwNQ_628a6666-b904-453f-98bd-c7939e11a732">133.0</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets reflects a $<ix:nonFraction unitRef="usd" contextRef="i915928be88b2414c93eeb0775ef69931_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODEyMw_b1f42d79-dfe6-45a7-b637-69e23ff7424c"><ix:nonFraction unitRef="usd" contextRef="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODEyMw_eec843c5-eefb-4d1c-8e95-965a668caa24">350.0</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $<ix:nonFraction unitRef="usd" contextRef="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODE0Mg_7673a66a-393f-4345-9d5b-3c52aac7275e"><ix:nonFraction unitRef="usd" contextRef="i3f3471ca51d841a8bc1d6e8d9212942e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODE0Mg_ad47fa5c-bcb9-4b85-90ae-27c767d6c766">191.6</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, amortization and impairment of acquired intangible assets also reflects a $<ix:nonFraction unitRef="usd" contextRef="ic5dd5cac2c4b4ef88f7c9af0cdbe95aa_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMzk1_61768925-cdcd-4cf7-84d1-8eb44254179f">44.3</ix:nonFraction>&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2020, we had <ix:nonFraction unitRef="usd" contextRef="icbe3131e1f0f4d2f96592abae7ae34ff_D20200401-20200630" decimals="-5" format="ixt-sec:numwordsen" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNTQz_52884ba4-87b0-49d1-abe7-271a39b1013f">no</ix:nonFraction> impairment charges.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of June 30, 2021, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Nightstar Therapeutics plc (NST) and Convergence Pharmaceuticals Holdings Ltd. (Convergence). For additional information on our acquisition of NST, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ic5dd5cac2c4b4ef88f7c9af0cdbe95aa_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjU1Mw_61768925-cdcd-4cf7-84d1-8eb44254179f">44.3</ix:nonFraction>&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of June 30, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;D assets was $<ix:nonFraction unitRef="usd" contextRef="ibc71ae0114074c328965f93fa714853d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjczNg_cb4bf3f0-52f6-4034-8762-104c71a5716b">136.0</ix:nonFraction>&#160;million, all of which is related to DPN.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i24a8c9ec7294416f95c6c5217be2c1f0" continuedAt="i756b677409a94dfcae8cb30e16a31c23"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="if424d27a99a040a8a69fe6179239ad68_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjg2NA_5b85988a-339b-4781-80dd-66a4a956f7f5">115.0</ix:nonFraction>&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODE5NA_03fb55b4-a64c-4909-9429-558b46fc5ad7">350.0</ix:nonFraction>&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D asset from $<ix:nonFraction unitRef="usd" contextRef="ic861662623824bafa546d7da7df31404_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODIxOA_890608ba-b682-4f0c-9122-911c0a54c5d2">365.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ib26ab77751224af3bdafebf334667bf5_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzOTAwNw_935c5b21-f662-44f1-aaa6-20abb3ea518d">15.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODI0NA_66a209a7-25d7-4a6b-9267-6874eddf4fae">191.6</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D asset from </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="i98b7babcbee94700b48f10861f4efe40_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODk2Mg_8ad3ef70-c1ee-4cc6-bff1-946c028ea9a5">220.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="i32c1c6a24b94432396492121d59bce8b_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODI2OA_b793ba19-8629-4bfc-a733-269f5faafb77">28.4</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are evaluating the results of our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112, including evaluation of any future development activities we may perform. Our estimates of the current fair values of the BIIB111 and BIIB112 programs were derived by using a discounted, probability-weighted calculation of future estimated cash flows associated with the programs under multiple scenarios, including the possibility that we will cease further development of BIIB111 and/or BIIB112, which could result in further impairment of these assets. The key assumptions in our estimates are the amount and timing of revenue, probability of technical and regulatory success, discount rate and clinical data associated with the programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we have entered into third-party manufacturing agreements related to the BIIB111 and BIIB112 programs and we may incur a financial penalty if these agreements are terminated. Should we decide to terminate either or both of these programs and/or manufacturing agreements, we will likely incur impairment charges related to the remaining book value of the applicable program as well as charges up to, in the aggregate, approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i4b3589e2b3b4439795b2b25630eaee3e_D20210701-20211231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNzE0NjgyNTU5ODIyOA_dd3f119a-fea3-4c13-a0ba-76ae21b8a874">30.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related to our inventory arrangements and other costs associated with discontinuing these programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM2Ng_8e3c31c8-00f1-4aa7-b299-8de04cbbaedf" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfMS0yLTEtMS0w_fecf58f0-443e-4539-bd79-266f1ccfa99b">110.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfMi0yLTEtMS0w_d06bdd94-3331-4710-8e24-130b9e1b4c98">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfMy0yLTEtMS0w_59f93bcc-4f3f-4495-aa39-4835249449c1">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfNC0yLTEtMS0w_2b302cef-78e4-4bf9-83bb-10fd7f91c32c">225.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfNS0yLTEtMS0w_b794e9dc-bda8-491e-9331-23889686747a">220.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfNi0yLTEtMS0w_1099c566-c9af-49c9-9c42-4fbb520c4379">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM5NA_ff59d7dd-7fc4-41f2-84fb-fe917fcf31ef" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjIwMjI5NzY0NjNkYTQ0YThhYmM5MmZhMDE4MjZkMzQ4L3RhYmxlcmFuZ2U6MjAyMjk3NjQ2M2RhNDRhOGFiYzkyZmEwMTgyNmQzNDhfMS0yLTEtMS0w_1b48a7e2-8878-4d2a-9e62-6629e7b844d0">5,762.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjIwMjI5NzY0NjNkYTQ0YThhYmM5MmZhMDE4MjZkMzQ4L3RhYmxlcmFuZ2U6MjAyMjk3NjQ2M2RhNDRhOGFiYzkyZmEwMTgyNmQzNDhfMy0yLTEtMS0w_fc807990-efa5-4245-904f-b6892166cd69">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjIwMjI5NzY0NjNkYTQ0YThhYmM5MmZhMDE4MjZkMzQ4L3RhYmxlcmFuZ2U6MjAyMjk3NjQ2M2RhNDRhOGFiYzkyZmEwMTgyNmQzNDhfNC0yLTEtMS0w_ca62fc8e-24c8-4eed-a88e-7dc73db6b3f1">5,763.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="i756b677409a94dfcae8cb30e16a31c23" continuedAt="i78fa64e4ca4d48ea8d0df43537032754"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDIyMA_47467e7f-d515-433a-951e-2de01ad74289">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i78fa64e4ca4d48ea8d0df43537032754">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_67"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Fair Value Measurements </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgzNg_f9633414-be63-44b1-b6ad-a869ead7dc2e" continuedAt="i33e116f14e3843489ead9a7b838a9d31" escape="true"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgyMA_d9ac1ad3-36d5-4811-9546-e47c4c39b74c" escape="true"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy0yLTEtMS0w_b26a925c-0be7-4653-9d54-6f3b4911cbe5">1,180.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy00LTEtMS0w_eacb84af-4c3a-4632-8c30-71f00e95ec13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy02LTEtMS0w_bd81765d-9961-46fc-bc46-09c4dc086a8a">1,180.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy04LTEtMS0w_fe1b04b9-af6b-4050-950c-30c812595d9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbd029fbc344b46a9e18552f63b771d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS0yLTEtMS0w_11361ac5-33e2-4d52-abe9-6b1fbfd8d30d">1,382.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bfd21709274d769bdfe5ee0c2a4f9d_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS00LTEtMS0w_9ed44b5b-b49b-4733-9f84-36e9a9f3c676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id690c3d268444a479ccd8676d8f87382_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS02LTEtMS0w_823c0692-851d-481c-8557-b8c2cfa0c855">1,382.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee42b4171fd43f7b3d5a343e610ffc2_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS04LTEtMS0w_ff3d3901-ff8d-4a93-9441-0d96638eed7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5278f4a26a6e47f587f7ca52b525d078_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi0yLTEtMS0w_8bc086c0-53a6-4435-b4ea-eeb88384ec43">688.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd88e5dc8c048bbad2674a4096e3603_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi00LTEtMS0w_a7d44c20-36cf-4fc3-940a-e36c6c26a38c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4bfc66e80d34cdda3587ae96c181943_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi02LTEtMS0w_0c1c4c43-ab9f-449e-930e-acce8f902c16">688.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b59ff6648844150b9a65bfbd8584495_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi04LTEtMS0w_137a4847-2be4-49ac-8dce-fd3213587a28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ef803d07a43c9b37becf139ada10c_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy0yLTEtMS0w_e3f6a21f-ba20-40b2-b4a3-c0de8b13f75e">152.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie818c37f85794462a4a3bb25a7063d68_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy00LTEtMS0w_ddf121ca-fd21-4f63-a8b6-8d363e9019e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e27733c20de4673aa52d098a7ee84bb_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy02LTEtMS0w_320dad1f-cfcd-4dfc-854a-39eb39cc64ce">152.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2010fabf284a188f6f32e901e8f4dd_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy04LTEtMS0w_3e745db0-9028-4fd0-bc74-b4619c9635fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC0yLTEtMS0w_6454e8b0-a583-4404-b600-9a62d33ce3bd">1,593.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC00LTEtMS0w_7a6ff2ee-16d8-43ac-b863-6d84b683e0c3">273.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC02LTEtMS0w_3b97de02-49ec-48e7-80ca-d4bfee4bd061">1,320.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC04LTEtMS0w_1e18a8a9-f8ea-481c-bf2a-ce5f20ea2ce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS0yLTEtMS0w_6cb8c3af-db9f-4326-9cd9-f6438ef094da">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS00LTEtMS0w_afaba8c3-a839-467a-9daa-c9aaf1623bef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS02LTEtMS0w_eb79f998-2ba2-4c47-b50c-50b7963bf049">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS04LTEtMS0w_6eeebc70-47b9-4d3a-a115-4592f4098a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtMi0xLTEtMA_868d9b6f-6e06-4bd9-9d78-fbd8cbb2ca51">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtNC0xLTEtMA_7032f50e-3535-431c-8e6c-f2c72f3560ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtNi0xLTEtMA_6b85c561-5dbb-4526-9d2c-e257eba890d5">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtOC0xLTEtMA_40376fb7-f769-45e2-98f8-423b17205e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtMi0xLTEtMA_8e0b199e-96cc-4e6f-8a03-f73b749863d1">5,052.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtNC0xLTEtMA_719ce53f-87af-462f-a9f7-89ad8018a505">273.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtNi0xLTEtMA_a16647ff-99ac-4fe5-bd11-88ab2e55f00d">4,778.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtOC0xLTEtMA_3e00d881-1bcd-43e9-b893-ed7bed4c3a00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtMi0xLTEtMA_388faf7b-51bb-4407-b2a8-b4acc1b216f0">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtNC0xLTEtMA_c7d9147f-5089-4cad-ba77-f33fcfd558d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtNi0xLTEtMA_aca03591-d990-4275-9b72-f26a6cc12852">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtOC0xLTEtMA_2638b12b-7cca-4d68-b6d8-9d6994b9cbed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtMi0xLTEtMA_baae58b7-85d8-4136-b46f-69c6e6209721">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtNC0xLTEtMA_0fadfbd4-a045-4dc3-8068-08fa39c244d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtNi0xLTEtMA_252f7434-ec5c-4490-83e2-146a6b148038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtOC0xLTEtMA_c84673ae-2fc0-4dca-9483-8f9b2baf4289">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtMi0xLTEtMA_05b515d6-fb0e-4168-b3c8-1d9cd1bd47ec">298.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtNC0xLTEtMA_b5532042-3d2b-4d6a-b72f-3d3be6af403c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtNi0xLTEtMA_0ac155ff-2c9d-434a-bb19-0cccfeeaade2">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtOC0xLTEtMA_b3d31b71-791d-430f-a953-fc0bcf5676e0">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy0yLTEtMS0w_87ffc606-ef6b-466d-9751-4d77990f4967">626.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy00LTEtMS0w_8ff1a855-313c-43dd-8e61-239eb03a0a4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy02LTEtMS0w_f9aa728e-5ca9-4fc8-a15a-88ad9a6118bb">626.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy04LTEtMS0w_79ad7c20-cf0b-41a0-bfdc-b7bc11e4c330">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bbdd06b85242b4acd39c16f2de4f68_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS0yLTEtMS0w_a2950643-18a6-4d4a-aef7-7b66169284e9">1,301.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17a07be4c334ab5bf381339cd0805c3_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS00LTEtMS0w_60ad8607-f451-46e3-8fb5-d4349cc9d438">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db3718d80134232900c7bf04328d7ae_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS02LTEtMS0w_886366da-7299-4261-8f80-8dee6ca8f0f2">1,301.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbea1376e99b45eea49529b1a794cfb5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS04LTEtMS0w_bbc1fbf3-0a87-4bb7-b7e7-750b4c1cc0b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1497c2e19e48d4a054f3ddaa892b41_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi0yLTEtMS0w_3f9aad60-adc1-41a8-b889-fe9a1ba1ad1d">627.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6febac69f96c45f0b01a347765248601_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi00LTEtMS0w_aedc2f96-0839-4994-9d30-23bac1691957">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e243522dafd43409ff7994995b9d578_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi02LTEtMS0w_f47c9164-42ec-4601-98d4-d5a75f62cfdd">627.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fec6d1e18f43c6aaa04084519b0b4a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi04LTEtMS0w_fe7b0f6c-d4b9-4a88-89c7-0a232cdd90ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f8c8feb0384cc4b6dd32e68d1156d9_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy0yLTEtMS0w_ccc76400-fdae-459e-8d8b-62eacd0a14be">122.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e051c5c511343dd9a80f274f5cbc761_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy00LTEtMS0w_e0a7e42b-3bd0-4a52-a9fb-bd1834dabb9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb3c6b56f5242c9ba547dfeab34e697_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy02LTEtMS0w_b4d9beeb-5029-4091-ac10-a79eca4aa1e3">122.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4035f415b24c6cbd58d80693db5b18_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy04LTEtMS0w_79833df2-693a-4e52-b384-72d93b1e311b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC0yLTEtMS0w_cb1f2726-8888-4c77-a315-f8984c8e64fe">1,974.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC00LTEtMS0w_d4332dd9-43b6-4ae1-9734-35d91e6c89e3">271.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC02LTEtMS0w_86511ee5-4a8f-4d23-b254-fd8b17745cef">1,703.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC04LTEtMS0w_1dffd8f7-3bed-4d2e-928a-6cf982755cbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS0yLTEtMS0w_fdee4017-5708-4f06-b2be-94a745ebdee3">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS00LTEtMS0w_011dce5e-2d32-4a7f-a89b-8224825c3528">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS02LTEtMS0w_da9360c2-eb86-4596-bac8-9f83ce59aec2">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS04LTEtMS0w_d993afcc-6525-43c8-bba5-7c72794f5ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtMi0xLTEtMA_95369646-f465-4521-a523-11fbce3c6a6b">28.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtNC0xLTEtMA_da5a6af5-d69b-4517-9484-5d498eef5139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtNi0xLTEtMA_e0bd2c5b-2cb1-4f39-817d-3394d2a20c4b">28.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtOC0xLTEtMA_15168254-62f4-4c77-a4af-535fc518394d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtMi0xLTEtMA_a1b5e053-da44-4f0d-8d19-61a25aec0753">4,700.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtNC0xLTEtMA_81cf47cf-b107-4404-a48d-76d04e70035b">271.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtNi0xLTEtMA_3cb06713-ad04-4076-a8b9-ebc554559bde">4,429.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtOC0xLTEtMA_242ee465-7176-4040-b9f9-83d8eaa9e2dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtMi0xLTEtMA_b5be65de-8017-4dfa-b008-0f13f1f6cfba">217.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtNC0xLTEtMA_e0592c6c-a2cf-4881-a267-6d20b584e912">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtNi0xLTEtMA_ca219adb-bb36-4df3-a714-11e334166699">217.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtOC0xLTEtMA_f4c31d8d-8db1-4ed4-9dab-13d4469070a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtMi0xLTEtMA_54438585-1948-4fc8-b2f6-1ec02ffc8059">259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtNC0xLTEtMA_b9655c31-9eac-4477-af42-6ee38adc09ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtNi0xLTEtMA_2bf1e0c4-2c77-4036-8d6d-246acf0d7df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtOC0xLTEtMA_b1c0df58-566f-41fe-8ef2-34c5d5f6153c">259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtMi0xLTEtMA_91245575-a4d6-45d5-a6f0-9efed945b3d6">477.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtNC0xLTEtMA_d2e8e60b-60a3-4fd3-b0ca-39777517badb">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a34184f549249be8306e9d072ccd958_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtNi0xLTEtMA_e7d7e62f-5791-4a41-821d-7b5abef88cc5">217.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtOC0xLTEtMA_1356d59f-bab6-4fc7-8e05-ef8cf64abe9a">259.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjgz_198f22ec-9a47-4898-84a6-fb1e0763e7af">no</ix:nonFraction> material impairments of our assets measured and carried at fair value during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021. In addition, there have been no changes in valuation techniques during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for a portion of our Sangamo investment expired during the second quarter of 2021. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i33e116f14e3843489ead9a7b838a9d31" continuedAt="id27c1cd0bf374c61a0767282539e407b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this portion of our Sangamo investment was a Level 1 measurement as of June 30, 2021. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of June 30, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfMy0yLTEtMS0w_baae58b7-85d8-4136-b46f-69c6e6209721">226.3</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b7d9660d3bf4a90965d36747d39593f_I20210630" decimals="4" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfMy04LTEtMS0w_933becef-03c3-4ec9-8bee-46d51914c226">0.68</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i260a3e69565e4b828bff65115e0af19f_I20210630" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfMy0xMC0xLTEtMA_24a00812-3366-4ce7-9c5e-04705c9143d8">0.68</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfOS0yLTEtMS0w_54438585-1948-4fc8-b2f6-1ec02ffc8059">259.8</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6c4677be3fb47c7b1f75c1d21d7e655_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfOS04LTEtMS0w_2ac23e19-01e3-4313-836d-afd0c2837a1c">0.60</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc509257f5be4a76b94830882324d568_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfOS0xMC0xLTEtMA_ca840c82-acbf-4e3e-ad54-27e49c9a62a5">0.60</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from <ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMTg1Ng_2e2a5147-a451-4acc-9ed4-a1cef39f53bb">21.7</ix:nonFraction>% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are recorded at fair value on a recurring basis, we record assets and liabilities at fair value on a nonrecurring basis as required by U.S. GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfNDM5ODA0NjUxNzkyMA_a4847fc4-1d70-4d21-8883-6381cf1f566c" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Book Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Book Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB111 intangible asset</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e963ce175141e289e8f4ab954e3f94_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMi0yLTEtMS0xMzA1Mw_f6db6383-be01-45e7-ae79-05eae090b28e">365.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71f9390e677c4071a7ae6a84252c90f2_D20210101-20210630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMi00LTEtMS0xMzA1NQ_2dc622a0-46cd-4b93-af95-f6624230fd79">350.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773881e5f2394e0ebf447f4efbf9d486_I20210630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMi02LTEtMS0xMzA1Nw_f0861137-bd51-4838-9c86-725215a18df3">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB112 intangible asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f856147db941a0804cfc73b59b772a_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMy0yLTEtMS0xMzA1Mw_f9fac5aa-9be0-4a38-abc1-2e28bd5bd43f">220.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0576235f4f574413b5c8e270830d6b36_D20210101-20210630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMy00LTEtMS0xMzA1NQ_0ec3e59b-bb90-4ce7-a3d1-3194b7ce4783">191.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i937eaac40dc143619d61ac7e212f0a77_I20210630" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMy02LTEtMS0xMzA1Nw_acf07189-3271-4009-8191-fff4b83f6244">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recorded a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMTA5OTUxMTYzNDIyMQ_03fb55b4-a64c-4909-9429-558b46fc5ad7">350.0</ix:nonFraction>&#160;million related to BIIB111 and $<ix:nonFraction unitRef="usd" contextRef="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMTA5OTUxMTYzNDIzNg_66a209a7-25d7-4a6b-9267-6874eddf4fae">191.6</ix:nonFraction>&#160;million related to BIIB112. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id27c1cd0bf374c61a0767282539e407b"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgxMA_cdf2d7ec-9a13-42bb-8c80-735362f90670" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy0yLTEtMS0w_f4391c7f-08ab-4db3-a59a-77e8cf434ecb">1,037.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy00LTEtMS0w_c988e66d-3ebd-4e7f-b1c8-e19ad2d46dd7">998.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id89cf8bc140442ae872b864148ab6939_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy02LTEtMS0w_bd94b78b-1532-4535-aed5-2400bc0b4fc7">1,054.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id89cf8bc140442ae872b864148ab6939_I20201231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy04LTEtMS0w_46764913-ffa1-4602-abc0-feacfb92e6cc">997.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f011c57e3b436783a11ba0e28c19ed_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC0yLTEtMS0w_c286b517-ba51-4138-87c4-f0314a03e864">1,945.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f011c57e3b436783a11ba0e28c19ed_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC00LTEtMS0w_42886671-55c0-48c0-9540-0e1de1eb95d0">1,742.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc580ad737ef4e489c1ba3d69c8dfe89_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC02LTEtMS0w_d0e1eafd-3ea3-46af-aee3-9ccc46e8bbeb">2,003.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc580ad737ef4e489c1ba3d69c8dfe89_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC04LTEtMS0w_3ea95076-ebdc-440c-b85c-59e2dd867660">1,741.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS0yLTEtMS0w_15848d4d-e365-45e1-a99c-4636802a774d">1,503.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS00LTEtMS0w_55c93e31-6d96-4fec-8076-0fb826e232ee">1,491.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e30f1dc0024078af380776f8c704ef_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS02LTEtMS0w_9bfe3f94-ab0b-49ba-b112-41ca512d0468">1,557.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e30f1dc0024078af380776f8c704ef_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS04LTEtMS0w_4c07ab7b-6257-41a8-9576-b2cee79c3d54">1,491.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi0yLTEtMS0w_ca919df6-5bb4-4d63-9cce-97e5df1901a9">1,483.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi00LTEtMS0w_3299e7c7-0841-49dd-bde2-74c16fc6ef64">1,099.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb9fb78022c43f0a0b87550768dcfd3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi02LTEtMS0w_052929a5-07fc-4097-ad72-32275360fe65">2,365.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb9fb78022c43f0a0b87550768dcfd3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi04LTEtMS0w_6ebcdbd8-eae6-4d62-8c24-ffe9cb3f1284">1,723.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630a522bf9a74f1f95a783e75d21daf3_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy0yLTEtMS0w_46c2574b-4a65-4c35-adb8-6431a1534006">1,471.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630a522bf9a74f1f95a783e75d21daf3_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy00LTEtMS0w_8d519dfb-9136-4b06-abbd-aefa4e019ea5">1,472.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fba93be0fea4ade8ac439ac8b9db515_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy02LTEtMS0w_c9911b1c-5eb0-4d78-97ec-7f6e627dcaf8">1,536.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fba93be0fea4ade8ac439ac8b9db515_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy04LTEtMS0w_6316ebec-679a-49d4-bc3b-3e3c59654bb9">1,472.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC0yLTEtMS0w_7214e087-e758-49d8-a8c1-5230323331ba">700.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC00LTEtMS0w_959e34d4-a1fe-412d-8995-b6e8787720f3">464.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a894a26a474d8a8a4ca98884aa9ca5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC02LTEtMS0w_18d62e0f-d06c-4a2a-b031-7faa01581b21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a894a26a474d8a8a4ca98884aa9ca5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC04LTEtMS0w_f15f55a9-cad0-4c6d-bdec-7cd0630ecdd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS0yLTEtMS0w_806d8d72-f0f2-47ad-a137-dca964e39a3b">8,140.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS00LTEtMS0w_52aab9a0-2caf-4c1f-ade2-44d7ace5ca83">7,269.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS02LTEtMS0w_9abd197c-2c20-4f1d-9325-e2dc4432c75e">8,515.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS04LTEtMS0w_4b2c3be0-cff0-45a4-a743-da71c1f3b4b9">7,426.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered <ix:nonFraction unitRef="number" contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjE5OQ_0efb1acd-9005-4368-8b5a-385ce9308f40">5.200</ix:nonFraction>% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $<ix:nonFraction unitRef="usd" contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjI4MQ_815a57fe-5f43-4109-b210-683011e739fb">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes were exchanged for approximately $<ix:nonFraction unitRef="usd" contextRef="ie394eb8420ae465f88327d5264884868_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjM0Mg_517263cf-d911-4835-ac76-7696e4bab1f8">700.7</ix:nonFraction>&#160;million of a new series of <ix:nonFraction unitRef="number" contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjM2NA_c91d50dc-fd16-4450-b5b7-dcd047d8adc2">3.250</ix:nonFraction>% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgyOQ_8bab030d-cfa1-44bf-aa5f-ac46c87b6816" continuedAt="i821c8d3d3a454223a73c9faa140b8e29" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><div><ix:continuation id="i821c8d3d3a454223a73c9faa140b8e29"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c9a173f74b432699e417cff17cf882_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi0yLTEtMS0w_2f1f1322-45d6-4bca-b64f-2d852b87e370">226.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ab760d5bc14df3ab137b467a13aa03_I20200331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi00LTEtMS0w_4e659306-20bd-40ba-bfac-f97fed7049a6">341.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi02LTEtMS0w_4be3d836-7a8b-40fc-8820-ce1e2b4599a4">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie454762cebb348ce9e3d9253487d13f0_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi04LTEtMS0w_636e89b0-7321-4164-b4e9-56ccc0741d2f">346.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy0yLTEtMS0w_2f589e08-a765-4a48-9c01-feb7e14125af">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy00LTEtMS0w_89c7c5f4-611a-4578-b22e-698908d6ab59">10.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy02LTEtMS0w_022d71eb-e8c7-4b19-b41b-311bf129103f">33.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy04LTEtMS0w_74fa092a-0602-4b84-9cdd-677931db093c">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS0yLTEtMS0w_877c8ec3-c310-4fe9-bbee-32e51139f05d">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5bed7f18604646be99d5feb31fc4b3_I20200630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS00LTEtMS0w_e9d9ac53-fd0a-411c-a002-c9e78a413105">351.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS02LTEtMS0w_5e8ed682-cbb2-4b50-a33c-51a8ff05e3d2">226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5bed7f18604646be99d5feb31fc4b3_I20200630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS04LTEtMS0w_9534c07d-4a35-4df6-8a2f-6c2fb2f7d8ec">351.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzI4MA_51c11b5d-6a65-44ba-b924-fe02b55df49f">226.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzI4Nw_60bd5a77-34e1-4e99-86bd-34c34cd85fe4">110.3</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_73"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Financial Instruments </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg3Mw_643124dc-c678-4962-b4a3-2847f5192486" continuedAt="i70665f8e7a84446f91e8481ad2669aed" escape="true"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg3OQ_6d739850-d50e-4344-991a-36a34065a58b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c698cd4a9e4be08876c788f019876a_I20210630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMS0yLTEtMS0w_b7e5586f-95f4-4342-bca3-0b28adc87854">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76ce0d61306a499d84402c0d7b2ac015_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMS00LTEtMS0w_e7815737-0368-4deb-84ad-3da3a273e43b">61.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7937d5eea9143a480379f4cf9a45fc4_I20210630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMi0yLTEtMS0w_31648f46-deff-492f-a4e6-cd43e833ace6">297.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47869cfa31654403b8a137ce71cddf41_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMi00LTEtMS0w_f4e77cb2-0352-4674-9ca0-373d8d1d07fc">37.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341192473b2c4e86ba0b46d1823dc869_I20210630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMy0yLTEtMS0w_2c8ceeac-0c9b-46bc-9d4e-8b5d40bb90f9">725.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0765b5a9983479983cc32b7829fb9a4_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMy00LTEtMS0w_2977099c-b25e-443b-8f46-adc53a451d30">505.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24972f1aece34e51acc03fa88f074792_I20210630" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNC0yLTEtMS0w_8fc38155-5741-48cf-a7a0-b0ef089c29c2">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f336c946104c0db5fe50289af1e486_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNC00LTEtMS0w_87a58fd1-1a40-4979-b48d-0a2665baee83">23.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNS0yLTEtMS0w_182a2fe8-a3d4-4170-ad0e-d92d9bd9e147">1,180.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNS00LTEtMS0w_65ab1d47-9039-428f-adbf-cd84619a416f">626.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg4Ng_7953ed3e-eb8e-4a46-8dee-d93e454ed50b" continuedAt="i692844a989a842d7803c6a0e7f8b5b75" escape="true">The following tables summarize our marketable debt and equity securities, classified as available for sale:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i692844a989a842d7803c6a0e7f8b5b75" continuedAt="iacc951061b434d099a0e06e2a69a7c19"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC0yLTEtMS0w_4f0e7ef3-88c9-4340-b73a-2f64f7c3ea9d">1,072.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC00LTEtMS0w_582bc532-e124-4746-bb9e-c504c37bdbc4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC02LTEtMS0w_45a3ab8f-74b2-4869-830f-75a7b6ea1bb2">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC04LTEtMS0w_d8922c05-6f67-4ec0-b71f-ce5427ba9a94">1,072.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS0yLTEtMS0w_2bb75569-3b71-4e45-a6f5-ea9a28790e66">309.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS00LTEtMS0w_f1df7da1-dc13-4939-a7b8-44b8ac57707e">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS02LTEtMS0w_b14fb898-2e07-4a2e-8cf6-ac20c8bedd6e">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS04LTEtMS0w_319d93a2-d98c-4ff8-992a-9ebaa1fb7f4b">310.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea966d9152224b339632f5f1382ae44a_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy0yLTEtMS0w_556e891c-f50c-42ba-9c13-1faa2fccaddd">236.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea966d9152224b339632f5f1382ae44a_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy00LTEtMS0w_13b46e77-f19a-4e61-9e68-b78c3939127f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea966d9152224b339632f5f1382ae44a_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy02LTEtMS0w_7c7dad6b-187d-411d-8ff0-cd6ed3685de8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea966d9152224b339632f5f1382ae44a_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy04LTEtMS0w_a618e795-fbcf-48c1-91c9-d2be39f6ca65">236.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d314e63f4cd44538653c170af449268_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC0yLTEtMS0w_c5bc9cd4-79d0-4afa-8bf8-d3df2bd3e78d">452.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d314e63f4cd44538653c170af449268_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC00LTEtMS0w_405a6bee-84e1-4ce4-b58f-d79f563b8637">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d314e63f4cd44538653c170af449268_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC02LTEtMS0w_b1ab4f88-40cb-46bc-a429-050b8b3da911">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d314e63f4cd44538653c170af449268_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC04LTEtMS0w_0dcab516-c591-43a3-ac5c-a732ca190fb7">452.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtMi0xLTEtMA_f2fc8280-20d5-4b77-b0e5-f14f858c2cac">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtNC0xLTEtMA_e1c8d23b-f983-4afc-badb-6de78ad0dc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtNi0xLTEtMA_5b25d423-bf7c-45ef-84f9-d1e02b54117b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtOC0xLTEtMA_50dda03c-786e-4436-8506-397e9a012bf4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtMi0xLTEtMA_c9ba5859-7017-4797-bfb4-68510cd12796">152.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtNC0xLTEtMA_3c97db1a-beb5-47f9-aafe-73b20363331d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtNi0xLTEtMA_313fd527-368e-4914-8b83-30d5e105f664">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtOC0xLTEtMA_8c2313b3-ec6f-4dc5-a2bb-8cbeea6b6989">152.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItMi0xLTEtMA_525202f9-278b-4c5f-9107-cbaed80a865d">2,223.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItNC0xLTEtMA_b4d01335-c9a1-4965-ae05-8be96eb257c7">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItNi0xLTEtMA_46a6b5f2-b2f5-4f67-9260-db3b0079132e">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItOC0xLTEtMA_27219c94-5a17-4c2d-a0ad-2c6b89731135">2,223.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtMi0xLTEtMA_9114088b-f86d-4b7a-9229-af3d7613a476">1,168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtNC0xLTEtMA_35c6e33c-1674-4fdf-93ed-19ab5ec7ba90">607.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtNi0xLTEtMA_3d91cfea-e683-4de9-a098-762606a91fdb">183.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtOC0xLTEtMA_f8bebdeb-d2cb-4df9-915c-028762dd8704">1,593.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2345724701914330b955cf8be98888d9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctMi0xLTEtMA_5a9adc23-5d0d-436a-9cda-dff54ce2f1b4">1,168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2345724701914330b955cf8be98888d9_I20210630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctNC0xLTEtMA_a5ce16e1-d72a-4132-bd3b-f6537995654b">607.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2345724701914330b955cf8be98888d9_I20210630" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctNi0xLTEtMA_a7d97087-9da0-47ca-9d19-200efbf50467">183.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2345724701914330b955cf8be98888d9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctOC0xLTEtMA_2d7aafde-adff-4ee2-bc8e-4ac68d5286f3">1,593.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i70665f8e7a84446f91e8481ad2669aed" continuedAt="i6b16e737f3ff4819a64f81f9a3b2fbec"><div><ix:continuation id="iacc951061b434d099a0e06e2a69a7c19"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddda160e4f824f399742551361ab9a2e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC0yLTEtMS0w_b1db981d-ec42-4f26-9165-4358c17cc57a">897.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddda160e4f824f399742551361ab9a2e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC00LTEtMS0w_267899e3-c14c-41ec-9797-789ed531b195">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddda160e4f824f399742551361ab9a2e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC02LTEtMS0w_3b58305b-e8ba-459d-a5ff-f36e3a81d7a9">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddda160e4f824f399742551361ab9a2e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC04LTEtMS0w_0b828e4f-a9c6-409a-931e-621dcd176a5d">898.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS0yLTEtMS0w_7f84a2b0-00ef-4a51-bb76-7576ae3001ae">402.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS00LTEtMS0w_f4f65e65-b324-49ea-b099-9a54fe84e2f2">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS02LTEtMS0w_b1d1ad41-b3b8-4820-82ed-9b09c4b53a87">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS04LTEtMS0w_90c7d5ae-7eaf-44c8-b679-fed79a61cdcc">403.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy0yLTEtMS0w_f1947585-f580-46bc-bd9a-2c06f9e27db3">380.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy00LTEtMS0w_ee00bc93-7e68-4e0b-8ffd-8c4404f74084">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy02LTEtMS0w_d51210d6-1a30-4445-ab1b-0c190be7ed7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy04LTEtMS0w_df784e18-44a0-42f2-a08d-7b7cd879936d">380.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC0yLTEtMS0w_4ca1fee9-33b7-4a35-962d-d282f56c3570">245.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC00LTEtMS0w_5f25cab2-f9bc-46ac-8831-6f9e631f1a4e">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC02LTEtMS0w_ec3f6c4c-dafb-4e7d-a62b-07098c3b2d5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC04LTEtMS0w_30985f68-99bb-4677-956f-ae5c8a922a14">246.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtMi0xLTEtMA_35396dd4-0348-4b1d-9e3e-264ba2bf6e6c">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtNC0xLTEtMA_e66a65bc-219a-432d-9eaa-8591fe06dfe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtNi0xLTEtMA_754115ab-83e4-4f96-8667-3162bab502c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtOC0xLTEtMA_e3a38a0a-76b4-4fb9-8b02-76950781e669">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtMi0xLTEtMA_a4f96ead-c3ff-4b0a-aceb-8d18ecfd66fe">122.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtNC0xLTEtMA_ed44a082-b7f1-4db4-81aa-bd0f0f838144">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtNi0xLTEtMA_69aba595-729a-4476-a25b-1187cd6560c5">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtOC0xLTEtMA_ed7fd0d2-05f2-4812-a4d8-5faa8e718289">122.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItMi0xLTEtMA_f1b050f0-d65d-4c0e-842d-0d55cce54b1d">2,049.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItNC0xLTEtMA_c14461d8-9e18-4194-ba38-4d1716b1aa7d">2.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItNi0xLTEtMA_70e9ec9b-dc46-4f69-916c-2f45dc3748cb">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItOC0xLTEtMA_a3aa897d-825d-4e38-b2b2-8a1b71fa9369">2,051.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtMi0xLTEtMA_d04d7a6e-e000-4b63-8246-297a6288b156">70.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtNC0xLTEtMA_c618398f-9c53-4199-b07c-4fa14eb5c170">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231" decimals="-5" format="ixt:zerodash" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtNi0xLTEtMA_af86643e-bd3d-4161-ac65-7fb6b9cfe39d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtOC0xLTEtMA_0122c112-6833-4aa6-a253-845164a45675">86.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtMi0xLTEtMA_b33aa918-a8d9-4bf2-b859-a4647ef884b7">1,168.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtNC0xLTEtMA_e5b16a6d-43cc-4a2b-95f0-be4294110fd1">733.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtNi0xLTEtMA_2dde3eb5-4f45-4f69-9a33-3989a8b7099d">14.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtOC0xLTEtMA_b522d89d-4db0-4376-b292-17d695a1cede">1,887.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctMi0xLTEtMA_40ed17ed-e830-4ea3-ab2b-fd15476a6302">1,239.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctNC0xLTEtMA_76485255-b616-4a11-8a5f-3d94c6771404">749.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctNi0xLTEtMA_0016e892-3d04-45d1-a3fe-c5318446e93e">14.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctOC0xLTEtMA_058c181b-5dd5-47de-96b5-b33317bea86b">1,974.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg4OA_c1218fd4-512e-4d27-a933-94dbe0ad1b3e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi0yLTEtMS0w_be1b0fac-9cde-44b1-855f-3e4c1c780f34">1,308.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi00LTEtMS0w_408d12e5-3a4e-4763-8d5e-3ddd23dc5aab">1,308.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi02LTEtMS0w_ec46d0b2-964f-4066-b681-6fdad4327044">1,278.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi04LTEtMS0w_912df18f-e27c-4945-bc44-71064dfcf7ef">1,278.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy0yLTEtMS0w_0eb06a9f-6305-4319-96f4-ee679f2936be">870.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy00LTEtMS0w_c6e3342e-6b5e-4903-82e4-70b7d175dbd2">870.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy02LTEtMS0w_809a4cc4-12ce-40ae-ae86-973d1dfc8baa">722.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy04LTEtMS0w_451b7f5d-28d3-4453-817f-6c6332ffd69a">721.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC0yLTEtMS0w_f3f6a598-1ce3-48de-ae6d-c1f4c2eedfc8">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC00LTEtMS0w_8940eab0-52e6-4be4-b649-e331edb05b4b">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC02LTEtMS0w_abdd799f-9686-485b-81ee-f4be9db89b07">49.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC04LTEtMS0w_83bae020-9c7c-41c3-aafe-219c82467ded">49.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS0yLTEtMS0w_5db1198a-1aa7-4ec1-97e7-8675050dcbae">2,223.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS00LTEtMS0w_ce7d3992-8fe6-406b-acb4-ebcb44e7b95b">2,223.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS02LTEtMS0w_bdabb683-3e8e-4955-b08e-15cebd5a2788">2,051.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS04LTEtMS0w_2899c450-76e6-4d68-9f86-2644e11edce9">2,049.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of June 30, 2021 and December 31, 2020, was approximately <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTAyOA_8a64da5f-d7ee-40c6-9da7-a1f368dd0a9f">13</ix:nonNumeric> months and <ix:nonNumeric contextRef="icaa604084a4f426cb962e44bba729d00_D20200101-20200930" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTA0Mg_950f0631-1fd8-4ccb-be75-f548785eb519">11</ix:nonNumeric> months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDkwMA_3d6ce53a-bd43-4ac0-ac96-2ed5fe2dd325" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi0yLTEtMS0w_ac849f1d-b462-45e0-99ed-fda87599442f">633.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi00LTEtMS0w_849e3364-260f-4072-856d-4ecd3ffd81ff">1,490.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi02LTEtMS0w_00df4afc-f9c2-4680-8e50-aaa7cdf3db11">1,452.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi04LTEtMS0w_ce162755-f90a-4042-928d-2f5aaa96e487">3,879.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy0yLTEtMS0w_a52e8f73-1c9c-451d-882e-eeeff42e5081">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy00LTEtMS0w_e5905099-d46a-4fed-9d22-ed600dbf2b35">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy02LTEtMS0w_1b3f1866-d927-405e-8386-1f0226794752">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy04LTEtMS0w_61053461-8091-4df7-b7b4-9484613f0792">11.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC0yLTEtMS0w_eeaacaf8-dd60-49a1-a481-737a96f53801">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC00LTEtMS0w_0aa0181d-3fa5-49af-96c1-121985a78d8b">5.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC02LTEtMS0w_c8e6fd05-bc9c-417c-9f47-10859b550e8c">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC04LTEtMS0w_adaf4bae-ba00-4116-aa5d-fabdd92da007">24.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="if1b531a1cb354dadb1d4b04d6c9d7dde_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTM1OA_5f10ec5f-622f-455f-9336-833ec76ad3b9">1,647.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5fc4527faa29483d89169d9c64e45fc4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTM2NQ_6d0ce0f1-4d44-4c82-922e-1b5db2f4cd4b">2,024.6</ix:nonFraction> million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i6b16e737f3ff4819a64f81f9a3b2fbec"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our strategic investment portfolio for the three months ended June 30, 2021, was primarily due to an increase in the fair value of our investment in Denali, partially offset by decreases in the fair values of our investments in Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock. The decrease in our strategic investment portfolio for the six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, was primarily due to decreases in the fair values of our investments in Ionis, Sage, Denali and Sangamo common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjIwMg_8c2b9253-da1b-4b85-8411-11d2aa239cf6">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjIwNg_3d5ff800-f95d-4f1b-b10f-afbeca036ee5">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjIxMA_65226e62-f273-4edd-9926-f222bd383de1">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i6c93ea4397fb4f4cacf7e9b9766c5d11_D20210101-20210630" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjg2NQ_989db727-4911-42a4-9d96-6e020882b7c4">zero</ix:nonFraction> based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzI3NQ_a394f47a-16cb-4812-9f02-2218c2b15256">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="i82cf1cd794bc4e22b1558829c36fdbe6_I20210630" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzI4Mw_bfcff615-27bd-49b2-906f-e08fbdf8116c">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzI4Nw_8609403c-6638-423d-b748-2def391ed8b1">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="ia3fe0fbe0a3c4dec98ff2998e5d84527_D20210101-20210630" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzU3NA_7113bb34-e5e9-4ca1-b0d0-5ba92fa48ab8">zero</ix:nonFraction> based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzkzMw_c5dc7682-1418-4700-b054-184d7b932999">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzkzNw_df30e7d7-e158-4a58-b58b-e1f4302ab1eb">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzk0MQ_d645e7cf-6c39-45fb-8a62-d28db742fae9">9.21</ix:nonFraction> per share, of which approximately <ix:nonFraction unitRef="shares" contextRef="i512790f7d615460ab79e03a4291d683a_I20210630" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDk0NzgwMjMzMDAwMg_f96858b6-6577-490c-92ea-ca4bb332f32d">12</ix:nonFraction>&#160;million shares remain subject to transfer restrictions as of June 30, 2021.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="ie46d4c476a5740f3a1de4a18cc7dd358_D20200401-20200430" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDYxNw_6f9c7667-6e46-47d2-8376-4d0bd226b052">zero</ix:nonFraction> based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_79"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Derivative Instruments </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzA0Ng_dc495ba3-b245-41f8-94be-cf91eca8627e" continuedAt="i9bd33f8794ea4ac09c0db575771bf526" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of June 30, 2021 and December 31, 2020, had durations of <ix:nonNumeric contextRef="id9f0d11ff3fc4f448b2f08227bf61ec8_D20210101-20210630" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjIz_20f04ece-c8af-419b-a08d-dda17221a2dc">1</ix:nonNumeric> to <ix:nonNumeric contextRef="ie4176720cd9a4369ad4b4aafcdcf8e71_D20210101-20210630" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjI5_b2e6272b-6054-4942-b38c-f61f94b40f78">18</ix:nonNumeric> months and <ix:nonNumeric contextRef="i3365b3ac299340f1817dd1c53085ac56_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjM2_30a0d1cd-57d5-4041-bc3b-92adc3e5a6cf">1</ix:nonNumeric> to <ix:nonNumeric contextRef="ie2e1c79ee9d842c499a267151200ea06_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjQy_911195b8-5ae2-4718-b096-7f015a018f9c">24</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzA0NQ_7e250cbb-35df-4227-88bc-9c3f120e4a6e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25afa94ed8e9481ab9840103fd7abdae_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMi0yLTEtMS0w_528a80ef-72d2-44ef-880d-80414987d725">2,269.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c4856250984299a9cced80dcf2d079_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMi00LTEtMS0w_5080c6b6-25ce-45ba-870c-0e81cc1a58ed">2,979.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f69c368cc9469e8e39f044f00e3e4f_I20210630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMy0yLTEtMS0w_4eb5ad24-1d77-48a4-9d45-87ad98214618">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfbd5e05042b4036a8d14b4e5ebca682_I20201231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMy00LTEtMS0w_dee42e35-bf41-49e6-89fd-0c35aa86e5d5">250.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011039cdd7d14a4cb9f0e79057e4cc60_I20210630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNC0yLTEtMS0w_60dba89e-667c-4e80-abda-b97c8d102aa8">109.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361c2d5b5f9a40ca84ea9fc27a68ea9f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNC00LTEtMS0w_9b375614-df16-4a60-802d-735a20451c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a45a9c2ad44e1fa1cf0df1ef188ea0_I20210630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNS0yLTEtMS0w_ef858128-9257-4383-85c5-e3fd68aef790">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2288b6bd35ab44fc89e7711afcecb9b0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNS00LTEtMS0w_7efa746d-e3f4-460b-9ae9-628fb6738197">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041267955427406394b3d10cc3f1a76e_I20210630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNi0yLTEtMS0w_fc48a9a5-7ebd-4b41-91f8-84e27f3e8299">53.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c013d5be0e0491980d059486bae596e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNi00LTEtMS0w_8a4f95bc-0b9c-425c-ad05-45fe1445d5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a47da70628b45368fa3c768152f89ab_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNy0yLTEtMS0w_899377b6-e49d-423d-8e65-cb585aa20aca">2,623.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34356bbd90064319b545c3acc5fab084_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNy00LTEtMS0w_9304f3f0-5fe7-4014-9fae-83671f432ea2">3,229.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of June 30, 2021, reflected aggregate net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTgxOQ_1fa47587-3e72-4eb1-b5f1-4ddff205c9d4">53.7</ix:nonFraction> million, composed of gross unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTg3Ng_61414f56-0746-4dd6-ba0c-60f3eac648c3">67.0</ix:nonFraction>&#160;million and gross unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTkyMw_d11438e4-86c4-4ba4-96d6-6f1044a77c1a">13.3</ix:nonFraction>&#160;million, compared to aggregate net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTk3NA_8545e93e-b639-4a40-b702-8d566346b22f">212.5</ix:nonFraction> million as of December 31, 2020. We expect the net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjAyNg_1fa47587-3e72-4eb1-b5f1-4ddff205c9d4">53.7</ix:nonFraction> million to be settled over the next <ix:nonNumeric contextRef="ie4176720cd9a4369ad4b4aafcdcf8e71_D20210101-20210630" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjA1Nw_16cf81d1-0067-42c9-a992-e016b9b28fef">18</ix:nonNumeric> months, of which $<ix:nonFraction unitRef="usd" contextRef="i62b264cff07c440eac3e823fa20d8f64_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjA3MA_cbad2739-5755-453c-999d-9fa3e1f1a9f1">58.2</ix:nonFraction> million of unrealized losses are expected to be settled over the next <ix:nonNumeric contextRef="id6d5e77b1f3d4a9fa12b15878cb707cf_D20210101-20210630" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjEzNQ_bd6211f7-4f8a-49b8-b900-cbddd6c4ba55">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzAzNg_74566b97-99fa-46a0-8d8e-105f8bc108a7" continuedAt="i812596f556e24795bfc952e5760fd607" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89bfefbfa10f41fab03c1114e9b9886d_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy0yLTEtMS0w_e690af6e-73d1-4c4e-a5b6-7d45a3ca620e">30.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefcc8d10a5a4365aafafd0f6a18ada6_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy00LTEtMS0w_cf5f0dc2-7912-47f5-a5b5-2c283635d744">23.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic773015e74094678bef62859130a7966_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy04LTEtMS0w_faca04d1-3b32-46aa-b54c-ce3e3a461376">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf78e07bf74c48a797d7b1e5be1d1a78_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy0xMC0xLTEtMA_ab55341d-8e5f-4b43-9718-cd6ffa0cbdeb">1.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8644901576fc48e89f7637ea72cd9a14_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC0yLTEtMS0w_fc4e1495-5fac-4a10-813c-a5abe1ac1cc1">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc16ed7a14e24bfa91d7bef98db547da_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC00LTEtMS0w_ba197a2a-845f-4a7f-beea-2d29ca0ecad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide0fa9272fb14f3d92662a3cf36c6a91_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC04LTEtMS0w_fe46aa99-e127-4c0d-833d-0ade30868e62">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7e5ea5d2434fdb8b011b6c00426a56_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC0xMC0xLTEtMA_8bec9539-1f2e-4fe5-b98f-4cc3bac41842">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i9bd33f8794ea4ac09c0db575771bf526" continuedAt="i14a1a0922fa74dc0a7bb266771423270"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i812596f556e24795bfc952e5760fd607"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7a2205485b42a29e91f52900709717_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy0yLTEtMS0xNTM5_36d89862-5d4d-4b6f-9328-7fc6bdc22ea1">53.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d9977b79f94870b4d88a3efdae4b18_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy00LTEtMS0xNTM0_b9b21a58-75ee-4dd3-bb0b-9e98ab3c09d4">50.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eaabdea048846fe96c2e448be0650d7_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy04LTEtMS0xNTQx_46dcc0d8-9260-4240-a6b9-c5f01cf3e5a1">3.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ff03e21ceb4d898ce5d84c9f83373b_D20200101-20200630" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy0xMC0xLTEtMTUzNg_25cf0ece-636f-44ab-8ab4-3eda5d015fa0">7.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7296f2fd8d4fcb8a228339d858558a_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC0yLTEtMS0xNTM5_23a64af0-f764-4ac3-9e6b-286ca7bc4025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be0b892adfa46da854229dbdc2b29e2_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC00LTEtMS0xNTM0_dea5ad31-e81b-43ce-966a-71cd31a5b8cb">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2404b4e4cf7047b6a33ade2b330db9ad_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC04LTEtMS0xNTQx_66b67286-1eef-4822-a703-acbe0b0c6935">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22a7aca0e9644a159e0edce9ec0ffa8e_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC0xMC0xLTEtMTUzNg_9d29f1d5-f763-41ca-afba-22f846d535d1">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our <ix:nonFraction unitRef="number" contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzA2MQ_6e720a3b-834c-4fc4-becf-2cac28f8b538">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="ia9fa629226d049e2a9ffe5ae168ceb55_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzE3NA_53f79fd7-1cee-40b0-acb6-61aa5ecde888">675.0</ix:nonFraction> million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our <ix:nonFraction unitRef="number" contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzMyOQ_6e720a3b-834c-4fc4-becf-2cac28f8b538">2.90</ix:nonFraction>% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our <ix:nonFraction unitRef="number" contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzY0MQ_6e720a3b-834c-4fc4-becf-2cac28f8b538">2.90</ix:nonFraction>% Senior Notes, resulting in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="if078c4e7fa004892b58a2d85cb5816aa_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzY5NQ_a9f7bbc7-567d-47ad-abad-862808116702">3.3</ix:nonFraction> million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="ie35fa105818345dcb7a4da4701cf3007_I20200630" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDIwOA_a2aa4096-e592-45d1-ac71-3e96b4d91014">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDIyOA_b9ee3de5-9d24-4d84-b297-7d369e6dc9f1">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDMyMQ_131714dc-8eaa-4576-9c1d-eec6100520ce">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDM0Mg_568b28c8-7cb5-4b53-9eb4-b06b3c3b2227">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of June 30, 2021, had a remaining duration of <ix:nonNumeric contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDcxNQ_ad4decfc-ab2b-4a06-aa40-99b07fb87fee">four months</ix:nonNumeric>. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTA2OA_e5a125b9-61b8-4d53-ba15-18270ef3fece">0.1</ix:nonFraction> million and net losses of $<ix:nonFraction unitRef="usd" contextRef="i2ac95fd0cd294483986cafbab07cd5d1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTA4OQ_4a929aeb-4f61-49c1-9a24-ca1420f562d2">21.2</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $<ix:nonFraction unitRef="usd" contextRef="i02aaf8bc41e445329bc5a2dee146c97a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTUyNA_e5a90c87-d08e-48c5-82c9-0a390d81e711">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb95e23801654e2bba2506940e05081b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTUzMQ_b0c99d7d-0f49-47d3-93ec-96e51c45c91d">0.2</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzAzMg_c854ad63-d769-4c70-8033-2523bc79a708" continuedAt="ia4521486fcf64bbd95febd75e78c44ba" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab366cb8c1584b168540336d12773aaf_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0yLTEtMS0w_3aea06b9-10b8-4792-99dc-344a59276485">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74eeb72d9da54664aaeffbd41250c0b4_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy00LTEtMS0w_1df02f38-fff9-4f66-aa9f-08bb310997c0">8.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab366cb8c1584b168540336d12773aaf_D20210401-20210630" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy04LTEtMS0w_c8279014-1342-4ade-95fe-5519a454194d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74eeb72d9da54664aaeffbd41250c0b4_D20200401-20200630" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0xMC0xLTEtMA_6638d71f-b349-42e7-b8a6-407743e32948">3.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08317e7cb534a3289414130d2f13dff_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0xNC0xLTEtMA_364944ca-406a-430d-99da-138066895a8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8b068d3ff24daca734cfd11aacfa1c_D20200401-20200630" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0xNi0xLTEtMA_118108e0-57ce-469a-8bf3-30710e5cb00c">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i14a1a0922fa74dc0a7bb266771423270"><div style="margin-top:5pt;text-align:center"><ix:continuation id="ia4521486fcf64bbd95febd75e78c44ba"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0yLTEtMS0xNTUw_b8e5ee3f-c431-462a-a3f4-0bc659466b54">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if261c4da0ab44775b42f4cccccfe73ec_D20200101-20200630" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy00LTEtMS0xNTU3_9a24f711-a151-4e4a-91b0-0dbcd757c39e">15.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy04LTEtMS0xNTUz_719c8e83-1ae6-4350-8286-3f05ab626f0d">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if261c4da0ab44775b42f4cccccfe73ec_D20200101-20200630" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0xMC0xLTEtMTU2MA_7ba9c8fb-25bd-40a5-b85e-cfa0640b2a6a">3.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3cd384eb084efab9ae4e2d17d5a9c7_D20210101-20210630" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0xNC0xLTEtMTU1NQ_9b4d6897-bb74-4610-8ca8-9ba660226bbc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0281011ecb3d433e9e4a910b3c2764cb_D20200101-20200630" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0xNi0xLTEtMTU2Mg_2d205afd-b087-4429-b08b-2c9def14fbd4">1.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="i4592ebbd81f14b13b42251b139794fe1_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjI0OA_3f07a1db-c1f7-44fa-a1af-b9209448a9a5">1,205.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i26b01c7943bb4de2afd50de4b1bd1d85_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjI1NQ_72ed1bf7-33de-4bb1-93a1-c83ff347d52b">1,158.0</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively. Net gains of $<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjMwMw_1012d344-c890-4442-902d-92c752c0175d">4.8</ix:nonFraction> million and net losses of $<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjE5OTAyMzI2MjY2Mw_c432d40a-4bb2-45d0-96c1-dda553240fd9">12.6</ix:nonFraction> million related to these contracts were recorded as a component of other income (expense), net for the three and six months ended June 30, 2021, respectively, compared to net gains of $<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjMxMA_d14529ed-a5c9-4cc4-8023-062f618700f0">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjE5OTAyMzI2Mjg4NA_1b947f68-dc81-4f9f-b054-070627dc5099">5.9</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzA0Mg_abd6b2be-4f77-434f-9ccf-f5960238aa99" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4431cd1978604f468b85792244a703c3_I20210630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMi00LTEtMS0w_e04fe89d-227c-43eb-979c-443c66fa837b">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if33dd48f244f4225b552ee2004b13a84_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMi02LTEtMS0w_f77b52b8-4a2e-40e3-856f-5d69e7ca6bb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b29717f14d4bcdb08b0e8f526654cf_I20210630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMy00LTEtMS0w_7a35f100-f730-481f-8d68-898ba6386582">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db5325f2f3e41fdbbd2d84f4bae2316_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMy02LTEtMS0w_bfa93afa-ade8-471a-a104-e57a0c2a36bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7d7619dfe248fb92239ddd3b9eb83a_I20210630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNC00LTEtMS0w_3b4a4adc-9972-4980-bb72-89099369b5f2">55.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffdc90f0b7184b6f826b98475df4665c_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNC02LTEtMS0w_41f8d4a7-4133-463f-9a4c-bcce61efdd89">157.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7819501654a14b97b346551b244f99e9_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNS00LTEtMS0w_d9494e95-07c4-44e2-aa58-ff94c8d78d02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1250cef8ffc24c32aa61879bf6b514d4_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNS02LTEtMS0w_9325a909-40d6-4c0f-a5ed-c497135be709">35.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54aba4f031f44f21b6560820384f079e_I20210630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOC00LTEtMS0w_9813a1a6-4e2f-4d7b-84c3-54c9483f8f3b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f4743c680e7440da17e364ec93d7b53_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOC02LTEtMS0w_4ef955e8-739d-4f15-b90a-049510210153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1bf393f58e4ed0abf1efa1dd592205_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOS00LTEtMS0w_55c021c9-2921-4aad-af2e-284393ea8a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433d1dcae59d4e858da20f98b3db0590_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOS02LTEtMS0w_9b971414-dd22-4f0f-a794-212e8df3c8e0">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b29bd51ce34a84a747af8d0b76aa9f_I20210630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTYtNC0xLTEtMA_56c8d0e3-172d-4438-a3cd-db66c3a4f64d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7354b1363641bda1fe4879d47cd10c_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTYtNi0xLTEtMA_b49823fa-d34b-4a75-940b-d3de3d33eefb">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf0486182bcb4de1b50c1c4e665beb58_I20210630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTctNC0xLTEtMA_fa695ba2-9e49-49c8-90ff-32398e5acdd0">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b7ae3032894fbdbbde3fe9f817db9a_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTctNi0xLTEtMA_ebc8ba01-69e9-4b7b-b6c0-ea90336f0a2b">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i904ca67b48e9438aa45cc860a3e98146_85"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Property, Plant and Equipment </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfOTY2_0a82e8dc-2b3c-424a-8625-d2c759a1c5b7" continuedAt="i75a7446d324f44dc86b5d102f90a1470" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTcx_ab28f2c5-768b-44b5-9d68-40b60b284a86">1,880.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTc4_e114eab4-c37c-45bd-a0c8-f0b16adda7c2">1,782.3</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively. For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMjY5_2b09cf13-5e68-4596-954d-6c82569a28a8">54.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTA5OTUxMTYyODc2Mg_887408fd-707b-4321-b7c0-652cc4b9b3e0">103.5</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMjg0_00df8e1b-0b5d-47d5-aafd-f2e83be55df5">51.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTA5OTUxMTYyODgwOA_55041a87-d32d-428d-9902-3c508773f263">99.7</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="ic7f7ccbfa9ed411e963f8ab905c572e1_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNjU3_e25c2a13-8b79-4a91-a94d-513e4d1dcfa3">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="i2998a0b67c1c4fdcad0435d7a30e8285_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNzMx_b2976477-c014-4b96-8c8a-651e0d46c9d1">290,000</ix:nonFraction> square feet of warehouse, utilities and support </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i75a7446d324f44dc86b5d102f90a1470">space and <ix:nonFraction unitRef="sqft" contextRef="i81df80dd2e3a491087572c5e78a6d533_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNzky_245a4246-da10-4d52-8321-73323d1418de">51,000</ix:nonFraction> square feet of administrative space. As of June 30, 2021 and December 31, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ib044e39931fe4842989f0f875a50f3ba_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfODcw_2a180b1f-ee1c-4688-8b3b-7c4a13f151f5">618.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icb7fbc25be7d405ab815f3b0802c4430_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfODc3_0dd33e08-cec8-4b19-971f-a89beb785b79">1.8</ix:nonFraction> billion, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="ib044e39931fe4842989f0f875a50f3ba_I20210630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNDk0NzgwMjMyNjQyMw_4ae1788e-247a-4356-93be-b82a3cc003e2">1.3</ix:nonFraction>&#160;billion of fixed assets being placed in service during the second quarter of 2021.</ix:continuation></span></div><div id="i904ca67b48e9438aa45cc860a3e98146_88"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzU4Ng_7248a11b-a664-4ccb-9b4b-3ab03ea76c76" continuedAt="i1e0ecbc42c67467b98265c518cf2a19b" escape="true"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indebtedness</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric></div><ix:continuation id="i1e0ecbc42c67467b98265c518cf2a19b"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjYx_b6e7838d-f711-49d0-8463-4ab9c83879d6">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ie394eb8420ae465f88327d5264884868_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:LongTermDebtExchangedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzU0_70684350-5219-4f8b-a59c-aa18f7566dca">700.7</ix:nonFraction>&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ifead4a76cf1c4aedb1f743dff60ab9c5_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfNDI3_a4b6dfb1-6bee-4d70-a9e1-fb9278b1ee89">151.8</ix:nonFraction>&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="biib:DebtInstrumentRedemptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfNzM4_97eea493-4860-494a-be53-e377394a7ab5">8.9</ix:nonFraction>&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfODEx_c3a87730-f226-4ce7-b090-b059d13f00ab">12.1</ix:nonFraction>&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfOTYx_4623b0d8-e1b1-481a-89d5-52260c6e294e">3.2</ix:nonFraction>&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the six months ended June 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTQzNw_a70854cf-450c-4dbc-b06d-db2dc5438d61">13.8</ix:nonFraction>&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTYwMg_9a62c9b0-1572-4270-b03a-afdd1532cfcd">6.1</ix:nonFraction>&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the six months ended June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i327c113b77e945e794ed2983beca310e_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTkwMA_6e903791-55c1-4081-a2ba-5194b60477f1">3.0</ix:nonFraction> billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$<ix:nonFraction unitRef="usd" contextRef="i5605847573354f9fbd73ba2055256fbc_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTk1NA_c2432f28-1db2-43b0-a30e-f73ae59dfe36">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i5605847573354f9fbd73ba2055256fbc_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTk4Nw_dd563cd0-cf13-4f02-b078-f8bab9f128a2">2.25</ix:nonFraction>% Senior Notes due May 1, 2030, valued at <ix:nonFraction unitRef="number" contextRef="i5605847573354f9fbd73ba2055256fbc_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjAyMQ_4d3273cb-30d5-46c4-ba81-d12f9db9aed3">99.973</ix:nonFraction>% of par; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$<ix:nonFraction unitRef="usd" contextRef="id4d713ade1b14480a777502c5e1bf27b_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjAzNg_fd6cff4f-1aee-4668-9e71-0790bd44f882">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id4d713ade1b14480a777502c5e1bf27b_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjA2OQ_53a0c5a9-794a-477e-879f-714876a35327">3.15</ix:nonFraction>% Senior Notes due May 1, 2050, valued at <ix:nonFraction unitRef="number" contextRef="id4d713ade1b14480a777502c5e1bf27b_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjEwMw_4d55a36f-5c94-43af-9fd0-171c5c331ef9">99.174</ix:nonFraction>% of par.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjE0MA_e44bfef4-7508-477e-80e4-63f8c0f206fd">24.4</ix:nonFraction> million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.90% Senior Notes due September 15, 2020</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjUzNw_f3bea007-328a-4aee-bea6-e156a70af446">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjU3MA_653f5732-db56-482e-a2aa-599cf035acaf">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, at <ix:nonFraction unitRef="number" contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjYxMw_767bdb87-4696-430f-a424-161d6836a997">99.792</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjYyOA_2c4e060a-6ad9-4bbb-83d8-d1be83fe8091">2.90</ix:nonFraction>% Senior Notes were senior unsecured obligations. In connection with our <ix:nonFraction unitRef="number" contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjcwMg_653f5732-db56-482e-a2aa-599cf035acaf">2.90</ix:nonFraction>% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our <ix:nonFraction unitRef="number" contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjkxMQ_5d192e58-f52d-4ad2-bb0d-3ea55b2f43ca">2.90</ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="id78d6dabfa0b4866b6108e9a2c352b12_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjk5MA_c6ada8ec-b4d1-4536-8917-cf90a1de1bdf">9.4</ix:nonFraction> million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $<ix:nonFraction unitRef="usd" contextRef="i49528d2d9baf4068bd97b947293b14ac_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzIzMw_7f847b7e-ff1b-4159-8146-f6127075c6cc">12.7</ix:nonFraction> million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="if078c4e7fa004892b58a2d85cb5816aa_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzM3Mg_a9f7bbc7-567d-47ad-abad-862808116702">3.3</ix:nonFraction> million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_97"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Equity </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTcxMQ_7ee3e492-32df-4fd0-a2d5-7cf2faca3f99" continuedAt="i88c631fda15647558f4fe9faf9e1ca23" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ib4010afcb4574fb5a96678335abc87c3_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTEx_da0fdc64-1a21-422a-a966-5b9e02fc9d37">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i7f180f950ceb4167854fd3cd90ea9c70_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMzk2_6b9c7fce-e531-4cc8-b867-7c5dd4dabdd7">1.6</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i0c0aa046537b415fa3f8df9b5a030319_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNDk0NzgwMjMyNjg0OQ_c2efebcf-48ee-42db-b570-e59aff3af6f5">3.8</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i7f180f950ceb4167854fd3cd90ea9c70_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNDUz_5811509f-b560-43a2-9b7b-dbf667d8318f">450.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c0aa046537b415fa3f8df9b5a030319_D20210101-20210630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNDk0NzgwMjMyNjg3Nw_3d80a294-a8c2-4d7f-8736-1ff380345dc3">1.1</ix:nonFraction> billion during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="ie53079fa10c74963b5f0f9ba19d3c804_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNTAx_d616f0dc-0df3-4d02-98e8-59cb2fddf0ad">3.6</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i43e9a82c06fb46bab58a5f1115cdafbd_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNjQz_aca9535f-6d55-4e1f-83db-936e97de196b">5.0</ix:nonFraction> billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTA5OTUxMTYyOTU4Ng_2d74724b-d651-44ee-b3e0-c3935354b36d">9.0</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i0cd5030b156d448aa845809d96101ccf_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfOTA5_d52047bf-9853-470b-88e2-05d507ee7f28">12.2</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTA5OTUxMTYyOTU5Nw_f3df4eae-5bbd-459e-a959-27680a77c52b">2.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i0cd5030b156d448aa845809d96101ccf_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfOTY2_a77f8fc9-302a-423e-9adf-e65a100d001d">3.7</ix:nonFraction>&#160;billion during the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i5e3c7e0b91104fac8e090638fd4b76a4_I20200630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTA3OA_e8d6b1b1-ae19-4b0e-969e-fa61a64509f3">5.0</ix:nonFraction> billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i377f7b2b4b52412c99af798994cc4777_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTM0MQ_6bf46a19-42f8-4383-a61a-3ead0240ea28">4.1</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i377f7b2b4b52412c99af798994cc4777_D20200401-20200630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTM5OA_8833089d-51d2-4336-9bea-93a20831b3f6">1.3</ix:nonFraction>&#160;billion during the six months ended June 30, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTcyMA_ed7c0652-2798-46a4-a0e7-32bf94165cf0" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5853a7e3ef491bae7a65e1700e49f3_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS0yLTEtMS0w_62a1dcc2-948e-4ad4-b503-f26a4ec5d882">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia36720c0b63744ff81262ab66ab00c7f_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS00LTEtMS0w_2b7c259c-3d52-45ed-865d-73d25d120248">179.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ca5708d24544f20a4280b1a87d305ef_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS02LTEtMS0w_7ec58c08-25da-413f-81c6-9f710bb8b2db">8.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f97bf2a176745928cd1dcd5ea7396f3_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS04LTEtMS0w_2e891472-bc43-4a4a-975f-3938cd4a9b27">66.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib92db432fc134e3e94c64ac21f29c319_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS0xMC0xLTEtMA_d95f9dec-acd1-4d74-9fcd-8f41755ffd83">46.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS0xMi0xLTEtMA_6dd23ba1-81c8-4f67-aae4-a7cc356330b5">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi0yLTEtMS0w_0b310390-14af-4b51-803f-72a38471c77c">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi00LTEtMS0w_42e98561-f65e-4691-9428-0599689369d6">90.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi02LTEtMS0w_045633e7-66ec-4efe-9a87-cdf8ce6622ea">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi04LTEtMS0w_8f4f9da2-9ab4-4872-81cc-bb74233499e7">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi0xMC0xLTEtMA_b11405b7-3a8e-4e7d-9cb8-705a6835a514">32.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi0xMi0xLTEtMA_ee9772c5-f406-4681-9692-e677d153cb65">78.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy0yLTEtMS0w_c2fdfafb-2e37-4f4b-be2a-6eedd63a4f69">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy00LTEtMS0w_8caa0cbd-37d6-46bf-82f5-783a759209bb">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy02LTEtMS0w_f96825cf-6fb3-4d37-859b-445c08aa91eb">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy04LTEtMS0w_fff4725c-58f7-480b-81b1-329b0c1489d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy0xMC0xLTEtMA_5ce48f4d-af6d-4208-ad61-18df3d514c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy0xMi0xLTEtMA_3eae466d-d266-4078-afbd-554547af5583">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC0yLTEtMS0w_c9bf8e94-8d64-448b-ba0d-365a11e3edba">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC00LTEtMS0w_0d149dc8-c535-47b9-b95d-5795bb8b2dbb">138.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC02LTEtMS0w_fa5d63ba-22fb-4b4f-997c-478a1ac82b23">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC04LTEtMS0w_a0a96223-72d3-4f78-9ac2-5044023174d1">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC0xMC0xLTEtMA_853aef1b-e25e-4c6e-b3be-dacac8daabd4">32.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC0xMi0xLTEtMA_6ecb06f8-08ab-4be7-bfe1-2d6a89a32fb6">127.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60fdc6283c6461ab18da2fc1f5f4f7c_I20210630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS0yLTEtMS0w_76e6e611-f4f7-4c04-816a-f5e5e1310088">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0beb22829148494f946ca0c797b83a17_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS00LTEtMS0w_8e9ee56b-fc2e-469f-a611-9eff43f713f6">40.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c400ae85bb449a972a93be398be207_I20210630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS02LTEtMS0w_87099c9d-83ad-45a2-98fe-99952d65e579">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if22b6d24018d47dc812ff8762a4fa3cd_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS04LTEtMS0w_d6fc0822-2292-4722-adb2-774d9937ba9e">63.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b30ac7e13f4d9c97c0e658be456894_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS0xMC0xLTEtMA_8598951e-bd99-4156-9877-d8b5101ecc97">79.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS0xMi0xLTEtMA_80cbdf4b-18aa-4aba-8cbb-5fc8867fc7b7">171.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e22cb23d684bd2bfc1ab92393bf68e_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS0yLTEtMS0w_e5d5581e-8d04-418f-9a84-73e7facd99de">4.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350abaf377694487bce4d1569f7c6563_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS00LTEtMS0w_08ad05c0-fed5-4cee-82b3-d931b90331f5">7.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b9bf78269b4fb284993468c59edd91_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS02LTEtMS0w_e7e159c6-6ecf-426b-af88-2f5669a0b2be">25.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45a327327cab48738dd4d95d812889ed_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS04LTEtMS0w_56c6f250-0857-404d-9834-bcee4036a434">32.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6ecb6a9ead4700bd2dc91367ec36e4_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS0xMC0xLTEtMA_803f95f5-a29e-40bc-8a4f-53f86ed57d4f">139.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i025174d34d0e4fed9880bf522bf39caf_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS0xMi0xLTEtMA_05a55db0-fb7b-4f6f-a7f6-a07a37892923">135.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi0yLTEtMS0w_6ac6dbc4-e19d-41d9-852a-11dcc28facc2">9.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi00LTEtMS0w_8ce04ce3-b91c-4b05-a0ce-5846354c4cc5">33.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi02LTEtMS0w_1895caf8-ddb1-45b6-af88-8f78e6f490ae">18.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi04LTEtMS0w_a60adbe8-ebbc-49d5-a13f-429685002d2b">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi0xMC0xLTEtMA_296c2c75-30bb-4d3b-b560-2c64ad7695a2">47.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi0xMi0xLTEtMA_0c39cbf3-f996-425c-9e25-3d1c554f516d">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy0yLTEtMS0w_43914352-a1b0-4622-ab83-0e1b46632997">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy00LTEtMS0w_becfe10a-3f18-4438-987c-557555613ef5">50.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy02LTEtMS0w_1df5029a-6f39-4037-aaea-a92e9042bbea">1.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy04LTEtMS0w_3c7bfc2d-914f-439a-bea9-68e418d6e21e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy0xMC0xLTEtMA_be28eeeb-8ebc-4435-9057-82e52945cd97">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy0xMi0xLTEtMA_8848e332-2399-4fc8-bcf5-a57eedbd099a">42.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC0yLTEtMS0w_4f7f2a88-5bbe-4fa4-8922-ea51318bc8a2">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC00LTEtMS0w_d42881da-4777-43d0-8c0a-18262be86c39">17.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC02LTEtMS0w_9db50bc1-2f1f-423c-9918-34340b421fea">16.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC04LTEtMS0w_f5d14c0b-9da9-41f6-92c2-59b840aae94b">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC0xMC0xLTEtMA_07abda15-ab7d-46ce-acc3-9321ae27f3a2">47.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC0xMi0xLTEtMA_85a6840d-1498-428e-8a87-2793d1670186">45.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8cc4cd6af248d9bfe66ed30639196d_I20200630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS0yLTEtMS0w_2c807f52-8deb-4edd-b1a3-9fe31fa0e199">5.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a59246306f44bb4b8c54ec6ff864503_I20200630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS00LTEtMS0w_e20c5398-3a03-4bee-b6ef-9fbc99e341d8">9.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f6ec19f64e41568b2068e96298f003_I20200630" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS02LTEtMS0w_dcc585b4-9fac-41da-8814-89aa9afe6f2b">41.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99da815ae3f44649e4b32bb305c0670_I20200630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS04LTEtMS0w_74f44ffb-1018-4f01-9dd1-5f1d90a773fd">31.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia94afab659f248cba857933e77ec8718_I20200630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS0xMC0xLTEtMA_b7f5474d-90e5-4171-8405-aa4d900893e0">186.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS0xMi0xLTEtMA_c83811d7-0bee-4a91-b6cd-d19d24df1a5e">181.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i88c631fda15647558f4fe9faf9e1ca23"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTczOA_88180ccd-426b-442d-8534-31ef9f8404ce" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.006%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f12d27ddfb1404aaf145062a7713f57_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy0zLTEtMS0w_e573ef5b-5431-4b5f-8627-7e454e4c8bb5">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92055b26fdd84bf0b0f9ed93e463988b_D20200401-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy01LTEtMS0w_a7ef58cb-e2e6-47e7-8172-8806c1cf6461">3.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbd9eee9380f42788da909d05cfb8fd7_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy03LTEtMS0w_8b3884c9-a854-4f93-b990-e6a4e7bf9cba">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4a22cdb164d4ec1b3e8b6f30d33a058_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy05LTEtMS0w_1adb9a17-88a7-4b88-b8b3-4a17decf18a1">12.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f12d27ddfb1404aaf145062a7713f57_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC0zLTEtMS0w_2a0bc6a4-bafb-4af6-92b8-1af5e14f6aa5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92055b26fdd84bf0b0f9ed93e463988b_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC01LTEtMS0w_de28eb09-2f6f-4876-802d-2fb206ade7c7">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbd9eee9380f42788da909d05cfb8fd7_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC03LTEtMS0w_95c688c0-e1d4-4b3a-bf4f-f24ff0c42038">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a22cdb164d4ec1b3e8b6f30d33a058_D20200101-20200630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC05LTEtMS0w_0646ff1f-222f-4d11-a079-6f94b30cf159">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi0zLTEtMS0w_c7ad4242-f524-404b-bf5d-196002af012d">30.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi01LTEtMS0w_89e21a64-06d8-4ae4-a022-c4c97373e758">23.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi03LTEtMS0w_7b5323af-7fb8-49a6-829a-ea36691476e7">53.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi05LTEtMS0w_83cb5a5f-06dd-4952-8bd1-0efec11b7152">50.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy0zLTEtMS0w_6e301a03-4638-483a-97d3-6e0f8e7d3b1d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy01LTEtMS0w_46f97a38-19d0-4af5-9538-4416c5b6a817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy03LTEtMS0w_93d08f9a-c3ea-4045-bada-876b5723685b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy05LTEtMS0w_1bb94b4a-142b-4ca6-bbd2-f43a02c4773a">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC0zLTEtMS0w_4d8d205a-91ef-4a42-9611-62d14479bff6">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC01LTEtMS0w_eea23f4c-4ec9-4704-9804-eb8bde6a4339">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC03LTEtMS0w_aa2e8e44-c04b-4046-b50e-4bbbb9c1a26f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC05LTEtMS0w_dbe7a66a-16fe-4b16-ab82-11909a7632e7">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS0zLTEtMS0w_717ee749-d339-4fdc-832e-3873d1263f61">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS01LTEtMS0w_36620a3e-916d-43b7-a45a-e0a4cc244a4c">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS03LTEtMS0w_acdd5248-893b-48b4-be3b-2a02e60f7387">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS05LTEtMS0w_5a461f4c-eb64-4390-b357-1c8a389ec22e">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2867d1e4c35544c591c011e82114911d_D20210401-20210630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtMy0xLTEtMA_b1503308-816b-4478-8b83-e5c22157b1fe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550626667d504f049e3f27be6c6e87d1_D20200401-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtNS0xLTEtMA_1bde3c37-d8b4-47ce-8c3a-06d61375789a">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc844f221fc242d7ac07b31786e87e81_D20210101-20210630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtNy0xLTEtMA_40dea29f-993b-434f-a040-26556250ee9a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec6ff2fc5d644a894df350de003ed08_D20200101-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtOS0xLTEtMA_cd2bcfd8-22c8-43b6-868f-24408a0376c0">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0d7f325ae73459e825690036a3d6239_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtMy0xLTEtMA_fff7ae1a-bf83-4fea-ae2d-d5b33d697f13">27.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida11029c7cd140e7b425e00d05e00a01_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtNS0xLTEtMA_2c147cc0-d27e-4376-9441-17fb16d457fa">27.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id85699448040462d8f5baad3e1537a64_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtNy0xLTEtMA_e56c3ee6-fa6b-4e53-8f55-ac4ddfac2aa2">49.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85035a7642e240e7bf1eb74af9286dba_D20200101-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtOS0xLTEtMA_121ce256-47db-44d0-873c-678439c99fb0">42.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i904ca67b48e9438aa45cc860a3e98146_100"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Earnings per Share </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90ZXh0cmVnaW9uOmUyYmM4MDVkMTgzYTQ3Mjk4MWFjYzQ1OGIyNzgzODc3XzIxMg_f51b54ee-bcbf-4749-9c3b-0fcfe25bf16c" escape="true"><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90ZXh0cmVnaW9uOmUyYmM4MDVkMTgzYTQ3Mjk4MWFjYzQ1OGIyNzgzODc3XzIyNQ_ab099c86-a9c9-4880-ba85-e050059a7d0e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtMi0xLTEtMA_232b2dec-5eac-418e-a975-d86f811acc67">448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtNC0xLTEtMA_5da21e50-2f68-4347-a7de-168585439c27">1,542.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtNi0xLTEtMA_411c5714-04d4-4582-b1f9-7ac52c2b65df">858.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtOC0xLTEtMA_8a5fdb7e-78ea-4753-a029-675acc765d3a">2,941.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtMi0xLTEtMA_c662533d-f319-4e52-bac1-bc0463bce3d8">149.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtNC0xLTEtMA_466c2f5b-839d-482b-a165-f9896d7bd740">160.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtNi0xLTEtMA_432e4fad-6eb2-4682-a018-3ec5dcdec1c4">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtOC0xLTEtMA_8f174852-9928-486d-b1c8-d449f97eab29">166.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c79aa09732f4485b81ca20d090dc9d2_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtMi0xLTEtMA_aff9079f-d3d4-447c-bf8e-cbb801826827">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic607ef111a0b40c98d2bb3abadd70ac3_D20200401-20200630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtNC0xLTEtMA_5b8493c5-b9bc-4ff5-b400-cb99c0490163">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2282dfbca39426985c7b4c02362b0f6_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtNi0xLTEtMA_d7027017-3dd7-4c11-8bda-c3b0783cb3e0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4eec312c192244b58a5937395a9f32ca_D20200101-20200630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtOC0xLTEtMA_65a4381f-2b89-47aa-a94e-9a4fe2b8d9ed">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f60cc29d37f4bb39e05aacb97220a95_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktMi0xLTEtMA_0fed06b5-39d8-4818-a3b3-b1430314f45f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida800d3221da45ab8bb24399a9800a50_D20200401-20200630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktNC0xLTEtMA_7bc69030-56cf-4f2b-b55c-e5580638eff9">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i743269d62e29412c951e960acc6995bf_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktNi0xLTEtMA_c10933c2-df36-4dee-809e-b4c8525240ae">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79cfcde33ee94b2091ef4e9994affc0a_D20200101-20200630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktOC0xLTEtMA_7cd9ee15-b32f-437a-888c-4724c3721760">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia69456628ebe4d798414fbd24865b055_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTItMS0xLTA_e7f025a8-31e1-4d65-b238-4dd62f16bef7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ca6ce9dd1204c9d8ee47ed61c9d49e3_D20200401-20200630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTQtMS0xLTA_e6ef4165-b06d-4d49-9a1a-26ec5f3fa884">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24286416527948f3a36f9903ba223e92_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTYtMS0xLTA_3afdd17d-986f-4616-88fc-a0c805a299a6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5868596776a48bcb3288f10554ae486_D20200101-20200630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTgtMS0xLTA_0f594a81-9548-46cf-865e-618edde0e4f2">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTItMS0xLTA_cb5e180c-2139-40b4-9e01-34386dbe6529">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTQtMS0xLTA_6c803ae3-8ebd-4c26-b954-cd1a313b947b">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTYtMS0xLTA_1e7b8de5-1ebd-4c12-a7d1-89bfef4c4194">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTgtMS0xLTA_4dfb0f47-b0cd-415f-91a7-2567234a5acb">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTItMS0xLTA_c47dfcc3-86f0-4920-af5f-7d50a171963e">150.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTQtMS0xLTA_0980a725-b0ff-4322-be4d-1dc0e2cfc6d7">160.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTYtMS0xLTA_9b0b5082-3204-407c-a1b9-a3496464e141">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTgtMS0xLTA_04cccabc-d2e2-4433-a2f5-db0560645a95">167.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_103"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Share-based Payments </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90ZXh0cmVnaW9uOjc3ZThlYTQ2NDI5YjRhZWZiMWJiZmUzMmQ1ZDRlZWRlXzY2OA_bb86fe75-ec29-4a58-9c7a-1a8460334ccd" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90ZXh0cmVnaW9uOjc3ZThlYTQ2NDI5YjRhZWZiMWJiZmUzMmQ1ZDRlZWRlXzY0NQ_4cb47bd7-afc9-43c4-a39b-128511672174" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7711bdabafa4868acf0cef411512b10_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItMi0xLTEtMA_41a83acd-0f42-40a2-bec0-e3ee1576518b">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea5a899ef244aa7ad5b55e212db3c75_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItNC0xLTEtMA_846a6a81-8125-462e-bbe1-81ee349b3ec1">15.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic508730c80624e0a9bd030c7f4a89e07_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItNi0xLTEtMA_e6ac521b-32fb-4708-9f7c-61c9dd91466b">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b1713d5c5845d3ac44180eebc6f115_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItOC0xLTEtMA_2b6088a6-a6b7-4a18-9de8-5cccf59ee68e">48.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33eb872c6b4401cbc20e2f4180db8ea_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtMi0xLTEtMA_075a0ced-e474-4766-b9d7-4dcdf0ff98e0">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic438578392a5405689d4d33d4518f669_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtNC0xLTEtMA_84c9c6cb-6855-475a-b49b-861b88238e05">30.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c7482558954653832964511911a842_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtNi0xLTEtMA_0642b27f-2c41-4a5b-8523-17dacf2a2d53">85.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed6e6d0ef254bcab5ae8ea84750ae16_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtOC0xLTEtMA_261961b2-fd67-4f21-9b4d-2e7c6d07031c">73.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtMi0xLTEtMA_ecfc9734-5d3f-4483-8604-eefdce520635">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtNC0xLTEtMA_f16e95f8-e6b9-444b-ae1a-21086f688dfa">45.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtNi0xLTEtMA_c75adfc7-058d-4c66-bb95-4fd45241da46">137.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtOC0xLTEtMA_b7e2d059-06de-40b5-8f7f-9b058bfeab68">121.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtMi0xLTEtMA_2a123220-336e-496b-b19a-4a49c10998c6">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtNC0xLTEtMA_13cc80e1-bc0c-4115-bea6-ceadb4f4a7be">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtNi0xLTEtMA_fde59ff6-d3e7-4269-9e8c-dae58c86320d">4.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtOC0xLTEtMA_cc53e6b3-3923-44ee-bf69-1ff8dfc407f5">3.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtMi0xLTEtMA_f66889ec-16b1-49f2-9866-d58b454b6305">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtNC0xLTEtMA_404b7d48-8f9a-4840-bbed-dc155f4ffd80">44.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtNi0xLTEtMA_5f4ad368-3868-4df0-9115-1f2d3d6b8cc2">133.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtOC0xLTEtMA_04b559a7-9a63-41ad-9e05-c47725cd13f3">118.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctMi0xLTEtMA_bec85203-4a3c-4385-8b17-28278cec2411">10.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctNC0xLTEtMA_b28f204e-9177-49b8-93b2-dd5709788313">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctNi0xLTEtMA_a981ce71-3e03-4924-ba94-136c73b2b158">24.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctOC0xLTEtMA_c9856265-13c9-4e68-a772-bb3e255d21bd">20.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d163820b4b429c8ac869eca01a9a0b_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtMi0xLTEtMA_ccdfa0d1-7a6e-4fda-a857-2befbea599e1">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812c1ff8e80b47b58ab63fcf9ec1c7fa_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtNC0xLTEtMA_68cef407-066a-4bf4-ab6f-4b7c90d8ba55">37.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1023665010a54e788e30ff06159d6b65_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtNi0xLTEtMA_f90cc298-0aab-43f5-9134-0bb29b992f29">108.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d84900139e040b39413a2c034c9a0a5_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtOC0xLTEtMA_67e37f3f-e598-4aa5-a3d4-a9f727760ca2">98.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90ZXh0cmVnaW9uOjc3ZThlYTQ2NDI5YjRhZWZiMWJiZmUzMmQ1ZDRlZWRlXzY0Mw_da875487-156b-4a54-bb72-433df35dbdce" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81326f8c0faf4c82934916df0e7ba73b_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItMi0xLTEtMA_bf6b5d3e-853d-4a29-9f3f-1a2e4b018a2f">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48408b16cb17457fa4d16374fac38f5f_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItNC0xLTEtMA_d15f30c8-6e34-4fdf-a829-3f8268ce7b2d">7.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af3d4e0eb01491fbe2b12666856a203_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItNi0xLTEtMA_513dfb0b-ec5a-4a4f-9da2-b945de375f8e">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55281e38b4084b1a87f417de6e85d628_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItOC0xLTEtMA_839ae98c-24ab-4e75-919b-90123d6f0707">26.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice3a443da8f344bfbcc4b77135174e59_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtMi0xLTEtMA_ff49543b-a859-49a6-8e62-1828c5e74639">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bf599004a64372aa741876daef053b_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtNC0xLTEtMA_abfe68dd-0f82-487d-ac21-95283d722a6d">34.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cf1f40f75d4c3eb9de865f64ecbbe5_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtNi0xLTEtMA_e896bd3d-dedd-4d9f-b672-e2196212411d">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627f7085dbc94df5a856a6ef66dae68a_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtOC0xLTEtMA_3ea93cbc-b3ba-45cb-bfb5-cf33eef94638">72.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f184261bc64a1c87dca1dc5e5dcb5c_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtMi0xLTEtMA_b7aef420-e084-460b-ba53-f7766a66222f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i327ede04c0d64a02a183dcb72ead44b0_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtNC0xLTEtMA_a3ff526c-401a-4503-82a7-c7b5fe2ee1cc">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63915734eeed4a7fa8f44b93a5f9dad2_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtNi0xLTEtMA_1cf589b8-0b5c-4ac2-a3d2-011d3edb1ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if414343ed3b64a0ebf09d1a0ac51b4ed_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtOC0xLTEtMA_aae58f39-f360-47d0-a8e5-09c93c38f6dd">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4be0f188a48449bb2c0674eb366a190_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtMi0xLTEtMA_72d505d6-bed5-4847-b929-eb2eaf86a3b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16260595953d496b8eddf5ebe0653440_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtNC0xLTEtMA_62e0a336-3a0f-42bf-94a0-b9772c698e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4ab76f4f554cc692c968485d75b3ad_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtNi0xLTEtMA_18419255-9fcc-432a-afb3-68cef09caabd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6e972a3b7174d6f895bab11575fb911_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtOC0xLTEtMA_43f8cdf5-3498-4106-bcae-34e19c01f4aa">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd08f32f2a474aaf85876113c161d15f_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtMi0xLTEtMA_22a2a593-e7e9-45bf-bfe8-1c927d94a9fc">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034140dcf36b473790fbcfecad31c0f5_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtNC0xLTEtMA_75d3e618-3ece-4f76-989c-320a030b589e">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15391fb757e741998e7ea0be726a8c97_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtNi0xLTEtMA_56d0191d-1a86-405f-a105-74aefdb89f76">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5126740cc446437cac3cd23b16210a6b_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtOC0xLTEtMA_ab56929d-f218-4955-9746-1fccb3c11273">12.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5def17fd84945bea951f1f209f4a742_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctMi0xLTEtMA_c0b4272c-0d2f-414c-85f1-84ce97688cb0">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dc2ebe6040c4f58b354ab2338b8717a_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctNC0xLTEtMA_fb6b9a4c-f33a-4fad-b798-497d7356daa0">4.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177c8a1d0d754674a0c18fab88e27143_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctNi0xLTEtMA_8fd95e52-681a-4c09-9a89-364080d4f1cb">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6bd17fd1a848c39c8365d388aeb423_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctOC0xLTEtMA_1129814d-84de-4c53-83ec-70ab888b7e2c">4.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c191952c6e484ba3dd03915045e4df_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtMi0xLTEtMA_f59cabe5-dc23-420e-9c62-ca0a14a8797e">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5386b3cc1f54a49bc7493b4ef834955_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtNC0xLTEtMA_3a0679e8-f0cd-47b2-a2b8-7da4d5335751">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7874f6e244472f9ef1586998fa6bd7_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtNi0xLTEtMA_33e2913d-401e-4fce-9f7b-594b53ee24c5">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dddb0afc8b342b58b72feb818dfc513_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtOC0xLTEtMA_6fcfd460-0f39-4af8-8ec5-1716a27ab32c">7.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTItMS0xLTA_6af9ad71-5efa-438c-9319-f11aff011cc3">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTQtMS0xLTA_576b7490-2cbb-4c42-9622-c720f1c6a669">45.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTYtMS0xLTA_11311df5-7579-4f2d-8c13-eec6bd577e5e">137.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTgtMS0xLTA_b8011757-b3c7-421b-a2cd-ccec92fe072a">121.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTItMS0xLTA_f0fbe86f-9e90-4676-9f52-7f4a9667a93f">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTQtMS0xLTA_b7cf527a-952a-4515-ac96-0e5a774aaa51">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTYtMS0xLTA_9fdfddb8-15ef-4e34-b497-e93f1c24d2da">4.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTgtMS0xLTA_8f359a50-18d0-4eae-acc5-a200fbc81ddd">3.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTItMS0xLTA_c4011a09-ce90-493e-914a-b2053dc8c067">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTQtMS0xLTA_9ca557cd-8424-48cc-91c0-b9797ae3748f">44.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTYtMS0xLTA_7ff1681b-dc89-4c13-9fd8-0cfffde7157c">133.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTgtMS0xLTA_c82d468b-7d2d-46db-810f-bed77584e67e">118.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div id="i904ca67b48e9438aa45cc860a3e98146_106"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;Income Taxes</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzMzMjI_fc070357-fc43-4a4f-b766-4dcfd73dc536" continuedAt="i7a0c561c13414183aef5e09317d558c4" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i7a0c561c13414183aef5e09317d558c4" continuedAt="i762ce1343c9342b597f153677a17f24b"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $<ix:nonFraction unitRef="usd" contextRef="i84f242af2dd048a2bc766c9493467dc0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxAssetsValueReductioninValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwNDA_873573e6-64f9-408f-9186-d8e0686af7a8">1.7</ix:nonFraction> billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $<ix:nonFraction unitRef="usd" contextRef="i84f242af2dd048a2bc766c9493467dc0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesValueReductioninValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzExODU_e55c84f0-9b35-4d1b-8176-e22d7b620b36">1.6</ix:nonFraction> billion. We continue to assess the realizability of these deferred tax assets and have recorded an increase in these deferred tax assets by approximately $<ix:nonFraction unitRef="usd" contextRef="i5336835708cc4dc48247e0e9ad7969f9_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxAssetIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIwODc_30c1a8ad-8f43-4b68-bda2-134fc7ef9b22"><ix:nonFraction unitRef="usd" contextRef="ia5082dfd8d8a4569a216ee449ace1886_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxAssetIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIwODc_5e491d23-ff5e-49b4-8645-36c45f35dfb0">92.6</ix:nonFraction></ix:nonFraction>&#160;million and an increase in these deferred tax liabilities by approximately $<ix:nonFraction unitRef="usd" contextRef="idf8d368179dc4c9290de72ce73993e6c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIxMDQ_953c13ae-ef99-405d-9e04-81c6fa774d39"><ix:nonFraction unitRef="usd" contextRef="i3cce66e5d593473eb28168ab00d42bbe_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIxMDQ_e6d24fc6-573a-4c63-a9f6-4d0b8fb23e21">88.7</ix:nonFraction></ix:nonFraction>&#160;million for the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzMzMTA_63408395-c798-490c-b6f4-705680d883a7" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItMS0xLTEtMA_4b3557cf-9c0a-43e2-80b1-3f6b9b98a25f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItMy0xLTEtMA_2c61841d-c5de-4806-9cb3-dd07b114e7d5">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItNS0xLTEtMA_7c12032a-54ca-46a6-98f4-98a4ae47fde4">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItNy0xLTEtMA_c7c99ee7-e866-4898-a079-a4cd4d2249df">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtMS0xLTEtMA_1d1f166c-4f58-4e2c-83b2-7dc6768f2756">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtMy0xLTEtMA_2a0b06b7-589c-4942-b9ea-a2789852601f">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtNS0xLTEtMA_cb3b7092-0fbf-4b90-af8f-eb3511a6273a">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtNy0xLTEtMA_0c898d1b-35ac-4796-a56c-2ff031354e86">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtMS0xLTEtMA_d9e4dc6c-619e-436b-bb87-617aafc8da4c">7.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtMy0xLTEtMA_6db91ce1-4a87-435a-bfc9-6f36733311b1">3.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtNS0xLTEtMA_91ddd6c3-f54e-4a53-873d-a7c3410850ec">9.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtNy0xLTEtMA_3040603f-5d04-4679-9be0-50a3ab5f8b92">3.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtMS0xLTEtMA_368f7ab9-4c3d-4a27-9dd5-124a5c73ddec">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtMy0xLTEtMA_38c84f4a-44b7-4b56-b627-091f6ca46801">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtNS0xLTEtMA_290a73f0-7489-41ad-9223-1a6bb02d9005">3.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtNy0xLTEtMA_275d4998-fce0-4ecc-93ca-4188178c325e">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtMS0xLTEtMA_fe8f595b-65da-4a11-bb33-9536f46aa39b">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtMy0xLTEtMA_9f2ce90e-ea5a-47ef-a597-676ab622eb7e">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtNS0xLTEtMA_2c1d07a4-fb36-4df9-8edf-ab66c4e3a624">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtNy0xLTEtMA_f55dc9e3-dfc6-4e5a-9bc3-1dadd7c06558">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktMS0xLTEtMA_2d24904f-d6d9-4bb8-a55b-69f47aac3a0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktMy0xLTEtMA_89a40df8-44ba-47d3-b7f8-61dc638f81a2">2.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktNS0xLTEtMA_09f86ed2-18d8-4354-b970-fa7e7bed1f15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktNy0xLTEtMA_0540b99e-423b-4477-9c82-1ace175b1d4d">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTEtMS0xLTA_3cb258f4-9173-4dd0-9f0f-014885c5aca5">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTMtMS0xLTA_b212cf11-af5e-43b7-9475-56daf508a45a">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTUtMS0xLTA_335ecc42-130d-4518-866e-d81497c7c9f5">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTctMS0xLTA_c056bf33-6663-40bd-b78f-b914abc6c8c6">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTEtMS0xLTY1ODM_b5adf60d-bc72-476a-8611-34e16d4bc87a">83.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTMtMS0xLTY1ODM_c47915b6-d93e-467e-8a1a-93c68e97bc18">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTUtMS0xLTY1ODM_8cdc24d2-9d26-4a92-aad8-c5d6de582952">46.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTctMS0xLTY1ODM_1578d2c4-d888-402f-bc2a-95794a7e251f">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTEtMS0xLTA_81bddba4-a941-498c-ad2e-43b3e5156606">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTMtMS0xLTA_b69e0108-d77b-4d9c-bacd-f5dfcdf9196f">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTUtMS0xLTA_7ec0fc84-2117-4d9e-a088-22ce13fa4f33">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTctMS0xLTA_4e83bb00-e40f-4897-8541-a3e344db8a4f">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTEtMS0xLTA_b1301735-2284-4b35-8415-22848ea99a92">70.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTMtMS0xLTA_3551595a-36c8-4395-8a6d-04b6cd3f313b">21.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTUtMS0xLTA_4ee18e89-7faa-4f78-9493-899927dc2c15">34.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTctMS0xLTA_9a4b88d1-1f09-49b6-b738-c092683b1ad1">19.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate were primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. We recorded a net deferred tax asset of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTEzMDE_384f0730-4831-459f-ab5d-524aebc3207b">500.0</ix:nonFraction>&#160;million. The net deferred tax asset is comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTI4NDY_e75e9d52-5135-4b41-9649-8a565ab98922">875.0</ix:nonFraction>&#160;million of gross deferred tax asset, reduced by approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTI4Mjc_8e843464-99ef-430a-8351-4a8adc174b8c">375.0</ix:nonFraction>&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed above, were primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market. Our 2020 effective tax rate reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, our 2021 effective tax rate reflects a decrease related to the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in 2021. The tax effects of this change in value of our equity investments were recorded discretely, as the changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i762ce1343c9342b597f153677a17f24b"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we increased our gross unrecognized tax benefits by approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTM4MTE_8e843464-99ef-430a-8351-4a8adc174b8c">375.0</ix:nonFraction>&#160;million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM, as discussed above. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset discussed above, and not as a separate liability on our condensed consolidated balance sheet.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzMxODU_932ddec4-6e8c-49d9-b65c-717352b03f0b">20.0</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div id="i904ca67b48e9438aa45cc860a3e98146_112"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyMzg_3259320e-4df1-446e-b5d8-2622fe9cb8fc" continuedAt="i08846be4fa454fe6820bd796fcc48ea2" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyNTU_80008175-7b16-4d1d-8b04-ac2b5f6e0a53" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItMi0xLTEtMA_740c607b-dd31-496c-9c1d-0cfec9aae5a8">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItNC0xLTEtMA_2ba2ce89-887a-40ed-b492-deb3225570cb">7.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItNi0xLTEtMA_b790a42d-3914-4508-8ede-99655b16e46b">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItOC0xLTEtMA_701d6068-6b84-44c9-b64f-25ba153cc221">32.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtMi0xLTEtMA_8b6a20af-05cf-4095-8098-319ec9343893">56.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtNC0xLTEtMA_1fae6d71-9c7c-4c18-aacf-ca4977ebecde">66.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtNi0xLTEtMA_c207bf11-c218-4411-9cf4-1e2c2e401484">121.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtOC0xLTEtMA_6a8c94de-1254-490a-a3cc-3ee374a7bf04">110.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtMi0xLTEtMA_bdf729ec-071d-4407-926f-06d6efd8d694">153.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtNC0xLTEtMA_9f2c9eda-e649-44b5-a813-2152fff740f8">106.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtNi0xLTEtMA_72530866-0c9e-49dd-8bbd-1574e2b12ba3">282.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtOC0xLTEtMA_95484d21-5c44-4bef-9ff2-5f028fd18fa6">29.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtMi0xLTEtMA_5a2d48a6-87a8-44d9-b7f7-ee9b7f50880e">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtNC0xLTEtMA_20601c1a-1b6b-4c77-8619-7dd0486afa4b">10.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtNi0xLTEtMA_ae57b245-4147-41b9-8462-7dc036b83daa">9.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtOC0xLTEtMA_5b4a591b-e8cf-48ef-9402-c36d103ef71f">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtMi0xLTEtMA_70ea0dd3-9a26-4a93-8629-76451db4b28f">3.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtNC0xLTEtMA_a0284cf0-3e04-45b4-b34b-38f52e5f9742">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtNi0xLTEtMA_20b17287-5406-4aaf-b788-ec623b511802">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtOC0xLTEtMA_8e1d15ee-b6f9-4fab-89df-0d1c38be1293">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctMi0xLTEtMA_e6765f8a-9349-49a1-92e7-1b7c3a07a117">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctNC0xLTEtMA_5d406f21-20b6-42ec-8bf0-4480b3aeb21a">63.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctNi0xLTEtMA_66212041-7879-447a-b0aa-327b1dcbd81a">410.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctOC0xLTEtMA_b4a8bf06-e470-418e-a887-f1ab3d58b161">57.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, net unrealized gains and realized gains on our holdings in equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzUzOA_11d2d361-8662-4107-9d0e-d61b0de0d40b">153.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzU0NQ_ab01a85f-6060-439d-b87f-606316b98c4a">0.4</ix:nonFraction> million, respectively, compared to net unrealized gains and realized gains (losses) of $<ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzYxMw_3e8c81b5-38a9-4340-9c54-c2e639003bb3">102.9</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzYyMA_d5719445-f329-40f9-9856-44e1b5698ed1">zero</ix:nonFraction>, respectively, in the prior year comparative period. The net unrealized gains recognized during the three months ended June 30, 2021, primarily reflect an increase in the fair value of Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i1d9d0511d58d472bb7e1f483ef7f6e88_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2MzAxOTk_6021e2f4-e316-4e76-9534-ed6538757e75">263.0</ix:nonFraction>&#160;million, partially offset by decreases in the fair value of Ionis, Sangamo and Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i1d9d0511d58d472bb7e1f483ef7f6e88_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzg1Ng_01aae5f0-600f-400c-b3ce-deef2c7e1a56">105.8</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2MjkyMzQ_0554b5da-1b17-4b8d-a1f0-03c09bca1816">288.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2MjkyNDI_11af56a1-c993-467c-acc5-f4384c360522">6.6</ix:nonFraction> million, respectively, compared to net unrealized gains and realized gains (losses) of $<ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2Mjk0MTU_b8036358-3df5-4d96-a7a3-72070a1f866d">42.0</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2Mjk0MjM_f8b368c1-92fb-4fb6-8fe8-7574d85b0b3e">zero</ix:nonFraction>, respectively, in the prior year comparative period. The net unrealized losses recognized during the six months ended June 30, 2021, primarily reflect decreases in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="ic33fdfdf2e5d4d1b9eed0a03f5eb93d0_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2Mjk4NTE_b9e516df-e940-4f77-9c10-1b9676c95637">284.8</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyNjE_627a476f-e6c9-441a-a6b5-efacc99af363" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of June 30, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItMi0xLTEtMA_2b8bec93-9bd0-419a-8586-704342120495">154.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItNC0xLTEtMA_b0a2b6b4-6d60-4e4f-9d17-4e4f89d15704">102.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItNi0xLTEtMA_0ba3ae75-314f-4a31-80b8-5cc52de84aeb">281.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItOC0xLTEtMA_98d000d4-3b9c-4369-b576-64a532f45dec">42.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtMi0xLTEtMA_ab01a85f-6060-439d-b87f-606316b98c4a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtNC0xLTEtMA_d5719445-f329-40f9-9856-44e1b5698ed1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtNi0xLTEtMA_11af56a1-c993-467c-acc5-f4384c360522">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtOC0xLTEtMA_f8b368c1-92fb-4fb6-8fe8-7574d85b0b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtMi0xLTEtMA_11d2d361-8662-4107-9d0e-d61b0de0d40b">153.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtNC0xLTEtMA_3e8c81b5-38a9-4340-9c54-c2e639003bb3">102.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtNi0xLTEtMA_0554b5da-1b17-4b8d-a1f0-03c09bca1816">288.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtOC0xLTEtMA_b8036358-3df5-4d96-a7a3-72070a1f866d">42.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i08846be4fa454fe6820bd796fcc48ea2"><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyNjI_566ad2bf-f1de-4669-bf0c-df1ccaca9791" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf361b51f5534b34939b0f745631d54d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzEtMi0xLTEtMA_bd8e9028-48d0-46b9-8d20-4f96a62ea3eb">1,042.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad6c76d74374942bcbb4934411ede69_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzEtNC0xLTEtMA_3da8fefd-7f97-41c8-bf19-81b530fcb003">1,080.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzItMi0xLTEtMA_09b24bf6-ba32-4d92-b7c5-c79d8c7a543d">383.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzItNC0xLTEtMA_2d7d202a-8686-4be6-828b-bb1de5ec80af">389.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtMi0xLTEtMTI5MzA_2a732740-c94b-43ca-a923-58bbe4039e0c">242.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtNC0xLTEtMTI5MzA_79aa8aad-7447-45d8-a86c-21e9d3060a72">333.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtMi0xLTEtMA_8c2879e1-3d21-4ebf-b968-440129721b05">240.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtNC0xLTEtMA_4dc2768a-176c-4a32-b5dd-8b8112382483">218.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzUtMi0xLTEtMA_2037efb4-ed2e-44fc-9a10-326c07eaa8d3">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzUtNC0xLTEtMA_a9b584f8-9bc6-46b1-a861-ca5e9b64009d">181.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzYtMi0xLTEtMA_c0ae4542-fa9b-4c4a-94f1-0c2b014f6a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzYtNC0xLTEtMA_7083f905-16e1-4129-8b61-46b0eacd0a34">149.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzctMi0xLTEtMA_55bd8ea7-3396-4341-8ff8-7c7f0eee7e97">760.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzctNC0xLTEtMA_13b091cc-97c3-4ec7-93b4-2843dce2fc09">791.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzgtMi0xLTEtMA_9e377ced-20a1-4586-8cb7-9af27f248914">2,741.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzgtNC0xLTEtMA_7e9cc0d6-7c9e-4157-8073-cb90e418e257">3,145.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzExMzE_26413be5-1d01-45b7-8e2e-b8203daa0155">1,356.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzExMzg_1c45e206-c774-4c27-8f7c-af45b946d416">1,329.6</ix:nonFraction> million as of June 30, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyMTU_a6998a9e-5ffd-4294-9ff2-4edbbd44ac15">652.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyMjI_6872e155-6607-4a87-bbaa-7d8e098889ef">709.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i904ca67b48e9438aa45cc860a3e98146_115"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;Collaborative and Other Relationships </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzc5_0b92e0f9-be98-40d5-805a-07d87fb3ef9b" continuedAt="i7d5da689db554485bc09a333b11d524a" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, <ix:nonFraction unitRef="product" contextRef="ie30cba3e2edd4bc08f2a74408c366d3b_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzMwNg_26c78e26-2a91-4e39-b4d8-9e0881dc3e93">two</ix:nonFraction> Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In addition, the Lecanemab Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzc4_0f1d6159-6b73-4757-bbad-3c1dad4970c3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080d328364f74b708ca4d19448cd3c44_D20210401-20210630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItMi0xLTEtMA_da991665-fbef-49fa-ace2-4ea4e53bc9ba">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60376f76b3314e2bbb38c6fa9587253b_D20200401-20200630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItNC0xLTEtMA_4c7525bf-7188-47cb-83ac-4144c1d9ff1c">33.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b682df909084551b169517453ffa2c0_D20210101-20210630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItNi0xLTEtMA_9a79a2f7-7490-41ce-9507-533f8921f763">117.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f83a2e2c6a4460c9814ca56bd7798e3_D20200101-20200630" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItOC0xLTEtMA_de67982d-684c-4514-a097-811780f37e30">77.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080d328364f74b708ca4d19448cd3c44_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtMi0xLTEtMA_0026d340-1a6f-4fc7-9057-404d7ba9b972">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60376f76b3314e2bbb38c6fa9587253b_D20200401-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtNC0xLTEtMA_836f31e4-d9f1-45d7-a157-ea69c7d0588a">17.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b682df909084551b169517453ffa2c0_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtNi0xLTEtMA_2b73406d-ee2a-43b7-bd12-c56ed92fed05">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f83a2e2c6a4460c9814ca56bd7798e3_D20200101-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtOC0xLTEtMA_358fa1e2-e467-4a22-ba2a-cffa021b35d3">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683dd88ba1804d5d81e60a6e361b15e2_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtMi0xLTEtMA_523cca8b-f903-496a-8a65-3d896f06bdd5">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf76ad095d44d08b376319fd02096b7_D20200401-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtNC0xLTEtMA_ad2551ef-a438-4055-9ebb-5274b4fb7278">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a1d8eb24644ccdb1958fc8538a767b_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtNi0xLTEtMA_6bd683f6-f6ad-4b7f-a8b3-1dc8009e27e8">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e917d9b36df462b8f02b672a61e80a6_D20200101-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtOC0xLTEtMA_3211ce34-6515-4bbb-9b6f-f4295d829cc7">6.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683dd88ba1804d5d81e60a6e361b15e2_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtMi0xLTEtMA_fbe9d8f9-59dc-45fc-8a4d-446945d4302f">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf76ad095d44d08b376319fd02096b7_D20200401-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtNC0xLTEtMA_3bbcb44d-e63e-4c0a-b3fb-95f71ec5fd2f">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a1d8eb24644ccdb1958fc8538a767b_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtNi0xLTEtMA_cfbced61-858e-458b-99ff-d4b843f6eae2">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e917d9b36df462b8f02b672a61e80a6_D20200101-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtOC0xLTEtMA_620a19bb-e0af-4a60-a4e2-7924e62511da">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i7d5da689db554485bc09a333b11d524a" continuedAt="ia1083f102ac045a4aa37300458c084f3"><div style="margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, we lead the ongoing development of ADUHELM, and we and Eisai will co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzI0MzM_16a475cc-af74-49b5-ac6a-5e5f2b5821cb">45.0</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of ADUHELM in patients with early Alzheimer's disease. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $<ix:nonFraction unitRef="usd" contextRef="i940aec5d7103466d9529cc5b08d8e33a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzMxNjg_15cfedd5-03a2-4394-bf5a-d39dfabfb2b9">45.0</ix:nonFraction> million related to the termination of various clinical trials and research and development contracts net of the expected <ix:nonFraction unitRef="number" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzMyODQ_16a475cc-af74-49b5-ac6a-5e5f2b5821cb">45.0</ix:nonFraction>% Eisai reimbursement of development costs incurred under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we and Eisai announced that we planned to pursue regulatory approval for ADUHELM in the U.S. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of ADUHELM to the FDA and made a $<ix:nonFraction unitRef="usd" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjU2NjY_3686da28-e9b4-4b11-9de5-22b82cc7867e">75.0</ix:nonFraction> million milestone payment to Neurimmune. We recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzM2Mjg_d21a2290-7741-4415-9c8b-ecee04197ecc">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzM2NTA_16a475cc-af74-49b5-ac6a-5e5f2b5821cb">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzM2NjY_3686da28-e9b4-4b11-9de5-22b82cc7867e">75.0</ix:nonFraction> million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $<ix:nonFraction unitRef="usd" contextRef="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjU4MzY_205efa98-18e2-41e6-8cd7-5de5b428b99c">100.0</ix:nonFraction>&#160;million milestone payment to Neurimmune. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0MDc_624761d7-d792-4015-829c-30982872aa91"><ix:nonFraction unitRef="usd" contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0MDc_c3a4c490-b0e6-4db6-9587-6b73ba15b698">45.0</ix:nonFraction></ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0Mjk_16a475cc-af74-49b5-ac6a-5e5f2b5821cb">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0MzI_205efa98-18e2-41e6-8cd7-5de5b428b99c">100.0</ix:nonFraction>&#160;million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense are shared in proportion to the same region-based profit split that is utilized to co-promote ADUHELM. <ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzcw_9c450b2d-e26e-40d1-8f65-30e14758a4da" continuedAt="id60f95f5c7e549eeb8a9a36be3737b78" escape="true">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</ix:nonNumeric></span></div><div><ix:continuation id="id60f95f5c7e549eeb8a9a36be3737b78"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0e9f1b5c6644324895da8c763579ea1_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItMi0xLTEtMA_7115a590-3462-40ce-92f3-44b14fb3b526">42.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657a17d9e3ef4c86b23042aa118c1b39_D20200401-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItNC0xLTEtMA_2dd2ff71-9991-4ba5-bfae-0051121d8e18">35.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa87cc62218145ad8330f96b7227e231_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItNi0xLTEtMA_885cb10d-554c-412b-8cf7-5da721fe6d83">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cbebcfd92341b9a4800299106bcc4f_D20200101-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItOC0xLTEtMA_bea988a4-8b24-49e1-a54b-c5f16ee745af">55.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0e9f1b5c6644324895da8c763579ea1_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtMi0xLTEtMA_27b1ecb8-5aa4-4065-9ee8-ee4e2d195453">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657a17d9e3ef4c86b23042aa118c1b39_D20200401-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtNC0xLTEtMA_e0d91a21-be5e-4293-a8b9-d1372b71c504">19.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa87cc62218145ad8330f96b7227e231_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtNi0xLTEtMA_962b1406-59a8-4dec-b657-8d868a3f76d5">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cbebcfd92341b9a4800299106bcc4f_D20200101-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtOC0xLTEtMA_ea492987-549c-4ca9-bf43-56a90efad7ff">30.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a1617e837c46c9af07f92da67420a5_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtMi0xLTEtMA_242cecd6-2019-4ada-a630-8b7ece06516d">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb715e3d5a940248b7d9789bde6f8cd_D20200401-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtNC0xLTEtMA_32636f24-bde2-4fb4-b1f9-d840a41dfc3c">45.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd89562ebcc4af9ab88aabef74b9794_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtNi0xLTEtMA_6f263e46-ba9c-480b-9bca-e8418c7429c3">237.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14520938d40f4be7b3788532f0a39e36_D20200101-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtOC0xLTEtMA_f442b233-ae2d-477b-93b8-a20cf1623921">67.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a1617e837c46c9af07f92da67420a5_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtMi0xLTEtMA_a13a5d4b-ff9e-4cff-9d6e-0c5426dd0cda">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb715e3d5a940248b7d9789bde6f8cd_D20200401-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtNC0xLTEtMA_5c5e7095-9494-4565-85f6-f509351538ac">25.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd89562ebcc4af9ab88aabef74b9794_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtNi0xLTEtMA_456e1fd3-6391-411c-a696-2bc9a8a5d23b">127.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14520938d40f4be7b3788532f0a39e36_D20200101-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtOC0xLTEtMA_8b353af5-408b-411a-98bc-4aec4f9f7273">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtMi0xLTEtMA_04d244a0-45c3-45b5-9268-cd369a19f623">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9789f6e0bd394724b1766f169596f0eb_D20200401-20200630" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtNC0xLTEtMA_091438cc-3395-43c3-ab6f-dde22da1432e">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtNi0xLTEtMA_170e9d53-c198-4b69-8c74-b50ffd7d62ac">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b30bd6c2b6a47a09c2ee57818fe9437_D20200101-20200630" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtOC0xLTEtMA_a7321de2-4f70-4e46-94f4-ffcc90320b38">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctMi0xLTEtMA_a933855b-b701-4739-80ac-6efef46d0a1b">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9789f6e0bd394724b1766f169596f0eb_D20200401-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctNC0xLTEtMA_45ad167b-e5fd-4071-a6a6-f8e1d3cedce8">33.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctNi0xLTEtMA_7c2daca0-4cc0-41ef-9243-2c24acd0bab8">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b30bd6c2b6a47a09c2ee57818fe9437_D20200101-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctOC0xLTEtMA_52e0fdf2-be92-4a11-8bc6-bdf3e764514a">33.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its <ix:nonFraction unitRef="number" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0NTc_16a475cc-af74-49b5-ac6a-5e5f2b5821cb">45.0</ix:nonFraction>% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTE4MDk_3f887941-b559-4c45-8d23-e2860a50b108"><ix:nonFraction unitRef="usd" contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTE4MDk_eda2c27c-88f2-4cc3-8760-564dfe4d9e64">40.1</ix:nonFraction></ix:nonFraction>&#160;million to reflect Eisai's 45.0% sharing of the net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia1083f102ac045a4aa37300458c084f3" continuedAt="ia50f197b57274aff9dacc973559403c7"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68eaa385cc39449cbea95fc77f8b73e5_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItMi0xLTEtMA_bba2bca5-22b9-4aaf-9c0c-e8bb9507517c">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53f50175e4b428ba3381dc4cbbabff9_D20200401-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItNC0xLTEtMA_842f5205-c92c-4dfe-b5ef-6e82466d04ef">6.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c297982d9641fcb3a085dda0c1bd2f_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItNi0xLTEtMA_fc63383e-e531-417a-96fd-1929e4b98291">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3b63d2e34c47ca90c46007d640803a_D20200101-20200630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItOC0xLTEtMA_ac1e5514-0e5a-4767-adc9-1495d7111c3a">25.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68eaa385cc39449cbea95fc77f8b73e5_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtMi0xLTEtMA_eb6efe9e-b6b2-48dc-a96e-617b39b52397">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53f50175e4b428ba3381dc4cbbabff9_D20200401-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtNC0xLTEtMA_90fe3f1d-3233-48ca-9e5e-de8152087782">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c297982d9641fcb3a085dda0c1bd2f_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtNi0xLTEtMA_d1a03b0d-1f81-4f5e-92f3-04445cd1a7ba">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3b63d2e34c47ca90c46007d640803a_D20200101-20200630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtOC0xLTEtMA_ffeefc25-0af6-41a7-a3fa-b6e63dc45437">12.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzU4OTY_8c2b9253-da1b-4b85-8411-11d2aa239cf6">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzU5Mzg_3d5ff800-f95d-4f1b-b10f-afbeca036ee5">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzU5NjU_65226e62-f273-4edd-9926-f222bd383de1">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzYyMTk_5b9ba581-a66d-46ae-9d4f-6a5a361cd582">209.0</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzYzOTk_2aabd2e1-bb36-453a-a5c9-2d1adf53a6d2">875.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzY1NjE_1a43e8fd-1b25-45da-9fa1-f402d7768d99">1.6</ix:nonFraction>&#160;billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9cc66426f84e3e828a71db655b5ca5_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItMi0xLTEtMA_b6a14092-060c-48f1-9f4e-6fee5e81742b">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d35c0b653e746d894c5a5ff25f40d74_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItNC0xLTEtMA_294c1dd3-cade-4cb3-81cf-e66d7d3911f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2fcfe4886749c19597e9ee5c80f50d_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItNi0xLTEtMTA5NTI_e257eb75-6c1f-42f1-ac90-85ac8d577422">93.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9327f22b43043478937934e403bdec8_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItOC0xLTEtMTA5NTU_a8602630-3623-41b3-af86-9d0741e0d554">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9cc66426f84e3e828a71db655b5ca5_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtMi0xLTEtMA_af121b8b-5954-49dd-8756-a907ba35f882">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d35c0b653e746d894c5a5ff25f40d74_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtNC0xLTEtMA_72aa70da-e427-4d8d-94a1-89b1dddbb5f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2fcfe4886749c19597e9ee5c80f50d_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtNi0xLTEtMTA5NTI_825d9594-c6fc-4641-8eef-2a69c3b18517">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9327f22b43043478937934e403bdec8_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtOC0xLTEtMTA5NTU_141d7556-bdc8-4641-aa4a-1464b92113b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70318dd2805c4be293874a85d342f3a0_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtMi0xLTEtMA_80e8ece4-4853-42ac-973e-244890439bcf">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6801ccc665a4e8db08e33134390d9c6_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtNC0xLTEtMA_85a71523-6ee1-427d-8ed8-78ee197c8454">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b163de37ced4db78033769ec4cfd792_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtNi0xLTEtMTA5NTI_1a78c843-2662-4dc1-9201-f8987af5c8fe">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658f7b7a80934324a5fde431814f9cd9_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtOC0xLTEtMTA5NTU_8f3db5ca-7c72-4c2e-a5ea-1de84ce01e50">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70318dd2805c4be293874a85d342f3a0_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtMi0xLTEtMA_c3480539-5319-404c-b3a8-0f4f0a0bd62e">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6801ccc665a4e8db08e33134390d9c6_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtNC0xLTEtMA_7a31f20e-5cfa-49a3-b469-c9ddf17c3500">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b163de37ced4db78033769ec4cfd792_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtNi0xLTEtMTA5NTI_7f7d7b3e-a2f7-4801-a3bc-cfec47c80a04">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658f7b7a80934324a5fde431814f9cd9_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtOC0xLTEtMTA5NTU_febfba2c-bc9c-4b88-918c-42592af4c38e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia50f197b57274aff9dacc973559403c7" continuedAt="ic8ddd785027142f6a51bd637ef91ea59"><div style="margin-top:4pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzc4NjM_a394f47a-16cb-4812-9f02-2218c2b15256">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="i82cf1cd794bc4e22b1558829c36fdbe6_I20210630" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzc5MTM_bfcff615-27bd-49b2-906f-e08fbdf8116c">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzc5NDA_8609403c-6638-423d-b748-2def391ed8b1">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzgxOTY_21d87393-f3a5-4cd0-ac72-f1458d8015ad">41.3</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzgzNzg_1313362a-fb5d-4d6d-8a25-677bc100212a">560.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzg1NDI_ba11806b-52d1-4afa-85f2-9cd9a4f816c1">1.1</ix:nonFraction>&#160;billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzQzOTgwNDY1NDkzNjg_47967d48-4079-426c-a8a5-a31642d1a96e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1ff74fe0d44db0b1983d0c557a90b0_D20210401-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItMi0xLTEtMTE3ODI_070e9a3b-ea6a-4f4a-98b3-63459f4ad693">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0eff84f0a64614b8a69a4c069072af_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItNC0xLTEtMTE3ODI_b0f9bf6e-a7da-4aa0-945f-7c90e57d2b0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c24d776c67459baefa074ef5ce43e8_D20210101-20210630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItNi0xLTEtMTE3ODI_4b28dfe9-10ac-4a1f-a19c-27dae5e59669">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0531061801234f06bd21a3e0b235a6a9_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItOC0xLTEtMTE3ODI_32a3eb3b-c011-46fe-8992-d4124c6d9524">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1ff74fe0d44db0b1983d0c557a90b0_D20210401-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtMi0xLTEtMTE3ODI_b22ad479-9fac-4fd2-a415-8ee6895cf47b">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0eff84f0a64614b8a69a4c069072af_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtNC0xLTEtMTE3ODI_ad526364-c358-4f5d-b58f-1bcc4605d30c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c24d776c67459baefa074ef5ce43e8_D20210101-20210630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtNi0xLTEtMTE3ODI_0199fcf1-7047-4adf-9997-bfa5b9fac812">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0531061801234f06bd21a3e0b235a6a9_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtOC0xLTEtMTE3ODI_a9f8e1f9-84fb-4847-9b51-a33cd21978b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="i26e88285d5d8470a8b499ee193fb4bbf_D20210101-20210630" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzkw_52ec4fda-49c5-47f0-8b23-dfff8790dc9b">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk1MDE_c5dc7682-1418-4700-b054-184d7b932999">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk1NDY_df30e7d7-e158-4a58-b58b-e1f4302ab1eb">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk1NzM_d645e7cf-6c39-45fb-8a62-d28db742fae9">9.21</ix:nonFraction> per share, of which approximately <ix:nonFraction unitRef="shares" contextRef="i512790f7d615460ab79e03a4291d683a_I20210630" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzQ5NDc4MDIzNTA1NzY_f96858b6-6577-490c-92ea-ca4bb332f32d">12</ix:nonFraction>&#160;million shares remain subject to transfer restrictions as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk4MzA_887f5f13-d2fa-4507-b8de-c8ebd46ddce9">83.0</ix:nonFraction> million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwMDEz_ff49d322-1a25-4d33-b17d-0b9c3a978d00">125.0</ix:nonFraction> million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwMjAw_57dde346-016d-4e2f-9d9d-cba6d113057e">2.4</ix:nonFraction> billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwMzYx_ea86783c-9f10-4023-9501-09d90b71e902">80.0</ix:nonFraction> million relates to the selection of targets, $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwNDAx_1a033fa5-2871-449f-92db-53386e0bac67">1.9</ix:nonFraction> billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $<ix:nonFraction unitRef="usd" contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwNTI4_7b2ea598-5699-4da0-bc83-49b6510b0444">380.0</ix:nonFraction> million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic8ddd785027142f6a51bd637ef91ea59" continuedAt="i5456bb1904f945e3899b64d92df96e07"><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we record</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed $<ix:nonFraction unitRef="usd" contextRef="i1453070338d24ee3b7ee1fb21644243d_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4NzY_89d997e3-2c5a-4757-ad4e-6749dd8c46c8"><ix:nonFraction unitRef="usd" contextRef="i525a88b3fbd24d928dea67537541252d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4NzY_f34fe3a5-250a-43a6-976d-07ce3a6f256d">77.2</ix:nonFraction></ix:nonFraction>&#160;million as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $<ix:nonFraction unitRef="usd" contextRef="i86a1f935392743a6b8a9a61a8026ab24_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4OTU_661118a2-a1d6-414e-a27b-62e2f2540280"><ix:nonFraction unitRef="usd" contextRef="ie24ae1e5faa24314a3a0baafdb89a376_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4OTU_a7683289-c6cf-4b89-8b8e-636659cb187a">9.6</ix:nonFraction></ix:nonFraction>&#160;million in the prior year comparative periods</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="ie35fa105818345dcb7a4da4701cf3007_I20200630" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMjQx_a2aa4096-e592-45d1-ac71-3e96b4d91014">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMjYx_b9ee3de5-9d24-4d84-b297-7d369e6dc9f1">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMzU0_131714dc-8eaa-4576-9c1d-eec6100520ce">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ie4bbf4a5ff6c4f5085293b4809ad89df_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMzc1_01b37358-ceaa-4757-b9f4-94c41d159dd4">676.6</ix:nonFraction> million) to Samsung BioLogics. As of June 30, 2021, our ownership percentage remained at approximately <ix:nonFraction unitRef="number" contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExNDYy_b9ee3de5-9d24-4d84-b297-7d369e6dc9f1">49.9</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i11863a558bbf46bca75ffd9f7fafbba7_I20181107" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEyNDc3_e88906bd-7038-4b25-aaa7-2e768260e763">675.0</ix:nonFraction> million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="ia4f071a5198246d4a5303f52da35079c_D20210101-20210630" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEyNjY5_c951be4f-8c5d-4f89-83f7-1339133bf03f">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i8ee4b7c75b03465cb35c3c8b87a54189_D20210101-20210630" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEyODM3_8f630d8d-3ab4-420c-b1a1-102ca44bd90c">15</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="i187bf0ed97484588819f3c772481972a_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzMzQ3_060a7fe9-e97a-4960-a91e-c86174054873">34.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTU3MDA_395d1a8e-a12e-4d52-94b1-d18993fa62c8">16.1</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="i4faa3349fe88498e9d027f1467d57c95_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTU3Mjk_92ea47fa-18f4-419f-91ef-100986b12426">15.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia27d340d112941fc9280b61618209c41_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTU3NTE_fc8bdf45-ed69-4740-9200-089f0d855788">0.4</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income on our investment for the three and six months ended June 30, 2021, reflects a $<ix:nonFraction unitRef="usd" contextRef="i187bf0ed97484588819f3c772481972a_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYyNDE_011d1622-1cc8-4632-bd64-ca8ca6a2aec2"><ix:nonFraction unitRef="usd" contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYyNDE_d09c16d3-7294-4b7e-8d07-c28fabc7b5d0">31.2</ix:nonFraction></ix:nonFraction>&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the current period based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNTYz_e7c8b34f-dfb2-4599-9ec2-3928a45e8ffd">691.6</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNTg0_d26b0986-0204-4cec-9866-405c73144f43">612.8</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="idcfeec350bdb466ab3c2f0500fc633e2_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNTky_6536ad20-f418-4a4f-a722-a3e17bd5a784">673.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="idcfeec350bdb466ab3c2f0500fc633e2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNjEz_9c508e44-1e79-4449-a953-5e1b79064215">620.2</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i5456bb1904f945e3899b64d92df96e07" continuedAt="idc5f9a7ff37046ef8613f28d2a40a301"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0MzIz_0b94f65b-b58d-4560-94b1-0c41fe204162">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0Mzcx_a07718e6-457c-4597-ade3-7ac9752a720a">63.0</ix:nonFraction> million was recorded as research and development expense in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i41b0165e2b7d4f55925670a51aac39ab_I20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0NDM1_7374409d-026a-4ab9-bc2c-a44bb34a9dcd">37.0</ix:nonFraction> million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $<ix:nonFraction unitRef="usd" contextRef="i22390c69ed8c484a87e99931785d60cd_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0NTU3_de386941-fd4c-4e01-83e0-02970365b137">15.0</ix:nonFraction>&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. We may pay Samsung Bioepis up to $<ix:nonFraction unitRef="usd" contextRef="i85191396f14a48159b6ea71eb3da36ae_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0NzIz_1c037df3-7fd2-47ff-b84a-6b787af679ea">195.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="i85191396f14a48159b6ea71eb3da36ae_D20210101-20210630" format="ixt-sec:durwordsen" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0OTIy_3684c25b-230d-43b0-9d01-532a007e3358">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0OTc0_7041b1c6-7361-4127-9734-2b2ef85fde90">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1NDQ0_1fe9645b-36f4-4694-a4e6-5e2a51bc04cb">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2021, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="i187bf0ed97484588819f3c772481972a_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1NzEw_df380882-3a87-4adf-be27-1756413c6d69">69.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYxMjI_d99077fa-4804-4181-8c3e-d0604a5ed513">138.4</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1NzQx_1fe9645b-36f4-4694-a4e6-5e2a51bc04cb">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="i4faa3349fe88498e9d027f1467d57c95_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1Nzk4_5800ecdf-3ccc-4d39-8443-28ef75a1e094">55.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia27d340d112941fc9280b61618209c41_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYxNTU_4424bb70-483f-43d6-967b-1ad73a4e37bb">127.2</ix:nonFraction> million, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1OTgz_7041b1c6-7361-4127-9734-2b2ef85fde90">60.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="i8dc20aceecce4ad98ad607135283cd1f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2NDU5_d01f869e-389a-42ed-bd7d-91e64a3d2175">158.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1d184845c0fd4540af43215a509def5f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2NDY2_b31943c3-1490-4e10-9d5e-cdcc2f7bf325">99.0</ix:nonFraction>&#160;million as of June 30, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="idc5f9a7ff37046ef8613f28d2a40a301" continuedAt="ibd90a50fdb7b4890ad9616b531636215"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd90a50fdb7b4890ad9616b531636215"> to our consolidated financial statements included in our 2020 Form 10-K.</ix:continuation> </span></div><div id="i904ca67b48e9438aa45cc860a3e98146_121"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzU0OTQ_e22b20bd-6932-45e5-95d0-fa49821a3253" continuedAt="i63fc1953c25b4cbb80ae2938777abe13" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="id238c93aacac4f80a409e4c0cd6eb474_D20210101-20210630" format="ixt-sec:duryear" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzc2OA_7968b515-680c-4fef-969e-21f5c6ef66e9">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="id238c93aacac4f80a409e4c0cd6eb474_D20210101-20210630" decimals="0" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzExMTE_339afb17-4df1-4f68-80ad-f20a051f52ff">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $<ix:nonFraction unitRef="usd" contextRef="i05bc48381d6b4149b19415bd7d37bd95_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEyNzE_32f1dab0-47ec-4cc3-bcdb-e5ef24e1e397">150.0</ix:nonFraction> million payment to Neurimmune in exchange for a <ix:nonFraction unitRef="number" contextRef="i05bc48381d6b4149b19415bd7d37bd95_D20171001-20171031" decimals="2" name="biib:Reductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEzMTQ_6233ec7d-9b5b-4305-a7a5-9b956c0d10cc">15.0</ix:nonFraction>% reduction in the previously negotiated royalty rates payable on products </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i63fc1953c25b4cbb80ae2938777abe13" continuedAt="id7dec00623884ab0851d769ddb304b18"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM. In May 2018 we made an additional $<ix:nonFraction unitRef="usd" contextRef="i3d03ddf77e1f433eaa830646366273e1_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE1Mzk_84fe6881-16b1-47da-b71c-91a849a4035d">50.0</ix:nonFraction> million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM, by an additional <ix:nonFraction unitRef="number" contextRef="i3d03ddf77e1f433eaa830646366273e1_D20180501-20180531" decimals="2" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE3NzQ_ec560caf-40df-4a62-9732-660d7bff1756">5.0</ix:nonFraction>%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="ifa100d41aa7e425a9482c71b0293c71e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzIzMTQ_839aa02c-12c0-4dac-92ed-443798670c16">75.0</ix:nonFraction> million&#160;upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $<ix:nonFraction unitRef="usd" contextRef="ifa100d41aa7e425a9482c71b0293c71e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI0NDM_839aa02c-12c0-4dac-92ed-443798670c16">75.0</ix:nonFraction> million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI2ODM_9dbf7ec8-3619-49c0-9be6-52c8a9213d7c">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI3MDU_99f7adf8-bb6d-4f0c-ab69-4fc79bdbe23c">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="ifa100d41aa7e425a9482c71b0293c71e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI3MjE_839aa02c-12c0-4dac-92ed-443798670c16">75.0</ix:nonFraction> million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i2a247039a04a4250a57179e383ed799e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzM1OTc_c5f7d652-b503-44cb-a14b-d4026129d500">100.0</ix:nonFraction>&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $<ix:nonFraction unitRef="usd" contextRef="i2a247039a04a4250a57179e383ed799e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzcxNDY4MjU1ODc5NjA_c5f7d652-b503-44cb-a14b-d4026129d500">100.0</ix:nonFraction>&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzU5MzY_d1cdf61d-983d-4bf3-a4f7-8316c23bfe9e">45.0</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzcxNDY4MjU1ODgyMDQ_99f7adf8-bb6d-4f0c-ab69-4fc79bdbe23c">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i2a247039a04a4250a57179e383ed799e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzQ5NDc4MDIzMzMxNDk_c5f7d652-b503-44cb-a14b-d4026129d500">100.0</ix:nonFraction>&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $<ix:nonFraction unitRef="usd" contextRef="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzU5NTY_7a171455-9d19-46c9-b11a-f414f82f03d2">100.0</ix:nonFraction>&#160;million in additional milestones to Neurimmune, which includes $<ix:nonFraction unitRef="usd" contextRef="ib43ae0706b95445a8789a5fcbf8ac563_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzU5NzU_54151986-5d9e-45c2-9f26-0710a7dba899">50.0</ix:nonFraction>&#160;million if launched in three or more countries in the European Union (E.U.) and $<ix:nonFraction unitRef="usd" contextRef="i361307437209490a864b62473d1cedf7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI5NzE_b368d755-8fe1-4a05-bff0-90bd10e70ba7">50.0</ix:nonFraction>&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021 and 2020, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, we recorded a net deferred tax asset of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE2NDkyNjc0NTIyNTU_384f0730-4831-459f-ab5d-524aebc3207b">500.0</ix:nonFraction>&#160;million. The net deferred tax asset is comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE2NDkyNjc0NTIyNjQ_e75e9d52-5135-4b41-9649-8a565ab98922">875.0</ix:nonFraction>&#160;million of gross deferred tax asset, reduced by approximately $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE2NDkyNjc0NTIyNzI_8e843464-99ef-430a-8351-4a8adc174b8c">375.0</ix:nonFraction>&#160;million of unrecognized tax benefit. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on commercial sales of ADUHELM to be shared with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzMzMDU_74fa802b-cf1c-40d9-a5e7-c7823442625f">15.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzQ2OTA_b6382065-a16c-4413-b803-307c0b75ed7c">12.8</ix:nonFraction> million, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="id7dec00623884ab0851d769ddb304b18"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div></ix:continuation><div id="i904ca67b48e9438aa45cc860a3e98146_127"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;Litigation </span></div><ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjcvZnJhZzplMTRiZmIyZWE0OWQ0ZmMwODU5OTg1ZDA3MzVhMTQ1Zi90ZXh0cmVnaW9uOmUxNGJmYjJlYTQ5ZDRmYzA4NTk5ODVkMDczNWExNDVmXzExOTk5_feef7698-9e1d-4798-a279-89f1b80bd937" continuedAt="iac983a28236347cc93d9347a9dc3dc94" escape="true"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and transferred to the U.S. District Court for the District of Massachusetts in March 2021. The action alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. We have filed a motion to dismiss the action, which is pending.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. The request for preliminary injunction was denied in June 2019 and the decision was affirmed on appeal in February 2021. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#8217;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing was held in May and June 2021.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iac983a28236347cc93d9347a9dc3dc94" continuedAt="i635a69b233964b219cfa94d01edb65ba"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. The case has been stayed pending proceedings at the European Patent Office (EPO).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjcvZnJhZzplMTRiZmIyZWE0OWQ0ZmMwODU5OTg1ZDA3MzVhMTQ1Zi90ZXh0cmVnaW9uOmUxNGJmYjJlYTQ5ZDRmYzA4NTk5ODVkMDczNWExNDVmXzUzNzM_f5842806-bf0a-4b2a-90c1-83738c236a77">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung BioLogics Arbitration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. We expect a hearing in the fourth quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i635a69b233964b219cfa94d01edb65ba"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc. A trial date has not yet been set.</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the EPO revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. The Polish Patent Office dismissed the action in February 2021. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#8216;263 Patent in the Polish Patent Office. The action was suspended by the Polish Patent Office in April 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. A hearing in the Italian action will be held in June 2022.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#8217;s and Mylan Ireland&#8217;s respective applications to market a generic version of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_130"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzAvZnJhZzo4ZDEwNTUyOTc1ZjM0NmNjYjBlM2MzMjBkZDVhYzc0Ni90ZXh0cmVnaW9uOjhkMTA1NTI5NzVmMzQ2Y2NiMGUzYzMyMGRkNWFjNzQ2XzQzOTgwNDY1MTU4MzI_c88ade80-519c-4a6f-88cf-e18caf91360c" continuedAt="i9a5f9c03d8924ec8be8a188912dfb386" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i9a5f9c03d8924ec8be8a188912dfb386"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the proposed collaboration, we will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">InnoCare will receive a $<ix:nonFraction unitRef="usd" contextRef="i8f888c4ff5e0416ba053664107506cc4_D20210701-20211231" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzAvZnJhZzo4ZDEwNTUyOTc1ZjM0NmNjYjBlM2MzMjBkZDVhYzc0Ni90ZXh0cmVnaW9uOjhkMTA1NTI5NzVmMzQ2Y2NiMGUzYzMyMGRkNWFjNzQ2XzEwOTk1MTE2MzIyODk_7c9b30ae-9856-46b7-8331-8ccc913c6038">125.0</ix:nonFraction>&#160;million upfront payment and is eligible to receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ic0a38fb832714a92860b173e6a8b3564_I20211231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzAvZnJhZzo4ZDEwNTUyOTc1ZjM0NmNjYjBlM2MzMjBkZDVhYzc0Ni90ZXh0cmVnaW9uOjhkMTA1NTI5NzVmMzQ2Y2NiMGUzYzMyMGRkNWFjNzQ2XzEwOTk1MTE2MzIzMjE_c98785de-5e1c-4d9d-bcd5-24232f276dec">812.5</ix:nonFraction>&#160;million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. InnoCare is also eligible to receive tiered royalties in the low to high teens on potential future net sales of any product resulting from the collaboration. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Closing of the collaboration is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and other customary closing conditions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_136"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to our patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of the facility received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products (SWISSMEDIC). We believe that the Solothurn facility will support our anticipated near-term needs for the manufacturing of ADUHELM and other biologic assets. In addition, we believe that the Solothurn site may provide us with the ability to further expand if we need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk and Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM (aducanumab)</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which we are developing in collaboration with Eisai Co., Ltd. (Eisai), based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. As part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer&#8217;s disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. ADUHELM product label states that treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population which was studied in clinical trials. We expect patient uptake will be gradual and we do not expect all eligible patients will be treated with ADUHELM for a variety of reasons, including appropriate patient selection criteria, a complex diagnostic and care pathway, the lack of readiness of healthcare providers and institutions to initiate treatment, concern regarding the accelerated approval of ADUHELM and its data and the ability to obtain and maintain adequate reimbursement for ADUHELM.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement with Eisai (ADUHELM Collaboration Agreement), we and Eisai will co-promote ADUHELM with a region-based profit split, with Eisai reimbursing us for <ix:nonFraction unitRef="number" contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzYvZnJhZzpjOTg2MTZlM2I5YTc0Y2RlODM5YTNjM2QzZDhlMDNhNi90ZXh0cmVnaW9uOmM5ODYxNmUzYjlhNzRjZGU4MzlhM2MzZDNkOGUwM2E2XzE2NDkyNjc0ODk5MDk_99f7adf8-bb6d-4f0c-ab69-4fc79bdbe23c">45.0</ix:nonFraction>% of development and commercialization costs incurred by the collaboration for the advancement of ADUHELM in the U.S. Shipments of ADUHELM commenced during the second quarter of 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made, and will continue to make, commercial, medical and infrastructure investments in support of activities associated with the launch of ADUHELM in the U.S., including the adding of headcount and the manufacture of pre-launch inventory.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application for aducanumab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive regulatory approval or are unable to successfully commercialize aducanumab in other jurisdictions, our financial condition, business and operations may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the European Union (E.U.). This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face TECFIDERA generic competition in the E.U. if regulatory data protection is not upheld and we expect that this would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report and the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 (glibenclamide IV) for large hemispheric infarction (LHI), a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. To help mitigate the impact of the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in an immaterial increase to the cost of the clinical trials underway.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. was $2.99 for the three months ended June 30, 2021, representing a decrease of 68.8% compared to $9.59 in the same period in 2020.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended June 30, 2021, compared to the three months ended June 30, 2020, reflects the following:</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenue was $2,775.0 million for the second quarter of 2021, representing a $906.6 million, or 24.6%, decrease compared to $3,681.6 million in the same period in 2020.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenue, net totaled $2,236.0 million for the second quarter of 2021, representing a $559.7 million, or 20.0%, decrease compared to $2,795.7 million in the same period in 2020. This decrease was primarily due to a $597.5 million, or 28.1%, decrease in MS product revenue, partially offset by a $5.1 million, or 1.0%, increase in SPINRAZA product revenue.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenue was primarily due to a decrease in U.S. TECFIDERA demand as well as higher discounts and allowances as a result of multiple TECFIDERA generic entrants in the U.S. market.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales in the first quarter of 2020, primarily in the E.U., that increased product revenue by approximately $100.0&#160;million. During the second quarter of 2020 we believe customers began to utilize the product purchased (approximately $75.0&#160;million) in the first quarter of 2020, which adversely affected sales in the second quarter of 2020.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenue from anti-CD20 therapeutic programs totaled $440.0 million for the second quarter of 2021, representing a $38.3 million, or 8.0%, decrease compared to $478.3 million in the same period in 2020. This decrease was primarily due to a $96.1&#160;million, or 37.6%, decrease in RITUXAN revenue, partially offset by a $48.7&#160;million, or 23.4%, increase in royalty revenue on sales of OCREVUS. We believe that sales of RITUXAN </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been adversely affected by the onset of biosimilars competition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other revenue totaled $99.0 million for the second quarter of 2021, representing a 75.7% decrease from $407.6 million in the same period in 2020.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">In the second quarter of 2020 other revenue reflects $329.4&#160;million in revenue related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expense was $2,289.3 million for the second quarter of 2021, representing a $582.2 million, or 34.1%, increase compared to $1,707.1 million in the same period in 2020.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of our collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement), we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">In the second quarter of 2021 we recorded a $350.0&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The increase in cost and expense for the second quarter of 2021 also reflects an increase in selling, general and administrative </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense in support of the launch of ADUHELM in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $1,996.3 million of net cash flows from operations for the six months ended June 30, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $3,965.9 million as of June 30, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We repurchased and retired approximately 1.6 million shares of our common stock at a cost of approximately $450.0 million during the second quarter of 2021 under a program authorized by our Board of Directors in October 2020 to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Approximately $3.6 billion remained available under our 2020 Share Repurchase Program as of June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions and Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton's tyrosine kinase inhibitor for the potential treatment of MS. Closing of the collaboration is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and other customary closing conditions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our proposed collaboration with InnoCare, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Subsequent Events</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes) for a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes) and cash, and an offer to purchase our tendered 2045 Senior Notes for cash.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">North Carolina Gene Therapy Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 we announced our plans to build a new gene therapy manufacturing facility in Research Triangle Park, North Carolina to support our growing gene therapy pipeline across multiple therapeutic areas. The new facility will be 175,000 square feet and is expected to be operational by 2023, with an estimated total investment of approximately $200.0&#160;million.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021 we announced that a portion of our Solothurn manufacturing facility received a GMP multi-product license from SWISSMEDIC.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Solothurn manufacturing facility, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB125 (zuranolone)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 we and Sage Therapeutics, Inc. (Sage) announced positive Phase 3 results for BIIB125 (zuranolone) for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab (BAN2401)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted Breakthrough Therapy designation for lecanemab, an anti-amyloid antibody for the potential treatment of Alzheimer's disease, which we are developing in collaboration with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(744.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,074.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,795.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(308.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,775.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,681.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(906.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,304.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,427.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,395.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,252.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(169.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(324.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,469.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,215.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,746.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i904ca67b48e9438aa45cc860a3e98146_145"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenue</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(611.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,795.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,291.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,159.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">954.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,012.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,231.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,059.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,252.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">***</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20210630_g2.jpg" alt="biib-20210630_g2.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenue includes sales from TECFIDERA and VUMERITY. In October 2019 the FDA approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, compared to the same periods in 2020, the decreases of 70.8% and 70.3%, respectively, in U.S. Fumarate revenue were primarily due to a decrease in TECFIDERA demand as well as higher discounts and allowances as a result of multiple TECFIDERA generic entrants in the U.S. market. The decrease was partially offset by an increase in VUMERITY sales volume.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases of 15.2% and 5.8%, respectively, in rest of world Fumarate revenue were primarily due to increases in TECFIDERA sales volumes of 13.0% and 4.0%, respectively, and an increase in pricing.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of 2020 that increased rest of world Fumarate revenue by approximately $28.0&#160;million. During the second quarter of 2020 we believe customers began to utilize the product purchased (approximately $17.0&#160;million in rest of world) in the first quarter of 2020, which adversely affected sales in the second quarter of 2020.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. We have appealed the judgments in both actions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate an increase in TECFIDERA sales volume in rest of world in 2021, compared to 2020, notwithstanding the increasing competition from additional treatments for MS and potential disruptions due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face TECFIDERA generic competition in the E.U. if regulatory data protection is not upheld and we expect that this would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volume driven by demand growth.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div><img src="biib-20210630_g3.jpg" alt="biib-20210630_g3.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases of 25.5% and 21.8%, respectively, in U.S. Interferon revenue were primarily due to decreases in Interferon sales volumes of 20.5% and 19.1%, respectively. The net declines in sales volumes reflect the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, compared to the same period in 2020, the increase of 5.3% in rest of world Interferon revenue was primarily due to an increase in Interferon sales volumes of 6.2%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the decrease of 2.4% in rest of world Interferon revenue was primarily due to a decrease in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of 2020 that increased rest of world Interferon revenue by approximately $25.0&#160;million, primarily in the rest of world. During the second quarter of 2020 we believe customers began to utilize the product purchased (approximately $15.0&#160;million in rest of world) in the first quarter of 2020, which adversely affected sales in the second quarter of 2020.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2021, compared to 2020, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20210630_g4.jpg" alt="biib-20210630_g4.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, compared to the same period in 2020, the increase of 22.8% in U.S. TYSABRI revenue was primarily due to an increase in pricing and a favorable volume impact, resulting from favorable shipping dynamics.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the increase of 9.8% in U.S. TYSABRI revenue was primarily due to an increase in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases of 19.4% and 5.0%, respectively, in rest of world TYSABRI revenue were primarily due to favorable volume impacts, partially offset by decreases in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI sales volume to modestly increase on a global basis in 2021, compared to 2020, despite increasing competition from additional treatments for MS, including OCREVUS. We expect to continue to face price reductions in certain European markets.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div><img src="biib-20210630_g5.jpg" alt="biib-20210630_g5.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases of 29.0% and 33.1%, respectively, in U.S. SPINRAZA revenue were primarily due to decreases in sales volumes resulting from increased competition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases of 23.3% and 17.7%, respectively, in rest of world SPINRAZA revenue were primarily due to increases in sales volumes of 17.2% and 14.3%, respectively, due in part to timing of shipments in developing markets and increases in patients. The increases were also due to the favorable impact of foreign currency exchange of 6.7% and 4.9%, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect that SPINRAZA revenue will be subject to increased competition resulting in higher discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months and lower prices in certain rest of world countries. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product and an oral product. We expect that we will experience competition from both products in additional jurisdictions in the future, which may adversely affect our sales of SPINRAZA.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alzheimer's Disease</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For the three and six months ended June 30, 2021, U.S. ADUHELM revenue was approximately $1.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2021 we expect modest sales of ADUHELM in the U.S.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI and FLIXABI</span></div><div><img src="biib-20210630_g6.jpg" alt="biib-20210630_g6.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases of 17.9% and 4.4%, respectively, in biosimilar revenue were primarily due to the favorable impact of higher volumes and foreign currency exchange, partially offset by decreases in pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of 2020 that increased biosimilar revenue by approximately $15.0&#160;million. During the second quarter of 2020 we believe customers began to utilize the product purchased (approximately $9.0&#160;million) in the first quarter of 2020, which adversely affected sales in the second quarter of 2020.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect modest revenue growth for our biosimilars business. We expect to continue to face price reductions in certain European countries.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_148"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20210630_g7.jpg" alt="biib-20210630_g7.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">807.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,105.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">953.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,617.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in U.S.&#160;product revenue, net were primarily due to decreases in sales volumes of RITUXAN in the U.S. of 29.8% and 40.0%, respectively, primarily due to the onset of competition from multiple biosimilar products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, product revenue, net also reflected increases in GAZYVA sales volume of 28.9% and 13.5%, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in collaboration costs and expense were primarily due to lower cost of sales on RITUXAN.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have recently been approved and are competing with RITUXAN and GAZYVA in the oncology and other markets. In November 2019, January 2020 and January 2021 biosimilar products referencing RITUXAN were launched in the U.S. and are being offered at lower prices. This competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITUXAN have decreased substantially compared to prior periods. We expect that biosimilar </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of royalty revenue on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, compared to the same periods in 2020, the increases in other revenue from anti-CD20 therapeutic programs were primarily due to sales growth of OCREVUS. Royalty revenue recognized on sales of OCREVUS for the three and six months ended June 30, 2021, totaled $257.0 million and $466.3&#160;million, respectively, compared to $208.2 million and $370.5&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_151"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(309.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(308.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(325.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(324.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other relationships primarily includes royalty revenue on biosimilar products from Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenue</span></div><div><img src="biib-20210630_g8.jpg" alt="biib-20210630_g8.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in other corporate revenue were primarily due to higher contract manufacturing revenue during the second quarter of 2020, resulting from $329.4&#160;million in revenue related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_154"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><img src="biib-20210630_g9.jpg" alt="biib-20210630_g9.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, reserves for discounts and allowances as a percentage of gross product revenue were 29.2% and 28.6%, respectively, compared to 26.0% and 25.8%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, compared to the same period in 2020, the increase in discounts was primarily driven by higher discount rates, partially offset by a decrease in gross sales.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the decrease in discounts was primarily driven by a decrease in gross sales.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in contractual adjustments were primarily caused by lower TECFIDERA sales in the U.S., resulting in lower Medicaid and managed care rebates, partially offset by pharmacy rebates.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, return reserves were relatively consistent.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_157"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">411.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">555.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">882.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(169.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,289.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,123.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(709.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,009.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,421.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20210630_g10.jpg" alt="biib-20210630_g10.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases in product cost of sales were primarily due to product mix and higher cost of sales associated with contract manufacturing agreements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases in royalty cost of sales were primarily due to higher royalties payable on higher sales of TYSABRI and VUMERITY.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="i904ca67b48e9438aa45cc860a3e98146_163"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><img src="biib-20210630_g11.jpg" alt="biib-20210630_g11.jpg" style="height:366px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20210630_g12.jpg" alt="biib-20210630_g12.jpg" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consists of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in research and development expense were primarily due to $208.0&#160;million in charges recognized upon the closing of our collaboration with Sangamo Therapeutics, Inc. (Sangamo) in the second quarter of 2020, partially offset by an increase in spending related to the EMBARK redosing study for aducanumab, the development of zuranolone for the potential treatment of MDD and PPD, the development of BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage, and the impact of business development license transactions.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in spending related to our early stage programs were primarily due to decreases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of opicinumab (anti-LINGO) in MS;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB054 (cinpanemab) in Parkinson's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of dapirolizumab pego, an anti-CD40L pegylated Fab that we are developing in collaboration with UCB, for the potential treatment of systemic lupus erytheatosus (SLE) into late stage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 (anti-BDCA2) for the potential treatment of SLE into late stage.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by increases in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali Therapeutics Inc. (Denali); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the close out costs related to the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the increases in spending associated with our late stage programs were primarily due to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of zuranolone for the potential treatment of MDD and PPD;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of dapirolizumab pego for the potential treatment of SLE into late stage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to lecanemab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of lecanemab in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="i904ca67b48e9438aa45cc860a3e98146_166"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20210630_g13.jpg" alt="biib-20210630_g13.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, selling, general and administrative expense increased 14.8% and 9.5%, respectively, primarily due to increases in personnel in support of the launch of ADUHELM in the U.S.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_169"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20210630_g14.jpg" alt="biib-20210630_g14.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets reflects a $350.0&#160;million </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment charge related to BIIB111 for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2020, we had no impairment charges.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant change to our valuation of our IPR&amp;D assets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of June 30, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;D assets was $136.0&#160;million, all of which is related to DPN.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $350.0&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D asset from $365.0&#160;million to $15.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> $191.6&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D asset from</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> $220.0&#160;million to $28.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are evaluating the results of our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112, including evaluation of any future development activities we may perform. Our estimates of the current fair values of the BIIB111 and BIIB112 programs were derived by using a discounted, probability-weighted calculation of future estimated </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">cash flows associated with the programs under multiple scenarios, including the possibility that we will cease further development of BIIB111 and/or BIIB112, which could result in further impairment of these assets. The key assumptions in our estimates are the amount and timing of revenue, probability of technical and regulatory success, discount rate and clinical data associated with the programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we have entered into third-party manufacturing agreements related to the BIIB111 and BIIB112 programs and we may incur a financial penalty if these agreements are terminated. Should we decide to terminate either or both of these programs and/or manufacturing agreements, we will likely incur impairment charges related to the remaining book value of the applicable program as well as charges up to, in the aggregate, approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$30.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to our inventory arrangements and other costs associated with discontinuing these programs.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_172"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit Sharing</span></div><div><img src="biib-20210630_g15.jpg" alt="biib-20210630_g15.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and, beginning in the second quarter of 2021, Eisai's 45.0% share of income and expenses in the U.S. related to the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recognized net profit-sharing expense of $69.9 million and $138.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits compared to a net profit sharing expense of $55.4 million and $127.2 million, respectively, in the prior year comparative periods. For the three and six months ended June 30, 2021, we also recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment made to </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurimmune related to the launch of ADUHELM in the U.S., and net profit-sharing income of $40.1&#160;million to reflect Eisai's 45.0% share of loss related to the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2020, we also recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment made to Neurimmune related to the submission of the Biologics License Application (BLA) for the approval of ADUHELM to the FDA.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div id="i904ca67b48e9438aa45cc860a3e98146_178"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20210630_g16.jpg" alt="biib-20210630_g16.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><img src="biib-20210630_g17.jpg" alt="biib-20210630_g17.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of BIIB118, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_184"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div><img src="biib-20210630_g18.jpg" alt="biib-20210630_g18.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, compared to the same period in 2020, the change in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other income (expense), net primarily reflects net unrealized gains on our holdings in equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the change in other income (expense), net primarily reflects net unrealized losses on our holdings in equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, net unrealized gains and realized gains on our holdings in equity securities were approximately $153.9 million and $0.4 million, respectively, compared to net unrealized gains and realized gains (losses) of $102.9 million and zero, respectively, in the prior year comparative period. The net unrealized gains recognized during the three months ended June 30, 2021, primarily reflect an increase in the fair value of Denali common stock of approximately $263.0&#160;million, partially offset by decreases in the fair value of Ionis, Sangamo and Sage common stock of approximately $105.8 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $288.4 million and $6.6 million, respectively, compared to net unrealized gains and realized gains (losses) of $42.0 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the six months ended June 30, 2021, primarily reflect decreases in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $284.8&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect a moderate increase in interest expense for 2021, compared to 2020, primarily due to lower interest being capitalized as a result of assets being placed into service during 2021.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax (Benefit) Provision</span></div><div><img src="biib-20210630_g19.jpg" alt="biib-20210630_g19.jpg" style="height:425px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate were primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. We recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed above, were primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market. Our 2020 effective tax rate reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, our 2021 effective tax rate reflects a decrease related to the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in 2021. The tax effects of this change in value of our equity investments were recorded discretely, as the changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_190"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20210630_g20.jpg" alt="biib-20210630_g20.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018. As of June 30, 2021, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. We recognize amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recognized net income on our investment of $34.3 million and $16.1 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net income on our investment of $15.1 million and $0.4 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income on our investment for the three and six months ended June 30, 2021, reflects a $31.2&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the current period based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_193"></div><div style="margin-top:14pt"><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div><img src="biib-20210630_g21.jpg" alt="biib-20210630_g21.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, we recorded a current year deferred tax benefit associated with the accelerated approval of ADUHELM by the FDA in the U.S. We recorded a net deferred tax asset of approximately $500.0&#160;million related to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, the changes in net income (loss) attributable to noncontrolling interests, net of tax was also due to the $100.0&#160;million milestone payment to Neurimmune related to the launch of ADUHELM in the U.S. during the second quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2020, the changes in net income (loss) attributable to noncontrolling interests, net of tax were primarily due to the $75.0 million milestone payment to Neurimmune related to the submission of the BLA for the approval of ADUHELM to the FDA.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div id="i904ca67b48e9438aa45cc860a3e98146_196"></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change&#160;%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,308.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">915.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,965.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,382.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,183.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,887.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,347.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,742.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i904ca67b48e9438aa45cc860a3e98146_199"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, certain significant cash flows were as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1,996.3 million in net cash flow provided by operating activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1,050.0 million used for share repurchases;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$170.0&#160;million used in connection with our Exchange Offer; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$164.5 million used for purchases of property, plant and equipment; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$100.0&#160;million milestone payment to Neurimmune.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed our operating and capital expenditures primarily through cash flow earned through our operations. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through our cash flow earned from our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. will continue to reduce our cash flow from operations in 2021 and will have a significant adverse impact on our future cash flow from operations. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had cash, cash equivalents and marketable securities totaling approximately $4.0 billion compared to approximately $3.4 billion as of December 31, 2020. The change in cash, cash equivalents and marketable securities at June 30, 2021, from December 31, 2020, was primarily due to net cash flow provided by operating activities, partially offset by cash used for share repurchases and capital expenditures, cash payments </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made in connection with our Exchange Offer and a milestone payment made to Neurimmune.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020, include the carrying value of our investment in Samsung Bioepis of $612.8 million and $620.2 million, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment may be limited and we may realize significantly less than the value of such investment. This investment is also subject to foreign currency exchange fluctuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sangamo, we purchased approximately 24 million shares of Sangamo common stock in April 2020. As of June 30, 2021 and December 31, 2020, the fair value of this investment was $271.6 million and $333.7&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Denali, we purchased approximately 13&#160;million shares of Denali common stock in September 2020. As of June 30, 2021 and December 31, 2020, the fair value of this investment was $901.5&#160;million and $935.7&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sage, we purchased approximately 6.2&#160;million shares of Sage common stock in December 2020. As of June 30, 2021 and December 31, 2020, the fair value of this investment was $293.3&#160;million and $433.9&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in Ionis common stock had a fair value of $114.7&#160;million and $249.1&#160;million as of June 30, 2021 and December 31, 2020, respectively. The decrease was partially due to the sale of a portion of our investment in Ionis common stock during the first quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$624.6&#160;million aggregate principal amount of our 2045 Senior Notes was exchanged for $700.7&#160;million aggregate principal amount of our 2051 Senior Notes and approximately $151.8&#160;million of aggregate cash payments; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$8.9&#160;million aggregate principal amount of our 2045 Senior Notes was redeemed for approximately $12.1&#160;million of aggregate cash payments, excluding accrued and unpaid interest.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior unsecured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of June 30, 2021 and December 31, 2020, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of June 30, 2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. The change in working capital at June 30, 2021, from December 31, 2020, reflects an increase in total current assets of approximately $296.6 million and a decrease in total current liabilities of approximately $395.0 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total current assets was primarily driven by an increase in net cash, cash equivalents and marketable securities, due to $1,996.3&#160;million of cash generated from operations, partially offset by cash used for share repurchases, capital expenditures and a Neurimmune milestone payment as well as cash payments made in conjunction with our Exchange Offer.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net decrease in current liabilities was primarily due to a reduction in accounts payable as well as accrued expense and other, which was primarily related to decreases in the accrual of contingent payments, the accrual for employee compensation and benefits and the fair values of derivative liabilities.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase Program, we repurchased and retired approximately 1.6 million and 3.8 million shares of our common stock at a cost of approximately $450.0 million and $1.1 billion during the three and six months ended June 30, 2021, respectively. Approximately $3.6 billion remained available under our 2020 Share Repurchase Program as of June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 9.0 million and 12.2&#160;million shares of our common stock at a cost of approximately $2.8 billion and $3.7&#160;billion during the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the six months ended June 30, 2020.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_202"></div></div></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,996.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,415.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow used in investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(389.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow used in financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,349.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,558.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the decrease </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in net cash flow provided by operating activities was primarily due to lower net income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the decrease in net cash flow used in investing activities was primarily due to higher capital expenditures and acquisitions of IPR&amp;D and other intangible assets in 2020 as well as the upfront payment made to Sangamo, partially offset by higher net proceeds received from the sale of marketable securities in 2020 as compared to the current year.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, compared to the same period in 2020, the decrease in net cash flow used in financing activities was primarily due to the greater number of shares repurchased in 2020 as compared to the comparative period in 2021, partially offset by cash used in connection with our Exchange Offer and a milestone payment to Neurimmune in 2021.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_205"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd., we agreed to make additional payments based upon the achievement of certain milestone events.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with this acquisition at its fair value on the acquisition date and revalue this obligation each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to this acquisition.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of June 30, 2021, we could trigger potential future milestone payments to third parties of up to approximately $10.5 billion, including approximately $2.0 billion in development milestones, approximately $1.2 billion in regulatory milestones and approximately $7.3 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of June 30, 2021, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $68.2&#160;million in milestones in 2021 under our current agreements. In addition, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $100.0&#160;million in additional milestones to Neurimmune, which includes $50.0&#160;million if launched in three or more countries in the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $43.7 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of June 30, 2021. We have approximately $646.8 million in cancellable future commitments based on existing CRO contracts as of June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM Corporation (FUJIFILM), we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of June 30, 2021, we have approximately $96.5 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, we have accrued income tax liabilities of approximately $633.0&#160;million and $697.0&#160;million, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of June 30, 2021, approximately $72.7&#160;million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_208"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_211"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2020 Form&#160;10-K.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_214"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of June 30, 2021, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 18 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of June 30, </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and December 31, 2020, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $386.4 million and $458.2 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next four months. As of June 30, 2021 and December 31, 2020, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $54.9 million and $56.9 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of June 30, 2021 and December 31, 2020, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $14.6 million and $13.2 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Pressure</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition in many markets from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face TECFIDERA generic competition in the E.U. if regulatory data protection is not upheld and we expect that this would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of June 30, 2021 and December 31, 2020. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="i904ca67b48e9438aa45cc860a3e98146_217"></div><div style="margin-top:12pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:8pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:8pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of June 30, 2021. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_223"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of June 30, 2021, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_226"></div><div style="margin-top:6pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction or greater acceptance of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:5pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM is in the early stages of commercial launch in the U.S. In addition to risks associated with new product launches and the other factors described in these Risk Factors, our ability to successfully commercialize ADUHELM may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of readiness of healthcare providers to initiate treatment as well as our ability to successfully identify eligible patients based on the information included in ADUHELM&#8217;s label;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">concern regarding the accelerated approval of ADUHELM and its data;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain adequate reimbursement for ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of market acceptance of ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the effectiveness of our commercial strategy for marketing ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in the manufacturing, distribution and supply of ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the approval of other new products for the same or similar indications; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to ADUHELM.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives are investigating the approval and price of ADUHELM. Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative, joint venture and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third parties. Reliance on third parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or third parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that may impact its operations and business or divert the attention of the Samsung Bioepis management team from its ongoing operations. In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment may be limited and we may realize significantly less than the value of such investment.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is increasing public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives are investigating the approval and price of ADUHELM. In addition, there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of Samsung Bioepis, collaboration partners and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If these third parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet higher than anticipated demand. We are dependent on a third-party for the manufacture of biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) in the label for certain of our products, may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. Further, the COVID-19 pandemic has caused us to modify our business practices, including the requirement that most of our office-based employees in the U.S. and our other key markets work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. In addition, remote or hybrid working arrangements could impact employees' productivity and morale. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the United Kingdom (U.K.), including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped. If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a portion of the Solothurn facility received a GMP multi-product license from SWISSMEDIC in May 2021, the manufacturing of a product or product candidate at the Solothurn facility must be approved by the applicable regulatory agencies, including the FDA. There can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of a product or a product candidate. If we do not receive the necessary regulatory approvals of the Solothurn facility or if our future growth and drug development plans increase, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control, including the impact of the COVID-19 pandemic. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. If we do not receive the necessary regulatory approvals to manufacture products or product candidates at the Solothurn facility, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act, which may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. Further, the new administration could introduce new tax laws or revise or issue new interpretations of the 2017 Tax Act.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) resulted in significant changes to the Swiss cantonal income tax system. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. We have also suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remote working arrangements could impact employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for LHI has been delayed as this study involves administration of BIIB093 in an acute hospital setting. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020 and is aimed at providing emergency assistance and health care for individuals, families and businesses and generally supporting the U.S. economy. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stoc</span><span style="color:#008080;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">k</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the second quarter of 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,620,858&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.63&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,620,858&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,550.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,550.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,620,858&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.63&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million and 3.8 million shares of our common stock at a cost of approximately $450.0 million and $1.1 billion during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, respectively. Approximately $3.6 billion remained available under our 2020 Share Repurchase Program as of June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 9.0 million and 12.2&#160;million shares of our common stock at a cost of approximately $2.8 billion and $3.7&#160;billion during the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the six months ended June 30, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i904ca67b48e9438aa45cc860a3e98146_235"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Biogen Inc.'s Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 8, 2021.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101amendedmanagemen.htm">Amended and Restated Biogen Inc. 2019 Performance-Based Management Incentive Plan, effective as of June 2, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021630xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021630xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2021630xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in Inline XBRL.</span></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contact or compensatory plan or arrangement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i904ca67b48e9438aa45cc860a3e98146_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i904ca67b48e9438aa45cc860a3e98146_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July&#160;22, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101amendedmanagemen.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i82118f57d7dd477299f79432812bbfeb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PERFORMANCE-BASED MANAGEMENT INCENTIVE PLAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. Purpose</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Performance-Based Management Incentive Plan (this &#8220;Plan&#8221;) is established by Biogen Inc. (the &#8220;Company&#8221;) to attract and retain persons of outstanding abilities and to stimulate efforts to bring about strong operating performance and reward the individuals who contribute to this performance. This Plan supersedes and replaces any performance-based management incentive plan previously adopted by the Company or its predecessors and applies to awards granted on or after January 1, 2019.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. Basic Concepts</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award programs under this Plan shall be developed under the following basic concepts&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> There shall be an identification of performance periods, which may be a minimum of six (6)&#160;and a maximum of sixty (60)&#160;consecutive months in length. Because multiple awards may be granted to a Participant under this Plan, performance periods need not be sequential and may overlap or occur simultaneously.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">With respect to each performance period, there shall be a determination of (i)&#160;eligible Participants, (ii)&#160;the amount of each participant&#8217;s target incentive awards, (iii)&#160; the applicable performance goals, based on the Performance Criteria listed in Section&#160;4.B below and&#47;or such other Company and&#47;or individual performance goals as may be approved by the Compensation and Management Development Committee of the Board of Directors of the Company (the &#8220;Committee&#8221;), and (iv)&#160;the extent to which performance relative to each such performance goal shall determine the amount of the award payable to a Participant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. Eligibility</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">&#160;Participation in this Plan shall be limited to executive officers of the Company and its subsidiaries and affiliates. Each employee participating in this Plan is referred to as a &#8220;Participant.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">Unless otherwise authorized by the Committee, Participants shall be excluded from participation in any other cash bonus or incentive program of the Company or any of its subsidiaries and affiliates&#59; provided, however, that Participants shall not be excluded from participation in any equity incentive plan adopted by the Company (whether or not such awards are settled in stock or in cash).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Determination of Awards</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> Except as provided otherwise in this Section&#160;4, awards under this Plan shall be paid on account of the attainment of one or more performance goals which&#58; (i)&#160;are established by the Committee&#59; (ii)&#160;are based on one or more of the criteria listed below in Section 4.B and&#47;or such other Company and&#47;or individual performance goals as may be approved by the Committee, and (iii)&#160;state the method for computing the amount of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">compensation payable to a Participant if the performance goal or goals are attained. Unless otherwise determined by the Committee, Performance Criteria or other performance goals shall be adopted with respect to each performance period by the Committee (A) for performance periods of one year or more, no later than ninety (90) days after the commencement of the performance period&#59; and (B) for periods of less than one year, before twenty-five percent (25%) of the performance period has elapsed. The Committee may waive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%"> </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">the achievement of one or more of the applicable performance goals in the case of the death or disability of the Participant or under such other circumstances as the Committee determines are appropriate. The Committee may provide that if certain specified goals are not met, no awards will be made for the performance period to which such goals relate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">Performance goals shall be based on specified Company or individual criteria, which may include objectively determinable measures of performance relating to any of, or to any combination of, the following (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on a consolidated basis or, as the context permits, on a divisional, functional, subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Committee specifies (&#8220;Performance Criteria&#8221;))&#58; sales&#59; revenues&#59; assets&#59; expenses&#59; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization or other items, whether or not on a continuing operations or an aggregate or per share basis&#59; return on equity, investment, capital or assets&#59; one or more operating ratios&#59; borrowing levels, leverage ratios or credit rating&#59; market share&#59; capital expenditures&#59; cash flow&#59; stock price&#59; stockholder return&#59; sales of particular products or services&#59; customer acquisition, expansion or retention&#59; acquisitions and divestitures (in whole or in part)&#59; joint ventures and strategic alliances&#59; spin-offs,&#160;split-ups&#160;and the like&#59; reorganizations&#59; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings&#59; or achievement of clinical trial or research objectives. A Performance Criterion and any targets with respect thereto determined by the Committee need not be based upon an increase, a positive or improved result or avoidance of loss and may be based on GAAP,&#160;non-GAAP&#160;or other metrics as contemplated hereby. The Committee may provide that one or more of the Performance Criteria applicable to an award will be adjusted to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria. Performance goals may also consist of such other individual performance criteria and&#47;or subjective Company performance criteria as determined by the Committee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">C. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">Except as provided in Section 8.B below, no incentive awards shall be paid to Participants under this Plan unless and until the Committee determines that the applicable Performance Criteria or other performance goals have been attained, and such determination will be final and conclusive.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">D. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">A Participant may receive an incentive award under this Plan that is less than, equal to or greater than his or her target incentive award. The Committee may in its sole discretion adjust an incentive award otherwise payable to a Participant, including on the basis of Company and&#47;or specific individual goals, which may be based on nonobjective factors related to the performance of the Company and&#47;or the Participant, as the case may be.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. Basis of Participation in Award Programs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> Awards may, but are not required to, be denominated in (i.e., valued by reference to) the Common Stock of the Company or units of Common Stock of the Company&#59; provided, however, that any awards denominated in cash will be paid in cash as provided in Section&#160;8.A below. Awards denominated in cash may be expressed as a percentage of the annual base pay of the Participant or as a specified dollar amount.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">In addition to any other terms and conditions set forth in this Plan, all or part of the grant, vesting and&#47;or payment of an award may be made subject to future service and such other restrictions and conditions as may be established by the Committee, and as may be set forth in any award agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Administration</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> The overall administration of this Plan shall be under the direction of the Committee. The Committee has discretionary authority, subject only to the express provisions of this Plan, to interpret this Plan&#59; determine eligibility for and grant awards&#59; determine, modify or waive the terms and conditions of any award&#59; prescribe forms, rules and procedures&#59; and otherwise do all things necessary or desirable to carry out the purposes of this Plan. Determinations of the Committee made under this Plan will be conclusive and will bind all persons. The Committee may delegate&#58; (i)&#160;to one or more of its members such of its duties, powers and responsibilities as it may determine and (ii)&#160;to such employees or other persons as it determines such ministerial tasks as it deems appropriate.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">Responsibility for the ministerial administration of this Plan (for example, payment of awards approved by the Committee) shall be under the direction of the Company&#8217;s Head of Human Resources.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. Determination of Incentive Awards&#59; Limitations on Awards</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> The maximum amount payable under this Plan to any Participant during any calendar year may not exceed $6,000,000 for the Chief Executive Officer and $3,000,000 for any other Participant.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">The final determination of the extent to which the Performance Criteria and&#47;or other performance goals were achieved for an award will be made by the Committee promptly following the availability of all necessary performance results.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">C. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">For the avoidance of doubt, in no event will any payment of an award exceed 225% of the Participant&#8217;s target incentive award.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. Payments&#59; Effect of Termination of Employment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> All payments of awards hereunder shall be made in cash within the sooner of 90&#160;days following the end of the applicable performance period or March 15 of the year following the calendar year in which the award was earned.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">If a Participant&#8217;s employment terminates during a performance period due to death or disability, a determination of the amount payable to the Participant or his or her </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">estate will be made as soon as practicable thereafter. Unless otherwise determined by the Committee, the amount to be paid under these circumstances shall be determined by multiplying the Participant&#8217;s target incentive award by a fraction, the numerator of which is the number of days completed during the performance period before termination of employment, and the denominator of which is the original length of the performance period. Payment of awards under this Section&#160;8.B will be made within the sooner of 90&#160;days of the termination of employment or March 15 of the year following the calendar year in which employment terminated. If a Participant&#8217;s employment terminates during a performance period for any reason other than death or disability, unless the Committee determines otherwise, payment will not be made in respect of any award.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C. Participants are required to maintain employment with the Company through the payout date to receive payment, unless this practice is in conflict with local law. If a Participant terminates employment for any reason other than death or disability after the end of the performance period but before the payout date, they will not be entitled to any award payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. General Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">A.</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> While it is the intent of the Company to continue this Plan indefinitely, the Company reserves the right to amend, modify or terminate this Plan, any incentive program under this Plan or any Participant&#8217;s participation in this Plan at any time or on such conditions as the Committee shall deem appropriate&#59; provided, however, that to the extent that stockholder approval is required pursuant to law or by reason of the rules of the applicable exchange on which shares of the Company&#8217;s common stock is publicly traded, no such amendment or modification shall be effective until such time as such stockholder approval is obtained. Except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%"> </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">as provided in 8.B above, no Participant shall have any right to any incentive award under this Plan until such award and the amount thereof has been finally approved by the Committee and communicated to such Participant after the end of the performance period for which the award is being made and the Participant remains employed with the Company through such date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">B. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">This Plan is not a contract between the Company and any Participant. Neither the establishment of this Plan, nor any action taken hereunder, shall be construed as giving any Participant any right to be retained in the employ of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">C. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">The Committee may cancel, rescind, withhold or otherwise limit or restrict any unpaid award (or require the repayment of an award) at any time if the Participant is not in compliance with all applicable provisions of this Plan and award agreement, if any, or if the Participant engages in any &#8220;Detrimental Activity&#8221; or as otherwise provided under any applicable clawback or recoupment policy of the Company, as in effect from time to time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">1)</font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%"> In particular, but not in limitation of the foregoing, in the event that a Participant engages or has engaged in Detrimental Activity, any amounts payable to the Participant in the year in which termination of employment occurs under this Plan may be forfeited and the entire amount of any payments made during such year of termination of employment shall be repaid to the Company. Each Participant, by accepting or being deemed to have accepted an award under this Plan, agrees to cooperate fully with the Committee to effectuate any forfeiture required under this Plan. The Participant (and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">neither the Committee nor the Company) will be solely responsible for any adverse tax or other consequences to a Participant that may arise in connection with this Section 9.C.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">2) </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">For purposes of this Plan, &#8220;Detrimental Activity&#8221; shall include any action or failure to act that, in the sole determination of the Committee&#58; (i)(a) constitutes financial malfeasance that is materially injurious to the Company, (b)&#160;violates the Company&#8217;s Code of Conduct, (c)&#160;results in the Company&#8217;s restatement of its earnings, financial results or financial statements or (d)&#160;results in a violation or breach of law or contract that is materially injurious to the Company or (ii)&#160;violates any non-competition, non-disclosure or non-solicitation agreement with the Company, or in the event that the Participant has not entered into any such agreement with the Company, the Participant engages in any &#8220;Competitive Activity.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">3) </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">For purposes of this Plan, &#8220;Competitive Activity&#8221; shall include&#58; (i)&#160; the rendering of services for any organization or engaging directly or indirectly in any business which is or becomes competitive with the Company, or which organization or business, or the rendering of services to such organization or business, is or becomes otherwise prejudicial to or in conflict with the interests of the Company&#59; (ii)&#160;the disclosure to anyone outside the Company, or the use in other than the Company&#8217;s business, without prior written authorization from the Company, of any confidential information or material relating to the business of the Company, acquired by the Participant either during or after employment with the Company or (iii)&#160;any attempt directly or indirectly to induce any employee of the Company to be employed or perform services elsewhere or any attempt directly or indirectly to solicit the trade or business of any current or prospective customer, supplier or partner of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">D. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">A Participant&#8217;s right and interest under this Plan may not be assigned or transferred, and any attempted assignment or transfer shall be null and void and shall extinguish, in the Company&#8217;s sole discretion, the Company&#8217;s obligation under this Plan to pay incentive awards with respect to the Participant.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">E. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">This Plan shall be unfunded. The Company shall not be required to establish any special or separate fund, or to make any other segregation of assets, to assure payment of awards.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">F. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">The Company shall have the right to deduct from incentive awards paid any taxes or other amounts required by law to be withheld.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">G. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">Awards under this Plan are intended either to be exempt from the rules of Section&#160;409A of the Code or to satisfy those rules, and shall be construed accordingly. Notwithstanding anything to the contrary in this Plan, neither the Company, nor any affiliate, nor the Committee, nor any person acting on behalf of the Company, any affiliate, or the Committee, shall be liable to any Participant or to the estate or beneficiary of any Participant or to any other holder of an award by reason of any acceleration of income, or any additional tax, asserted by reason of the failure of an award to satisfy the requirements of Section&#160;409A of the Code or by reason of Section&#160;4999 of the Code.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:10pt;font-weight:400;line-height:109%">H. </font><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:109%">The validity, construction, interpretation and effect of this Plan shall exclusively be governed by and determined in accordance with the laws of the State of Delaware, without giving effect to its conflict of laws provisions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Approved 02.12.2019, amended 06.02.21)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>biib-2021630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9ee3c968852d432ea43a2c2d1d6c2140_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 22, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>biib-2021630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia6a1d5598f8f4075806da8cc8a424291_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 22, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>biib-2021630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2807b197c027444d9c30161bd4814ce8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 22, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 22, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:00d4ab53-132a-461c-a04e-3900c9e9172a,g:268dc15b-49f4-4ca1-9cf5-eeb8cc02f2b7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2104102 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2405402 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2106103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2307301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesbyProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails">
        <link:definition>2408403 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1">
        <link:definition>2409404 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2">
        <link:definition>2410405 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2411406 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2412407 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2413408 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2114104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2315302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2416409 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2117105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2318303 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2419410 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2322304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2423412 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2424413 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNonrecurringAssetsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails">
        <link:definition>2426415 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2427416 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2428417 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2129107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2330305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2431418 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2432419 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2433420 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2434421 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2435422 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2436423 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2137108 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2338306 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2439424 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment">
        <link:definition>2140109 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2441425 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessNotes" roleURI="http://www.biogenidec.com/role/IndebtednessNotes">
        <link:definition>2142110 - Disclosure - Indebtedness (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2443426 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2144111 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2345307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2446427 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2447428 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2448429 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2149112 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2350308 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2451430 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2152113 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2353309 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2454431 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2455432 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2156114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2357310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2458433 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2459434 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2160115 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2361311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2462435 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2463436 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2164116 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2365312 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2466437 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2467438 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2168117 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2469439 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2170118 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2471440 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>2172119 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsDetails">
        <link:definition>2473441 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageParValueOfSeniorNotes" abstract="false" name="PercentageParValueOfSeniorNotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_VixotrigineMember" abstract="true" name="VixotrigineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" abstract="false" name="PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesValueReductioninValue" abstract="false" name="DeferredTaxLiabilitiesValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" abstract="false" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="us-types:durationStringItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AcquisitionsAbstract" abstract="true" name="AcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" abstract="false" name="DeferredTaxLiabilitiesIncreaseDecreaseInValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_A2.90SeniorNotesDueSept152020Member" abstract="true" name="A2.90SeniorNotesDueSept152020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" abstract="false" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NightstarMember" abstract="true" name="NightstarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ADUHELMMember" abstract="true" name="ADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" abstract="true" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_NoncontrollingInterestIncreaseDecreaseOther" abstract="false" name="NoncontrollingInterestIncreaseDecreaseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_InnoCarePharmaLimitedInnoCareAgreementMember" abstract="true" name="InnoCarePharmaLimitedInnoCareAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxAssetsValueReductioninValue" abstract="false" name="DeferredTaxAssetsValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_October2020ShareRepurchaseProgramMember" abstract="true" name="October2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashSettledPerformanceSharesMember" abstract="true" name="CashSettledPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BIIB112Member" abstract="true" name="BIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DividendYieldPercentage" abstract="false" name="DividendYieldPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_SangamoCommonStockMember" abstract="true" name="SangamoCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_Reductioninroyaltyratepayableoncommercialsales" abstract="false" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2018ShareRepurchaseProgramMember" abstract="true" name="A2018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Investmentincommonstocksharespurchased" abstract="false" name="Investmentincommonstocksharespurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" abstract="true" name="FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" abstract="false" name="GlobalLicensingCollaborationAgreementPurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Biogenshareofcopromotionprofitsorlosses" abstract="false" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" abstract="false" name="EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetDomain" abstract="true" name="ResearchanddevelopmentassetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB111AndBIIB112Member" abstract="true" name="BIIB111AndBIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_LongTermDebtExchangedAmount" abstract="false" name="LongTermDebtExchangedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" abstract="false" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DeferredTaxAssetIncreaseDecreaseInValue" abstract="false" name="DeferredTaxAssetIncreaseDecreaseInValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InLicensedPatentsMember" abstract="true" name="InLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_December2019ShareRepurchaseProgramMember" abstract="true" name="December2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_March2019ShareRepurchaseProgramMember" abstract="true" name="March2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" abstract="false" name="EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB118Member" abstract="true" name="BIIB118Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:00d4ab53-132a-461c-a04e-3900c9e9172a,g:268dc15b-49f4-4ca1-9cf5-eeb8cc02f2b7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b131c4e-39e3-4f01-9c5b-168fa37e898d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6c8fb44c-c0d3-4515-aba8-be572ae7725b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6b131c4e-39e3-4f01-9c5b-168fa37e898d" xlink:to="loc_us-gaap_ProfitLoss_6c8fb44c-c0d3-4515-aba8-be572ae7725b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8809776b-40b4-4780-961d-7e53678f41c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6b131c4e-39e3-4f01-9c5b-168fa37e898d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8809776b-40b4-4780-961d-7e53678f41c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ff81741-14fb-4794-a15b-58e9a51b47dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_571ba260-8b74-4b58-a7fa-e81cc7069fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ff81741-14fb-4794-a15b-58e9a51b47dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_571ba260-8b74-4b58-a7fa-e81cc7069fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_44a93738-2c65-4c8b-a52f-11c58bb85004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ff81741-14fb-4794-a15b-58e9a51b47dc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_44a93738-2c65-4c8b-a52f-11c58bb85004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4756d42a-09ba-44d2-92a9-b7d0517b36d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4756d42a-09ba-44d2-92a9-b7d0517b36d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_487e78a0-f4f2-4c9f-adce-4b6923b00f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_487e78a0-f4f2-4c9f-adce-4b6923b00f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_650462c6-f2a9-414d-8916-a414a40c809f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_650462c6-f2a9-414d-8916-a414a40c809f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_e4c78d0a-f263-46dd-a5ad-09b98af502b7" xlink:href="biib-20210630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_biib_Collaborationprofitlosssharing_e4c78d0a-f263-46dd-a5ad-09b98af502b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d0ee0ecf-31e8-4c34-bdeb-a34fc3b108ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d0ee0ecf-31e8-4c34-bdeb-a34fc3b108ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d0fb5730-b30d-47ef-9afb-f0db56baf856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d0fb5730-b30d-47ef-9afb-f0db56baf856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_528eef42-dc86-4f31-a4cb-6001ccf2196a" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_32e2f895-84cd-4d6d-b1e6-523eb49a35e1" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_528eef42-dc86-4f31-a4cb-6001ccf2196a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_21f68ad0-c92b-401a-b7a4-d83f38fc21a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5915ce96-3b8c-4242-b110-8651114de549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_21f68ad0-c92b-401a-b7a4-d83f38fc21a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5915ce96-3b8c-4242-b110-8651114de549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8cfa62e4-619d-45cb-a79b-a425cc47c458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_21f68ad0-c92b-401a-b7a4-d83f38fc21a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8cfa62e4-619d-45cb-a79b-a425cc47c458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7c92de1f-2bab-4c0f-94c2-82ed37015e08" xlink:href="biib-20210630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_21f68ad0-c92b-401a-b7a4-d83f38fc21a2" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7c92de1f-2bab-4c0f-94c2-82ed37015e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_236ab464-e45c-4ad2-bedf-bd35a71cccd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b02ce546-566a-430f-a686-33a8b8933f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_236ab464-e45c-4ad2-bedf-bd35a71cccd6" xlink:to="loc_us-gaap_Revenues_b02ce546-566a-430f-a686-33a8b8933f64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_08b0485f-ce27-4b53-8704-52f8c54fedc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_236ab464-e45c-4ad2-bedf-bd35a71cccd6" xlink:to="loc_us-gaap_CostsAndExpenses_08b0485f-ce27-4b53-8704-52f8c54fedc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9fa152d-d3d2-4684-a2bb-05ac599b90f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c57526b-bc3e-4f7d-a49c-8d68c50bdf3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9fa152d-d3d2-4684-a2bb-05ac599b90f7" xlink:to="loc_us-gaap_NetIncomeLoss_4c57526b-bc3e-4f7d-a49c-8d68c50bdf3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bbd5cea9-6338-49d2-bc48-f46f774fc5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9fa152d-d3d2-4684-a2bb-05ac599b90f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bbd5cea9-6338-49d2-bc48-f46f774fc5d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4470ab50-e6b6-44d9-bc6f-04908281b02a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d023a655-5008-4823-b8b4-7acd21953ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4470ab50-e6b6-44d9-bc6f-04908281b02a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d023a655-5008-4823-b8b4-7acd21953ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_78a53bc2-ba70-43ae-ab36-641f92104c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4470ab50-e6b6-44d9-bc6f-04908281b02a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_78a53bc2-ba70-43ae-ab36-641f92104c22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_b0f27a98-4ce7-4105-9077-bf75ad44519a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4470ab50-e6b6-44d9-bc6f-04908281b02a" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_b0f27a98-4ce7-4105-9077-bf75ad44519a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_683816c0-1ee0-4e92-803d-8eb57a2d2d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4470ab50-e6b6-44d9-bc6f-04908281b02a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_683816c0-1ee0-4e92-803d-8eb57a2d2d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3b471e61-ee94-4b26-9e21-d7f778dfae34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4470ab50-e6b6-44d9-bc6f-04908281b02a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3b471e61-ee94-4b26-9e21-d7f778dfae34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b736f8f-5f4b-42c1-8aa5-76fbd45cd71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8a679f12-b728-43dd-9bff-46dd702fc288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b736f8f-5f4b-42c1-8aa5-76fbd45cd71e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8a679f12-b728-43dd-9bff-46dd702fc288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_86cafcbc-fb7a-477e-9a3a-c83e2a8e796e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b736f8f-5f4b-42c1-8aa5-76fbd45cd71e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_86cafcbc-fb7a-477e-9a3a-c83e2a8e796e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71f10a64-0ce5-4ac1-9bde-6a847687813e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dee56a5f-a859-483e-8231-78bbd2f835bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71f10a64-0ce5-4ac1-9bde-6a847687813e" xlink:to="loc_us-gaap_StockholdersEquity_dee56a5f-a859-483e-8231-78bbd2f835bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_cc4cde8b-7021-46f3-9013-bebb92f573a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71f10a64-0ce5-4ac1-9bde-6a847687813e" xlink:to="loc_us-gaap_MinorityInterest_cc4cde8b-7021-46f3-9013-bebb92f573a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_def7cb03-3ff0-44e4-a886-6ef68809277f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_32e209cf-2edb-4428-ace1-6307a388c1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_def7cb03-3ff0-44e4-a886-6ef68809277f" xlink:to="loc_us-gaap_TaxesPayableCurrent_32e209cf-2edb-4428-ace1-6307a388c1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a73f214b-d4a1-436e-820c-63a2351c31df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_def7cb03-3ff0-44e4-a886-6ef68809277f" xlink:to="loc_us-gaap_AccountsPayableCurrent_a73f214b-d4a1-436e-820c-63a2351c31df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f1464251-da11-4b5c-8fca-66905e532cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_def7cb03-3ff0-44e4-a886-6ef68809277f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f1464251-da11-4b5c-8fca-66905e532cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_562f0614-ed6a-4ce3-bddc-3186e4ca04b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:to="loc_us-gaap_PreferredStockValue_562f0614-ed6a-4ce3-bddc-3186e4ca04b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c4c2cb4a-3b7c-48f3-9614-ea4af0cbf70b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:to="loc_us-gaap_CommonStockValue_c4c2cb4a-3b7c-48f3-9614-ea4af0cbf70b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7f9847d5-da81-4b4f-adc5-77a01dac5f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7f9847d5-da81-4b4f-adc5-77a01dac5f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bbb23cfd-df4a-4257-80a2-725d7327eda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bbb23cfd-df4a-4257-80a2-725d7327eda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2e43a3a-b5ff-4e50-a07f-75bce50e3703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2e43a3a-b5ff-4e50-a07f-75bce50e3703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_68202dd2-d2a2-41e5-9511-3f653e5d7715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dadd5c4-3a85-4a95-9168-5d446080dee0" xlink:to="loc_us-gaap_TreasuryStockValue_68202dd2-d2a2-41e5-9511-3f653e5d7715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c3af37b-053a-46b1-b55b-c2124834d9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ae758aec-207e-40c6-b700-549fa38917fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c3af37b-053a-46b1-b55b-c2124834d9f3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ae758aec-207e-40c6-b700-549fa38917fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7407ec9f-1220-45e8-8248-f0a2914632bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c3af37b-053a-46b1-b55b-c2124834d9f3" xlink:to="loc_us-gaap_Liabilities_7407ec9f-1220-45e8-8248-f0a2914632bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e2054767-d187-42c7-a9b0-b4715a96f927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c3af37b-053a-46b1-b55b-c2124834d9f3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e2054767-d187-42c7-a9b0-b4715a96f927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_07668c57-2846-4945-949f-45d55b126028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_AssetsCurrent_07668c57-2846-4945-949f-45d55b126028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_997ebc1a-947c-4db1-a419-268d19fd409c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_997ebc1a-947c-4db1-a419-268d19fd409c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_afb52fc4-0105-4843-ad07-fdaa6e530222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_afb52fc4-0105-4843-ad07-fdaa6e530222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_41537bec-1123-4a8d-90ca-180c93e3bfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_41537bec-1123-4a8d-90ca-180c93e3bfca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd75c404-dd2c-461f-91db-39610dfc8e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd75c404-dd2c-461f-91db-39610dfc8e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_44b3e90a-850d-47ee-ab5d-6bb79333ba34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_Goodwill_44b3e90a-850d-47ee-ab5d-6bb79333ba34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_15b6f89f-9ded-41ce-b2fb-266cf544c644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_15b6f89f-9ded-41ce-b2fb-266cf544c644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4314f441-47f2-4a52-98ef-7557c9407ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b665f35d-17e1-4f9b-b8ff-aa3f48a0df9b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4314f441-47f2-4a52-98ef-7557c9407ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c56feb5-09c0-4986-bffa-b13a68224bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c56feb5-09c0-4986-bffa-b13a68224bde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5bd767fd-f616-44f2-8872-651b879354cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5bd767fd-f616-44f2-8872-651b879354cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_15b70484-7fb7-491b-891e-55333a3de08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_15b70484-7fb7-491b-891e-55333a3de08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_a86c9f51-f226-499a-accd-6279c00a0e4d" xlink:href="biib-20210630.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_a86c9f51-f226-499a-accd-6279c00a0e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_73e115d5-98d3-4535-9817-abd7bbc54a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:to="loc_us-gaap_InventoryNet_73e115d5-98d3-4535-9817-abd7bbc54a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2b462a49-d38e-42cc-8303-5044ba22a362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1c4551d0-0fd8-4887-b0c0-7807de446adc" xlink:to="loc_us-gaap_OtherAssetsCurrent_2b462a49-d38e-42cc-8303-5044ba22a362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52e8766e-4fdc-470e-8c93-3794059e4481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8a94fb37-d9ff-4d07-850b-90a1f6add1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_52e8766e-4fdc-470e-8c93-3794059e4481" xlink:to="loc_us-gaap_LiabilitiesCurrent_8a94fb37-d9ff-4d07-850b-90a1f6add1ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_21bec5f4-21a9-4cac-be7f-55b2397d19f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_52e8766e-4fdc-470e-8c93-3794059e4481" xlink:to="loc_us-gaap_LongTermDebt_21bec5f4-21a9-4cac-be7f-55b2397d19f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7df86a3e-4551-42b5-ab3b-adccf1e1ba97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_52e8766e-4fdc-470e-8c93-3794059e4481" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7df86a3e-4551-42b5-ab3b-adccf1e1ba97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f7ed076-1196-4360-8018-a9198f5eb7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_52e8766e-4fdc-470e-8c93-3794059e4481" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f7ed076-1196-4360-8018-a9198f5eb7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_67c78212-87b7-4ee6-9d10-38950503f859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_52e8766e-4fdc-470e-8c93-3794059e4481" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_67c78212-87b7-4ee6-9d10-38950503f859" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfff9079-2620-4b78-9700-d115ee591910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e135cf4-968d-4436-9adf-9a69f632aef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfff9079-2620-4b78-9700-d115ee591910" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e135cf4-968d-4436-9adf-9a69f632aef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_abbd7c28-4a16-489a-b6ef-dd752bc40ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfff9079-2620-4b78-9700-d115ee591910" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_abbd7c28-4a16-489a-b6ef-dd752bc40ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c05c6773-6ed6-44f9-bcf2-51e909e8567d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dfff9079-2620-4b78-9700-d115ee591910" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c05c6773-6ed6-44f9-bcf2-51e909e8567d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8cb75c43-94d8-41d7-a9d4-57f135b15961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8cb75c43-94d8-41d7-a9d4-57f135b15961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_c46de29f-6add-4469-a907-af7f0299934e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_c46de29f-6add-4469-a907-af7f0299934e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_c78d1d4d-7d42-4cf7-8004-ae23718abb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_c78d1d4d-7d42-4cf7-8004-ae23718abb65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9b433e0d-0d07-4303-9857-c2ab3c990cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9b433e0d-0d07-4303-9857-c2ab3c990cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cbde5126-ed28-4466-b273-3f4408eaa05e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cbde5126-ed28-4466-b273-3f4408eaa05e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b1b0ce69-9d92-45c9-a8b2-7032b9406f69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b1b0ce69-9d92-45c9-a8b2-7032b9406f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_58ee5199-7ea5-400c-abe2-bcfe7c77aa44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_58ee5199-7ea5-400c-abe2-bcfe7c77aa44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_96539ade-1ddb-4520-b12a-cbf66b7315e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9ff7674-5d14-46de-81ed-1ce2676619f3" xlink:to="loc_us-gaap_RepaymentsOfDebt_96539ade-1ddb-4520-b12a-cbf66b7315e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_cbcae5ef-ea47-4c14-b2ff-384b285a7ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_cbcae5ef-ea47-4c14-b2ff-384b285a7ca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_420ef664-c0ab-4160-8139-5978327bd268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_420ef664-c0ab-4160-8139-5978327bd268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0eebc959-ed87-4bbd-8a8f-a336f91996b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0eebc959-ed87-4bbd-8a8f-a336f91996b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_48c566e4-efd8-4e12-8686-a28aa354bdd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_48c566e4-efd8-4e12-8686-a28aa354bdd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_26c839fd-f1e4-41b9-8c52-c56063c69948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_26c839fd-f1e4-41b9-8c52-c56063c69948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_68a13ea9-dc12-42d5-bfb1-9577e82fe307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_68a13ea9-dc12-42d5-bfb1-9577e82fe307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37b97a01-76f2-48ef-bc27-7adf0f8252f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37b97a01-76f2-48ef-bc27-7adf0f8252f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8e5765bd-b2bb-4d66-9aef-b4a43c8f6190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8e5765bd-b2bb-4d66-9aef-b4a43c8f6190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_47fcfd37-99c9-4c33-aea0-d04c73ca1514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_315be884-d9b5-41f6-acf2-d99ad8d1553f" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_47fcfd37-99c9-4c33-aea0-d04c73ca1514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9eb7c9ac-80c1-45d2-ad1a-bbcd9b4c0418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9eb7c9ac-80c1-45d2-ad1a-bbcd9b4c0418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bab26b88-8400-4eee-bf67-bac69a92fe53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bab26b88-8400-4eee-bf67-bac69a92fe53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d3b37158-b622-4775-9769-95015edb4740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d3b37158-b622-4775-9769-95015edb4740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4486fd2b-ac1d-4ef5-b144-a3cbff2b130f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4486fd2b-ac1d-4ef5-b144-a3cbff2b130f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_781da2f7-8984-446a-9f3b-1beeb9a617cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_781da2f7-8984-446a-9f3b-1beeb9a617cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a9a33dad-c1e7-47eb-9e46-d7d985b036a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a9a33dad-c1e7-47eb-9e46-d7d985b036a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_073b5e35-a55b-4967-ae52-30b879c711d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_ShareBasedCompensation_073b5e35-a55b-4967-ae52-30b879c711d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f9b819b1-644b-442b-ad45-e603451800ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f9b819b1-644b-442b-ad45-e603451800ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_33f237fd-0fc1-4a2e-bd06-62b0755fe543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_ProfitLoss_33f237fd-0fc1-4a2e-bd06-62b0755fe543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_71914f41-b894-44b4-8fae-fda319ea2bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_71914f41-b894-44b4-8fae-fda319ea2bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_281dc681-fddc-43e6-b0c0-61f8726578c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_281dc681-fddc-43e6-b0c0-61f8726578c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f968d2fc-5dfd-400a-994e-b983a769b7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f968d2fc-5dfd-400a-994e-b983a769b7c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c3b438e0-7501-4a7a-8249-2b991d6fd921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c3b438e0-7501-4a7a-8249-2b991d6fd921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8d963a5d-977d-494a-9663-eef42866f9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8d963a5d-977d-494a-9663-eef42866f9c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_3fdd5991-62a6-41ee-b1e7-ee1a0f2a7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_3fdd5991-62a6-41ee-b1e7-ee1a0f2a7ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_12984faf-9296-4b30-940b-7df7a5892e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_12984faf-9296-4b30-940b-7df7a5892e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_06400bc4-9713-454b-a00f-b3dc338ff304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64eb43f5-27b5-4368-998b-a054a858f51c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_06400bc4-9713-454b-a00f-b3dc338ff304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_919ba3f4-0e1f-4064-b4f3-2ddcfd4f3fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_6d0c0b0c-40a7-4ec2-91eb-e2bdab48fa07" xlink:href="biib-20210630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_919ba3f4-0e1f-4064-b4f3-2ddcfd4f3fb4" xlink:to="loc_biib_ShareOfCoPromotionProfits_6d0c0b0c-40a7-4ec2-91eb-e2bdab48fa07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_c928d7f6-ada5-4fd9-b481-2e387a315df3" xlink:href="biib-20210630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f76e0ed6-a07e-49a0-995c-b5fa2ba8647d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_c928d7f6-ada5-4fd9-b481-2e387a315df3" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f76e0ed6-a07e-49a0-995c-b5fa2ba8647d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_54e71909-e041-4098-8ce2-051ddd762815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_c928d7f6-ada5-4fd9-b481-2e387a315df3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_54e71909-e041-4098-8ce2-051ddd762815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da13b78a-7b95-41eb-8e0c-8f6f6bb6d37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_c928d7f6-ada5-4fd9-b481-2e387a315df3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da13b78a-7b95-41eb-8e0c-8f6f6bb6d37b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21ebdaf8-d6e9-4418-9f49-026576d8e827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_96d95425-0a0e-4f85-ae6e-0640338a35f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21ebdaf8-d6e9-4418-9f49-026576d8e827" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_96d95425-0a0e-4f85-ae6e-0640338a35f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a875c37-0ef6-450d-8e0e-cb76af3bd2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21ebdaf8-d6e9-4418-9f49-026576d8e827" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a875c37-0ef6-450d-8e0e-cb76af3bd2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b04863f8-9605-4a30-b5a2-fbe4f5ceee2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_101dc1bc-36f8-4aa4-af6c-ae93130163fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b04863f8-9605-4a30-b5a2-fbe4f5ceee2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_101dc1bc-36f8-4aa4-af6c-ae93130163fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b36302ac-b68a-441b-8dfc-3b2a8d5d4e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b04863f8-9605-4a30-b5a2-fbe4f5ceee2e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b36302ac-b68a-441b-8dfc-3b2a8d5d4e72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a359111b-b7c9-4428-982b-03ae0f2cc081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bfa2639d-d20e-4a47-b6d1-22a4e25d1610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a359111b-b7c9-4428-982b-03ae0f2cc081" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bfa2639d-d20e-4a47-b6d1-22a4e25d1610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_841d2347-11e0-4d85-9fb3-02543deb2779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a359111b-b7c9-4428-982b-03ae0f2cc081" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_841d2347-11e0-4d85-9fb3-02543deb2779" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac03f612-67f7-4c5c-b495-c11faa12ccbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4b6b7f69-3a12-48ed-b326-fab15c23093f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac03f612-67f7-4c5c-b495-c11faa12ccbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4b6b7f69-3a12-48ed-b326-fab15c23093f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_daa39ad5-2037-46ca-8d8b-abe44a99026e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac03f612-67f7-4c5c-b495-c11faa12ccbe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_daa39ad5-2037-46ca-8d8b-abe44a99026e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e4aebe3e-ac9f-4475-b3ed-3336ace5bd2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac03f612-67f7-4c5c-b495-c11faa12ccbe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e4aebe3e-ac9f-4475-b3ed-3336ace5bd2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_1d40da55-fea0-489a-a145-a2bd6d46c37a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3f840cff-cabb-462e-91ad-a17c245fd1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_1d40da55-fea0-489a-a145-a2bd6d46c37a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3f840cff-cabb-462e-91ad-a17c245fd1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c4465ecf-4f01-4c7c-96cc-a0a692e1774f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_1d40da55-fea0-489a-a145-a2bd6d46c37a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c4465ecf-4f01-4c7c-96cc-a0a692e1774f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_45b39749-cd34-4987-af46-f3914689867c" xlink:href="biib-20210630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_1d40da55-fea0-489a-a145-a2bd6d46c37a" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_45b39749-cd34-4987-af46-f3914689867c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4b6e6cf-f886-490c-94cc-ba8b5db95373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3fd023e5-3baa-4e3f-919c-9f2a74d97981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4b6e6cf-f886-490c-94cc-ba8b5db95373" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3fd023e5-3baa-4e3f-919c-9f2a74d97981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5eec7f34-eedc-4d88-b9dd-fb9a78d94124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4b6e6cf-f886-490c-94cc-ba8b5db95373" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5eec7f34-eedc-4d88-b9dd-fb9a78d94124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_c06581ce-18be-4ed6-a9ff-5a656574e583" xlink:href="biib-20210630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a4b6e6cf-f886-490c-94cc-ba8b5db95373" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_c06581ce-18be-4ed6-a9ff-5a656574e583" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_961f9620-db3c-4671-81ab-3e25e85c3b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_87e1bf29-3eda-43c2-b654-113ba9070b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_961f9620-db3c-4671-81ab-3e25e85c3b20" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_87e1bf29-3eda-43c2-b654-113ba9070b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33bc5211-0733-40c1-a891-ba36605bea86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9162b10-4b77-4735-a51e-6d467e789aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33bc5211-0733-40c1-a891-ba36605bea86" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9162b10-4b77-4735-a51e-6d467e789aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fde78301-86ba-4420-b850-9ea891c3fa65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33bc5211-0733-40c1-a891-ba36605bea86" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fde78301-86ba-4420-b850-9ea891c3fa65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1d8b0448-ea96-4baa-bb5a-2c298d475ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_23c6b33f-fe16-43b3-aca4-ed43de0a5efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1d8b0448-ea96-4baa-bb5a-2c298d475ff1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_23c6b33f-fe16-43b3-aca4-ed43de0a5efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1d822623-cbd5-4c24-821c-c51fa8bbba62" xlink:href="biib-20210630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1d8b0448-ea96-4baa-bb5a-2c298d475ff1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1d822623-cbd5-4c24-821c-c51fa8bbba62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_954dd446-2edb-4373-bbbe-b4e71333faa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8c5f6631-9158-4411-ba52-cdbb0011b5cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_954dd446-2edb-4373-bbbe-b4e71333faa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8c5f6631-9158-4411-ba52-cdbb0011b5cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2489d226-ae1d-4ed7-a725-1d45b3832bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_954dd446-2edb-4373-bbbe-b4e71333faa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2489d226-ae1d-4ed7-a725-1d45b3832bb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1112bd7c-88e3-4a0f-9fd7-34f3c08a1e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1112bd7c-88e3-4a0f-9fd7-34f3c08a1e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9bf3dd43-e301-423a-b949-995b32ae8a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9bf3dd43-e301-423a-b949-995b32ae8a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4c604b4d-cd13-486f-815a-26c3bd8d379b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4c604b4d-cd13-486f-815a-26c3bd8d379b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_91e7946e-49a5-4d61-bfb8-2ebe0de0c6b8" xlink:href="biib-20210630.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_91e7946e-49a5-4d61-bfb8-2ebe0de0c6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_12182794-ff88-4682-a38f-35addbf2dc4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_12182794-ff88-4682-a38f-35addbf2dc4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8416150a-1384-4d49-854f-b79f15423894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8416150a-1384-4d49-854f-b79f15423894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_f0de37df-afab-4576-8e27-e4caa1ed79e1" xlink:href="biib-20210630.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_f0de37df-afab-4576-8e27-e4caa1ed79e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a91408d7-59dc-47f1-a337-8a00f59e2738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a91408d7-59dc-47f1-a337-8a00f59e2738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_119540ca-9d81-4510-ae68-b03d834fa07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b0d67a84-f770-4d49-b5bf-a07e7ade1ac5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_119540ca-9d81-4510-ae68-b03d834fa07f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_25823155-8c4b-4872-9969-1c6241fe8282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_42c77917-e1af-49a9-bbb8-ce1df777679c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_25823155-8c4b-4872-9969-1c6241fe8282" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_42c77917-e1af-49a9-bbb8-ce1df777679c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7757c988-ea26-43a8-a527-655c540b9daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_25823155-8c4b-4872-9969-1c6241fe8282" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7757c988-ea26-43a8-a527-655c540b9daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c57332d3-7621-428d-94f0-149443b8a809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a6676e32-9672-49b3-b50f-5833bdc4e16e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c57332d3-7621-428d-94f0-149443b8a809" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a6676e32-9672-49b3-b50f-5833bdc4e16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1edd6cff-f4ed-4c56-a134-e4515eecb238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c57332d3-7621-428d-94f0-149443b8a809" xlink:to="loc_us-gaap_InterestExpense_1edd6cff-f4ed-4c56-a134-e4515eecb238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_c6c84220-3553-4034-b71f-8e25f5cbb3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c57332d3-7621-428d-94f0-149443b8a809" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_c6c84220-3553-4034-b71f-8e25f5cbb3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4e2af136-f634-401a-81ab-31321f308232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c57332d3-7621-428d-94f0-149443b8a809" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4e2af136-f634-401a-81ab-31321f308232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ade392be-4f54-4915-91a2-a38d1d17d3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c57332d3-7621-428d-94f0-149443b8a809" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ade392be-4f54-4915-91a2-a38d1d17d3c3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:00d4ab53-132a-461c-a04e-3900c9e9172a,g:268dc15b-49f4-4ca1-9cf5-eeb8cc02f2b7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="ieb1e50c97e304676ab533a55f5deab67_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_571e5aac-7e55-4412-b127-71c1059556cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_Revenues_571e5aac-7e55-4412-b127-71c1059556cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a185f2b-cc8e-4241-83a9-ba6244003c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a185f2b-cc8e-4241-83a9-ba6244003c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0ea67a9f-a753-48c2-b6f3-c79a0fecdc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0ea67a9f-a753-48c2-b6f3-c79a0fecdc40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0c9213d2-b649-481a-b9a7-4393baee99ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0c9213d2-b649-481a-b9a7-4393baee99ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_87d27cb2-febf-4a86-940c-bb067b10827a" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_87d27cb2-febf-4a86-940c-bb067b10827a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_42026487-8413-4528-b12f-74d85db81fe9" xlink:href="biib-20210630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_biib_Collaborationprofitlosssharing_42026487-8413-4528-b12f-74d85db81fe9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fdf22224-8d8e-4c50-a66d-73a813a93f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fdf22224-8d8e-4c50-a66d-73a813a93f7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f8607c45-4f13-4628-b0ce-1b99c3274727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f8607c45-4f13-4628-b0ce-1b99c3274727" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_34c5aabb-9e02-4276-8933-4bb1937eee01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_CostsAndExpenses_34c5aabb-9e02-4276-8933-4bb1937eee01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e1d8abed-46e4-43b4-a703-1dffe2b75937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_OperatingIncomeLoss_e1d8abed-46e4-43b4-a703-1dffe2b75937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_862b312f-5d66-4295-b753-8bbfe4a400ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_862b312f-5d66-4295-b753-8bbfe4a400ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15e04862-4536-4563-b00f-d3519a2d8088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15e04862-4536-4563-b00f-d3519a2d8088" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84d6c157-0fa9-47fc-ae14-9c0a20243783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84d6c157-0fa9-47fc-ae14-9c0a20243783" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7be3ae25-da56-4e06-9794-eb8505e21a41" xlink:href="biib-20210630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7be3ae25-da56-4e06-9794-eb8505e21a41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_878ac688-9795-441a-a2bf-544c4bef6acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_ProfitLoss_878ac688-9795-441a-a2bf-544c4bef6acf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d593145-e57a-439c-81f4-1b809cd03343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d593145-e57a-439c-81f4-1b809cd03343" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dcdf06c7-1b00-4c39-bc36-c6f939b67702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_NetIncomeLoss_dcdf06c7-1b00-4c39-bc36-c6f939b67702" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bea092df-b114-4c42-9a6c-644fabeef148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:to="loc_us-gaap_EarningsPerShareBasic_bea092df-b114-4c42-9a6c-644fabeef148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_470ef2a2-b9d5-4bbf-a79d-3f37fe7013b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_470ef2a2-b9d5-4bbf-a79d-3f37fe7013b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48b61635-2b10-4235-a9f9-65a6aeeadb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48b61635-2b10-4235-a9f9-65a6aeeadb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93168548-c5c1-455e-8907-093c69ebfd21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93168548-c5c1-455e-8907-093c69ebfd21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:to="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6584e55-7281-4b98-9fbc-24fd29fa62fd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:to="loc_srt_ProductsAndServicesDomain_f6584e55-7281-4b98-9fbc-24fd29fa62fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:to="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_76bb0887-6ecd-4bbc-86aa-48643ce0711a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:to="loc_us-gaap_ProductMember_76bb0887-6ecd-4bbc-86aa-48643ce0711a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_612f5475-a719-4b4a-9491-0398a4a84436" xlink:href="biib-20210630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_612f5475-a719-4b4a-9491-0398a4a84436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b117443d-5604-484d-80d9-fea68c2bb7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b117443d-5604-484d-80d9-fea68c2bb7ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="ibec944ae19a548ca83ab4019d53f2d54_CondensedConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2e029dd8-8551-4eba-bde9-607da5832217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:to="loc_us-gaap_ProfitLoss_2e029dd8-8551-4eba-bde9-607da5832217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_adfba7b1-2f65-4cab-80ca-5be4b2fcab21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_adfba7b1-2f65-4cab-80ca-5be4b2fcab21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0b0ffd49-c80f-4d7e-8524-df5f5c5ac989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0b0ffd49-c80f-4d7e-8524-df5f5c5ac989" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_df269ac8-8e9b-4751-9ed2-bb10fe9487f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_df269ac8-8e9b-4751-9ed2-bb10fe9487f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9d24aebf-cf7e-4984-8dd5-5449e0785c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_ShareBasedCompensation_9d24aebf-cf7e-4984-8dd5-5449e0785c6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_90d11df0-d292-4b16-9583-b78d7e1cad7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_90d11df0-d292-4b16-9583-b78d7e1cad7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d341ad1a-cd5c-49fd-b3bf-8e75a16ae6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d341ad1a-cd5c-49fd-b3bf-8e75a16ae6ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bb5f93f-5c85-4c6c-9984-0dca76e096c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bb5f93f-5c85-4c6c-9984-0dca76e096c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_b3b71140-9264-46c9-9221-8a1b6469ced7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_b3b71140-9264-46c9-9221-8a1b6469ced7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5ebec6-95c1-457e-9963-3f5135d73945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5ebec6-95c1-457e-9963-3f5135d73945" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_961b2ddf-5369-4299-9b8a-d52a97dfed8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_961b2ddf-5369-4299-9b8a-d52a97dfed8e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9baee435-586e-436a-9bb5-9faeee43c5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9baee435-586e-436a-9bb5-9faeee43c5bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_87955547-36c1-4e59-bec4-78c2b20ee681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_87955547-36c1-4e59-bec4-78c2b20ee681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_479cf418-2772-4b85-8c3b-c7b868c6db66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_479cf418-2772-4b85-8c3b-c7b868c6db66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ca5347e-b1eb-446c-9bea-55129204472c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ca5347e-b1eb-446c-9bea-55129204472c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46afb6eb-ad94-4a46-9818-aeb70c583337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46afb6eb-ad94-4a46-9818-aeb70c583337" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b750c2e5-31f7-4157-be0b-6ea20ed5a100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b750c2e5-31f7-4157-be0b-6ea20ed5a100" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_830cee84-ad38-4f3a-8a16-b250eaca706c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_830cee84-ad38-4f3a-8a16-b250eaca706c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cca67557-42be-4c82-8f2b-d1ba5dcac03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cca67557-42be-4c82-8f2b-d1ba5dcac03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13ff1274-7cc8-4148-9305-c9a2779f8e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13ff1274-7cc8-4148-9305-c9a2779f8e39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c74df109-bd55-4d12-a6f5-63ec4b5b3af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c74df109-bd55-4d12-a6f5-63ec4b5b3af5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cce0a04c-995c-401f-b656-147831e709c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cce0a04c-995c-401f-b656-147831e709c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b379398-e6c8-4892-b780-69a6a21c8365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b379398-e6c8-4892-b780-69a6a21c8365" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3ed6ce04-b480-4f95-933c-5555f6b6a0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3ed6ce04-b480-4f95-933c-5555f6b6a0f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3044c07c-ac74-4185-9ef3-cb509576bd10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3044c07c-ac74-4185-9ef3-cb509576bd10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_689ce837-1ecb-46b0-954d-a8143399142a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_689ce837-1ecb-46b0-954d-a8143399142a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_27830a58-0baa-4c88-a53d-a26e44ec0406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_27830a58-0baa-4c88-a53d-a26e44ec0406" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_111ba34e-fac6-497f-81bc-9a963ea4922c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_111ba34e-fac6-497f-81bc-9a963ea4922c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_65dc29c2-def7-4caa-93bb-878f22aebb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_65dc29c2-def7-4caa-93bb-878f22aebb55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_83952ef5-c3a2-426b-8fa0-cdbc8ad5849f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_83952ef5-c3a2-426b-8fa0-cdbc8ad5849f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_c487b26f-3c31-4d09-8f2c-cb05049f1961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_RepaymentsOfDebt_c487b26f-3c31-4d09-8f2c-cb05049f1961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ddd88f44-ca9b-4eb1-b902-c5b873ba3843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ddd88f44-ca9b-4eb1-b902-c5b873ba3843" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0b32ef3c-f547-445e-a63b-33e4a7821daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0b32ef3c-f547-445e-a63b-33e4a7821daf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a55ea023-2001-4bd8-b7b8-b0a1b86fe7e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a55ea023-2001-4bd8-b7b8-b0a1b86fe7e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_1d970afb-4c8c-4939-bfcb-e385df5c7527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_1d970afb-4c8c-4939-bfcb-e385df5c7527" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_10ec0a5a-c11f-4570-979e-8a90a4332d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_10ec0a5a-c11f-4570-979e-8a90a4332d88" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16acdd62-5c28-4849-a51f-5f2f76566454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16acdd62-5c28-4849-a51f-5f2f76566454" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_26ccb66c-28a7-41c6-abf0-05c30929d4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_26ccb66c-28a7-41c6-abf0-05c30929d4f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_33e2ce10-b58d-4a61-82ce-b03e955c7d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_33e2ce10-b58d-4a61-82ce-b03e955c7d8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acf38364-da27-416a-8343-5c46eda5d29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acf38364-da27-416a-8343-5c46eda5d29b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ec4679a-40f3-460f-8b96-e2643aea30b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c56c3b6-b1a0-404d-bee0-b41c927936de_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c56c3b6-b1a0-404d-bee0-b41c927936de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_e8a59f50-fb33-41e0-9005-59d586f99d47" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:to="loc_biib_SangamoCommonStockMember_e8a59f50-fb33-41e0-9005-59d586f99d47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_a78a2b5e-7ff9-45ea-9b08-70e7e6f423e8" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:to="loc_biib_DenaliTherapeuticsIncMember_a78a2b5e-7ff9-45ea-9b08-70e7e6f423e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="i3ae9b06f0d5d4b77857ced578f943055_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6e563f01-fb75-4e34-b7fc-682d45d56d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6e563f01-fb75-4e34-b7fc-682d45d56d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569fdf55-c27b-4a30-9976-c316e8bf3ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569fdf55-c27b-4a30-9976-c316e8bf3ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9b6facc-8cec-4810-b78c-dba2c54c7b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_ProfitLoss_e9b6facc-8cec-4810-b78c-dba2c54c7b08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_468dfc68-d103-4993-b142-7583fe0a2988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_468dfc68-d103-4993-b142-7583fe0a2988" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_95f8f66a-8c6c-4cd2-b6dc-c8e37f641e35" xlink:href="biib-20210630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_95f8f66a-8c6c-4cd2-b6dc-c8e37f641e35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_eadbc6fc-5e36-4f27-879a-123ac6bf2b65" xlink:href="biib-20210630.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_eadbc6fc-5e36-4f27-879a-123ac6bf2b65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9b95cce3-79b4-4045-8744-808c4b764873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9b95cce3-79b4-4045-8744-808c4b764873" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c34bbf07-847d-4c12-9df1-bd7d5cca8faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c34bbf07-847d-4c12-9df1-bd7d5cca8faf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8d5dbc2d-70d0-41d0-84bd-20f782a4a8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8d5dbc2d-70d0-41d0-84bd-20f782a4a8b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2290956d-694e-4375-99a4-1e47f0f1166c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2290956d-694e-4375-99a4-1e47f0f1166c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_82f820c7-f01f-4e15-a2c6-2c3a46e53ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_82f820c7-f01f-4e15-a2c6-2c3a46e53ea1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_c325df9e-b8fd-4969-978a-870d17244278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_c325df9e-b8fd-4969-978a-870d17244278" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4f87d52-103c-4940-abcd-ea5c467b3070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4f87d52-103c-4940-abcd-ea5c467b3070" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_38b769d7-71bf-4426-b003-0254fcafb61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_38b769d7-71bf-4426-b003-0254fcafb61a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c9d7b5e0-ac1e-4e4d-845a-27157b0238ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c9d7b5e0-ac1e-4e4d-845a-27157b0238ab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_a4119712-bea8-4e86-a4b0-eb0949d4fa70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockholdersEquityOther_a4119712-bea8-4e86-a4b0-eb0949d4fa70" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b390ef0-9f55-4df3-a9f4-0ddd5923e02e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_34d53ffb-a8e5-4f20-8938-2ffede95c5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_964721f2-0985-4ba7-8d23-5674de96a12b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_964721f2-0985-4ba7-8d23-5674de96a12b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ff82105a-190a-42ca-b69d-4c4cb47b80e0" xlink:href="biib-20210630.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_ff82105a-190a-42ca-b69d-4c4cb47b80e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_2eec3d89-8eec-4479-a103-b7b448c18525" xlink:href="biib-20210630.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_2eec3d89-8eec-4479-a103-b7b448c18525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_65160930-5ba6-4af9-bf96-0c623f4609b0" xlink:href="biib-20210630.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_65160930-5ba6-4af9-bf96-0c623f4609b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e13f6f7f-145b-43c5-896b-4e2a89353665_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:to="loc_us-gaap_EquityComponentDomain_e13f6f7f-145b-43c5-896b-4e2a89353665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:to="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4b080274-c836-446f-9e6d-8472babca9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_PreferredStockMember_4b080274-c836-446f-9e6d-8472babca9dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00ff0fba-c355-457e-9ed1-ad5dfe62837c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_CommonStockMember_00ff0fba-c355-457e-9ed1-ad5dfe62837c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c4241d04-63a2-4140-957d-9f98f17ac767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c4241d04-63a2-4140-957d-9f98f17ac767" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30f8a2a4-e2ef-47b5-81d3-b412c5ecf031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30f8a2a4-e2ef-47b5-81d3-b412c5ecf031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac901487-9d17-4e6f-975c-f1f7fd1bdd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_RetainedEarningsMember_ac901487-9d17-4e6f-975c-f1f7fd1bdd78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ada5866e-712c-4601-ab1e-6e12774ca8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_TreasuryStockMember_ada5866e-712c-4601-ab1e-6e12774ca8e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_4579cafa-f825-41ab-b554-75e6160246f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_ParentMember_4579cafa-f825-41ab-b554-75e6160246f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9e031c63-bd3b-4228-8860-b49a3a38a9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9e031c63-bd3b-4228-8860-b49a3a38a9e5" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" id="i276ef5a6986d40a292780f770de61628_BusinessAcquisitionDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9ab9f292-a082-4d33-89f4-acc733fda524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9ab9f292-a082-4d33-89f4-acc733fda524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_9ed114e2-3cd9-4faa-adce-5c906a037cf0" xlink:href="biib-20210630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_9ed114e2-3cd9-4faa-adce-5c906a037cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a3f56db-636a-41f1-92d9-f1df2b410c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a3f56db-636a-41f1-92d9-f1df2b410c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_43b7c5dc-4656-45a5-92e6-76ae51705acd" xlink:href="biib-20210630.xsd#biib_BIIB118Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a3f56db-636a-41f1-92d9-f1df2b410c20" xlink:to="loc_biib_BIIB118Member_43b7c5dc-4656-45a5-92e6-76ae51705acd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended" id="i2e45a5db161f4aad8f1fbc2e0c6f95f7_RevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_268a392a-8161-4d94-8925-90a50be568e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1dc36ee2-acd2-460c-a055-6b69f58eb25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_268a392a-8161-4d94-8925-90a50be568e1" xlink:to="loc_us-gaap_Revenues_1dc36ee2-acd2-460c-a055-6b69f58eb25b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_268a392a-8161-4d94-8925-90a50be568e1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:to="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d815e46-ee9a-427e-9614-6aedf7195590_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:to="loc_srt_ProductsAndServicesDomain_6d815e46-ee9a-427e-9614-6aedf7195590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:to="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_82e88bff-9cef-41dd-9c1a-8a00a8a12636" xlink:href="biib-20210630.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FumarateMember_82e88bff-9cef-41dd-9c1a-8a00a8a12636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_0a9b76a5-89e3-4982-8334-e8d3753a13e0" xlink:href="biib-20210630.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_InterferonMember_0a9b76a5-89e3-4982-8334-e8d3753a13e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_189c9992-83ea-4b38-8611-2a576ba5eccf" xlink:href="biib-20210630.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_TysabriProductMember_189c9992-83ea-4b38-8611-2a576ba5eccf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_51213d24-39cf-4765-ae98-37724596e5ac" xlink:href="biib-20210630.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FAMPYRAMember_51213d24-39cf-4765-ae98-37724596e5ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_26ac9d05-7df6-4d50-aba0-39c21b8e371c" xlink:href="biib-20210630.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_ZINBRYTAMember_26ac9d05-7df6-4d50-aba0-39c21b8e371c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_08259fff-fbc7-4a55-9c4e-66bb98b37c27" xlink:href="biib-20210630.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_MSProductRevenuesMember_08259fff-fbc7-4a55-9c4e-66bb98b37c27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_58260de6-8ac6-4f71-9a15-4937543961f7" xlink:href="biib-20210630.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_SPINRAZAMember_58260de6-8ac6-4f71-9a15-4937543961f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_98cb4db1-5127-4741-962a-3df360aab07c" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_ADUHELMMember_98cb4db1-5127-4741-962a-3df360aab07c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_6f94b66c-7f6d-4153-bbae-259f45c5727c" xlink:href="biib-20210630.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_BENEPALIMember_6f94b66c-7f6d-4153-bbae-259f45c5727c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_46e66148-20bf-4fc0-b715-9243372c9bd6" xlink:href="biib-20210630.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_IMRALDIMember_46e66148-20bf-4fc0-b715-9243372c9bd6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_56fdae4c-f6d7-4407-825d-dffd65ca14fc" xlink:href="biib-20210630.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FLIXABIMember_56fdae4c-f6d7-4407-825d-dffd65ca14fc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_218a4f32-5f21-4846-a9c0-54aa6f6f0716" xlink:href="biib-20210630.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_BiosimilarsMember_218a4f32-5f21-4846-a9c0-54aa6f6f0716" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_1b7ed7d5-baab-4857-9543-32b1bee36e35" xlink:href="biib-20210630.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FUMADERMMember_1b7ed7d5-baab-4857-9543-32b1bee36e35" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_149f97df-5192-441d-a668-049ffcb24b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_us-gaap_ProductMember_149f97df-5192-441d-a668-049ffcb24b3b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:to="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6834615e-68fd-4062-baeb-cbdfb80adba2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:to="loc_srt_SegmentGeographicalDomain_6834615e-68fd-4062-baeb-cbdfb80adba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:to="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_42d5466c-1150-4a17-9a8a-6eae895a7451" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:to="loc_country_US_42d5466c-1150-4a17-9a8a-6eae895a7451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_25c401c5-6ca6-44f4-b608-3b1de55a02ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:to="loc_us-gaap_NonUsMember_25c401c5-6ca6-44f4-b608-3b1de55a02ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="ic0b3c2bd56164bc689c1779d12d6f14c_ReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2f27317b-216e-454c-b032-31a20587c65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2f27317b-216e-454c-b032-31a20587c65f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2c0f7b8c-ec2d-4a4a-8eed-0d2a499d3f6b" xlink:href="biib-20210630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2c0f7b8c-ec2d-4a4a-8eed-0d2a499d3f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_ef67f58a-41bc-486f-b938-41ce4afecba9" xlink:href="biib-20210630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_ef67f58a-41bc-486f-b938-41ce4afecba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_20cd74e3-3b85-4312-9999-bc5c543197df" xlink:href="biib-20210630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_20cd74e3-3b85-4312-9999-bc5c543197df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_89b05b49-f29e-4fc9-a3a2-c1a2905ace51" xlink:href="biib-20210630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_89b05b49-f29e-4fc9-a3a2-c1a2905ace51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3c6b6527-77ff-429f-8e2b-9cab54a2597f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3d0bbbf9-45cc-41db-bd31-1a620305ce61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3d0bbbf9-45cc-41db-bd31-1a620305ce61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_b58b0dc3-86fb-4b63-9678-a61a9262d92b" xlink:href="biib-20210630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:to="loc_biib_ReserveforCashDiscountsMember_b58b0dc3-86fb-4b63-9678-a61a9262d92b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_a863602f-6489-4d12-8d7b-e63d32c63a73" xlink:href="biib-20210630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:to="loc_biib_ContractualAdjustmentsMember_a863602f-6489-4d12-8d7b-e63d32c63a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_afa2a8ff-11e0-43d4-b0c0-08274ccb1230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_afa2a8ff-11e0-43d4-b0c0-08274ccb1230" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210630.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="ic05e85b4c420428fb029dc1ccb794de7_ReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7a70de48-77c4-43b5-89cb-8ad73c381d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_411202ee-e2d0-4019-b4f9-1b0e83af285b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7a70de48-77c4-43b5-89cb-8ad73c381d1b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_411202ee-e2d0-4019-b4f9-1b0e83af285b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7a70de48-77c4-43b5-89cb-8ad73c381d1b" xlink:to="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_58310d11-fbee-4cdb-aef1-3faacd4cd73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:to="loc_us-gaap_AccountsReceivableMember_58310d11-fbee-4cdb-aef1-3faacd4cd73a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_caada933-fb9b-4a89-ae49-5328af68bf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_caada933-fb9b-4a89-ae49-5328af68bf9d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="i15ecdb4bbd0f464d906b30281ff1a53d_RevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_e135d7fb-7565-47ac-90e2-bab21fc6fff0" xlink:href="biib-20210630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_biib_ShareOfCoPromotionProfits_e135d7fb-7565-47ac-90e2-bab21fc6fff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_e56545a4-dbfa-480d-90f6-17c3aaa960c3" xlink:href="biib-20210630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_e56545a4-dbfa-480d-90f6-17c3aaa960c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f1b344f8-24f4-4e59-9883-20c393e8b843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_us-gaap_Revenues_f1b344f8-24f4-4e59-9883-20c393e8b843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:to="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf8860bd-b114-47a8-a022-92ac9adb4b05_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:to="loc_srt_ProductsAndServicesDomain_cf8860bd-b114-47a8-a022-92ac9adb4b05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ce635a8-fd61-4e8a-904f-72afb81968f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:to="loc_srt_ProductsAndServicesDomain_6ce635a8-fd61-4e8a-904f-72afb81968f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba7f63c7-f150-41de-a763-138ca67eec01" xlink:href="biib-20210630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ce635a8-fd61-4e8a-904f-72afb81968f7" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba7f63c7-f150-41de-a763-138ca67eec01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:to="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ef8dc235-6ac6-416c-9064-bf47f5328113_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:to="loc_srt_NameOfMajorCustomerDomain_ef8dc235-6ac6-416c-9064-bf47f5328113_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_32ae54eb-9a72-4544-8103-8b164d629bab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:to="loc_srt_NameOfMajorCustomerDomain_32ae54eb-9a72-4544-8103-8b164d629bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_30f2b1b0-f9c7-452a-a17c-d556396826e0" xlink:href="biib-20210630.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_32ae54eb-9a72-4544-8103-8b164d629bab" xlink:to="loc_biib_RocheGroupGenentechMember_30f2b1b0-f9c7-452a-a17c-d556396826e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" id="i78682ac7424943af9c0d02d699fc8e3f_OtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_83b1535c-20b9-4e2d-8cee-0245f3f78ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aeef6ad1-0042-4632-a384-596e16c58740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_83b1535c-20b9-4e2d-8cee-0245f3f78ad8" xlink:to="loc_us-gaap_Revenues_aeef6ad1-0042-4632-a384-596e16c58740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_83b1535c-20b9-4e2d-8cee-0245f3f78ad8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73a2b698-b87f-40af-b8fa-72aad5499d8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73a2b698-b87f-40af-b8fa-72aad5499d8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953285f9-941f-4487-be45-4beab52cea20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953285f9-941f-4487-be45-4beab52cea20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5fdf67a3-f4ad-4cb9-a54d-c9de64d3a690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953285f9-941f-4487-be45-4beab52cea20" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5fdf67a3-f4ad-4cb9-a54d-c9de64d3a690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a643595a-60c5-40f3-9d22-06a316e4817c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:to="loc_srt_ProductsAndServicesDomain_a643595a-60c5-40f3-9d22-06a316e4817c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:to="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_647f2b5e-44e5-4bf9-9070-a93ffaf0a7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:to="loc_us-gaap_RoyaltyMember_647f2b5e-44e5-4bf9-9070-a93ffaf0a7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_cf03bc8a-0fc5-4653-a8c7-d7e51395c854" xlink:href="biib-20210630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:to="loc_biib_OthercorporaterevenuesMember_cf03bc8a-0fc5-4653-a8c7-d7e51395c854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9335d478-88a2-4fc7-9f50-2de9c90f8431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9335d478-88a2-4fc7-9f50-2de9c90f8431" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_009388c4-0638-498c-ab63-18f0246185bb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:to="loc_srt_NameOfMajorCustomerDomain_009388c4-0638-498c-ab63-18f0246185bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:to="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a9e186de-f44a-42a4-b110-92c31bea6798" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a9e186de-f44a-42a4-b110-92c31bea6798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_e7066036-9f8c-42c7-97f2-fb0df60641e6" xlink:href="biib-20210630.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:to="loc_biib_ZINBRYTAMember_e7066036-9f8c-42c7-97f2-fb0df60641e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" id="i8d5416da38564b1e8bec127a13b9f7d2_RevenuesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e3f042b6-b371-43fa-8f5f-6f93154efc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_us-gaap_Revenues_e3f042b6-b371-43fa-8f5f-6f93154efc57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_1df73b3e-0943-4e0e-82b5-cbf3f54d8a4d" xlink:href="biib-20210630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_1df73b3e-0943-4e0e-82b5-cbf3f54d8a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_4d33f6ec-a392-41a3-a0c2-54f3d0035918" xlink:href="biib-20210630.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_biib_NumberOfWholesalers_4d33f6ec-a392-41a3-a0c2-54f3d0035918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:to="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:to="loc_srt_ProductsAndServicesDomain_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:to="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_037106b2-7191-45a7-a0e6-2df43311561c" xlink:href="biib-20210630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:to="loc_biib_OthercorporaterevenuesMember_037106b2-7191-45a7-a0e6-2df43311561c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b85c0d65-2523-425b-9a32-a84145530427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b85c0d65-2523-425b-9a32-a84145530427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:to="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_08f2b50d-6161-44b8-b253-c05510be1278_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:to="loc_srt_NameOfMajorCustomerDomain_08f2b50d-6161-44b8-b253-c05510be1278_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:to="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_6449cb31-da85-480b-80a3-e083acd71914" xlink:href="biib-20210630.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:to="loc_biib_DistributorOneMember_6449cb31-da85-480b-80a3-e083acd71914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_11735179-7465-4c68-bb01-338b0a0abda7" xlink:href="biib-20210630.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:to="loc_biib_DistributorTwoMember_11735179-7465-4c68-bb01-338b0a0abda7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="ia37b86b8b9a640579e9a0634fbf704e0_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5923bb86-fc7b-4227-875a-1422abba90bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5923bb86-fc7b-4227-875a-1422abba90bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_4cfa6340-6a59-41a1-920c-f3cfe482574a" xlink:href="biib-20210630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_4cfa6340-6a59-41a1-920c-f3cfe482574a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79c99e64-ea4a-4eef-8577-86b01bc04b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79c99e64-ea4a-4eef-8577-86b01bc04b50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_034a8656-0c85-42dd-9cc8-7afef9c8b9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_034a8656-0c85-42dd-9cc8-7afef9c8b9e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8504fcc5-8811-4ac6-9b63-7a467b0ef639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8504fcc5-8811-4ac6-9b63-7a467b0ef639" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f189039d-f95b-45f2-a32a-f59d8d889796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f189039d-f95b-45f2-a32a-f59d8d889796" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_015a11da-6cdf-444b-af83-79f38cf1860d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_015a11da-6cdf-444b-af83-79f38cf1860d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2d80c0cf-15bc-4da5-b2d9-7ec43d21936b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2d80c0cf-15bc-4da5-b2d9-7ec43d21936b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05f15844-963c-4942-b2b2-8fb867e6b88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05f15844-963c-4942-b2b2-8fb867e6b88d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_3205d24d-8124-496c-a4f0-b706d2b40648" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_3205d24d-8124-496c-a4f0-b706d2b40648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_686806b4-d32b-450b-bc4e-54481837c25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_686806b4-d32b-450b-bc4e-54481837c25a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc7486f4-2258-4a96-8499-36380fdee9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc7486f4-2258-4a96-8499-36380fdee9a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0198436a-f4a0-40b3-93a7-4f88560322e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0198436a-f4a0-40b3-93a7-4f88560322e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2a0bb562-413c-41c6-99cd-bcc0b1fed184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2a0bb562-413c-41c6-99cd-bcc0b1fed184" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_859dd882-8cc0-41c1-97fa-568391c9d491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_859dd882-8cc0-41c1-97fa-568391c9d491" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fd831dac-706b-4f27-aa3d-427935d7869a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fd831dac-706b-4f27-aa3d-427935d7869a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7c8ddae0-b403-44e0-9753-8e17031da5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7c8ddae0-b403-44e0-9753-8e17031da5dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_07e4c669-c0a6-4544-a70d-f3c6a458cd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_07e4c669-c0a6-4544-a70d-f3c6a458cd39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_be8b7424-944f-4a1c-856b-a9f4449ac345_default" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_be8b7424-944f-4a1c-856b-a9f4449ac345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_e3b08fc2-7409-4d3e-a53e-4a11da9bdc47" xlink:href="biib-20210630.xsd#biib_VixotrigineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_VixotrigineMember_e3b08fc2-7409-4d3e-a53e-4a11da9bdc47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_469d4f2a-d73e-4f4b-bca7-adc45376d676" xlink:href="biib-20210630.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_TGNMember_469d4f2a-d73e-4f4b-bca7-adc45376d676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_b362f7c9-4046-4c31-a657-75f189ff35c0" xlink:href="biib-20210630.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_BIIB111Member_b362f7c9-4046-4c31-a657-75f189ff35c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_ba0f2b31-0737-475c-a78a-61c7d9205edb" xlink:href="biib-20210630.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_BIIB112Member_ba0f2b31-0737-475c-a78a-61c7d9205edb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_5885e59e-efae-4f6c-bd6b-9877d90db84a" xlink:href="biib-20210630.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_BIIB111AndBIIB112Member_5885e59e-efae-4f6c-bd6b-9877d90db84a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe36e80d-df25-4fd1-a684-25d9f72ee87a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe36e80d-df25-4fd1-a684-25d9f72ee87a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_853bf947-ca75-45df-b898-8d47d9d0e038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_853bf947-ca75-45df-b898-8d47d9d0e038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_5feeeb2e-576b-4132-b6dd-66ef10218161" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_853bf947-ca75-45df-b898-8d47d9d0e038" xlink:to="loc_biib_NightstarMember_5feeeb2e-576b-4132-b6dd-66ef10218161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfe376dd-c5be-4722-9a9d-8ecd65f73c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfe376dd-c5be-4722-9a9d-8ecd65f73c4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_d959d5c4-129d-48a0-8457-ef413db6b7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_d959d5c4-129d-48a0-8457-ef413db6b7c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c6cbd02-4698-4c73-9ba3-2e7cbf750055_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c6cbd02-4698-4c73-9ba3-2e7cbf750055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb810875-1da1-41fa-ad6e-d485ed368a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb810875-1da1-41fa-ad6e-d485ed368a8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_b7920fe8-ac32-4142-8733-e93a36b7e944" xlink:href="biib-20210630.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_biib_OutLicensedPatentsMember_b7920fe8-ac32-4142-8733-e93a36b7e944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a21f077d-e8b3-4aae-9da0-2d4189c046b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a21f077d-e8b3-4aae-9da0-2d4189c046b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember_486b582a-30da-40e9-a862-886245ea29b8" xlink:href="biib-20210630.xsd#biib_InLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_biib_InLicensedPatentsMember_486b582a-30da-40e9-a862-886245ea29b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:to="loc_srt_ProductsAndServicesDomain_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:to="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_3f79adc9-12c5-4657-9cdf-90b7a09f64cd" xlink:href="biib-20210630.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:to="loc_biib_TysabriProductMember_3f79adc9-12c5-4657-9cdf-90b7a09f64cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_baa1e59d-f1e0-4b36-91f7-ccc3a7528b86" xlink:href="biib-20210630.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:to="loc_biib_FumarateMember_baa1e59d-f1e0-4b36-91f7-ccc3a7528b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:to="loc_srt_RangeMember_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:to="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c8137fa-d54a-4d4e-83d9-c30372f8f121" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:to="loc_srt_MinimumMember_2c8137fa-d54a-4d4e-83d9-c30372f8f121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cf3aad8c-fbde-44c3-baff-95c52327f668" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:to="loc_srt_MaximumMember_cf3aad8c-fbde-44c3-baff-95c52327f668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7f430ec6-9dfe-4e02-9ea0-59430c61b639_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7f430ec6-9dfe-4e02-9ea0-59430c61b639_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_39124a80-2f7e-4278-9f44-7a47f3d6b744" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:to="loc_srt_ScenarioUnspecifiedDomain_39124a80-2f7e-4278-9f44-7a47f3d6b744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bf8c6a5a-8bf9-4fcc-89d6-abfb3882e69a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_39124a80-2f7e-4278-9f44-7a47f3d6b744" xlink:to="loc_srt_ScenarioForecastMember_bf8c6a5a-8bf9-4fcc-89d6-abfb3882e69a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ib41e6dfd8fdd4f94ba53a829f91cf6ae_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccf62f99-3616-4534-8c9a-fc896a5483de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccf62f99-3616-4534-8c9a-fc896a5483de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25a52918-5b6b-4fe5-be7e-6ed881a3af09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25a52918-5b6b-4fe5-be7e-6ed881a3af09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bee09b0-0e6d-462d-8bce-709e3ada8c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bee09b0-0e6d-462d-8bce-709e3ada8c88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b01f425f-ad64-40bb-89f8-6ef5fd00981a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b01f425f-ad64-40bb-89f8-6ef5fd00981a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_547ab827-c2b8-4b27-86e8-30d1d6ea1ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_547ab827-c2b8-4b27-86e8-30d1d6ea1ab9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_3c880244-ff8d-4caa-b13d-e76e52f4e861" xlink:href="biib-20210630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_3c880244-ff8d-4caa-b13d-e76e52f4e861" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4d0c3a68-648a-4fcd-a437-bec0208ed7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4d0c3a68-648a-4fcd-a437-bec0208ed7bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_fc14f618-1f3a-401d-965d-7a94b1e76b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_fc14f618-1f3a-401d-965d-7a94b1e76b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9fff5a-ee41-4115-b0ef-5602abc091f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9fff5a-ee41-4115-b0ef-5602abc091f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4a3f07e0-108a-4a78-a608-aa4762de1b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4a3f07e0-108a-4a78-a608-aa4762de1b84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccf62f99-3616-4534-8c9a-fc896a5483de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c99d3e18-b040-43a6-9701-90f31c242fb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c99d3e18-b040-43a6-9701-90f31c242fb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ca53b5d8-7956-4f59-bda4-0df811474963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ca53b5d8-7956-4f59-bda4-0df811474963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7d0b53db-e774-4e3b-bde9-1f0b0947cb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7d0b53db-e774-4e3b-bde9-1f0b0947cb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aacf174b-7251-4fac-a268-553256ba267a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aacf174b-7251-4fac-a268-553256ba267a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98948ac2-e95b-4188-88a9-674837717585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98948ac2-e95b-4188-88a9-674837717585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d9abf20d-bc2c-436f-b0bd-274b10e6680e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98948ac2-e95b-4188-88a9-674837717585" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d9abf20d-bc2c-436f-b0bd-274b10e6680e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8c4c8c0c-9053-410c-afdb-6fd0acc55efe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8c4c8c0c-9053-410c-afdb-6fd0acc55efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_754ec2ac-e671-4fef-aa4b-ee86a1b54109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_754ec2ac-e671-4fef-aa4b-ee86a1b54109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_ffaef9b6-af0a-4b7e-bb67-287c2203f20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_ffaef9b6-af0a-4b7e-bb67-287c2203f20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5bd0d53d-18b5-48b0-a88a-6edccd6d10df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5bd0d53d-18b5-48b0-a88a-6edccd6d10df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" id="ie769d405484e4dddad01dd16c48f58be_FairValueMeasurementsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f97b19bd-37c1-4157-a279-75bcf6d857dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_AssetImpairmentCharges_f97b19bd-37c1-4157-a279-75bcf6d857dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e6ee0241-10c5-42c6-af38-3d75c0516f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e6ee0241-10c5-42c6-af38-3d75c0516f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dbef2d86-410b-47a4-9b9f-a0709fc22db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dbef2d86-410b-47a4-9b9f-a0709fc22db4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_aca798d9-b4e3-4627-a272-643853b39cee" xlink:href="biib-20210630.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_aca798d9-b4e3-4627-a272-643853b39cee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:to="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21486ed2-3cbe-4406-bb55-3b74b8daea5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21486ed2-3cbe-4406-bb55-3b74b8daea5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_61d9526f-ca0c-4e67-b7c9-502f1d7adf40" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_61d9526f-ca0c-4e67-b7c9-502f1d7adf40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c850f542-7878-4f97-ad28-0a43c67861e0" xlink:href="biib-20210630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c850f542-7878-4f97-ad28-0a43c67861e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d88860ce-ccb2-4ee1-a1a0-79ac7ae2d2b3" xlink:href="biib-20210630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d88860ce-ccb2-4ee1-a1a0-79ac7ae2d2b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9e06cc6c-0af6-4603-9ee5-baa8aa7803b3" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9e06cc6c-0af6-4603-9ee5-baa8aa7803b3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="ice973c264ee34e8a9d3c7e4f707f86e6_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f114e2c1-ea41-494e-a000-43965db0a619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f114e2c1-ea41-494e-a000-43965db0a619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b72deaff-3d6c-4477-9499-3d55dad5167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b72deaff-3d6c-4477-9499-3d55dad5167f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:to="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bded6cd6-b2c1-4f3c-b6cd-afa210b98237_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:to="loc_srt_RangeMember_bded6cd6-b2c1-4f3c-b6cd-afa210b98237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:to="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6d136d8-5b1a-4b5d-bf41-02019da9417e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:to="loc_srt_MinimumMember_b6d136d8-5b1a-4b5d-bf41-02019da9417e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19a163b2-5a63-4853-8565-aa63835d80cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:to="loc_srt_MaximumMember_19a163b2-5a63-4853-8565-aa63835d80cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_f585b193-b1cf-4f5a-8576-3d5b74097c18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:to="loc_srt_WeightedAverageMember_f585b193-b1cf-4f5a-8576-3d5b74097c18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37a3a723-0623-4d7a-afc9-3394617e1258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37a3a723-0623-4d7a-afc9-3394617e1258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b4f07e6d-2e83-4829-99ce-06a0fefe3cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37a3a723-0623-4d7a-afc9-3394617e1258" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b4f07e6d-2e83-4829-99ce-06a0fefe3cbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsNonrecurringAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="extended" id="ief47f4bab56b4736a238568ca8f13c9c_FairValueMeasurementsNonrecurringAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12acd9db-549c-4d43-9bdb-3f4107f0741f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:href="biib-20210630.xsd#biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12acd9db-549c-4d43-9bdb-3f4107f0741f" xlink:to="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_654f6650-5dca-4d66-8309-8f22b9496946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_654f6650-5dca-4d66-8309-8f22b9496946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9cbe9b43-7ee4-42e1-93b9-d7e4ac02ce21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9cbe9b43-7ee4-42e1-93b9-d7e4ac02ce21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_8e883ea0-b0bd-4c89-9ec2-ed7682fad3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12acd9db-549c-4d43-9bdb-3f4107f0741f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_7d1d6e70-ba09-4837-a16f-7dd211d3a64f_default" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_7d1d6e70-ba09-4837-a16f-7dd211d3a64f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_7f40c6f1-57bb-4fb4-b481-dd6f65b848dc" xlink:href="biib-20210630.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:to="loc_biib_BIIB111Member_7f40c6f1-57bb-4fb4-b481-dd6f65b848dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_70df34ed-fb5e-4d3c-a61e-94ac333b7038" xlink:href="biib-20210630.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:to="loc_biib_BIIB112Member_70df34ed-fb5e-4d3c-a61e-94ac333b7038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_888fb76f-0bac-4923-9518-ae59855fd718_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_888fb76f-0bac-4923-9518-ae59855fd718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bf76d27-6c02-4d67-8870-e098e36e6fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bf76d27-6c02-4d67-8870-e098e36e6fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_9aa1e100-8c9c-4a63-96e1-ea9fe799c3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bf76d27-6c02-4d67-8870-e098e36e6fe8" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_9aa1e100-8c9c-4a63-96e1-ea9fe799c3c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2de03915-80b9-42c6-aa08-c4378b2d1dfa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2de03915-80b9-42c6-aa08-c4378b2d1dfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_640aecce-9cc6-4b71-93c7-cef72b277671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_640aecce-9cc6-4b71-93c7-cef72b277671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_b929aad4-f8fd-4a7a-8239-b2c4b90a042e" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_640aecce-9cc6-4b71-93c7-cef72b277671" xlink:to="loc_biib_NightstarMember_b929aad4-f8fd-4a7a-8239-b2c4b90a042e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="ie739a57a777e480a93abf8b0f3559afe_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_a8e7d2b5-298f-48c2-8f46-549bd53bd9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_a8e7d2b5-298f-48c2-8f46-549bd53bd9a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_6fa5346c-e606-4a38-98c1-9cddb3eca893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_NotesPayable_6fa5346c-e606-4a38-98c1-9cddb3eca893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4816cc21-8012-410a-9533-6acce322f3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4816cc21-8012-410a-9533-6acce322f3b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80e46b8c-ed7e-4110-99ec-cc45ece335fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80e46b8c-ed7e-4110-99ec-cc45ece335fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_34cc734f-6891-422f-bc1e-721c801b39d6" xlink:href="biib-20210630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_biib_LongTermDebtExchangedAmount_34cc734f-6891-422f-bc1e-721c801b39d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74919f71-c944-413e-82d7-2b091c08f082_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74919f71-c944-413e-82d7-2b091c08f082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43a2aa00-ee3a-49b8-a389-c8d21ea30a72" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43a2aa00-ee3a-49b8-a389-c8d21ea30a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_756119aa-ad46-4e96-86bb-c988fa60a1f4" xlink:href="biib-20210630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_756119aa-ad46-4e96-86bb-c988fa60a1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_06114570-e35c-40ed-9b86-b39ca6ed7c4b" xlink:href="biib-20210630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_06114570-e35c-40ed-9b86-b39ca6ed7c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_7c9dbd40-d933-4ea3-9fbe-539c5b5e04ff" xlink:href="biib-20210630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_7c9dbd40-d933-4ea3-9fbe-539c5b5e04ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5a4a7edf-6ede-4bd5-8b48-0c03bc4df499" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5a4a7edf-6ede-4bd5-8b48-0c03bc4df499" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_c2f23fa4-59c9-4953-a912-4e4a673fce9f" xlink:href="biib-20210630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_c2f23fa4-59c9-4953-a912-4e4a673fce9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_59cb0fb5-defb-48d8-b0a2-14c25f88c238" xlink:href="biib-20210630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_59cb0fb5-defb-48d8-b0a2-14c25f88c238" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="id0be5c73d5754220bce9d6932b4e961e_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_640cf666-cf99-4b1b-aa60-02a7fb877b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_640cf666-cf99-4b1b-aa60-02a7fb877b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a32a622c-57a4-480a-9f05-19c3c3176e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a32a622c-57a4-480a-9f05-19c3c3176e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1fb493ef-0103-4373-8927-f2d0f813f517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc223781-7b46-4a31-b29e-b5ff6cfc2b08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc223781-7b46-4a31-b29e-b5ff6cfc2b08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_63545b55-232d-4d0d-a592-b4da0a61b6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_63545b55-232d-4d0d-a592-b4da0a61b6bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e31c4bb0-b240-4f4c-84e9-78101800038e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_63545b55-232d-4d0d-a592-b4da0a61b6bc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e31c4bb0-b240-4f4c-84e9-78101800038e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="ica0cf714d167488983797e4ca832b99e_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_848dab07-7c11-473f-956f-f6c3b2577eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_7d54f9e3-ee6b-4b56-8dfb-01652ed06b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_848dab07-7c11-473f-956f-f6c3b2577eea" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_7d54f9e3-ee6b-4b56-8dfb-01652ed06b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_a34f15bc-cc98-495a-84bb-d98597016d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_7d54f9e3-ee6b-4b56-8dfb-01652ed06b20" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_a34f15bc-cc98-495a-84bb-d98597016d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_848dab07-7c11-473f-956f-f6c3b2577eea" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:to="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a429e448-2e88-4d92-ae79-69e43417693e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a429e448-2e88-4d92-ae79-69e43417693e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8298feb9-61d6-4213-809d-b2d02a81a5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_CommercialPaperMember_8298feb9-61d6-4213-809d-b2d02a81a5ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_91c818c1-c473-4df9-aeca-0206cf36c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_91c818c1-c473-4df9-aeca-0206cf36c4c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ce2e045f-f444-42b3-aeac-7e23cd8146b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ce2e045f-f444-42b3-aeac-7e23cd8146b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_9bcaab95-9385-4ae9-9f11-09fbac21d3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_DebtSecuritiesMember_9bcaab95-9385-4ae9-9f11-09fbac21d3b7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="ia2d1a4dfb2b44a92a7ee4f412d487cdf_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c0527f9-c085-424b-b6fe-cb85c4c45276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c0527f9-c085-424b-b6fe-cb85c4c45276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07bce263-b9d7-449b-80d8-d37316de587d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07bce263-b9d7-449b-80d8-d37316de587d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5896c3d4-abcc-4fe9-8b28-24ed146936c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5896c3d4-abcc-4fe9-8b28-24ed146936c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d58ed56-419e-400a-aee8-7f2945601722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d58ed56-419e-400a-aee8-7f2945601722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_449acbdf-b9fe-4e1c-b354-e5b6048db2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleSecurities_449acbdf-b9fe-4e1c-b354-e5b6048db2aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_9f597774-37ed-4e07-a5ee-c891f0152c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_9f597774-37ed-4e07-a5ee-c891f0152c81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b96ad198-f6cc-45d2-b7a9-e04478384880" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b96ad198-f6cc-45d2-b7a9-e04478384880" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_38e7ef76-6acb-4337-9b79-afc0a8edf8dc" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_38e7ef76-6acb-4337-9b79-afc0a8edf8dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_becf11e3-1fd5-4891-bdfa-8caf5e5e7fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_becf11e3-1fd5-4891-bdfa-8caf5e5e7fb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_431c0726-0da4-44a9-bae7-7c5bf595bba0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_431c0726-0da4-44a9-bae7-7c5bf595bba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_a249e7b6-457c-4079-b1c1-bec918a53587" xlink:href="biib-20210630.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_a249e7b6-457c-4079-b1c1-bec918a53587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d1b76e83-b843-4f6e-a7a3-a4ef6445d6ef" xlink:href="biib-20210630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d1b76e83-b843-4f6e-a7a3-a4ef6445d6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_413fa86e-6782-4b2e-b4f8-a01d37a60365" xlink:href="biib-20210630.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_413fa86e-6782-4b2e-b4f8-a01d37a60365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_516a424b-a52d-4452-b1f7-ea1c3c36fcee" xlink:href="biib-20210630.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_516a424b-a52d-4452-b1f7-ea1c3c36fcee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_a69fe0b9-493e-41a5-96aa-00538a239196" xlink:href="biib-20210630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_a69fe0b9-493e-41a5-96aa-00538a239196" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4c9d2597-fae7-4eb9-9fdd-eb84e4d97eac" xlink:href="biib-20210630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4c9d2597-fae7-4eb9-9fdd-eb84e4d97eac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_6437c3d0-7dcd-4e6a-8b6f-e5384d751558" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_EquitySecuritiesCurrentMember_6437c3d0-7dcd-4e6a-8b6f-e5384d751558" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_ddb30c66-904a-485f-a164-1d80de5619b2" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_ddb30c66-904a-485f-a164-1d80de5619b2" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="i83d91e8d8e554f92b9c626b31d81f514_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_d798b92c-c874-4f55-b09e-99891f8d9a46" xlink:href="biib-20210630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_StrategicInvestmentPortfolio_d798b92c-c874-4f55-b09e-99891f8d9a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_35898ad9-e9ba-4f36-965f-8707bc0dd3a2" xlink:href="biib-20210630.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_Investmentincommonstocksharespurchased_35898ad9-e9ba-4f36-965f-8707bc0dd3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_33f545c6-d484-44fe-9c9f-d05fa45c75b7" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_33f545c6-d484-44fe-9c9f-d05fa45c75b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_f35a3196-60a5-49d8-8fd3-5b7f57944478" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_f35a3196-60a5-49d8-8fd3-5b7f57944478" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_324ce439-f517-4c96-bc77-b1eaebe1561c" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_324ce439-f517-4c96-bc77-b1eaebe1561c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_5fab0cfc-aa8f-4685-a1ff-66e6c72c1074" xlink:href="biib-20210630.xsd#biib_DividendYieldPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_DividendYieldPercentage_5fab0cfc-aa8f-4685-a1ff-66e6c72c1074" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_1387f49d-f8e2-4994-ad5a-0b985fbc67bd" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_1387f49d-f8e2-4994-ad5a-0b985fbc67bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_94b32f9c-737d-47f1-bba6-41c0a798b4b6_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:to="loc_dei_EntityDomain_94b32f9c-737d-47f1-bba6-41c0a798b4b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:to="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_b0fb3235-3c0a-40ce-b961-5722dfce71bd" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:to="loc_biib_DenaliTherapeuticsIncMember_b0fb3235-3c0a-40ce-b961-5722dfce71bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_49e41af4-806a-4922-b732-81976cc5ff1a" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:to="loc_biib_SangamoCommonStockMember_49e41af4-806a-4922-b732-81976cc5ff1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ca6758e3-2610-4aee-a006-1a9047819412_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ca6758e3-2610-4aee-a006-1a9047819412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07b9e94e-db79-4790-8fb7-5ad0c13e7dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07b9e94e-db79-4790-8fb7-5ad0c13e7dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_8b87b3bc-dbe4-4464-b636-0ae476149544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07b9e94e-db79-4790-8fb7-5ad0c13e7dab" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_8b87b3bc-dbe4-4464-b636-0ae476149544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6eaad485-9b82-4b02-92a7-a86825014751_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6eaad485-9b82-4b02-92a7-a86825014751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e8e5b53-0ae7-4d5f-a47b-1e80ce4fb9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e8e5b53-0ae7-4d5f-a47b-1e80ce4fb9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_59ed5fc0-73ba-43a8-ac5f-8b898d2831e3" xlink:href="biib-20210630.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e8e5b53-0ae7-4d5f-a47b-1e80ce4fb9c1" xlink:to="loc_biib_StrategicInvestmentsMember_59ed5fc0-73ba-43a8-ac5f-8b898d2831e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5c3b88d0-49cd-46ce-b767-db4c12c23e38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5c3b88d0-49cd-46ce-b767-db4c12c23e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_47a06ef2-9bc8-492e-8d1c-8d31a1a55171" xlink:href="biib-20210630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:to="loc_biib_SageTherapeuticsIncMember_47a06ef2-9bc8-492e-8d1c-8d31a1a55171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_e94a631c-22b7-42d7-aef4-d83803bac6db" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_e94a631c-22b7-42d7-aef4-d83803bac6db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_c13cefdd-029c-4fc6-8438-f7b8cc76fd1d" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:to="loc_biib_DenaliTherapeuticsIncMember_c13cefdd-029c-4fc6-8438-f7b8cc76fd1d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="if9c8e9c30e07461bafd1b8d8911b76a2_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_fe451b38-7d87-4cfd-995f-9ca53c022945" xlink:href="biib-20210630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_fe451b38-7d87-4cfd-995f-9ca53c022945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_a27a85ab-6b76-4c2d-8b86-afadf8de52ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_a27a85ab-6b76-4c2d-8b86-afadf8de52ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1455d68c-d4be-44a3-9a9b-ea57136798d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1455d68c-d4be-44a3-9a9b-ea57136798d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_95686b40-49db-41d3-b0fa-77cca0e21490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_95686b40-49db-41d3-b0fa-77cca0e21490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ef664d6e-1859-449b-8677-1652090940ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ef664d6e-1859-449b-8677-1652090940ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_6df8bbf3-beab-46ce-82e5-4a2005ca79ae" xlink:href="biib-20210630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_6df8bbf3-beab-46ce-82e5-4a2005ca79ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_962de1b3-2b4a-4ed4-b739-b5102947e0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_962de1b3-2b4a-4ed4-b739-b5102947e0a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ac9b1cd4-7136-4d3f-bf17-bcd593f40576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ac9b1cd4-7136-4d3f-bf17-bcd593f40576" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_56befa7b-0b12-4866-87da-ddb294d40a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeTermOfContract_56befa7b-0b12-4866-87da-ddb294d40a2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_be89a973-051d-4808-9f04-1b2691ff9683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_be89a973-051d-4808-9f04-1b2691ff9683" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_f6b9e993-2094-47f9-b0bf-2667369a01cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_f6b9e993-2094-47f9-b0bf-2667369a01cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ff7bdb1c-cd6b-4047-8aa9-1d37f97ead58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ff7bdb1c-cd6b-4047-8aa9-1d37f97ead58" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8619aa48-c55c-413c-9af8-84e874142336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8619aa48-c55c-413c-9af8-84e874142336" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6a2988bc-7eb1-4f48-b813-6c18365fe93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6a2988bc-7eb1-4f48-b813-6c18365fe93f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_95616b39-27c2-4076-a8b5-b6e2d96476f9" xlink:href="biib-20210630.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_95616b39-27c2-4076-a8b5-b6e2d96476f9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_9cab1ed9-d00e-41bb-bca8-5a655fd32d5e" xlink:href="biib-20210630.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_9cab1ed9-d00e-41bb-bca8-5a655fd32d5e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cdbc9918-9c4a-4393-853f-5ff2e6164a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cdbc9918-9c4a-4393-853f-5ff2e6164a3c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0431f443-665f-4026-b435-60e4975c3594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0431f443-665f-4026-b435-60e4975c3594" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e898b7f5-9caf-4b8a-a003-3608ce8e1dcd" xlink:href="biib-20210630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e898b7f5-9caf-4b8a-a003-3608ce8e1dcd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_bb05d019-f64c-4bbe-84e4-469d984779b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_bb05d019-f64c-4bbe-84e4-469d984779b3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b2587239-a4f1-471c-8abc-540172655920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b2587239-a4f1-471c-8abc-540172655920" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_d569c10a-4e73-4d46-b874-ca6135f07b58_default" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:to="loc_biib_DerivativeMaturityDomain_d569c10a-4e73-4d46-b874-ca6135f07b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_b87fce9a-2a05-4030-81b5-f60858150086" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:to="loc_biib_DerivativeMaturityDomain_b87fce9a-2a05-4030-81b5-f60858150086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_57a364d7-b52c-4345-99f3-d596ec42029b" xlink:href="biib-20210630.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_b87fce9a-2a05-4030-81b5-f60858150086" xlink:to="loc_biib_ShorttermderivativeMember_57a364d7-b52c-4345-99f3-d596ec42029b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_07f4eb2a-5f15-4f01-8ae0-2de5f7ad1974" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_07f4eb2a-5f15-4f01-8ae0-2de5f7ad1974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0fcd6b38-eca8-4d2c-9a87-acd54cd5695b" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_07f4eb2a-5f15-4f01-8ae0-2de5f7ad1974" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0fcd6b38-eca8-4d2c-9a87-acd54cd5695b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29fafd8a-1c19-4cc1-8285-281adf7af883_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29fafd8a-1c19-4cc1-8285-281adf7af883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_58b5b65c-112f-42b7-b467-19b28eb45604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_58b5b65c-112f-42b7-b467-19b28eb45604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_d1e62300-f42b-498c-b3a2-83bd0bfb5bc1" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_58b5b65c-112f-42b7-b467-19b28eb45604" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_d1e62300-f42b-498c-b3a2-83bd0bfb5bc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_849a3fb1-c109-437c-8152-24e1a9566f4c_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:to="loc_currency_AllCurrenciesDomain_849a3fb1-c109-437c-8152-24e1a9566f4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:to="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_d43aee05-c35a-4b05-ba7c-ab6a3aae9ecc" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_EUR_d43aee05-c35a-4b05-ba7c-ab6a3aae9ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_1e2669fa-3e62-42f9-ac28-22f9b202da5e" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_GBP_1e2669fa-3e62-42f9-ac28-22f9b202da5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_c8f9596a-2a2f-454d-a705-d5d07823c8c4" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_CHF_c8f9596a-2a2f-454d-a705-d5d07823c8c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_d2b0004c-d6b0-44bc-ae7a-a505937fdd23" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_JPY_d2b0004c-d6b0-44bc-ae7a-a505937fdd23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_c60788cb-720a-4856-842f-6b7d231b6a79" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_CAD_c60788cb-720a-4856-842f-6b7d231b6a79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0d6041f8-951d-4690-83b7-a8aa63526527_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0d6041f8-951d-4690-83b7-a8aa63526527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_171669e1-b2a6-4222-abe0-efbb2a746c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_InterestExpenseMember_171669e1-b2a6-4222-abe0-efbb2a746c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5a6121c1-44f7-48be-b5d6-b6ee2b2d8e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_SalesMember_5a6121c1-44f7-48be-b5d6-b6ee2b2d8e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_ffff58db-af9e-485c-826f-059fe4a25e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_OperatingExpenseMember_ffff58db-af9e-485c-826f-059fe4a25e0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_62de47af-8edc-49ed-a7f2-aab226b282da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_62de47af-8edc-49ed-a7f2-aab226b282da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_201c1e07-32b7-4376-851e-deca4b95b957_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:to="loc_us-gaap_HedgingRelationshipDomain_201c1e07-32b7-4376-851e-deca4b95b957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_fd73dcc4-5844-4788-bb5e-bce43d426d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_us-gaap_CashFlowHedgingMember_fd73dcc4-5844-4788-bb5e-bce43d426d1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_006cf79b-cd68-45f3-9fdc-1a5bb8e80619" xlink:href="biib-20210630.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_biib_CashflowsrevenueMember_006cf79b-cd68-45f3-9fdc-1a5bb8e80619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_b1a8e5c4-8711-4975-8ca6-049d630ecb6d" xlink:href="biib-20210630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_biib_CashflowsoperatingexpensesMember_b1a8e5c4-8711-4975-8ca6-049d630ecb6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8b45fb61-5bc8-4905-9f5f-20930060de4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8b45fb61-5bc8-4905-9f5f-20930060de4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_82950d8b-c190-474e-8914-047ac911121d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_82950d8b-c190-474e-8914-047ac911121d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_17aa536c-30f0-4a3c-a780-6bd90fa61b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_17aa536c-30f0-4a3c-a780-6bd90fa61b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8087657c-63f0-4e32-97e4-cf595907359f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:to="loc_us-gaap_InterestRateSwapMember_8087657c-63f0-4e32-97e4-cf595907359f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9f5bad52-0e39-462e-83f1-b616b89a1cd5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9f5bad52-0e39-462e-83f1-b616b89a1cd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_97ada7d9-cbcb-45ad-9746-53bd203aafb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_97ada7d9-cbcb-45ad-9746-53bd203aafb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_cb114d01-c7dd-430b-85b6-6077b13595b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_cb114d01-c7dd-430b-85b6-6077b13595b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ceb9eb28-0479-4836-a8d8-a01d69de5275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ceb9eb28-0479-4836-a8d8-a01d69de5275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_affe6501-e3cf-4b94-828e-503e741ad322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_affe6501-e3cf-4b94-828e-503e741ad322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:to="loc_us-gaap_HedgingDesignationDomain_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:to="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aea51d09-01c3-4e19-b81b-de60a17a9941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aea51d09-01c3-4e19-b81b-de60a17a9941" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8fdba9f1-913d-46fc-8db5-6a69636c4077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:to="loc_us-gaap_NondesignatedMember_8fdba9f1-913d-46fc-8db5-6a69636c4077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f2f7dd1-03f1-4890-9300-a5df64807ccb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:to="loc_srt_RangeMember_0f2f7dd1-03f1-4890-9300-a5df64807ccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:to="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2580d0f5-6ed1-4ad1-9bf5-aced9ae0ba89" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:to="loc_srt_MinimumMember_2580d0f5-6ed1-4ad1-9bf5-aced9ae0ba89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ee68438-c6da-42fe-a754-f3054923e659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:to="loc_srt_MaximumMember_5ee68438-c6da-42fe-a754-f3054923e659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_aaacacd1-194b-4a92-a47c-28a18f708f8d_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:to="loc_dei_EntityDomain_aaacacd1-194b-4a92-a47c-28a18f708f8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_02a5a7e6-9d04-4955-a074-069775441777" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:to="loc_dei_EntityDomain_02a5a7e6-9d04-4955-a074-069775441777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_3cd0beb1-23f9-4233-b43c-d6412a8daea2" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_02a5a7e6-9d04-4955-a074-069775441777" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_3cd0beb1-23f9-4233-b43c-d6412a8daea2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i6266716711d4450d89058bf585aff95a_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a2c3dbd-d653-4f53-88ad-0a2779fd1e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a2c3dbd-d653-4f53-88ad-0a2779fd1e47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1246371a-8dff-422c-87e7-ea679f77eb31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_Depreciation_1246371a-8dff-422c-87e7-ea679f77eb31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_d62ea4b1-a3a5-4a48-a102-e875e11b0e3c" xlink:href="biib-20210630.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_biib_NumberOfSquareFeet_d62ea4b1-a3a5-4a48-a102-e875e11b0e3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9121f888-fc53-42aa-a3f0-e8a66a19623b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_ConstructionInProgressGross_9121f888-fc53-42aa-a3f0-e8a66a19623b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_40fc088f-a5bf-4e04-8343-a74d04f310d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_40fc088f-a5bf-4e04-8343-a74d04f310d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:href="biib-20210630.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:to="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_a148e76f-1fd8-451f-92c1-10ac55345f02_default" xlink:href="biib-20210630.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:to="loc_biib_FacilityLocationDomain_a148e76f-1fd8-451f-92c1-10ac55345f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_7146fa2a-0d55-4011-8d72-69fb0053a0ec" xlink:href="biib-20210630.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:to="loc_biib_FacilityLocationDomain_7146fa2a-0d55-4011-8d72-69fb0053a0ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_ab530a77-ebbf-4b0e-8906-fc858779bcad" xlink:href="biib-20210630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_7146fa2a-0d55-4011-8d72-69fb0053a0ec" xlink:to="loc_biib_SolothurnSwitzerlandMember_ab530a77-ebbf-4b0e-8906-fc858779bcad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:href="biib-20210630.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:to="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_57b7785d-6950-43e1-8cd2-4b0d111fd523_default" xlink:href="biib-20210630.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:to="loc_biib_FacilityTypeDomain_57b7785d-6950-43e1-8cd2-4b0d111fd523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:href="biib-20210630.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:to="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_8ccbf204-703f-4c3f-bb5f-04818ef198a1" xlink:href="biib-20210630.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:to="loc_biib_BiologicsManufacturingMember_8ccbf204-703f-4c3f-bb5f-04818ef198a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_71a6ed86-3916-4ad6-b7c1-b8afba64603e" xlink:href="biib-20210630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_71a6ed86-3916-4ad6-b7c1-b8afba64603e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_efe97fe9-9272-49c6-9d81-5e8d972c31c8" xlink:href="biib-20210630.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:to="loc_biib_AdministrativeSpaceMember_efe97fe9-9272-49c6-9d81-5e8d972c31c8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="i010ec130e66c40efaa41e92b3cae8b9e_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1edefd4-7c2b-47e4-a45e-d49946e2208f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1edefd4-7c2b-47e4-a45e-d49946e2208f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a767f47e-0a03-4ed1-b734-ede612e45884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a767f47e-0a03-4ed1-b734-ede612e45884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_996b8a4d-7fe1-4ec9-ba73-6a3f18bd4152" xlink:href="biib-20210630.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_996b8a4d-7fe1-4ec9-ba73-6a3f18bd4152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_012ec8f0-e0d3-48a4-94bd-564f0a4e8a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_012ec8f0-e0d3-48a4-94bd-564f0a4e8a62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_bde27664-2acb-4cb0-9306-d72af5770d07" xlink:href="biib-20210630.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_bde27664-2acb-4cb0-9306-d72af5770d07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_b9f107c0-457c-4f6d-8be4-aa9461d7ca5f" xlink:href="biib-20210630.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_b9f107c0-457c-4f6d-8be4-aa9461d7ca5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1c91bdc6-d2e3-4299-836c-3c36bc31a95d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1c91bdc6-d2e3-4299-836c-3c36bc31a95d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_ba7d5605-4c09-4011-8561-fd30f00cc308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_ba7d5605-4c09-4011-8561-fd30f00cc308" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_fd352519-5722-45fd-ad33-9b2b707469fa" xlink:href="biib-20210630.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_fd352519-5722-45fd-ad33-9b2b707469fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_d1a296ca-f984-4c83-8d79-f9eb3f316df1" xlink:href="biib-20210630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_LongTermDebtExchangedAmount_d1a296ca-f984-4c83-8d79-f9eb3f316df1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_480427c6-9845-45cb-b2b4-31762c949927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_480427c6-9845-45cb-b2b4-31762c949927" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_de4c96b8-d943-4038-8ff5-f1ff12b4501c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_RepaymentsOfDebt_de4c96b8-d943-4038-8ff5-f1ff12b4501c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_89c8e345-e5c4-4845-b891-c93ae7fcc33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_InterestExpense_89c8e345-e5c4-4845-b891-c93ae7fcc33d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14976940-6a39-424b-944b-e35b619d34a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14976940-6a39-424b-944b-e35b619d34a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_55770e67-67da-411c-b736-84caa1e82193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_55770e67-67da-411c-b736-84caa1e82193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_c54979da-4de1-4288-b92a-f641183cda15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_55770e67-67da-411c-b736-84caa1e82193" xlink:to="loc_us-gaap_InterestExpenseMember_c54979da-4de1-4288-b92a-f641183cda15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3d098460-ad47-427e-ad78-432d569a350c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3d098460-ad47-427e-ad78-432d569a350c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2191f922-f631-48d6-8350-c0eaeb20f9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2191f922-f631-48d6-8350-c0eaeb20f9db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bf19e139-e420-42d0-a7e2-bbd9a50d9c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2191f922-f631-48d6-8350-c0eaeb20f9db" xlink:to="loc_us-gaap_InterestRateSwapMember_bf19e139-e420-42d0-a7e2-bbd9a50d9c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c3fa481-6b54-4581-b927-13e312958acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c3fa481-6b54-4581-b927-13e312958acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d15d0bc5-c336-442d-abf8-4a4080167833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c3fa481-6b54-4581-b927-13e312958acc" xlink:to="loc_us-gaap_SeniorNotesMember_d15d0bc5-c336-442d-abf8-4a4080167833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9911da03-ae66-4103-83ef-85f6f894c655_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9911da03-ae66-4103-83ef-85f6f894c655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_55ece565-8d1b-4d45-b5c6-82a55a24d3de" xlink:href="biib-20210630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_55ece565-8d1b-4d45-b5c6-82a55a24d3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_910d15a9-0728-4aef-abe6-e4bc50975fa5" xlink:href="biib-20210630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_910d15a9-0728-4aef-abe6-e4bc50975fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_298d4ebc-9a44-447c-9135-9539217eadb6" xlink:href="biib-20210630.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_298d4ebc-9a44-447c-9135-9539217eadb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_a5b16bf7-8fad-4075-bb1b-e6d58edc67e9" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_a5b16bf7-8fad-4075-bb1b-e6d58edc67e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_353e551f-50dd-4f86-bb7a-7d5289b1bfc1" xlink:href="biib-20210630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_353e551f-50dd-4f86-bb7a-7d5289b1bfc1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="i89b5a8a39f9c4a8092b1a6d58441195a_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdb2f983-6083-4756-863a-b0a261614709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdb2f983-6083-4756-863a-b0a261614709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3dda8383-c784-409b-aaea-a8647acc94fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3dda8383-c784-409b-aaea-a8647acc94fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ce4e014-a0f5-4b43-89b6-e2c904ccf61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ce4e014-a0f5-4b43-89b6-e2c904ccf61d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1b078fb2-d2ac-4c55-b6e0-e4e9c5186d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1b078fb2-d2ac-4c55-b6e0-e4e9c5186d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b8881715-7f26-4ab7-bd76-bc3edefa9ff8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b8881715-7f26-4ab7-bd76-bc3edefa9ff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_4b95be3d-c1f8-4cf3-a247-7918fd3449c2" xlink:href="biib-20210630.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_4b95be3d-c1f8-4cf3-a247-7918fd3449c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_f4ec2399-a4c7-4667-b360-70e92600d5e1" xlink:href="biib-20210630.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_f4ec2399-a4c7-4667-b360-70e92600d5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_d2c68acb-bf8d-40cd-8f19-ae84e11a68ad" xlink:href="biib-20210630.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_d2c68acb-bf8d-40cd-8f19-ae84e11a68ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="if3982e11ca2c4568a79d297f2ba8900c_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87642981-a7da-46d9-81ee-1a6af24eb493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87642981-a7da-46d9-81ee-1a6af24eb493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cdd3e9cd-5f1d-4d36-b123-4d2997220b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e409e984-2a14-402f-b5c7-ca4454e1aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e409e984-2a14-402f-b5c7-ca4454e1aeb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_81e0e4ac-2a1c-42f9-bf65-ceb17e561d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_81e0e4ac-2a1c-42f9-bf65-ceb17e561d0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6071e025-dd2f-4436-be02-8444315bfe36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6071e025-dd2f-4436-be02-8444315bfe36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c0e19b2b-dd9a-40cb-89ef-13a12578d431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0e38421-21d8-4628-80e9-ab11a26ec973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0e38421-21d8-4628-80e9-ab11a26ec973" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_38bc29d5-5b1a-4d04-ac79-32b66c848ebd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:to="loc_us-gaap_EquityComponentDomain_38bc29d5-5b1a-4d04-ac79-32b66c848ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:to="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_21b9ead7-8179-42c6-a645-b653ce041400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_21b9ead7-8179-42c6-a645-b653ce041400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b4bdde0c-cd1b-4acd-912d-1f3a2de39c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b4bdde0c-cd1b-4acd-912d-1f3a2de39c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_981f889c-5305-424d-8c73-9811dba419e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_981f889c-5305-424d-8c73-9811dba419e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_50010cd3-8c9f-4561-adfe-ad18959f7e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_50010cd3-8c9f-4561-adfe-ad18959f7e47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_72d92dee-5407-4d26-a2c4-99e93c2cf00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_72d92dee-5407-4d26-a2c4-99e93c2cf00b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i7005602a24474c2fa0528338947d50df_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_841c857d-0b71-4ff7-8d18-dfe7e522df6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_841c857d-0b71-4ff7-8d18-dfe7e522df6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59cf1aaa-406c-4d38-81b2-68d8cf63e9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_59cf1aaa-406c-4d38-81b2-68d8cf63e9ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a6fbeef6-9ea9-447d-8b13-ab377746db89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_Revenues_a6fbeef6-9ea9-447d-8b13-ab377746db89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_306a6495-affb-4280-9696-ee4921218dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_OperatingExpenses_306a6495-affb-4280-9696-ee4921218dec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a16a1194-2217-48a7-97d6-c60bb0360d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_NetIncomeLoss_a16a1194-2217-48a7-97d6-c60bb0360d0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a14ddfa-491c-4af8-935e-177392809587_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:to="loc_us-gaap_EquityComponentDomain_0a14ddfa-491c-4af8-935e-177392809587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:to="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6009a070-cb13-49de-a013-87f5814ca686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6009a070-cb13-49de-a013-87f5814ca686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9a366285-78cc-4b9e-bb4d-e39dc08db129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9a366285-78cc-4b9e-bb4d-e39dc08db129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_a15f3645-fe85-4793-94fb-aa3bcf2e7e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_a15f3645-fe85-4793-94fb-aa3bcf2e7e0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37c1ceff-a40f-44b4-9480-673b6e6e031a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37c1ceff-a40f-44b4-9480-673b6e6e031a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cb6f9635-05b2-4364-9fb0-b910c2a4ba51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cb6f9635-05b2-4364-9fb0-b910c2a4ba51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9b900656-9682-43a8-a201-c72aa91666fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cb6f9635-05b2-4364-9fb0-b910c2a4ba51" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9b900656-9682-43a8-a201-c72aa91666fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="i3dad9fd7c768485190c35522ddc31c6c_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bfc1d0c9-441d-4b2a-be78-de3e184e5b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:href="biib-20210630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bfc1d0c9-441d-4b2a-be78-de3e184e5b74" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9566d284-2666-415e-9c4b-5bf13092a158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9566d284-2666-415e-9c4b-5bf13092a158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_75afb173-6ed3-4459-ad27-d0dc954d298d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9566d284-2666-415e-9c4b-5bf13092a158" xlink:to="loc_us-gaap_NetIncomeLoss_75afb173-6ed3-4459-ad27-d0dc954d298d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57086093-36f1-4bd6-83bb-4b40c7944fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57086093-36f1-4bd6-83bb-4b40c7944fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c0720479-66fa-4913-807f-c78da8ed8dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c0720479-66fa-4913-807f-c78da8ed8dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3464ca2e-17f7-4bb3-86db-d89f39a25e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3464ca2e-17f7-4bb3-86db-d89f39a25e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_404d075f-baf9-4414-8d90-2e006e0b0743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_404d075f-baf9-4414-8d90-2e006e0b0743" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bfc1d0c9-441d-4b2a-be78-de3e184e5b74" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ef1827fe-954b-401d-9459-65fb9649feee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ef1827fe-954b-401d-9459-65fb9649feee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_63fe64ab-3071-4c7b-9e4a-ffa23f02dc5b" xlink:href="biib-20210630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_63fe64ab-3071-4c7b-9e4a-ffa23f02dc5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_814dc691-5d4d-4915-9114-87d129eff717" xlink:href="biib-20210630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:to="loc_biib_MarketStockUnitsMember_814dc691-5d4d-4915-9114-87d129eff717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_aa86734b-2303-434c-ad9a-183bed2d700a" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_aa86734b-2303-434c-ad9a-183bed2d700a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="i738c0e5c1f0e4f619fc01742d282f6d7_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_875279a0-ee76-430a-9cf1-8ae957e92248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_875279a0-ee76-430a-9cf1-8ae957e92248" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dee9e17-8e56-4477-b126-1b161881150e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dee9e17-8e56-4477-b126-1b161881150e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d55199a7-8b19-4dec-bdd0-78fc876f0042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d55199a7-8b19-4dec-bdd0-78fc876f0042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8436196d-85ea-4337-b992-fd5dc9dad92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8436196d-85ea-4337-b992-fd5dc9dad92a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_c8a7a3dd-7ae3-4f1b-8522-4d6c4cf47b87" xlink:href="biib-20210630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_c8a7a3dd-7ae3-4f1b-8522-4d6c4cf47b87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d157fe4b-2afd-46c2-a67e-00adb3584726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d157fe4b-2afd-46c2-a67e-00adb3584726" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_875279a0-ee76-430a-9cf1-8ae957e92248" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89328755-81ea-4f90-9eee-d1cf9f95f43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89328755-81ea-4f90-9eee-d1cf9f95f43b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c40635b-478c-481f-8a38-31d24cb19c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c40635b-478c-481f-8a38-31d24cb19c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_1111d7c0-9448-4c17-bb88-6b86020dd657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:to="loc_us-gaap_ParentMember_1111d7c0-9448-4c17-bb88-6b86020dd657" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="ie84dda49b5444b3f9454e81ee4653ffd_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_915cf966-9f25-416c-99e6-71dd478ec0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:href="biib-20210630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_915cf966-9f25-416c-99e6-71dd478ec0dd" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_709c9144-0144-41cc-b547-b5b9caef4a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_709c9144-0144-41cc-b547-b5b9caef4a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_61b2d766-6348-43dc-b9c5-a1f74a07de38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_61b2d766-6348-43dc-b9c5-a1f74a07de38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_83fa133c-54b1-4e98-9097-6bcddd8f77e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_83fa133c-54b1-4e98-9097-6bcddd8f77e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3a677373-4691-4713-9bb8-bc64b4fd31d4" xlink:href="biib-20210630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3a677373-4691-4713-9bb8-bc64b4fd31d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_915cf966-9f25-416c-99e6-71dd478ec0dd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da0f3cb7-56a2-4f18-8b86-9125540ad590_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da0f3cb7-56a2-4f18-8b86-9125540ad590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f63f215-abaa-4ed9-87d3-8f6ddce59282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f63f215-abaa-4ed9-87d3-8f6ddce59282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_0633b045-ddb4-4884-9dbe-4b75343b6f89" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f63f215-abaa-4ed9-87d3-8f6ddce59282" xlink:to="loc_biib_NightstarMember_0633b045-ddb4-4884-9dbe-4b75343b6f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:to="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f02c245c-1931-4874-8a97-e43afc942cf0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f02c245c-1931-4874-8a97-e43afc942cf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_73b80751-dddf-4564-8a97-501bd6a77327" xlink:href="biib-20210630.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_MarketStockUnitsMember_73b80751-dddf-4564-8a97-501bd6a77327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_62887ff6-9f99-49af-87d5-9e731d55bae5" xlink:href="biib-20210630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_62887ff6-9f99-49af-87d5-9e731d55bae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_111ade9d-aef8-4da3-ae8c-9ffb3a8d737f" xlink:href="biib-20210630.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_CashSettledPerformanceSharesMember_111ade9d-aef8-4da3-ae8c-9ffb3a8d737f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_724c2fa8-7979-48a4-9244-d7a56998052b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_us-gaap_PerformanceSharesMember_724c2fa8-7979-48a4-9244-d7a56998052b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_cfb5d17c-8571-474d-91b5-bf8e0cab4df8" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_cfb5d17c-8571-474d-91b5-bf8e0cab4df8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_24d8159e-460d-47d3-ac03-105b2fffefe5" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_24d8159e-460d-47d3-ac03-105b2fffefe5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_be679734-8621-4a90-8823-d454ebd0cf49" xlink:href="biib-20210630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_be679734-8621-4a90-8823-d454ebd0cf49" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i5fb3931ce96e4a83ade750132cf9ab7d_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_4cba4370-37f8-4bb5-9524-ec0d1c259575" xlink:href="biib-20210630.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_4cba4370-37f8-4bb5-9524-ec0d1c259575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_8a3b44c8-09cf-4a2b-9e77-d7749f53e379" xlink:href="biib-20210630.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_8a3b44c8-09cf-4a2b-9e77-d7749f53e379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_9f8bfdcc-2bfa-4bf1-91ea-4dbe61020f2d" xlink:href="biib-20210630.xsd#biib_DeferredTaxAssetIncreaseDecreaseInValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_9f8bfdcc-2bfa-4bf1-91ea-4dbe61020f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_6ff41a34-74a9-4e67-ab31-7e93de8ed050" xlink:href="biib-20210630.xsd#biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_6ff41a34-74a9-4e67-ab31-7e93de8ed050" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_509a5383-d4fa-41a5-8e4f-d4520bfa1504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_509a5383-d4fa-41a5-8e4f-d4520bfa1504" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d7c90565-a339-4ba6-8c52-e203d75b93f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d7c90565-a339-4ba6-8c52-e203d75b93f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_549b4a76-e0b7-45a5-b1a9-8264c8315729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_549b4a76-e0b7-45a5-b1a9-8264c8315729" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_05b0b1fa-cee1-487f-a8e3-eafe64b66745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_05b0b1fa-cee1-487f-a8e3-eafe64b66745" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:to="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e4152a4-872a-462d-b288-498f361b6279_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:to="loc_srt_ProductsAndServicesDomain_1e4152a4-872a-462d-b288-498f361b6279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_039acd53-df6a-47cc-a424-f651aac1dbb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:to="loc_srt_ProductsAndServicesDomain_039acd53-df6a-47cc-a424-f651aac1dbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_7a9c6a64-bad5-41f7-97f9-6f2ee3f5212b" xlink:href="biib-20210630.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_039acd53-df6a-47cc-a424-f651aac1dbb8" xlink:to="loc_biib_TECFIDERAMember_7a9c6a64-bad5-41f7-97f9-6f2ee3f5212b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="i2ecd3da713fe46bd8cb09497568437ae_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0ac21d79-09b2-4b90-bf74-fb12807eeeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0ac21d79-09b2-4b90-bf74-fb12807eeeee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b19d8d39-a13d-4ace-b092-22b12b8e3ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_InterestExpense_b19d8d39-a13d-4ace-b092-22b12b8e3ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_e13b2d6a-b3a2-4653-a2b4-807f86c421c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_e13b2d6a-b3a2-4653-a2b4-807f86c421c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b67a0601-f9c2-4712-9d9a-d50494032545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b67a0601-f9c2-4712-9d9a-d50494032545" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_872b068e-2878-49b4-b4f5-643a1017e56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_872b068e-2878-49b4-b4f5-643a1017e56b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bbaf76cb-c876-47e0-b7b1-c771094506d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bbaf76cb-c876-47e0-b7b1-c771094506d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bbf05303-12b3-43fe-ae78-6e6fde5609ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bbf05303-12b3-43fe-ae78-6e6fde5609ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3d8a7b9e-0df1-4d52-a555-bb78f1d20f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3d8a7b9e-0df1-4d52-a555-bb78f1d20f8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_de899f19-6499-44f1-8378-cf68dba7ab55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_de899f19-6499-44f1-8378-cf68dba7ab55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_bdf84485-947f-4ce2-a3c7-b6283ed2d84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_bdf84485-947f-4ce2-a3c7-b6283ed2d84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a55ecb33-90be-4bad-8531-844e96084494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a55ecb33-90be-4bad-8531-844e96084494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c35a5feb-0ff1-40b8-a87c-f997b90b7412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c35a5feb-0ff1-40b8-a87c-f997b90b7412" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_a366153e-bbff-4322-aa6b-078b717db5ef" xlink:href="biib-20210630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_biib_Collaborationexpensesaccrual_a366153e-bbff-4322-aa6b-078b717db5ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_89553dcd-3727-4bf2-9794-516399c6a568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_89553dcd-3727-4bf2-9794-516399c6a568" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8e26eb98-9b25-4881-85f4-dccd8bad3ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8e26eb98-9b25-4881-85f4-dccd8bad3ca7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dcae492b-ae9f-4753-9433-78d0713fac9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dcae492b-ae9f-4753-9433-78d0713fac9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_61ead5a2-e330-4ce7-bd3a-ddda2c3aaa36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_61ead5a2-e330-4ce7-bd3a-ddda2c3aaa36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_08058a49-da67-4da2-9a4c-bfbdb88e439d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_08058a49-da67-4da2-9a4c-bfbdb88e439d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7fa710b8-7257-450b-9db2-796e5d86981f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7fa710b8-7257-450b-9db2-796e5d86981f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7c71e0ec-7c77-4d45-a9ab-984e67c3b912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fa710b8-7257-450b-9db2-796e5d86981f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7c71e0ec-7c77-4d45-a9ab-984e67c3b912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:to="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dcbd8999-6d26-4937-8c80-b03d42bc0842_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:to="loc_dei_EntityDomain_dcbd8999-6d26-4937-8c80-b03d42bc0842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3f14897c-e817-46ce-ba34-55e5efd2a936" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:to="loc_dei_EntityDomain_3f14897c-e817-46ce-ba34-55e5efd2a936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_84dfb578-8826-4e6c-b1aa-f2d62c26b6a5" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3f14897c-e817-46ce-ba34-55e5efd2a936" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_84dfb578-8826-4e6c-b1aa-f2d62c26b6a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="i3015e6733aba40c38c8bf8d22411f2c2_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee03df6e-13f1-4ec4-9405-eb6a64c35cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee03df6e-13f1-4ec4-9405-eb6a64c35cf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ed5713c8-6341-43c3-9008-f88f76556db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ed5713c8-6341-43c3-9008-f88f76556db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b9f024aa-bcf3-44ee-b928-d56b16c19b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b9f024aa-bcf3-44ee-b928-d56b16c19b60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ce692ec6-139d-4c8e-a34a-3d9a1520f589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ce692ec6-139d-4c8e-a34a-3d9a1520f589" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_676171b1-f066-4222-96fd-a58d08b92836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_676171b1-f066-4222-96fd-a58d08b92836" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:to="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d900bf37-132b-498b-af0f-35d7262fbf19_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:to="loc_dei_EntityDomain_d900bf37-132b-498b-af0f-35d7262fbf19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fff89d34-d6b1-4afe-97bc-db903ada3dba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:to="loc_dei_EntityDomain_fff89d34-d6b1-4afe-97bc-db903ada3dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_0c4f97f3-6527-4f2d-a85d-c512ab997e31" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fff89d34-d6b1-4afe-97bc-db903ada3dba" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_0c4f97f3-6527-4f2d-a85d-c512ab997e31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="ic896fc7c4dca4915b6d313b038ce994f_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_81f87980-64fc-4e96-9ce0-218dc3ce9d80" xlink:href="biib-20210630.xsd#biib_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_NumberOfProductCandidates_81f87980-64fc-4e96-9ce0-218dc3ce9d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_eb56689a-b65f-4595-9966-b19b1f703b89" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_eb56689a-b65f-4595-9966-b19b1f703b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_1817a976-21b4-47a1-9955-067a205c4f4f" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_1817a976-21b4-47a1-9955-067a205c4f4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_cdee435f-038b-483a-8d00-bb6dbad132c9" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_cdee435f-038b-483a-8d00-bb6dbad132c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7a647699-acc1-43fb-944d-08d8dbd5e20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7a647699-acc1-43fb-944d-08d8dbd5e20c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_2cc57159-b680-4259-871d-200c1cd66c91" xlink:href="biib-20210630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_ExpenseIncurredByCollaboration_2cc57159-b680-4259-871d-200c1cd66c91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_7e9bf85f-a5c9-4889-ae28-2c7d46438025" xlink:href="biib-20210630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_Expenseincurredbythecollaboration_7e9bf85f-a5c9-4889-ae28-2c7d46438025" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_620cf2de-2320-4431-bf02-3d5faed99dde" xlink:href="biib-20210630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_620cf2de-2320-4431-bf02-3d5faed99dde" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_676239f8-556b-465b-9a4d-88fb352c8435" xlink:href="biib-20210630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_676239f8-556b-465b-9a4d-88fb352c8435" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_144e6de5-c8ec-4a39-928b-085b95b7f736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_LossOnContractTermination_144e6de5-c8ec-4a39-928b-085b95b7f736" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f4784cda-1f73-46c1-b138-4710910cfa5d" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f4784cda-1f73-46c1-b138-4710910cfa5d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_62b51291-3eab-43b6-8748-425fcb999a9e" xlink:href="biib-20210630.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_CollaborationAgreementTerm_62b51291-3eab-43b6-8748-425fcb999a9e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_38f93dbe-a5f9-46e0-970f-435d36727377" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_38f93dbe-a5f9-46e0-970f-435d36727377" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_59a7559c-d0be-4d76-b194-5f8a2aab5db0" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_59a7559c-d0be-4d76-b194-5f8a2aab5db0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_5d2718c3-cd62-48a5-8e59-7bcb6a532b42" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_5d2718c3-cd62-48a5-8e59-7bcb6a532b42" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_0ee74c9d-1da9-4fa4-ad23-2b0b0ca0ebb0" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_0ee74c9d-1da9-4fa4-ad23-2b0b0ca0ebb0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_79291f2e-0dec-43ce-880a-ec600f40e2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_79291f2e-0dec-43ce-880a-ec600f40e2c7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_228b1d9f-087c-44b1-bd64-2b2539d15aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_228b1d9f-087c-44b1-bd64-2b2539d15aca" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_1081935c-be01-4a0d-b631-de4f7611fea0" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_1081935c-be01-4a0d-b631-de4f7611fea0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_cb435b26-d45b-4d30-85f4-1792bf6703cc" xlink:href="biib-20210630.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_Termofcollaborationagreement_cb435b26-d45b-4d30-85f4-1792bf6703cc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_e2d0fb76-2b9f-42d4-b5a9-92bacc619758" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_AdditionalMilestonePayment_e2d0fb76-2b9f-42d4-b5a9-92bacc619758" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_83ee063d-e104-43cc-b672-f4724fd5fec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_83ee063d-e104-43cc-b672-f4724fd5fec3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_abc80780-c46a-4541-b8fe-42d9b52f2dec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_abc80780-c46a-4541-b8fe-42d9b52f2dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_affdf152-3e10-48c4-9e7c-048afe449ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_affdf152-3e10-48c4-9e7c-048afe449ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fdd69a33-364e-435b-a6a8-a9d1d51f737a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fdd69a33-364e-435b-a6a8-a9d1d51f737a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af99a093-8c61-46cb-98c0-f1ebc134e2e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af99a093-8c61-46cb-98c0-f1ebc134e2e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_94c6d494-98b0-4c61-bac9-b496e2d12791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_us-gaap_CollaborativeArrangementMember_94c6d494-98b0-4c61-bac9-b496e2d12791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_cc0afb83-a6a7-4209-a32b-546dcfa0e9aa" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_EisaiMember_cc0afb83-a6a7-4209-a32b-546dcfa0e9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_1267f95d-14b3-455f-b2df-fba75b247ea4" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_DenaliTherapeuticsIncMember_1267f95d-14b3-455f-b2df-fba75b247ea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_5ead45d0-eef3-4af5-bbec-904803494a2d" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f2778d9a-7b19-4164-915d-114017a86af7" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f2778d9a-7b19-4164-915d-114017a86af7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_d1c41b0a-5029-402a-899a-722c009e4a48" xlink:href="biib-20210630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_SageTherapeuticsIncMember_d1c41b0a-5029-402a-899a-722c009e4a48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_a986cfd4-7157-487b-9f45-98cc082b5e3a" xlink:href="biib-20210630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_UCBPharmaS.A.Member_a986cfd4-7157-487b-9f45-98cc082b5e3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_e71dd693-7b38-42ba-b607-e2890789f536" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_e71dd693-7b38-42ba-b607-e2890789f536" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_38559fcc-8e08-4342-a3c5-0477868c7b2b" xlink:href="biib-20210630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_OtherresearchanddiscoveryMember_38559fcc-8e08-4342-a3c5-0477868c7b2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d8fd2dad-e58c-4fe9-879f-eb819ac330a3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:to="loc_srt_ProductsAndServicesDomain_d8fd2dad-e58c-4fe9-879f-eb819ac330a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:to="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_52794149-ea52-4878-aa27-3ac7d4a552c3" xlink:href="biib-20210630.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:to="loc_biib_E2609andBAN2401Member_52794149-ea52-4878-aa27-3ac7d4a552c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_9ea2733e-57f8-4b6f-99e9-92a3f8aa96cf" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:to="loc_biib_ADUHELMMember_9ea2733e-57f8-4b6f-99e9-92a3f8aa96cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d99f33a8-8e66-45d6-a1e1-ae318af98525_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:to="loc_dei_EntityDomain_d99f33a8-8e66-45d6-a1e1-ae318af98525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_088d26f2-c089-41ba-8dd7-b09c3c3bb20d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:to="loc_dei_EntityDomain_088d26f2-c089-41ba-8dd7-b09c3c3bb20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_d2410918-c555-4aa9-a39f-c41654bd3a70" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_088d26f2-c089-41ba-8dd7-b09c3c3bb20d" xlink:to="loc_biib_SangamoCommonStockMember_d2410918-c555-4aa9-a39f-c41654bd3a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6a6f7519-402e-40ad-8f2c-9e8ce6066f88_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6a6f7519-402e-40ad-8f2c-9e8ce6066f88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_ffac0f07-f1a9-41ce-a260-2c56762eb2d7" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:to="loc_biib_DenaliTherapeuticsIncMember_ffac0f07-f1a9-41ce-a260-2c56762eb2d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_8b1a4ad4-84db-4243-865a-e556c02b7f89" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_8b1a4ad4-84db-4243-865a-e556c02b7f89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="i208ef3da277c411eaf9f70c42de48598_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75ba2b6e-802d-4a22-b0d9-82d665fb03e0" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75ba2b6e-802d-4a22-b0d9-82d665fb03e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_14c0c4be-b138-4aac-9ebc-3ecc816166bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_LossOnContractTermination_14c0c4be-b138-4aac-9ebc-3ecc816166bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_c9e28c59-540b-4d05-b4b4-a76f73789da1" xlink:href="biib-20210630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_c9e28c59-540b-4d05-b4b4-a76f73789da1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_daa716a5-a239-4a38-8d56-7bb2228a56a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_daa716a5-a239-4a38-8d56-7bb2228a56a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_552e4b15-32b7-44d0-a05f-895cd867f053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_552e4b15-32b7-44d0-a05f-895cd867f053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_04530cac-4850-4ec8-baaf-907c45201b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_04530cac-4850-4ec8-baaf-907c45201b8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_cb6789e1-9582-4bfe-86a8-83d5cf0ff136" xlink:href="biib-20210630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_cb6789e1-9582-4bfe-86a8-83d5cf0ff136" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4b159b9f-2985-4bcc-a64f-a2487b576cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4b159b9f-2985-4bcc-a64f-a2487b576cbd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b6debee7-09a8-4fe7-9d56-b53962568a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b6debee7-09a8-4fe7-9d56-b53962568a14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9bdcc6d9-c245-4ebd-9cc4-1f857ab4d334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_EquityMethodInvestments_9bdcc6d9-c245-4ebd-9cc4-1f857ab4d334" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_443809cf-72a6-46ea-8638-63e67cdae4c9" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_443809cf-72a6-46ea-8638-63e67cdae4c9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c789d90-7325-4e6c-8228-1d2d4a9854c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c789d90-7325-4e6c-8228-1d2d4a9854c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_54ff74e2-ed05-40fb-bb01-ff2cd5a50ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_54ff74e2-ed05-40fb-bb01-ff2cd5a50ca8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_fbd0d744-8654-4fcb-a9cf-a26653f01623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_fbd0d744-8654-4fcb-a9cf-a26653f01623" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1bda17ac-a296-4bc1-a747-737b3733a1fd" xlink:href="biib-20210630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1bda17ac-a296-4bc1-a747-737b3733a1fd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_a0f2edfc-2970-4e3a-b305-c5b6d2ed5bbd" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_AdditionalMilestonePayment_a0f2edfc-2970-4e3a-b305-c5b6d2ed5bbd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_15e8de79-6f01-4a8d-bc27-28e4798ba198" xlink:href="biib-20210630.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_ContractOptionExerciseFee_15e8de79-6f01-4a8d-bc27-28e4798ba198" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_c0964a45-8659-46f8-8dcc-37496ea338fd" xlink:href="biib-20210630.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_c0964a45-8659-46f8-8dcc-37496ea338fd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_d0ccd650-2412-446b-a331-f34901baf5ec" xlink:href="biib-20210630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_Collaborationprofitlosssharing_d0ccd650-2412-446b-a331-f34901baf5ec" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32bd0a67-0def-44d7-9153-2478c87126f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_Revenues_32bd0a67-0def-44d7-9153-2478c87126f6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_abee8951-7967-4cf2-b3a4-463243fec283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_abee8951-7967-4cf2-b3a4-463243fec283" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_0fa23d87-7f97-4c29-bdd8-2112ffd0330b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_0fa23d87-7f97-4c29-bdd8-2112ffd0330b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_a4f11020-f01c-4464-aa07-41d7139bd323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_a4f11020-f01c-4464-aa07-41d7139bd323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_d619c5c1-580f-441f-886c-3fa3a03cfa59" xlink:href="biib-20210630.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_a4f11020-f01c-4464-aa07-41d7139bd323" xlink:to="loc_biib_NeurimmuneMember_d619c5c1-580f-441f-886c-3fa3a03cfa59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_abec1cd4-cff6-4b13-b242-4b883d3b72a0_default" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_abec1cd4-cff6-4b13-b242-4b883d3b72a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_3dc5c5c1-8359-4b0d-8b52-4ad160cda90c" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_3dc5c5c1-8359-4b0d-8b52-4ad160cda90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_98b7c006-2ff5-4f80-98a7-925b4181f557" xlink:href="biib-20210630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_3dc5c5c1-8359-4b0d-8b52-4ad160cda90c" xlink:to="loc_biib_RegulatoryMilestonesMember_98b7c006-2ff5-4f80-98a7-925b4181f557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20497464-bcfa-4ad9-a8c8-1ad456456752_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_20497464-bcfa-4ad9-a8c8-1ad456456752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_cfb8950f-3730-449c-aa33-b695046866bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:to="loc_us-gaap_InventoriesMember_cfb8950f-3730-449c-aa33-b695046866bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_83e7dd86-2c23-42f5-b808-992631255e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_83e7dd86-2c23-42f5-b808-992631255e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_14f8982c-4fda-4ee5-b0dc-f95477d8a285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_14f8982c-4fda-4ee5-b0dc-f95477d8a285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf5a4382-042a-4e97-96d8-ca68074bfd48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf5a4382-042a-4e97-96d8-ca68074bfd48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_91560b0b-bb30-42e9-bb6d-6593fb4be1e9" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:to="loc_biib_EisaiMember_91560b0b-bb30-42e9-bb6d-6593fb4be1e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5b10174e-4dea-44f3-848d-6ea7fcb1b09d" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5b10174e-4dea-44f3-848d-6ea7fcb1b09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7765dd31-1927-48ab-9ed7-5efc74fb8a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7765dd31-1927-48ab-9ed7-5efc74fb8a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ffc98c3c-9233-4e14-b5bc-a4426f497b6a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ffc98c3c-9233-4e14-b5bc-a4426f497b6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5e49ec75-dffd-44ba-b159-8bfaa09cc5e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5e49ec75-dffd-44ba-b159-8bfaa09cc5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_b93e3b9c-a5de-4db9-af2a-018104d09667" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5e49ec75-dffd-44ba-b159-8bfaa09cc5e3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_b93e3b9c-a5de-4db9-af2a-018104d09667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe13dfef-d406-4d4b-8d45-cb873b6adbb8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:to="loc_srt_ProductsAndServicesDomain_fe13dfef-d406-4d4b-8d45-cb873b6adbb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af21ae05-37ff-4022-a645-d451df3086d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:to="loc_srt_ProductsAndServicesDomain_af21ae05-37ff-4022-a645-d451df3086d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_90ed4679-591f-461f-9fb8-a51b5fe9d086" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af21ae05-37ff-4022-a645-d451df3086d6" xlink:to="loc_biib_ADUHELMMember_90ed4679-591f-461f-9fb8-a51b5fe9d086" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="i2054c2fe1124483db96b14c70042e995_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_aafed871-27d3-4e7f-8de3-18c62f793d21" xlink:href="biib-20210630.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_CollaborationAgreementTerm_aafed871-27d3-4e7f-8de3-18c62f793d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_5ae0f5cf-3b6b-4f38-b057-4af829eefcb1" xlink:href="biib-20210630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_5ae0f5cf-3b6b-4f38-b057-4af829eefcb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_cd014d51-f636-428f-8f54-938f8a0627e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_cd014d51-f636-428f-8f54-938f8a0627e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_0c85c4c8-c2bb-4778-9bf8-965f078cad80" xlink:href="biib-20210630.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_0c85c4c8-c2bb-4778-9bf8-965f078cad80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_d6894e4c-b8ae-4140-9c9f-df8c8edd0452" xlink:href="biib-20210630.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_d6894e4c-b8ae-4140-9c9f-df8c8edd0452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_de6cd445-bc1f-4481-b3d7-921ca9873191" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_de6cd445-bc1f-4481-b3d7-921ca9873191" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bf0bf810-cb30-4efe-8f80-4edb0ddfb11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bf0bf810-cb30-4efe-8f80-4edb0ddfb11a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_a9132435-f39f-468c-8471-92d5cb583f56" xlink:href="biib-20210630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_a9132435-f39f-468c-8471-92d5cb583f56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_055505b4-31a6-4369-af1c-ef4b1c98ca78" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_AdditionalMilestonePayment_055505b4-31a6-4369-af1c-ef4b1c98ca78" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_74dda0d4-b57a-4bd8-bf92-1353a6fffc37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_74dda0d4-b57a-4bd8-bf92-1353a6fffc37" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b7295a11-9b23-4a58-b1c7-d1f511b1a5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b7295a11-9b23-4a58-b1c7-d1f511b1a5bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cb92019d-3da2-402f-b20b-4badb0319bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cb92019d-3da2-402f-b20b-4badb0319bc1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1fef3409-dc2c-4f66-8ee6-519dddf19aa6" xlink:href="biib-20210630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1fef3409-dc2c-4f66-8ee6-519dddf19aa6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f88e5619-7adb-40e5-9a53-1657b9ef7755_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f88e5619-7adb-40e5-9a53-1657b9ef7755_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96441f81-d793-46e0-891e-bb8710b0d444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96441f81-d793-46e0-891e-bb8710b0d444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_52e835e4-e75d-43ed-8c82-4c6171f6591f" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96441f81-d793-46e0-891e-bb8710b0d444" xlink:to="loc_biib_EisaiMember_52e835e4-e75d-43ed-8c82-4c6171f6591f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_82d43854-1e13-42d8-ab12-15a204d63077_default" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_82d43854-1e13-42d8-ab12-15a204d63077_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_05de153c-4e4a-42df-b89e-9bb4faeb356b" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_05de153c-4e4a-42df-b89e-9bb4faeb356b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_b40dafce-f935-48fc-b06c-a3e1a42809c3" xlink:href="biib-20210630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_05de153c-4e4a-42df-b89e-9bb4faeb356b" xlink:to="loc_biib_RegulatoryMilestonesMember_b40dafce-f935-48fc-b06c-a3e1a42809c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b7e74ea-218f-4d96-83b7-8c2b89a338e2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:to="loc_srt_SegmentGeographicalDomain_2b7e74ea-218f-4d96-83b7-8c2b89a338e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:to="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_9cc845ee-4ff6-40c6-bd51-f65c00a5039c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:to="loc_country_JP_9cc845ee-4ff6-40c6-bd51-f65c00a5039c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d7993666-6e71-4a24-9fea-44cecf349e95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:to="loc_srt_EuropeMember_d7993666-6e71-4a24-9fea-44cecf349e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3c2c989c-d1c2-435b-aae6-e74fe812f10e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3c2c989c-d1c2-435b-aae6-e74fe812f10e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c01f2661-650d-4545-903f-5d5e34e4a95d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c01f2661-650d-4545-903f-5d5e34e4a95d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_8231bf4f-382f-4ecd-955b-f3d6691befe2" xlink:href="biib-20210630.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c01f2661-650d-4545-903f-5d5e34e4a95d" xlink:to="loc_biib_NeurimmuneMember_8231bf4f-382f-4ecd-955b-f3d6691befe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68104b15-78c2-4596-a69b-7e93c2a1aa7d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:to="loc_srt_ProductsAndServicesDomain_68104b15-78c2-4596-a69b-7e93c2a1aa7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ca0fe7d-6ff3-4c45-9b46-222077d031e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:to="loc_srt_ProductsAndServicesDomain_6ca0fe7d-6ff3-4c45-9b46-222077d031e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_4391d031-2f9b-488d-bc83-90be170a3cfe" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ca0fe7d-6ff3-4c45-9b46-222077d031e7" xlink:to="loc_biib_ADUHELMMember_4391d031-2f9b-488d-bc83-90be170a3cfe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="extended" id="id501b7ab6bac40398ea6ded2e785e420_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e7212354-b5a3-4c9b-a323-f33dd19abbbc" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e7212354-b5a3-4c9b-a323-f33dd19abbbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6b85a4c1-0b34-48c7-ab78-a8af7ba1ed22" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6b85a4c1-0b34-48c7-ab78-a8af7ba1ed22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46aa7084-f986-4e7a-b507-6f3b53001f73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_46aa7084-f986-4e7a-b507-6f3b53001f73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72a7b01f-556c-4634-9682-5c3487003028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72a7b01f-556c-4634-9682-5c3487003028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_b66a73f5-cc3d-45fd-aed9-3855f84c4384" xlink:href="biib-20210630.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72a7b01f-556c-4634-9682-5c3487003028" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_b66a73f5-cc3d-45fd-aed9-3855f84c4384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7f65d68e-4b4f-42d5-9023-e7472bc06164_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7f65d68e-4b4f-42d5-9023-e7472bc06164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5f36836d-8a1f-4647-a58f-d25c4cd5b60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5f36836d-8a1f-4647-a58f-d25c4cd5b60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_98548eed-2290-45f7-a93b-e9276c093ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5f36836d-8a1f-4647-a58f-d25c4cd5b60c" xlink:to="loc_us-gaap_SubsequentEventMember_98548eed-2290-45f7-a93b-e9276c093ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_24582e34-5113-47a4-8aa5-1a9144241776_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:to="loc_srt_ScenarioUnspecifiedDomain_24582e34-5113-47a4-8aa5-1a9144241776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e38e24c5-cd84-4c65-a733-f943dfc47c79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e38e24c5-cd84-4c65-a733-f943dfc47c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9c506b94-622b-4dfd-82a0-8180814b2801" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e38e24c5-cd84-4c65-a733-f943dfc47c79" xlink:to="loc_srt_ScenarioForecastMember_9c506b94-622b-4dfd-82a0-8180814b2801" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:00d4ab53-132a-461c-a04e-3900c9e9172a,g:268dc15b-49f4-4ca1-9cf5-eeb8cc02f2b7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_b2438d9b-3a6e-4e3d-96fb-8c5b15a5af75_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20210630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d9905688-bc6b-4e58-836d-5975f43bbac5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_ccbd5146-050c-41b5-905f-e32c01c09e6e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e3eb5b5d-1a39-4c3b-9277-11d8f569884f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_f8de0241-e72b-4488-90df-7c3e159c843b_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20210630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_6e7b620c-e30f-4209-9a2a-76449410efc8_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20210630.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_c09243b5-6c17-481e-895d-887716f4780e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_43e79a11-7dc5-48f9-9647-fe6edecf090e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_b8015a48-76ae-474c-bfb5-7c4417225c91_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_03179bbc-c5d9-4a51-bc80-ed15d04ed005_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_84d4d014-be66-41bd-9ba8-3e6b39691ba1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_84233486-036a-4fde-8365-93574de3766f_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20210630.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_dd599b5d-ffcb-4af1-b9c0-3190efd9afb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6eb4f69d-8cd7-4de8-8649-36499b702e74_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ff046f1a-0637-4fab-96ca-c64ee0bc506d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_2410e6a6-01ce-41da-8c19-b1be2c0ac59f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_365ef20d-9691-4249-99ae-49863adbbef1_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20210630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_ca6ad0d5-92ba-4164-b5ef-e283d3782517_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:href="biib-20210630.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:to="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_9da997ce-8180-46fe-8441-0f4fc3c967cd_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210630.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b07690aa-517c-460c-8d4f-055e1e31b6d4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9d8c0e14-f9ed-4b1b-8e4b-3a41cd0aab8c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35eea0eb-e842-4b3b-b1c4-6b4340f0a376_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_12c9bf35-0f05-407b-81a7-0f6a90c4ebc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Sangamo Therapeutics, Inc. stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8e662f3c-560f-4d37-b9e4-61b2d27f98cf_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a95e4eb6-b43b-439c-9587-7fe420010fe7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_6e6a6e40-0c96-41c0-90b7-759ea2787ed4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_1c80241b-a047-4acf-a841-dae8b8f3fc3e_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8b543d2f-b9ec-4cf9-ae1a-0b7bcd195f99_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a478610a-da64-40ab-90bc-1990b21377a8_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e41a1a9c-6d42-4836-bdaf-4a85e1d5d8b5_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_b86fa678-137a-441a-813f-476a83ba144c_terseLabel_en-US" xlink:label="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_label_en-US" xlink:label="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_documentation_en-US" xlink:label="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" xlink:href="biib-20210630.xsd#biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" xlink:to="lab_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_545743f1-1430-483e-af31-543d66a8b3f0_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_label_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) Other</link:label>
    <link:label id="lab_biib_NoncontrollingInterestIncreaseDecreaseOther_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:href="biib-20210630.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:to="lab_biib_NoncontrollingInterestIncreaseDecreaseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_219114a7-b4e4-470d-90e0-ec9720200c44_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_1458e081-c536-4d35-9eff-27c7c862aa01_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20210630.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_633f7dba-97bc-41ce-8096-5d02fcf04e05_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ed9b1b76-8306-47f9-854b-f598a6d9fe2c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_ecca0952-8a94-4216-ad08-5daf09dd7820_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_5f931b1b-f3af-4c79-a976-eaa8924794d6_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20210630.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_850a76a4-a8e4-429b-8f87-daffa240058c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_06071add-2024-4ae6-8730-15a302ae7ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1a73ea29-e88e-4a87-8a6c-d73fc1511873_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_6e584e32-986f-4898-82b2-16f2af8717a1_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20210630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_6f6f1d49-0e83-47fa-a709-532187c41272_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:to="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_23af5522-41ca-401b-bf37-f746756d5af4_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_565902ed-29bd-4763-aaaf-d19c1a2f3b47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d3027699-373f-45f1-9244-a17c0ca2cd82_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f2b4d1fd-99ed-4784-9fb8-8301e448d160_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_355237b6-b28c-4172-b40f-fe43ddee568b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8fd7868e-c1e6-48a8-99fd-f78c566b757c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a7bdd228-4416-4d1a-8c3d-3bbc2699a406_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e94de1f9-8202-43da-bff6-86aa3cd3fc3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ffe4249-80ca-4c9c-b5eb-3530f0dc8862_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ea241124-2f3a-48c9-b388-28f17975afe9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_f8a67bf8-1c95-433e-a2f5-8ef3b1332ebc_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_ac646c94-778e-4a64-a39f-a1d5f433ccf2_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain" xlink:to="lab_biib_ResearchanddevelopmentassetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f770e364-14a7-4de4-a552-46e94abb1d6d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_710258c5-ccb5-4307-9b63-a5be8d525079_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_75c436d5-39d4-488e-973b-9f122d5c9ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_cf906e88-ae35-4502-8dae-5755748e295b_terseLabel_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_label_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement [Member]</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_documentation_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:href="biib-20210630.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:to="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ac22cbb5-3d3c-4f87-a66a-944a0e3b73c9_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_3b375d11-cff9-4cfc-805c-f9c3e6d2eb30_terseLabel_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_label_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member" xlink:href="biib-20210630.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111AndBIIB112Member" xlink:to="lab_biib_BIIB111AndBIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_38d0d60a-5b2b-4746-afa3-e3d8750bf3eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f5671481-a876-4804-917c-ed2109a302f2_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_276741de-0255-4d3b-acde-adc6c9921c50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f0fa5bb0-2303-4bf6-9b89-939c7a43dd20_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_9fc4eef6-20af-49f1-a9ae-2aef8a150828_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_49625fc2-02b9-4f20-b3c5-04c572b1db77_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3e23166d-18bd-46a2-a878-0da87e281912_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_438c5efe-a37d-4a70-8cba-ae4f1d385e3f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_4ff9658f-5f28-4f28-8c4d-a751b9decb7c_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20210630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_32f52c82-c1da-4e40-ace9-66dab7ceff5c_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b6d29428-53fb-4e54-8dbd-eec45dabd826_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_a5b7e7c1-baad-458c-bbe0-5e3b705d3997_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20210630.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5e0f7e67-6eae-45f2-bdec-55a3821a0bd2_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_5310f4e2-b989-4d98-a31d-cb41a2a29190_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20210630.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_84f36f0f-a2c9-482b-b8db-6a0c7d12c33b_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20210630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_f7aec4c3-e627-459f-b820-2ff560c6f0e8_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20210630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5a661807-f29e-42d8-a3e5-63294d46af4b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2d7be693-2d1b-4a1d-ba43-03bd842de956_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_54922c03-9141-4a37-aff5-0dbf7c216aa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_358a02d8-f4d2-4f28-8f3d-a2f4a12ca6fa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_588f3bf4-73d3-4f6f-8c02-2418d0475820_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, shares purchased per share (in usd per share)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_106837bf-aae8-42f2-96a2-9c0858fcdd38_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_ae50a415-2f48-419f-bf67-dee32c8153e5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4445e88d-85ef-47a3-b9cb-5637d238792a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_116e216a-0b02-4f2b-bdd2-28b51d711f36_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0c0c9696-ae65-4912-b1eb-d7a7b8ef253e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ded6a2ce-1361-478f-ab74-46129b65c66e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_bc3ad595-50d7-460b-9049-40d66fbe857f_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20210630.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6c5355f0-412d-4fa1-80f1-e1ace6bd92b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_9d0dd2fe-2ec0-4144-b961-e4cf13790708_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20210630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5c8f5bb1-1fdd-4f10-806f-81e14bb425bf_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_5d531d70-a894-47b0-9a3e-a28541510052_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_b561587b-608c-4b4e-9ce7-b2430c0f6ec6_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20210630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_21c3ca7d-b26c-4e6f-844a-985ca440ff51_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9bdc4453-4a3d-46e7-b62e-1806eae3e049_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5840e4df-7db3-4286-ac5f-1c106bb7b32c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_4bf34bff-148d-4eb8-9115-3c9c4cc549bb_terseLabel_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_label_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_documentation_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:href="biib-20210630.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:to="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_b75b72cb-cbc7-406c-a9e5-d1889ab97995_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune tax impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:href="biib-20210630.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:to="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_24d25ef8-9ce9-49ff-8ccd-812f8b9f4993_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_009d91fb-f867-41fc-95e8-f3e28ee5b161_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_46d2f901-6a11-479c-9051-08d25cfc71cd_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20210630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_27885179-ee80-4772-94c6-b9121c60af13_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d581d4f4-190f-43e2-9bef-37a30ebcafc8_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5223f210-4190-40cc-a7a8-4df023a4cbc6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_d377df28-6e01-4b72-81ab-534cd6c9ffd0_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20210630.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_18dbb252-ece0-4d14-801a-441ee58ab2cb_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f762576-016c-402c-b6cc-c44ca1b2323e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_3868ba99-87cf-4cee-822b-527c385a8427_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20210630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_15ab4578-43b4-4005-a603-3b4ddff73499_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_291fec35-b0d0-441d-b6de-90461b9c819d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4b1076c2-52e5-4df7-9717-450aecbeb5c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_52351d56-b696-43d3-a25d-b4d7d628a5f1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_e96cfcb7-5cd4-4730-8b55-22bc57bd285b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_d9e668d4-a8a1-4e80-8595-36100ceb8565_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_6e41e2c1-1899-45ce-9625-12502150b9ea_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20210630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_908c071c-593c-4a70-bd38-011e01c85b61_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_680c2f61-955b-4705-a673-9b0f1508acf8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_60d902f5-e2f9-4423-bdec-fc57de990ed9_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_5fde12c4-1eac-44b6-a21d-e484b20e6333_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20210630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a02818c7-5edf-40ae-b39d-421ca68a2d59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_058bb303-02e8-4d34-9ecf-0945c89fb3e9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1e497105-4ee6-42a3-b9a2-6c7912430cb9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_cfe4029b-84f0-4134-bb83-9ceb311caddb_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_67a783a1-8479-4955-9e2e-95a83dde8523_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20210630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_8c9e2f86-6993-4b2f-a7dc-ba7a69994815_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20210630.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ae837438-d979-43b1-bdc5-cd0904b4109d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c82324d-35e5-431e-a63b-ac391e07aa58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_b73f2eb8-39a8-450a-9811-b13e3fdda6a5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_ecb95ea9-7650-4992-9651-42e3f3c9c6a0_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20210630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_76e77ebd-7a3d-4181-b52e-5ab949242d15_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_e6a737aa-730b-4eef-ad69-62618914a1a7_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20210630.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_f52a5b41-f5c1-4c42-9d1f-51d618afb4af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e9e79e1b-6b67-4f4c-a400-5bead4041cf2_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9eab7ba4-0d04-4e9d-82d9-236b67b821a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6e7514e1-42cc-4683-b54e-0517a1c37c4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ae6b190c-00e0-4821-84bc-11bac3a0a965_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2dd940bb-13d9-44d9-a1d3-ca419b340553_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e6c5540e-6519-4c1c-9667-e9b403f06bbe_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f84aa12e-95e6-41cd-9c95-27b2e7829437_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_8e4d8bd2-d47e-42bb-aa65-cb826970bc13_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_e03839fc-a1c8-45fd-bac5-144b4449a8af_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_3801d7d2-278d-4179-a4b3-a8b2f409bc36_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20210630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_97e4b128-387d-4b83-b6d7-e11c24f6f3c0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_5586bfcb-5c07-4683-8234-2a3a4a12b82f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_9c95cfd7-8904-4619-a4cc-25fabbe323e5_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_b7d7340e-93e2-430e-938f-3b346de59040_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20210630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_a2641342-47d6-4454-8e6d-a12580f5967f_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20210630.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1471d216-eefd-4578-b527-a3dee06c072b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_73580da9-db19-4762-990c-72c9dd72a662_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20210630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_aab335ef-545f-45b1-b7fb-223b79adde8a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9e9ba504-923c-46c2-a50b-68056a4cd217_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InLicensedPatentsMember_0a6d6190-ea99-4212-82d6-1e74ac564f95_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember" xlink:href="biib-20210630.xsd#biib_InLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember" xlink:to="lab_biib_InLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5945194c-d186-4044-bbf7-596676e5a0b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f8614e59-c0f6-4bcb-81c0-6c116b200cad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_4ec78a6a-4cd3-4152-af8b-18ad83286ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1ed745b3-0551-43b3-ac03-13c7ea717702_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c52f2b7-e9ba-4db1-91f9-ee97e3682b44_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_20fbd15c-3dd9-423b-8582-a24213ab47f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_ab130eea-3d1e-4038-8214-b93d25b7485b_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember" xlink:href="biib-20210630.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19ce96f6-de13-491d-8ec8-143764774837_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_118e154f-d533-45c6-a3e7-e2e30242e496_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_9098e84f-74de-4522-9489-9fe5b36f300e_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_5a809860-99c2-4c55-9ef3-32823326ddaf_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_709cd294-87a2-4eb8-a016-ab18d5965961_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a3ccba28-5423-44ff-ab56-1a24f78ffa2f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7bb6f2a4-25f8-4550-82c6-5db7ed5ec8be_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_f4abf209-2331-4964-83c8-7094d08c66ed_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20210630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_0b25f5a5-99f3-4472-bc09-7e896b3ec007_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0774e0de-af55-4025-bc36-59f4436bf4c5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_24c8045e-db87-4896-a288-1d849a668c24_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_6ab7d9ea-8cd4-41fe-986d-c0dcbac09714_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_31c0dbd2-5dc9-43c8-a430-292959d81a2d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_aa435986-1011-4d4c-8500-cee3f404755f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f0c41a4b-9b26-4bec-aa15-c48b98481c24_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_25699ad2-1507-4e1d-893b-1e368dceda19_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0419f5c7-d98d-4e69-9268-aadfb7216395_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ad1a34a9-7cf9-49fb-b6bb-3a6777b4de25_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_c73e035a-f9a3-4888-9f9f-2d4328e33050_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2d7d38e4-efb5-41fc-a880-775117abea5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b0f643ca-7341-4c3f-833e-21504e896ed8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_ac1c5b80-ea23-43da-a1ca-4995e54e2d25_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5249602c-37b0-4aab-aaff-d652db78b7ab_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_addaadcb-dc03-4952-9e4e-34670da41b9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a0e2d9ff-3938-4d43-a19c-63d89ecf432c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e105a543-19ab-4b47-9209-6e4dfb45437f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_74b38801-22d1-492a-8bd8-424ebdc35bc5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_794803d8-1a62-4e28-a75c-b40846d250d0_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_2accb3af-65c8-4c7d-8991-db6a5f7f40f4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_c4aaf86a-374d-4712-9611-b3fb339c2636_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20210630.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_d2db145e-aaec-45f0-af64-44d98907886b_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue_3d492c02-6322-4487-85dc-36eddca8a143_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, increase (decrease) in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Increase (Decrease) In Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Increase (Decrease) In Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:href="biib-20210630.xsd#biib_DeferredTaxAssetIncreaseDecreaseInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:to="lab_biib_DeferredTaxAssetIncreaseDecreaseInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_fe827c3c-0bc2-44a6-9059-1a98e586f1d5_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20210630.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_53661da7-ecb5-49a9-a46e-aa27160adf69_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20210630.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4ac448a5-aca2-417d-a3d3-5b2aa6f6bd9e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a9dbc078-5756-4743-a3a1-5bc2f86ab310_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7313c362-d4ce-4b46-90d3-6cf659ee72ad_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfProductCandidates_7ee29512-a6ea-4c93-b06f-1c8d81f968a0_terseLabel_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_label_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates" xlink:href="biib-20210630.xsd#biib_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfProductCandidates" xlink:to="lab_biib_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ec5e5253-b5ed-4932-bcd5-c5f89ed4d753_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_8d8f5477-e081-404a-80d2-bc872bea9efc_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ecab8029-67ba-47df-bd13-700d3cf19180_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_36b9c829-bbb3-48c7-9e92-380016d5bef5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2272159c-ed4d-4b87-838e-d127afa610b1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_58d3020e-35b5-464c-9401-295662e8094e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_161cfc0f-d991-4818-a1e8-229d39d33c9d_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f2e83ae7-d897-481d-8d5c-7fda13916189_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_551e4073-d28c-4e94-bfc4-daddac94a2d0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_9ba249d9-ba4e-4d09-bcbd-85670ec1b32d_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes" xlink:href="biib-20210630.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes" xlink:to="lab_biib_PercentageParValueOfSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4fad37a5-31e7-47d5-9d6e-933fb75e23d1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c6e83374-ff02-467b-9954-13dd313d70b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_fcfb4c5b-9851-4faa-a701-5ebee2dc1226_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6d2faa40-2e29-4726-aa70-b8f8bdd892ba_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_1b253204-4580-4d14-a61d-ebe72676a7e6_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20210630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_651c2143-4b6f-48d3-a52c-c3302093bdde_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_aa0701d0-bd08-4f8c-999b-c14f0b884e0b_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_767b5b35-17b8-4dd9-bc37-3caf3073b001_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_ae9e38f3-cacc-4a20-aebe-b7c9333e3c37_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_dda5de71-5988-46f7-a9a8-0ce789c9985c_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20210630.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_2642e30b-3916-4b3b-b791-99fb584f2e1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_be8dcde4-a84d-4687-8ede-99ca9481611e_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_49250c5d-4201-4217-8a32-73b84ce7bf68_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20210630.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f600e39d-33a1-45d0-ad24-b0a6aecfada7_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_482b7c12-e8d7-45ed-981b-f5799e15b42c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB118Member_f2fcb29d-b27c-4d61-954c-3cb2b7736a79_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_label_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_documentation_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member" xlink:href="biib-20210630.xsd#biib_BIIB118Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member" xlink:to="lab_biib_BIIB118Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b2c44a80-929d-4067-8b5e-d34f2b2c1e15_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_987930eb-6bce-49b1-9612-b7ffb00a0839_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_34f9575a-755e-461f-a281-f38ca5e588c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_abf4ce92-9584-4845-bcc0-5a82787e009a_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ab5f2e51-b3ab-42ee-b463-a43458bfdb52_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_6b35841f-0475-49a0-a473-6ec3412ab3a2_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_83e8759b-3e48-4b01-aadd-36a44caf1e03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_905ee551-14e9-4330-8106-c3bf57ba79be_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20210630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_26036011-9493-461a-9b1b-7c36e33a6fa8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_e75edb4e-cddb-42e2-899e-68567a1071d2_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b5a64ff3-62d2-4403-9ea8-7204c005557e_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_97a23ceb-9678-41e0-afb4-df6c26f0d271_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20210630.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_0dd22c3b-3c18-4ccb-99ff-825122745d59_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20210630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_dd75dcda-64cb-4e44-811e-f8b675c108e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7089c2fd-1f06-477d-b42b-0a9cd341e92f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_ca49e6b8-cd1a-4669-8079-c58d40d700be_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e9704638-2ced-44f9-abbf-c3155ce65e1c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_19b781fe-848e-4356-99e7-9ef689f19c22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_33d72361-2168-4ecc-bbc8-1df23cca4ee1_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20210630.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_6cf555a8-6186-47b6-b314-1960b522f8d3_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_667f1a00-3632-4875-aa69-7ed10e0c84c4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1d46649c-6f3b-45b7-be6b-29432407f88b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_982b5cf3-ed49-4bd4-8288-e54999885850_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_7b7300ff-fda6-47a5-a111-de58dead95e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a92869d7-03c8-47fb-94a1-b359327d9cff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ce3152df-ced4-4cb6-afc7-81df8b715cb2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_6061b40f-421a-4c7c-9b9b-881bde545a60_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20210630.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_ddabf780-cd46-4e41-8fc3-cd48add18262_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_8b5a7a93-6ac6-42aa-ab00-def1530c8410_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_de96886e-1a08-4152-a694-a60f5d604d18_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a8cc68bf-48eb-468d-a4fb-ea2451925ec4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_8ce1aa5b-7c1f-42a4-a7a6-dfa9ddaa6483_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_e28fde48-4ea5-45ff-901c-fdb4cdcf91a2_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_627a6056-961b-477a-896f-64c107d29821_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_d5ce4bdb-4ef8-4f2a-992e-3b5aaa55afcc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_18a1e176-b1cd-4b28-b359-3a2e153f47c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_1f53aab0-3e4a-4d3f-aed2-4415a6a4bffa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86273a-0f66-409c-b7aa-fa2520df080e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_60b21660-ef5d-4516-bf9c-f7cca70aa74b_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_5aff806e-9862-47ee-bf8d-dc15d646fc81_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_0391b084-2e2b-467b-91c0-1c6e3d3f3a3c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_9df9e9c7-6602-4d82-9d5c-345ac646e547_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_7c0df5cb-1c2c-46c0-8333-8eab3411e74d_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_728084ce-590e-48a6-ace6-be28bea8713c_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_38cb270d-d5d6-465f-b6a2-3df024609ca5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8be14444-3e27-48bd-afee-ece06e12d40b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_712ae864-950b-4e80-a81c-9ce3d20d2434_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20210630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_a6c9d833-1987-4a45-b185-0bfd4d1030b0_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_fc885b34-8822-414f-bda6-6b09fe4e8f5c_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20210630.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_16116f71-93c6-4823-8769-c1b8ddf9a862_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_d9c3be70-5783-4eab-b82a-cdef6b62bdcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from settlement of swap</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_6401d9d9-b33d-4bd4-9f7e-3210451ab35c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9ca55633-d4e1-4993-8275-8e44882fdc28_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f47f391d-dbba-4662-b7d7-3559db8af844_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_3e8e0042-65cd-4e3e-8727-83d952507349_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_87a88fca-620e-4470-baf2-531278a358f1_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0a9984e1-af1c-482b-ad12-085060fac3d8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_199a2e4e-31ee-4dc2-9dd4-0db4712f0050_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_1f4e5241-fcfc-48bc-85aa-7448de3b9181_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_0c4b32a2-3931-4123-bb11-812d0c70e320_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, amount, shares purchased (in shares)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_18a33723-1f19-4873-b5ce-303133d93373_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_282f53eb-87a7-4362-8f84-cdb5aa498596_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20210630.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_a4c7dc73-3377-4652-87ec-ca695d77e1d2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses recognized on the decrease in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b799ef5-d796-4047-a1d3-598d7384e81d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_04d03da8-3ecf-4c80-b86e-d1a8a171183a_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_13f33bb3-67b4-4fda-a2bc-fbf875d17634_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20210630.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65c90d0b-f6e8-4724-afdb-80b5dda73ae9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_50011320-873e-445a-a7fc-9cf724e86c2a_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_198dcddb-6e87-464b-9066-264f49fa011d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_aaa0d7cd-680e-4fe7-a0eb-ecef15ab2196_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20210630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_444a09b2-1e49-4431-aee2-406b7393c298_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e14c3178-0db4-41b4-8ac1-33f0f956ec81_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_49237dd3-885b-4e19-a6da-19d973a557f2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_09951759-b9d7-435d-a3ce-08857c626a2b_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6ba63ba8-f8c5-4fe6-957c-269f6a5d29f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e7336d47-4340-470a-a9b5-4383197f5e81_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a16d9648-c01d-4d88-98ef-4b63691a7029_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_809674b7-cecf-4116-9549-7a4a9aeefb2e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_cf243c7d-d84e-49ad-9846-d5126b14558b_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20210630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_0b48a1da-9139-4583-967d-6cbae3fb2487_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20210630.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b3279846-7bf4-4e1d-893e-2cdbfe133e8e_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_45fe9468-fe08-42e7-9253-b2f39b363dd2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_61a3b2da-d319-4546-a676-d3f2dd8ad76b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_64c3cb2d-8b53-4e91-a3c5-8d057b83692d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_a5322b82-433c-416e-9f98-da29644f871f_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount" xlink:href="biib-20210630.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionAmount" xlink:to="lab_biib_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a16236aa-361b-4084-9fb0-8e147dcecfcf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_6d01a17a-25da-495b-bdec-cbcc95211013_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_34329924-c288-478e-b5f4-28d0df61376a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_88f6293f-dd79-466d-998e-21159b44c213_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_81150f77-ca34-4af3-a6d0-2828a8caf1b8_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_38bb8527-e277-4af7-a5e3-1fe188a96a1b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_d085d149-2d34-453f-9a94-eab12d1be8aa_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_52defcc6-1469-42a4-a5cc-5cb672dc30f0_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_fb6169c7-67dd-4103-abc4-5c456141bd19_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ac4cc9b-fdbe-4d39-9adc-e73c14513099_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3adb2ef1-9f88-4b7e-bbac-5698a83e1c22_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5f511283-2e84-479e-8b86-b982e65604b2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ca2550b6-83c0-4dea-830e-43044567eb71_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ca3d1d9d-da51-4236-8947-7e54d181d4e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9a7b61cc-6854-4e37-8e35-66bd1a51988f_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_265b04f4-f496-4128-bcf7-25e8a76e74a8_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e5506590-39e6-4e62-9cc7-3e21ba44dc75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_552f95c3-c2b1-421e-91ff-83f3551324dc_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20210630.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_9c2a412d-afc2-4e58-ab34-c76d70ad0aaf_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquisitionsAbstract_229d291e-a1c9-4c7a-b703-35465f05d959_terseLabel_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract" xlink:href="biib-20210630.xsd#biib_AcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract" xlink:to="lab_biib_AcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_14738111-4cfd-4521-839d-f6dc9baec227_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20210630.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8e514460-99e0-443f-98ad-3bba92d25f4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5d8975ff-8ca5-4c68-9d6c-c7490571181a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f961eb75-e8cc-4578-9109-cf98aac591f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ae336b66-4d45-4e70-a542-d584b4c74c11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_42508ca1-5fa7-4883-bd5b-a17576b2a038_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8141f1f3-d9e3-45fd-a880-55fc8cf2e967_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, gain on derivative</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_997da41b-13e6-4f6f-ab98-78a63c9953ad_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8878c293-5609-4152-a78a-f37866712630_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_90411e46-fd7a-4c85-9804-eccc8fcc1966_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_7e8eef92-a0d2-45ab-80cb-6e2fe6a4e18e_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20210630.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b6ad2e76-f304-4828-9bf1-76e547f6c9ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0d2b6ac5-b518-4386-b011-3ec497fed5a0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_24a09084-e812-4d48-ba2c-3d0fd19878e5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_60ee57ac-619c-4f60-a55e-42fdf39a3ae2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_a4ce0049-b26f-47ac-80bb-8ce8ffba33c3_periodStartLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_27f7f6d7-e2e8-4c6b-8827-71e995a80a78_periodEndLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Book Value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_c3a3a8f1-a247-4154-b706-faf5feb1cfff_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20210630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6273fa08-03e4-4ae4-a7a3-45df55eb3dda_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_47d0eabf-cbbb-48e8-9d44-69d5aa500d09_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, purchase price per share (in usd per share)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_55f2d703-1979-4370-a72d-45af0bd67105_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5b8933ce-2709-482d-bf25-d9759604345f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_7a4e7a01-b13e-4fcb-a42b-00636679483d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_09cc71b0-3b81-4ad1-a6cb-fc3abd0235de_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b360c293-c2c5-4d32-a16d-a35de2a83a54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_48e7dbb9-343c-404c-a4f1-b6c841cc86a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_65d55599-3df7-4464-b3d8-ba25ab973e48_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7b9126b5-f0a1-4210-ac56-bba4880d6d4f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_6084c79b-ff13-419e-b39b-e97578e3b031_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_768414f7-923a-4f80-8733-c08d3ee85a3c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a3884ea5-bdc4-4788-9e9f-d3d7ded09df2_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ee0e1c05-1412-4ecd-aeb8-c318125b46ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8a93d592-500c-47c8-8a8c-1f3e94b3f48b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_5a1064bd-657a-41d8-b9ed-559f5a820556_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_093904c2-6d7c-442e-adc7-2188f51aa5a8_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_eface533-734d-4728-b441-bd67cf9ddab0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b20743f1-81da-46c0-b54e-ee68df1f46ea_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_00198f11-9b3a-4df3-8105-845394bf8871_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20210630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8785e25c-a9e7-418e-97bb-4b30336dcad8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_98809db1-06c6-4ce5-b9d9-3072dba1908a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_c1754022-379e-4920-9b26-7d89317f37be_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20210630.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_32d1cd33-fb56-4280-888d-e185457a453e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_a862ed20-afe0-4083-b786-f4fe1a6fab2b_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_62d66b35-717b-46d4-ace0-606c06cb9c0b_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution by noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20210630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_3a9c0827-3b50-4abe-ae77-eb34b74a11e7_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_ef6913d7-7cbe-4195-ac0e-db953d2dd09f_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20210630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_83f35bb5-1264-40f2-8149-82653e30b90f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4596976f-f56e-497b-8a98-1460a4294533_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_d4e48186-220e-4ef1-b428-d12e166bd715_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210630.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_0efd0ba6-3e1d-43b9-9b18-03d542dc89e9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_2eb3885e-7312-497f-876b-a354eb0ada35_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_f9c43c5b-9941-4c7e-96d2-c8fbc56c1d1f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_ef286396-4713-4bed-838c-3dd3dfe6de6f_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20210630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_629a0c19-dca3-4992-919e-11c435956742_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01eaaca2-74e7-4bfd-b61b-5f68b1ca0adc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fcd734f0-ec2f-476a-9ef6-e887d836b2bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb9414eb-cb3a-4c29-8713-f087fb8c3d77_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9f06ffd2-5c31-421a-9207-4f69d4371a9c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ef48a658-35d6-415c-98da-ba3470973b18_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ed5ce90d-81fc-42f1-86c3-e7c776431f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_c5b49d13-2451-4c02-a7d3-cb39cd1f1b42_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20210630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e3dfb51-2596-48d4-9f64-0f6895d4e6d4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_cb6dfb9b-49fc-4ccb-a6b6-f4735610702d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_6a8a2ffe-4871-40f4-8b4d-264b5d82f39d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ff575d7c-adc0-4899-ab77-bbc3dd6ba949_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_fe17248a-44ed-4d46-bd4d-d4cff09c71cd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_21ed0290-8390-410f-a6ec-2a17a80df827_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_9055f68f-6473-4e36-808a-adedd5ec1c57_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20210630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_511f5d21-1b1c-4a3d-9674-9c9bea1be8b5_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_3368b4a2-bef5-4a61-aa78-a8dcff8d44a8_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_8a422342-3ff0-4df5-865b-5a9a5f3b641b_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20210630.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_b5078b69-3ff4-4689-a424-2943caff83a7_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_946e1304-75eb-4ff8-84c2-a1a1d5207fb9_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20210630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cdd0661e-226b-45e7-a571-92d4900cf942_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6084f797-8813-40ce-9190-6a58de9d46fc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_9078b9a3-8b36-42f3-940f-225518312b8b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8edff784-6c13-4709-96b8-381d45499a58_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_91a6515a-af59-46b7-a9fc-64d2f237a448_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_9c7cc39c-4dd4-42db-8216-0236fda0bf03_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_75e984f3-e76a-4da7-82b7-af2c440414b1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_983b6e82-bc5f-4de7-aa94-178a8e872619_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cd3b0a31-8daa-4f9f-8c17-6771a4ede08b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_cdd3a4b3-0fd1-407c-a420-b1e34a3c80c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_fc033d36-ef47-4419-9e8e-6b1db0b93864_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_a42fd4b0-84ca-4be4-8ade-b15bc62bf16a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_12868897-d452-44ec-b088-40301e429d33_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_6782bca9-ebd7-4e90-8926-073c46d8ff61_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_09bf70d5-12ea-4ac5-ad18-13169253b958_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_8af249fb-c099-4a1f-a59e-679c0cc6c479_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20210630.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9c6215c9-91a3-4963-9e53-953965b5506b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_91e72afa-e921-44dc-9bd5-49f3f9ae0b31_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3ec53395-5856-42cd-894f-af1156a9ac20_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9372f8d4-9e2e-43c9-98ca-707016912ad0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4a665ca4-f821-4125-a31d-a2d61f6ebf75_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b3d640ae-6569-42c9-84cf-fc36f2029924_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a049a7b5-3500-4bba-a8d1-6f249a541bf5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_bb6a1b5a-5fe0-44a2-aed4-d2082d2144fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2dc111c6-11af-47bf-bb61-fd14a51060e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_859d1e95-3be0-4579-aaa9-5328be355e8d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_643303f6-2f9f-44b3-bf29-519b7b54e158_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2da94714-2ce1-4252-8a07-7626935f8058_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b2fe0ac7-016b-42f9-954e-35c1295d7f26_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_153d3abf-47c2-4310-b752-8dbd1ba5b863_terseLabel_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_label_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_documentation_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount" xlink:href="biib-20210630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongTermDebtExchangedAmount" xlink:to="lab_biib_LongTermDebtExchangedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_031ef2fe-c414-471b-91a1-18f1b7af830d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b66d8e67-ff96-4573-b240-0b9f9993f6a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_326b4807-c917-4589-a9a9-0b2f6784a6f8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NightstarMember_fa69851d-78bf-42f9-8585-e3747e1e5073_terseLabel_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_label_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_documentation_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember" xlink:to="lab_biib_NightstarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_07e8031e-c013-4c3f-8e6a-0c5da10c4ecb_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_90635383-fadc-4036-b08c-f7c9fe8d341b_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_bf83356c-ccb6-4462-b413-f5c016ff4965_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7d53c0a0-46fe-4d52-aa55-852c81b6ea98_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_33ec145a-d8d2-4973-9515-c998ded13e5d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_aba1e2f7-7e5b-4613-b26a-76fb3c05452c_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20210630.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b0828b36-b907-4a8a-9110-3eef9a33aa26_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_02f0cafa-e794-4375-b903-641e9c66ce37_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20210630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_222564d4-02f2-44e6-a972-1cf7245dcb6b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_432826cb-7758-49f0-b974-fd0b3eb0d6d9_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20210630.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6d63b321-e569-41e8-9280-da8223d08210_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_f96db95d-cbfd-444e-8294-44629b89c491_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20210630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fde51f8d-6988-4781-90ca-5b470682b8d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_1b7691f6-31a7-4a09-9baf-df1ca960bfb1_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20210630.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_7c1e2071-c871-40d1-a76d-f20d516ca573_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_b6ccee26-fb04-4a68-9b61-8526c35bf964_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_f3fd09d4-94d9-4940-881f-8550281b1330_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7bf10233-45db-473d-86ef-91900460eac0_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_f065b2ee-60ec-457f-a448-e260bc2e84ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_65b4b30b-2fc9-48b7-ac1f-1f4bd48ade23_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e16082d4-0d53-4c9b-9187-ca67db3e1279_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8e77510f-f004-4d36-a24c-aa982ed2bea1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_52c1d568-843c-4c22-9365-9121cbf7e439_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ce58d37a-f4ad-4570-ae43-adefe07ccc16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e3242fa2-5fca-4960-9d14-6d5a5c744648_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5aa1c819-f816-4adb-aa4f-a0dfc066795e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_b3cdc2df-1bad-4836-94c6-3d0341373ce7_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20210630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40be88d7-11af-4dce-bfbe-148d0303043b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_85d2b090-ba01-4f21-adc1-93ae248d9e40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_93da7116-eee4-4b61-9cc4-15e328eadd24_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_f29bb08b-aa84-4c20-b081-188496cf47b6_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20210630.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_a5bf7f3f-af2f-4432-adeb-4725e223fdc2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_417f13f8-46df-4927-96d4-40191718514e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_8f65fc63-55e6-4b5e-b050-ab2af0d4492f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_43ffc138-68a2-491b-a093-21a18c10d13f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_985fed61-e7df-40de-b341-58458f9838a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_18361657-4a90-4c43-9111-fa058f4ed9c6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_fe6ab571-8684-4064-9c33-bc7b164c9a14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements, nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f6c45622-fe40-4454-8277-b407fee8b97b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bc75150f-3776-45cb-86ac-8b6c1381ef23_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_a5bc711c-3b13-4667-ac47-599c0bf86e3e_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20210630.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_38a648c3-29e2-4631-b515-fbd0526108ce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_fa10984a-b658-4992-8a7f-fd0e4160cbdd_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_92a193a1-f343-4093-bc79-b3adb109ad62_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20210630.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_62368f74-3452-4e00-87c4-ba9440d9898a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ccf2940-d4f1-4888-b5d2-ac5bb264a525_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_15bb784c-d1ca-4ebe-858e-b33f15d10111_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0e1f1e40-db36-4e79-842f-2c6f23503c8c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0e764a9d-ebd5-4891-ac36-44cdefe14028_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VixotrigineMember_9effd039-3359-474d-b134-519c58fde570_terseLabel_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:label id="lab_biib_VixotrigineMember_label_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine [Member]</link:label>
    <link:label id="lab_biib_VixotrigineMember_documentation_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember" xlink:href="biib-20210630.xsd#biib_VixotrigineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VixotrigineMember" xlink:to="lab_biib_VixotrigineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc1df101-537d-48cc-9c56-188bd22f0006_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_acef9cad-8aa4-4aec-b459-1c9f8a7ca918_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_bdf16927-0c21-45ea-83d2-a7ccec9f4445_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:href="biib-20210630.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_de0546dd-89f6-4ce7-a255-5af3e4230235_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased" xlink:href="biib-20210630.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased" xlink:to="lab_biib_Investmentincommonstocksharespurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_407fe46a-1051-4cba-aaca-a7a7781b464c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_cbf2c594-4e1e-403e-b818-8456cd005ebe_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20210630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d08d93e9-2071-453b-b17d-39067e4cbda2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_342414c7-c654-4b03-b456-03631b0c5375_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_676f8d40-c62b-4ad7-8c6a-8a42e4288380_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64951e55-62e9-463b-b541-2310c6b0bef0_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_fb68b840-e2d2-47e9-aae6-641506d2dcc0_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember" xlink:href="biib-20210630.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_99bb1991-20f1-4674-8586-df36800808f3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_48a15928-ba25-4408-833d-4fa9aa39809f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_67324419-8be0-44e1-9583-8db203d1c8a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_8a959dae-6dbd-4925-a4bb-b2b96c5a0a7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_63996ba5-8679-465c-96b9-24261d168c08_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1f9a685f-a525-4917-a0fc-1321e5368f1f_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoCommonStockMember_37f0790f-cdee-41a6-a93e-61f6e5e57dbc_terseLabel_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_label_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_documentation_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoCommonStockMember" xlink:to="lab_biib_SangamoCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ace5043a-4170-41f6-947e-950d24ef7763_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_fdbe52db-d342-4f7f-962d-93968fe372df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1cf1c9cf-6b4b-479f-9043-73a55ef3a83b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_619010ee-22b0-497c-ac50-9a022326fef4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_3ce6c3df-a693-4d6b-9435-f4783b69f578_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_31ccf120-9922-46ee-8836-421f38ba5652_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_f533de2b-e2d6-49e5-b4ec-7270587884da_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_label_en-US" xlink:label="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Consolidated and Nonconsolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:to="lab_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6bb20684-19ab-4077-a42b-8804303fc21c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5879fad6-f224-446c-829e-75de4a7b1fdd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_5d9cd77d-e6cf-4767-a412-d5faef018bf4_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20210630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_dbdd591c-1c60-490b-9de6-307a909811a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7b9cff28-6b5b-47c3-af7b-0ecc9b290690_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_80f30c7d-dd39-4453-875b-d38babac968f_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20210630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_efee645e-4e86-4b70-be6b-5e76094aea30_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_57dffe54-8299-466c-a3b6-417ba699f634_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20210630.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9d0eb6ed-37cc-4897-b6f4-f1adac8ac3b8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_32a27640-50f3-470e-bc0e-05d027e89596_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20210630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ed34585a-106f-4272-a13d-e2eb585d9db0_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_ba516f36-67b5-4ece-b351-63100b34a165_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20210630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_98cc986d-52a3-430f-9331-3f1d632117d7_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3b1cc1f1-6a5a-474f-b022-e0304f135a84_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_51eddfb6-ac68-4f1a-b700-01c874258d68_terseLabel_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_label_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_documentation_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:href="biib-20210630.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:to="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_35192515-3bab-4e9d-9c0c-80151062d9ab_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_094ccfb9-17b2-4cce-af75-fd0a2069d68f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_359b291e-dd74-45c3-8112-24175f20c2ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_43e9a7b3-9f3e-4e63-a402-69236470d247_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2cd52377-2ea1-432f-a955-b0c9d4100568_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e09b2624-1810-4cda-ae81-b2740398e23b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8672908d-918a-4849-813f-c827f07c3e2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_8a44260c-1d7c-4641-ab92-3918ced6bcc2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d4d36bd0-4fba-4dea-ad95-0f9b42b092ac_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_85bf2d19-b564-4b1f-b8ef-ad73ae2533c4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4649f512-318d-4728-be81-855dfcc88b43_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9fe85915-0fa2-42c9-b71f-3d88b2b2b916_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_65de57ca-077c-4638-a066-4254cac651ec_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20210630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_f48467c4-b14a-40ff-8135-769b110dc9fc_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20210630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_18fabc5f-45cf-479c-bd5f-11920b296553_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_052ce9bf-a85d-4df0-a842-cac2e5a6b347_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_2f774fa6-45e7-425d-b2d9-fcf446bd13dd_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_811eb5d2-9dc1-42e1-88fc-8d76dd51d380_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20210630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6d9ec131-818c-42fe-a854-4a587321db3c_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20210630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_85873ae9-59a3-48cc-8ad9-642041dec604_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_63923e95-0ced-4dda-81e2-ca9f8f95151c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4cc40eda-c629-454f-994a-2dca947bb712_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_70c3f703-4c0c-4b08-9ac6-19c7a464bc9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a00324ba-f4a0-40a2-b797-ed917f850f90_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1db6c8e1-4c0c-479b-8bfa-121fdbd9dc57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_6201d7af-5b6c-4d1f-8c79-396bf30fe210_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20210630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_59ca094a-354a-4483-982a-4324d7067cdb_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember" xlink:href="biib-20210630.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember" xlink:to="lab_biib_CashSettledPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_e8ccef3b-0fe1-443d-b515-c466a9bfaab6_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20210630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_096570dd-8ece-4677-9c8e-ebff8e83e3bd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b7d4ce77-d858-4076-a086-e0c00194a503_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59434126-ef77-42cb-a44c-632c163dfd6a_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d7d91a4a-9a3f-4a5e-a5d5-c5dfc620deb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00850a38-facf-4655-ae98-382e2309f8da_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f7d930ea-8757-4104-946a-95d6faafdeb1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a505432e-d4f0-428b-bf83-4c9f68c5e98d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_7b527fc3-01c7-4682-be05-0fb559229c21_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_38702f26-fd98-49e4-8882-1f8a1f218fcd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d5e81891-47a0-407d-bac3-3b6abf1cf1fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6e39bb3f-60ae-448e-9738-83eadc7147c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_a96656e4-81cc-4031-82f0-ba7531c264d8_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_037d23df-bbf6-4d6a-a60b-307e7fc0e2df_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20210630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_2e9a8e5c-f749-44a2-b8df-39f2837f2e25_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_08d8dc3b-ea39-440a-b4d6-a5439cc94db0_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe81bfe1-f8e5-4e32-b899-9e291e494473_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5f196051-67de-4e3d-9ff9-9d298b5319bd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_75ea6c61-1cb2-40f0-9a91-1d0267061689_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_d9e1c6c2-f006-417b-a06e-3e033580c168_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, increase (decrease) in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax Liabilities, Increase (Decrease) In Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax Liabilities, Increase (Decrease) In Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:href="biib-20210630.xsd#biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:to="lab_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_f597c031-3b25-4612-9ad2-4c46ed532360_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember" xlink:href="biib-20210630.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_0ae435e5-3074-40f8-ad34-1320fa56ca3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_566264b3-b94a-43c5-9734-f22e0a352f1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5bb69ec4-0e13-4469-af9c-67cd9d320ef7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_01c160a2-f197-43df-89df-b13043f74f2e_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20210630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f25b34c4-dbc5-45d8-9c35-ddd377534eb3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_74801a65-2f3e-4213-8388-f3d530434943_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_697515ec-f963-4fda-8c91-8420da6a4dc2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_203622ee-75c3-492d-b811-1f184e7459c9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ce05a72f-1784-4cb7-a5e5-63eea96fa07d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_b647e7c7-314c-483f-a266-4b3bcd51ad90_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20210630.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_65d7761e-8772-450f-a3bc-d8766e59a506_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_e83666ca-b513-4394-8cce-6e397ea7577e_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20210630.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_76d85643-df8d-4e85-bfe8-7e05b5d3a617_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_73dc777c-f3bd-4b45-a43e-a0d432d889fc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_50abdb4a-bd87-4a5b-b866-0eef04d28889_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_c6d45096-cf8c-4e0a-9a76-ca71c5ed9378_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_4917d0b3-ec4e-4f81-835b-b3d0ef85f643_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20210630.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_520795b2-a8e0-48ec-92e8-ada757dfcfb2_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8257296a-7afc-4baa-a8f4-3f5ae378ef5e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2db1d09-8677-409f-8529-cbd4e49c19d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_9a882854-aa78-452d-bdc2-15ef3bf8edc4_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0528bd44-f6aa-4e62-938f-d6517d4fa7a1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_414a29e8-44f4-447f-bb84-0cbea800f63c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_00ef41ed-0138-4f94-af0a-bae79763fe04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_017015ae-3d8f-41f8-813c-9be102779dec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_e6b8a7de-da14-4d2b-aa72-51f3a655b3c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_389819b6-4fc0-49df-abf4-041ae0d8af68_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6cfa4e85-3ff8-4d72-9e46-54fa72553167_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_7ec26384-b748-4d77-a509-67135e1dcb4b_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20210630.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_45543e6d-dfb0-4fb5-b53c-dc35533f28e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_89eb25e9-d3c3-4552-af39-63d8e8c40445_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_8a198f51-ac4b-46ab-9357-3eb2966139ef_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20210630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2268132b-f56a-44f4-aed7-9e946de9dd86_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e3ca8309-0fca-4e0d-9f50-777a85c905fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1a9d2fd0-3f33-424c-b087-99a41d4bafbe_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c68377ad-ae62-4274-8203-436845eb58a8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0feefc45-b208-4d02-b979-6f41e4ec76c9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_df355953-4756-4fc3-b2d5-cbdd395a8f35_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_d09ec084-fb7c-450d-9c97-5efbde4f371b_terseLabel_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember" xlink:href="biib-20210630.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_October2020ShareRepurchaseProgramMember" xlink:to="lab_biib_October2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3d8d5cb7-cc57-40cf-b1f6-b981a479e7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_501d3a45-583c-4593-9f4d-4d088517d505_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_13057915-b495-4f3c-8ed5-0e9e9495d56b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ADUHELMMember_5c5c4eea-1e90-4710-aef8-2099248de174_terseLabel_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:label id="lab_biib_ADUHELMMember_label_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM [Member]</link:label>
    <link:label id="lab_biib_ADUHELMMember_documentation_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ADUHELMMember" xlink:to="lab_biib_ADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_71ffeaff-b956-4fd5-8582-b03c135555e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a760d4ce-c9f4-47a9-8928-e8ec20584bc3_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_f7976d0c-0141-4452-acc5-5458a6aa0d92_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20210630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_0925669d-5fcf-48d8-adaf-84c9f61e3879_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20210630.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_3f2be9df-5bd0-4ec7-93a2-23759fad8950_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20210630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_0dc5cf25-8776-4154-a98c-0f8d245f04e4_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20210630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_37342680-e6f7-4297-940e-345d0ebbfa5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DividendYieldPercentage_4da47276-b88a-4ea6-87fd-ffad48f2ae45_terseLabel_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_label_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_documentation_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage" xlink:href="biib-20210630.xsd#biib_DividendYieldPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DividendYieldPercentage" xlink:to="lab_biib_DividendYieldPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_beb89fdd-4ae2-4423-9212-82f34906c9e7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1efa7b08-1cd4-4052-8ac7-45224fe32604_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_68b3d576-d245-4d4a-8126-dd5bd69c447c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_a8e5cc44-f0cf-4f79-9931-113a7b353f6f_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_9c1e626c-3279-49e7-b4ce-8ca4796a4171_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_732d4eb7-b3e7-422f-b378-345fdc242742_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_a2a003e8-356e-48f0-9f36-9f8d13622ba2_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_f7ea7099-785c-46c3-b081-82a0a7b8c233_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_1aad58b7-b9b6-4259-9758-712a4760b07a_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_09210fe1-332a-4a00-bcea-71da91c36a1a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_3af74f21-a695-4fdc-887c-6f7b9b1aa179_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_04d475c1-4c5d-4921-a3a8-6e925d107219_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:href="biib-20210630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_77297bfc-5b55-4098-a283-513033b8247f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d6f1d0fc-9295-429a-baf7-a61dab110279_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5f632eec-56ce-4498-bd1d-60a47039edb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3dad37a6-3ef6-4f8e-84d6-a796e17abc97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_443d5c10-79f1-4cb5-87d2-443f1cf71dec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86f5c8b6-9e78-48b7-902a-66c76e324810_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_412003ae-43fc-4f8f-af29-e6931bdc18ad_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9f18b8d0-fd30-4556-8dc5-755726ca7948_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_f37be79c-55c3-466d-87b0-cebade8d65f7_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e6326090-a30d-40e0-b7b6-487720df926d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_d25a6127-7590-441b-8252-b9bfabe4d7c4_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20210630.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_a68d1c21-1684-4e89-8331-d71c0c1bdac2_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20210630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_1e021fe0-818a-4b90-b6e7-ab8a1e3bd65a_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:href="biib-20210630.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:to="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_f2e0109d-a1f4-40ea-b915-6805ebb836ab_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20210630.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB112Member_1f1ee9c5-fcef-4111-96f4-54f474026fe8_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_label_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member" xlink:href="biib-20210630.xsd#biib_BIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member" xlink:to="lab_biib_BIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_32b04ad3-67c2-47ee-af3b-e87d844ac20c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_8e629368-344f-40d0-9f48-7a08bc6a842a_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20210630.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_2e9f6b4e-3a0e-4497-b35c-d0980b040349_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_c874e9c5-a048-4ca4-afed-ec8beecc5c69_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_dcb458e9-6369-45bc-9fda-edf1b2433cf2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_91d36899-0ff7-491d-b106-3a9a016a8682_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_866f5eb6-c04e-4b22-954f-3c599e387ab9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d10cbd31-d779-44b2-94f8-7aac6ca47f45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2c384241-265e-4ffb-a7c4-d35078486d94_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_96cc88e3-44b1-4c1b-a311-84b94161ff0c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_980e8279-fe58-42a2-8e8d-1fb9a48577b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_493b660a-f3ae-48f5-bd6c-b57f36cab578_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20210630.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_9f8e67bf-c72c-4eba-9e46-b2fa9b510a5f_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_628793fe-fa84-479f-ac54-45fd76cc1266_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d49e76e-7f05-440f-bc4f-6c06e5b4d63d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5eedd1d1-47ae-4fa8-b10c-05752cf29e95_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_2ca4907a-e3a4-4616-bd2d-f5d70a93ae56_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_28e3f0b9-1a0f-4c72-911f-4168ce0b6b67_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3a88d948-b19b-4a11-8e58-d496e933cb8e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_d3d615c9-0e40-401f-9a83-e5e97d843517_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_959292ec-0e0a-41da-9226-3a6ac94f5e1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_965dbdea-b66b-4f38-81fd-a62dc31e6efd_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e674f1f1-e7a4-4efb-b8ff-15cc3839aac0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57f70f4e-fc4f-414e-bb75-d7913febb562_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2a44972c-4b3d-4ada-a78f-7f461701666d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_54289ba8-66b1-484b-a4bc-9ee45654e3a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_5c49fbfa-1046-4acb-9322-903e5b0740d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_5650a951-72c4-4908-9d97-f1a3c1809438_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20210630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_0742f811-3fab-4004-989e-352cdbaee731_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20210630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_439df9ba-a734-4905-92a0-7d8d3c4d843f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1bd25b6c-e26a-4352-adc4-14a55d2e349d_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_013cfaaa-af66-4b69-a6f1-3ef3d26e9e35_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e147722-936c-4142-8698-ef4a32b676e3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03ed54a8-5b6f-4040-8b2b-751f7286d18b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_945ffde6-901a-4434-811c-847a38307184_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_2ade8f3a-1639-4d35-a5af-e3d2818d044c_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_2e84ba2b-cf15-48d6-bd9e-99e67eb00302_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20210630.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_03ebf46f-6677-417e-a442-ad00fbaabe7e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f58d17af-2136-4e7a-b988-70e2cedd8133_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_904cef3c-5d75-4837-9486-11cc68f5cf42_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_6bffbf2b-1878-4fc7-9738-db66110b8043_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_7ba41aea-c20a-43a3-93b1-dca7ea9e91d7_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_b6f3e473-f699-4d60-b3bf-94ea75fbc9f0_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_caecdd25-1bed-4eca-8e68-436b2e85dce7_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_44a350a5-fea8-4768-b3e1-7367e7323da7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_46d83995-02b3-4215-b74c-2e8ab5358599_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_0baea287-aaa3-4bd6-94a4-2c24a3b913d2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e6e336e8-f693-4b85-9372-f2ef238281cf_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e157bcd-df8f-43f0-b7ce-9f7e7996a9f6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db7beb30-4e9c-4144-b104-6f0279eb77d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7b2ccfb-50f6-4363-b897-ac07cc27c417_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_568425b4-d216-4aec-b53f-03fd86b7f2ee_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_21ab2198-8db6-4699-ad38-8e98f8c62250_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ed07a318-1d50-44e8-ab77-2848c2a8d578_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4ee31886-fbc9-489f-bdda-56668bf027d9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_afe7f0d3-47d9-4e1a-9a4b-39af5d831ab9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5e3556d5-b585-4356-9521-04b0c8244266_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e505c6df-c1d7-4651-a45f-4ff3ce775774_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_62c2b933-ac5c-4568-a71b-5e6df63123ec_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_10d0df21-fd9e-4685-bc25-754b6a3da5db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_b4f99154-a59f-4582-883b-7b1b3a49d5aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f4cf4f90-594f-41bd-a131-096605a647a5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ac2e7050-d678-4708-8819-5f1f1888fcb0_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f7b2a787-50e1-4f6a-a188-9c17c83585fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_fbf26d6b-16f6-49a8-89bd-95b757b8c9de_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20210630.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_18be69db-948b-4a24-bd05-09ffd1a5c1e5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7ed049b7-d52f-45ad-8e6d-a0bb633f7b9d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7ff33631-743c-4671-9ab9-71a82a9a829f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e29e707a-4b9c-470a-9f32-3487b7d082e4_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9ab2e1b6-c730-4f33-a0a8-352f1bf84318_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e14efaae-5191-4714-a296-455e74b12507_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d0c7f1b1-4fb4-4523-9e0f-78fd1743976a_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7aa34b0d-e6f9-4f55-be3e-7d1c36a5ed99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e59e0c83-e4e3-4c0e-8204-5090cec2d955_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_848abfa7-18f7-4df2-9cd0-d9c128d910b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_f88a4c24-de6a-414e-9f73-1b8b28325789_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c000d849-385a-4cc6-88fa-4a68e66126a1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_9b105eb0-4581-4d15-b087-fde10472c830_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration agreement, shares, purchased (in shares)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_3ec448f0-7274-499b-aee0-e5cd067014e4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b0d4ed17-81be-4814-8a68-0d24b5f24dc1_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_725734c0-6385-4178-a370-ab9d836709aa_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_93f2530b-2376-4051-9e36-4a544f04bb81_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_dc2769c8-564d-4a10-97fe-2f8b088040e4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_a51aa837-c44a-4b77-b8fe-b1ba238f17ac_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20210630.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f411ab07-ef11-4fdd-8109-7334af94761c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_70e4879f-7623-4664-8e72-8c8d8378afb5_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19cb1f5d-0e90-4ebe-8dd6-c25367faa2c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_49fa59fa-20ff-4d20-8861-60d1ec988759_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_47f4f2b9-3a57-4ee0-a3bc-36a7d528d6ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_003b101d-ef01-44c2-bedd-37db62cacc59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_bcca8660-b813-4fd9-97cb-605ee7ccbdd6_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20210630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_c30bb8d0-3221-4c52-b775-8f42af7e265b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_d266a4ac-22e9-4111-a1b7-2931f2476519_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20210630.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_b149909f-d413-4501-b55a-162625baa3d9_terseLabel_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of early call premium and write off of remaining unamortized debt issuance costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_label_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_documentation_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:href="biib-20210630.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:to="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_655357c3-a1b5-49fa-8074-7f357fd015ff_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cefc2e32-7225-4067-b355-de1b7c37cac3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_03f537f3-d07e-427b-a312-2a915b3653dc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a96782c6-2fd1-436c-a06d-b44e746f0b86_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_10236d40-6bfa-425b-b4b6-bb1e3ddc8762_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_525d2b96-0e6f-4847-982d-84e8fcb93018_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_61fc8f26-6922-4e80-9061-30c80f9e8a14_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_18dca886-589f-426f-a82d-7eb7bab38414_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_024012ab-113b-4ba7-b8f6-b748a4180755_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2844e7a-b8c2-4232-b47e-9b1a24dc4c28_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_393acfdc-5dab-4ee7-af1f-02e36d5a3874_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_682164ad-b485-446f-b3c7-63acaf5601d3_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20210630.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d49502a9-21c9-443c-8bd7-0d9923f5452a_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0e9ca459-665c-4609-a770-28d2c7b065ee_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_92688cd7-49e4-4b29-94c8-d6dbdeae155e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_41d534a2-e767-410e-afa5-c0be3012dce2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a0560d7c-ce97-445e-a1f8-7b5f85599e8b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_ce825b0b-438f-42f8-8aa0-137999e1b1f9_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20210630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_28be5583-c2a9-453f-b16d-91b500f2d4f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73d378fb-9fc4-41de-93bb-9f8bc3b0a7ec_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_edaebe87-ade7-4846-8717-1d8decfe46c7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b408511e-f241-4844-bede-64352dd4f6b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_f075dc96-a7c4-43d0-9487-14df0538d99d_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20210630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:00d4ab53-132a-461c-a04e-3900c9e9172a,g:268dc15b-49f4-4ca1-9cf5-eeb8cc02f2b7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_040c9a96-bfae-4729-b877-81a6033d4520" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_DocumentType_040c9a96-bfae-4729-b877-81a6033d4520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3dc9a529-8f05-4960-8dc4-7f46cc69f82d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_DocumentQuarterlyReport_3dc9a529-8f05-4960-8dc4-7f46cc69f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3698f660-f6c2-45fa-bc92-e4018f900d2a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_DocumentPeriodEndDate_3698f660-f6c2-45fa-bc92-e4018f900d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ad9506d7-b0f2-4b3b-9c0b-96bb1d8c577f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_DocumentTransitionReport_ad9506d7-b0f2-4b3b-9c0b-96bb1d8c577f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_32bb3d3c-159e-4ee8-94e6-ec2b0bd26eeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityFileNumber_32bb3d3c-159e-4ee8-94e6-ec2b0bd26eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_72131af5-ae6c-404a-849f-b035cdff70c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityRegistrantName_72131af5-ae6c-404a-849f-b035cdff70c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e143859c-340e-4e11-85ba-6fdfcc4c723b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityCentralIndexKey_e143859c-340e-4e11-85ba-6fdfcc4c723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_abaf6cf4-d452-48a7-8b2b-9593ef0727dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_CurrentFiscalYearEndDate_abaf6cf4-d452-48a7-8b2b-9593ef0727dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8983c13d-ae53-457b-a588-471ec01c23ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_DocumentFiscalYearFocus_8983c13d-ae53-457b-a588-471ec01c23ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7062877a-2731-48fe-8f38-b8cd22c1bfaf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7062877a-2731-48fe-8f38-b8cd22c1bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e6c2ef5a-4884-44c5-a0bd-234d019c4cbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_AmendmentFlag_e6c2ef5a-4884-44c5-a0bd-234d019c4cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cd4a44f8-f68a-43ed-ac50-6d990b082f34" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cd4a44f8-f68a-43ed-ac50-6d990b082f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_819e7b30-8e75-462e-8877-dd987c049a39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityTaxIdentificationNumber_819e7b30-8e75-462e-8877-dd987c049a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_28c3728b-1cfc-4149-b89a-f690cb89d12e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityAddressAddressLine1_28c3728b-1cfc-4149-b89a-f690cb89d12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bf1fcee6-0f02-4fed-a418-a3780c6be1d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityAddressCityOrTown_bf1fcee6-0f02-4fed-a418-a3780c6be1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e002ea13-fe93-4858-bf1b-aeb50ee2b7f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityAddressStateOrProvince_e002ea13-fe93-4858-bf1b-aeb50ee2b7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_90cc91fe-4b7b-4a2a-a133-8be8a0a794dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityAddressPostalZipCode_90cc91fe-4b7b-4a2a-a133-8be8a0a794dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3f20bc41-617b-4867-ba59-69faada61775" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_CityAreaCode_3f20bc41-617b-4867-ba59-69faada61775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2effa4b0-ef3c-4d0f-a902-7f3c7171f3bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_LocalPhoneNumber_2effa4b0-ef3c-4d0f-a902-7f3c7171f3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e7d2b464-8740-44f8-8736-246883775fcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_Security12bTitle_e7d2b464-8740-44f8-8736-246883775fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_722ee35e-d1ae-4c0d-963e-94c439d35000" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_TradingSymbol_722ee35e-d1ae-4c0d-963e-94c439d35000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3c57b56f-d9c1-40a1-b354-f281821e5891" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_SecurityExchangeName_3c57b56f-d9c1-40a1-b354-f281821e5891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_fc013186-957e-4f7f-9e0d-405a0e674822" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityCurrentReportingStatus_fc013186-957e-4f7f-9e0d-405a0e674822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_493c83bf-2f26-4312-83e2-afda96a21004" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityInteractiveDataCurrent_493c83bf-2f26-4312-83e2-afda96a21004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2ee42d54-1b9f-44f5-ad4f-d4d80cc9ff35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityFilerCategory_2ee42d54-1b9f-44f5-ad4f-d4d80cc9ff35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1a2c7a35-0fc4-4e19-a17d-fdb389f50d5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntitySmallBusiness_1a2c7a35-0fc4-4e19-a17d-fdb389f50d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e849c852-7ee2-45eb-8fd5-a15be9c07e0a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityEmergingGrowthCompany_e849c852-7ee2-45eb-8fd5-a15be9c07e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3f0e4a4d-277c-4a72-8d53-ccd340c999bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityShellCompany_3f0e4a4d-277c-4a72-8d53-ccd340c999bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_69a83df5-2765-41d8-9039-23e71674f37c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_292aabb9-92b7-4e77-a2a4-7261776370b5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_69a83df5-2765-41d8-9039-23e71674f37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_61019678-fe4e-42bc-8ad2-4ee5490107ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61019678-fe4e-42bc-8ad2-4ee5490107ad" xlink:to="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:to="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f6584e55-7281-4b98-9fbc-24fd29fa62fd" xlink:to="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_76bb0887-6ecd-4bbc-86aa-48643ce0711a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:to="loc_us-gaap_ProductMember_76bb0887-6ecd-4bbc-86aa-48643ce0711a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_612f5475-a719-4b4a-9491-0398a4a84436" xlink:href="biib-20210630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_612f5475-a719-4b4a-9491-0398a4a84436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b117443d-5604-484d-80d9-fea68c2bb7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_23624222-ae40-43ac-b89f-8eb93d17de2f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b117443d-5604-484d-80d9-fea68c2bb7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7bdb917-faa4-4bb4-ae49-aa702d59e5ee" xlink:to="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_571e5aac-7e55-4412-b127-71c1059556cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_Revenues_571e5aac-7e55-4412-b127-71c1059556cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a185f2b-cc8e-4241-83a9-ba6244003c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a185f2b-cc8e-4241-83a9-ba6244003c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0ea67a9f-a753-48c2-b6f3-c79a0fecdc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0ea67a9f-a753-48c2-b6f3-c79a0fecdc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0c9213d2-b649-481a-b9a7-4393baee99ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0c9213d2-b649-481a-b9a7-4393baee99ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_87d27cb2-febf-4a86-940c-bb067b10827a" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_87d27cb2-febf-4a86-940c-bb067b10827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_42026487-8413-4528-b12f-74d85db81fe9" xlink:href="biib-20210630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_biib_Collaborationprofitlosssharing_42026487-8413-4528-b12f-74d85db81fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fdf22224-8d8e-4c50-a66d-73a813a93f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fdf22224-8d8e-4c50-a66d-73a813a93f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f8607c45-4f13-4628-b0ce-1b99c3274727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f8607c45-4f13-4628-b0ce-1b99c3274727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_34c5aabb-9e02-4276-8933-4bb1937eee01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37605f8e-5158-4d5c-afd0-595e39228347" xlink:to="loc_us-gaap_CostsAndExpenses_34c5aabb-9e02-4276-8933-4bb1937eee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e1d8abed-46e4-43b4-a703-1dffe2b75937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_OperatingIncomeLoss_e1d8abed-46e4-43b4-a703-1dffe2b75937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_862b312f-5d66-4295-b753-8bbfe4a400ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_862b312f-5d66-4295-b753-8bbfe4a400ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15e04862-4536-4563-b00f-d3519a2d8088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15e04862-4536-4563-b00f-d3519a2d8088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84d6c157-0fa9-47fc-ae14-9c0a20243783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84d6c157-0fa9-47fc-ae14-9c0a20243783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7be3ae25-da56-4e06-9794-eb8505e21a41" xlink:href="biib-20210630.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7be3ae25-da56-4e06-9794-eb8505e21a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_878ac688-9795-441a-a2bf-544c4bef6acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_ProfitLoss_878ac688-9795-441a-a2bf-544c4bef6acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d593145-e57a-439c-81f4-1b809cd03343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d593145-e57a-439c-81f4-1b809cd03343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dcdf06c7-1b00-4c39-bc36-c6f939b67702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_NetIncomeLoss_dcdf06c7-1b00-4c39-bc36-c6f939b67702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bea092df-b114-4c42-9a6c-644fabeef148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:to="loc_us-gaap_EarningsPerShareBasic_bea092df-b114-4c42-9a6c-644fabeef148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_470ef2a2-b9d5-4bbf-a79d-3f37fe7013b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8fb28f97-a958-40ff-b5d5-dd652b79d41e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_470ef2a2-b9d5-4bbf-a79d-3f37fe7013b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c17c92e-7165-4780-a5e9-115370b8e611" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48b61635-2b10-4235-a9f9-65a6aeeadb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48b61635-2b10-4235-a9f9-65a6aeeadb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93168548-c5c1-455e-8907-093c69ebfd21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d38ddbd9-aab0-406f-8e35-cb131d844292" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93168548-c5c1-455e-8907-093c69ebfd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_79738986-1240-47d0-aaae-4ae65b700e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b25c3877-a3da-4fd2-9ea4-9e181205d73b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_79738986-1240-47d0-aaae-4ae65b700e1f" xlink:to="loc_us-gaap_NetIncomeLoss_b25c3877-a3da-4fd2-9ea4-9e181205d73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_79738986-1240-47d0-aaae-4ae65b700e1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a747f076-ec65-460e-b285-53cd75c538ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a747f076-ec65-460e-b285-53cd75c538ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7d65d928-045b-4ca3-a22d-44a91bd886da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7d65d928-045b-4ca3-a22d-44a91bd886da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_be36ddaa-f4d3-4987-b3c2-6e04da9ff383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_be36ddaa-f4d3-4987-b3c2-6e04da9ff383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3c46ead7-e080-4884-8bd9-4a63c38f1116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3c46ead7-e080-4884-8bd9-4a63c38f1116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9210de25-5c22-4b63-b02c-a3ccd509c6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9210de25-5c22-4b63-b02c-a3ccd509c6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c39958cd-2b1e-4e3d-a7b9-ce01a3a68626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c39958cd-2b1e-4e3d-a7b9-ce01a3a68626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bf70912-100a-4aa9-a58a-5f11ffdc231b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bf70912-100a-4aa9-a58a-5f11ffdc231b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_06632ae7-0584-4423-95cc-d80900067a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_06632ae7-0584-4423-95cc-d80900067a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_71bccf35-c6aa-40e0-9159-d025c81a35fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cafd564c-5fca-4a7e-957f-98018c61dba5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_71bccf35-c6aa-40e0-9159-d025c81a35fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_18404b09-69ef-4368-a126-1509ffbfd98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18404b09-69ef-4368-a126-1509ffbfd98b" xlink:to="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5b4a57d-1cb4-42c0-bcb3-731e50538440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5b4a57d-1cb4-42c0-bcb3-731e50538440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_614736fb-cb5d-41f8-acd6-3431de4800e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_614736fb-cb5d-41f8-acd6-3431de4800e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_362d7a1e-b328-4f2e-9509-c7a1f68de642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_362d7a1e-b328-4f2e-9509-c7a1f68de642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_57d43b99-9e95-4feb-bc86-93bc8a134c16" xlink:href="biib-20210630.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_57d43b99-9e95-4feb-bc86-93bc8a134c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b0ad1193-7b7d-46f3-8a91-fde084c0fb63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_us-gaap_InventoryNet_b0ad1193-7b7d-46f3-8a91-fde084c0fb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2697a2bb-614b-4420-96d6-e201bc7970c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_us-gaap_OtherAssetsCurrent_2697a2bb-614b-4420-96d6-e201bc7970c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1b489582-ffbe-48d4-8e2b-bc0cb46ba159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd239f85-4502-4754-804a-e0c2a6fbe6f6" xlink:to="loc_us-gaap_AssetsCurrent_1b489582-ffbe-48d4-8e2b-bc0cb46ba159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a2620228-19de-424e-aa7f-0b8504b322f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a2620228-19de-424e-aa7f-0b8504b322f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d60f24a7-7730-4a27-963e-c0d1331fd90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d60f24a7-7730-4a27-963e-c0d1331fd90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fab21f01-1a71-4dc9-bfd8-31d28f873ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fab21f01-1a71-4dc9-bfd8-31d28f873ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c77ddca-3b84-44c6-a75a-4982cf25826f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c77ddca-3b84-44c6-a75a-4982cf25826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b59497b9-aa29-47b3-9f3c-d4ee383adadd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_Goodwill_b59497b9-aa29-47b3-9f3c-d4ee383adadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_d9418670-2e1e-4638-a9eb-3cb86865c5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_d9418670-2e1e-4638-a9eb-3cb86865c5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d0dfee2e-29f7-4bc2-9b87-a7610d3033af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d0dfee2e-29f7-4bc2-9b87-a7610d3033af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e5695d3-948b-4ba1-a219-a591a183abe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5f50dba7-2cad-4dec-a94d-cb9ea32f5675" xlink:to="loc_us-gaap_Assets_9e5695d3-948b-4ba1-a219-a591a183abe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18404b09-69ef-4368-a126-1509ffbfd98b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eb770eba-cf81-4d59-845b-4681fa6c4ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eb770eba-cf81-4d59-845b-4681fa6c4ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_0a2c9b00-dc18-4941-9e26-34a617ae8209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb770eba-cf81-4d59-845b-4681fa6c4ee5" xlink:to="loc_us-gaap_TaxesPayableCurrent_0a2c9b00-dc18-4941-9e26-34a617ae8209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d62ee47a-de75-43ee-be21-586fa6fd0b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb770eba-cf81-4d59-845b-4681fa6c4ee5" xlink:to="loc_us-gaap_AccountsPayableCurrent_d62ee47a-de75-43ee-be21-586fa6fd0b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5aba1ac0-bc9f-4dbe-b497-2334a8994d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb770eba-cf81-4d59-845b-4681fa6c4ee5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5aba1ac0-bc9f-4dbe-b497-2334a8994d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f6f94b98-4e9e-4bd2-8e92-837eb8fab933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb770eba-cf81-4d59-845b-4681fa6c4ee5" xlink:to="loc_us-gaap_LiabilitiesCurrent_f6f94b98-4e9e-4bd2-8e92-837eb8fab933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a0467f45-218a-4abe-b03b-1e94db5407cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_LongTermDebt_a0467f45-218a-4abe-b03b-1e94db5407cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_893324e3-ac19-4f27-a3c1-096a8a122da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_893324e3-ac19-4f27-a3c1-096a8a122da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_25e8988d-9d98-4c55-9a85-75127199100a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_25e8988d-9d98-4c55-9a85-75127199100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_528cb406-75f9-417f-aac5-722c55775b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_528cb406-75f9-417f-aac5-722c55775b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b0373bc-fde2-4d8f-a60b-48d061076b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_Liabilities_6b0373bc-fde2-4d8f-a60b-48d061076b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2054b9b5-a524-4a51-b7fc-1a391d73e6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2054b9b5-a524-4a51-b7fc-1a391d73e6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_eb258c57-d1e9-4b8e-bf22-9b65529adc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_eb258c57-d1e9-4b8e-bf22-9b65529adc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_eb258c57-d1e9-4b8e-bf22-9b65529adc10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f4b559b0-3c2b-4242-8172-a4ac2003a543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_PreferredStockValue_f4b559b0-3c2b-4242-8172-a4ac2003a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f990f5dd-a5aa-451f-8daa-d75d4d3e54bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_CommonStockValue_f990f5dd-a5aa-451f-8daa-d75d4d3e54bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e1106444-f3e2-4391-8497-faa585849e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e1106444-f3e2-4391-8497-faa585849e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e5cc132-acae-474d-adc3-eb880f76bf6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e5cc132-acae-474d-adc3-eb880f76bf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_244e2155-5466-495a-9a3d-20b8d6d83174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_244e2155-5466-495a-9a3d-20b8d6d83174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a9cef6f5-76d2-4dba-a03b-971fcb59b2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_TreasuryStockValue_a9cef6f5-76d2-4dba-a03b-971fcb59b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d6415a5-ddb0-4b9c-9505-380b30a9233d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_092c26f6-f2d9-461d-a83c-62ef23a2c266" xlink:to="loc_us-gaap_StockholdersEquity_3d6415a5-ddb0-4b9c-9505-380b30a9233d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_78438280-367e-4c75-a8c7-7ce11e625dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_eb258c57-d1e9-4b8e-bf22-9b65529adc10" xlink:to="loc_us-gaap_MinorityInterest_78438280-367e-4c75-a8c7-7ce11e625dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7dbad912-bbb2-4cf8-a97b-4127b83d0ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_eb258c57-d1e9-4b8e-bf22-9b65529adc10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7dbad912-bbb2-4cf8-a97b-4127b83d0ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f8652ab-cbb3-449a-9cad-bef64ed8428f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3762a040-6015-4f9a-9fea-d1f3c9d137d5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f8652ab-cbb3-449a-9cad-bef64ed8428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d4b06d06-149d-4bd9-ab9e-1fa6a41132c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_71a13524-7823-45ea-b8b5-cfd99f6aef1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d4b06d06-149d-4bd9-ab9e-1fa6a41132c9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_71a13524-7823-45ea-b8b5-cfd99f6aef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fa4de187-f26b-4ae7-a551-58b6b58ecc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d4b06d06-149d-4bd9-ab9e-1fa6a41132c9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fa4de187-f26b-4ae7-a551-58b6b58ecc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_634869d5-963a-485c-ab83-57968fbf23f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_634869d5-963a-485c-ab83-57968fbf23f7" xlink:to="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c56c3b6-b1a0-404d-bee0-b41c927936de" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_e8a59f50-fb33-41e0-9005-59d586f99d47" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:to="loc_biib_SangamoCommonStockMember_e8a59f50-fb33-41e0-9005-59d586f99d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_a78a2b5e-7ff9-45ea-9b08-70e7e6f423e8" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_51a27150-74e6-444f-bb79-aabe239b1cb9" xlink:to="loc_biib_DenaliTherapeuticsIncMember_a78a2b5e-7ff9-45ea-9b08-70e7e6f423e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37b5568b-25c7-49a1-b8ad-abfd883af7d9" xlink:to="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2e029dd8-8551-4eba-bde9-607da5832217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:to="loc_us-gaap_ProfitLoss_2e029dd8-8551-4eba-bde9-607da5832217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d2f0069-2f6a-43ba-917a-30b56a4180d6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_adfba7b1-2f65-4cab-80ca-5be4b2fcab21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_adfba7b1-2f65-4cab-80ca-5be4b2fcab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0b0ffd49-c80f-4d7e-8524-df5f5c5ac989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0b0ffd49-c80f-4d7e-8524-df5f5c5ac989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_df269ac8-8e9b-4751-9ed2-bb10fe9487f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_df269ac8-8e9b-4751-9ed2-bb10fe9487f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9d24aebf-cf7e-4984-8dd5-5449e0785c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_ShareBasedCompensation_9d24aebf-cf7e-4984-8dd5-5449e0785c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_90d11df0-d292-4b16-9583-b78d7e1cad7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_90d11df0-d292-4b16-9583-b78d7e1cad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d341ad1a-cd5c-49fd-b3bf-8e75a16ae6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d341ad1a-cd5c-49fd-b3bf-8e75a16ae6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bb5f93f-5c85-4c6c-9984-0dca76e096c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bb5f93f-5c85-4c6c-9984-0dca76e096c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_b3b71140-9264-46c9-9221-8a1b6469ced7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_b3b71140-9264-46c9-9221-8a1b6469ced7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5ebec6-95c1-457e-9963-3f5135d73945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5e5ebec6-95c1-457e-9963-3f5135d73945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_961b2ddf-5369-4299-9b8a-d52a97dfed8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_961b2ddf-5369-4299-9b8a-d52a97dfed8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9baee435-586e-436a-9bb5-9faeee43c5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9baee435-586e-436a-9bb5-9faeee43c5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_87955547-36c1-4e59-bec4-78c2b20ee681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_87955547-36c1-4e59-bec4-78c2b20ee681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_479cf418-2772-4b85-8c3b-c7b868c6db66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_479cf418-2772-4b85-8c3b-c7b868c6db66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ca5347e-b1eb-446c-9bea-55129204472c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3ca5347e-b1eb-446c-9bea-55129204472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46afb6eb-ad94-4a46-9818-aeb70c583337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46afb6eb-ad94-4a46-9818-aeb70c583337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b750c2e5-31f7-4157-be0b-6ea20ed5a100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89435110-cd51-4b79-a194-804be14f76c2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b750c2e5-31f7-4157-be0b-6ea20ed5a100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_830cee84-ad38-4f3a-8a16-b250eaca706c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_216a74d5-b76e-4051-bb2c-3444c5fd7ee6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_830cee84-ad38-4f3a-8a16-b250eaca706c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cca67557-42be-4c82-8f2b-d1ba5dcac03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_cca67557-42be-4c82-8f2b-d1ba5dcac03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13ff1274-7cc8-4148-9305-c9a2779f8e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13ff1274-7cc8-4148-9305-c9a2779f8e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c74df109-bd55-4d12-a6f5-63ec4b5b3af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c74df109-bd55-4d12-a6f5-63ec4b5b3af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cce0a04c-995c-401f-b656-147831e709c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cce0a04c-995c-401f-b656-147831e709c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b379398-e6c8-4892-b780-69a6a21c8365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b379398-e6c8-4892-b780-69a6a21c8365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3ed6ce04-b480-4f95-933c-5555f6b6a0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3ed6ce04-b480-4f95-933c-5555f6b6a0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3044c07c-ac74-4185-9ef3-cb509576bd10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3044c07c-ac74-4185-9ef3-cb509576bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_689ce837-1ecb-46b0-954d-a8143399142a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_689ce837-1ecb-46b0-954d-a8143399142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_27830a58-0baa-4c88-a53d-a26e44ec0406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_27830a58-0baa-4c88-a53d-a26e44ec0406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_111ba34e-fac6-497f-81bc-9a963ea4922c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3785d785-b4eb-4f0e-a55b-7b199bfb6807" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_111ba34e-fac6-497f-81bc-9a963ea4922c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_65dc29c2-def7-4caa-93bb-878f22aebb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_65dc29c2-def7-4caa-93bb-878f22aebb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_83952ef5-c3a2-426b-8fa0-cdbc8ad5849f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_83952ef5-c3a2-426b-8fa0-cdbc8ad5849f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_c487b26f-3c31-4d09-8f2c-cb05049f1961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_RepaymentsOfDebt_c487b26f-3c31-4d09-8f2c-cb05049f1961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ddd88f44-ca9b-4eb1-b902-c5b873ba3843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ddd88f44-ca9b-4eb1-b902-c5b873ba3843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0b32ef3c-f547-445e-a63b-33e4a7821daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0b32ef3c-f547-445e-a63b-33e4a7821daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a55ea023-2001-4bd8-b7b8-b0a1b86fe7e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_a55ea023-2001-4bd8-b7b8-b0a1b86fe7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_1d970afb-4c8c-4939-bfcb-e385df5c7527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_1d970afb-4c8c-4939-bfcb-e385df5c7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_10ec0a5a-c11f-4570-979e-8a90a4332d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_10ec0a5a-c11f-4570-979e-8a90a4332d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16acdd62-5c28-4849-a51f-5f2f76566454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3eb8686a-a557-4e63-b1cd-c349a442cfb5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16acdd62-5c28-4849-a51f-5f2f76566454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_26ccb66c-28a7-41c6-abf0-05c30929d4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_26ccb66c-28a7-41c6-abf0-05c30929d4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_33e2ce10-b58d-4a61-82ce-b03e955c7d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_33e2ce10-b58d-4a61-82ce-b03e955c7d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acf38364-da27-416a-8343-5c46eda5d29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acf38364-da27-416a-8343-5c46eda5d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ec4679a-40f3-460f-8b96-e2643aea30b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3466aeca-ba76-4710-8d8f-e091e62d60b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ec4679a-40f3-460f-8b96-e2643aea30b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20210630.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7477f7da-aac8-45b3-91cf-b3ea7b74bcbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7477f7da-aac8-45b3-91cf-b3ea7b74bcbf" xlink:to="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_964721f2-0985-4ba7-8d23-5674de96a12b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ff82105a-190a-42ca-b69d-4c4cb47b80e0" xlink:href="biib-20210630.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_ff82105a-190a-42ca-b69d-4c4cb47b80e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_2eec3d89-8eec-4479-a103-b7b448c18525" xlink:href="biib-20210630.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_2eec3d89-8eec-4479-a103-b7b448c18525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_65160930-5ba6-4af9-bf96-0c623f4609b0" xlink:href="biib-20210630.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_56015ca6-cf22-4102-9ba9-6521d0e32938" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_65160930-5ba6-4af9-bf96-0c623f4609b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e13f6f7f-145b-43c5-896b-4e2a89353665" xlink:to="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4b080274-c836-446f-9e6d-8472babca9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_PreferredStockMember_4b080274-c836-446f-9e6d-8472babca9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00ff0fba-c355-457e-9ed1-ad5dfe62837c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_CommonStockMember_00ff0fba-c355-457e-9ed1-ad5dfe62837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c4241d04-63a2-4140-957d-9f98f17ac767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c4241d04-63a2-4140-957d-9f98f17ac767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30f8a2a4-e2ef-47b5-81d3-b412c5ecf031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30f8a2a4-e2ef-47b5-81d3-b412c5ecf031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac901487-9d17-4e6f-975c-f1f7fd1bdd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_RetainedEarningsMember_ac901487-9d17-4e6f-975c-f1f7fd1bdd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ada5866e-712c-4601-ab1e-6e12774ca8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_TreasuryStockMember_ada5866e-712c-4601-ab1e-6e12774ca8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_4579cafa-f825-41ab-b554-75e6160246f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_ParentMember_4579cafa-f825-41ab-b554-75e6160246f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9e031c63-bd3b-4228-8860-b49a3a38a9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_515190bd-5f5a-49f7-80f7-bde250b3177d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9e031c63-bd3b-4228-8860-b49a3a38a9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df8e89ca-1e76-4ded-b9a1-ed7f9bf7f599" xlink:to="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6e563f01-fb75-4e34-b7fc-682d45d56d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6e563f01-fb75-4e34-b7fc-682d45d56d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569fdf55-c27b-4a30-9976-c316e8bf3ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569fdf55-c27b-4a30-9976-c316e8bf3ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9b6facc-8cec-4810-b78c-dba2c54c7b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_ProfitLoss_e9b6facc-8cec-4810-b78c-dba2c54c7b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_468dfc68-d103-4993-b142-7583fe0a2988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_468dfc68-d103-4993-b142-7583fe0a2988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_95f8f66a-8c6c-4cd2-b6dc-c8e37f641e35" xlink:href="biib-20210630.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_95f8f66a-8c6c-4cd2-b6dc-c8e37f641e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_eadbc6fc-5e36-4f27-879a-123ac6bf2b65" xlink:href="biib-20210630.xsd#biib_NoncontrollingInterestIncreaseDecreaseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_biib_NoncontrollingInterestIncreaseDecreaseOther_eadbc6fc-5e36-4f27-879a-123ac6bf2b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9b95cce3-79b4-4045-8744-808c4b764873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9b95cce3-79b4-4045-8744-808c4b764873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c34bbf07-847d-4c12-9df1-bd7d5cca8faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c34bbf07-847d-4c12-9df1-bd7d5cca8faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8d5dbc2d-70d0-41d0-84bd-20f782a4a8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8d5dbc2d-70d0-41d0-84bd-20f782a4a8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2290956d-694e-4375-99a4-1e47f0f1166c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_2290956d-694e-4375-99a4-1e47f0f1166c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_82f820c7-f01f-4e15-a2c6-2c3a46e53ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_82f820c7-f01f-4e15-a2c6-2c3a46e53ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_c325df9e-b8fd-4969-978a-870d17244278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_c325df9e-b8fd-4969-978a-870d17244278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4f87d52-103c-4940-abcd-ea5c467b3070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4f87d52-103c-4940-abcd-ea5c467b3070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_38b769d7-71bf-4426-b003-0254fcafb61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_38b769d7-71bf-4426-b003-0254fcafb61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c9d7b5e0-ac1e-4e4d-845a-27157b0238ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c9d7b5e0-ac1e-4e4d-845a-27157b0238ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_a4119712-bea8-4e86-a4b0-eb0949d4fa70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockholdersEquityOther_a4119712-bea8-4e86-a4b0-eb0949d4fa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b390ef0-9f55-4df3-a9f4-0ddd5923e02e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b390ef0-9f55-4df3-a9f4-0ddd5923e02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_34d53ffb-a8e5-4f20-8938-2ffede95c5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df0915ee-3dd6-4a9e-bf62-53074c7cb27e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_34d53ffb-a8e5-4f20-8938-2ffede95c5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20210630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c960b494-ee1b-409a-b26a-a68dd60871fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ac447251-1517-4dbc-b5cc-3009fcd49847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c960b494-ee1b-409a-b26a-a68dd60871fa" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ac447251-1517-4dbc-b5cc-3009fcd49847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20210630.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c99ce146-b06b-4d18-9216-ab4625c2e5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_bea48618-89af-4d7a-a5d1-c64c92eebe9c" xlink:href="biib-20210630.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c99ce146-b06b-4d18-9216-ab4625c2e5f4" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_bea48618-89af-4d7a-a5d1-c64c92eebe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a64e477b-a3f8-4257-831b-b08962414787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c99ce146-b06b-4d18-9216-ab4625c2e5f4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a64e477b-a3f8-4257-831b-b08962414787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f3e3718c-fb7c-4664-af74-619869e7db21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c99ce146-b06b-4d18-9216-ab4625c2e5f4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f3e3718c-fb7c-4664-af74-619869e7db21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8fc24522-0c98-46e9-8282-e60c203ecff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c99ce146-b06b-4d18-9216-ab4625c2e5f4" xlink:to="loc_us-gaap_UseOfEstimates_8fc24522-0c98-46e9-8282-e60c203ecff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a74d3820-5b48-4e49-bfb1-8bed324b0797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c99ce146-b06b-4d18-9216-ab4625c2e5f4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a74d3820-5b48-4e49-bfb1-8bed324b0797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b423d79e-bb4c-441a-ab74-41adeabe0cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_166ed815-8926-434b-95a0-68ed8f09066e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b423d79e-bb4c-441a-ab74-41adeabe0cd6" xlink:to="loc_us-gaap_NumberOfReportableSegments_166ed815-8926-434b-95a0-68ed8f09066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_cab8848b-d03e-47f6-b543-2d3521e35b03" xlink:href="biib-20210630.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b423d79e-bb4c-441a-ab74-41adeabe0cd6" xlink:to="loc_biib_InterestInSubsidiary_cab8848b-d03e-47f6-b543-2d3521e35b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20210630.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_eb634555-d2c4-4df6-a334-fc2b3facdaf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5bb02c5c-7233-443a-bf78-01e3f5abe9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_eb634555-d2c4-4df6-a334-fc2b3facdaf3" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5bb02c5c-7233-443a-bf78-01e3f5abe9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract_fd8d7807-13a5-4219-b962-efe22f784b2f" xlink:href="biib-20210630.xsd#biib_AcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_fd8d7807-13a5-4219-b962-efe22f784b2f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a3f56db-636a-41f1-92d9-f1df2b410c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8ff6eedf-ad17-4ef6-8f2c-e40647912fc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a3f56db-636a-41f1-92d9-f1df2b410c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_43b7c5dc-4656-45a5-92e6-76ae51705acd" xlink:href="biib-20210630.xsd#biib_BIIB118Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6a3f56db-636a-41f1-92d9-f1df2b410c20" xlink:to="loc_biib_BIIB118Member_43b7c5dc-4656-45a5-92e6-76ae51705acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3a2c549-cf5d-42c3-be18-640025f32b04" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9ab9f292-a082-4d33-89f4-acc733fda524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9ab9f292-a082-4d33-89f4-acc733fda524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_9ed114e2-3cd9-4faa-adce-5c906a037cf0" xlink:href="biib-20210630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ecf4b3e5-1ae1-43cb-bd11-f2cf31e2dc08" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_9ed114e2-3cd9-4faa-adce-5c906a037cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20210630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0b07e098-361d-49d9-b211-2651db64d0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4b076ef7-9eb5-4b3d-b963-24e29d6718f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0b07e098-361d-49d9-b211-2651db64d0da" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4b076ef7-9eb5-4b3d-b963-24e29d6718f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49d391af-92a9-4c99-89a1-b740844cdf5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6b496940-3151-4136-a0b6-eceff8d828f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49d391af-92a9-4c99-89a1-b740844cdf5f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6b496940-3151-4136-a0b6-eceff8d828f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_bb40a300-5e04-4457-8443-8e896a9d3716" xlink:href="biib-20210630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49d391af-92a9-4c99-89a1-b740844cdf5f" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_bb40a300-5e04-4457-8443-8e896a9d3716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ad59613b-af1e-4af2-8f34-21ee46137e0a" xlink:href="biib-20210630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49d391af-92a9-4c99-89a1-b740844cdf5f" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ad59613b-af1e-4af2-8f34-21ee46137e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_d7aaeb84-f402-4aa6-a21f-90f9396fd9bb" xlink:href="biib-20210630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49d391af-92a9-4c99-89a1-b740844cdf5f" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_d7aaeb84-f402-4aa6-a21f-90f9396fd9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_eea0325f-aff0-482f-9572-dd4ed4d35dd5" xlink:href="biib-20210630.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49d391af-92a9-4c99-89a1-b740844cdf5f" xlink:to="loc_biib_OtherrevenuesTableTextBlock_eea0325f-aff0-482f-9572-dd4ed4d35dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_3c431b51-4266-44b0-a625-0df8ee1e9bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_3c431b51-4266-44b0-a625-0df8ee1e9bf3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:to="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6d815e46-ee9a-427e-9614-6aedf7195590" xlink:to="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_82e88bff-9cef-41dd-9c1a-8a00a8a12636" xlink:href="biib-20210630.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FumarateMember_82e88bff-9cef-41dd-9c1a-8a00a8a12636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_0a9b76a5-89e3-4982-8334-e8d3753a13e0" xlink:href="biib-20210630.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_InterferonMember_0a9b76a5-89e3-4982-8334-e8d3753a13e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_189c9992-83ea-4b38-8611-2a576ba5eccf" xlink:href="biib-20210630.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_TysabriProductMember_189c9992-83ea-4b38-8611-2a576ba5eccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_51213d24-39cf-4765-ae98-37724596e5ac" xlink:href="biib-20210630.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FAMPYRAMember_51213d24-39cf-4765-ae98-37724596e5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_26ac9d05-7df6-4d50-aba0-39c21b8e371c" xlink:href="biib-20210630.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_ZINBRYTAMember_26ac9d05-7df6-4d50-aba0-39c21b8e371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_08259fff-fbc7-4a55-9c4e-66bb98b37c27" xlink:href="biib-20210630.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_MSProductRevenuesMember_08259fff-fbc7-4a55-9c4e-66bb98b37c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_58260de6-8ac6-4f71-9a15-4937543961f7" xlink:href="biib-20210630.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_SPINRAZAMember_58260de6-8ac6-4f71-9a15-4937543961f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_98cb4db1-5127-4741-962a-3df360aab07c" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_ADUHELMMember_98cb4db1-5127-4741-962a-3df360aab07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_6f94b66c-7f6d-4153-bbae-259f45c5727c" xlink:href="biib-20210630.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_BENEPALIMember_6f94b66c-7f6d-4153-bbae-259f45c5727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_46e66148-20bf-4fc0-b715-9243372c9bd6" xlink:href="biib-20210630.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_IMRALDIMember_46e66148-20bf-4fc0-b715-9243372c9bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_56fdae4c-f6d7-4407-825d-dffd65ca14fc" xlink:href="biib-20210630.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FLIXABIMember_56fdae4c-f6d7-4407-825d-dffd65ca14fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_218a4f32-5f21-4846-a9c0-54aa6f6f0716" xlink:href="biib-20210630.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_BiosimilarsMember_218a4f32-5f21-4846-a9c0-54aa6f6f0716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_1b7ed7d5-baab-4857-9543-32b1bee36e35" xlink:href="biib-20210630.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_biib_FUMADERMMember_1b7ed7d5-baab-4857-9543-32b1bee36e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_149f97df-5192-441d-a668-049ffcb24b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af45c1b4-7804-4351-8a27-bdc2a6b0a9f0" xlink:to="loc_us-gaap_ProductMember_149f97df-5192-441d-a668-049ffcb24b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:to="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6834615e-68fd-4062-baeb-cbdfb80adba2" xlink:to="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_42d5466c-1150-4a17-9a8a-6eae895a7451" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:to="loc_country_US_42d5466c-1150-4a17-9a8a-6eae895a7451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_25c401c5-6ca6-44f4-b608-3b1de55a02ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5cf6c7fb-bb99-4169-827d-c434f453d568" xlink:to="loc_us-gaap_NonUsMember_25c401c5-6ca6-44f4-b608-3b1de55a02ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_268a392a-8161-4d94-8925-90a50be568e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_467af921-5fc2-4aba-937d-567eb12be355" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_268a392a-8161-4d94-8925-90a50be568e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1dc36ee2-acd2-460c-a055-6b69f58eb25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_268a392a-8161-4d94-8925-90a50be568e1" xlink:to="loc_us-gaap_Revenues_1dc36ee2-acd2-460c-a055-6b69f58eb25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_cf040397-c9ef-4845-ad1f-166016d65fb4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_cf040397-c9ef-4845-ad1f-166016d65fb4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3d0bbbf9-45cc-41db-bd31-1a620305ce61" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_b58b0dc3-86fb-4b63-9678-a61a9262d92b" xlink:href="biib-20210630.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:to="loc_biib_ReserveforCashDiscountsMember_b58b0dc3-86fb-4b63-9678-a61a9262d92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_a863602f-6489-4d12-8d7b-e63d32c63a73" xlink:href="biib-20210630.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:to="loc_biib_ContractualAdjustmentsMember_a863602f-6489-4d12-8d7b-e63d32c63a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_afa2a8ff-11e0-43d4-b0c0-08274ccb1230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_af217472-2522-4a57-bcac-2eb14bda8687" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_afa2a8ff-11e0-43d4-b0c0-08274ccb1230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d1f9d376-c270-4e2a-8d16-17172ccc9280" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2f27317b-216e-454c-b032-31a20587c65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2f27317b-216e-454c-b032-31a20587c65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2c0f7b8c-ec2d-4a4a-8eed-0d2a499d3f6b" xlink:href="biib-20210630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_2c0f7b8c-ec2d-4a4a-8eed-0d2a499d3f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_ef67f58a-41bc-486f-b938-41ce4afecba9" xlink:href="biib-20210630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_ef67f58a-41bc-486f-b938-41ce4afecba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_20cd74e3-3b85-4312-9999-bc5c543197df" xlink:href="biib-20210630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_20cd74e3-3b85-4312-9999-bc5c543197df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_89b05b49-f29e-4fc9-a3a2-c1a2905ace51" xlink:href="biib-20210630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_89b05b49-f29e-4fc9-a3a2-c1a2905ace51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3c6b6527-77ff-429f-8e2b-9cab54a2597f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a509fa70-2e31-4099-acd9-78dbb5778608" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_3c6b6527-77ff-429f-8e2b-9cab54a2597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20210630.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_d724d671-3a41-49b8-80ee-6e8de9d9496f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_d724d671-3a41-49b8-80ee-6e8de9d9496f" xlink:to="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dd89b67d-c1c4-4889-be5f-a3e78d1f4ca4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_58310d11-fbee-4cdb-aef1-3faacd4cd73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:to="loc_us-gaap_AccountsReceivableMember_58310d11-fbee-4cdb-aef1-3faacd4cd73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_caada933-fb9b-4a89-ae49-5328af68bf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3d7f7591-b271-4e80-b08f-b8112982167f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_caada933-fb9b-4a89-ae49-5328af68bf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7a70de48-77c4-43b5-89cb-8ad73c381d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b63c27c4-7308-48de-b138-416bc18b318b" xlink:to="loc_us-gaap_StatementLineItems_7a70de48-77c4-43b5-89cb-8ad73c381d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_411202ee-e2d0-4019-b4f9-1b0e83af285b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7a70de48-77c4-43b5-89cb-8ad73c381d1b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_411202ee-e2d0-4019-b4f9-1b0e83af285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3644bf8c-4b41-470f-ab7b-2f0d29ee5a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3644bf8c-4b41-470f-ab7b-2f0d29ee5a46" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:to="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ce635a8-fd61-4e8a-904f-72afb81968f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cf8860bd-b114-47a8-a022-92ac9adb4b05" xlink:to="loc_srt_ProductsAndServicesDomain_6ce635a8-fd61-4e8a-904f-72afb81968f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba7f63c7-f150-41de-a763-138ca67eec01" xlink:href="biib-20210630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ce635a8-fd61-4e8a-904f-72afb81968f7" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ba7f63c7-f150-41de-a763-138ca67eec01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:to="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_32ae54eb-9a72-4544-8103-8b164d629bab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ef8dc235-6ac6-416c-9064-bf47f5328113" xlink:to="loc_srt_NameOfMajorCustomerDomain_32ae54eb-9a72-4544-8103-8b164d629bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_30f2b1b0-f9c7-452a-a17c-d556396826e0" xlink:href="biib-20210630.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_32ae54eb-9a72-4544-8103-8b164d629bab" xlink:to="loc_biib_RocheGroupGenentechMember_30f2b1b0-f9c7-452a-a17c-d556396826e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afcc6974-85dc-4af7-bada-4c3479bc1b5e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_e135d7fb-7565-47ac-90e2-bab21fc6fff0" xlink:href="biib-20210630.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_biib_ShareOfCoPromotionProfits_e135d7fb-7565-47ac-90e2-bab21fc6fff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_e56545a4-dbfa-480d-90f6-17c3aaa960c3" xlink:href="biib-20210630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_e56545a4-dbfa-480d-90f6-17c3aaa960c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f1b344f8-24f4-4e59-9883-20c393e8b843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e41d3076-8f5c-4ace-99f2-03915c87a1d5" xlink:to="loc_us-gaap_Revenues_f1b344f8-24f4-4e59-9883-20c393e8b843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_40deaad5-fc7c-4f4d-858d-356af70ab2ee" xlink:href="biib-20210630.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_40deaad5-fc7c-4f4d-858d-356af70ab2ee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953285f9-941f-4487-be45-4beab52cea20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73a2b698-b87f-40af-b8fa-72aad5499d8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953285f9-941f-4487-be45-4beab52cea20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5fdf67a3-f4ad-4cb9-a54d-c9de64d3a690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_953285f9-941f-4487-be45-4beab52cea20" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5fdf67a3-f4ad-4cb9-a54d-c9de64d3a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a643595a-60c5-40f3-9d22-06a316e4817c" xlink:to="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_647f2b5e-44e5-4bf9-9070-a93ffaf0a7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:to="loc_us-gaap_RoyaltyMember_647f2b5e-44e5-4bf9-9070-a93ffaf0a7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_cf03bc8a-0fc5-4653-a8c7-d7e51395c854" xlink:href="biib-20210630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:to="loc_biib_OthercorporaterevenuesMember_cf03bc8a-0fc5-4653-a8c7-d7e51395c854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9335d478-88a2-4fc7-9f50-2de9c90f8431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7aa1f8ef-22ab-4f71-80a5-f52c14308e3a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9335d478-88a2-4fc7-9f50-2de9c90f8431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_009388c4-0638-498c-ab63-18f0246185bb" xlink:to="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a9e186de-f44a-42a4-b110-92c31bea6798" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a9e186de-f44a-42a4-b110-92c31bea6798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_e7066036-9f8c-42c7-97f2-fb0df60641e6" xlink:href="biib-20210630.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9ec125fe-bb03-4c2c-a341-22e82ded1bca" xlink:to="loc_biib_ZINBRYTAMember_e7066036-9f8c-42c7-97f2-fb0df60641e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_83b1535c-20b9-4e2d-8cee-0245f3f78ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bdcf5332-78a9-493d-a5b8-c10252603f5a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_83b1535c-20b9-4e2d-8cee-0245f3f78ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aeef6ad1-0042-4632-a384-596e16c58740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_83b1535c-20b9-4e2d-8cee-0245f3f78ad8" xlink:to="loc_us-gaap_Revenues_aeef6ad1-0042-4632-a384-596e16c58740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#RevenuesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_54893033-9d8d-4594-8704-445d0a096900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_54893033-9d8d-4594-8704-445d0a096900" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:to="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f6b5dc3f-bacb-4213-8ceb-e33a3b98508d" xlink:to="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_037106b2-7191-45a7-a0e6-2df43311561c" xlink:href="biib-20210630.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:to="loc_biib_OthercorporaterevenuesMember_037106b2-7191-45a7-a0e6-2df43311561c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b85c0d65-2523-425b-9a32-a84145530427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e83f81c9-b8ad-4f1b-ba92-d16f09225cf7" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b85c0d65-2523-425b-9a32-a84145530427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:to="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_08f2b50d-6161-44b8-b253-c05510be1278" xlink:to="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_6449cb31-da85-480b-80a3-e083acd71914" xlink:href="biib-20210630.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:to="loc_biib_DistributorOneMember_6449cb31-da85-480b-80a3-e083acd71914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_11735179-7465-4c68-bb01-338b0a0abda7" xlink:href="biib-20210630.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aab3423a-8462-4daf-a5e0-9793b691e2be" xlink:to="loc_biib_DistributorTwoMember_11735179-7465-4c68-bb01-338b0a0abda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58fa1ce7-4299-475b-9b0a-1e22a7154c42" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e3f042b6-b371-43fa-8f5f-6f93154efc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_us-gaap_Revenues_e3f042b6-b371-43fa-8f5f-6f93154efc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_1df73b3e-0943-4e0e-82b5-cbf3f54d8a4d" xlink:href="biib-20210630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_1df73b3e-0943-4e0e-82b5-cbf3f54d8a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_4d33f6ec-a392-41a3-a0c2-54f3d0035918" xlink:href="biib-20210630.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ea94bc3e-f20e-44bd-9ff8-5be8c30aa025" xlink:to="loc_biib_NumberOfWholesalers_4d33f6ec-a392-41a3-a0c2-54f3d0035918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20210630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_cf3d799d-b9ba-4ddd-be5a-742402d53b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_8f34362a-f9ec-4b85-a11f-72c94d12f460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_cf3d799d-b9ba-4ddd-be5a-742402d53b40" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_8f34362a-f9ec-4b85-a11f-72c94d12f460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20210630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_22c1d8eb-daf6-43fc-8d15-6837e2045b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d05a719f-b468-4ea2-af1a-36d466a2307b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_22c1d8eb-daf6-43fc-8d15-6837e2045b87" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d05a719f-b468-4ea2-af1a-36d466a2307b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2c2c2a4f-8b7c-41c6-ba24-ae66b3050b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_913780e2-acb6-400d-9ea5-45926b9e6c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2c2c2a4f-8b7c-41c6-ba24-ae66b3050b37" xlink:to="loc_us-gaap_InventoryNetAbstract_913780e2-acb6-400d-9ea5-45926b9e6c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_25ddc5a4-40d2-4f27-bc49-d8aa3e25607c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_913780e2-acb6-400d-9ea5-45926b9e6c2e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_25ddc5a4-40d2-4f27-bc49-d8aa3e25607c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d8b7ed82-0442-428e-85f0-33d06f5cd2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_913780e2-acb6-400d-9ea5-45926b9e6c2e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d8b7ed82-0442-428e-85f0-33d06f5cd2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_99e4c16a-3a5b-49e3-b6d7-48b1d785a9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_913780e2-acb6-400d-9ea5-45926b9e6c2e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_99e4c16a-3a5b-49e3-b6d7-48b1d785a9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_fd1f92c5-7a92-459b-af7f-70c2eb862a84" xlink:href="biib-20210630.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_913780e2-acb6-400d-9ea5-45926b9e6c2e" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_fd1f92c5-7a92-459b-af7f-70c2eb862a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20210630.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82b673ee-43fe-45f0-b1a4-640e7a5380bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d90964ba-71e3-4242-8b1f-03c80b2f71ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82b673ee-43fe-45f0-b1a4-640e7a5380bc" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d90964ba-71e3-4242-8b1f-03c80b2f71ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20210630.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d029a6a8-847d-4600-a466-86ec7d4defda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_bd88e8cb-a7c8-4ab3-a78d-8ef167420219" xlink:href="biib-20210630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d029a6a8-847d-4600-a466-86ec7d4defda" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_bd88e8cb-a7c8-4ab3-a78d-8ef167420219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_cfd60f8c-797e-443f-ba70-7ae093fee03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d029a6a8-847d-4600-a466-86ec7d4defda" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_cfd60f8c-797e-443f-ba70-7ae093fee03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_86cf4df4-61a5-4f96-b8c2-6a6596c96e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d029a6a8-847d-4600-a466-86ec7d4defda" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_86cf4df4-61a5-4f96-b8c2-6a6596c96e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe6a1328-2fd2-48a2-b5a8-2c5d4f3daaac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe6a1328-2fd2-48a2-b5a8-2c5d4f3daaac" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_be8b7424-944f-4a1c-856b-a9f4449ac345" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_e3b08fc2-7409-4d3e-a53e-4a11da9bdc47" xlink:href="biib-20210630.xsd#biib_VixotrigineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_VixotrigineMember_e3b08fc2-7409-4d3e-a53e-4a11da9bdc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_469d4f2a-d73e-4f4b-bca7-adc45376d676" xlink:href="biib-20210630.xsd#biib_TGNMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_TGNMember_469d4f2a-d73e-4f4b-bca7-adc45376d676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_b362f7c9-4046-4c31-a657-75f189ff35c0" xlink:href="biib-20210630.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_BIIB111Member_b362f7c9-4046-4c31-a657-75f189ff35c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_ba0f2b31-0737-475c-a78a-61c7d9205edb" xlink:href="biib-20210630.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_BIIB112Member_ba0f2b31-0737-475c-a78a-61c7d9205edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_5885e59e-efae-4f6c-bd6b-9877d90db84a" xlink:href="biib-20210630.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6e3a47b1-a4b8-4af8-bb5d-6f257fd523b8" xlink:to="loc_biib_BIIB111AndBIIB112Member_5885e59e-efae-4f6c-bd6b-9877d90db84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_853bf947-ca75-45df-b898-8d47d9d0e038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fe36e80d-df25-4fd1-a684-25d9f72ee87a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_853bf947-ca75-45df-b898-8d47d9d0e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_5feeeb2e-576b-4132-b6dd-66ef10218161" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_853bf947-ca75-45df-b898-8d47d9d0e038" xlink:to="loc_biib_NightstarMember_5feeeb2e-576b-4132-b6dd-66ef10218161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0fa1a14-ed0b-4c72-b1ce-7b4ceb5ad138" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfe376dd-c5be-4722-9a9d-8ecd65f73c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfe376dd-c5be-4722-9a9d-8ecd65f73c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_d959d5c4-129d-48a0-8457-ef413db6b7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f38c969-3bfb-473b-bfa3-a0901725a5f8" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_d959d5c4-129d-48a0-8457-ef413db6b7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7c6cbd02-4698-4c73-9ba3-2e7cbf750055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb810875-1da1-41fa-ad6e-d485ed368a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb810875-1da1-41fa-ad6e-d485ed368a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_b7920fe8-ac32-4142-8733-e93a36b7e944" xlink:href="biib-20210630.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_biib_OutLicensedPatentsMember_b7920fe8-ac32-4142-8733-e93a36b7e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a21f077d-e8b3-4aae-9da0-2d4189c046b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a21f077d-e8b3-4aae-9da0-2d4189c046b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember_486b582a-30da-40e9-a862-886245ea29b8" xlink:href="biib-20210630.xsd#biib_InLicensedPatentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_877904a4-a7d2-4a2c-8a0a-dd688be006f0" xlink:to="loc_biib_InLicensedPatentsMember_486b582a-30da-40e9-a862-886245ea29b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ae827028-a2f2-4f62-80e0-dce5f5c2bbd0" xlink:to="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_3f79adc9-12c5-4657-9cdf-90b7a09f64cd" xlink:href="biib-20210630.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:to="loc_biib_TysabriProductMember_3f79adc9-12c5-4657-9cdf-90b7a09f64cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_baa1e59d-f1e0-4b36-91f7-ccc3a7528b86" xlink:href="biib-20210630.xsd#biib_FumarateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0c94089-0526-42ed-81a0-4bee4d565dc9" xlink:to="loc_biib_FumarateMember_baa1e59d-f1e0-4b36-91f7-ccc3a7528b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8d3b213-2651-4ef9-93b1-3a3e1d0f3c67" xlink:to="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c8137fa-d54a-4d4e-83d9-c30372f8f121" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:to="loc_srt_MinimumMember_2c8137fa-d54a-4d4e-83d9-c30372f8f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cf3aad8c-fbde-44c3-baff-95c52327f668" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_47de907f-27f5-43f5-85fb-97ec3b136cdb" xlink:to="loc_srt_MaximumMember_cf3aad8c-fbde-44c3-baff-95c52327f668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_39124a80-2f7e-4278-9f44-7a47f3d6b744" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7f430ec6-9dfe-4e02-9ea0-59430c61b639" xlink:to="loc_srt_ScenarioUnspecifiedDomain_39124a80-2f7e-4278-9f44-7a47f3d6b744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bf8c6a5a-8bf9-4fcc-89d6-abfb3882e69a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_39124a80-2f7e-4278-9f44-7a47f3d6b744" xlink:to="loc_srt_ScenarioForecastMember_bf8c6a5a-8bf9-4fcc-89d6-abfb3882e69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2985c089-5335-4195-bd6c-04f4b566ae29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5923bb86-fc7b-4227-875a-1422abba90bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5923bb86-fc7b-4227-875a-1422abba90bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_4cfa6340-6a59-41a1-920c-f3cfe482574a" xlink:href="biib-20210630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_4cfa6340-6a59-41a1-920c-f3cfe482574a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79c99e64-ea4a-4eef-8577-86b01bc04b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79c99e64-ea4a-4eef-8577-86b01bc04b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_034a8656-0c85-42dd-9cc8-7afef9c8b9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_034a8656-0c85-42dd-9cc8-7afef9c8b9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8504fcc5-8811-4ac6-9b63-7a467b0ef639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8504fcc5-8811-4ac6-9b63-7a467b0ef639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f189039d-f95b-45f2-a32a-f59d8d889796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f189039d-f95b-45f2-a32a-f59d8d889796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_015a11da-6cdf-444b-af83-79f38cf1860d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_015a11da-6cdf-444b-af83-79f38cf1860d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2d80c0cf-15bc-4da5-b2d9-7ec43d21936b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2d80c0cf-15bc-4da5-b2d9-7ec43d21936b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05f15844-963c-4942-b2b2-8fb867e6b88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a88ff805-5214-46cf-8c28-d0fe6fe2e934" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05f15844-963c-4942-b2b2-8fb867e6b88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_3205d24d-8124-496c-a4f0-b706d2b40648" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_3205d24d-8124-496c-a4f0-b706d2b40648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_686806b4-d32b-450b-bc4e-54481837c25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_686806b4-d32b-450b-bc4e-54481837c25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc7486f4-2258-4a96-8499-36380fdee9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc7486f4-2258-4a96-8499-36380fdee9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0198436a-f4a0-40b3-93a7-4f88560322e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0198436a-f4a0-40b3-93a7-4f88560322e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2a0bb562-413c-41c6-99cd-bcc0b1fed184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2a0bb562-413c-41c6-99cd-bcc0b1fed184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_859dd882-8cc0-41c1-97fa-568391c9d491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_859dd882-8cc0-41c1-97fa-568391c9d491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fd831dac-706b-4f27-aa3d-427935d7869a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fd831dac-706b-4f27-aa3d-427935d7869a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7c8ddae0-b403-44e0-9753-8e17031da5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7c8ddae0-b403-44e0-9753-8e17031da5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_07e4c669-c0a6-4544-a70d-f3c6a458cd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cd257cf8-af76-4eb6-97bb-86dc53885b02" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_07e4c669-c0a6-4544-a70d-f3c6a458cd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e75b02c1-3461-4785-af68-11b0630d7350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_63b0f997-0642-4c08-b753-9e2452ac0ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e75b02c1-3461-4785-af68-11b0630d7350" xlink:to="loc_us-gaap_GoodwillRollForward_63b0f997-0642-4c08-b753-9e2452ac0ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_33fdfb85-5ebb-44d7-83ac-70c20c736797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_63b0f997-0642-4c08-b753-9e2452ac0ae3" xlink:to="loc_us-gaap_Goodwill_33fdfb85-5ebb-44d7-83ac-70c20c736797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9eccf64e-1b78-496f-b415-360251a3336b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_63b0f997-0642-4c08-b753-9e2452ac0ae3" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_9eccf64e-1b78-496f-b415-360251a3336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7d959962-1df0-40c6-9879-d70345b778ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_63b0f997-0642-4c08-b753-9e2452ac0ae3" xlink:to="loc_us-gaap_Goodwill_7d959962-1df0-40c6-9879-d70345b778ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0fb35d8e-6a27-40da-a2ef-45466085d543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e75b02c1-3461-4785-af68-11b0630d7350" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0fb35d8e-6a27-40da-a2ef-45466085d543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d88f55c3-88ff-4a48-8eb6-ed012fd1df23" xlink:href="biib-20210630.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e75b02c1-3461-4785-af68-11b0630d7350" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d88f55c3-88ff-4a48-8eb6-ed012fd1df23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_109bd51b-1d7d-4810-aeab-874b3bc936db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e75b02c1-3461-4785-af68-11b0630d7350" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_109bd51b-1d7d-4810-aeab-874b3bc936db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9386d4d7-a249-49f4-8ec9-8b189cb7f8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e75b02c1-3461-4785-af68-11b0630d7350" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9386d4d7-a249-49f4-8ec9-8b189cb7f8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0b1cd5ac-876b-4f4c-a2c7-5febb16d7b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_437545a3-3845-4f9a-bfd4-7a11d3a3a6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0b1cd5ac-876b-4f4c-a2c7-5febb16d7b24" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_437545a3-3845-4f9a-bfd4-7a11d3a3a6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fda41865-6c6c-4698-b943-25f96785c82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_553389b6-d2b2-41a6-b4c6-9d0702d6c350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fda41865-6c6c-4698-b943-25f96785c82e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_553389b6-d2b2-41a6-b4c6-9d0702d6c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_59f58b04-8781-4d2d-b69c-90eacb724944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fda41865-6c6c-4698-b943-25f96785c82e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_59f58b04-8781-4d2d-b69c-90eacb724944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_60a313e3-7feb-45e9-a796-e48aa86b0dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fda41865-6c6c-4698-b943-25f96785c82e" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_60a313e3-7feb-45e9-a796-e48aa86b0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_649aeee8-f2bc-4e23-8842-ba2da4c05494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fda41865-6c6c-4698-b943-25f96785c82e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_649aeee8-f2bc-4e23-8842-ba2da4c05494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f431ba50-0971-4a93-989c-b1379693a3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f431ba50-0971-4a93-989c-b1379693a3f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c99d3e18-b040-43a6-9701-90f31c242fb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ca53b5d8-7956-4f59-bda4-0df811474963" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ca53b5d8-7956-4f59-bda4-0df811474963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7d0b53db-e774-4e3b-bde9-1f0b0947cb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7d0b53db-e774-4e3b-bde9-1f0b0947cb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aacf174b-7251-4fac-a268-553256ba267a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3aff43c-f415-4d46-be59-85f3bbd1fa4b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aacf174b-7251-4fac-a268-553256ba267a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98948ac2-e95b-4188-88a9-674837717585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d487f17a-9f87-4f95-b4e1-be1b0bbc3d64" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98948ac2-e95b-4188-88a9-674837717585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d9abf20d-bc2c-436f-b0bd-274b10e6680e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98948ac2-e95b-4188-88a9-674837717585" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d9abf20d-bc2c-436f-b0bd-274b10e6680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8c4c8c0c-9053-410c-afdb-6fd0acc55efe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_754ec2ac-e671-4fef-aa4b-ee86a1b54109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_754ec2ac-e671-4fef-aa4b-ee86a1b54109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_ffaef9b6-af0a-4b7e-bb67-287c2203f20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_ffaef9b6-af0a-4b7e-bb67-287c2203f20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5bd0d53d-18b5-48b0-a88a-6edccd6d10df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a1c48050-1915-4129-b771-6242c4715e7a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5bd0d53d-18b5-48b0-a88a-6edccd6d10df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccf62f99-3616-4534-8c9a-fc896a5483de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be25328a-f954-4170-835f-a2fa5c498d62" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccf62f99-3616-4534-8c9a-fc896a5483de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccf62f99-3616-4534-8c9a-fc896a5483de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25a52918-5b6b-4fe5-be7e-6ed881a3af09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25a52918-5b6b-4fe5-be7e-6ed881a3af09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bee09b0-0e6d-462d-8bce-709e3ada8c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bee09b0-0e6d-462d-8bce-709e3ada8c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b01f425f-ad64-40bb-89f8-6ef5fd00981a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b01f425f-ad64-40bb-89f8-6ef5fd00981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_547ab827-c2b8-4b27-86e8-30d1d6ea1ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_547ab827-c2b8-4b27-86e8-30d1d6ea1ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_3c880244-ff8d-4caa-b13d-e76e52f4e861" xlink:href="biib-20210630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_3c880244-ff8d-4caa-b13d-e76e52f4e861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4d0c3a68-648a-4fcd-a437-bec0208ed7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0c20131c-a828-45c0-adb6-159ac987b5dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4d0c3a68-648a-4fcd-a437-bec0208ed7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_ef135608-01f7-4f08-90eb-753c688d575e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_fc14f618-1f3a-401d-965d-7a94b1e76b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_fc14f618-1f3a-401d-965d-7a94b1e76b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9fff5a-ee41-4115-b0ef-5602abc091f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9fff5a-ee41-4115-b0ef-5602abc091f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4a3f07e0-108a-4a78-a608-aa4762de1b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7cbbb042-2f2c-4b44-8dc7-e5899eb23299" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4a3f07e0-108a-4a78-a608-aa4762de1b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_417aa11a-9452-4f71-9e59-f23213aefc50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_417aa11a-9452-4f71-9e59-f23213aefc50" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:to="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_21486ed2-3cbe-4406-bb55-3b74b8daea5a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_61d9526f-ca0c-4e67-b7c9-502f1d7adf40" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_61d9526f-ca0c-4e67-b7c9-502f1d7adf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c850f542-7878-4f97-ad28-0a43c67861e0" xlink:href="biib-20210630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_c850f542-7878-4f97-ad28-0a43c67861e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d88860ce-ccb2-4ee1-a1a0-79ac7ae2d2b3" xlink:href="biib-20210630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d88860ce-ccb2-4ee1-a1a0-79ac7ae2d2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9e06cc6c-0af6-4603-9ee5-baa8aa7803b3" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b4320b6-0a46-4115-9a7c-c68684507d03" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9e06cc6c-0af6-4603-9ee5-baa8aa7803b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_d699b071-db00-468b-857d-ad5dc32deeb3" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f97b19bd-37c1-4157-a279-75bcf6d857dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_AssetImpairmentCharges_f97b19bd-37c1-4157-a279-75bcf6d857dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e6ee0241-10c5-42c6-af38-3d75c0516f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e6ee0241-10c5-42c6-af38-3d75c0516f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dbef2d86-410b-47a4-9b9f-a0709fc22db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dbef2d86-410b-47a4-9b9f-a0709fc22db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_aca798d9-b4e3-4627-a272-643853b39cee" xlink:href="biib-20210630.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_eb733ebb-77cb-432d-bbbd-b8a17d541e3b" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_aca798d9-b4e3-4627-a272-643853b39cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4d32206c-4cd6-4a77-ba79-ef372e48608f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4d32206c-4cd6-4a77-ba79-ef372e48608f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:to="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bded6cd6-b2c1-4f3c-b6cd-afa210b98237" xlink:to="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6d136d8-5b1a-4b5d-bf41-02019da9417e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:to="loc_srt_MinimumMember_b6d136d8-5b1a-4b5d-bf41-02019da9417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19a163b2-5a63-4853-8565-aa63835d80cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:to="loc_srt_MaximumMember_19a163b2-5a63-4853-8565-aa63835d80cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_f585b193-b1cf-4f5a-8576-3d5b74097c18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52f88703-f1c1-406e-9224-4b416034a363" xlink:to="loc_srt_WeightedAverageMember_f585b193-b1cf-4f5a-8576-3d5b74097c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37a3a723-0623-4d7a-afc9-3394617e1258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b71b49b9-d15d-4ce6-89c5-f69ddc8070fb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37a3a723-0623-4d7a-afc9-3394617e1258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b4f07e6d-2e83-4829-99ce-06a0fefe3cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37a3a723-0623-4d7a-afc9-3394617e1258" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b4f07e6d-2e83-4829-99ce-06a0fefe3cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28120b5e-0234-4068-a1a0-c65bf39abfe3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f114e2c1-ea41-494e-a000-43965db0a619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f114e2c1-ea41-494e-a000-43965db0a619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b72deaff-3d6c-4477-9499-3d55dad5167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3065c309-9845-4f78-9628-d03d98f3b26b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b72deaff-3d6c-4477-9499-3d55dad5167f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsNonrecurringAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06ca8333-93e3-469b-8803-5ca54a2d6fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06ca8333-93e3-469b-8803-5ca54a2d6fb0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:href="biib-20210630.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7d1d6e70-ba09-4837-a16f-7dd211d3a64f" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_7f40c6f1-57bb-4fb4-b481-dd6f65b848dc" xlink:href="biib-20210630.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:to="loc_biib_BIIB111Member_7f40c6f1-57bb-4fb4-b481-dd6f65b848dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_70df34ed-fb5e-4d3c-a61e-94ac333b7038" xlink:href="biib-20210630.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_08477fc3-2702-47ef-af86-283fee438e6e" xlink:to="loc_biib_BIIB112Member_70df34ed-fb5e-4d3c-a61e-94ac333b7038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bf76d27-6c02-4d67-8870-e098e36e6fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888fb76f-0bac-4923-9518-ae59855fd718" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bf76d27-6c02-4d67-8870-e098e36e6fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_9aa1e100-8c9c-4a63-96e1-ea9fe799c3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bf76d27-6c02-4d67-8870-e098e36e6fe8" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_9aa1e100-8c9c-4a63-96e1-ea9fe799c3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_640aecce-9cc6-4b71-93c7-cef72b277671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2de03915-80b9-42c6-aa08-c4378b2d1dfa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_640aecce-9cc6-4b71-93c7-cef72b277671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_b929aad4-f8fd-4a7a-8239-b2c4b90a042e" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_640aecce-9cc6-4b71-93c7-cef72b277671" xlink:to="loc_biib_NightstarMember_b929aad4-f8fd-4a7a-8239-b2c4b90a042e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12acd9db-549c-4d43-9bdb-3f4107f0741f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d695142-f8e1-4327-bd27-21e8b6d8d018" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12acd9db-549c-4d43-9bdb-3f4107f0741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:href="biib-20210630.xsd#biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12acd9db-549c-4d43-9bdb-3f4107f0741f" xlink:to="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_654f6650-5dca-4d66-8309-8f22b9496946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_654f6650-5dca-4d66-8309-8f22b9496946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9cbe9b43-7ee4-42e1-93b9-d7e4ac02ce21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9cbe9b43-7ee4-42e1-93b9-d7e4ac02ce21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_8e883ea0-b0bd-4c89-9ec2-ed7682fad3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward_058215c5-42af-4cc6-bd6d-c16e131cb82c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_8e883ea0-b0bd-4c89-9ec2-ed7682fad3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_618af334-2a99-4658-bacc-d477d3c62bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_618af334-2a99-4658-bacc-d477d3c62bf8" xlink:to="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_74919f71-c944-413e-82d7-2b091c08f082" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43a2aa00-ee3a-49b8-a389-c8d21ea30a72" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_43a2aa00-ee3a-49b8-a389-c8d21ea30a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_756119aa-ad46-4e96-86bb-c988fa60a1f4" xlink:href="biib-20210630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_756119aa-ad46-4e96-86bb-c988fa60a1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_06114570-e35c-40ed-9b86-b39ca6ed7c4b" xlink:href="biib-20210630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_06114570-e35c-40ed-9b86-b39ca6ed7c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_7c9dbd40-d933-4ea3-9fbe-539c5b5e04ff" xlink:href="biib-20210630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_7c9dbd40-d933-4ea3-9fbe-539c5b5e04ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5a4a7edf-6ede-4bd5-8b48-0c03bc4df499" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_5a4a7edf-6ede-4bd5-8b48-0c03bc4df499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_c2f23fa4-59c9-4953-a912-4e4a673fce9f" xlink:href="biib-20210630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_c2f23fa4-59c9-4953-a912-4e4a673fce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_59cb0fb5-defb-48d8-b0a2-14c25f88c238" xlink:href="biib-20210630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3dd5cd8-4550-441d-8b83-1d7b667d4c95" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_59cb0fb5-defb-48d8-b0a2-14c25f88c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9055b966-fcc4-4279-be31-0310456fed3c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_a8e7d2b5-298f-48c2-8f46-549bd53bd9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_a8e7d2b5-298f-48c2-8f46-549bd53bd9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_6fa5346c-e606-4a38-98c1-9cddb3eca893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_NotesPayable_6fa5346c-e606-4a38-98c1-9cddb3eca893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4816cc21-8012-410a-9533-6acce322f3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4816cc21-8012-410a-9533-6acce322f3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80e46b8c-ed7e-4110-99ec-cc45ece335fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_80e46b8c-ed7e-4110-99ec-cc45ece335fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_34cc734f-6891-422f-bc1e-721c801b39d6" xlink:href="biib-20210630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ca35ac7-00b5-4be7-ad1c-9bacb21ae81d" xlink:to="loc_biib_LongTermDebtExchangedAmount_34cc734f-6891-422f-bc1e-721c801b39d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20210630.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7a4a52cb-1d5c-4a97-b6a6-90a6977d3d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7a4a52cb-1d5c-4a97-b6a6-90a6977d3d14" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_63545b55-232d-4d0d-a592-b4da0a61b6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc223781-7b46-4a31-b29e-b5ff6cfc2b08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_63545b55-232d-4d0d-a592-b4da0a61b6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e31c4bb0-b240-4f4c-84e9-78101800038e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_63545b55-232d-4d0d-a592-b4da0a61b6bc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e31c4bb0-b240-4f4c-84e9-78101800038e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a62e261-c22c-4eec-a9b7-20ead1fd30cb" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_640cf666-cf99-4b1b-aa60-02a7fb877b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_640cf666-cf99-4b1b-aa60-02a7fb877b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a32a622c-57a4-480a-9f05-19c3c3176e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a32a622c-57a4-480a-9f05-19c3c3176e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1fb493ef-0103-4373-8927-f2d0f813f517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_e7f7b69d-f093-4f0a-9d42-1a0821d60b8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1fb493ef-0103-4373-8927-f2d0f813f517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_475f6000-df8c-4d27-88a4-c58cda8e1170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_89871b64-0464-4bb5-879d-bc455c1f31e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_475f6000-df8c-4d27-88a4-c58cda8e1170" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_89871b64-0464-4bb5-879d-bc455c1f31e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3eab4af7-2e9a-4781-9eb7-5403621de1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6c1d9689-cc31-4bf7-b9f4-85449aec6428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3eab4af7-2e9a-4781-9eb7-5403621de1c2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6c1d9689-cc31-4bf7-b9f4-85449aec6428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_6151f3e3-a1ef-4f97-acb0-7e92e243777a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3eab4af7-2e9a-4781-9eb7-5403621de1c2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_6151f3e3-a1ef-4f97-acb0-7e92e243777a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_caa92f77-7565-4c25-8f74-dabe1d21b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3eab4af7-2e9a-4781-9eb7-5403621de1c2" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_caa92f77-7565-4c25-8f74-dabe1d21b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_708c6c1b-663a-436e-b5b0-8206282a0f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3eab4af7-2e9a-4781-9eb7-5403621de1c2" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_708c6c1b-663a-436e-b5b0-8206282a0f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a12d25c-706b-4688-833c-3b00b6abf3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a12d25c-706b-4688-833c-3b00b6abf3e8" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:to="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a429e448-2e88-4d92-ae79-69e43417693e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8298feb9-61d6-4213-809d-b2d02a81a5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_CommercialPaperMember_8298feb9-61d6-4213-809d-b2d02a81a5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_91c818c1-c473-4df9-aeca-0206cf36c4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_91c818c1-c473-4df9-aeca-0206cf36c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ce2e045f-f444-42b3-aeac-7e23cd8146b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ce2e045f-f444-42b3-aeac-7e23cd8146b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_9bcaab95-9385-4ae9-9f11-09fbac21d3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_eb7d873f-90d8-4f80-b86c-f55f1f0fb253" xlink:to="loc_us-gaap_DebtSecuritiesMember_9bcaab95-9385-4ae9-9f11-09fbac21d3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_848dab07-7c11-473f-956f-f6c3b2577eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_8b5fc37e-b68d-4d3d-9834-4b21bf0bb06f" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_848dab07-7c11-473f-956f-f6c3b2577eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_7d54f9e3-ee6b-4b56-8dfb-01652ed06b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_848dab07-7c11-473f-956f-f6c3b2577eea" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_7d54f9e3-ee6b-4b56-8dfb-01652ed06b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_a34f15bc-cc98-495a-84bb-d98597016d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_7d54f9e3-ee6b-4b56-8dfb-01652ed06b20" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_a34f15bc-cc98-495a-84bb-d98597016d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c44c6b0e-5702-4fe3-a36a-02d6f1205608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c44c6b0e-5702-4fe3-a36a-02d6f1205608" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_431c0726-0da4-44a9-bae7-7c5bf595bba0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_a249e7b6-457c-4079-b1c1-bec918a53587" xlink:href="biib-20210630.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_a249e7b6-457c-4079-b1c1-bec918a53587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d1b76e83-b843-4f6e-a7a3-a4ef6445d6ef" xlink:href="biib-20210630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d1b76e83-b843-4f6e-a7a3-a4ef6445d6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_413fa86e-6782-4b2e-b4f8-a01d37a60365" xlink:href="biib-20210630.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_413fa86e-6782-4b2e-b4f8-a01d37a60365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_516a424b-a52d-4452-b1f7-ea1c3c36fcee" xlink:href="biib-20210630.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_516a424b-a52d-4452-b1f7-ea1c3c36fcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_a69fe0b9-493e-41a5-96aa-00538a239196" xlink:href="biib-20210630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_a69fe0b9-493e-41a5-96aa-00538a239196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4c9d2597-fae7-4eb9-9fdd-eb84e4d97eac" xlink:href="biib-20210630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4c9d2597-fae7-4eb9-9fdd-eb84e4d97eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_6437c3d0-7dcd-4e6a-8b6f-e5384d751558" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_EquitySecuritiesCurrentMember_6437c3d0-7dcd-4e6a-8b6f-e5384d751558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_ddb30c66-904a-485f-a164-1d80de5619b2" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f23e512-5733-42c8-bf6e-998cad9fc2bc" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_ddb30c66-904a-485f-a164-1d80de5619b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5b0f399d-01d2-4135-96c8-0f1de01e387a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c0527f9-c085-424b-b6fe-cb85c4c45276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c0527f9-c085-424b-b6fe-cb85c4c45276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07bce263-b9d7-449b-80d8-d37316de587d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07bce263-b9d7-449b-80d8-d37316de587d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5896c3d4-abcc-4fe9-8b28-24ed146936c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5896c3d4-abcc-4fe9-8b28-24ed146936c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d58ed56-419e-400a-aee8-7f2945601722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7d58ed56-419e-400a-aee8-7f2945601722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_449acbdf-b9fe-4e1c-b354-e5b6048db2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_AvailableForSaleSecurities_449acbdf-b9fe-4e1c-b354-e5b6048db2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_9f597774-37ed-4e07-a5ee-c891f0152c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_9f597774-37ed-4e07-a5ee-c891f0152c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b96ad198-f6cc-45d2-b7a9-e04478384880" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b96ad198-f6cc-45d2-b7a9-e04478384880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_38e7ef76-6acb-4337-9b79-afc0a8edf8dc" xlink:href="biib-20210630.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_38e7ef76-6acb-4337-9b79-afc0a8edf8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_becf11e3-1fd5-4891-bdfa-8caf5e5e7fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6aff1b68-ca89-408a-a7a3-b6e2387d39fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_becf11e3-1fd5-4891-bdfa-8caf5e5e7fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ed05d5e4-0d84-4edf-b5bc-6741f49a617f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ed05d5e4-0d84-4edf-b5bc-6741f49a617f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0fdf4977-44c7-4bb3-a307-2f148f102e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0fdf4977-44c7-4bb3-a307-2f148f102e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cbe19914-feda-415a-b0a3-844d2a660218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cbe19914-feda-415a-b0a3-844d2a660218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e7e43b73-d214-414f-abe8-37ac4103380e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e7e43b73-d214-414f-abe8-37ac4103380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a0861f74-7af6-4505-b079-184f89a6149c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a0861f74-7af6-4505-b079-184f89a6149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_5e6f71d3-b25e-408c-9d53-5c5706bf5940" xlink:href="biib-20210630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_5e6f71d3-b25e-408c-9d53-5c5706bf5940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_fe010c46-2825-4d22-868b-40a03185e32c" xlink:href="biib-20210630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_fe010c46-2825-4d22-868b-40a03185e32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bb56aa1b-0276-4ba9-aba7-03aebde524da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bb56aa1b-0276-4ba9-aba7-03aebde524da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_4cc24d4c-bf0e-4d1e-b8ca-bfb9e41c131b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_229fbaa8-3cfb-4686-8418-1780711143fb" xlink:to="loc_us-gaap_AvailableForSaleSecurities_4cc24d4c-bf0e-4d1e-b8ca-bfb9e41c131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb3a1d0b-75c3-45a5-b267-bfd1e03fa8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5e89a5a5-4313-42b6-bed3-7499e5d0eb94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb3a1d0b-75c3-45a5-b267-bfd1e03fa8e2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5e89a5a5-4313-42b6-bed3-7499e5d0eb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c54f6714-8469-4abb-82a9-446192520e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb3a1d0b-75c3-45a5-b267-bfd1e03fa8e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c54f6714-8469-4abb-82a9-446192520e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_68227542-e249-4943-975c-63ebc200d5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb3a1d0b-75c3-45a5-b267-bfd1e03fa8e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_68227542-e249-4943-975c-63ebc200d5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_49de1736-a958-4544-be2a-359ef0d8b93e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_fccaed61-5344-439b-a74a-3114c429b5dc" xlink:href="biib-20210630.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_49de1736-a958-4544-be2a-359ef0d8b93e" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_fccaed61-5344-439b-a74a-3114c429b5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20210630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cd3814a2-7ed7-48d4-b585-407f2041c48d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cd3814a2-7ed7-48d4-b585-407f2041c48d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_94b32f9c-737d-47f1-bba6-41c0a798b4b6" xlink:to="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_b0fb3235-3c0a-40ce-b961-5722dfce71bd" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:to="loc_biib_DenaliTherapeuticsIncMember_b0fb3235-3c0a-40ce-b961-5722dfce71bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_49e41af4-806a-4922-b732-81976cc5ff1a" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_176c770b-0b02-493d-be61-d3cd534d416b" xlink:to="loc_biib_SangamoCommonStockMember_49e41af4-806a-4922-b732-81976cc5ff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07b9e94e-db79-4790-8fb7-5ad0c13e7dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ca6758e3-2610-4aee-a006-1a9047819412" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07b9e94e-db79-4790-8fb7-5ad0c13e7dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_8b87b3bc-dbe4-4464-b636-0ae476149544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07b9e94e-db79-4790-8fb7-5ad0c13e7dab" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_8b87b3bc-dbe4-4464-b636-0ae476149544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e8e5b53-0ae7-4d5f-a47b-1e80ce4fb9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6eaad485-9b82-4b02-92a7-a86825014751" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e8e5b53-0ae7-4d5f-a47b-1e80ce4fb9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_59ed5fc0-73ba-43a8-ac5f-8b898d2831e3" xlink:href="biib-20210630.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e8e5b53-0ae7-4d5f-a47b-1e80ce4fb9c1" xlink:to="loc_biib_StrategicInvestmentsMember_59ed5fc0-73ba-43a8-ac5f-8b898d2831e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5c3b88d0-49cd-46ce-b767-db4c12c23e38" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_47a06ef2-9bc8-492e-8d1c-8d31a1a55171" xlink:href="biib-20210630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:to="loc_biib_SageTherapeuticsIncMember_47a06ef2-9bc8-492e-8d1c-8d31a1a55171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_e94a631c-22b7-42d7-aef4-d83803bac6db" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_e94a631c-22b7-42d7-aef4-d83803bac6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_c13cefdd-029c-4fc6-8438-f7b8cc76fd1d" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad03f571-b188-4205-b958-26428cb9a6e8" xlink:to="loc_biib_DenaliTherapeuticsIncMember_c13cefdd-029c-4fc6-8438-f7b8cc76fd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9dce316d-25a2-4f1e-9395-73d9513c5c25" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_d798b92c-c874-4f55-b09e-99891f8d9a46" xlink:href="biib-20210630.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_StrategicInvestmentPortfolio_d798b92c-c874-4f55-b09e-99891f8d9a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_35898ad9-e9ba-4f36-965f-8707bc0dd3a2" xlink:href="biib-20210630.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_Investmentincommonstocksharespurchased_35898ad9-e9ba-4f36-965f-8707bc0dd3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_33f545c6-d484-44fe-9c9f-d05fa45c75b7" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_33f545c6-d484-44fe-9c9f-d05fa45c75b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_f35a3196-60a5-49d8-8fd3-5b7f57944478" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_f35a3196-60a5-49d8-8fd3-5b7f57944478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_324ce439-f517-4c96-bc77-b1eaebe1561c" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_324ce439-f517-4c96-bc77-b1eaebe1561c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_5fab0cfc-aa8f-4685-a1ff-66e6c72c1074" xlink:href="biib-20210630.xsd#biib_DividendYieldPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_DividendYieldPercentage_5fab0cfc-aa8f-4685-a1ff-66e6c72c1074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_1387f49d-f8e2-4994-ad5a-0b985fbc67bd" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7aef3559-a6cf-4dfd-9715-4ff82b3d08e8" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_1387f49d-f8e2-4994-ad5a-0b985fbc67bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20210630.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_75726cd5-09ce-490f-bee5-60e189aa85e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_eaf7abad-5a93-466d-a7da-dc82ca70561f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_75726cd5-09ce-490f-bee5-60e189aa85e7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_eaf7abad-5a93-466d-a7da-dc82ca70561f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20210630.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78ebc12b-a924-4daa-ad70-a88250cac859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_f8dbd8f7-87f5-405c-8fc7-101dfd54337f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78ebc12b-a924-4daa-ad70-a88250cac859" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_f8dbd8f7-87f5-405c-8fc7-101dfd54337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c59c27ab-5128-4605-b9db-b9dab5e3b329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78ebc12b-a924-4daa-ad70-a88250cac859" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c59c27ab-5128-4605-b9db-b9dab5e3b329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3a496b0b-3cbb-4339-8d61-7bc83e1d792f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78ebc12b-a924-4daa-ad70-a88250cac859" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3a496b0b-3cbb-4339-8d61-7bc83e1d792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_68d13894-5ec6-426f-ba60-b7be2e7e0305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78ebc12b-a924-4daa-ad70-a88250cac859" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_68d13894-5ec6-426f-ba60-b7be2e7e0305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46604958-d312-4187-93ae-f300a81579f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46604958-d312-4187-93ae-f300a81579f1" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_b87fce9a-2a05-4030-81b5-f60858150086" xlink:href="biib-20210630.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_d569c10a-4e73-4d46-b874-ca6135f07b58" xlink:to="loc_biib_DerivativeMaturityDomain_b87fce9a-2a05-4030-81b5-f60858150086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_57a364d7-b52c-4345-99f3-d596ec42029b" xlink:href="biib-20210630.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_b87fce9a-2a05-4030-81b5-f60858150086" xlink:to="loc_biib_ShorttermderivativeMember_57a364d7-b52c-4345-99f3-d596ec42029b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_07f4eb2a-5f15-4f01-8ae0-2de5f7ad1974" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9d8909a7-9b20-4e01-b9b0-ecb0b1f6db47" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_07f4eb2a-5f15-4f01-8ae0-2de5f7ad1974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0fcd6b38-eca8-4d2c-9a87-acd54cd5695b" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_07f4eb2a-5f15-4f01-8ae0-2de5f7ad1974" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0fcd6b38-eca8-4d2c-9a87-acd54cd5695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_58b5b65c-112f-42b7-b467-19b28eb45604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_29fafd8a-1c19-4cc1-8285-281adf7af883" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_58b5b65c-112f-42b7-b467-19b28eb45604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_d1e62300-f42b-498c-b3a2-83bd0bfb5bc1" xlink:href="biib-20210630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_58b5b65c-112f-42b7-b467-19b28eb45604" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_d1e62300-f42b-498c-b3a2-83bd0bfb5bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_849a3fb1-c109-437c-8152-24e1a9566f4c" xlink:to="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_d43aee05-c35a-4b05-ba7c-ab6a3aae9ecc" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_EUR_d43aee05-c35a-4b05-ba7c-ab6a3aae9ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_1e2669fa-3e62-42f9-ac28-22f9b202da5e" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_GBP_1e2669fa-3e62-42f9-ac28-22f9b202da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_c8f9596a-2a2f-454d-a705-d5d07823c8c4" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_CHF_c8f9596a-2a2f-454d-a705-d5d07823c8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_d2b0004c-d6b0-44bc-ae7a-a505937fdd23" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_JPY_d2b0004c-d6b0-44bc-ae7a-a505937fdd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_c60788cb-720a-4856-842f-6b7d231b6a79" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_8701be1b-f478-431d-a8df-d648d3027987" xlink:to="loc_currency_CAD_c60788cb-720a-4856-842f-6b7d231b6a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d6041f8-951d-4690-83b7-a8aa63526527" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_171669e1-b2a6-4222-abe0-efbb2a746c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_InterestExpenseMember_171669e1-b2a6-4222-abe0-efbb2a746c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5a6121c1-44f7-48be-b5d6-b6ee2b2d8e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_SalesMember_5a6121c1-44f7-48be-b5d6-b6ee2b2d8e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_ffff58db-af9e-485c-826f-059fe4a25e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_OperatingExpenseMember_ffff58db-af9e-485c-826f-059fe4a25e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_62de47af-8edc-49ed-a7f2-aab226b282da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97efd869-ccd6-4cd7-8b65-00d0c169fa0c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_62de47af-8edc-49ed-a7f2-aab226b282da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_201c1e07-32b7-4376-851e-deca4b95b957" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_fd73dcc4-5844-4788-bb5e-bce43d426d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_us-gaap_CashFlowHedgingMember_fd73dcc4-5844-4788-bb5e-bce43d426d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_006cf79b-cd68-45f3-9fdc-1a5bb8e80619" xlink:href="biib-20210630.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_biib_CashflowsrevenueMember_006cf79b-cd68-45f3-9fdc-1a5bb8e80619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_b1a8e5c4-8711-4975-8ca6-049d630ecb6d" xlink:href="biib-20210630.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_biib_CashflowsoperatingexpensesMember_b1a8e5c4-8711-4975-8ca6-049d630ecb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8b45fb61-5bc8-4905-9f5f-20930060de4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_c988f99b-ade6-4c2a-9cef-316eca7dac8d" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8b45fb61-5bc8-4905-9f5f-20930060de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_82950d8b-c190-474e-8914-047ac911121d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_17aa536c-30f0-4a3c-a780-6bd90fa61b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_17aa536c-30f0-4a3c-a780-6bd90fa61b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8087657c-63f0-4e32-97e4-cf595907359f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17cc8815-0c8c-4fa2-ba48-c26eb906d1cd" xlink:to="loc_us-gaap_InterestRateSwapMember_8087657c-63f0-4e32-97e4-cf595907359f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9f5bad52-0e39-462e-83f1-b616b89a1cd5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_97ada7d9-cbcb-45ad-9746-53bd203aafb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_97ada7d9-cbcb-45ad-9746-53bd203aafb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_cb114d01-c7dd-430b-85b6-6077b13595b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_cb114d01-c7dd-430b-85b6-6077b13595b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ceb9eb28-0479-4836-a8d8-a01d69de5275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ceb9eb28-0479-4836-a8d8-a01d69de5275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_affe6501-e3cf-4b94-828e-503e741ad322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88dc68c4-6912-4e38-80d8-4ba1c193d26c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_affe6501-e3cf-4b94-828e-503e741ad322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d6f0aaa2-8a84-4cdf-b64a-5ec97830e49f" xlink:to="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aea51d09-01c3-4e19-b81b-de60a17a9941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aea51d09-01c3-4e19-b81b-de60a17a9941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8fdba9f1-913d-46fc-8db5-6a69636c4077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3a1d8667-46dc-402c-bc4b-538aa567a1ab" xlink:to="loc_us-gaap_NondesignatedMember_8fdba9f1-913d-46fc-8db5-6a69636c4077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f2f7dd1-03f1-4890-9300-a5df64807ccb" xlink:to="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2580d0f5-6ed1-4ad1-9bf5-aced9ae0ba89" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:to="loc_srt_MinimumMember_2580d0f5-6ed1-4ad1-9bf5-aced9ae0ba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ee68438-c6da-42fe-a754-f3054923e659" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_609b709e-c88d-4d20-8e2b-0008c33a66f0" xlink:to="loc_srt_MaximumMember_5ee68438-c6da-42fe-a754-f3054923e659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_02a5a7e6-9d04-4955-a074-069775441777" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_aaacacd1-194b-4a92-a47c-28a18f708f8d" xlink:to="loc_dei_EntityDomain_02a5a7e6-9d04-4955-a074-069775441777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_3cd0beb1-23f9-4233-b43c-d6412a8daea2" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_02a5a7e6-9d04-4955-a074-069775441777" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_3cd0beb1-23f9-4233-b43c-d6412a8daea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6729ef90-5431-4641-8ddb-e8bec2b56d13" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_fe451b38-7d87-4cfd-995f-9ca53c022945" xlink:href="biib-20210630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_fe451b38-7d87-4cfd-995f-9ca53c022945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_a27a85ab-6b76-4c2d-8b86-afadf8de52ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_a27a85ab-6b76-4c2d-8b86-afadf8de52ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1455d68c-d4be-44a3-9a9b-ea57136798d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1455d68c-d4be-44a3-9a9b-ea57136798d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_95686b40-49db-41d3-b0fa-77cca0e21490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_95686b40-49db-41d3-b0fa-77cca0e21490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ef664d6e-1859-449b-8677-1652090940ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ef664d6e-1859-449b-8677-1652090940ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_6df8bbf3-beab-46ce-82e5-4a2005ca79ae" xlink:href="biib-20210630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_6df8bbf3-beab-46ce-82e5-4a2005ca79ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_962de1b3-2b4a-4ed4-b739-b5102947e0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_962de1b3-2b4a-4ed4-b739-b5102947e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ac9b1cd4-7136-4d3f-bf17-bcd593f40576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ac9b1cd4-7136-4d3f-bf17-bcd593f40576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_56befa7b-0b12-4866-87da-ddb294d40a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeTermOfContract_56befa7b-0b12-4866-87da-ddb294d40a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_be89a973-051d-4808-9f04-1b2691ff9683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_be89a973-051d-4808-9f04-1b2691ff9683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_f6b9e993-2094-47f9-b0bf-2667369a01cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_f6b9e993-2094-47f9-b0bf-2667369a01cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ff7bdb1c-cd6b-4047-8aa9-1d37f97ead58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ff7bdb1c-cd6b-4047-8aa9-1d37f97ead58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8619aa48-c55c-413c-9af8-84e874142336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8619aa48-c55c-413c-9af8-84e874142336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6a2988bc-7eb1-4f48-b813-6c18365fe93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_6a2988bc-7eb1-4f48-b813-6c18365fe93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_95616b39-27c2-4076-a8b5-b6e2d96476f9" xlink:href="biib-20210630.xsd#biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax_95616b39-27c2-4076-a8b5-b6e2d96476f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_9cab1ed9-d00e-41bb-bca8-5a655fd32d5e" xlink:href="biib-20210630.xsd#biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax_9cab1ed9-d00e-41bb-bca8-5a655fd32d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cdbc9918-9c4a-4393-853f-5ff2e6164a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cdbc9918-9c4a-4393-853f-5ff2e6164a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0431f443-665f-4026-b435-60e4975c3594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0431f443-665f-4026-b435-60e4975c3594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e898b7f5-9caf-4b8a-a003-3608ce8e1dcd" xlink:href="biib-20210630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e898b7f5-9caf-4b8a-a003-3608ce8e1dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_bb05d019-f64c-4bbe-84e4-469d984779b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_bb05d019-f64c-4bbe-84e4-469d984779b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b2587239-a4f1-471c-8abc-540172655920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_c0845274-c3ff-4b3e-9fca-2aa1c20fc8c3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b2587239-a4f1-471c-8abc-540172655920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20210630.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1a5790cd-1c6b-4356-a7b6-1bfc68db3661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_36df885c-1020-4ed4-8dde-c8a69ffb1705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1a5790cd-1c6b-4356-a7b6-1bfc68db3661" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_36df885c-1020-4ed4-8dde-c8a69ffb1705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53b18bef-f032-4f6e-9167-4086b18fb7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53b18bef-f032-4f6e-9167-4086b18fb7f1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:href="biib-20210630.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:to="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_7146fa2a-0d55-4011-8d72-69fb0053a0ec" xlink:href="biib-20210630.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_a148e76f-1fd8-451f-92c1-10ac55345f02" xlink:to="loc_biib_FacilityLocationDomain_7146fa2a-0d55-4011-8d72-69fb0053a0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_ab530a77-ebbf-4b0e-8906-fc858779bcad" xlink:href="biib-20210630.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_7146fa2a-0d55-4011-8d72-69fb0053a0ec" xlink:to="loc_biib_SolothurnSwitzerlandMember_ab530a77-ebbf-4b0e-8906-fc858779bcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:href="biib-20210630.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:to="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:href="biib-20210630.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_57b7785d-6950-43e1-8cd2-4b0d111fd523" xlink:to="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_8ccbf204-703f-4c3f-bb5f-04818ef198a1" xlink:href="biib-20210630.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:to="loc_biib_BiologicsManufacturingMember_8ccbf204-703f-4c3f-bb5f-04818ef198a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_71a6ed86-3916-4ad6-b7c1-b8afba64603e" xlink:href="biib-20210630.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_71a6ed86-3916-4ad6-b7c1-b8afba64603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_efe97fe9-9272-49c6-9d81-5e8d972c31c8" xlink:href="biib-20210630.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_197d2be3-6c72-4f53-9cef-04eb24da4cfc" xlink:to="loc_biib_AdministrativeSpaceMember_efe97fe9-9272-49c6-9d81-5e8d972c31c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba7c30ef-4c2f-4bee-819e-aaf7943f2589" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a2c3dbd-d653-4f53-88ad-0a2779fd1e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a2c3dbd-d653-4f53-88ad-0a2779fd1e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1246371a-8dff-422c-87e7-ea679f77eb31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_Depreciation_1246371a-8dff-422c-87e7-ea679f77eb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_d62ea4b1-a3a5-4a48-a102-e875e11b0e3c" xlink:href="biib-20210630.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_biib_NumberOfSquareFeet_d62ea4b1-a3a5-4a48-a102-e875e11b0e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9121f888-fc53-42aa-a3f0-e8a66a19623b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_ConstructionInProgressGross_9121f888-fc53-42aa-a3f0-e8a66a19623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_40fc088f-a5bf-4e04-8343-a74d04f310d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4489dd82-bd96-426b-a829-581c08e46b21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_40fc088f-a5bf-4e04-8343-a74d04f310d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20210630.xsd#IndebtednessNotes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7c53280e-b92e-4a72-9bb0-334f50f3d9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7560b87e-64b4-429e-9a3d-158bc32e194b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7c53280e-b92e-4a72-9bb0-334f50f3d9cb" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7560b87e-64b4-429e-9a3d-158bc32e194b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cc2e0212-0187-4687-87eb-11075e600861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cc2e0212-0187-4687-87eb-11075e600861" xlink:to="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_55770e67-67da-411c-b736-84caa1e82193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14976940-6a39-424b-944b-e35b619d34a5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_55770e67-67da-411c-b736-84caa1e82193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_c54979da-4de1-4288-b92a-f641183cda15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_55770e67-67da-411c-b736-84caa1e82193" xlink:to="loc_us-gaap_InterestExpenseMember_c54979da-4de1-4288-b92a-f641183cda15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2191f922-f631-48d6-8350-c0eaeb20f9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3d098460-ad47-427e-ad78-432d569a350c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2191f922-f631-48d6-8350-c0eaeb20f9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bf19e139-e420-42d0-a7e2-bbd9a50d9c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2191f922-f631-48d6-8350-c0eaeb20f9db" xlink:to="loc_us-gaap_InterestRateSwapMember_bf19e139-e420-42d0-a7e2-bbd9a50d9c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c3fa481-6b54-4581-b927-13e312958acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f9de5ce9-e062-4f9c-b1af-cffe1fe0bf87" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c3fa481-6b54-4581-b927-13e312958acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d15d0bc5-c336-442d-abf8-4a4080167833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c3fa481-6b54-4581-b927-13e312958acc" xlink:to="loc_us-gaap_SeniorNotesMember_d15d0bc5-c336-442d-abf8-4a4080167833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9911da03-ae66-4103-83ef-85f6f894c655" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_55ece565-8d1b-4d45-b5c6-82a55a24d3de" xlink:href="biib-20210630.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_55ece565-8d1b-4d45-b5c6-82a55a24d3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_910d15a9-0728-4aef-abe6-e4bc50975fa5" xlink:href="biib-20210630.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_910d15a9-0728-4aef-abe6-e4bc50975fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_298d4ebc-9a44-447c-9135-9539217eadb6" xlink:href="biib-20210630.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_298d4ebc-9a44-447c-9135-9539217eadb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_a5b16bf7-8fad-4075-bb1b-e6d58edc67e9" xlink:href="biib-20210630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_a5b16bf7-8fad-4075-bb1b-e6d58edc67e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_353e551f-50dd-4f86-bb7a-7d5289b1bfc1" xlink:href="biib-20210630.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d9b3051-3a09-46cb-8ca6-3408f0d37d05" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_353e551f-50dd-4f86-bb7a-7d5289b1bfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c72fb845-ddc9-404e-9eab-82a71a48b58f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1edefd4-7c2b-47e4-a45e-d49946e2208f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1edefd4-7c2b-47e4-a45e-d49946e2208f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a767f47e-0a03-4ed1-b734-ede612e45884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a767f47e-0a03-4ed1-b734-ede612e45884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_996b8a4d-7fe1-4ec9-ba73-6a3f18bd4152" xlink:href="biib-20210630.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_996b8a4d-7fe1-4ec9-ba73-6a3f18bd4152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_012ec8f0-e0d3-48a4-94bd-564f0a4e8a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_012ec8f0-e0d3-48a4-94bd-564f0a4e8a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_bde27664-2acb-4cb0-9306-d72af5770d07" xlink:href="biib-20210630.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_bde27664-2acb-4cb0-9306-d72af5770d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_b9f107c0-457c-4f6d-8be4-aa9461d7ca5f" xlink:href="biib-20210630.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_b9f107c0-457c-4f6d-8be4-aa9461d7ca5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1c91bdc6-d2e3-4299-836c-3c36bc31a95d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1c91bdc6-d2e3-4299-836c-3c36bc31a95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_ba7d5605-4c09-4011-8561-fd30f00cc308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_ba7d5605-4c09-4011-8561-fd30f00cc308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_fd352519-5722-45fd-ad33-9b2b707469fa" xlink:href="biib-20210630.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_fd352519-5722-45fd-ad33-9b2b707469fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_d1a296ca-f984-4c83-8d79-f9eb3f316df1" xlink:href="biib-20210630.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_biib_LongTermDebtExchangedAmount_d1a296ca-f984-4c83-8d79-f9eb3f316df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_480427c6-9845-45cb-b2b4-31762c949927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_480427c6-9845-45cb-b2b4-31762c949927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_de4c96b8-d943-4038-8ff5-f1ff12b4501c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_RepaymentsOfDebt_de4c96b8-d943-4038-8ff5-f1ff12b4501c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_89c8e345-e5c4-4845-b891-c93ae7fcc33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_134485d8-e830-4702-b101-28932b2f7f9c" xlink:to="loc_us-gaap_InterestExpense_89c8e345-e5c4-4845-b891-c93ae7fcc33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20210630.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1774850d-d369-4872-821b-e55617ea2dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d81d6414-2a83-4ad8-a862-c0ce113dc829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1774850d-d369-4872-821b-e55617ea2dce" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d81d6414-2a83-4ad8-a862-c0ce113dc829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20210630.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_84106edc-749a-4708-995f-c904205ea8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b1ab08a8-e06b-4f2d-9d4b-0a902b719c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_84106edc-749a-4708-995f-c904205ea8e6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b1ab08a8-e06b-4f2d-9d4b-0a902b719c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e5501360-8ffc-4cdf-8f1c-6beafa500074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_84106edc-749a-4708-995f-c904205ea8e6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e5501360-8ffc-4cdf-8f1c-6beafa500074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d2907511-63c2-4022-b19a-991be36fe658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d2907511-63c2-4022-b19a-991be36fe658" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b8881715-7f26-4ab7-bd76-bc3edefa9ff8" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_4b95be3d-c1f8-4cf3-a247-7918fd3449c2" xlink:href="biib-20210630.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_4b95be3d-c1f8-4cf3-a247-7918fd3449c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_f4ec2399-a4c7-4667-b360-70e92600d5e1" xlink:href="biib-20210630.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_f4ec2399-a4c7-4667-b360-70e92600d5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_d2c68acb-bf8d-40cd-8f19-ae84e11a68ad" xlink:href="biib-20210630.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_54dfd251-9970-4991-90a1-2ec1eb0d8529" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_d2c68acb-bf8d-40cd-8f19-ae84e11a68ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72f847f3-0d45-41d5-840a-02580f7e5ff7" xlink:to="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdb2f983-6083-4756-863a-b0a261614709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdb2f983-6083-4756-863a-b0a261614709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3dda8383-c784-409b-aaea-a8647acc94fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3dda8383-c784-409b-aaea-a8647acc94fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ce4e014-a0f5-4b43-89b6-e2c904ccf61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5ce4e014-a0f5-4b43-89b6-e2c904ccf61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1b078fb2-d2ac-4c55-b6e0-e4e9c5186d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_623c716b-0f55-4e01-80e0-b4f586e51458" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1b078fb2-d2ac-4c55-b6e0-e4e9c5186d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e78763c9-78cd-404b-ade7-2faf5cd03f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e78763c9-78cd-404b-ade7-2faf5cd03f8a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38bc29d5-5b1a-4d04-ac79-32b66c848ebd" xlink:to="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_21b9ead7-8179-42c6-a645-b653ce041400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_21b9ead7-8179-42c6-a645-b653ce041400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b4bdde0c-cd1b-4acd-912d-1f3a2de39c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b4bdde0c-cd1b-4acd-912d-1f3a2de39c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_981f889c-5305-424d-8c73-9811dba419e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_981f889c-5305-424d-8c73-9811dba419e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_50010cd3-8c9f-4561-adfe-ad18959f7e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_50010cd3-8c9f-4561-adfe-ad18959f7e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_72d92dee-5407-4d26-a2c4-99e93c2cf00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e944591-b6af-4ed6-82db-9409bb4b2590" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_72d92dee-5407-4d26-a2c4-99e93c2cf00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c3113ac-e69e-4356-876e-af0d19d82c7c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87642981-a7da-46d9-81ee-1a6af24eb493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87642981-a7da-46d9-81ee-1a6af24eb493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cdd3e9cd-5f1d-4d36-b123-4d2997220b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cdd3e9cd-5f1d-4d36-b123-4d2997220b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e409e984-2a14-402f-b5c7-ca4454e1aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e409e984-2a14-402f-b5c7-ca4454e1aeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_81e0e4ac-2a1c-42f9-bf65-ceb17e561d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_81e0e4ac-2a1c-42f9-bf65-ceb17e561d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6071e025-dd2f-4436-be02-8444315bfe36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6071e025-dd2f-4436-be02-8444315bfe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c0e19b2b-dd9a-40cb-89ef-13a12578d431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c0e19b2b-dd9a-40cb-89ef-13a12578d431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0e38421-21d8-4628-80e9-ab11a26ec973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cf360a41-2853-4d34-8307-a3f05b909d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a0e38421-21d8-4628-80e9-ab11a26ec973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_92d54356-5164-479d-94ff-86ac2360d96a" xlink:href="biib-20210630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_92d54356-5164-479d-94ff-86ac2360d96a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a14ddfa-491c-4af8-935e-177392809587" xlink:to="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6009a070-cb13-49de-a013-87f5814ca686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6009a070-cb13-49de-a013-87f5814ca686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9a366285-78cc-4b9e-bb4d-e39dc08db129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9a366285-78cc-4b9e-bb4d-e39dc08db129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_a15f3645-fe85-4793-94fb-aa3bcf2e7e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8596168d-5d7b-4685-a3f3-96b709feac6d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_a15f3645-fe85-4793-94fb-aa3bcf2e7e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cb6f9635-05b2-4364-9fb0-b910c2a4ba51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_37c1ceff-a40f-44b4-9480-673b6e6e031a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cb6f9635-05b2-4364-9fb0-b910c2a4ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9b900656-9682-43a8-a201-c72aa91666fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cb6f9635-05b2-4364-9fb0-b910c2a4ba51" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9b900656-9682-43a8-a201-c72aa91666fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_51c6270f-061f-4b82-84c1-60d871dbc68a" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_841c857d-0b71-4ff7-8d18-dfe7e522df6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_841c857d-0b71-4ff7-8d18-dfe7e522df6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59cf1aaa-406c-4d38-81b2-68d8cf63e9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_59cf1aaa-406c-4d38-81b2-68d8cf63e9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a6fbeef6-9ea9-447d-8b13-ab377746db89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_Revenues_a6fbeef6-9ea9-447d-8b13-ab377746db89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_306a6495-affb-4280-9696-ee4921218dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_OperatingExpenses_306a6495-affb-4280-9696-ee4921218dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a16a1194-2217-48a7-97d6-c60bb0360d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_d2fab136-f9a7-4875-a27d-b37cdeeb2752" xlink:to="loc_us-gaap_NetIncomeLoss_a16a1194-2217-48a7-97d6-c60bb0360d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20210630.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ccb0a47e-7db2-4f49-94c7-6451f77d8088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_050d493a-dcd0-444d-baee-5e4461fa2318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ccb0a47e-7db2-4f49-94c7-6451f77d8088" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_050d493a-dcd0-444d-baee-5e4461fa2318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20210630.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f3617965-e8c2-4cc4-a1d3-f6a4ba2671f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_acc3117d-bfa2-404b-b6b1-a88318c7b47e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3617965-e8c2-4cc4-a1d3-f6a4ba2671f7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_acc3117d-bfa2-404b-b6b1-a88318c7b47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8296cba8-2b7b-4fc3-86e6-9d5ae61de6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8296cba8-2b7b-4fc3-86e6-9d5ae61de6a2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef1827fe-954b-401d-9459-65fb9649feee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_63fe64ab-3071-4c7b-9e4a-ffa23f02dc5b" xlink:href="biib-20210630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_63fe64ab-3071-4c7b-9e4a-ffa23f02dc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_814dc691-5d4d-4915-9114-87d129eff717" xlink:href="biib-20210630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:to="loc_biib_MarketStockUnitsMember_814dc691-5d4d-4915-9114-87d129eff717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_aa86734b-2303-434c-ad9a-183bed2d700a" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0412928d-3bc6-4115-a181-b4c8af63f436" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_aa86734b-2303-434c-ad9a-183bed2d700a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bfc1d0c9-441d-4b2a-be78-de3e184e5b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b6a9bde5-7c04-4115-9bc3-dde9bfa62e2c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bfc1d0c9-441d-4b2a-be78-de3e184e5b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:href="biib-20210630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bfc1d0c9-441d-4b2a-be78-de3e184e5b74" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9566d284-2666-415e-9c4b-5bf13092a158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9566d284-2666-415e-9c4b-5bf13092a158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_75afb173-6ed3-4459-ad27-d0dc954d298d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9566d284-2666-415e-9c4b-5bf13092a158" xlink:to="loc_us-gaap_NetIncomeLoss_75afb173-6ed3-4459-ad27-d0dc954d298d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_34eb16e4-6054-4c72-95c5-1556c71ff8f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57086093-36f1-4bd6-83bb-4b40c7944fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57086093-36f1-4bd6-83bb-4b40c7944fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c0720479-66fa-4913-807f-c78da8ed8dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c0720479-66fa-4913-807f-c78da8ed8dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3464ca2e-17f7-4bb3-86db-d89f39a25e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9de48e82-a54b-4105-b551-ce36bd562e4d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3464ca2e-17f7-4bb3-86db-d89f39a25e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_404d075f-baf9-4414-8d90-2e006e0b0743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_aaa07792-45b0-4b6c-a975-166966b13df5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_404d075f-baf9-4414-8d90-2e006e0b0743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20210630.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af790f83-a8af-4ec7-939f-97664b588c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ec4f8cc-2a2b-4a2b-9718-b77733ee2b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af790f83-a8af-4ec7-939f-97664b588c71" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ec4f8cc-2a2b-4a2b-9718-b77733ee2b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd62d1f4-cfdf-4957-85be-165e8fa74b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dd80fe6a-8438-4957-98d4-c617c17c2d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd62d1f4-cfdf-4957-85be-165e8fa74b14" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dd80fe6a-8438-4957-98d4-c617c17c2d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_861679bf-3290-49e9-8c91-3211d4d76c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd62d1f4-cfdf-4957-85be-165e8fa74b14" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_861679bf-3290-49e9-8c91-3211d4d76c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a59f3726-c87d-445c-b4f4-b0452ea63972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a59f3726-c87d-445c-b4f4-b0452ea63972" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_59fb888c-96b3-4a1e-b9a7-0fd4037ce4a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89328755-81ea-4f90-9eee-d1cf9f95f43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_89328755-81ea-4f90-9eee-d1cf9f95f43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c40635b-478c-481f-8a38-31d24cb19c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6c40635b-478c-481f-8a38-31d24cb19c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_1111d7c0-9448-4c17-bb88-6b86020dd657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_161092fc-0ad7-4213-a217-035624549f46" xlink:to="loc_us-gaap_ParentMember_1111d7c0-9448-4c17-bb88-6b86020dd657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_875279a0-ee76-430a-9cf1-8ae957e92248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9dd09603-58ee-49cb-bf99-ecc8ceb40b1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_875279a0-ee76-430a-9cf1-8ae957e92248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_875279a0-ee76-430a-9cf1-8ae957e92248" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dee9e17-8e56-4477-b126-1b161881150e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4dee9e17-8e56-4477-b126-1b161881150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d55199a7-8b19-4dec-bdd0-78fc876f0042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d55199a7-8b19-4dec-bdd0-78fc876f0042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8436196d-85ea-4337-b992-fd5dc9dad92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8436196d-85ea-4337-b992-fd5dc9dad92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_c8a7a3dd-7ae3-4f1b-8522-4d6c4cf47b87" xlink:href="biib-20210630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_c8a7a3dd-7ae3-4f1b-8522-4d6c4cf47b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d157fe4b-2afd-46c2-a67e-00adb3584726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_e78e72d0-4497-4888-9d18-736f3b4be5f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d157fe4b-2afd-46c2-a67e-00adb3584726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20210630.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed0842b5-2ec7-4290-9b57-0e3b4c890465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed0842b5-2ec7-4290-9b57-0e3b4c890465" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f63f215-abaa-4ed9-87d3-8f6ddce59282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_da0f3cb7-56a2-4f18-8b86-9125540ad590" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f63f215-abaa-4ed9-87d3-8f6ddce59282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_0633b045-ddb4-4884-9dbe-4b75343b6f89" xlink:href="biib-20210630.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f63f215-abaa-4ed9-87d3-8f6ddce59282" xlink:to="loc_biib_NightstarMember_0633b045-ddb4-4884-9dbe-4b75343b6f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:to="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f02c245c-1931-4874-8a97-e43afc942cf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_73b80751-dddf-4564-8a97-501bd6a77327" xlink:href="biib-20210630.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_MarketStockUnitsMember_73b80751-dddf-4564-8a97-501bd6a77327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_62887ff6-9f99-49af-87d5-9e731d55bae5" xlink:href="biib-20210630.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_62887ff6-9f99-49af-87d5-9e731d55bae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_111ade9d-aef8-4da3-ae8c-9ffb3a8d737f" xlink:href="biib-20210630.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_CashSettledPerformanceSharesMember_111ade9d-aef8-4da3-ae8c-9ffb3a8d737f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_724c2fa8-7979-48a4-9244-d7a56998052b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_us-gaap_PerformanceSharesMember_724c2fa8-7979-48a4-9244-d7a56998052b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_cfb5d17c-8571-474d-91b5-bf8e0cab4df8" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_cfb5d17c-8571-474d-91b5-bf8e0cab4df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_24d8159e-460d-47d3-ac03-105b2fffefe5" xlink:href="biib-20210630.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_24d8159e-460d-47d3-ac03-105b2fffefe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_be679734-8621-4a90-8823-d454ebd0cf49" xlink:href="biib-20210630.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87335914-fa2a-4050-b5c0-4a18e649d7ca" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_be679734-8621-4a90-8823-d454ebd0cf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_915cf966-9f25-416c-99e6-71dd478ec0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b0ce294-c23f-49a3-b31c-afeb8428de2c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_915cf966-9f25-416c-99e6-71dd478ec0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:href="biib-20210630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_915cf966-9f25-416c-99e6-71dd478ec0dd" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_709c9144-0144-41cc-b547-b5b9caef4a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_709c9144-0144-41cc-b547-b5b9caef4a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_61b2d766-6348-43dc-b9c5-a1f74a07de38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_61b2d766-6348-43dc-b9c5-a1f74a07de38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_83fa133c-54b1-4e98-9097-6bcddd8f77e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_83fa133c-54b1-4e98-9097-6bcddd8f77e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3a677373-4691-4713-9bb8-bc64b4fd31d4" xlink:href="biib-20210630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_905d48c9-ab89-455d-b068-aead342c3906" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3a677373-4691-4713-9bb8-bc64b4fd31d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d79375a0-1309-466e-8f2d-834e62709516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_daba4f97-0264-4d35-ac25-d1cb49d8c93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d79375a0-1309-466e-8f2d-834e62709516" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_daba4f97-0264-4d35-ac25-d1cb49d8c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1681df37-0d6d-452d-a46d-22e076cf0292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_581999c5-27b8-47de-bd0a-c1e35cce37ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1681df37-0d6d-452d-a46d-22e076cf0292" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_581999c5-27b8-47de-bd0a-c1e35cce37ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a7c7265-5a1b-4778-b33d-e61d6e54e62f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a7c7265-5a1b-4778-b33d-e61d6e54e62f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:to="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_039acd53-df6a-47cc-a424-f651aac1dbb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1e4152a4-872a-462d-b288-498f361b6279" xlink:to="loc_srt_ProductsAndServicesDomain_039acd53-df6a-47cc-a424-f651aac1dbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_7a9c6a64-bad5-41f7-97f9-6f2ee3f5212b" xlink:href="biib-20210630.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_039acd53-df6a-47cc-a424-f651aac1dbb8" xlink:to="loc_biib_TECFIDERAMember_7a9c6a64-bad5-41f7-97f9-6f2ee3f5212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_bdee6032-f472-453c-956a-d95d501621a3" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_4cba4370-37f8-4bb5-9524-ec0d1c259575" xlink:href="biib-20210630.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_4cba4370-37f8-4bb5-9524-ec0d1c259575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_8a3b44c8-09cf-4a2b-9e77-d7749f53e379" xlink:href="biib-20210630.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_8a3b44c8-09cf-4a2b-9e77-d7749f53e379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_9f8bfdcc-2bfa-4bf1-91ea-4dbe61020f2d" xlink:href="biib-20210630.xsd#biib_DeferredTaxAssetIncreaseDecreaseInValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxAssetIncreaseDecreaseInValue_9f8bfdcc-2bfa-4bf1-91ea-4dbe61020f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_6ff41a34-74a9-4e67-ab31-7e93de8ed050" xlink:href="biib-20210630.xsd#biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue_6ff41a34-74a9-4e67-ab31-7e93de8ed050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_509a5383-d4fa-41a5-8e4f-d4520bfa1504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_509a5383-d4fa-41a5-8e4f-d4520bfa1504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d7c90565-a339-4ba6-8c52-e203d75b93f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d7c90565-a339-4ba6-8c52-e203d75b93f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_549b4a76-e0b7-45a5-b1a9-8264c8315729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_549b4a76-e0b7-45a5-b1a9-8264c8315729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_05b0b1fa-cee1-487f-a8e3-eafe64b66745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4e5280c6-8c84-4aff-bfd2-3698f36dd5fa" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_05b0b1fa-cee1-487f-a8e3-eafe64b66745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4220fbfc-e02c-438e-a854-b960b4608de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4220fbfc-e02c-438e-a854-b960b4608de3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b24cdf2b-86f5-4a5b-b237-5c6f846f57dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b24cdf2b-86f5-4a5b-b237-5c6f846f57dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_33c5175f-7ad3-4af9-af72-78e41a12d7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_33c5175f-7ad3-4af9-af72-78e41a12d7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_923b5d1f-2014-4d88-b951-23de17cff8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_923b5d1f-2014-4d88-b951-23de17cff8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_fa6bf2f2-bb36-4768-8ccf-45ee38bb71f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_fa6bf2f2-bb36-4768-8ccf-45ee38bb71f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_8a81f486-6e07-4111-b99e-f4fb5aa40e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_8a81f486-6e07-4111-b99e-f4fb5aa40e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c674e1a4-d3a5-4339-92c9-2b7ad67deb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_c674e1a4-d3a5-4339-92c9-2b7ad67deb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_635490cd-c62d-4c46-8e3a-4b9293c86284" xlink:href="biib-20210630.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_635490cd-c62d-4c46-8e3a-4b9293c86284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_9a130259-238e-45b0-990c-f8e6b19e4361" xlink:href="biib-20210630.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_9a130259-238e-45b0-990c-f8e6b19e4361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c31795e8-5b65-461f-9ff6-6c3d36ee5348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c31795e8-5b65-461f-9ff6-6c3d36ee5348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a4a69276-414c-45fa-b958-f761a8253d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c9679b1b-ece5-457e-968d-0156c502046b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a4a69276-414c-45fa-b958-f761a8253d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24b1a40f-c976-4505-989e-2cf1c0893111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_65d56e32-7f51-4ced-ac3f-0bed9e6e0999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24b1a40f-c976-4505-989e-2cf1c0893111" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_65d56e32-7f51-4ced-ac3f-0bed9e6e0999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26eb7370-21d3-4803-9800-42a9bc8e3746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5839a3b0-f935-4ef0-87c1-2bfca53654c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26eb7370-21d3-4803-9800-42a9bc8e3746" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5839a3b0-f935-4ef0-87c1-2bfca53654c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_2e5c3256-7730-439f-9836-35cfd089847d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26eb7370-21d3-4803-9800-42a9bc8e3746" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_2e5c3256-7730-439f-9836-35cfd089847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48e21998-4f45-4843-8d75-da71a9b0b785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26eb7370-21d3-4803-9800-42a9bc8e3746" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48e21998-4f45-4843-8d75-da71a9b0b785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_331d325d-cf3d-42cf-989c-69b1a5716618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_331d325d-cf3d-42cf-989c-69b1a5716618" xlink:to="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7fa710b8-7257-450b-9db2-796e5d86981f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08058a49-da67-4da2-9a4c-bfbdb88e439d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7fa710b8-7257-450b-9db2-796e5d86981f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7c71e0ec-7c77-4d45-a9ab-984e67c3b912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7fa710b8-7257-450b-9db2-796e5d86981f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7c71e0ec-7c77-4d45-a9ab-984e67c3b912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:to="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3f14897c-e817-46ce-ba34-55e5efd2a936" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_dcbd8999-6d26-4937-8c80-b03d42bc0842" xlink:to="loc_dei_EntityDomain_3f14897c-e817-46ce-ba34-55e5efd2a936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_84dfb578-8826-4e6c-b1aa-f2d62c26b6a5" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3f14897c-e817-46ce-ba34-55e5efd2a936" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_84dfb578-8826-4e6c-b1aa-f2d62c26b6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80418497-343c-425b-a027-9d4c34fa7421" xlink:to="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0ac21d79-09b2-4b90-bf74-fb12807eeeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0ac21d79-09b2-4b90-bf74-fb12807eeeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b19d8d39-a13d-4ace-b092-22b12b8e3ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_InterestExpense_b19d8d39-a13d-4ace-b092-22b12b8e3ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_e13b2d6a-b3a2-4653-a2b4-807f86c421c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_e13b2d6a-b3a2-4653-a2b4-807f86c421c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b67a0601-f9c2-4712-9d9a-d50494032545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b67a0601-f9c2-4712-9d9a-d50494032545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_872b068e-2878-49b4-b4f5-643a1017e56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_872b068e-2878-49b4-b4f5-643a1017e56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bbaf76cb-c876-47e0-b7b1-c771094506d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_6e12b4c6-5a32-4c26-8a60-0a78fa892d06" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bbaf76cb-c876-47e0-b7b1-c771094506d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bbf05303-12b3-43fe-ae78-6e6fde5609ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_bbf05303-12b3-43fe-ae78-6e6fde5609ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3d8a7b9e-0df1-4d52-a555-bb78f1d20f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3d8a7b9e-0df1-4d52-a555-bb78f1d20f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_de899f19-6499-44f1-8378-cf68dba7ab55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_77748f8b-3df9-4939-87d1-3b27d1a5acf8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_de899f19-6499-44f1-8378-cf68dba7ab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_79881555-eb6f-4062-913b-485809cfb7f8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_bdf84485-947f-4ce2-a3c7-b6283ed2d84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_bdf84485-947f-4ce2-a3c7-b6283ed2d84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a55ecb33-90be-4bad-8531-844e96084494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a55ecb33-90be-4bad-8531-844e96084494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c35a5feb-0ff1-40b8-a87c-f997b90b7412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c35a5feb-0ff1-40b8-a87c-f997b90b7412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_a366153e-bbff-4322-aa6b-078b717db5ef" xlink:href="biib-20210630.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_biib_Collaborationexpensesaccrual_a366153e-bbff-4322-aa6b-078b717db5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_89553dcd-3727-4bf2-9794-516399c6a568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_89553dcd-3727-4bf2-9794-516399c6a568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8e26eb98-9b25-4881-85f4-dccd8bad3ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_8e26eb98-9b25-4881-85f4-dccd8bad3ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dcae492b-ae9f-4753-9433-78d0713fac9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dcae492b-ae9f-4753-9433-78d0713fac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_61ead5a2-e330-4ce7-bd3a-ddda2c3aaa36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_798e344f-0ceb-4aea-8306-6d9a820de822" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_61ead5a2-e330-4ce7-bd3a-ddda2c3aaa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20210630.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_055000af-c3fd-48fb-83c2-23f6949fb23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_055000af-c3fd-48fb-83c2-23f6949fb23b" xlink:to="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:to="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fff89d34-d6b1-4afe-97bc-db903ada3dba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d900bf37-132b-498b-af0f-35d7262fbf19" xlink:to="loc_dei_EntityDomain_fff89d34-d6b1-4afe-97bc-db903ada3dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_0c4f97f3-6527-4f2d-a85d-c512ab997e31" xlink:href="biib-20210630.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fff89d34-d6b1-4afe-97bc-db903ada3dba" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_0c4f97f3-6527-4f2d-a85d-c512ab997e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8196289e-5db5-4233-9a98-d6bf2a0364e7" xlink:to="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee03df6e-13f1-4ec4-9405-eb6a64c35cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee03df6e-13f1-4ec4-9405-eb6a64c35cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ed5713c8-6341-43c3-9008-f88f76556db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ed5713c8-6341-43c3-9008-f88f76556db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b9f024aa-bcf3-44ee-b928-d56b16c19b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b9f024aa-bcf3-44ee-b928-d56b16c19b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ce692ec6-139d-4c8e-a34a-3d9a1520f589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ce692ec6-139d-4c8e-a34a-3d9a1520f589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_676171b1-f066-4222-96fd-a58d08b92836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f42e57e-abf7-4ad0-8991-fe0e02ac0ef4" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_676171b1-f066-4222-96fd-a58d08b92836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20210630.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed00c13c-1a15-4dcc-82bb-9fd0ab7d5f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5e25b059-539d-4e18-ae52-8ba682ab0b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed00c13c-1a15-4dcc-82bb-9fd0ab7d5f1b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5e25b059-539d-4e18-ae52-8ba682ab0b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20210630.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e92ea830-fb7f-4f4b-9230-74229a168e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_b63d4437-d0d6-4e4d-aca9-5ae41973e1df" xlink:href="biib-20210630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e92ea830-fb7f-4f4b-9230-74229a168e45" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_b63d4437-d0d6-4e4d-aca9-5ae41973e1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_6d65e792-ba33-4e00-874e-b53129878c63" xlink:href="biib-20210630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e92ea830-fb7f-4f4b-9230-74229a168e45" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_6d65e792-ba33-4e00-874e-b53129878c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_476e0ba2-8270-448b-b5f8-70c19895ca57" xlink:href="biib-20210630.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e92ea830-fb7f-4f4b-9230-74229a168e45" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_476e0ba2-8270-448b-b5f8-70c19895ca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e260a995-1550-4ec3-a1cb-2c7f54130e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e260a995-1550-4ec3-a1cb-2c7f54130e9e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abc80780-c46a-4541-b8fe-42d9b52f2dec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_affdf152-3e10-48c4-9e7c-048afe449ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_affdf152-3e10-48c4-9e7c-048afe449ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fdd69a33-364e-435b-a6a8-a9d1d51f737a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fe9d1d5-e2ea-4a31-ab78-6e90434496bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fdd69a33-364e-435b-a6a8-a9d1d51f737a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_af99a093-8c61-46cb-98c0-f1ebc134e2e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_94c6d494-98b0-4c61-bac9-b496e2d12791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_us-gaap_CollaborativeArrangementMember_94c6d494-98b0-4c61-bac9-b496e2d12791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_cc0afb83-a6a7-4209-a32b-546dcfa0e9aa" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_EisaiMember_cc0afb83-a6a7-4209-a32b-546dcfa0e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_1267f95d-14b3-455f-b2df-fba75b247ea4" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_DenaliTherapeuticsIncMember_1267f95d-14b3-455f-b2df-fba75b247ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_5ead45d0-eef3-4af5-bbec-904803494a2d" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f2778d9a-7b19-4164-915d-114017a86af7" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f2778d9a-7b19-4164-915d-114017a86af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_d1c41b0a-5029-402a-899a-722c009e4a48" xlink:href="biib-20210630.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_SageTherapeuticsIncMember_d1c41b0a-5029-402a-899a-722c009e4a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_a986cfd4-7157-487b-9f45-98cc082b5e3a" xlink:href="biib-20210630.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_UCBPharmaS.A.Member_a986cfd4-7157-487b-9f45-98cc082b5e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_e71dd693-7b38-42ba-b607-e2890789f536" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_e71dd693-7b38-42ba-b607-e2890789f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_38559fcc-8e08-4342-a3c5-0477868c7b2b" xlink:href="biib-20210630.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5299dac9-fcd9-4b9e-a4e1-132a9f2c64f7" xlink:to="loc_biib_OtherresearchanddiscoveryMember_38559fcc-8e08-4342-a3c5-0477868c7b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d8fd2dad-e58c-4fe9-879f-eb819ac330a3" xlink:to="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_52794149-ea52-4878-aa27-3ac7d4a552c3" xlink:href="biib-20210630.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:to="loc_biib_E2609andBAN2401Member_52794149-ea52-4878-aa27-3ac7d4a552c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_9ea2733e-57f8-4b6f-99e9-92a3f8aa96cf" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5eafeac0-a849-4335-a762-a952a797d046" xlink:to="loc_biib_ADUHELMMember_9ea2733e-57f8-4b6f-99e9-92a3f8aa96cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_088d26f2-c089-41ba-8dd7-b09c3c3bb20d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d99f33a8-8e66-45d6-a1e1-ae318af98525" xlink:to="loc_dei_EntityDomain_088d26f2-c089-41ba-8dd7-b09c3c3bb20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_d2410918-c555-4aa9-a39f-c41654bd3a70" xlink:href="biib-20210630.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_088d26f2-c089-41ba-8dd7-b09c3c3bb20d" xlink:to="loc_biib_SangamoCommonStockMember_d2410918-c555-4aa9-a39f-c41654bd3a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a6f7519-402e-40ad-8f2c-9e8ce6066f88" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_ffac0f07-f1a9-41ce-a260-2c56762eb2d7" xlink:href="biib-20210630.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:to="loc_biib_DenaliTherapeuticsIncMember_ffac0f07-f1a9-41ce-a260-2c56762eb2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_8b1a4ad4-84db-4243-865a-e556c02b7f89" xlink:href="biib-20210630.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_577cec42-3c35-4fbe-b40e-3373d1ac0273" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_8b1a4ad4-84db-4243-865a-e556c02b7f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a0a24d2-d008-46cc-b2f1-a24d3df3759a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_81f87980-64fc-4e96-9ce0-218dc3ce9d80" xlink:href="biib-20210630.xsd#biib_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_NumberOfProductCandidates_81f87980-64fc-4e96-9ce0-218dc3ce9d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_eb56689a-b65f-4595-9966-b19b1f703b89" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_eb56689a-b65f-4595-9966-b19b1f703b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_1817a976-21b4-47a1-9955-067a205c4f4f" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_1817a976-21b4-47a1-9955-067a205c4f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_cdee435f-038b-483a-8d00-bb6dbad132c9" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_cdee435f-038b-483a-8d00-bb6dbad132c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7a647699-acc1-43fb-944d-08d8dbd5e20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7a647699-acc1-43fb-944d-08d8dbd5e20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_2cc57159-b680-4259-871d-200c1cd66c91" xlink:href="biib-20210630.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_ExpenseIncurredByCollaboration_2cc57159-b680-4259-871d-200c1cd66c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_7e9bf85f-a5c9-4889-ae28-2c7d46438025" xlink:href="biib-20210630.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_Expenseincurredbythecollaboration_7e9bf85f-a5c9-4889-ae28-2c7d46438025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_620cf2de-2320-4431-bf02-3d5faed99dde" xlink:href="biib-20210630.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_620cf2de-2320-4431-bf02-3d5faed99dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_676239f8-556b-465b-9a4d-88fb352c8435" xlink:href="biib-20210630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_676239f8-556b-465b-9a4d-88fb352c8435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_144e6de5-c8ec-4a39-928b-085b95b7f736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_LossOnContractTermination_144e6de5-c8ec-4a39-928b-085b95b7f736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f4784cda-1f73-46c1-b138-4710910cfa5d" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f4784cda-1f73-46c1-b138-4710910cfa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_62b51291-3eab-43b6-8748-425fcb999a9e" xlink:href="biib-20210630.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_CollaborationAgreementTerm_62b51291-3eab-43b6-8748-425fcb999a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_38f93dbe-a5f9-46e0-970f-435d36727377" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_38f93dbe-a5f9-46e0-970f-435d36727377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_59a7559c-d0be-4d76-b194-5f8a2aab5db0" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_59a7559c-d0be-4d76-b194-5f8a2aab5db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_5d2718c3-cd62-48a5-8e59-7bcb6a532b42" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_5d2718c3-cd62-48a5-8e59-7bcb6a532b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_0ee74c9d-1da9-4fa4-ad23-2b0b0ca0ebb0" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_0ee74c9d-1da9-4fa4-ad23-2b0b0ca0ebb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_79291f2e-0dec-43ce-880a-ec600f40e2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_79291f2e-0dec-43ce-880a-ec600f40e2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_228b1d9f-087c-44b1-bd64-2b2539d15aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_228b1d9f-087c-44b1-bd64-2b2539d15aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_1081935c-be01-4a0d-b631-de4f7611fea0" xlink:href="biib-20210630.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_1081935c-be01-4a0d-b631-de4f7611fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_cb435b26-d45b-4d30-85f4-1792bf6703cc" xlink:href="biib-20210630.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_Termofcollaborationagreement_cb435b26-d45b-4d30-85f4-1792bf6703cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_e2d0fb76-2b9f-42d4-b5a9-92bacc619758" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_biib_AdditionalMilestonePayment_e2d0fb76-2b9f-42d4-b5a9-92bacc619758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_83ee063d-e104-43cc-b672-f4724fd5fec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b9d7b7-0b22-489c-a632-c56fe49fcb96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_83ee063d-e104-43cc-b672-f4724fd5fec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1c646789-cd75-421f-93b3-4f32e724b000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1c646789-cd75-421f-93b3-4f32e724b000" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_a4f11020-f01c-4464-aa07-41d7139bd323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_0fa23d87-7f97-4c29-bdd8-2112ffd0330b" xlink:to="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_a4f11020-f01c-4464-aa07-41d7139bd323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_d619c5c1-580f-441f-886c-3fa3a03cfa59" xlink:href="biib-20210630.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_a4f11020-f01c-4464-aa07-41d7139bd323" xlink:to="loc_biib_NeurimmuneMember_d619c5c1-580f-441f-886c-3fa3a03cfa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_3dc5c5c1-8359-4b0d-8b52-4ad160cda90c" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_abec1cd4-cff6-4b13-b242-4b883d3b72a0" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_3dc5c5c1-8359-4b0d-8b52-4ad160cda90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_98b7c006-2ff5-4f80-98a7-925b4181f557" xlink:href="biib-20210630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_3dc5c5c1-8359-4b0d-8b52-4ad160cda90c" xlink:to="loc_biib_RegulatoryMilestonesMember_98b7c006-2ff5-4f80-98a7-925b4181f557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_20497464-bcfa-4ad9-a8c8-1ad456456752" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_cfb8950f-3730-449c-aa33-b695046866bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:to="loc_us-gaap_InventoriesMember_cfb8950f-3730-449c-aa33-b695046866bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_83e7dd86-2c23-42f5-b808-992631255e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_83e7dd86-2c23-42f5-b808-992631255e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_14f8982c-4fda-4ee5-b0dc-f95477d8a285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9ca8efab-7edc-4465-b269-08ca7cd480b8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_14f8982c-4fda-4ee5-b0dc-f95477d8a285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf5a4382-042a-4e97-96d8-ca68074bfd48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_91560b0b-bb30-42e9-bb6d-6593fb4be1e9" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:to="loc_biib_EisaiMember_91560b0b-bb30-42e9-bb6d-6593fb4be1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5b10174e-4dea-44f3-848d-6ea7fcb1b09d" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5b10174e-4dea-44f3-848d-6ea7fcb1b09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7765dd31-1927-48ab-9ed7-5efc74fb8a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3f11a6e-c923-4c06-87dd-8fe275a18682" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7765dd31-1927-48ab-9ed7-5efc74fb8a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5e49ec75-dffd-44ba-b159-8bfaa09cc5e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ffc98c3c-9233-4e14-b5bc-a4426f497b6a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5e49ec75-dffd-44ba-b159-8bfaa09cc5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_b93e3b9c-a5de-4db9-af2a-018104d09667" xlink:href="biib-20210630.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5e49ec75-dffd-44ba-b159-8bfaa09cc5e3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_b93e3b9c-a5de-4db9-af2a-018104d09667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af21ae05-37ff-4022-a645-d451df3086d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe13dfef-d406-4d4b-8d45-cb873b6adbb8" xlink:to="loc_srt_ProductsAndServicesDomain_af21ae05-37ff-4022-a645-d451df3086d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_90ed4679-591f-461f-9fb8-a51b5fe9d086" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af21ae05-37ff-4022-a645-d451df3086d6" xlink:to="loc_biib_ADUHELMMember_90ed4679-591f-461f-9fb8-a51b5fe9d086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fc3d7d6d-3956-4b03-917a-0d2a98bac0c6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75ba2b6e-802d-4a22-b0d9-82d665fb03e0" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75ba2b6e-802d-4a22-b0d9-82d665fb03e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_14c0c4be-b138-4aac-9ebc-3ecc816166bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_LossOnContractTermination_14c0c4be-b138-4aac-9ebc-3ecc816166bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_c9e28c59-540b-4d05-b4b4-a76f73789da1" xlink:href="biib-20210630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_c9e28c59-540b-4d05-b4b4-a76f73789da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_daa716a5-a239-4a38-8d56-7bb2228a56a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_daa716a5-a239-4a38-8d56-7bb2228a56a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_552e4b15-32b7-44d0-a05f-895cd867f053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_552e4b15-32b7-44d0-a05f-895cd867f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_04530cac-4850-4ec8-baaf-907c45201b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_04530cac-4850-4ec8-baaf-907c45201b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_cb6789e1-9582-4bfe-86a8-83d5cf0ff136" xlink:href="biib-20210630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_cb6789e1-9582-4bfe-86a8-83d5cf0ff136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4b159b9f-2985-4bcc-a64f-a2487b576cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4b159b9f-2985-4bcc-a64f-a2487b576cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b6debee7-09a8-4fe7-9d56-b53962568a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b6debee7-09a8-4fe7-9d56-b53962568a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9bdcc6d9-c245-4ebd-9cc4-1f857ab4d334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_EquityMethodInvestments_9bdcc6d9-c245-4ebd-9cc4-1f857ab4d334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_443809cf-72a6-46ea-8638-63e67cdae4c9" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_443809cf-72a6-46ea-8638-63e67cdae4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c789d90-7325-4e6c-8228-1d2d4a9854c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c789d90-7325-4e6c-8228-1d2d4a9854c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_54ff74e2-ed05-40fb-bb01-ff2cd5a50ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_54ff74e2-ed05-40fb-bb01-ff2cd5a50ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_fbd0d744-8654-4fcb-a9cf-a26653f01623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_fbd0d744-8654-4fcb-a9cf-a26653f01623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1bda17ac-a296-4bc1-a747-737b3733a1fd" xlink:href="biib-20210630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1bda17ac-a296-4bc1-a747-737b3733a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_a0f2edfc-2970-4e3a-b305-c5b6d2ed5bbd" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_AdditionalMilestonePayment_a0f2edfc-2970-4e3a-b305-c5b6d2ed5bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_15e8de79-6f01-4a8d-bc27-28e4798ba198" xlink:href="biib-20210630.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_ContractOptionExerciseFee_15e8de79-6f01-4a8d-bc27-28e4798ba198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_c0964a45-8659-46f8-8dcc-37496ea338fd" xlink:href="biib-20210630.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_c0964a45-8659-46f8-8dcc-37496ea338fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_d0ccd650-2412-446b-a331-f34901baf5ec" xlink:href="biib-20210630.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_biib_Collaborationprofitlosssharing_d0ccd650-2412-446b-a331-f34901baf5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32bd0a67-0def-44d7-9153-2478c87126f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_Revenues_32bd0a67-0def-44d7-9153-2478c87126f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_abee8951-7967-4cf2-b3a4-463243fec283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_089db00a-8f22-498b-90ad-967d73c10320" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_abee8951-7967-4cf2-b3a4-463243fec283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20210630.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_2d816866-4b11-4eca-b238-d3203db0ea44" xlink:href="biib-20210630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3bdc9afa-721a-4c8f-b7b9-f2175c97f21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_2d816866-4b11-4eca-b238-d3203db0ea44" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3bdc9afa-721a-4c8f-b7b9-f2175c97f21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_73a2afbc-323e-4bbf-99b3-c272fc1bc955" xlink:href="biib-20210630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_73a2afbc-323e-4bbf-99b3-c272fc1bc955" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96441f81-d793-46e0-891e-bb8710b0d444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f88e5619-7adb-40e5-9a53-1657b9ef7755" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96441f81-d793-46e0-891e-bb8710b0d444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_52e835e4-e75d-43ed-8c82-4c6171f6591f" xlink:href="biib-20210630.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96441f81-d793-46e0-891e-bb8710b0d444" xlink:to="loc_biib_EisaiMember_52e835e4-e75d-43ed-8c82-4c6171f6591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_05de153c-4e4a-42df-b89e-9bb4faeb356b" xlink:href="biib-20210630.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_82d43854-1e13-42d8-ab12-15a204d63077" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_05de153c-4e4a-42df-b89e-9bb4faeb356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_b40dafce-f935-48fc-b06c-a3e1a42809c3" xlink:href="biib-20210630.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_05de153c-4e4a-42df-b89e-9bb4faeb356b" xlink:to="loc_biib_RegulatoryMilestonesMember_b40dafce-f935-48fc-b06c-a3e1a42809c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2b7e74ea-218f-4d96-83b7-8c2b89a338e2" xlink:to="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_9cc845ee-4ff6-40c6-bd51-f65c00a5039c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:to="loc_country_JP_9cc845ee-4ff6-40c6-bd51-f65c00a5039c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d7993666-6e71-4a24-9fea-44cecf349e95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_90b2939d-08f5-4391-bd38-b708ed6f42aa" xlink:to="loc_srt_EuropeMember_d7993666-6e71-4a24-9fea-44cecf349e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c01f2661-650d-4545-903f-5d5e34e4a95d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3c2c989c-d1c2-435b-aae6-e74fe812f10e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c01f2661-650d-4545-903f-5d5e34e4a95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_8231bf4f-382f-4ecd-955b-f3d6691befe2" xlink:href="biib-20210630.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c01f2661-650d-4545-903f-5d5e34e4a95d" xlink:to="loc_biib_NeurimmuneMember_8231bf4f-382f-4ecd-955b-f3d6691befe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ca0fe7d-6ff3-4c45-9b46-222077d031e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_68104b15-78c2-4596-a69b-7e93c2a1aa7d" xlink:to="loc_srt_ProductsAndServicesDomain_6ca0fe7d-6ff3-4c45-9b46-222077d031e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_4391d031-2f9b-488d-bc83-90be170a3cfe" xlink:href="biib-20210630.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ca0fe7d-6ff3-4c45-9b46-222077d031e7" xlink:to="loc_biib_ADUHELMMember_4391d031-2f9b-488d-bc83-90be170a3cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_27003539-f8ab-4215-8685-a8c2cb5f5ccc" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_aafed871-27d3-4e7f-8de3-18c62f793d21" xlink:href="biib-20210630.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_CollaborationAgreementTerm_aafed871-27d3-4e7f-8de3-18c62f793d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_5ae0f5cf-3b6b-4f38-b057-4af829eefcb1" xlink:href="biib-20210630.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_5ae0f5cf-3b6b-4f38-b057-4af829eefcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_cd014d51-f636-428f-8f54-938f8a0627e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_cd014d51-f636-428f-8f54-938f8a0627e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_0c85c4c8-c2bb-4778-9bf8-965f078cad80" xlink:href="biib-20210630.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_0c85c4c8-c2bb-4778-9bf8-965f078cad80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_d6894e4c-b8ae-4140-9c9f-df8c8edd0452" xlink:href="biib-20210630.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_d6894e4c-b8ae-4140-9c9f-df8c8edd0452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_de6cd445-bc1f-4481-b3d7-921ca9873191" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_de6cd445-bc1f-4481-b3d7-921ca9873191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bf0bf810-cb30-4efe-8f80-4edb0ddfb11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bf0bf810-cb30-4efe-8f80-4edb0ddfb11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_a9132435-f39f-468c-8471-92d5cb583f56" xlink:href="biib-20210630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_a9132435-f39f-468c-8471-92d5cb583f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_055505b4-31a6-4369-af1c-ef4b1c98ca78" xlink:href="biib-20210630.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_AdditionalMilestonePayment_055505b4-31a6-4369-af1c-ef4b1c98ca78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_74dda0d4-b57a-4bd8-bf92-1353a6fffc37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_74dda0d4-b57a-4bd8-bf92-1353a6fffc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b7295a11-9b23-4a58-b1c7-d1f511b1a5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b7295a11-9b23-4a58-b1c7-d1f511b1a5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cb92019d-3da2-402f-b20b-4badb0319bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cb92019d-3da2-402f-b20b-4badb0319bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1fef3409-dc2c-4f66-8ee6-519dddf19aa6" xlink:href="biib-20210630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_075a2e91-5a23-40a8-9d3c-8f7f3af141bd" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1fef3409-dc2c-4f66-8ee6-519dddf19aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20210630.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_c902f18d-99f9-4c93-8018-f1bd40a69c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1885a43d-2959-4f61-a966-7dba6a0aec76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_c902f18d-99f9-4c93-8018-f1bd40a69c31" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1885a43d-2959-4f61-a966-7dba6a0aec76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_f14b5a88-ebbb-4b8d-baf2-d9f6ba571a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d7c3c446-ffc3-48c7-8d33-de1f662abaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_f14b5a88-ebbb-4b8d-baf2-d9f6ba571a86" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d7c3c446-ffc3-48c7-8d33-de1f662abaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="simple" xlink:href="biib-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4d263204-3801-45da-84ae-b8a1c060f436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3209a03f-6fed-49a3-9323-c70a4a433d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4d263204-3801-45da-84ae-b8a1c060f436" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3209a03f-6fed-49a3-9323-c70a4a433d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="biib-20210630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1108da5a-7db4-414e-88f0-d585e5a94476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1108da5a-7db4-414e-88f0-d585e5a94476" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72a7b01f-556c-4634-9682-5c3487003028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_46aa7084-f986-4e7a-b507-6f3b53001f73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72a7b01f-556c-4634-9682-5c3487003028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_b66a73f5-cc3d-45fd-aed9-3855f84c4384" xlink:href="biib-20210630.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72a7b01f-556c-4634-9682-5c3487003028" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_b66a73f5-cc3d-45fd-aed9-3855f84c4384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5f36836d-8a1f-4647-a58f-d25c4cd5b60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7f65d68e-4b4f-42d5-9023-e7472bc06164" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5f36836d-8a1f-4647-a58f-d25c4cd5b60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_98548eed-2290-45f7-a93b-e9276c093ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5f36836d-8a1f-4647-a58f-d25c4cd5b60c" xlink:to="loc_us-gaap_SubsequentEventMember_98548eed-2290-45f7-a93b-e9276c093ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e38e24c5-cd84-4c65-a733-f943dfc47c79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_24582e34-5113-47a4-8aa5-1a9144241776" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e38e24c5-cd84-4c65-a733-f943dfc47c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9c506b94-622b-4dfd-82a0-8180814b2801" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e38e24c5-cd84-4c65-a733-f943dfc47c79" xlink:to="loc_srt_ScenarioForecastMember_9c506b94-622b-4dfd-82a0-8180814b2801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf79a4c3-027d-4bc8-8d42-04929e9d8c91" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e7212354-b5a3-4c9b-a323-f33dd19abbbc" xlink:href="biib-20210630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e7212354-b5a3-4c9b-a323-f33dd19abbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6b85a4c1-0b34-48c7-ab78-a8af7ba1ed22" xlink:href="biib-20210630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c01f1fa1-179b-4437-9ba4-8833a72d44f6" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6b85a4c1-0b34-48c7-ab78-a8af7ba1ed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20210630_g1.jpg
<TEXT>
begin 644 biib-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  E@    $  0"6     0 !_^%2)&AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^#0H)
M"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^0FEO9V5N7TQO9V]?,3(P,S$T/"]R9&8Z;&D^
M#0H)"0D)/"]R9&8Z06QT/@T*"0D)/"]D8SIT:71L93X-"@D)/"]R9&8Z1&5S
M8W)I<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^
M#0H)"0D\>&UP.DUE=&%D871A1&%T93XR,#$T+3$R+3 U5#$P.C0Y.C(P+3 U
M.C P/"]X;7 Z365T861A=&%$871E/@T*"0D)/'AM<#I-;V1I9GE$871E/C(P
M,30M,3(M,#54,34Z-#DZ,C=:/"]X;7 Z36]D:69Y1&%T93X-"@D)"3QX;7 Z
M0W)E871E1&%T93XR,#$T+3$R+3 U5#$P.C0Y.C(P+3 U.C P/"]X;7 Z0W)E
M871E1&%T93X-"@D)"3QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A-86-I;G1O<V@I/"]X;7 Z0W)E871O<E1O;VP^#0H)"0D\>&UP
M.E1H=6UB;F%I;',^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@T*"0D)"0D)/'AM<$=);6<Z:&5I9VAT/C@X
M/"]X;7!'26UG.FAE:6=H=#X-"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'
M/"]X;7!'26UG.F9O<FUA=#X-"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T
M04%14VM:2E)G04)!9T5"3$%%<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!
M0311:VQ.02LP04%!04%!0D%"3$%!04%!14$-"D%117-!04%!05%!0B\K24U7
M16Q$43$Y455K.4=357A&04%%0D%!04U317AP8FTX0T5!04%B5S4P8VQ*2%%I
M0EE75F]G0C@T04%G04H-"D%!64%-44%!65=.>F-%,512;%%!04%!05-55D1)
M2$Y34C!)04%!04%!04%!04%!04%!04%!4&)704%%04%!04$P>3%)54-!9T%!
M04$-"D%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!4EDS0GED04%!059!04%!07H-"EI'5GI9=T%!
M05E104%!0G-D,U)W9$%!04%F04%!04%566UT=V1!04%!9U%!04%!56-L:%I7
M9T%!06AG04%!055:,6A:5V=!04%I=T$-"D%!0559;&A:5V=!04%K04%!04%5
M6D<Q=5I!04%!;%%!04%"=UI',6M:04%!07-104%!0TED;E9L6D%!04$P=T%!
M04-'9&UL;&1W04$-"D$Y44%!04%K8DA6=&%104%!+V=!04%!56)75FAC=T%!
M0D%W04%!06MD1U9J84%!04)$04%!04%-8VQ24U%W04%"1'=!04%G35HQ4E,-
M"E%W04%"1'=!04%G35EL4E-1=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U
M8VUL;F%(46=+1TUP241%-4]49V=31U8S8D=6,&1#,5$-"EE73G)96$IK245.
M=F)80FAB;FM!04=2;&,R34%!04%!04%!045N3E-2,$EG4U561$YJ135.:EET
M36DT>$%!04%!04%!04%!04%!05,-"F,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04$-"D%!04%!04%!04%!04%&:%I7:4%!04%!04%!1'I544%"04%!
M04%28DU71FQA24%!04%!04%!04%!04%!04%!04%!04)95U9O9T%!04$-"D%!
M04%B-DE!041J,4%!041K1FA:5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L
M84E!04%!04%!04-39T%!05!H04%!=',Y:UI83FH-"D%!04%!04%!04):2E)5
M36=A2%(P8T1O=DPS9#-D>35P6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-
M9V%(4C!C1&]V3#-D,V1Y-7 -"EI73759,F=!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!6D=6
M>EEW04$-"D%!04%!04%U4U561$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&
M2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!
M04%U4U561$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F18
M26=C,T)H63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!04%!04%!04%!04%!
M04%!04=2;&,R34%!04%!04%!04Q&2FQ:;59Y6E<U:EI30E=A5U8S85<U;DE%
M3G9B;5)P9$=L=F)I0G -"F)I0DI254TR351K,DYI,'E,:D5!04%!04%!04%!
M04%!04-X4UI76FQC;59U63)59U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7
M-&<-"E-55D1.:D4U3FI9=$UI-'A!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!0C)A5U8S04%!04%!051P4#1!1D8X=4%"1% -"D9!040W8W=!
M0D)-3$%!3F-N9T%!04%&65=6;V=!04%!04%"34-664%504%!049C9C4R,6Q9
M6$U!04%!04%!04%!44%!04%!04%!04$-"D%!04%!04%!04%!04%!2U!!04%!
M06Y.<%IY04%!04%!43%*54E'3C%C;EE!04%!04%!045!04%!04%504-G05!!
M0E%!1U%!94%#34$-"DM!071!1$E!3G=!-T%%04%244)+044X059!0EI!1C1!
M67=";T%',$%C9T(S04AW06=10T=!27-!:T%#5D%*;T%N=T-K04MK07)G0WD-
M"D%,8T%V041"04U907EW1%%!3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"
M1%%%5$%2:T)(=T5L05-S0DUG131!5#1"4E%&34%624(-"E=11F=!5V-"8F=&
M,4%8=T)G=T=,05I)0FUG1VA!86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"
M*V=)1$%G=T-&04ED06E90TQW230-"D%K14-3=TI506PP0UIW2GA!;F]#:$%+
M3T%P9T-O9TMS07)90W=13$Q!=%5#-$%,<D%V541!04U,07A91$E1371!>F=$
M47=.4$$Q;T0-"EIG3GE!,S1$:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%1
M1T)"345)05%T0D1S15-!4E9"1TU%8U%2*T))=T5M9U-O0DQ917A!5%0-"D)/
M144X050K0E$P1DA!57)"5&]&4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8
M;$)F64="9UE70FEC1TYW6DE";&M'86=:-T)O=T<-"FY1879"<T%',%%B:D)V
M54A"=V-:0GES2%!19%!",D5(9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G
M>4-%64E79VAU0TE)26QG:7$-"D-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8
M:TIJ=VUK0V)O2GIW;FQ#9G-+15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R
M>D-W<TP-"DEG<S5#,45,85%U04,U9TQS079)0RM%3"M1=U-$0V]-47=X8T1(
M54UJ9WEN1$U!33)1>GI$43!.2F<Q0416;TYD03)/1&%K3G=W,V4-"D1F9T]%
M=S1U1&MK3UI!-2]$<'-/=&<W4T1U-%!#43AL1#!%4%AG.39$-5E0<W<O4$0K
M=U%#4D%M145-45E20BM%2G-1=5)$6$5055(-"D5X17A%53A28E)'345A;U)Y
M4DAO16=C4TIH2D9%;5%3:$)+:D5S35,T>$U$17E-5%%X3FI%-$U4<$)01D4K
M555":%%N1D5K56%H4TP-"D9+,%5Z:%1W1E))5DY"5E=&6&=6;7A7.49E05=!
M>%EM1FMK5V)"85!&<DE7,6AB-D9X,%A14F1L1C1K6')H9E-&+V-91WAH04='
M55D-"FEH:79'3E59*VAK9T=555IA>&U21V)C6C-2;T5':6]A55)P,T=P-&%X
M4G)S1WA18D]X=&I'-&]B<VAV84A!26-+:'A32$AS8V]X>DT-"DA0561(:#%(
M2%A!9&U2,T1(97=E1F@U04AM;V5L0C8K2'5K9D5X."M(,FMF;$(K+T@K;V=&
M4T)"24=W9VU#1$5)4$%H2$-&24E856@-"F]32$])9G-I2GE*5DEO26ER>4QD
M27=O:D]#3FU)-5%J=VE0=TI".&M44U(X2DMS:S)I54I*5&=L84-76$IC8VPY
M>5EN2FQC;6AY83,-"DIU9VY'0V1*2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'
M2U1G<&%Y;61+9$%Q06EO,4MM9W%M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,-
M"F)I>6E,3F-T1$,Q0DQ8671Q>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](
M3"\T=TY40G--2U%W,GI%4TU5;WAG:D<V369)>4MJ2FH-"DUP<WDQ1$U.33!9
M>F9Z3S1-+T4P2WI2;$Y*-# R1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K
M3C)!,VY$9EA/0E$T541I34]-9S4-"D)4;$-/6#@U=D1N-4]J639D1'%Y3W4X
M-TQ4=')/-F\W-D1W;E!'53AP1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH
M4#)%+V]J+VD-"E%#3D%:14-M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP
M1&954$%204Y%4C!32U)--49%:U964EIP1C-K66E2;61'<3!B=U)Z5D@-"F4P
M9D%3059)4S!I4E-.9$I(56QJ4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P
M36-K>39444I.4VLR5%1D>$]*535U5')D4$%%.4H-"E0U3E S5D%N54A&474Q
M14=55D)2;3%(;55J1E-F1DQ(57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*
M5T0Q6F-6<6Q7.3%D158U2E@-"C1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L
M<C%7,%9B;%9V;%A$5F-H;'I76%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%6
M9U8R0W$-"EE0>&A4,D=I6696:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!7
M5U-:961M4%=A4UIU:&Y05V546BML;U R:5=A3WAP43)M86%F1G$-"E-'<69A
M=F1R5#)U;F$O.7-6,GEV8E%H=%E',C5B:$IU83(W16)X-79E1R]28T-T=VAN
M1&=C5'!X;%A(=V-K='EP;DU"8S$Q>G5(454-"F1(0C!Z2%5O9%E6,31862MD
M<'0R*TAD5V0W3C1%6&AU94UX-4MN;4IE960V4FYQ;&5W4C=9,W9#9D-&.&=8
M>FAF548Y;U@T0F9M2BL-"G=N.&IF-%(O-5E"2&=+:4)#;T9R9V,R0TU)2U-G
M=E-$5C1/-FA",D5G251J:%5E1G$T64]H;DM',31C-V@U*TE"26AP:4TV2DTT
M;5H-"FEF-DM:27)+:7I#3&QO=CAJ1T]->6\P>&I::4XO-#5M:G,V4$YO*V5K
M06%18G!$5VM4*U)Q2DE2:VYQ4S0U3DYK-V%524I32VQ04U8-"E@U6$IL:E-7
M;C5C2VPS5U@T2FA-;4QI6DI*;5%M9GEA84IR5FTP2V)R-7=C;DEM8SDU,6MN
M9$ME44HV=6YX,F9I-2\V;T=M9S)+1D@-"F]B86E*<4M7;W=A:F1Q4&UP1F%K
M>#95-'!A;6U'<6%,<'8R;F)Q9F=Q1DMO>$MK,W%A;7%(2W%0<7=+<F1A=G!R
M1GES,$LQ17)B:74-"DQA-FAR>&%V:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ
M<G)1;'1*>3%%-U=+=&=',F5B8G=T,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4-
M"G4V93A)8GEB=E)7.6HW-$MV;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$
M5TU057A&2$5Z<U9,>&-J1U)S8D1X,$A(=CAG.7E,>DH-"D]S;35Y:FI+=#AS
M,GDW8DU.8WDQ>E183G1C-#)Z<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14
M>'122C%-=E94=%A2,6Q85S).9&,-"C$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW
M1C-)<F1%3C)7,VAZ96]T.' S-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K
M+T]7135G,VT-"FQU8V8U-FYO375I.#958G P3W!B-G58<F-/=C<W26)T164R
M8S=I:G5T3SE!-SAZ=U=01&PX6$QX+R]+33AX;GIP+U$P.4U,,5506&4-"CEM
M,S(K+V5+*T)N-'%0:S0K8V8V5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O
M+R\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44$-"D)G445"055%0F=51D)G
M:T="45E*0W=G1T)G9TQ$06]+0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-
M5$9"451%>'=B1WAS8TAX.&8-"DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H
M55)&4F]F2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&8-"DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%7045!07=%4D%!
M25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!448-"D%W24=!
M44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!04%104-!=U%&0F=C24-1
M;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34(-"D%G35)"04%&25))>%%614=%
M,D5I8UE%54UP1VA">%=X46E00E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS
M4$-.55%N:S9/>DYH9%4-"EI(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+
M0G)Y-"]013%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95@-"G W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR
M96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1544-"D)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC
M=D5Z2D121&=H85-5>5=I63=,0T(S4%,-"DYE2D5G>&15:W=G2D-H9UI*:EI&
M1VED:V1&53,X<4]Z=WEG<# K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<-"C%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT
M>4YJ;RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$-
M"D%!=T1!44%#15%-4D%$.$$Y43,Y+V)71G$Y>F-T>&I4=S-*2C9!1'54:V]2
M36I167EK26EY.# Q+W=!-#8W8S-+>3(X<E=C151";V\-"EEZ,4E0-UHO82M8
M5$YL:3 X04XY,UA:33AI9'1M3BM99E!V;4<O;6%/-'579V=04S-G2FI3;G91
M.&TK:S5D2%,T=TMQ,G%E;VY,<7@-"FAY1UES1TQC=#9N<CE/8W!R.4=C138O
M:%!*67ET3TY%.#)E63E+;%9R3SEK15DV=U-%=D52-&-'<5!U>D=H;6Q(:U<R
M1U-1-48W0C4-"E X-U<R=E)E:DUG='12459E1W9W=4(Q84UN9C5J=&UX=V%K
M5#(V=61J>6-8=EI.;5,R=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W4-"GA6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9G*W588C9R<D0R
M-FUT=F%S63!8<UA'>G0Y*S):,DM00D<K<&-,2DP-"FEL6%%-9C%U>45)27!M
M4FIL8E)K:E1!9&9H3%%/-F9B:7%W.7=/;WI+-D].,5-+>'9W>$%9+T-E=5EE
M<G=$3FI-9794,W-X<WE+,'0-"BM63G,T<61G,%A):D9K96I1>G=8354X1$=/
M5TIG>4]/>$=5.%I"<T]40TPR8E1R=UAL;$1C:6=-:3%91'-W,EEF9FY266-N
M2$%38VP-"D5:87)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)Z1%$W,$DO<75A<W@-"C5%*S4S
M>F%:675T>'E54$U&-'-P62M/2$9';4]75$-B=&=Z;DTR3&E&9S%O2U1/1C-1
M35%P.7$W6E-','92=DQ&<71X64Q+-2MW>%$-"F=$=T%0-FIN2#ET=T5-*S,X
M478Y2#9(33 T=4Q+8E=*5F]&1D)M;T1L9TTX.'%%+V\U:U!26D14-45!-79/
M>GHV2S@R861:;G$W1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3AB=F5E;39L9%=B8D=#5FQ(
M*W(-"E@T5#E),WIC>#E545A54SE*25-V54PX1E-786=(56Y,27AA-5-9:G%U
M;WE3:&]B96]$8DY*-V4R5$HW;4E#;&]0;#8O,4,V5S)S-%<-"FQK4%=N4E(T
M<V5G2'IY;DIK:FIJ>%-.0G-J17E.0C90<#)L2%1,9&).9V9546MY16EL5U!8
M3T8W43%2>C5426EU9SEZ<W-74&=&2G0-"F%X-VI-5TEB9WIZ>2]!671/56M5
M36I&+V\V1#E78B]247)(-S!V0B]Z6C$W6$Q8.'=.5F=T9%)U;TE%*W(X26]P
M<$515G1O>6%+<$$-"D93834Q*V=X44]'2DE(6#=Y.#ER<W-H;4E"4%0W;4MP
M<C-M-E)E4V%J<41Q96I,3DU2*T1:;&Y&:C=O+TE/2TUU5'9L.7)N,3=Z9$<-
M"G9*.5(Q0D9(5FUM;4$O1G-2:7@Y,&9K1D]82C-Y*S%.=$4O3E!Z=G!--D].
M4VQV6590>#(Y-'AN5F@T8VYQ-"\R3$1+8W5H>%1(2W8-"F,R-#EB;&=E9"LY
M.4-E55!.3F@U;C!/2%9,449/4DM4=T4Q84M69G1)5#,V,4(W:D]D,4=!-' X
M2F5G=UIX;&IX0C1F*V)/=F$U82\-"FU"<7-&<G%.,4)!;C%F:$9&3DEI0W1T
M1U125DE!<5183C=O355$:&E30C$K.'5K,3)747I%06YP.7HQ8CAN-W4W=2])
M;&Q09%136$4-"GI35&AP6E=,<V%3<T)6;4I/86IT0TE'66=B8VYA-D-23TE%
M*V).37=N361I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G,-"E9D
M:7)S5F1I<DAD83AJ-EAQ*W%#+W5*2DEZ=T-Y>'A52$UR,$I*0C=B6FM9.51+
M16%$:C5.4$=5<DQ"+T]0-6-8,&5O<3)K=VUE=VT-"D=Y1F@K-EEB14U84%$Y
M46-Y.%=U9TDK<S T;6)3>31V5'E59$TO2W%/;VLQ4S0R-BMH0C$K;'E0,41-
M3% R=T]50CA3,EDY168T:7H-"D=X,#=4=$UT>&(R34-14D1Q1D<U23=S5'5X
M*V5A4$YN;FM.>4YU9$-!:4M#;&5145A(.31T5TA2:#%(,#5I5$%,26AD<%=H
M=%!/04,-"F9253%D<61"-&902C9F5$=C=DI&57I&5E9&0W%+2V]O04]W1V(P
M0VA3=FUJ.#1V+T%#62MR+SA!4G8X03E1<U=D5#)D+V-2*U S;#4-"G)T1"LK
M;#A0=40Q+SAL=B]!0U@Q:B]X:VXO-5!.;6TW4R]V:CA(8CEN9C-)*TQ/1U98
M56\T1$MW25I32V=G.5%2;4$U>C4S+T%$<C@-"G5A6&\S;6%#5%1O:W0T<BM$
M,7!,9$)25FM$1E-Y<4YL1&)B1'983VLW37I3;D$X6%%V4&1O-%EW;G0Q6D@O
M>FIV8U1(.4]7*S5G2#$-"F5194-U9E5"+W=#0T$O1$U8=&=$,&XS=5(R4U0V
M:#=K,3@V96-0>7<P+WI.95=E=#9#.3=Q8UAP+U=,;&)E0U%.>6E2:RM*-499
M,%$-"F=B:DMT3G X.&]!=VQ59F57,U5A:D)'6D5O,TPS0FUF:V95=$(Q3'DU
M0F0V1F%'># Q,FM%5G-Y2D=62W51>#1O>G)U,B]834Q646X-"D=:17IC;DXP
M,#139T1!545X,6I7.4LP87AE*S%/-5,Q=%4R3'5E<#=+<6EP62MW1F-R>#1P
M5$Y21FQS>5I)=T9Y3D(U,V4O.#5!95<-"EEP:6QP65A6>D=#4C9P-%)G*S9G
M;&I4-3!Z67@W2FU2=5%(6%,W5F=$<T-56&]V-39E56(K9%E,>$HY3EIJ4EI:
M9TAI<5115EI#4U -"G!7;G9K379:95-)<U9*;FHW5'AY3DA:-DI&3$9,1VMS
M5')*1DE!>4]P1$MY;F-%16)%2$YC4E1S06)5-S(Y=$Q',&QU-WE:24QA1F4-
M"E5S,&@T<6](:51H:D5Y3D1M:55H15=E5'IJ5E!Z.#AQ,C!R4C).<F,S+T@O
M04AA07-56BM833@O=E5:<V]D;%I$>DE$<G Y<5EX>4(-"DM#9R\U>4<P;&TO
M,&I2-VE.9D=/5DA0,T5*:WHR4DQP24U",G)(<D5P9')V+T]15GDO2U!1=$Y7
M269S,T8T951F.&EK24%0*WI/5S0-"G5Y4B]'9FLQ-64Q5"]!4&UZ<CAQ9DTK
M;V59+TMX=F12;$4Q-4AC>7=Y=4960G12,4%#9T1:6$%Z03$K0T]02E5E5D]D
M;V-X>5DW4$\-"C!8-7$O35AY=#5:8C!R*S5-;#53;W-R8V5P3%-L4GE&47$Q
M+WEI36AG,&543'5"=#-S."MR>#0K6C,W;4=N+VY)6%)/5D)P5GIX<G,-"F5C
M9&%F3"LS33,K4THO>F<T9CA!2W-F-7!:8C55+TTS>7(U;&Q&=&%43F(S>"MZ
M6C-)0U-.459006=S<F9)1W9T;4AN,%=41G5D>#,-"FAY.$=S>#5.:'I:6&U)
M-51Z:38O4&IY:&)833%U.6YQ0F5&,FI9<DA$4W%':'!7665'8D]06E=1:3=J
M.78V;EA3-U1X9S%5=G,O5WD-"F)Z9C4W.'8K5EE%9E5P5V$T;$)-1G!#03!R
M9V)6;U-!1CDR3UEU;C!S.' Y4$IY8RMP:&E(<5E:8F8X04]16&PQ-6Q7-# R
M-FAI2F\-"EI&36)K9357<35M>3=*;E=X1&AJ=%=&-V=V4CE',7)3.6$P*U!5
M3DUU1G5B5U0W36DQ1D-/<7-P;U9).$1M='E9<%%.4T9&,D]02D<-"EEU2G-)
M,TLR8G-68U%#2T560C9J16A51F-A5VML5$<S02M",T=9=5139SAT:S)G6#!3
M.$HR94]N>F(K;5EX,%4K.$QA*T1Y*V])864-"E1L+VMR="M*>6-.0U T:71P
M=$9&2$5G4TY1<41O0FUD1TEI2T-&,E-6.'HO04IX9BM42#%F+V\S+W=#;U=,
M3V\W3R]U22](-WDX,3(-"F@O9E,K2#-":V9K1#@S=$4X="M73&938G%Y=5IP
M;UAK6G!)=E0T;FTU654U340S>D8Q9EHX<W51>4)$:S986'AX=T530WE#6"]N
M250-"GDK23)-5VU88GE!9D-R;4Y62CDR1$Y4-W-X>#)24'%1,VYT5TAC6&PR
M=6%R-6HX*RM:1W59<E(U-VQW23=E,&=5=4EO;$HT<EAW<7@-"DQ-9G=Z831S
M8TY00W(R9%IL;E!03S8S93<O;&HU26)Y<&]*:'53<F%L94U*<GAL,T-K0VEX
M9SEW;2LO:51M9S%U<#A79&HV4GED-V\-"CE.-%5+4$UV1G9Z:2]W1$IJ-G8O
M04Y'+R]53$9M.#=/+W5)+T@W>398=$0K*VPX4'5$,3,X;5I%:B],<7IK9&=Q
M23EW>DUE9T%L66L-"FY.3C)K3'I(-$\S-U!0-VMF1C1R-2\X04]L-35P,3)7
M-5IY3E!H67!95R]13$=$<WA(.'HY5RLW;TTS;6LP=WA1<G(Q9$QQ=%%C<W(-
M"C9D1V$K5"]Y3"]33VMW-FAR9#5*871C;TI)<E-&5C5Q:F)Q6%IU5S5'+T=M
M,EE/;S=5-%IC34)D3V)P*WI/2TYY3E=K4#5J9FQ:8V4-"E9)63<K,75$96%8
M22]P<S=+1FMI8VEQ:#9B14Y4-U@P6FMA4%A$2V%)<512<3E%8U%S1S1P-2M2
M+VYE-6<Q16578C)5=F%825IT4#4-"D=V<'EQ0WI)2R]S=4MM;FHX.&\W5#!W
M369%2$UC,B]S,U5K2&=023AL,S4O-B]D='%L;&]58FQB4T]%6%5Y1%E023=-
M<3AV2&EQ8F8-"E!",E1I2$-:.653.7%:5'A#2%1M;&XU469L-7!V;5=3-C%(
M5F<P;&A:<W-59'-R1F95:TDU2&UY,&)I;W P3SEF=G0W43%K<U92:GH-"DQ6
M;TY*2$I:;'E$,%AZ1BM49FLK+W="36QJ,#)Z1FAF<6@K<E1X=3E/64=W9%=9
M9V<Y*RMA,T0R:FMJ3#%'=S=(3#)F:FQ(,&EI*V4-"DQ+-49T95$S0FE38U)/
M<FU'5E%Y3T9.4W)!.5%E;61(2TYI;FYO;6IB-DXX,V599$HX;F535W8Y1G,T
M3$MF54]!<V]);VMJ6#%:57(-"C9J2V=!2E)"6#=H;DXV9D1,3FQQ4DIR;3E&
M;GEX=S1R:4%,-5!$+TM(;&Y5=D]F;5@V<3 W8W!/5GAF,VML6%E*56-M3F9T
M37AA9SD-"C@S=6]Z>'=W=79C2%,V9D1,3D]R.35E>F8X<4TX:F95+U$T,U!R
M8V%F5R]74'%6.&5.4%0O=T-&>E-F>7!L=3EN8V9Y8FEQ=#-I+VT-"B]W07-A
M:C50.'AM>6%9;&\K33EL94I60WE6*T9X43%69WEK9&5O>F0V9E!(3D,O;4A4
M86I#8TTV*U0V0B],6'I7+VUB>71"951K1RL-"F=*=#<R;3%:14%03"]:<5$S
M>GIN=&)G.$Q)44]834\O,&5F>$U92C4Y6'I4<E@O2%IV.$$O;4EL+W=#2FY/
M;7AF4U!C.#-K*V\K.38-"D9O9FMB6"]Z23%#-SAY-FQD9E5B1S1K6EE82VU2
M;4-'9U-*4U9(0E!S.'$Y9D4Q>E@U9%9$5%)%26EY-T1(<' V9VUC:E%3;CAX
M9GD-"G9U+TM+43-K5GHY9# R9"]4.55R=V5/4VA)5F=#=TE)0F]C=#!E=4=B
M87%K,6%V4DA&=F1H3F9Y1S%Q93(X,%1A5UA0,6$O9UIV5#<-"F5R1#A3="]W
M2$E:5C)R:D)X.%A51G,W37E%5#1E:&4O6GIZ=C-9<3=&6%EQ-T9867$W1EA9
M<2M:+W=!-'8O2FHV=CA!.4<O+T%&0W@-"EHQ2%HS.7A(-"]E6&UU,% W-EAW
M*S1*,35(+THR,CAY*UA)3EAF5DAT;6UA4E1#<TEC1# S2R]A3'(Q<&Q'<3=2
M3TM::E9T*VTW4$<-"E-!;&1*-B\O041J=F$X5'<Q>'<S66TS0D@O2G=::B]Y
M=V8U=C)T+SAK:BMD.6IZ>GI:-5$X=V539%9H17-X55-697DQ0S-::T1C858-
M"F]24FQ:86EO>EIA9E51>G@K.$]U>C9E94=8,T8V>BM4,S5I6&9M0TMB4CE7
M9C%.4W1%.5='-#9'5T5%2V58*U5P23,W9RMX>E5D;S8-"DU9+U9(-E,W8G,O
M5FY*-EIF54AM6#5X9BM42#%F+V\S+W=#;U=,3G R9"]C4BM0,VPQ;F%(.3E,
M-&9C1V4K5V)I4S,O04-'=EI)>E(-"B]2=3!R-U!+>4@X1WI8-7AE<DAV1&XT
M5%=K4'AE4#A!;#9Z4SDQ+U1,2C$U2F,S8T5,3#1I4U)622](3GIM;'=W2C=G
M6%59;SA5=T\-"CAH.61G04-G,D$V1$]/9719>BM:;'!(9&51.6%J:S9*8FU5
M8E8K2TEI4F9X6$UR4E-R3D@S=4YR23-I;#=N>F0U5W5M=%!-,FLS2VL-"F=W
M,VM$-V5!:U=O*VM:,#)E3C0U1'E,>FU#5E1I9DU06"]Z>#AK,V5O=WAE67)&
M9E5E>&A-5CE&*S$V2W-85C%(9FE78FPW9DQ.3C(-"EAQ4D4X0C8X;F(Y<&%9
M>4A'3VY.9T@U8F9M3DPU475B:4]A,TXQ<'0S>$TP845+-D]T44A3=7@R3D-$
M-V(U<TYB;R]'06\Q24]";SD-"E@T4DYI=U=C95EF>CDP>5142F]D1'-R;&(R
M5D-I5#-):E)9>3(S24)(:TQ%9'5M64](<VU1;&-Y2SAN3GDY<5)-86E$9FTX
M,#AK*U0-"DY4.# V=DAA,C!B3%IO=TXW9# K0TM/=2LO5&M2.6QF-%9Z6C9N
M57AX4G,X*VIR9$YP-5I:54]85FYN+T%$:T9.-F,K:&%F1T]&=D0-"D9+-F]/
M;3521BLT2FUV-TI&:5(V=60R<60T:#4O=T-69D]M="M6-4QI6%-J17-L,$97
M5G!%1#=)4U%"6' Q>EDU.4Y(3%A&,&-$0G$-"DI9<C1E<DEV*U8T*V90.$%F
M='8O04UI4B]836(K4SA0;C@S22]L3$PU36,X,65C=&$X,%1W5#9Q63)K=&Q:
M23)J44HX3$=T1%1R;50-"F<P,&-126HQ8V90<4I:4T1,;SE*+W=#8V0W;5-U
M=5=P,VHO,&569EDO=D90,S=F9&UT-UAJ.4HY-W-E>50Y43EZ>6)7=BM/>F8O
M.$$-"DU23"]!351/8F)&.4DY>G%S;C%(,W9Q:GEH6E(R4&QB4TQ61C1I2S!H
M1$0O04-I9TQ(-E=*3V-P<4IC5U-2.'DY4G T.$]/23AM3"\-"D%*-"\X;TA,
M+W=!>$U0-GIM5C):+V9F075.,FPO9&9&-5HK4S,O:W=B2"]J2% X03AM5WIB
M9'!F,THK2#-U<C=/+W9H.%@P;&Y-=E(-"G5X5C)+=7A6,DMU>%8R2W5X5CAZ
M+VY&+S5-9E8O=T1O,R\V:%ES-FIS-RLT:CAF=DQZ6&%(.3E,-&9C2'(O-4QF
M*U,K<V8X06I*4"\-"D%-;FUZ5&1P9C-X*T1T*WIV-VMF1FY/641N4$AV*V-G
M=%<P.7)85&1+5C%E+U-6<FE24E%T2$AX-&IL-&-Y9'9L;34W27AM>DQO-FH-
M"G1824M%97)%=GE25UDK9G)9>#$T3$)/6F%F>3A+8B\W26I->G1/=D)0=D1I
M9&TS-&\K2T8O3TPO04UM4'$O.$$P8B\Y47-75#=/+W4-"DDO2#=Y=S=1+W9P
M9D0W9SE).&DV6DIQ;C5+>C9F14]5,7A&94Q#;S=Y8S-+1"]G9TTQ;7%N=V%O
M2'5P,E=M:'AA879E.$XP-C=A>#$-"DLQ=D].5W1:;S5U4&E9,D15+T1.-T]0
M1D5J=F1(0UA$24AU9EAL;&57,3=A43-L<S1K=#=H1FQH:TA2:V-60BLW3U!L
M17A.2&U(<F\-"GE%:%DU350O041C,65$5'9)=6]+-VA:<C%287=*,UEY16-Q
M9DI!>'I,-U!X;5=595<W:6$O24DT:C4W4$)F24]M4S9L-7HP93%J6&P-"B]P
M56-S;B]'3T9V568O:%5/9$)Q-3A/2U(X;E$V5TA&:VE03FPS-35E84Y2=69-
M:C9#<VI2-F99<$=Z46EO5U-74D)*>F(K8FE'04@-"FAV;4@R6&=I26-F575:
M,FQM2FYW9$%Y;CAV4$MV-6$V=C5.<S)N=')E-'9+2#8X,'-N1V1:<3!917%Y
M<W$O>6IW>D4Q;6901$MA2D$-"C9D>FQA5$)H;FI&9U@Q6D)"*U=0-5AW4T-2
M3E!G3$1T2F-3>4PO=TQY378T6FIN5S5Z,5!Y+UDS:E)90C K,6QU;C)M;C)T
M;VM';G<-"GA15VDO=T(S2$%Q<D=01V=88DU/8VE48W5B;'AI04M(2C5(+T%-
M-41A835J,&95,5@Y,G!L='!7.$-W5C1X+W=R-75/>4HO5D@T=7 -"C=7:#E-
M:W8O04]C9F159V<Q;E4Y3FMC3$IE=WAY46<W8VI!5W%"-SA:0V9O>7IT94)-
M4DQU+U,Q.6Q406M9.2\V2'5M848S:D=F3F8-"C5H*U<O2SDQ8C)U<'E3971C
M;UI!<TMH>7%!,$1/2V=G36$P*U)Z2W=A3V5517@V3TYN,6--4D%L,5(O;'9Z
M6&]F;5,Q:W5D26YA94L-"D8O5&Q,4GE2,&%L869'<3$R,S)Y=DYG;FE.4T10
M1&YJ:T9X9DLK=&8X9&TO+W=#66E8+VE:>G$X6#!J,U!,-5!Q4'9F5V5I9CAC
M87<-"B]W0UEA3"]I07IK8W8Q2#-V5C0O<$AU65HK95 O2T)Y+W=$351$*W,U
M;3EM9C,S=TQH.7!F,UAX95=F:W0O-4U'>"\T>'HO.&U7>F(-"F1P9C-**T@S
M=7(W3R]V:#A8,&QN3792=7A6,DMU>%8R2W5X5C)+=7A6.'HO04IX9BM42#%F
M+V\S+W=#;U=,3V\W3R]U22](-WDX,3(-"F@O9E,K2#-"2710.#-E84Y.=%9T
M3$163&TQ=&M*2U%X4TUQ9W-A;6="-VY,-39F2$DR66=L;VAN;D550U%%43-N
M-WIS>6Q4<FPW43<-"F)4=40Y-$]2+TM9=C5O*U1,.#%L+VY(-7!61$)Q5W%8
M=D-'3V$Y=EIJ6&EO85=2>64K,5=/5VMX:4XY9S%!4VMD='DK9U!Y:R],>68-
M"GDQ6GIA:'%903%A.55)66=19E)H0C5C2VHY<&I1=#AH;E!D;V%W6E1W>"MK
M3R\P1VM/35A,-FDX<"]/3"]W06U0<2\O045B+T%054P-"D9M,S=/+W5)+T@W
M>39R=$0K*VPX4'5$,2]W1$IB+WE8,6HO>&MN+S503FUM-U,O=FHX2&(Y;F8S
M22M,>GHX,B]Y,79D3S%+-#$S4V\-"D1,<&0P>&QU631W4V)E4G0S2E5F-W)9
M-V<Y=6YH;7@W4#%O;$51:V954'1D9G(Y1UEY330O4V9S670U82]-9GIB-61T
M5&%A9&1J-G -"E5L8F5:0DEI:S=K<%AD82M!3DUY.#)J>#5$8VAU-'5(5C5-
M66](6D-A>C5G.#!E8G13:"MU>7DS.3$Y:3)T;VLR5W954GAO2V(P,S(-"G%C
M;FIW-#A-9'1G>'E:6C5:8C=L-U@K52]W0U<P;FQU,V)63E559G!I-E1I26A1
M*VA'9'ET4C%D=C)Q9DQ.2'(Y8C1P-%DO4U!T9'H-"F]D2#19-'!F569S65 K
M971X-6)N.'=21WEL6CE::5%286EQ04=)2TXP1$Y8*SA7=$-!3VY7:$=:+UI9
M;4EB+U0P8TQT37=-.79Q-G,-"D%U3D$Q,C)53F,V9&11<7=$0G!)6D9"0G!1
M,4DY.#)!>7=026AW1&EM3UE+1RMP6&XK*TI0*T%B*VU3-&@S<T]%.7ET<#)Q
M-G)P5C$-"C8Y:&145V1W:#-A2FU1,4A:9T]V>4]#94]->%)&:&Q#8V]'=V%E
M-RM79%1T+W=!>F9);#-P,G)!4C9H0U)(3DUI.4I!3U5--G(R<BL-"C!V>C9!
M-6]-.$1P8V]L2&PK3$1V8TUX<6-2:DQN*TXS:D]U95@O369L1%=64S574S%U
M65@U,FPW2%5)+T4W4$4O9CA!5T\K8G)&;&@-"FUJ='5/-3 R5$901$QF63DW
M230O>GDX.7)B0T5Y5WIU0E0V=S!)-3$X9&E%<B]S8WAJ,EAH=3DS24AA5U=U
M:D@Y4#!V>E8U,S$Q,FH-"D5L.694<T1C,V-M,&-9-F-N641I:6=D05!K0FU2
M4$IJ=U$W9S!1:&MZ5#=Y*VMF2B]L97HX<S9$8C968DAM639V8U15;UI*5RLR
M-4@-"C1$=T9--7)56GIL;5I&-E!4-%)J9TEH.'1A,2]X,F(O05 U:4IF.$%I
M6GIQ<U@P:C-03#50<5!V9E=E:68X8V%W+S5H;W8X06E!>FL-"F-V,4@S=E8T
M+W!(=5E:*V50+TM">2\X04U41"MS-6TY;68S,W=,:#EP9C-8>&579FMT+S5-
M1W@O-'AZ+T%02FQS,C-A6#EY9F@Y-W$-"BMZ=C<T9D8W6C5G+TU$4G1"=35,
M9E5)8FQ22'<O9F]I3VI'4DAD1D%$.#9T-F)+2W(Q*R].2&@P:W-G=4Y/-GDV
M<4]-,&):3FU+-4P-"G-69&ER<U9D:7)S5F1I<4=M,'942C5$3$YA47EY=%1K
M-WAO>D=G;TMK:7942D-C:'E,17=I95E79F]44G8K5T,R+S5&2B]41#1S=3@-
M"F\X3U!C2&9O5%)V*U=#,B\U1DHO5$AX6F0U6'<T.7=6-V4P=&):4W1V0VM+
M;G%),4-G+V-":U1);FUY15%/4W)G4VAP=$PP>651>7H-"E=K37-R535/.&%-
M>&]+0W!)<C!Y46Y)8VEX34EN;49A0T-#0TU245)R1D=/:4EO5E)8,D=!:VYM
M:T%$:W9W2E-7-CAL955,=55Z6$<-"FI78VMR9F%C=U(X:69C9V(U9DA5-4)S
M2D@U=$UT4&I/-6E0:VI.33!(4DY,0D=M,D9V6CAV=$=#2DEY9FU604HK;DE4
M>7IN.5)*6G<-"GA2:CE)05(R5G,S>4YQ13DU6BM:3&UE-5AN95<Y-#AK>7EI
M=DM22E-71$1V5FAV;EE104U!0GE)95-M4TIK;FYB-E$X="]M6#53,3(-"C!J
M:U,K:71,<&=057,W;#%J:U9U-$A,:4A(=75C,6TP5U1'959J=D0P94A7635J
M;E(W:RMF5TY*4TU3=F4R-GA'<$1T2V=88G)U5%0-"DUC635D>&)Z:VHS:#1:
M*V0R=CA!;&969%)S53!H-')M.'1X24PR.&=O5EE(:G=4,4)S.4M%.39:=G5Z
M35=3151X8D1O2%(Y<%I94TD-"C1D>C%:4#A!.#0K-E)D5RMK86YQ8W%L66(K
M4TM/,W)T>49U2#5-4&)L2E0V37AE,7-G36A(=2]3-5A:5TUI2FPS+V]E<%A6
M;F%88TP-"E%88T5D>$$S,F]P5E8P4'I69U)M<&I)9S).;F%3:4-+2U1F-$(X
M:SAU6#9#<V$Q<B]C2E0W<55Y+W=$3C5F-7@K8E0K5GAF>E(X:S4-"G1,3S!S
M-%)"85%2,CA#+UII:595469*5D%'57EK4V)*='5J14%51EA)<%%B84YP1$U7
M87AT>7A.4U1%:$I**VI**TI,=DQ$=S0Y=U(-"FEQ<7%&54%+0E%!8D%!6D)M
M<'HR.79C4BMN4$5K,&1A.$I&1$Q597AW9VMC:T5!.#%+1%1.3F=K17-&<$1&
M24]J<$=Q<TLK-$=%>FL-"F5:44E22$E+:W1P851%;5='3U%M;%-Y:'$P-F12
M,G)G16E%;4E+<F=3-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$-"C=&6%EQ-T970BME4'EJ,%1Z3F-T<45-<F%D<6(O=T(W36EH-#5+0V=,
M>#%89F)Q0U!E=6)$4SEO4WA#:G9&=V14;TDU1%DR:S@X=68-"GE".#-X=E-#
M-G-P,#=(;DEJ9E-$1U(K3V)'4&$R4'%#-C0Y;#5/:$-K;C5#*V1M64%Y,DM!
M+W1'5U-G*S9-;D0O2W5,>E(O2F58>5H-"E(U9"])0WAG;5-F6'(T,UE5,4YP
M8F=X;V8Y85%N;5(X9W9Z>D9Z9')%:6]#;DMX9&QG1S5M,W)&=&)7.71B>#(Y
M=D=S5453:$EO:T$-"E965E)104%D<S%"2DIS=3%!049"57=*9&ER<U9D:7)S
M5F1I<G-69&ER<U9F+SEK/3PO>&UP1TEM9SII;6%G93X-"@D)"0D)/"]R9&8Z
M;&D^#0H)"0D)/"]R9&8Z06QT/@T*"0D)/"]X;7 Z5&AU;6)N86EL<SX-"@D)
M/"]R9&8Z1&5S8W)I<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^#0H)
M"0D\>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C X.# Q,3<T,#<R,#8X,3$X
M,C)!.4,U-3 Q,$,Q,#)&/"]X;7!-33I);G-T86YC94E$/@T*"0D)/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#HP.#@P,3$W-# W,C V.#$Q.#(R03E#-34P
M,3!#,3 R1CPO>&UP34TZ1&]C=6UE;G1)1#X-"@D)"3QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U
M,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@T*"0D)/'AM<$U-.E)E
M;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N0VQA<W,^
M#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@T*"0D)"3QS=%)E9CII;G-T86YC94E$/G5U:60Z-F$V9F0Y,F0M9#0Y
M,2TU-C0W+6(U8F(M8F,P968Y.#1D,V8P/"]S=%)E9CII;G-T86YC94E$/@T*
M"0D)"3QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,#,X,#$Q-S0P-S(P-C@Q
M,3@P.#-%144Q040S0T1$034\+W-T4F5F.F1O8W5M96YT240^#0H)"0D)/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^#0H)
M"0D)/'-T4F5F.G)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO<W12968Z<F5N
M9&ET:6]N0VQA<W,^#0H)"0D\+WAM<$U-.D1E<FEV961&<F]M/@T*"0D)/'AM
M<$U-.DAI<W1O<GD^#0H)"0D)/')D9CI397$^#0H)"0D)"3QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#I&13=&,3$W-# W,C V.#$Q.#(R048Q,T)%-$-".#DV-3PO<W1%
M=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N/C(P,30M,3(M,#)4
M,30Z,S Z,3$M,#4Z,# \+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*$UA8VEN=&]S:"D\
M+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C X.# Q,3<T,#<R,#8X,3$X,C)!.4,U-3 Q,$,Q,#)&
M/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H96X^,C Q-"TQ
M,BTP-50Q,#HT.3HR,"TP-3HP,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H36%C:6YT
M;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X-"@D)"0D)"3QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"3PO
M<F1F.E-E<3X-"@D)"3PO>&UP34TZ2&ES=&]R>3X-"@D)/"]R9&8Z1&5S8W)I
M<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS
M.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R
M+S$N,"\B/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT
M/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)/"]R9&8Z1&5S8W)I
M<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^#0H)"0D\<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^#0H)"3PO<F1F.D1E<V-R:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX
M;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
MGP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3
M 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!
ML0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q
M GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#
M9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^
M!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/
M!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS
M"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-
M)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B
M0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@
M5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>3
M9^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO
M>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6
M=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_
MY8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AI
MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:D
MQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZA
MKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y
M2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4
MQ%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/
M-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IV
MVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WF
MEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,
M\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_
M;?___]L 0P " 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+
M"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'
M" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20210630_g10.jpg
<TEXT>
begin 644 biib-20210630_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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MO?&">*9;=9M+"[9I9':266W8F0E=DA.0<$?H;X8_8>T#]N#_ ()N_"?]G_\
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M@6%M%; :Q:0/(CPVUT]WO<D[7V[OF43(K]+_ ,$E/%7PH^+W_!8/]H7XU_\
M!/'0S9_LTWO@#2K+5]0T+2GL/#VM^-TG0R75A$42-F6U$J2O&H#,0[;A(CL
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M?^4B\_\ C-'_  V1^S?_ -%&_P#*1>?_ !FC^S,R_P"?,_\ P%_Y!_;63?\
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3HPYJDDEW;LC.C1K8BHH4HN4GT2;?W(]5HK!^%WQ.\#_&CX>:/\5OAIK?\
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MPG\0_#UW-9ZII>J6T)DLW%WYGFW#M.L481V=I"^U<.RL/LKX+?\ !/[]C_\
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M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
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M_P#4[_I__P"2_P#VQ\G_ ,1%_P"H7_R?_P"T/TXHK\QZ*/\ 4[_I_P#^2_\
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M/XU^)[6)F*QZQ,JEVR?O=SWK]"*_/O\ :+_Y+IXJ_P"PU-_Z%7U'"'^^5/\
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M/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110
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MB_#?_DG>@?\ 8%M?_1*UM5^,5OXTO5G](X;_ ':'HOR"OS[_ &B_^2Z>*O\
ML-3?^A5^@E?GW^T7_P ET\5?]AJ;_P!"KZCA#_?*G^']4?#>(/\ R+Z/^/\
M1G%T445]^?DX4444 %%%% !1110 4444 %%%% !7WO\ LK?\F^^&/^O)_P#T
M:]?!%?>_[*W_ ";[X8_Z\G_]&O7RO%W^X0_Q?HS[SP^_Y&M7_ __ $J)Z#11
M17YZ?K@4444 %%%% !45W?66GQ":_O(H$+!0\T@4$GH,GO4M?+O_  5P\0?\
M$S_"O[,&G>(/^"K,L2?#6T\;6$NGR36VKS!-96.=K9MNDJTY(43]1Y?][G%
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M\,?]>3_^C7KX(K[W_96_Y-]\,?\ 7D__ *->OE>+O]PA_B_1GWGA]_R-:O\
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MRO5J*/\ B(G&/_05_P"24_\ Y /]3N'/^?'_ )-/_P"2/*?^&8_^IW_\IO\
M]LH_X9C_ .IW_P#*;_\ ;*]6HH_XB)QC_P!!7_DE/_Y /]3N'/\ GQ_Y-/\
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MWWPQ_P!>3_\ HUZ^"*^]_P!E;_DWWPQ_UY/_ .C7KY7B[_<(?XOT9]YX??\
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MS^(/[6WP5O\ Q3JEAHBZ1;R0>.M;TR+[$)991$T-A>012?/-(=S*6(;!.
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M_P"@RK_X,G_F']BY-_T#4_\ P"/^1RG_  I'X7_]"Q_Y.S__ !='_"D?A?\
M]"Q_Y.S_ /Q==711_K+Q'_T&5?\ P9/_ ##^Q<F_Z!J?_@$?\CE/^%(_"_\
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MS!5!9B!DLP4#N2!WJQ7YW?MO?'CXQ_''XR?%C]G6R^/-E\/M#^'.H^$(]/\
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MR]IR\K72^_S1\MQ%Q+_8-2G#V7/S)OXK6M\F?IQ17YCT5['^IW_3_P#\E_\
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MZ6OBS])/$=1_Y"$__79OYFH:EOF+7LS%2"96)![<U%7XS/XV 4445(!1110
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MR[_D84?\<?S1^@E%%%?C9_1AB_$C_DG>O_\ 8%NO_1+5^<-?H]\2/^2=Z_\
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M**^+/TD^>=1_Y"$__79OYFH:FU'_ )"$_P#UV;^9J&OQF?QL HHHJ0"BBB@
MHHHH **** "BBB@ HHHH ^@?#_\ R ;'_KSB_P#0!5NJGA__ ) -C_UYQ?\
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M_P#;WZ'Z?X=_P\3ZP_\ ;@HHHKXL_23YYU'_ )"$_P#UV;^9J&IM1_Y"$_\
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M7ZU1_@Q]$ 5X7X__ .1TU/\ Z_'_ )U[I7A?C_\ Y'34_P#K\?\ G7S'%O\
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M_4[_ /E-_P#ME'_#,?\ U.__ )3?_ME>K44?\1$XQ_Z"O_)*?_R ?ZG<.?\
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MABH3DYZKE47MWO*/<^+XJX<QV>5:4J$HKE33YFUO;LF?/U%?0/\ PI'X7_\
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M?J*^@?\ A2/PO_Z%C_R=G_\ BZ/^%(_"_P#Z%C_R=G_^+H_XBSPY_P ^JO\
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M=1_ZXC_T(5R8_P#W&K_AE^3 \0HHHK\B **** "BBB@ HHHH **** "BBB@
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MK8\ ?\CIIG_7XG\Z\M_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
MPMC_ /&JTH\*>QK1J>VO9I_#V_[> ^QJ*^.?^'(7[)O_ $4;XI_^%L?_ (U1
M_P .0OV3?^BC?%/_ ,+8_P#QJOL /KOQ!_R ;[_KSE_] -?/U<+_ ,.0OV3?
M^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U7AYODW]JSA+VG+RWZ7W^:
M [JBN%_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J\?\
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M\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU1_JA_T__P#)?_M@.ZHKA?\
MAR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :H_U0_P"G_P#Y+_\
M; >@:=_R$(/^NR_S%?0U?'/_  Y"_9-_Z*-\4_\ PMC_ /&J/^'(7[)O_11O
MBG_X6Q_^-5[>493_ &5&:Y^;FMTMM?S?<#[&HKXY_P"'(7[)O_11OBG_ .%L
M?_C5'_#D+]DW_HHWQ3_\+8__ !JO9 ] U'_D(3_]=F_F:AKA?^'(7[)O_11O
MBG_X6Q_^-4?\.0OV3?\ HHWQ3_\ "V/_ ,:KXQ\(W=_;_P#DO_VP'=45PO\
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MC?%/_P +8_\ QJC_ %0_Z?\ _DO_ -L!W5%<+_PY"_9-_P"BC?%/_P +8_\
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M/5OC+\<_B)I/A3PKH5OY^K:[K=XL%O;H2%7+-U9F*JJC+,S*J@D@5\J^ ?\
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M ()X?L>ZUXN^)_@S3)-"N;>31O#?PXTK2HR_BG4;I76+2+6T1")7N&+*RA"
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M 5+110 4444 %%%% !1110 4444 %%%% !1110 4444 9WB_P?X1^(/A>_\
M!'CWPMIVN:+JMJ]MJFD:O8QW-K>0.,-%+%("DB$<%6!!'44WP9X)\&?#CPK8
M>!/AYX1TS0=#TJV6WTS1M%L([6TLX5Z1Q0Q*J1J.RJ !6G10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $=Y=V^GVDM_=R;(H(VDE?!.U0,DX')X%8'_"V
MOA]_T,'_ )*2_P#Q%:7C'_D4=5_[!L__ *+:O!*^:SS.<5EE6$:23NKZW_1H
M#VG_ (6U\/O^A@_\E)?_ (BKNA>./"_B:\:PT35//E2,R,GD.N%! SEE ZD5
MX37:_ K_ )&ZY_[!K_\ HR.O/R_B/'8O&PHSC&TG;1._Y@>KT445]J 4444
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MQYUK)'*F)88V^1USMP<@D'M-)TJPT/2K;1-*@\JUL[=(+:+<6V1HH51DDDX
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M3H8^G4J.T5)-GFYQAZV*RJM1I*\I1:2\VO/0_/BBOIS_ (=R?]5C_P#+>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20210630_g11.jpg
<TEXT>
begin 644 biib-20210630_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
M8_V#[;YMW/<;OL_G3>7CSMN/,;.W.1G ]OHH ^8?^"@__!.W6/VN?&/PY_:)
M^!7QVN?A7\9OA%J%W<>!?'4&BQZC;M;W<0BN]/O;1W07-M,B@$;PR$DK]YE;
MC_V=?^":7[05]^V3HO[?/_!1#]JK3?BAXY\$Z#=Z3\,O#WA3PA_8NA>%DNU\
MN\NHXVFFDN+F:/\ =F1V&U21AL1^7]G44 > ?LF_L,?\,O?M)_'[]H7_ (6C
M_;G_  O+QAI^N_V1_8GV;^Q/LUG]F\GS?/D^T[OO;]D6.FT]:]_HHH ^+O%?
M_!,/]IKP/^V3\1?VL?V)?^"@,?POM/BY>:5??$'P9KGPHM?$=M=7EC;BV6>V
MFDN[=[7S(@=XP^78MG 55]2^#7[#'_"H_P#@H)\:/V[/^%H_VA_PM[P_X<TS
M_A%O[$\K^R?[*MWA\S[3Y[>?YN_=M\J/9C&7ZU[_ $4 ?/GPU_8.M? /_!0;
MXM_MTWWQ(CU2'XJ^"]#\/S>#I=!"K8+IZ.ID-P9F$XE#\H8DVXZMFO!/AI_P
M2X_;\_8CM-1^$7_!-S_@H%X<\-_"&[U:YOO#_@#XF_#0ZY)X0^T3---#87<5
MW"\D'F.[+%,#MR?F9F9C]_44 <'^S1\.OC-\*_@WIG@O]H+X_2_$_P 702W,
MNK^,Y/#=OI O6EGDD1$M+<M'!'$C+$H#,2L8+,S$D]Y110!\\?\ !,G]@K_A
MW-^SI?\ P!_X6M_PF/V[QQK'B+^UO["_L[9]ON#-Y'E>?-G9G;OWC=UVKTJQ
M\"?V&/\ A2G[?'QY_;A_X6C_ &G_ ,+NT_PO:_\ ",?V)Y/]B_V/8R6N[[3Y
M[?:?.\S?CRX]F,9?.:]_HH \ ^#7[#'_  J/_@H)\:/V[/\ A:/]H?\ "WO#
M_AS3/^$6_L3RO[)_LJW>'S/M/GMY_F[]VWRH]F,9?K1_P3"_88_X=P?L8^&O
MV1/^%H_\)E_PCVH:K=?\)#_8G]G?:/MNHW%[M\CSYMFS[1LSYAW;-V%SM'O]
M% 'PM??\$O\ ]KO]FGXW>//BG_P3!_;3T/X?^&OB?XCF\1>+OA?\0? 7]N:1
M;ZW. +C4+"2*X@FM3+M4O#\R%@.0JHB>M^'OV'_B+\8OV/?'G[*W_!2+]H.'
MXTCXB37*ZKJ&F^$+?P_!IEE)# D5I9PPO*5\B6$W$<\CO)YKY/"JH^A-8US1
M/#UF=1U_6+6QMPP4SWEPL29/0;F(&:GMKFVO+=+NSN$EBE0/%+&X974C(((X
M(/K0!\(> _V#_P#@LQ\(/!=C\ _AI_P5N\)R^"]'LTL="\4>*/@=#J'B>RLH
MUV10NYO5MKJ1$"KYTL>YRNYE))!^X/!NC:MX<\(:5X>U_P 33ZU?6&FP6][K
M-U$D<M_,D:J]PZH JL[ N0HP"Q XJQJ.N:)H\MO!JVL6MJ]W+Y=JES<*AF?^
MZ@8C<?8<U:H ^-_VHO\ @G1^TOJ7[;8_X* _L&?M5:)\._&FL>"8?"GCO0O&
M7@LZUI&NV4$S36\^U)X98+B(MMRK$,H4?+\_F5_V*?\ @E#\1OV9OV[_ !C_
M ,%!OC+^V5J'Q/\ &7Q ^'D/A[Q3#>>$(M.A%U'=QS+/:B*X=;>V2&&&!+78
MQ&PR-,[.U?:%-FFBMXFGGE5$12SN[8"@<DDGH* /"O\ @G]^Q-_PPM\._&W@
M+_A9G_"4_P#"8_%CQ!XU^U_V-]A^R?VI<^?]DV^=+YGE?=\W*[^NQ>E>9_"7
M_@CS\+/#?[&?QR_8D^-?Q!F\9^&?CA\1O$?BK4KFUT@:=-I?]J3131119FG#
MRVTL,<B3' 9T4F, $'ZYTC6]%\060U+0=7M;ZW9BJW%G<+*A(ZC<I(R*DU#4
M=/TBRDU+5;^&UMX5W2W%Q*$1!ZEB0 * /S<^+'_!&O\ X*+_ +3_ .R??_L'
M?M.?\%7++4_AK#HZ6.EWVB?"=(-;U;R ILCJL[7Q$\<+QQ2/'%Y;W#1+OEY;
M=^@/P1^&_P#PIOX+^$/A#_;/]I?\(KX7T_1_[1^S^3]J^S6T<'F^7N;9NV;M
MNYL9QDXS726MU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O5>\\0Z!I^I6^C7^N6<
M%Y=Y^RVDURBRS?[BDY;\!0!\[?MA_LS?M_?$/XLZ;\8?V*?^"@<'PT2T\/II
MNJ> O$_P]@U[1-5D2::5;HEIHYK6;$H1GB)W+$@(XKS7X%_\$M/VC/$O[9_A
M']O/_@H[^V5:_%3Q9\-M.O[7X8>$_"O@M-#T+PY)>Q^5=76SSI9+J9X\+N<C
M;M0_-LCV?;]% 'S'\'/^"?\ X^^ 'Q._::^,WPK_ &B;.U\2?'_7+;5M#NK_
M ,%?:(?"5U!8&TC9HOMB_P!H@-B7!, XVG(YKS>S_P""$O[.K?\ !.S4?V)O
M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
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MECJ%AJGC_1]"AT"ZN8)WE6*1(+9FCMYXX71=\> 7CWA5SM'YL? 3]@W]G_\
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M&J0Z?I7AR/7K?2[6 R*[->7EW/D0VT80EBJN[,R(JDMD 'IU%?G_ 'O[(?\
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M@#YYU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI **** "BBB@
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M** /GB^4)>S(,X$K 9^M15-J/_(0G_Z[-_,U#7XS/XV 4445(!1110 4444
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MHH **** "O;_ (9_\B+IW_7$_P#H1KQ"O;_AG_R(NG?]<3_Z$:^IX3_WZ?\
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MF:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P__ ,@&Q_Z\XO\
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MT'CWX<?$#7K21-.\0:?.]U<75E'=!2JRVUU=.K0L0S%MP!&TD ^Q/^"0,?\
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MF1*%DV8+,T6%^WZ_,C_@GUX[\'_MK_\ !=KXR_\ !0#]E"">_P#@S8_ W3_
MFI>.(;&6WT_Q7XF34(;CSK9I%7[5]GMH3;M( =N$P=KH6_3>@ HHHH ****
M/GG4?^0A/_UV;^9J&IM1_P"0A/\ ]=F_F:AK\9G\; ****D HHHH **** "B
MBB@ HHHH **** /H'P__ ,@&Q_Z\XO\ T 5;JIX?_P"0#8_]><7_ * *MU^Q
MT?X,?1 %>%^/_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\ Z_'_ )U\QQ;_ +I3
M_P 7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7
MB%>W_#/_ )$73O\ KB?_ $(U]3PG_OT_\/ZH#=HHHK[\ HHHH **** "N/\
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MD"^6Q# /N<NBK&%WLSJH4L0*_+K]E#XC_P#!9?\ X(O?\$XO!_AOXT?\$\?
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M>\8VFLQ^-_%9TNRB?5(+*WA!,223N=J3-\D9'[O#,N1D ]F_8M_X*F_L*?\
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M/&Y5D0J2,\9P:R?^%M?#[_H8/_)27_XBC_A;7P^_Z&#_ ,E)?_B*Q_M++O\
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M_79OYFH:FU'_ )"$_P#UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@
MHHHH ^@?#_\ R ;'_KSB_P#0!5NJGA__ ) -C_UYQ?\ H JW7['1_@Q]$ 5X
M7X__ .1TU/\ Z_'_ )U[I7A?C_\ Y'34_P#K\?\ G7S'%O\ NE/_ !?H!CT4
M45\& 4444 %%%% !1110 4444 %%%% !7M_PS_Y$73O^N)_]"->(5[?\,_\
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M_P @&Q_Z\XO_ $ 5;JIX?_Y -C_UYQ?^@"K=?L='^#'T0!7A?C__ )'34_\
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MFI_]?C_SKW2O"_'_ /R.FI_]?C_SKYCBW_=*?^+] ,>BBBO@P"BBB@ HHHH
M**** "BBB@ HHHH *]O^&?\ R(NG?]<3_P"A&O$*]O\ AG_R(NG?]<3_ .A&
MOJ>$_P#?I_X?U0&[1117WX!1110 4444 %%%% 'PO^UQ_P %#OVE_P#@F+^T
M=K'Q)_;'^'UOXB_94\4:C91:%\2/"%FTFI_#NY>&&!K?5K11NN;26X#R)<1!
MG0R["')CC$G[&W[:7[9O_!2W]H3P]^T+\"_ ,?PZ_9.T*6_:WUCQ;8YU_P"*
M<K6UQ;0R6UN>=.TZ*=TG$C?O93;H.CR)&S]J?]B']G#Q=^UO/^UW_P %7OVM
M/#>J?#G1-1MU^"WPE\<ZS::5X6T65+6)9[R[CN'2/5+UYS,R^;N6.-U7#_+L
MM_L[?\$];;]A[]L_0_$7[!_[2.F^'O@OX]%_J?CO]GS4[U;FQ4M:2M#JWAT;
MB]I_I9MA-$O[AHI&((V1( #[<HHHH \+_P"">_\ R1/5O^Q[UG_TI->K_$S_
M )$74?\ KB/_ $(5Y1_P3W_Y(GJW_8]ZS_Z4FO5_B9_R(NH_]<1_Z$*Y,?\
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MH **** "BBB@ HHHH ]JT7P9I4^C6DSW-V"]M&Q"W3 <J*M?\(/I'_/S>_\
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M2>#/A/X4U6UN9-7NKC27MO.RLVX+:6:3NB+&<99B<*,?/^F>+_\ @E!\'?\
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M."_WRG_B7YH#W2BBBOU\"IX@_P"0#??]><O_ * :^?J^@?$'_(!OO^O.7_T
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M>*<H2E!M>SJNS<6G:Z3MM=+L'_#PO]L#_HKW_E T_P#^1Z/^'A?[8'_17O\
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MB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\ U^/_ #KW2O"_'_\ R.FI_P#7X_\
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M4444 >%_\$]_^2)ZM_V/>L_^E)KU?XF?\B+J/_7$?^A"O*/^">__ "1/5O\
ML>]9_P#2DUZO\3/^1%U'_KB/_0A7)C_]QJ_X9?DP/$****_(@"BBB@ K\7Z_
M:"BOVCPA\7O^(5?7?]B^L_6?9_\ +SV?+[/VG_3N=[\_E:W6^GY9XE^&G_$1
M/JG^U^P]A[3_ )=\_-S\G]^%K<GG>_2VOXOT5^T%%?M'_$WO_4E_\N?_ +W/
MRS_B6G_J:_\ E#_[L?%__!(;_FH7_<)_]O:^T***_F/Q#XO_ -?.,,3GOL/8
M^VY/<YN>W)3A3^+EC>_+?X5:]M;7/WS@KAG_ %/X9H91[7VOLN?WN7EOS3E/
MX>:5K<UMW>U_(BO+&RU&W:TU"SBGB;[T4T893]0>*XWQ'^S7^S]XLW-KWP8\
M-3.WWIETB*.0_P# T4-^M=O17S6!S7-,LGSX.O.D^\)2B_\ R5H][%Y=E^/C
MRXJC&HNTHJ7YIGC-Q^P5^SK!,UWX2TC6?#D[G)GT'Q%=0G/J SLH_ 5?\(?L
MG_%32O$]C!\,OVR_'VF3&X402ZZ8-76(YX.R55# >AKU>MCP!_R.FF?]?B?S
MKZW!^(7&53$TXXC&2K*Z7[Y1K]?^GT9GA/@KA9.]'#*D_P#ITY4?_33@8_\
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MFE%7=-)7;2NVEW9].4445^2'Z2%%%% !7M_PS_Y$73O^N)_]"->(5[?\,_\
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MT0!7SE\9_AWX \;^,-4B\9^!](U93=N,:EIL4_\ Z&IKZ-KPOQ__ ,CIJ?\
MU^/_ #KY_B7$XC"4:56A-PDI:.+::T[K4RK4*.(ING5BI1?1I-?<SPG6OV%O
MV:=3NSJFD^!IM#O?X+SP_JD]HZ?14?8/^^:I_P##+OQ8\+\_"W]KSQE9!?N0
M>)8H=7C'^R!*%P/Y5[517G4_$'C%05.MBY5XK:-=1KQMVY:T:BMY6/G)\&<,
M.3G2PRI2?6DY47ZWI.#O\SQ79^WKX.^[-\/O&-LO]Y;C3[M_RS$*#^T]\8/"
MW'Q1_9!\7VJK]^?PQ<0:NF/[V(RI [^HKVJBK_UKRS%?[_E.'G_>A[2C+Y*G
M-4OOI,G_ %=Q^'_W/,:T/*?)5C\W4@ZG_E1'Y6_MC^.])^)?[2'B/QMHEC?V
MUM>_8PEOJ=HT$\92S@C8/&W*G<A^HP>]>8U[1_P4+_Y/ \7_ /</_P#3?;5X
MO7^GW $Z%3@3*I4(.$'AJ#C%OF:7LH63E97:6E[*^]D?P#QE&M#B_,8U9<TU
M7K7:5DW[25VE=VN];7=MKL*]H_X)Z?\ )X'A#_N(?^F^YKQ>O:/^">G_ ">!
MX0_[B'_ION:P\2/^3=YQ_P!@N(_],S->!?\ DMLK_P"PBA_Z=B?IQ1117^29
M_I&%%%% !7M_PS_Y$73O^N)_]"->(5[?\,_^1%T[_KB?_0C7U/"?^_3_ ,/Z
MH#=HHHK[\ HHHH **** "BBB@#\J]>\+?\%%_P!J'_@K%^T!XH_X)K?%CP1\
M"]$\"2Z-X6^)>L>)=$DUF;QYJZZ;%<073V+YAA^S03) DZ&.1X]H=I5"I%]*
M_LN? #_@LQX)^.VA>)_VKO\ @H)\-_&_@"U^U?V_X7T#X4)IEW>[K65(/+N1
M(3'LG:&0\?,L;+_%7G?[0/\ P3*_X*<ZM^WEXZ_;'_8T_P""F'ASX5:?XVLM
M.L[[PK)\)K?4DNXK.U2*-KPRR[+F=6\W9<;%E6)UBWE$51Z)^RY^S/\ \%AO
MA]\=M"\7_M3_ /!3?P?\0O =I]J_MWP?I7P7L])GU#?:RI!MNXY"T6R=H93@
M?,(RO1J /K^BBB@#PO\ X)[_ /)$]6_['O6?_2DUZO\ $S_D1=1_ZXC_ -"%
M>4?\$]_^2)ZM_P!CWK/_ *4FO5_B9_R(NH_]<1_Z$*Y,?_N-7_#+\F!XA111
M7Y$ 5\A_\%./^":'Q;_X*$^*/ %]X;_:\A\#^'_ NH?VH?"&I?#V/7=/U74U
M<&&ZN8I+N!)1&N5$4BR)\S<?,P/UY16U"O5PU55*;LUY)_G<#YT_9X_9T_X*
M&_#OXHV/B?\ : _X*/Z7\1/"UO!,EYX3M?@C8Z(]R[1LL;"[ANY&CV.5? 4[
MMNWC.:Y/_@I!_P $^OVJOV]?#NO_  A\-?MYV?@/X9^)=(MK35O!C_":VU6:
M66*83&87S7D,J[G2/Y !C9U.XU];T5I'&5H5E5C926WNQ_*UK^=K@>+?L9_
M?]J7X!^&;_PO^TC^U[9_%:!;>RM_#)M/AQ;^'SI,,*.CJWDW$WVG>#%RQ!7R
MCUW'%_\ 9<^ _P ;_@7\#;WX;?%3]J/4OB/XEGU*_N;/QKK&C>3+;).Q,$/D
MM/*'6'@#+@,!T6O6J*SG7J3;O;6U]$MO1:?+?J!^?NK?\$H/^"BNM_M-:3^U
M[J/_  5QTM_'>B>%)O#FG:F/V=K$1QZ?+,9GC,(U+RV)<D[R-PZ9K[J\&:7X
MPT'P#I6B^+_%4/B#Q!9:/!!JFN?8%LX]2O$B59+CR$+"!9) S^6I8(&V@G%;
M%%57Q5;$)*=M-K1BOR2 \%_9P_8BTWX;?!CQYX0^-OB6/Q?XM^+NH:C??%3Q
M/!;M;C4WNXV@6WA5F9H;:WM?+MX8]Q"*F>K-7E?P1_X)F_'CPUXD^#WA;X__
M +4>D>,/AS^S[<?:/AIH>F^#7L-1OIXK1[.QEU2Y:ZD24VEO(R((8H@YPS]P
M?LZBJ6,Q"YM=_)=K:=M--.@!6QX _P"1TTS_ *_$_G6/6QX _P"1TTS_ *_$
M_G2P7^^4_P#$OS0'NE%%%?KX%3Q!_P @&^_Z\Y?_ $ U\_5] ^(/^0#??]><
MO_H!KY^KX?B[^+2]'^@!1117QX!17)_'/X/:!\?_ (2ZW\'/%6O:WIFG:_:B
MWO+[PWJKV5[&F]6/E3I\T9.W:2.=I([U\"_\$POV:_A/^R5_P6&_::^"/P5T
MJ^M-!T_P%X2GB74M7N+Z>2::%I99'FN'=V+.S'DX&<  <5U4:%.K1J3YK2BK
MVMNKI;W\^S _2:BO$OVM_P#@G+^Q?^W9J.AZM^U=\$H/%UQX;AGAT62;6;ZU
M^S),4:4 6L\8;<8T^]G&WC'-?"O[ 7[!7[)6D?\ !;OXA>//V2_@];>%_ W[
M/'A6'0/-M=4O+I=0\5ZA%*+EP]S-(?W%K)/;N@P%<*<?-DW1P^'JT92<VG%7
M?NJV]DK\U]6UT _5>J^IZMI6B6;:AK.IV]I;J0&GNIEC0$G !9B!5BOQ:LOV
MC?V%?VV_VF?BO\:?^"B&B^-_BH/#OCK4M ^%_P (/"6A:KJUIX6\/V!$+:S=
M6UAA(I;J3?EYF)_=MM!4*4,'@Y8KF>MH[V5WKMI=?F!^T<,T-Q"EQ;RK)&ZA
MD=&R&!Y!!'45%8:IIFJK(^F:C!<K#*T4I@F5PCCJIP>&'<=:_/SXK7'P TW_
M ((7?$W7O^"/VHW0\+W6BWEWID7AJ]O)+K3T>YB.JQQK<L;BVF2V^TL(CM*$
M@J "M<K^S]XT_8%^"7[?'A[Q[_P3S\4^%=.^$ND?L]ZMJOQQO_!UV'TBTMH9
M;:32[B_*$JNH_+=Y\S_22F_<"":TC@.:$I)NZ;5FNR3][71N]DM;O0#]+FU'
M3TOUTMKZ$73Q&1+8RCS&0'!8+U(!(&>G-35\G_\ !/S0-3^(7B_7/^"@'[0"
M1Z3XX^,MM'%X!\+ZI.B77A[P9 3)86*QD[A--N-[<!?^6DZJ0/*Q7UA7'7I*
MC4Y+WM^?7[GI<";3O^0A!_UV7^8KZ&KYYT[_ )"$'_79?YBOH:OL>$?@K>L?
MU ****^R ^>=1_Y"$_\ UV;^9J&IM1_Y"$__ %V;^9J&OQF?QL KG/BY\6_A
MO\!_AIK7QB^+WB^ST'PUX=L'O-8U:^?;';Q+WXR68G"JB@LS,JJ"2 >CKSO]
MJ']E'X!?MG_">?X'_M*^ SXD\+7-[#=SZ6-5N[/=-"VZ-O,M98I."<XW8/<&
MG3]G[1>TOR];;V\@/D[]G[X:_%/_ (*K?';PM^WM^TOX3O/#/P:\%:A_:?P"
M^%VI)MN=6N?^67B75$R0K8^:VAYV@ALX):=?VQ)+?X9_\%S/V6/BKXNNOLNA
M^*/!GB?PG87TK8A34_*,L4+,>%>7S41!U9L 9P:[G2_^"$G_  2XT:]M]0TS
M]GO6HI;25)+<_P#"U/$Q",I!7Y3J1! ('!&*]X_:<_93^ 7[8WPQD^$'[1?P
M\M_$6AF[CO+:.2>6">SNH\^7<6\\+++!*NY@'1@<,RG*L0?3EC,,JZ<&^2TH
MVLE9-6T]YW>MW>UW^ ?*'_!1"2'XD_\ !6W]B_X0>%;DSZQX?U7Q-XKUV&W?
MYK#38[*)$EE_NI+)')$I/#,I7O7V_9>-?!NH^*;SP/I_BW3)]:TZ%)M0T>&_
MC:ZM8W */)$&WHK C!( .>*\A_92_P""=?[*O[&OB/6/'GP<\&:A+XIU^V2V
MUCQ=XG\07>K:I<VZ$%8/M%W([)$"JG8FU244L"5!'9^%_P!F'X&^#/V@O%'[
M4WAKP/\ 9O'GC/2K33?$NN_VG<O]LMK956"/R'E,,>T*HW(BL<<DUS5ZM"I&
M,(MVA&R=EJW)MWUT6K[[+N!\J?\ !?7_ )-W^#W_ &<QX._]'3U]F_$OX;>!
M?C%\/M9^%7Q.\,6NM>'O$.FS6&LZ5>*3'=6\JE70X((R#P000<$$$ U\]_';
M_@C/_P $XOVE_B7JOQ?^-OP$O];\0:U?)>:C=_\ "P->MHWG5%176""^2*,A
M5&-B+Z]2:];_ &8_V4/@/^QS\/;CX5_L[^#[K1-"N=5DU*>SN_$%]J3-<R1Q
MQN_FWL\T@!6*,;0VT8R "2356MAWA:<(2ES1;>R2UMUYF]+=ON ^,_CY^Q_\
M*_A1\3="_8O_ &4-=\7W'Q/^+_AQM'\1>./$WC.^UJ_\"?#:VE4WRVDEW)(;
M-)6*VENB@;YI=Q8F$$<GXH^(_P"TMHOP1_:.^.?[/?[2$_PS\,_LH>(+OPK\
M-_A/IFB:?+HUY8Z)I]K-*-2\^!KB<W:R&./RY8O+PI7<Q)K]!O!7[/7PR\!_
M&3QA\?M'TVYF\5^.(K*#6]5OKQYF6VM(V2WM8%;B"%=[N40 ,\C.V6.:\S^,
M/_!+S]CGXZ?%+5/BO\0/ VL/<^(KBSG\8Z'IWBW4+/1_$\MIM^S2:E803+;W
MK1[% ,B'(4!MPXKHI8^E=*K=K35I.[NKZ/I;1?\ !8'LOPL\:/\ $CX8^'/B
M)+I3V#:_H-GJ+6,IRUN9X4E\L^Z[L?A6]21QI$BQ1(%50 JJ, #T%+7DMIO0
M#Z!\/_\ (!L?^O.+_P! %6ZJ>'_^0#8_]><7_H JW7[%1_@Q]$ 5X7X__P"1
MTU/_ *_'_G7NE>%^/_\ D=-3_P"OQ_YU\QQ;_NE/_%^@&/1117P8!1110!^8
M_P#P4+_Y/ \7_P#</_\ 3?;5XO7[045_6W#?TI?]7N'<'E7]D<_U>E3I<WUC
MEYO9P4.:WL':]KVN[;7>Y_-V>_1[_MK.\5F']I<GMJDZG+[&_+SR<K7]JKVO
M:]E?LC\7Z]H_X)Z?\G@>$/\ N(?^F^YK].**.)/I2_ZP\.XS*O[(Y/K%*I2Y
MOK'-R^T@X<UO8*]KWM=7VNMPR+Z/?]BYWA<P_M+G]C4A4Y?8VYN22E:_M7:]
MK7L[=F%%%%?R2?TB%%%% !7M_P ,_P#D1=._ZXG_ -"->(5[?\,_^1%T[_KB
M?_0C7U/"?^_3_P /ZH#=HHHK[\ HHHH **** "BBB@#@_C3^U-^S'^S;':S?
MM$_M&> _ *7JEK-_&OB^RTH3@'!*&YE3> >N,US?PM_X*$_L"_''QW8_"WX*
M?MP_!_QAXGU3S?[,\.>%OB7I6H7]WY<3S2>5;P7#R2;(HY)&VJ=JHS' !-?G
MO9^'O^"5=K_P6._::M/^"K'B/X,Z_P",]1N- NOAFWQ?U33;O3K+PZ-+B5K&
M&*^=H+2ZCN/,=X75)726.9 R2%C]:_LS>'O^"%=C\;M$NOV-]#_9,A^)"?:?
M^$<D^&5MX877!FVE%Q]F-B//_P"/;S]^S_EEYF[Y=U 'UG1110!X7_P3W_Y(
MGJW_ &/>L_\ I2:]7^)G_(BZC_UQ'_H0KRC_ ()[_P#)$]6_['O6?_2DUZO\
M3/\ D1=1_P"N(_\ 0A7)C_\ <:O^&7Y,#Q"BBBOR( HHHH **** "BBB@ HH
MHH **** "MCP!_R.FF?]?B?SK'K8\ ?\CIIG_7XG\ZZ<%_OE/_$OS0'NE%%%
M?KX%3Q!_R ;[_KSE_P#0#7S]7T#X@_Y -]_UYR_^@&OGZOA^+OXM+T?Z %%%
M%?'@<]\6/BK\/O@;\-M:^+WQ6\2Q:/X<\.V#WNLZI-$[I:P(,LY6-68@>@!-
M?E;^SG_P5G_X)X>&O^"P/[0'Q_US]IG2[?P?XU\&^%=/\+ZVVEWQ2_N;:WV3
MQJH@+J4;@EE /8FOUSHKLPV(H483C.#?,K:22TNG_*^P'F_[8'[1OAG]D7]E
M_P =?M*^+?+:T\'>'+C4$MY7VBZN%7;;VX/K+,T<0]Y!7BW_  19_9R\2_L_
M_L&^'M>^)GF2^._B=>W/CSQ]>3IMEGU+5&$_[P=0Z0>1&P_OH_3.*^L:*R5?
MEPSI);M-OTV7XM_=V \N\%?M>_"+Q[^U5XT_8YT%M3_X3'P'HECJNO":R"VO
MV>[56A\N7<=[8<9&!BO@G_@GW\:/V7_^"1'QI_:._9L_;)\8V?P]U?7?BU?>
M,/"'B/7K65(/$OARYC0VHMYU1EF>!A*'B!+"2=U4$A\?J/5#7?"OACQ3'#%X
MF\.6&HI;R^9 M_9I,(W_ +RAP<'W'-:TL32IQE3<7RR2OKK==;V[WTMUW ^(
MO^"'/A[6=7TCX^?M)Z/X/O\ P_X ^+?QPU/Q'\-M-U&R>U>ZTUE5?[06!@#$
MEPP! P,B/^[M)Z#]HGPCX6_:]_:IL/\ @G[\.O#.GV?P[\(W-EXR_:'FTNRC
MAAU.8N)=*\/R[  [7$D8N[@$9\B"-=W[W%?9@  P!@#H!5:QT?2-,N+F[TW2
MK:WEO)?-O)8(%1IWP!N<@99L #)YP!3EC'+$2K)6;VUVZ)^;2_'4#\=_VLA^
MRT+3]LR/]J_[ /VD4\>L/@.M]_R,2V'V.T_X1H>'\?O@GVKS/,^R_P 6_P V
MOUR^%'_";?\ "K?#7_"RMO\ PD?]@6?_  D&S&/MOD)Y^-O&/,W=.*T[OP[X
M?U#5;;7;_0K.>^LPPL[R:U1I8 WW@CD97/?!&:N48G%K$4XQM:WG?HEIV6FP
M$VG?\A"#_KLO\Q7T-7SSIW_(0@_Z[+_,5]#5]3PC\%;UC^H!1117V0'SSJ/_
M "$)_P#KLW\S4-3:C_R$)_\ KLW\S4-?C,_C8!1114@%%%% !1110 4444 %
M%%% !1110!] ^'_^0#8_]><7_H JW53P_P#\@&Q_Z\XO_0!5NOV.C_!CZ( K
MPOQ__P CIJ?_ %^/_.O=*\+\?_\ (Z:G_P!?C_SKYCBW_=*?^+] ,>BBBO@P
M"OB&W_X*S_'C3_VOOAM^SA\2?^"<GBGP3X>^)_B6^T?P_P",_%GC&TAGE:UB
M:5Y5T^**20J5V$;Y(\B08)P17V]7PM_P4Z_Y21_L-?\ 91/$G_IMAKNP$:52
MJX3C>ZEWTM%OHUU76X'T3^WU^U=_PP[^R'XU_:K_ .$"_P"$H_X0^Q@N/[!_
MM7[%]K\RZA@V^?Y4OEX\W=G8V=N.,Y'D_P '/VR/^"HGQ"\:>&;+QU_P2+L_
M#'A76K^T75?%*_M":3?-IEC*R[[O[*EJLDY2-B_E*0S8V@@FO7?VZOV5+#]M
M[]E'Q?\ LL:IXTF\/6WB^VMK>XUBWLA<26Z17<,YVQEU!)$6T$G W9P<8/Q=
M^V#8_MN_\$>_ASHW[8^A?MW^*/BQ\/?#^NZ;I_Q$^'WQ#TBQ)FTZXG2W\ZPG
MMHHV@E1G7:@&.06+*A1ML'3P]:BJ:474;:7-S=E:W*TKWOOY ?I97SO^VQ^W
MT?V8/&'A'X"_"'X*:I\4_B[X_P#/?PGX T?48K)?LL(S-?7MW*"EG;)T\QE.
MY@0!A6*_1%?E?\=? /[2/QI_X.)->^%OPF^-=S\.TN/V=K-[_P 86.F076IV
MFA)?HTUOIWV@-%#)->R(K2E&*J)"HSUQP%"E6JR=2UHQ;UO;3O;7[M0/MS]D
MWXT?MP?$3Q'JWAO]KO\ 8QTOX;PVMC'<:1KVA?$2WUNVU!R^U[<QI%') Z##
M;FRK \'(->+:)_P5K^(>J:1HW[2MQ^R]:P_L]>(?B.O@_2_B /&6[5P6U%M-
MCU>33?LP1;%[M?+ $YF"D2;""%JK^S;\4/VH?V4O^"F(_P"">7QS_:$U/XM>
M#_&OPXF\6^ _$_B6QMHM9TF>WN##/97$ENB+<1LJM()"H(.U0 -U<Q\3?^"?
M_B7]FC]GVX^&_P 7_P!JSP_8_LJ?#7QG+\0)=&7PG*OB'[+!J#ZK%HC7GVDP
MR6XNV!5EA$\GR1KMR,=<:.%56U1+WN5JW-9IWO;KS7M9/2]^@'U5\;_VJ-0\
M!_M&_#?]E?X8>#(?$GBWQK/-J6NQ2WIAB\.^&K;BYU28JC$DRM%;PQG:)99"
M-ZA&->R5^<?P)^+?[4'A/XZ)JV@_L_Z-X@_:/_:#\-3>.=<T[QIXCETS3?A_
MX)LI4MM+TIY8K:>5I=TZAXXXEW7,\SR$!!7U_P#L2?M6V?[8OP+C^*4O@>X\
M+ZWI^NZCH'B[PM=7BW+Z1J]A<O;W5MYRA5F4.FY7 &Y'4D*<@<F*PLJ,$TM%
MN[[MWZ=M&D^MK]0/7:]O^&?_ "(NG?\ 7$_^A&O$*]O^&?\ R(NG?]<3_P"A
M&O;X3_WZ?^']4!NT445]^ 4444 %%%% !7F?[7_[4W@K]B_]G_6OVB_B'X.\
M5:_I.ARVJ7.E>"M$.HZE,9[F.W4Q0!EW@-*K-R,*&/:O3*\P_:U^*?[0?P9^
M%:?$/]G']G,_%35;'5(3K'@^V\10Z;>SZ:5?SI;.2<&*2X0^6RPN4$@#J&#%
M: /S"^*__!4?_@A5\=OB!J/Q7^-7_!&;XE>+/$^KM&VJ^(/$7[+]G>7EV4C6
M)#)-+(SN5C1$&2<*@'05Z5_P3K_:P_X(Q?$O]L?P?X)_9._X),^)/AG\0+W^
MT/[ \;W_ .SS9Z%#INS3[F2?=?1L6@\RW2:$8^^90AX<UZAI_P#P<A_\$N_#
M^HGPA^TCXW\<_!3Q;$/],\&?%CX9:MI^H6Q'4,88)H3SW$ASVIEG_P ' '[.
M7Q^OF\%_\$U/@/\ $_\ :0\2R.(H?^$2\(W6D:'9RGO?ZKJD<,5G'V+[9.2,
M YH ^]:*QOAW>>.=1^'^A:A\3]$L-,\2SZ-:R>(=.TN[:XM;6^:)3/%#*RJ9
M(UD+JKD LH!(&<5LT >%_P#!/?\ Y(GJW_8]ZS_Z4FO5_B9_R(NH_P#7$?\
MH0KRC_@GO_R1/5O^Q[UG_P!*37J_Q,_Y$74?^N(_]"%<F/\ ]QJ_X9?DP/$*
M***_(@"BBB@ HHHH **** "BBB@ HHHH *V/ '_(Z:9_U^)_.L>MCP!_R.FF
M?]?B?SKIP7^^4_\ $OS0'NE%%%?KX%3Q!_R ;[_KSE_] -?/U?0/B#_D WW_
M %YR_P#H!KY^KX?B[^+2]'^@!1117QX!1110 4444 %%%% !1110 4444 3:
M=_R$(/\ KLO\Q7T-7SSIW_(0@_Z[+_,5]#5]MPC\%;UC^H!1117V0'SSJ/\
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M&OGZOH'Q!_R ;[_KSE_] -?/U?#\7?Q:7H_T ****^/ **** "BBB@ HHHH
M**** "BBB@";3O\ D(0?]=E_F*^AJ^>=._Y"$'_79?YBOH:OMN$?@K>L?U *
M***^R ^>=1_Y"$__ %V;^9J&IM1_Y"$__79OYFH:_&9_&P"BBBI **** "BB
MB@ HHHH **** "BBB@#Z!\/_ /(!L?\ KSB_] %6ZJ>'_P#D V/_ %YQ?^@"
MK=?L='^#'T0!7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\
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M  R5_P %/?\ HYCX6?\ A(77_P 71_PR5_P4]_Z.8^%G_A(77_Q=?9]%<?\
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MLS$L?^$/N>2?^!TW_ADK_@I[_P!',?"S_P )"Z_^+K[/HKB_LW+G_P N8?\
M@*_R ^,/^&2O^"GO_1S'PL_\)"Z_^+H_X9*_X*>_]',?"S_PD+K_ .+K[/HH
M_LW+O^?,/_ 5_D!\8?\ #)7_  4]_P"CF/A9_P"$A=?_ !='_#)7_!3W_HYC
MX6?^$A=?_%U]GT4?V;EW_/F'_@*_R ^"/C5\$O\ @IA\(/A5KGQ,U']HWX:7
M$&C6)N)8;3PE.)' (&%+L5SSW%;?AK]F+_@IQXA\.:?K\/[2OPO1+ZRBN$23
MPA<[E#H& .'QGGM7TK^UWX4\1^.?V:?&/A'PCI$M_J5_H[16=G  7E?<IVC/
M?BNO^'UC=Z7X!T/3-0MVBGM]'MHIXGZHZQ*&4^X((H_LW+O^?,/_  %?Y ?)
M'_#)7_!3W_HYCX6?^$A=?_%T?\,E?\%/?^CF/A9_X2%U_P#%U]GT4?V;EW_/
MF'_@*_R ^,/^&2O^"GO_ $<Q\+/_  D+K_XNC_ADK_@I[_T<Q\+/_"0NO_BZ
M^SZ*/[-R[_GS#_P%?Y ?&'_#)7_!3W_HYCX6?^$A=?\ Q='_  R5_P %/?\
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M2_PDFU2[U%-1USQ=\2_&'CC47O[!3OGDN$G,ZI:I",E B*JA!D-SD ^\J*^
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M6>51;^'-'5[79!;HSJKR9S+)EF8@EF_8RPMIK.QAM+B_ENI(HE1[JX5!),0
M"[!%50QZG:JC)X '%2T %%%% 'X6?'C_ (+&?\$^?^"H?[75_P##;]LO]JG3
MOAU^R[\*_$8-O\/;_3M0;4?BMJ]N^4N;\6T#B#2H7 9+9B'E8!I%!P(?UY_9
M^_;'_9+^._[,K?M-_L]_$[3=4^&.D65W_P 3S3M.GM[:UM[%6$X6%XD=5B6,
MC:$Z+A0>*]:HH _$S2_^"U/_  2^@_X.%M1_;"E_:VT=?AM-^R(OA*+Q3_8^
MH>4VM?\ "2Q7?V/R_L_F[O(4R;MFS QNSQ7[1>#_ !;X=\?^$M+\=^$-32]T
MG6].@O\ 2[U$95N+::-9(Y & (#(RG! //(K1HH **** "BBB@ HHHH *^$_
M^"\_[-'QV^*7P2^&/[4_[+W@>?Q5X\_9S^+FE?$&P\(V@)N-?L+5C]LLH5 R
MTK+L<*,LZQ.BAG90?NRB@#X0G_X.1_\ @DNOP8'Q/M/V@IY]?>W"0_"V/0+K
M_A*'U(_*-,^P^7D7!E(BSGRMW/F;?FKS[_@FRWB'_@E5_P $SOC=_P %)O\
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MN#TKZWO_  AX3U77+7Q-JGA?3KG4K%2++4+BRC>>W!ZA)"-R?@16C0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@HA^PA\*?VJ]*TJ^^'^L>)_'$?B6TUO4FL[62)=+L9$$DRR1E!YJ1D$,,D
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ME=G#9#,2":_935?!WA'7=6L]>UOPKIMY?:>VZPO;JQCDEMCUS&[ E#]"*TJ
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M^&8E\<_$P1>&]=N9IK[25^S08M+B29Y)9)HA^[=I'=RR$LS$DG[5^/<:1?\
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M^)-5MM>\1>#-)O[ZR_X\[V]TZ*66#G/R.RDKSSP10!\$^*/^">_[+O[1G_!
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M%P,%I5^1DSYF3G:  #[\HK\V+/\ :)_X*2?\$[/^"D/P(_9-_:Z_:TT7X_\
MP_\ VA9-9T[2==D^'-GX=UKP[J-A!',"8]//DSP-YT*EBN0&8_+Y8\S[$_;
M_;Z_9._8/\/:3KW[3GQ7BT.7Q#=M:>&]%L].N=0U/6)U +):V5I')/-MW+N9
M4VKO7<5W#(!['17B7['O_!1']D?]NQ==L_V<OB;+?ZOX6FCC\3^&-:T2\TG5
MM):0$QF>SO8HIE1@#MD"E#@@-D$#RCQQ_P %Y/\ @F9X%\::[X.E^,/B+6HO
M"VHR6'B?Q#X3^&NNZQI&EW,9(DCEO;.SDA)7'S%&<#N>#@ ^Q**\J_: _;=_
M96_9:^ ]K^TQ\>_C-IGAWP7J,=LVE:K<QRR/J#7";X(K:WC1I[B5T^811HSX
M#';A3CC/V3/^"J7[$O[:?Q!OOA!\%?B;J$7C+3].&HS>$/%OA74-#U*2R) %
MU%!?P1-/%DC+1[@N1NQD9 /HBBOE[]I+_@L9^P;^RM\6=:^!OQ-\>^)[OQ3X
M92"3Q3IOA3X<ZUK(T6.:WCN8GN9K.TDBCW0RQR;=Y;:X)'->I_#G]LO]F+XO
M?LQ2_ME?"_XP:;KWPT@T*[UB?Q1I<<LJ1VEJCO<EHE3SEDC$;AH2GFAE*[-W
M% 'IU%?+GP>_X++_ /!._P#:&^+/A/X,? ;XVWGB_6/&5M#/ID^A^#]4DLK8
M2VINXH[NZ:V6&SF:$;O)F9)5) 9%) .=\9O^"X'_  3<^!_Q7USX+>(/C1JV
MN:]X4E\KQ?'X'\":OK]OH#@D,EW/I]K-%$ZD,&3<70J0R@C% 'UI17Y[?\%)
M?^"@FE_"[XW?L3?&SP+^TE_PCOP=^(?B35-7\5:T;YK33M6T#^PQ>V\MQY@4
M^5M99 K -D@8SQ7M_P"RY_P6 _8#_;#^-,G[/'P6^,%^?&3:<^HZ;H7B7PAJ
M>BS:K9)G=<6@O[>$7"  MA,MM5FV[5) !]-445\G_'?_ (+8_P#!/+]G7XD^
M(?A3X_\ B7XGN=5\'W1M_&,GAOX9Z[JMIH3A58BYN;2SDA3"L"0'8C/(% 'U
MA17EY_;2_9=?]E"Y_;DT_P",6FZA\*;3PW/KT_C'28IKR 6$(8S2B.!'E9D*
M.K1A#(K(RE0P(KP;Q%_P7\_X)0^&/$FF:'J7[3S&QU-[2/\ X2F#PAJTFB64
MUS&DD,%UJ M?L]M+MD3?'(ZM"25E$95@ #[)HKSG]I[]K;]G/]C3X+WG[0?[
M2WQ6T[PMX1LGBC;5;H/*;B63_5PP10J\MQ*^"5CB5F(5B!@$CX#_ &L_^"P_
MPQ^/?QK_ &6?!?[&7Q]\2:+J&K?M+Z!I7Q$\(ZIH5_H6I7>BW4%T56:TOH8I
M)K25HQB1 T99<;@W% 'ZA445\U?M0_\ !7/]@W]D#XOK\ OC#\6=1E\9IIRZ
MCJ7ASPGX0U/7;K2K%@"+F\33[>;[-'M*M^\PQ5E8*5(- 'TK17PW_P $I?VO
M]6_:V_:]_:TU30?CD_C;X>:1XR\,-\-I8+_S[*TL+K0XYW%M_<5Y"69>H;((
M!!%=!X]_X+V?\$L_AUX[U;P/K7[1=U>0^'M4_LWQ)XHT/P7J^HZ%I-WN"^3<
M:G;6KVJ$,0"1(54_>*X. #[$HKR_QG^V?^S'X \;_"[X?>)_BQ:1ZA\:)9X_
MAA-:V=Q<V6NM%;+<D1WD,;VT>Z%U>/S9$\[.(]YXJ[^T1^U7\!/V4=,\,:M\
M>_'G]AQ^,_&5CX4\+1QZ7=7LVI:S>%A;6D45K%)(6?8WS%0JA268"@#T.BO
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M.?[-92R>6DR 1R-&D;CF-Y%^:OTMTW4+35].M]5L)&>"Z@26%FC9248 @E6
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M\$_/_P"%83PZG=PIH8FM%LY L<<JQS@P(J 3+(%QD8/-7_BS^RY\"?CE\2O
M'Q>^*7@;^U/$7PNUBXU3P+J/]IW4']F7<\/D2R>7#*D<VZ/Y=LJNHZ@ \T ?
M'_['#+#_ ,'!O[9<,K!7F^'?P[DA1C@NBV,RE@.X!(!(Z$XK] *^=_VJ/^"4
M7[ O[:7Q,M?C/^T1\!VU/Q9::6NFIXCT7Q7JVB7DMHKEUAEETRZMVG16)($A
M;;VQ7T%INGVFD:=;Z581LD%K D4*M(S$(H  +,23P!R22>] 'X_?\$_K/_@H
MSJW_  48_;A;]G7Q]\ M)\9)\>)EUZW^+?A'6-0UQM $0&B/%)97]N%L?LH
MC4H<,&.[!4#Z^_X)R_L0_M+_ +,'[3/[0'[2_P"T_P#%7X97M[\9I=!U._\
M#OPQT2]TW3-.N[&WN;>:],-[<3.KW*E&D??\[Q.Q]N\_:R_X)3?L5_ME_$BQ
M^-OQ4^'^JZ7X]TZR%E;>// _BJ^T'5S:@Y$$EQ8RQF>,=A+OV_PXR:7X2_\
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M-4U[5[O<8[2T@C,DLA"@LV%4_*H+$X !) K\W?V0?$__  5'_P""P?P@UO\
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MA^T+X>E\R<W[S$8@:?S?-21B!N"AC[_X^_X*G?&J3P?^Q+_P4/\ #GB$:/\
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M'?"+]G_6KOQ0T7C3Q!I]UJWBCQ$T'DVL4$-E+*L-O;DF0RLV) 2!@].9U_\
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M!J6@IJMU>F2)4LXK+3C)(D;1F5VE>11^[50K;B1]<T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20210630_g12.jpg
<TEXT>
begin 644 biib-20210630_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
M\^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG
M_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SX
MP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_
M //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=
MI_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJ
MY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?
M]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?
M#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]
M!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!6MO%'
MA^\G6UM=5B>1SA$4\DU?J)+&RC8/'9Q*PZ%8P"*EH **** "BBB@ HHHH **
M** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)K
MW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A
M?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %?H/^R5_P FZ>%O^O%__1TE?GQ7Z#_LE?\
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MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
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M3;P]_P!@.T_]$I6Y6'\,?^2;>'O^P':?^B4K<H *_.K]I/\ Y+WXM_[#D_\
MZ%7Z*U^=7[2?_)>_%O\ V')__0J .(HHHH **** "BBB@ HHHH **** "BBB
M@ K]!_V2O^3=/"W_ %XO_P"CI*_/BOT'_9*_Y-T\+?\ 7B__ *.DH ]%HHHH
M **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/
M?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P?$W_(QZ
MA_U_2_\ H9JC5[Q-_P C'J'_ %_2_P#H9JC0 4444 ?)W[=_[/O[5&L>#_$?
MB+X6?M1:B^AZKKNC3#P+?^!H-3^R2+J%F-]M.CQS)&C()V1O,7"N/E#%AZG^
MR[^R@O[/NL^+OB1XQ^)^H^-_'?CZ\MKCQ;XKU"RBM!<"VB,5M!#;1?)!#&C,
M H+'YCEC@ >O44 >/6G[)YN?VV[O]LGQ9X^_M-[?P8GAWPIX<_LKRTT:,R>9
M<3^=YK>;)(Q<9$:;4?;\V :]AHHH \>_8_\ V3O^&7=,\97VO>/O^$K\3>//
M&=WXB\1>(3I7V/S9)B-D"Q>;+MCC (4;S]YN!G Z+XL_"CXD^/?B/X#\8>#/
MCC?^%]+\+:K/=>(O#]I8^;'XDA=%5+>5_-3RPA4L#M?.[H*[^B@#Y8_:I_X)
M_?&K]H/]IWP_^TAX1_:XM_#B^$;)8_"WAO5?AY#K-KIMR<^9>(LMU&AF8X(<
MQEDV+AOE7'IW[/WPG_:O^'_B6]U+X_?M=67Q#TV:Q\JRTRV^'%MHQMI]ZGSC
M+%/(7&T,NP@#YLYXKUFB@ HHHH _3#X8_P#)-O#W_8#M/_1*5N5A_#'_ ))M
MX>_[ =I_Z)2MR@ K\ZOVD_\ DO?BW_L.3_\ H5?HK7YU?M)_\E[\6_\ 8<G_
M /0J .(HHHH **** "BBB@ HHHH **** "BBB@ K]!_V2O\ DW3PM_UXO_Z.
MDK\^*_0?]DK_ )-T\+?]>+_^CI* /1:*** "BBB@ HHHH **** "BBB@ HHH
MH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\P?$W_(QZA_U_2_^AFJ-=[X@^ WQ7GUZ
M^GB\*Y5[R5E/VZ#D%C_MU3_X4#\6_P#H4_\ R?M__CE ''45V/\ PH'XM_\
M0I_^3]O_ /'*/^% _%O_ *%/_P G[?\ ^.4 <=178_\ "@?BW_T*?_D_;_\
MQRC_ (4#\6_^A3_\G[?_ ..4 <=178_\*!^+?_0I_P#D_;__ !RC_A0/Q;_Z
M%/\ \G[?_P".4 <=178_\*!^+?\ T*?_ )/V_P#\<H_X4#\6_P#H4_\ R?M_
M_CE ''45V/\ PH'XM_\ 0I_^3]O_ /'*/^% _%O_ *%/_P G[?\ ^.4 <=17
M8_\ "@?BW_T*?_D_;_\ QRC_ (4#\6_^A3_\G[?_ ..4 ??_ ,,?^2;>'O\
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M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
M)$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/M__ ,?T
M_P#UV;^9J&IK_P#X_I_^NS?S-0T %%%% !1110 4444 %%%% !1110 4444
M>^^'_P#D V/_ %YQ?^@"K=5/#_\ R ;'_KSB_P#0!5N@ K\ZOVD_^2]^+?\
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MZVW@OP%;P7<TR36MJ8FO;H/,[NZ33QPNISQM9>V!] _\%)_V@=3_ &<OV/\
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M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M/_UV;^9J&@ HHHH **** "BBB@ HHHH **** "BBB@#WWP__ ,@&Q_Z\XO\
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M444 %%%% !1110 4444 %%%% !1110 4444 ?/M__P ?T_\ UV;^9J&IK_\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
MH4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^
MA0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O
M?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH \5O_ /C^G_Z[-_,U
M#4MZQ:\E8J03*Q(/;FHJ "BBB@ HHHH **** "BBB@ HHHH **** /??#_\
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M;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH
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M)M<UFTLDD?;&UW<K&';T!8C)]J^,O^"-GP;_ &F/!O[.GP_\?>+/VPKOQ=X
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M^/\ SKW&O#O'G_(Y:G_U^/\ SH R**** "BBB@ HHHH **** "BBB@ HHHH
M*]L^&O\ R(VG?]<3_P"A&O$Z]L^&O_(C:=_UQ/\ Z$: -RBBB@ HHHH ****
M "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>
ML_\ I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y]O_\ C^G_ .NS?S-0
MU-?_ /']/_UV;^9J&@ KYN_X*&?&O_@GWX/T/2/A%_P42\)V-UX3\2)-<V.H
M^)O!T^H:/;W$)5</<QQ2+93[924=C&2-^UL\'Z1HH _&+_@CC9^!=._:;^ \
M?_!.OQ%XON/#5QX)UJ3]J*PCN=0E\,6MSY!_LUD-S^Y2_:X(RL!.$'11YN?O
M;XZ_\%0?^"6/A#XB>(/@7^TS\:_"NG>(/"5V;?5="\9:!,3&7C5]T7FP,DRN
MC+\T18'H>017NO[/7P5T']G/X*^'/@?X7U6\OM/\-:<MG:7=_L\Z5 2<OL 7
M//8"M_Q!X*\&^+)89O%/A+3-3>V.;=]0L(YC$?52ZG;^% 'YP_\ !+3P-KGQ
MDU#]L;QI^Q8VJ_#/X+?$VYM[;X#:G)HLMI:V>K'2YX+[6K"SD"%(#=/!,H4(
M&"+'A#$57R3_ (*!_L,_M[_L;?\ !'+QK\(=1_:\^'VJ_"_PIX=M(;OPSI/P
MK:SO;]6U&W9I#=M=N1,\[^=)(5)=B_\ >X_8M55%"(H"@8  X I: /EWX2?'
M?4?V%_V%-"^+/_!0[]H+2-1L(CI\2>)]#\'3VMO86EQ#!':PRP0&=V*OD-,!
MCYP2% )KY*_X*W_ML?LK?\%*_@IX9_8I_8.\;0?$_P"+/B7QUI%YX8NO#&FS
MS+X52WN5>;5)KAHPENB1[D8[@0LI)&T$U^JLL45Q$T$\2NCJ5='7(8'J".XK
M/\/>#O"'A%9E\*>%=-TP7#[[@:?8QP^:WJVP#<?<T <!\<OVOOA#^SU\6_AE
M\%?B$VIC6OBSK=SI7A,6-D)8C<01I(_G-N'EKB1<'!SS7#?M,_\ !1K_ ()X
M_ CXF3?L\_M9_&'0= UF+3X-3CTWQ7H\S6UQ!(6"2QRM"T+L"K J&WKCD $$
M_159_B'PIX6\76BV'BOPUI^J0(VY(=1LTG16]0'! - 'YT?\$X]?^%GQM_X*
MY?%']HK]@+PI+IOP!N/A3:Z3XIU?2]%DT[1/$?C!+\.MS:0LD:R/':EXWD51
M\V]CGSE9OTGJ.SLK/3K6.QT^TB@@A0)%##&%1%'0 #@#VJ2@#WWP_P#\@&Q_
MZ\XO_0!5NJGA_P#Y -C_ -><7_H JW0 5X=X\_Y'+4_^OQ_YU[C7AWCS_D<M
M3_Z_'_G0!D4444 %%%% !1110 4444 %%%% !1110 5[9\-?^1&T[_KB?_0C
M7B=>V?#7_D1M._ZXG_T(T ;E%%% !1110 4444 %%%% !1110 4444 >%_\
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M_P#2DU[I7SU^P7X;L-6^#FK75S-<*P\<:RN(IRHQ]I;L*]M_X0?2/^?F]_\
M MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH
M V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH \5O_P#C^G_Z
M[-_,U#4MZH2\E09P)6 S]:BH **** "BBB@ HHHH **** "BBB@ HHHH ]]\
M/_\ (!L?^O.+_P! %6ZYW1?!FE3Z-:3/<W8+VT;$+=,!RHJU_P (/I'_ #\W
MO_@6U &Q7AWCS_D<M3_Z_'_G7K/_  @^D?\ /S>_^!;5Y#XQMH[/Q3?VL3,5
MCN652[9/7N>] &;1110 4444 %%%% !1110 4444 %%%% !7MGPU_P"1&T[_
M *XG_P!"->)UZQX"\)Z;?^$+&\FN+H,\1)"7+*/O'H* .PHK+L_"6FV-TEW#
M<71:-LJ'N6(_$5J4 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_8]Z
MS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'S[?_\ ']/_ -=F_F:AJ:__ ./Z?_KLW\S4- !1110 4444 %%%% !1
M110 4444 %%%% 'OOA__ ) -C_UYQ?\ H JW53P__P @&Q_Z\XO_ $ 5;H *
M\.\>?\CEJ?\ U^/_ #KW&O#O'G_(Y:G_ -?C_P Z ,BBBB@ HHHH **** "B
MBB@ HHHH **** "O;/AK_P B-IW_ %Q/_H1KQ.O;/AK_ ,B-IW_7$_\ H1H
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M'[+XT6?@E[#QWI%C?7EG>31&=&D>6QF9(Y]K1P_Z0D;;=V-X#D$ ^E?VC/\
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MZRG\3WBVOA;4_$7@W5=+T[6)F.%2WN[JVCA8L<!067<2 N20*^K:_'O]O/\
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M)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH ****
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MOV"]8O[#X.:M!;:!<7*_\)QK)\R(C&?M+<<U[;_PDNK_ /0H7O\ WTM>1_\
M!/?_ )(GJW_8]ZS_ .E)KW2@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X2
M75_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X
M275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK
M8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^E
MH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@
M#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275
M_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7
M_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?
M^^EK8HH ^?+UBUY*Q4@F5B0>W-15-?\ _']/_P!=F_F:AH **** "BBB@ HH
MHH **** "BBB@ HHHH ]FT7Q%JL>C6D:>%+MPMM& ZLN&^4<U:_X275_^A0O
M?^^EJ[X?_P"0#8_]><7_ * *MT 8_P#PDNK_ /0H7O\ WTM>0^,9I+CQ3?SR
MV[1,]RQ:-^J\]#7NU>'>//\ D<M3_P"OQ_YT 9%%%% !1110 4444 %%%% !
M1110 4444 %>L> M=U*U\(6-O#X9NIU6(@2HRX;YCTKR>O;/AK_R(VG?]<3_
M .A&@"Q9Z]J5S=)!-X9NH59L-*[+A?<UJ444 %%%% !1110 4444 %%%% !1
M110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\E_P#!0G_@HOXQ
M_9U^)F@?LA?LT_L^WWQ,^+GC3P?JOB"VTQ/$D.C6.@Z/:#9)J=W>2I(5 D;;
M'''&[.R%<J2NX ^M**^0/^"1W[2O[<GQT_9]\ I^UI^RTN@V%U\)="U71OBG
M;?$>VUE?%<DMI;DR7%L(8I[.YD603LK!TR7 D8BO&?C%^UE^UI^W/^V3\4OV
M?/V9_P!L[0OV<?@Y\"=2M- \:?%"YT2PO]4\3>)IHS+)IUH=0(@MH;=5VNV/
M,+KQN5_D /TEHKQ_]B?X5?M$?"'X2W?AS]HW]L5OCC?7.MO>>'?&<WA*RTB5
M-*>W@$5K(ED3%<,LBSN+@ %UF4$?+D_GQ_P7>_X*P?ME?!^+Q5H/_!.+XA6G
MAO3?@A>:*?C-X[?0K/45EU/5;N&VL_#MLMY#+%YRP3/>7#JI:,""/<C.RL ?
MK/17EO[7GPE_:4^,_P *8_"'[*W[6TWP7\3KJT-Q)XPA\#6'B$O:JD@DM?LM
M]^Z&]F1O,^\OEX'WC7YO?M'WW_!9K]EW]N']F_\ 9*T;_@LQ>_$K6OC#XSE?
M7="/[/WAC3%T[PUIZK/J5Z\L<4K F+<D:X3<P?#@K0!^N=%%? '[;W[8?[4?
MQJ_;HNO^"<'[&'[0'A[X-Z?X&\$V_BKXX?&S7-(MM0ET.&[D"6.EV4%VPMUN
M)E(D:27A8W!0AD*N ??]%?/7[ WP9_:9^%&D^(-0^-O_  43D_:%\.:TEE)X
M+U*Z\'Z9I\VE%#<"Z!N=/.R\24M!M+ &,PN 2&X^A: "BBB@ HHHH ^?;_\
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M(^&X_"'P;T73/B9>>!M(T[XC>++>_N=0N=1O8+6%;A([J[=I%MC.C,D*>7$
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M"ZDNI+6VEDFFN[F3'F7-Q/,SRW$S!5!DD=FPJKG"@";]J7]E'X!?MI_!R]^
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MHK\LZ* /U,HK\LZ* /U,HK\P?#/_ ",>G_\ 7]%_Z&*_3Z@ HHHH _+WQ/\
M\C+J/_7]-_Z&:HU>\3_\C+J/_7]-_P"AFJ-?P17_ (\O5_F?&/<****R$%%%
M% !1110 4444 %%%% !1110!^FGPQ_Y)MX>_[ =I_P"B4K<K#^&/_)-O#W_8
M#M/_ $2E;E?WC@/]QI?X8_DC[*'P(*\.\>?\CEJ?_7X_\Z]QKP[QY_R.6I_]
M?C_SKK*,BBBB@ HHHH **** "BBB@ HHHH **** "O;/AK_R(VG?]<3_ .A&
MO$Z]L^&O_(C:=_UQ/_H1H W**** "BBB@ HHHH **** /S__ &POVWO'.O\
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M;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH
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M];I>65S'-%(N8Y8G#*P]01P:DH::8'Z:?#'_ ))MX>_[ =I_Z)2MRL/X8_\
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M<?9^=((N/]7Y_!^3UYVT 8W[37[#7_!3SXM?'+7OB'\ _P#@LYK/PN\(ZE)
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M5M >)==TNQU**6YTYI5+1">-6+0EU5BN\#<%)&<4 ?FA^V]\7O\ @L'^R/\
MMH_ ;Q%XQ_;@\'R?#3XL_M/Z7X,A^&WA7X9VBNN@W5U(Z"YU&\628S?9XUC<
MPB/YG9E<8 K]1:_/#_@O!_R67]A;_L\_PM_*:OT/H **** "BBB@##^)W_)-
MO$/_ & [O_T2]?F?7Z8?$[_DFWB'_L!W?_HEZ_,^@ HHHH **** "BBB@ HH
MHH **** "BBB@"]X9_Y&/3_^OZ+_ -#%?I]7Y@^&?^1CT_\ Z_HO_0Q7Z?4
M%%%% 'Y>^)_^1EU'_K^F_P#0S5&KWB?_ )&74?\ K^F_]#-4:_@BO_'EZO\
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M>_&3_@BYXD^$OAO4/M7]I?$&_P#B)HU_#I7EVLTL>Z"V02OYLB) -IX,P8\
MUYSXV^*G_!5[]NW]M;XT? G]C7]I_P %_ /P#\$=;T[0+C6M2^'L7B/6O$&H
MW&GPWLDAANG6&"W59D5"/F8?-DYPOJ7[+G[)O_!73X9_';0O&_[3_P#P5KT?
MXG>!K+[5_;G@>U^ VEZ+)J6^UECAQ>02M)#Y<[Q3?*#N$10\,: /K^BBB@#Y
MZ_8+MO$DOP<U9M)U*WBB_P"$XUG*RPECG[2W.:]M^Q>-_P#H-V7_ (#'_&O(
M_P#@GO\ \D3U;_L>]9_]*37NE &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
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M !<N--G^(.MOJ]Y<#5)+"*2&U/DRR-%!LCED7$*1AMV6W$#'J%% 'QI\9/\
M@@)_P2D_:!^)^L?&;XO_ +,.H:OXDU[7Y];U._/Q5\30*;^:1I))HXH=02*
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M_#'\D?90^!!7AWCS_D<M3_Z_'_G7N->'>//^1RU/_K\?^==91D4444 %%%%
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M/_I2:Z_]K7_DW3Q3_P!>*?\ HZ.N0_X)[_\ )$]6_P"Q[UG_ -*377_M:_\
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M_HEZ_,^OTP^)W_)-O$/_ & [O_T2]?F?0 4444 %%%% !1110 4444 %%%%
M!1110!>\,_\ (QZ?_P!?T7_H8K]/J_,'PS_R,>G_ /7]%_Z&*_3Z@ HHHH _
M+WQ/_P C+J/_ %_3?^AFJ-7O$_\ R,NH_P#7]-_Z&:HU_!%?^/+U?YGQCW"B
MBBLA!1110 4444 %%%% !1110 4444 ?II\,?^2;>'O^P':?^B4K<K#^&/\
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M>1H(PS;[BYCMX^"1QOE7/H,GM6W>:A8Z?I\NJWMW'%;00M+-.[85$49+$^@
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M^:JG\1^H44451 4444 %%%% !1110 4444 %%%% 'Z/?#?\ Y)WH'_8%M?\
MT2M;58OPW_Y)WH'_ &!;7_T2M;5?C%;^-+U9_2.&_P!VAZ+\@K\Y_P!I;_DO
MOB[_ +#D_P#Z%7Z,5^<_[2W_ "7WQ=_V')__ $*OQ'QL_P"1)AO^OG_MK.#-
MOX,?4X>BBBOYL/!"BBB@ HHHH **** "BBB@ HHHH *_0K]DG_DW/PK_ ->+
M_P#HYZ_/6OT*_9)_Y-S\*_\ 7B__ *.>OV/P4_Y*/$?]>G_Z7 ]3*?X\O3]4
M>C4445_3)] %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
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M??%W_8<G_P#0J_$?&S_D28;_ *^?^VLX,V_@Q]3AZ***_FP\$**** "BBB@
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MUB%671[4,">A$2UL_P#"8^&/^@U!_P!]5^,5OXTO5G](X;_=H>B_(TJ_.?\
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M/+T_5'H*6-E&P>.SB5AT*Q@$5+117],GT 4444 %%%% !1110 4444 %%%%
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M/_7$?^A"O)_^">__ "1/5O\ L>]9_P#2DUZQ\2O^1&U'_KB/_0A0!XG1110
M4444 %%%% !1110 4444 %%%% !6OX#_ .1RTS_K\3^=9%:_@/\ Y'+3/^OQ
M/YT >XT444 8?Q._Y)MXA_[ =W_Z)>OS/K],/B=_R3;Q#_V [O\ ]$O7YGT
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M&+&=QB6</)C(9HEZY.:Y'XV:]_P4#_8*^%>D_M?_ !9_:I'Q%TK3M1L!\4O
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MHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37K'Q*_Y$;4?^N(_]"%>3_\
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M\U5/XC]0HHHJB HHHH **** "BBB@ HHHH **** /T>^&_\ R3O0/^P+:_\
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MY?LL_L^?LC^ V^&G[.7PKTWPKH\MVUW=06(=Y;NX8 --/-*S2W$A  WR,S8
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MKR?_ ()[_P#)$]6_['O6?_2DUZQ\2O\ D1M1_P"N(_\ 0A0!XG1110 4444
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M_OE3_#^J/AO$'_D7T?\ '^C.+HHHK[\_)PHHHH **** "BBB@ HHHH ****
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MG^(E\0+X/L?'6^ZT74;?[5;V\HO],D59"89FD&QL*90#\R< 'PMXQ_9C\<?
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MS[SP^_Y&M7_ _P#TJ)Z#1117YZ?K@4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KTWXRZWIGASX8ZOK>LW/DVMO;JTTNQFVC>HZ*"3R>
MPKS+_@GO_P D3U;_ +'O6?\ TI-==^UM_P FY^*O^O%/_1R5Y^;XNI@,JQ&*
MII.5.$Y*^UXQ;5]M--=414DX4W)=$>%_\- ?"/\ Z&W_ ,D+C_XW1_PT!\(_
M^AM_\D+C_P"-U\TT5_./_$:N*?\ GS1_\!G_ /+#P?[6Q/9?C_F?2W_#0'PC
M_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S311_Q&KBG_ )\T?_ 9_P#R
MP/[6Q/9?C_F?2W_#0'PC_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S31
M1_Q&KBG_ )\T?_ 9_P#RP/[6Q/9?C_F?2W_#0'PC_P"AM_\ )"X_^-T?\- ?
M"/\ Z&W_ ,D+C_XW7S311_Q&KBG_ )\T?_ 9_P#RP/[6Q/9?C_F?2W_#0'PC
M_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S311_Q&KBG_ )\T?_ 9_P#R
MP/[6Q/9?C_F?2W_#0'PC_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S31
M1_Q&KBG_ )\T?_ 9_P#RP/[6Q/9?C_F?2W_#0'PC_P"AM_\ )"X_^-UO_"WX
MU_#+7?B+HVCZ5XF\VYN=0CCAC^Q3+N8G@9* #\:^2J[C]FG_ )+[X1_[#D'_
M *%7=EOC#Q-C,QHX>=&BHSG&+M&=[-I.W[S<NGFF(G446EJ_/_,_1BBBBOZ0
M/>*GB#_D WW_ %YR_P#H!KP*O??$'_(!OO\ KSE_] ->!4 %%%% &9XQ\%^$
MOB#H$GA7QQX=L]5TV6>&:6QOH!)$TD,J31,5/&4DC1P>S*#VK3HHH **** "
MBBB@ HHHH **** )K#_C^@_Z[+_,5]!5\^V'_']!_P!=E_F*^@J "BBB@#YY
MU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI **** "BBB@ HHHH
M **** "BBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^
M#'T0!7Y]_M%_\ET\5?\ 8:F_]"K]!*_/O]HO_DNGBK_L-3?^A5]EPA_OE3_#
M^J/S_P 0?^1?1_Q_HSBZ***^_/R<"0H+,0 !R37.?"7XH^%/C5\.M*^*/@B:
M9]+UFV$]F;B,)(%R1AE!.T\=,U\N_P#!4GP_KNH^/_A-KWQ-^'7BSQ?\#=-O
M]3?XG^'O!\,\\CSM @L)[NWMV$D]K')O9@/E'.X'*JW+_P#!'>'_ ()XZMX5
MT7Q%^S]?Z-:_%.V\*-9^+]-M+NYM;J6,RHSO):2E4EVLD7[Y$;;G&_YB#YKQ
MTOK_ -7LDO-V;V=TK:[M;]'M;7V5ED/[*^MWDWI\,;I:R5I.^CT3VT36]]/H
M+]H7_@HM^Q9^RMXF;P5\>/CSIVAZQ'%'+)I26-U>7,:.,HS1VT4C*".02!QS
M7L>D:K8:[I-KKFE3^;:WEND]M+L*[XW4,IP0",@@X(!KY=_X+%>$_"MM_P $
M\/BYXLMO#.GQZK<Z+9)<:FED@N)56^M@JM(!N8 < $\"O:[;2?$FO?LMQZ'X
M-NS;ZO>^ !!I4XDV&.Y>QVQ-N_APY4Y[8K6%:NL7.G*S22:LG?5R5GJ[[=D8
MU,-A7@*5:%TW)QE=IK11=U9*WQ=6SS7Q;_P58_85\%^-+_P5K/QFDD;2+_[#
MK.L6'AZ_NM,T^YW!?*FO8H&@4AB 3O*J3\Q&#CV[Q#\2?A_X4\ 7'Q6\1^--
M,L_#5KIW]H3Z[->(+5;7:'$WF9VE"I!!!.<C&<BO@;]B;]KC]C'X-_\ !,U?
MV>?B]K>EZ-XKT'2-5T3Q?\,M2AV:O?ZE)+,KP+:$>9</.74 J& WA21M('(_
M"2Q@^//_  ;M7GA#XM_%FV\(PZ/%<6D?B'6S*8$6RU<2VUO(L:M(RDK';JJ*
MS#Y-JL0%/GT\TJ..\9-P<TEI9JWNMMOOOIL]#UJV1T(SLE.$55C3;>O,I7]Z
M*27:]O>W5GW^N/ /_!5G]AKXC^,-*\&:)\6KNUFU^Z6W\/7^M^%]1T^RU25C
MA4AN;B!(F+'  +#<2 ,DBOHJOS)_;#_:7\6_M8_LO^"O@-\8?V5=?^"?AKQ3
MKVCIJ'Q)\66+II&@K%*CH;7RHC)"\@7RHVN%MT59"&91DC]-@01D'(/0UV8'
M%5,1.<9--*VJ3CO?2S;?SZW\F>=FF I8.G3E&+BY.2:<E+:UGS126MW=;JU]
MFCR_]HO]LG]G;]E4Z79_&?QX;+4=<9QHNB:=IMQ?W]]M^\T=O;(\A4=W("CI
MG/%:'[//[4GP*_:H\,W?BGX'>.XM7ATV[^RZK:R6LMM=Z?/_ ,\Y[>=$EB;@
MXW* <'!.#7RYXV^(WP\_9D_X+#ZS\5/VH=:M= T'QA\*;73_ (>^+M</EV%O
M+!,&N[,7#?)#(QW2')7AQD_O &YW]GC]H[X=?%'_ (+>>*-1^ .J1ZCX5\3?
M"-8-7U?3XS]CUC4+*XC NXGP!.(U/V82C*Y5P"<9K#^T9QQ*C)JSGR\OVO)[
M]?39K4ZO['IRP;G&,KJG[3G^P^\;6W6J^+=/2VWZ"U][_LK?\F^^&/\ KR?_
M -&O7P17WO\ LK?\F^^&/^O)_P#T:]>;Q=_N$/\ %^C/:\/O^1K5_P #_P#2
MHGH-%%%?GI^N!1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_
M .E)KKOVMO\ DW/Q5_UXI_Z.2N1_X)[_ /)$]6_['O6?_2DUUW[6W_)N?BK_
M *\4_P#1R5XO$G_).XS_ *]5/_2&95_X$O1_D?GK1117\.GR 4444 %%?+_Q
M&_X*M_LN>!_C7IGPXL/'@U;284U./Q9K.B^'M1U"+3;FW\CRXUEMH'CDYDD\
MPH7\O:N[;N&?;/$'[0GPA\-? >;]IC4?&,'_  A<7A]=:7641MLMFT8D1T4@
M,S.&4*N-Q+ 8R<5Z>(R7-L+&E*K0G'VGPWBU=MM)+3=VT6[33V:-)4JL;73U
M.THKY<\ ?MA?MR_%&/2_B)X/_P"">31^!=8DBDL;C6?B):6FKO8R,,7C6AC(
M3Y#O\DON(& 3D5ZO^TI\;?BG\&M*TIOA'^S1X@^)>IZK<21"QT:_@M(K0(H(
M>>><[8U8G .#R#5ULDQU#%0P\G#GE?15*;LUNI-2M&W]YH;HS4E'2_JO\]#T
MRBO'_P!AK]JJZ_;*^ %K\;K[X=?\(K-/JM[8S:+_ &N+[RFMYFB)\X11ALE<
M\+QZGK7L%<6,PF(P&*GAJZM.#<6KIV:T>J;3^3L1.,H2<9;H**^=/B)^T)_P
M4(TOQ=K5O\,O^"?NFZOH&E:A/#I^H:E\4[.UN=9@C<JLT4/E-Y <#*K(V>1G
M%=Y^R)^U)X2_:^^#%O\ %SPMH%_H\JW]QIVM:%JB@7&F7\#;9K=R.&P2"",9
M5ER%.5'7B,FQV&PGUJ7*X72;C.$^5M-I249-QO9[I;-;Z%2I3C'FZ>J?Y'I]
M=Q^S3_R7WPC_ -AR#_T*N'KN/V:?^2^^$?\ L.0?^A4\B_Y'>%_Z^0_]*04?
MXT?5'Z,4445_<Y]@5/$'_(!OO^O.7_T UX%7OOB#_D WW_7G+_Z :\"H ***
M* "BBB@ HHHH **** "BBB@ HHHH FL/^/Z#_KLO\Q7T%7S[8?\ ']!_UV7^
M8KZ"H **** /GG4?^0A/_P!=F_F:AJ;4?^0A/_UV;^9J&OQF?QL HHHJ0"BB
MB@ HHHH **** "BBB@ HHHH ^@?#_P#R ;'_ *\XO_0!5NJGA_\ Y -C_P!>
M<7_H JW7['1_@Q]$ 5^??[1?_)=/%7_8:F_]"K]!*_/O]HO_ )+IXJ_[#4W_
M *%7V7"'^^5/\/ZH_/\ Q!_Y%]'_ !_HSBZ***^_/R<\R^/GQ$_:9^'>KZ3?
M_!#]G6R^(>D30S+K5G%XM@TO4+64%/+>+[4!#,A&\,K.A! ()Z5\B?L%_ ?X
MY_''QQ\!?VD/%WPATSP)X;^%?A'4[>SU7^VH+O4_%K7L+0(KK;@B&VBR[A9&
M+;B<*-Y(_0BJ'A;PKX;\$>'K3PGX0T2VTW3+&(16=C9PB.*%.NU5' '-<57!
M^VQ$:DI.RUMI:Z::Z7W5]_PNCT\/F7U;"3I0@E*6G-K>S4D^MKVE9:?C9GRI
M_P %2],_;!^-_P &/%W[*_P(_8^NO%&F>)M'M5C\:KXZTNRB@F6Y25XS:W,B
M2-@1 ;L@'?QT->O?LB>./VA?$W@MO#GQ\_9?NOAO+H-A8VFFM<^+[#5?[5Q&
MRR.OV-F\G843A^OF<?=->N45<<*XXIU^=ZJUO=M;6RVOI?OZF<\<IX%8;V44
MD[W]Z]W9-_%;5)+:W:Q\:_%#XJ?ML>/M4U'P]\._^"8=MH/Q N$EL-,^)FO>
M)]*FLM*1MT:WRSQ@SR;4(<1* V< @X(+OC+_ ,$T-<M?^"8&C_L8? _7K2X\
M0^$9;/5M.N=3S';ZMJ4-T;J<2==J2R23;0Q(7,8)P,C[(HK)Y?3FI>TDY<R:
MZ*R>]K):NRU\D;K-ZU)P]C!049*5ES.[6U^9O17=DK+5GPG^U)K?[>7[>/P"
MN_V1E_83O_ -SXHFLX/%WB[Q-XJL+C3-*ABN(IY)+<0NTET2T0"[5! .?<?3
M_CG4_C]\/?%'PS\#?!OX96?B+PO-=-9>.]<U#4XH9](LXH8Q%.B-(AF9VW A
M5<C'09KTVBKIX1PDYN;<G97TV3O;16UN[Z7U]#*KF"J0C3C2BH1YG;WFKR23
M>LF]+*VMM-GK?P_]K7XG?%?P??6/AK0OV$[OXP>&+VT\V\GL]7T\?9+L.0L3
MVMWRX*X82KD#D$5Q7[&O[./QAOOV@O$?[;'[1_P_TOP7K.I>&8/"_@;X>Z5>
M17*>&]#BE\]DEFB C::6;YR(QM09'\6U?J6BJEA5.NJDY-VU2TLG\E=^5W^A
M,,?*GA71IP2;5G+WKM7OU;2O;5I)VT[W*^]_V5O^3??#'_7D_P#Z->O@BOO?
M]E;_ )-]\,?]>3_^C7KY_B[_ '"'^+]&?6^'W_(UJ_X'_P"E1/0:***_/3]<
M"BBB@ HHHH **** "BBB@ HHHH ^?OV!O$&BZ9\&M6MM0U&.*3_A.=9;:YYQ
M]I;FNL_:L\3Z!>_L]^)[6TU6*21[) J*>3^]2N<_X)^6EK/\%=6>:VC<_P#"
M=:R,L@)_X^376_M9V5G%^SKXIDCM(E86*898P"/WJ5XO$G_).XS_ *]5/_2&
M95_X$O1_D?GU1117\.GR 5%?6BW]C-8O+)&LT31F2)MKJ",94]CSP:EJ*^M3
M>V,UDMS+"9HF030MAX\C&Y3V(ZCWIK1@?G'X-\(_MC_\$\?B!\+?@^GP'TCX
MH^'_  ?IGBL^%KOP;K"V6J:AI\\MM//)/;3KM:XBW+\D;'S-^ 25);IO^"H_
M[1/A']HG_@D*/CS\&XIYO#6NZSI4ES97L'E,L45^$DMYT1N"MQ$J,%8C*Y!(
M(-=3\0OV5_VX!\>OA]X=M/VZ=3O+1-$U^"U\5S?#*S>^TJ!ELPT<DZ2+#)+*
M  DK1JRF)FPY)(]MTO\ 85^!6F?L9-^PS]AOI_!TFC26,LL]P&NWE>4SM=E]
MNWSOM#><#MVAP,+M&VOTW$9SE%#&8',J\HU*T:D9R=-5$I1]I4<W)344I.5G
M'E2UYKV7*>A*K34X5'9N]]+]W??^M_(^?OVD/#7[<?['G[/<G[9$7[8VI>)]
M<\-"TO\ Q;X#U'1K*+0+RVDECCFM+5(XQ);B/S/EDWEF"=BU?:WA'Q':>,?"
MFF>+M/B=(-5T^&\@23[RI+&K@''?#"OD_7O^">_[5'Q>\$Z;^SS^T9^VK%XB
M^%VGSVPO].TSP<EEJVO6MNZO#;7=V)F"@%$W.B[GV9/)R/??CK\-/CCXO\*Z
M7H'[.7Q[L_AM<6,X^T74O@N#6$GMQ&56!8I98Q%@X.X$\#&*\#-ZN7XRE0HN
MO2=3FFW4C"4(*#4>2,E&FI-IJ3T@VDTK]%A5<))*ZOKJE96Z=/T/#?\ @BG_
M ,F.V_\ V.NO?^ETE?6M?+W[$?["W[17['3Z?X2F_;,M?$O@:VO;Z[O/"G_"
MM(+*2YGN=[%A=_:I)$"RN), $$+MX!KV+PM\*?B3H?[0GBCXM:Q\<;_4O#.M
MZ5:6ND>!);';;Z/-$JB2X27S3O,A!)'EKC=U-<O$<L!C<\Q6)H8B,H3<IQ:4
MU>\O@]Z$6I6UO\-E;FOH*OR3K2DI:;]?NV.:_:F\$_MN^+0@_9+^-G@[PH@T
MQTFC\2>''NY7NBQVNDH)6-=N!S%)SS@]*X#_ ()'ZKX,'[,^K> =%\(ZCHWB
M/PAX]U;1_B)#JNIK>S7/B".16N[GSU1%D5]Z8PBA<;>=NYKOB7]G[_@I1_:^
MH:=X'_;[\/P:+>7<SV5QJGPMMYK_ $V%W)2)6681SF-2%#N 6QEN:]$_9"_9
M4\)_LA?"F3X=>'O$>HZ[?ZGK%SK/B;Q'J[ W.KZE<%3-<R8X7.U5 YP%&2QR
MQZ<1B,%A^'9X3VU.<G*#C[.,HRTYK^T;A#F2O:*?,T]597NY2A&@XW3VVO\
MCHCU*NU_9RN(+3X[>%+FYD"1IK4)=CT W5Q5=O\ LV(DGQ[\))(H93KD&01D
M'YJ\;(O^1WA?^OD/_2D94?XT?5'Z#_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5
M7/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"O[G/L#)USQ;X;FT6\BBUB%F:UD"@'J
M2IKQ.O=]?L+%="O66RA!%I)@B,?W37A% !1110 4444 %%%% !1110 4444
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M]"K$_P#@BK_\B']HY?\ \_H?^!+_ #(:[C]FG_DOOA'_ +#D'_H5<;]@N_\
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M_P#R ;'_ *\XO_0!5NOV.C_!CZ( K\^_VB_^2Z>*O^PU-_Z%7Z"5^??[1?\
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M;MV"1@GWNO*SFG@:.:UH8)WI*3Y7>ZMY/JNSZK4SJJ"J-0V+WAC_ )&73O\
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M2_9N^'OC#XM?M(ZK:77Q9^,OBV7Q9\08=-8&TTN:08ATV @D-';QDKNR<LS
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M?_[ MU_Z):OSAK[O@_\ @5?5?DS\L\0_]YP_I+\T%%%%?8GYT%%%% !1110
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MHH **** /"_^">__ "1/5O\ L>]9_P#2DUZO\3/^1%U'_KB/_0A7E'_!/?\
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MU5X:O'$T(U8]3+&X6>"Q4Z$G=Q?W]G\T7?#?_(Q6'_7[%_Z&*_2NOS4\-_\
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MZB= MM1L_!GAMDEO;QYA&1!$S[5)'F9+' VJ3CM7XR?M&?MJ?LB_&W_@FO\
MM _'CXE?M+>$]4_: ^.>GV'V7P;9WKS3>&M#M]1MY+#08"4"@Q0AYYRNW?.[
MDY* U^P7[$7[0/P8_:/_ &;?#?C3X&?$33O$VE6&FVVEWE]IKEDAO(;:'S83
MD#YEW+GZUU8O!1PN&A)P=U)J3=[/2+^[5I-;VOZ!Y/\ L+?\%(/BQ^U7^TK\
M1OV8OC5^QM??"37OA_HFF:I+;:EXTM]4GN8;T,T0=+>%4@.P*V!(Y^;!"D5]
M8U\+?LK_ /*>/]JG_LG?@O\ ])*^Z:X\="G"LN2-DXQ=M>L4WO=@?+7[6G_!
M0GXB_"[]IW0?V(/V3_V:W^*/Q2UGPK)XFU&SO?$T>CZ9H6CK,8!=7-R\<A8M
M*-@C5<_,IS\R@S?L??\ !0/Q]\9/VB_%/[%W[4/[.,OPO^*_A?PW#XB32[7Q
M''J^G:SHTDJP_;;6Z2.,X65T1HV7(+8R2&"^#?M?P_%3XJ?\%B] \.?\$^+S
M3_#/QE\&_"4_\++\<>*9A-H3^&[B[$EOI<UBL1ENK@SE)EDCDAV*1N9^ D_[
M#\7Q0^%O_!73QUX+_;XGM/$7QO\ %WPJ@O/ _CKPQ*(]!?PG!>XDTV"S,2RV
M<RW2^:_FR3^9MR&3 \WN>%P_U2_*N;DYMWS7OO:_+RV^=M0/T1KV_P"&?_(B
MZ=_UQ/\ Z$:\0KV_X9_\B+IW_7$_^A&N_A/_ 'Z?^']4!NT445]^ 4444 %%
M%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KU?XF?\B+J/\ UQ'_
M *$*\H_X)[_\D3U;_L>]9_\ 2DUZO\3/^1%U'_KB/_0A7)C_ /<:O^&7Y,#Q
M"BBBOR( JKK&MZ-X=T]M6\0:O:V-JCHCW-Y<+%&K.X1%+,0 69E4#N6 ')JU
M7Y5_\%$_VE?CY^T=\??C9^RGIW[2VG_"[PY\*-6\"Q:7X2MM#LI]8\92ZAJ%
MC,VH"6\#%(+61XRJP(=Q5/,(#%6ZL'A98NKRIV2W?E=+I?J_\P/U4HKS?]F3
MX9?M!?"GP?J/AK]H;]I9_BG?-JS3:1X@N/"5II%Q!9&*,"WFCM,12NLBR-YH
M5"0X!7Y<G\]?VE?V"O@/^R-_P5/_ &0_B#\-KKQ3J7B'QG\1_$!\0:WXL\5W
M>I3SJE@)$C42N8XE5I7P$5>" 2<"JP^&I5JDH.>J3:LKIV3?6S6W;Y ?JE17
M)_'/X/:!\?\ X2ZW\'/%6O:WIFG:_:BWO+[PWJKV5[&F]6/E3I\T9.W:2.=I
M([U\"_\ !,+]FOX3_LE?\%AOVFO@C\%=*OK30=/\!>$IXEU+5[B^GDFFA:66
M1YKAW=BSLQY.!G  '%31H4ZM&I/FM**O:VZNEO?S[,#])J*\=_:__8;^"G[<
M6BZ)X5^.VH>*6T;1;J:<Z1X>\4W.F0:@9%52MS]F97E4!?E&X8)/K7SC_P &
MXNFV6C_\$RM,TC38?+M[7Q[XDAMX]Q.U%U&55&223@ <GFA8>G+".LI:II-6
M[WZW\NP'WA117P#^W3_P2D_X(Z?!+X-?$_\ ;1^,G[(VGW]UI>GZCXBU::7Q
M;K$1U&_D+2",!+P*K3W#J@"@ -(  !4X>G2JSY9MIO:R3N_G*('W]6QX _Y'
M33/^OQ/YU\0?\$&_V2Y?V1?^":W@K0M9TK[%KOC8R>,?$-J P$,]^D9ABVL2
M5,=I':QL"<AHVS7V_P" /^1TTS_K\3^=;TJ<*.9QA&5TII7VO9_,#W2BBBOU
MD#%^)'_).]?_ .P+=?\ HEJ_.&OT>^)'_).]?_[ MU_Z):OSAK[O@_\ @5?5
M?DS\L\0_]YP_I+\T%%%%?8GYT%%%% !1110 4444 %%%% !1110!=\-_\C%8
M?]?L7_H8K]*Z_-3PW_R,5A_U^Q?^ABOTKKX?C#XZ/_;WZ'Z?X=_P\3ZP_P#;
M@HHHKXL_23YYU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI ***
M* "BBB@ HHHH **** "BBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%
M_P"@"K=?L='^#'T0!7A?C_\ Y'34_P#K\?\ G7NE>%^/_P#D=-3_ .OQ_P"=
M?,<6_P"Z4_\ %^@&/1117P8'C_[37P*_:2^)^N:)XL_9N_;&U#X7W^E6\\%]
M8S^#[37-+U5)&1@9[:=HW61"AVO%*C8=@<@U\R?\$OO^"=_Q#MM ^#G[5'[6
M/QOUOQ-KOP^\)7EI\-_ \_A6+1K3PE]M0PW3R1AFFNKEXAL\R5E 5N$R%(^^
MZ*ZH8RM3H.E&VO6RO;6ZO:^M^^VFS ^2/^"D'_!/K]JK]O7P[K_PA\-?MYV?
M@/X9^)=(MK35O!C_  FMM5FEEBF$QF%\UY#*NYTC^0 8V=3N->E_L>?L^_M.
M?!#PAJ?@K]I[]K73_BY9/9V=IX>BA^&MMH*Z9;Q1R1R1N(KB;[4)%,0R^-OE
MGKO./;**3Q=:5!47;E7]V-^G6U[Z+KJ!X3^W5^PKX'_;,_9.\9?LRZ5=Z5X.
MN/%EE!;Q^);?PU%=/8F.YBGW"(/$7R(BN/,7[V><8/<WOPC\5^'OV>Y/A%\$
M?'UEX0U^'P^ECI'BI/#45W':721+&+MK-G5)ONY*,XSTW5WM%9^WJ\BA?1._
MST_R7D!\ >!_^"4?_!0_P#^TAXL_:JT/_@K7I8\8>.=/T^P\47K?L\V)2ZMK
M-=D"+&=1*1$+P6503U.:^KOCE\$/B[\3OBW\,_'WP^_:1U/P9HO@O6[F\\6>
M%['33-%XMMY(T5+69_.3R51E9@VV3.\\"O4:*UJ8RO5FI2M=*WPQ6EK=%VV[
M= /E']J/_@GK\7?%O[5ME^W1^QG^TM#\-?B/_P (L/#GB6VUKPRNKZ1XBTY9
M?-C2>'S(WBD1L8E1B<(@ 7DM+^RC_P $^/BEX _:CU?]N7]L#]I!/B9\3[_P
MLOAO1?[*\-II.D^'M*\X3/;VT DD9V:0%C*[!L.XQ\Q-?5-%'UW$>R]G?2UM
ME>W:]KV^?EL 5[?\,_\ D1=._P"N)_\ 0C7B%>W_  S_ .1%T[_KB?\ T(U[
M_"?^_3_P_J@-VBBBOOP"BBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5
MO^Q[UG_TI->K_$S_ )$74?\ KB/_ $(5Y1_P3W_Y(GJW_8]ZS_Z4FO5_B9_R
M(NH_]<1_Z$*Y,?\ [C5_PR_)@>(4445^1 %?F7_P6J^,7_!*SXC^'/$7PL_:
M?\+:38_%#PQK6B6FFZAXH\*7=G=W&G/J-E+<M8ZBL8$]O]EEN,K'*2I$AVJP
M!K]-*XWX^_!;0?V@_AA=?"SQ-JMY96=WJ.G7CW%CL\T/9WT%X@&\$89[=5/'
MW6.,'!KKP5>&'Q$9ROHUL[=?1_<!\=?\$48]7MO&/QQLO@MK_C?4_P!FN'7]
M(7X$WGCI[QY&_P!$<ZHMBUZ!.UBLYB$98;3@X);S"?#_ /@H_P#\%2/V"/$7
M_!0O]E[7]%_:,TV>S^$_Q$\1?\+"G73;T#1MUHEN-X,(+_O4=/W>[D>G-?K/
M16\<=2^MRKS@W=6T:6\>5MOE=V][Z:Z@>8Z%^V5^S-XE_9A?]LW0_BM:7'PR
MCTVXU!_%BVEP(1;02O#+)Y9C$N%DC=<;,_+P"*_-K]G/_@K/_P $\/#7_!8'
M]H#X_P"N?M,Z7;^#_&O@WPKI_A?6VTN^*7]S;6^R>-5$!=2C<$LH![$U^N=%
M94,1AJ,:BE!OF5OB2LKI_P KN]-]/0#R[]J;]M+]F#]BCPOIGC3]J/XM6?A'
M3-8OS9:;=WEG<3"><(9"@$$;D':I.2 .*^#?^#=#]NK]DZZ_9QT7]CV#XR63
M?$G5/&7B74+#PL+*Y\V:V-S/=B02>5Y0'D*SX+@X&,9XK]0Z*5/$4(825)Q;
M<FG>ZM=7MIR^>NOW >7>"OVO?A%X]_:J\:?L<Z"VI_\ "8^ ]$L=5UX3606U
M^SW:JT/ER[CO;#C(P,5\L_\ !7J27]JW]H+X"_\ !*S19'ELO'_BH>+_ (I1
M1,<)X7TEO-,,OHMQ.I1&YQ);KZX/WO14T<1"A652,=4M->MM]NCU2_$!L444
M$2PPQJB(H5$48"@= !V%;7@#_D=-,_Z_$_G6/6QX _Y'33/^OQ/YTL'_ +Y3
M_P 2_- >Z4445^O@8OQ(_P"2=Z__ -@6Z_\ 1+5^<-?I+XTLO[2\':MIWF[/
MM&F3Q[]N=NZ-AG'?K7QA_P ,Q_\ 4[_^4W_[97O9/Q+DF0TYPQU7D<FFO=D[
MVW^%/\3X'C+)<SS:M1EA:?,HIWUBMVN[1Y317JW_  S'_P!3O_Y3?_ME'_#,
M?_4[_P#E-_\ ME>S_P 1$X._Z"O_ "2I_P#('Q?^IW$?_/C_ ,FA_P#)'E-%
M>K?\,Q_]3O\ ^4W_ .V4?\,Q_P#4[_\ E-_^V4?\1$X._P"@K_R2I_\ (!_J
M=Q'_ ,^/_)H?_)'E-%>K?\,Q_P#4[_\ E-_^V4?\,Q_]3O\ ^4W_ .V4?\1$
MX._Z"O\ R2I_\@'^IW$?_/C_ ,FA_P#)'E-%>K?\,Q_]3O\ ^4W_ .V4?\,Q
M_P#4[_\ E-_^V4?\1$X._P"@K_R2I_\ (!_J=Q'_ ,^/_)H?_)'E-%>K?\,Q
M_P#4[_\ E-_^V4?\,Q_]3O\ ^4W_ .V4?\1$X._Z"O\ R2I_\@'^IW$?_/C_
M ,FA_P#)'E-%>K?\,Q_]3O\ ^4W_ .V4?\,Q_P#4[_\ E-_^V4?\1$X._P"@
MK_R2I_\ (!_J=Q'_ ,^/_)H?_)'FWAO_ )&*P_Z_8O\ T,5^E=?$^B_LT_9M
M9M+C_A-=WEW4;8_LW&<,#_STK[8KP\YXARC/G!X"KS\E[^[)6O:WQ)=GL?=\
M&91F.4PKK%0Y>;EMJGM>^S?<****\0^W/P@\<_\ !2?]M73O&VL:?9?&C9#!
MJMQ'$G_".::=JK(P R;?)X%97_#S3]M[_HMG_EMZ;_\ (U>0?$?_ )*'KW_8
M:NO_ $<U8U?TW3X,X/=.+>74-E_RYI__ ")_,M3/\]51I8JIO_/+_,]X_P"'
MFG[;W_1;/_+;TW_Y&H_X>:?MO?\ 1;/_ "V]-_\ D:O!Z*T_U+X._P"A;A__
M  33_P#D3/\ M_/?^@NK_P"#)?YGO'_#S3]M[_HMG_EMZ;_\C4?\/-/VWO\
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M )U[I7A?C_\ Y'34_P#K\?\ G7QO%O\ NE/_ !?H;F/1117P8!1110 4444
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M7V'"/P5O6/Z@0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%345]D!_-9\1@!\0M>
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M]%L_\MO3?_D:C_B /&/_ #_P_P#X%4_^5!_Q$O(O^?=7[H__ "9^M%%?DO\
M\/-/VWO^BV?^6WIO_P C4?\ #S3]M[_HMG_EMZ;_ /(U'_$ >,?^?^'_ / J
MG_RH/^(EY%_S[J_='_Y,_6BBOR7_ .'FG[;W_1;/_+;TW_Y&H_X>:?MO?]%L
M_P#+;TW_ .1J/^( \8_\_P##_P#@53_Y4'_$2\B_Y]U?NC_\F?K117Y+_P##
MS3]M[_HMG_EMZ;_\C4?\/-/VWO\ HMG_ );>F_\ R-1_Q 'C'_G_ (?_ ,"J
M?_*@_P"(EY%_S[J_='_Y,_6BBOR7_P"'FG[;W_1;/_+;TW_Y&H_X>:?MO?\
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M$\/AE-^V(^L-X_;2)CJ;>(@PU$VWVJ;[$;O=\WV@VGV<OO\ GW9W_/NKQ/\
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M;XJ?]CI>_P#H=?T"U_/U_P %$_\ D^;XJ?\ 8Z7O_H=?I7A7_P C:O\ X/\
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MJ?\ R(?V_D7_ $%TO_!D?\SWBBO!_P#AYI^Q#_T6S_RV]2_^1J/^'FG[$/\
MT6S_ ,MO4O\ Y&H_U+XQ_P"A;B/_  34_P#D0_M_(O\ H+I?^#(_YGOVG?\
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M%4,91]K2=UJMFFFG9IIV::>Z:N+$X:MA*OLZJL]'NFFFKIIJZ::V:85^]?\
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M((-95;1E&<5*+NGLS"490DXR5FC9^''_ "4/0?\ L-6O_HY:_I3K^:SX<?\
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MH_\ Z'SX6?GK'_Q5'_#@G]H__H?/A9^>L?\ Q5?<?\12X?\ ^?57_P !A_\
M)GQ?_$-,]_Y^4OOE_P#('YZ5=L_$FOZ?H5[X9L=8N(M/U*6&2_LHY2([AXMW
ME,Z]&*[WQGIN/K7W]_PX)_:/_P"A\^%GYZQ_\51_PX)_:/\ ^A\^%GYZQ_\
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M_P 12X?_ .?57_P&'_R8?\0TSW_GY2^^7_R!^>E?O7_P2N_Y1^?#+_L"S?\
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M=(\D/./G4'*_C0!<HHJGI'B'0/$"2RZ!KEG?+!(8YFL[E)1&_P#=;:3@^QH
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M** /./VN_"GB/QS^S3XQ\(^$=(EO]2O]':*SLX "\K[E.T9[\5U_P^L;O2_
M.AZ9J%NT4]OH]M%/$_5'6)0RGW!!%;%% !115.^\0Z!IE_;Z5J6N6=O=7AQ:
M6T]RB23GT12<MU[4 7**** "BBB@ HHHH **** "BBB@ HHHH **** /(/V*
M? OB[X??"?4M$\::#/IUW-XPU2ZC@N  S0R3ED?@]".17K]%% !15/5_$.@>
M'TBEU_7+.Q6>01PM>7*1"1_[J[B,GV%7* "BJMSKFBV6I0:->:Q:Q7ET";6U
MEN%628#KM4G+8[XJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!^>'_!9/XG_&/XX?M5_L\?\$B/@M\4]9\#VGQRO]6U7XH^+/#=R;?4
MH/#6EV_GRV=M,,F%KK;+&9!R"B*0R.ZM)\=O^#<[]@6P^!]V_P"Q!\,KSX0?
M%OPYILEU\.OB7X0\3:A#J=IJD:%H3<2O.QN8Y' 6029)5VVE3@BO_P %EOA[
M\6O@#^UG^SK_ ,%?/A3\,]9\9Z3\$+[5](^*_AKPY:&XU$^&]4M_(DOX(1@R
M_9=TLC(#U=&.U$D=='X^_P#!Q1_P3XB^!5S>?L:?&1?B[\5/$NG/:_#3X:>#
M=%O+G5M3U:6-A;QRVYA#VR*V'D,@4A$;"LV%( ?L.:AX _X+_P#_  1[^%GB
MW]L;^V)Q?WA_X3W2_#6MS:3'K=_ILUS92)<-:LC_ &>XPMRT,;(-S( 0%Q7S
M_P#MW?L,_LH?\$T/VS?V2M6_X):^#)_AW\8O&_QJT_1=7\(>%M9NY+?Q)X-"
MNVKR7]M+*ZM#"HC)EX($CMRR*\?I7P>\>:#_ ,&U'_! OP=?_M$^')M8\7Z3
M#()O#VEN"+SQ+JD]Q=I8O,N4CCA!,<DW(VVS% [,BMY-_P $KO\ @H/_ ,$K
M](^+[?M9?M@?\%#?"_Q"_:K^+3V^EW-Q:Z%JIL/"MK/*HM_#FCJ]KL@MT9U5
MY,YEDRS,02S '[(U\L?#_P#9P^,^B?\ !9#XC_M5ZIX-\KP#KWP(\/\ AW2=
M>_M&V;S]2MM2O9YH/($AF7;'+&V]D"'=@,2"!]3T4 ?GQ\=_^""7_!&#P9\'
M?'GQ=_:+^&-V\PL+[6_%7Q:\3^-]1EUBR95>5KU+@S[8FBP&1$0(2J@HV2#K
M?\$1(_CY^U=_P0Y\$^'/VN?&7BQ=5\9^$-9TB#Q1_:,EMKLNB3S75O8WJW'+
MQW'V1HVBG^9B%BERQ.X_#OQX_P""QG_!/G_@J'^UU?\ PV_;+_:IT[X=?LN_
M"OQ&#;_#V_T[4&U'XK:O;OE+F_%M X@TJ%P&2V8AY6 :10<"']>?V?OVQ_V2
M_CO^S*W[3?[/?Q.TW5/ACI%E=_\ $\T[3I[>VM;>Q5A.%A>)'58EC(VA.BX4
M'B@#\[_V%_V)?@1^P7_P<J>(/@[^S_9ZVNFZA^Q9)K.J7?B/Q'=:I>7M_+XJ
MLXGGDFN79LE((EVKM4;,A022?UJK\3-+_P""U/\ P2^@_P"#A;4?VPI?VMM'
M7X;3?LB+X2B\4_V/J'E-K7_"2Q7?V/R_L_F[O(4R;MFS QNSQ7[1>#_%OAWQ
M_P"$M+\=^$-32]TG6].@O]+O41E6XMIHUDCD 8 @,C*<$ \\B@#1HHHH ***
M* "BBB@ KX7_ ."\'[4/QW^$'P/^&G[,7[+/C67PO\0OVBOBSI7P^TGQ;; ^
M=H%G=L1=W\)!RLB+L0,,,@E9U*NBD?=%?"?_  7G_9H^.WQ2^"7PQ_:G_9>\
M#S^*O'G[.?Q<TKX@V'A&T!-QK]A:L?MEE"H&6E9=CA1EG6)T4,[*" 5)O^#:
M[_@E0?A&? UC\']8MO%ZP&6+XO1^++[_ (2E=3QG^U/MGFX,_F?O-NWRL\>7
MMXKF?^"5OBWX@_\ !2C_ ()\?%G]@[]N?XE:]J?BSX2?%/5/A?XZ\7>'M6>P
MU'78-,NH7CN3<1Y=6E56MY'!WR+&[%MTA>NNG_X.1_\ @DNOP8'Q/M/V@IY]
M?>W"0_"V/0+K_A*'U(_*-,^P^7D7!E(BSGRMW/F;?FKS[_@FRWB'_@E5_P $
MSOC=_P %)O\ @H%X*U'PWXB^)OQ%UOXK^,O"-E:F2^TI=1GC2TTS8=N)F=E.
M'V^6UUMDV;&V@'C'_!9[_@F1^P'_ ,$T/V1M#_:%_P"">WPXO?A;^T+8>.M#
MTSX+7G@WQ#?RZGXAU2>^A273Y(YYY/MB/;&=V#@D^6 20Y1_V-T1]6DT6TDU
M^&*.^:UC-[' <HLVT;PN?X=V<>U?B#^PW_P5<_X)D_&O]H!/^"GO_!4?]N'P
MN/B@JSP?";X4PZ7JEUI?PLTF0XVH5M#'/J<RX,UT,XR%7: %3]OM"UO2_$NB
M6?B/0[Q;BRU"UCN;.X52!+%(H9& (!&5(///- 'S%\<OV</C/XQ_X*V? 7]I
MSPYX-^T^!_!?PW\8Z5XFUO\ M&V3['=WQL?LL?DM()I-_DR?,B,J[?F*Y&<'
MXO\ _!"K_@EM\;/B5XT^/W[3?P+E\=>(?%EY/>ZQKGC'Q?J#BPA()\FU5)XX
M[."-<[=BJR@<L< U]BU^+_\ P5&_X+ ?LP_M3?MD>(/^"7/Q6_:LC^"WP/\
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MPOW4SO,9SFZ=I?\ 6<$X&% %>E?MS?\ !%OX,?L0_LQ^,_VO_P#@DUXE\8?
MSXE?#+P_=^*+*U\-^--1NM(U^*RB:YFL+VPO9YH9DDBCD55 5=Y3<&4$50_X
M+L?'[X0?LM_\%5?^"?GQ\^/GC:#PYX0\.:S\0YM:UJY@EE2U1].TN)6*Q*[G
M+R(ORJ?O>E7_ -NG_@M=\ _VT_V8_&?['O\ P2BL/$WQV^*7Q.\.W?A>P3PI
MX0U"'3= BOHFMI;^^OKJ"*&!(HI7<'<0'";]JDM0!]R_L#_M-C]LW]BSX7_M
M3R:3'87'CKP58:KJ%A 28[:[DB'VB)"224682*I/)4 FO-/VI?V</C/\1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:QXP@T_3K<VVG;I+JU'V02,TMP@F!:, CYD4C-^#_P '[SX-?\% ?@E\5_\
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MDM+C4/#NH6%I'OEGLI8XDR!N8H0!D\#DU=HJ9P52#B^N@'BW_"I?B#_T+_\
MY-Q?_%T?\*E^(/\ T+__ )-Q?_%U[317S7^J>7?SS^]?_(@>>_"?P/XH\,^(
MIK_6]+\B)[)HU?ST;+%T.,*Q/0&O0J**]O X&EE^']C3;:WUWU]$@"BBBNP
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M3M^,7[&E[\>M1U[QO\>;/7[GXF?%[6-&1[C4M;U:V:":^^QI*JK%&"NRV64
M!3\X+,U?1'P%_9[T7X/?LG^"_P!E+Q)J,/B;3O"WP\T[PG?W=Q8>3'JL%M81
MV;NT.]_+654),>]L!\;FQD^AT4 ?G#X<_P""/G_!0GX&_!K5?V(/V4O^"H]O
MX8^ VHM>6VCV>N?#1-1\4>&-*NG=IM.L]1^U(LBXDD"3R1B2(.-F-BUW7[9?
M_!/+]@7X+?\ !*7PU^S5\1OB[>?"3P#\&+_1+_P/\4UN@M[X5U^.]6*SU=I
MNTRR7=VWFL0J'[5(<Q##I]R56UG1=&\1Z7/H?B'2;:_LKJ,QW-G>P++%,AZJ
MR,"&'L10!^%/[7=OJ?[9WQU_9M_9QMO^"O>E?M=_$"/XU:#J^F:-\+/"^F:=
MHOA?1;.43:IKNJ?V9/<I+<K$JQIYDJ!%FF"0Y<FOU@\9_L,?\)=_P4H\%_\
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MXM^'/_!(G1M;\(>'KZZ6TM[OXZ6D.O:_90NX6ZMK2.SDCB:1%$B022F0[@N
MQP.D\1?\%?\ ]EW0_P#@E[8_\%5;:WUF]\%ZOHD-QHV@6]LIU2\U&6X^QII2
M1ABIN!=AH&P2JE'?)5<T ?5E%?FA^U9_P6O_ ."@?[ '[+U[^U3^V7_P21BT
MC1KIK2/0;7PY\98+YK.ZN)XU6TU5EL2;,^29G$\:3QF6-(6$9E5A]-_M[?\
M!0N?]D?Q1X#^ WP<^!6I?%?XR?%.[NHO ?P[TO5HM/26"UC$EW?7M[,K)9VL
M2$9D*L6)PJG#%0#Z4HKXY^ O_!23]H;3?VM/#/[%7_!0C]CZT^$_BKXA:5?7
MWPQ\1>&_'$>O:)XC>RC$MY8^;Y$$EM=11$2;'4JZ@D,/E#?8U !17YP?L^_\
M%H/VWOVY/#WC#5/V'/\ @EY;>(6^'WB_5-!\4WWBGXN0Z9837-K,RQVME,]E
MNN+F2$),X9$BMQ-$&D<O\OIFF?\ !9OP)XH_X)7_ ! _X*1^$_@GJG]K?"]=
M0L?''PJUS5197ND:[8S1Q76ESW"PR!&7S$<2>4<HZ$HK$JH!]IT5\<_LO?\
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M'XN\/+\8;:UT7PO%!<,EM,U\]NTEW]HA,<@CBAW*2ZL5VY(!]/T5\D?LD?\
M!1CXT^/?VK-0_83_ &W/V3E^$GQ.7PBWBCPO)I'B^/7=%\3:3'.L$TMM=+%"
MT<T4CJ&@=-VW+YQ@5YTG_!7G]J[XS?M.?&C]D']C/_@G4/&GB?X->+$TO5M?
MUSXEPZ7HQM'A#Q3RRO:%TN)7$B):QB7Y87D>5 %5@#[\HK\\/@E_P6<_:O\
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M^5>\_P#CU'_#&_[-_P#T3G_RKWG_ ,>K] _UMRW^2?W+_P"2/R;_ (A_G/\
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MWPH^+TWCE_!FE[Y;G5;73?%>HR7-I"N6,CB.624)RS&+ #,0#^Z7_"'^$O\
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M\)-4\?Z?KEB-7M-4CMTU>S%C=7$=H)(FDA>(,NXINVX"U];_ +9O_!.OX_\
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M)J'CW]D37;CPY\/X;Q=]QKNFZNQD\*3%.KB0W"QE%!VQ6_?!K]%OV%OV8/\
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MO%__ "*6J?\ 8.G_ /1;4 >$4444 =G\#?\ D;;C_L'/_P"C(Z]5KRKX&_\
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M#GBO6O%']FZE>>%M1LKF2SOY[MDD+W=K:PW$X_BE\N.(.IQ)7T+X _X.0?\
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MC6OCSXGU2\OYC(C1VL^D.))#()0GRR1X5U#9&W< #[8_;@_X*M^//V5?VW/
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M_'C2;R5?V%-3UO6/B[=7,+"VU75-'NFTSPQY;-]XI&Z3 G=YBJY![@ _1_\
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M]!;Q-\5=9\666C6%Q$L%V6FN0\%OY@= $\Q6=E4A6V$@ ?\ \$>_C/\ #O\
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M9_L3X>^-_#7Q)A\0V<6MNI:#2-0"VT)@GE VQR)O1WX7*AW3X]_;G\-^+O\
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MV\C1R76G::UK*50M&_E"9U:8 8"DX'$_#7X6:Q\<O^"JG_!3GX(>'=56PO\
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MX^''Q$\(?#^"7P/XVTW7+W2KK0=4AMK9+^.UU:V!BA96>)-LK;9!$C*I* J
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M_!$K_@F)X!T+QU>^%[[7/BQ\%M/L_$VF7'DW.D2S>&[F-+R*3^"2)F$BMV*
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M P P!0!^Q%GK6C:C>7&G:?JUK/<6C!;N"&=6>$GH'4'*D^]-UG7]"\.6@O\
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M?LOV>\6Y^U_:_/._=MV^5Y*XSG>>E?0]% 'R1\'_ /@EG_PJC]FW]JS]GO\
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MX^C^$?!5[\)K73=0L8E=/LQEU.&[<W'E1AH\>2N\,"2-O/UG10!Q?[1?[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20210630_g13.jpg
<TEXT>
begin 644 biib-20210630_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
MC.:S?VA?^";7[1FG?MG:U^WI_P $\OVJM(^&7C#QUH-EI'Q1\.>+O!QUK1/$
MRV:F.SO61)X9(+J&+]V&5B&0 ?+E_,^S:* /CC]@/_@E=X\_8]_:[^*O[9_Q
M8_:^U#XI^+?B_H>EVWB:74/"<>G"*[M"^9(?*N'5+?88XHK<(/*CA4&20Y8_
M8]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YX?\ !33_ )3C?\$Y
MO^PA\4?_ $P65?H?7YX?\%-/^4XW_!.;_L(?%'_TP65 'TA\"?VY_P#A=?[?
M'QY_8>_X5=_9G_"D=/\ "]U_PD_]M^=_;7]L6,EUM^S>0OV;R?+V9\R3?G.$
MQBCX-?MS_P#"W/\ @H)\:/V$_P#A5W]G_P#"H?#_ (<U/_A*?[;\W^UO[5MW
MF\O[-Y"^1Y6S;N\V3?G.$Z5\?K^U)\"/^":__!=S]HWQ7^VGX]M_ /AKX[?#
MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
MRXS@9KI/CY_P6M_8@^)__!%'Q;\'_ _B=M0^+.L_ C4O"=[\%X-(N#K>CZDN
MCR6M\MU:F,-!;686>:6=]L?E6[$-D@4 ?;O_  1X_P"44'[-O_9#_#'_ *;+
M>KW[9O\ P3%_9%_X*">+?"_B#]K?PAJ_BS3?"-O<IIGA-_$EW::3-+,T;&XN
M+>VDC^T2+Y0";V*@,WRG.11_X(\?\HH/V;?^R'^&/_39;UXE_P %V/\ @L9I
MG_!,WP!X7^$7P]UC2M/^*7Q4FDM/#&O^)K>5M'\+V:ND=QK%YY:.TPA\Q2D"
M*[.PR58+L< \@_9Q^ ?P@_8:_P"#@W2_V6O^";JWNB> -7^#%[K7Q\^'>FZK
M<76C:+=B3;IEWLFD<6UW*QA&P$-Y3[@ LK9T?#/P"^%?_!83_@L-^T=I/[9F
MAMXS^&'[-T&@^%?AW\/+^^F73!J=]:RW&H:E-#$ZB2X#QM$K-G]VR@C,:D=+
M_P $7?VH/^".O@#48OV8OV6/VV;?XL?&SXDWEQK7CSQEJVDZBNL>,]5C@DN+
MBYEEG@58XHXUF,4&_;&@(!9V=WYKP1\??A+_ ,$B/^"R/[21_;,\3Q^"/AU^
MTA;Z#XM^&WC_ %:VD72YK^RM9+?4=.EN%4I'<>9(9%1B/D523F5 P!TW_!*W
M1Y_V5/\ @H+^U%_P2)\,^+=7D^&'A?2M%\7?"73[K59)[CPS8:I;8O;""64L
MZPQSO&85).S!8Y:1B</]M?\ X(5?\$9?V8OV&?B/\9O&OP[O]"UGPQX4O-63
MXOZGXVU&?Q#%JL<1-M=+<27&)+EKCR@D04)([*@3Y@*UO^"6GBO2_P!J+_@H
M9^U3_P %?=&L+VR^$.LZ1H_A#X:>(]0TZ6#^WK#2K;=J.I11NHD:W,T:>6X7
MYAN7 :-E'R1_P^)_X)P?\%2?VKY/BQ_P4+_:NTOP1\ ?AAXC\SX5? O4-,OY
MI?&&H0G*:_K@MX'C:)<_N;(L0.=XQO\ / /H+XZ_MM?MK_ 7_@U_\(_'+QOX
MGU/3_CAXP\&Z)X?L?$%_(T=]%)J5ZEM#>R.?G6Z.GMYOF'YQ,0Y^8&L+_@I/
M_P $E?V<O^"6O_!/ _MS?L+Z9>^%?CA\"I-*UT?$=-8NFO/%9^V6\6HQ:INE
M*W,5RLLLCQD;<@(,(64^[_\ !7G0-'_X*O?\$4?$?Q)_8(U=/'A$MGXK\ OI
MME,/[7DTG4@;B&*&1$D:0I!=1HFT%W554'<#7A?_  4S_P""M?[,7_!3W_@G
M"/V+/V&?%#^+OC7\?9-)T&Q^'%OI]Q]N\-LUY;RZA)J8,8%K';)%*CR,=N<.
MNZ,,P /U;^%OCS3_ (I_#+PY\3M)A,=KXCT&SU2VC+AML=Q"DJC(ZX#CFMZL
M'X6> [#X5_#'PY\,-*F,EKX;T&STNVD*[2T=O"D2G';(0<5O4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q7\+O\ @FM^
MTIXR_P""BVC?\%!OVY?VHM$\8S?#>QUG3O@UX(\)>$SIUGH4.H;HI;JYF>1W
MN;AK9A$WRJN0&!X"U]J44 9_B'PIX6\76L=EXK\-:?JD,,PFAAU&S2=4D'1P
M'! 89.".:T  !@"BB@ HHHH R8O ?@>#Q*_C.'P9I*:PZ[7U9=.B%RPQC!EV
M[CQ[UK444 9?BCP3X,\;VT=EXT\(Z7J\,3%HH=4L([A4/J!(I -:%I:6EA:Q
MV5C;1PPPH$BAB0*J*!@  < #TJ2B@#.USPAX3\3SVMSXE\+Z=J,EC+YMC)?6
M4<S6\G]]"X.QN!R,'BN<_:+^!7@W]I[X$>+?V=OB)>ZG;^'_ !KH-SHVN/H]
MY]GN6L[A#',B2;6V[T9D)P>&-=I10!E^!_!7A3X;>"](^'7@30K?2]#T#2[?
M3M&TRT3;%:6L$:Q10H.RJBJH'H*U*** "JNM:'HGB72YM$\1:/:W]E<+MGL[
MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2OGK]@OPW8:M\'-6NKF:
MX5AXXUE<13E1C[2W85[;_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?
M\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C
M_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^
MD?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z
M1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S
M>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_
MS\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
M\(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D
M?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^
MD?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>
M_P#@6U &Q1679^$M-L;I+N&XNBT;94/<L1^(K4H **** "BBB@ HHHH ****
M "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^>=1_Y"$__79OYFH:FU'_ )"$_P#U
MV;^9J&OQF?QL#XY_X*5_M6?&?X:?M"_ W]DGX5?&O1_A-:_%N]UDZS\5=;TF
MWO/[.6PMXY([*U2[/V;[3</*$!E! ^7:K,<5G_\ !&_X-_M+^#?V=?A_X]\6
M?MA7?B[P#JG@8BQ\!ZIX,T^"32KDS*8Y8;^V5))(PJRJ8Y5;/F AAMP?1?\
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MS5+*XE7PII$N[Y+&*%&>:_E52$8 +%N4[@QWQ>R?\$KOC]_P2YG\ 0_LC?\
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MT*G@BJWA_P +^&?"=D=-\*^';#3+<N7-OI]HD*%CWVH ,^]7J*5W:P!1112
M*RU\$>"T\0'Q8GA#2QJIZZF-/C^T>G^LV[OUK4HIIM ?0/A__D V/_7G%_Z
M*MU4\/\ _(!L?^O.+_T 5;K]BH_P8^B *X77_C5_8>M7.C_\(UYOV:8IYGVS
M;NQWQL.*[JO"_'__ ".FI_\ 7X_\Z\/B+'8K X>$J$K-NVR?3S3 Z[_A?_\
MU*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NO.:*^2_UASC_G[_Y+'_(#T;_A?_\
MU*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NO.:*/]8<X_P"?O_DL?\@/1O\ A?\
M_P!2E_Y/_P#VNC_A?_\ U*7_ )/_ /VNO.:*/]8<X_Y^_P#DL?\ (#T;_A?_
M /U*7_D__P#:Z/\ A?\ _P!2E_Y/_P#VNO.:*/\ 6'./^?O_ )+'_(#T;_A?
M_P#U*7_D_P#_ &NC_A?_ /U*7_D__P#:Z\YHH_UASC_G[_Y+'_(#T;_A?_\
MU*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NO.:*/]8<X_P"?O_DL?\@/1O\ A?\
M_P!2E_Y/_P#VNNX\,ZU_PD6A6VM?9O)^T(6\K?NV\D=<#/3TKP&O;_AG_P B
M+IW_ %Q/_H1KW^'LTQ^.Q<H5YW2C?9+6Z[) ;M%%%?7@%%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_R$)_^NS?S-0U-J/\
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MRN[)R[OAF4*Q^IX72=24_9J.ED[N[U5]VUO;9+70#[)HHHK[, HHHH ****
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MN*5>W_#/_D1=._ZXG_T(U]3PSBJU?&2C.UE"RT2=DUI=*X&[1117VX!1110
M4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['
MO6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXU%7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A__ ) -C_UYQ?\
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M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344
M0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_
M 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9
MVG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 ?/.H "_G '
M_+9OYFH:FU'_ )"$_P#UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@
MHHHH ][T"PL6T*R9K*$DVD>28Q_=%6_[.T__ )\8?^_0J+P__P @&Q_Z\XO_
M $ 5;K]CH_P8^B A_L[3_P#GQA_[]"O$/'B)'XRU)(U"@7;X & .:]UKPOQ_
M_P CIJ?_ %^/_.OF.+?]TI_XOT QZ***^# **** "BBB@ HHHH **** "BBB
M@ KVKX;V5G+X'TZ22TB9C"<LT8)/S&O%:]O^&?\ R(NG?]<3_P"A&OJ>$_\
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M_P#^1TU/_K\?^=>Z5X7X_P#^1TU/_K\?^=?,<6_[I3_Q?H!CT445\& 4444
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M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>=1_P"0A/\
M]=F_F:AJ;4?^0A/_ -=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH **
M** /H'P__P @&Q_Z\XO_ $ 5;JIX?_Y -C_UYQ?^@"K=?L='^#'T0!7A?C__
M )'34_\ K\?^=>Z5X7X__P"1TU/_ *_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%%
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M%% !1110!\\ZC_R$)_\ KLW\S4-3:C_R$)_^NS?S-0U^,S^-@%%%%2 4444
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M_P"G'_DW_P!J!]&45\YT4?ZW_P#3C_R;_P"U ^C**^<Z*/\ 6_\ Z<?^3?\
MVH'T917SG6QX _Y'33/^OQ/YUI1XK]M6C3]C:[2^+O\ ]N@>Z4445]@ 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_P A"?\ Z[-_
M,U#4VH_\A"?_ *[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?
M0/A__D V/_7G%_Z *MU4\/\ _(!L?^O.+_T 5;K]CH_P8^B *\+\?_\ (Z:G
M_P!?C_SKW2O"_'__ ".FI_\ 7X_\Z^8XM_W2G_B_0#'HHHKX, HHHH ****
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MJ55U37-%T-(Y-:UBULUFDV1-=7"QAV_NC<1D^U>7_!3PU\;_ -G+X0^);_\
M:?\ VEY?BFVE2W.IV7B"7PC::1=0:=';*QMY8[3$4SJR2L)0J;@X!7Y<G\D?
MV=?CC_P3,_:F\#ZK^V5_P5(\->,_B[X]\3WEWJ&N1:3X=UK5M"^%^BFXD2TT
M\M9 06H$"+,WWI<2 MAB2^^&P#K\\DVXQLO=3;;?9/E[=;?B!^Y%5--\0:#K
M,TUOI&MVEW);MMN$MKE9#$?1@I.T\'K7BG@3]G3]BS]H;]@[1?V>_AQ GB'X
M(ZYH5LFC6VF>)+PI<Z<DZSQPBZ647.T.@1@9 X"LC=Q7YO?M+?#+_@F1X?\
MB5\-_#/_  10NK*U_:.LOB-81V$'PTU:_F2/3(YB-1&JEG: 6BQK^\\T[C]W
ME&<%8;!T\1.4+R33?V=$N\G?3ST=O,#]EZ*\2_:W_P""<O[%_P"W9J.AZM^U
M=\$H/%UQX;AGAT62;6;ZU^S),4:4 6L\8;<8T^]G&WC'-?"O[ /[!7[)6D?\
M%N_B'X\_9+^#UOX7\#_L\>%(?#_F6NJ7=TNH>*]0BE%S('NII#^XM9)[=T4@
M*X4_Q<Q1P^'JT)3<VG%7?NJV]DK\U]6UT _5>JE_X@T'2KN&PU/6[2VGN3BW
MAGN51Y3G&%!.6_"K=?GO^W'^R?\ \$ /@KXZ\0^,_P!NO0_"NF>+?';WFO:A
M>>(?$NJ2:E>^;*_F2VR13%T ?*HD"@+M 5:RPU*%:IRRYO\ MV/,_NN@/T(K
M3\%S26_BO3YXK=I62Y4K&G5N>@KXM_X(;Z3\>-'_ & ='M?CA<^(Y+5O$.I2
M?#S_ (3!V;55\+M-G3A<[_F#;-Q56^[&8P %"@?:_@#_ )'33/\ K\3^=;TJ
M7L,RC3O>TTK_ # ]<_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBBOUD#'_X2
M75_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_
M^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_
M .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W
M_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?
M^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^E
MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH ^>+YBU[,Q4@F5B0>W
M-15-J/\ R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'M
M6B^(M5CT:TC3PI=N%MHP'5EPWRCFK7_"2ZO_ -"A>_\ ?2U=\/\ _(!L?^O.
M+_T 5;K]CH_P8^B Q_\ A)=7_P"A0O?^^EKQ[QI-)<>*]0GEMVB9[EBT;]5Y
MZ&O>:\+\?_\ (Z:G_P!?C_SKYCBW_=*?^+] ,>BBBO@P"BBB@ HHHH ****
M"BBB@ HHHH *]<\ Z[J5KX/L;>'PS=3*L1 E1EPWS'I7D=>W_#/_ )$73O\
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M.G7CW%CL\T/9WT%X@&\$89[=5/'W6.,'!KKP5>&'Q$9ROHUL[=?1_<!\2_\
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M51110!X7_P $]_\ DB>K?]CWK/\ Z4FO5_B9_P B+J/_ %Q'_H0KRC_@GO\
M\D3U;_L>]9_]*37J_P 3/^1%U'_KB/\ T(5R8_\ W&K_ (9?DP/$****_(@"
MBBB@ HHHH **** "BBB@ HHHH *V/ '_ ".FF?\ 7XG\ZQZV/ '_ ".FF?\
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MR?9[F')\J=-VQTR=KJPR<5L444 >%_\ !/?_ )(GJW_8]ZS_ .E)KU?XF?\
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MZ21F.=KM+N:2;$:R)L8<^9NSE0#]044EBJRH>QTY?\,;_?:_X@3:=_R$(/\
MKLO\Q7T-7SSIW_(0@_Z[+_,5]#5]=PC\%;UC^H!1117V0'SSJ/\ R$)_^NS?
MS-0U-J/_ "$)_P#KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110
M!] ^'_\ D V/_7G%_P"@"K=5/#__ " ;'_KSB_\ 0!5NOV.C_!CZ( KPOQ__
M ,CIJ?\ U^/_ #KW2O"_'_\ R.FI_P#7X_\ .OF.+?\ =*?^+] ,>BBBO@P"
MBBB@ HHHH **** "BBB@ HHHH *]O^&?_(BZ=_UQ/_H1KQ"O;_AG_P B+IW_
M %Q/_H1KZGA/_?I_X?U0&[1117WX!1110 4444 %%%% !1110 4444 >%_\
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M_P"N(_\ 0A7)C_\ <:O^&7Y,#Q"BBBOR( HHHH **** "BBB@ HHHH ****
M"MCP!_R.FF?]?B?SK'K8\ ?\CIIG_7XG\ZZ<%_OE/_$OS0'NE%%%?KX%3Q!_
MR ;[_KSE_P#0#7S]7T#X@_Y -]_UYR_^@&OGZOA^+OXM+T?Z %%%%?'@%%%%
M !1110 4444 %%%% !1110!-IW_(0@_Z[+_,5]#5\\Z=_P A"#_KLO\ ,5]#
M5]MPC\%;UC^H!1117V0'SSJ/_(0G_P"NS?S-0U-J/_(0G_Z[-_,U#7XS/XV
M4445(!1110 4444 %%%% !1110 4444 ?0/A_P#Y -C_ -><7_H JW53P_\
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MBB@ HHHH **** "BBB@ HHHH *]O^&?_ "(NG?\ 7$_^A&O$*]<\ ^$]-O\
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MB+IW_7$_^A&O$*]O^&?_ "(NG?\ 7$_^A&OJ>$_]^G_A_5 ;M%%%??@%%%%
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M1117V0'SSJ/_ "$)_P#KLW\S4-3:C_R$)_\ KLW\S4-?C,_C8!1114@%%%%
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MKIP7^^4_\2_- >Z4445^O@5/$'_(!OO^O.7_ - -?/U?0/B#_D WW_7G+_Z
M:^?J^'XN_BTO1_H 4445\> 4444 %%%% !1110 4444 %%%% $VG?\A"#_KL
MO\Q7T-7SSIW_ "$(/^NR_P Q7T-7VW"/P5O6/Z@%%%%?9 ?/.H_\A"?_ *[-
M_,U#4VH_\A"?_KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!]
M ^'_ /D V/\ UYQ?^@"K=5/#_P#R ;'_ *\XO_0!5NOV.C_!CZ( KPOQ_P#\
MCIJ?_7X_\Z]TKPOQ_P#\CIJ?_7X_\Z^8XM_W2G_B_0#'HHHKX, HHHH ****
M "BBB@ HHHH **** "O;_AG_ ,B+IW_7$_\ H1KQ"O;_ (9_\B+IW_7$_P#H
M1KZGA/\ WZ?^']4!NT445]^ 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB
M>K?]CWK/_I2:]7^)G_(BZC_UQ'_H0KRC_@GO_P D3U;_ +'O6?\ TI->K_$S
M_D1=1_ZXC_T(5R8__<:O^&7Y,#Q"BBBOR( HHHH **** "BBB@ HHHH ****
M "MCP!_R.FF?]?B?SK'K8\ ?\CIIG_7XG\ZZ<%_OE/\ Q+\T![I1117Z^!4\
M0?\ (!OO^O.7_P! -?/U?0/B#_D WW_7G+_Z :^?J^'XN_BTO1_H 4445\>
M4444 %%%% !1110 4444 %%%% $VG?\ (0@_Z[+_ #%?0U?/.G?\A"#_ *[+
M_,5]#5]MPC\%;UC^H!1117V0'SSJ/_(0G_Z[-_,U#4VH_P#(0G_Z[-_,U#7X
MS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A_\ Y -C_P!><7_H JW5
M3P__ ,@&Q_Z\XO\ T 5;K]CH_P &/H@"O"_'_P#R.FI_]?C_ ,Z]TKPOQ_\
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MB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\ U^/_ #KW2O"_'_\ R.FI_P#7X_\
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M,IX.I&*NW%_DP-:BO%O^'BG[%'_1PFB_]^Y__C='_#Q3]BC_ *.$T7_OW/\
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M>+?\/%/V*/\ HX31?^_<_P#\;H_X>*?L4?\ 1PFB_P#?N?\ ^-U\K_9N8_\
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M9_\ @+_R ]IHKQ;_ (>*?L4?]'":+_W[G_\ C='_  \4_8H_Z.$T7_OW/_\
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M'_1PFB_]^Y__ (W1_9N8_P#/F?\ X"_\@/::*\6_X>*?L4?]'":+_P!^Y_\
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M!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\
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M[S2GYIRR^1@IAPP^XZ_/#1O^5JS5O^S$%_\ 4OAK]#Z "BBB@ HHHH ****
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M_P )=_;'W_.UB?3?L/V7R>,>1YOG>;SNV^6,;CX+X[_;^_X*^/K&O^)/@O\
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M38L\A!=6\W"M]1_"S]A#PEI/_!).T_8M_8(\<^,/@1;ZYX.6'1O%.O>&9?\
MA(M(FN9%EN[B\MI7MY!?2;ID<AHS&TFZ(J$C ^N** /S=_99_P""._\ P4Y_
M8M^"FD_L]_LU_P#!8_PKX:\+:.':WLH/V4M+DDFE<[I)YY9-4:2>9VY:1V+'
M@9P !^C&A6NJ6.B6=EKFK+?WL-K&EY?+;B$7,H4!Y!&"0FYLG:"0,XSQ5JB@
M K\Y?'7_  1>_;AO/^"@OCC_ (*%_"C_ (*M:=H?B?Q.CV'AV#Q)\ +/7Y/"
MFB[F,>FV,MSJ2K"@#8=XXHVE)9FY=]WZ-44 >-_LG?!+]JKX:^ M<\*?MH?M
M<:;\;;W5+PFRU"#X8VOAN*ULVB"/:O;P3SK.&;<Q=B.&VXP*^/+'_@BK^VQ\
M)?A!XD_88_9:_P""F*>$/V<?$UU?I!X9U#X=QW_B+PUI=](\EWI=AJ37*@Q/
MYLP662/S(Q*2,L-S?I/10!QG[.WP#^&?[+/P+\)_LZ?!S13I_A?P9H5OI6BV
MSOO<0Q(%#R-@;Y'.7=\99V9CR:[.BB@ HHHH **** "BBB@#YP^-W_!/O_A<
M?_!2'X)?\%!O^%M_V=_PISP_K^F?\(C_ &#YW]K_ -IVKV_F?:O/7[/Y>_=M
M\J3?C&5ZU]'T44 ?/'[!_P"P3_PQ+XS^.GB[_A:W_"3?\+I^-&J>/_L_]A?8
MO[&^V!!]BW>?+]HV;/\ 78CW9^X*\J_;)_X)7_M+?&[_ (*':+_P46_93_;[
MM/@_XGTGX2)X"DL;WX26_B1)[7^T;J^DEW3WT*(6:=%V^62ODYW_ #D#[<HH
M ^$=*_X(S_$SXY?%[PI\6O\ @J!_P4"\3_M!6_@36(]7\)> H?!=CX7\,PW\
M>?*N;FPM&E-XZ$DJ9).[*VY&9#]W444 %?FA\/?^")7_  4*^#7[3OQ*_:S^
M$W_!8;2[7QC\3M4>76-=\0_LX6.KW]O8AR8-.AN+G5"8;:)0BB*)8T/EH2OR
M(%_2^B@#RS]G+X6?M2?#GX(7?@C]HK]JZS^)7C>:>Z:T\=6OP]M]#CMT= ($
M-A#/*C^4P+$EQOS@XQ7Q/J/_  1H_P""H.J?M=:?^W)>_P#!:S1V^(^E^!9/
M!]GJX_9AT\1)I+W1NFA, U7RBWFL6WE=V.,XK]*Z* ,?X=Z/XP\/?#_0O#_Q
M"\9Q^(]?L='M;?7/$,6F+9+JEXD2K-="W1F6W$D@9Q$K,$W;02!FMBBB@ HH
MHH **** "OG#]O3_ ()]_P##;WQ'^ OQ _X6W_PC'_"D/C!I_CK[)_8/VW^V
MOLI!^Q[_ #XOLV['^MQ)C^X:^CZ* "OGCX&_L$_\*8_X*&_'/]O3_A:W]I?\
M+HT?PW8?\(I_87D_V/\ V39_9M_VKSV^T>;]['E1[.F7ZU]#T4 ?'_\ P4K_
M ."9?Q?_ &V_CW\"_P!I?X!_M@P?"+Q?\"[GQ!/HM_<_#J+Q$EX^J0V<+$Q2
MW=NB;$MG&&$F[SL_*4Y\_P#'/_!&C]IS]KIK'P=_P4V_X*H^*_BY\.[/4(;R
MZ^&G@_X=V'@S3=8>)U=([][26::ZAW*I\O>N"H*E&&:_0"B@"KH>AZ-X8T2S
M\-^'-*M[#3]/M8[:PL;2$1Q6\,:A$C1% "JJ@  <  "K5%% 'YV?&+_@C+^V
MGXR_X**>)O\ @HK\*O\ @J9I_A[Q#J-C_9?@_3O$GP&M/$(\(Z7M -G8R7.I
M(D6X[R\L<4;OYC[B=[[OJW]C[X,?MA_"/0-=TW]L7]M#3_C1=ZA<Q-HUY9_"
MZU\,KIL(1A)$T=O<3"XWDJ=S%=NW&#FO9J* /SALO^",O[:WP+\"^,/V2_V'
M_P#@I';?#_X >--2U">+PGJGPY34M9\(VU^[->66E7WVE L3F278SIOA,A92
M7S(WV]^RM^S1\*_V./V=O"'[,'P3TJ2S\+^"]&CT[2X[AP\LH7+/-*P #2RR
M,\KL  7D8X&<5Z!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20210630_g14.jpg
<TEXT>
begin 644 biib-20210630_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
M!#*SUS0+77KW1I[V7]J+2+0K>6DGE3Q[+C3D<A7XW ;3U!(KZ8_9M_;P\;?&
M#_@H!^T/^R%X\\$:-H.D?!70O!U_::I'>LT\SZOILEW<)<.Q\O;$Z;590 1D
MFO$/^#9/_E'5KW_9</&'_IP->3^"/V%?@9^W#_P7[_;-T/\ :7TF[\2>#/#_
M (>^'4\_@2;4IX=,U6^DT0BWN;N*%T^T&W5)Q&CDH&N6<J65"H!^L-E?66IV
M<>H:;>17%O,@>&>"0.CJ>A##@CW%1ZAK&D:2T":KJMM;&YF$-L+B=4,LAZ(N
M3\S'L!S7YU_\$E/ASX:_8_\ ^"H7[7O[ OP/6ZT[X4>'(/!WBGP=X1EOI9[?
M0+O4K"9[Z.V\QF*QRR*C[<X78H'OXK_P;A?\$O\ ]DKXU?L _#S]KC]H+P)+
MXY\8V'C?6+OP-=:]JER\/A*.QUZY:**PA618H<W44ET[A=SO,0Q*JJ@ _7S5
MM>T/08XY=<UFTLDFD$<37=PL8=ST4%B,GVJW7X/_ +,?B'X,?\% _&_Q<_:S
M_;U_X)5_M!?M+:YJWQ/UO0_"=YH&DZ?>>'O"6@VDWD6^EV,4^L6IAF7!:63R
M@S.P8-N+,W>G]HG]N3_@G#_P1 _:KUVT^&/Q0\!:7X*\816/[.C_ !2,;Z[H
M?AW5[NSM(X6DCGN ?L+7,WDN9'P?+7.   #]F4UW1)-7?P^FLVC7Z1"1[(7"
MF94_O%,[@.>N*M5^%7Q#_8P^ -E^RG=:1^S7_P $8?VQ-$_: T[1CJ/@_P"/
MMW9::NMR>*4C\R/4;N]3Q!)(T4UP/WJA'41R/LCR%Q^S7[+7B+XM>+_V9/AS
MXL^/OAU]'\=ZIX$TB[\:Z3)$J-9:O)91/>0%5X4I.TBX' V\4 =GJFK:5H=D
M^I:UJ=O9VT>/,N+J98T7/ RS$ 5):7=I?VT=[8W,<T,J!HIHG#*ZGH01P17Y
MW_\ !4JX_8:^,W[9?AG]GWQG_P $Y_%?[4GQETKP/_:MKX.TO4H[?2/#FCR7
M3H+N\DO;N"RAEEEW*I97D(0#**5W>:?\$7[OQA^SM_P53^-G[$>C?LP^(O@?
MX"U'X7:5XYTOX/:YXYL]?@T+4#>&TGN+.6SN;B.WBN1(':'?D-$#M51&* /U
M6U;6M&T&U%[KFK6ME"9 @FNYUC4L>BY8@9/I5FOQ_P#^"2?_  2M_9"_;9\$
M?'OXD?MF?#U_B+$G[3GCS3?"V@:UJMTNGZ!;"_S-);012(J7,TK,7N.9-L<*
MJRA.>)\#_M<_'[]D;_@W!_:/'PR^)FK-J_P?^,VN_#'X?>)M2OV>\TK26UVS
ML(9#<'YE>"&^E$;C_5E(@N @P ?J/_P4"_:QN_V1OV+OBO\ M*> +/2->USX
M<>$KG5DT2\NB8VEC7<L<PC8.@/X&O0?@!\1=0^+_ ,!_!/Q:U;3X;2[\4>$=
M-U>ZM;8DQPR7-K',R*6YV@N0,\X%?EC_ ,%4_P#@B#^Q!^R9_P $>?B3XZ_9
M[\+W'AGXA^#/ $D^H?$BVUFY&H^* Q1=0BU)C(5NTO%:7,;@HDCHT878HK]+
M?V(O^3+_ (0_]DOT#_TW04 >._MW?\%+/&7[./Q^\%?L5_LL_LP7_P 8_C5X
M[T2YURQ\+)XC@T;3])T>!S&^H7U[,KB*,R!U1%0EVC9<JQ0/I?LK_M.?\%(?
M&?QGC^%7[8W_  3AT_X?Z)<Z7/=6?Q#\)_%6UU[3S/'MQ:2VX@BGA=@Q(<@H
M2I'6N-_X*'?\$R_CS\=_VFO!O[?W["_[4UO\*OC5X*\*W'AG[3KGAY-4TC7]
M&DF>?[#=1'YHPLLDCB10Y&[A0RJZ^?\ [/W_  46_P""CO[.W[=7P^_X)_?\
M%8_@[\-7F^+EIJ7_  K#XK?"*^NQIU_=V,(FFM+JVO/WB2%&0;P(U#21J$<,
MSH ?87P0\9?M2^(_BY\3]"^.GP?T?P[X/T;7K6'X6ZYIVK)<3^(-/:WW3SW$
M:RN8'2;Y K*A(YP>M>GU^=W_  3-\'>%/B)^WQ_P40\ ^._#UGJ^B:W\3]&L
M-7TK4(%E@O+:70S'+#(C<,C(S*0>"":^*/$/BGXN_#W]JJ\_X->O 7[5>FVW
MP@\1^+X$L_B/)K$AUOP[X5N+::]G\#>:R%&O9 @AA<N3Y$VPJ=XBC /WHKX5
M_P""OO\ P6NL_P#@DW\4?A#X&U;]FF[\=Z;\2AJ]SK.K6'B8V<OA_3]-^RR7
M=TMN+2;[7LMYY9BF^+BW(W?-E?LCX2_"?X=? GX8Z#\&OA'X2M-"\,>&-*AT
M[0](L4VQ6MM$@5$&>3P.6)+,22222:_._P#X*S?"OP9\=/\ @M3^P[\%?B-I
M@O= \7>$/B_HVMVAQ^]M;GPJ895YZ$H[8/8T ?:/[;/[9?P__8L_8S\:?MEZ
M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
MC.:S?VA?^";7[1FG?MG:U^WI_P $\OVJM(^&7C#QUH-EI'Q1\.>+O!QUK1/$
MRV:F.SO61)X9(+J&+]V&5B&0 ?+E_,^S:* /CC]@/_@E=X\_8]_:[^*O[9_Q
M8_:^U#XI^+?B_H>EVWB:74/"<>G"*[M"^9(?*N'5+?88XHK<(/*CA4&20Y8_
M8]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YX?\ !33_ )3C?\$Y
MO^PA\4?_ $P65?H?7YX?\%-/^4XW_!.;_L(?%'_TP65 'TA\"?VY_P#A=?[?
M'QY_8>_X5=_9G_"D=/\ "]U_PD_]M^=_;7]L6,EUM^S>0OV;R?+V9\R3?G.$
MQBCX-?MS_P#"W/\ @H)\:/V$_P#A5W]G_P#"H?#_ (<U/_A*?[;\W^UO[5MW
MF\O[-Y"^1Y6S;N\V3?G.$Z5\?K^U)\"/^":__!=S]HWQ7^VGX]M_ /AKX[?#
MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E?>
M(M$TV?[+?ZE'%( #L8\XJ+_A,?#'_0:@_P"^J\@_8-N;G7?@YJM[KEP]Y,OC
M;5XUENW,C!%N2%7+9. .@[5[7_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH
M_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#
M_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J
M#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_
M .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^
MA0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/
M_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/
MC#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9V
MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
MSXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#
M_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0
M:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A
M0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#
M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A
M?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
MY(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>=1_Y"$_\
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M_@Q]$ 4445J 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/^-;%%?J8&/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
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MQ[UG_P!*37J_Q,_Y$74?^N(_]"%>4?\ !/?_ )(GJW_8]ZS_ .E)KU?XF?\
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M*6_B)KNJ*S4I132>^X' ^%_V8?@;X,_:"\4?M3>&O _V;QYXSTJTTWQ+KO\
M:=R_VRVME58(_(>4PQ[0JC<B*QQR37COQV_X(S_\$XOVE_B7JOQ?^-OP$O\
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M?_2DUZO\3/\ D1=1_P"N(_\ 0A7)C_\ <:O^&7Y,#Q"BBBOR( HHHH ****
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M?X,?1 %%%%:@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -<1_P"A"N3'_P"XU?\ #+\F!XA1117Y$ 4444 %%%% !1110 4444 %%%%
M!6QX _Y'33/^OQ/YUCUL> /^1TTS_K\3^==."_WRG_B7YH#W2BBBOU\ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YYU'_D(3_P#79OYF
MH:FU'_D(3_\ 79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!
M\/\ _(!L?^O.+_T 5;JIX?\ ^0#8_P#7G%_Z *MU^QT?X,?1 %%%%:@%%%%
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MXC_T(5R8_P#W&K_AE^3 \0HHHK\B **** "BBB@ HHHH **** "BBB@ K8\
M?\CIIG_7XG\ZQZV/ '_(Z:9_U^)_.NG!?[Y3_P 2_- >Z4445^O@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?/.H_P#(0G_Z[-_,U#4V
MH_\ (0G_ .NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?
M_P"0#8_]><7_ * *MU4\/_\ (!L?^O.+_P! %6Z_8Z/\&/H@"BBBM0"BBB@
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MK/\ Z4FO5_B9_P B+J/_ %Q'_H0KDQ_^XU?\,OR8'B%%%%?D0!1110 4444
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M !Z9*YKDS',J&64U.JFTW;2WZM >KT5XM_PMKX@_]#!_Y*1?_$4?\+:^(/\
MT,'_ )*1?_$5Y'^MF7?R3^Y?_) >TT5XM_PMKX@_]#!_Y*1?_$4?\+:^(/\
MT,'_ )*1?_$4?ZV9=_)/[E_\D![317BW_"VOB#_T,'_DI%_\11_PMKX@_P#0
MP?\ DI%_\11_K9EW\D_N7_R0'M-%>+?\+:^(/_0P?^2D7_Q%'_"VOB#_ -#!
M_P"2D7_Q%'^MF7?R3^Y?_) >TT5XM_PMKX@_]#!_Y*1?_$4?\+:^(/\ T,'_
M )*1?_$4?ZV9=_)/[E_\D![317BW_"VOB#_T,'_DI%_\11_PMKX@_P#0P?\
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MZ!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^#'T0!7A?C_\
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M -<1_P"A"N3'_P"XU?\ #+\F!XA1117Y$ 4444 %%%% !1110 4444 %%%%
M!6QX _Y'33/^OQ/YUCUL> /^1TTS_K\3^==."_WRG_B7YH#W2BBBOU\"IX@_
MY -]_P!><O\ Z :^?J^@?$'_ " ;[_KSE_\ 0#7S]7P_%W\6EZ/] "BBBOCP
M"BH[N[MK"TEOKV=8H88VDFE<X5% R23V  K\X[#_ (*A_MH?M+_&WX8_%']C
MW]C675/AQX@T_P 5MX5M/$OQ.M]'F\;P6<EI"]X8/LTPLQ"^[R1,Q,GFL?D
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M$(/^NR_S%?0U?:\(_!6]8_J 4445]D!\\ZC_ ,A"?_KLW\S4-3:C_P A"?\
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ML,T;)-%)#,RNI&"I!CY!'&*^'_'O['/_  1$UOX]>"_$'AD^&+3P)96.M?\
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M<T4 <-_PR_\ LT_]&\>!?_"2L_\ XU1_PR_^S3_T;QX%_P#"2L__ (U7<T4
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M_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\
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MAO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\
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MT4 <AHG[/GP#\,ZM;Z_X<^"'A#3[ZTD$EK>V/AJUBFA<=&1UC!4^X-=?110
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MO?\ !+^_\;?LX^&+N_(\;7/Q%M[#7-?TVQD>.\U33]*>W8O#&8Y2J/('D$3
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MYCM+R>TN[#,)N(U\Y45Y5",I$C!@:^:/V^?V#]$NO^"UO@+]B'P?\3M7\/\
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M_@M9H[?$?2_ LG@^SU<?LPZ>(DTE[HW30F :KY1;S6+;RN['&<5^E=% &/\
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M&G_&B[U"YB;1KRS^%UKX97380C"2)H[>XF%QO)4[F*[=N,'->S44 ?G#9?\
M!&7]M;X%^!?&'[)?[#__  4CMOA_\ /&FI:A/%X3U3X<IJ6L^$;:_=FO++2K
M[[2@6)S)+L9TWPF0LI+YD;[>_96_9H^%?[''[.WA#]F#X)Z5)9^%_!>C1Z=I
M<=PX>64+EGFE8 !I99&>5V  +R,<#.*] HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20210630_g15.jpg
<TEXT>
begin 644 biib-20210630_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
M!;']L;XX?#73=5B\,:MX+\!+X<OM7TV6SDU2SBM+B)+Z.*95=8)BK/$S %XB
MDF ' H UOV>O^"U'[>W[<?P0O?C5^Q)_P2:_X2&T\/:QJ.G^(V\2?%ZWTZ"X
MN;6>11:Z:[V8>\E:(1.SM''%&\HB#2,KE?=O!7_!8K]E_P 0?\$M(O\ @JWX
MJL]8T/P='I$LFH^'I85EU.#4X[MK%M+1,J))VO%\E"=BMN5VV*21YC_P;+JJ
M_P#!)_P^0H!/Q!\7$X'7_B>WE?#_ (*_9E^+_P"U'_P;1^*/#GP/\.:OKNO>
M%/VA=;\41^&] N'BOM5MK'Q'-)<6]LR?,)A$SRH$^<O$H4%BH(!]M^,?^"M'
M[>W[.?@2Q_:B_;5_X)82>!/@I/>6JZ_KFD?%"WU;7_"=E<2)'%?:AIB6J90-
M)'YL<4C20[CD,5(/Z 6-]9:I8PZGIMW'/;W$2RV\\+ADD1AE64C@@@@@^]?B
MWXD^)/\ P0"^-'P&G3XM?\%A?VD-5TC7[#[/K?PS\4?'SQ1>ZE*YP'T^YT<^
M9)+('&PQ^6ZLPX+#!K]DOA]X9T/P7X"T/P=X8CF73-)TBVLM.6X8F0011*D8
M8GDMM49)[T ?)/\ P4V_8]_X(VZYXBL?VQ?^"I?AGPP?+M;;POI6N>-_$M]!
M81<W-S';QP1SK#YK9G8OL+L$QNPH%>"_\$%_#?@O2/VN/VB=1_8"U'79?V.)
MFTF/X<+J5S>/IA\1K&3J?]D"\_>_9E9F61ON,_EA2P08^H/VI?\ @JC_ ,$M
M_@3\7M1_9@_;(^.?AGP[XATBWM=1;1_&NA3FVFBFCW13P2O T$IPS*=K%U(8
M$#O\J_\ !(S6OAA\</\ @K]\>OVH_P#@GKX,GT?]F35?AQINE:AJ6G>'Y=*T
M3Q-XTCND9KVQ@=(U8QVPGCE=(QEWW'_6JS@'._\ !-;]A7]F/_@M5X1^+G_!
M1#_@H/X"?XC:IX\^)VN:'\/[;4M8ND@\)>&;&7[/:VU@D,JB"3<)':5<,S!6
MX9G+_0G_  0!^,7Q4\3?LW?$S]ESXS^.=1\3ZW^SK\<_$7PUM?$>L3&6[U/3
M+"2,V<TSGEV$<IB!/)2%.O6OG[_@F%^W/^R]_P $:O _Q?\ ^">'_!03XEP?
M#76OAS\3M=UOP7+K5A.(O%7AB^E^TVEY8,D9%RY8RJ8DRZG:N-P95]=_X(I6
M7B;]GW]AKX[?\%#?VD/!FL^&8OB]\5O&'QBET*_M"M_I^@2*)8$>%B,.8;>2
M55)&4ECZ4 ?HG7AW[:O_  3Q_9G_ ."A%AX9\-?M4Z)K>O>'?#-]/>)X5M/$
MEU8:?J4TBHJM>);.CW CV912X4%FR&SBNQ_97_:3^'?[8/[/7A3]IKX2V^J1
M^&O&6EC4-%76K'[-<F LRJSQY.W.W(Y(*D$=:^=/^"V7_!63PU_P2B_9IL/&
M-GHUOJ7COQSJ3Z+\/K34U==-@N]H+WM](O*VT"NKLJ_/(2JK@%G0 ^8-5_98
M_9__ .">7_!=3]G'X.?\$O\ 1[OPC/X[\.^(+KX^_#G0M6N9])/AZ"U L=2N
MH)9'%O)]I\Q(W&-SQH, L1+V'QM^%'@K_@JG_P %S?%O[(W[3T,WB#X-_L[?
M"O2]4_X5R]_+%8:OXFU5A+'>WB1.IG$5J^U$;A6 (X=P^/\ \$</VO?^"1?P
M[\=?V!IO_!032_C'^U!\;M3B?QYXZN]#U)+G7=0*EDL+,RVJ):V$ !2*$;%V
MH"0,*B;'QA^*_@/_ ():?\%V_%O[4W[46IGPU\(_VCOA3I>FVOQ#N;.1M.TW
MQ+I)6);&[E12(/,M$WJ[X#$@#[KE0#1_82\(:5_P3G_X+6?$+_@F1\&[J]LO
M@YX]^"EK\4? _@ZXOY;BV\,ZBFI'3KRVL_-9FBBG*R3M'D@%% P*Z;XU?\$#
M/^",7A/X3>.?BS^TE\,;R[F^P7NL^+?BQXN\<ZC+JUGM5YGO1<F8)"8L;E5(
MPGR@%&R0>6_88\;:'_P49_X+=?$3_@I1\$ENM3^#OP[^"5M\+?"'C)[.2&S\
M2:K)J1U&\FLS(JF6.#=)"S@8)=""00:^5_VA?^"Q?_!/W_@J#^U_JOPB_;!_
M:UM/AQ^RQ\+]=0+X&N+#4!J'Q9U>!\B6^^S0N8-)A=05MV*O*0K, V!  ?<7
M_!#!_CI^T_\ \$2?!NA?M3>-?%DMYXK\.ZUI&F^*;B]>VUR?099[FWL;SS\E
MTG^S%&BFY8JL4F6)W'P3]D;]A[X"?L#?\'+4'PD_9]LM=73]7_8PGUS6;WQ)
MXEN]5O+_ %"3Q0('GDFNI'8$Q6T*[5VH-F0H+,3^A_[.W[9O[(/QZ_9FF_:2
M_9R^)^EZI\,= M+J-]:TS39[>ULX+&/,R+"\2.JQ(OW53&!A<U^56J?\%J?^
M"7T__!PMIW[847[6VCM\-H?V1&\)2^*?['U#REUK_A)9;O['Y?V?S=WD,)-V
MS9@XW9XH _;.O$/VOOC1^VK\,[[P_P"'?V./V,M-^*-UJ\=T^L:QX@^(UOX?
MT[01&8A&)-T,TURTN]]JQ1X40L6894'U[P?XM\.^/_"6E^._"&II>Z3K>G07
M^EWJ(RK<6TT:R1R , 0&1E." >>17YF_\%=/BMX'M_\ @I[\*_@1^W[^T+XP
M^&/[+NL?">_O[74= \3WN@Z=XB\9K?[#IVI:A9,DBPQV(69$,B+O9>?FY /I
M;]B[_@HE\5/C'^TKXH_8<_;"_9<;X1_%[PWX4@\566F6/BN+6]*\1:#)<?93
MJ%G=)'$P"7&(GBD0,I8<GY@ODO@[_@L)^V!^TM\6/C-\!?V*O^";:>*_$'P8
M^*>J^$]=UOQ'\3X=+T:2VM7$<%PLSVF]KJX99_\ 1(U<0I$KR3_O$5OFS_@F
MA-^QI=_\'"DEW^P)HGB5_AG_ ,,LZG%I_BO7_$FMZI;^([U-?LA<W-A/K%Q-
M+):1G9;[XR(FE@F*[L;C]-?\$)XT'C_]MV4(-Q_;>\9 MCD@166!^I_.@#U/
M]DG_ (*N?#'X\_L9?$/]J_XX> K[X6WGP8UG6]%^,?A'5+U+Z7P[J6E()+J%
M)8U472E&0QLJC>S;0"1S\I_M6_\ !3_]NCXN?\$Q_BE^T'\0O^"7][X8^"/C
M_P"$FN6^A^(H/B);WOB+3K&_TV:&QU2]TE8%"VTC30O((YFD@B<R%75"3Q'@
M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_
M $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4F
MO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7X__ .1TU/\
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M<^'I$O\ 09X[V*2XO9KR.%?L\ A$@?>^ 75RN(RRZ89S^OS]DI>R<G:WP?\
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M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KPOQ__P CIJ?_ %^/_.O=*\+\?_\
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\
M:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'
M_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W
M9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H
M-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[
M%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QK
MQ[QHMRGBO4%O)5>47+>8Z+@$Y["O>:\+\?\ _(Z:G_U^/_.OD^+?]TI_XOT
MQZ***^# **** "BBB@ HHHH **** "BBB@ KUSP#:^*Y/!]B]AJMK'"8CL1X
M"2!N/4UY'7M_PS_Y$73O^N)_]"-?4\)_[]/_  _J@+-G:>+4ND>^U:U>(-^\
M1+<@D>QK4HHK[\ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['O6?_
M $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.FI_]?C_ ,Z^3XM_W2G_ (OT QZ***^# **** "BBB@ HHHH **** "BBB@
MKV_X9_\ (BZ=_P!<3_Z$:\0KV_X9_P#(BZ=_UQ/_ *$:^IX3_P!^G_A_5 ;M
M%%%??@%%%% !1110 5D^+/ /@7QZ-.'CGP9I6LC1]3CU+21JNG1W'V*\C5E2
MYB\Q3Y<JJ[@2+A@';!Y-:U% 'AW@S]O;X2^+/'/Q[\.WFDZGI6B_L\SP0^,O
M%E^(_L5PYTM=3N1 $8R$6\#H)"ZK\S87<!FOG7]CC_@LQ>_MD_%3P9\'_P!H
M+_@GUXJ^&/@GX[:)J-W\$O%7BO6+/4K/QK9V]O\ :)8KBUC0&Q>2TW3)'(9%
ME0':S J6XW]L[_@EK_P4A\:_$GX^?#G]COXW?"W2/@_^U-<64_Q*F\8P:@==
M\,R"RAL-1.FK;J8;E;JV@ *S,N"Y4; /,/OWQ=_87\<:_P#M-_LDO\-+?2;+
MX5_L\KJUSJ:W5\POY91H9TK2[>"-8]K(HD=Y&++PJ@ Y. #ZA\,^&?#G@OPW
MI_@[P?H-GI6D:38Q66EZ7IULL-O9VT2!(H8HT 6-$15554    # J]110!X7
M_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 45STGQ6\ Q2-%)KV&5B&'V67@C_ (#3?^%M
M?#[_ *&#_P E)?\ XBN+^TLN7_+Z'_@2_P P.CHKG/\ A;7P^_Z&#_R4E_\
MB*/^%M?#[_H8/_)27_XBC^TLN_Y_0_\  E_F!T=%<Y_PMKX??]#!_P"2DO\
M\11_PMKX??\ 0P?^2DO_ ,11_:67?\_H?^!+_,#HZ*YS_A;7P^_Z&#_R4E_^
M(H_X6U\/O^A@_P#)27_XBC^TLN_Y_0_\"7^8'1T5SG_"VOA]_P!#!_Y*2_\
MQ%'_  MKX??]#!_Y*2__ !%']I9=_P _H?\ @2_S Z.BN<_X6U\/O^A@_P#)
M27_XBC_A;7P^_P"A@_\ )27_ .(H_M++O^?T/_ E_F!T=%<Y_P +:^'W_0P?
M^2DO_P 11_PMKX??]#!_Y*2__$4?VEEW_/Z'_@2_S Z.BF6\\5U;I=0/N21
MR-C&01D'FGUV)IJZ *\+\?\ _(Z:G_U^/_.O=*\+\?\ _(Z:G_U^/_.OE.+?
M]TI_XOT QZ***^# **** "BBB@ HHHH **** "BBB@ KV_X9_P#(BZ=_UQ/_
M *$:\0KV_P"&?_(BZ=_UQ/\ Z$:^IX3_ -^G_A_5 ;M%%%??@%%%% !1110
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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M&"78NKZ=(L%W8WGENDC3J80\32)^\1F" ,:ZG_@GU^RY^T1\*?BK^T!^V/\
M%?X3^'O WB#XRWNF76C?"?0=:CNX-*_LZSEA62YN8E6%[JYDE+RM&"H/S;F+
M';[M>?M<LCS2M;9*2:=N5?#T=KM]G?N!X!^R@G_!7C_@EW^R = OOV&?!7C3
MPEX7U36-;U;3],^(VWQ"]I<7DUW(T<20O S(DAQ&CR,VP@#) K]!/V9/VA_A
MA^V%^SWX4_:.^%<LESX=\6Z;'?Z>E["%E@=7*O%(H) EBFC=&P2 \9P2,&OE
M7XA?MM_\%7O'?P_U/X6> ?\ @D#KGA_QSJNGR64.MZW\3='GT+2Y)%*&Z:>-
MPUPD>=XC559\8Z]>[_9R^ OQZ_X)B?\ !,SP-\!O@1\)X/C!XO\ !=L!J6@6
MWB*'25OY+N]ENKYK>XNAL CDN)#&' +J@'REN,L7%5H\\U%5)2Z25FG>[?O-
M+6UGIN^P'RK_ ,%3/VDO'7[4D_P[_9@_:*_9.\2_ GP/>_%G3+B?XU^/PMQ:
M64EM.QBAM&L%F6WN+D95);B2%%4ON.,E?U9K\V_VS(_^"B'_  5C^#;_ +$J
M?\$^]3^#OA'Q+K>G/XZ^(/C[Q?IUPUA96MW%=%+*UM6>2>9FA4*_"8!5MH?>
MOV?\:/%_[4/@WXH_"_PK\!O@QIOB7P?JNKSVWQ+UW4-8B@F\/V"1IY,\4;S(
MUPS,7!5%D(VY(&:C%QC*C2IJT6N:Z4DUT=[W>KM:U^BMN!J?M(_%CQK\#OA\
M_P 0/AQ^SQXB^)6JM>P6K>'O"DMK'>-$=Y\TM<R1IL0YR-V?GX'6OB?_ ()?
M^,A^T+_P5!^/?[37Q*\('X5>/I?"FE:%<?!/5+>=-7CT^)D9=:O'>&.*X,I6
M-(V@,BI&RJS_ #(7^COVFOVK/VQ_@1\4)-$^&W_!.KQ!\4O!TNG0RVGBCPGX
MUTZ"X2Z)82V\ME<LL@"X4B525.[& 1D^7?L:_ 7]KGXQ?\%#O$W_  4Q_:P^
M#%E\*XG^%\7@/P1\/4U^#4M0:R^W"]DO;Z:W_=*YD!"H"2%?:P'EAG*$52P=
M1RLN:.CYDV]4[<MW^2:[@?;E%%%>4!] ^'_^0#8_]><7_H JW53P_P#\@&Q_
MZ\XO_0!5NOV.C_!CZ( KPOQ__P CIJ?_ %^/_.O=*\+\?_\ (Z:G_P!?C_SK
MYCBW_=*?^+] ,>BBBO@P"BBB@ HHHH **** "BBB@ HHHH *]O\ AG_R(NG?
M]<3_ .A&O$*]O^&?_(BZ=_UQ/_H1KZGA/_?I_P"']4!NT445]^ 4444 %%%%
M !7D_P"V3\(OVHOC7\(X_!W[(O[7W_"DO%2ZQ#<2>,O^%?V7B3?:*D@DM?LE
MZZQC>S1MYF=R^7@?>->L5\Q?\%9?#7_!.GQ?^S+IWAW_ (*=ZV;'X=W7C2PC
ML)!J>IVADU=HYUMD\S32)N5,W!.SUZ"@#QW_ (=X?\%U_P#I8J_\U&\,?_)%
M>@?LN?L:?\%8?A1\=M"\?_M+_P#!:#_A;/@FP^U?VW\/_P#AG30M!_M7?:RQ
MP_Z=:S--!Y4SQ3_*#O\ )V'Y7)KX4_:'_8__ .#17]E#XQZU^S]^T)XJN/#7
MC'P[)"FM:'=>//&<LEJTL$<\8+0S.AS%+&W#'[W/.17HG_!,WPK_ ,&P>F_M
MN^";W_@G?\2_[0^,2?VE_P (?9_\)/XJN/,SIMT+O]W?L;=L69N3^\'&,K\P
M6@#]9J*** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW
M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /GG4?\ D(3_ /79OYFH:FU'_D(3
M_P#79OYFH:_&9_&P"BBBI S/&'@OPG\0= D\+>-_#MGJNFRSPS2V-] )(FDA
ME2:)BIXRDD:.#V90>U:=%%.[M8 HHHI %%%% !1110 4444 ?0/A_P#Y -C_
M -><7_H JW53P_\ \@&Q_P"O.+_T 5;K]CH_P8^B *\+\?\ _(Z:G_U^/_.O
M=*\+\?\ _(Z:G_U^/_.OF.+?]TI_XOT QZ***^# **** "BBB@ HHHH ****
M "BBB@ KV_X9_P#(BZ=_UQ/_ *$:\0KV_P"&?_(BZ=_UQ/\ Z$:^IX3_ -^G
M_A_5 ;M%%%??@%%%% !1110 55U?0]%U^V6SUW1[6]A602+%=VZR*''1@&!&
M1D\U:HH ^"_VE_\ @I;KS_M4^,_V8?V*?^"6.O?M%>+OA_\ 8T^(NNQ:IIFB
M:5I5S<0+-#:?;KY&$\XA*ED &WA<D@@;O[(_[3W[>WQ$_:%\/^#OC3_P0S_X
M4[X9O/M?]I_$?_A;.@:G_9&RTF>/_1K2%9I/-D5(/D(V^?N/RJ17@>L?M-?M
M5? W_@K)\??"G_!*S]AK4?CKI6I7&C7GQVLM7\4V/AK3]$\4#3XHXCI^IW+L
M)C+9B W%N87*2QAE8!F%?4'[,W[7'_!53XG_ !NT3P-^TC_P2!L_A;X+OOM/
M]M>.XOVB-(UUM,V6TLD.+&WM4DG\R9(H?E8;/-WG(0@@'UG1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*^>OV"]8O[#X.:M!;:!<7*_\ "<:R?,B(QG[2W'->V_\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!XCJ/\ R$)_^NS?S-0U+?,6
MO9F*D$RL2#VYJ*OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#_\
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M_KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_ /D V/\
MUYQ?^@"K=5/#_P#R ;'_ *\XO_0!5NOV.C_!CZ( KPOQ_P#\CIJ?_7X_\Z]T
MKPOQ_P#\CIJ?_7X_\Z^8XM_W2G_B_0#'HHHKX, HHHH **** "BBB@ HHHH
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M3#CY#$'_ (* /TJHHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
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M%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>W_#/_ )$73O\
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M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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M@#Z!\/\ _(!L?^O.+_T 5;JIX?\ ^0#8_P#7G%_Z *MU^QT?X,?1 %>%^/\
M_D=-3_Z_'_G7NE>%^/\ _D=-3_Z_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !11
M10 4444 %%%% !1110 5[?\ #/\ Y$73O^N)_P#0C7B%>W_#/_D1=._ZXG_T
M(U]3PG_OT_\ #^J W:***^_ **** "BBB@ HHHH **** "BBB@#PO_@GO_R1
M/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH ****
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MSXNZ_P")O$'AS0X)XH?!U_<M"KZ$8[B**6-[=8H]RM&@S(2NY"CM]NU\F?\
M!)K]E?X^? #P9\4/BU^T[HFEZ%XU^,_Q4U'QIJ?A'1K];J#0$N=H2T,R?)-*
M,,7=25.5Y)!-?6=<V82C/&3E%W5_Z];;7Z[@3:=_R$(/^NR_S%?0U?/.G?\
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M2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!4\0?\@&^_Z\Y?_0#7S]7T#X@_Y -]_P!><O\ Z :^?J^'XN_B
MTO1_H 4445\> 5F:CX+\)ZOXITSQOJGAVSN-7T6"XATG4I8 9K2.X""=8VZJ
M'\J/<!UV+Z5IT4TVM@"BBBD 4444 %%%% !1110!-IW_ "$(/^NR_P Q7T-7
MSSIW_(0@_P"NR_S%?0U?;<(_!6]8_J 4445]D!\\ZC_R$)_^NS?S-0U-J/\
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M ".FI_\ 7X_\Z]TKPOQ__P CIJ?_ %^/_.OF.+?]TI_XOT QZ***^# ****
M"BBB@ HHHH **** "BBB@ KV_P"&?_(BZ=_UQ/\ Z$:\0KV_X9_\B+IW_7$_
M^A&OJ>$_]^G_ (?U0&[1117WX!1110 4444 %%%% !1110 4444 >%_\$]_^
M2)ZM_P!CWK/_ *4FO=*^&/V?/^"?GP5_:6\)ZM\2/'OBOQO9W_\ PEFJVGD^
M'_%L]E;[$NG(/EIQN^8Y/?BNO\0?\$G/V9/"FC7'B&/Q;\2KUK5-PM;SXB7W
ME2<@8;RW1L<YX8=*SK5(T:4JDMDF_N ^N**^%_\ AAK]G'_H">)__#C:Y_\
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M] 3Q/_X<;7/_ )-H_P!;,N_DG]R_^2 ^Z**^%_\ AAK]G'_H">)__#C:Y_\
M)M'_  PU^SC_ - 3Q/\ ^'&US_Y-H_ULR[^2?W+_ .2 ^Z**^%_^&&OV<?\
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M_(='_#+^G?\ 17/%O_?.F_\ R'1_JGF/\\/O?_R('HGA_P#Y -C_ -><7_H
MJW7RWJW_  2._9MUO5+G6=1^(?Q0:XN[AYIVC\?7$:EW8LV$0!5&2>%  Z
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MX!&)(VX=>>AKZ,KZ< HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\
ML>]9_P#2DUZO\3/^1%U'_KB/_0A7E'_!/?\ Y(GJW_8]ZS_Z4FO5_B9_R(NH
M_P#7$?\ H0KDQ_\ N-7_  R_)@>(4445^1 %%%% !1110 4444 %%%% !111
M0 5L> /^1TTS_K\3^=8];'@#_D=-,_Z_$_G73@O]\I_XE^: ]THHHK]? ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/
M5O\ L>]9_P#2DUZO\3/^1%U'_KB/_0A7E'_!/?\ Y(GJW_8]ZS_Z4FO5_B9_
MR(NH_P#7$?\ H0KDQ_\ N-7_  R_)@>(4445^1 1W=K;7UK+8WMNDL,T;)-%
M(H974C!4@]01QBOB#Q[_ ,$)OV&];^/7@OQ!X9_9\L;3P)96.M?\);X8A\8:
MO#:3W$WV4VGE6:7/D+&&CG,B($1LIN5\#;]QT5O1Q-?#MNG)J_9V_KR XWQ1
M^S_\(O%/P$U']F.;P1867@C4O#$WA]] TRV2"W@T^2 P&&)%&V,!&PN!\N 1
MTK@/V0?V;_B5\-_V*=+_ &2/VHM?TOQ.=&T.Z\+?VKHE]<QG5="4/;VC2L5B
MD@N39F-)!&S;74LLIR"/<:*E5JB@XWZW^8'QN/\ @@%_P2<74SK2_LT:H+QH
M?):['Q2\3>:8\YV;O[2SMSSC.,UZW^TO_P $\_V6/VM/!_A3P;\8_!NJ2Q>!
M49?!]_I'BF_L+S2]T<<3%)[>97<E(D!\POG;GKS7MM%:2QN,E)2E4DVMM7IZ
M ?/_ .RI_P $P?V,OV-O&U]\5/@Y\,[F7QAJ5J;:\\8>)M=N]6U-H./W23W<
MCF)3@ B,+N &[.!7H7_#,'P,_P"&E_\ AL+_ (0?_BXW_"'_ /"+?\)%_:=U
M_P @G[1]I^S?9_-\C_6_-YGE^9VW8XKOJ*B>(KU).4I-MJV_3MZ ?*/CS_@B
M'_P3(^)?Q*\1_%_Q?^SO?R^(O%VL3ZKXBU"S^(GB"T^V7<TC222F.WOTC7+N
MQVJH49P !Q7K/[-W['GP)_8J^'NL^"/V5_A_)I-MJ=V^H26&K>*]2ODN+SRE
MC4M/>2W,D2$(BG8"!RP0G.?5:*J>+Q52').;:[-MK[@/!_\ @GI^R7XF_9-^
M"VIV7Q3\0Z=K?Q%\=>+M1\7?$K7-)\PVMWK%[+N=+<R*K^1%&L4,>Y5RL>[:
MNXJ/I#P!_P CIIG_ %^)_.L>MCP!_P CIIG_ %^)_.M,/4G6S"$Y;N2_- >Z
M4445^N %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P -S_LC_P#1>M!_[_/_ /$T >KT5Y1_PW/^R/\ ]%ZT'_O\_P#\31_PW/\
MLC_]%ZT'_O\ /_\ $T >KT5Y1_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\
MT7K0?^_S_P#Q- 'J]%>4?\-S_LC_ /1>M!_[_/\ _$T?\-S_ +(__1>M!_[_
M #__ !- 'J]%>4?\-S_LC_\ 1>M!_P"_S_\ Q-'_  W/^R/_ -%ZT'_O\_\
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M7K0?^_S_ /Q- 'J]%>4?\-S_ +(__1>M!_[_ #__ !-'_#<_[(__ $7K0?\
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M!_[_ #__ !-'_#<_[(__ $7K0?\ O\__ ,30!ZO17DEO^W?^R'=(9(OCQHH
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M_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XFMVB@#"_P"%7?#/_HG>A?\
M@HA_^)H_X5=\,_\ HG>A?^"B'_XFMVB@#"_X5=\,_P#HG>A?^"B'_P")H_X5
M=\,_^B=Z%_X*(?\ XFMVB@#"_P"%7?#/_HG>A?\ @HA_^)H_X5=\,_\ HG>A
M?^"B'_XFMVB@#"_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XFMV
MB@#"_P"%7?#/_HG>A?\ @HA_^)H_X5=\,_\ HG>A?^"B'_XFMVB@#"_X5=\,
M_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XFMVB@#"_P"%7?#/_HG>A?\
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MT+6?$NO^)]<@T+P!X!\+6OVC5O$^KS'$5I;1_JSGA1@ ,[(C_./Q!_X*I_\
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MT22SMH-MN7>:4_-.67R,%,.&'W'7YX:-_P K5FK?]F(+_P"I?#7Z'T %%%%
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M$,#7L7_!*[]A"#_@G+^Q;X:_9LOO%_\ PD7B".>ZU?QIXB5"JZEK-Y*9[J5
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MAE=-A",)(FCM[B87&\E3N8KMVXP<U[-10!^<-E_P1E_;6^!?@7QA^R7^P_\
M\%([;X?_   \::EJ$\7A/5/ARFI:SX1MK]V:\LM*OOM*!8G,DNQG3?"9"RDO
MF1OM[]E;]FCX5_L<?L[>$/V8/@GI4EGX7\%Z-'IVEQW#AY90N6>:5@ &EED9
MY78  O(QP,XKT"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20210630_g16.jpg
<TEXT>
begin 644 biib-20210630_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
MC.:S?VA?^";7[1FG?MG:U^WI_P $\OVJM(^&7C#QUH-EI'Q1\.>+O!QUK1/$
MRV:F.SO61)X9(+J&+]V&5B&0 ?+E_,^S:* /CC]@/_@E=X\_8]_:[^*O[9_Q
M8_:^U#XI^+?B_H>EVWB:74/"<>G"*[M"^9(?*N'5+?88XHK<(/*CA4&20Y8_
M8]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YX?\ !33_ )3C?\$Y
MO^PA\4?_ $P65?H?7YX?\%-/^4XW_!.;_L(?%'_TP65 'TA\"?VY_P#A=?[?
M'QY_8>_X5=_9G_"D=/\ "]U_PD_]M^=_;7]L6,EUM^S>0OV;R?+V9\R3?G.$
MQBCX-?MS_P#"W/\ @H)\:/V$_P#A5W]G_P#"H?#_ (<U/_A*?[;\W^UO[5MW
MF\O[-Y"^1Y6S;N\V3?G.$Z5\?K^U)\"/^":__!=S]HWQ7^VGX]M_ /AKX[?#
MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A
M?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW/\ ^2 ]7_X7CX;_ .?*?_/X4?\ "\?#?_/E/_G\*\HHH_ULS'^2'W/_ .2
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M$VG?\A"#_KLO\Q7T-7SSIW_(0@_Z[+_,5]#5]=PC\%;UC^H!1117V0!1110
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M110 4444 %%%% !1110 4444 %%%>4>+_B7XVTOQ/?:=8:UY<,-RRQI]FC.
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M+_,5]#5\\Z=_R$(/^NR_S%?0U?;<(_!6]8_J 4445]D 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7A?C_ /Y'34_^OQ_YU[I7A?C_ /Y'34_^
MOQ_YU\GQ;_NE/_%^@&/1117P8!114=W=VUA:2WU[.L4,,;232N<*B@9))[
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M7=$\4:)9^)O#.LVNHZ;J-K'=:?J%A<+-!=02*'CECD0E71E(8,"0000<&K5
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M110 4444 %>%^/\ _D=-3_Z_'_G7NE>%^/\ _D=-3_Z_'_G7R?%O^Z4_\7Z
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M )74?8OVM?\ GMX2_P#!W)_\KJ]/HH^H4.\__!D__D@/,/L7[6O_ #V\)?\
M@[D_^5U'V+]K7_GMX2_\'<G_ ,KJ]/HH^H4.\_\ P9/_ .2 \P^Q?M:_\]O"
M7_@[D_\ E=1]B_:U_P">WA+_ ,'<G_RNKT^BCZA0[S_\&3_^2 \P^Q?M:_\
M/;PE_P"#N3_Y74?8OVM?^>WA+_P=R?\ RNKT^BCZA0[S_P#!D_\ Y(#S#[%^
MUK_SV\)?^#N3_P"5U9_BG1?VUM1\.WMAX3\2>#-+U.6W9;'4+F]DN8[>0CAV
MB^PIY@']W<N?6O7Z*<<#1C)-.7_@<_\ Y(#Y3_X5)_P5]_Z.X^%G_A"R4?\
M"I/^"OO_ $=Q\+/_  A9*^K**[ /EBQ^$?\ P5G-["-?_:F^%]Y8>:OVVSC\
M&RPM/#GYXPX!V%ER-V#C.<&NU_X4S\=/^@-X2_\ "ENO_D&O<J*X<9EN"Q[3
MKPO;;5K\F@/#?^%,_'3_ * WA+_PI;K_ .0:/^%,_'3_ * WA+_PI;K_ .0:
M]RHKC_U>R?\ Y]?^32_S \-_X4S\=/\ H#>$O_"ENO\ Y!H_X4S\=/\ H#>$
MO_"ENO\ Y!KW*BC_ %>R?_GU_P"32_S \-_X4S\=/^@-X2_\*6Z_^0:/^%,_
M'3_H#>$O_"ENO_D&O<J*/]7LG_Y]?^32_P P/#?^%,_'3_H#>$O_  I;K_Y!
MH_X4S\=/^@-X2_\ "ENO_D&O<J*/]7LG_P"?7_DTO\P/#?\ A3/QT_Z WA+_
M ,*6Z_\ D&C_ (4S\=/^@-X2_P#"ENO_ )!KW*BC_5[)_P#GU_Y-+_,#PW_A
M3/QT_P"@-X2_\*6Z_P#D&C_A3/QT_P"@-X2_\*6Z_P#D&O<J*/\ 5[)_^?7_
M )-+_,#PJ;X,_'\0N;#3O",,^T^3,WB*Y<(_9BOV(;L'!QGFN(_X5)_P5]_Z
M.X^%G_A"R5]645W8/+\)@$U0C:^^K>WJV!\I_P#"I/\ @K[_ -'<?"S_ ,(6
M2C_A4G_!7W_H[CX6?^$+)7U9178!\=O/_P %#H7,,_[:'A<.APX3X0Q$9'7!
M^W#(_"D^U_\ !0G_ */1\,?^&@B_^3J[_4?^0A/_ -=F_F:AK\REQ#G"DU[7
M_P EC_D!PWVO_@H3_P!'H^&/_#01?_)U'VO_ (*$_P#1Z/AC_P -!%_\G5W-
M%+_6'./^?O\ Y+'_ " X;[7_ ,%"?^CT?#'_ (:"+_Y.H^U_\%"?^CT?#'_A
MH(O_ ).KN:*/]8<X_P"?O_DL?\@.&^U_\%"?^CT?#'_AH(O_ ).H^U_\%"?^
MCT?#'_AH(O\ Y.KN:*/]8<X_Y^_^2Q_R X;[7_P4)_Z/1\,?^&@B_P#DZC[7
M_P %"?\ H]'PQ_X:"+_Y.KN:*/\ 6'./^?O_ )+'_(#AOM?_  4)_P"CT?#'
M_AH(O_DZC[7_ ,%"?^CT?#'_ (:"+_Y.KN:*/]8<X_Y^_P#DL?\ (#AOM?\
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M )"$_P#UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#_\
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M'_KSB_\ 0!5NOV.C_!CZ( HHHK4 HHHH **** "BBB@ HHHH **** "BBB@
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M/\&/H@"BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JKJ^AZ+K]LMGKNCVM["L@D6*[MUD4..C ,",C)YJU10!\%_M+_ /!2
MW7G_ &J?&?[,/[%/_!+'7OVBO%WP_P#L:?$778M4TS1-*TJYN(%FAM/MU\C"
M><0E2R #;PN200-W]D?]I[]O;XB?M"^'_!WQI_X(9_\ "G?#-Y]K_M/XC_\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
MPF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#
M4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4
M'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I4
M5F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/
MAC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z
M#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!
MI45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_P
MF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^
M&/\ H-0?]]4?\)CX8_Z#4'_?5 'A>H_\A"?_ *[-_,U#4M^RO?3.IR#*Q!_&
MHJ_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/_\ (!L?^O.+_P!
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MMU4\/_\ (!L?^O.+_P! %6Z_8Z/\&/H@"BBBM0"BBB@ HHHH **** "BBB@
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MX=7_ &6_V2_!7A#4RA0ZY8Z0LNHE",%/MDV^?:1U7?CVH ];^'GB_P#X6%X
MT/Q]_P (QJ^B?VYH]MJ']C>(++[-?V'G1+)]GN8<GRITW;'3)VNK#)Q6Q110
M!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG%_Z *MU^QT?X,?1 %%%%:@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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M** "BBB@ HHHH ^>=1_Y"$__ %V;^9J&IM1_Y"$__79OYFH:_&9_&P"BBBI
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MK?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GG4?^0A/_UV
M;^9J&IM1_P"0A/\ ]=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH ***
M* /H'P__ ,@&Q_Z\XO\ T 5;JIX?_P"0#8_]><7_ * *MU^QT?X,?1 %%%%:
M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?/.H_P#(0G_Z[-_,U#4VH_\ (0G_
M .NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?_P"0#8_]
M><7_ * *MU4\/_\ (!L?^O.+_P! %6Z_8Z/\&/H@"BBBM0"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\
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M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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M?2/^?F]_\"VH_P"$'TC_ )^;W_P+:M0-BBL?_A!](_Y^;W_P+:C_ (0?2/\
MGYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^
M?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_
M ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W
M_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ
M -BBLNS\):;8W27<-Q=%HVRH>Y8C\16I0 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
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M_P#HO6@_]_G_ /B: /5Z*\H_X;G_ &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\
M?Y__ (F@#U>BO*/^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\
M^)H ]7HKRC_AN?\ 9'_Z+UH/_?Y__B:/^&Y_V1_^B]:#_P!_G_\ B: /5Z*\
MH_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XF@#U>BO*/^&Y
M_P!D?_HO6@_]_G_^)H_X;G_9'_Z+UH/_ '^?_P")H ]7HKRC_AN?]D?_ *+U
MH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B: /5Z*\H_X;G_ &1_^B]:#_W^
M?_XFC_AN?]D?_HO6@_\ ?Y__ (F@#U>BO*/^&Y_V1_\ HO6@_P#?Y_\ XFF3
M_MV_LB6T+3R?'C1"JC)$;2.?P"H2?PH ]:HKR=/VZ?V1G4./CSH6",C,C@_D
M5XI?^&Y_V1_^B]:#_P!_G_\ B: /5Z*\H_X;G_9'_P"B]:#_ -_G_P#B:/\
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M_P#HO6@_]_G_ /B: /5Z*\H_X;G_ &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\
M?Y__ (F@#U>BO)+?]N_]D.Z0R1?'C10 Q&)#(AR/9D!Q[U)_PW/^R/\ ]%ZT
M'_O\_P#\30!ZO17E'_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/
M_P#$T >KT5Y1_P -S_LC_P#1>M!_[_/_ /$T?\-S_LC_ /1>M!_[_/\ _$T
M>KT5Y1_PW/\ LC_]%ZT'_O\ /_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q- 'J]%>
M<>%/VN_V:?'/B.T\(^$?C'H]_J5_+Y5G9P2L7E?&=HRO7BO1Z "BBB@ HHHH
M **** "BBB@ HHHH R]6\$>"]>O#J&N>$-+O;@J%,]WI\<CD#H-S*3BJW_"K
MOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
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M_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XFMVB@#"_P"%7?#/_HG>A?\
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M_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]"_\
M!1#_ /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[T+_P40__ !-'
M_"KOAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\
M1.]"_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_
M ,36[10!A?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-;M%
M'SK^P1X#\#:O\&M5N=5\&:3=2+XWUA%DN-.B=@HN2 N2IX Z"O;?^%7?#/\
MZ)WH7_@HA_\ B:@^%OPI\(_![P[/X7\%PSI:7&I7%](+B<R-YTS[W.3VST':
MNDH PO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)WH7_@HA_^)K=HH PO^%7?
M#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_
M (*(?_B:/^%7?#/_ *)WH7_@HA_^)K=HH Q['X?> =+O(]0TSP1H]O<1-NBG
M@TR)'0^H8+D&MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \$_X*
M%?\ !0KX/_\ !.SX0Z?\0OB)H6L^)=?\3ZY!H7@#P#X6M?M&K>)]7F.(K2VC
M_5G/"C  9V1'^<?B#_P53_X*;_LP>!7_ &C/VR?^"/LFA_"NRC6Y\5:AX#^+
MUEK^M^%[+/S7-S8K;Q+<)&OS2&*0"-0S,0JDC!_X*'?99/\ @X6_83B^)+#_
M (1H:#XY;PTMUC[.=<_LT^O'F8^R[.^_R\<XK]#/B7'X)E^'/B"+XEBV/AQM
M$NQX@%[CR?L/DMY_F9XV>7OS[9H \?\ C;^VIXDLOV5_"_[2G[$'[/FJ_M O
MXZEL?^$/T;PMK,&G17-O=0O,EY<7=T-EG;JJ!7>1<H[JA4-P/G[2O^"MO[7W
M[/OQW^'?PI_X*<?\$[HOA1X<^+'BB#PUX.^(?A3XE6WB+3[?6I_^/>PODCAC
M:W,A! ER5."0NU)&3)_X-:+OQ99_\$/OA;>^/;EHK2&\\0/I,UX^W9IZZO>$
M,2W1 XEP3P% QQBN=\1^(]7_ ."[O[9_@1?A#;RQ?LJ_LZ?$F'Q-J7CYT*I\
M1O%]@66VM--/_+2PM6>3S;CE)2S*N?D>@#]-*\0\*?ME?\)/_P %"_%_[!O_
M  KCR/\ A%/A?I7C#_A*O[8W?:OMMY<VWV7[-Y(V;/L^[S/-;=OQL7&3[?7#
MZ5^SA\&-$_:&UC]JO2_!OE>/M>\+VGAW5M>_M&Y;S]-MII)X8/(,AA7;)+(V
M]4#G=@L0   ?(7C'_@HE_P %@([?6/B3\./^"(]U=^"=%EN'B@U_XSV%EXBU
MBTB+9G@TY;>0Q.54LL#L9'X &6%>\_LV?\%!?AI^UY^P)!^WW^SQX&\1^)-,
MN_"NHZI9>#+.U3^V;B]LA,LNE)'NVFZ,\#0I\VUV9&#;6!K@/^"FG_!0KQ7\
M!+C1OV./V.?#L'C3]I7XH6TD'@+PHDH\G0;8AEDU_4VP1;V5OAF&[F9TV*"
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M[6_VA--T.^GTM)S':7D]I=V&83<1KYRHKRJ$92)&# U\T?M\_L'Z)=?\%K?
M7[$/@_XG:OX?^"G[7EY<>.?C;\.-,54M-6U/P_#-=R;&!#0QWS)!]H";69X]
MY9B$"?LII6E:9H6F6VB:+IT%G9V<"06EI:Q".*")%"HB*H 50   . !B@#\S
M_P!G_P#X+5?\%3?VH-;\?>'?@I_P0SL]6N_AEXWN_"/C2*3]J+2+;[#J]MM\
MZW!FTY1,%W#]Y'N0YX8UWOQV_P""M_[9_P //VP/ 7["/PB_X)B67C/XF>*/
M@-8?$?Q+H=U\<K/2X_#\DMU/:7>FBX>PDAN_L\T(43HZB7?E8P!DY7_!!_\
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M%9$^'TG_  3"_:#7XH_9O[$_X4YXB-U]JQC>-.F,6W/_ "T\WR]F.=^S'.*
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MCB\T*7"/*(5-PLT;=)X[8*2A(*M&[[?UXHH ^3?VV/\ @FO/^T__ ,$XM/\
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MY.5R#(/,V\[<UZG10!^:D'_!&C_@J#;?M@3?MV1?\%K-''Q)N/AX/!$NL?\
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MI)=T]]"B%FG1=OEDKY.=_P Y ^W** /A'2O^",_Q,^.7Q>\*?%K_ (*@?\%
MO$_[05OX$UB/5_"7@*'P78^%_#,-_'GRKFYL+1I3>.A)*F23NRMN1F0_=U%%
M !7YH?#W_@B5_P %"O@U^T[\2OVL_A-_P6&TNU\8_$[5'EUC7?$/[.%CJ]_;
MV(<F#3H;BYU0F&VB4(HBB6-#Y:$K\B!?TOHH \L_9R^%G[4GPY^"%WX(_:*_
M:NL_B5XWFGNFM/'5K\/;?0X[='0"!#80SRH_E,"Q)<;\X.,5\3ZC_P $:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20210630_g17.jpg
<TEXT>
begin 644 biib-20210630_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
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M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-
M;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P
M&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+Q
MO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_
M &+QO_T&[+_P&/\ C7$Z[\6O%6AZQ<Z1(MO(;>4H7"8#8[XKTZO"_'__ ".F
MI_\ 7X_\Z^>XBQV*P.'A*A*S;MLGT\TP-S_A=_B?_GW@_+_ZU'_"[_$__/O!
M^7_UJXNBODO]8<X_Y^_^2Q_R [3_ (7?XG_Y]X/R_P#K4?\ "[_$_P#S[P?E
M_P#6KBZ*/]8<X_Y^_P#DL?\ (#M/^%W^)_\ GW@_+_ZU'_"[_$__ #[P?E_]
M:N+HH_UASC_G[_Y+'_(#M/\ A=_B?_GW@_+_ .M1_P +O\3_ //O!^7_ -:N
M+HH_UASC_G[_ .2Q_P @.T_X7?XG_P"?>#\O_K4?\+O\3_\ /O!^7_UJXNBC
M_6'./^?O_DL?\@.T_P"%W^)_^?>#\O\ ZU'_  N_Q/\ \^\'Y?\ UJXNBC_6
M'./^?O\ Y+'_ " [3_A=_B?_ )]X/R_^M79>'+WQIXAT2WUJ/5+2);A"PC:W
M)(Y(Z_A7C->W_#/_ )$73O\ KB?_ $(U[_#V:8_'8N4*\[I1OLEK==D@+-G:
M>+4ND>^U:U>(-^\1+<@D>QK4HHKZ\ HHHH **** "BBB@ HHHH **** /"_^
M">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O"_'_P#R.FI_]?C_ ,Z]TKPOQ_\ \CIJ?_7X_P#.OD^+?]TI_P"+
M] ,>BBBO@P"BBB@ HHHH **** "BBB@ HHHH *]O^&?_ "(NG?\ 7$_^A&O$
M*]O^&?\ R(NG?]<3_P"A&OJ>$_\ ?I_X?U0&[1117WX!1110 4444 %%%% !
M1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI
M->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7A?C_ /Y'34_^OQ_YU[I7A?C_ /Y'34_^OQ_YU\GQ
M;_NE/_%^@&/1117P8!1110 4444 %%%% !1110 4444 %>W_  S_ .1%T[_K
MB?\ T(UXA7M_PS_Y$73O^N)_]"-?4\)_[]/_  _J@-VBBBOOP"BBB@ HHHH
M**** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\+\?_P#(Z:G_ -?C_P Z]TKPOQ__ ,CIJ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOQ__P CIJ?_ %^/
M_.O=*\+\?_\ (Z:G_P!?C_SKY/BW_=*?^+] ,>BBBO@P"BBB@ HHHH ****
M"BBB@ HHHH *]O\ AG_R(NG?]<3_ .A&O$*]O^&?_(BZ=_UQ/_H1KZGA/_?I
M_P"']4!NT445]^ 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^/_P#D
M=-3_ .OQ_P"=>Z5X7X__ .1TU/\ Z_'_ )U\GQ;_ +I3_P 7Z 8]%%%?!@%%
M%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>W_#/_ )$73O\
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M 4444 %%%% !1110 4444 %%%% !1110 5X7X_\ ^1TU/_K\?^=>Z5X7X_\
M^1TU/_K\?^=?)\6_[I3_ ,7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110
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M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3L]>@H \=_X=X?\ !=?_ *6*O_-1O#'_ ,D5Z!^RY^QI_P %8?A1\=M"\?\
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M *\+\?\ _(Z:G_U^/_.O=*\+\?\ _(Z:G_U^/_.OD^+?]TI_XOT QZ***^#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X
M7X__ .1TU/\ Z_'_ )U[I7A?C_\ Y'34_P#K\?\ G7R?%O\ NE/_ !?H!CT4
M45\& 4444 %%%% !1110 4444 %%%% !7M_PS_Y$73O^N)_]"->(5[?\,_\
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MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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MBB@ HHHH *]O^&?_ "(NG?\ 7$_^A&O$*]O^&?\ R(NG?]<3_P"A&OJ>$_\
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M@#_D=-,_Z_$_G71A,QS"6*IIUI-.2^T^_J![I1117ZF 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!XW>_%;Q]%>2Q1Z]A5E8*/LL7 !_W
M:B_X6U\0?^A@_P#)2+_XBL+4?^0A/_UV;^9J&OR:699BI/\ ?3_\"?\ F!T?
M_"VOB#_T,'_DI%_\11_PMKX@_P#0P?\ DI%_\17.45/]I9C_ ,_I_P#@3_S
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M* "BBB@#YYU'_D(3_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P"BBBI ****
M"BBB@ HHHH **** "BBB@#Z!\/\ _(!L?^O.+_T 5;JIX?\ ^0#8_P#7G%_Z
M *MU^QT?X,?1 %>%^/\ _D=-3_Z_'_G7NE>%^/\ _D=-3_Z_'_G7S'%O^Z4_
M\7Z 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\ #/\ Y$73O^N)_P#0
MC7B%>W_#/_D1=._ZXG_T(U]3PG_OT_\ #^J W:***^_ **** "BBB@ HHHH
M**** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37J_Q,_Y$74?^N(_]"%>4?\ !/?_
M )(GJW_8]ZS_ .E)KU?XF?\ (BZC_P!<1_Z$*Y,?_N-7_#+\F!XA1117Y$ 4
M444 %%%% !1110 4444 %%%% !6QX _Y'33/^OQ/YUCUL> /^1TTS_K\3^==
M."_WRG_B7YH#W2BBBOU\ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#YYU'_D(3_\ 79OYFH:FU'_D(3_]=F_F:AK\9G\; ****D HHHH
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MZ_$_G73@O]\I_P")?F@/=****_7P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /GG4?^0A/_UV;^9J&IM1_P"0A/\ ]=F_F:AK\9G\; **
M**D HHHH **** "BBB@ HHHH **** /H'P__ ,@&Q_Z\XO\ T 5;JIX?_P"0
M#8_]><7_ * *MU^QT?X,?1 %>%^/_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\
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M%% !1110 4444 %%%% 'T#X?_P"0#8_]><7_ * *MU4\/_\ (!L?^O.+_P!
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MO/P-X&\&?#+P=I?P\^'7A33]"T'1+&.RT?1M)LTM[:RMXU"I%%&@"HBJ  H
M Q7A'_#V[_@G1_T=)HO_ ( 7G_QFFO\ \%</^"<T:%V_:CT? _NZ?>D_D(*
M/HZBOG(?\%;_ /@G.0"/VH]&Y];"\_\ C-+_ ,/;O^"='_1TFB_^ %Y_\9H
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MYC_SYG_X"_\ (#VFBO%O^'BG[%'_ $<)HO\ W[G_ /C='_#Q3]BC_HX31?\
MOW/_ /&Z/[-S'_GS/_P%_P"0'M-%>+?\/%/V*/\ HX31?^_<_P#\;H_X>*?L
M4?\ 1PFB_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/NKP__P @&Q_Z\XO_ $ 5;KYJ
MT?\ X*S?\$[;72+6UG_:AT57CMD5U^PWAP0H!'$-6?\ A[=_P3H_Z.DT7_P
MO/\ XS7ZO235**?9 ?1E>%^/_P#D=-3_ .OQ_P"=8_\ P]N_X)T?]'2:+_X
M7G_QFO)_%_\ P4C_ &'M4\3WVHV'[1.BR0S7+-&_DW R">N#'FOG>)\/7Q&%
M@J4')WZ)OIY >L45XM_P\4_8H_Z.$T7_ +]S_P#QNC_AXI^Q1_T<)HO_ '[G
M_P#C=?%?V;F/_/F?_@+_ ,@/::*\6_X>*?L4?]'":+_W[G_^-T?\/%/V*/\
MHX31?^_<_P#\;H_LW,?^?,__  %_Y >TT5XM_P /%/V*/^CA-%_[]S__ !NC
M_AXI^Q1_T<)HO_?N?_XW1_9N8_\ /F?_ ("_\@/::*\4C_X*,?L3RKN7]H/1
MQSCYH;@?SCIW_#Q3]BC_ *.$T7_OW/\ _&Z/[-S'_GS/_P !?^0'M-%>+?\
M#Q3]BC_HX31?^_<__P ;H_X>*?L4?]'":+_W[G_^-T?V;F/_ #YG_P" O_(#
MVFBO%O\ AXI^Q1_T<)HO_?N?_P"-T?\ #Q3]BC_HX31?^_<__P ;H_LW,?\
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MS_\  ;1_C#\&K'2?@EX1M8+_ ,:RQ7T-MX;M42XC^SL=D@6,!USS@Y%>U?\
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MT4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_ .-5W-%
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M"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\
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M^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\
MV:?^C>/ O_A)6?\ \:KN:* .&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-
MX\"_^$E9_P#QJNYHH X;_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X
M25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\
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M_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\
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MN_ WP)XCO;<Z5J,MQX(:U3^UX]1LO,6;3!'NVM.9(]B<@.)(VXW8'BG[(O\
MP5\^/GQ\_P""@-K^PE\??^"</B#X,W6J_#.Z\:Z'JGBCQY:WE[<V,5VEJHDL
M;: B M(9!\\^Y?*^X0P->Q?\$KOV$(/^"<O[%OAK]FR^\7_\)%X@CGNM7\:>
M(E0JNI:S>2F>ZE0$ B,,PC3(!*1H6 8FOGGQW_RM)^!O^S,+[_U(Y: /T/HH
MHH **** "BBB@"EXDN=?L_#M_>>%-)MM0U2*RE?3;"]OFMH;FX"$QQR3+'(8
MD9L*7$;E02=K8P? ?^"=/_!0WPQ^WE\(_$/B3Q!\/IOAUX]\ >)+SP_\4_AM
MK&JK<W7A?4;=V&UYMD8FADC7S(YPBHXW@<HV/HNOR"_X+Y_LNZSX2_; ^$GC
M?]G3XS:Q\.+O]KKQ1IWP6^.!T"%"-:TF>:'R[S#<+=QP"6V\S&YH9 @*KN#@
M'O\ X)_X*Z?MJ_M1:3XF^*?_  3Q_P""6<?Q>^&FE>.+OP[X9\;:A\;[+PX?
M$D=JH6XU&WM[NQ8?9//W11NLKF38Q(0JR#AO 7_!:K_@J;\3/VC_ ![^R9X,
M_P""&=G=>//AG9:9=^,]';]J+2(UL8M0A\^T83/IPBEWQ\XC9BO1L'BOT1^#
M'P=^&_[/?PF\._ _X0>%K?1?#'A32(-,T/2[4?);V\2!%&3RS$#+,<LS$L22
M2:^%OV&_^5AK]N;_ +$_X;_^F>@#3_:2_P""N7[:/[.5Y^SA\(=6_P""7]I>
M?&/]H*Y\4P#X:R?'*RBBT!](>!T!U-+"2"Z^T6LZSYQ%Y1_=G>V2&>,O^"T'
M[1'[)3V/BC_@IW_P2T\:?!OP'>ZC%97'Q*\+>.M/\9:1I+RN$22^^Q)%-:Q%
MBJ[S&22RA58G%<__ ,%6O^4VO_!.'_L8/B-_Z:=.KZ<_X*R)\/I/^"87[0:_
M%'[-_8G_  ISQ$;K[5C&\:=,8MN?^6GF^7LQSOV8YQ0![UHNM:/XDT:T\1>'
MM4M[ZPO[:.YL;VTF62*XA=0R2(ZDAE92"".""#7C/QN_;*_X4W^VU\"_V.?^
M%<?VE_PNG3_%EU_PD?\ ;'D_V-_8EI:7&W[/Y+?:/.^U;<^9'Y>S.'W8'#_\
M$0F\7O\ \$B?V=F\<>?]N_X53I/E_:<[OLODC[+U[?9_)Q[8KV_QO^SA\&/B
M/\;? O[1GC/P;]L\9?#2WU:#P3K/]HW,?]G1ZG#%#?#RHY%BF\R.")<RHY3;
ME-I)) /G+X\?MG?\%3;+XR^)?A_^R9_P2;3Q;X9\,WHMX_''C;XN6.@1:\PC
M5V%C:M#)*4RVT3.0A*GWQV__  3<_P""B_A3_@H5\,?$^NS_  KUGX=^-OAY
MXLN?#'Q+^'WB*>.6XT'58 "\8F0!9X2"=LH5=Q1_E&WF]_P4/_X*$?#+_@GY
M\)+3Q/KNBW?BKQSXJOAI'PP^&>AG?JGBW5W(6.U@0!BL89T,LQ4K&I'WF9$?
MP7]D']ASXZ_LC?\ !/K]H3XK_'O7+;4/CO\ &^T\2>-O'W]@<VVF:C/83?9M
M,M""=R6XPH;)R[OAF4*2 <_%_P %JOVNOC)X-\8_M2_L3_\ !,RX^)/P!\$Z
MGJ%LWCFZ^)%OIFJ>*+>P9EO;S2=.:WD,T,9CD*;G#3;"JA7#(OV[^R[^TE\+
M/VP?V>O"/[3?P3U>2]\+^--%BU+299XPDL:MD/#*H)"2QR*\;J"0'C89.,U\
MT_\ !O4GA;_ARE\ TT=;<V)\&3_:A@;#,;ZZ^T;L\?ZWS=V>^:X+_@UK\X?\
M$=_!RVIE.CCQEXH'APN?E^Q?VS=;=G^SYGF_CF@#]$**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \ _P""B'_!/'X5?\%$OA+I?@GQGXHU
MGPGXH\):]#K_ ,._B'X7F$6J>%]7A.8[J!OXE. 'C) 8 $%71'3X&_X*._LR
M?\%P[?X3>&?A3\=_VJM2^-7P-USQ#!HOQFMO@+\+XM)\<7FA2X1Y1"IN%FC;
MI/';!24)!5HW?;^O%% 'R;^VQ_P37G_:?_X)Q:?_ ,$^_P!DKX^7OP&\*C3[
M#3A=:7X8DO))-"AA96TQX7N+:9!*#'YK-('8(Z2!A(X/!?L[?\$W/^"I7[.6
MA^#_ (:>#O\ @KSX2MO /A(VEO!X-TC]E;2K*)]/A=2]JDJZBS1%T#*9<,VY
MRYW-G/W?10 4444 ?F3\%/\ @B'_ ,%&/V=OC7\1/VA?A1_P65TJ/QC\3M7-
MYXI\3^(/V:K'5-1FB!_=6:W%QJC-%;1@*%AC"1C:N% 50OW'\$/A9^U)X(_9
MVNOAW\;?VKK/QU\0Y8+Y;7XD6_P]M])B@>4-]F?^S8IY(W\G*Y!D'F;>=N:]
M3HH _-2#_@C1_P %0;;]L";]NR+_ (+6:./B3<?#P>")=8_X9AT_RCHHO5O?
M(^S_ -J^4&\]0WF;=^.,XXK]&O!^G>(M'\):7I'B_P 2)K.K6NG00ZIK"6*V
MJWURL:K).(5+"(.X9M@)"[L G&:T:* "BBB@ HHHH **** "O)_VW/V+_@=^
MW_\ LWZ_^R_^T%HUQ<Z#KJ(\=W83"*\TR[B;?!>6TI!\N:-P&4D%2,JRLC,I
M]8HH _*3]MG]EW_@X._9]_9!U/PI\#O^"@7_  N#P_I$<-IJ,&A_#J&P^(5[
MH1;9<+:7GF31SWR0\+)L6>0@NK>;A6^H_A9^PAX2TG_@DG:?L6_L$>.?&'P(
MM]<\'+#HWBG7O#,O_"1:1-<R++=W%Y;2O;R"^DW3(Y#1F-I-T14)&!]<44 ?
MF[^RS_P1W_X*<_L6_!32?V>_V:_^"Q_A7PUX6T<.UO90?LI:7))-*YW23SRR
M:HTD\SMRTCL6/ S@ #]&-"M=4L=$L[+7-66_O8;6-+R^6W$(N90H#R",$A-S
M9.T$@9QGBK5% !7YR^.O^"+W[<-Y_P %!?''_!0OX4?\%6M.T/Q/XG1[#P[!
MXD^ %GK\GA31=S&/3;&6YU)5A0!L.\<4;2DLS<N^[]&J* /&_P!D[X)?M5?#
M7P%KGA3]M#]KC3?C;>ZI>$V6H0?#&U\-Q6MFT01[5[>">=9PS;F+L1PVW&!7
MQY8_\$5?VV/A+\(/$G[#'[+7_!3%/"'[./B:ZOT@\,ZA\.X[_P 1>&M+OI'D
MN]+L-2:Y4&)_-F"RR1^9&)21EAN;])Z* .,_9V^ ?PS_ &6?@7X3_9T^#FBG
M3_"_@S0K?2M%MG?>XAB0*'D; WR.<N[XRSLS'DUV=%% !1110 4444 %%%%
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MB5F";MH) S6Q110 4444 %%%% !7SA^WI_P3[_X;>^(_P%^('_"V_P#A&/\
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M-?H!10!5T/0]&\,:)9^&_#FE6]AI^GVL=M86-I"(XK>&-0B1HB@!550  .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20210630_g18.jpg
<TEXT>
begin 644 biib-20210630_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E?>
M(M$TV?[+?ZE'%( #L8\XJ+_A,?#'_0:@_P"^J\@_8-N;G7?@YJM[KEP]Y,OC
M;5XUENW,C!%N2%7+9. .@[5[7_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH
M_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#
M_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J
M#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_
M .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^
MA0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/
M_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/
MC#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9V
MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A
M?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
MD3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->S>)M:_X1W0KG6OLWG?9T
M#>5OV[N0.N#CKZ5XS_P3W_Y(GJW_ &/>L_\ I2:]7^)G_(BZC_UQ'_H0KGQ<
MY4L+4G'=1;7R0'+?\+__ .I2_P#)_P#^UT?\+_\ ^I2_\G__ +77G-%?G/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\
ML>]9_P#2DUZO\3/^1%U'_KB/_0A7QK^SY_P3\^"O[2WA/5OB1X]\5^-[._\
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M>?9-5\,:MX>U;P_?*,O;7T>MV*(Z?[6)'7/;=FHHO^"97[6'[1GQ<\%>/?\
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MG"-,!"<J2ZN$[+]GG]H_]K']I']L;P)K_P"TI_P0UUKX=2Z19ZI:Z=\7M?\
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M%2_#[_H7_P#R;E_^+KYG_5/,?YX?>_\ Y$#Q:BO:?^%2_#[_ *%__P FY?\
MXNC_ (5+\/O^A?\ _)N7_P"+H_U3S'^>'WO_ .1 \6HKVG_A4OP^_P"A?_\
M)N7_ .+H_P"%2_#[_H7_ /R;E_\ BZ/]4\Q_GA][_P#D0/%J*]I_X5+\/O\
MH7__ ";E_P#BZ/\ A4OP^_Z%_P#\FY?_ (NC_5/,?YX?>_\ Y$#Q:BO:?^%2
M_#[_ *%__P FY?\ XNC_ (5+\/O^A?\ _)N7_P"+H_U3S'^>'WO_ .1 \6HK
MVG_A4OP^_P"A?_\ )N7_ .+H_P"%2_#[_H7_ /R;E_\ BZ/]4\Q_GA][_P#D
M0/%J]O\ AG_R(NG?]<3_ .A&H?\ A4OP^_Z%_P#\FY?_ (NMS3-,LM'L(],T
MZ#RX(5Q&FXG SGJ237M9'DN*RS$RJ591::MHWW3ZI 3T445]. 4444 %%%%
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MG%_Z *MU4\/_ /(!L?\ KSB_] %6Z_8Z/\&/H@"BBBM0"BBB@ HHHH ****
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MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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M %%%% 'SSJ/_ "$)_P#KLW\S4-3:C_R$)_\ KLW\S4-?C,_C8!1114@%%%%
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M_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P"BBBI **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ;>,K3Q#/\1?B]K?C:&Y3P\MB^E0Z@+<#3E(EE,J1^1GS 4#;_\ 5KCGQO\
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M_1>M!_[_ #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\30!PO\ PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\ /_\ $UW7_"KO
MAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q- ' S?MW_LAP/'&_QXT4
MF1L*4,C 'W(3"CW.*D_X;G_9'_Z+UH/_ '^?_P")KC/VI? ?@:P^,OP6MK'P
M9I,,=UXWE2YCATZ)5E7[,QVL OS#/8U[;_PJ[X9_]$[T+_P40_\ Q- '"_\
M#<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_
M\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0?^_S_P#Q-'_#
M<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P4
M0_\ Q- '"_\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_P
MJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0
M?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ
M[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?
M^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\
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M &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\ ?Y__ (FNZ_X5=\,_^B=Z%_X*(?\
MXFC_ (5=\,_^B=Z%_P""B'_XF@#A?^&Y_P!D?_HO6@_]_G_^)H_X;G_9'_Z+
MUH/_ '^?_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H
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M1_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\
M1.]"_P#!1#_\30!PO_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/
M_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!PO_#<
M_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]$[T+
M_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!PO_#<_P"R/_T7K0?^_P __P 3
M1_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\
M1.]"_P#!1#_\30!PO_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/
M_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!PO_#<
M_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]$[T+
M_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!PO_#<_P"R/_T7K0?^_P __P 3
M1_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\
M1.]"_P#!1#_\30!PO_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/
M_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!P-O\
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M;WQ[<M%:0WGB!])FO'V[-/75[PAB6Z('$N"> H&.,5SOB/Q'J_\ P7=_;/\
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M T:*** "BBB@ HHHH *_-C_@X9^RO\0?V)H/'S > 7_:^\-CQ2+C'V8S?/\
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MTK3;=8;>VA6*").B(H 51[  "OSC_99_X([_ /!3G]BWX*:3^SW^S7_P6/\
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MW\S[5YZ_9_+W[MOE2;\8RO6OH^@#\\/^"#__ "67]NG_ +//\4_RAK/\9?\
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M<%_P:U^</^"._@Y;4RG1QXR\4#PX7/R_8O[9NMNS_9\SS?QS5&R_X(R_MK?
MOP+XP_9+_8?_ ."D=M\/_@!XTU+4)XO">J?#E-2UGPC;7[LUY9:5??:4"Q.9
M)=C.F^$R%E)?,C?;W[*W[-'PK_8X_9V\(?LP?!/2I+/POX+T:/3M+CN'#RRA
M<L\TK  -++(SRNP !>1C@9Q0!Z!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20210630_g19.jpg
<TEXT>
begin 644 biib-20210630_g19.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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M ,%2_P!LFR_8$_8#^)O[4S31_P!I^'O#DD?AF"0;OM&L7!%M8Q[>K W,L18
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M;\,V=MX@B>Q:ZU:"&ZOWBTV*6*1D82);2VB.KD.FTAOF!KHO^"Y/_!7O0O\
M@E3\$O#5AX=@T^7XD?%*_N-+\ R:^LHTG2_)\@76J7[QJS&"V%U QB0&24N
MHP'9?N*B@#\P/^",_P"UA_P2 ^'/BP?";X5_M\67QB_:,^,FJ&^\?^.]2T34
M8]1\5ZFD+RM'&9K94MK2&-)!#;AE1$7NQY_3^BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?
M]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L+4/B7X)TN]ETZ_UKRYH7*R)]FD.".V0N
M*W:\+\?_ /(Z:G_U^/\ SKQ,\S*OEE",Z23;=M;]O)H#U'_A;7P^_P"A@_\
M)27_ .(H_P"%M?#[_H8/_)27_P"(KQ:BOF?];,Q_DA]S_P#D@/:?^%M?#[_H
M8/\ R4E_^(H_X6U\/O\ H8/_ "4E_P#B*\6HH_ULS'^2'W/_ .2 ]I_X6U\/
MO^A@_P#)27_XBC_A;7P^_P"A@_\ )27_ .(KQ:BC_6S,?Y(?<_\ Y(#VG_A;
M7P^_Z&#_ ,E)?_B*/^%M?#[_ *&#_P E)?\ XBO%J*/];,Q_DA]S_P#D@/:?
M^%M?#[_H8/\ R4E_^(H_X6U\/O\ H8/_ "4E_P#B*\6HH_ULS'^2'W/_ .2
M]I_X6U\/O^A@_P#)27_XBC_A;7P^_P"A@_\ )27_ .(KQ:BC_6S,?Y(?<_\
MY(#VG_A;7P^_Z&#_ ,E)?_B*W-,U.RUBPCU/3I_,@F7,;[2,C..A -?/5>W_
M  S_ .1%T[_KB?\ T(U[61YUBLSQ,J=6,4DKZ)]TNK8&[1117TX!1110 444
M4 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O
M^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7A?C_ /Y'34_^OQ_YU[I7A?C_ /Y'34_^
MOQ_YU\GQ;_NE/_%^@&/1117P8!1110 4444 %%%% !1110 4444 %>W_  S_
M .1%T[_KB?\ T(UXA7M_PS_Y$73O^N)_]"-?4\)_[]/_  _J@-VBBBOOP"BB
MB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>
MK?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%?!@%%%% !1110 4444 %%%% !1110 5[?\ #/\ Y$73O^N)_P#0C7B%>N>
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M(JS0 4444 %%%4X_$.@3:P_AZ+7+-K^)-\EBMRAF1?[Q3.X#D<X[T 7****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\+\?_P#(Z:G_ -?C_P Z]TKPOQ__ ,CIJ?\ U^/_ #KY/BW_ '2G_B_0#'HH
MHKX, HHHH **** "BBB@ HHHH **** "O;_AG_R(NG?]<3_Z$:\0KV_X9_\
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MX!Z=\!OB/J_Q8_:+O[*X^ VN>%O"EU>6^MI>:#;:3&J7<2E()+"99F99"N,
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M9>-F@MRJV+7N4%^9C*94MR8U3<%P RCWOP__ ,$O_P#@JM^S+8_&3QA\(O\
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M?\,_^1%T[_KB?_0C7U/"?^_3_P /ZH#=HHHK[\ HHHH **** "BBB@#\P/\
M@H=^W5_P4I\<:E^TQJ/[!WQ-\(_"_P  _LJ>&99_%'BK6?"R:SJWBO7(]*&I
MR6%K%.?(M;>.)XHVE=6?>^Y0Z\+]$?$O]L/XU_"_]H[]D'P?<:CIMYX4^.-G
MJFE>,HIM. NX]3CT,:C9W,#H0$0O#-'(FTC$B$8VX/BW_!2'_@EI^W?XI\0_
M'#Q=_P $WOB[X @T?]I/P@=%^,/PZ^)T%TEL;H6!T]=7TNZM59H+HVQ57CD7
MRW:/>V\[57I?V+_^"?G[?WB[]I#X?_M9?\%0OBI\/9)_@YX;N=)^$7PR^%-O
M=G3--GN;5;.XU2]N;L"2XNFME,80 QKO+*4.5(!]]T444 >%_P#!/?\ Y(GJ
MW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 44RXGBM;=[J=]J1H6=L9P ,D\5S_ /PMKX??
M]#!_Y*2__$5A6Q6&P[2JS4;]VE^8'1U2\2:);^)O#M_X;NYGCBU"REMI9(\;
ME61"I(SQG!K)_P"%M?#[_H8/_)27_P"(H_X6U\/O^A@_\E)?_B*Q_M++O^?T
M/_ E_F!5^ /P@T3]GOX$^"O@%X9U.ZO=-\#^$M-\/Z?>7^WSYX+.UCMHY)-@
M"[V6,$X &2< "NMKG/\ A;7P^_Z&#_R4E_\ B*/^%M?#[_H8/_)27_XBC^TL
MN_Y_0_\  E_F!T=%<Y_PMKX??]#!_P"2DO\ \11_PMKX??\ 0P?^2DO_ ,11
M_:67?\_H?^!+_,#HZS=)\'>$- U.[UO0O"NFV5[J#;K^[M+&..6Y;.<R.H!<
MY]2:SO\ A;7P^_Z&#_R4E_\ B*/^%M?#[_H8/_)27_XBC^TLN_Y_0_\  E_F
M!T=%<Y_PMKX??]#!_P"2DO\ \11_PMKX??\ 0P?^2DO_ ,11_:67?\_H?^!+
M_,#HZ*YS_A;7P^_Z&#_R4E_^(H_X6U\/O^A@_P#)27_XBC^TLN_Y_0_\"7^8
M'1T5ST?Q6\ RR+%'KV69@%'V67DG_@-=#6]'$X?$7]E-2MV:?Y %%%%; %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7X_P#^1TU/_K\?^=>Z
M5X7X_P#^1TU/_K\?^=?)\6_[I3_Q?H!CT445\& 4444 %%%% !1110 4444
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444
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M_P""GG[97@SQK\0/ GA*]TGX*?#7P38C3]*T*![=+>_U")9R+F^N7@"Q-(R
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MX9T];0-"^IZC<@A9C:0J\<*J[&) >, 5[C\,_A#_ ,$J_P!DW]K'X 6GPO\
M^"?7A/P3XX^+^BZO>?#[QMX<\)V,*:9<6^E?:+FRDG5EECEELYYPNU"KJDJD
MCH?E[_@IE<?';]A2+]MCP-J_[*GCWQYX#_:L\)7%]X&\?_#WP^=4&AZW)H T
MN73M7C0B2VA\R*.2*8!DVR$ %M^ST']E[XD_%[_@J3^UG^S=X^\%_LM_$'P!
M\'_V;=(O-4UGQG\2M .DS>*->GT<Z;!9Z;;N2\D$0EEE><_*VW80A">8 ?J)
M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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M_P G;LJ=3[H__)GW+169X+LO$FG>%-/L_&&L?VAJJ6J_VA=B)$$DI&6PJ *
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M$'_79?YBOH:OGG3O^0A!_P!=E_F*^AJ^VX1^"MZQ_4 HHHK[( HHHH ****
M"BBO-/VI]:^*GA/X;-XT^%?B)K*;2Y0^HPK9PS>;;G@M^\1L%#@\8^4L3T%;
MX:@\37C232<G:[V_4YL9BHX+"SKRBY**NTK7LM[7:VWW/2Z*^%?^&R/VD/\
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M+_P9(/J6._Z"9?\ @,/_ )$Y3_A\C^RM_P!##I/_ (5-G_\ %4?\/D?V5O\
MH8=)_P#"IL__ (JOH/2?@=\%+[2[:^OO@_X6FFFMT>::7P_;,SL5!+$E,DD\
MDFK'_"@_@7_T1;PE_P"$Y:__ !NOLH8O"S@I>P6OG+_,/J6._P"@F7_@,/\
MY$^=/^'R/[*W_0PZ3_X5-G_\52_\+XE^)?\ Q7_A'P!?7NF:O_I-C=VMU%)'
M+&W(964X8'U%?17_  H/X%_]$6\)?^$Y:_\ QNC_ (4'\"_^B+>$O_"<M?\
MXW7!F-# YC3C"=".COJY_I-!]2QW_03+_P !A_\ (GSK_P + \3_ /1+=6_[
M^)_C1_PL#Q/_ -$MU;_OXG^-?17_  H/X%_]$6\)?^$Y:_\ QNC_ (4'\"_^
MB+>$O_"<M?\ XW7D_P!@Y7_SXA_Y5_\ EH?4L=_T$R_\!A_\B?.O_"P/$_\
MT2W5O^_B?XT?\+ \3_\ 1+=6_P"_B?XU]%?\*#^!?_1%O"7_ (3EK_\ &Z/^
M%!_ O_HBWA+_ ,)RU_\ C=']@Y7_ ,^(?^5?_EH?4L=_T$R_\!A_\B?.5QXX
M\0W=O):W/PHU1XY4*2(SQX92,$'GTKP[Q'HM[H&KRV%[IT]KSNBBN0-X0GY<
MXX/'<>E??W_"@_@7_P!$6\)?^$Y:_P#QNO(OVQ?V=?"-K\.5\;_#CP9INE3:
M-*7OX-*L(X%FMVP&9EC4;BA"G/92WI7UW![P^3XYTJ<8QA4LG;GW7P_%.2ZV
MVZ^1\MQ7D6)Q67.NZKG*GJDU%:?:V2]?D?-'@+PK-XR\4VNAH"(W??<N/X(A
MRQ_H/<BOI&""&U@2VMXPD<:!8T48"@#  JQ^Q[^SIX0G^&Q\:_$?P7INJSZU
M()+&'5=/CG$%NN0K*)%(4N2S9'5=M>M_\*#^!?\ T1;PE_X3EK_\;KS^.L+4
MX@S*,(UN6G2325K^\_B>Z\E\O,[>#,I_L_*U6FO?JZ^D?LK]?F>/T5[!_P *
M#^!?_1%O"7_A.6O_ ,;H_P"%!_ O_HBWA+_PG+7_ .-U\-_JA_T__P#)?_MC
MZ\\?HKV#_A0?P+_Z(MX2_P#"<M?_ (W1_P *#^!?_1%O"7_A.6O_ ,;H_P!4
M/^G_ /Y+_P#; >/U:A_X*$_L6_"2)?AS\2/VA] TC7-*'E:AIMT\GF0.?F ;
M"$?=8'KWKU;_ (4'\"_^B+>$O_"<M?\ XW1_PH/X%_\ 1%O"7_A.6O\ \;KU
M,IR+^RZ\JGM.:ZMM;JGW?8#@_ /_  42_8F^*/C+3OA]\/\ ]HSP_JNM:M<B
M#3M.MGD\R>0]%7* 9X->T5S>D_!KX0:#J,.L:'\*O#=E=V[[[>ZM-"MXY(F]
M594!4^XKI*^@ **** "BBB@ HHHH ***^4OVL/@W^VQ\;_COIWQ/_8)_X*7>
M'O!#^"M.6Q\1_"O6/!EMKNDZK=F61RU^Z7*7%H61E3$8#@194@DT ?5M%5/#
M_P#;W]@V7_"4FT.I_9(_[2.GAO(\_:/,\O?\VS=G;NYQC/-6Z /"_P#@GO\
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M;QR2A6E;&=J@_>. 3@>E34 ?0/A__D V/_7G%_Z *MU4\/\ _(!L?^O.+_T
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M(1,4FG2&)U1@,2%CD+0!]KT444 >%_\ !/?_ )(GJW_8]ZS_ .E)KU?XF?\
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M&/\ 1/+K]R/ '_(Z:9_U^)_.LZE!T\?2FW>\DMK;-;:OW=;1?D![I1117Z<
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_P A"?\
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MU_%*R.JZS:VEM9:;X?T<$S:_KMQMBM]/M5P69YKA@HP"57<Y&%-? 7_!5/\
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M#_%MFE09[<BNH_;]OW^('C;1_P!@3]GJVM]&\=_&BVDG^(GBO1[2..\T'P9
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MBK#(P0RDJ>ZTJRGTW2[;3KG4[B]D@MTCDO;L();AE4 R/Y:JFYB,G:JKDG
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MY84 ?J%1110!X7_P3W_Y(GJW_8]ZS_Z4FO5_B9_R(NH_]<1_Z$*\H_X)[_\
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MJUU<S7"L/'&LKB*<J,?:6["O5?'WA/3;#P??7D-Q=%DB! >Y9A]X=17)C_\
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M'_/S>_\ @6U 'B.H_P#(0G_Z[-_,U#4M\H2]F09P)6 S]:BK\9G\; ****D
MHHHH **** "BBB@ HHHH **** /H'P__ ,@&Q_Z\XO\ T 5;KG=%\&:5/HUI
M,]S=@O;1L0MTP'*BK7_"#Z1_S\WO_@6U?L='^#'T0&Q16/\ \(/I'_/S>_\
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M,P<\*:\@_P"&1O\ @Y;_ .DMWP?_ /#,VW_QBO1_V1_V=/\ @N)X$_:$\/\
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M** "BBB@#YYU'_D(3_\ 79OYFH:FU'_D(3_]=F_F:AK\9G\; ****D HHHH
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M !='_"I?B#_T+_\ Y-Q?_%T?V;F/_/F?_@+_ ,@.<HKH_P#A4OQ!_P"A?_\
M)N+_ .+H_P"%2_$'_H7_ /R;B_\ BZ/[-S'_ )\S_P# 7_D!SE%='_PJ7X@_
M]"__ .3<7_Q='_"I?B#_ -"__P"3<7_Q=']FYC_SYG_X"_\ (#G**Z/_ (5+
M\0?^A?\ _)N+_P"+H_X5+\0?^A?_ /)N+_XNC^S<Q_Y\S_\  7_D!Z]X?_Y
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BH-5U73-"TRYUO6]2@L[*S@>>[N[J98XH(D4L\CNQ
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M/["WA/XN_$NS2S\>:7+=^&OB3IZ*%^S:_ILS6MY\J\()&C$X4<*LZCM7TI0
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MB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPW=^R'_T7C1/^^I/_B* /6J*\E_X;N_9#_Z+QHG_ 'U)_P#$4?\ #=W[(?\
MT7C1/^^I/_B* /6J*\E_X;N_9#_Z+QHG_?4G_P 11_PW=^R'_P!%XT3_ +ZD
M_P#B* /6J*\BF_;S_9!MXFFD^.^CD*,D(LK'\ $)-.7]O#]D-U#CX\:+@C(S
MY@/Y%* /6Z*\E_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/_B* /6J*
M\E_X;N_9#_Z+QHG_ 'U)_P#$4?\ #=W[(?\ T7C1/^^I/_B* /6J*\E_X;N_
M9#_Z+QHG_?4G_P 11_PW=^R'_P!%XT3_ +ZD_P#B* /6J*\E_P"&[OV0_P#H
MO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_P"(H ]:HKR7_AN[]D/_ *+QHG_?4G_Q
M%'_#=W[(?_1>-$_[ZD_^(H ]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA
M_P#1>-$_[ZD_^(H ]:HKR7_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\
MOJ3_ .(H ]:HKR7_ (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^^I/_ (B@
M#UJBO(8/V]?V0+E#)'\=M( #$?O$F0\>S(/SJ3_AN[]D/_HO&B?]]2?_ !%
M'K5%>2_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\10!ZU17D
MO_#=W[(?_1>-$_[ZD_\ B*/^&[OV0_\ HO&B?]]2?_$4 >M45Y+_ ,-W?LA_
M]%XT3_OJ3_XBC_AN[]D/_HO&B?\ ?4G_ ,10!ZU17FOA/]L+]F;QSXCL_"/A
M+XQ:3?:EJ$PBL[.$OOE<]%&5QFO2J "BBB@ HHHH **** "BBB@ HHHH R=8
M\!>!?$-Z=2U_P7I-]<%0IN+S3HI7('0;F4G JK_PJ;X5_P#1-/#_ /X)H/\
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MKD]S@"K- '/_ /"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\
M$5T%% '/_P#"IOA7_P!$T\/_ /@F@_\ B*/^%3?"O_HFGA__ ,$T'_Q%=!10
M!S__  J;X5_]$T\/_P#@F@_^(H_X5-\*_P#HFGA__P $T'_Q%=!10!S_ /PJ
M;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044 <_\ \*F^%?\
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M>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(KH** .?_ .%3?"O_ *)IX?\
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M>X\G[#Y+>?YF>-GE[\^V: /'_C;^VIXDLOV5_"_[2G[$'[/FJ_M OXZEL?\
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M>/>68A G[*:5I6F:%IEMHFBZ=!9V=G D%I:6L0CB@B10J(BJ %4   #@ 8H
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MS\._&WP\\67/ACXE_#[Q%/'+<:#JL !>,3( L\)!.V4*NXH_RC;S>_X*'_\
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M_P"(O#6EWTCR7>EV&I-<J#$_FS!99(_,C$I(RPW-^D]% '&?L[? /X9_LL_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>_%CQQX
MH\,^(H;#1-4\B)[)9&3R$;+%W&<LI/0"N8_X6U\0?^A@_P#)2+_XBM+XZ_\
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M*'39O$>@7BE0;NTA ACN+>;9$S1@*^3D?+N< ^[:*_(#]@KQ'_P6U_X*+?\
M!+'1/VZ;_P#X*8KX%\11:-K-SX2T?1_ACHLL?B.2QN[I!/JSO %3S)(6MUBM
MXXT2&*.5A*[M70?"7XJ?\%>?^"A__!-:V_X*>^!/VY=-^#=_%X'O-6\*_##P
MQX"T_4-.U.;34ECGFU&ZOEDE_P!,N+6<I%%A+:&2('SG5V(!^K]%?FO^T9_P
M6K\<>%/^"3G[/W[4?@V;P=X3^(_[1=[H?A_3M:\8W0@\/>%+RZC8ZAJMTTK@
M?9+;RI64._\ '&6W ,#Y!X__ ."COB_]@G7O GQNT3_@O/\ #']JG0M2\::9
MHOQ/^&)N/"T=\+*]G$,FJ:0ND2>?&UNSJYMV\R,IN+,-N0 ?L/7)^#/CI\'_
M (B?$?Q=\(? WQ$TO5/$_@*:SB\9Z'9W(>XT=[N$SVRSK_ 9(@77U S765^.
M7[&G[*_[=WCG_@K5^W-H7PN_X*D^(? ^JZ1XG\%OXAUVT^$_AV_?7DN-'FEM
M$>*ZMVCM_LL/[A3$%,H^>3<W- '[&T5\&_\ !4CXOVGPH^+=@?B;_P %S-,_
M9I\.WNAQ'2? FF>&-%N-6OK@/*'OWFO4FG: G:@2.)$!B;+DMA<K_@BQ_P %
M"/B%^V\GQZ_9C\5_M4Z/\5+_ .$.KZ;:^'?CMX-T&WL/[?TS5;.:6UN6M&C:
MV2\MY+>>-P(S$7C *. 6< _0>BOR;\2_\%:/^"@'[--OXF_X)6_$_P &S>._
MVQ=0\0II?P1\7P>'8K72/&&B7QG>#Q/<)!&+>V6QBBF%S"%V;X%'S 3M'^FO
MP#\&_%#X??!GPWX-^-?Q>N/'WB[3]*BC\2>,;G2K6Q.JWF,RRK;VD4<,*;B0
MB*N0BJ&+MN=@#KZ*^ /^"MW_  4:\9?!/]I;X5?L#_"G]JKP%\"-0^(6E7_B
M#QG\9_B%+8^1X:T:V/EQQV<5_(EM->7,P>-!*2J"-CM;.4\T_9J_X*'>)?@/
M_P %#?A5^R=%_P %7O ?[6OP^^-$6IV$5_IE]H,FO^"M9M+;[3"TS:.P2:SN
M@KQCS$W*XX8!2' /U*HK\W?VIO\ @I_^T%_P2#_:8\;:3^W')KOQ.^$_Q$L+
MC5OV>M>T+PW;QWUIK4:C=X.N190(K&1F5K:YD4N4)WO*0_EZ_P 7?C!_P4X_
M97_X(B_%O]K?]I+XWV]M\<W\/77BC2M.T[PWIGV+P&LTL9M](A3[.5N_(C;:
M\ESY[-(S#>X56(!^A=%?EQXML/\ @M?IO[ $'_!3ZU_X*!V4?C+2OA[%XYN_
M@8WPYTP^&[C2X[,7DNERW 07;7;6X8O<)(H\\LD:QQE67<_;@_X+,ZI/\#_V
M6]'_ &>OC+X*^#>M?M4Z1_;4OQ-^)=S:G3O .C06$-W>2NMT\=O-=[YTMX%E
M;RY)%9<992 #]*Z*_)[X>?\ !1+Q/^RA^V;\%OAII?\ P62^'_[6_@/XQ^,8
M_!WB#0K6\\.OK_A;5+F-C9ZE;G1F!>S>91%(DR%8MR[6+.,=G!\5?^"G'[7_
M /P5K_:M_8<^$G[8\?PT^%_POM_!-U8:]8>!]-O]7TAM0T-;A[&S:>(*1=3-
M/-)/<><\0M4CA""1F4 _2ZBOS]_8,_:S_;3\#?$7]K3]B;]HKQHOQI\;?LY6
M.F:QX(\56^A0Z;>>*K+5-*GOK2QN(+4",3H\*PET4%S+GG&3X=_P3H^.W[2/
M_!1#X<^&OBWH_P#P<(Z?HGQ=UK_2]<^"MCX \-BWT&4.QDTHZ9=(+Z58P#']
MH\S<VTL&)YH _7.BOSH_X*=_\%'O%_AO]NSPI_P3=^'/[;OP_P#V;K*?P _C
M3XA_&3QU/IOG0VK71M;72-,CU.1+9KN5E>1V<,4B&]1E&5L3]AK_ (*&>)O!
M'_!1_P /?L#ZK_P4M\"?M6>"_B9X/U/5?!OC3P_>:*^L^&=4T]1-/IU__9#^
M3+#+;^9+'*Z+(6C90"J$T ?IE1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y1\=?^1NMO^P:G_HR2N*KZ,HKY7&\,_7,5.M[6
MW,[VY;_^W ?.=>]^#O\ D4=*_P"P;!_Z+6M&BNW*,D_LJI*?M.:ZMM;]6 44
M45[H!1110!\:?LJ?LH_'WX;?\%D_VK/VK/&O@+[%X!^)7AOP3:^"M>_M2UD_
MM&:PTWR;M?(CE::'RY/ES*B!NJEAS5S_ ((@_LN?';]D#]B*;X0_M$^!O^$=
M\1-\2/$VJ+IW]IVMWFTN]2FGMY/,MI9(_GC96V[MRYPP!XKZ_HH _+/X7_\
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M'+P/\?K;PI?6\NB?$O1]#N] O=)TY[&6":/4Y(_.64L9%:,D*  <DG;^B-%
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MED^(RN,75E%\VR3=_P 4CHR;B'"9Y*:H0FE'=R22UZ:2>IIT445Y)[P4444
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MTY\?+/PGKM[X8E\06.GWFDWLQNK%+A;8F)H8'224S.L:6ZDS2$_)&U<QJO\
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M%?Q5^&_QP^'.C?%WX0>-=.\1^&?$-@E[HNMZ3<K-;W<#CAT8?B".H(((!!%
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MEFYA)X")Y9)K]F_A-^RY\"?@;\2O'_Q>^%O@;^R_$7Q1UBWU3QUJ/]IW4_\
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M_P!L+0]2^+FB^,+/3/VF]5FF\3:!HJ:7IFH73VL*W=Y;VJ2RI!'(\6["R.I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20210630_g2.jpg
<TEXT>
begin 644 biib-20210630_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#@D,;1?^"P_P#P41B^'Q_XHX>//"3#RL>1_;9L+S^T]N./,\_=YG?.W/-
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MHQ^V9X4\8:/\'/$A\1>#/!GPZ^'!T6&ZUA8C'#>WES-=3RL(PS,(8PJ%CDG
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M4#XQC\+W>IS1^(#HO]GF=;O4+B\"^1Y\VW8)_+SYAW;-V%SM'T)110 4444
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MP=1TV_LY(IY(QW6&YC\EC_>.*^_-6U2PT/2[G6M4G\JUL[=Y[F7:3LC12S'
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M\1^9\*O@7J&F7\TOC#4(3E-?UP6\#QM$N?W-D6('.\8W^> ?07QU_;:_;7^
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M;B275-/N);&YF<=FE>W,V.WF_A7$_P#!'#X':I_P3%_X(L> _#G[1ML=$O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX
M8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)C
MX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]
M4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U
M!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_
M *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX
M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M*UA=H1)AP\;K@LJACN\S$?N/_!1;_@E'^RS^W3X.\4^-_$/P;L9OBM)X!O\
M1?"/C"WU^_TFXAE:";[)%/-8S1M-;K/(&,<@D3!8%&!(/8_L'_\ !/']E_\
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MW8_X)":%?VNIZ5^S/KT4UG,DML?^%Q>+&",A!7Y3JA! ('!&* .@_P""@?\
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M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
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M_P#MP_UZ_P"H?_R?_P"U/ULHK\DZ*/\ B'W_ %$_^2?_ &X?Z]?]0_\ Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!2";4_%7Q8\!^/[/6K/3]3B3Q#IRV\D%SIKRD+&65N)$+<;P>IX'!QYK\/\
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MYR:3<=5*;?23V3N[_*YS8]8:K6@X54UR13=I:.,4NL5NU96^=CT'P7K7P_\
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M_P"0?VMANS_#_,^P**^/_P#AJ3X[?]#U_P"4RU_^-4?\-2?';_H>O_*9:_\
MQJC^R<3W7X_Y!_:V&[/\/\S[ HKX_P#^&I/CM_T/7_E,M?\ XU1_PU)\=O\
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M 'Z!4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4
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M8Q@'WG1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7\_7_!1/_D^;XJ?]CI>_P#H=?T"U_/U_P %$_\
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M:M\+GLIM5T'5UA,5S97=K<SPDQ,S;DF5MJJJ_>9G">%?\$YM?_:M\9?M^?\
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M;XJ?]CI>_P#H=?T"U_/U_P %$_\ D^;XJ?\ 8Z7O_H=?J7A7_P C:O\ X/\
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MF4JK# )!Q74_\$]/^"??@7]@/X7:YX<M/'>K>.?&GCCQ%/XB^)GQ&\2(HO\
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M[>W%I;"W5MEH8\Q!QEB6*1Z7_!6W_E*A_P $]O\ LJ'BG_TU05[E_P $Y/\
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MJO\ E_/_ ,"E_F>D_P##7?[1?_12Y_\ P MO_C='_#7?[1?_ $4N?_P MO\
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M "B6/_QBC_4/./\ GY3^^7_R(?Z[95_)/[H__)'WS_P@^D?\_-[_ .!;4?\
M"#Z1_P _-[_X%M2^ -4OM;\!Z)K6J3^;<WFD6T]Q+M"[Y'B5F.  !DD\ 8K7
MKXN<'3FXOIH?70DIP4EU,?\ X0?2/^?F]_\  MJ_ [_@H1;1V?[;OQ1M8F8K
M'XRO%4NV3]_N>]?T$U_/U_P43_Y/F^*G_8Z7O_H=?J'A7_R-J_\ @_\ ;D?F
MWB;_ ,BNA_C_ /;6>,4445^Y'XL%%%% !1110 4444 %%%% !1110 5^Z_\
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M^E4]?F7BG_R)*/\ U\7_ *3(_1_#/_D<UO\ KV__ $J)] T445^$'[:%%%%
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MF83ZI5POO7NI]+?RGZ?X=8OZW2Q/NVLX];_S!1117Y:?I1^47BK_ )&?4O\
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M&E\6VNNQ%(T#1W45W;HB21ONX#(C@J0RB@#U.BOR _X)IZI_P5I_X*#?LI>
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M22ZQ/\/_ !BWQRL=+2_35K1?A[,R0KJ$D>_]^#Y?S&$)W?OZG;7)ZMIGB_\
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M^!K32_$-N;82^<T;,1;W$8++,BL%0D  8).3^W=_P0S_ &.?VGO$<'Q2\&?
MRSTSQCK?Q.T#6O'NIZ;XQU?1X]8T^+5+>;4VEBLKA(I;J2V68)*4$@D8,LB-
MAQ]'_#/]A[]DWX-?LUZG^R!\*_@;HV@?#C6],O;#6?#.F+)$E]#>1-#<F:4-
MYTLDD;%6E9S(1CYN!@ ^*/\ @I!_P15_X)"?!+_@GI\1OB-X4_9Z\,?"O5/
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MD4<: !5 '04 ;-%%% !1110!Q?[2'_)N_CW_ +$O5/\ TDEK^<>OZ./VD/\
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MV.E[_P"AU_0+7\_7_!1/_D^;XJ?]CI>_^AU^F>%?_(VK_P"#_P!N1^=>)O\
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M$EU?_H4+W_OI:_*NBC_B'W_43_Y)_P#;A_KU_P!0_P#Y/_\ :GZJ?\)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM?E711_P 0^_ZB?_)/_MP_UZ_ZA_\ R?\
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M!_[#5K_Z.6OZ4Z_'/%C^+A/2?_MI^M^%W\+%>L/_ &X****_(3]6/YK/B/\
M\E#U[_L-77_HYJQJV?B/_P E#U[_ +#5U_Z.:L:O[ H_PH^B/Y.J_P 67JPH
MHHK0@**GU+3-2T:^ETO5]/GM;F!MLUO<Q&.2,^C*P!!^M04DTU= TT[,***F
MAT[4+BUEOK>QFD@AQYTR1$I'GIN(X'XTVTMP2;V(:*** "BBB@ HHHH _HX_
M9O\ ^3=_ 7_8EZ7_ .DD5=I7%_LW_P#)N_@+_L2]+_\ 22*NTK^0\7_O=3_$
M_P S^K,+_NM/_"OR"OY^O^"B?_)\WQ4_['2]_P#0Z_H%K^?K_@HG_P GS?%3
M_L=+W_T.OTKPK_Y&U?\ P?\ MR/SSQ-_Y%=#_'_[:SQBBBBOW(_%@HHHH **
M** "BBB@ HHHH **** "OWK_ ."5W_*/SX9?]@6;_P!*IZ_!2OWK_P""5W_*
M/SX9?]@6;_TJGK\R\4_^1)1_Z^+_ -)D?H_AG_R.:W_7M_\ I43Z!HHHK\(/
MVT**** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU=_X*&>,
M?^$ _8R\>^,/[.^U_8=+C?[-YWE[\W$2XW8..OH:I?\ !/?_ )(GJW_8]ZS_
M .E)JE_P51_Y1^?$W_L"P_\ I5!7IY+%2SG#1>SJ0_\ 2D>=G$G'*<1);J$_
M_26?DI_PW1_U2[_RM_\ VBC_ (;H_P"J7?\ E;_^T5\_T5_4G]G8/^7\7_F?
MS3_:.,_F_!?Y'T!_PW1_U2[_ ,K?_P!HH_X;H_ZI=_Y6_P#[17S_ %/IVF:E
MJ]V+#2=/GNIV5F6&WB+N0JEF.%!. H)/H 3VI/+\$E=Q_%_Y@LPQK=E+\%_D
M>\_\-T?]4N_\K?\ ]HH_X;H_ZI=_Y6__ +17S_4ZZ7J;6!U5=.G-JK;6N1"W
ME@^F[&,T/+\$MX_B_P#,:S#&O:7X+_(]Y_X;H_ZI=_Y6_P#[11_PW1_U2[_R
MM_\ VBOG^IQI>IM8'55TZ<VH?:;D0MY8;TW8QGVH>7X);Q_%_P"8+,,:]I?@
MO\CWG_ANC_JEW_E;_P#M%'_#='_5+O\ RM__ &BO 8HI)Y%AAC9W=@J(HR6)
MZ #O3[RRO-/N&L]0M)8)4^_%-&59?J#R*?\ 9^"O;E_%_P"8O[0QMK\WX+_(
M][_X;H_ZI=_Y6_\ [11_PW1_U2[_ ,K?_P!HKY_HH_L[!_R_B_\ ,/[1QG\W
MX+_(^@/^&Z/^J7?^5O\ ^T5ZE^Q+^V%_PF?[6_P\\*?\*[^S?VAXIM8/M']K
M[_+W/C.WR1GZ9%?%M>S_ /!.S_D^;X5_]CI9?^AUP9K@,)'*Z[4?L2ZO^5^9
MW99C\7+,J"<OMQZ+^9>1_0+1117\KG],G%_M(?\ )N_CW_L2]4_])):_G'K^
MCC]I#_DW?Q[_ -B7JG_I)+7\X]?M?A1_NF*_Q1_)GX[XH?[UAO\ #+\T%%%%
M?K)^6A1110 4444 %%%% !1110 4444 ;/PX_P"2AZ#_ -AJU_\ 1RU_2G7\
MUGPX_P"2AZ#_ -AJU_\ 1RU_2G7XSXL?Q<)Z3_\ ;3]>\+OX6*]8?^W!1117
MY"?JQ_-9\1_^2AZ]_P!AJZ_]'-6-6S\1_P#DH>O?]AJZ_P#1S5C5_8%'^%'T
M1_)U7^++U85]%_L6_ ;X;^-?A#\4/V@/'GPTU'Q_/\/[;3?[-\!Z9J$UO]L:
MZF='N9VMQYWDPJA8B/&><E0,U\Z5[-^R)\-/VMO$6J:A\0?V/]>NH-?T9HX;
MJST3Q%%::C+#(&;*P/(AN8LH RJ'P=N5[UP9QS?V?*U54]8^\VXJW,KIR5G'
MF7NW6JO='?E-OKT;TW4T>B7,]G9J+T?*_>L]':S.Q_X*-?$;X*^(_C%XM\*:
M!^SM;^'O%ECXHS=>*K'Q)=RK?0"-@\<EI,61'+&,AT*XV$;3G(^A?V=_%/[5
MNF?\$[_A-HW[)/QQ\,>$=3EUO7VUF+7]8TVV:Z0WA$"QK>*Q8[A+]P?4]*E_
MX*+7/BJ\^"7Q4?\ ;"T?P]#K4/B;34^!UV\-I'KD\/F_Z:&\C]XUJ(0?FE R
MQZD^7CY'\$_\$\?VR?B7X+T7XB?#OX(7^N:)X@M_-TS4--N[>1&7>4(<>8#$
M0RD$.%Z9Z<U\AAE@,QR*A&O4A3C3FM:C]I";]GLG-JZ][;[,HM):7/JL0\=E
M^=UI4(2FZD7I!>SG%>TZJ"=G[N_VHR3;UL7?VL]&_;'\>?M/:5X%_;)FN_\
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M^"@/B/PO^S!91^(DLK"/3M 6._BC%]#86JI*\<DC*C@LLK+@_.N",Y KT?\
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M1_#/_D<UO^O;_P#2HGT#1117X0?MH4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)JE_P51_Y1^?$W_L"P_P#I5!5W_@GO_P D3U;_ +'O
M6?\ TI-4O^"J/_*/SXF_]@6'_P!*H*]7(_\ D=X7_KY#_P!*1YF=?\B?$_\
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M<VGPQO*R;2TE?7;@_P!C+5KWX'?L/?%W]JSX7:=;-\0-)UK2]%T[6Y+5)Y=
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M4Z*'&+=[!=I6"BBBF(**** /Z./V;_\ DW?P%_V)>E_^DD5=I7%_LW_\F[^
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M\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU3_XBS_U!_\ E3_[F+_B%O\
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MQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C55_Q%G_J#_\ *G_W,G_B%O\
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M19_Z@_\ RI_]S#_B%O\ U%_^4_\ [<_%FBOVF_X<A?LF_P#11OBG_P"%L?\
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M;EMJG?:1\[Q/P[_K'A84?:^SY97OR\U]+=T?BS17[3?\.0OV3?\ HHWQ3_\
M"V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5?<_\19_Z@_\ RI_]S/B_^(6_]1?_
M )3_ /MS\6:*_:;_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
M&J/^(L_]0?\ Y4_^YA_Q"W_J+_\ *?\ ]N?BS17[3?\ #D+]DW_HHWQ3_P#"
MV/\ \:H_X<A?LF_]%&^*?_A;'_XU1_Q%G_J#_P#*G_W,/^(6_P#47_Y3_P#M
MS\6:*_5C]D__ ()-?LY?&/X;W_BGQ5X]^(T5S;^)]1L(UL/%[1H8H9BB$@QG
MYL#DYYKT[_AR%^R;_P!%&^*?_A;'_P"-4?\ $6?^H/\ \J?_ ',/^(6_]1?_
M )3_ /MS\6:*_:;_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\
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M)>6<&I>+C+;O(AR!(GEC>OJ,\U]25\(?;A1110 4444 %%%% !1110 4444
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MJ%Y/X:U&6P\4ZEH/@+6M1T_1KB-]CI<75O:/$"K9!VLV,'.* /M2BN/\)_M
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MGXAD:/3_ !#874:Q:AI%Q(N#&)XD"K)G"Y=<H)3(GS)^WE_P6%_X*$Z9\-M
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M]FM8FD1&9F<LK(C@MM,;?IA86%EI5C#IFFVD<%M;1+%;P1(%2-% "JH'
M ]J /%;;]C7[/_P4CO?^"A'_  L?/VOX'VWP\_X1'^Q_N>3K$^I?;OM7G<Y\
M_P KR?*XV[O,.=H;^V;^TS^RW_P3K_92U_XL_%S1M,L/#$"2VUCX3TO38O,\
M0ZC<[RFG6ULJXGGN7+ KM(P7=\*KL/<:_'Z^\#_\%B_''_!1K5?VU?VK_P#@
MD)JOQ5LO ^ISVO[/OA.P^.GA?3]$\*6N\C^U#;SW+O<ZC,JHWGR!#'_"BE8A
M$ ?5'_!!K]C7XF?LK_\ !+;PW\%?VE/!D&GZEXEO=6UO4O =Y$)8-"L]2N'E
M32G1P00L3CS(V'#RR(<X.?.=3\)>%?!'_!SSX \-^"_#.GZ1IUO^Q??""PTN
MRCMX8Q_PD<O"I& H_ 5]F?LY?%_]I'XH?!"[\?\ Q[_9"O/A?XPAGNDM? %U
MXWT[5Y+A(T!A<7EFQ@7S6)4 G*8RW!K\X]?O/^"S6M?\%7M!_P""DJ_\$4-8
MCL=&^",_@)O"9_:!\)F66234WO?M8N/M. H#;/+V$Y&=W:@#];Z*Q_AWKGBK
MQ-\/]"\2>._!$GAG7-0T>UN=9\-RZA%=MI-W)$KS6AGA)CF,3EHS(AV/LW+P
M16Q0 4444 %%%% !7X^_M^M^UM_P1N_:HUG2?^">>B:5>>%?VU==31?"OAW4
M+];>V\#?$JZEB@.K0HP*_9[B&1YFC *^= -VU$1'_8*OBC_@K?\ LC_M"?M.
M_&K]D?Q;\#OA]_;FG_#']I#1_%/CFX_M:TMO[-TF @RW.VXE1IMO_/.(/(>R
MF@#VK_@GG^P]\.O^">O[+&@?LX> ;R74KFUWW_BSQ->9-UXBUJ?#WFHW#,2S
M/+)TW%BJ*B9(05\N_L-_\K#7[<W_ &)_PW_],]?H?7QI^RI^RC\??AM_P63_
M &K/VK/&O@+[%X!^)7AOP3:^"M>_M2UD_M&:PTWR;M?(CE::'RY/ES*B!NJE
MAS0!Y7_P5:_Y3:_\$X?^Q@^(W_IITZO:_P#@MI^R-\$_VKO^";OQ;M_BGX0T
MZ?5?"?P_U?Q!X0\136RB[T34K&TDNH)X)\;XAOB57"D;XV=3P:\K_P""P7[/
MW[;/B?\ ;H_9$_;"_9!_90G^+=M\%-1\8W7BO0K;QMI6B.!J%GI]O;*)=0FC
M!W&.=LHKX\K#;=RDX'[4=I_P6U_X*=?";5?V/)/V+/#7[,'@CQI;'3/B!X^\
M4_%2P\3:G)I$N%NK:PL]+!022QEHR9I K([KF,D/0!].?\$B_CAXZ_:1_P""
M9/P.^-?Q.U*6^\1:Y\.M.?6M0G8F2]N8X_)>X<GJ\AC,C'U<UN?&[]C7_A<G
M[;7P+_;&_P"%C_V;_P *6T_Q9:_\(Y_8_G?VS_;=I:6^[[1YR_9_)^R[L>7)
MYF_&4VY/H'[/_P $? G[-/P,\(?L]?#"RDM_#W@GPW9:)HT<SAI/L]M"L2,[
M #<Y"[F;'S,2>]=?0!P7Q@^)W[/O[('PG\7?M#?%75=#\&^&-+BDU?Q9KK6R
M0B5\*OF2;%W3S.0D:C#2.Q1%!) KX!_X)(^$/BU\%/V+?VJ_^"A'_"M;CX?:
M;\9/%OB7XD_##P!?6XBDTO2TLI'M+J:$#;#+<%1(4 QL6-APP Y7]OCX4?\
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M1110 4444 %%%% !1110 4444 %%%% !6!\3?A1\+?C7X0G^'OQD^&N@>+=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSA^TG\'OVM/A-8_&_P"!'B&^U3PUJ4\\5G>ZCX?OM+E=X96BD!M[Z&&=,.K
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MX4W&I3^ =7_M.ZA_LN2_MA;79\J*58I_,A4+B9'"XRNT\T ?('_!/#_E.O\
M\%%?^Z1?^HQ<TG_!L,RK_P $:_AW:,P$MOXE\5QW$1/S1/\ \)#J!VL.JG!!
MP>>17V!\._V7/@3\*/CM\1?VE_ '@;[!XV^+/]D?\+ UO^T[J7^U?[+M6M;'
M]S)*T,'E0NR?N4CWYR^YL&O+?AU_P2+_ .">WPB_:./[6'PM^ <OAWQLVMW.
MKM=:-XQUBWL&O;A'2:8Z:EV+$EQ(V08,9(.,@$ 'YX_\$ ]-_P""K.K_ +$6
MK7W[/GQ/_9KL=6E^*'B0_%&S^(G@;7;SQ)'XD-_)]I_M*:TU.&-Y2GDE/W:D
M1&,')!8T?V\_V(?C?^P7_P $0/C%\-?C;\1_#.L^'O%G[3&F^+?&6G_#;3;J
MSTSP]X>U'5-.DN]-MX9Y))(;=+A1(J;SA9@"3DFOT#^/G_!&#]@O]H'XR:I^
MT'J7@CQ-X1\9^( H\3:_\-O'FI^'I-; & ;M+&>..9N3F0KO;/+&O3/@Y^P5
M^R5\"/V<=5_9*^'WP=M/^%?:]]L/B#P_K=]<ZHNJM=KMN7N9;V266=I !N+L
M>@QC H ^/?\ @YSM/V>?^'%/CI=8BT-;"$^'O^%:_8Q%Y:WGVZV%O]AV_+C[
M(;@?N^/(\W'RYK] ?A-_R2OPS_V+]E_Z(2OD;2O^#>?_ ()56WA:[\!>)O@?
MXA\3>'I+!['2= \4_$K7;VTT"V9U9H]-1[S-B3L53)$5DV;DW['=6^T=)TJP
MT/2K;1-*@\JUL[=(+:+<6V1HH51DDDX ').: /F?]NS_ ()??L(?\%)?%FFW
M'QUTFXA^(/@JS3^QO%O@SQ,^F>(-%MYF=D'F0MGRF82L@E1U#&0H 2Q/R=^S
MJ?VD?^"9'_!9KX:?\$WM._;<\>?&WX5_%WP!K.K_ -B_%/54U36_!<MC#--%
M/]L 5S;RF PHNU$)=ALR@:OK[]KG_@DK^P]^VQ\3[/XZ?&?X>:S;>/-/TQ-.
MLO&OA+QEJ6BZC%:([NL)DLYXU=0SL1O5B,\8JY^QO_P2O_8D_81\6:Q\2O@%
M\*[D>,?$-L+?7?''B?Q!>:SK%[#E3Y1NKV61T0E$)2/8K%%+ E00 >#?\$1G
M1?C[^W-:LP$J_M>:X[1D_,%:UMMK8]#@X/?!J'X>_M'?\%&/^"AG[3?QQ\&?
MLD?';X;?!3P#\%_B5/X)N+S6OAU)XFUW7]4MH(S<W,L37MK#!;$LBQ$99@C9
M)VXKW?XB?\$DO^"?7Q1_:3/[7GBGX"20_$.34[+4;OQ!H7B_5]*%[=6A4P37
M-O97<5O=,NQ03+&^X##;@2*POCQ_P1;_ & ?VA_CAK7[0?C/X>^(]*\0^*XH
MHO&__"&^/=5T2U\3I&NU5OX+&XB2X^7@M@,P/S%J /BW_@DAJ>H7O[#G_!0_
M0O\ A:.E^-(;3XN^/-OB'P[HJZ=IVIW+Z)&+BZM;1)94@BED4N$21UP003G-
M?1'_  3INOB*O_!N1X(N?@H\[^+X_P!FR[_X17["29?[373K@6P3;SO$X0#'
M.?>OJ']FK]B+]E3]CW0_$_A;]FOX,Z;X4TKQCK']I^(=)L9II+2XN/L\=ME(
M99'C@C\F&-/*B5(P%^[DDGB/V8/^"37[ ?[&/Q3E^,G[,?P-N?"6M26US;B*
MS\::S+I\,4[AY5BT^:\>TA!8 C9"NWG;C)H ^$_^"*W@O_@I?XM_X)1_#'1_
MV4/B)^R))\.=1\-3076E>(OAUX@O;U[F221;^'4FAU5(IKDRF59?W:JV>%"D
M"O2_"/\ P10^-NA_\$U/@I^RAI'[76@:?\4_@'\49_&OPX\6P:$]]I N8KR]
MDCL)K2XD\QX(UNVBSN+Q&-<9 VGVOXB_\$*?^"=7CWXCZY\3M'\ ^+?!5[XJ
MO7N_%=A\./B/K&@6&LSO]^6>TLKF.'<W5BBH6)).22:['Q]_P24_8+^(7[.7
M@S]E6_\ @[>Z;X.^'5_-?>!8/#_B_5;"\T6ZE,IDGBO(;E;AG<SS%C([[C(2
M<T >1?L[_M\_MY_"_P#;T\&_\$[O^"E7P=^&<NN_$3PSJFK_  _^(OP=U2\:
MPN_[/C\RXAN[*^!FMG,>3Y@<H7PJA@24^[J^=?V3_P#@E?\ L<?L<?$J^^-W
MPQ\(:[K'CS4--_LZX\<^//&&H:_JJ66[=]FBGOII#!'D9*QA=V!NS@5]%4 %
M%%% !7SI_P %,_\ DB&C?]C7#_Z37-?1=><_M,_ '_AHOP/9^#?^$L_L?[)J
MJ7OVG[!]HW[8I$V;?,3'^LSG/;IS7JY)B:.#S:C6K.T8N[>K_+4\W.,/6Q66
M5:5)7E):+_AS\V:*^MO^'6O_ %73_P MC_[IH_X=:_\ 5=/_ "V/_NFOU?\
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M  ]UG^UKN#^RI+^&.&[/E0RK%/YD<,:XF20+MRNTDD@'YG:A^SQXF_X)<_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20210630_g20.jpg
<TEXT>
begin 644 biib-20210630_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
M!0K4_P#@IK^R:G[3&M? U_AU>+XIU+1+OPO+XA_M-K>6SE$;,9_L\&23GY?+
MXQU-?G+^RG\0OB)^V9XU_9R_X(G_ !8>XOM8_9@^(>K:C\?9I(F6.^TOPG,D
M'AO(;(F@O'NK!F!)W?9RW/2L#X!?M1_%/]CC_@U^^/\ \>?@GK%SIGBFR^+7
MB+3=)U>T.V73FO\ Q%;6#W*,.4DCCN79''*R!"/6@#]Q8-=T2ZU6;0K;6;22
M^MT#SV<=PIEC4XP60'('(Y([U:K\G/V\O^")O[&_[%?_  3&\4?M'_LTV&H>
M%?C?\'/"3^+]'^-UAKUT-<U+5K-!<7$US,TI$ZW6V56B8&,>=\JC %9?[?NF
M7'_!0?\ :-_X)=W7Q"US5?#P^*?A_P 2ZQXG/AG49+*<P7/A?3KR\LHYHR)(
MDFC,MLS(RN(YFVLIP0 ?K=INM:-K)G&D:M:W1MIC#<BVG63RI!U1MI.UAZ'F
MO'?@W^VYX+^,W[:/QF_8IT?P;JEGK/P6L?#MSK.L7,D9M=075[1[J$0A27!C
M5"K;@.3QFOAWXC?L=?L[?\$N?^"Q/[(VK?L+^ %^'ND_&-_%GA3XE^&M%OI_
ML&N6UKI:W=G++%)(P\V*<E]XY;"Y/!SP7[-__!)3_@G+\>?^"VW[:GPS^+W[
M*?A_7=!\,6W@75-!TV[GN0EG>:IIMQ=7\RE)02TT_P"\;)(ST '% 'W[X:_;
M5\5:Q_P5&\9?L(:CX6TJW\.^%_@OIOC6+Q 9I!=//<:A-;/"X)V")4C# XSD
MG)Q7T-INIZ;K-C'J>CZC!=VTH)BN+:99$<9QPRD@\@C\*_+?XN_L7?"7]LK_
M (.(?&7PO^.MO>ZEX TG]EK0;S5O!4&IS6UGKLR:S<);1WODLK3V\1+R>0S;
M&D6)F#;,'I/V /@MX$_84_X+?_&K]B3]E^PF\-_"SQ#\#-&\>0^"4O)9K#2M
M9_M!K&26UCD=O)61/F=01N(4<*B!0#]'KKQ+X<LM6AT"\U^RAO[@9M[*6Z19
MI1SRJ$[FZ'H.U7:_!?X9? []C+]D'P%K'A/_ (+Z?\$JOB1KWC>Y\2ZC<>.?
MVJ1I%WXCT/6A->2O!?MJ-C/]HTU1"\*+$D:L/+R0KY4?N9\,M1\$ZQ\-_#^K
M?#368-1\.76AVDWA_4+:Z,\=U9-"C02I(23(K1E6#Y.X'.3F@#Y%_;E_X*C?
MM*_L[_MQ^$OV#OV4OV 8OC3XK\4_#J;Q>&F^+%KX:6VMHKN2VD3_ $JTEC?&
MQ6SYBD[\!>,UVW[)'[4O_!3'XO?%H>$?VK?^"5-I\'O"G]F33'QA#\>=*\1L
M+E2OEV_V2UMHY/GRW[S=A=O(YKY'_P""@WAC]J?Q;_P<3?"72?V/?BKX5\'>
M,/\ AF'4W&L>,?#DFJ6?V4:O-YL?D1RQ-O8E<-NP,'@YK[-_9%^&O_!3[P;\
M2;[4_P!M7]J'X7^-O"LFARQ:?I7@KX>7&DW46H&:$I,\TMU*&B$2SJ4V@EI$
M.?E((!]!ZKK&DZ%9MJ.MZI;6=NK -/=3K&@). "S$#D\5.K*ZAT8$$9!!X(K
M\??^"6'_  3&_9+_ &W_ (H?MG>/_P!KOP)-X^T[3?VW?B#IGA_PCK6J7(TK
M2IO.MY+B^BMXI$4W4RRPQ-*V65+6,(5R^["^#W[3WQ@_80_X(F?MR>$_A!XU
MUF=_V<_CKXJ\ _"74;Z[>YNM$T=[G3[>S"R.2S-:F^ED1FR!L7C:NV@#]1/V
MVOVEI?V8?V1?BW^T!X,ATO6-=^&WP]U7Q##HEW<_))+:V<D\<<P0AT1R@&1@
MX/%;G[)GQ@U?]H;]E?X9_'[Q!I-M87_CGX?Z-X@O;&S9C#;37MC#<O&A8EBJ
MM(0,G. ,U^8O[:/_  1#_8F^!G_!%OQ[\6/ACX?O]+^*N@?!>_U[5?BW!KET
M=8\17+:>9M1CO96E(N(+U#/$\+@QA9\J RJ1@?MQ_''QUIW_  3[_P""=_[%
M^D>'?B'J_A/XT>#M#7XB:%\*9(X]>\0:/IGAZPGDT>W>2XMPBW)G'F8EC8QP
MN QR58 _8_2]=T37/._L76;2\^S3&*X^RW"R>5(.J-M)VL/0\TNJZSH^A6OV
M[6]5MK. N$\ZZG6--QZ#+$#)]*_&B/X&V?PA_:8^"'Q@_P""5?\ P1P_:)^!
M'B+1OB/I>G?$FZU?2-/L]"U[P;.YBU""_2#6+HS2QADFCE:,LK(S%BP3'KO@
MC]FWX/\ _!6#_@L-^TW'^W'X4/C?P?\ L]+X;\+_  Q^'FLW$O\ 95B]]827
M5[J4ENKJDUQ+(N$D8'$9 YV1E0#ZP^#O[;GC/XE?\%.OC)^PKJ'@[2[?0_AK
MX'\.ZYINMP22&ZO)=15S)'("=@5=HV[0#SS7TG7Y;_\ !*K]FGP=^R/_ ,%S
M/VKO@9\--:U.?PKIGPU\'2^&--U74Y;Q]&LIEEE73XY9F9S!"S.L2L24B,:9
M(4&OU(H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#'^(7A3_A// .N>!_M_P!D_MG1[FQ^U>5YGD^=
M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_
M $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4F
MO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^&]?VCO^D>7B?_PX.A__ "16M17@_P"MF8_R0^Y__) 9/_#>O[1W_2/+Q/\
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ME?5E%>^!\N#]O7]HXC)_X)X>*%/]U_'^A@CZ@SY!]J7_ (;U_:._Z1Y>)_\
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M7]H[_I'EXG_\.#H?_P D5[__ ,*E^'W_ $+_ /Y-R_\ Q='_  J7X??]"_\
M^3<O_P 77!_QD7_3K_R<#P#_ (;U_:._Z1Y>)_\ PX.A_P#R11_PWK^T=_TC
MR\3_ /AP=#_^2*]__P"%2_#[_H7_ /R;E_\ BZ/^%2_#[_H7_P#R;E_^+H_X
MR+_IU_Y.!X!_PWK^T=_TCR\3_P#AP=#_ /DBC_AO7]H[_I'EXG_\.#H?_P D
M5[__ ,*E^'W_ $+_ /Y-R_\ Q='_  J7X??]"_\ ^3<O_P 71_QD7_3K_P G
M \ _X;U_:._Z1Y>)_P#PX.A__)%'_#>O[1W_ $CR\3_^'!T/_P"2*]__ .%2
M_#[_ *%__P FY?\ XNC_ (5+\/O^A?\ _)N7_P"+H_XR+_IU_P"3@> ?\-Z_
MM'?](\O$_P#X<'0__DBC_AO7]H[_ *1Y>)__  X.A_\ R17O_P#PJ7X??]"_
M_P"3<O\ \71_PJ7X??\ 0O\ _DW+_P#%T?\ &1?].O\ R<#P#_AO7]H[_I'E
MXG_\.#H?_P D4?\ #>O[1W_2/+Q/_P"'!T/_ .2*]_\ ^%2_#[_H7_\ R;E_
M^+H_X5+\/O\ H7__ ";E_P#BZ/\ C(O^G7_DX'@'_#>O[1W_ $CR\3_^'!T/
M_P"2*KR_\% /VFXY"D?_  3&^)5PHZ36>L6,\3?[LD;,K#W!-?0__"I?A]_T
M+_\ Y-R__%UN:9IEEH]A'IFG0>7!"N(TW$X&<]22:ZL)_:OM']:Y.6VG+S7O
M\^@'SU\+/VU/V@?'_P 0](\&>)O^">WQ$\,6&HW8ANO$&J7=LUO8H0?WD@7D
MJ,=O6OHRBBO0 **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?
M_2DUZO\ $S_D1=1_ZXC_ -"%>4?\$]_^2)ZM_P!CWK/_ *4FO5_B9_R(NH_]
M<1_Z$*Y,?_N-7_#+\F!XA1117Y$ 4444 %%%% !1110 4444 %%%% !6QX _
MY'33/^OQ/YUCUL> /^1TTS_K\3^==."_WRG_ (E^: ]THHHK]? J>(/^0#??
M]><O_H!KY^KZ!\0?\@&^_P"O.7_T U\_5\/Q=_%I>C_0 HHHKX\ HHHH ***
M* "BBB@ HHHH **** )M._Y"$'_79?YBOH:OGG3O^0A!_P!=E_F*^AJ^VX1^
M"MZQ_4 HHHK[(#YYU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI
M **** "BBB@ HHHH **** "BBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/
M_7G%_P"@"K=?L='^#'T0!1116H!1110 5QGB_P"/'P_\$?&;P?\  C7KJ=-?
M\<6.J7>A(D0,31V MS/O8D;3_I,>T8.[YNF*ZO5EU-]+N4T62%+PV[BT>X!,
M:R[3M+ <[<XSCM7\Y_PIT7_@GC\._CA\+_!'_!=+X'>*=!^+-S)XUC^.?C;X
MQ:9JLUKXDU&6ZM3I-U8:C"6C-HD7F+&\!CCB.<G#J[@']&MQ<6]G;R7=W.D4
M42%Y99&"JB@9))/  '>O-?V7OVM?A#^UU\"HOVE/A/=7T?@N\N[^/2];UJV%
MI'?VUI/) ]]%N8G[,[1.R2/M+( ^ ""?DK_@L7\6?!_[+'_!OUX]U7]D#Q.E
M_P"'3\.])\*^!=6TW76U%9=,U&YM-+26.\:1VG_T6X8K,79F(#;B>:I_\%MM
M'D_88_X-T_B-\+O@Y/\ 8+?PE\-?#_@RS>U;9_H4]]IVDSC(&?G@GE!/4[SG
MK0!Z9X _X+T_\$KOB9\6=.^$7A3]IH//K>MG1M \1WGA?4[;0=5U$,4^RV^J
M2VZVDKE@54B3:Y&$9LKG["KX/_X*=?LH_![1?^#?7XA_L^Z=X8L(]!\ _ G[
M9X=CAA7%O<Z39+=6\\9QD.9+<$N/F;>V2=QS]'_\$\_B1XH^,G[ ?P-^+WC>
M^:ZUKQ5\'O#.L:O<NV6FNKG2K:>5R>Y+NQ_&@#V&O%/V3_\ @HK^QC^W)XS\
M?^ /V4OC?:^,M3^&&I06'C9;'2KV&&RGF>YCB$<\\*172LUG<8DMWD0B,'=A
ME+>1?\%/OC9\1OB;XL\+_P#!*[]EGQ-<:;\1OC'8S7'C'Q1IS?O? W@B-Q'J
M.K$C[EQ-DV=KG&9I68,IC%>(_P#!&+X.?#C]GK_@K9^WO\#OA#X8@T;PQX4M
M_A-IFAZ9;#Y8+>'P[>(HSU9CC+,<EF)8DDDT ?=GPG_:N^$_QA^.'Q'_ &<_
M#TNHV?C#X6WEC%XGTC5;/R6:WO;?S[2]MR&(FMI5#J'!R'B=6"D8KTJOS]_:
M[U&7]GW_ (+_ '[*?Q/\-_ND^-_P\\8_#_QBJ' F@TR&+5K!V7.&<7$K*&QD
M*6&<'%?H%0 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM
M_P!CWK/_ *4FO5_B9_R(NH_]<1_Z$*\H_P"">_\ R1/5O^Q[UG_TI->K_$S_
M )$74?\ KB/_ $(5R8__ '&K_AE^3 \0HHHK\B **** "BBB@ HHHH ****
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MTNK7OEK']IN7C4&>78B)YCEFVHHS@"MR@ HHHH **** "BBB@ HHHH ****
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MJ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KU?XF?\ (BZC_P!<1_Z$*\H_
MX)[_ /)$]6_['O6?_2DUZO\ $S_D1=1_ZXC_ -"%<F/_ -QJ_P"&7Y,#Q"BB
MBOR( HHHH **** "BBB@ HHHH **** "MCP!_P CIIG_ %^)_.L>MCP!_P C
MIIG_ %^)_.NG!?[Y3_Q+\T![I1117Z^!4\0?\@&^_P"O.7_T U\_5] ^(/\
MD WW_7G+_P"@&OGZOA^+OXM+T?Z %%%%?'@%%%% !1110 4444 %%%% !111
M0!-IW_(0@_Z[+_,5]#5\\Z=_R$(/^NR_S%?0U?;<(_!6]8_J 4445]D!\\ZC
M_P A"?\ Z[-_,U#4VH_\A"?_ *[-_,U#7XS/XV 4445(!1110 4444 %%%%
M!1110 4444 ?0/A__D V/_7G%_Z *MU4\/\ _(!L?^O.+_T 5;K]CH_P8^B
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M-_P4&^-WQ3^(Z7-G\!M1M(/ ?@F_2*.'3HU\.6]Q:D;561_M]].1EV;) "8
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M_P!=E_F*^AJ^>=._Y"$'_79?YBOH:OK^$?@K>L?U ****^R ^>=1_P"0A/\
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MGO\ \D3U;_L>]9_]*37J_P 3/^1%U'_KB/\ T(5Y1_P3W_Y(GJW_ &/>L_\
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MUV^F*J>'C2I592C9IQ23=[<UW>ZLGHM.EF!%\<?^"N/QQ^!O[3_@OX*^*/\
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M_P#R ;'_ *\XO_0!5NOUFC_!CZ( HHHK4 HHHH **** "BBB@ HHHH ****
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M_P#R;E_^+KHZ*/[-R[_GS#_P%?Y <Y_PJ7X??]"__P"3<O\ \71_PJ7X??\
M0O\ _DW+_P#%UT=%']FY=_SYA_X"O\@.<_X5+\/O^A?_ /)N7_XNC_A4OP^_
MZ%__ ,FY?_BZZ.BC^S<N_P"?,/\ P%?Y <Y_PJ7X??\ 0O\ _DW+_P#%T?\
M"I?A]_T+_P#Y-R__ !=='11_9N7?\^8?^ K_ " YS_A4OP^_Z%__ ,FY?_BZ
M/^%2_#[_ *%__P FY?\ XNNCHH_LW+O^?,/_  %?Y <Y_P *E^'W_0O_ /DW
M+_\ %T?\*E^'W_0O_P#DW+_\771T4?V;EW_/F'_@*_R 9;P16MNEK FU(T"H
MN<X & .:?1178DDK( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ5?:#]J\C0?'OQ>GU32;KS[66V/GVKQ@2[5F+ID_+(B-_#0!]?T444 >%_\
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M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->K_$S_D1=1_ZX
MC_T(5Y1_P3W_ .2)ZM_V/>L_^E)KU?XF?\B+J/\ UQ'_ *$*Y,?_ +C5_P ,
MOR8'B%%%%?D0!1110 4444 %%%% !1110 4444 %;'@#_D=-,_Z_$_G6/6QX
M _Y'33/^OQ/YUTX+_?*?^)?F@/=****_7P"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DUZO\3/^1%U'_KB/_0A7
ME'_!/?\ Y(GJW_8]ZS_Z4FO5_B9_R(NH_P#7$?\ H0KDQ_\ N-7_  R_)@>(
M4445^1 %%%% !1110 4444 %%%% !1110 5L> /^1TTS_K\3^=8];'@#_D=-
M,_Z_$_G73@O]\I_XE^: ]THHHK]? **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37J_P 3/^1%U'_KB/\ T(5Y
M1_P3W_Y(GJW_ &/>L_\ I2:]7^)G_(BZC_UQ'_H0KDQ_^XU?\,OR8'B%%%%?
MD0!7QE\6O^"WW[%WPW_:*T?X2:9\31KNAV\>L1>.O$/A[PIJVJ0Z/=VOV;RH
MDFL[:2*7)EE$I0OY6Q-Q3<,_8VI6*:GIUQILD\L2W$#Q-+ ^UT# C*GL1G@]
MC7Y)_#_P'^W_ /\ !*3XI?!;X!Q_LR:%\:?"W@'1_&[>"K[X?^(%T_6M5TNY
MGL[FYEN;2Z3:UW#O3$<3-YOF85BREF]'+\/AZ[ESZM;*ZC?1ZW:MI9???H!^
MG\G[0OP>7]GU_P!J:'QK;R^ T\)MXE'B!%81/I8MS<_: & ;!B&[! /;&>*\
MU_9Z_:=_:$^+W["5I^UI>?L\1WGBCQ'HT^N^$/AOI>JK;3W-C*Y?3H);FX)C
M2>6W,4CN0J*9",?+D_,?_!6#]K_P)^U%_P &_/C/]IK]G6_O;;P[XQT[2K96
MNK3RKBQA?7;6SO()HT+!65A-"X!93SM+ @G]"_"V@:-X3\,:;X6\.6Z1:=IE
MA#:V$4>-J0QH$11CC 4 5%2C&AA^:4=7-JSZ**5UTWYM?0#X>^*?_!3_ /;U
M_9,\.1_'#]MC_@F9;^&?A;#>V\/B3Q%X/^*MIK=]X>CFE6))IK5((_/0.ZJ3
M&P +#GH#]T6&K:;JFE0ZYI]]'+9W-NL\%RK?(\3*&5P?0@@YK\T_^"PWPL_X
M*"1?!GQ;\0_CK\4_#'CC]G/1_$RZMXT^%W@VP;0M=O?#L5\LL-NVH2K<"8Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?2]^P'PE\3_^";G_  44_:W\,M\$/VT/^"CND7WPRO+B$^)="^'WPSBTJ_\
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M_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\: /=**\+_X=[_!/_H;?'?\
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M_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\: /=**\+_X=[_!/_H;?'?\
MX65S_C1_P[W^"?\ T-OCO_PLKG_&@#W2BO"_^'>_P3_Z&WQW_P"%E<_XT?\
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M=_XIGFA9L$8=&.&'/0UZ_0 4444 %%%% !1110 4444 %%%% !1110 4444
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MXI\'ZYYHT[5[:WF@W-%(T4B/%.B2PNKHRE)$5ACD<B@#O:*^2?C?_P %TO\
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MO^#<'XEZI^U=_P $;/@OXG^.FEP>(=5\'W=]INE:EK5JMPZ?V?>7%M9W$32
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MPJ1@*/P%?9G[.7Q?_:1^*'P0N_'_ ,>_V0KSX7^,(9[I+7P!=>-].U>2X2-
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MEOO$6N?#K3GUK4)V)DO;F./R7N')ZO(8S(Q]7-;GQN_8U_X7)^VU\"_VQO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20210630_g21.jpg
<TEXT>
begin 644 biib-20210630_g21.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
M!0K4_P#@IK^R:G[3&M? U_AU>+XIU+1+OPO+XA_M-K>6SE$;,9_L\&23GY?+
MXQU-?G+^RG\0OB)^V9XU_9R_X(G_ !8>XOM8_9@^(>K:C\?9I(F6.^TOPG,D
M'AO(;(F@O'NK!F!)W?9RW/2L#X!?M1_%/]CC_@U^^/\ \>?@GK%SIGBFR^+7
MB+3=)U>T.V73FO\ Q%;6#W*,.4DCCN79''*R!"/6@#]Q8-=T2ZU6;0K;6;22
M^MT#SV<=PIEC4XP60'('(Y([U:K\G/V\O^")O[&_[%?_  3&\4?M'_LTV&H>
M%?C?\'/"3^+]'^-UAKUT-<U+5K-!<7$US,TI$ZW6V56B8&,>=\JC %9?[?NF
M7'_!0?\ :-_X)=W7Q"US5?#P^*?A_P 2ZQXG/AG49+*<P7/A?3KR\LHYHR)(
MDFC,MLS(RN(YFVLIP0 ?K=INM:-K)G&D:M:W1MIC#<BVG63RI!U1MI.UAZ'F
MO'?@W^VYX+^,W[:/QF_8IT?P;JEGK/P6L?#MSK.L7,D9M=075[1[J$0A27!C
M5"K;@.3QFOAWXC?L=?L[?\$N?^"Q/[(VK?L+^ %^'ND_&-_%GA3XE^&M%OI_
ML&N6UKI:W=G++%)(P\V*<E]XY;"Y/!SP7[-__!)3_@G+\>?^"VW[:GPS^+W[
M*?A_7=!\,6W@75-!TV[GN0EG>:IIMQ=7\RE)02TT_P"\;)(ST '% 'W[X:_;
M5\5:Q_P5&\9?L(:CX6TJW\.^%_@OIOC6+Q 9I!=//<:A-;/"X)V")4C# XSD
MG)Q7T-INIZ;K-C'J>CZC!=VTH)BN+:99$<9QPRD@\@C\*_+?XN_L7?"7]LK_
M (.(?&7PO^.MO>ZEX TG]EK0;S5O!4&IS6UGKLR:S<);1WODLK3V\1+R>0S;
M&D6)F#;,'I/V /@MX$_84_X+?_&K]B3]E^PF\-_"SQ#\#-&\>0^"4O)9K#2M
M9_M!K&26UCD=O)61/F=01N(4<*B!0#]'KKQ+X<LM6AT"\U^RAO[@9M[*6Z19
MI1SRJ$[FZ'H.U7:_!?X9? []C+]D'P%K'A/_ (+Z?\$JOB1KWC>Y\2ZC<>.?
MVJ1I%WXCT/6A->2O!?MJ-C/]HTU1"\*+$D:L/+R0KY4?N9\,M1\$ZQ\-_#^K
M?#368-1\.76AVDWA_4+:Z,\=U9-"C02I(23(K1E6#Y.X'.3F@#Y%_;E_X*C?
MM*_L[_MQ^$OV#OV4OV 8OC3XK\4_#J;Q>&F^+%KX:6VMHKN2VD3_ $JTEC?&
MQ6SYBD[\!>,UVW[)'[4O_!3'XO?%H>$?VK?^"5-I\'O"G]F33'QA#\>=*\1L
M+E2OEV_V2UMHY/GRW[S=A=O(YKY'_P""@WAC]J?Q;_P<3?"72?V/?BKX5\'>
M,/\ AF'4W&L>,?#DFJ6?V4:O-YL?D1RQ-O8E<-NP,'@YK[-_9%^&O_!3[P;\
M2;[4_P!M7]J'X7^-O"LFARQ:?I7@KX>7&DW46H&:$I,\TMU*&B$2SJ4V@EI$
M.?E((!]!ZKK&DZ%9MJ.MZI;6=NK -/=3K&@). "S$#D\5.K*ZAT8$$9!!X(K
M\??^"6'_  3&_9+_ &W_ (H?MG>/_P!KOP)-X^T[3?VW?B#IGA_PCK6J7(TK
M2IO.MY+B^BMXI$4W4RRPQ-*V65+6,(5R^["^#W[3WQ@_80_X(F?MR>$_A!XU
MUF=_V<_CKXJ\ _"74;Z[>YNM$T=[G3[>S"R.2S-:F^ED1FR!L7C:NV@#]1/V
MVOVEI?V8?V1?BW^T!X,ATO6-=^&WP]U7Q##HEW<_))+:V<D\<<P0AT1R@&1@
MX/%;G[)GQ@U?]H;]E?X9_'[Q!I-M87_CGX?Z-X@O;&S9C#;37MC#<O&A8EBJ
MM(0,G. ,U^8O[:/_  1#_8F^!G_!%OQ[\6/ACX?O]+^*N@?!>_U[5?BW!KET
M=8\17+:>9M1CO96E(N(+U#/$\+@QA9\J RJ1@?MQ_''QUIW_  3[_P""=_[%
M^D>'?B'J_A/XT>#M#7XB:%\*9(X]>\0:/IGAZPGDT>W>2XMPBW)G'F8EC8QP
MN QR58 _8_2]=T37/._L76;2\^S3&*X^RW"R>5(.J-M)VL/0\TNJZSH^A6OV
M[6]5MK. N$\ZZG6--QZ#+$#)]*_&B/X&V?PA_:8^"'Q@_P""5?\ P1P_:)^!
M'B+1OB/I>G?$FZU?2-/L]"U[P;.YBU""_2#6+HS2QADFCE:,LK(S%BP3'KO@
MC]FWX/\ _!6#_@L-^TW'^W'X4/C?P?\ L]+X;\+_  Q^'FLW$O\ 95B]]827
M5[J4ENKJDUQ+(N$D8'$9 YV1E0#ZP^#O[;GC/XE?\%.OC)^PKJ'@[2[?0_AK
MX'\.ZYINMP22&ZO)=15S)'("=@5=HV[0#SS7TG7Y;_\ !*K]FGP=^R/_ ,%S
M/VKO@9\--:U.?PKIGPU\'2^&--U74Y;Q]&LIEEE73XY9F9S!"S.L2L24B,:9
M(4&OU(H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#'^(7A3_A// .N>!_M_P!D_MG1[FQ^U>5YGD^=
M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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MQ3N/@YKGA6T\/ZQ9>";#0X8A?V-W=3A(;5 Q7(B0&620_NL@KN(K] J_._\
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MG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH B2QLHV#QV<
M2L.A6, BI:** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
M2DUZO\3/^1%U'_KB/_0A7E'_  3W_P"2)ZM_V/>L_P#I2:]7^)G_ "(NH_\
M7$?^A"N3'_[C5_PR_)@>(4445^1 %%%% !1110 4444 %%%% !1110 5L> /
M^1TTS_K\3^=8];'@#_D=-,_Z_$_G73@O]\I_XE^: ]THHHK]? **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>=1_Y"$__ %V;^9J&IM1_
MY"$__79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/_ /(!
ML?\ KSB_] %6ZJ>'_P#D V/_ %YQ?^@"K=?L='^#'T0!1116H!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X
M7_P3W_Y(GJW_ &/>L_\ I2:]7^)G_(BZC_UQ'_H0KRC_ ()[_P#)$]6_['O6
M?_2DUZO\3/\ D1=1_P"N(_\ 0A7)C_\ <:O^&7Y,#Q"BBBOR( HHHH ****
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M_D=-,_Z_$_G73@O]\I_XE^: ]THHHK]? **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^>=1_Y"$_\ UV;^9J&IM1_Y"$__ %V;^9J&OQF?
MQL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#_ /R ;'_KSB_] %6ZJ>'_
M /D V/\ UYQ?^@"K=?L='^#'T0!1116H!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CW
MK/\ Z4FO5_B9_P B+J/_ %Q'_H0KRC_@GO\ \D3U;_L>]9_]*37J_P 3/^1%
MU'_KB/\ T(5R8_\ W&K_ (9?DP/$****_(@"BBB@ HHHH **** "BBB@ HHH
MH *V/ '_ ".FF?\ 7XG\ZQZV/ '_ ".FF?\ 7XG\ZZ<%_OE/_$OS0'NE%%%?
MKX!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SSJ/_ "$)
M_P#KLW\S4-3:C_R$)_\ KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%%
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M_-[_ .!;4?\ "#Z1_P _-[_X%M6Q17Z^!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M.6C\Q/E;;D<$5L444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO5_B9_R(NH_P#7$?\
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MXP366H>/_A/\1K^?3Y;/6K:U2T^WZ;>1?(!-#%'YJ3'&Y<J#D;)/V??V5?\
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M110 4444 %%%% !1110 4444 %%%% !7@G_!1?PM^SUXK^!6GVW[3'[:6M?
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M"BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMU^QT?X,?1 %%%%:@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7F_[6GQ&_:(^%'P&UGQU^RI^SE'\6/'-G):C2/ DOBRVT-=05
M[B-)F^V77[J+RX6DEPWWO+VCEA7I%>8?M;^&/VL_$OPH#_L5_%#PIX9\<Z;J
MD5[:IXXT*2^TG6($5P^GW7DLLUO'(65O/AS(AC& 0S"@#X__ .'@W_!P#_TK
MW:?_ .)3>&_\*]$_91_;$_X+ _%3X^Z!X"_:D_X(Y6?PJ\"7_P!J_MWQ[%\?
M=$UMM+V6LTD.+*U'FS>9.D4/R_<\[>>%-<1J7_!6#_@H]\"F/AS]J3_@AW\5
MM1U" [/[;^!VN6GBK3M0QQYT:KY<T"L>1'*-ZCK5G1_VWO\ @L?^UU(/#?[,
M?_!,N#X(:9<';/\ $C]HCQ&A>R4_>,6B6/\ I$TH&2F^18BV QQF@#[YHK'^
M'FC>+/#G@#0_#WCWQG_PD>NV&CVUOK7B'^SDL_[4NTB59KKR(R4@\QPS^6I*
MINVC@5L4 >%_\$]_^2)ZM_V/>L_^E)KU?XF?\B+J/_7$?^A"O*/^">__ "1/
M5O\ L>]9_P#2DUZO\3/^1%U'_KB/_0A7)C_]QJ_X9?DP/$****_(@"BBB@ H
MHHH **** "BBB@ HHHH *V/ '_(Z:9_U^)_.L>MCP!_R.FF?]?B?SKIP7^^4
M_P#$OS0'NE%%%?KX!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'SSJ/_(0G_Z[-_,U#4VH_P#(0G_Z[-_,U#7XS/XV 4445(!1110 4444
M %%%% !1110 4444 ?0/A_\ Y -C_P!><7_H JW53P__ ,@&Q_Z\XO\ T 5;
MK]CH_P &/H@"BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MA$4\DU?J)+&RC8/'9Q*PZ%8P"*EH **** "BBB@ HHHH **** "BBB@#PO\
MX)[_ /)$]6_['O6?_2DUZO\ $S_D1=1_ZXC_ -"%>4?\$]_^2)ZM_P!CWK/_
M *4FO5_B9_R(NH_]<1_Z$*Y,?_N-7_#+\F!XA1117Y$ 4444 %%%% !1110
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M:B]U_6;2QA9PBS7EPL2ECT7+$#/M5I'21!)&P96&58'((K^?KX%?M6?\$O\
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M#>+OA9\+OB]>> /$?B#0+FQT3QMIUG]HGT.YDC*QW<<7F1[VC)#!=ZYQ]X4
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M^MF7?R3^Y?\ R0'M-%>+?\+:^(/_ $,'_DI%_P#$4?\ "VOB#_T,'_DI%_\
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M+3]G']HKXE77Q1\6>(_&NE7MW#%'+9^&O$7V.T&Q<;EB$9 8]6/<DGJ:XO\
MX<A?LF_]%&^*?_A;'_XU65>E[>A*G>W,FOO5@.ZHKA?^'(7[)O\ T4;XI_\
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M-W?V_P#Y+_\ ; =U17"_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\
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M@U+Q<9;=Y$.0)$\L;U]1GFOJ2OH "BBB@ HHHH **** "BBB@ HHHH ****
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MKXMT309=:U*PT[0M1CACL8YX('F6ZFMDMY );F!=J2,QWY (#$?25 !1110
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M4 ?7U%<3^SQ^T?\  S]K'X2Z5\=OV<?B=I?B_P ):TC-I^M:3,6C<J=KHRL
M\4BL"K1NJNI&& -?.OQ*_P""\G_!++X3?%G5?A!XQ_:5(NO#^LC2/$NO:?X5
MU.\T31K\N$^S76I06SVL+AR%;,F$.0Y4@X /L"BH-+U33-<TRWUK1=1@O+.\
M@2>TN[699(IXG4,KHRDAE((((."""*GH **** "BBB@ HHKD_CI\;OAM^S;\
M(/$/QX^,6L76G>%O"NFOJ&OZC9:-=Z@]I:ICS)O(M(I9G5!\S%4;:H9CA5)
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M-7Q%M?%/@_7/-&G:O;6\T&YHI&BD1XIT26%U=&4I(BL,<CD4 =[17R3\;_\
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M$\3^"?@5^T]XE\)>"[?Q# +R)-*MKM)K> B4,&,4Z/,"?NM(I&, UC?M5?\
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M;?L?:;K4>I/X*\/B#4M1A0K'=W\TLES>3(I&0CW,\S*#R%(SSFO;Z "BBB@
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M%XD\=^")/#.N:AH]K<ZSX;EU"*[;2;N2)7FM#/"3',8G+1F1#L?9N7@BMB@
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M1J.RJ !6G10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20210630_g3.jpg
<TEXT>
begin 644 biib-20210630_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Q_B%XK_ .$#\ ZYXX^P?:_[&T>YOOLOF^7Y
MWDQ-)LW8.W.W&<'&<X-?G;^S+_P6*_X*Q_M@? OP]^TC^S]_P0JLM:\'>*;:
M2?0]4E_:ET>U:XCCFDA8F*?3TD3$D;C#*.F>A!K[[_:$_P"2!^./^Q/U/_TE
MDK\H?^"'?PB_X+'>(O\ @E5\'M9_9O\ VR?@WX:\$SZ->G0-#\2?"NZO[ZUC
M&HW0=9;A+Q%D)D#L"%& P';- 'ZX_#OQ!XMU_P"&VA>*?B7X+C\*Z[>Z':W?
MB#P[_:L=ZND7;PJ\]K]I0*DXB<NGFJ K[-P !K3TG6-(UZR74]#U6VO;9R0E
MQ:3K(C$'!PRD@\U^<W_!3?PF_P"VK_P50_9T_P""9'QGUZ__ .%2:AX)USQW
M\0?#6FZA+9Q>+[BT(AM+*X:)E<V\<@,IC#88,<\JK+S'CO\ 9Q^%/_!)?_@L
M)^S':_L,^'Y/!7@G]H9_$7ACXF_#72KV8Z3>RV5C'<V>IQ6[LRPW$;N [J!F
M-2HQYDA8 _4+4M3TW1[*34]7U""UMHAF6XN90B(,XR68@#DU+#-%<1+/!*KH
MZAD=&R&!Y!!'45^1G[)7_!.K]FG]N;_@JW^W%K'[6?A:?QIX=\-_$_18]&\#
MW^I7$>DK>RZ2#)?S012*MQ.(U2.,R9$2M*5&7R/UD\'^$O#O@'PEI?@7PAIB
M66DZ+IT%AI=E&S,MO;PQK''&"Q)(5%49))XY- 'DO[-/[;G@O]IKX^?&KX >
M&_!NJ:=?_!+Q19:)K5]?21F'4);FU^TK) $)8*%X.X YKD_@K^W/XJ^)'_!2
M/X^?L6>(_"VCZ?X>^$'A?PQJNGZ^L[BXNCJ=M)-,)]S;%6,IA2 .,YKX)_X)
MQ_\ !(O_ ()O_%[_ (*&_MD^'?B3^R?X>U:R^'GQ9T:'P7;W$]T%TI)M.%S(
ML>V4$[IOG.[//MQ75:1^PW\#OVW_ /@X+_:M\.?M*:9>^(O!N@^ O ES<>!9
M-2FATS5KQ]/*P3WD<+J;@0*LWEQN2FZ<N5+(A !^KUC?V.J6<>H:;>17%O,@
M>&>"0.CJ>A##@CW%17NNZ)IM[;Z;J.LVEO<WC%;2WGN%1YR.H12<L?I7YC?L
M&Z=X;_X)O?M]_MK?LJ_ #2+R'X6>"OA]H/Q$\(> 6OII[;1[Z;3[F2]AM1(S
M,B7$D:,5SQM4# %?)_[#O@']G#]L']E2V_:6_;K_ ."0_P"T_P#M$?%+XJ+>
M:IXA^+^FZ;ITUL%DN91!#HLCZY ]E;VZ!4C"11E61N H55 /WSKY?_:W_:E_
MX*8_"'XM'PC^RE_P2IM/C#X4_LR&8>,)OCSI7AQC<L6\RW^R75M))\F%_>;L
M-NX'%9W_  12/[6UA_P3_P##?@[]M'PYXML/%OAO5]2TFPE\>!/[9O='BN7_
M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
M!#*SUS0+77KW1I[V7]J+2+0K>6DGE3Q[+C3D<A7XW ;3U!(KZ8_9M_;P\;?&
M#_@H!^T/^R%X\\$:-H.D?!70O!U_::I'>LT\SZOILEW<)<.Q\O;$Z;590 1D
MFO$/^#9/_E'5KW_9</&'_IP->3^"/V%?@9^W#_P7[_;-T/\ :7TF[\2>#/#_
M (>^'4\_@2;4IX=,U6^DT0BWN;N*%T^T&W5)Q&CDH&N6<J65"H!^L-E?66IV
M<>H:;>17%O,@>&>"0.CJ>A##@CW%1ZAK&D:2T":KJMM;&YF$-L+B=4,LAZ(N
M3\S'L!S7YU_\$E/ASX:_8_\ ^"H7[7O[ OP/6ZT[X4>'(/!WBGP=X1EOI9[?
M0+O4K"9[Z.V\QF*QRR*C[<X78H'OXK_P;A?\$O\ ]DKXU?L _#S]KC]H+P)+
MXY\8V'C?6+OP-=:]JER\/A*.QUZY:**PA618H<W44ET[A=SO,0Q*JJ@ _7S5
MM>T/08XY=<UFTLDFD$<37=PL8=ST4%B,GVJW7X/_ +,?B'X,?\% _&_Q<_:S
M_;U_X)5_M!?M+:YJWQ/UO0_"=YH&DZ?>>'O"6@VDWD6^EV,4^L6IAF7!:63R
M@S.P8-N+,W>G]HG]N3_@G#_P1 _:KUVT^&/Q0\!:7X*\816/[.C_ !2,;Z[H
M?AW5[NSM(X6DCGN ?L+7,WDN9'P?+7.   #]F4UW1)-7?P^FLVC7Z1"1[(7"
MF94_O%,[@.>N*M5^%7Q#_8P^ -E^RG=:1^S7_P $8?VQ-$_: T[1CJ/@_P"/
MMW9::NMR>*4C\R/4;N]3Q!)(T4UP/WJA'41R/LCR%Q^S7[+7B+XM>+_V9/AS
MXL^/OAU]'\=ZIX$TB[\:Z3)$J-9:O)91/>0%5X4I.TBX' V\4 =GJFK:5H=D
M^I:UJ=O9VT>/,N+J98T7/ RS$ 5):7=I?VT=[8W,<T,J!HIHG#*ZGH01P17Y
MW_\ !4JX_8:^,W[9?AG]GWQG_P $Y_%?[4GQETKP/_:MKX.TO4H[?2/#FCR7
M3H+N\DO;N"RAEEEW*I97D(0#**5W>:?\$7[OQA^SM_P53^-G[$>C?LP^(O@?
MX"U'X7:5XYTOX/:YXYL]?@T+4#>&TGN+.6SN;B.WBN1(':'?D-$#M51&* /U
M6U;6M&T&U%[KFK6ME"9 @FNYUC4L>BY8@9/I5FOQ_P#^"2?_  2M_9"_;9\$
M?'OXD?MF?#U_B+$G[3GCS3?"V@:UJMTNGZ!;"_S-);012(J7,TK,7N.9-L<*
MJRA.>)\#_M<_'[]D;_@W!_:/'PR^)FK-J_P?^,VN_#'X?>)M2OV>\TK26UVS
ML(9#<'YE>"&^E$;C_5E(@N @P ?J/_P4"_:QN_V1OV+OBO\ M*> +/2->USX
M<>$KG5DT2\NB8VEC7<L<PC8.@/X&O0?@!\1=0^+_ ,!_!/Q:U;3X;2[\4>$=
M-U>ZM;8DQPR7-K',R*6YV@N0,\X%?EC_ ,%4_P#@B#^Q!^R9_P $>?B3XZ_9
M[\+W'AGXA^#/ $D^H?$BVUFY&H^* Q1=0BU)C(5NTO%:7,;@HDCHT878HK]+
M?V(O^3+_ (0_]DOT#_TW04 >._MW?\%+/&7[./Q^\%?L5_LL_LP7_P 8_C5X
M[T2YURQ\+)XC@T;3])T>!S&^H7U[,KB*,R!U1%0EVC9<JQ0/I?LK_M.?\%(?
M&?QGC^%7[8W_  3AT_X?Z)<Z7/=6?Q#\)_%6UU[3S/'MQ:2VX@BGA=@Q(<@H
M2I'6N-_X*'?\$R_CS\=_VFO!O[?W["_[4UO\*OC5X*\*W'AG[3KGAY-4TC7]
M&DF>?[#=1'YHPLLDCB10Y&[A0RJZ^?\ [/W_  46_P""CO[.W[=7P^_X)_?\
M%8_@[\-7F^+EIJ7_  K#XK?"*^NQIU_=V,(FFM+JVO/WB2%&0;P(U#21J$<,
MSH ?87P0\9?M2^(_BY\3]"^.GP?T?P[X/T;7K6'X6ZYIVK)<3^(-/:WW3SW$
M:RN8'2;Y K*A(YP>M>GU^=W_  3-\'>%/B)^WQ_P40\ ^._#UGJ^B:W\3]&L
M-7TK4(%E@O+:70S'+#(C<,C(S*0>"":^*/$/BGXN_#W]JJ\_X->O 7[5>FVW
MP@\1^+X$L_B/)K$AUOP[X5N+::]G\#>:R%&O9 @AA<N3Y$VPJ=XBC /WHKX5
M_P""OO\ P6NL_P#@DW\4?A#X&U;]FF[\=Z;\2AJ]SK.K6'B8V<OA_3]-^RR7
M=TMN+2;[7LMYY9BF^+BW(W?-E?LCX2_"?X=? GX8Z#\&OA'X2M-"\,>&-*AT
M[0](L4VQ6MM$@5$&>3P.6)+,22222:_._P#X*S?"OP9\=/\ @M3^P[\%?B-I
M@O= \7>$/B_HVMVAQ^]M;GPJ895YZ$H[8/8T ?:/[;/[9?P__8L_8S\:?MEZ
M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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MX>U/2;K3-4TB1P2@N+.\CCFC5@&VOMV-M8!B5('>?'OX]?"']E_X.^(/C_\
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MB@ HHHH **** "BBB@ HHHH *^-O^"[O@[]I[QS_ ,$_-2T+]F'0?%NLR?\
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MZH7_ .7/_P#<U'_#TK_JA?\ Y<__ -S4?ZH\0_\ /G_R:'_R0?ZTY#_S^_\
M)9?_ ")];45\D_\ #TK_ *H7_P"7/_\ <U'_  ]*_P"J%_\ ES__ '-1_JCQ
M#_SY_P#)H?\ R0?ZTY#_ ,_O_)9?_(GUM17R3_P]*_ZH7_Y<_P#]S5](?!SX
MB_\ "VOAGI'Q%_L?^S_[4MVE^Q_:/-\K#LN-^U=WW<]!UKAQ^1YIE=)5,33Y
M8MV6L7KOT;[';@<YRW,:CIX>IS-*^S6GS2.FHHHKR3TPHHHH **** "BBB@
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MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^
MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_
M^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X2
M75_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X
M275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6@#8K\T/VHO\ DX?QC_V'[C_T*OT7_P"$EU?_
M *%"]_[Z6OSC_:7FDN/C]XNGEMVB9]<G+1OU7YNAK[S@'_D85?\ #^J/B>-_
M]QI?XOT9P]%%%?JA^:A1110 4444 %%%% !1110 4444 %?I!^QS_P FS^$O
M^O!__1TE?F_7Z&_LC:[J5K^SCX5MX?#-U.JV+@2HRX;]])TKX;CW_D5T_P#'
M_P"VR/LN"?\ D95/\'ZH]?HK+L]>U*YND@F\,W4*LV&E=EPON:U*_*#]."BB
MB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>
MK?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG)S]3?$3X.?"KXM?"K4_@;\2/A]I.L>#]8TEM,U+PY>V:M:36A7;Y/EXPJ@
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MGO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110
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M2\01V/CO7KO2].DC</?V=G]H:%]IV$QY!9=V,@$''2OH+PIXG^$WP"TKP?\
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M/*^71IN7/;[*UTE9M6L[G-@(QI8>I.?*DXR2ES+FVM;EOU>FUTG>^@?'QY-
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M.RW\=TVE74D2O+:&:+Y)C$Y:/S$^5MN1P16Q0!X7_P $]_\ DB>K?]CWK/\
MZ4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!^47BK_D9]2_Z_YO_0S5"K_BK_D9]2_Z_P";_P!#-4*_HVG_  UZ'X#4
M^-^H44459(45)=VEW87#V=];20RQG$D4J%64^A!Y%+;65Y>L5L[264J,L(HR
MV!Z\4KJUQV=[$5%!!!P1@CJ*DCM;J6%[B*VD:./'F2*A*K]3VIW0K-D=%%%
M!1110 4444 ?J=\*O^27^&_^P!9_^B$K>K!^%7_)+_#?_8 L_P#T0E;U?SKB
M/]XGZO\ ,_>L/_ AZ+\@K\T/VHO^3A_&/_8?N/\ T*OTOK\T/VHO^3A_&/\
MV'[C_P!"K[;@'_D85?\ #^J/C^-_]QI?XOT9P5%%%?JA^:A1110 4444 %%%
M% !1110 4444 %?I!^QS_P FS^$O^O!__1TE?F_7Z0?L<_\ )L_A+_KP?_T=
M)7PW'O\ R*Z?^/\ ]MD?9<$_\C*I_@_5'IE%%%?E!^G!1110 4444 %%%% '
MY\R_\%%OB%\&)O\ @H-\;OBG\1TN;/X#:C:0> _!-^D4<.G1KX<M[BU(VJLC
M_;[Z<C+LV2 $P!BO)OV0M(_;N_8O_:$_9+\=?'W]NOXB_%&X_:FL]1M_BIX
M\;WJ3V&@ZDVB/J\$ND0A1]A2W>,P2(OR,K$A4^55TO\ @J=KO_!!J;]NJ _M
M-_LG>+OC'\=="TVPO-?\._"KPSJVJSQVT862R.K6]G-%:W&%V%$N-[>7Y89?
M+9 ?2_@O^WC^R'^WO^WO\)->O/V(/VF= \=>#[77H? ?B;Q[\,KW2-!T7[5I
MTAO9)W,QB$DL%OY".ZL=SJBXWDT ?H%1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*
M\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y1
M>*O^1GU+_K_F_P#0S5"K_BK_ )&?4O\ K_F_]#-4*_HVG_#7H?@-3XWZA7J7
MP#^''A37_!'B_P")GB/PG=>)9/#,5K]E\.6ER\7GF9V5I9#'^\\M N<+C/.2
M ,UY;7>?!'PG\:]4N[GQ/\#M2FCU*P*QS0:?JB073H^3Q&S*94RO(&><9%<F
M8W^J2M44-5JW9;JZNM5?:ZU5]#JP%OK2O!SWT2N]GK9Z.V]GH[:F[^U-XI\
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M ,IEK_\ &J/^&I/CM_T/7_E,M?\ XU1_9.)[K\?\@_M;#=G^'^9]@45\?_\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\
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M_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444
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M>H> O$>L3ZM%BUE-OY$=P/*;-P(%?=TC+D<@4 ?7]%%% 'A?_!/?_DB>K?\
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M;_H>O_*9:_\ QJC^R<3W7X_Y!_:V&[/\/\S[ HKX_P#^&I/CM_T/7_E,M?\
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MMDCGF@%T8[IK,,76W9BC@%V!5@< 'S1_P7]\>>*O^"C7[,_Q&_:T\/:_=0?
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M7]@4?X4?1'\G5?XLO5A1116A 4444 %%%% !1110 4444 %%%% ']''[-_\
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M4/7O^PU=?^CFK&K^P*/\*/HC^3JO\67JPHHHK0@**** "BBB@ HHHH ****
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M/U_P43_Y/F^*G_8Z7O\ Z'7] M?S]?\ !1/_ )/F^*G_ &.E[_Z'7Z5X5_\
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MM>W*]KZ;VOY7L[V/3RE866+2K+M:][7NM[:[7MYVOH>5_$#P_P""?#^J00^
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MLVN>+]4_:!_98\0^*_'6E0Z?<>"M1LQHMQIB-;6MV9Y-DD1@4^69%!#;E4,
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M,?\ 0:@_[ZK\"?\ @H7<07?[;_Q2N;:0/&_C*\*,.A&^OTKPK_Y&U?\ P?\
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M&!/')\%_:(^!?C']FGXT^(/@;X^>W?5/#]VL4\UHY:*9'C66*5,@':\;HX!
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M_P#2HGOB6-E&P>.SB5AT*Q@$5+117X0?MH4444 %%%% !1110 4444 %%%%
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MAA^SY_P63\1>+OB';SIX?UCPI;Z'XNFLDWSV2W6F0H90JY+,@\DD#)V@X!.
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M1110!X7_ ,$]_P#DB>K?]CWK/_I2:I?\%4?^4?GQ-_[ L/\ Z505=_X)[_\
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MU=?^CFK&K9^(_P#R4/7O^PU=?^CFK&K^P*/\*/HC^3JO\67JPHHHK0@****
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MLW_\F[^ O^Q+TO\ ])(J[2OY#Q?^]U/\3_,_JS"_[K3_ ,*_(*_GZ_X*)_\
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M1_#/_D<UO^O;_P#2HGT#1117X0?MH4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)JE_P51_Y1^?$W_L"P_P#I5!5W_@GO_P D3U;_ +'O
M6?\ TI-4O^"J/_*/SXF_]@6'_P!*H*]7(_\ D=X7_KY#_P!*1YF=?\B?$_\
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MY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU7Y*?J9])?M(?\
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M_P#*?_VY^+-%?M-_PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\
MC5'_ !%G_J#_ /*G_P!S#_B%O_47_P"4_P#[<_%FBOVF_P"'(7[)O_11OBG_
M .%L?_C5'_#D+]DW_HHWQ3_\+8__ !JC_B+/_4'_ .5/_N8?\0M_ZB__ "G_
M /;GXY?#C_DH>@_]AJU_]'+7]*=?'/\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?L
MF_\ 11OBG_X6Q_\ C5?&<6<5_P"M$Z,O8^S]GS?:YKWM_=C:UO,^OX7X8_U:
MA5C[7VG/;[/+:U_[SON?8U%?'/\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\
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MSY97OR\U]+=T?BS17[3?\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\
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M;XI_^%L?_C5'_$6?^H/_ ,J?_<P_XA;_ -1?_E/_ .W/Q9HK]IO^'(7[)O\
MT4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J/^(L_]0?_ )4_^YA_Q"W_
M *B__*?_ -N?BS17[3?\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"'(7[)O_11OBG_
M .%L?_C5'_$6?^H/_P J?_<P_P"(6_\ 47_Y3_\ MS\6:_>O_@E=_P H_/AE
M_P!@6;_TJGKSK_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\
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MXU_$[4I;[Q%KGPZTY]:U"=B9+VYCC\E[AR>KR&,R,?5S6Y\;OV-?^%R?MM?
MO]L;_A8_]F_\*6T_Q9:_\(Y_8_G?VS_;=I:6^[[1YR_9_)^R[L>7)YF_&4VY
M/H'[/_P1\"?LT_ SPA^SU\,+*2W\/>"?#=EHFC1S.&D^SVT*Q(SL -SD+N9L
M?,Q)[UU] '!?&#XG?L^_L@?"?Q=^T-\5=5T/P;X8TN*35_%FNM;)")7PJ^9)
ML7=/,Y"1J,-([%$4$D"O@'_@DCX0^+7P4_8M_:K_ ."A'_"M;CX?:;\9/%OB
M7XD_##P!?6XBDTO2TLI'M+J:$#;#+<%1(4 QL6-APP Y7]OCX4?\%6_VD_\
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M'%&H 5%4<*H   '  J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;:KK&JHU]]D33M/AO,PH ")'FVEA\^,>7A_;/V5/V;OV[/V:/B;JWB+]HO\
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M:'+%7YHK5>3DF?F37["?\&_'_)FGB;_LIU[_ .F[3J\Q_P"(<W_J\7_S'O\
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M4?VDS^UYXI^ DD/Q#DU.RU&[\0:%XOU?2A>W5H5,$US;V5W%;W3+L4$RQON
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MO&6HZ'-HUWXK\;^/M5UR].GRR1R26R->W$B1(SQ1L=BJ24&2<5YA!_P;T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20210630_g4.jpg
<TEXT>
begin 644 biib-20210630_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
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M=?MP?LO65U)977Q/VRPR%)%_L6].&!P1D0^M1_\ #=/[*_\ T5+_ ,HE]_\
M&*_/WQ5_R,^I?]?\W_H9JA7ZQ#@3*)13YZGWQ_\ D3\QEQKFJDUR0^Z7_P D
M?HC_ ,-T_LK_ /14O_*)??\ QBC_ (;I_97_ .BI?^42^_\ C%?G=15?ZAY/
M_P _*GWQ_P#D2?\ 7;-?Y(?=+_Y(_1'_ (;I_97_ .BI?^42^_\ C%'_  W3
M^RO_ -%2_P#*)??_ !BOSNHH_P!0\G_Y^5/OC_\ (A_KMFO\D/NE_P#)'Z(_
M\-T_LK_]%2_\HE]_\8H_X;I_97_Z*E_Y1+[_ .,5^=U%'^H>3_\ /RI]\?\
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MA!J-E%<.BW),NQ'C#!@$]'+* >I_L8?\%(/B+\7_ -I7Q%^PO^V1^S,WP?\
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M0 4444 %%%% !1110 4444 %%%% !1110!^47BK_ )&?4O\ K_F_]#-4*O\
MBK_D9]2_Z_YO_0S5"OZ-I_PUZ'X#4^-^H44459(4444 %%%% !1110 4444
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M'O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_HJ7_E$L?\ XQ7DE%?I/]C9/_T#T_\ P"/^1^??VMFO_01/_P #E_F>M_\
M#=/[5'_14O\ RB6/_P 8H_X;I_:H_P"BI?\ E$L?_C%>244?V-D__0/3_P#
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M>F <Y!YK].Q/MOJ\_8M*=G:^U[:7^9^=X?V7MX>UORW5[;VOK;Y'HOCWX7?
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M&GP9\*?"'PKXG^%-E)*]QJ=Y87NLR74C?VBUOA&F"%BB*SABH4#Y2*Y+P/\
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
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M(^RX)_Y&53_!^J/3****_*#]."BBB@ HHHH **** "BN0^)O[07P%^"GE?\
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M<>'[;3-.^Q30Q,C&RNO.W*S+AE95W-D5UGP\_8$^!?\ P3@_;'_X)[_"_P"
M7P\TKP[\4]2TCQ'IWQ4U31T"3^)=/@\-F;4I]0=#_I %_P"0\3/D*Y54P
M#]3_ (>:1XO\/^ -#T'X@^,$\0Z_8Z/;6^N:_%IR6:ZG>)$JS70MT)6 22!G
M\M20F[:"0,UL444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNE?/7[!=MXDE^#FK-I.I6\47_"<:SE982QS]I;G->V_8O&__ $&[+_P&/^-
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M  3^:*F;VJ/W.O?_ (!^@%%?G_15_P!C_P!_\/\ @D?VQ_<_'_@'Z 45^?\
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MRJRVBFW\E<[FBOSN_P"&Z?VJ/^BI?^42Q_\ C%'_  W3^U1_T5+_ ,HEC_\
M&*^P_P!0\X_Y^4_OE_\ (GRG^NV5?R3^Z/\ \D?HC17YW?\ #=/[5'_14O\
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MQ_S\I_?+_P"1#_7;*OY)_='_ .2/T1HK\[O^&Z?VJ/\ HJ7_ )1+'_XQ76_
M;]L/]HSQI\9O#7A3Q+\1/M.GZAJ\,%W;_P!D6:>9&S8(W)"&'U!!K.MP1FU"
MC*I*<+13>\NFO\II1XQRRM5C3C"=Y-+:/73^8^Y****^-/K HHHH ***;//!
M:P/<W,R1QQH6DDD8!54#)))Z "@!U%5M'UC2/$.D6OB#P_JEM?6%];)<65[9
MSK+#<0NH9)$=25=64@A@2"""*LT %%%4E\2^''UH^'$U^R.HJF]K 72><%ZY
MV9W8]\4 7:*"0!DFJFC^(-!\0Q23Z!K=G?)%(8Y7L[E)0CCJI*DX/M0!;HHJ
M#4]4TS1;*34]8U&"TMHAF6XN9EC1!G'+,0!S0!/13+>X@NX$NK6=)8I4#QR1
ML&5U(R"".H([T^@ HHHH **** /YK/B/_P E#U[_ +#5U_Z.:L:MGXC_ /)0
M]>_[#5U_Z.:L:O[ H_PH^B/Y.J_Q9>K"BBBM" HHHH **** "BBB@ HHHH *
M*** /Z./V;_^3=_ 7_8EZ7_Z215VE<7^S?\ \F[^ O\ L2]+_P#22*NTK^0\
M7_O=3_$_S/ZLPO\ NM/_  K\@K\T/VHO^3A_&/\ V'[C_P!"K]+Z_"_]O?\
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M?\@_M;#=G^'^9]@45\?_ /#4GQV_Z'K_ ,IEK_\ &J/^&I/CM_T/7_E,M?\
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MQ>M=)\7^"O"VL74MKK_@=59M6N;^VEE<>7 @!60@?>D?YFA4IZ]<?M]^.O\
M@BY_P04^$_QE_;AT#6-;^)MMX4TWP[IOAK4)G^U7>MS6\\UI97DQ!,/E6T!\
MZ1\L/L[J-SE0WC7_  2F_;\_X)4>'?B\?VDOVG_^"B7AOXE_M7?&2>TTK4]3
M@T#5%L]!BN)D6V\-Z.KVNRWM(Y'1"^09G&]VQC !^PU?E]XN^#7P]_X*U?\
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MQ8201>*)$NDOM0N;7S%5GABGB6+S,8?<N,X8+^DU !1110 4444 ?S6?$?\
MY*'KW_8:NO\ T<U8U;/Q'_Y*'KW_ &&KK_T<U8U?V!1_A1]$?R=5_BR]6%%%
M%:$!1110 4444 %%%% !1110 4444 ?T<?LW_P#)N_@+_L2]+_\ 22*NTKB_
MV;_^3=_ 7_8EZ7_Z215VE?R'B_\ >ZG^)_F?U9A?]UI_X5^05_/U_P %$_\
MD^;XJ?\ 8Z7O_H=?T"U_/U_P43_Y/F^*G_8Z7O\ Z'7Z5X5_\C:O_@_]N1^>
M>)O_ "*Z'^/_ -M9XQ1117[D?BP4444 %%%% !1110 4444 %%%% !7[U_\
M!*[_ )1^?#+_ + LW_I5/7X*5^]?_!*[_E'Y\,O^P+-_Z53U^9>*?_(DH_\
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M ]3]*[4?L1_M.,"5^'$1V@EL:_8< =_]?6=;,,!AY*-6K&+:OK)+3OJ]BZ6
MQU>+=*E*26FD6]>VB/*:**ZGX;_!?XC_ !8%U-X*T 36UB ;V^N;F."W@ST#
M22,JY/IG/M715K4J$'.I)12ZMV1C2I5:TU"G%MOHM6<M170_$7X5^//A1JD.
ME>.M!>S>YA\VTE65)8KB/^]'(A*N.G0\9&<5SU.G5IUH*=-II[-:H52G4I3<
M)IIKH]&7_"O_ ",^F_\ 7_#_ .ABOU=K\HO"O_(SZ;_U_P /_H8K]7:_-_$#
M^)A_27_MI^@<#?PZ_K']0HHHK\Z/O3^:SXC_ /)0]>_[#5U_Z.:L:MGXC_\
M)0]>_P"PU=?^CFK&K^P*/\*/HC^3JO\ %EZL****T("BBB@ HHHH **** "B
MBB@ HHHH _HX_9O_ .3=_ 7_ &)>E_\ I)%7:5Q?[-__ ";OX"_[$O2__22*
MNTK^0\7_ +W4_P 3_,_JS"_[K3_PK\@K^?K_ (*)_P#)\WQ4_P"QTO?_ $.O
MZ!:_GZ_X*)_\GS?%3_L=+W_T.OTKPK_Y&U?_  ?^W(_//$W_ )%=#_'_ .VL
M\8HHHK]R/Q8**** "BBB@ HHHH **** "BBB@ K]Z_\ @E=_RC\^&7_8%F_]
M*IZ_!2OWK_X)7?\ */SX9?\ 8%F_]*IZ_,O%/_D24?\ KXO_ $F1^C^&?_(Y
MK?\ 7M_^E1/H&BBBOP@_;0HHHH **** "BBB@ HHHH **** /"_^">__ "1/
M5O\ L>]9_P#2DUU'[8W_ ";/XM_Z\$_]'1UR_P#P3W_Y(GJW_8]ZS_Z4FNH_
M;&_Y-G\6_P#7@G_HZ.N_*O\ D:4/\<?_ $I'%F7_ "+JW^"7Y,_-^BBBOZ!/
MPP**** "BBB@ HHHH **** "BBB@ KO?V7?^3A_!W_8?M_\ T*N"KO?V7?\
MDX?P=_V'[?\ ]"KCS'_D7UO\,OR9UX#_ 'ZE_BC^:/TOHHHK^>S]U,'XJ_\
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M1110 4444 %%%% !1110 4444 %?O7_P2N_Y1^?#+_L"S?\ I5/7X*5^]?\
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M5&XI+^][.[?1KE5NYS5L%@\+C)4J\JD4DMZ:4FW_ '>>UNJ?,[]CPVBOJ_\
MX*K6EA-XB^&/B_Q9X;T_1_B5X@^'5KJ'Q*T_3K98/],<_NY9HE $<[KN+K@$
M848QC/?_  6_:M^*G[07["?[0GA'QG!H5EI'AOP;I TC3- T&"RBB9KHHSL8
MUW.Q$:Y+,>^,9-<KSNL\NI8R%%.,I*,O>M:\U"\?=?,KNZ^&ZUZG3')J*S"K
MA)U6I13<?=O>T'.S]Y<KLK/>STZ'PC117TS_ ,$K=5\#Z3\?-=GU1-&/C%_
MFI)\*CX@$?V0>)"$^R F3Y Y^94+<9) ^8K7JYABW@<%4Q"CS<JO;_@]%W=M
M%J>9@,*L;C(4'+EYG:__  .K[+J]#YMOM+U/3"@U+3I[<RKNC$\+)O7U&1R*
M@K]!V\3?M;-^S+\88/\ @I[;WG_"/2^&)H_ 8\8VD$=Z?$^?]%^P!5$A4?,S
ME,H$7J%W9_/BN;*\REF"J*2C[C2O&7/%W2>DK1U5[-6T.G,\OC@'3<6_>5[2
MCRR5FUJKO1VNG?4*_=?_ ()=^$]-O_V!OAK>37%T&?1I20ERRC_CZFZ"OPHK
M]Z_^"5W_ "C\^&7_ &!9O_2J>OA_%/\ Y$E'_KXO_29'V?AG_P CFM_U[?\
MZ5$]ML_"6FV-TEW#<71:-LJ'N6(_$5J445^$'[:%%%% !1110 4444 %%%%
M!1110!X7_P $]_\ DB>K?]CWK/\ Z4FJ7_!5'_E'Y\3?^P+#_P"E4%7?^">_
M_)$]6_['O6?_ $I-4O\ @JC_ ,H_/B;_ -@6'_TJ@KU<C_Y'>%_Z^0_]*1YF
M=?\ (GQ/_7N?_I+/P4HHHK^KS^7@HHHH **** "BBB@ HHHH **** "O9_\
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M_I+/P4HHHK^KS^7@HHHH **** "BBB@ HHHH **** "O9_\ @G9_R?-\*_\
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M^E>%?_(VK_X/_;D?GGB;_P BNA_C_P#;6>,4445^Y'XL%%%% !1110 4444
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MJ_\ @_\ ;D?GGB;_ ,BNA_C_ /;6>,4445^Y'XL%%%% !1110 4444 %%%%
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M* "BBB@ KV?_ ()V?\GS?"O_ +'2R_\ 0Z\8KV?_ ()V?\GS?"O_ +'2R_\
M0Z\_-O\ D58C_!/_ -)9WY5_R-*'^./_ *4C^@6BBBOY+/ZE.+_:0_Y-W\>_
M]B7JG_I)+7\X]?T<?M(?\F[^/?\ L2]4_P#226OYQZ_:_"C_ '3%?XH_DS\=
M\4/]ZPW^&7YH****_63\M.C^+OQ*U7XP_$K6?B=KEA;VMWK5X;B>WM-WEHQ
M&%W$G''<USE%%13IPI4U""LDK+T1=2<ZLW.3NV[OU844459 4444 %%%% !1
M110!L_#C_DH>@_\ 8:M?_1RU_2G7\UGPX_Y*'H/_ &&K7_T<M?TIU^,^+'\7
M">D__;3]>\+OX6*]8?\ MP4445^0GZL?S6?$?_DH>O?]AJZ_]'-6-6S\1_\
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M***_J\_EX**** "BBB@ HHHH **** "BBB@ KV?_ ()V?\GS?"O_ +'2R_\
M0Z\8KV?_ ()V?\GS?"O_ +'2R_\ 0Z\_-O\ D58C_!/_ -)9WY5_R-*'^./_
M *4C^@6BBBOY+/ZE.+_:0_Y-W\>_]B7JG_I)+7\X]?T<?M(?\F[^/?\ L2]4
M_P#226OYQZ_:_"C_ '3%?XH_DS\=\4/]ZPW^&7YH****_63\M"BBB@ HHHH
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M.]_VLO\ HV3XI_\ A$#_ .2*_?RBC_7_ (M_Z"?_ "2G_P#(!_J+PK_T#_\
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M('_R11_P[W_:R_Z-D^*?_A$#_P"2*_?RBC_7_BW_ *"?_)*?_P @'^HO"O\
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M#_X=[_M9?]&R?%/_ ,(@?_)%'_#O?]K+_HV3XI_^$0/_ )(K]_**/]?^+?\
MH)_\DI__ " ?ZB\*_P#0/_Y//_Y(_GT\3_L-_M+>#M NO$_B7]GKXDV%A91>
M9=7E[X.6.*)?[S,;C"CWJU8_L!_M4ZC90ZA9?LU_%"6&>)9(I8O!0975AD$'
M[1R"#G-?M5^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B4H_U_P"+?^@G
M_P DI_\ R ?ZB\*_] __ )//_P"2/P@_X=[_ +67_1LGQ3_\(@?_ "11_P .
M]_VLO^C9/BG_ .$0/_DBOW\HH_U_XM_Z"?\ R2G_ /(!_J+PK_T#_P#D\_\
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M'JW_  3R_9EL_&_PX\ 1>+OB1XY\6V'@WX5>$YY2L6IZ_?%EMQ*5(;RD".[
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M<_!GC+['X-^)>C_$*?QMHW]G6TG]HR:9IVGS6)\V2-I8?+DGE;$3H'W8?<
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M#16=A:QVUI$TK.4B10J@LQ+-@ <DDGN30!:KXA_X*!_MZ?&+Q=\84_X)A_\
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M<?VM=VW]FZM!S%<[;>5%FV_\\Y0\9[J: /1H((+6!+:VA2..- L<:* JJ!@
M = !7YY?L-_\K#7[<W_8G_#?_P!,]?H?7G?@;]E'X!?#;]H;QS^U9X*\!?8O
M'WQ*L]-M?&NO?VI=2?VC#80^3:+Y$DK0P^7'\N8D0MU8L>: /B3_ (*M?\IM
M?^"</_8P?$;_ --.G5[A_P %K_VK?@Q^RM_P36^+NI?%7Q7I]O?^*OA_K'A[
MPEH4\Z_:=;U.]LY+6"VAASOE^>92^T'9&'8\"NW_ &U?^"9G[$W_  4/OO">
MI_M??!V?Q3<^!C?'PI<6WBS5=*>P-X(!<X;3[J OO%M /GW8V?+C<V>,^ '_
M  1#_P""6'[,GQ*L_C%\)_V0=''BC3I5ETS7?$VLZCKUQ8R*<I) VJ7-QY+J
M>5=-K*>010!O?\$A_@EX\_9S_P""8OP-^#'Q0TV:Q\1:)\.=.36=/N%(DLKB
M2/SGMW!Z/&9/+8=BAKZ-HHH ^*_^"A__  4"^*]K\4K3_@FY_P $Y+"T\1_M
M#^*[$3:EJLR"72_AGI#X#ZUJC8*B0*P,%L06D9D)5@T<<W6? _\ X)K^"/V/
M?^"<WC?]D'X*ZG>Z]X@\6>&M=G\2>+M<DW7WBCQ%J%I(D^H73$GYY)"B@$G:
MB(I9B"QQ_C%_P07_ ."5/Q[^,_B;]H3XH?LTZA>>,/&-_P#;?$FL6/Q*\1V!
MO9\!=QBM-0CB7@<!4 'IS7K?['?_  3_ /V3_P!@;1-;\.?LJ?#F_P##MGXB
MNX;G6(K[Q=JNK&:6)65"&U&ZG:/ 9AA"H.>0<"@#YN_X(#_'WX8Z;_P0S^&7
MC_Q%XBMM+T_X<>%-4L?&[7;A&T:73;FY^U"X4X,3+&@E(;!VR*>A!JM_P;&^
M#O$OAG_@C[X"\0^)M&DTYO%VOZ_X@L+&6/8T5I<ZK<F X_NO&JR*1P4D4]Z[
MWXP_\$'_ /@F;\</BOKOQ:\9?!35;:;Q;JBZEXU\/Z!XUU33=&\1W@8/Y][8
M6UPD$KEAN8A1O8EGW%F)^M?#?AOP]X.\/6'A'PEH=II>E:79Q6FF:;I]LL,%
MI;QH$CBCC0!4154*J@    4 7:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#F/C9\1O^%/?!KQ=\7/[&_M'_ (1;PQ?ZO_9_VCR?
MM7V:WDF\KS-K;-VS;NVMC.<'&*_/#_B(R_ZLZ_\ ,A?_ 'OK[I_;7_Y,T^+?
M_9,=>_\ 3=/7\\%?J?A_PYDN=X.M4QM+G<9)+WI+2W]UH_,^.^(,WR;%T88.
MKR*46W[L7K?^\F?IM_Q$9?\ 5G7_ )D+_P"]]>Z?\$^_^"K_ /PW7\9=3^$?
M_"A/^$6_L[PQ-J_]H?\ "4_;O,\NXMH?*\O[+%C/VC=NW'&S&.<C\5:^Z?\
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MV>6^#_QC\!Z);:]?^'/^$EBU;3=7T*=S&FJV%ZB1^9")5,<BNBF)BJDL=P4
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M_P#%GBC58+#3-+LI;O4;ZY<+';P1H7DD=CT554DGL!7YX:'_ ,%FOVZ/B_\
M!?5?VW?V9?\ @E+>>*O@'IINKG3=;U3XEP:=XE\0:5;.ZSZE9Z4;5\(!'(R0
MO+YDH3Y?O# !^B][>V>FV<VHZC=Q6]O;Q-)///($2-%&69F/   ))/  K"^'
MGQ>^$WQ=M+J_^$_Q0\.^*(+*817L_AW6X+U+>0C(1S"[!&(YP<&ORZ_X+R_M
MI^-_VHO^".WAOXG?LC_"P>*/A'\8Y=!;Q!XME\:II-YI\<NL62)I3V?DR-*9
MY/,M9F651"4?(D4D'[?_ .";7PFN/A;\']7AUK_@G!\./V9]2N=?*2>$?AOK
M.GZC!JEM';P^5?SW%E96JM*6>:+8Z,X$(;>?,P #Z(HKP'Q_^W)_PK;_ (*.
M_#_]@GQ/\+O*L?B7\.]6U_POXY_MO_7ZGITR?:=+^Q^3_#:N+CSQ-_L>7_'7
MFG[('_!7_P )_M:_\%&?C#^P%I_P:N-$C^&7VT:%XTEUWSHO$[V%W#9:FL=O
M]G3R#;W,Z1G$LN[D_+C% 'V317Q)X2_X+:?"9_V!/B=_P47^*/PLOM$\#>#?
MB-J_ACP5;Z1JPU*\\:Q6MZEC:7-NAAA$4EU<ET$.9%C$98RL =O)^)?^"O7[
M:7[+UKX3^,/_  47_P""::?"_P"$/B[6K/3+OQEH7Q0@UN\\'2W;!+9M7LUM
MHMD19@))(W81'Y2&<JC 'Z#UE^(/&_@OPE?:;IGBKQ?I>F7.M7@M-'M]0U".
M%[ZX()$,*NP,LF 3M7)P.E?)?[=?_!5GQG^R/^V7\./V)?A?^Q[J_P 5/%?Q
M2\):CJ?A:'1O%,-@S7EM)@6\OG0F.&W\L232W32 1)$Q$<API\!_;V\:_M,>
M/OBW^PAK_P"UG\#M%^'OB[_AK!(Y/#V@>*UUFV%L+&;RI1<B*/)8$Y4H,%?<
M4 ?J-67;^-_!=WXNN/A_:^+]+EUZTLTN[O1(]0C:\AMW;:LSPAMZQD\!B,$\
M9KY0_:@_X*4?&_1/VP6_8*_8*_9/M_BW\0]$\-P:_P#$*_USQBFA:+X4LKAL
M6L<]QY$SRW,P&Y850$(ROEAO"_.W_!.KX\>.OC[_ ,' _P <=;^+'P*U/X;>
M+]#_ &>M#T?Q3X0U+48KU;2[BU+S ]O=P@)=VTD4T,L<P5"RR %58%0 ?J91
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YE^VO_R9
MI\6_^R8Z]_Z;IZ_G@K^EGQMX-\-_$7P9J_P^\9:;]LTC7=,N-.U6T\YX_/MI
MXVCECWH59=R,PRI!&<@@\U\[_P##G+_@G#_T;G_Y=^L?_)=?HO!7%V6\-X6K
M2Q,)MSDFN51>RMK>2/@.,>%<QXAQ-*IAI02BFGS-K=WTM%GX75]T_P#!OQ_R
M>7XF_P"R8WO_ *<=.K[H_P"'.7_!.'_HW/\ \N_6/_DNNZ_9]_8'_9,_99\9
MW/Q!^ _PH_L+5[S3'TZYN_[=O[K?;/)'(T>RXGD49>&,Y S\N,X)!][/O$/)
M<TR>MA*5.HI3C974;?.TV_P/"R/@+.,LS:CBJM2FXP=W9RO\KQ7YGL-%%%?C
MA^N!1110!\??\%]?V;/BM^UO_P $A_C1\"?@AX=FUCQ1J.CZ??Z7I-LA>:]^
MP:K9ZA)!$HY>5XK6140<LY51R:\ZE_X.2_\ @F6?V6F^+,7QVA/C\^'_ )?A
M,NE77_"0_P!N^5M_LO[(8MWF?:?W6_\ U7\6_;S7Z#5E?\()X'_X2;_A-?\
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M'"O[,6@27!N6T[]G/Q3 MQ(OS.4DA3?WP2,_F:T/^"SW_)V'["?_ &=!:_\
MI!/7W]10!^8NE?M$?"/_ ()<?\%NOVC?%7[:_BR'P5X-_:4\.^$-9^''Q"UR
M)TTN6XT;3Y+"\TN6ZP4BF4OYJHY4"/;DY= V5_P3H_:@^'G[7W_!PA\>?C1\
M'[*[E\(7'[/^AVGAKQ#<Z=+;1^(;>'4%1K^ 2JK/ TWG11RXQ(L 9<J0:_4'
MQ#X8\->+M._LCQ7X>L=3M/,5_LNHVB3Q[EZ-M<$9'8]JN11101+##&J(BA41
M1@*!T '84 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20210630_g5.jpg
<TEXT>
begin 644 biib-20210630_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
M!0K4_P#@IK^R:G[3&M? U_AU>+XIU+1+OPO+XA_M-K>6SE$;,9_L\&23GY?+
MXQU-?G+^RG\0OB)^V9XU_9R_X(G_ !8>XOM8_9@^(>K:C\?9I(F6.^TOPG,D
M'AO(;(F@O'NK!F!)W?9RW/2L#X!?M1_%/]CC_@U^^/\ \>?@GK%SIGBFR^+7
MB+3=)U>T.V73FO\ Q%;6#W*,.4DCCN79''*R!"/6@#]Q8-=T2ZU6;0K;6;22
M^MT#SV<=PIEC4XP60'('(Y([U:K\G/V\O^")O[&_[%?_  3&\4?M'_LTV&H>
M%?C?\'/"3^+]'^-UAKUT-<U+5K-!<7$US,TI$ZW6V56B8&,>=\JC %9?[?NF
M7'_!0?\ :-_X)=W7Q"US5?#P^*?A_P 2ZQXG/AG49+*<P7/A?3KR\LHYHR)(
MDFC,MLS(RN(YFVLIP0 ?K=INM:-K)G&D:M:W1MIC#<BVG63RI!U1MI.UAZ'F
MO'?@W^VYX+^,W[:/QF_8IT?P;JEGK/P6L?#MSK.L7,D9M=075[1[J$0A27!C
M5"K;@.3QFOAWXC?L=?L[?\$N?^"Q/[(VK?L+^ %^'ND_&-_%GA3XE^&M%OI_
ML&N6UKI:W=G++%)(P\V*<E]XY;"Y/!SP7[-__!)3_@G+\>?^"VW[:GPS^+W[
M*?A_7=!\,6W@75-!TV[GN0EG>:IIMQ=7\RE)02TT_P"\;)(ST '% 'W[X:_;
M5\5:Q_P5&\9?L(:CX6TJW\.^%_@OIOC6+Q 9I!=//<:A-;/"X)V")4C# XSD
MG)Q7T-INIZ;K-C'J>CZC!=VTH)BN+:99$<9QPRD@\@C\*_+?XN_L7?"7]LK_
M (.(?&7PO^.MO>ZEX TG]EK0;S5O!4&IS6UGKLR:S<);1WODLK3V\1+R>0S;
M&D6)F#;,'I/V /@MX$_84_X+?_&K]B3]E^PF\-_"SQ#\#-&\>0^"4O)9K#2M
M9_M!K&26UCD=O)61/F=01N(4<*B!0#]'KKQ+X<LM6AT"\U^RAO[@9M[*6Z19
MI1SRJ$[FZ'H.U7:_!?X9? []C+]D'P%K'A/_ (+Z?\$JOB1KWC>Y\2ZC<>.?
MVJ1I%WXCT/6A->2O!?MJ-C/]HTU1"\*+$D:L/+R0KY4?N9\,M1\$ZQ\-_#^K
M?#368-1\.76AVDWA_4+:Z,\=U9-"C02I(23(K1E6#Y.X'.3F@#Y%_;E_X*C?
MM*_L[_MQ^$OV#OV4OV 8OC3XK\4_#J;Q>&F^+%KX:6VMHKN2VD3_ $JTEC?&
MQ6SYBD[\!>,UVW[)'[4O_!3'XO?%H>$?VK?^"5-I\'O"G]F33'QA#\>=*\1L
M+E2OEV_V2UMHY/GRW[S=A=O(YKY'_P""@WAC]J?Q;_P<3?"72?V/?BKX5\'>
M,/\ AF'4W&L>,?#DFJ6?V4:O-YL?D1RQ-O8E<-NP,'@YK[-_9%^&O_!3[P;\
M2;[4_P!M7]J'X7^-O"LFARQ:?I7@KX>7&DW46H&:$I,\TMU*&B$2SJ4V@EI$
M.?E((!]!ZKK&DZ%9MJ.MZI;6=NK -/=3K&@). "S$#D\5.K*ZAT8$$9!!X(K
M\??^"6'_  3&_9+_ &W_ (H?MG>/_P!KOP)-X^T[3?VW?B#IGA_PCK6J7(TK
M2IO.MY+B^BMXI$4W4RRPQ-*V65+6,(5R^["^#W[3WQ@_80_X(F?MR>$_A!XU
MUF=_V<_CKXJ\ _"74;Z[>YNM$T=[G3[>S"R.2S-:F^ED1FR!L7C:NV@#]1/V
MVOVEI?V8?V1?BW^T!X,ATO6-=^&WP]U7Q##HEW<_))+:V<D\<<P0AT1R@&1@
MX/%;G[)GQ@U?]H;]E?X9_'[Q!I-M87_CGX?Z-X@O;&S9C#;37MC#<O&A8EBJ
MM(0,G. ,U^8O[:/_  1#_8F^!G_!%OQ[\6/ACX?O]+^*N@?!>_U[5?BW!KET
M=8\17+:>9M1CO96E(N(+U#/$\+@QA9\J RJ1@?MQ_''QUIW_  3[_P""=_[%
M^D>'?B'J_A/XT>#M#7XB:%\*9(X]>\0:/IGAZPGDT>W>2XMPBW)G'F8EC8QP
MN QR58 _8_2]=T37/._L76;2\^S3&*X^RW"R>5(.J-M)VL/0\TNJZSH^A6OV
M[6]5MK. N$\ZZG6--QZ#+$#)]*_&B/X&V?PA_:8^"'Q@_P""5?\ P1P_:)^!
M'B+1OB/I>G?$FZU?2-/L]"U[P;.YBU""_2#6+HS2QADFCE:,LK(S%BP3'KO@
MC]FWX/\ _!6#_@L-^TW'^W'X4/C?P?\ L]+X;\+_  Q^'FLW$O\ 95B]]827
M5[J4ENKJDUQ+(N$D8'$9 YV1E0#ZP^#O[;GC/XE?\%.OC)^PKJ'@[2[?0_AK
MX'\.ZYINMP22&ZO)=15S)'("=@5=HV[0#SS7TG7Y;_\ !*K]FGP=^R/_ ,%S
M/VKO@9\--:U.?PKIGPU\'2^&--U74Y;Q]&LIEEE73XY9F9S!"S.L2L24B,:9
M(4&OU(H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#'^(7A3_A// .N>!_M_P!D_MG1[FQ^U>5YGD^=
M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
MC.:S?VA?^";7[1FG?MG:U^WI_P $\OVJM(^&7C#QUH-EI'Q1\.>+O!QUK1/$
MRV:F.SO61)X9(+J&+]V&5B&0 ?+E_,^S:* /CC]@/_@E=X\_8]_:[^*O[9_Q
M8_:^U#XI^+?B_H>EVWB:74/"<>G"*[M"^9(?*N'5+?88XHK<(/*CA4&20Y8_
M8]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YX?\ !33_ )3C?\$Y
MO^PA\4?_ $P65?H?7YX?\%-/^4XW_!.;_L(?%'_TP65 'TA\"?VY_P#A=?[?
M'QY_8>_X5=_9G_"D=/\ "]U_PD_]M^=_;7]L6,EUM^S>0OV;R?+V9\R3?G.$
MQBCX-?MS_P#"W/\ @H)\:/V$_P#A5W]G_P#"H?#_ (<U/_A*?[;\W^UO[5MW
MF\O[-Y"^1Y6S;N\V3?G.$Z5\?K^U)\"/^":__!=S]HWQ7^VGX]M_ /AKX[?#
MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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M82G5P\8MRE9\R;Z7Z-'CYSF%;+J,9TTFV[:W[>31]$_\-+_!+_H=?_*;<_\
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M_*;<_P#QNNO\/Z_I'BG1H/$&@W?GVERA:";RV7<,D=& (Y!ZBOA^OKO]G_\
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M:\)HH_USXE_Y_P#_ )+#_P"1#^WLU_Y^?A'_ "/=O^&UO^J:?^5G_P"TT?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M7;_^BUK3K,\$_P#(F:1_V"[?_P!%K6G7],X7_=H>B_(_6*/\*/H@KX[^-/\
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M !1110 4444 %?7?[/\ _P D=T+_ *]6_P#1C5\B5]=_L_\ _)'="_Z]6_\
M1C5]_P"'?_(VJ_X'_P"E1/I.&/\ ?)_X?U1V-%%%?L)]P%%%% !1110 445Y
MA^UOXQ_:K\'?"E7_ &,_@[X=\8^.-1U2&QLXO%_B$Z=I6DQ.KE]0NV16FFBB
M*J##"/-<R *0 6 !Z?17Y^ZE_P $O?\ @J?\>'/B7]IK_@MWXW\/7EQ\X\-_
M WP;::!INFYY\F.=V>XN5!Z/-AR.M6='_9 _X+6_LB2_\))^S_\ \%&=%_:!
MT>W.^?X<_'CPK'87-R@^\MOK=ANE29APOG1M$&P6&": /OFBL?X>:YXI\3^
M-#\2>./!3^&M:U#1[:YUCP[+?QW3:5=21*\MH9HODF,3EH_,3Y6VY'!%;% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?#NN?\ (:O/^OJ3_P!"-5:M:Y_R&KS_ *^I
M/_0C56OYBJ?Q'ZGY+/XV%%%%02%%%% !1110 4444 %%%% !1110!]L^"?\
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M/A+^R'\?_P!GC6? ^M>(_"MU+\./$DFH6]_IGB:&U5I;@1RQ8:WF5/G,+KD
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MG]DO_@HMJW[<'PQ_9^UOXI>"OB!X$M-!\6:/X2G@.L:->6C@PSQ03.@GA=%
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MA\!^)O'OPRO=(T'1?M6G2&]DG<S&(22P6_D([JQW.J+C>30!^@5%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?#NN?\ (:O/^OJ3_P!"-5:M:Y_R&KS_ *^I/_0C
M56OYBJ?Q'ZGY+/XV%%%%02%%%% !1110 4444 %%%% !1110!]L^"?\ D3-(
M_P"P7;_^BUK3K,\$_P#(F:1_V"[?_P!%K6G7],X7_=H>B_(_6*/\*/H@KX[^
M-/\ R5CQ!_V%)?YU]B5\=_&G_DK'B#_L*2_SKX/Q%_Y%U'_'^C/G.*/]UI_X
MOT.7HHHK\B/BCRG]HGX+?M!?$?6='\3_ +/W[6-]\-[W38)H;RRF\*VNLZ;J
M:.R,#-;S-&ZNA0[7CE0X=@<BOG7_ ()P_L&>.[?1/A/^TM^T]\8M8\0ZSX%\
M+W=K\/\ P;/X:CTFU\+_ &Q3%<NZ M+<W#QC;OD( 4\)D*1]P45Z%+,L31PD
MJ$+)/KRQO:TDU>U]>9K?;39LZ88NK"BZ<;:];*]M;ZVOK?OMILSYE^/'[#WQ
M@F_:2O/VOOV-/V@++X?^,]?T2#2?&VG:]X;&J:5XA@@XMY9(Q)&\4\2X42*Q
MRBA< %MV]^QE^Q/J7[-_BGQM\;?BW\7;CX@_%#XD7=O+XM\62Z6EC"L%NACM
MK.UMD9A##&IQ]XEL G& ![Y14RS+%SP_L6U:R6RNTM4G*UVE965^B[(3Q5>5
M+V;>EK;*]ELK[V7^78^)OCI_P33_ &W/CG\;/"OQKUC_ (*6Z?:W7@#7[[4O
M ELOP0M'&E_:5V&-V%^HN<1!4W.O.W=@$U[SK_P:_:NU3]FBR^&^G?MAQV7Q
M+M+A9IOB9!X M1#=[;AW\M],:5HE0Q%83A\_+O!#' ]@HJJN9XNM&$9\MH;>
MY!6W=M(ZJ[;:=TWJT.>+K344[6CM[L?\MO+8^+?&W_!.C]L/]JPZ=X'_ &\/
MVV],\1_#JQU:WO\ 4O _@GP''I2Z\\$@DBCN[EI7<1!E!,:C!Z@JRJP^B?C)
M\&OBC\0_B=\.O&G@+]H#4/"&C^#]7GNO$WAJRT[S8O%$#HBI;2N)4\I4*LP.
MV3.[H*])HI5<RQ55QO9*-[)1BDN96;LE:[[[Z+71"GBJTVKVTO9))+7?2UK^
M>_W'BO[3WPL_;:\9>)].\0_LI?M4Z!X*LX; V^J:!XC\"1ZI#<R[RPN4F\Q)
M(V"G;LY4X!X-4/V.OV)9/V</$7BKXS_%7XLWOQ&^*?CR2$^+/'&H:?':!H(5
MVPV=K;1DI;6Z#^!22Q )/"A?>:*CZ]B%AG05E%Z.T8IM7O9R2NU?N^B[(7UB
MJJ7LU9+T5WZNUV%?7?[/_P#R1W0O^O5O_1C5\B5]=_L__P#)'="_Z]6_]&-7
MV?AW_P C:K_@?_I43W>&/]\G_A_5'8T445^PGW 4444 %%%% !1110!^4D?[
M??P[_P""8'_!5G]IGPQXN_9<^-/C#0/B=K&A^('\8^"?AE=:@+'48M)@AEL&
MD&%N;;;LDBEC8F.26:)D&WS&^G/V7/\ @M#^SW^UE\=M"_9^\#_L\_'C0M4U
M_P"U?9=5\9_">[TS38/(M9;EO.N9#MCW+"RKG[SLB]6KA_CY^V+_ ,%-?VF/
MVO/'G[(W_!++P=\,-"T?X1R6-G\2/BO\6C>3P/JMU;)=+ING6MI\SO'#)&9)
M) 5RQ7Y,(9)/V=?VR?\ @I5^SO\ MB^"/V+O^"IO@KX9:Q:?%B#44^&'Q6^$
MKW<-K+J-E;-=3:;J%K=_-%*T"NT<B;4)0*!(68Q@'WG1110!X7_P3W_Y(GJW
M_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444
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M_BSX1_\ !3ZY\"^&[R5&TSPHGP<T74ETY!&JLOVFX/F2Y<,^6Z;\= *^:?\
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M(M;NV86MA"6X4ML=BQSM2-R S *P!]%T5\ :+_P4H_:A^"GQ>^'?@'_@I?\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
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M;;_XW1_PTO\ &W_H=?\ RFVW_P ;H_XB'DO_ #[J?='_ .3#_6? ?RR^Y?\
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MS,=_)^*_S#ZGB/Y?Q1])45\V_P##PG_JD7_E?_\ N>C_ (>$_P#5(O\ RO\
M_P!ST?V9COY/Q7^8?4\1_+^*/I*BOFW_ (>$_P#5(O\ RO\ _P!ST?\ #PG_
M *I%_P"5_P#^YZ/[,QW\GXK_ ##ZGB/Y?Q1])45\V_\ #PG_ *I%_P"5_P#^
MYZ/^'A/_ %2+_P K_P#]ST?V9COY/Q7^8?4\1_+^*/I*BOFW_AX3_P!4B_\
M*_\ _<]'_#PG_JD7_E?_ /N>C^S,=_)^*_S#ZGB/Y?Q1])5]=_L__P#)'="_
MZ]6_]&-7Y9?\/"?^J1?^5_\ ^YZ_2[]B_P <?\+)_9@\(>-_[+^Q?VAI[O\
M9?/\SR\32+C=M7/3/0=:^YX"P>(P^:5)5(V7(^J_FB?0\.4*M+%S<E]G]4>H
M4445^L'V04444 %%%% !117F_P"UI\1OVB/A1\!M9\=?LJ?LY1_%CQS9R6HT
MCP)+XLMM#74%>XC29OMEU^ZB\N%I)<-][R]HY84 ?G%I_P#P49_9>_X)<?\
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M!3'PY^U)_P $._BMJ.H0'9_;?P.URT\5:=J&./.C5?+F@5CR(Y1O4=:LZ/\
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MV[_]#KYSBO\ W2G_ (OT/+SC^#'U/)Z***^%/GPHHHH **** "BBB@ HHHH
M**** "OVB_X)O_\ )D7P^_[!,O\ Z4S5^+M?M%_P3?\ ^3(OA]_V"9?_ $IF
MKZ?A7_?I_P"']4>MD_\ O$O3]4>W4445]Z?1!1110 4444 %%%% !1110 44
M44 >%_\ !/?_ )(GJW_8]ZS_ .E)KT/]H#_DCNN_]>J_^C%KRO\ 8+\-V&K?
M!S5KJYFN%8>.-97$4Y48^TMV%>@_'+PGIMA\)]:O(;BZ+);*0'N68??7J*\[
M-_\ D4XC_!/_ -)9RXW_ '.I_AE^3/E>BBBOYP/RT*_.'_@H+^SK^U7^SIX[
M^+_[2WP6\.^%O''@[XMZQX-N/$>DZIJC6&LZ5?:=?6<-M%;RLC12V\KA%.\@
MQ^9D#"$O^CU?&O\ P41_9K_:_P!<\$>*/$WPA_:YU-_#^L>(=#G'P]U'X?6^
MK?8Y%U*Q7S+2XCDBGCB1D%PT;^8N$<90,6'LY%75'').44I63YD[-<T7;W5=
M.Z33T6FK.[+JGL\0KM).R=[V>J?3TN>L?L;?MIZ/^U/J7C+P%XC^$.N?#WXA
M> +ZUMO'/@KQ T4LMFUQ$9+>:.>$E+B&1$8K(,9"YQM*LW#?M^_![_@I?\3-
M"\4:?^RK\=_!VE^&[[1?(7PS<:&8M7ND,16YAAU!_-CADE!98W,/R%@=PQN'
M;?LP_L57'[/TOQ ^(/BGXUZOXR^)7Q.E@D\6^/;[3H;0L;>!H+2.WM8OW<$4
M*,VU,L23RQ  'F.O?LB_\%7/%6A7'PTUS_@I[H2:%>V[6UYXAT[X16]OK3P,
M-K!2EQY44A4D>:@!4G<H! K:D\%3S!U:%2$8KETG&4D]%S<JY6[)IVO:5K=;
MFD'AXXESIRBDK?$FUTO;1NU]KV=C-_9Y^$7P(_X*&?\ !&#PY\#?@<FI> ?!
MOB?PW%IL4=TJW]UIKVFHC[4&8F,3N\UO+^]PH;S ^P?<KB/VK++]L;_@E-X"
MTC]K#1?VU/$GQ/\  NAZUI]CX\\"^.]*LB9K">9(/-LI[>)&@D1G7:@&.026
M"E&^E-'_ &,]>^!W[&^@_LI_L7?&JX^'5UX72+^R/%%]H4&KO*WG--<&X@D*
M1R&X=Y"Y&W:9"5 P /*/$7_!.3]K#]I[Q)X>L_V^_P!LW3?%W@7PWK<.JCP%
MX.\#QZ5!K-U"VZ(WDYE=VC!SF(#!!X*D!JZL/C<+]9G*=6/L'.4G"47*;3[/
ME?O-)*_,K-7?GM2KT?:R<IKV?,WRM7DT_.SU:MK?1ZD'[1.]O^"XW[.XUD#[
M(OPS\4'1?,Z?;/*D\[9_M>3C..U+_P %$O-7_@I#^Q>^B;/[5_X2_P 3A2,^
M9]C_ +/@^T].=NSKV_6O8?VV/V+Y/VIT\'^// /Q0N? GQ'^&^LR:GX$\9VN
MGI=BTDD0)/;S0.5$UO,BJKID9VCJ-RMS'P"_8;^,%I^TK;_M@_ME?M 67Q \
M::+H,NC^"]/T+PV-+TKP_;S'_2)8XS)(\L\HRID8C"LRX8;=N5#%X2-*E7<T
MI0ISARV=VY<Z5M+6]^[NUL]-KYTZ]%0A4<M8PE&VMVWS6\K>]KKT?D?3=?DU
M-_P4&_8T_:.L/C=^UI\9_P!H?P[8^(-2\!Z_X/\ @EX%O9G^TZ1I#6TT;7+I
MMPEY?S!6;^)(EBCW$$BOT=\(?!SXI^'_ -ICQ=\:-;_:!U'5?">OZ/96FB?#
MN;3REMHD\*J);F.;SCO:4@DCRUQNZFKOQ@_9_P# OQ4^$OBGX86^A:3I<GB/
MP[?:7'J::-%(UHUQ \0F"#;N*;]VW<N<8R.M<F7XK!8&;4[RYN7WHNW*MY+6
M+OT3:Z)I-IF6%K4,/)\VM[:K2W5K5/T=O/HSPK_@BW\;?A1\4O\ @G[\._!W
MP]\<V.K:IX-\*6.G^*+*U<E].NBC$129 PV >F>E?;'P6_Y*QX?_ .PI%_.O
M#?V0OV<M-_9._9Q\(_ *QUN#5I/#&AP:?<:W%I:V;:@T8QYK1AWVDYZ%VQZU
M[;\(;:.\^)^A6LK,%DU&-6*-@]>Q[4XU:-?B%5*-^5U4U?SEZ+\M 4Z=3,U*
M&SFOS/LFBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:OZ&/TTE\;?\ (F:O
M_P!@NX_]%M7Q-7V%XP\&:5!X1U69+F[)33IV :Z8CB-J^/:_*/$?_></Z2_-
M'QO%/\6EZ/\ 0****_-CY4^-?^"B/[-?[7^N>"/%'B;X0_M<ZF_A_6/$.ASC
MX>ZC\/K?5OL<BZE8KYEI<1R13QQ(R"X:-_,7".,H&+#U/]F?]BO5/V?5^(?Q
M"UKXY:GXM^*7Q.:&7Q/\0=3TB"$"2VMV@LD@LHCY44,"L2L6XELD,Q& /=Z*
M]&69XF6$6'T2ZVC%-KW;)M*[UBGJ]7:][(ZGBZKH^RTMZ+7;?37;Y]=CX-_9
MZ_X)3_MP_LOQ^(9?A+_P4_TV"_\ %NM2:KXGUK4_@1:7M_JEV^?GFN)]0:1P
M,G:N=J[F( +,3[S\;?V*=0_:G_8QE_9:_:<^,EQX@UVX1)I?'^C:'%I<R7\-
MP9K>ZBM4=TC*81"@8[E#<J6R/>:*JMF^/KUHUI-<Z:::A"+NMM5%-^CT'4QN
M(J5%-M<R=[I13T\TD?$WQ"_X)T?MQ_M->"[3X ?M??M\Z9K_ ,-8[NV?7[+P
MQ\/DTW5/$L,$BR)%<W'GNL +HC,8U.2O3O7V)+X&\%7$%O;W7A+39DM+9+>V
M$UE&_E1*,*B[@<*.PK5HK#$8_$XF,8R:25VE%**N[7=HI:NR^Y&=7$U:J2=D
MET226N^UCPGX7_L-^&OAG^VG\0_VO8/$-C<IXYT72;"T\-)X>2(:2]E'L,R3
MB0[S(><"--OJW6NN\(?!SXI^'_VF/%WQHUO]H'4=5\)Z_H]E::)\.YM/*6VB
M3PJHEN8YO..]I2"2/+7&[J:](HJ9XS$U6W-WO%1V6RM9;:;+5:^>K%*O5F[R
M=]$NFRM;\M]SY2\5_LU_\%4_[;U+3/ '_!2#PU;Z#?7L[V-SJ_PAMIM2TJ!W
M)2%&6<1W!C4A0\B@MM!;FO3_ -B?]CSP9^Q/\')?AAX8\4:GXAU'5M<NM<\5
M^*-:8&[UK5;DJ9[J0#A<[$4+SA4&2S98^O45I6S'$UJ'LG91=F^6,8WMM?E2
MO;S*GB:LZ?([)>22OZV2N6M#_P"0U9_]?4?_ *$*^XJ^'-&4/K%HAS@W,8./
M]X5]E_\ "#Z1_P _-[_X%M7Z+X;_ ,+$^L/_ &X^HX6^"K\OU-BBL?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:OTT^L/C77/^0U>?\ 7U)_Z$:JU\;>,?VL
MOV@;+Q=JME;?$ K'#J4Z1@Z5:'"B1@.3%S6;_P -=_M#_P#10O\ RDVG_P :
MK^>*F38IS>JW\_\ (_,I8"LY/5?U\C[;HKXD_P"&N_VA_P#HH7_E)M/_ (U1
M_P -=_M#_P#10O\ RDVG_P :J/[&Q7>/X_Y$_4*W=?U\C[;HKXD_X:[_ &A_
M^BA?^4FT_P#C5'_#7?[0_P#T4+_RDVG_ ,:H_L;%=X_C_D'U"MW7]?(^VZ*^
M)/\ AKO]H?\ Z*%_Y2;3_P"-4?\ #7?[0_\ T4+_ ,I-I_\ &J/[&Q7>/X_Y
M!]0K=U_7R/MNBOB3_AKO]H?_ **%_P"4FT_^-4?\-=_M#_\ 10O_ "DVG_QJ
MC^QL5WC^/^0?4*W=?U\C[;HKXD_X:[_:'_Z*%_Y2;3_XU1_PUW^T/_T4+_RD
MVG_QJC^QL5WC^/\ D'U"MW7]?(^VZ*^)/^&N_P!H?_HH7_E)M/\ XU1_PUW^
MT/\ ]%"_\I-I_P#&J/[&Q7>/X_Y!]0K=U_7R/VT\$_\ (F:1_P!@NW_]%K6G
M7!?!OPY;:[\(/"FMZG?7;W-YX;L9[AUN"H9WMT9C@8 Y)X'%=+_P@^D?\_-[
M_P"!;5_0F'5L/!>2_(_3*2M2BO)&Q7XC_MU?\GB?$C_L;;O_ -#K]H/^$'TC
M_GYO?_ MJ_%K]M^VCL_VN_B):Q,Q6/Q5=JI=LG[_ '/>OF^*_P#=*?\ B_0\
MK./X,?4\LHHHKX4^?"BBB@ HHHH **** "BBB@ HHHH *_:+_@F__P F1?#[
M_L$R_P#I3-7XNU^QW_!.WPGIM_\ L6^ ;R:XN@SZ5*2$N64?\?,O05]/PK_O
MT_\ #^J/6R?_ 'B7I^J/H*BLNS\):;8W27<-Q=%HVRH>Y8C\16I7WI]$%%%%
M !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]#_: _P"2.Z[_
M ->J_P#HQ:\\_P"">_\ R1/5O^Q[UG_TI->A_M ?\D=UW_KU7_T8M>=F_P#R
M*<1_@G_Z2SEQO^YU/\,OR9\B4445_.!^6A1110 4444 %%%% !1110 4444
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M_JCT<G_WB7I^J/;J***^]/H@HHHH **** "BBB@ HHHH **** /"_P#@GO\
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MV%[R_#_(/J%'N_Z^1]M_\-=_L\?]%"_\I-W_ /&J/^&N_P!GC_HH7_E)N_\
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MJC_AKO\ :'_Z*%_Y2;3_ .-4?V-BN\?Q_P @^H5NZ_KY'VW17Q)_PUW^T/\
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M%_Y2;3_XU7IG[&O[3GQQ\4_M4^ ?#FO>-_/L[WQ-;17,/]FVR[T+X(RL8(_
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M81(Q&<G))Y( -<#\)?%/[2_P(^"*?LU7_P"S7JFIZYHUI<6&C>*+.]MET2>
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M^_[!,O\ Z4S5^+M?M%_P3?\ ^3(OA]_V"9?_ $IFKZ?A7_?I_P"']4>MD_\
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M^VKI.D?M/Z+^SGX=\"2ZK!J&H'3M2\3+J(C@LKT0F9K94\MO.=(S&7PR[3(
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MUQ<RW.OW%FMQ_9.GVR;Y95B?Y7D;D)NRN5(."01B?"'_ )2'_%[_ +%C0O\
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M;3_T.OFS]GCX"^'_ -GCP"_@W1]9O-4NK[49M2UO6=0(,^H7LV/,F?' SM4
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M_P#L4M-_])8ZZRN3^ ?_ "0OP7_V*6F_^DL==97Z_1_@Q]$?:T_@7H%?B/\
MMU?\GB?$C_L;;O\ ]#K]N*_$?]NK_D\3XD?]C;=_^AU\UQ7_ +I3_P 7Z'E9
MQ_!CZGD]%%%?"GSX4444 %%%% !1110 4444 %%%% !7[1?\$W_^3(OA]_V"
M9?\ TIFK\7:_:+_@F_\ \F1?#[_L$R_^E,U?3\*_[]/_  _JCULG_P!XEZ?J
MCVZBBBOO3Z(**** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
MTI-3?\%(/^3(OB#_ -@F+_TIAKF_C]_P2T_9Q_:*^)5U\4?%GB/QKI5[=PQ1
MRV?AKQ%]CM!L7&Y8A&0&/5CW))ZFN+_X<A?LF_\ 11OBG_X6Q_\ C595Z7MZ
M$J=[<R:^]6(J0]I3<>ZL?EK17ZE?\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\
MT4;XI_\ A;'_ .-5\E_JE_T^_P#)?_MCQO[&_P"GGX?\$_+6BOU*_P"'(7[)
MO_11OBG_ .%L?_C5'_#D+]DW_HHWQ3_\+8__ !JC_5+_ *??^2__ &P?V-_T
M\_#_ ()^6M%?J5_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\
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M &%KC_T:U9-?J5_PY"_9-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\
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M#^QO^GGX?\$_+6BOU*_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
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MB$@QGYL#DYYKT[_AR%^R;_T4;XI_^%L?_C5'^J7_ $^_\E_^V#^QO^GGX?\
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M5/VEKZ\CT346L=>U[1O .M7NE:9<*VPI+>06C0\-P2K,HSR:^K+3X^?!2_\
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M0/'+'(A*NC*0RL"0001UH N4444 %%%% !1110 4444 %%%% !1110 4444
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M\%^&=/TC3K?]B^^$%AI=E';PQC_A(Y>%2,!1^ K[,_9R^+_[2/Q0^"%WX_\
MCW^R%>?"_P 80SW26O@"Z\;Z=J\EPD: PN+RS8P+YK$J 3E,9;@U^<>OWG_!
M9K6O^"KV@_\ !25?^"*&L1V.C?!&?P$WA,_M ^$S++))J;WOVL7'VG 4!MGE
M["<C.[M0!^M]%8_P[USQ5XF^'^A>)/'?@B3PSKFH:/:W.L^&Y=0BNVTF[DB5
MYK0SPDQS&)RT9D0['V;EX(K8H **** "BBB@ K\??V_6_:V_X(W?M4:SI/\
MP3ST32KSPK^VKKJ:+X5\.ZA?K;VW@;XE74L4!U:%&!7[/<0R/,T8!7SH!NVH
MB(_[!5\4?\%;_P!D?]H3]IWXU?LC^+?@=\/O[<T_X8_M(:/XI\<W']K6EM_9
MNDP$&6YVW$J--M_YYQ!Y#V4T >U?\$\_V'OAU_P3U_98T#]G#P#>2ZE<VN^_
M\6>)KS)NO$6M3X>\U&X9B69Y9.FXL5143)""OEW]AO\ Y6&OVYO^Q/\ AO\
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MM?XK:C\#/@5\5]0;QCINFG4CX9\3^$M2T2\NK ,%^UP1W]O"9XLD9*99<Y8
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M?[5OQ@^.>BZ=\/\ 4TM6T7Q':R/>QZL;E=]LEFELLDEV\J99$A5V906 P"0
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M?L\_\.*?'2ZQ%H:V$)\/?\*U^QB+RUO/MUL+?[#M^7'V0W _=\>1YN/ES7Z
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MC_"S1/@M^T1\#]-UOPWX9NX+GPS8V=S<::^CRPQ^7$UI/8R0S6VU/D C=1M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20210630_g6.jpg
<TEXT>
begin 644 biib-20210630_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Q_B%XK_ .$#\ ZYXX^P?:_[&T>YOOLOF^7Y
MWDQ-)LW8.W.W&<'&<X-?G;^S+_P6*_X*Q_M@? OP]^TC^S]_P0JLM:\'>*;:
M2?0]4E_:ET>U:XCCFDA8F*?3TD3$D;C#*.F>A!K[[_:$_P"2!^./^Q/U/_TE
MDK\H?^"'?PB_X+'>(O\ @E5\'M9_9O\ VR?@WX:\$SZ->G0-#\2?"NZO[ZUC
M&HW0=9;A+Q%D)D#L"%& P';- 'ZX_#OQ!XMU_P"&VA>*?B7X+C\*Z[>Z':W?
MB#P[_:L=ZND7;PJ\]K]I0*DXB<NGFJ K[-P !K3TG6-(UZR74]#U6VO;9R0E
MQ:3K(C$'!PRD@\U^<W_!3?PF_P"VK_P50_9T_P""9'QGUZ__ .%2:AX)USQW
M\0?#6FZA+9Q>+[BT(AM+*X:)E<V\<@,IC#88,<\JK+S'CO\ 9Q^%/_!)?_@L
M)^S':_L,^'Y/!7@G]H9_$7ACXF_#72KV8Z3>RV5C'<V>IQ6[LRPW$;N [J!F
M-2HQYDA8 _4+4M3TW1[*34]7U""UMHAF6XN90B(,XR68@#DU+#-%<1+/!*KH
MZAD=&R&!Y!!'45^1G[)7_!.K]FG]N;_@JW^W%K'[6?A:?QIX=\-_$_18]&\#
MW^I7$>DK>RZ2#)?S012*MQ.(U2.,R9$2M*5&7R/UD\'^$O#O@'PEI?@7PAIB
M66DZ+IT%AI=E&S,MO;PQK''&"Q)(5%49))XY- 'DO[-/[;G@O]IKX^?&KX >
M&_!NJ:=?_!+Q19:)K5]?21F'4);FU^TK) $)8*%X.X YKD_@K^W/XJ^)'_!2
M/X^?L6>(_"VCZ?X>^$'A?PQJNGZ^L[BXNCJ=M)-,)]S;%6,IA2 .,YKX)_X)
MQ_\ !(O_ ()O_%[_ (*&_MD^'?B3^R?X>U:R^'GQ9T:'P7;W$]T%TI)M.%S(
ML>V4$[IOG.[//MQ75:1^PW\#OVW_ /@X+_:M\.?M*:9>^(O!N@^ O ES<>!9
M-2FATS5KQ]/*P3WD<+J;@0*LWEQN2FZ<N5+(A !^KUC?V.J6<>H:;>17%O,@
M>&>"0.CJ>A##@CW%17NNZ)IM[;Z;J.LVEO<WC%;2WGN%1YR.H12<L?I7YC?L
M&Z=X;_X)O?M]_MK?LJ_ #2+R'X6>"OA]H/Q$\(> 6OII[;1[Z;3[F2]AM1(S
M,B7$D:,5SQM4# %?)_[#O@']G#]L']E2V_:6_;K_ ."0_P"T_P#M$?%+XJ+>
M:IXA^+^FZ;ITUL%DN91!#HLCZY ]E;VZ!4C"11E61N H55 /WSKY?_:W_:E_
MX*8_"'XM'PC^RE_P2IM/C#X4_LR&8>,)OCSI7AQC<L6\RW^R75M))\F%_>;L
M-NX'%9W_  12/[6UA_P3_P##?@[]M'PYXML/%OAO5]2TFPE\>!/[9O='BN7_
M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
M!;']L;XX?#73=5B\,:MX+\!+X<OM7TV6SDU2SBM+B)+Z.*95=8)BK/$S %XB
MDF ' H UOV>O^"U'[>W[<?P0O?C5^Q)_P2:_X2&T\/:QJ.G^(V\2?%ZWTZ"X
MN;6>11:Z:[V8>\E:(1.SM''%&\HB#2,KE?=O!7_!8K]E_P 0?\$M(O\ @JWX
MJL]8T/P='I$LFH^'I85EU.#4X[MK%M+1,J))VO%\E"=BMN5VV*21YC_P;+JJ
M_P#!)_P^0H!/Q!\7$X'7_B>WE?#_ (*_9E^+_P"U'_P;1^*/#GP/\.:OKNO>
M%/VA=;\41^&] N'BOM5MK'Q'-)<6]LR?,)A$SRH$^<O$H4%BH(!]M^,?^"M'
M[>W[.?@2Q_:B_;5_X)82>!/@I/>6JZ_KFD?%"WU;7_"=E<2)'%?:AIB6J90-
M)'YL<4C20[CD,5(/Z 6-]9:I8PZGIMW'/;W$2RV\\+ADD1AE64C@@@@@^]?B
MWXD^)/\ P0"^-'P&G3XM?\%A?VD-5TC7[#[/K?PS\4?'SQ1>ZE*YP'T^YT<^
M9)+('&PQ^6ZLPX+#!K]DOA]X9T/P7X"T/P=X8CF73-)TBVLM.6X8F0011*D8
M8GDMM49)[T ?)/\ P4V_8]_X(VZYXBL?VQ?^"I?AGPP?+M;;POI6N>-_$M]!
M81<W-S';QP1SK#YK9G8OL+L$QNPH%>"_\$%_#?@O2/VN/VB=1_8"U'79?V.)
MFTF/X<+J5S>/IA\1K&3J?]D"\_>_9E9F61ON,_EA2P08^H/VI?\ @JC_ ,$M
M_@3\7M1_9@_;(^.?AGP[XATBWM=1;1_&NA3FVFBFCW13P2O T$IPS*=K%U(8
M$#O\J_\ !(S6OAA\</\ @K]\>OVH_P#@GKX,GT?]F35?AQINE:AJ6G>'Y=*T
M3Q-XTCND9KVQ@=(U8QVPGCE=(QEWW'_6JS@'._\ !-;]A7]F/_@M5X1^+G_!
M1#_@H/X"?XC:IX\^)VN:'\/[;4M8ND@\)>&;&7[/:VU@D,JB"3<)':5<,S!6
MX9G+_0G_  0!^,7Q4\3?LW?$S]ESXS^.=1\3ZW^SK\<_$7PUM?$>L3&6[U/3
M+"2,V<TSGEV$<IB!/)2%.O6OG[_@F%^W/^R]_P $:O _Q?\ ^">'_!03XEP?
M#76OAS\3M=UOP7+K5A.(O%7AB^E^TVEY8,D9%RY8RJ8DRZG:N-P95]=_X(I6
M7B;]GW]AKX[?\%#?VD/!FL^&8OB]\5O&'QBET*_M"M_I^@2*)8$>%B,.8;>2
M55)&4ECZ4 ?HG7AW[:O_  3Q_9G_ ."A%AX9\-?M4Z)K>O>'?#-]/>)X5M/$
MEU8:?J4TBHJM>);.CW CV912X4%FR&SBNQ_97_:3^'?[8/[/7A3]IKX2V^J1
M^&O&6EC4-%76K'[-<F LRJSQY.W.W(Y(*D$=:^=/^"V7_!63PU_P2B_9IL/&
M-GHUOJ7COQSJ3Z+\/K34U==-@N]H+WM](O*VT"NKLJ_/(2JK@%G0 ^8-5_98
M_9__ .">7_!=3]G'X.?\$O\ 1[OPC/X[\.^(+KX^_#G0M6N9])/AZ"U L=2N
MH)9'%O)]I\Q(W&-SQH, L1+V'QM^%'@K_@JG_P %S?%O[(W[3T,WB#X-_L[?
M"O2]4_X5R]_+%8:OXFU5A+'>WB1.IG$5J^U$;A6 (X=P^/\ \$</VO?^"1?P
M[\=?V!IO_!032_C'^U!\;M3B?QYXZN]#U)+G7=0*EDL+,RVJ):V$ !2*$;%V
MH"0,*B;'QA^*_@/_ ():?\%V_%O[4W[46IGPU\(_VCOA3I>FVOQ#N;.1M.TW
MQ+I)6);&[E12(/,M$WJ[X#$@#[KE0#1_82\(:5_P3G_X+6?$+_@F1\&[J]LO
M@YX]^"EK\4? _@ZXOY;BV\,ZBFI'3KRVL_-9FBBG*R3M'D@%% P*Z;XU?\$#
M/^",7A/X3>.?BS^TE\,;R[F^P7NL^+?BQXN\<ZC+JUGM5YGO1<F8)"8L;E5(
MPGR@%&R0>6_88\;:'_P49_X+=?$3_@I1\$ENM3^#OP[^"5M\+?"'C)[.2&S\
M2:K)J1U&\FLS(JF6.#=)"S@8)=""00:^5_VA?^"Q?_!/W_@J#^U_JOPB_;!_
M:UM/AQ^RQ\+]=0+X&N+#4!J'Q9U>!\B6^^S0N8-)A=05MV*O*0K, V!  ?<7
M_!#!_CI^T_\ \$2?!NA?M3>-?%DMYXK\.ZUI&F^*;B]>VUR?099[FWL;SS\E
MTG^S%&BFY8JL4F6)W'P3]D;]A[X"?L#?\'+4'PD_9]LM=73]7_8PGUS6;WQ)
MXEN]5O+_ %"3Q0('GDFNI'8$Q6T*[5VH-F0H+,3^A_[.W[9O[(/QZ_9FF_:2
M_9R^)^EZI\,= M+J-]:TS39[>ULX+&/,R+"\2.JQ(OW53&!A<U^56J?\%J?^
M"7T__!PMIW[847[6VCM\-H?V1&\)2^*?['U#REUK_A)9;O['Y?V?S=WD,)-V
MS9@XW9XH _;.O$/VOOC1^VK\,[[P_P"'?V./V,M-^*-UJ\=T^L:QX@^(UOX?
MT[01&8A&)-T,TURTN]]JQ1X40L6894'U[P?XM\.^/_"6E^._"&II>Z3K>G07
M^EWJ(RK<6TT:R1R , 0&1E." >>17YF_\%=/BMX'M_\ @I[\*_@1^W[^T+XP
M^&/[+NL?">_O[74= \3WN@Z=XB\9K?[#IVI:A9,DBPQV(69$,B+O9>?FY /I
M;]B[_@HE\5/C'^TKXH_8<_;"_9<;X1_%[PWX4@\566F6/BN+6]*\1:#)<?93
MJ%G=)'$P"7&(GBD0,I8<GY@ODO@[_@L)^V!^TM\6/C-\!?V*O^";:>*_$'P8
M^*>J^$]=UOQ'\3X=+T:2VM7$<%PLSVF]KJX99_\ 1(U<0I$KR3_O$5OFS_@F
MA-^QI=_\'"DEW^P)HGB5_AG_ ,,LZG%I_BO7_$FMZI;^([U-?LA<W-A/K%Q-
M+):1G9;[XR(FE@F*[L;C]-?\$)XT'C_]MV4(-Q_;>\9 MCD@166!^I_.@#U/
M]DG_ (*N?#'X\_L9?$/]J_XX> K[X6WGP8UG6]%^,?A'5+U+Z7P[J6E()+J%
M)8U472E&0QLJC>S;0"1S\I_M6_\ !3_]NCXN?\$Q_BE^T'\0O^"7][X8^"/C
M_P"$FN6^A^(H/B);WOB+3K&_TV:&QU2]TE8%"VTC30O((YFD@B<R%75"3Q'@
M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*/CG]DR+Q;\3=264M;1ZS>>(;8/:6HR0EK;0Q06L0!QLME;C=@?L-0 4444
M%%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*^
M>OV"]8O[#X.:M!;:!<7*_P#"<:R?,B(QG[2W'->V_P#"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &%-^T/\';>9[>;QAAT8JP_L^XX(.#_P LZ;_PT;\&
M?^AR_P#*=<?_ !NOF+5F+:K<L5()N')![?,:KU^F1X,RMQ3YY_?'_P"1/Q^?
MB!G,9->SI_=+_P"3/J7_ (:-^#/_ $.7_E.N/_C='_#1OP9_Z'+_ ,IUQ_\
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M_P"-T?\ #1OP9_Z'+_RG7'_QNOEJBC_4O*_YY_?'_P"1#_B(.=?\^Z?W2_\
MDSZE_P"&C?@S_P!#E_Y3KC_XW1_PT;\&?^AR_P#*=<?_ !NOEJBC_4O*_P">
M?WQ_^1#_ (B#G7_/NG]TO_DS[7LKRVU"SBU"SDWPSQ+)$^"-RL,@X/(X-2UR
MWA'Q%JL?A33(T\*7;A=/A <,N&_=KS6C_P )+J__ $*%[_WTM?FE2*A4<5T9
M^O49NI1C-[M)FQ16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM0:&Q7CW[<OQ
MV_9I^ ?P'N-=_:_\'W&L_#S6[^/1_$D/_"&3:]9PPS)(WF7UK#%*WV7,85G,
M;*K.F< Y'I/_  DNK_\ 0H7O_?2T?\)+JW?PA>_]]+_C0!_/EX&MOV)3^T[J
M>O?\$1O$VO6WQKN?VI-+7P;I'PLFU,:#<>!/[.TIKYM5@(^QQZ>L[:ADR!9-
M^Y<%%^7]E?VQ/^"EW_!.C]E'XBV?[.W[;/QFT/PO?:[H$>M:?9^*]%N)=/OK
M;[1+'D3>2\!D22 DQLP<91@#G->A?"+X2Z1\#_$?Q \2^%[+6[^7XC^.7\4Z
MM'>B)5M+EM.L;#RHMH!\OR["-OFR=SMSC '3>(XM.\8:<=(\6_"Q-4M"P8VN
MHVL4\>1T.UP1F@#\POV,?'7[//[4?_!>G_AHS_@E?X5$?PET?X/7FD_'#QKX
M8\/RZ9X>\0ZPUQNL;=08XX[J[CRCF55R44_,0IS?_P""AVL?\&_&@?M?>/\
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M'LIP^;8F=.LVDE?2W?S3/G>*L[Q>1X6G5H1BW*5O>3?2_1H^@/\ AHWX,_\
M0Y?^4ZX_^-T?\-&_!G_H<O\ RG7'_P ;KY:HKZ[_ %+RO^>?WQ_^1/AO^(@Y
MU_S[I_=+_P"3/J7_ (:-^#/_ $.7_E.N/_C='_#1OP9_Z'+_ ,IUQ_\ &Z^6
MJ*/]2\K_ )Y_?'_Y$/\ B(.=?\^Z?W2_^3/J7_AHWX,_]#E_Y3KC_P"-T?\
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M,PI8I5Z<K6<7RIOE]U))-7NU9):N[[GS%H__  2Q_9C\1_LI^%OV:_B3X?\
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
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M **!_P"4JT_^-5YQ17VGMZ_\S^]GP/U7#?R+[D>C_P##6W[0?_10/_*5:?\
MQJC_ (:V_:#_ .B@?^4JT_\ C5><44>WK_S/[V'U7#?R+[D>C_\ #6W[0?\
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MKP3XF\27OVF^N]-D:XG\I4WD3RC.%  X Z"OQBK]C_\ @G9_R99X!_[!4O\
MZ4RU\YQ-4J3P<%)M^]^C/JN$J-&GCYN$4O=Z+S1[31117Q)^@A1110 4444
M%%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q
M[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %?L?_P $[/\ DRSP#_V"I?\ TIEK\<*_8_\ X)V?\F6> ?\
ML%2_^E,M?/<2?[I#_%^C/I^%?]^G_A_5'M-%%%?&'WH4444 %%%% !1110 4
M444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2OGK]@O6+^P^#FK06V@7%RO\
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M/#]K>)',X 9U,L9<$A1QNQQTK>K&I.+7(I*^B;_X#UN<U&5*$D^>47;5I?\
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M6?L%'^%'T05^+?[;_P#R=W\1/^QKN_\ T.OVDK\6_P!M_P#Y.[^(G_8UW?\
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M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?@YXY_P"1VUC_ +"MQ_Z,:LJM7QS_ ,CMK'_85N/_ $8U
M95?J4/@1^.S^-A1115$A1110 4444 %%%% !1110 4444 ?N=\"?^2(>#?\
ML5-._P#2:.NJKE?@3_R1#P;_ -BIIW_I-'755^7U?XLO5G[!1_A1]$%?BW^V
M_P#\G=_$3_L:[O\ ]#K]I*_%O]M__D[OXB?]C7=_^AU[_#?^\S]/U/F>*_\
M=*?^+]&>5T445]B?"A1110 4444 %%%% !1110 4444 %?L?_P $[/\ DRSP
M#_V"I?\ TIEK\<*_8_\ X)V?\F6> ?\ L%2_^E,M?/<2?[I#_%^C/I^%?]^G
M_A_5'M-%%%?&'WH4444 %%%% !1110!^9/\ P4D_8A^ 'PU_:VUC]O/XQ?\
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M110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444
M%%5-8U_0O#L$-SX@UJTL8[B[AM;>2\N5B66>5Q'%$I8C<[NRJJCEF8  DU;H
M **IQ^(= EUA_#T6N6;:A''ODL5N4,RKQ\Q3.X#D<X[U<H **JZ?KFBZM<7%
MII>L6MS+:2>7=Q6]PKM"_P#=< Y4\'@^E/U+4]-T:RDU+6-1@M+:(9EN+F98
MT0=.68@"@">BHK*]L]2M([_3KN*X@F0/%-#('1U/0@C@CW%2T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?SV>/_
M (]_":W\=ZW!-XKPZ:O<JP^PS\$2L#_!61_PT!\(_P#H;?\ R0N/_C=>#?%'
M_DIGB+_L.W?_ *.>L*OOHXVKRK1?U\S\UEE]%R>K_#_(^EO^&@/A'_T-O_DA
M<?\ QNC_ (: ^$?_ $-O_DA<?_&Z^::*KZ[5[+^OF+^SJ'=_A_D?2W_#0'PC
M_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S311]=J]E_7S#^SJ'=_A_D?
M2W_#0'PC_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S311]=J]E_7S#^S
MJ'=_A_D?2W_#0'PC_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW7S311]=J
M]E_7S#^SJ'=_A_D?2W_#0'PC_P"AM_\ )"X_^-T?\- ?"/\ Z&W_ ,D+C_XW
M7S311]=J]E_7S#^SJ'=_A_D?2W_#0'PC_P"AM_\ )"X_^-T?\- ?"/\ Z&W_
M ,D+C_XW7S311]=J]E_7S#^SJ'=_A_D?U(_L_7=O?_ 7P1?6DF^*;PAILD38
M(RIM8R#@\]*Z^N$_9;_Y-E^'7_8B:1_Z115W=?!5'>;?F?I%-6II>05^+?[;
M_P#R=W\1/^QKN_\ T.OVDK^=[_@I%\:_B;H7[>?Q9T?2O$WE6UMXWO8X8_L4
M+;5$G R4)/XU[>05HT<1-R[?J?/\2T)U\-!1[_H=317S3_PT!\7/^AM_\D+?
M_P"-T?\ #0'Q<_Z&W_R0M_\ XW7U7UVEV?\ 7S/C?[.K]U^/^1]+45\T_P##
M0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1]=I=G_7S#^SJ_=?C_D?
M2U%?-/\ PT!\7/\ H;?_ "0M_P#XW1_PT!\7/^AM_P#)"W_^-T?7:79_U\P_
MLZOW7X_Y'TM17S3_ ,- ?%S_ *&W_P D+?\ ^-T?\- ?%S_H;?\ R0M__C='
MUVEV?]?,/[.K]U^/^1]+45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_
M ,D+?_XW1]=I=G_7S#^SJ_=?C_D?2U%?-/\ PT!\7/\ H;?_ "0M_P#XW1_P
MT!\7/^AM_P#)"W_^-T?7:79_U\P_LZOW7X_Y'TM7['_\$[/^3+/ /_8*E_\
M2F6OYVO^&@/BY_T-O_DA;_\ QNOZ!?\ @DWK>I^(_P#@G=\+M;UFY\ZZN-$F
M::78J[C]KG'10 .!V%>%G^(A6PT5'O\ HSZ'AO"U*&,FY-?#^J/HFBBBOE#[
M0**** "BBB@ KR_]K/\ :3U/]EKX<6/Q"TK]G7XC?$V2]\06VEMH'PQT!=2U
M"W68.3=R1&1-MO'LP[YXWKP<UZA7D_[9/_#<O_"HX_\ AWQ_PJ?_ (3S^V(?
M._X7+_:?]D?V?LD\W']F_OO/W^5MS\F-^><4 ?'/_!4'X[_LQ?$[XO:C\ OV
MGO\ @@Y\?_C[;^$7BCTGQWX8^#T.I6$JS013N+"_%S',$!?RY I4>9$P(.T&
MI_\ @EM\>?V:?AY\7-/_ &=/V8O^"%'Q]_9^LO%AG_M;QSXJ^#\.EZ;']GM9
MKA!?W_VB29@QC,40<L/,F51C<36Q_P =37_5@'_E[UZ!^RY_P_T_X7MH7_#:
MW_#('_"LO]*_X2;_ (5;_P )3_;O_'K+]G^R_;_]'_X^?(W[_P#EEYFWYMM
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M$XO^"?WQ&C^)'B7XP>/M"N_$T&D:=/CPIX=M+A+J]OM1+H!:F/9&OEOAV)8
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M1BKM[(F<X4X.<W9+5M[)&U17$?\ #1OP9_Z'+_RG7'_QNC_AHWX,_P#0Y?\
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M[*RCB>Y?GYI&4 N>3R<GFM&N(_X:-^#/_0Y?^4ZX_P#C='_#1OP9_P"AR_\
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M,]?6TTSPWI-SJ>M3I;R3-;VMO$TLTGEQ*SOM16.U%9CC !) KXNF_P"#F?\
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ML7.G?$.ST;6-)O<3!W$-^%@N;?RC&1ME20,'X;*B@#YJ_P"#>*S_ ."1NM?
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M%%7=U\;/XV?<T_@7H0_V=I__ #XP_P#?H5_-S_P4V1(_^"@?Q?2-0H'CN^P
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M;:+=>#K:*\O$D>TM)->599UCV[RBF++!=RY('&X9ZBC_ %8SQ?\ +K_R:/\
M\D"XQX<?_+__ ,EG_P#(GN]%>(_\-C_]4Y_\J_\ ]IJMI_[<.CZL\T>E>#[:
MY:W?9.MOKZN8V]&Q%P>#P?2C_5C//^?7_DT?_D@_UQX<_P"?_P#Y+/\ ^1/=
MZ*\0?]LI(T,DGP["JHRS'6, #_OS4.G?MM:;J]HM_I/@F"Z@8D+-;ZZKH<<'
M!6(BC_5C//\ GU_Y-'_Y(/\ 7'ARU_;_ /DL_P#Y$]UHKQ'_ (;'_P"J<_\
ME7_^TU!J7[;FF:/:&_U?P5!:P*0&FN==5$!/ Y:("C_5C/%_RZ_\FC_\D"XQ
MX;?_ "__ /)9_P#R)[K17A\/[9L5Q$L\'P^5T=0R.FLY# \@@B'D4[_AL?\
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M6"%<O(0"=JCN3C ^M?E9^SS\3?VL/^"B'Q2^$?QZM/V[[7P;XA\0V/C-M/\
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M_P );X(T:RU/6Q-9A;;R+I5:+RY-WSMAAD8&*^'_ -A+XP?LV_\ !*OXO_M
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MRD%^,'_8]WW_ *,->IE/\:7H>3G7\"/K^AX51117O'S@4444 %%%% !1110
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M .U4?\-:_P#5/_\ RJ__ &JOT3ZU0[_F?EWU+$_R_BO\SV2BO&_^&M?^J?\
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M^#2O,!(+A&#NH.%*KC*E37QK449RJ4[O_A_/YEUX1IU.5>7R\OD?U"_LM_\
M)LOPZ_[$32/_ $BBKNZX3]EO_DV7X=?]B)I'_I%%7=U\E/XV?9T_@7H%?S:?
M\%./^4@OQ@_['N^_]&&OZ2Z_FT_X*<?\I!?C!_V/=]_Z,->IE/\ &EZ'DYU_
M CZ_H>%4445[Q\X%6-4TG5-#U"72-;TVXL[N!]L]K=0M')&WHRL 0?K7TO\
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MNTNS_KYB_LZOW7X_Y'TM17S3_P - ?%S_H;?_)"W_P#C='_#0'Q<_P"AM_\
M)"W_ /C='UVEV?\ 7S#^SJ_=?C_D?2U6M.US6]'61-)UBZM5F7$PMKAD#CT.
MTC/XU\O_ /#0'Q<_Z&W_ ,D+?_XW1_PT!\7/^AM_\D+?_P"-T/&T7T?]?,:R
M^NMFOQ_R/I8DDY)HKYI_X: ^+G_0V_\ DA;_ /QNC_AH#XN?]#;_ .2%O_\
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M=U_9VG_\^,/_ 'Z%<5^RW_R;+\.O^Q$TC_TBBKNZ^-G\;/N:?P+T(?[.T_\
MY\8?^_0K^;G_ (*;(D?_  4#^+Z1J% \=WV !@#]X:_I,K^;3_@IQ_RD%^,'
M_8]WW_HPUZF4_P :7H>3G7\"/K^AX51117O'S@4444 %%%% !1110 4444 %
M%%% !7]%'_!(.RLY?^";GPHDDM(F8Z%-EFC!)_TR>OYUZ_HM_P""0'_*-GX4
M?]@*;_TLGKRLV_@1]?T/7R;_ 'F7I^J/HY+&RC8/'9Q*PZ%8P"*EHHKP#Z4*
M*** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI-8'_!7_P#Y
M1L_%?_L!0_\ I9!6_P#\$]_^2)ZM_P!CWK/_ *4FL#_@K_\ \HV?BO\ ]@*'
M_P!+(*VP_P#'AZK\S'$?[O/T?Y'\Z5%%%?7'Q(4458TS2=4UN\73M&TVXN[A
MD=E@M86D<JJEF(503@*I8^@!/:@"O1110 4458OM(U73$BDU+3+BW6=-T#3P
ML@D7U7(Y'(Y'K0!7HHHH **** "O=?\ @F/_ ,I!?@__ -CW8_\ HP5X57NO
M_!,?_E(+\'_^Q[L?_1@K.M_!EZ,UH?QX^J_,_I+HHHKX\^W.$_:D_P"39?B+
M_P!B)J__ *12U_+U7]0O[4G_ ";+\1?^Q$U?_P!(I:_EZKW,H^"?R/GL[^.'
MHPHHHKV#Q HHHH **** "BBB@ HHHH **** -WX7?\E,\._]AVT_]')7]4=?
MRN?"[_DIGAW_ +#MI_Z.2OZHZ\3-]X?/]#W\D^&?R_4****\8]T_E<^*/_)3
M/$7_ &';O_T<]85;OQ1_Y*9XB_[#MW_Z.>L*OLX_"CX1[A1113$%%%% !111
M0 4444 %%%% !1110!_4+^RW_P FR_#K_L1-(_\ 2**N[KA/V6_^39?AU_V(
MFD?^D45=W7QL_C9]S3^!>@5_-I_P4X_Y2"_&#_L>[[_T8:_I+K^;3_@IQ_RD
M%^,'_8]WW_HPUZF4_P :7H>3G7\"/K^AX51117O'S@4444 %%%% !1110 44
M44 %%%% !7]%O_!(#_E&S\*/^P%-_P"ED]?SI5_1;_P2 _Y1L_"C_L!3?^ED
M]>5FW\"/K^AZ^3?[S+T_5'TG1117@'TH4444 %%%% !1110 4444 %%%% 'A
M?_!/?_DB>K?]CWK/_I2:P/\ @K__ ,HV?BO_ -@*'_TL@K?_ .">_P#R1/5O
M^Q[UG_TI-8'_  5__P"4;/Q7_P"P%#_Z605MA_X\/5?F8XC_ '>?H_R/YTJ*
M**^N/B0K]$?V(O@/\'/@=\&_A1^T5>_ >]^(.N_$;3O%TFH>))]6NHM,\+QV
M5E>1+9&.U*AIKA$<%IF&T%M@R-P_.ZOO?_@E5\,/^"A_@;7-#^(7P!\0ZC=_
M#[Q!I>K7-_9>'_$=M=6T%\MC=1P"[L6D)AF^T1P8+Q@,"GS$$BN7%W]EO;\+
MZ;'7@_XVU_E>VJUM^!\A?'WQ]\%_B+XFLM=^"GP'7X>VBZ:L>IZ+!XDN=3@E
MNA(Y,\3W.9(U*%%\LLV"A(/.!]J_ ?\ ;%^,'[2O_!/3]I;P7X[M_#UCHOA;
MP+HPT72?#GARWL(H6>[*.[&-=\C$1KDNQYR1C)KS;_@JS)IL_A?X2W7Q4T;P
MG8?'>71M2;XO6WA%+54'^DI_9[7:VI,*W9A\PN%.1D9 78!ZU^PS_P $^?VQ
MM#_8J_:!T;5?@??PW/Q&\$:)_P (5$U_:DZIBY>8[,2X3]VZM\^WKZ\5E5G2
M=",I::JUW?[2O9O\^QM1A6CB91CKH[V5OLNUTMO3N?"O[/\ \?/'7[-/Q'A^
M+'PTM]*.MVEK-#87&KZ7'>):O(FWSDCE!3S%SE2P(!YP:^W?V(_VL_VAOVU?
M"WQ@\'_MP>*X_&?PITGX;:AJFMZIK^F6R#0]051]CEMIHXU,=PS;PD8/.TE1
ME>?F/X(?\$\_C_\ %K]L>W_8J\0:-'X8\40R"3Q -1FCD&EVHA2=YB(W(E/E
M.A5%;+%U!*\D?5_[9?[%O[<D?PZ3]DG]DK]DG7="^#?ABX:ZO]1N-4L%OO&-
M]&/GU2^(G#%?ES%#@!%"DJ"$2-XB5"4E&ZN^NFB\G^0L-'$0BY6?*NFNK[-?
MG<^*/V9OVM_BM^R5JNJ^(?A!9^'EU35;>*$:GK7AZWOY;((Q8-;^>K+&Q)Y.
MTY 'I7N/_!<F^NM4_;VOM2OI=\]QX-T.69]H&YVLHR3@<#D]J\ _9Z_97^/_
M .U9X@O_  M^S[\-[GQ+?Z79BZO[:UN8(C#"7"!R9G0'YB!P2>:^PO\ @N!^
MR)^T;!\<=4_:;F^%]TO@73_"VA65YXA^UP>7%.((;<H4\SS"?-8)D+C)STYJ
MYRI1Q<=5=I_I8B$:TL%+1V37IUO_ ,$_/ROUOE\5?\%$;C]G;X ^$_V%?VB/
M".@0'X.:4M_X:U+7=&BOKW4"&($4-ZC2$F,Q 8VKR/>OS1\5?LT?$OP=^SMX
M6_:?UA;#_A&/&&K7>G:.8KLM<>=;,RR;X]ORC*G!R<UZCX<_X)*_\%#?$=UH
MUUX8_9ZU"YM-:MK>[TO6[;5+0V9@E19(YC,)=L8VD$AL,O0@'BC$*E4LW)*U
M]]4+#.M3;48MW2VT??L]SR_]JR]_:%U']H/Q/>?M66]]%\0&O57Q(NHV<4$I
ME6)$0E(56/:8U0JR#:RX8$@Y/9_\$Q_^4@OP?_['NQ_]&"N^_P""R?Q!\'>-
MOVI="T'PWXUL_$VJ>#_AMH_AWQCXDL)_-BU/6+<2FXF$G_+0XD1">S(0>0:X
M'_@F/_RD%^#_ /V/=C_Z,%5S<V$;M;3]">7DQB5[^]^I_271117RA]D<)^U)
M_P FR_$7_L1-7_\ 2*6OY>J_J%_:D_Y-E^(O_8B:O_Z12U_+U7N91\$_D?/9
MW\</1A1117L'B!5C5-)U30]0ETC6]-N+.[@?;/:W4+1R1MZ,K $'ZU]+_L'_
M +.OPM\>?!3XM_M)?$3X4ZG\2+CX;6NEC2_AUI.I36WVYKR:1'NKA[8>?Y$*
MQER(\9^;<5 S5W_@J#\4/@-XH^-_C/P=X=_9DMO#7C+3_%H-WXPT_P 47LR:
MA;B)@\<MG.71'+-&0\97&PC:=V1C[9.KR)?UI_F;^PM1]HW:^RU\_+R/E.BO
MN[_@BM^V+\8/#7[3GPV_97\.6_AZQ\-:IK-\=7N8?#EN=0OU:VGF"273J9-J
MLJX"E< 8Z9KY'\1>%;OQU^T;?>"+"0)/K/C:6QA<C.UYKPQ@X[\L*:J/VCBU
M:RO^?^0I4H^RC*+O=VV]/\SD(-,U*ZLY=0MM.GDMX,>?.D+%(\]-S 8&?>H*
M_0?]LS]OOXP?L._M>G]F#]F&[MM"^&'PN%CI?_"&KI\!M]>'V>*2\>]W(3,\
MS2.C.3G ###$DSZU_P $^O@YXC_X+7O\#++PZT7PXN8$\8R:':Q%=U@;$7C6
M<:+R$:XS$%7!$;87! K)8FT>:2LFKKT7ZZFKPMY<L'=IJ+]7^FA^?(TC56TX
MZPNF7!M%?8UT(6\L-Z;L8S[57K],?C!XB_X+-:EI/BG4_ ^L>%]'\.Z;H\YO
M?@GX2O\ 1;BY\/:*R%?(ETU%:0;8F ;K("> I&%_,ZM*-5U4WI\G?]#.M25)
MI:_-6_4FL-.U#5;D66EV$US,P)6*WB+L0.O &:CEBEMY6@GB9'1BKHZX*D=0
M1V->U_!3_@H9^U3^S=\+5^$OP#\=6OA.Q>_EN[[4-+T:V-_>N^W"RW$B.Y1=
MORJI4#)SFO;O^"C/B+5_BI^Q+\!_CS^T/I%A;_&/Q,^IF[U&&PBM;S6=!1P+
M6[NHXU49/R>6Q W*S,.IP.I.-1)K1NV^OW6_4(TH2IN2>J5WIIO;>_Z'R#\+
MO^2F>'?^P[:?^CDK^J.OY7/A=_R4SP[_ -AVT_\ 1R5_5'7E9OO#Y_H>QDGP
MS^7ZA1117C'NG\KGQ1_Y*9XB_P"P[=_^CGK"K=^*/_)3/$7_ &';O_T<]85?
M9Q^%'PCW"BBBF(**** "BBB@ HHHH **** "BBB@#^H7]EO_ )-E^'7_ &(F
MD?\ I%%7=UPG[+?_ ";+\.O^Q$TC_P!(HJ[NOC9_&S[FG\"] K^;3_@IQ_RD
M%^,'_8]WW_HPU_277\VG_!3C_E(+\8/^Q[OO_1AKU,I_C2]#R<Z_@1]?T/"J
M***]X^<"BBB@ HHHH **** "BBB@ HHHH *_HM_X) ?\HV?A1_V IO\ TLGK
M^=*OZ+?^"0'_ "C9^%'_ & IO_2R>O*S;^!'U_0]?)O]YEZ?JCZ3HHHKP#Z4
M**** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*36!_P5__ .4;
M/Q7_ .P%#_Z605O_ /!/?_DB>K?]CWK/_I2:P/\ @K__ ,HV?BO_ -@*'_TL
M@K;#_P >'JOS,<1_N\_1_D?SI4445]<?$A74?!KXJZQ\%?B!;_$/0=.MKNZM
MK*]MD@N]WEE;FTFM7)VD'(69B.>H&<CBN7HI-)JS&FT[H****8@HHHH ****
M "M"T\6>*M/TF70;#Q+J$%C-GSK*&]=8I,]=R X/XBL^BC< KW7_ ()C_P#*
M07X/_P#8]V/_ *,%>%5[K_P3'_Y2"_!__L>['_T8*SK?P9>C-:'\>/JOS/Z2
MZ***^//MSA/VI/\ DV7XB_\ 8B:O_P"D4M?R]5_4+^U)_P FR_$7_L1-7_\
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MR]5[F4?!/Y'SV=_'#T84445[!X@4444 %%%% !1110 4444 %%%% &[\+O\
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M!_RC9^%'_8"F_P#2R>O*S;^!'U_0]?)O]YEZ?JCZ3HHHKP#Z4**** "BBB@
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M_P +8_\ QJOL:B@#XY_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
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M!_'#]D[_ (),_M6_MI7GP_N/AQ<?$[6/'?Q9^''P\FC\F3PMITFG/+IZ21
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M&_$/B,1M(GAJY2XTW4Y54;G*6E]%#/(%'+;4.T<G KZ+K\X_^#FKX!> KO\
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M].\*>';_ ,4ZNMR;33;*6ZNA96,MU,8XT+MY<,*O),^ <1QJSL<!5)(%<?\
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MKJEPL"Y_NI&RQJ.R1J* /OZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M BY/)_3FPL+'2K&'2]+LHK:VMHEBM[>WC"1Q1J %15'"J   !P *EH ****
M/QW\(>$/^"R^O_M^ZQ^WA^V#_P $==6^)^L>'+J>R^!OARR^//A6QT3P-IK'
M:UQ#;RW,C3ZA, "]T^UAT55 18_TU^"'Q?\ VD?'_P"SM=?$[XP_LA7G@#QY
M#!?/;_#&X\;Z=J4L[Q!OLZ?;[5C;+Y^%P2<1[_FZ&O4Z* /R0LKS_@LU:?\
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MG5V"1-"<B,J?-P&RK ?I)10!^97[3/[.O_!5?_@LQ8:-^S5^U9^S3X>_9L^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /Q'_ .#D[_D^;PI_V2>Q_P#3GJE?GO7Z$?\ !R=_R?-X
M4_[)/8_^G/5*_/>OJ\%_NL/0^.Q_^^3]0K^FC]@O_DQGX+_]DG\.?^FRWK^9
M>OZ:/V"_^3&?@O\ ]DG\.?\ ILMZX<W_ (<?4[\E_BS]#UBBBBO"/H@HHHH
M_,O7/&__  4S_:Z_X+ ?M'_LD? ;_@I3?_!SP3\)-"\(WNB:78_"7P_KIE?4
MM,2:8-+>P>:/WJN_+M_K,#: !7?_ /!.O]JC]MGP]_P4/^+/_!,#]L_XQ^'O
MBU=^!?!&F>+?#_Q2T3PM%HES+;W4B1M97]G;LT$4W[Q739@E%+$L'4)\^Z#^
MPE\'/VX?^#@?]LC2OB]XJ\>:7'X=\+?#^6Q;P-X[O]#>1IM&0,)FLY$,P C7
M:&SMR<=371?L$^ _"/\ P37_ ."Z/BW_ ()P_LX^)+CQ;X'^(WP=7Q_XLN-?
M-O?Z]X=UJ&\>!$NM35!<W$$D)1EBNF=D:Z1D*AR9  _9[U;_ (*Z_P#!0+]J
MC]IW1_A=_P %;[GX3>%_A+\<=1\)^'/#<'P*\.:V!9Q@21YN+B..4[58+\Y=
MCC)8YKZ=UKPQ^W3^Q7_P3S^/7Q#^.7[?$_QA\<:%\/M?U_P9XLG^&&DZ"=$D
MM=)FEA06UJ'AN<3QB7,JMG.T@KQ7Q1_P3\_X)M? 7]MK]LW]MOQI\6_&GQ*T
MN[T;]I[5K*UB\$?$G4M$@>,HLF9([25%D?+'YF!.,#H*^S/CW^R#\,/V*_\
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MWZE_BC^:.+,?^1?6_P $OR9^0M%%%?I)^4'WY_P0V_YJA_W!/_;^OORO@/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\&O%7[/O[,'P3'A?PAXUN9[CQ-HX\1ZE>"\DFMUMI#YMU<2RQ9A55Q&R@8R
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MP^"7@ Z1JOQ-\63>)?'.H3:O=WLVJ:G+PTI:ZED,2 9"PQ[(D!(1%R:_./\
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MB!\8?<.*^H-)TJPT/2K;1-*@\JUL[=(+:+<6V1HH51DDDX ').:L44 %%%%
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M,H&2-E:.%F=HDC9W+?1EW:6E_:RV%_;1SP3QM'-#,@9)$(P58'@@@X(-244
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20210630_g7.jpg
<TEXT>
begin 644 biib-20210630_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
M8_V#[;YMW/<;OL_G3>7CSMN/,;.W.1G ]OHH ^8?^"@__!.W6/VN?&/PY_:)
M^!7QVN?A7\9OA%J%W<>!?'4&BQZC;M;W<0BN]/O;1W07-M,B@$;PR$DK]YE;
MC_V=?^":7[05]^V3HO[?/_!1#]JK3?BAXY\$Z#=Z3\,O#WA3PA_8NA>%DNU\
MN\NHXVFFDN+F:/\ =F1V&U21AL1^7]G44 > ?LF_L,?\,O?M)_'[]H7_ (6C
M_;G_  O+QAI^N_V1_8GV;^Q/LUG]F\GS?/D^T[OO;]D6.FT]:]_HHH ^+O%?
M_!,/]IKP/^V3\1?VL?V)?^"@,?POM/BY>:5??$'P9KGPHM?$=M=7EC;BV6>V
MFDN[=[7S(@=XP^78MG 55]2^#7[#'_"H_P#@H)\:/V[/^%H_VA_PM[P_X<TS
M_A%O[$\K^R?[*MWA\S[3Y[>?YN_=M\J/9C&7ZU[_ $4 ?/GPU_8.M? /_!0;
MXM_MTWWQ(CU2'XJ^"]#\/S>#I=!"K8+IZ.ID-P9F$XE#\H8DVXZMFO!/AI_P
M2X_;\_8CM-1^$7_!-S_@H%X<\-_"&[U:YOO#_@#XF_#0ZY)X0^T3---#87<5
MW"\D'F.[+%,#MR?F9F9C]_44 <'^S1\.OC-\*_@WIG@O]H+X_2_$_P 702W,
MNK^,Y/#=OI O6EGDD1$M+<M'!'$C+$H#,2L8+,S$D]Y110!\\?\ !,G]@K_A
MW-^SI?\ P!_X6M_PF/V[QQK'B+^UO["_L[9]ON#-Y'E>?-G9G;OWC=UVKTJQ
M\"?V&/\ A2G[?'QY_;A_X6C_ &G_ ,+NT_PO:_\ ",?V)Y/]B_V/8R6N[[3Y
M[?:?.\S?CRX]F,9?.:]_HH \ ^#7[#'_  J/_@H)\:/V[/\ A:/]H?\ "WO#
M_AS3/^$6_L3RO[)_LJW>'S/M/GMY_F[]VWRH]F,9?K1_P3"_88_X=P?L8^&O
MV1/^%H_\)E_PCVH:K=?\)#_8G]G?:/MNHW%[M\CSYMFS[1LSYAW;-V%SM'O]
M% 'PM??\$O\ ]KO]FGXW>//BG_P3!_;3T/X?^&OB?XCF\1>+OA?\0? 7]N:1
M;ZW. +C4+"2*X@FM3+M4O#\R%@.0JHB>M^'OV'_B+\8OV/?'G[*W_!2+]H.'
MXTCXB37*ZKJ&F^$+?P_!IEE)# D5I9PPO*5\B6$W$<\CO)YKY/"JH^A-8US1
M/#UF=1U_6+6QMPP4SWEPL29/0;F(&:GMKFVO+=+NSN$EBE0/%+&X974C(((X
M(/K0!\(> _V#_P#@LQ\(/!=C\ _AI_P5N\)R^"]'LTL="\4>*/@=#J'B>RLH
MUV10NYO5MKJ1$"KYTL>YRNYE))!^X/!NC:MX<\(:5X>U_P 33ZU?6&FP6][K
M-U$D<M_,D:J]PZH JL[ N0HP"Q XJQJ.N:)H\MO!JVL6MJ]W+Y=JES<*AF?^
MZ@8C<?8<U:H ^-_VHO\ @G1^TOJ7[;8_X* _L&?M5:)\._&FL>"8?"GCO0O&
M7@LZUI&NV4$S36\^U)X98+B(MMRK$,H4?+\_F5_V*?\ @E#\1OV9OV[_ !C_
M ,%!OC+^V5J'Q/\ &7Q ^'D/A[Q3#>>$(M.A%U'=QS+/:B*X=;>V2&&&!+78
MQ&PR-,[.U?:%-FFBMXFGGE5$12SN[8"@<DDGH* /"O\ @G]^Q-_PPM\._&W@
M+_A9G_"4_P#"8_%CQ!XU^U_V-]A^R?VI<^?]DV^=+YGE?=\W*[^NQ>E>9_"7
M_@CS\+/#?[&?QR_8D^-?Q!F\9^&?CA\1O$?BK4KFUT@:=-I?]J3131119FG#
MRVTL,<B3' 9T4F, $'ZYTC6]%\060U+0=7M;ZW9BJW%G<+*A(ZC<I(R*DU#4
M=/TBRDU+5;^&UMX5W2W%Q*$1!ZEB0 * /S<^+'_!&O\ X*+_ +3_ .R??_L'
M?M.?\%7++4_AK#HZ6.EWVB?"=(-;U;R ILCJL[7Q$\<+QQ2/'%Y;W#1+OEY;
M=^@/P1^&_P#PIOX+^$/A#_;/]I?\(KX7T_1_[1^S^3]J^S6T<'F^7N;9NV;M
MNYL9QDXS726MU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O5>\\0Z!I^I6^C7^N6<
M%Y=Y^RVDURBRS?[BDY;\!0!\[?MA_LS?M_?$/XLZ;\8?V*?^"@<'PT2T\/II
MNJ> O$_P]@U[1-5D2::5;HEIHYK6;$H1GB)W+$@(XKS7X%_\$M/VC/$O[9_A
M']O/_@H[^V5:_%3Q9\-M.O[7X8>$_"O@M-#T+PY)>Q^5=76SSI9+J9X\+N<C
M;M0_-LCV?;]% 'S'\'/^"?\ X^^ 'Q._::^,WPK_ &B;.U\2?'_7+;5M#NK_
M ,%?:(?"5U!8&TC9HOMB_P!H@-B7!, XVG(YKS>S_P""$O[.K?\ !.S4?V)O
M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
M<O\ !3PQ\3?!7PE\.^$/C-\3+7QGXITS2H;;7/%EGH/]EIJ\Z+M:Y^RB:80,
M^ S*LA7<6*A00H\@_:#_ &"?^%[_ /!0']GO]NC_ (6M_97_  H>W\51?\(M
M_87G_P!N?VSIHLL_:?/3[-Y./,_U4OF?=^3[U?0]% '+>'?@=\%?"'Q,UWXT
M^$_A!X6TOQCXHAAB\3>+-.\/VT&IZO'"JI$EU=(@EN%1555$C,%"@#  KY@_
M9T_X(X_"OX7_ /!.KQ]_P3A^-GQ#F\>>%_B%K^N:CJFIVVCC2YK<:A<_:(Q$
MAFG EMY%1TD)(+QJ2F/EK[(JMK&L:1X>TBZ\0>(-4MK&PL;9[B]O;R=8H;>%
M%+/([L0J*J@DL2  "30!^=/B'_@CU_P4*^-OP3TS]AO]J/\ X*D6_B3X#6!M
M+75K71/AJFG^*?$NE6SHT.FW>HFZ=(UQ'&KSI&9) GSYWM7TE\<?^">FA?%;
M]JO]FG]HSPMX\A\,Z9^S@^OKIWA&WT'SH]4@U'2X]/CA6;ST^RK L88?NY=X
M^7Y,;J^@M U_0O%6B6GB;POK5IJ6FZA;)<6&H6%RLT%S"ZADDCD0E75@00P)
M!!R*GO+VSTZUDOM0NXH((D+2S32!411U))X H \$_:D_88_X:5_:Q_9]_:@_
MX6C_ &+_ ,*)\0:UJ?\ 8?\ 8GVG^W/[0L!:>7YWGI]F\O&_=LEW=,+UKS+X
MV?\ !,?]HT_MI>,_VV_V'OV]5^$.N_$OP_I6F_$+1]:^%MKXGL]3?38VBM+B
M(2W5NUNZQ,4(!8-DGOQ]BZ9JFF:U91ZGH^HP7=M*,Q7%M,LB.,XX920>:;JV
ML:1H-DVIZYJMM96R$![B[G6-%).!EF( YH \-\(?L1S^&/\ @HOXE_X* W/Q
M3%W)XC^$FF^"9/"PT/RQ"UK>RW1O/M/GG=O,FWRO*&W&=YSBJ^D?L)2Z1_P4
MJ\4?\%$(?BRV_P 1_!NU\!IX370\&T,-^UV+X7?GG?G.SRO)&,9WGI7T%'(D
MJ"6)PRL 593D$>M5)/$.@0ZPGAZ77+-;^5-\=BUR@F=>?F"9W$<'G':@#X+^
M*/\ P3N_X*__ !V^#VN_LH?&?_@JOX(U;X?>*M(GT?Q1XCM?@1%:^)+_ $R=
M#%<6XV7WV2)Y(F>,S+'E=VX+GBOMCX(_"+P?^S[\%_"'P%^'D4\?A_P1X7T_
M0-#2ZF\R5;.SMH[>$.^!N;RXUR<<G)KJ*JVNN:+?:C<:19:Q:S7=H!]JM8KA
M6DASTWJ#E<]LT ?'/[;/_!,']H_X_?MT^$OV]OV6/V[[3X/^*?"WPYG\(""\
M^%$'B1+FVFNY+F23]_>PHA.]5QL8C9D-S@=G^S!^S)_P4S^&'Q<M/%O[3G_!
M4?2/BGX2BM)TNO!]I\ ]/\/O/*R$12"\@O9738V&VA"&Q@D5].T4 > ?L"_L
M,?\ ##G_  NK_BZ/_"4?\+@_: \1_$W_ ) GV+^R/[5^S_\ $O\ ]?+]H\K[
M/_K_ -WOW_ZM,<\5\'_^"37PU\(_"7]IOX&?&'QV_C/PQ^TQ\4O$7BW6;.+2
M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1
M6/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\
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M<1<59#PIAH5\UK>SA-\J?+*5W:]K0C)[+KH?H/17YD_\1 /B?_HVF#_PKO\
M[CH_XB ?$_\ T;3!_P"%=_\ <=>__P 0ZXR_Z!?_ ">G_P#)GR7_ !&3PW_Z
M#O\ RE6_^5GZ0>&/ ?@OP5?:UJ7A+PO9:=<>(M6.J:]-9VZHU_>F"& W$I'W
MY/*@ACW'G;$H["M:OS)_XB ?$_\ T;3!_P"%=_\ <='_ !$ ^)_^C:8/_"N_
M^XZ/^(=<9?\ 0+_Y/3_^3#_B,GAO_P!!W_E*M_\ *S]-J*_,G_B(!\3_ /1M
M,'_A7?\ W'1_Q$ ^)_\ HVF#_P *[_[CH_XAUQE_T"_^3T__ ),/^(R>&_\
MT'?^4JW_ ,K/TVHK\R?^(@'Q/_T;3!_X5W_W'1_Q$ ^)_P#HVF#_ ,*[_P"X
MZ/\ B'7&7_0+_P"3T_\ Y,/^(R>&_P#T'?\ E*M_\K/TVHK\R?\ B(!\3_\
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M,:_<[_@F#_R87\-_^P/+_P"E4U?E7BY_R(J'_7U?^DR/WOZ/?_)5XK_KP_\
MTY ]ZHHHK^?#^O0HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['O6?_
M $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@DDL ?H_'XAT"76'\/1:Y9MJ$<>^2Q6Y0S*O'S%,[@.1SCO5ROR0_P""K?\
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M.-Y_Z'7ZUX1?\CC$?]>__;D?S[](;_DG<'_U]?\ Z1(\>HHHK]^/Y)"BBB@
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M\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G/4?\
M@K/_ ,$_-*U"?2[_ ./WESVTS13Q_P#"*ZJ=KJ2",BUP>0>E0_\ #W;_ ()X
M_P#1P?\ Y:>K?_(E?C#\0_\ D?\ 7/\ L,7/_HUJQZ_H2GX3<.3IJ3JU=5_-
M#_Y6?R!6^D!QE3JRBJ&'T;7PU/\ Y:?MM_P]V_X)X_\ 1P?_ ):>K?\ R)1_
MP]V_X)X_]'!_^6GJW_R)7XDT5?\ Q"7AS_G[5_\  H?_ "LS_P")@^,_^@?#
M_P#@%3_Y:?MM_P /=O\ @GC_ -'!_P#EIZM_\B4?\/=O^">/_1P?_EIZM_\
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M)-%'_$)>'/\ G[5_\"A_\K#_ (F#XS_Z!\/_ . 5/_EI^VW_  ]V_P"">/\
MT<'_ .6GJW_R)1_P]V_X)X_]'!_^6GJW_P B5^)-%'_$)>'/^?M7_P "A_\
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M)1=[;V^=Z_<[_@F#_P F%_#?_L#R_P#I5-7X8U^YW_!,'_DPOX;_ /8'E_\
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MS6NW=OWY3>K\[=DC^A+]GBPL6^ '@9FLH23X.TS),8_Y](Z[#^SM/_Y\8?\
MOT*Y3]G?_DW_ ,"_]B=IG_I)%78U_'F-_P!\J?XG^;/]&LM_Y%U'_!'\D0_V
M=I__ #XP_P#?H5^#O_!0!$C_ &U_B<D:A0/&-Y@ 8 ^>OWHK\&/^"@?_ ">S
M\3_^QQO/_0Z_4?"+_D<8C_KW_P"W(_"OI#?\D[@_^OK_ /2)'CU%%%?OQ_)(
M4444 %%%% !1110 4444 %%%% !7[D_\$Q+*SE_8.^&\DEI$S'1Y<LT8)/\
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MG[3_ &'I6BZ++#<S^3;2SS;':W0#;!%*Q^8952.<XH ^LZ*** /"_P#@GO\
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M[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?SG_$/_D?]<_[#%S_
M .C6K'K8^(?_ "/^N?\ 88N?_1K5CU_:E'^#'T1_F;B?]YGZO\PHHHK0Q"BB
MB@ HHHH **** "BBB@ HHHH _H7_ &=_^3?_  +_ -B=IG_I)%78UQW[._\
MR;_X%_[$[3/_ $DBKL:_C#&_[Y4_Q/\ -G^E>6_\BZC_ ((_D@K\&/\ @H'_
M ,GL_$__ +'&\_\ 0Z_>>OP8_P""@?\ R>S\3_\ L<;S_P!#K]1\(O\ D<8C
M_KW_ .W(_"OI#?\ ).X/_KZ__2)'CU%%%?OQ_)(4444 %%%% !1110 4444
M%%%% !7[G?\ !,'_ ),+^&__ &!Y?_2J:OPQK]SO^"8/_)A?PW_[ \O_ *53
M5^5>+G_(BH?]?5_Z3(_>_H]_\E7BO^O#_P#3D#WJBBBOY\/Z]"BBB@ HHHH
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MT1_F;B?]YGZO\PHHHK0Q"BBB@ HHHH **** "BBB@ HHHH _H7_9W_Y-_P#
MO_8G:9_Z215V-<=^SO\ \F_^!?\ L3M,_P#22*NQK^,,;_OE3_$_S9_I7EO_
M "+J/^"/Y(*_G#_X*8?$GQIIG[?_ ,7=/L=:V0P^.KY8T^S1G $AXR5S7]'E
M?S3?\%/_ /E(7\8O^Q]O_P#T8:^KX)Q%?#XZJZ4W%\O1M=5V/BO$3!8/&Y=1
MCB*<9I3NE))]'W3/*O\ A:_C_P#Z#_\ Y*Q?_$T?\+7\?_\ 0?\ _)6+_P")
MKG:*_2?[2S'_ )_3_P# G_F?D?\ 8&1?] M/_P  C_D=%_PM?Q__ -!__P E
M8O\ XFC_ (6OX_\ ^@__ .2L7_Q-<[11_:68_P#/Z?\ X$_\P_L#(O\ H%I_
M^ 1_R.B_X6OX_P#^@_\ ^2L7_P 31_PM?Q__ -!__P E8O\ XFN=HH_M+,?^
M?T__  )_YA_8&1?] M/_ , C_D=%_P +7\?_ /0?_P#)6+_XFC_A:_C_ /Z#
M_P#Y*Q?_ !-<[11_:68_\_I_^!/_ ##^P,B_Z!:?_@$?\CHO^%K^/_\ H/\
M_DK%_P#$T?\ "U_'_P#T'_\ R5B_^)KG:*/[2S'_ )_3_P# G_F']@9%_P!
MM/\ \ C_ )'1?\+7\?\ _0?_ /)6+_XFC_A:_C__ *#_ /Y*Q?\ Q-<[11_:
M68_\_I_^!/\ S#^P,B_Z!:?_ (!'_(Z+_A:_C_\ Z#__ )*Q?_$U_0__ ,$B
MM2O=8_X)P?"K4M1F\R>70YC(^T#)^V3CH !7\WU?T=?\$=_^4:7PF_[ ,_\
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M\,/CMX-\*>-_B)J_CR'1+&\UJYU6RW^'X(A!---'*)5MKB<A5B61SMD&W?\
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M]B\;_P#0;LO_  &/^-?GG_Q$(_\ 5HO_ )?W_P!P4?\ $0C_ -6B_P#E_?\
MW!1_Q#KC+_H%_P#)Z?\ \F'_ !&3PW_Z#O\ RE6_^5GZ&?8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-?GG_Q$(_\ 5HO_ )?W_P!P4?\ $0C_ -6B_P#E
M_?\ W!1_Q#KC+_H%_P#)Z?\ \F'_ !&3PW_Z#O\ RE6_^5GZ&?8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-?GG_Q$(_\ 5HO_ )?W_P!P4?\ $0C_ -6B
M_P#E_?\ W!1_Q#KC+_H%_P#)Z?\ \F'_ !&3PW_Z#O\ RE6_^5GZ&?8O&_\
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M &&+G_T:U8]?VI1_@Q]$?YFXG_>9^K_,****T,0HHHH **** "BBB@ HHHH
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M\2Y=(DM47P;\+_#QU36[[SKB.$F"V#+Y@C\SS'Y&V-';M7I%>8?M;^+OVKO
M7PH'C']CSX1>&?'OB?3M4BFO_!WB3Q VE'5M."OYT-I=[6C@NRWEE&F'E8#A
ML$@@ ^ O&'_!53X%?$/Q'<^,?'__  ;7_M9:YJ]Z5-YJNL?LJ6MS<SE5"*7E
MD<LV%55&2<!0.@KT7]A[]MCX!?%S]J+PQ\//!7_!"+X\?!G4]0^V_9OB5XS_
M &=+70=-T?R[*>5O.OHSN@\U4:W7'WWG1.CU+J7_  <5?LL_"%CH7[:7[,WQ
MZ^".OP'9=Z?XR^%]U<6SR#J;:[L?.CN8B>%D7 ;K@59T?_@MSXL_:CD'A?\
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M% !1110 4444 %%%% !1110!_0O^SO\ \F_^!?\ L3M,_P#22*NQKCOV=_\
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M1Q.-K86?M:D8QC.-6,9P2BHRE=TIIU*B5YU%&+NY.*7,?3?[!WB:_P#V)O\
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MR48IOSY5Z'[ST445_'Q_HN<=^T1_R;_XZ_[$[4__ $DEK^>BOZ%_VB/^3?\
MQU_V)VI_^DDM?ST5^Z^$'^YXO_%'\F?RM](K_D8Y?_@J?G$****_8S^< HHH
MH **** "BBB@ HHHH **** -CX>?\C_H?_88MO\ T:M?T85_.?\ #S_D?]#_
M .PQ;?\ HU:_HPK\/\8?XV#]*G_MA_47T<_]VS+UI?E4"BBBOQ<_I8_FN^(W
MQ4\!Q?$+7HI-=PRZS=!A]EEX/G-_LUC?\+7\ ?\ 0?\ _)67_P")KS;XI?\
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MDDM?ST5^Z^$'^YXO_%'\F?RM](K_ )&.7_X*GYQ"BBBOV,_G **** "BBB@
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M^R9+IL2PR6JK#+&#+,1(N>0RDY4@8_@'_@F-^W3\5_ 6@?$_X8?L_P"I>(=
M\2VWG:3J>EWMM)&R[RA$@\T-"0RL") O3/3FO6/^"K=U!X"^$'[/?[+'C3QC
M8ZW\2?AIX.U"#QY/8WZW7V W$\+VFG23*2"]O'&Z;03@%2.&!)1C0HX_EI2A
M)S<[M)<T;W>KN]$_=UMT#$3Q%?+>:M&<(P4+)M\D[6C91:6K7O73>ESTS]KC
M]N;]JO\ 9C_X*&/^RC\"+>'0?AYX3UC3="T'X6V>BP-8:I8RQ0YCEC:,M.;D
M2L2Y);]X,'(S6=XA^!'[)_[)7_!>.#P#\6M-TJQ^&(UE=3L;3547^S[*6[T\
MS6\<H;Y5@CO'"C=\JJJ;OE#5V/PFT;_@LSKUUX;TSXK> /"VB:;I>FP(WQX\
M6Z'H\VH:!HNT%KB+5'9B2L+,58;I,G)(.6&)\,_VK/@#^T?_ ,%TKSXRZGJV
MFQ>'Y()])^'6L>( /LJ:A;V M[*[D\T?\M)4=X]X!#2Q]& KAA>$)*FDTJ4E
M)P=[O2S;MONU>[W^?HU&JDX2J-IRK1<%4C91CK=)7UBO=3M9;6ZV]"^#/C+_
M (*)P?%;QQ+_ ,%6[-Q\ O["U,>,E\2V5FNDX,;_ &-=*90/,E,WE+$(2Q(.
M?O;2/R:K]/?V'_@1_P %(/A#^USJOQ'_ &Z]1\0:=\+;73]4_P"%KZGX]\0+
M<Z+JMD]M,HCVR2-'<[I6C*A <#T&5/PCX&_9I\9_'/PO\3OBY\)K>RC\,_#F
MV74]5CO[LI,EE--(L(C7!\Q@$Y!(^IKT,NG1HU:FL;6AK#2-W=6_Q?FN4\S-
M:=>O1I+EGS7GI/6=E9W_ ,*5[::/FW/J?_@G_P"(_B;IG_!/OQMI_P"P/#"?
MC^WC^"3Q"+"W@?6V\)_90 ;$2 LR"ZVAQ&"PWL3U0U7_ ."B_B'XC:G^PO\
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M0?\ !3NRLXOV#OB1)':1*PT>+#+& 1_I4->OD'_(]PG_ %]I_P#I2/GN+?\
MDE,?_P!>*O\ Z;D?AM1117]@G^= 4444 %%%% !1110 4444 %%%% !7KW[
MEQ!:?MI?#*YN9 D:>+[,NQZ ;Z\AKV#_ ()_HDG[:_PQ210P/C&SR",@_/7F
MYS_R)\1_U[G_ .DL]KAO_DHL'_U]I_\ I:/W6_X3'PQ_T&H/^^J/^$Q\,?\
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MMF8_R0^Y_P#R0?\ $-<B_P"?E3[X_P#R![-_PM?P!_T'_P#R5E_^)H_X6OX
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M>*/A[XT^)&J>*/A3\+4\%>'[N5&TWPNFM3ZB+!1&JLOVB?\ >2Y8,^6Z;L=
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M[T;/I>VBVW/G;2?"?BG7]-O]8T+PUJ%[9Z5$LNIW5I9O)'9HQ(#RLH(C4D$
MM@'%?0G[/O[8_P &K3]F>X_8Z_:^^#^L^*?!,/B-M=\+ZQX5U=++5=#O639,
ML9E1XI8G4DE& P78_,2NSQ[X<?M!?%[X2>!_&'PW^'OB[^S]%\>Z=%8^+++[
M!;R_;K>-F9$WRQL\6"S',94G/)-==^S=^W3^T'^RMX=U#P=\+=3T*71]4O1>
MW>E^(/"]EJ,7VD($$R_:(F9&V@#Y2 <<@UUXFE4K0:Y4[-./O-/UNEH]^]UO
MN<>$K4L/43YFKIJ7NJ2]+-JZVWM9[;'UC^U?\2OA5HO_  1@\*> _AY\(+SP
M1HWBKXJM<>!M*US4OM>IZKIUM;L;C5[F38@+/<2",!%"*GE!<CFOSMKNOV@_
MVE?C?^U/X[_X6/\ '?Q]=:]JBVZV]LTL:10VD"DE8888E6.% 23M10,DDY))
MKA:6!PKPM%J6[;;U;W\WJ_7KN/,L9'&5U*.T8J*T2T7DM%Z+9:7>Y_4I^RO_
M ,FP_#C_ +$+1_\ TBAKO*X/]E?_ )-A^''_ &(6C_\ I%#7>5^0UOXTO5G[
MEA_X$/1?D%?S3?\ !3__ )2%_&+_ +'V_P#_ $8:_I9K^:;_ (*?_P#*0OXQ
M?]C[?_\ HPU]5P?_ +Y4_P /ZH^,X[_W"E_B_1GA%%%%?H)^8!1110 4444
M%%%% !1110 4444 %?T=?\$=_P#E&E\)O^P#/_Z67%?SBU_1U_P1W_Y1I?";
M_L S_P#I9<5\GQA_N%/_ !?HS[;@7_D95/\ !_[<CZ6HHHK\[/U(**** "BB
MB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37._\%B/^4:7Q9_[ ,'_
M *66]=%_P3W_ .2)ZM_V/>L_^E)KG?\ @L1_RC2^+/\ V 8/_2RWKLR[_D84
M?\4?S1PYG_R+:_\ @E_Z2S^<6BBBOV0_!0JQI>DZKKEZNFZ+IEQ>7#([+;VL
M+2.552[$*H)P%4L3V )[57K]%_V'O@)\&O@7\&?A-^T;>_ 2]^(6N_$?3?&$
MFH>)9]7NHM+\+1V5E>1+9&.U*AIKA$<%IF&T%O+!*AAR8S%QP=+F:NWHEYV;
MZVZ)_IJ=V P4\=6Y$[)6;>NB;2Z)O=K];(_.BBN[^/\ X_\ @K\1_$]CKWP1
M^ B_#NS735BU/18/$ESJ<$MT)')GB>YS)&I0HOEEFP4)!YP/MKX"_MD_&+]I
MC_@G;^TUX*\>6_AVPT3PMX$T4:)I/AOPY;6$,+/>%'=C&N^1B(UR78\Y(QDU
M.(Q56A2C4Y-&TG=V:NTNET]^_P RL+@Z.(K2INIJDVFE=.T7+KRM;=OD?G51
M77_ OX]?%K]FGXD6?Q=^"'B]]"\16$4T5IJ4=I#.8TEC:.0;)D=#E&(Y4XSQ
M7Z*?L7_\%-/VY+[]F7XV_M<?M"_'JZUC0O!_AQ-%\'Z?-HUA;I=>([Y@L#AH
M($=_(&UV3=C;+GMD+&XG$8:/-""DM%K)IW;LDERO\QX#"87%RY*E247J](II
M)*[;?.GT?0_+Z**2:1888V=W8*B*,EB>@ [U+J&F:EI%R;+5=/GM9@ 3%<1,
MC 'H<$ U]G_\$F-<N-(^''QLA^ D>EG]H2?P_IX^$O\ :$<#7#0"=SJ:V/G_
M "&Z^SX8+]X[1M! >NX_:0\3_M%7G_!-+Q?I_P#P4^MY1\0)O%>F-\$1XIM8
M(]>VB9?[3;:H$HM!!QN<;2[@9/R8RJ9A*&*]ERK=+?WG>VJC;5*^KOT?8VI9
M7&I@_;<[NXRE\/NKEO[KE?23MHK=8]S\\:L6&CZMJHE.EZ7<W(A3?,;>!G\M
M?5L#@>YJO7Z=ZSXM_;=_X9T^!UO_ ,$A;>_/@>'P-9Q^,AX(L;66[3Q:&;[<
M-3#*74_ZI@9,1L&8C*[:VQF*>&Y4DO>>[=DM+ZNSWZ'/@<%'%\[;?NI.T5S2
M=W;176W5W/S$KW?_ ()@?\I"_@[_ -C[8?\ HP5V7_!8/5OAIK/[5UC<^#8]
M"7Q*G@;2X_BK_P (R(_L)\5@2?;Q&8_D)'[I6*Y^=7S\VZN-_P""8'_*0OX.
M_P#8^V'_ *,%34K?6,LE4M:\6[?(THT%ALXA2O?EFE?YH_I9HHHK\>/W4X/]
MJC_DV'XC_P#8A:Q_Z135_+77]2G[5'_)L/Q'_P"Q"UC_ -(IJ_EKK[W@[^!6
M]5^3/S7CS^/0])?F@HHHK[,^!/N'_@G1^V3XBL+_ ,'?LP?'OX#:%XR\,:/H
M_B*_\%:CJ\4]GJ>E6\NG7DUS#:W<9!,$YCD0Y5L%B0?D4+YK^W;^SU\!?!GP
MF^$G[4G[.N@:]X:T+XLZ?JDK>"/$=_\ :Y])FL;A(6:*<JK36\F\%&<;B%SG
MYMJN_8V_X*6_'S]G.]T?P/KOQ+NKGP)H]AJ266BW.@V.HFSEFM+@1>0;J)GA
M7[3(C,$905W A@2I\D^*W[4?Q^^.'Q-L?C#\6/B;?:YX@TMH3I=W>)'Y=FL3
M[XTA@51#%&&Y\M4"9)R.37D4\)B(9@ZD4HQZV;M+XNEK)W:;:V\[L]RKC<-4
MRQ4IMRELKQ2<;<GVKW:LG%)[^7*CZ5^$?@#P;_P2[\!:1^U/^T%HD&J?&G7;
M#[;\)OAM>*"N@Q."(];U->JL#DPP'#;ADX8$P_,GA/\ :#^.7A7XWR_M)^%O
M'-]'XX%]=:E-XC\I)IA/<!UFG.]64$B5^2."P(P0*]LU#_@M#_P4CU:Z-[JO
MQ\T^YF8 --<?#S0'8@=.38YKR_P_^VM^TGX8_:*NOVK=%\>V\/CJ^1TO=570
M+$13(\(@=#:B'[.%:-0I C'KUYJ\/0Q:YY5XQE*2_F;7E&SCI'OO?K<SQ.)P
M3]G##SG&$7_*D_.5U/67;9):)H^P/^"7?[4?[2'[:WQ;\2_LQ?M:>.=0^('P
MNUWP;J=SXO?Q0JW*Z$L4+/%?13,-UNZR[%7#  N& !4$? 7@#P/XC^)OCK1O
MAQX/L#=:MK^JV^G:9;+UEN)I%CC7\685[?\ %K_@J3^V3\7_ (<ZA\)-2\=Z
M7H7AW6$V:WIOA#PS9:4-27&"L[V\2NZD$@IN"L#@@BO'O@_\7?B#\!?B5I'Q
M?^%6MQZ;XAT*X,^E7\NGP70@E*,F_P JX1XV(#'!93@X(P0"*PV&K474FHQB
MY)6BGI=7U>BWNKV6R6Y.+Q>'Q$:5.4Y346[R:]ZS:T2N]%9M7>[>Q](?\%>_
M&_AO2?C7X:_8\^&]\)?"OP+\)VWABU>/A;G4MBR7]R1VD>4JC_[4)KY:NO"?
MBFQ\/6OBZ]\-:A#I-]*\5EJDMFZV]PZ<,B2$;788.0"2.]-\4>)M>\:>)=1\
M8^*=3DO=3U:^FO=1O9B-]Q/*Y>21L=V9B3]:Z7Q#^T%\7O%7P5\/_L[Z]XN\
M_P '>%M1N;[0='^P6Z_9;BX8M,_FK&)7W%CP[L!G@"NC#T9X:A"G&SMN_P W
MZMG+B<13Q>)J5975_A2Z;))Z[*.G79'IG@#_ (*5_P#!0+X8KX<\(>!/VA_$
MNGVOABUM]/T3P_!'&+9(H@J1PM;[-LW  ^=69L\DDUW?_!:;P1X5\)_M7Z'X
M@TCPA8^'=<\7?#71O$'CKP_I\(BCT_7+@2_:8_+'W&(2-V'4ERQR6).%X5_X
M*_\ [<GA#0--T?3O&OAN:ZT:PAL]&UR]\!Z5+?V4,2".)4F:WR2J@ ,VX^I-
M?/OQ&^)'CSXO>-]2^)/Q.\67NN:]J]P9]2U349S)+.^  23T  "@# 4
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MQ2M_&EZL_H+#_P "'HOR"OYIO^"G_P#RD+^,7_8^W_\ Z,-?TLU_--_P4_\
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M44 %%%% !1110 4444 %%%% !7]'7_!'?_E&E\)O^P#/_P"EEQ7\XM?T=?\
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M .1/RIHK]5O^(<GXP_\ 0S?"S_P(US_XY1_Q#D_&'_H9OA9_X$:Y_P#'*/\
M6_+?Y)_='_Y(/]1LV_GA]\O_ )$_*FBOTE^)7_!"KXB_#;Q;X0\):KJ_PYFF
M\7:PVGV3VL^LE(G$9?=)NE!VX'\.378_\0Y/QA_Z&;X6?^!&N?\ QRC_ %OR
MW^2?W1_^2#_4;-OYX??+_P"1/RIHK]5O^(<GXP_]#-\+/_ C7/\ XY1_Q#D_
M&'_H9OA9_P"!&N?_ !RC_6_+?Y)_='_Y(/\ 4;-OYX??+_Y$_*FBOU6_XAR?
MC#_T,WPL_P# C7/_ (Y1_P 0Y/QA_P"AF^%G_@1KG_QRC_6_+?Y)_='_ .2#
M_4;-OYX??+_Y$_*FO=_^"8'_ "D+^#O_ &/MA_Z,%?;_ /Q#D_&'_H9OA9_X
M$:Y_\<K>^%__  06_:8^#/Q#T?XK?#7X@?"S3=?T"_CO=(O\:O-Y$Z'*OLE9
MD;![,I'M6.(XKRZK0G!0G=IK9=5_B-\+P7FE#$PJ2G"T6GO+H[_RGZN45\<_
M\*7_ ."UO_1Y'PL_\)'_ .YJ/^%+_P#!:W_H\CX6?^$C_P#<U?GY^G'T5^U1
M_P FP_$?_L0M8_\ 2*:OY:Z_?OQ5^SA_P61\;>%]2\&>)_VNOA9<Z;J]A-9:
MA;?\(LZ>;!*ACD3<EN&7*L1E2",\$&OEK_B')^,/_0S?"S_P(US_ ..5]-D&
M=87*J<XU5)\S6R73U:/D>)L@QF<U*<J$HKE3OS-];=DS\J:*_5;_ (AR?C#_
M -#-\+/_  (US_XY1_Q#D_&'_H9OA9_X$:Y_\<KZ#_6_+?Y)_='_ .2/F/\
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M/#[Y?_(GY:T5^JW_ !#D_&'_ *&;X6?^!&N?_'*/^(<GXP_]#-\+/_ C7/\
MXY1_K?EO\D_NC_\ )!_J-FW\\/OE_P#(GY4T5^JW_$.3\8?^AF^%G_@1KG_Q
MRC_B')^,/_0S?"S_ ,"-<_\ CE'^M^6_R3^Z/_R0?ZC9M_/#[Y?_ ")^5-%?
MJM_Q#D_&'_H9OA9_X$:Y_P#'*/\ B')^,/\ T,WPL_\  C7/_CE'^M^6_P D
M_NC_ /)!_J-FW\\/OE_\B?I]^RO_ ,FP_#C_ +$+1_\ TBAKO*^*O"O[.'_!
M9'P3X7TWP9X8_:Z^%EMIND6$-EI]M_PBSOY4$2".--SVY9L*H&6))QR2:O\
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M?$OPAXFU"'4[35(T+0FXE>=C<QR. L@DR2KMM*G!%?\ X++?#WXM? ']K/\
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M;^!<OCKQ#XLO)[W6-<\8^+]0<6$)!/DVJI/''9P1KG;L564#EC@&OL6OQ?\
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MVD]>NO#'[1'P4\-W/@V;X-W>F7!UC5-7M3)!IL=G&B'[3'<*;8B5"4&\DMM
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M0[6*XOO&GQ!U'Q!J=K=:]K-Y*;B]NI#;7,6\-*Q5"X+"-$!).2<K]MR.,_\
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M6GQ,^'OCC4_#5IIFI6UD=3.F7-C=+9JL4N)SN1R VT'L0J_-?PT_X*8^)?\
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M$[7;O/@W1/C)X,^R6NK7B@KMT^\!99)/F*JQ6/>6"*69PI /NNBBB@ HHHH
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MHUI/=O;6+23RD1NY5%!PQ!(8#8VI^TC_ ,$O_CWX6_8$_8R_9"^".GGQS?\
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MNSDU/XA?%SQ-J?AKQVMLPM;R_M-6AD@OPH!(@ENK-@VW<1&[@9(Q7VY\:?\
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M\,:[\/K'4K&/4M O+EXW36;&.]=8II"%\APK!@J@C@[E_0VB@#\V?A)\'/\
M@I+^T3_P6A^'7_!0;X\_LGK\-?AAH7PIUOPYI6AW?C#3;[4M+:5P\<U\D$QQ
M/<LYQ' )4BC@C#N'+ >S_P#!,G]ESX[?L]?M"?M8^./C!X&_LC2_B9\>)_$7
M@BZ_M.UN/[2TUK2*,3[8)7:'YE8;)0C\9VXKZ_HH _-?X_\ [('Q_P#V0O\
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M J+X;#4;#XE+K4)OIO$OVV.,Z8;3S_-$7V8R2^:80NY N_)VGUZBB@ HHHH
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M?"W2=0?69+I%@AMTL(VE>1R<1^7M</N(V%&#8(- 'RI_P2J_:%_;E_X*(?\
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M'[%\%?@+\-K*/XB:?!I-I,-9\6ZF6EMH#<O$TT:0VNYBL,B8E@*N&!('@?\
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M!>75MH]VIO-+9Y[<F*4"-Y8%>,[&2V0C@U^C- !1110 4444 %%%% !1110
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M;GX706UG;1>"]#U*[TFT%O:NKP0?Z!+"QA5D0^46V,5&Y3BO2$\'^$X_"0\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %?-O_!7;_E'C\0O^X3_ .G:SKZ2KYM_X*[?\H\?B%_W"?\
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M,#@'(^X+C_@DWX%O/^"+Z_\ !):RUZ/3+=OAA'H;:[!"61=8&+E[\H,%E;4
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MJU_^U]<_'KXM?&KXF>'? 7PI;Q=X,L-(TW0=<U!KA3(L-@HW0%$9UC<L5:%
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M@^!=4^'6FZ3;Z<VK%XX+[39+4>;$L$B']W)(Y<%=S,<L/._VB?V>?VO?'O\
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MNPCDN=,DFA>"5H)"-T1>*1XVVD;E8@YKX"\=?LT?MU?\$UOV[?B9^V3^P=\
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M^B?%WPMHJ65KXJL'L&N;'4&M=OE13AED62-%\O,8 !Y+<YHWP_\ VS?V _\
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MJ/\ LS?LRWWQDT6X^"UU\,?'_@S0-;M++5;"V_M3^U+:_MA=NB3@S'RV0,&
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M110 445P?[3/[37P0_8[^">L?M%?M'>-O^$<\&Z!):)J^L_V;<W?D-<W<-I
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MBM!&I:Y9^ /&.J:Y:ZK%O(UFU\/6$_FN&'^LCNT$H/4/&I[5]):1_P $,/\
M@FMHWQ>TGXMQ?!74[B/P]KIUOPWX*O\ QEJ=QX9TC4BY?[5:Z1).;2%MY+!%
MC\M2?E08&/>_'?[+GP)^)GQ\\!?M/^-_ WVWQS\,;?5(/ ^N?VG=1_V;'J,"
MP7@\F.589O,C15S*CE<93:>: /BC_@MK%H=Q^VO^P?:_&-83\,'^/-W_ ,)
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M"^HBWU*PE::=7TR<V^IV%UY2KME!9WB_TEL*&#YH?\$5/V%O'WP5^,_QB_;
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20210630_g8.jpg
<TEXT>
begin 644 biib-20210630_g8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@#
M( )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
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M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
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MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
M=J?110 5G:=X0\)Z1K5WXDTGPOIUKJ-^!]OO[>RC2>YQT\QU 9_Q)K1HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ
M+]@C5-3U?X-:K<ZMJ,]U(OC?6$62XF9V"BY("Y8G@#H.U>VT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_
M $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC[1=(^'NG0V'C'2V)MM54Q!C+"&^98]S,JHV&55"L P(KYC_ ."ND%M\6/\
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ME)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
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M /[71_PO_P#ZE+_R?_\ M=><T4?ZPYQ_S]_\EC_D!Z-_PO\ _P"I2_\ )_\
M^UT?\+__ .I2_P#)_P#^UUYS11_K#G'_ #]_\EC_ ) >C?\ "_\ _J4O_)__
M .UT?\+_ /\ J4O_ "?_ /M=><T4?ZPYQ_S]_P#)8_Y >C?\+_\ ^I2_\G__
M +71_P +_P#^I2_\G_\ [77G-%'^L.<?\_?_ "6/^0'HW_"__P#J4O\ R?\
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M\0Z?I\UU-YJ17\< AM/-F,[Q+*ER8O,&Z1OOGL?"G[//AC]O3_@@AX#\ ?\
M!/OP=<^&M3\#:O;:KX9\)^+]1261M<TO497O+2YN0J1NTTS7+K+MC1FE0LL*
MEE3IK83 QJ)-)14U%V;NEK\=[I/3=::2\@/9I?\ @IY^UE\"=5\(^+?V^/V
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M_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>%^/_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\ Z_'_ )U\GQ;_ +I3_P 7
MZ 8]%%%?!@%%%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>W
M_#/_ )$73O\ KB?_ $(U]3PG_OT_\/ZH#=HHHK[\ HHHH **** "BBB@ HHH
MH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KPOQ_P#\CIJ?_7X_\Z]TKPOQ_P#\CIJ?_7X_\Z^3XM_W
M2G_B_0#'HHHKX, HHHH **** "BBB@ HHHH **** "O;_AG_ ,B+IW_7$_\
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MSW-O'N\\.I5IDQL ^7@_^"/VJ?'C]H__ (-H/&_[*VG?LT>(]&M4^!?C+3_
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M:<QKC<"F!MC0+^G= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'FVMY;O!<Q;BN^-U*L,@@C()Y!S5BB@#@_V9?V9O@C^QU\#M!_9N_9Q\$_\
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M3U;_ +'O6?\ TI->Z4 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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MHKX\ HJKK&MZ-X=T]M6\0:O:V-JCHCW-Y<+%&K.X1%+,0 69E4#N6 ')JU0
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M /Y'34_^OQ_YU\GQ;_NE/_%^@&/1117P8!1110 4444 %%%% !1110 4444
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M* *GB#_D WW_ %YR_P#H!KY^KZ!\0?\ (!OO^O.7_P! -?/U?#\7?Q:7H_T
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M* "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IX@_Y -]_UYR_^@&O
MGZOH'Q!_R ;[_KSE_P#0#7S]7P_%W\6EZ/\ 0 HHHKX\ HHHH **** "BBB@
M HHHH **** )M._Y"$'_ %V7^8KZ&KYYT[_D(0?]=E_F*^AJ^VX1^"MZQ_4
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MBB@ HHHH *\+\?\ _(Z:G_U^/_.O=*\+\?\ _(Z:G_U^/_.OD^+?]TI_XOT
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MQ"13&'6([2'#/7H/P_\ VX/^"//_  4-_P""@'P$N_@5^V[#KGC/X90^(/\
MA77PXT;0[NVL;VXN=)DCN)Y3-9J-T%E#.8U#HJY;AB0* /T+HHHH \+_ .">
M_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH J>(/^0#??]><O_H!KY^KZ!\0?\@&^_Z\
MY?\ T U\_5\/Q=_%I>C_ $ ****^/ **** "BBB@ HHHH **** "BBB@";3O
M^0A!_P!=E_F*^AJ^>=._Y"$'_79?YBOH:OMN$?@K>L?U ****^R **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOQ__P CIJ?_ %^/_.O=*\+\
M?_\ (Z:G_P!?C_SKY/BW_=*?^+] ,>BBBO@P"BBB@ HHHH **** "BBB@ HH
MHH *]O\ AG_R(NG?]<3_ .A&O$*]O^&?_(BZ=_UQ/_H1KZGA/_?I_P"']4!N
MT445]^ 4444 %%%% !1110!^1VA_MG?\$N?V#/\ @LK^U+HW[=/Q)\(Q>+_&
MNI:!JWASQCK>A27[Z=9+H]O$^B2N(9&LWC(690,13131?.70HOU]^S-_P53_
M ."0W[2/QNT3X+_LO?M$> ]=\=:S]I_L/2M%T66&YG\FVEGFV.UN@&V"*5C\
MPRJD<YQ7F7[87[;WCG7_ -KCQ+^R7^P!_P $P-$^/OQ!\'6=C<?%#Q9XDU+3
M]'T;P[)=0B2UM9;NYC9KJY:#8_E*050K@MM=4E_8P_;>\8Z;^USH'[(?[>?_
M  3'T?\ 9_\ B9XITR^OOAEXD\.ZAI^KZ/XF%K"7O+>WO+:-6MKE("SF%BQ,
M88DKN17 /ONBBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7SU^P7X;L-6^#FK75S
M-<*P\<:RN(IRHQ]I;L*]M_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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M0/B#_D WW_7G+_Z :^?J^'XN_BTO1_H 4445\> 4444 %%%% !1110 4444
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M\(S_ ,&,7_/SI_\ X-OB-_\ '*]\_P""86A_\&I-G^W)X'N?^":\]F?C6O\
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M_P#\CIJ?_7X_\Z]TKPOQ_P#\CIJ?_7X_\Z^3XM_W2G_B_0#'HHHKX, HHHH
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M )5)/XU[K_PF/AC_ *#4'_?5?;<(_!6]8_J!I45F_P#"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU7V0&E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 >3?MK_\
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MC;,6D1<@AT_2A/%/A^2,RQZG&RKU8 D#]* /D/\ :5_X*=_&VR_;#U7]@?\
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
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M/V]/"7P^\-R:'#97W@_Q9\*8=82*[265GOX+H31R;G1XT,+@QCR PY=JM_\
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M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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MZ;@>0_LE_L(_LK?L/Z'J>C?LV?"FWT.77)UGU[5[B]GO=0U.1<X:>ZN7>60
MLQ"EMJEV( W'/KU%%14J5*LW*;;;ZL#Z!\/_ /(!L?\ KSB_] %6ZJ>'_P#D
M V/_ %YQ?^@"K=?L%'^#'T0!7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_
MYU\QQ;_NE/\ Q?H!CT445\& 4444 %%%% !1110 4444 %%%% !7M_PS_P"1
M%T[_ *XG_P!"->(5[?\ #/\ Y$73O^N)_P#0C7U/"?\ OT_\/ZH#=HHHK[\
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M/_%^@&/1117P8!1110 4444 %%%% !1110 4444 %>W_  S_ .1%T[_KB?\
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M^%IZ9-=ZQ<>!$>5K9]2@"--++]D#-MVF0Q^7M!^6OSW_ &MOA'_P1_\ C?\
M!&+]CC_@E#\4?B#\??B=XV:/2?A1\-KKQYKFK^&?A[!,ZQW6L-!=?N+&.WM9
M)@KS%WC9U8 ;6=0#]8?CQ\)OV%O^"CW[#'@#]I']O;P/97?P_L_!UG\09[;5
M->O+/3].2?35N'FN/L\L?FQQ12/Q)N48W8R 1\)?LF^#?V&K+_@LO\(KW_@@
MIJDA\#6WA[76_:CC\&ZE?2^%!8FU"Z0)3<,8FO&N3)L6$EAY:L0 )"?OGXH?
MM3?L,_\ !*;X"?"7]FK]KGXOV?AW0;CPA%X7\/ZEKNC7$]C?KIEG:V[QSO'%
M)'"7C=& E*JP#@$[<5\.^+OC1^QU^VO_ ,%C/V9_%G_!('2+#6->\$:KJ5S\
M<OB+\/O#DMCI,'AB2V %AJ%RL4<5TTKAA$AW[7( ()X /V"K\#/CA\/?^"5M
MW_P5C_;#\<?\%0OV/?B'\0+.+QEX?_X1;7_"WA;Q!=V>EVR:+#]L:>;2Y(XT
M4,8"=Y9N#@=<_LKIW[;?P3U/]N:__P"">=J^K?\ "PM.^&P\<W"M8 6/]E&]
MCLQB;=DR^;*OR;?NY.>U>0?$'_@O-_P28^$?C+QA\./BM^V'HWAOQ%X$UR]T
MGQ-H.KZ1?QW<%U;2/'(L<8MR;D$KE6AWAPPP<G% '<_\$O-(_P""?FD?L<^'
MC_P3&GTI_A'=W-U=:,NDZC>7"QW$DI:X63[:[7$4HD)W12[60\;17T)7YS_\
M&Z_@CQ1)X"_:!_:8T[X6ZGX&^&_QF^/FK>*OA/X5U6P-G(-'D1%6^6VP! D^
M%VH !B$;<IL9OT8H **** "BBB@"IX@_Y -]_P!><O\ Z :^?J^@?$'_ " ;
M[_KSE_\ 0#7S]7P_%W\6EZ/] "BBBOCP"BBB@ HHHH **** "BBB@ HHHH F
MT[_D(0?]=E_F*^AJ^>=._P"0A!_UV7^8KZ&K[;A'X*WK']0"BBBOL@/GG4?^
M0A/_ -=F_F:AJ;4?^0A/_P!=F_F:AK\9G\; ****D HHHH **** "BBB@ HH
MHH **** /H'P_P#\@&Q_Z\XO_0!5NJGA_P#Y -C_ -><7_H JW7['1_@Q]$
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MW_/Z'_@2_P P+?\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2U4_X6U\/O\
MH8/_ "4E_P#B*/\ A;7P^_Z&#_R4E_\ B*/[2R[_ )_0_P# E_F!;_X275_^
MA0O?^^EH_P"$EU?_ *%"]_[Z6JG_  MKX??]#!_Y*2__ !%3:?\ $OP3JE[%
MIUAK7F33.%C3[-(,D]LE<4XYCE\I)*M%M_WE_F!+_P )+J__ $*%[_WTM'_"
M2ZO_ -"A>_\ ?2UL45V <[K7B+59-&NXW\*7:!K:0%V9<+\IYKQ6OH'Q!_R
M;[_KSE_] -?/U?#\7?Q:7H_T ****^/ **** "BBB@ HHHH **** "BBB@"6
MQ8K>PL%)(E4@#OS7M_\ PDNK_P#0H7O_ 'TM>(Z=_P A"#_KLO\ ,5]#5]MP
MC\%;UC^H&/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q17V0'SQ?,6O9F*D
M$RL2#VYJ*IM1_P"0A/\ ]=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH
M **** /:M%\1:K'HUI&GA2[<+;1@.K+AOE'-6O\ A)=7_P"A0O?^^EJ[X?\
M^0#8_P#7G%_Z *MU^QT?X,?1 8__  DNK_\ 0H7O_?2UX]XTFDN/%>H3RV[1
M,]RQ:-^J\]#7O->%^/\ _D=-3_Z_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !11
M10 4444 %%%% !1110 5ZYX!UW4K7P?8V\/AFZF58B!*C+AOF/2O(Z]O^&?_
M "(NG?\ 7$_^A&OJ>$_]^G_A_5 6;/7M2N;I()O#-U"K-AI79<+[FM2BBOOP
M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37J_Q,_Y$
M74?^N(_]"%>4?\$]_P#DB>K?]CWK/_I2:]7^)G_(BZC_ -<1_P"A"N3'_P"X
MU?\ #+\F!XA1117Y$ 4444 %%<GXH^,_@CP?\6/"OP8UJYF36O&-EJ-UHRK&
M#&R60@,V]B?E/^D1[1@YYZ8K3^(7Q"\#?"?P1JGQ*^)GBRPT+0-$LGN]6U?4
M[E88+6%!EG=VX _F< <FJY)::;[>?0#9HKY3^&7_  6M_P""<7Q8\=Z+X \.
M_'"^LI_$]XMKX6U/Q%X.U73-/UB9CA4M[NZMHX6+' 4%EW$@+DD"N_\ VM_^
M"B_['7["VHZ'I7[4GQ8G\-7'B.&>71DA\+:IJ/GI"4$A)L;:8)@R)P^TG/&<
M'&SP>+510=.7,]E9W?R ]MHKYB_9Z_X+(?\ !.3]JGXS:1^SY\"/V@;C6_%^
MNQW#Z7I$G@?6[/SE@@DGE8RW5E'$@6.)SEG&2 HRQ /T[45:-:A+EJ1<7YIK
M\P"BOG#XH_\ !73_ ()S?!OXV0_LY_$#]J#2K?QM-KD6CGP_8Z7?7TL5])(L
M:02M;02)"V]E!WLH&>2*^CZ4Z-:DDYQ:3VNK7] "MCP!_P CIIG_ %^)_.L>
MMCP!_P CIIG_ %^)_.M<%_OE/_$OS0'NE%%%?KX%3Q!_R ;[_KSE_P#0#7S]
M7T#X@_Y -]_UYR_^@&OGZOA^+OXM+T?Z %%%%?'@%%%% !1110 4444 %%%%
M !1110!-IW_(0@_Z[+_,5]#5\\Z=_P A"#_KLO\ ,5]#5]MPC\%;UC^H!111
M7V0'SSJ/_(0G_P"NS?S-0U-J/_(0G_Z[-_,U#7XS/XV 4445(!1110 4444
M%%%% !1110 4444 ?0/A_P#Y -C_ -><7_H JW53P_\ \@&Q_P"O.+_T 5;K
M]CH_P8^B *\+\?\ _(Z:G_U^/_.O=*\+\?\ _(Z:G_U^/_.OF.+?]TI_XOT
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MGA__ ) -C_UYQ?\ H JW7['1_@Q]$ 5X7X__ .1TU/\ Z_'_ )U[I7A?C_\
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M_P"A"O*/^">__)$]6_['O6?_ $I->K_$S_D1=1_ZXC_T(5R8_P#W&K_AE^3
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M^&?_ "(NG?\ 7$_^A&OJ>$_]^G_A_5 ;M%%%??@%%%% !1110 4444 %%%%
M!1110!X7_P $]_\ DB>K?]CWK/\ Z4FO5_B9_P B+J/_ %Q'_H0KRC_@GO\
M\D3U;_L>]9_]*37J_P 3/^1%U'_KB/\ T(5R8_\ W&K_ (9?DP/$****_(@"
MBBB@ HHHH **** "BBB@ HHHH *V/ '_ ".FF?\ 7XG\ZQZV/ '_ ".FF?\
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M4'_Q%%/PKS^M!3IUZ+3ZJ4VO_2!5N.LLP]1TZM&K&2W3C%/[G(^@:]O^&?\
MR(NG?]<3_P"A&O@__A=WQ0_Z&?\ \DH/_B*^U?V;=7U'7O@?X>U?5KCS;B>T
M9I9-@7<?,<=%  Z5VX7@G->&9O$8J<)1DN5<KDW??K&.FAZ63\3X#.\1*C0C
M)-*_O))6NETD^YW%%%%=Y]&%%%% !1110 4444 %%%% !1110!X7_P $]_\
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MV.O:3)>7'VJ9B\S>9D?*6/"]A1_P@/\ P4$_Z+_X$_\ "4D_^*H ]THKPO\
MX0'_ (*"?]%_\"?^$I)_\51_P@/_  4$_P"B_P#@3_PE)/\ XJ@#W2BO"_\
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M/3=)L(+6VA7$5O;1!$0=<!5  J:O"_\ A ?^"@G_ $7_ ,"?^$I)_P#%4?\
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ML;:[FLY(95DVO;W2/#/$X4H\;C#*Q&0>:XG_ (0'_@H)_P!%_P# G_A*2?\
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ML_B_XFDUB6XMO%%EX M_#:0V;1Q*EK]EMYYE8JZROYNX%O-"X&P$\W_P@/\
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M?6,5PJ2>%7W .@;!PV,\]J /H*BO"_\ A ?^"@G_ $7_ ,"?^$I)_P#%4?\
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M>%_\(#_P4$_Z+_X$_P#"4D_^*H_X0'_@H)_T7_P)_P"$I)_\50![I17A?_"
M_P#!03_HO_@3_P )23_XJC_A ?\ @H)_T7_P)_X2DG_Q5 'NE%>%_P#" _\
M!03_ *+_ .!/_"4D_P#BJ/\ A ?^"@G_ $7_ ,"?^$I)_P#%4 >Z45Y!X%\&
M_MIV'BZPO/B!\9_!^H:+'.#J-E8>''BFECP?E1RWRG..:]?H **** "BBB@
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M[VX0O;V;W"B651G)5"<L!@\@=J +5%%% !1110 4444 %%%% !1110 4444
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M"K),!UVJ3EL=\5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3#9-'(%MXK=1;!84&SY6&-I"K]D? KXD_L#?\%$?^"?OC[]FC_@G3\1] N_
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M1M<0J<Y5)"-RCD\ ]ZT:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SK_ ,(>
M$]5URU\3:IX7TZYU*Q4BRU"XLHWGMP>H20C<GX$5HT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?-O[8GQ]^+7PK^)MCX>\!^+/L%G-H45Q)#]@@ES*9IU
M+9DC8]$48SCCZUY/_P -D?M(?]%&_P#*19__ !FNG_X*"_\ )9M,_P"Q8A_]
M*+FO"J_3<HP&!JY92E.E%MK=Q3?Y'XGQ#FN:4,ZKPIUYQBI:)2DDODF>G?\
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MG>$?&OA?4=!OM0B +;K9-0@B%S\JLVV,LP56)& 37NWB_P".GP?\ _%'P?\
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MA1]C?E5K\UO_ &T^!S/@?^T<?4Q/UCEYW>W)>WSYE^1^8]?HC\$_^2,^$?\
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M;QGXJ\:>.#;+XI\??$GQ?<Z[K=_#;J5@MVNKDEA$@)PJ@9XW;MJX /?:***
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MLOA"[DUJSB\5^(_$NN>%(M,T*V,RBXN[>: R2WYB3<Z)'&ID( R@.1^@=%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-20210630_g9.jpg
<TEXT>
begin 644 biib-20210630_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +/FO#&[JTWV9HXV8,VXQ9+,26/UC0!^9'[+7_!:K_@J=^V=\-;CXN?LZ_\
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M];)KFE>%_#G]H:786=Z$&M7,I2.RM8Y0KA?M$\L$2N%?'FAMK8P>*_X)/_\
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M$T>_;D;L;LXR,XQD5Y1_P3>_8U_X=\_L2^ ?V.?^%C_\)=_P@^GW%K_PD?\
M8_V#[;YMW/<;OL_G3>7CSMN/,;.W.1G ]OHH ^8?^"@__!.W6/VN?&/PY_:)
M^!7QVN?A7\9OA%J%W<>!?'4&BQZC;M;W<0BN]/O;1W07-M,B@$;PR$DK]YE;
MC_V=?^":7[05]^V3HO[?/_!1#]JK3?BAXY\$Z#=Z3\,O#WA3PA_8NA>%DNU\
MN\NHXVFFDN+F:/\ =F1V&U21AL1^7]G44 > ?LF_L,?\,O?M)_'[]H7_ (6C
M_;G_  O+QAI^N_V1_8GV;^Q/LUG]F\GS?/D^T[OO;]D6.FT]:]_HHH ^+O%?
M_!,/]IKP/^V3\1?VL?V)?^"@,?POM/BY>:5??$'P9KGPHM?$=M=7EC;BV6>V
MFDN[=[7S(@=XP^78MG 55]2^#7[#'_"H_P#@H)\:/V[/^%H_VA_PM[P_X<TS
M_A%O[$\K^R?[*MWA\S[3Y[>?YN_=M\J/9C&7ZU[_ $4 ?/GPU_8.M? /_!0;
MXM_MTWWQ(CU2'XJ^"]#\/S>#I=!"K8+IZ.ID-P9F$XE#\H8DVXZMFO!/AI_P
M2X_;\_8CM-1^$7_!-S_@H%X<\-_"&[U:YOO#_@#XF_#0ZY)X0^T3---#87<5
MW"\D'F.[+%,#MR?F9F9C]_44 <'^S1\.OC-\*_@WIG@O]H+X_2_$_P 702W,
MNK^,Y/#=OI O6EGDD1$M+<M'!'$C+$H#,2L8+,S$D]Y110!\\?\ !,G]@K_A
MW-^SI?\ P!_X6M_PF/V[QQK'B+^UO["_L[9]ON#-Y'E>?-G9G;OWC=UVKTJQ
M\"?V&/\ A2G[?'QY_;A_X6C_ &G_ ,+NT_PO:_\ ",?V)Y/]B_V/8R6N[[3Y
M[?:?.\S?CRX]F,9?.:]_HH \ ^#7[#'_  J/_@H)\:/V[/\ A:/]H?\ "WO#
M_AS3/^$6_L3RO[)_LJW>'S/M/GMY_F[]VWRH]F,9?K1_P3"_88_X=P?L8^&O
MV1/^%H_\)E_PCVH:K=?\)#_8G]G?:/MNHW%[M\CSYMFS[1LSYAW;-V%SM'O]
M% 'PM??\$O\ ]KO]FGXW>//BG_P3!_;3T/X?^&OB?XCF\1>+OA?\0? 7]N:1
M;ZW. +C4+"2*X@FM3+M4O#\R%@.0JHB>M^'OV'_B+\8OV/?'G[*W_!2+]H.'
MXTCXB37*ZKJ&F^$+?P_!IEE)# D5I9PPO*5\B6$W$<\CO)YKY/"JH^A-8US1
M/#UF=1U_6+6QMPP4SWEPL29/0;F(&:GMKFVO+=+NSN$EBE0/%+&X974C(((X
M(/K0!\(> _V#_P#@LQ\(/!=C\ _AI_P5N\)R^"]'LTL="\4>*/@=#J'B>RLH
MUV10NYO5MKJ1$"KYTL>YRNYE))!^X/!NC:MX<\(:5X>U_P 33ZU?6&FP6][K
M-U$D<M_,D:J]PZH JL[ N0HP"Q XJQJ.N:)H\MO!JVL6MJ]W+Y=JES<*AF?^
MZ@8C<?8<U:H ^-_VHO\ @G1^TOJ7[;8_X* _L&?M5:)\._&FL>"8?"GCO0O&
M7@LZUI&NV4$S36\^U)X98+B(MMRK$,H4?+\_F5_V*?\ @E#\1OV9OV[_ !C_
M ,%!OC+^V5J'Q/\ &7Q ^'D/A[Q3#>>$(M.A%U'=QS+/:B*X=;>V2&&&!+78
MQ&PR-,[.U?:%-FFBMXFGGE5$12SN[8"@<DDGH* /"O\ @G]^Q-_PPM\._&W@
M+_A9G_"4_P#"8_%CQ!XU^U_V-]A^R?VI<^?]DV^=+YGE?=\W*[^NQ>E>9_"7
M_@CS\+/#?[&?QR_8D^-?Q!F\9^&?CA\1O$?BK4KFUT@:=-I?]J3131119FG#
MRVTL,<B3' 9T4F, $'ZYTC6]%\060U+0=7M;ZW9BJW%G<+*A(ZC<I(R*DU#4
M=/TBRDU+5;^&UMX5W2W%Q*$1!ZEB0 * /S<^+'_!&O\ X*+_ +3_ .R??_L'
M?M.?\%7++4_AK#HZ6.EWVB?"=(-;U;R ILCJL[7Q$\<+QQ2/'%Y;W#1+OEY;
M=^@/P1^&_P#PIOX+^$/A#_;/]I?\(KX7T_1_[1^S^3]J^S6T<'F^7N;9NV;M
MNYL9QDXS726MU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O5>\\0Z!I^I6^C7^N6<
M%Y=Y^RVDURBRS?[BDY;\!0!\[?MA_LS?M_?$/XLZ;\8?V*?^"@<'PT2T\/II
MNJ> O$_P]@U[1-5D2::5;HEIHYK6;$H1GB)W+$@(XKS7X%_\$M/VC/$O[9_A
M']O/_@H[^V5:_%3Q9\-M.O[7X8>$_"O@M-#T+PY)>Q^5=76SSI9+J9X\+N<C
M;M0_-LCV?;]% 'S'\'/^"?\ X^^ 'Q._::^,WPK_ &B;.U\2?'_7+;5M#NK_
M ,%?:(?"5U!8&TC9HOMB_P!H@-B7!, XVG(YKS>S_P""$O[.K?\ !.S4?V)O
M$/CK5=0\8ZOKK>,-3^.+V^S7I?&Y<RKXC5A(6259/E6,2Y\G,1D)9I#]R44
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M/[/DT>'5888S:1R>=+YLD)A#I<8C^;:?+7;S]:44 ?FOXO\ ^"-G_!1+XO\
M[)6I?\$]/C)_P5;MKOX11^'&T?1KW3?A4D?B.\MHH]MC;ZA=F]V2P0,D!D$:
MI)=)$4>1!(QKV_XY_P#!)KPG\;OV)?@[^S)_PN[6?#7CCX#Z=H3_  T^+GAW
M3DCO-+U;3+*.U2\^RR.Z/#*(SYEJSE64@;\J&KZYHH ^1/A'^S9_P6"3XC^&
M[_\ :#_X*5>!+WPEH.JP7.KZ5X+^"D=E?>)X(W#&WN+BXNY5M%DQAC!'NQD
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MWP;JGP_\6Z]%)'IE\^D6DME=VGV@*46=6<-L8@[<?WTW+_P2=_:*\&?M5_\
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M7]GKXB?M5_L??\%3_@%\);%KOQ-X@_:'\3C0[!#A[VYAM[*X2V7MNE,7E+G
MRXS@9KI/CY_P6M_8@^)__!%'Q;\'_ _B=M0^+.L_ C4O"=[\%X-(N#K>CZDN
MCR6M\MU:F,-!;686>:6=]L?E6[$-D@4 ?;O_  1X_P"44'[-O_9#_#'_ *;+
M>KW[9O\ P3%_9%_X*">+?"_B#]K?PAJ_BS3?"-O<IIGA-_$EW::3-+,T;&XN
M+>VDC^T2+Y0";V*@,WRG.11_X(\?\HH/V;?^R'^&/_39;UXE_P %V/\ @L9I
MG_!,WP!X7^$7P]UC2M/^*7Q4FDM/#&O^)K>5M'\+V:ND=QK%YY:.TPA\Q2D"
M*[.PR58+L< \@_9Q^ ?P@_8:_P"#@W2_V6O^";JWNB> -7^#%[K7Q\^'>FZK
M<76C:+=B3;IEWLFD<6UW*QA&P$-Y3[@ LK9T?#/P"^%?_!83_@L-^T=I/[9F
MAMXS^&'[-T&@^%?AW\/+^^F73!J=]:RW&H:E-#$ZB2X#QM$K-G]VR@C,:D=+
M_P $7?VH/^".O@#48OV8OV6/VV;?XL?&SXDWEQK7CSQEJVDZBNL>,]5C@DN+
MBYEEG@58XHXUF,4&_;&@(!9V=WYKP1\??A+_ ,$B/^"R/[21_;,\3Q^"/AU^
MTA;Z#XM^&WC_ %:VD72YK^RM9+?4=.EN%4I'<>9(9%1B/D523F5 P!TW_!*W
M1Y_V5/\ @H+^U%_P2)\,^+=7D^&'A?2M%\7?"73[K59)[CPS8:I;8O;""64L
MZPQSO&85).S!8Y:1B</]M?\ X(5?\$9?V8OV&?B/\9O&OP[O]"UGPQX4O-63
MXOZGXVU&?Q#%JL<1-M=+<27&)+EKCR@D04)([*@3Y@*UO^"6GBO2_P!J+_@H
M9^U3_P %?=&L+VR^$.LZ1H_A#X:>(]0TZ6#^WK#2K;=J.I11NHD:W,T:>6X7
MYAN7 :-E'R1_P^)_X)P?\%2?VKY/BQ_P4+_:NTOP1\ ?AAXC\SX5? O4-,OY
MI?&&H0G*:_K@MX'C:)<_N;(L0.=XQO\ / /H+XZ_MM?MK_ 7_@U_\(_'+QOX
MGU/3_CAXP\&Z)X?L?$%_(T=]%)J5ZEM#>R.?G6Z.GMYOF'YQ,0Y^8&L+_@I/
M_P $E?V<O^"6O_!/ _MS?L+Z9>^%?CA\"I-*UT?$=-8NFO/%9^V6\6HQ:INE
M*W,5RLLLCQD;<@(,(64^[_\ !7G0-'_X*O?\$4?$?Q)_8(U=/'A$MGXK\ OI
MME,/[7DTG4@;B&*&1$D:0I!=1HFT%W554'<#7A?_  4S_P""M?[,7_!3W_@G
M"/V+/V&?%#^+OC7\?9-)T&Q^'%OI]Q]N\-LUY;RZA)J8,8%K';)%*CR,=N<.
MNZ,,P /U;^%OCS3_ (I_#+PY\3M)A,=KXCT&SU2VC+AML=Q"DJC(ZX#CFMZL
M'X6> [#X5_#'PY\,-*F,EKX;T&STNVD*[2T=O"D2G';(0<5O4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q7\+O\ @FM^
MTIXR_P""BVC?\%!OVY?VHM$\8S?#>QUG3O@UX(\)>$SIUGH4.H;HI;JYF>1W
MN;AK9A$WRJN0&!X"U]J44 9_B'PIX6\76L=EXK\-:?JD,,PFAAU&S2=4D'1P
M'! 89.".:T  !@"BB@ HHHH R8O ?@>#Q*_C.'P9I*:PZ[7U9=.B%RPQC!EV
M[CQ[UK444 9?BCP3X,\;VT=EXT\(Z7J\,3%HH=4L([A4/J!(I -:%I:6EA:Q
MV5C;1PPPH$BAB0*J*!@  < #TJ2B@#.USPAX3\3SVMSXE\+Z=J,EC+YMC)?6
M4<S6\G]]"X.QN!R,'BN<_:+^!7@W]I[X$>+?V=OB)>ZG;^'_ !KH-SHVN/H]
MY]GN6L[A#',B2;6V[T9D)P>&-=I10!E^!_!7A3X;>"](^'7@30K?2]#T#2[?
M3M&TRT3;%:6L$:Q10H.RJBJH'H*U*** "JNM:'HGB72YM$\1:/:W]E<+MGL[
MVW66*09SAD8$'D \BK5% $&FZ9INC6$.E:1I\%I:V\82"VMHA''&HZ*JJ %
M]!4]%% !1110 51\0^&/#?B[3&T3Q9X>L=4LG8,]IJ-HD\3$'()1P02/I5ZB
M@!EM;6UE;1V=G;I%#$@2**) JHH& H X  XQ3Z** "L^S\)>%-.UZY\4Z?X8
MT^#5+Q EYJ4-E&L\ZC& \@&Y@,#@GM6A10 4444 %4?$7ACPUXOTQM%\6>'K
M'5+-V#/::C:)/$Q'0E7!!(^E7J* &6]O;V=O':6D"111($BBC4*J*!@  <
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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ME3!\\;6;:V #Z*HK\NO^"L/Q>_X+!_L=?$+PC\?O#W[</@_2?AGXG_: \/\
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MB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110
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M&\4:=X@\2?"'Q/XNL]&NDN-'\,^./B/K.KZ19R)]W%G<W+1RJ!QLE#J1P0:
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M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M#&N> O#=S:1W?@+2/V8=*T:*[TV':OV&&>"_8VBF-0BLB'8,87C%?95 &/\
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M]?Q7_0)4^^E_\L/O2BO@O_AMK]I#_HH'_E*L_P#XS1_PVU^TA_T4#_RE6?\
M\9H^J4/^@B'W5/\ Y /K^*_Z!*GWTO\ Y8?>E%?!?_#;7[2'_10/_*59_P#Q
MFC_AMK]I#_HH'_E*L_\ XS1]4H?]!$/NJ?\ R ?7\5_T"5/OI?\ RP^]**^"
M_P#AMK]I#_HH'_E*L_\ XS1_PVU^TA_T4#_RE6?_ ,9H^J4/^@B'W5/_ ) /
MK^*_Z!*GWTO_ )8?>E%9?@;4[S6O!.CZQJ,OF7%WI5O-.^T#<[1JS'   Y)Z
M<5J5Q/1GI)W5PK\ZOVD_^2]^+?\ L.3_ /H5?HK7YU?M)_\ )>_%O_8<G_\
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M_DW3PM_UXO\ ^CI*_/BOT'_9*_Y-T\+?]>+_ /HZ2@#T6BBB@ HHHH ****
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MH$"0K$RLQ.,G<,J"1]_U4LO#^@Z;J%QJVG:)9V]U=G-U<PVR)),?]M@,M^-
M'GGC'XZ_"O\ 9L\0_#+X">)'U#[;XSG.B>%OLMH'C+VT,>?-;</+&TKS@U\V
M_M"IX%_9,_X*MZ!^V7\;H#9^!O%GPVE\.1^*YK5Y+;1-;2=2AF90?)66V4QJ
MYP"9).@5B/N"HKZQL=3M)-/U*SBN()5VRP3QAT<>A!X(H ^*_A%X\\'_ +6'
M_!5]/V@_V;YSJO@SP=\*I="\4^,[.W=+/4K^6Z,D5E'(0!.44K(6&0-N,\+G
M[9J#3=,TW1[*/3=(T^"UMXAB*WMH@B(/0*H %3T %?H/^R5_R;IX6_Z\7_\
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M6U'_  @^D?\ /S>_^!;5L44 ?F!XC4)XAOT&<"]E S_OFJ57O$W_ ",>H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'Y@^)O^1CU#_K^E_P#0S5&KWB;_ )&/4/\ K^E_
M]#-4: "BBB@ HHHH **** "BBB@ HHHH **** /TP^&/_)-O#W_8#M/_ $2E
M;E8?PQ_Y)MX>_P"P':?^B4K<H *_.K]I/_DO?BW_ +#D_P#Z%7Z*U^=7[2?_
M "7OQ;_V')__ $*@#B**** "BBB@ HHHH **** "BBB@ HHHH *_0?\ 9*_Y
M-T\+?]>+_P#HZ2OSXK]!_P!DK_DW3PM_UXO_ .CI* /1:*** "BBB@ HHHH
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M_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
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MQ?\ ]'24 >@)8V4;!X[.)6'0K& 14M%% !1110 4444 %%%% !1110 4444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?F#XF_P"1CU#_ *_I?_0S5&KWB;_D8]0_
MZ_I?_0S5&@ HHHH **** "BBB@ HHHH **** "BBB@#],/AC_P DV\/?]@.T
M_P#1*5N5A_#'_DFWA[_L!VG_ *)2MR@ K\ZOVD_^2]^+?^PY/_Z%7Z*U^=7[
M2?\ R7OQ;_V')_\ T*@#B**** "BBB@ HHHH **** "BBB@ HHHH *_0?]DK
M_DW3PM_UXO\ ^CI*_/BOT'_9*_Y-T\+?]>+_ /HZ2@#T6BBB@ HHHH ****
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M2LSR$(BC<[,S8R222:V*** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Y@^)O\ D8]0_P"OZ7_T,U1J]XF_
MY&/4/^OZ7_T,U1H **** "BBB@ HHHH **** "BBB@ HHHH _3#X8_\ )-O#
MW_8#M/\ T2E;E8?PQ_Y)MX>_[ =I_P"B4K<H *_.K]I/_DO?BW_L.3_^A5^B
MM?G5^TG_ ,E[\6_]AR?_ -"H XBBBB@ HHHH **** "BBB@ HHHH **** "O
MT'_9*_Y-T\+?]>+_ /HZ2OSXK]!_V2O^3=/"W_7B_P#Z.DH ]%HHHH ****
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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MT'_@L!X4\+6W_!/CXM>*[?PUI\>J7.C627&I)9H+B55OK8*K2 ;F ' !/ H
M^GM)U6PUS2K;6]*G\VUO+=)[:7:5WQNH93@@$9!'!&:K^+?%.@^!O"NI^-O%
M-_\ 9=,T?3YK[4KKRF?R8(D,DC[4!9L*I.%!)QP":S_A-_R2OPS_ -B_9?\
MHA*S_P!H7PKKOCKX ^.?!/A>R^TZGK/@_4['3K;S%3S9Y;62.--S$*N68#)(
M SR10!X?9_\ !9G_ ()O7[QI9_M!W,GG,!$5\"ZYAL].?L6*]Y^,/QG^%OP
M^'][\4OC)XUL] T'3POVK4+UC@,QPJ*J@M(['@(@+$] :^./ OQO_;N_X)V_
MLS>$[?X]?LH>'M7^'W@C0K+3O$&I^#_%YN-5T^VC58FNW@>,)*!U*(V #RX
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M\I=_MZ@ HHHH **** /S!\3?\C'J'_7]+_Z&:HU>\3?\C'J'_7]+_P"AFJ-
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MU;1?%>IV,EI'JNK>/-,FTC3W=2AN#*C S*F=P0 %L8K]9/\ @B[^S*_['?\
MP3"^$G[.EQK<>HW/A_1KI]0O(01')=7-_<W<^S.#L$L\@4D E0"0#Q7RI7Z#
M_LE?\FZ>%O\ KQ?_ -'24 >BT444 %%%% !1110 5QOQP_9Y^!G[2WA.V\!_
MM _"?0?&.BV>J0ZE:Z7XATY+J"*\B#"*=4<$!U#MANHW&NRHH _,C_@H?\8?
M^"'GAO\ :^\1?#_XN?\ !-Z^_:"^-:VMG>>.K+X:_!,>)M4T]'MXUMFOI3L5
M&,"1[5+E@@3( *Y/^">OQ$_X)?Z[^V!X0TK]G;_@A7\8/@WXQE_M#^Q_B1XI
M_9QCT&PTC&GW)E\V_65C!YL(E@7@[VG5/XZPM8_;M\&?\$XO^"M/Q^^&'P<_
M9O\ B?\ M ?\++FT3Q5X]TSX*^"Y]6UCP'JJZ?';+:W@;9!+!<0I'<QD3JT+
M/(C*0RFOJ']F;_@JW>_M*?&[1/@I-_P3(_:S^'BZU]ISXP^)OPEATS0]/\FV
MEG_TFY6]D,>_RO*3"'=+)&O&[( /K.BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE
M>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@#\>_P!NS]EO]O;]@;XW^-?C7\!?
MACX+^+OP[^,W[4/@3QJFE7/B,Z/XFLM?BUFQ$&D^=/&UM):33HD4<C,/($K,
MR@!MWUQ\,OVB? O_  6<_8E^/7[-<?@#Q'\*/'/]F:S\/_B-X1\66T9O?#FI
MW6GO%',7B)2YA*NK)(N-ZQD8 QGS?_@I+^QC_P %$KZYTS7O@K_P4,U>\\+Z
MU\??"6IZ9X*UWX0V>MR^%9G\0VDB74%Y%-!*UE9N1.89U=?*A*&2-<L/I#]@
M_P#8#TK]B?PIXVO]1^,6M^/OB)\3O$LOB'XB?$77;."WGU74&C$2&.V@ BMH
M(D4".%<A02,D$  'PAI7[0O_  4K^!'_  2JU'_@F_X^_P""8WBNS\;^"_@]
M=^#)?BG)KFF_\(+#HUKI[V@UJ2]\[S3LLT$QMA"9'=-N 6*CZ8_X-Q8?$UO_
M ,$3O@%'XM29;H^&[YHA.#N^S'5;PVQ&?X?(,17_ &<5Q_Q'_P""7O\ P52_
M:C\(S_LX?MB_\%;['6?A+J86V\76_@7X06FAZ]XHL,_O+.:Z6>2.T64<2&%"
M&7*%2K,*^[/ _P .?"_PG^&.D_";X2:+9:%HWAS0X=*\-Z?%;L]O86\$(B@C
M";@61%51C<"0/O G- 'Y_?"S_C8'_P '!GC'XNRC[9X!_8Z\&#PIX;<_-#+X
MQU=2VH3IG@M#;*]M(O57BB/<9\F_X*2>#_VG_BO_ ,'*OP5^$GP"^,/_  K\
MZO\ LU7D8\<+I$-]=:'#_:>HR:A+I\4X,0O)88+:V$CJPC2X9\$JN/N[_@F)
M_P $_;+_ ()S_L\:A\)M0^*<GCSQ5XG\:ZMXL\=^.[C1AI\FO:M?3[WG: 33
M>7B)88\>8V?++<;MHS/^"@?_  3OUS]K'QK\//VD/@'\=KCX5_&CX2WEW+X(
M\<1:+'J5M+:W<8CN].OK1V07%M,@ ^\&C)++U((!X'\+/B-^V+_P3T_X*P_"
MS]@OXQ_M9^(/C=\,OV@/"VOW7A#4_'5C9IKOAK5](M3>7"/<6L48N+:2$  ,
M@PSC;MV,9/T5OK.'4;*;3[D$QSQ-'( <':PP?YU\;_LQ?\$SOCO:?MD67_!0
M+_@H+^U58_%3XC>&O#5QH/P\TGPSX1&B:'X5M;C(NIHHC-+)/<S*S(97881V
M7# (4]O^!O[/WQL^&/[1_P 7OC%\0?VJ-6\9^%OB!=Z1+X)^']]I1AMO Z6D
M$T=S'!+Y[^>+EY$D8^7%M,0&&SD 'P)_P3[\2_\ !1;_ ()$?LX3?\$T+C_@
MF?X[^+5QX/U[5T^$7Q$\%:KIL>@:[8WE[/>0R:G/<7$;Z:RRW$@DW(Y"C@'
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M )1K+_XS1_PVK^TS_P!%+_\ *-9?_&: /N'[%XW_ .@W9?\ @,?\:/L7C?\
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M #U_\=%'L\M_Y^3_ / %_P#+ ]KG/_/FG_X,E_\ *C]+_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !K\T/MMS_SU_P#'11]MN?\ GK_XZ*/9Y;_S\G_X O\
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M*O@'0_BAX"U7[?H?B31[;5-%OO(>+[1:7$2S0R;)%5TW(ZG:P##." >*V*
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M17:?LZ7$%I\=/"ES<R!(TUJ NQZ ;J /T8HK-_X3'PQ_T&H/^^J/^$Q\,?\
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M*Y+X;>+?#</PZT"*76(59=%M0P)Z$0K6W_PF/AC_ *#4'_?5 &E7YU?M)_\
M)>_%O_8<G_\ 0J_0/_A,?#'_ $&H/^^J_/G]HNX@N_CIXKN;:0/&^M3E&'0C
M=0!Q=%%% !1110 4444 %%%% !1110 4444 %?H/^R5_R;IX6_Z\7_\ 1TE?
MGQ7WQ^RIXGT"R_9\\,6MWJL4<B63AD8\C]Z] 'JE%4+;Q1X?O)UM;758GD<X
M1%/)-7Z "BBB@ HHHH **** "BBB@ HHHH \'_X)^6EK/\%=6>:VC<_\)UK(
MRR G_CY-==^UE96<7[._BB2.TB5A9)AEC (_?)7*_P#!/?\ Y(GJW_8]ZS_Z
M4FNO_:U_Y-T\4_\ 7BG_ *.CH _/BBBB@ HHHH **** "BBB@ HHHH ****
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MQL_:*^'>O:3X/_9W_93N_B%?:E:RSW>I7/B2#2M.TQ58*!+-*K%W;.1&@W$
MFN1_9\_;=\>>+OC_ ''[*'[3O[/TWPY\>-H9UC0TM]>CU/3]:LE?:[PSHB;7
M4YS&P)PC$D8Q0!]%445\P^*/VY_CIXY^+'C'X<_L:_LL1?$*R^'E^=.\6>(-
M5\81:3;OJ2KNDL+0/$YFE3[K,=JJW!&"K, ?3U=O^S9_R7OPE_V'(/\ T*OG
M[]D_]ISP=^UM\'+7XL^$=*O-+D%Y/I^MZ%J0 N=)U"!ML]K*!_$IP0>,JRG
MS@>^_L[K<O\ '+PJMG*J2G6H?+=UR =W<4 ?HS16/]B\;_\ 0;LO_ 8_XT?8
MO&__ $&[+_P&/^- $?Q._P"2;>(?^P'=_P#HEZ_,^OT:^)%GXR7X=Z^9]9M&
M0:+=;U6V()'DMGO7YRT %%%% !17@7[8O_!07X*?LI6S^%KKQ5;7_C4M92Q>
M%[6PNKR9+66[BBDFE6U1S"!&[LGF%=[!57<6 /H/P6_:1^$_[1_@K4?&_P #
M/$#ZY!IEW)975O<6%Q8317B1K)Y$D=U&CQMMD0Y*XPP/- '>45\D>/?VW_\
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M !H _-GQ-_R,>H?]?TO_ *&:HU=\1AAXAOPY!/VV7)'KO-4J "BBB@ HHHH
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M7_DW3Q3_ ->*?^CHZY#_ ()[_P#)$]6_['O6?_2DUU_[6O\ R;IXI_Z\4_\
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M:?!_P3J=]J1%Y-?ZQK>IN&N=4OYFW37,I'&YL* .RHH))!) /6O#/_(QZ?\
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M%=9^U1X3TVP_9^\37D-Q=%DLD(#W+,/]:G44 ?!E%%% !1110 4444 %%%%
M!1110 4444 %=O\ LV?\E[\)?]AR#_T*N(KL_P!G>VCO/CEX5M968+)K4*L4
M;!^]V/:@#]&:*Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH C^)W_)-O$/\
MV [O_P!$O7YGU^C7Q(\&:5!\.]?F2YNR4T6Z8!KIB.(6K\Y: "BBB@ HHHH
M**** "BBB@ HHHH **** +WAG_D8]/\ ^OZ+_P!#%?I]7Y@>'%#^(;!#G!O8
M@<?[XK])_P#A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:@#\V?$W_(QZA_U_2_^AFJ-=WKWP&^*DFN7KP^%B4:[D*$WT'(W''\=5/\
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M^9]?IA\3O^2;>(?^P'=_^B7K\SZ "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !7;_LV?\ )>_"7_8<@_\ 0JXBNW_9L_Y+WX2_[#D'_H5 'Z*T444
M8?Q._P"2;>(?^P'=_P#HEZ_,^OTP^)W_ "3;Q#_V [O_ -$O7YGT %%%% !1
M110 4444 %%%% !1110 4444 7O#/_(QZ?\ ]?T7_H8K]/J_,'PS_P C'I__
M %_1?^ABOT^H **** /GG4?^0A/_ -=F_F:AJ;4?^0A/_P!=F_F:AK\9G\;
M****D HHHH **** "BBB@ HHHH **** /H'P_P#\@&Q_Z\XO_0!5NJGA_P#Y
M -C_ -><7_H JW7['1_@Q]$ 5X7X_P#^1TU/_K\?^=>Z5X7X_P#^1TU/_K\?
M^=?,<6_[I3_Q?H!CT445\& 4455L];T;4=0O-)T_5[6>ZT]T2_MH;A6DMF=
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M %O_ .G'_DW_ -J!\?T5]@44?ZW_ /3C_P F_P#M0/C^BOL"BC_6_P#Z<?\
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MX,?1 8__  DNK_\ 0H7O_?2UX]XTFDN/%>H3RV[1,]RQ:-^J\]#7O->%^/\
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M/_?I_P"']4!9L]>U*YND@F\,W4*LV&E=EPON:U***^_ **** "BBB@ HHHH
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MMZK7MM?Y@?<OQ!^(7@?X3^"-4^)7Q+\5V&A:!HED]WJVKZG<K%!:P(,L[NW
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MX1_LT_"S3_"F@BY:YFMK(O))=3L &FGFE9I9Y"%4;Y&9L*HS@ ";P]^R_P#
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M,J31,5/&4DC1P>S*#VKHPU:-"LIRBI6MO?OY- ?+'_!-O]E3XX_#/XX_'/\
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MG_X6Q_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J^QJ* /S_ /VFO^"0G[-/PH^
MGBGXB^&O'_Q)DO\ 2-+:>U2]\8L\3,& ^91&"1SZBNG\$_\ !%C]E;7O!FD:
MY>_$3XH+->Z9;SRK%XT(4,\:L<#RN!DU]4?M!?#.^^,OP7\1?"_3-3BLKC6]
M.:VBNIT+)&20<D#DCBNA\):-+X<\*:9X>GF61[#3X;=Y$& Y2-5)'L<4 ?)/
M_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU7V-10!\<_\
M#D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU7V-10!\<_P##D+]D
MW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'_P"-5]C44 ?'/_#D+]DW_HHW
MQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5?8U% 'QS_PY"_9-_P"BC?%/
M_P +8_\ QJC_ (<A?LF_]%&^*?\ X6Q_^-5]C44 ?'/_  Y"_9-_Z*-\4_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ+/K.MQ>7Y6B7"I#"EM/*9HE$Q?R59\EMBO(G<?!K_@IQ^U)HG[:O@G]C/\
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M//TK _X8J_9F_P"B:?\ E9O?_CU 'P-7Z1_ S_DB7@[_ +%73_\ TFCKE?\
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M/F3>#M/ Y'/%:5 'P?\ 'Q53_@VE\0(B@ ?L7D  < ?\(N*^>/VQ-43X:_\
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M\2O 7AK_ (-D/#OC[6O%EC!H^G?LK7$-W?O<KY:31Z3+ \6<\R"93%LZE_E
MSQ7T/^R3_P $L/V%OV%_&&H>.?V6O@Y?>&;W4](DTNZ@?QMK.H6:VCS1S-%'
M:7MY-;PC?&A!CC4@ J"%8@^:^'O^" '_  2T\->)]0U>P^ NI/HM_=W%V/ E
MQXWU5_#EI=3A@]Q!IOVGR(I!N9D(7]TVUH@C(A4 ^$/VB/"V@>.?^#:3]B_P
M3XKTR.]TO6/B!\.;'4K.892>WEN9(Y(V]F5B#]:^Z?\ @X.L;'2_^")WQZTS
M3+.*VMK?P5!%;V\$81(D6]M0JJHX4    < "O:=7_P""=G['.N_LY^!OV2]5
M^#WF_#[X;:IIFH^"_#__  D&H+_9USI[E[.3SQ<">;RV).V61U;^(-7;_M#_
M +/7P?\ VK?@MX@_9Y^/OA#^WO!_BFS%KKVC_P!H7%K]JA$BR!?-MI(Y4^9%
M.4=3QUQF@#XD_P""K/PH^''AS_@VZ\;?#C0_!FGVVAZ%\$M)?2-,AM56*U>W
M%I)"Z*!@,KJK;NN[GJ36W\<_V)OVE/VDH/V;_P!NW]D']H/PSX7^,WPS^&X@
MBM/'^A/J6CZY9:I8VXGCN1$ZSV[%HVQ-%EB&9?<?7'Q=_9F^"/QW_9[U/]E;
MXK>"?[5\!:SH::/J6@_VE<P>=9(%"Q>?#(DRX"+\RN&XZ]:\P_:0_P""5G[&
MW[4;>$-0\?\ A7Q-I>K> M!71?"'B#P=X]U;1[_3M/&S_1Q-:7*&5?D0YEWG
M*YSDG(!P'[ /[?G[3GQ/_:R^(7_!/_\ ;L^!_@_PW\5OA_X7L/$(\0?#;69[
MW0=<TNZD\M9(EN5%Q:NLA'[N4EF!8_*%!;[*KQ+]CO\ X)X_LH_L)PZ]=?L]
M?#^ZMM9\63Q3>+/%>OZY=ZMK&LO&"(_M%Y>222NJ G:@8(N20H))/MM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>biib-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20210630"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20210630.xsd" xlink:type="simple"/>
    <context id="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib889c2d4156d4791a136cd35997ec490_I20210721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-07-21</instant>
        </period>
    </context>
    <context id="ie7cf54c2c77a4e6c9dbf0332cbd0f00c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49b5d4606fd747a98fc6804633f0b093_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i948d754496294f759ddb105ceeca7aa1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf3aacf570724f99badb8ea0d3a29373_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9e165fd1993b481c8583fa0659f62931_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02a7b47c3caa498fbd7d5570bba5dfb5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i597ac0475acb4b008433332ad02431ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieaebd3ec3de74756a298f2a7c57d8b32_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id563dc7eefa34305b99b4e811541cfce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22951db8734f44ec9b10b05a829c8cb7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i892ed7dcf1654ee7a0c75a99e9a162b8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i92244e16cec54d629634c4fa97c7505d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7b0791f187a342618d92225b098c9d17_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i60b121f8efd14872a1e30df2ef86c797_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcac24a08e5e42818462bbc94b13c07f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief6833d5d8e1488588e71a36bbe9c769_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i025174d34d0e4fed9880bf522bf39caf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a1c8cc7d1984bd2986f1829be158a77_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibc82ffb87eb341eb9922b2fe03938ef1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i881e688a79754d32bd4eaef661200a43_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c3490a5f63c46eca7c3d7b457bc76b1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b15e57dd5eb4ecda365d4f991fa27a8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iee8812efb9d84361a4d49aff1088e74b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a59ef186277439e93b9cb5d517c2f8e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i890d1bfbc3404c338c8adf2e20d53e18_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if0c7280649ce4b709f5ceef9dca96ca8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic4231dfa8299436094f9cbd4382d29bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b8169d797254002b81948999f73a837_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dfbafcd38f34defb5d883855aba00e1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1cd3814086244d508377429d979db225_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74292aa380dd4293a8ab78259fb0e8fd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62788c451f3146bbb9013bf26f1e565a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib434b673b42b4084b62db622b022d71f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idd1fb2ad6d46412c862aa18af17395f5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i94926bf743db49f1aa339479ffa0244e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7ee3f5cdf6da46f3bbd994edd429f1d6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic3240d0cbbf2494d9586ee74965f1b85_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ide200ffdc85b47c8a5734609c9cd5e17_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d6c47b7744b4c20842a09b8f4244db0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i514061955b07437c95410fb7d8491901_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib8001088915642409667fe820a47d9b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib94de1f81562452191bd4f557a5d4d18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5721ea124d3a4b198cd7d7caa427c5ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b80cd19565047b394b037487d83b697_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97e2df370b96408ba273c05e55e0cef7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0829016ca6b341a59a77978d812303fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ba68db7328d4088b2362283392e5a4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i433038a0a2e04b4a9718b3a120978075_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d83325fe697454bacf1a67ada1d4e30_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i829fb96209e04376a983019df1ad41d5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34d3cbd78d4e4e8a828d2ff80ce13faa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc688f4fb4ba4c3e9b5aba00112dcd1b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i50339615ca3c47dc93e748d4d2d021e0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if55c7e84188d4fc58a512a4f573231f5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78b2ecb22ef74586961d6a6a7339b061_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iee86344392cc4815b2010b4698cb5995_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i732c024e790641aaabfd3fb6981c4767_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6f73c932ef614e2b809c4c6773f7b46f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4a136827ea89494eb44b4f53d790b6f4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0888859ea81d4a4b9b7e7be25c61e121_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3300c292f1f6481daedcd2a3fd9d0d4c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i072ed2cc59e146fabce4bf0c8984c641_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i02b1a00011ea462489b26d05daea35c5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8633c1b979664edba4ec90abfc549bf1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1f72654aca994523940646887601ba08_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia66fd684614f472ab9ae858337e37137_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08d7b9a6dc614f7dbb3208265a4d8bb3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib552a12f17ae45c9bd51081076579744_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icb4529d1da0b4585a765bc987c30b140_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6b4edbd823d74be5afee6c24f030f8c4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia746808beaea4283b2a877a9fbf80dae_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia379321841ec4c9b893de5b4c3c0049a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6ecf6373de814aeaa2667c45b15358df_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i19d526c2292440b7a5a31fc1b5888e03_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i570dc5bd6835411ea0f2c6404bf2707d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1c053e7c564a44a0bafea18992724f4f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia5a510bf622c4fa8919b08f823833b36_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9f0a20b044aa4874a09f45a93c3dec1f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8fba909ac97644db8c749b15a7d893ad_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibeccde350a794ad3a057220538aae69a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6c2c7cddf4e4e6fa048863f067c096f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dc71f78bf134170821013d4e0e24571_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifdc925cb31f04e6eb50fc1c74378baa1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66ee4e438b174ae69ecb16ee0621c73b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75cc8f1ab2514617bcec62bafc7b0a4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibedb54914b4a4be1bb1f89fa85924372_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ideb7cbe5c0ee40cf910d38587c7169eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i703486666e174b76b44043f8976ce92e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i03fe4f4d72bc4079969e2e9ed876d281_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53a6be740b88408b97794cbc0105f101_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i948a3706ba984935b4f52d3af4515a54_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1aa7cd1f56a4406b8baf99c16459364c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i912a36fc12da4b8493cc611846c2ffb2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5bce9f6487694050a70f9480c769461e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id653e67025f441eca2b7a99e95e1a140_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide90025ae7d14057a14eaf2dffb72595_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8d4db9869c24b76826c44a5bad5b4d9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff71a4c7590448a39c9de6e0fc71bedb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44c71f71a23d4cc3a2b3597fe3bfca81_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5972e118118f4152ad8f8978769af8e0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i843c3b0a19d643c98f098c2cbdda56c8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i454fe0c0d5134bb092b7b31a87c40846_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3c40ac7856a4709b06d820f5782887c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia41f1626c54d4651b01a960a763e25d1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib44acf878e9a40e293c35b91d422db18_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1ec14a0b4c5428e96dc682fe53e2adb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieaaded065ec24455a1510514fd2e792d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icde9c2714ad74d01aea890f100a512e3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42ad626e97a14a56ab100e2a98cd07db_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5de49699ab2b4ef2950e4d9cf8d55bd7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie3f953a78b614e29b9d12ce31c18106a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib847f37c0de04daf96e1223d256cd610_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8f3bd6129bb04c41922bebfc2cfdb7dd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice992f8d6bde4f81ba988f03ad04702d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i913530b0c7a04680a81480a377dc75e9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4f26c5f8f7b644c1a6ae043ec51ab4c2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4cf57f3df80b47afbcf37febeca4a0ea_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i353e33f7e0a94012bc4281ed787c9554_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia7ac4b25470f4639aaafda04d93ef98e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id8841bf5e9b84dc9ae7268750ef2bb0f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i73c0c612c5734c7fb188c1543fa11185_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifbb5970ca1764f70aa1f12bc6e44c3e2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i644dc9ce5a6049f0bb8a6913c237d0e8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i74762eae8227417c92bc8b0acd73d688_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i23feca6c7c1644d1801a7f85831cd895_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifdc3f2e402ed45da9a6e36c3ef2bfb5e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id99acb96aa164c78bdba482e516c404d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia755e6ceac1747b180c2cc6df3ef4066_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i85e782c4b0e049938858ca5e31f73ec7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i76b65b40d820457fb4b9fa1f07a65f61_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i83dafc6720834c76a63a5163e4f532eb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e4a9f31dff843009dabe3a4e826ee4f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4af0c1582a2a408baa70b8e99def7c62_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b7281dae8894892967238587445989c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i231ad3d6d41645d3945da088fec9f599_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3cf8bb8c3fe841d0ba7abd41f7fb1ee4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i17628a71886641909400cb4619218426_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea9a9b26fba3467cba137763a14e9be3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ide17051dcca44f5ea4cc198403e62293_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f0293658e6748dfa458ae395ab995a5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i36d15291982e4ca994818b360dcda3ad_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id24d10cad1d34675a3fc968bdbb574a2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ab460f1c1bc4867a271a58701f0e028_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7301eef41d9640ed921b3e6efe6127c0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i93e99a1a7e774a0e815fa6a725ad326b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70a34315115c4b8589338e15d7ea6439_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i664fb5d936da45f59b4e592bfb74ac94_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e6e9d15df534c6caeb9f68534bdb18f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i347194d919304c0c812e6741db0e657f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifb2598e479464106bcdb82c4a4df0181_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a8798ca731041d684373855710bb939_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ed6f9bb6cf4494cbb6951ffc4427cff_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i19a873d0cc0244a8b91d944434d46b46_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iee1d133f9df644b8b0d7cd4410031d4c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3369c80db6c4ee5a519938ac9f89bcb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4585d796bb774ac1bea9b1ff5af52ba1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i11d5ada70f524874932a465b9b730154_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie31f861e6a524cd19f95e0d648eb24ca_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibb689c657f6b45ccb27299e839af1320_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i18dbf21007504156bc2266d82193def3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia538789f89324807b17b67af0a111518_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i765e12ebae8140ec80846e0ec971b64a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i87fedca069ca4c35895923673877e4ac_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idbc0ef98c72c43c0a4299bf74ba8c183_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if442ac7b0d344adc8562bfde02e57543_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if619b64750344bd396a36966f4e1d8db_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id888d7b35a7049cc9a61406634e23db2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i23586c6cb02341758cd17f3eda3f41ea_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05cd0486507d4bb9b3535aa6a9703959_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id76ba5beae9b4ebcb9b0d537208ce555_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i49ffa6986e434982a6f8ec10fd4f5706_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i549472d5a38946e59e5b1caa96706fe7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4dd3b810e859443a898e81c46682f449_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6084fcf81a7a4f17a2138fa073f7d226_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9f337b2eb414f3fa41dc8811176125d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i271aab5d507d493c86b6444f888c9ad3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9512deae649d4c98b378b690ec4b9532_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f99b0163013464e974cb8cb0fc170e9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id8a00992695e4dd1be1075fc2e7e7f10_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb24c52b894b4b7b83524d55b0ce82ba_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3255c22b11a4fda8d05a99d09fef6ac_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8f3957759bb4881946620abdea1906e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ida0e61991f2f4369b1013159e84567ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie21d03e014ce4af4a87f80e4d2f06f89_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d3038a0c2bf415589f4da253eeb15a5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47e951773a30439e95ed2c070c0d26f7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id69bc97b92384fe9b8b1109cb7b609ea_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0d698ae847c34141bd30186c02516ab9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if352a0720bb54a1f95411b27afbe2fdd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7dc18c39667846fbb99cfe5795bb832b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib6fdc86037324795b46c202ca0d00be3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4e95d1f892c4f938eea104fc6553abf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5fe219fd14a84e3980655fdb9727e9c2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8273fa766cef4c98862e9f44eb96455b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i22959fc6b46c4630bfb1d8629dd63f34_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i25f8875d0f60402ba93a3ddeb81920eb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76548eed129741f499223726cdcc1f1f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f82ef87090045aab2b1cb5b17aeea9b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6ba409194c834bf3a16a2de8f61db0ed_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ida1adad387b4453c8301620505216a13_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i38367c3fd9fe456cafc14d56b87cb674_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i132d903ffcdf44229d51ea6ed57f6217_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i653b99dd16f24c3e8a3cb8ab81b27bda_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1fc05073dde7472d85556d435dfeaf18_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0e757557007b47cda6f71a9ebaa17530_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icac584f59af64735be732faa98be7b4c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic0370bfbe4664865b37fa1b911566c9f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i952aaf5b1c50480eba24ec10039104f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9ec420238dde4d4b9a44da7620294099_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8a50f8d869747819b54ebbf6d2af672_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i722f82ed215948ea88263cf586031bef_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifdaa47b325f24a16bea0eec2bea1a4a2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1a76f1d5912f4b52aeb510ca5da3346c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i907f1e7563f14378b1ecd1b5ef055a57_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3345cb93fc40480f8456095f9d4fc38f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic2bc0914169f4c2cb3ffcf46eff93a7e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3f8adae560f142bb811699bb9d9628d7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc3232a5cc744549b80ca58b6a95c533_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0a40b518b8b4d188979f3929210955d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74bb1c58883a4dc99af1b4e416cf52b4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85f1e6f6cea24d9e98d7885cab1433a5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e96adf1d0b34fd48f31726b6ff44a4c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2cc9787466b46abbef67317ed6f0fa0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28fad1ddd69340d38bd387385c2d5c25_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2db8c7cca1d041038bed1f6b7d4ab6b2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i08947c7925794460a22599c198525943_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i387134594a0c4e6cad32daab163ac56a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibfa741e73d69423689689570e4a4b68e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i68ce3cc5ca544c28aad1d97c409db5fc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i592a4b594aed46f581483bbad038153f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3a3892d49afb415e99c3cba37acf71fc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05d64b2e8b964e8d8aa87f143c540622_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id21894b409b844989e613f38670ae21a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cb9c645dd194a048e1a08eff82cb7f3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1fdda44309f8410d9f5d04e02ea87a60_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1be3e03b30c944c68f2524da9d3dd097_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i098fb6e6a3044546a3431b4d1b2a365e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2b0e971c4d3c436ba2b2b28e78c71d81_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe0d22abebca4da6a32bd29921ecf3dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83e0421e29db4f0ca253c4ef2ea6cad5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i81d2503001f7463ba388d1b6a4c3cf5e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id01d8f96012745ff89b701ea923ba757_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idf07a847be8e4948957569950fc2b185_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iab5abd3f3f9f445291db02d0de25095f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i409b88462b9b4206b6f0ad945e5c7a09_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i243da6c48d9248179768b97ac1550b9b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0d74bd6f2b1d4e72a7d2229724e592c2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i720052044b584f03b3810ec2f322ddf2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i55ed419e0f084f27aea90bd9a24d8bd1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i635500abf5b347d6a57cfe76e6ceb55d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3d301e27c3914f82885e217461346e41_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if458daa2b72f4bda93915b366f415c9a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib22f26cdb1e1424a8f3ca3d681e15ffc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a60f7b09c98409e9ddc3f0e238fdfc8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ec1e52281e643248c39bb68e766f607_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ee71674694843249ecd53f5a7dbe42b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia2a55a2a9bc94211851b88701a3d8e7d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia613a30223bf4bf883786f9f016d0237_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia8965948dfbe425a85da6fca9e06c6da_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7c1d6b7809484ea6979801fe0bebf01f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib7e542e2b2e7467bb76adfbda503ec69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48dc4d3a85fb44099d30fed3e469b5f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9e902f930d64955b720bc0e0fd5de58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0214f5546f034d149788dc3f904a7419_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8dda4e5979a3455ba24bfb6dccd4adcd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib98775b1b10a41a392536907027ba668_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iad52dd82f08d441e93f786ded8f4be36_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i702781d7d4d143c985f549228c64fa29_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1bba8977699149f58c07fbe9bcb19689_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf361b51f5534b34939b0f745631d54d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3ad6c76d74374942bcbb4934411ede69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee771fa2648044888a8356de8f0d5e38_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib47ae3a613a94bfbaea1fea5774148fc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78c38ac27d6b4276ba03f7c2e9d29e86_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia5645d9467cc4e1c9a27bfe42553e646_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i907bc0d2ec594c419d577f002f5b337b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i340b682e29fc4f8595ff4caf9fd4f83e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if5698b182a7d4143989d02e2a19043a0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icbcba6dffaf3400cb18c2f40d6b7d5fd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5df461441ec4e59bcc1bb4b499e5d18_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3c6292523b5a4b84be8b5aa038a4e8c9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4937d91a9de34cd3a68c76b9f4988ba5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i49dbdd6ccc5c4f4e8c800f8f4c3db2ed_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c0174dd54e1428da6b9c96728976e62_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8ffe2c761d3548bbae62483d2028c1e7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ab0fad6e18f47efaf41fe8fc095a1f6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78be0a546c174fa2a2cdab944955d487_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i720dbccd07034f98942db90af7a7d38a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7236fcab1a8f44a8b21addbfbcd77b5e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d874a874e60463fb1b3910e76852f6c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd2696c492034bfeaae4a745a688853c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i564232db534949ec8f4d4776b844bc62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i425b64c01d0a489ebae1f721822fbfd3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idcf72f9358a9449ea227a870a11d948e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i292c5e4fd4e242e9875eefba463479ee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b4c60f1930e46e492d95823df89a04a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i915928be88b2414c93eeb0775ef69931_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3f3471ca51d841a8bc1d6e8d9212942e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5dd5cac2c4b4ef88f7c9af0cdbe95aa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icbe3131e1f0f4d2f96592abae7ae34ff_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc71ae0114074c328965f93fa714853d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if424d27a99a040a8a69fe6179239ad68_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic861662623824bafa546d7da7df31404_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib26ab77751224af3bdafebf334667bf5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i98b7babcbee94700b48f10861f4efe40_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i32c1c6a24b94432396492121d59bce8b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b3589e2b3b4439795b2b25630eaee3e_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09027731e61a42988fe6ef2a4a7fd42c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i23be9c67c76d4186b731732ff57d13fb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c307d55279b419ea2386fe0de0cb1b2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie349b92369f646b9b58c66a22bfd7298_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9e4ef37dfe9481b8471820d3e30119f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06bfb17addc54ed589cce69a74b3cb7a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id615384c43134264bf0013bc467194b5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07d3862fcf4b48ee9108d423b5ba2d58_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i919f06b975ef48769887372c1ad1d83c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie3dabc6e71e4430c9f009009824d5f5f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6fbd029fbc344b46a9e18552f63b771d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia2bfd21709274d769bdfe5ee0c2a4f9d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id690c3d268444a479ccd8676d8f87382_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5ee42b4171fd43f7b3d5a343e610ffc2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5278f4a26a6e47f587f7ca52b525d078_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iedd88e5dc8c048bbad2674a4096e3603_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id4bfc66e80d34cdda3587ae96c181943_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7b59ff6648844150b9a65bfbd8584495_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie36ef803d07a43c9b37becf139ada10c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie818c37f85794462a4a3bb25a7063d68_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e27733c20de4673aa52d098a7ee84bb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ief2010fabf284a188f6f32e901e8f4dd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i597e26ec891640fba08ea16a165c80d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a34184f549249be8306e9d072ccd958_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea8d5194bfdc4c11856e1dd30d419809_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96bbdd06b85242b4acd39c16f2de4f68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if17a07be4c334ab5bf381339cd0805c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0db3718d80134232900c7bf04328d7ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbea1376e99b45eea49529b1a794cfb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief1497c2e19e48d4a054f3ddaa892b41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6febac69f96c45f0b01a347765248601_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e243522dafd43409ff7994995b9d578_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74fec6d1e18f43c6aaa04084519b0b4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74f8c8feb0384cc4b6dd32e68d1156d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e051c5c511343dd9a80f274f5cbc761_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cb3c6b56f5242c9ba547dfeab34e697_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a4035f415b24c6cbd58d80693db5b18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b7d9660d3bf4a90965d36747d39593f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i260a3e69565e4b828bff65115e0af19f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic6c4677be3fb47c7b1f75c1d21d7e655_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc509257f5be4a76b94830882324d568_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89e963ce175141e289e8f4ab954e3f94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71f9390e677c4071a7ae6a84252c90f2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i773881e5f2394e0ebf447f4efbf9d486_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i56f856147db941a0804cfc73b59b772a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0576235f4f574413b5c8e270830d6b36_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i937eaac40dc143619d61ac7e212f0a77_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id89cf8bc140442ae872b864148ab6939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37f011c57e3b436783a11ba0e28c19ed_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifc580ad737ef4e489c1ba3d69c8dfe89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieca50968196b4b61ac6745902e8f15f7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61e30f1dc0024078af380776f8c704ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6bb9fb78022c43f0a0b87550768dcfd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i630a522bf9a74f1f95a783e75d21daf3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4fba93be0fea4ade8ac439ac8b9db515_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1fb36c730ba45d4ab09be804637ed64_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i51a894a26a474d8a8a4ca98884aa9ca5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie394eb8420ae465f88327d5264884868_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i75c9a173f74b432699e417cff17cf882_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib4ab760d5bc14df3ab137b467a13aa03_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie454762cebb348ce9e3d9253487d13f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida5bed7f18604646be99d5feb31fc4b3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic8dcc2572e864232810d889863e8b6a1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i703ad29a631c4d6a98bdf0bded3bfc94_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iea767474fca14a4e9823a37eee15721d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia7c698cd4a9e4be08876c788f019876a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i76ce0d61306a499d84402c0d7b2ac015_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7937d5eea9143a480379f4cf9a45fc4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47869cfa31654403b8a137ce71cddf41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i341192473b2c4e86ba0b46d1823dc869_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia0765b5a9983479983cc32b7829fb9a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24972f1aece34e51acc03fa88f074792_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia9f336c946104c0db5fe50289af1e486_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedcd05b4880a4540810666063e3fa5c4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i025802fa7e3847d4ae2eef093ae4c52e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iea966d9152224b339632f5f1382ae44a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4d314e63f4cd44538653c170af449268_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9a12db724d6a4e459f2d028b6a9183ac_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie9cfa41b71984268a5cb3226a08be9b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2da4427e9e314137b7a5b4ca1ca37219_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2345724701914330b955cf8be98888d9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iddda160e4f824f399742551361ab9a2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd259f1cd1d64891b5247097034ba0e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i046a19b35a87471dbbfd93c7cac2007f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dc1544fae3a46a4beeec639311e70a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84100fb99b304864bdd82f94e09a5f4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccdddbc872c141098bb571cc14541a6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaa604084a4f426cb962e44bba729d00_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1b531a1cb354dadb1d4b04d6c9d7dde_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5fc4527faa29483d89169d9c64e45fc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i6c93ea4397fb4f4cacf7e9b9766c5d11_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i82cf1cd794bc4e22b1558829c36fdbe6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia3fe0fbe0a3c4dec98ff2998e5d84527_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i266a572040e74f2e820d9c7521db5009_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i512790f7d615460ab79e03a4291d683a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie46d4c476a5740f3a1de4a18cc7dd358_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="id9f0d11ff3fc4f448b2f08227bf61ec8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4176720cd9a4369ad4b4aafcdcf8e71_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3365b3ac299340f1817dd1c53085ac56_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie2e1c79ee9d842c499a267151200ea06_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i25afa94ed8e9481ab9840103fd7abdae_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i20c4856250984299a9cced80dcf2d079_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50f69c368cc9469e8e39f044f00e3e4f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idfbd5e05042b4036a8d14b4e5ebca682_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i011039cdd7d14a4cb9f0e79057e4cc60_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i361c2d5b5f9a40ca84ea9fc27a68ea9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31a45a9c2ad44e1fa1cf0df1ef188ea0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2288b6bd35ab44fc89e7711afcecb9b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i041267955427406394b3d10cc3f1a76e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7c013d5be0e0491980d059486bae596e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a47da70628b45368fa3c768152f89ab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i34356bbd90064319b545c3acc5fab084_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62b264cff07c440eac3e823fa20d8f64_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id6d5e77b1f3d4a9fa12b15878cb707cf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i89bfefbfa10f41fab03c1114e9b9886d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idefcc8d10a5a4365aafafd0f6a18ada6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic773015e74094678bef62859130a7966_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf78e07bf74c48a797d7b1e5be1d1a78_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8644901576fc48e89f7637ea72cd9a14_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifc16ed7a14e24bfa91d7bef98db547da_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide0fa9272fb14f3d92662a3cf36c6a91_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd7e5ea5d2434fdb8b011b6c00426a56_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6e7a2205485b42a29e91f52900709717_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i67d9977b79f94870b4d88a3efdae4b18_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9eaabdea048846fe96c2e448be0650d7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i27ff03e21ceb4d898ce5d84c9f83373b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieb7296f2fd8d4fcb8a228339d858558a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1be0b892adfa46da854229dbdc2b29e2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2404b4e4cf7047b6a33ade2b330db9ad_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22a7aca0e9644a159e0edce9ec0ffa8e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia9fa629226d049e2a9ffe5ae168ceb55_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if078c4e7fa004892b58a2d85cb5816aa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie35fa105818345dcb7a4da4701cf3007_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ac95fd0cd294483986cafbab07cd5d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02aaf8bc41e445329bc5a2dee146c97a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idb95e23801654e2bba2506940e05081b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab366cb8c1584b168540336d12773aaf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74eeb72d9da54664aaeffbd41250c0b4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id08317e7cb534a3289414130d2f13dff_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d8b068d3ff24daca734cfd11aacfa1c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if261c4da0ab44775b42f4cccccfe73ec_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide3cd384eb084efab9ae4e2d17d5a9c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0281011ecb3d433e9e4a910b3c2764cb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4592ebbd81f14b13b42251b139794fe1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i26b01c7943bb4de2afd50de4b1bd1d85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4431cd1978604f468b85792244a703c3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if33dd48f244f4225b552ee2004b13a84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02b29717f14d4bcdb08b0e8f526654cf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4db5325f2f3e41fdbbd2d84f4bae2316_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d7d7619dfe248fb92239ddd3b9eb83a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iffdc90f0b7184b6f826b98475df4665c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7819501654a14b97b346551b244f99e9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1250cef8ffc24c32aa61879bf6b514d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54aba4f031f44f21b6560820384f079e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8f4743c680e7440da17e364ec93d7b53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b1bf393f58e4ed0abf1efa1dd592205_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i433d1dcae59d4e858da20f98b3db0590_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29b29bd51ce34a84a747af8d0b76aa9f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8b7354b1363641bda1fe4879d47cd10c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf0486182bcb4de1b50c1c4e665beb58_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i19b7ae3032894fbdbbde3fe9f817db9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7f7ccbfa9ed411e963f8ab905c572e1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2998a0b67c1c4fdcad0435d7a30e8285_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i81df80dd2e3a491087572c5e78a6d533_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib044e39931fe4842989f0f875a50f3ba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icb7fbc25be7d405ab815f3b0802c4430_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifead4a76cf1c4aedb1f743dff60ab9c5_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i327c113b77e945e794ed2983beca310e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i5605847573354f9fbd73ba2055256fbc_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="id4d713ade1b14480a777502c5e1bf27b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i28e27eba29354cb480fbbc98ca1d08a4_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="id78d6dabfa0b4866b6108e9a2c352b12_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49528d2d9baf4068bd97b947293b14ac_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib4010afcb4574fb5a96678335abc87c3_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i7f180f950ceb4167854fd3cd90ea9c70_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0c0aa046537b415fa3f8df9b5a030319_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie53079fa10c74963b5f0f9ba19d3c804_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:October2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i43e9a82c06fb46bab58a5f1115cdafbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cd5030b156d448aa845809d96101ccf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e3c7e0b91104fac8e090638fd4b76a4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i377f7b2b4b52412c99af798994cc4777_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icb5853a7e3ef491bae7a65e1700e49f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia36720c0b63744ff81262ab66ab00c7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ca5708d24544f20a4280b1a87d305ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f97bf2a176745928cd1dcd5ea7396f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib92db432fc134e3e94c64ac21f29c319_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia60fdc6283c6461ab18da2fc1f5f4f7c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0beb22829148494f946ca0c797b83a17_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i87c400ae85bb449a972a93be398be207_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if22b6d24018d47dc812ff8762a4fa3cd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61b30ac7e13f4d9c97c0e658be456894_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i22e22cb23d684bd2bfc1ab92393bf68e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i350abaf377694487bce4d1569f7c6563_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2b9bf78269b4fb284993468c59edd91_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45a327327cab48738dd4d95d812889ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b6ecb6a9ead4700bd2dc91367ec36e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9e8cc4cd6af248d9bfe66ed30639196d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4a59246306f44bb4b8c54ec6ff864503_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i04f6ec19f64e41568b2068e96298f003_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id99da815ae3f44649e4b32bb305c0670_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia94afab659f248cba857933e77ec8718_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3f12d27ddfb1404aaf145062a7713f57_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i92055b26fdd84bf0b0f9ed93e463988b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifbd9eee9380f42788da909d05cfb8fd7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic4a22cdb164d4ec1b3e8b6f30d33a058_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f51c78567604483a89db091767965c6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2867d1e4c35544c591c011e82114911d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i550626667d504f049e3f27be6c6e87d1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc844f221fc242d7ac07b31786e87e81_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icec6ff2fc5d644a894df350de003ed08_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie0d7f325ae73459e825690036a3d6239_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida11029c7cd140e7b425e00d05e00a01_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id85699448040462d8f5baad3e1537a64_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85035a7642e240e7bf1eb74af9286dba_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0c79aa09732f4485b81ca20d090dc9d2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic607ef111a0b40c98d2bb3abadd70ac3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2282dfbca39426985c7b4c02362b0f6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4eec312c192244b58a5937395a9f32ca_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0f60cc29d37f4bb39e05aacb97220a95_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida800d3221da45ab8bb24399a9800a50_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i743269d62e29412c951e960acc6995bf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79cfcde33ee94b2091ef4e9994affc0a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia69456628ebe4d798414fbd24865b055_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ca6ce9dd1204c9d8ee47ed61c9d49e3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i24286416527948f3a36f9903ba223e92_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia5868596776a48bcb3288f10554ae486_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7711bdabafa4868acf0cef411512b10_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idea5a899ef244aa7ad5b55e212db3c75_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic508730c80624e0a9bd030c7f4a89e07_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1b1713d5c5845d3ac44180eebc6f115_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib33eb872c6b4401cbc20e2f4180db8ea_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic438578392a5405689d4d33d4518f669_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id8c7482558954653832964511911a842_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibed6e6d0ef254bcab5ae8ea84750ae16_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i19d163820b4b429c8ac869eca01a9a0b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i812c1ff8e80b47b58ab63fcf9ec1c7fa_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1023665010a54e788e30ff06159d6b65_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d84900139e040b39413a2c034c9a0a5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i81326f8c0faf4c82934916df0e7ba73b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i48408b16cb17457fa4d16374fac38f5f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8af3d4e0eb01491fbe2b12666856a203_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55281e38b4084b1a87f417de6e85d628_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ice3a443da8f344bfbcc4b77135174e59_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3bf599004a64372aa741876daef053b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67cf1f40f75d4c3eb9de865f64ecbbe5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i627f7085dbc94df5a856a6ef66dae68a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i47f184261bc64a1c87dca1dc5e5dcb5c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i327ede04c0d64a02a183dcb72ead44b0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i63915734eeed4a7fa8f44b93a5f9dad2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if414343ed3b64a0ebf09d1a0ac51b4ed_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib4be0f188a48449bb2c0674eb366a190_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i16260595953d496b8eddf5ebe0653440_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0a4ab76f4f554cc692c968485d75b3ad_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6e972a3b7174d6f895bab11575fb911_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idd08f32f2a474aaf85876113c161d15f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i034140dcf36b473790fbcfecad31c0f5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15391fb757e741998e7ea0be726a8c97_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5126740cc446437cac3cd23b16210a6b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib5def17fd84945bea951f1f209f4a742_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6dc2ebe6040c4f58b354ab2338b8717a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i177c8a1d0d754674a0c18fab88e27143_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5b6bd17fd1a848c39c8365d388aeb423_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8c191952c6e484ba3dd03915045e4df_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5386b3cc1f54a49bc7493b4ef834955_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc7874f6e244472f9ef1586998fa6bd7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9dddb0afc8b342b58b72feb818dfc513_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i84f242af2dd048a2bc766c9493467dc0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5336835708cc4dc48247e0e9ad7969f9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia5082dfd8d8a4569a216ee449ace1886_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf8d368179dc4c9290de72ce73993e6c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3cce66e5d593473eb28168ab00d42bbe_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d9d0511d58d472bb7e1f483ef7f6e88_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic33fdfdf2e5d4d1b9eed0a03f5eb93d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie30cba3e2edd4bc08f2a74408c366d3b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i080d328364f74b708ca4d19448cd3c44_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60376f76b3314e2bbb38c6fa9587253b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b682df909084551b169517453ffa2c0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f83a2e2c6a4460c9814ca56bd7798e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i683dd88ba1804d5d81e60a6e361b15e2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0cf76ad095d44d08b376319fd02096b7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i69a1d8eb24644ccdb1958fc8538a767b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e917d9b36df462b8f02b672a61e80a6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i940aec5d7103466d9529cc5b08d8e33a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95d0e998a1764fefaa1b533582262643_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic0e9f1b5c6644324895da8c763579ea1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i657a17d9e3ef4c86b23042aa118c1b39_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifa87cc62218145ad8330f96b7227e231_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if2cbebcfd92341b9a4800299106bcc4f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70a1617e837c46c9af07f92da67420a5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibfb715e3d5a940248b7d9789bde6f8cd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5bd89562ebcc4af9ab88aabef74b9794_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i14520938d40f4be7b3788532f0a39e36_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9789f6e0bd394724b1766f169596f0eb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2b30bd6c2b6a47a09c2ee57818fe9437_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68eaa385cc39449cbea95fc77f8b73e5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia53f50175e4b428ba3381dc4cbbabff9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i33c297982d9641fcb3a085dda0c1bd2f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icf3b63d2e34c47ca90c46007d640803a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibb9cc66426f84e3e828a71db655b5ca5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d35c0b653e746d894c5a5ff25f40d74_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ice2fcfe4886749c19597e9ee5c80f50d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9327f22b43043478937934e403bdec8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70318dd2805c4be293874a85d342f3a0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id6801ccc665a4e8db08e33134390d9c6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b163de37ced4db78033769ec4cfd792_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i658f7b7a80934324a5fde431814f9cd9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7c1ff74fe0d44db0b1983d0c557a90b0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe0eff84f0a64614b8a69a4c069072af_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i94c24d776c67459baefa074ef5ce43e8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0531061801234f06bd21a3e0b235a6a9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i26e88285d5d8470a8b499ee193fb4bbf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1453070338d24ee3b7ee1fb21644243d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i525a88b3fbd24d928dea67537541252d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i86a1f935392743a6b8a9a61a8026ab24_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie24ae1e5faa24314a3a0baafdb89a376_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie4bbf4a5ff6c4f5085293b4809ad89df_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11863a558bbf46bca75ffd9f7fafbba7_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="ia4f071a5198246d4a5303f52da35079c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ee4b7c75b03465cb35c3c8b87a54189_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i187bf0ed97484588819f3c772481972a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4faa3349fe88498e9d027f1467d57c95_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia27d340d112941fc9280b61618209c41_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idcfeec350bdb466ab3c2f0500fc633e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11706266e0b64d6b838208836874f7c9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41b0165e2b7d4f55925670a51aac39ab_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i22390c69ed8c484a87e99931785d60cd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85191396f14a48159b6ea71eb3da36ae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8dc20aceecce4ad98ad607135283cd1f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1d184845c0fd4540af43215a509def5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id238c93aacac4f80a409e4c0cd6eb474_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05bc48381d6b4149b19415bd7d37bd95_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i3d03ddf77e1f433eaa830646366273e1_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ifa100d41aa7e425a9482c71b0293c71e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a247039a04a4250a57179e383ed799e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib43ae0706b95445a8789a5fcbf8ac563_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i361307437209490a864b62473d1cedf7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8f888c4ff5e0416ba053664107506cc4_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic0a38fb832714a92860b173e6a8b3564_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl8xLTEtMS0xLTA_470615df-e9f9-4833-98be-fcf9e49f446d">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl8yLTEtMS0xLTA_cce4702a-db22-4856-b999-1de9ef355ffa">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl8zLTEtMS0xLTA_742b5cb8-5c67-4222-820a-2f96c69e998a">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl80LTEtMS0xLTA_49357a99-9043-4f51-9e05-53d36c615d6a">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl81LTEtMS0xLTA_3b2f5a2d-2a91-4222-8276-6da0ec3557a5">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib889c2d4156d4791a136cd35997ec490_I20210721"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80L2ZyYWc6MzYyZThhOGU4YWQyNDUzMmFiNjRjMTAyZTVlMzIwYzYvdGFibGU6ODNkMGFlZjU5ZjdmNGFiNGI5MWZhMjM2MTZlZTZhNjYvdGFibGVyYW5nZTo4M2QwYWVmNTlmN2Y0YWI0YjkxZmEyMzYxNmVlNmE2Nl82LTItMS0xLTA_9e74c52b-44e8-4c46-a48c-b8c0a14b4abc"
      unitRef="shares">149033443</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMS0xLTEtMS0w_7a289f25-7de9-4ee7-9679-48f110fd0bb1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMS0zLTEtMS0w_4dd40ee9-efd2-46b5-a8d1-fed76ecef980"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMi0xLTEtMS0w_e1b06504-9f19-4049-afca-16a2a08d6b51"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yOC9mcmFnOmQ0MmEzYjdiY2IzODQ4YjJiZjk0ZjQ0MTc3NDQ2YjQwL3RhYmxlOmIxMDcwZGZhMWViNjQxMDk4MjlmZDExYjQzZTM4MWFkL3RhYmxlcmFuZ2U6YjEwNzBkZmExZWI2NDEwOTgyOWZkMTFiNDNlMzgxYWRfMi0zLTEtMS0w_408cf44a-2e70-4392-a04e-47f334eced16"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i09027731e61a42988fe6ef2a4a7fd42c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfMS0xLTEtMS0w_8b95d170-0d44-4dde-b270-80fa0b961bb8">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i23be9c67c76d4186b731732ff57d13fb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfMi0xLTEtMS0w_a9256ab5-6779-4874-851b-dd7a6e5544cf">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9c307d55279b419ea2386fe0de0cb1b2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfMy0xLTEtMS0w_6eb46d1b-0be0-4b32-bf95-d7b9b5f60da5">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie349b92369f646b9b58c66a22bfd7298_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNC0xLTEtMS0w_e6578637-4476-41c0-9107-a3cace72dfa4">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id9e4ef37dfe9481b8471820d3e30119f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNS0xLTEtMS0w_3f211575-9ddf-4901-bc3c-8f54c6743af4">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i06bfb17addc54ed589cce69a74b3cb7a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNi0xLTEtMS0w_690e65b9-ddde-480f-8fbb-62efb561bcc0">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="id615384c43134264bf0013bc467194b5_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfNy0xLTEtMS0w_2250fa2f-6cd7-4808-8f62-e8d8c48d43f0">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i07d3862fcf4b48ee9108d423b5ba2d58_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RhYmxlOjlhNDI2ZDc4NWM3YjRjNGNiMDQ0ZGZhOTYxYzQ1ODE4L3RhYmxlcmFuZ2U6OWE0MjZkNzg1YzdiNGM0Y2IwNDRkZmE5NjFjNDU4MThfOC0xLTEtMS0w_d67c0d00-1312-45d8-bcf6-116442489e56">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RleHRyZWdpb246YzhiMTAyYWM4M2U1NDhmNWIwNWM0MDg4YTgwYmZkMWNfMzk_aea3b2e2-3ef7-4413-8bd8-2869d86a78d0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RleHRyZWdpb246YzhiMTAyYWM4M2U1NDhmNWIwNWM0MDg4YTgwYmZkMWNfNTI_1d6c27dd-2380-4183-977f-a4c4ad30177a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82NC9mcmFnOmM4YjEwMmFjODNlNTQ4ZjViMDVjNDA4OGE4MGJmZDFjL3RleHRyZWdpb246YzhiMTAyYWM4M2U1NDhmNWIwNWM0MDg4YTgwYmZkMWNfNTU_4f6dfafc-599f-46a7-8c48-4d04e4b2a47c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfNS0xLTEtMS0w_b1a08774-d147-4efe-8af6-854e715324e7"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfNi0xLTEtMS0w_f8028dcc-031f-4204-9f10-cd63cc6210f0"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i37f011c57e3b436783a11ba0e28c19ed_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfNy0xLTEtMS0w_e58df55d-fb94-42e7-82da-d865395f7686"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfOC0xLTEtMS0w_a4661480-63fc-4abc-9808-1f1bf4524dd8"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfOS0xLTEtMS0w_ad0c6608-07ba-4318-a522-9b14fd5b01fc"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i630a522bf9a74f1f95a783e75d21daf3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfMTAtMS0xLTEtMA_020cafba-dfb7-4c2d-b71d-940b1fe1babf"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmYxZTMxZGM0NzdmYTQ0ZWRhNDlkNDVhZjMyYTJmMGI2L3RhYmxlcmFuZ2U6ZjFlMzFkYzQ3N2ZhNDRlZGE0OWQ0NWFmMzJhMmYwYjZfMTEtMS0xLTEtMA_385b2256-fa28-4311-a231-244b2c63b6be"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i703ad29a631c4d6a98bdf0bded3bfc94_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmY2ZGU2MDUwNjBiNjQ2MGRhNGY5ZGFkMGM4Mzk0ZGEwL3RhYmxlcmFuZ2U6ZjZkZTYwNTA2MGI2NDYwZGE0ZjlkYWQwYzgzOTRkYTBfNS00LTEtMS0w_e9abd1ee-9f43-4196-99e5-b40051dbe2ca"
      unitRef="number">0.0083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iea767474fca14a4e9823a37eee15721d_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RhYmxlOmY2ZGU2MDUwNjBiNjQ2MGRhNGY5ZGFkMGM4Mzk0ZGEwL3RhYmxlcmFuZ2U6ZjZkZTYwNTA2MGI2NDYwZGE0ZjlkYWQwYzgzOTRkYTBfNi00LTEtMS0w_75d92c1e-4bac-42c7-a4ba-5afaf751adc1"
      unitRef="number">0.0118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83MC9mcmFnOjk1Y2MzZDFkYTU5NzQzODBhNDA5N2E0YjdjNjRkMjBlL3RleHRyZWdpb246OTVjYzNkMWRhNTk3NDM4MGE0MDk3YTRiN2M2NGQyMGVfMTI_d2087288-ab8d-4a0c-9ed8-d3626b7a77e4"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <dei:DocumentType
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDA5_94fe6d78-41fe-4cbd-96e9-5605d3afd51b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6NTZkZjVkZDY3Yzg5NGNkM2EzYjYxZjk3ZDhhYmNkZTkvdGFibGVyYW5nZTo1NmRmNWRkNjdjODk0Y2QzYTNiNjFmOTdkOGFiY2RlOV8wLTAtMS0xLTA_7aad80d5-87ba-4bad-b464-f28417100a77">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18xMjQ_e831f6e0-1e38-44fa-b116-b55dfc179f6c">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6MGM2NjFkN2VmZWMxNGQ0YWEwNzg3ZGRlNjE1YmU1MWUvdGFibGVyYW5nZTowYzY2MWQ3ZWZlYzE0ZDRhYTA3ODdkZGU2MTViZTUxZV8wLTAtMS0xLTA_374d0e11-c342-4f87-b060-eae8787bed4f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEw_c0905868-5033-400f-b798-33c0847763b2">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE2_eb719ae6-7a53-4a0f-bde8-efd85515fb7a">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6YTQ4NTg4NDVmZDg0NDYxNDgxNjQ1NWM4NmU4MWYzNzUvdGFibGVyYW5nZTphNDg1ODg0NWZkODQ0NjE0ODE2NDU1Yzg2ZTgxZjM3NV8wLTAtMS0xLTA_2f784d92-eed3-4022-a709-62f36794357f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6YTQ4NTg4NDVmZDg0NDYxNDgxNjQ1NWM4NmU4MWYzNzUvdGFibGVyYW5nZTphNDg1ODg0NWZkODQ0NjE0ODE2NDU1Yzg2ZTgxZjM3NV8wLTItMS0xLTA_83a7cd76-d4fd-498a-96d3-4689d4e652c3">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEx_60bbfbcf-a387-4399-90c6-4d23ae1ff329">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEy_d16a0b46-de49-49b3-a7a7-9bb656f8a5b9">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE3_e30d116c-8de6-4aa7-8ceb-fdd87a5a0124">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE4_c3d1cc67-8db8-4615-b74f-7ca17a4631d1">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDEz_e3bb91b0-0304-4b46-8638-f3e79436d701">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE0_30182bf4-ed3b-4567-b6ab-e8d5312a5bdd">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZmJiMzAzYWJmMGM1NDhhZjljZWViNjU0MGIzNmI1YzgvdGFibGVyYW5nZTpmYmIzMDNhYmYwYzU0OGFmOWNlZWI2NTQwYjM2YjVjOF8xLTAtMS0xLTA_65efd2c7-7ed7-4269-8478-d54ff6fa0c88">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZmJiMzAzYWJmMGM1NDhhZjljZWViNjU0MGIzNmI1YzgvdGFibGVyYW5nZTpmYmIzMDNhYmYwYzU0OGFmOWNlZWI2NTQwYjM2YjVjOF8xLTItMS0xLTA_14431537-9cca-4723-8163-4f18635cca48">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZmJiMzAzYWJmMGM1NDhhZjljZWViNjU0MGIzNmI1YzgvdGFibGVyYW5nZTpmYmIzMDNhYmYwYzU0OGFmOWNlZWI2NTQwYjM2YjVjOF8xLTQtMS0xLTA_f7a0f1ea-01ed-4ab8-be36-79303843d45a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE1_f0c6a423-6347-40f3-a3d5-902ef3c29f7f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDE5_b216a551-e6b7-4d33-8daf-78a8bcec7de7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZjY1M2VkNjRkOTI4NDNkYTliMGZkMDhjNTgyYWM1MTgvdGFibGVyYW5nZTpmNjUzZWQ2NGQ5Mjg0M2RhOWIwZmQwOGM1ODJhYzUxOF8wLTAtMS0xLTA_f45b272d-471a-48cd-9f7a-57f33847075b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZjY1M2VkNjRkOTI4NDNkYTliMGZkMDhjNTgyYWM1MTgvdGFibGVyYW5nZTpmNjUzZWQ2NGQ5Mjg0M2RhOWIwZmQwOGM1ODJhYzUxOF8xLTQtMS0xLTA_fea6bee6-ff3b-402e-8c32-dfeb8a1d0d25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGFibGU6ZjY1M2VkNjRkOTI4NDNkYTliMGZkMDhjNTgyYWM1MTgvdGFibGVyYW5nZTpmNjUzZWQ2NGQ5Mjg0M2RhOWIwZmQwOGM1ODJhYzUxOF8yLTQtMS0xLTA_1824e267-d1ce-4892-9df6-0364b6302378">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18yMDA4_861b8488-462d-4547-8faa-5962effcf200">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib889c2d4156d4791a136cd35997ec490_I20210721"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xL2ZyYWc6NjEwZjMwNjlhOGQxNDVmOTk4MDM4M2I3YjcyOTZjMDMvdGV4dHJlZ2lvbjo2MTBmMzA2OWE4ZDE0NWY5OTgwMzgzYjdiNzI5NmMwM18xOTk2_9e74c52b-44e8-4c46-a48c-b8c0a14b4abc"
      unitRef="shares">149033443</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="ie7cf54c2c77a4e6c9dbf0332cbd0f00c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy0xLTEtMS0w_3562d9f9-be38-401e-8a43-8bdb263e98bd"
      unitRef="usd">2236000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49b5d4606fd747a98fc6804633f0b093_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy0zLTEtMS0w_e9227720-3125-4f1f-b0ff-085ec1098ae2"
      unitRef="usd">2795700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i948d754496294f759ddb105ceeca7aa1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy01LTEtMS0w_155c3bc8-e45e-42a2-a3ef-b4162eca3158"
      unitRef="usd">4447700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf3aacf570724f99badb8ea0d3a29373_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMy03LTEtMS0w_ff90e24c-742b-4ec7-8af3-05b8079a724d"
      unitRef="usd">5700300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e165fd1993b481c8583fa0659f62931_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC0xLTEtMS0w_4cae9e0c-9df6-4943-a558-59a8f277f4d0"
      unitRef="usd">440000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02a7b47c3caa498fbd7d5570bba5dfb5_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC0zLTEtMS0w_b0dcdb73-7d3d-45f0-8343-52db2aa1bde4"
      unitRef="usd">478300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i597ac0475acb4b008433332ad02431ea_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC01LTEtMS0w_177018e9-cab1-4506-ab48-30c51c64f84f"
      unitRef="usd">829000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaebd3ec3de74756a298f2a7c57d8b32_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNC03LTEtMS0w_daf5801d-bb7a-45c1-93dd-de6f2cfa494c"
      unitRef="usd">998700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id563dc7eefa34305b99b4e811541cfce_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS0xLTEtMS0w_3a5d2b36-22fe-49db-b438-032f648b32e1"
      unitRef="usd">99000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22951db8734f44ec9b10b05a829c8cb7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS0zLTEtMS0w_088b3d37-fc3e-4f66-bf27-4f0a2d99f96e"
      unitRef="usd">407600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i892ed7dcf1654ee7a0c75a99e9a162b8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS01LTEtMS0w_c639dbc5-65ac-4371-8527-2dc325929779"
      unitRef="usd">192300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92244e16cec54d629634c4fa97c7505d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNS03LTEtMS0w_7326a4ae-57d7-4ee8-ab1a-39f5954ef0f8"
      unitRef="usd">516900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi0xLTEtMS0w_6bd5d17b-da7d-492f-b6e1-5d8dbdfecdd3"
      unitRef="usd">2775000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi0zLTEtMS0w_e9126d98-7d00-4876-8f8c-49ba66b0f281"
      unitRef="usd">3681600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi01LTEtMS0w_a2f12fe2-4efd-4c85-8f16-ff964316048f"
      unitRef="usd">5469000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfNi03LTEtMS0w_cd094cd9-f922-453a-ad40-543d6dcad31d"
      unitRef="usd">7215900000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC0xLTEtMS0w_dfa45bde-4cb2-4075-8c20-8e1395c57441"
      unitRef="usd">459700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC0zLTEtMS0w_c6b574b0-a1b3-4b1e-8f92-bb131bca2125"
      unitRef="usd">411100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC01LTEtMS0w_29382302-58cf-4d35-812c-9f1fca96d1ab"
      unitRef="usd">937800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOC03LTEtMS0w_80b14a5f-49c2-455e-acb4-f55a86abd4b7"
      unitRef="usd">865500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS0xLTEtMS0w_175df58b-fbc7-4143-a11a-8c44807a0833"
      unitRef="usd">585100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS0zLTEtMS0w_16183e02-b0b8-4677-a70c-cb813b5fde08"
      unitRef="usd">647600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS01LTEtMS0w_9f90a31e-ee89-4fe2-9fe7-9b390c004743"
      unitRef="usd">1099300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfOS03LTEtMS0w_ce6e4aee-32b8-41ec-bd61-e7993d73132e"
      unitRef="usd">1123900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtMS0xLTEtMA_8659759b-d0c7-498c-ba75-e7e7eb205a67"
      unitRef="usd">637300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtMy0xLTEtMA_1624a187-9666-495a-8df2-de9fab71e65a"
      unitRef="usd">555100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtNS0xLTEtMA_e06a745d-10db-4ed1-9e28-77e7f348c148"
      unitRef="usd">1232300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTAtNy0xLTEtMA_eec190bf-86a5-4be1-b488-ebc3058bde67"
      unitRef="usd">1125200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtMS0xLTEtMA_05ed352f-8fad-4657-82b2-bea1ded51171"
      unitRef="usd">604100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtMy0xLTEtMA_a613122d-380f-442a-a766-b64cfbc964f3"
      unitRef="usd">61500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtNS0xLTEtMA_174045cf-24c3-407c-82a7-206992ebbc4b"
      unitRef="usd">702200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTEtNy0xLTEtMA_628a6666-b904-453f-98bd-c7939e11a732"
      unitRef="usd">133000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItMS0xLTEtMA_aa9a570e-016f-4ff1-8b5a-a091500dae4c"
      unitRef="usd">-15200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItMy0xLTEtMA_9afb2d9e-ca28-40b6-aaac-7f6fd399d8b6"
      unitRef="usd">21800000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItNS0xLTEtMA_07e9a2cd-fe4e-45ab-b946-ed2bfd44f450"
      unitRef="usd">53300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTItNy0xLTEtMA_4dab44fd-1ddd-4f1e-996f-980761ee6577"
      unitRef="usd">93500000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtMS0xLTEtMA_2f589e08-a765-4a48-9c01-feb7e14125af"
      unitRef="usd">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtMy0xLTEtMA_89c7c5f4-611a-4578-b22e-698908d6ab59"
      unitRef="usd">-10000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtNS0xLTEtMA_022d71eb-e8c7-4b19-b41b-311bf129103f"
      unitRef="usd">33500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTQtNy0xLTEtMA_74fa092a-0602-4b84-9cdd-677931db093c"
      unitRef="usd">-5500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtMS0xLTEtMA_f593a0fd-1833-4b56-9209-f0480b51df8c"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtMy0xLTEtMA_722bc253-e056-484f-92da-8c4b943557d2"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtNS0xLTEtMA_7a3820ee-ebeb-402c-a42d-120f2ea30106"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTYtNy0xLTEtMA_b20d8ff4-10aa-42c9-9a3e-b5685f6da809"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctMS0xLTEtMA_19f8cd13-9818-4581-a830-923fbd9e4c33"
      unitRef="usd">2289300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctMy0xLTEtMA_3a48bc97-c8a2-42b5-9957-e4c3e6c94147"
      unitRef="usd">1707100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctNS0xLTEtMA_ec657286-6ba6-4d17-943a-180355753c41"
      unitRef="usd">4009400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTctNy0xLTEtMA_9eaf6028-9648-49c7-b16c-d55c29d434dd"
      unitRef="usd">3421600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtMS0xLTEtMA_f379c4e6-d7a7-42c2-8439-a5e22bec7040"
      unitRef="usd">485700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtMy0xLTEtMA_740bba8d-2dcb-4261-a755-a26414d3b3a9"
      unitRef="usd">1974500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtNS0xLTEtMA_4135cf8d-0186-4cc7-b937-e15091a8a3c1"
      unitRef="usd">1459600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTgtNy0xLTEtMA_9a575974-1deb-43e9-9647-d645381857a4"
      unitRef="usd">3794300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktMS0xLTEtMA_3f899a08-ccfc-4ab0-92b5-20469b2ca6cd"
      unitRef="usd">96400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktMy0xLTEtMA_f862d5ec-938d-4096-90ea-8c714fa1a6bd"
      unitRef="usd">63000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktNS0xLTEtMA_2b93320d-f5ab-4a20-af77-da0c9c578aab"
      unitRef="usd">-410500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMTktNy0xLTEtMA_ce502122-5e73-4e33-bf32-8c786c75aeb6"
      unitRef="usd">-57500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtMS0xLTEtMA_5f788a40-9517-40b4-ae3e-87e9d3b54443"
      unitRef="usd">582100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtMy0xLTEtMA_4f477735-ca35-41b2-8397-8b9ce5923047"
      unitRef="usd">2037500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtNS0xLTEtMA_cafc8ea0-c505-4552-b370-b76d719a99c0"
      unitRef="usd">1049100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjAtNy0xLTEtMA_e9a9f138-81b7-4b23-86fb-f8eb9d482750"
      unitRef="usd">3736800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtMS0xLTEtMA_0868dbec-1ffb-4bc5-860d-ce601af9c3b4"
      unitRef="usd">-409100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtMy0xLTEtMA_43541e35-29ad-4b8a-af2b-af1246621b05"
      unitRef="usd">446100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtNS0xLTEtMA_15900a21-3113-4294-a6cd-836daeea3354"
      unitRef="usd">-364900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjEtNy0xLTEtMA_1a568997-ff14-49b2-9e26-1639789bc250"
      unitRef="usd">738200000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItMS0xLTEtMA_41f494b6-a642-4f76-a105-cb11ebdf1e19"
      unitRef="usd">34300000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItMy0xLTEtMA_4ef59bf6-b83e-41b8-9a59-b6410c39ba14"
      unitRef="usd">15100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItNS0xLTEtMA_451eb6b2-78f5-46d5-b982-751fb8cee191"
      unitRef="usd">16100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjItNy0xLTEtMA_be9a0663-67f8-4a9f-804a-6dfb017aa944"
      unitRef="usd">400000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtMS0xLTEtMA_640015b0-22c5-4bf4-961c-6177e55fbad9"
      unitRef="usd">1025500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtMy0xLTEtMA_586eba6d-fba3-43ac-be7b-f2c43b29a9be"
      unitRef="usd">1606500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtNS0xLTEtMA_34efbcc5-c4fb-4380-b737-90cb48312ba4"
      unitRef="usd">1430100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjMtNy0xLTEtMA_3621b3fa-7cfe-4ef9-818a-ed642c079836"
      unitRef="usd">2999000000.0</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtMS0xLTEtMA_128db8f4-ba0f-4877-a019-575374ff75b2"
      unitRef="usd">577000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtMy0xLTEtMA_fca574b8-f6cf-440b-a582-02b6eeada7ff"
      unitRef="usd">64400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtNS0xLTEtMA_8afcaa9a-f910-4fa4-8b38-c078ce7417ba"
      unitRef="usd">571400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjQtNy0xLTEtMA_f732c0c8-701f-4268-b1cb-aaf380c0c65e"
      unitRef="usd">57800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtMS0xLTEtMA_232b2dec-5eac-418e-a975-d86f811acc67"
      unitRef="usd">448500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtMy0xLTEtMA_5da21e50-2f68-4347-a7de-168585439c27"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtNS0xLTEtMA_411c5714-04d4-4582-b1f9-7ac52c2b65df"
      unitRef="usd">858700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjUtNy0xLTEtMA_8a5fdb7e-78ea-4753-a029-675acc765d3a"
      unitRef="usd">2941200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtMS0xLTEtMA_ce293d3b-fefe-45e2-a61b-6f4ef64d4a7d"
      unitRef="usdPerShare">3.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtMy0xLTEtMA_ad6eab33-e00d-4e8c-9bc7-0d2938b28d5b"
      unitRef="usdPerShare">9.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtNS0xLTEtMA_d991a889-cd63-41df-80f8-b15e642a20ac"
      unitRef="usdPerShare">5.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjgtNy0xLTEtMA_35c6ea5e-5379-4386-b839-bec81fa042c4"
      unitRef="usdPerShare">17.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktMS0xLTEtMA_e2936ca9-146d-4571-bab5-ec4f77aaf248"
      unitRef="usdPerShare">2.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktMy0xLTEtMA_a9d6a07a-17ba-41de-8f2f-47e2a6c8255e"
      unitRef="usdPerShare">9.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktNS0xLTEtMA_2e0d2c36-b70d-4213-9381-ce2b4c0a2317"
      unitRef="usdPerShare">5.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMjktNy0xLTEtMA_f8c1b31e-bd77-4723-a0fa-7c514cf72cd7"
      unitRef="usdPerShare">17.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItMS0xLTEtMA_c662533d-f319-4e52-bac1-bc0463bce3d8"
      unitRef="shares">149700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItMy0xLTEtMA_466c2f5b-839d-482b-a165-f9896d7bd740"
      unitRef="shares">160600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItNS0xLTEtMA_432e4fad-6eb2-4682-a018-3ec5dcdec1c4"
      unitRef="shares">150800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzItNy0xLTEtMA_8f174852-9928-486d-b1c8-d449f97eab29"
      unitRef="shares">166700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtMS0xLTEtMA_c47dfcc3-86f0-4920-af5f-7d50a171963e"
      unitRef="shares">150100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtMy0xLTEtMA_0980a725-b0ff-4322-be4d-1dc0e2cfc6d7"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtNS0xLTEtMA_9b0b5082-3204-407c-a1b9-a3496464e141"
      unitRef="shares">151200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xOS9mcmFnOjFhYTZlMzJkYjhmZTRmODBiZWQ3NmNhNTRlODAwNzgyL3RhYmxlOmRkYzA1ZmQxM2QzYzQ0NjFiY2M3MGE1NDA2MWU3MDVkL3RhYmxlcmFuZ2U6ZGRjMDVmZDEzZDNjNDQ2MWJjYzcwYTU0MDYxZTcwNWRfMzMtNy0xLTEtMA_04cccabc-d2e2-4433-a2f5-db0560645a95"
      unitRef="shares">167000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi0xLTEtMS0w_4fadf593-cf16-4490-af6b-614c5bbfe18a"
      unitRef="usd">448500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi0zLTEtMS0w_daa4664b-03de-430d-8c00-be10b4260ed4"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi01LTEtMS0w_4b569c81-89d3-44a8-b7b0-37d5c49c13e2"
      unitRef="usd">858700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMi03LTEtMS0w_769bb5b6-e2b5-4f51-a77c-9469d114a02b"
      unitRef="usd">2941200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC0xLTEtMS0w_dae99992-d5b9-492c-a2bc-8b40c94767eb"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC0zLTEtMS0w_45d1bced-74d7-4f83-9622-84dfea2939bf"
      unitRef="usd">8700000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC01LTEtMS0w_fbe29517-0fbd-4411-bcef-920b2c24312c"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNC03LTEtMS0w_9c96e18f-a0da-4d6e-94df-ccf08a0dc30c"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS0xLTEtMS0w_38a3d801-3639-4757-8494-d18a737bdfa6"
      unitRef="usd">-11000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS0zLTEtMS0w_b6291bea-1f9e-478d-b40f-6868ae6ba814"
      unitRef="usd">-51200000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS01LTEtMS0w_18369ab9-1763-4461-8639-c705b8d461bc"
      unitRef="usd">138600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNS03LTEtMS0w_25eb0e28-66dc-42e4-b1e7-7cf7b0f49539"
      unitRef="usd">-17400000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi0xLTEtMS0w_5062eab5-610f-48b1-b7c5-2b39410f5759"
      unitRef="usd">-2300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi0zLTEtMS0w_693392c5-8360-40fa-9c6f-815be5442e44"
      unitRef="usd">-6200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi01LTEtMS0w_ec041a72-2313-46f5-8788-c7b78b31cfa9"
      unitRef="usd">20100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNi03LTEtMS0w_2a64449c-4802-4061-8e63-3c2ede91a22b"
      unitRef="usd">16800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy0xLTEtMS0w_60a4d7eb-a06d-489e-8789-276982149852"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy0zLTEtMS0w_99292259-50e2-4937-8169-f7a832fc956c"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy01LTEtMS0w_268a7aba-5b7d-4995-8267-8aec204187d6"
      unitRef="usd">-2400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfNy03LTEtMS0w_3a507cf1-01b3-4e7e-a4a5-16c16509a074"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC0xLTEtMS0w_eaf08ae3-f8ee-4f26-9c8a-162322565f15"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC0zLTEtMS0w_e0d56da3-a62a-417c-b90a-28e392650a64"
      unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC01LTEtMS0w_caaf026e-b574-4bdf-8ab6-13590a7c1b25"
      unitRef="usd">-32600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOC03LTEtMS0w_e660cb57-0b61-4972-8984-d2ba1433d48e"
      unitRef="usd">-47000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS0xLTEtMS0w_07274664-e5f8-4bd1-bcf2-1d766c1a10a1"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS0zLTEtMS0w_4f42ca16-81d6-43cd-a28b-d468c74e267a"
      unitRef="usd">-31700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS01LTEtMS0w_7a39e0c4-13ee-4d5b-bc65-654de4434ced"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfOS03LTEtMS0w_9235dc31-c618-4ddf-ad78-7361f42f6118"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtMS0xLTEtMA_8733dd15-7aef-4cd6-8bcc-7428c151b52e"
      unitRef="usd">451000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtMy0xLTEtMA_c7de6e8d-a7cd-4a1e-9773-5d38e7232253"
      unitRef="usd">1510400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtNS0xLTEtMA_a002981d-588c-405b-9f07-a8823c20c34e"
      unitRef="usd">985900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTAtNy0xLTEtMA_ebbc1a1e-9c5b-4cd9-8969-0f33066e2bc0"
      unitRef="usd">2895400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtMS0xLTEtMA_2fb5c42e-a81b-457e-8e24-e2d9b24904a7"
      unitRef="usd">576900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtMy0xLTEtMA_1910e9ea-a6e2-4844-82ff-749cb560d188"
      unitRef="usd">65500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtNS0xLTEtMA_690d9818-4eb6-487e-9174-305be1eec00b"
      unitRef="usd">572000000.0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTEtNy0xLTEtMA_8c2351b1-9c67-4539-b18b-c4764b50fd48"
      unitRef="usd">59600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItMS0xLTEtMA_6b4218bf-161e-486e-8125-982f3901b12f"
      unitRef="usd">1027900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItMy0xLTEtMA_57fcab83-98fe-4c05-9150-b7d8213dfff9"
      unitRef="usd">1575900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItNS0xLTEtMA_b121ac2b-bc14-4ade-a7d1-758a5a98cb49"
      unitRef="usd">1557900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yMi9mcmFnOmU4ZTRlNGYyMjdlODRjYzhhZDg1Mjc1Y2E3ZjBhOGYwL3RhYmxlOjg1MTE2ZTQ3MjZhNzQwNjc4YjFjMmZlYzRiZjVmMjQzL3RhYmxlcmFuZ2U6ODUxMTZlNDcyNmE3NDA2NzhiMWMyZmVjNGJmNWYyNDNfMTItNy0xLTEtMA_030d8b06-d074-4b74-918d-81280058b0cf"
      unitRef="usd">2955000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMy0xLTEtMS0w_07ddfd8b-3e53-47c0-b30a-b5723cebcd45"
      unitRef="usd">1742000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMy0zLTEtMS0w_44e611b9-94b6-4772-9a46-c6632a8d96c7"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNC0xLTEtMS0w_62c6d8ac-81b2-45f1-b705-d75072b24dbd"
      unitRef="usd">1308800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNC0zLTEtMS0w_07c7009b-785d-453c-8afe-588d10920361"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNS0xLTEtMS0w_c935efd3-5a8b-4124-82fd-c93bf4b78e01"
      unitRef="usd">1688000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNS0zLTEtMS0w_d0cfe4b1-bac2-44d9-8e64-4cea333db679"
      unitRef="usd">1913800000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNi0xLTEtMS0w_b79a0da5-38ed-457a-8e4f-9d631c96decc"
      unitRef="usd">422200000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNi0zLTEtMS0w_dba94cc7-8a44-41a4-b1e0-2e26ee2e9bd0"
      unitRef="usd">413500000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNy0xLTEtMS0w_eaca3d1f-a161-43a4-8e8b-275e8c8ea0d7"
      unitRef="usd">1254800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNy0zLTEtMS0w_a5fdc7f0-a77c-4599-8a52-a9919fe7544b"
      unitRef="usd">1068600000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOC0xLTEtMS0w_67570ed0-a052-4c71-9a84-8466e968f00a"
      unitRef="usd">767900000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOC0zLTEtMS0w_77f43b76-e909-470c-acf2-b813e8612be0"
      unitRef="usd">881100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOS0xLTEtMS0w_62f53eab-e648-41eb-8bd3-e0da4ea9e863"
      unitRef="usd">7183700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfOS0zLTEtMS0w_df35afe2-10dd-4a32-9065-4d6b184703f6"
      unitRef="usd">6887100000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTAtMS0xLTEtMA_7e906172-e9ec-44fc-8a13-f1bcdc91f226"
      unitRef="usd">915100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTAtMy0xLTEtMA_2581fdc3-9981-4052-abf3-3130090e52b9"
      unitRef="usd">772100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTEtMS0xLTEtMA_df98682f-2ee9-458d-a745-ef53aa9e39dc"
      unitRef="usd">3442200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTEtMy0xLTEtMA_4b0182ff-6694-4f5c-813c-25fea53e51f8"
      unitRef="usd">3411500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTItMS0xLTEtMA_c0f8ce02-1e02-458c-a802-6bd46969e757"
      unitRef="usd">402500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTItMy0xLTEtMA_a87ac96f-e852-4e2b-8afc-199bef46ed03"
      unitRef="usd">433300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTMtMS0xLTEtMA_af67ade8-e95e-437f-bdaf-8e4cb99ef46b"
      unitRef="usd">2385000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTMtMy0xLTEtMA_6a54222b-6f75-4eae-836e-bf90c081e178"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTQtMS0xLTEtMA_650c41fb-388a-4c98-b8fd-17b3580973aa"
      unitRef="usd">5763900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTQtMy0xLTEtMA_1b48a7e2-8878-4d2a-9e62-6629e7b844d0"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTUtMS0xLTEtMA_dbbba736-c70b-4c64-978c-a18d4be6a717"
      unitRef="usd">1849900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTUtMy0xLTEtMA_ab727692-d5cb-4148-8708-8bd452c3fd56"
      unitRef="usd">1369500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTYtMS0xLTEtMA_88697db4-1ffd-4991-8634-499b8c397ac8"
      unitRef="usd">2528100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTYtMy0xLTEtMA_2f9edeff-599f-4656-be8a-7063a21e67a2"
      unitRef="usd">2899000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTctMS0xLTEtMA_7fc20db1-b10b-4037-95a9-9369eb71ecff"
      unitRef="usd">24470400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMTctMy0xLTEtMA_ee1e76eb-0888-4c8b-a1ee-1161926bd482"
      unitRef="usd">24618900000</us-gaap:Assets>
    <us-gaap:TaxesPayableCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjEtMS0xLTEtMA_c6c02439-2cbe-4eaa-a32f-5f102bd89d42"
      unitRef="usd">230900000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjEtMy0xLTEtMA_cd188abe-b064-479b-8fd9-19e70f4cf593"
      unitRef="usd">142000000.0</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjItMS0xLTEtMA_a5522864-f782-40a7-b732-be466d14e566"
      unitRef="usd">375300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjItMy0xLTEtMA_fba3dd32-d5d2-4430-a6a9-dfa9f1a43df5"
      unitRef="usd">454900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjMtMS0xLTEtMA_c490cfe9-b37f-4d4d-89ff-8c9a40a3aec8"
      unitRef="usd">2741000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjMtMy0xLTEtMA_7e9cc0d6-7c9e-4157-8073-cb90e418e257"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjQtMS0xLTEtMA_d6f246cc-d00e-410f-917c-ed9cfd293785"
      unitRef="usd">3347200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjQtMy0xLTEtMA_cd0e007d-70a0-4e24-8a82-a3bd7e1ca4f0"
      unitRef="usd">3742200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjUtMS0xLTEtMA_62e2470c-29a9-4335-a9a2-3950ea356989"
      unitRef="usd">7269200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjUtMy0xLTEtMA_e232f5ba-2c7e-49bd-9195-bc152cb5dee6"
      unitRef="usd">7426200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjYtMS0xLTEtMA_ad84c76b-3ed4-4e48-b239-927baba25186"
      unitRef="usd">918900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjYtMy0xLTEtMA_7afeb487-f9cc-4d86-afa6-42c1041ff6e4"
      unitRef="usd">1032800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjctMS0xLTEtMA_85bbc8bc-56f0-46b2-8ebf-653f9dfd19cc"
      unitRef="usd">363900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjctMy0xLTEtMA_5c5f97fa-b985-4afb-961f-877796d02960"
      unitRef="usd">402000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjgtMS0xLTEtMA_26413be5-1d01-45b7-8e2e-b8203daa0155"
      unitRef="usd">1356400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjgtMy0xLTEtMA_1c45e206-c774-4c27-8f7c-af45b946d416"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjktMS0xLTEtMA_97d492fb-0c1c-4db6-baa8-6a2785ab2cd2"
      unitRef="usd">13255600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMjktMy0xLTEtMA_941bb4f5-554d-4d72-a7a0-473ddabdc0fc"
      unitRef="usd">13932800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzAtMS0xLTEtMA_01ffb28c-ccee-42c9-ae95-1ced9a36097f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzAtMy0xLTEtMA_a92bfe99-d795-4239-a80b-d94b2e848f40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzMtMS0xLTEtMA_9e54d8bc-453e-4221-9c4c-e4d43b0fcebf"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzMtMy0xLTEtMA_5cb5a422-f0cb-4170-8f89-e3dcb12b963f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzQtMS0xLTEtMA_e3129235-2df9-4c47-8b11-05dcd4e875a7"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzQtMy0xLTEtMA_8e85da44-b70d-42d1-8e3e-4b2182283908"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzUtMS0xLTEtMA_721095e5-d054-4cf2-a1cb-f1413f8df385"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzUtMy0xLTEtMA_24c3cf85-97b8-4b52-8c80-0c0a0dbd44e0"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzYtMS0xLTEtMA_b7fa0550-dd9e-44d3-9edf-81fa36418b43"
      unitRef="usd">-171800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzYtMy0xLTEtMA_6dd23ba1-81c8-4f67-aae4-a7cc356330b5"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzctMS0xLTEtMA_d73a1acb-1b00-40c8-b2e5-798438056bba"
      unitRef="usd">13900700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzctMy0xLTEtMA_b9d2817b-69c2-465e-a00d-d903cf89cc69"
      unitRef="usd">13976300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzgtMS0xLTEtMA_ffecaf23-a487-4ab0-9422-974f08a19cf9"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzgtMy0xLTEtMA_0aae3c69-7251-4e3a-9cf3-cd404afffe52"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzktMS0xLTEtMA_1d5a21ce-d09b-448b-b8e3-8963cad9a420"
      unitRef="usd">10751900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfMzktMy0xLTEtMA_fe4ed7ad-e97e-4584-97ee-db7e211cd756"
      unitRef="usd">10700300000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDAtMS0xLTEtMA_cae0e03f-dcae-4327-993b-a86f320335c2"
      unitRef="usd">462900000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDAtMy0xLTEtMA_5acbff93-63a1-4bd6-bf5c-e67306a65da6"
      unitRef="usd">-14200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDEtMS0xLTEtMA_4f0fd602-c9fb-4413-8ddf-864e3c6ae3b7"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDEtMy0xLTEtMA_e23bb792-0480-497d-ad97-072ea6558697"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDItMS0xLTEtMA_a0f0a004-cd1f-41e0-ae59-d9992b7e0f13"
      unitRef="usd">24470400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8yNS9mcmFnOjlkYzExZTA5Njg1YTQzNzg4NTliOWRmMzA3YzRlMjBiL3RhYmxlOjQyODYzZWQ2OTQ4MTRmNTRiNzkxOGZlMjU1ODMwMTAzL3RhYmxlcmFuZ2U6NDI4NjNlZDY5NDgxNGY1NGI3OTE4ZmUyNTU4MzAxMDNfNDItMy0xLTEtMA_2842555f-8687-4a59-8be7-d06acdb760c4"
      unitRef="usd">24618900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMy0xLTEtMS0w_70d64d0e-7bc7-4fab-9ee8-3c4c7c2491a6"
      unitRef="usd">1430100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMy0zLTEtMS0w_8d90b8e3-bc19-4c63-9b42-796dfcd6736c"
      unitRef="usd">2999000000.0</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNS0xLTEtMS0w_1319130e-ed2f-47e1-be69-6cc3023f145f"
      unitRef="usd">219800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNS0zLTEtMS0w_65cc93bf-3986-4733-a78c-a0ec46fc632c"
      unitRef="usd">232800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0xLTEtMS0xMjAxNw_83c049fa-b5e1-4b5e-89cc-d2cfd5122196"
      unitRef="usd">585900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0zLTEtMS0xMjAyNQ_9690b687-7aeb-4df8-a7e8-9b79fad4067a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0xLTEtMS0w_3a0f5be4-6d4e-4e43-9564-abcdce653f9d"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNi0zLTEtMS0w_f0e37791-376b-4555-abe7-1f51d0154298"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNy0xLTEtMS0w_a05ec578-c496-44ad-8da7-f3a72fbd9ce4"
      unitRef="usd">124100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNy0zLTEtMS0w_0f828d58-6470-4dc1-ac9f-2d43d7663f0b"
      unitRef="usd">115800000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOC0xLTEtMS0w_66448f47-fb1d-4167-af82-2b017e5e88f3"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOC0zLTEtMS0w_c3c637ff-e644-4adf-92f5-132a99926e1d"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOS0xLTEtMS0w_b48d0be6-9db3-4e7c-a53a-cdd38b7679a7"
      unitRef="usd">33500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfOS0zLTEtMS0w_6b45227a-9060-4e34-adc0-17ae3859d5d8"
      unitRef="usd">-5500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTAtMS0xLTEtMA_a1f4665c-f86f-4d25-8713-c117d259b742"
      unitRef="usd">-622800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTAtMy0xLTEtMA_7055f28f-96a4-4ab9-9c16-7be2252ccf90"
      unitRef="usd">180200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTEtMS0xLTEtMA_4c5069d5-c5ac-4a07-a3da-fbc5db93735d"
      unitRef="usd">-283600000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTEtMy0xLTEtMA_8706fd7e-cd38-422f-99b4-be70749149ed"
      unitRef="usd">39700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTItMS0xLTEtMA_8b387b0d-f152-4c20-80b4-65ef2abf4ca4"
      unitRef="usd">16100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTItMy0xLTEtMA_362f7df0-4865-4095-84ac-1822c42bfadd"
      unitRef="usd">-1600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTMtMS0xLTEtMA_d171ef40-71df-4e05-bf11-fdc48cad5bde"
      unitRef="usd">-112400000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTMtMy0xLTEtMA_0dfc8d8e-e8b6-4823-b402-36ca48b1f8d8"
      unitRef="usd">-83700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTUtMS0xLTEtMA_3ed4986b-563a-4bc4-a48a-3f2d9d4df37e"
      unitRef="usd">-211500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTUtMy0xLTEtMA_657f3289-0f11-4842-b25e-7d5d0cf010c8"
      unitRef="usd">268800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTYtMS0xLTEtMA_2b458593-9b8f-4575-a339-6004ade32ad4"
      unitRef="usd">8700000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTYtMy0xLTEtMA_9ac2bfb8-03de-481d-b522-b13794995167"
      unitRef="usd">-149100000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTctMS0xLTEtMA_49d305e8-9e4e-4396-838d-dee59dd1e822"
      unitRef="usd">193800000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTctMy0xLTEtMA_564f01c1-f2f7-40b7-9efd-cfd16617fcce"
      unitRef="usd">188200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTgtMS0xLTEtMA_91cc8268-89ae-446a-8c09-b09b6647a813"
      unitRef="usd">-188400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTgtMy0xLTEtMA_72dab038-5aeb-4538-957f-21ec42479028"
      unitRef="usd">-441400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTktMS0xLTEtMA_b7b07b50-22d8-4cdc-966b-c94d272fc87a"
      unitRef="usd">171500000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMTktMy0xLTEtMA_836981ba-753d-4e1b-b3f3-8d6ca7d16bef"
      unitRef="usd">504600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjAtMS0xLTEtMA_365b445b-4f05-4e50-a6e2-56fa080efc1b"
      unitRef="usd">97300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjAtMy0xLTEtMA_cabb5bc8-4002-4e5b-a91f-ef35d05b966c"
      unitRef="usd">-9900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjEtMS0xLTEtMA_f6adad02-b594-4944-a842-1b283ceb821b"
      unitRef="usd">1996300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjEtMy0xLTEtMA_731eb423-545d-496a-b2ab-c6ea72a5ba87"
      unitRef="usd">3415800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjMtMS0xLTEtMA_64722401-130c-42a5-8cfe-53e571391e31"
      unitRef="usd">1452700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjMtMy0xLTEtMA_3db655e8-eeae-46a1-989e-08d89de395ad"
      unitRef="usd">3879900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjQtMS0xLTEtMA_0405b816-d901-433e-880e-245eb6e6aba6"
      unitRef="usd">1626900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjQtMy0xLTEtMA_44eacdb5-8048-4ef4-afe3-d24e6c4cd636"
      unitRef="usd">3753900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ibcac24a08e5e42818462bbc94b13c07f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjUtMS0xLTEtMA_d81083f9-0c6a-4dd9-8057-7f1103eac746"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ief6833d5d8e1488588e71a36bbe9c769_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjUtMy0xLTEtMA_332bce7a-c5d1-4d02-87d9-cff99c963b8b"
      unitRef="usd">141800000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjctMS0xLTEtMA_de9c51a9-6fc8-46a0-8aa7-e6579536f9e2"
      unitRef="usd">28100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjctMy0xLTEtMA_068b200c-3ddb-4f28-9ab7-932fec8b9718"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjgtMS0xLTEtMA_ed937573-69c5-4230-928f-cbaa03805b56"
      unitRef="usd">164500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjgtMy0xLTEtMA_57a02346-f19c-42c0-8489-48a86b5c9396"
      unitRef="usd">254700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjktMS0xLTEtMA_aa2a8e36-0eb9-42d2-bd14-44869ade4bf5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMjktMy0xLTEtMA_60d619b1-46e5-4fe5-a5f6-1d404e8a2ec4"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzAtMS0xLTEtMA_b86dd859-6e5b-47c6-a516-2e853d2a01bb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzAtMy0xLTEtMA_f6696b9c-21fb-4a58-91c3-cbb06f596f51"
      unitRef="usd">37000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzMtMS0xLTEtMA_d6cc8f15-9d22-4cfb-b4c1-1fd54f506f05"
      unitRef="usd">91200000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzMtMy0xLTEtMA_8ff2d11f-dca1-4588-b2d0-be0d1689d9de"
      unitRef="usd">500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzQtMS0xLTEtMA_ce5b3ed6-4764-47c4-a12e-4dbbfe5746a9"
      unitRef="usd">-2000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzQtMy0xLTEtMA_49f42dd5-a7a4-4672-b468-b0a498cb549b"
      unitRef="usd">7800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzUtMS0xLTEtMA_14534638-e04a-4e34-9ae2-864b6ec107fb"
      unitRef="usd">-217400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzUtMy0xLTEtMA_640cfeec-60e8-4df2-9394-43b01c4fd79c"
      unitRef="usd">-389800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzctMS0xLTEtMA_15403116-7061-4c62-93f1-4e02668f3c86"
      unitRef="usd">1050000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzctMy0xLTEtMA_ee3a7a83-19a4-45cb-bc83-892d45e6de9d"
      unitRef="usd">5029100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzgtMS0xLTEtMA_4965cebb-4495-47cd-9be0-17eae045f85e"
      unitRef="usd">14200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzgtMy0xLTEtMA_20096a9f-c3d0-466b-82bb-f2e14a39e240"
      unitRef="usd">19200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzktMS0xLTEtMA_46e9931d-c5ca-4a2d-afef-5e605665dac9"
      unitRef="usd">170000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfMzktMy0xLTEtMA_d3d5a86e-5997-4874-82db-37178c41fe95"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDAtMS0xLTEtMA_e5189de3-a86c-43cb-ab7f-9a753d664db9"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDAtMy0xLTEtMA_29e8897d-c2e6-45ff-a9f9-f6b646ab5092"
      unitRef="usd">2967300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDEtMS0xLTEtMA_fcecf31e-73bb-4664-ad1d-50abc8ddbefd"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDEtMy0xLTEtMA_61299b32-a8f7-4c50-9f5e-996c3f5ef155"
      unitRef="usd">1500000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDItMS0xLTEtMA_68b3534f-4017-4c0c-b0b1-416123b0edd5"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDItMy0xLTEtMA_87ec7c11-b107-4bde-a96e-5ce2e3650e03"
      unitRef="usd">-3300000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDMtMS0xLTEtMA_83741579-4f69-450a-bf5d-3ecae3c795d5"
      unitRef="usd">94800000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDMtMy0xLTEtMA_5b58835e-46cd-4cc6-a84e-bc0b5e26f01e"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDQtMS0xLTEtMA_6cf618c6-a3b2-400e-bb04-09c700087924"
      unitRef="usd">-20500000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDQtMy0xLTEtMA_b592d58f-5ab9-4b12-88e3-dbfc7e2687ee"
      unitRef="usd">19000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDUtMS0xLTEtMA_d1adb37f-1868-4184-a55e-99af29be425c"
      unitRef="usd">-1349500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDUtMy0xLTEtMA_c8a09484-fceb-4bda-bc72-cee67a8eb87f"
      unitRef="usd">-3558700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDYtMS0xLTEtMA_4a7bc2c3-ce5f-4f23-b6fa-7faa3ee3c033"
      unitRef="usd">429400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDYtMy0xLTEtMA_e8719a0c-bacb-48be-a9a6-0c011687140b"
      unitRef="usd">-532700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDctMS0xLTEtMA_f129e717-7cc0-4a75-afc4-0a7d22a609c8"
      unitRef="usd">-18600000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDctMy0xLTEtMA_044079c5-9816-48ff-bff2-eef9e767c992"
      unitRef="usd">3900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDgtMS0xLTEtMA_5c100f6a-83b7-4f9e-b667-a49101c1cf3b"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i025174d34d0e4fed9880bf522bf39caf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDgtMy0xLTEtMA_d575ed43-564f-4656-a65e-101ef1418ff0"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDktMS0xLTEtMA_df0f3266-d0bb-48fb-b89b-f37fa0111a0b"
      unitRef="usd">1742000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zMS9mcmFnOjE2NWEwYzg0ZmQ4MjQwZjg4ZmVlNDBhYTFmY2VmYWMzL3RhYmxlOjE4ZjJlZWJiN2I3YTQ0ZjBhYmJjNzBkYWNmZGZmOTJhL3RhYmxlcmFuZ2U6MThmMmVlYmI3YjdhNDRmMGFiYmM3MGRhY2ZkZmY5MmFfNDktMy0xLTEtMA_f0b063f1-c585-4cae-b818-cbd56dac47fb"
      unitRef="usd">2384900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc82ffb87eb341eb9922b2fe03938ef1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xLTEtMS0w_0427b195-521f-41ed-b8c2-96da95d605ae"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc82ffb87eb341eb9922b2fe03938ef1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0zLTEtMS0w_fb25fa1d-dd69-4d0f-9941-69a08612679c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i881e688a79754d32bd4eaef661200a43_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi01LTEtMS0w_c8e2ab17-960a-459c-a423-3e0cf9725be2"
      unitRef="shares">174400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i881e688a79754d32bd4eaef661200a43_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi03LTEtMS0w_f435b5cf-d0a3-49cc-8173-2d42262c756a"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c3490a5f63c46eca7c3d7b457bc76b1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi05LTEtMS0w_e9a39824-fb6a-4d90-bbd6-7c97479f27ce"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b15e57dd5eb4ecda365d4f991fa27a8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xMS0xLTEtMA_cae4a16b-59e4-4c2f-81e3-8db3f06eca89"
      unitRef="usd">-174300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee8812efb9d84361a4d49aff1088e74b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xMy0xLTEtMA_38a84680-9caf-441b-894f-71408c7a245a"
      unitRef="usd">13833500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a59ef186277439e93b9cb5d517c2f8e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xNS0xLTEtMA_852631fa-cd46-4777-b6f7-c4dded838823"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a59ef186277439e93b9cb5d517c2f8e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xNy0xLTEtMA_a255f77e-b3ec-4e78-9c77-6b161eaa1ecc"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i890d1bfbc3404c338c8adf2e20d53e18_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0xOS0xLTEtMA_9148f492-ecec-42c5-9ff3-10791508aa26"
      unitRef="usd">10682200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0c7280649ce4b709f5ceef9dca96ca8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0yMS0xLTEtMA_a29ac7f3-72be-4bea-931f-bb0bfbd68e5e"
      unitRef="usd">-19000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4231dfa8299436094f9cbd4382d29bb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMi0yMy0xLTEtMA_3db9cef2-5be3-489f-82df-013ceb656171"
      unitRef="usd">10663200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0xMy0xLTEtMA_d746eb2e-3fbe-463b-93c9-0185165648ab"
      unitRef="usd">448500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0xOS0xLTEtMA_c13ec420-2ff7-443c-aa79-36d091d29c8d"
      unitRef="usd">448500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0yMS0xLTEtMA_0fafad19-bc39-4c14-9428-1ed4e68153e1"
      unitRef="usd">577000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMy0yMy0xLTEtMA_0c61e225-f358-4ce4-8818-3ee89014cb92"
      unitRef="usd">1025500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b8169d797254002b81948999f73a837_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0xMS0xLTEtMA_34fe993a-cd04-48e6-9f4c-46184b69b9dc"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0xOS0xLTEtMA_257540d1-7caa-4c3d-9501-6bc4dfcd61fe"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0yMS0xLTEtMA_5b90a32d-0f22-4026-a523-51e9dd84e678"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNC0yMy0xLTEtMA_7be1ef21-9596-4284-ac12-39d631a27b0d"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNS0xOS0xLTEtMA_8e89ca84-6ea0-4afb-a07e-39a75ffd5354"
      unitRef="usd">0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNS0yMS0xLTEtMA_713a0ae3-6914-40ca-8ce5-6a0181da914c"
      unitRef="usd">5000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNS0yMy0xLTEtMA_a30c5c6d-91cb-4b34-bf96-58b1344372b1"
      unitRef="usd">5000000.0</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ie79eb4a65ad34b0caba5a5b6d72f3a6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0yMS0xLTEtMTEyNA_975ddf7c-13fe-462a-8d9b-e34e4d263092"
      unitRef="usd">-100000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0yMy0xLTEtMTEyNA_d288d293-5cbe-4b9b-8c53-91a037caa9b8"
      unitRef="usd">-100000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi01LTEtMS0w_141b080c-91d0-4f20-bdad-f18266ec38cf"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0xNS0xLTEtMA_8fdfe3bb-1764-4f72-994a-84c8e4191fc9"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0xNy0xLTEtMA_65af8bdb-f255-4132-8d9f-019ca72e9ed8"
      unitRef="usd">450000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5dfbafcd38f34defb5d883855aba00e1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0xOS0xLTEtMA_c863881f-ab91-44fb-ab11-4b2feea2915a"
      unitRef="usd">450000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNi0yMy0xLTEtMA_af41a241-d55d-4784-85eb-a51044c6a3be"
      unitRef="usd">450000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i1cd3814086244d508377429d979db225_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy01LTEtMS0w_186189b2-88ae-444f-a010-712a9e5eb9d0"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i1cd3814086244d508377429d979db225_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy03LTEtMS0w_e01c6e4b-f1db-474d-9e65-fae79101f96e"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i74292aa380dd4293a8ab78259fb0e8fd_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy05LTEtMS0w_a592ddd0-1bd3-4098-aa83-34dc71166746"
      unitRef="usd">69500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i62788c451f3146bbb9013bf26f1e565a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xMy0xLTEtMA_657a687a-92f7-4c2e-9023-ee2121ca6ae8"
      unitRef="usd">380500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xNS0xLTEtMA_c264c2f7-c04f-49ec-87e7-7671321f9af2"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i688dfb60261d4f2ab120d49f13d9301d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xNy0xLTEtMA_a580c54a-12c4-4027-b43f-2609f6e922ed"
      unitRef="usd">-450000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5dfbafcd38f34defb5d883855aba00e1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0xOS0xLTEtMA_fbd72695-fc0e-4033-bbdb-69f2f09b1b46"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfNy0yMy0xLTEtMA_09f69e04-016b-437f-8e7b-d98d3e5dd269"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC01LTEtMS0w_cdc7dcc3-873c-4742-b821-90b75c61c00d"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC03LTEtMS0w_39c50454-81f3-4b55-8a3e-fee8b98f8f97"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC05LTEtMS0w_62571719-ece4-4452-9750-5098063322fe"
      unitRef="usd">13700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC0xOS0xLTEtMA_3e3708e7-801e-4b86-ac04-264172e82edd"
      unitRef="usd">13700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOC0yMy0xLTEtMA_cb17d0ac-d189-4948-93f7-56f5c7cb8e53"
      unitRef="usd">13700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS01LTEtMS0w_3e5aa27e-ad94-4be2-8f22-4169d2faf8b6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1beef211fde647bfa9e67dfc2372c7f8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS03LTEtMS0w_71b8da7b-9a54-4572-b881-9759c5548b6c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS05LTEtMS0w_92eb3e76-f4b7-411b-b846-0940b4e5faea"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS0xMy0xLTEtMA_c424044e-a4cf-4dc6-abee-fbb28f043172"
      unitRef="usd">-800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS0xOS0xLTEtMA_199730bc-e006-4d4f-950f-ac7fb8e10276"
      unitRef="usd">-800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfOS0yMy0xLTEtMA_7ebda0b0-dafd-4041-90a4-700abecb0134"
      unitRef="usd">-800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTAtOS0xLTEtMA_bafb4a4e-1ff0-4a99-a4db-ef1564255cc9"
      unitRef="usd">-55800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTAtMTktMS0xLTA_f6461e21-c128-4df5-a5e6-c757d05867c3"
      unitRef="usd">-55800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTAtMjMtMS0xLTA_1524286f-f58a-4e97-a52d-84745c61de3c"
      unitRef="usd">-55800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="ib434b673b42b4084b62db622b022d71f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtOS0xLTEtMA_6337bb70-373a-42f8-8cc6-1bf8aac316f5"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icdf9f6a40d2c446abee885582eaf92db_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtMTMtMS0xLTA_e80aeb9e-63ae-4fc9-8030-51b7961aa514"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i55412012a7c844f28ee2b29a7a510a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtMTktMS0xLTA_05851c9f-a9db-4193-8f41-04f1c1209b91"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTEtMjMtMS0xLTA_da485bef-d0d5-4c41-a4d4-4119f339a65f"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMS0xLTEtMA_907b0041-4009-4ced-b339-38bc27ea0280"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMy0xLTEtMA_55fae5ae-73c4-4990-8b80-b9a19065e109"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItNS0xLTEtMA_d8035cb3-8af9-43c0-868a-2f136e989429"
      unitRef="shares">172900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItNy0xLTEtMA_ca076932-3a3f-4149-ab04-7ca2f52b530c"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94926bf743db49f1aa339479ffa0244e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItOS0xLTEtMA_76f50d41-773a-4acd-ad14-c0ba220d1cc6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ee3f5cdf6da46f3bbd994edd429f1d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTEtMS0xLTA_cbceed07-2998-4ee0-ac58-38c8d7b95992"
      unitRef="usd">-171800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3240d0cbbf2494d9586ee74965f1b85_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTMtMS0xLTA_18e84a42-891e-4e2b-8dc7-5d47ce9929c3"
      unitRef="usd">13900700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTUtMS0xLTA_d2fddc27-9a45-4b7f-8fba-9797f894913f"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTctMS0xLTA_6a51891a-08be-431b-9cb3-393f8e5314d6"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d6c47b7744b4c20842a09b8f4244db0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMTktMS0xLTA_65e9704f-5682-406e-928e-c9934d1202ad"
      unitRef="usd">10751900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i514061955b07437c95410fb7d8491901_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMjEtMS0xLTA_9040b3ad-6f2f-42a5-bee5-2a4cbfbb91c5"
      unitRef="usd">462900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjQ0YjQ0MmI3Yzc5NDRiN2I4ZTA2NTZjNmQ3MTliN2I3L3RhYmxlcmFuZ2U6NDRiNDQyYjdjNzk0NGI3YjhlMDY1NmM2ZDcxOWI3YjdfMTItMjMtMS0xLTA_8a4a8620-312f-4ae6-a2b3-412bb42e8168"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib8001088915642409667fe820a47d9b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xLTEtMS02MDg_828becd4-6430-4d63-b4e9-305cad536380"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8001088915642409667fe820a47d9b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0zLTEtMS02NTQ_9e51bfd7-76cc-4ba6-a1ce-3acde7c481e9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib94de1f81562452191bd4f557a5d4d18_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi01LTEtMS02MDQ_f6851356-6a20-4667-8d32-130f079fde14"
      unitRef="shares">176200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib94de1f81562452191bd4f557a5d4d18_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi03LTEtMS02NTQ_f2db5244-9f6e-435b-a44b-4b4644ae4f48"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5721ea124d3a4b198cd7d7caa427c5ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi05LTEtMS02NTQ_0c78e4a4-c871-46a9-8701-4dc94ae90f9c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b80cd19565047b394b037487d83b697_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xMS0xLTEtNjU0_84a3bd99-68ac-4d7d-a2ef-e424bdd1cd4a"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97e2df370b96408ba273c05e55e0cef7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xMy0xLTEtNjU0_9c3a2ed7-2cb8-4314-a939-bfc42d934793"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0829016ca6b341a59a77978d812303fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xNS0xLTEtNjU0_72e7107a-fb09-4591-bccf-4ff96b82ad84"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0829016ca6b341a59a77978d812303fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xNy0xLTEtNjU0_7ec7d171-2851-4784-b256-5b6e3244b24e"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ba68db7328d4088b2362283392e5a4a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0xOS0xLTEtNjU0_c5b061c0-4582-4870-a61f-451a5b7262d5"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i433038a0a2e04b4a9718b3a120978075_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0yMS0xLTEtNjU0_6eb6dc17-80d6-49f0-8529-36ccf10a20b9"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMi0yMy0xLTEtNjU0_ecec2867-bb38-4c08-b6c0-a03e21884328"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0xMy0xLTEtNjU0_abc60d36-3737-4826-a148-475df80e58d4"
      unitRef="usd">858700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0xOS0xLTEtNjU0_9c3f85ca-45d3-4728-9a7c-834efd7018a1"
      unitRef="usd">858700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0yMS0xLTEtNjU0_3326f9f0-4406-42ea-89fe-45e58b8441dd"
      unitRef="usd">571400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMy0yMy0xLTEtNjU0_a9bc9a9e-d5b7-4414-b03f-5b89cc201fd8"
      unitRef="usd">1430100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9d83325fe697454bacf1a67ada1d4e30_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0xMS0xLTEtNjU0_ffc874cf-ea3d-4640-ab24-4ab065ea9892"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0xOS0xLTEtNjU0_e0e00d29-ff1e-4450-a35e-8115a4a5f1cc"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0yMS0xLTEtNjU0_8abd2c07-a94b-4289-9c79-9548cc75eebc"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNC0yMy0xLTEtNjU0_1cafe643-5031-42e6-b935-5e2a0f58ad27"
      unitRef="usd">127800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNS0yMS0xLTEtNjU0_7ee7c371-f971-415f-87f4-0e401e61b87c"
      unitRef="usd">5100000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNS0yMy0xLTEtNjU0_26fa441b-a914-4c06-b66b-49801b1abf48"
      unitRef="usd">5100000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ibbf0a9acc87746508e09c6fd7fa35c29_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNi0yMS0xLTEtNjU0_b752bf1f-83e2-4333-b2ae-0c90c53e9b7a"
      unitRef="usd">-100000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNi0yMy0xLTEtNjU0_b821b936-d280-4beb-8bc7-41ca73df7418"
      unitRef="usd">-100000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0xNS0xLTEtNjU0_07e87a9a-3fdd-4269-8685-e7c5ef3374e1"
      unitRef="shares">3800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0xNy0xLTEtNjU0_fc18578c-dbfa-44bb-aa9c-dacc50c54d96"
      unitRef="usd">1050000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i829fb96209e04376a983019df1ad41d5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0xOS0xLTEtNjU0_2916bb94-1c93-4765-9f6d-6e6585b787aa"
      unitRef="usd">1050000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i34d3cbd78d4e4e8a828d2ff80ce13faa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfNy0yMy0xLTEtNjU0_7f118563-35d3-417e-9e13-d1078669ab4f"
      unitRef="usd">1050000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="icc688f4fb4ba4c3e9b5aba00112dcd1b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC01LTEtMS02NTQ_38a42788-f636-4ed2-ac8e-745388cb1acc"
      unitRef="shares">3800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i50339615ca3c47dc93e748d4d2d021e0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC05LTEtMS02NTQ_62f0e6ce-02b0-4bd5-93d3-1af7f0b0d2f4"
      unitRef="usd">163300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if55c7e84188d4fc58a512a4f573231f5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0xMy0xLTEtNjU0_7be51b14-e8a4-4925-b045-919e3752042f"
      unitRef="usd">886700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0xNS0xLTEtNjU0_08ce3f4e-de02-423d-a7c7-b0854d965336"
      unitRef="shares">3800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i94120d0f1cae44e6b623b8357e863abc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0xNy0xLTEtNjU0_53e790a1-5541-4758-bd3a-d6af45b92ac1"
      unitRef="usd">-1050000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i34d3cbd78d4e4e8a828d2ff80ce13faa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOC0yMy0xLTEtNjU0_83323a9b-8158-4dcd-aec4-38d453847b28"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS01LTEtMS02NTQ_bcb4d07a-f581-4b07-953d-b3e3d4d212e9"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS03LTEtMS02NTQ_86b8ed38-cb04-4836-8d81-31a590b914f1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS05LTEtMS02NTQ_5c25a626-7e2d-4fd7-8086-9799b4e3e75e"
      unitRef="usd">33400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS0xOS0xLTEtNjU0_5851fa15-110d-4d95-88de-43145f40051a"
      unitRef="usd">33400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfOS0yMy0xLTEtNjU0_f5b6a592-205e-4b0b-92e9-50d591341ab4"
      unitRef="usd">33400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtNS0xLTEtNjU0_64015daf-599e-4956-81c3-c99a57192dc6"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3f8a786c2c794b15a9856cd597d44178_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtNy0xLTEtNjU0_d0361e5f-2efa-4c78-bb80-4d12d1032c12"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtOS0xLTEtNjU0_c5f06f80-0f93-44a9-9d4f-523927c38b1d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtMTMtMS0xLTY1NA_4bb33bd2-20d4-4388-85a6-875337230ec1"
      unitRef="usd">-47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtMTktMS0xLTY1NA_013f1c64-3554-486f-a5af-ff5d5281a04c"
      unitRef="usd">-47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTAtMjMtMS0xLTY1NA_4a518741-ea9c-41fd-986a-3340a98ff9e1"
      unitRef="usd">-47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTEtOS0xLTEtNjU0_96131207-8d5e-4bed-82b2-0a23f9f78b41"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTEtMTktMS0xLTY1NA_e75dade7-dcfb-4f24-b41b-6b1761c75adf"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTEtMjMtMS0xLTY1NA_11a540ae-e530-4f37-a978-ebd6433c016b"
      unitRef="usd">-128400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i5e04141f61d84f8aa2222585ca55a5d4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItOS0xLTEtNjU0_ddc4816e-6eed-4df2-9ae2-ac1d4b994572"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0cc542ba6d0141f486b37a2a2025678b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMTMtMS0xLTY1NA_8031ef62-297e-46e9-8151-de1480c10948"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ibc4379e8579e4de1bb7918322b1af1a3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMTktMS0xLTY1NA_999951ef-6c68-4eba-bfa0-b45d96fdd6a9"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMjMtMS0xLTY1NA_a4ee935b-c1cc-4994-ab3a-7c4e92fe3aa4"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTItMS0xLTEtNjA4_439387f6-f1ee-4f9f-b1f4-b9558348aaf5"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecfb66c1a8e240e58b6db5aeb85b6c4f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMy0xLTEtNjU4_5644a621-c75a-4fcb-85ab-733040b8810b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtNS0xLTEtMTI5ODg_9d300bc9-0f1f-42c2-bcd6-734e7956b99c"
      unitRef="shares">172900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd1fb2ad6d46412c862aa18af17395f5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtNy0xLTEtMTI5ODg_20ca0039-8e15-4e18-88b9-db5786490e99"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94926bf743db49f1aa339479ffa0244e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtOS0xLTEtMTI5ODg_e62b3059-b49a-43a4-85f4-a4dddd8a2131"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ee3f5cdf6da46f3bbd994edd429f1d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTEtMS0xLTEyOTg4_08941624-03a5-4562-b450-94885c79afe1"
      unitRef="usd">-171800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3240d0cbbf2494d9586ee74965f1b85_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTMtMS0xLTEyOTg4_45115c0e-7b27-4657-bd33-f475362f936c"
      unitRef="usd">13900700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTUtMS0xLTEyOTg4_c69bd047-ab37-4087-ae97-0f730f5898d4"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide200ffdc85b47c8a5734609c9cd5e17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTctMS0xLTEyOTg4_85a2e827-2fc3-46ad-9298-90fec94f5b7c"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d6c47b7744b4c20842a09b8f4244db0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMTktMS0xLTEyOTg4_c0898852-1759-4792-bc3e-7582bb398406"
      unitRef="usd">10751900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i514061955b07437c95410fb7d8491901_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMjEtMS0xLTEyOTg4_30434753-74b3-434b-8018-14a8aa747859"
      unitRef="usd">462900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjZkOGJlNWVhMjg3ZjQ5Mjg5M2E1ZWZiNTViNmNhNDgwL3RhYmxlcmFuZ2U6NmQ4YmU1ZWEyODdmNDkyODkzYTVlZmI1NWI2Y2E0ODBfMTMtMjMtMS0xLTEyOTg4_4b581e7b-fe31-4262-8786-4bcedc1838be"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i78b2ecb22ef74586961d6a6a7339b061_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xLTEtMS0w_6a08589a-e06c-4103-99d5-bb780d3272bd"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78b2ecb22ef74586961d6a6a7339b061_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0zLTEtMS0w_e81d9657-bb27-4c0f-846f-1233d7ed0c74"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iee86344392cc4815b2010b4698cb5995_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi01LTEtMS0w_dbfc2920-c4fa-4ea8-bbd6-7298a05c8ac6"
      unitRef="shares">191100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee86344392cc4815b2010b4698cb5995_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi03LTEtMS0w_5d216f0b-e4c9-4d2b-a793-7edb4920aef7"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i732c024e790641aaabfd3fb6981c4767_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi05LTEtMS0w_940a93ba-53cd-4435-a533-b9517ea76a1d"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f73c932ef614e2b809c4c6773f7b46f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xMS0xLTEtMA_3bc65571-70bc-4823-a3e0-2cbf0ff0c7d2"
      unitRef="usd">-149300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a136827ea89494eb44b4f53d790b6f4_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xMy0xLTEtMA_00a4f1f8-4eca-4816-815f-6f88b92b345b"
      unitRef="usd">15673100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0888859ea81d4a4b9b7e7be25c61e121_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xNS0xLTEtMA_27cb767b-a20b-4be3-87d7-0e576bd71ca8"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0888859ea81d4a4b9b7e7be25c61e121_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xNy0xLTEtMA_970b7c39-c632-4fe0-99a1-e9a17dc18337"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3300c292f1f6481daedcd2a3fd9d0d4c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0xOS0xLTEtMA_1796d3d5-30ee-4a87-ab19-12fd2f73ba3a"
      unitRef="usd">12546900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i072ed2cc59e146fabce4bf0c8984c641_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0yMS0xLTEtMA_d06d8439-1cf5-43d2-8431-da1a3b912acd"
      unitRef="usd">-10000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02b1a00011ea462489b26d05daea35c5_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMi0yMy0xLTEtMA_4486422f-e660-4373-9af9-a9dc6bca76e7"
      unitRef="usd">12536900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0xMy0xLTEtMA_0aa132db-858c-4b87-a0fd-1fe77b01b64d"
      unitRef="usd">1542100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0xOS0xLTEtMA_d77c4ade-80a4-4712-853c-e3ec3f2b08b6"
      unitRef="usd">1542100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8633c1b979664edba4ec90abfc549bf1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0yMS0xLTEtMA_83f49a7d-ba36-4443-ae9c-1c085b72b661"
      unitRef="usd">64400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMy0yMy0xLTEtMA_8d50240a-1e4d-4372-a25b-439abb5fd8bf"
      unitRef="usd">1606500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1f72654aca994523940646887601ba08_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0xMS0xLTEtMA_53b99094-c1eb-4d3f-a0b3-523c9285c9dd"
      unitRef="usd">-31700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0xOS0xLTEtMA_3fc913ab-2573-4cab-8062-b54beebf7480"
      unitRef="usd">-31700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8633c1b979664edba4ec90abfc549bf1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0yMS0xLTEtMA_8df09587-e429-4309-866c-33d2d5299aa4"
      unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNC0yMy0xLTEtMA_916420e2-b796-45fd-9411-d536b764e60b"
      unitRef="usd">-30600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNi0yMS0xLTEtMTEzOQ_4b220544-2de7-40e6-8969-6431675e70e9"
      unitRef="usd">-75000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfNi0yMy0xLTEtMTEzOQ_d041e5a8-149e-4dad-9f21-de94c6f4d0ae"
      unitRef="usd">-75000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0xNS0xLTEtMA_2b062139-e06f-4d9d-812b-258de0fbb503"
      unitRef="shares">9000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0xNy0xLTEtMA_ad10aa8f-b00c-4ef0-beed-1c66f340a92d"
      unitRef="usd">2808900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i08d7b9a6dc614f7dbb3208265a4d8bb3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0xOS0xLTEtMA_9daa51f9-3cef-4d90-95da-2b8588d3f7e2"
      unitRef="usd">2808900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib552a12f17ae45c9bd51081076579744_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOC0yMy0xLTEtMA_8fa73612-d3a4-4ad4-b5ff-44ca37a663c8"
      unitRef="usd">2808900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="icb4529d1da0b4585a765bc987c30b140_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS01LTEtMS0w_1b002dd2-700a-402f-9824-81667620f9d6"
      unitRef="shares">9000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icb4529d1da0b4585a765bc987c30b140_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS03LTEtMS0w_07412792-783e-44e6-8162-1f5d7e2e8775"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6b4edbd823d74be5afee6c24f030f8c4_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS05LTEtMS0w_05ca400d-236b-4ae5-9594-a825a16f3cb3"
      unitRef="usd">60700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia746808beaea4283b2a877a9fbf80dae_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xMy0xLTEtMA_0d7bf7dd-0439-408a-89fb-f3daf17b97e3"
      unitRef="usd">2748200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xNS0xLTEtMA_96a12913-a8ee-4ec4-9f77-156f9d69b05d"
      unitRef="shares">9000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9b3c76bac0f742e6b7b6ed3028d484e3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xNy0xLTEtMA_87bf45ab-a9b9-4fab-af0e-ba777862a004"
      unitRef="usd">-2808900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i08d7b9a6dc614f7dbb3208265a4d8bb3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0xOS0xLTEtMA_1277226b-ec65-4db6-aa14-6b7c9deafe13"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib552a12f17ae45c9bd51081076579744_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfOS0yMy0xLTEtMA_6b7c6c38-42ec-4ba7-bb16-696edb986b5b"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtNS0xLTEtMA_62f1411c-4b85-43e7-acc0-2347e1c04d15"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtNy0xLTEtMA_73a9a088-0ba7-48c2-aca7-34748491d353"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtOS0xLTEtMA_1e0c3697-4e14-49cd-8791-bbb8b491c51a"
      unitRef="usd">11100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtMTktMS0xLTA_32dd4335-7898-4cb9-ba88-3d3411e6ad0f"
      unitRef="usd">11100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTAtMjMtMS0xLTA_73b48699-98ce-4c8a-961f-d146be4a15b2"
      unitRef="usd">11100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtNS0xLTEtMA_910e59f7-5b42-4cac-90d3-1d0770d09d32"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00c9d503a82844e59901b99fd94cf547_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtNy0xLTEtMA_c8d083a1-4927-4927-9514-66cf35db209e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtOS0xLTEtMA_28dd93ca-3bd0-4f48-8128-9174a6a24b16"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtMTMtMS0xLTA_2d5edfd3-92f8-4d3c-84b6-6b22405232a0"
      unitRef="usd">-300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtMTktMS0xLTA_74341c84-5f9f-4cec-9113-19f85f5ffba2"
      unitRef="usd">-300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTEtMjMtMS0xLTA_35cca2b0-54a6-4984-be58-40c0f3c7aa5c"
      unitRef="usd">-300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifaba28afc82c4d8c9fb0261efbfe5519_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItOS0xLTEtMA_acade68e-a79f-49e2-a01c-55032850ad18"
      unitRef="usd">-49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7cd0539f52aa4337a7f0b696070e11ce_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItMTMtMS0xLTA_02c59bfb-b663-4df8-80e6-31e17e40f689"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03656555509242af8f7cb05bcb3a9171_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItMTktMS0xLTA_f1e91b4f-d695-41a4-bf65-647d1f45176a"
      unitRef="usd">-49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTItMjMtMS0xLTA_b6085845-2cf1-4d4e-ac78-53a42be46bc7"
      unitRef="usd">-49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMS0xLTEtMA_53428a09-5d78-4ef0-89dc-e519a7915fc1"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMy0xLTEtMA_976a56af-a015-4c5f-af68-32c0e26d9076"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtNS0xLTEtMA_d6e8df4b-e4e2-4841-ae97-faa23297418f"
      unitRef="shares">182100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtNy0xLTEtMA_8855f89e-c439-4ba0-a8b8-5f98c1f6a09b"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19d526c2292440b7a5a31fc1b5888e03_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtOS0xLTEtMA_4d8a9c60-d749-4bf9-8a3a-95f4251b2f39"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i570dc5bd6835411ea0f2c6404bf2707d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTEtMS0xLTA_9461628f-529d-4f7c-8fe5-754475d6e39c"
      unitRef="usd">-181000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c053e7c564a44a0bafea18992724f4f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTMtMS0xLTA_0791c539-ddeb-4e0b-9c48-8952d3da8bf2"
      unitRef="usd">14466700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTUtMS0xLTA_0241c67a-45a0-493a-969a-daba487bed3f"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTctMS0xLTA_887dc502-ac37-48c4-b032-6f75d6de70dd"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f0a20b044aa4874a09f45a93c3dec1f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMTktMS0xLTA_a0b60fe9-b8ee-4fc8-8b76-8569bec05d5b"
      unitRef="usd">11308700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fba909ac97644db8c749b15a7d893ad_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMjEtMS0xLTA_51c489de-c3a1-4f8e-ace8-e7b49993a21c"
      unitRef="usd">-19500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOjI4Y2E5ODM0Njg0NDRjMDQ5MWZmNzA4OGU4ODU4MWM5L3RhYmxlcmFuZ2U6MjhjYTk4MzQ2ODQ0NGMwNDkxZmY3MDg4ZTg4NTgxYzlfMTQtMjMtMS0xLTA_01cd8407-1e50-41a0-8efa-bb79fb3c7dd4"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibeccde350a794ad3a057220538aae69a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xLTEtMS0xMTUz_f51548dd-cce9-4784-98d2-c6fcda986f3e"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibeccde350a794ad3a057220538aae69a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0zLTEtMS0xMTUz_05c2e115-f54f-4aa3-bb16-13d716f4966f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia6c2c7cddf4e4e6fa048863f067c096f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi01LTEtMS0xMTUz_d98a2360-919f-4837-a21a-2aeb1b685f77"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6c2c7cddf4e4e6fa048863f067c096f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi03LTEtMS0xMTUz_73f48a42-9233-4e0d-a7f8-b9f213c2e834"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8dc71f78bf134170821013d4e0e24571_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi05LTEtMS0xMTUz_dbb9aa1f-5734-4985-afa7-c4dc25dde851"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdc925cb31f04e6eb50fc1c74378baa1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xMS0xLTEtMTE1Mw_158cacd1-3b00-445f-82cf-c9802c0a5835"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66ee4e438b174ae69ecb16ee0621c73b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xMy0xLTEtMTE1Mw_2f9448b5-38a5-4b66-8d92-8a211d14ec42"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i75cc8f1ab2514617bcec62bafc7b0a4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xNS0xLTEtMTE1Mw_f23408a8-4236-474a-8c15-716b09c399d0"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75cc8f1ab2514617bcec62bafc7b0a4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xNy0xLTEtMTE1Mw_904d84c1-e1ac-4bea-b026-b8c139b520c9"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibedb54914b4a4be1bb1f89fa85924372_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0xOS0xLTEtMTE1Mw_0e9c1707-dfc4-47f9-a4f8-0d6e9ba5ac30"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideb7cbe5c0ee40cf910d38587c7169eb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0yMS0xLTEtMTE1Mw_7952b06a-a1f6-4e44-aac0-87ccc0c2e868"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i025174d34d0e4fed9880bf522bf39caf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMi0yMy0xLTEtMTE1Mw_bdf759d0-5be9-4d3c-a1a4-705d59995845"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0xMy0xLTEtMTE1Mw_8869c191-c9e5-4114-99de-b877f71f38d3"
      unitRef="usd">2941200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0xOS0xLTEtMTE1Mw_221de883-e671-4b78-ad9c-7c93a6396a33"
      unitRef="usd">2941200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0yMS0xLTEtMTE1Mw_d0874572-8e1e-4480-a06c-7f911cdc75c9"
      unitRef="usd">57800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMy0yMy0xLTEtMTE1Mw_f2f93a28-9cea-4ff4-99be-e69281b78388"
      unitRef="usd">2999000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i03fe4f4d72bc4079969e2e9ed876d281_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0xMS0xLTEtMTE1Mw_7f09bf34-2cef-491a-94ab-43ebf30cb000"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0xOS0xLTEtMTE1Mw_47f49b02-e84e-4301-bbb3-1a62fdc2ba29"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0yMS0xLTEtMTE1Mw_ad5db68e-938d-4dc7-bf22-2ea1e1d1f7f1"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNC0yMy0xLTEtMTE1Mw_b892af7e-50da-4e8f-b444-3c71972885c5"
      unitRef="usd">-44000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ia66fd684614f472ab9ae858337e37137_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNi0yMS0xLTEtMTE1Mw_9469a4f6-7ad7-4765-ab63-6a1a981fa778"
      unitRef="usd">-75000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <biib:NoncontrollingInterestIncreaseDecreaseOther
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNi0yMy0xLTEtMTE1Mw_6fefa83e-b754-4016-9b47-92276b91124f"
      unitRef="usd">-75000000.0</biib:NoncontrollingInterestIncreaseDecreaseOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0xNS0xLTEtMTE1Mw_bb055e56-ffbc-4446-9dc1-8c4abf71262f"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0xNy0xLTEtMTE1Mw_4caaccae-9170-4c78-8ee6-9c954cc2dec5"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i948a3706ba984935b4f52d3af4515a54_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0xOS0xLTEtMTE1Mw_fea9da9d-42fe-4e3a-9a0e-9e7c0325851c"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1aa7cd1f56a4406b8baf99c16459364c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfNy0yMy0xLTEtMTE1Mw_427a18b4-ce62-4af0-bfcf-5c02c1dd043c"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i912a36fc12da4b8493cc611846c2ffb2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC01LTEtMS0xMTUz_91bc407c-942f-49ec-be3b-1474424629ed"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5bce9f6487694050a70f9480c769461e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC05LTEtMS0xMTUz_69293f4a-f2bf-41b3-b601-cfebe25e516f"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id653e67025f441eca2b7a99e95e1a140_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC0xMy0xLTEtMTE1Mw_9daecfc0-31e4-4295-afe7-30ce0924aa1c"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC0xNS0xLTEtMTE1Mw_f7aa7b74-5f9b-4126-a117-01bef742edda"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i53a6be740b88408b97794cbc0105f101_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOC0xNy0xLTEtMTE1Mw_21990b8c-08c2-4c29-9f6a-398ec40d7a6b"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0xNS0xLTEtMTE1Mw_b8bb8cde-0679-4995-a18e-14911eac755d"
      unitRef="shares">12200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0xNy0xLTEtMTE1Mw_a5e6437e-1917-46f8-b40e-831269fe562b"
      unitRef="usd">3750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ide90025ae7d14057a14eaf2dffb72595_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0xOS0xLTEtMTE1Mw_d62adb20-1b3f-4882-9b61-54204676bffd"
      unitRef="usd">3750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic8d4db9869c24b76826c44a5bad5b4d9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfOS0yMy0xLTEtMTE1Mw_154be291-4e1e-4f0f-aefd-aba6ac0d4fea"
      unitRef="usd">3750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iff71a4c7590448a39c9de6e0fc71bedb_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtNS0xLTEtMTE1Mw_29c92412-193c-4844-85d9-44fc672f6f36"
      unitRef="shares">12200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iff71a4c7590448a39c9de6e0fc71bedb_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtNy0xLTEtMTE1Mw_0b3a6b2d-426f-4919-a017-64723d030b33"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i44c71f71a23d4cc3a2b3597fe3bfca81_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtOS0xLTEtMTE1Mw_8887d08a-64a4-4605-8ec5-4a52fa39a5d2"
      unitRef="usd">76200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5972e118118f4152ad8f8978769af8e0_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTMtMS0xLTExNTM_b7aa7627-e4ee-4488-944f-ee9a926f1933"
      unitRef="usd">3673800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTUtMS0xLTExNTM_ba094629-2bfe-471e-8768-f9320ab4c7dd"
      unitRef="shares">12200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i2930d90ffabc478aaa43f84f50f784ee_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTctMS0xLTExNTM_e60c2f69-2407-42a8-9947-ba5c2dd76f7b"
      unitRef="usd">-3750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ide90025ae7d14057a14eaf2dffb72595_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMTktMS0xLTExNTM_438c5f9a-778c-4d20-ae7c-7b1d61ab0372"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic8d4db9869c24b76826c44a5bad5b4d9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTAtMjMtMS0xLTExNTM_c9d5d7da-d153-46a8-a4e7-51e0aa81f4ed"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtNS0xLTEtMTE1Mw_dfe0b17e-9764-49c8-8f3b-e0095030dc58"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtNy0xLTEtMTE1Mw_8e36ea44-10ff-4d9a-9c0c-9832b622eb29"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtOS0xLTEtMTE1Mw_c7ef9655-2f14-4a74-bad0-11c7a2489d56"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtMTktMS0xLTExNTM_b084d240-d576-4832-a379-8d40cf36cdc8"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTEtMjMtMS0xLTExNTM_2939ed26-6d98-406b-be4e-527d57c43084"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItNS0xLTEtMTE1Mw_a1b1364d-4732-4926-b4c9-b93f5fee8414"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iff91d15ae57b46cb80abe64bbfb8cc74_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItNy0xLTEtMTE1Mw_a7623301-ace6-47c2-be44-6074be6209ad"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItOS0xLTEtMTE1Mw_3d5f853d-630d-4633-a0b8-8bfccb9b4dbb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItMTMtMS0xLTExNTM_07b512db-8d2b-46d1-b4c4-1141fc8dff6a"
      unitRef="usd">-48000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItMTktMS0xLTExNTM_baf80d43-6683-48d8-b22c-bba31625ad08"
      unitRef="usd">-48000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTItMjMtMS0xLTExNTM_9daf68aa-9e46-4f76-ba88-474a706fbb26"
      unitRef="usd">-48000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtOS0xLTEtMTE1Mw_70772dcb-880c-438c-8e95-030510e976e6"
      unitRef="usd">-118800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ead0f13c7c342f0a9554e9ec06c9854_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtMTMtMS0xLTExNTM_61e0b8d9-bf96-4095-b968-05a83529f31f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtMTktMS0xLTExNTM_18a64295-1eb4-4375-8166-dcc7bb2a0704"
      unitRef="usd">-118800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTMtMjMtMS0xLTExNTM_f81ef52a-b964-41c0-8a40-d53f702f3fb0"
      unitRef="usd">-118800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i9a3777be73b140e484eef3f99dbf03ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTQtOS0xLTEtMTE1Mw_a29e3f8f-e799-41f4-8244-d940edbd4db2"
      unitRef="usd">-700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i703486666e174b76b44043f8976ce92e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTQtMTktMS0xLTExNTM_877486cc-f85e-4ef1-b94c-277b10816105"
      unitRef="usd">-700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTQtMjMtMS0xLTExNTM_b2633add-16bf-4e83-8a1d-c6a9e896dfea"
      unitRef="usd">-700000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMS0xLTEtMTI5OTY_ae4e2f60-f6f8-4970-944c-6d93ea8c8ab2"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia379321841ec4c9b893de5b4c3c0049a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMy0xLTEtMTI5OTY_8469ef2d-e5c8-4745-b635-3b25b07be6cc"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtNS0xLTEtMTI5OTY_eb70a97c-164f-4895-be6e-5efa3de5679f"
      unitRef="shares">182100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ecf6373de814aeaa2667c45b15358df_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtNy0xLTEtMTI5OTY_6b101eae-4292-4417-bf80-eecfd9e74a94"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19d526c2292440b7a5a31fc1b5888e03_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtOS0xLTEtMTI5OTY_759113af-2f26-456d-9ed1-c4757a159a9f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i570dc5bd6835411ea0f2c6404bf2707d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTEtMS0xLTEyOTk2_00990e37-7ffe-4c4d-a3cd-6f4b9def84cc"
      unitRef="usd">-181000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c053e7c564a44a0bafea18992724f4f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTMtMS0xLTEyOTk2_8fdd8c40-c71e-48f1-b199-6b0c56babce3"
      unitRef="usd">14466700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTUtMS0xLTEyOTk2_65f37f63-e4e4-4432-b749-c895d542683a"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5a510bf622c4fa8919b08f823833b36_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTctMS0xLTEyOTk2_6e19718c-1d4b-4fb7-9b65-b54471712e9a"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f0a20b044aa4874a09f45a93c3dec1f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMTktMS0xLTEyOTk2_ce011ed5-87e3-4a71-8d47-11e0fdfd65ab"
      unitRef="usd">11308700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fba909ac97644db8c749b15a7d893ad_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMjEtMS0xLTEyOTk2_1bed5132-8622-48a8-be6e-ec92db3374e1"
      unitRef="usd">-19500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8zNC9mcmFnOjhlNTU5ZGNkODVhZTQwZGE5YzE5MmM2MjcwYmYzN2M5L3RhYmxlOmVkYmRlNzFhZTdmNDQwN2ViMmZhZmUzMWJhMTg3MGNlL3RhYmxlcmFuZ2U6ZWRiZGU3MWFlN2Y0NDA3ZWIyZmFmZTMxYmExODcwY2VfMTUtMjMtMS0xLTEyOTk2_ba7a7484-59fe-451a-bde0-67ae01f48685"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQxNA_e77d2a6d-e520-4929-9210-7ad6edf61c20">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:9pt"&gt;&lt;span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQyMQ_ef0d294e-384e-46cc-a899-085c86a87ce4">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQ1Mg_a1823ab1-2cdd-4405-af88-38cf91882b1c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfNDM5OQ_af45dc6f-f821-4252-a21e-2c41dcd088aa"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQwNA_8ee70f9a-3e11-4792-b0c6-0647cd738647">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfNDkwOQ_0a9d0cb2-c32d-4dbf-aa6c-25c015eaf49a"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQ0MQ_5a07394e-b4df-45d3-a76d-a13e94145259">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80MC9mcmFnOjhmZGI2N2VhY2FjNDQyMTk4MmI4MjEzOTdkZTU4OGZjL3RleHRyZWdpb246OGZkYjY3ZWFjYWM0NDIxOTgyYjgyMTM5N2RlNTg4ZmNfODQyNA_59e01dab-80bd-4dff-9cc3-ff5c8523284e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:9pt"&gt;&lt;span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 the FASB issued Accounting Standards Update No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80My9mcmFnOjUyNmJlYmIyMDg5ZTRjZmU5YWYxODY0ZjQwNTVlZTkzL3RleHRyZWdpb246NTI2YmViYjIwODllNGNmZTlhZjE4NjRmNDA1NWVlOTNfOTQw_d77671a5-fd9d-4ac1-afa1-449ba9b8cd66">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;amp;D) in our &lt;/span&gt;&lt;/div&gt;condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80My9mcmFnOjUyNmJlYmIyMDg5ZTRjZmU5YWYxODY0ZjQwNTVlZTkzL3RleHRyZWdpb246NTI2YmViYjIwODllNGNmZTlhZjE4NjRmNDA1NWVlOTNfNTIz_3388234f-f302-401b-ac2e-d48c3396ee1f"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl80My9mcmFnOjUyNmJlYmIyMDg5ZTRjZmU5YWYxODY0ZjQwNTVlZTkzL3RleHRyZWdpb246NTI2YmViYjIwODllNGNmZTlhZjE4NjRmNDA1NWVlOTNfNzky_fd722fc4-f77e-4043-8d65-a4cb254c61e8"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMzMQ_f55b1f0c-f9c9-4d9d-94b1-c3a5ba7d6525">&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;578.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,511.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;615.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,721.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,074.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,795.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;*** &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the United States (U.S.) during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,699.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,291.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;954.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,577.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,012.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,859.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,244.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,059.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,570.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,304.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,395.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;*** &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 30.2% and 9.9% of gross product revenue for the three months ended June 30, 2021, and 30.1% and 9.6% of gross product revenue for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 31.7% and 17.9% of gross product revenue for the three months ended June 30, 2020, and 30.8% and 16.2% of gross product revenue for the six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,577.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,960.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(275.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(906.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,182.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(676.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(802.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,042.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;352.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMxOA_cf8835b8-9090-49af-90c0-f83c4ef7f6dd">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;578.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,511.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;615.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,721.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,074.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,795.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;*** &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the United States (U.S.) during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,699.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,291.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;454.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;521.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;954.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,577.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,012.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,859.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,244.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,059.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Alzheimer's disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM***&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilar product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,570.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,304.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,395.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;*** &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i843c3b0a19d643c98f098c2cbdda56c8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC0yLTEtMS0w_fa459e66-41dc-4293-a528-e82296d2e1f4"
      unitRef="usd">269100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i454fe0c0d5134bb092b7b31a87c40846_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC00LTEtMS0w_0ddadb26-dd57-4a82-a6d0-de34a2470f2d"
      unitRef="usd">309400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3c40ac7856a4709b06d820f5782887c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC02LTEtMS0w_43950abe-bf05-4db0-a37a-076540d7eee1"
      unitRef="usd">578500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia41f1626c54d4651b01a960a763e25d1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC04LTEtMS0w_28cea7be-a359-49ef-ba3e-3720762a3531"
      unitRef="usd">921700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib44acf878e9a40e293c35b91d422db18_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC0xMC0xLTEtMA_e68b45a9-4ac0-4228-bf33-f40b246dda57"
      unitRef="usd">268600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1ec14a0b4c5428e96dc682fe53e2adb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNC0xMi0xLTEtMA_cf6c9f88-fa1a-4d30-9281-0e82e8e165fd"
      unitRef="usd">1190300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaaded065ec24455a1510514fd2e792d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS0yLTEtMS0w_06e07ae8-1226-41d3-aa3c-d1438a508b78"
      unitRef="usd">257400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icde9c2714ad74d01aea890f100a512e3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS00LTEtMS0w_a21e73ac-8362-4f04-8cb8-1c1edda883ac"
      unitRef="usd">143000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42ad626e97a14a56ab100e2a98cd07db_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS02LTEtMS0w_e09f35ec-492a-4770-9e8d-27b005f0c55b"
      unitRef="usd">400400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5de49699ab2b4ef2950e4d9cf8d55bd7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS04LTEtMS0w_4ad96ef6-82fd-4813-af1b-b1b8cbd8996d"
      unitRef="usd">345600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3f953a78b614e29b9d12ce31c18106a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS0xMC0xLTEtMA_3c8a9c61-9ffe-4a0d-920c-cf5cde954589"
      unitRef="usd">135800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib847f37c0de04daf96e1223d256cd610_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNS0xMi0xLTEtMA_85d1f5fb-4704-446c-bc28-3082aaca1f2b"
      unitRef="usd">481400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f3bd6129bb04c41922bebfc2cfdb7dd_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi0yLTEtMS0w_59352008-0cab-4347-9226-19c789d6f6f0"
      unitRef="usd">299800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice992f8d6bde4f81ba988f03ad04702d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi00LTEtMS0w_78ca4148-7ed0-4cb5-875a-393f651fcad9"
      unitRef="usd">224400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i913530b0c7a04680a81480a377dc75e9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi02LTEtMS0w_a889adf5-9926-4ae8-ba15-dda8e553333e"
      unitRef="usd">524200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f26c5f8f7b644c1a6ae043ec51ab4c2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi04LTEtMS0w_bf7ebf79-bf69-4438-9a94-c159bc3103ff"
      unitRef="usd">244100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cf57f3df80b47afbcf37febeca4a0ea_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi0xMC0xLTEtMA_ac83b998-2208-472f-8e95-0fa1c61aff1a"
      unitRef="usd">187900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i353e33f7e0a94012bc4281ed787c9554_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNi0xMi0xLTEtMA_f860a078-6c90-49f1-9bab-218ffaa271de"
      unitRef="usd">432000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7ac4b25470f4639aaafda04d93ef98e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy0yLTEtMS0w_c4ffb340-8916-4f0c-a406-61e6870546cf"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8841bf5e9b84dc9ae7268750ef2bb0f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy00LTEtMS0w_33e181b7-d9cc-45f7-a1a6-e41b87737df7"
      unitRef="usd">26100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73c0c612c5734c7fb188c1543fa11185_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy02LTEtMS0w_e1808e30-809b-44df-8293-48e4c14330ee"
      unitRef="usd">26100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbb5970ca1764f70aa1f12bc6e44c3e2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy04LTEtMS0w_20cee530-7e14-4e4b-b49e-1e40db2df012"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i644dc9ce5a6049f0bb8a6913c237d0e8_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy0xMC0xLTEtMA_4b9c4026-11c0-4e75-af6e-7157155e751b"
      unitRef="usd">23000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74762eae8227417c92bc8b0acd73d688_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfNy0xMi0xLTEtMA_51e0de48-62ec-4d59-84cf-3b6dde5fe18d"
      unitRef="usd">23000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23feca6c7c1644d1801a7f85831cd895_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC0yLTEtMS0w_f32a5279-d6ee-4a60-ac2d-c786dc604a83"
      unitRef="usd">826300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdc3f2e402ed45da9a6e36c3ef2bfb5e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC00LTEtMS0w_88b8def6-48a3-4ded-80f4-d7c148fe1067"
      unitRef="usd">702900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id99acb96aa164c78bdba482e516c404d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC02LTEtMS0w_15ac7205-75ba-4ab1-9429-5323e9314339"
      unitRef="usd">1529200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia755e6ceac1747b180c2cc6df3ef4066_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC04LTEtMS0w_afee9e70-80f9-44e4-adeb-9aaf2211d986"
      unitRef="usd">1511400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85e782c4b0e049938858ca5e31f73ec7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC0xMC0xLTEtMA_39d3fdd7-de4b-4f85-aed4-fc3ade2a4063"
      unitRef="usd">615300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76b65b40d820457fb4b9fa1f07a65f61_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfOC0xMi0xLTEtMA_f03a1320-a4e8-4f4f-95a8-59acc15447e1"
      unitRef="usd">2126700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83dafc6720834c76a63a5163e4f532eb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtMi0xLTEtMA_0292d581-d332-4661-bf66-e67432b6505d"
      unitRef="usd">149300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e4a9f31dff843009dabe3a4e826ee4f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtNC0xLTEtMA_10303c01-5733-4275-b18b-a51c1f96a35e"
      unitRef="usd">350400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4af0c1582a2a408baa70b8e99def7c62_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtNi0xLTEtMA_83fb9205-9625-4383-bc2e-40bd08df0079"
      unitRef="usd">499700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b7281dae8894892967238587445989c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtOC0xLTEtMA_58fd33a5-e043-42ef-a91c-333dde242946"
      unitRef="usd">210300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i231ad3d6d41645d3945da088fec9f599_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtMTAtMS0xLTA_76dde262-3668-44d1-87bc-b4ab83019a56"
      unitRef="usd">284300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3cf8bb8c3fe841d0ba7abd41f7fb1ee4_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTEtMTItMS0xLTA_03155d5f-59cb-4a33-9f7d-ae43cb8e7320"
      unitRef="usd">494600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17628a71886641909400cb4619218426_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMi0xLTEtNDUyOQ_f46ebc1d-cd9e-4e73-9d39-57c61203f750"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea9a9b26fba3467cba137763a14e9be3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNC0xLTEtNDUyOQ_8015a109-527c-4957-8885-f1a3d152add0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide17051dcca44f5ea4cc198403e62293_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNi0xLTEtMTMwMDE_b8ee15ab-27ae-435d-983b-03324a80f302"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f0293658e6748dfa458ae395ab995a5_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtOC0xLTEtNDUzNA_bac1be2b-644d-486a-b29d-6901cce22ae4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36d15291982e4ca994818b360dcda3ad_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTAtMS0xLTQ1MzQ_749bb2c8-7997-4798-919e-267e2d84735c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id24d10cad1d34675a3fc968bdbb574a2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTItMS0xLTEzMDAx_bb43634e-02cd-44e9-a4a2-9e06dab04bf4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ab460f1c1bc4867a271a58701f0e028_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMi0xLTEtMA_9ff2f81d-5c17-43b1-92aa-1aabeec8db4c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7301eef41d9640ed921b3e6efe6127c0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNC0xLTEtMA_68721ee6-4d9f-4ce1-acd7-1b2f590e5ada"
      unitRef="usd">121500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93e99a1a7e774a0e815fa6a725ad326b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtNi0xLTEtMA_ec62fe08-f553-4ddc-b396-410a6948986e"
      unitRef="usd">121500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70a34315115c4b8589338e15d7ea6439_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtOC0xLTEtMA_58d1589d-2036-4aac-931e-915b751d9afe"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i664fb5d936da45f59b4e592bfb74ac94_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTAtMS0xLTA_d26fdcd1-5c06-47cc-96b6-c45ec0cc7f6c"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e6e9d15df534c6caeb9f68534bdb18f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTQtMTItMS0xLTA_936e54b7-d10b-4f12-b43a-486728c09db2"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i347194d919304c0c812e6741db0e657f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtMi0xLTEtMA_72a6c860-f401-483c-818e-dcf714c284c4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb2598e479464106bcdb82c4a4df0181_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtNC0xLTEtMA_12804f53-abdb-45b3-ad6d-41bc931067d9"
      unitRef="usd">55600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a8798ca731041d684373855710bb939_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtNi0xLTEtMA_f3ba960c-77ee-4b02-b7cf-fac2ecbd2e65"
      unitRef="usd">55600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ed6f9bb6cf4494cbb6951ffc4427cff_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtOC0xLTEtMA_480d81e3-18d7-48cd-bd22-6a7b3045733b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19a873d0cc0244a8b91d944434d46b46_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtMTAtMS0xLTA_bf7605ef-31c5-4b69-ba68-29a86fc10145"
      unitRef="usd">44800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee1d133f9df644b8b0d7cd4410031d4c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTUtMTItMS0xLTA_951d17a7-0b24-4591-b11c-90181fa2a17c"
      unitRef="usd">44800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3369c80db6c4ee5a519938ac9f89bcb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtMi0xLTEtMA_9cd69082-0af0-4609-bad3-069c281bee20"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4585d796bb774ac1bea9b1ff5af52ba1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtNC0xLTEtMA_7e96ebed-61be-4421-92c3-e90397446e4b"
      unitRef="usd">25300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11d5ada70f524874932a465b9b730154_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtNi0xLTEtMA_3051b7e1-c411-41db-92fa-165c5f89c2a4"
      unitRef="usd">25300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie31f861e6a524cd19f95e0d648eb24ca_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtOC0xLTEtMA_0a84b9a6-5458-4034-b2c3-a38ca0d98874"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb689c657f6b45ccb27299e839af1320_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtMTAtMS0xLTA_af58121b-5f4c-4a67-8a2b-6958ef11a916"
      unitRef="usd">20600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18dbf21007504156bc2266d82193def3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTYtMTItMS0xLTA_76d2a2be-5039-493a-b526-5db880160b9c"
      unitRef="usd">20600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia538789f89324807b17b67af0a111518_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctMi0xLTEtMA_fd588f95-257d-447a-8ec1-61c86a8737d1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i765e12ebae8140ec80846e0ec971b64a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctNC0xLTEtMA_c49b6a6b-f8ee-43cf-a67c-a09f1a8c526a"
      unitRef="usd">202400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87fedca069ca4c35895923673877e4ac_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctNi0xLTEtMA_6bc4c247-57c5-4c24-8116-0372b5398733"
      unitRef="usd">202400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbc0ef98c72c43c0a4299bf74ba8c183_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctOC0xLTEtMA_d8450593-091a-4c6d-8c3e-5bce7f0959cd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if442ac7b0d344adc8562bfde02e57543_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctMTAtMS0xLTA_18e6a4c7-7e2c-41b0-85f6-47f13534b6eb"
      unitRef="usd">171600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if619b64750344bd396a36966f4e1d8db_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMTctMTItMS0xLTA_e99575e5-0233-43a5-b951-a34665ee7ec2"
      unitRef="usd">171600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id888d7b35a7049cc9a61406634e23db2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtMi0xLTEtMA_54d79f3b-3d1f-45a8-8717-f9880ae7d0dd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23586c6cb02341758cd17f3eda3f41ea_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtNC0xLTEtMA_1492a3a5-e069-4371-82be-119afd6a14dd"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05cd0486507d4bb9b3535aa6a9703959_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtNi0xLTEtMA_3b66b0da-43e9-4fa4-b274-ef4572902091"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id76ba5beae9b4ebcb9b0d537208ce555_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtOC0xLTEtMA_54f6def3-87c5-4fd6-a10e-7f49f14b0c55"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49ffa6986e434982a6f8ec10fd4f5706_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtMTAtMS0xLTA_38d37970-2581-4b3a-8b3d-3fc2027702d7"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i549472d5a38946e59e5b1caa96706fe7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjAtMTItMS0xLTA_e0d9712b-0e91-4cfb-b781-8b482e52d944"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4dd3b810e859443a898e81c46682f449_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtMi0xLTEtMA_0a8eaea8-c0df-4cdd-997b-aed9cb5502e1"
      unitRef="usd">977200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6084fcf81a7a4f17a2138fa073f7d226_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtNC0xLTEtMA_070ce11d-1eb1-46a3-aff4-7c6baa5c79ad"
      unitRef="usd">1258800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7cf54c2c77a4e6c9dbf0332cbd0f00c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtNi0xLTEtMA_2630ac93-c1d3-4124-9dfa-59c9b93a50f3"
      unitRef="usd">2236000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9f337b2eb414f3fa41dc8811176125d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtOC0xLTEtMA_ee66638b-310f-4859-a7db-c6542ab02df3"
      unitRef="usd">1721700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i271aab5d507d493c86b6444f888c9ad3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtMTAtMS0xLTA_1bd8e1fa-5a41-4557-bc9b-8e4f3c89144a"
      unitRef="usd">1074000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49b5d4606fd747a98fc6804633f0b093_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjg0MGZlNGFhYTNiMTRiNDA5Mzc3YzQ0MWRkN2ExMDVjL3RhYmxlcmFuZ2U6ODQwZmU0YWFhM2IxNGI0MDkzNzdjNDQxZGQ3YTEwNWNfMjEtMTItMS0xLTA_045d0326-87a2-4c4c-938b-64386709b536"
      unitRef="usd">2795700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9512deae649d4c98b378b690ec4b9532_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC0yLTEtMS0yOTA3_068d2be6-780e-4614-9489-71497ee32ecd"
      unitRef="usd">505100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f99b0163013464e974cb8cb0fc170e9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC00LTEtMS0yOTA3_3f3a1794-4f77-458a-920d-311beca8fd88"
      unitRef="usd">626300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8a00992695e4dd1be1075fc2e7e7f10_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC02LTEtMS0xMzAwOA_d59947c9-3b58-4d48-afa9-b85cc05b52c5"
      unitRef="usd">1131400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb24c52b894b4b7b83524d55b0ce82ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC04LTEtMS0yODk4_f6baed7b-af97-4403-84ee-4dbaf73b0a44"
      unitRef="usd">1699200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3255c22b11a4fda8d05a99d09fef6ac_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC0xMC0xLTEtMjg5OA_708b3c0d-786c-4e2d-8612-b43511fb017e"
      unitRef="usd">591900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8f3957759bb4881946620abdea1906e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNC0xMi0xLTEtMTMwMTA_31a0d6f9-73ef-4ffd-9903-515ee493e221"
      unitRef="usd">2291100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida0e61991f2f4369b1013159e84567ea_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS0yLTEtMS0yOTA3_b2237410-3afc-4fba-8d11-91727b7d7a66"
      unitRef="usd">499200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie21d03e014ce4af4a87f80e4d2f06f89_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS00LTEtMS0yOTA3_56f80f17-d36a-4eef-94e2-65ab10ab1a6c"
      unitRef="usd">301700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d3038a0c2bf415589f4da253eeb15a5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS02LTEtMS0xMzAwOA_ef8a9c97-c488-4a0c-9950-d4202461759a"
      unitRef="usd">800900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47e951773a30439e95ed2c070c0d26f7_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS04LTEtMS0yODk4_1dd4a17a-c25c-4bb4-aae3-242570c6f5b1"
      unitRef="usd">638200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id69bc97b92384fe9b8b1109cb7b609ea_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS0xMC0xLTEtMjg5OA_7eabe062-e20e-4359-a749-4dc52a8b37bb"
      unitRef="usd">309200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d698ae847c34141bd30186c02516ab9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNS0xMi0xLTEtMTMwMTA_9da47317-464c-43bf-a477-d793b0647441"
      unitRef="usd">947400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if352a0720bb54a1f95411b27afbe2fdd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi0yLTEtMS0yOTA3_0dbbceed-af18-419e-affa-1e10449be66a"
      unitRef="usd">573100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dc18c39667846fbb99cfe5795bb832b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi00LTEtMS0yOTA3_ccf6de82-3b48-40c8-8c06-c9295502c92a"
      unitRef="usd">454400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6fdc86037324795b46c202ca0d00be3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi02LTEtMS0xMzAwOA_8450b277-e5af-4503-943e-ce95f414be3c"
      unitRef="usd">1027500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4e95d1f892c4f938eea104fc6553abf_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi04LTEtMS0yODk4_185c08a1-d429-472f-bb98-18249634a846"
      unitRef="usd">521800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fe219fd14a84e3980655fdb9727e9c2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi0xMC0xLTEtMjg5OA_6e7ff099-65e8-459a-9523-afb473b874ff"
      unitRef="usd">432600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8273fa766cef4c98862e9f44eb96455b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNi0xMi0xLTEtMTMwMTA_3c5c2b63-6ab8-4425-98d5-4e7aceab6427"
      unitRef="usd">954400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22959fc6b46c4630bfb1d8629dd63f34_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy0yLTEtMS0yOTA3_ba2524ff-2f3f-4689-96c1-a3b616ca3c65"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i25f8875d0f60402ba93a3ddeb81920eb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy00LTEtMS0yOTA3_22d76915-7e42-4715-8211-c96fa1093e95"
      unitRef="usd">52700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76548eed129741f499223726cdcc1f1f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy02LTEtMS0xMzAwOA_34d9a302-2f23-4ce8-97ad-79711dddd1be"
      unitRef="usd">52700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f82ef87090045aab2b1cb5b17aeea9b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy04LTEtMS0yODk4_7f47cdaf-6f3a-4705-ae04-f2e443bbb6ec"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ba409194c834bf3a16a2de8f61db0ed_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy0xMC0xLTEtMjg5OA_01ce224e-aa1c-47ca-abde-89f1bcaff6a8"
      unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida1adad387b4453c8301620505216a13_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfNy0xMi0xLTEtMTMwMTA_35307ae1-4559-4c41-86ce-55e1848444d5"
      unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38367c3fd9fe456cafc14d56b87cb674_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC0yLTEtMS0xMzAxNA_0b927bed-924d-4e1f-a03a-67572efb1868"
      unitRef="usd">1577400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i132d903ffcdf44229d51ea6ed57f6217_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC00LTEtMS0xMzAxNA_68a2613b-ca7e-4de5-b565-a096729ca448"
      unitRef="usd">1435100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i653b99dd16f24c3e8a3cb8ab81b27bda_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC02LTEtMS0xMzAxNA_17805dee-dd81-4273-8376-0d525d3a13dd"
      unitRef="usd">3012500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fc05073dde7472d85556d435dfeaf18_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC04LTEtMS0xMzAxMg_4a0afd72-059f-42de-9424-2a51895131f9"
      unitRef="usd">2859200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e757557007b47cda6f71a9ebaa17530_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC0xMC0xLTEtMTMwMTI_b172c349-1d66-46b3-a9e7-c354ec4c7e43"
      unitRef="usd">1385000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icac584f59af64735be732faa98be7b4c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfOC0xMi0xLTEtMTMwMTA_ceaa418c-175e-401a-804d-f00dbf1d757b"
      unitRef="usd">4244200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0370bfbe4664865b37fa1b911566c9f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtMi0xLTEtMjkwOQ_836fdb58-a8e4-48c0-ba73-a88065b7998e"
      unitRef="usd">298000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i952aaf5b1c50480eba24ec10039104f0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtNC0xLTEtMjkwOQ_24c71c8a-4b64-4d0f-8e67-6eee1dff9eca"
      unitRef="usd">722200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ec420238dde4d4b9a44da7620294099_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtNi0xLTEtNDU0NQ_57bee566-f117-452b-a803-35ec3e0666fb"
      unitRef="usd">1020200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8a50f8d869747819b54ebbf6d2af672_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtOC0xLTEtMjkwMA_ae1af200-c79a-43b9-a7f3-cdba99da88e0"
      unitRef="usd">445700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i722f82ed215948ea88263cf586031bef_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtMTAtMS0xLTI5MDA_a4bc1ff4-6a07-4d00-847b-3b5435e4e787"
      unitRef="usd">613900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdaa47b325f24a16bea0eec2bea1a4a2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTEtMTItMS0xLTQ1NTI_c3cd80ae-59e6-4afb-a91f-d796c5d420d4"
      unitRef="usd">1059600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a76f1d5912f4b52aeb510ca5da3346c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMi0xLTEtNDU2MA_7502c5aa-0426-4471-9e9b-c91ac1eb67f5"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i907f1e7563f14378b1ecd1b5ef055a57_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtNC0xLTEtNDU2MA_e3ee6c10-e378-4fd3-aa7e-858423ee086c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3345cb93fc40480f8456095f9d4fc38f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtNi0xLTEtNDU0Ng_631df5d3-6f90-4fef-948c-74f67fea9bc8"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2bc0914169f4c2cb3ffcf46eff93a7e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtOC0xLTEtNDU2NA_19baf4d9-4d35-4559-ae33-77ce7a5ec4aa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f8adae560f142bb811699bb9d9628d7_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMTAtMS0xLTQ1NjQ_5adc3803-06ac-433c-a54d-0c43413b27ec"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc3232a5cc744549b80ca58b6a95c533_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMTItMS0xLTQ1NTM_e1c8263e-a150-49f0-89d2-aaef52399236"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0a40b518b8b4d188979f3929210955d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMi0xLTEtMjkxMQ_419edfc3-2c5d-4f55-b783-bc9ff0a47cee"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74bb1c58883a4dc99af1b4e416cf52b4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtNC0xLTEtMjkxMQ_f6b2cbc9-8f11-4202-b7da-5a3582ec9114"
      unitRef="usd">243200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85f1e6f6cea24d9e98d7885cab1433a5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTctNi0xLTEtMTMwMjQ_584c3fae-d367-480f-b9d5-d009f058cd8b"
      unitRef="usd">243200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e96adf1d0b34fd48f31726b6ff44a4c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtOC0xLTEtMjkwMg_76dba587-fe3b-409d-b059-2fcee8f564c9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2cc9787466b46abbef67317ed6f0fa0_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTQtMTAtMS0xLTI5MDI_78849921-d848-4205-ab25-74ea80154bbc"
      unitRef="usd">239700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28fad1ddd69340d38bd387385c2d5c25_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTctMTItMS0xLTEzMDI2_9e89dc9c-e699-4698-8987-6de458ccff80"
      unitRef="usd">239700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2db8c7cca1d041038bed1f6b7d4ab6b2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtMi0xLTEtMjkxMQ_dd3c26da-a209-4803-a3c9-88b493367f6b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08947c7925794460a22599c198525943_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtNC0xLTEtMjkxMQ_11a6665d-da2e-4801-8a3b-81174e8b45eb"
      unitRef="usd">113500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i387134594a0c4e6cad32daab163ac56a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTgtNi0xLTEtMTMwMjQ_86bd8611-5d89-481c-b095-6cb3635839eb"
      unitRef="usd">113500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibfa741e73d69423689689570e4a4b68e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtOC0xLTEtMjkwMg_1ebaf71b-5e3b-4e62-848d-28a71349484b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68ce3cc5ca544c28aad1d97c409db5fc_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTUtMTAtMS0xLTI5MDI_e142abf3-6bf2-4e8d-b408-33e96bbaec07"
      unitRef="usd">106400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i592a4b594aed46f581483bbad038153f_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTgtMTItMS0xLTEzMDI2_10038b9c-3aed-42bb-ab44-aa465c047402"
      unitRef="usd">106400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a3892d49afb415e99c3cba37acf71fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtMi0xLTEtMjkxMQ_7a29c69f-9a8d-4e8c-abe8-b52bfbfdcefa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05d64b2e8b964e8d8aa87f143c540622_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtNC0xLTEtMjkxMQ_0f28741a-112f-42d2-91ba-604dfa7d141e"
      unitRef="usd">50800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id21894b409b844989e613f38670ae21a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTktNi0xLTEtMTMwMjQ_eceaded1-959e-432e-aad5-cc0fe7699aa2"
      unitRef="usd">50800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cb9c645dd194a048e1a08eff82cb7f3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtOC0xLTEtMjkwMg_d9e628bc-db94-4e75-9086-7d6d82e1e45b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fdda44309f8410d9f5d04e02ea87a60_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTYtMTAtMS0xLTI5MDI_8aa770b2-bac5-434d-877a-b274619fd59b"
      unitRef="usd">44300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1be3e03b30c944c68f2524da9d3dd097_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMTktMTItMS0xLTEzMDI2_903378ab-8903-45c0-a558-e03458906f88"
      unitRef="usd">44300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i098fb6e6a3044546a3431b4d1b2a365e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMi0xLTEtMTMwMjA_479a8cbe-ff4a-4adc-b261-20d625d96750"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b0e971c4d3c436ba2b2b28e78c71d81_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtNC0xLTEtMTMwMjI_a454ce91-5a70-416d-9d2d-44f164a031c2"
      unitRef="usd">407500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe0d22abebca4da6a32bd29921ecf3dd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtNi0xLTEtMTMwMjQ_c1788150-4320-4e62-b6b5-481264982d2b"
      unitRef="usd">407500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83e0421e29db4f0ca253c4ef2ea6cad5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtOC0xLTEtMTMwMjg_0cdeb258-969b-4ce5-a5ba-e9371c613a9c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81d2503001f7463ba388d1b6a4c3cf5e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMTAtMS0xLTEzMDI4_99193ffa-54c5-4371-8138-96bfd379003c"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id01d8f96012745ff89b701ea923ba757_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMTItMS0xLTEzMDI2_6a9e286f-c89c-4d40-84d3-25b355b6f3a4"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf07a847be8e4948957569950fc2b185_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMi0xLTEtMjkxMw_d82842cd-99c5-4adf-b2ac-a1ca7a50ee56"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab5abd3f3f9f445291db02d0de25095f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtNC0xLTEtMjkxMw_4f3b33b9-6bc8-44a3-84bc-0b1cfd952ccb"
      unitRef="usd">5900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i409b88462b9b4206b6f0ad945e5c7a09_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjMtNi0xLTEtMTMwNDA_3164af13-440a-4c84-a53d-97bbedae1d64"
      unitRef="usd">5900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i243da6c48d9248179768b97ac1550b9b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtOC0xLTEtMjkwNA_cdc98183-1ea1-40ff-8743-592c84071c8e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d74bd6f2b1d4e72a7d2229724e592c2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjAtMTAtMS0xLTI5MDQ_f712222e-f2d2-4603-9b91-83cea6ecabac"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i720052044b584f03b3810ec2f322ddf2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjMtMTItMS0xLTEzMDM2_fcff3779-f08c-449e-881f-8141b70f124d"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55ed419e0f084f27aea90bd9a24d8bd1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtMi0xLTEtMTMwMzg_84627a99-97c0-417d-b865-3d3072ac894d"
      unitRef="usd">1877000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i635500abf5b347d6a57cfe76e6ceb55d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtNC0xLTEtMTMwMzQ_2b6817e8-d4c2-4aa8-b54d-d34479c86e16"
      unitRef="usd">2570700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i948d754496294f759ddb105ceeca7aa1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtNi0xLTEtMTMwMzQ_bed6c78d-2a11-49c7-bca0-413159ce48a8"
      unitRef="usd">4447700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d301e27c3914f82885e217461346e41_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtOC0xLTEtMTMwMzY_8f7e8767-7ace-4f56-9428-56b5ac77304c"
      unitRef="usd">3304900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if458daa2b72f4bda93915b366f415c9a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtMTAtMS0xLTEzMDM2_55f62f59-b323-49c9-98eb-96b0ce437ec2"
      unitRef="usd">2395400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf3aacf570724f99badb8ea0d3a29373_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQyNTEwZmY5ODU3MTRmNDk5ZjNiNzE4MjA2MmZjOTZkL3RhYmxlcmFuZ2U6ZDI1MTBmZjk4NTcxNGY0OTlmM2I3MTgyMDYyZmM5NmRfMjQtMTItMS0xLTEzMDM2_457e44d6-e65e-4347-856a-60eab504938a"
      unitRef="usd">5700300000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjYx_04a194bd-fe4a-4141-9757-a33c9e46cb35"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjYx_0beded98-04e7-4358-a350-c3de37a17627"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ib22f26cdb1e1424a8f3ca3d681e15ffc_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjkx_c0b6aaaa-bbd1-46ee-bad2-32583aeeaf0b"
      unitRef="number">0.302</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i3a60f7b09c98409e9ddc3f0e238fdfc8_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMjk4_cacd4d7d-c993-4419-9a01-7fc4c6997f75"
      unitRef="number">0.099</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i8ec1e52281e643248c39bb68e766f607_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NDkxOQ_943fe824-616e-4ee7-80b0-282566e2e723"
      unitRef="number">0.301</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i2ee71674694843249ecd53f5a7dbe42b_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NDkyOQ_9e043b75-80cf-4cad-8fd8-1cf9228e21d1"
      unitRef="number">0.096</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTA1NA_04a194bd-fe4a-4141-9757-a33c9e46cb35"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTA1NA_0beded98-04e7-4358-a350-c3de37a17627"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ia2a55a2a9bc94211851b88701a3d8e7d_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzU4_689dcabb-3e42-4c78-9264-0807aa47f8a9"
      unitRef="number">0.317</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ia613a30223bf4bf883786f9f016d0237_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzY1_47f0698a-f9e3-49eb-9fbd-7d81fed7a5f2"
      unitRef="number">0.179</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ia8965948dfbe425a85da6fca9e06c6da_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTIxMw_f7680288-cb35-47bc-9ce1-f83294ae6bc6"
      unitRef="number">0.308</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i7c1d6b7809484ea6979801fe0bebf01f_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMzI5ODUzNDg4NTIyMQ_aa9c5488-267b-447e-a94d-1942ebd72dd0"
      unitRef="number">0.162</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMyOQ_36541e5c-b663-489c-8545-9cd8a87f97a5">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,577.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,960.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(275.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(906.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,182.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(676.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(802.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib7e542e2b2e7467bb76adfbda503ec69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS0yLTEtMS0w_1c59ae7a-4724-4c5f-bc03-fccd25889d34"
      unitRef="usd">141400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i48dc4d3a85fb44099d30fed3e469b5f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS00LTEtMS0w_1cd0c382-d866-4d96-b256-b27acb6b7c0c"
      unitRef="usd">1093000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie9e902f930d64955b720bc0e0fd5de58_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS02LTEtMS0w_fe3350ae-43b1-4198-9e79-22b623363eeb"
      unitRef="usd">41600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMS04LTEtMS0w_b13aa9d3-5298-4966-8471-6477ecec13c8"
      unitRef="usd">1276000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi0yLTEtMS0w_68e57eb8-dc50-43cf-8621-9bfded0ee8cc"
      unitRef="usd">375600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi00LTEtMS0w_39a148d5-bc96-41d7-8d05-7712b71a1426"
      unitRef="usd">1577000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi02LTEtMS0w_afe839fa-6d06-4180-b68b-74fb271847eb"
      unitRef="usd">7400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMi04LTEtMS0w_646e5610-bb5c-4a04-ac2f-1adfe816c29a"
      unitRef="usd">1960000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy0yLTEtMS0w_5e02f365-e865-4c59-ac31-e2a00a11c54f"
      unitRef="usd">-1100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy00LTEtMS0w_c4f3ff33-921c-49bd-9633-303f39a5cfc2"
      unitRef="usd">51500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy02LTEtMS0w_dc052e47-ea5d-4b60-a75f-0356add874c0"
      unitRef="usd">-1600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfMy04LTEtMS0w_b742e0a1-1ff2-4e6e-ba0e-f60b9888369c"
      unitRef="usd">48800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC0yLTEtMS0w_ece2fe62-d726-46a3-8512-e3aa4a129b9c"
      unitRef="usd">275500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC00LTEtMS0w_1c8323fd-9c85-41c4-8e80-f8c25674ac06"
      unitRef="usd">906900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC02LTEtMS0w_e3e282a8-eca0-4a99-9623-4339a1ed0a0c"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNC04LTEtMS0w_e5787705-6b87-4342-80a3-d1837a73b28e"
      unitRef="usd">1182400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i8194052cb07a46ccaf5fe611a73cad50_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS0yLTEtMS0w_35670fca-f256-49cd-93f8-364e3c9c7274"
      unitRef="usd">119200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="if2d9c2da101f423eb41f8bcdcc402335_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS00LTEtMS0w_42451646-9d2f-4ac5-9e50-9eb89d046069"
      unitRef="usd">676400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i0214f5546f034d149788dc3f904a7419_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS02LTEtMS0w_6b3190ef-2ce4-48b1-9fde-47c3db263d33"
      unitRef="usd">6900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNS04LTEtMS0w_d157377a-cfc5-4695-90d9-2ece0120a02c"
      unitRef="usd">802500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8dda4e5979a3455ba24bfb6dccd4adcd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi0yLTEtMS0w_4cd2b23b-1ce2-412c-9502-f8808a815e41"
      unitRef="usd">123400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib98775b1b10a41a392536907027ba668_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi00LTEtMS0w_96d55c63-6abb-45c6-99b9-ca93ed9ef2ae"
      unitRef="usd">1035200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iad52dd82f08d441e93f786ded8f4be36_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi02LTEtMS0w_ee7a8d33-2846-4ac4-af1c-d356232d63b6"
      unitRef="usd">43700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmUyMjVhOGFiMjY4NjQxOTQ4OTk5ZDcwZDExNGE4OTk1L3RhYmxlcmFuZ2U6ZTIyNWE4YWIyNjg2NDE5NDg5OTlkNzBkMTE0YTg5OTVfNi04LTEtMS0w_8b2eea61-2ba4-4de3-bac3-d2d6b623cfad"
      unitRef="usd">1202300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMzMw_bdf007c0-56ee-46a7-94f6-1b356637cc61">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,042.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i702781d7d4d143c985f549228c64fa29_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMS0yLTEtMS0w_92abc7f5-fbfd-4625-b807-b8158e7219db"
      unitRef="usd">160200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1bba8977699149f58c07fbe9bcb19689_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMS00LTEtMS0w_e9fee869-ed83-477d-9a09-3fca864a6f09"
      unitRef="usd">195400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idf361b51f5534b34939b0f745631d54d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMi0yLTEtMS0w_d2676922-ce75-4852-8e31-6305cc93cea2"
      unitRef="usd">1042100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3ad6c76d74374942bcbb4934411ede69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMi00LTEtMS0w_b2369f00-2a75-4096-8aeb-19083b786cdb"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMy0yLTEtMS0w_acb5c7c9-09b8-47fa-acf8-536ead6f7958"
      unitRef="usd">1202300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjE5Y2EwNmNmZGQ2OTQ2MDBiMzRhNGNiNjVmMzc2NWE1L3RhYmxlcmFuZ2U6MTljYTA2Y2ZkZDY5NDYwMGIzNGE0Y2I2NWYzNzY1YTVfMy00LTEtMS0w_efce314d-0d3c-4bf9-a0fc-6539345829c7"
      unitRef="usd">1276000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMwOQ_f3e076e5-3335-4543-9d04-f64a158105dc">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;352.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi0yLTEtMS0w_fb23f6fc-48c0-412c-a76c-f5688584b651"
      unitRef="usd">178800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="iee771fa2648044888a8356de8f0d5e38_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi00LTEtMS0w_8e907471-f667-4501-a9d4-c387aff86882"
      unitRef="usd">257500000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="ib47ae3a613a94bfbaea1fea5774148fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi02LTEtMS0w_0dc1600a-8a39-41c7-94a8-ad90776f15bc"
      unitRef="usd">352900000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i78c38ac27d6b4276ba03f7c2e9d29e86_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMi04LTEtMS0w_1eb3872b-36c2-462e-a480-3c2eee1d0c46"
      unitRef="usd">598800000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy0yLTEtMS0w_568fbb05-f932-4a60-81b2-e119fd35676b"
      unitRef="usd">261200000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="iee771fa2648044888a8356de8f0d5e38_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy00LTEtMS0w_e4949e3b-c526-4c34-a9bd-1b223551df95"
      unitRef="usd">220800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="ib47ae3a613a94bfbaea1fea5774148fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy02LTEtMS0w_dcd05803-8183-4a24-b5bb-7864cef1e6e3"
      unitRef="usd">476100000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i78c38ac27d6b4276ba03f7c2e9d29e86_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfMy04LTEtMS0w_7a007d5c-2077-4b25-ab7a-a513bcfa7d09"
      unitRef="usd">399900000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="i9e165fd1993b481c8583fa0659f62931_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC0yLTEtMS0w_49f74083-60d1-44e2-aab7-f354e5b688a6"
      unitRef="usd">440000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02a7b47c3caa498fbd7d5570bba5dfb5_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC00LTEtMS0w_90ed6d74-ebb6-4d87-99eb-ee8fe7b585e6"
      unitRef="usd">478300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i597ac0475acb4b008433332ad02431ea_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC02LTEtMS0w_63ace6aa-0ae1-4f89-8f23-10f4dfd1ff03"
      unitRef="usd">829000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaebd3ec3de74756a298f2a7c57d8b32_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOjliNDdkOWMzNTlhNjQ4YzQ4NDQ1OTg2NGI3NGY0YzQ4L3RhYmxlcmFuZ2U6OWI0N2Q5YzM1OWE2NDhjNDg0NDU5ODY0Yjc0ZjRjNDhfNC04LTEtMS0w_276f0cf0-8c11-4588-9ab2-c3cece9232dc"
      unitRef="usd">998700000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RleHRyZWdpb246ZmI2MjVhOWE3MTdhNGMxNmJlYzE4OWE4NzUwMTA4NDZfMTMwMw_c98c96f3-db56-490f-adba-c3c3d5dfceb0">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;516.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="ia5645d9467cc4e1c9a27bfe42553e646_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy0yLTEtMS0w_167ea8cd-f965-4cbf-8620-c6d0c7e99224"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i907bc0d2ec594c419d577f002f5b337b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy00LTEtMS0w_56f78a9d-93bb-4621-baa1-e438420ec295"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i340b682e29fc4f8595ff4caf9fd4f83e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy02LTEtMS0w_703d322b-fe04-406f-bbc6-af79da2c4b62"
      unitRef="usd">9400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5698b182a7d4143989d02e2a19043a0_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfMy04LTEtMS0w_859b75c7-359a-4297-adc5-dc063495cf6f"
      unitRef="usd">8200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbcba6dffaf3400cb18c2f40d6b7d5fd_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC0yLTEtMS0w_11afad26-bd39-4e3a-b3f8-58ea32556293"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5df461441ec4e59bcc1bb4b499e5d18_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC00LTEtMS0w_620273b8-56e0-4d9d-ae88-c64008e9ded3"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c6292523b5a4b84be8b5aa038a4e8c9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC02LTEtMS0w_72a53df5-18b6-46d5-bea9-c32eda56733f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4937d91a9de34cd3a68c76b9f4988ba5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNC04LTEtMS0w_4c330210-a563-43fd-a7e2-bd7266780c32"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49dbdd6ccc5c4f4e8c800f8f4c3db2ed_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi0yLTEtMS0w_3b68932e-9f9e-4537-aa85-14d69fd43139"
      unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c0174dd54e1428da6b9c96728976e62_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi00LTEtMS0w_3add91c4-5b08-44c2-ad25-0a3b1fb7e7ed"
      unitRef="usd">7100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ffe2c761d3548bbae62483d2028c1e7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi02LTEtMS0w_28851d80-adeb-4d73-b96a-7798e3d899df"
      unitRef="usd">12600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ab0fad6e18f47efaf41fe8fc095a1f6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNi04LTEtMS0w_0e72aaf3-16ef-4b14-b091-9992a23de0e6"
      unitRef="usd">18500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78be0a546c174fa2a2cdab944955d487_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy0yLTEtMS0w_37f449ac-0e94-4db7-a104-268a9aa74170"
      unitRef="usd">87100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i720dbccd07034f98942db90af7a7d38a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy00LTEtMS0w_cf776424-93e4-4691-9a1e-b307f0c12ea7"
      unitRef="usd">395500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7236fcab1a8f44a8b21addbfbcd77b5e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy02LTEtMS0w_8b274511-ba1b-4c27-88b6-1db502620198"
      unitRef="usd">170300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d874a874e60463fb1b3910e76852f6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfNy04LTEtMS0w_684a8bb7-e972-443d-b770-fe70a077d970"
      unitRef="usd">489500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id563dc7eefa34305b99b4e811541cfce_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC0yLTEtMS0w_1a938aad-7507-4075-9b3f-de088a3ea520"
      unitRef="usd">99000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22951db8734f44ec9b10b05a829c8cb7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC00LTEtMS0w_20829678-0b91-426a-b929-bd2c8bf59ce5"
      unitRef="usd">407600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i892ed7dcf1654ee7a0c75a99e9a162b8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC02LTEtMS0w_0d2a37ae-e5b2-4d46-b7af-40cec56a76bd"
      unitRef="usd">192300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92244e16cec54d629634c4fa97c7505d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81Mi9mcmFnOmZiNjI1YTlhNzE3YTRjMTZiZWMxODlhODc1MDEwODQ2L3RhYmxlOmQ0MjA4OTA1MTEyYjQyMjhiNzk3MzFkZWU0ZmQ5MzkyL3RhYmxlcmFuZ2U6ZDQyMDg5MDUxMTJiNDIyOGI3OTczMWRlZTRmZDkzOTJfOC04LTEtMS0w_c221beba-b140-4586-8b0b-b0141527d455"
      unitRef="usd">516900000</us-gaap:Revenues>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RleHRyZWdpb246NDAxZDAyMzA3MzlkNGM4MjhmYTJjYjRmNjc3N2VhNmZfODE_c4f8ae0f-cb29-4e18-8046-8450e54ada82">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,254.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RleHRyZWdpb246NDAxZDAyMzA3MzlkNGM4MjhmYTJjYjRmNjc3N2VhNmZfODQ_527af207-29da-48f8-8c90-121c57650241">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,254.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMS0yLTEtMS0w_55a6c992-6ced-48c0-a596-c8ab25e96d5a"
      unitRef="usd">328000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMS00LTEtMS0w_929ae83f-26c6-4fae-a596-e7b337238e9c"
      unitRef="usd">314900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMi0yLTEtMS0w_37ea9b9f-b0b0-4b31-a65c-d4cc6beca1ad"
      unitRef="usd">723000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMi00LTEtMS0w_2b601b75-1a47-4972-9670-a8966573f72b"
      unitRef="usd">544500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMy0yLTEtMS0w_1298a831-e8c6-4153-a9fd-d26ba2da8153"
      unitRef="usd">203800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfMy00LTEtMS0w_20ad11fd-686d-4806-a065-b5799936626d"
      unitRef="usd">209200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfNC0yLTEtMS0w_7387933c-23ae-4415-b292-11140f354464"
      unitRef="usd">1254800000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl81OC9mcmFnOjQwMWQwMjMwNzM5ZDRjODI4ZmEyY2I0ZjY3NzdlYTZmL3RhYmxlOjk5OWM1NzdhOWY3MzQ2MWQ4NTBjNDQ4YTkzZjMwODYyL3RhYmxlcmFuZ2U6OTk5YzU3N2E5ZjczNDYxZDg1MGM0NDhhOTNmMzA4NjJfNC00LTEtMS0w_87860d02-b501-45c8-a522-ea559a63007c"
      unitRef="usd">1068600000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM3Mg_2ba79867-113a-478d-b1f1-9afafdeab412">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,141.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,637.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets totaled $604.1 million and $702.2 million, respectively, compared to $61.5 million and $133.0 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets reflects a $350.0&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2021, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2020, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of June 30, 2021, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of Nightstar Therapeutics plc (NST) and Convergence Pharmaceuticals Holdings Ltd. (Convergence). For additional information on our acquisition of NST, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of June 30, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;amp;D assets was $136.0&#160;million, all of which is related to DPN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB111 and BIIB112&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $350.0&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;amp;D asset from $365.0&#160;million to $15.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$191.6&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; during the second quarter of 2021, which resulted in a reduction of the IPR&amp;amp;D asset from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$220.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$28.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; are evaluating the results of our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112, including evaluation of any future development activities we may perform. Our estimates of the current fair values of the BIIB111 and BIIB112 programs were derived by using a discounted, probability-weighted calculation of future estimated cash flows associated with the programs under multiple scenarios, including the possibility that we will cease further development of BIIB111 and/or BIIB112, which could result in further impairment of these assets. The key assumptions in our estimates are the amount and timing of revenue, probability of technical and regulatory success, discount rate and clinical data associated with the programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, we have entered into third-party manufacturing agreements related to the BIIB111 and BIIB112 programs and we may incur a financial penalty if these agreements are terminated. Should we decide to terminate either or both of these programs and/or manufacturing agreements, we will likely incur impairment charges related to the remaining book value of the applicable program as well as charges up to, in the aggregate, approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$30.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related to our inventory arrangements and other costs associated with discontinuing these programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,763.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM3NA_49716e16-a23d-44e0-8de0-b92c126ca033">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,141.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,637.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibd2696c492034bfeaae4a745a688853c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi0zLTEtMS0w_5888b240-41ee-4a38-b9a3-e325e2aba973"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibd2696c492034bfeaae4a745a688853c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi01LTEtMS0w_adde1eee-ee81-4ed8-9643-aa3111e36a15"
      unitRef="usd">5252700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibd2696c492034bfeaae4a745a688853c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi03LTEtMS0w_208ed058-96bb-444c-84e3-89d8626b0bfe"
      unitRef="usd">2141600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i564232db534949ec8f4d4776b844bc62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi05LTEtMS0w_dd7b7bf2-80e5-4b50-9e51-75c4722bd6c8"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i564232db534949ec8f4d4776b844bc62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi0xMS0xLTEtMA_276350fd-4369-4b08-acf0-ed2a2ba96365"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i564232db534949ec8f4d4776b844bc62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMi0xMy0xLTEtMA_115fcf8f-1b5f-484a-92eb-a3c9295fa318"
      unitRef="usd">2257800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i425b64c01d0a489ebae1f721822fbfd3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy0zLTEtMS0w_7d6e52ad-4685-4538-9f78-654403ec4570"
      unitRef="usd">179400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i425b64c01d0a489ebae1f721822fbfd3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy01LTEtMS0w_e3cfd676-6f4e-4f71-9075-81d2806c0b69"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i425b64c01d0a489ebae1f721822fbfd3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy03LTEtMS0w_97e4775d-ef5d-41d8-bacc-ab919b164907"
      unitRef="usd">179400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="idcf72f9358a9449ea227a870a11d948e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy05LTEtMS0w_5ec48280-16af-4a26-aa01-aca457c74c02"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idcf72f9358a9449ea227a870a11d948e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy0xMS0xLTEtMA_25257413-4e2e-48e1-bffb-0d5699d219f7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="idcf72f9358a9449ea227a870a11d948e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfMy0xMy0xLTEtMA_3f1ebfc4-e596-40b9-92f4-9b7edabbe358"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i292c5e4fd4e242e9875eefba463479ee_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC0zLTEtMS0w_f90de67d-969a-4e67-a924-66a774d93caa"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i292c5e4fd4e242e9875eefba463479ee_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC01LTEtMS0w_3b01ab14-e04d-4aff-9f70-296301fd2fb3"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i292c5e4fd4e242e9875eefba463479ee_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC03LTEtMS0w_20e50b5a-4fe4-43dc-b0b6-9cbb5793ad18"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4b4c60f1930e46e492d95823df89a04a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC05LTEtMS0w_aa06722e-d81c-43c4-b0a7-268164303cc2"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4b4c60f1930e46e492d95823df89a04a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC0xMS0xLTEtMA_e86f9b16-4cf2-4c67-af7d-2a04e1fc64dd"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4b4c60f1930e46e492d95823df89a04a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNC0xMy0xLTEtMA_890d3319-21f6-4ba6-9bb9-6bfdcbb9c538"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS0zLTEtMS0w_ed7f7440-2033-42fa-9b47-aebc092014b0"
      unitRef="usd">7637700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS01LTEtMS0w_22cbf57a-8709-4f88-b741-bb9ea2571825"
      unitRef="usd">5252700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS03LTEtMS0w_395a2ee4-1c97-4a21-939c-5f07793cafa2"
      unitRef="usd">2385000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS05LTEtMS0w_89a3728d-51b0-4474-aced-44bac3ccc1b6"
      unitRef="usd">8220800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS0xMS0xLTEtMA_b16d63ff-4a56-4143-bb45-15944479d0a7"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOmYzYmNlMzU1NDg4YzRjNzRhOTJiOTIwN2M4NjlkNjY0L3RhYmxlcmFuZ2U6ZjNiY2UzNTU0ODhjNGM3NGE5MmI5MjA3Yzg2OWQ2NjRfNS0xMy0xLTEtMA_6a54222b-6f75-4eae-836e-bf90c081e178"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjQx_05ed352f-8fad-4657-82b2-bea1ded51171"
      unitRef="usd">604100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMzI5ODUzNDg4Nzc1NQ_174045cf-24c3-407c-82a7-206992ebbc4b"
      unitRef="usd">702200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjU3_a613122d-380f-442a-a766-b64cfbc964f3"
      unitRef="usd">61500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMzI5ODUzNDg4NzgwNQ_628a6666-b904-453f-98bd-c7939e11a732"
      unitRef="usd">133000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i915928be88b2414c93eeb0775ef69931_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODEyMw_b1f42d79-dfe6-45a7-b637-69e23ff7424c"
      unitRef="usd">350000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODEyMw_eec843c5-eefb-4d1c-8e95-965a668caa24"
      unitRef="usd">350000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODE0Mg_7673a66a-393f-4345-9d5b-3c52aac7275e"
      unitRef="usd">191600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i3f3471ca51d841a8bc1d6e8d9212942e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODE0Mg_ad47fa5c-bcb9-4b85-90ae-27c767d6c766"
      unitRef="usd">191600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic5dd5cac2c4b4ef88f7c9af0cdbe95aa_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMzk1_61768925-cdcd-4cf7-84d1-8eb44254179f"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="icbe3131e1f0f4d2f96592abae7ae34ff_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNTQz_52884ba4-87b0-49d1-abe7-271a39b1013f"
      unitRef="usd">0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic5dd5cac2c4b4ef88f7c9af0cdbe95aa_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjU1Mw_61768925-cdcd-4cf7-84d1-8eb44254179f"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibc71ae0114074c328965f93fa714853d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjczNg_cb4bf3f0-52f6-4034-8762-104c71a5716b"
      unitRef="usd">136000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if424d27a99a040a8a69fe6179239ad68_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMjg2NA_5b85988a-339b-4781-80dd-66a4a956f7f5"
      unitRef="usd">115000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODE5NA_03fb55b4-a64c-4909-9429-558b46fc5ad7"
      unitRef="usd">350000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic861662623824bafa546d7da7df31404_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODIxOA_890608ba-b682-4f0c-9122-911c0a54c5d2"
      unitRef="usd">365000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib26ab77751224af3bdafebf334667bf5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzOTAwNw_935c5b21-f662-44f1-aaa6-20abb3ea518d"
      unitRef="usd">15000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODI0NA_66a209a7-25d7-4a6b-9267-6874eddf4fae"
      unitRef="usd">191600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i98b7babcbee94700b48f10861f4efe40_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODk2Mg_8ad3ef70-c1ee-4cc6-bff1-946c028ea9a5"
      unitRef="usd">220000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i32c1c6a24b94432396492121d59bce8b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfMTA5OTUxMTYzODI2OA_b793ba19-8629-4bfc-a733-269f5faafb77"
      unitRef="usd">28400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4b3589e2b3b4439795b2b25630eaee3e_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNzE0NjgyNTU5ODIyOA_dd3f119a-fea3-4c13-a0ba-76ae21b8a874"
      unitRef="usd">30000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM2Ng_8e3c31c8-00f1-4aa7-b299-8de04cbbaedf">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfMS0yLTEtMS0w_fecf58f0-443e-4539-bd79-266f1ccfa99b"
      unitRef="usd">110000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfMi0yLTEtMS0w_d06bdd94-3331-4710-8e24-130b9e1b4c98"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfMy0yLTEtMS0w_59f93bcc-4f3f-4495-aa39-4835249449c1"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfNC0yLTEtMS0w_2b302cef-78e4-4bf9-83bb-10fd7f91c32c"
      unitRef="usd">225000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfNS0yLTEtMS0w_b794e9dc-bda8-491e-9331-23889686747a"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjY1YTIyZDE3OTMwZjRlZGVhNGFiZjMxNGI3NTc3MWYyL3RhYmxlcmFuZ2U6NjVhMjJkMTc5MzBmNGVkZWE0YWJmMzE0Yjc1NzcxZjJfNi0yLTEtMS0w_1099c566-c9af-49c9-9c42-4fbb520c4379"
      unitRef="usd">200000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDM5NA_ff59d7dd-7fc4-41f2-84fb-fe917fcf31ef">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,763.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjIwMjI5NzY0NjNkYTQ0YThhYmM5MmZhMDE4MjZkMzQ4L3RhYmxlcmFuZ2U6MjAyMjk3NjQ2M2RhNDRhOGFiYzkyZmEwMTgyNmQzNDhfMS0yLTEtMS0w_1b48a7e2-8878-4d2a-9e62-6629e7b844d0"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjIwMjI5NzY0NjNkYTQ0YThhYmM5MmZhMDE4MjZkMzQ4L3RhYmxlcmFuZ2U6MjAyMjk3NjQ2M2RhNDRhOGFiYzkyZmEwMTgyNmQzNDhfMy0yLTEtMS0w_fc807990-efa5-4245-904f-b6892166cd69"
      unitRef="usd">1800000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RhYmxlOjIwMjI5NzY0NjNkYTQ0YThhYmM5MmZhMDE4MjZkMzQ4L3RhYmxlcmFuZ2U6MjAyMjk3NjQ2M2RhNDRhOGFiYzkyZmEwMTgyNmQzNDhfNC0yLTEtMS0w_ca62fc8e-24c8-4eed-a88e-7dc73db6b3f1"
      unitRef="usd">5763900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82MS9mcmFnOjBkZGQyZmUyMjhmODRiNjU5YmIwYjViOGFlMjljZTczL3RleHRyZWdpb246MGRkZDJmZTIyOGY4NGI2NTliYjBiNWI4YWUyOWNlNzNfNDIyMA_47467e7f-d515-433a-951e-2de01ad74289"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgzNg_f9633414-be63-44b1-b6ad-a869ead7dc2e">&lt;div style="margin-top:3pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,052.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,778.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value during the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021. In addition, there have been no changes in valuation techniques during the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for a portion of our Sangamo investment expired during the second quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of this portion of our Sangamo investment was a Level 1 measurement as of June 30, 2021. For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of June 30, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.68%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 to 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 to 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 21.7% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to assets and liabilities that are recorded at fair value on a recurring basis, we record assets and liabilities at fair value on a nonrecurring basis as required by U.S. GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ending Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BIIB111 intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(350.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BIIB112 intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(191.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2021, we recorded a partial impairment charge of $350.0&#160;million related to BIIB111 and $191.6&#160;million related to BIIB112. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5, Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,037.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,945.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,471.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,140.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, approximately $226.3 million and $110.3 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expense and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgyMA_d9ac1ad3-36d5-4811-9546-e47c4c39b74c">&lt;div style="margin-top:3pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,052.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,778.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy0yLTEtMS0w_b26a925c-0be7-4653-9d54-6f3b4911cbe5"
      unitRef="usd">1180200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy00LTEtMS0w_eacb84af-4c3a-4632-8c30-71f00e95ec13"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy02LTEtMS0w_bd81765d-9961-46fc-bc46-09c4dc086a8a"
      unitRef="usd">1180200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMy04LTEtMS0w_fe1b04b9-af6b-4050-950c-30c812595d9c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fbd029fbc344b46a9e18552f63b771d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS0yLTEtMS0w_11361ac5-33e2-4d52-abe9-6b1fbfd8d30d"
      unitRef="usd">1382500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2bfd21709274d769bdfe5ee0c2a4f9d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS00LTEtMS0w_9ed44b5b-b49b-4733-9f84-36e9a9f3c676"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id690c3d268444a479ccd8676d8f87382_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS02LTEtMS0w_823c0692-851d-481c-8557-b8c2cfa0c855"
      unitRef="usd">1382500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ee42b4171fd43f7b3d5a343e610ffc2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNS04LTEtMS0w_ff3d3901-ff8d-4a93-9441-0d96638eed7d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5278f4a26a6e47f587f7ca52b525d078_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi0yLTEtMS0w_8bc086c0-53a6-4435-b4ea-eeb88384ec43"
      unitRef="usd">688600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedd88e5dc8c048bbad2674a4096e3603_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi00LTEtMS0w_a7d44c20-36cf-4fc3-940a-e36c6c26a38c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4bfc66e80d34cdda3587ae96c181943_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi02LTEtMS0w_0c1c4c43-ab9f-449e-930e-acce8f902c16"
      unitRef="usd">688600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b59ff6648844150b9a65bfbd8584495_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNi04LTEtMS0w_137a4847-2be4-49ac-8dce-fd3213587a28"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie36ef803d07a43c9b37becf139ada10c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy0yLTEtMS0w_e3f6a21f-ba20-40b2-b4a3-c0de8b13f75e"
      unitRef="usd">152800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie818c37f85794462a4a3bb25a7063d68_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy00LTEtMS0w_ddf121ca-fd21-4f63-a8b6-8d363e9019e6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e27733c20de4673aa52d098a7ee84bb_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy02LTEtMS0w_320dad1f-cfcd-4dfc-854a-39eb39cc64ce"
      unitRef="usd">152800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief2010fabf284a188f6f32e901e8f4dd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfNy04LTEtMS0w_3e745db0-9028-4fd0-bc74-b4619c9635fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC0yLTEtMS0w_6454e8b0-a583-4404-b600-9a62d33ce3bd"
      unitRef="usd">1593500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC00LTEtMS0w_7a6ff2ee-16d8-43ac-b863-6d84b683e0c3"
      unitRef="usd">273300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC02LTEtMS0w_3b97de02-49ec-48e7-80ca-d4bfee4bd061"
      unitRef="usd">1320200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOC04LTEtMS0w_1e18a8a9-f8ea-481c-bf2a-ce5f20ea2ce9"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS0yLTEtMS0w_6cb8c3af-db9f-4326-9cd9-f6438ef094da"
      unitRef="usd">20800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS00LTEtMS0w_afaba8c3-a839-467a-9daa-c9aaf1623bef"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS02LTEtMS0w_eb79f998-2ba2-4c47-b50c-50b7963bf049"
      unitRef="usd">20800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfOS04LTEtMS0w_6eeebc70-47b9-4d3a-a115-4592f4098a95"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtMi0xLTEtMA_868d9b6f-6e06-4bd9-9d78-fbd8cbb2ca51"
      unitRef="usd">33700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtNC0xLTEtMA_7032f50e-3535-431c-8e6c-f2c72f3560ab"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtNi0xLTEtMA_6b85c561-5dbb-4526-9d2c-e257eba890d5"
      unitRef="usd">33700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTAtOC0xLTEtMA_40376fb7-f769-45e2-98f8-423b17205e13"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtMi0xLTEtMA_8e0b199e-96cc-4e6f-8a03-f73b749863d1"
      unitRef="usd">5052100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtNC0xLTEtMA_719ce53f-87af-462f-a9f7-89ad8018a505"
      unitRef="usd">273300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtNi0xLTEtMA_a16647ff-99ac-4fe5-bd11-88ab2e55f00d"
      unitRef="usd">4778800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTEtOC0xLTEtMA_3e00d881-1bcd-43e9-b893-ed7bed4c3a00"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtMi0xLTEtMA_388faf7b-51bb-4407-b2a8-b4acc1b216f0"
      unitRef="usd">72400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtNC0xLTEtMA_c7d9147f-5089-4cad-ba77-f33fcfd558d5"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtNi0xLTEtMA_aca03591-d990-4275-9b72-f26a6cc12852"
      unitRef="usd">72400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTMtOC0xLTEtMA_2638b12b-7cca-4d68-b6d8-9d6994b9cbed"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtMi0xLTEtMA_baae58b7-85d8-4136-b46f-69c6e6209721"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtNC0xLTEtMA_0fadfbd4-a045-4dc3-8068-08fa39c244d3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtNi0xLTEtMA_252f7434-ec5c-4490-83e2-146a6b148038"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTQtOC0xLTEtMA_c84673ae-2fc0-4dca-9483-8f9b2baf4289"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtMi0xLTEtMA_05b515d6-fb0e-4168-b3c8-1d9cd1bd47ec"
      unitRef="usd">298700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i919f06b975ef48769887372c1ad1d83c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtNC0xLTEtMA_b5532042-3d2b-4d6a-b72f-3d3be6af403c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2c4dc467e8714d3e9dbfb3519f917de9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtNi0xLTEtMA_0ac155ff-2c9d-434a-bb19-0cccfeeaade2"
      unitRef="usd">72400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie3dabc6e71e4430c9f009009824d5f5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjQ2Mjc0NjVkNGI2MzRiYzZhMzgwMGUxN2IyOTU3MTg2L3RhYmxlcmFuZ2U6NDYyNzQ2NWQ0YjYzNGJjNmEzODAwZTE3YjI5NTcxODZfMTUtOC0xLTEtMA_b3d31b71-791d-430f-a953-fc0bcf5676e0"
      unitRef="usd">226300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy0yLTEtMS0w_87ffc606-ef6b-466d-9751-4d77990f4967"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy00LTEtMS0w_8ff1a855-313c-43dd-8e61-239eb03a0a4b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy02LTEtMS0w_f9aa728e-5ca9-4fc8-a15a-88ad9a6118bb"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMy04LTEtMS0w_79ad7c20-cf0b-41a0-bfdc-b7bc11e4c330"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96bbdd06b85242b4acd39c16f2de4f68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS0yLTEtMS0w_a2950643-18a6-4d4a-aef7-7b66169284e9"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if17a07be4c334ab5bf381339cd0805c3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS00LTEtMS0w_60ad8607-f451-46e3-8fb5-d4349cc9d438"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0db3718d80134232900c7bf04328d7ae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS02LTEtMS0w_886366da-7299-4261-8f80-8dee6ca8f0f2"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbea1376e99b45eea49529b1a794cfb5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNS04LTEtMS0w_bbc1fbf3-0a87-4bb7-b7e7-750b4c1cc0b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief1497c2e19e48d4a054f3ddaa892b41_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi0yLTEtMS0w_3f9aad60-adc1-41a8-b889-fe9a1ba1ad1d"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6febac69f96c45f0b01a347765248601_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi00LTEtMS0w_aedc2f96-0839-4994-9d30-23bac1691957"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e243522dafd43409ff7994995b9d578_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi02LTEtMS0w_f47c9164-42ec-4601-98d4-d5a75f62cfdd"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74fec6d1e18f43c6aaa04084519b0b4a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNi04LTEtMS0w_fe7b0f6c-d4b9-4a88-89c7-0a232cdd90ea"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74f8c8feb0384cc4b6dd32e68d1156d9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy0yLTEtMS0w_ccc76400-fdae-459e-8d8b-62eacd0a14be"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e051c5c511343dd9a80f274f5cbc761_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy00LTEtMS0w_e0a7e42b-3bd0-4a52-a9fb-bd1834dabb9e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5cb3c6b56f5242c9ba547dfeab34e697_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy02LTEtMS0w_b4d9beeb-5029-4091-ac10-a79eca4aa1e3"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a4035f415b24c6cbd58d80693db5b18_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfNy04LTEtMS0w_79833df2-693a-4e52-b384-72d93b1e311b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC0yLTEtMS0w_cb1f2726-8888-4c77-a315-f8984c8e64fe"
      unitRef="usd">1974300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC00LTEtMS0w_d4332dd9-43b6-4ae1-9734-35d91e6c89e3"
      unitRef="usd">271100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC02LTEtMS0w_86511ee5-4a8f-4d23-b254-fd8b17745cef"
      unitRef="usd">1703200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOC04LTEtMS0w_1dffd8f7-3bed-4d2e-928a-6cf982755cbe"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS0yLTEtMS0w_fdee4017-5708-4f06-b2be-94a745ebdee3"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS00LTEtMS0w_011dce5e-2d32-4a7f-a89b-8224825c3528"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS02LTEtMS0w_da9360c2-eb86-4596-bac8-9f83ce59aec2"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfOS04LTEtMS0w_d993afcc-6525-43c8-bba5-7c72794f5ac6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtMi0xLTEtMA_95369646-f465-4521-a523-11fbce3c6a6b"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtNC0xLTEtMA_da5a6af5-d69b-4517-9484-5d498eef5139"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtNi0xLTEtMA_e0bd2c5b-2cb1-4f39-817d-3394d2a20c4b"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTAtOC0xLTEtMA_15168254-62f4-4c77-a4af-535fc518394d"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtMi0xLTEtMA_a1b5e053-da44-4f0d-8d19-61a25aec0753"
      unitRef="usd">4700900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtNC0xLTEtMA_81cf47cf-b107-4404-a48d-76d04e70035b"
      unitRef="usd">271100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtNi0xLTEtMA_3cb06713-ad04-4076-a8b9-ebc554559bde"
      unitRef="usd">4429800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTEtOC0xLTEtMA_242ee465-7176-4040-b9f9-83d8eaa9e2dc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtMi0xLTEtMA_b5be65de-8017-4dfa-b008-0f13f1f6cfba"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtNC0xLTEtMA_e0592c6c-a2cf-4881-a267-6d20b584e912"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtNi0xLTEtMA_ca219adb-bb36-4df3-a714-11e334166699"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTMtOC0xLTEtMA_f4c31d8d-8db1-4ed4-9dab-13d4469070a8"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtMi0xLTEtMA_54438585-1948-4fc8-b2f6-1ec02ffc8059"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtNC0xLTEtMA_b9655c31-9eac-4477-af42-6ee38adc09ee"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtNi0xLTEtMA_2bf1e0c4-2c77-4036-8d6d-246acf0d7df1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTQtOC0xLTEtMA_b1c0df58-566f-41fe-8ef2-34c5d5f6153c"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtMi0xLTEtMA_91245575-a4d6-45d5-a6f0-9efed945b3d6"
      unitRef="usd">477000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i597e26ec891640fba08ea16a165c80d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtNC0xLTEtMA_d2e8e60b-60a3-4fd3-b0ca-39777517badb"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5a34184f549249be8306e9d072ccd958_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtNi0xLTEtMA_e7d7e62f-5791-4a41-821d-7b5abef88cc5"
      unitRef="usd">217200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iea8d5194bfdc4c11856e1dd30d419809_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmZkNDMxZmI3NjY2MzQ0ZTc5NzE5YTQ2ODlkMGJjNTdlL3RhYmxlcmFuZ2U6ZmQ0MzFmYjc2NjYzNDRlNzk3MTlhNDY4OWQwYmM1N2VfMTUtOC0xLTEtMA_1356d59f-bab6-4fc7-8e05-ef8cf64abe9a"
      unitRef="usd">259800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjgz_198f22ec-9a47-4898-84a6-fb1e0763e7af"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfMy0yLTEtMS0w_baae58b7-85d8-4136-b46f-69c6e6209721"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8b7d9660d3bf4a90965d36747d39593f_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfMy04LTEtMS0w_933becef-03c3-4ec9-8bee-46d51914c226"
      unitRef="number">0.68</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i260a3e69565e4b828bff65115e0af19f_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfMy0xMC0xLTEtMA_24a00812-3366-4ce7-9c5e-04705c9143d8"
      unitRef="number">0.0068</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfOS0yLTEtMS0w_54438585-1948-4fc8-b2f6-1ec02ffc8059"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic6c4677be3fb47c7b1f75c1d21d7e655_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfOS04LTEtMS0w_2ac23e19-01e3-4313-836d-afd0c2837a1c"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="icc509257f5be4a76b94830882324d568_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmY3MjRjNTk5ZmZmMjRlMzE4OWRiOGU1ODNjNTM1YWJlL3RhYmxlcmFuZ2U6ZjcyNGM1OTlmZmYyNGUzMTg5ZGI4ZTU4M2M1MzVhYmVfOS0xMC0xLTEtMA_ca840c82-acbf-4e3e-ad54-27e49c9a62a5"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMTg1Ng_2e2a5147-a451-4acc-9ed4-a1cef39f53bb"
      unitRef="number">0.217</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfNDM5ODA0NjUxNzkyMA_a4847fc4-1d70-4d21-8883-6381cf1f566c">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ending Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BIIB111 intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(350.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BIIB112 intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(191.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i89e963ce175141e289e8f4ab954e3f94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMi0yLTEtMS0xMzA1Mw_f6db6383-be01-45e7-ae79-05eae090b28e"
      unitRef="usd">365000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i71f9390e677c4071a7ae6a84252c90f2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMi00LTEtMS0xMzA1NQ_2dc622a0-46cd-4b93-af95-f6624230fd79"
      unitRef="usd">350000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i773881e5f2394e0ebf447f4efbf9d486_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMi02LTEtMS0xMzA1Nw_f0861137-bd51-4838-9c86-725215a18df3"
      unitRef="usd">15000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i56f856147db941a0804cfc73b59b772a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMy0yLTEtMS0xMzA1Mw_f9fac5aa-9be0-4a38-abc1-2e28bd5bd43f"
      unitRef="usd">220000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i0576235f4f574413b5c8e270830d6b36_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMy00LTEtMS0xMzA1NQ_0ec3e59b-bb90-4ce7-a3d1-3194b7ce4783"
      unitRef="usd">191600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i937eaac40dc143619d61ac7e212f0a77_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmNhMThiYmJjZDQzMTQzZTdiMjRhZmI5MDEzYjU0MjZiL3RhYmxlcmFuZ2U6Y2ExOGJiYmNkNDMxNDNlN2IyNGFmYjkwMTNiNTQyNmJfMy02LTEtMS0xMzA1Nw_acf07189-3271-4009-8191-fff4b83f6244"
      unitRef="usd">28400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if327acee1fe2422a8663469d2a750e0c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMTA5OTUxMTYzNDIyMQ_03fb55b4-a64c-4909-9429-558b46fc5ad7"
      unitRef="usd">350000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ib00b4f711a2443449ca9a4b2dcf7e609_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMTA5OTUxMTYzNDIzNg_66a209a7-25d7-4a6b-9267-6874eddf4fae"
      unitRef="usd">191600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgxMA_cdf2d7ec-9a13-42bb-8c80-735362f90670">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,037.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,945.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,471.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,140.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy0yLTEtMS0w_f4391c7f-08ab-4db3-a59a-77e8cf434ecb"
      unitRef="usd">1037800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i3db86160260d4d37be3e2bfa3da3ffa0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy00LTEtMS0w_c988e66d-3ebd-4e7f-b1c8-e19ad2d46dd7"
      unitRef="usd">998500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="id89cf8bc140442ae872b864148ab6939_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy02LTEtMS0w_bd94b78b-1532-4535-aed5-2400bc0b4fc7"
      unitRef="usd">1054100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="id89cf8bc140442ae872b864148ab6939_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfMy04LTEtMS0w_46764913-ffa1-4602-abc0-feacfb92e6cc"
      unitRef="usd">997900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i37f011c57e3b436783a11ba0e28c19ed_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC0yLTEtMS0w_c286b517-ba51-4138-87c4-f0314a03e864"
      unitRef="usd">1945300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i37f011c57e3b436783a11ba0e28c19ed_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC00LTEtMS0w_42886671-55c0-48c0-9540-0e1de1eb95d0"
      unitRef="usd">1742000000.0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ifc580ad737ef4e489c1ba3d69c8dfe89_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC02LTEtMS0w_d0e1eafd-3ea3-46af-aee3-9ccc46e8bbeb"
      unitRef="usd">2003100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ifc580ad737ef4e489c1ba3d69c8dfe89_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNC04LTEtMS0w_3ea95076-ebdc-440c-b85c-59e2dd867660"
      unitRef="usd">1741200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS0yLTEtMS0w_15848d4d-e365-45e1-a99c-4636802a774d"
      unitRef="usd">1503300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS00LTEtMS0w_55c93e31-6d96-4fec-8076-0fb826e232ee"
      unitRef="usd">1491600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i61e30f1dc0024078af380776f8c704ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS02LTEtMS0w_9bfe3f94-ab0b-49ba-b112-41ca512d0468"
      unitRef="usd">1557200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i61e30f1dc0024078af380776f8c704ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNS04LTEtMS0w_4c07ab7b-6257-41a8-9576-b2cee79c3d54"
      unitRef="usd">1491100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi0yLTEtMS0w_ca919df6-5bb4-4d63-9cce-97e5df1901a9"
      unitRef="usd">1483100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i6d2d7b9d384c4f4eb46c7f612658f1c8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi00LTEtMS0w_3299e7c7-0841-49dd-bde2-74c16fc6ef64"
      unitRef="usd">1099700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i6bb9fb78022c43f0a0b87550768dcfd3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi02LTEtMS0w_052929a5-07fc-4097-ad72-32275360fe65"
      unitRef="usd">2365100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i6bb9fb78022c43f0a0b87550768dcfd3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNi04LTEtMS0w_6ebcdbd8-eae6-4d62-8c24-ffe9cb3f1284"
      unitRef="usd">1723400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i630a522bf9a74f1f95a783e75d21daf3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy0yLTEtMS0w_46c2574b-4a65-4c35-adb8-6431a1534006"
      unitRef="usd">1471100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i630a522bf9a74f1f95a783e75d21daf3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy00LTEtMS0w_8d519dfb-9136-4b06-abbd-aefa4e019ea5"
      unitRef="usd">1472900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4fba93be0fea4ade8ac439ac8b9db515_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy02LTEtMS0w_c9911b1c-5eb0-4d78-97ec-7f6e627dcaf8"
      unitRef="usd">1536400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i4fba93be0fea4ade8ac439ac8b9db515_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfNy04LTEtMS0w_6316ebec-679a-49d4-bc3b-3e3c59654bb9"
      unitRef="usd">1472600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC0yLTEtMS0w_7214e087-e758-49d8-a8c1-5230323331ba"
      unitRef="usd">700100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC00LTEtMS0w_959e34d4-a1fe-412d-8995-b6e8787720f3"
      unitRef="usd">464500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i51a894a26a474d8a8a4ca98884aa9ca5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC02LTEtMS0w_18d62e0f-d06c-4a2a-b031-7faa01581b21"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i51a894a26a474d8a8a4ca98884aa9ca5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOC04LTEtMS0w_f15f55a9-cad0-4c6d-bdec-7cd0630ecdd7"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS0yLTEtMS0w_806d8d72-f0f2-47ad-a137-dca964e39a3b"
      unitRef="usd">8140700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS00LTEtMS0w_52aab9a0-2caf-4c1f-ade2-44d7ace5ca83"
      unitRef="usd">7269200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS02LTEtMS0w_9abd197c-2c20-4f1d-9325-e2dc4432c75e"
      unitRef="usd">8515900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOjg4MmI0NWU0YzRjZDRlZTY4YmFhNDZlMzIzYmU2ZWMzL3RhYmxlcmFuZ2U6ODgyYjQ1ZTRjNGNkNGVlNjhiYWE0NmUzMjNiZTZlYzNfOS04LTEtMS0w_4b2c3be0-cff0-45a4-a743-da71c1f3b4b9"
      unitRef="usd">7426200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieca50968196b4b61ac6745902e8f15f7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjE5OQ_0efb1acd-9005-4368-8b5a-385ce9308f40"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:LongTermDebtExchangedAmount
      contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjI4MQ_815a57fe-5f43-4109-b210-683011e739fb"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="ie394eb8420ae465f88327d5264884868_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjM0Mg_517263cf-d911-4835-ac76-7696e4bab1f8"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1fb36c730ba45d4ab09be804637ed64_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMjM2NA_c91d50dc-fd16-4450-b5b7-dcd047d8adc2"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzgyOQ_8bab030d-cfa1-44bf-aa5f-ac46c87b6816">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i75c9a173f74b432699e417cff17cf882_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi0yLTEtMS0w_2f1f1322-45d6-4bca-b64f-2d852b87e370"
      unitRef="usd">226000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib4ab760d5bc14df3ab137b467a13aa03_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi00LTEtMS0w_4e659306-20bd-40ba-bfac-f97fed7049a6"
      unitRef="usd">341600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibdb01ad1d8554d36ac1c85479c0a9d0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi02LTEtMS0w_4be3d836-7a8b-40fc-8820-ce1e2b4599a4"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie454762cebb348ce9e3d9253487d13f0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMi04LTEtMS0w_636e89b0-7321-4164-b4e9-56ccc0741d2f"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy0yLTEtMS0w_2f589e08-a765-4a48-9c01-feb7e14125af"
      unitRef="usd">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy00LTEtMS0w_89c7c5f4-611a-4578-b22e-698908d6ab59"
      unitRef="usd">-10000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy02LTEtMS0w_022d71eb-e8c7-4b19-b41b-311bf129103f"
      unitRef="usd">33500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfMy04LTEtMS0w_74fa092a-0602-4b84-9cdd-677931db093c"
      unitRef="usd">-5500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS0yLTEtMS0w_877c8ec3-c310-4fe9-bbee-32e51139f05d"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ida5bed7f18604646be99d5feb31fc4b3_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS00LTEtMS0w_e9d9ac53-fd0a-411c-a002-c9e78a413105"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6f98fda190d242ab8aa70b53d46f8e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS02LTEtMS0w_5e8ed682-cbb2-4b50-a33c-51a8ff05e3d2"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ida5bed7f18604646be99d5feb31fc4b3_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RhYmxlOmU0ZTk5YjM2YWNkYzQyMWE5Y2FiOWFlY2QyZmNiNTQzL3RhYmxlcmFuZ2U6ZTRlOTliMzZhY2RjNDIxYTljYWI5YWVjZDJmY2I1NDNfNS04LTEtMS0w_9534c07d-4a35-4df6-8a2f-6c2fb2f7d8ec"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzI4MA_51c11b5d-6a65-44ba-b924-fe02b55df49f"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl82Ny9mcmFnOjkyMzNlODYxYTBkMjRiY2Q4MmFhYWNjZGFiODY4MTc1L3RleHRyZWdpb246OTIzM2U4NjFhMGQyNGJjZDgyYWFhY2NkYWI4NjgxNzVfMzI4Nw_60bd5a77-34e1-4e99-86bd-34c34cd85fe4"
      unitRef="usd">110300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg3Mw_643124dc-c678-4962-b4a3-2847f5192486">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;725.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,308.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,308.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities available-for-sale as of June 30, 2021 and December 31, 2020, was approximately 13 months and 11 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,490.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,879.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $1,647.8 million and $2,024.6 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in our strategic investment portfolio for the three months ended June 30, 2021, was primarily due to an increase in the fair value of our investment in Denali, partially offset by decreases in the fair values of our investments in Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock. The decrease in our strategic investment portfolio for the six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, was primarily due to decreases in the fair values of our investments in Ionis, Sage, Denali and Sangamo common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Sage, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Denali, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of June 30, 2021.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#x2019;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangement with Sangamo, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg3OQ_6d739850-d50e-4344-991a-36a34065a58b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;725.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia7c698cd4a9e4be08876c788f019876a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMS0yLTEtMS0w_b7e5586f-95f4-4342-bca3-0b28adc87854"
      unitRef="usd">130000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i76ce0d61306a499d84402c0d7b2ac015_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMS00LTEtMS0w_e7815737-0368-4deb-84ad-3da3a273e43b"
      unitRef="usd">61100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id7937d5eea9143a480379f4cf9a45fc4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMi0yLTEtMS0w_31648f46-deff-492f-a4e6-cd43e833ace6"
      unitRef="usd">297800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i47869cfa31654403b8a137ce71cddf41_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMi00LTEtMS0w_f4e77cb2-0352-4674-9ca0-373d8d1d07fc"
      unitRef="usd">37400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i341192473b2c4e86ba0b46d1823dc869_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMy0yLTEtMS0w_2c8ceeac-0c9b-46bc-9d4e-8b5d40bb90f9"
      unitRef="usd">725900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia0765b5a9983479983cc32b7829fb9a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfMy00LTEtMS0w_2977099c-b25e-443b-8f46-adc53a451d30"
      unitRef="usd">505100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i24972f1aece34e51acc03fa88f074792_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNC0yLTEtMS0w_8fc38155-5741-48cf-a7a0-b0ef089c29c2"
      unitRef="usd">26500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia9f336c946104c0db5fe50289af1e486_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNC00LTEtMS0w_87a58fd1-1a40-4979-b48d-0a2665baee83"
      unitRef="usd">23300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNS0yLTEtMS0w_182a2fe8-a3d4-4170-ad0e-d92d9bd9e147"
      unitRef="usd">1180200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmM4YjQxM2M0MjBkMjQ3YWFiOGQwMjVlZDc0NTgxOGE3L3RhYmxlcmFuZ2U6YzhiNDEzYzQyMGQyNDdhYWI4ZDAyNWVkNzQ1ODE4YTdfNS00LTEtMS0w_65ab1d47-9039-428f-adbf-cd84619a416f"
      unitRef="usd">626900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg4Ng_7953ed3e-eb8e-4a46-8dee-d93e454ed50b">The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC0yLTEtMS0w_4f0e7ef3-88c9-4340-b73a-2f64f7c3ea9d"
      unitRef="usd">1072200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC00LTEtMS0w_582bc532-e124-4746-bb9e-c504c37bdbc4"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC02LTEtMS0w_45a3ab8f-74b2-4869-830f-75a7b6ea1bb2"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedcd05b4880a4540810666063e3fa5c4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNC04LTEtMS0w_d8922c05-6f67-4ec0-b71f-ce5427ba9a94"
      unitRef="usd">1072100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS0yLTEtMS0w_2bb75569-3b71-4e45-a6f5-ea9a28790e66"
      unitRef="usd">309900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS00LTEtMS0w_f1df7da1-dc13-4939-a7b8-44b8ac57707e"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS02LTEtMS0w_b14fb898-2e07-4a2e-8cf6-ac20c8bedd6e"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i025802fa7e3847d4ae2eef093ae4c52e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNS04LTEtMS0w_319d93a2-d98c-4ff8-992a-9ebaa1fb7f4b"
      unitRef="usd">310400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea966d9152224b339632f5f1382ae44a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy0yLTEtMS0w_556e891c-f50c-42ba-9c13-1faa2fccaddd"
      unitRef="usd">236500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea966d9152224b339632f5f1382ae44a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy00LTEtMS0w_13b46e77-f19a-4e61-9e68-b78c3939127f"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea966d9152224b339632f5f1382ae44a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy02LTEtMS0w_7c7dad6b-187d-411d-8ff0-cd6ed3685de8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea966d9152224b339632f5f1382ae44a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfNy04LTEtMS0w_a618e795-fbcf-48c1-91c9-d2be39f6ca65"
      unitRef="usd">236600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4d314e63f4cd44538653c170af449268_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC0yLTEtMS0w_c5bc9cd4-79d0-4afa-8bf8-d3df2bd3e78d"
      unitRef="usd">452100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d314e63f4cd44538653c170af449268_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC00LTEtMS0w_405a6bee-84e1-4ce4-b58f-d79f563b8637"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d314e63f4cd44538653c170af449268_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC02LTEtMS0w_b1ab4f88-40cb-46bc-a429-050b8b3da911"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d314e63f4cd44538653c170af449268_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfOC04LTEtMS0w_0dcab516-c591-43a3-ac5c-a732ca190fb7"
      unitRef="usd">452000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtMi0xLTEtMA_f2fc8280-20d5-4b77-b0e5-f14f858c2cac"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtNC0xLTEtMA_e1c8d23b-f983-4afc-badb-6de78ad0dc9f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtNi0xLTEtMA_5b25d423-bf7c-45ef-84f9-d1e02b54117b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a12db724d6a4e459f2d028b6a9183ac_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTAtOC0xLTEtMA_50dda03c-786e-4436-8506-397e9a012bf4"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtMi0xLTEtMA_c9ba5859-7017-4797-bfb4-68510cd12796"
      unitRef="usd">152700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtNC0xLTEtMA_3c97db1a-beb5-47f9-aafe-73b20363331d"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtNi0xLTEtMA_313fd527-368e-4914-8b83-30d5e105f664"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9cfa41b71984268a5cb3226a08be9b7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTEtOC0xLTEtMA_8c2313b3-ec6f-4dc5-a2bb-8cbeea6b6989"
      unitRef="usd">152600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItMi0xLTEtMA_525202f9-278b-4c5f-9107-cbaed80a865d"
      unitRef="usd">2223600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItNC0xLTEtMA_b4d01335-c9a1-4965-ae05-8be96eb257c7"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItNi0xLTEtMA_46a6b5f2-b2f5-4f67-9260-db3b0079132e"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTItOC0xLTEtMA_27219c94-5a17-4c2d-a0ad-2c6b89731135"
      unitRef="usd">2223900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtMi0xLTEtMA_9114088b-f86d-4b7a-9229-af3d7613a476"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtNC0xLTEtMA_35c6e33c-1674-4fdf-93ed-19ab5ec7ba90"
      unitRef="usd">607600000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtNi0xLTEtMA_3d91cfea-e683-4de9-a098-762606a91fdb"
      unitRef="usd">183000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2da4427e9e314137b7a5b4ca1ca37219_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTYtOC0xLTEtMA_f8bebdeb-d2cb-4df9-915c-028762dd8704"
      unitRef="usd">1593500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i2345724701914330b955cf8be98888d9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctMi0xLTEtMA_5a9adc23-5d0d-436a-9cda-dff54ce2f1b4"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2345724701914330b955cf8be98888d9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctNC0xLTEtMA_a5ce16e1-d72a-4132-bd3b-f6537995654b"
      unitRef="usd">607600000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2345724701914330b955cf8be98888d9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctNi0xLTEtMA_a7d97087-9da0-47ca-9d19-200efbf50467"
      unitRef="usd">183000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2345724701914330b955cf8be98888d9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjEyYjA3Nzk1MTdkMDQ1OWI4OTI3ZTg0NGEyYTdiNTg5L3RhYmxlcmFuZ2U6MTJiMDc3OTUxN2QwNDU5Yjg5MjdlODQ0YTJhN2I1ODlfMTctOC0xLTEtMA_2d7aafde-adff-4ee2-bc8e-4ac68d5286f3"
      unitRef="usd">1593500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iddda160e4f824f399742551361ab9a2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC0yLTEtMS0w_b1db981d-ec42-4f26-9165-4358c17cc57a"
      unitRef="usd">897800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iddda160e4f824f399742551361ab9a2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC00LTEtMS0w_267899e3-c14c-41ec-9797-789ed531b195"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iddda160e4f824f399742551361ab9a2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC02LTEtMS0w_3b58305b-e8ba-459d-a5ff-f36e3a81d7a9"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddda160e4f824f399742551361ab9a2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNC04LTEtMS0w_0b828e4f-a9c6-409a-931e-621dcd176a5d"
      unitRef="usd">898000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS0yLTEtMS0w_7f84a2b0-00ef-4a51-bb76-7576ae3001ae"
      unitRef="usd">402500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS00LTEtMS0w_f4f65e65-b324-49ea-b099-9a54fe84e2f2"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS02LTEtMS0w_b1d1ad41-b3b8-4820-82ed-9b09c4b53a87"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd259f1cd1d64891b5247097034ba0e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNS04LTEtMS0w_90c7d5ae-7eaf-44c8-b679-fed79a61cdcc"
      unitRef="usd">403500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy0yLTEtMS0w_f1947585-f580-46bc-bd9a-2c06f9e27db3"
      unitRef="usd">380600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy00LTEtMS0w_ee00bc93-7e68-4e0b-8ffd-8c4404f74084"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy02LTEtMS0w_d51210d6-1a30-4445-ab1b-0c190be7ed7f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb090da29b27466d8dc5cd89cbf9dd57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfNy04LTEtMS0w_df784e18-44a0-42f2-a08d-7b7cd879936d"
      unitRef="usd">380700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC0yLTEtMS0w_4ca1fee9-33b7-4a35-962d-d282f56c3570"
      unitRef="usd">245900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC00LTEtMS0w_5f25cab2-f9bc-46ac-8831-6f9e631f1a4e"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC02LTEtMS0w_ec3f6c4c-dafb-4e7d-a62b-07098c3b2d5f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i046a19b35a87471dbbfd93c7cac2007f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfOC04LTEtMS0w_30985f68-99bb-4677-956f-ae5c8a922a14"
      unitRef="usd">246400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtMi0xLTEtMA_35396dd4-0348-4b1d-9e3e-264ba2bf6e6c"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtNC0xLTEtMA_e66a65bc-219a-432d-9eaa-8591fe06dfe7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtNi0xLTEtMA_754115ab-83e4-4f96-8667-3162bab502c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2dc1544fae3a46a4beeec639311e70a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTAtOC0xLTEtMA_e3a38a0a-76b4-4fb9-8b02-76950781e669"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtMi0xLTEtMA_a4f96ead-c3ff-4b0a-aceb-8d18ecfd66fe"
      unitRef="usd">122100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtNC0xLTEtMA_ed44a082-b7f1-4db4-81aa-bd0f0f838144"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtNi0xLTEtMA_69aba595-729a-4476-a25b-1187cd6560c5"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cad9ecfa340459b9eb2d3c45d1f26c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTEtOC0xLTEtMA_ed7fd0d2-05f2-4812-a4d8-5faa8e718289"
      unitRef="usd">122200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItMi0xLTEtMA_f1b050f0-d65d-4c0e-842d-0d55cce54b1d"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItNC0xLTEtMA_c14461d8-9e18-4194-ba38-4d1716b1aa7d"
      unitRef="usd">2300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItNi0xLTEtMA_70e9ec9b-dc46-4f69-916c-2f45dc3748cb"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTItOC0xLTEtMA_a3aa897d-825d-4e38-b2b2-8a1b71fa9369"
      unitRef="usd">2051000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtMi0xLTEtMA_d04d7a6e-e000-4b63-8246-297a6288b156"
      unitRef="usd">70600000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtNC0xLTEtMA_c618398f-9c53-4199-b07c-4fa14eb5c170"
      unitRef="usd">15900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtNi0xLTEtMA_af86643e-bd3d-4161-ac65-7fb6b9cfe39d"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i84100fb99b304864bdd82f94e09a5f4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTUtOC0xLTEtMA_0122c112-6833-4aa6-a253-845164a45675"
      unitRef="usd">86500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtMi0xLTEtMA_b33aa918-a8d9-4bf2-b859-a4647ef884b7"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtNC0xLTEtMA_e5b16a6d-43cc-4a2b-95f0-be4294110fd1"
      unitRef="usd">733800000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtNi0xLTEtMA_2dde3eb5-4f45-4f69-9a33-3989a8b7099d"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iccdddbc872c141098bb571cc14541a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTYtOC0xLTEtMA_b522d89d-4db0-4376-b292-17d695a1cede"
      unitRef="usd">1887800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctMi0xLTEtMA_40ed17ed-e830-4ea3-ab2b-fd15476a6302"
      unitRef="usd">1239500000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctNC0xLTEtMA_76485255-b616-4a11-8a5f-3d94c6771404"
      unitRef="usd">749700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctNi0xLTEtMA_0016e892-3d04-45d1-a3fe-c5318446e93e"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmE1ZTA4YjM0ZTc3NjRiZDhhOTc0N2Y4YTA4YmQ3MDgxL3RhYmxlcmFuZ2U6YTVlMDhiMzRlNzc2NGJkOGE5NzQ3ZjhhMDhiZDcwODFfMTctOC0xLTEtMA_058c181b-5dd5-47de-96b5-b33317bea86b"
      unitRef="usd">1974300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDg4OA_c1218fd4-512e-4d27-a933-94dbe0ad1b3e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,308.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,308.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi0yLTEtMS0w_be1b0fac-9cde-44b1-855f-3e4c1c780f34"
      unitRef="usd">1308800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi00LTEtMS0w_408d12e5-3a4e-4763-8d5e-3ddd23dc5aab"
      unitRef="usd">1308900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi02LTEtMS0w_ec46d0b2-964f-4066-b681-6fdad4327044"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMi04LTEtMS0w_912df18f-e27c-4945-bc44-71064dfcf7ef"
      unitRef="usd">1278600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy0yLTEtMS0w_0eb06a9f-6305-4319-96f4-ee679f2936be"
      unitRef="usd">870900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy00LTEtMS0w_c6e3342e-6b5e-4903-82e4-70b7d175dbd2"
      unitRef="usd">870500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy02LTEtMS0w_809a4cc4-12ce-40ae-ae86-973d1dfc8baa"
      unitRef="usd">722600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfMy04LTEtMS0w_451b7f5d-28d3-4453-817f-6c6332ffd69a"
      unitRef="usd">721300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC0yLTEtMS0w_f3f6a598-1ce3-48de-ae6d-c1f4c2eedfc8"
      unitRef="usd">44200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC00LTEtMS0w_8940eab0-52e6-4be4-b649-e331edb05b4b"
      unitRef="usd">44200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC02LTEtMS0w_abdd799f-9686-485b-81ee-f4be9db89b07"
      unitRef="usd">49500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNC04LTEtMS0w_83bae020-9c7c-41c3-aafe-219c82467ded"
      unitRef="usd">49200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecurities
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS0yLTEtMS0w_5db1198a-1aa7-4ec1-97e7-8675050dcbae"
      unitRef="usd">2223900000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS00LTEtMS0w_ce7d3992-8fe6-406b-acb4-ebcb44e7b95b"
      unitRef="usd">2223600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS02LTEtMS0w_bdabb683-3e8e-4955-b08e-15cebd5a2788"
      unitRef="usd">2051000000.0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOmVkMDc1ODUwZTQ5NjQxZDM4M2QxZTg2OWQ4ZTgwN2E1L3RhYmxlcmFuZ2U6ZWQwNzU4NTBlNDk2NDFkMzgzZDFlODY5ZDhlODA3YTVfNS04LTEtMS0w_2899c450-76e6-4d68-9f86-2644e11edce9"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTAyOA_8a64da5f-d7ee-40c6-9da7-a1f368dd0a9f">P13M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="icaa604084a4f426cb962e44bba729d00_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTA0Mg_950f0631-1fd8-4ccb-be75-f548785eb519">P11M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDkwMA_3d6ce53a-bd43-4ac0-ac96-2ed5fe2dd325">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,490.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,879.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi0yLTEtMS0w_ac849f1d-b462-45e0-99ed-fda87599442f"
      unitRef="usd">633500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi00LTEtMS0w_849e3364-260f-4072-856d-4ecd3ffd81ff"
      unitRef="usd">1490600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi02LTEtMS0w_00df4afc-f9c2-4680-8e50-aaa7cdf3db11"
      unitRef="usd">1452700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMi04LTEtMS0w_ce162755-f90a-4042-928d-2f5aaa96e487"
      unitRef="usd">3879900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy0yLTEtMS0w_a52e8f73-1c9c-451d-882e-eeeff42e5081"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy00LTEtMS0w_e5905099-d46a-4fed-9d22-ed600dbf2b35"
      unitRef="usd">6100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy02LTEtMS0w_1b3f1866-d927-405e-8386-1f0226794752"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfMy04LTEtMS0w_61053461-8091-4df7-b7b4-9484613f0792"
      unitRef="usd">11800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC0yLTEtMS0w_eeaacaf8-dd60-49a1-a481-737a96f53801"
      unitRef="usd">500000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC00LTEtMS0w_0aa0181d-3fa5-49af-96c1-121985a78d8b"
      unitRef="usd">5200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC02LTEtMS0w_c8e6fd05-bc9c-417c-9f47-10859b550e8c"
      unitRef="usd">1200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RhYmxlOjBkNWEzMGM1ZTliMzQ3NDViOTIxNTEwYThkMmI2MzQ5L3RhYmxlcmFuZ2U6MGQ1YTMwYzVlOWIzNDc0NWI5MjE1MTBhOGQyYjYzNDlfNC04LTEtMS0w_adaf4bae-ba00-4116-aa5d-fabdd92da007"
      unitRef="usd">24300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="if1b531a1cb354dadb1d4b04d6c9d7dde_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTM1OA_5f10ec5f-622f-455f-9336-833ec76ad3b9"
      unitRef="usd">1647800000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="i5fc4527faa29483d89169d9c64e45fc4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMTM2NQ_6d0ce0f1-4d44-4c82-922e-1b5db2f4cd4b"
      unitRef="usd">2024600000</biib:StrategicInvestmentPortfolio>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjIwMg_8c2b9253-da1b-4b85-8411-11d2aa239cf6"
      unitRef="usd">650000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjIwNg_3d5ff800-f95d-4f1b-b10f-afbeca036ee5"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjIxMA_65226e62-f273-4edd-9926-f222bd383de1"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <biib:DividendYieldPercentage
      contextRef="i6c93ea4397fb4f4cacf7e9b9766c5d11_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMjg2NQ_989db727-4911-42a4-9d96-6e020882b7c4"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzI3NQ_a394f47a-16cb-4812-9f02-2218c2b15256"
      unitRef="usd">465000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i82cf1cd794bc4e22b1558829c36fdbe6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzI4Mw_bfcff615-27bd-49b2-906f-e08fbdf8116c"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzI4Nw_8609403c-6638-423d-b748-2def391ed8b1"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:DividendYieldPercentage
      contextRef="ia3fe0fbe0a3c4dec98ff2998e5d84527_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzU3NA_7113bb34-e5e9-4ca1-b0d0-5ba92fa48ab8"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzkzMw_c5dc7682-1418-4700-b054-184d7b932999"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzkzNw_df30e7d7-e158-4a58-b58b-e1f4302ab1eb"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfMzk0MQ_d645e7cf-6c39-45fb-8a62-d28db742fae9"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i512790f7d615460ab79e03a4291d683a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDk0NzgwMjMzMDAwMg_f96858b6-6577-490c-92ea-ca4bb332f32d"
      unitRef="shares">12000000</biib:Investmentincommonstocksharespurchased>
    <biib:DividendYieldPercentage
      contextRef="ie46d4c476a5740f3a1de4a18cc7dd358_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83My9mcmFnOjA5ODQ2MDM1NThmMTRjYzg4NGNhMGVjOTY2Mjg1OGUwL3RleHRyZWdpb246MDk4NDYwMzU1OGYxNGNjODg0Y2EwZWM5NjYyODU4ZTBfNDYxNw_6f9c7667-6e46-47d2-8376-4d0bd226b052"
      unitRef="number">0</biib:DividendYieldPercentage>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzA0Ng_dc495ba3-b245-41f8-94be-cf91eca8627e">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts in effect as of June 30, 2021 and December 31, 2020, had durations of 1 to 18 months and 1 to 24 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of June 30, 2021, reflected aggregate net unrealized losses of $53.7 million, composed of gross unrealized losses of approximately $67.0&#160;million and gross unrealized gains of approximately $13.3&#160;million, compared to aggregate net unrealized losses of $212.5 million as of December 31, 2020. We expect the net unrealized losses of $53.7 million to be settled over the next 18 months, of which $58.2 million of unrealized losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of June 30, 2021, had a remaining duration of four months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $0.1 million and net losses of $21.2 million as of June 30, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.1 million and $0.2 million as of June 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,205.1 million and $1,158.0 million as of June 30, 2021 and December 31, 2020, respectively. Net gains of $4.8 million and net losses of $12.6 million related to these contracts were recorded as a component of other income (expense), net for the three and six months ended June 30, 2021, respectively, compared to net gains of $8.3 million and $5.9 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="id9f0d11ff3fc4f448b2f08227bf61ec8_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjIz_20f04ece-c8af-419b-a08d-dda17221a2dc">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ie4176720cd9a4369ad4b4aafcdcf8e71_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjI5_b2e6272b-6054-4942-b38c-f61f94b40f78">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i3365b3ac299340f1817dd1c53085ac56_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjM2_30a0d1cd-57d5-4041-bc3b-92adc3e5a6cf">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ie2e1c79ee9d842c499a267151200ea06_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjQy_911195b8-5ae2-4718-b096-7f015a018f9c">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzA0NQ_7e250cbb-35df-4227-88bc-9c3f120e4a6e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,269.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i25afa94ed8e9481ab9840103fd7abdae_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMi0yLTEtMS0w_528a80ef-72d2-44ef-880d-80414987d725"
      unitRef="usd">2269200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i20c4856250984299a9cced80dcf2d079_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMi00LTEtMS0w_5080c6b6-25ce-45ba-870c-0e81cc1a58ed"
      unitRef="usd">2979100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i50f69c368cc9469e8e39f044f00e3e4f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMy0yLTEtMS0w_4eb5ad24-1d77-48a4-9d45-87ad98214618"
      unitRef="usd">128600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idfbd5e05042b4036a8d14b4e5ebca682_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfMy00LTEtMS0w_dee42e35-bf41-49e6-89fd-0c35aa86e5d5"
      unitRef="usd">250600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i011039cdd7d14a4cb9f0e79057e4cc60_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNC0yLTEtMS0w_60dba89e-667c-4e80-abda-b97c8d102aa8"
      unitRef="usd">109900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i361c2d5b5f9a40ca84ea9fc27a68ea9f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNC00LTEtMS0w_9b375614-df16-4a60-802d-735a20451c4b"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i31a45a9c2ad44e1fa1cf0df1ef188ea0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNS0yLTEtMS0w_ef858128-9257-4383-85c5-e3fd68aef790"
      unitRef="usd">62500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2288b6bd35ab44fc89e7711afcecb9b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNS00LTEtMS0w_7efa746d-e3f4-460b-9ae9-628fb6738197"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i041267955427406394b3d10cc3f1a76e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNi0yLTEtMS0w_fc48a9a5-7ebd-4b41-91f8-84e27f3e8299"
      unitRef="usd">53300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7c013d5be0e0491980d059486bae596e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNi00LTEtMS0w_8a4f95bc-0b9c-425c-ad05-45fe1445d5ab"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5a47da70628b45368fa3c768152f89ab_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNy0yLTEtMS0w_899377b6-e49d-423d-8e65-cb585aa20aca"
      unitRef="usd">2623500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i34356bbd90064319b545c3acc5fab084_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjRkMzI5YjMwMTg5NjQ4ZGE5OTM5ZmNhZGY1ODMxYzVhL3RhYmxlcmFuZ2U6NGQzMjliMzAxODk2NDhkYTk5MzlmY2FkZjU4MzFjNWFfNy00LTEtMS0w_9304f3f0-5fe7-4014-9fae-83671f432ea2"
      unitRef="usd">3229700000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTgxOQ_1fa47587-3e72-4eb1-b5f1-4ddff205c9d4"
      unitRef="usd">-53700000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTg3Ng_61414f56-0746-4dd6-ba0c-60f3eac648c3"
      unitRef="usd">67000000.0</biib:UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTkyMw_d11438e4-86c4-4ba4-96d6-6f1044a77c1a"
      unitRef="usd">13300000</biib:UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMTk3NA_8545e93e-b639-4a40-b702-8d566346b22f"
      unitRef="usd">212500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjAyNg_1fa47587-3e72-4eb1-b5f1-4ddff205c9d4"
      unitRef="usd">-53700000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ie4176720cd9a4369ad4b4aafcdcf8e71_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjA1Nw_16cf81d1-0067-42c9-a992-e016b9b28fef">P18M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i62b264cff07c440eac3e823fa20d8f64_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjA3MA_cbad2739-5755-453c-999d-9fa3e1f1a9f1"
      unitRef="usd">-58200000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="id6d5e77b1f3d4a9fa12b15878cb707cf_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjEzNQ_bd6211f7-4f8a-49b8-b900-cbddd6c4ba55">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzAzNg_74566b97-99fa-46a0-8d8e-105f8bc108a7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i89bfefbfa10f41fab03c1114e9b9886d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy0yLTEtMS0w_e690af6e-73d1-4c4e-a5b6-7d45a3ca620e"
      unitRef="usd">-30700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="idefcc8d10a5a4365aafafd0f6a18ada6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy00LTEtMS0w_cf5f0dc2-7912-47f5-a5b5-2c283635d744"
      unitRef="usd">23700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic773015e74094678bef62859130a7966_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy04LTEtMS0w_faca04d1-3b32-46aa-b54c-ce3e3a461376"
      unitRef="usd">-800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ibf78e07bf74c48a797d7b1e5be1d1a78_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfMy0xMC0xLTEtMA_ab55341d-8e5f-4b43-9718-cd6ffa0cbdeb"
      unitRef="usd">-1600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8644901576fc48e89f7637ea72cd9a14_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC0yLTEtMS0w_fc4e1495-5fac-4a10-813c-a5abe1ac1cc1"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ifc16ed7a14e24bfa91d7bef98db547da_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC00LTEtMS0w_ba197a2a-845f-4a7f-beea-2d29ca0ecad7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ide0fa9272fb14f3d92662a3cf36c6a91_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC04LTEtMS0w_fe46aa99-e127-4c0d-833d-0ade30868e62"
      unitRef="usd">-300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="idd7e5ea5d2434fdb8b011b6c00426a56_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjgzZGRlODEyYzYwNjQ3ZmNhZTYwZTBmZjliNDhjNzA0L3RhYmxlcmFuZ2U6ODNkZGU4MTJjNjA2NDdmY2FlNjBlMGZmOWI0OGM3MDRfNC0xMC0xLTEtMA_8bec9539-1f2e-4fe5-b98f-4cc3bac41842"
      unitRef="usd">-200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6e7a2205485b42a29e91f52900709717_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy0yLTEtMS0xNTM5_36d89862-5d4d-4b6f-9328-7fc6bdc22ea1"
      unitRef="usd">-53800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i67d9977b79f94870b4d88a3efdae4b18_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy00LTEtMS0xNTM0_b9b21a58-75ee-4dd3-bb0b-9e98ab3c09d4"
      unitRef="usd">50700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i9eaabdea048846fe96c2e448be0650d7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy04LTEtMS0xNTQx_46dcc0d8-9260-4240-a6b9-c5f01cf3e5a1"
      unitRef="usd">-3800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i27ff03e21ceb4d898ce5d84c9f83373b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfMy0xMC0xLTEtMTUzNg_25cf0ece-636f-44ab-8ab4-3eda5d015fa0"
      unitRef="usd">7700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ieb7296f2fd8d4fcb8a228339d858558a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC0yLTEtMS0xNTM5_23a64af0-f764-4ac3-9e6b-286ca7bc4025"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i1be0b892adfa46da854229dbdc2b29e2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC00LTEtMS0xNTM0_dea5ad31-e81b-43ce-966a-71cd31a5b8cb"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i2404b4e4cf7047b6a33ade2b330db9ad_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC04LTEtMS0xNTQx_66b67286-1eef-4822-a703-acbe0b0c6935"
      unitRef="usd">-400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i22a7aca0e9644a159e0edce9ec0ffa8e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQ3Y2NkMTY2NTc5NzQ0YTI4NzkyNjY4MWMzNWU4MTA0L3RhYmxlcmFuZ2U6NDdjY2QxNjY1Nzk3NDRhMjg3OTI2NjgxYzM1ZTgxMDRfNC0xMC0xLTEtMTUzNg_9d29f1d5-f763-41ca-afba-22f846d535d1"
      unitRef="usd">-1100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzA2MQ_6e720a3b-834c-4fc4-becf-2cac28f8b538"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia9fa629226d049e2a9ffe5ae168ceb55_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzE3NA_53f79fd7-1cee-40b0-acb6-61aa5ecde888"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzMyOQ_6e720a3b-834c-4fc4-becf-2cac28f8b538"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8dcc2572e864232810d889863e8b6a1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzY0MQ_6e720a3b-834c-4fc4-becf-2cac28f8b538"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if078c4e7fa004892b58a2d85cb5816aa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMzY5NQ_a9f7bbc7-567d-47ad-abad-862808116702"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="ie35fa105818345dcb7a4da4701cf3007_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDIwOA_a2aa4096-e592-45d1-ac71-3e96b4d91014"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDIyOA_b9ee3de5-9d24-4d84-b297-7d369e6dc9f1"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDMyMQ_131714dc-8eaa-4576-9c1d-eec6100520ce"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDM0Mg_568b28c8-7cb5-4b53-9eb4-b06b3c3b2227"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNDcxNQ_ad4decfc-ab2b-4a06-aa40-99b07fb87fee">P4M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTA2OA_e5a125b9-61b8-4d53-ba15-18270ef3fece"
      unitRef="usd">100000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i2ac95fd0cd294483986cafbab07cd5d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTA4OQ_4a929aeb-4f61-49c1-9a24-ca1420f562d2"
      unitRef="usd">21200000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i02aaf8bc41e445329bc5a2dee146c97a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTUyNA_e5a90c87-d08e-48c5-82c9-0a390d81e711"
      unitRef="usd">100000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="idb95e23801654e2bba2506940e05081b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNTUzMQ_b0c99d7d-0f49-47d3-93ec-96e51c45c91d"
      unitRef="usd">200000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzAzMg_c854ad63-d769-4c70-8033-2523bc79a708">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="iab366cb8c1584b168540336d12773aaf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0yLTEtMS0w_3aea06b9-10b8-4792-99dc-344a59276485"
      unitRef="usd">-2500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i74eeb72d9da54664aaeffbd41250c0b4_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy00LTEtMS0w_1df02f38-fff9-4f66-aa9f-08bb310997c0"
      unitRef="usd">-8800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="iab366cb8c1584b168540336d12773aaf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy04LTEtMS0w_c8279014-1342-4ade-95fe-5519a454194d"
      unitRef="usd">300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i74eeb72d9da54664aaeffbd41250c0b4_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0xMC0xLTEtMA_6638d71f-b349-42e7-b8a6-407743e32948"
      unitRef="usd">3500000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="id08317e7cb534a3289414130d2f13dff_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0xNC0xLTEtMA_364944ca-406a-430d-99da-138066895a8a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i7d8b068d3ff24daca734cfd11aacfa1c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOmMxOTE4MDVlMjZkNTQ0YjRiNTliNGI3MjExODFjM2NlL3RhYmxlcmFuZ2U6YzE5MTgwNWUyNmQ1NDRiNGI1OWI0YjcyMTE4MWMzY2VfMy0xNi0xLTEtMA_118108e0-57ce-469a-8bf3-30710e5cb00c"
      unitRef="usd">800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0yLTEtMS0xNTUw_b8e5ee3f-c431-462a-a3f4-0bc659466b54"
      unitRef="usd">21300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="if261c4da0ab44775b42f4cccccfe73ec_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy00LTEtMS0xNTU3_9a24f711-a151-4e4a-91b0-0dbcd757c39e"
      unitRef="usd">15400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="ia5c68be1f4724d6c863d2927c8867e94_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy04LTEtMS0xNTUz_719c8e83-1ae6-4350-8286-3f05ab626f0d"
      unitRef="usd">-1100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="if261c4da0ab44775b42f4cccccfe73ec_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0xMC0xLTEtMTU2MA_7ba9c8fb-25bd-40a5-b85e-cfa0640b2a6a"
      unitRef="usd">3200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="ide3cd384eb084efab9ae4e2d17d5a9c7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0xNC0xLTEtMTU1NQ_9b4d6897-bb74-4610-8ca8-9ba660226bbc"
      unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i0281011ecb3d433e9e4a910b3c2764cb_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjY0NTQ0NWEwNWM3NzRkYzViMzA4ZTdiZDQyZGI2MjUxL3RhYmxlcmFuZ2U6NjQ1NDQ1YTA1Yzc3NGRjNWIzMDhlN2JkNDJkYjYyNTFfMy0xNi0xLTEtMTU2Mg_2d205afd-b087-4429-b08b-2c9def14fbd4"
      unitRef="usd">1700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4592ebbd81f14b13b42251b139794fe1_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjI0OA_3f07a1db-c1f7-44fa-a1af-b9209448a9a5"
      unitRef="usd">1205100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i26b01c7943bb4de2afd50de4b1bd1d85_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjI1NQ_72ed1bf7-33de-4bb1-93a1-c83ff347d52b"
      unitRef="usd">1158000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjMwMw_1012d344-c890-4442-902d-92c752c0175d"
      unitRef="usd">4800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjE5OTAyMzI2MjY2Mw_c432d40a-4bb2-45d0-96c1-dda553240fd9"
      unitRef="usd">12600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNjMxMA_d14529ed-a5c9-4cc4-8023-062f618700f0"
      unitRef="usd">8300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfMjE5OTAyMzI2Mjg4NA_1b947f68-dc81-4f9f-b054-070627dc5099"
      unitRef="usd">-5900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RleHRyZWdpb246NjE5NTNmZmU0MDgyNDg4Y2E2MGFjNWY5YWVhOGYyNGNfNzA0Mg_abd6b2be-4f77-434f-9ccf-f5960238aa99">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4431cd1978604f468b85792244a703c3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMi00LTEtMS0w_e04fe89d-227c-43eb-979c-443c66fa837b"
      unitRef="usd">9700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if33dd48f244f4225b552ee2004b13a84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMi02LTEtMS0w_f77b52b8-4a2e-40e3-856f-5d69e7ca6bb0"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i02b29717f14d4bcdb08b0e8f526654cf_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMy00LTEtMS0w_7a35f100-f730-481f-8d68-898ba6386582"
      unitRef="usd">7400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4db5325f2f3e41fdbbd2d84f4bae2316_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMy02LTEtMS0w_bfa93afa-ade8-471a-a104-e57a0c2a36bb"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7d7d7619dfe248fb92239ddd3b9eb83a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNC00LTEtMS0w_3b4a4adc-9972-4980-bb72-89099369b5f2"
      unitRef="usd">55200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iffdc90f0b7184b6f826b98475df4665c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNC02LTEtMS0w_41f8d4a7-4133-463f-9a4c-bcce61efdd89"
      unitRef="usd">157100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7819501654a14b97b346551b244f99e9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNS00LTEtMS0w_d9494e95-07c4-44e2-aa58-ff94c8d78d02"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1250cef8ffc24c32aa61879bf6b514d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfNS02LTEtMS0w_9325a909-40d6-4c0f-a5ed-c497135be709"
      unitRef="usd">35700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i54aba4f031f44f21b6560820384f079e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOC00LTEtMS0w_9813a1a6-4e2f-4d7b-84c3-54c9483f8f3b"
      unitRef="usd">400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8f4743c680e7440da17e364ec93d7b53_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOC02LTEtMS0w_4ef955e8-739d-4f15-b90a-049510210153"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3b1bf393f58e4ed0abf1efa1dd592205_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOS00LTEtMS0w_55c021c9-2921-4aad-af2e-284393ea8a65"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i433d1dcae59d4e858da20f98b3db0590_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfOS02LTEtMS0w_9b971414-dd22-4f0f-a794-212e8df3c8e0"
      unitRef="usd">19700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i29b29bd51ce34a84a747af8d0b76aa9f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTYtNC0xLTEtMA_56c8d0e3-172d-4438-a3cd-db66c3a4f64d"
      unitRef="usd">3300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8b7354b1363641bda1fe4879d47cd10c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTYtNi0xLTEtMA_b49823fa-d34b-4a75-940b-d3de3d33eefb"
      unitRef="usd">20500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="idf0486182bcb4de1b50c1c4e665beb58_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTctNC0xLTEtMA_fa695ba2-9e49-49c8-90ff-32398e5acdd0"
      unitRef="usd">17200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i19b7ae3032894fbdbbde3fe9f817db9a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl83OS9mcmFnOjYxOTUzZmZlNDA4MjQ4OGNhNjBhYzVmOWFlYThmMjRjL3RhYmxlOjQxNWUxZjhmZGM5NzQ2NTNhYzdiZTdlODIxNjYzN2I1L3RhYmxlcmFuZ2U6NDE1ZTFmOGZkYzk3NDY1M2FjN2JlN2U4MjE2NjM3YjVfMTctNi0xLTEtMA_ebc8ba01-69e9-4b7b-b6c0-ea90336f0a2b"
      unitRef="usd">4700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfOTY2_0a82e8dc-2b3c-424a-8625-d2c759a1c5b7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,880.3 million and $1,782.3 million as of June 30, 2021 and December 31, 2020, respectively. For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, depreciation expense totaled $54.7 million and $103.5 million, respectively, compared to $51.3 million and $99.7 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support &lt;/span&gt;&lt;/div&gt;space and 51,000 square feet of administrative space. As of June 30, 2021 and December 31, 2020, we had approximately $618.4 million and $1.8 billion, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.3&#160;billion of fixed assets being placed in service during the second quarter of 2021.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTcx_ab28f2c5-768b-44b5-9d68-40b60b284a86"
      unitRef="usd">1880300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTc4_e114eab4-c37c-45bd-a0c8-f0b16adda7c2"
      unitRef="usd">1782300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMjY5_2b09cf13-5e68-4596-954d-6c82569a28a8"
      unitRef="usd">54700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTA5OTUxMTYyODc2Mg_887408fd-707b-4321-b7c0-652cc4b9b3e0"
      unitRef="usd">103500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMjg0_00df8e1b-0b5d-47d5-aafd-f2e83be55df5"
      unitRef="usd">51300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfMTA5OTUxMTYyODgwOA_55041a87-d32d-428d-9902-3c508773f263"
      unitRef="usd">99700000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="ic7f7ccbfa9ed411e963f8ab905c572e1_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNjU3_e25c2a13-8b79-4a91-a94d-513e4d1dcfa3"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i2998a0b67c1c4fdcad0435d7a30e8285_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNzMx_b2976477-c014-4b96-8c8a-651e0d46c9d1"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i81df80dd2e3a491087572c5e78a6d533_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNzky_245a4246-da10-4d52-8321-73323d1418de"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="ib044e39931fe4842989f0f875a50f3ba_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfODcw_2a180b1f-ee1c-4688-8b3b-7c4a13f151f5"
      unitRef="usd">618400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="icb7fbc25be7d405ab815f3b0802c4430_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfODc3_0dd33e08-cec8-4b19-971f-a89beb785b79"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib044e39931fe4842989f0f875a50f3ba_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84NS9mcmFnOjI0OWJjZGIzMzc1YjRjOTQ4Nzc2ODM1OTk0YmYyMTk5L3RleHRyZWdpb246MjQ5YmNkYjMzNzViNGM5NDg3NzY4MzU5OTRiZjIxOTlfNDk0NzgwMjMyNjQyMw_4ae1788e-247a-4356-93be-b82a3cc003e2"
      unitRef="usd">1300000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzU4Ng_7248a11b-a664-4ccb-9b4b-3ab03ea76c76">&lt;span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the six months ended June 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt"&gt;$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt"&gt;$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2.90% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with our 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Derivative Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <biib:LongTermDebtExchangedAmount
      contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjYx_b6e7838d-f711-49d0-8463-4ab9c83879d6"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="ie394eb8420ae465f88327d5264884868_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzU0_70684350-5219-4f8b-a59c-aa18f7566dca"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="ifead4a76cf1c4aedb1f743dff60ab9c5_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfNDI3_a4b6dfb1-6bee-4d70-a9e1-fb9278b1ee89"
      unitRef="usd">151800000</us-gaap:RepaymentsOfSeniorDebt>
    <biib:DebtInstrumentRedemptionAmount
      contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfNzM4_97eea493-4860-494a-be53-e377394a7ab5"
      unitRef="usd">8900000</biib:DebtInstrumentRedemptionAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i5834f88fa78846e1bd30b08fd9f33272_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfODEx_c3a87730-f226-4ce7-b090-b059d13f00ab"
      unitRef="usd">12100000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfOTYx_4623b0d8-e1b1-481a-89d5-52260c6e294e"
      unitRef="usd">3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTQzNw_a70854cf-450c-4dbc-b06d-db2dc5438d61"
      unitRef="usd">13800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpense
      contextRef="i967943fdf1d4433fb1c89d58a5c5d7ec_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTYwMg_9a62c9b0-1572-4270-b03a-afdd1532cfcd"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i327c113b77e945e794ed2983beca310e_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTkwMA_6e903791-55c1-4081-a2ba-5194b60477f1"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5605847573354f9fbd73ba2055256fbc_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTk1NA_c2432f28-1db2-43b0-a30e-f73ae59dfe36"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5605847573354f9fbd73ba2055256fbc_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMTk4Nw_dd563cd0-cf13-4f02-b078-f8bab9f128a2"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i5605847573354f9fbd73ba2055256fbc_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjAyMQ_4d3273cb-30d5-46c4-ba81-d12f9db9aed3"
      unitRef="number">0.99973</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id4d713ade1b14480a777502c5e1bf27b_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjAzNg_fd6cff4f-1aee-4668-9e71-0790bd44f882"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id4d713ade1b14480a777502c5e1bf27b_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjA2OQ_53a0c5a9-794a-477e-879f-714876a35327"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="id4d713ade1b14480a777502c5e1bf27b_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjEwMw_4d55a36f-5c94-43af-9fd0-171c5c331ef9"
      unitRef="number">0.99174</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjE0MA_e44bfef4-7508-477e-80e4-63f8c0f206fd"
      unitRef="usd">24400000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjUzNw_f3bea007-328a-4aee-bea6-e156a70af446"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjU3MA_653f5732-db56-482e-a2aa-599cf035acaf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjYxMw_767bdb87-4696-430f-a424-161d6836a997"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjYyOA_2c4e060a-6ad9-4bbb-83d8-d1be83fe8091"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjcwMg_653f5732-db56-482e-a2aa-599cf035acaf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28e27eba29354cb480fbbc98ca1d08a4_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjkxMQ_5d192e58-f52d-4ad2-bb0d-3ea55b2f43ca"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain
      contextRef="id78d6dabfa0b4866b6108e9a2c352b12_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMjk5MA_c6ada8ec-b4d1-4536-8917-cf90a1de1bdf"
      unitRef="usd">9400000</biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain>
    <biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts
      contextRef="i49528d2d9baf4068bd97b947293b14ac_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzIzMw_7f847b7e-ff1b-4159-8146-f6127075c6cc"
      unitRef="usd">12700000</biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if078c4e7fa004892b58a2d85cb5816aa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl84OC9mcmFnOmU4ZWQyOTk1MDNmYjQyMGNiOWY3NDczZGUxZTViNDMyL3RleHRyZWdpb246ZThlZDI5OTUwM2ZiNDIwY2I5Zjc0NzNkZTFlNWI0MzJfMzM3Mg_a9f7bbc7-567d-47ad-abad-862808116702"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTcxMQ_7ee3e492-32df-4fd0-a2d5-7cf2faca3f99">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million and 3.8 million shares of our common stock at a cost of approximately $450.0 million and $1.1 billion during the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, respectively. Approximately $3.6 billion remained available under our 2020 Share Repurchase Program as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 9.0 million and 12.2&#160;million shares of our common stock at a cost of approximately $2.8 billion and $3.7&#160;billion during the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the six months ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(181.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ib4010afcb4574fb5a96678335abc87c3_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTEx_da0fdc64-1a21-422a-a966-5b9e02fc9d37"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7f180f950ceb4167854fd3cd90ea9c70_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMzk2_6b9c7fce-e531-4cc8-b867-7c5dd4dabdd7"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0c0aa046537b415fa3f8df9b5a030319_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNDk0NzgwMjMyNjg0OQ_c2efebcf-48ee-42db-b570-e59aff3af6f5"
      unitRef="shares">3800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7f180f950ceb4167854fd3cd90ea9c70_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNDUz_5811509f-b560-43a2-9b7b-dbf667d8318f"
      unitRef="usd">450000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0c0aa046537b415fa3f8df9b5a030319_D20210101-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNDk0NzgwMjMyNjg3Nw_3d80a294-a8c2-4d7f-8736-1ff380345dc3"
      unitRef="usd">1100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie53079fa10c74963b5f0f9ba19d3c804_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNTAx_d616f0dc-0df3-4d02-98e8-59cb2fddf0ad"
      unitRef="usd">3600000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i43e9a82c06fb46bab58a5f1115cdafbd_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfNjQz_aca9535f-6d55-4e1f-83db-936e97de196b"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTA5OTUxMTYyOTU4Ng_2d74724b-d651-44ee-b3e0-c3935354b36d"
      unitRef="shares">9000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0cd5030b156d448aa845809d96101ccf_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfOTA5_d52047bf-9853-470b-88e2-05d507ee7f28"
      unitRef="shares">12200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i609ebabe90ae49db92c44eb73460af46_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTA5OTUxMTYyOTU5Nw_f3df4eae-5bbd-459e-a959-27680a77c52b"
      unitRef="usd">2800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0cd5030b156d448aa845809d96101ccf_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfOTY2_a77f8fc9-302a-423e-9adf-e65a100d001d"
      unitRef="usd">3700000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5e3c7e0b91104fac8e090638fd4b76a4_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTA3OA_e8d6b1b1-ae19-4b0e-969e-fa61a64509f3"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i377f7b2b4b52412c99af798994cc4777_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTM0MQ_6bf46a19-42f8-4383-a61a-3ead0240ea28"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i377f7b2b4b52412c99af798994cc4777_D20200401-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTM5OA_8833089d-51d2-4336-9bea-93a20831b3f6"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTcyMA_ed7c0652-2798-46a4-a0e7-32bf94165cf0">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(181.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icb5853a7e3ef491bae7a65e1700e49f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS0yLTEtMS0w_62a1dcc2-948e-4ad4-b503-f26a4ec5d882"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia36720c0b63744ff81262ab66ab00c7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS00LTEtMS0w_2b7c259c-3d52-45ed-865d-73d25d120248"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ca5708d24544f20a4280b1a87d305ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS02LTEtMS0w_7ec58c08-25da-413f-81c6-9f710bb8b2db"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f97bf2a176745928cd1dcd5ea7396f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS04LTEtMS0w_2e891472-bc43-4a4a-975f-3938cd4a9b27"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib92db432fc134e3e94c64ac21f29c319_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS0xMC0xLTEtMA_d95f9dec-acd1-4d74-9fcd-8f41755ffd83"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMS0xMi0xLTEtMA_6dd23ba1-81c8-4f67-aae4-a7cc356330b5"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi0yLTEtMS0w_0b310390-14af-4b51-803f-72a38471c77c"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi00LTEtMS0w_42e98561-f65e-4691-9428-0599689369d6"
      unitRef="usd">90200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi02LTEtMS0w_045633e7-66ec-4efe-9a87-cdf8ce6622ea"
      unitRef="usd">20200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi04LTEtMS0w_8f4f9da2-9ab4-4872-81cc-bb74233499e7"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi0xMC0xLTEtMA_b11405b7-3a8e-4e7d-9cb8-705a6835a514"
      unitRef="usd">-32600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMi0xMi0xLTEtMA_ee9772c5-f406-4681-9692-e677d153cb65"
      unitRef="usd">78200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy0yLTEtMS0w_c2fdfafb-2e37-4f4b-be2a-6eedd63a4f69"
      unitRef="usd">700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy00LTEtMS0w_8caa0cbd-37d6-46bf-82f5-783a759209bb"
      unitRef="usd">48400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy02LTEtMS0w_f96825cf-6fb3-4d37-859b-445c08aa91eb"
      unitRef="usd">-100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy04LTEtMS0w_fff4725c-58f7-480b-81b1-329b0c1489d4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy0xMC0xLTEtMA_5ce48f4d-af6d-4208-ad61-18df3d514c7c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfMy0xMi0xLTEtMA_3eae466d-d266-4078-afbd-554547af5583"
      unitRef="usd">49000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie1827848ffcf4801bf78c2ae7d243b8f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC0yLTEtMS0w_c9bf8e94-8d64-448b-ba0d-365a11e3edba"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i346d2dd0cb2d4741b9b43df81901fb3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC00LTEtMS0w_0d149dc8-c535-47b9-b95d-5795bb8b2dbb"
      unitRef="usd">138600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5761be54393c4bd0829adf3efcde2b70_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC02LTEtMS0w_fa5d63ba-22fb-4b4f-997c-478a1ac82b23"
      unitRef="usd">20100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i833708d8e2ca46a68ec94827e2bc8a99_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC04LTEtMS0w_a0a96223-72d3-4f78-9ac2-5044023174d1"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie19709c6f77d418dbdd3c60e264e2fd1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC0xMC0xLTEtMA_853aef1b-e25e-4c6e-b3be-dacac8daabd4"
      unitRef="usd">-32600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNC0xMi0xLTEtMA_6ecb06f8-08ab-4be7-bfe1-2d6a89a32fb6"
      unitRef="usd">127200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia60fdc6283c6461ab18da2fc1f5f4f7c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS0yLTEtMS0w_76e6e611-f4f7-4c04-816a-f5e5e1310088"
      unitRef="usd">100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0beb22829148494f946ca0c797b83a17_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS00LTEtMS0w_8e9ee56b-fc2e-469f-a611-9eff43f713f6"
      unitRef="usd">-40400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i87c400ae85bb449a972a93be398be207_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS02LTEtMS0w_87099c9d-83ad-45a2-98fe-99952d65e579"
      unitRef="usd">11600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if22b6d24018d47dc812ff8762a4fa3cd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS04LTEtMS0w_d6fc0822-2292-4722-adb2-774d9937ba9e"
      unitRef="usd">-63900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i61b30ac7e13f4d9c97c0e658be456894_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS0xMC0xLTEtMA_8598951e-bd99-4156-9877-d8b5101ecc97"
      unitRef="usd">-79200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmU2NjNlY2ZiYzQ3NzQ5ZTliYjYwZDQ4MGNjNTQ4OGVkL3RhYmxlcmFuZ2U6ZTY2M2VjZmJjNDc3NDllOWJiNjBkNDgwY2M1NDg4ZWRfNS0xMi0xLTEtMA_80cbdf4b-18aa-4aba-8cbb-5fc8867fc7b7"
      unitRef="usd">-171800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i22e22cb23d684bd2bfc1ab92393bf68e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS0yLTEtMS0w_e5d5581e-8d04-418f-9a84-73e7facd99de"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i350abaf377694487bce4d1569f7c6563_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS00LTEtMS0w_08ad05c0-fed5-4cee-82b3-d931b90331f5"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic2b9bf78269b4fb284993468c59edd91_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS02LTEtMS0w_e7e159c6-6ecf-426b-af88-2f5669a0b2be"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i45a327327cab48738dd4d95d812889ed_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS04LTEtMS0w_56c6f250-0857-404d-9834-bcee4036a434"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7b6ecb6a9ead4700bd2dc91367ec36e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS0xMC0xLTEtMA_803f95f5-a29e-40bc-8a4f-53f86ed57d4f"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i025174d34d0e4fed9880bf522bf39caf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMS0xMi0xLTEtMA_05a55db0-fb7b-4f6f-a7f6-a07a37892923"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi0yLTEtMS0w_6ac6dbc4-e19d-41d9-852a-11dcc28facc2"
      unitRef="usd">-9000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi00LTEtMS0w_8ce04ce3-b91c-4b05-a0ce-5846354c4cc5"
      unitRef="usd">33200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi02LTEtMS0w_1895caf8-ddb1-45b6-af88-8f78e6f490ae"
      unitRef="usd">18600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi04LTEtMS0w_a60adbe8-ebbc-49d5-a13f-429685002d2b"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi0xMC0xLTEtMA_296c2c75-30bb-4d3b-b560-2c64ad7695a2"
      unitRef="usd">-47000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMi0xMi0xLTEtMA_0c39cbf3-f996-425c-9e25-3d1c554f516d"
      unitRef="usd">-3300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy0yLTEtMS0w_43914352-a1b0-4622-ab83-0e1b46632997"
      unitRef="usd">9900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy00LTEtMS0w_becfe10a-3f18-4438-987c-557555613ef5"
      unitRef="usd">-50600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy02LTEtMS0w_1df5029a-6f39-4037-aaea-a92e9042bbea"
      unitRef="usd">-1800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy04LTEtMS0w_3c7bfc2d-914f-439a-bea9-68e418d6e21e"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy0xMC0xLTEtMA_be28eeeb-8ebc-4435-9057-82e52945cd97"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfMy0xMi0xLTEtMA_8848e332-2399-4fc8-bcf5-a57eedbd099a"
      unitRef="usd">-42500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i21f7d6d4b4954834824637645cc8e87c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC0yLTEtMS0w_4f7f2a88-5bbe-4fa4-8922-ea51318bc8a2"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a60b84a86994d27883d0703571b5a22_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC00LTEtMS0w_d42881da-4777-43d0-8c0a-18262be86c39"
      unitRef="usd">-17400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3547d3a5847647a88a0f87b6b8719d62_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC02LTEtMS0w_9db50bc1-2f1f-423c-9918-34340b421fea"
      unitRef="usd">16800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i25f178dae51343f3bc0de1c1fe515aea_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC04LTEtMS0w_f5d14c0b-9da9-41f6-92c2-59b840aae94b"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib6acf8b1df344363a27d5c7b7419e144_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC0xMC0xLTEtMA_07abda15-ab7d-46ce-acc3-9321ae27f3a2"
      unitRef="usd">-47000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNC0xMi0xLTEtMA_85a6840d-1498-428e-8a87-2793d1670186"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e8cc4cd6af248d9bfe66ed30639196d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS0yLTEtMS0w_2c807f52-8deb-4edd-b1a3-9fe31fa0e199"
      unitRef="usd">5100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a59246306f44bb4b8c54ec6ff864503_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS00LTEtMS0w_e20c5398-3a03-4bee-b6ef-9fbc99e341d8"
      unitRef="usd">-9600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i04f6ec19f64e41568b2068e96298f003_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS02LTEtMS0w_dcc585b4-9fac-41da-8814-89aa9afe6f2b"
      unitRef="usd">41900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id99da815ae3f44649e4b32bb305c0670_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS04LTEtMS0w_74f44ffb-1018-4f01-9dd1-5f1d90a773fd"
      unitRef="usd">-31900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia94afab659f248cba857933e77ec8718_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS0xMC0xLTEtMA_b7f5474d-90e5-4171-8405-aa4d900893e0"
      unitRef="usd">-186500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a1c8cc7d1984bd2986f1829be158a77_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOjFmOWQwMTE1ZWJlZTRiOThhMzUyNjU1YTgwOTE3NDFjL3RhYmxlcmFuZ2U6MWY5ZDAxMTVlYmVlNGI5OGEzNTI2NTVhODA5MTc0MWNfNS0xMi0xLTEtMA_c83811d7-0bee-4a91-b6cd-d19d24df1a5e"
      unitRef="usd">-181000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RleHRyZWdpb246ODlmMWMyNWFiMjY2NGY5Y2I0ODAzODU0MDYxNTk4MTFfMTczOA_88180ccd-426b-442d-8534-31ef9f8404ce">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3f12d27ddfb1404aaf145062a7713f57_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy0zLTEtMS0w_e573ef5b-5431-4b5f-8627-7e454e4c8bb5"
      unitRef="usd">-400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i92055b26fdd84bf0b0f9ed93e463988b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy01LTEtMS0w_a7ef58cb-e2e6-47e7-8172-8806c1cf6461"
      unitRef="usd">3900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifbd9eee9380f42788da909d05cfb8fd7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy03LTEtMS0w_8b3884c9-a854-4f93-b990-e6a4e7bf9cba"
      unitRef="usd">-900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic4a22cdb164d4ec1b3e8b6f30d33a058_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMy05LTEtMS0w_1adb9a17-88a7-4b88-b8b3-4a17decf18a1"
      unitRef="usd">-12500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3f12d27ddfb1404aaf145062a7713f57_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC0zLTEtMS0w_2a0bc6a4-bafb-4af6-92b8-1af5e14f6aa5"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i92055b26fdd84bf0b0f9ed93e463988b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC01LTEtMS0w_de28eb09-2f6f-4876-802d-2fb206ade7c7"
      unitRef="usd">-800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifbd9eee9380f42788da909d05cfb8fd7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC03LTEtMS0w_95c688c0-e1d4-4b3a-bf4f-f24ff0c42038"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic4a22cdb164d4ec1b3e8b6f30d33a058_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNC05LTEtMS0w_0646ff1f-222f-4d11-a079-6f94b30cf159"
      unitRef="usd">2600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi0zLTEtMS0w_c7ad4242-f524-404b-bf5d-196002af012d"
      unitRef="usd">30700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi01LTEtMS0w_89e21a64-06d8-4ae4-a022-c4c97373e758"
      unitRef="usd">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi03LTEtMS0w_7b5323af-7fb8-49a6-829a-ea36691476e7"
      unitRef="usd">53800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNi05LTEtMS0w_83cb5a5f-06dd-4952-8bd1-0efec11b7152"
      unitRef="usd">50700000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy0zLTEtMS0w_6e301a03-4638-483a-97d3-6e0f8e7d3b1d"
      unitRef="usd">-400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy01LTEtMS0w_46f97a38-19d0-4af5-9538-4416c5b6a817"
      unitRef="usd">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy03LTEtMS0w_93d08f9a-c3ea-4045-bada-876b5723685b"
      unitRef="usd">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfNy05LTEtMS0w_1bb94b4a-142b-4ca6-bbd2-f43a02c4773a"
      unitRef="usd">100000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC0zLTEtMS0w_4d8d205a-91ef-4a42-9611-62d14479bff6"
      unitRef="usd">-100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC01LTEtMS0w_eea23f4c-4ec9-4704-9804-eb8bde6a4339"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC03LTEtMS0w_aa2e8e44-c04b-4046-b50e-4bbbb9c1a26f"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOC05LTEtMS0w_dbe7a66a-16fe-4b16-ab82-11909a7632e7"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0a29ccea04ab4bf5a37c18d80d1fd3e0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS0zLTEtMS0w_717ee749-d339-4fdc-832e-3873d1263f61"
      unitRef="usd">3000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i03540ca987654784a87d1134bdaec1b7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS01LTEtMS0w_36620a3e-916d-43b7-a45a-e0a4cc244a4c"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id3be584f5a6349cbbb558e6c3ed98868_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS03LTEtMS0w_acdd5248-893b-48b4-be3b-2a02e60f7387"
      unitRef="usd">5300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f51c78567604483a89db091767965c6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfOS05LTEtMS0w_5a461f4c-eb64-4390-b357-1c8a389ec22e"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2867d1e4c35544c591c011e82114911d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtMy0xLTEtMA_b1503308-816b-4478-8b83-e5c22157b1fe"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i550626667d504f049e3f27be6c6e87d1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtNS0xLTEtMA_1bde3c37-d8b4-47ce-8c3a-06d61375789a"
      unitRef="usd">900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifc844f221fc242d7ac07b31786e87e81_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtNy0xLTEtMA_40dea29f-993b-434f-a040-26556250ee9a"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icec6ff2fc5d644a894df350de003ed08_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTEtOS0xLTEtMA_cd2bcfd8-22c8-43b6-868f-24408a0376c0"
      unitRef="usd">1800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ie0d7f325ae73459e825690036a3d6239_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtMy0xLTEtMA_fff7ae1a-bf83-4fea-ae2d-d5b33d697f13"
      unitRef="usd">-27600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ida11029c7cd140e7b425e00d05e00a01_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtNS0xLTEtMA_2c147cc0-d27e-4376-9441-17fb16d457fa"
      unitRef="usd">27700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id85699448040462d8f5baad3e1537a64_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtNy0xLTEtMA_e56c3ee6-fa6b-4e53-8f55-ac4ddfac2aa2"
      unitRef="usd">-49000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i85035a7642e240e7bf1eb74af9286dba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl85Ny9mcmFnOjg5ZjFjMjVhYjI2NjRmOWNiNDgwMzg1NDA2MTU5ODExL3RhYmxlOmFjM2QwNjU3ZDJhOTRhNGJhNjIwYjcxODgyMjIyYTY1L3RhYmxlcmFuZ2U6YWMzZDA2NTdkMmE5NGE0YmE2MjBiNzE4ODIyMjJhNjVfMTQtOS0xLTEtMA_121ce256-47db-44d0-873c-678439c99fb0"
      unitRef="usd">42500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90ZXh0cmVnaW9uOmUyYmM4MDVkMTgzYTQ3Mjk4MWFjYzQ1OGIyNzgzODc3XzIxMg_f51b54ee-bcbf-4749-9c3b-0fcfe25bf16c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,941.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90ZXh0cmVnaW9uOmUyYmM4MDVkMTgzYTQ3Mjk4MWFjYzQ1OGIyNzgzODc3XzIyNQ_ab099c86-a9c9-4880-ba85-e050059a7d0e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,941.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtMi0xLTEtMA_232b2dec-5eac-418e-a975-d86f811acc67"
      unitRef="usd">448500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtNC0xLTEtMA_5da21e50-2f68-4347-a7de-168585439c27"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtNi0xLTEtMA_411c5714-04d4-4582-b1f9-7ac52c2b65df"
      unitRef="usd">858700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzMtOC0xLTEtMA_8a5fdb7e-78ea-4753-a029-675acc765d3a"
      unitRef="usd">2941200000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtMi0xLTEtMA_c662533d-f319-4e52-bac1-bc0463bce3d8"
      unitRef="shares">149700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtNC0xLTEtMA_466c2f5b-839d-482b-a165-f9896d7bd740"
      unitRef="shares">160600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtNi0xLTEtMA_432e4fad-6eb2-4682-a018-3ec5dcdec1c4"
      unitRef="shares">150800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzUtOC0xLTEtMA_8f174852-9928-486d-b1c8-d449f97eab29"
      unitRef="shares">166700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0c79aa09732f4485b81ca20d090dc9d2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtMi0xLTEtMA_aff9079f-d3d4-447c-bf8e-cbb801826827"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic607ef111a0b40c98d2bb3abadd70ac3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtNC0xLTEtMA_5b8493c5-b9bc-4ff5-b400-cb99c0490163"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if2282dfbca39426985c7b4c02362b0f6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtNi0xLTEtMA_d7027017-3dd7-4c11-8bda-c3b0783cb3e0"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4eec312c192244b58a5937395a9f32ca_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzgtOC0xLTEtMA_65a4381f-2b89-47aa-a94e-9a4fe2b8d9ed"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0f60cc29d37f4bb39e05aacb97220a95_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktMi0xLTEtMA_0fed06b5-39d8-4818-a3b3-b1430314f45f"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ida800d3221da45ab8bb24399a9800a50_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktNC0xLTEtMA_7bc69030-56cf-4f2b-b55c-e5580638eff9"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i743269d62e29412c951e960acc6995bf_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktNi0xLTEtMA_c10933c2-df36-4dee-809e-b4c8525240ae"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i79cfcde33ee94b2091ef4e9994affc0a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzktOC0xLTEtMA_7cd9ee15-b32f-437a-888c-4724c3721760"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia69456628ebe4d798414fbd24865b055_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTItMS0xLTA_e7f025a8-31e1-4d65-b238-4dd62f16bef7"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4ca6ce9dd1204c9d8ee47ed61c9d49e3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTQtMS0xLTA_e6ef4165-b06d-4d49-9a1a-26ec5f3fa884"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i24286416527948f3a36f9903ba223e92_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTYtMS0xLTA_3afdd17d-986f-4616-88fc-a0c805a299a6"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia5868596776a48bcb3288f10554ae486_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEwLTgtMS0xLTA_0f594a81-9548-46cf-865e-618edde0e4f2"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTItMS0xLTA_cb5e180c-2139-40b4-9e01-34386dbe6529"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTQtMS0xLTA_6c803ae3-8ebd-4c26-b954-cd1a313b947b"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTYtMS0xLTA_1e7b8de5-1ebd-4c12-a7d1-89bfef4c4194"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzExLTgtMS0xLTA_4dfb0f47-b0cd-415f-91a7-2567234a5acb"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTItMS0xLTA_c47dfcc3-86f0-4920-af5f-7d50a171963e"
      unitRef="shares">150100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTQtMS0xLTA_0980a725-b0ff-4322-be4d-1dc0e2cfc6d7"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTYtMS0xLTA_9b0b5082-3204-407c-a1b9-a3496464e141"
      unitRef="shares">151200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDAvZnJhZzplMmJjODA1ZDE4M2E0NzI5ODFhY2M0NThiMjc4Mzg3Ny90YWJsZTpjYWUxMmRkZjUwZDM0M2EwOWVmYmU4OWRjYzg5YTE3Ni90YWJsZXJhbmdlOmNhZTEyZGRmNTBkMzQzYTA5ZWZiZTg5ZGNjODlhMTc2XzEyLTgtMS0xLTA_04cccabc-d2e2-4433-a2f5-db0560645a95"
      unitRef="shares">167000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90ZXh0cmVnaW9uOjc3ZThlYTQ2NDI5YjRhZWZiMWJiZmUzMmQ1ZDRlZWRlXzY2OA_bb86fe75-ec29-4a58-9c7a-1a8460334ccd">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90ZXh0cmVnaW9uOjc3ZThlYTQ2NDI5YjRhZWZiMWJiZmUzMmQ1ZDRlZWRlXzY0NQ_4cb47bd7-afc9-43c4-a39b-128511672174">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7711bdabafa4868acf0cef411512b10_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItMi0xLTEtMA_41a83acd-0f42-40a2-bec0-e3ee1576518b"
      unitRef="usd">19100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idea5a899ef244aa7ad5b55e212db3c75_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItNC0xLTEtMA_846a6a81-8125-462e-bbe1-81ee349b3ec1"
      unitRef="usd">15200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic508730c80624e0a9bd030c7f4a89e07_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItNi0xLTEtMA_e6ac521b-32fb-4708-9f7c-61c9dd91466b"
      unitRef="usd">52700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1b1713d5c5845d3ac44180eebc6f115_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzItOC0xLTEtMA_2b6088a6-a6b7-4a18-9de8-5cccf59ee68e"
      unitRef="usd">48500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib33eb872c6b4401cbc20e2f4180db8ea_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtMi0xLTEtMA_075a0ced-e474-4766-b9d7-4dcdf0ff98e0"
      unitRef="usd">40300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic438578392a5405689d4d33d4518f669_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtNC0xLTEtMA_84c9c6cb-6855-475a-b49b-861b88238e05"
      unitRef="usd">30300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id8c7482558954653832964511911a842_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtNi0xLTEtMA_0642b27f-2c41-4a5b-8523-17dacf2a2d53"
      unitRef="usd">85200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibed6e6d0ef254bcab5ae8ea84750ae16_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzMtOC0xLTEtMA_261961b2-fd67-4f21-9b4d-2e7c6d07031c"
      unitRef="usd">73400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtMi0xLTEtMA_ecfc9734-5d3f-4483-8604-eefdce520635"
      unitRef="usd">59400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtNC0xLTEtMA_f16e95f8-e6b9-444b-ae1a-21086f688dfa"
      unitRef="usd">45500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtNi0xLTEtMA_c75adfc7-058d-4c66-bb95-4fd45241da46"
      unitRef="usd">137900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzQtOC0xLTEtMA_b7e2d059-06de-40b5-8f7f-9b058bfeab68"
      unitRef="usd">121900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtMi0xLTEtMA_2a123220-336e-496b-b19a-4a49c10998c6"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtNC0xLTEtMA_13cc80e1-bc0c-4115-bea6-ceadb4f4a7be"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtNi0xLTEtMA_fde59ff6-d3e7-4269-9e8c-dae58c86320d"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzUtOC0xLTEtMA_cc53e6b3-3923-44ee-bf69-1ff8dfc407f5"
      unitRef="usd">3000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtMi0xLTEtMA_f66889ec-16b1-49f2-9866-d58b454b6305"
      unitRef="usd">57700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtNC0xLTEtMA_404b7d48-8f9a-4840-bbed-dc155f4ffd80"
      unitRef="usd">44000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtNi0xLTEtMA_5f4ad368-3868-4df0-9115-1f2d3d6b8cc2"
      unitRef="usd">133600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzYtOC0xLTEtMA_04b559a7-9a63-41ad-9e05-c47725cd13f3"
      unitRef="usd">118900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctMi0xLTEtMA_bec85203-4a3c-4385-8b17-28278cec2411"
      unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctNC0xLTEtMA_b28f204e-9177-49b8-93b2-dd5709788313"
      unitRef="usd">7000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctNi0xLTEtMA_a981ce71-3e03-4924-ba94-136c73b2b158"
      unitRef="usd">24900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzctOC0xLTEtMA_c9856265-13c9-4e68-a772-bb3e255d21bd"
      unitRef="usd">20300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19d163820b4b429c8ac869eca01a9a0b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtMi0xLTEtMA_ccdfa0d1-7a6e-4fda-a857-2befbea599e1"
      unitRef="usd">46800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i812c1ff8e80b47b58ab63fcf9ec1c7fa_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtNC0xLTEtMA_68cef407-066a-4bf4-ab6f-4b7c90d8ba55"
      unitRef="usd">37000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1023665010a54e788e30ff06159d6b65_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtNi0xLTEtMA_f90cc298-0aab-43f5-9134-0bb29b992f29"
      unitRef="usd">108700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2d84900139e040b39413a2c034c9a0a5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTpmMzgxZWJhZDBhMzc0N2FjYTI5YjNjNGZlM2FmZThkOS90YWJsZXJhbmdlOmYzODFlYmFkMGEzNzQ3YWNhMjliM2M0ZmUzYWZlOGQ5XzgtOC0xLTEtMA_67e37f3f-e598-4aa5-a3d4-a9f727760ca2"
      unitRef="usd">98600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90ZXh0cmVnaW9uOjc3ZThlYTQ2NDI5YjRhZWZiMWJiZmUzMmQ1ZDRlZWRlXzY0Mw_da875487-156b-4a54-bb72-433df35dbdce">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81326f8c0faf4c82934916df0e7ba73b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItMi0xLTEtMA_bf6b5d3e-853d-4a29-9f3f-1a2e4b018a2f"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48408b16cb17457fa4d16374fac38f5f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItNC0xLTEtMA_d15f30c8-6e34-4fdf-a829-3f8268ce7b2d"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8af3d4e0eb01491fbe2b12666856a203_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItNi0xLTEtMA_513dfb0b-ec5a-4a4f-9da2-b945de375f8e"
      unitRef="usd">25800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55281e38b4084b1a87f417de6e85d628_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzItOC0xLTEtMA_839ae98c-24ab-4e75-919b-90123d6f0707"
      unitRef="usd">26500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice3a443da8f344bfbcc4b77135174e59_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtMi0xLTEtMA_ff49543b-a859-49a6-8e62-1828c5e74639"
      unitRef="usd">40400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3bf599004a64372aa741876daef053b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtNC0xLTEtMA_abfe68dd-0f82-487d-ac21-95283d722a6d"
      unitRef="usd">34500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67cf1f40f75d4c3eb9de865f64ecbbe5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtNi0xLTEtMA_e896bd3d-dedd-4d9f-b672-e2196212411d"
      unitRef="usd">83200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i627f7085dbc94df5a856a6ef66dae68a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzMtOC0xLTEtMA_3ea93cbc-b3ba-45cb-bfb5-cf33eef94638"
      unitRef="usd">72000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i47f184261bc64a1c87dca1dc5e5dcb5c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtMi0xLTEtMA_b7aef420-e084-460b-ba53-f7766a66222f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i327ede04c0d64a02a183dcb72ead44b0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtNC0xLTEtMA_a3ff526c-401a-4503-82a7-c7b5fe2ee1cc"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i63915734eeed4a7fa8f44b93a5f9dad2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtNi0xLTEtMA_1cf589b8-0b5c-4ac2-a3d2-011d3edb1ab0"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if414343ed3b64a0ebf09d1a0ac51b4ed_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzQtOC0xLTEtMA_aae58f39-f360-47d0-a8e5-09c93c38f6dd"
      unitRef="usd">-1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib4be0f188a48449bb2c0674eb366a190_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtMi0xLTEtMA_72d505d6-bed5-4847-b929-eb2eaf86a3b7"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16260595953d496b8eddf5ebe0653440_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtNC0xLTEtMA_62e0a336-3a0f-42bf-94a0-b9772c698e80"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a4ab76f4f554cc692c968485d75b3ad_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtNi0xLTEtMA_18419255-9fcc-432a-afb3-68cef09caabd"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6e972a3b7174d6f895bab11575fb911_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzUtOC0xLTEtMA_43f8cdf5-3498-4106-bcae-34e19c01f4aa"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd08f32f2a474aaf85876113c161d15f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtMi0xLTEtMA_22a2a593-e7e9-45bf-bfe8-1c927d94a9fc"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i034140dcf36b473790fbcfecad31c0f5_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtNC0xLTEtMA_75d3e618-3ece-4f76-989c-320a030b589e"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15391fb757e741998e7ea0be726a8c97_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtNi0xLTEtMA_56d0191d-1a86-405f-a105-74aefdb89f76"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5126740cc446437cac3cd23b16210a6b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzYtOC0xLTEtMA_ab56929d-f218-4955-9746-1fccb3c11273"
      unitRef="usd">12400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5def17fd84945bea951f1f209f4a742_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctMi0xLTEtMA_c0b4272c-0d2f-414c-85f1-84ce97688cb0"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6dc2ebe6040c4f58b354ab2338b8717a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctNC0xLTEtMA_fb6b9a4c-f33a-4fad-b798-497d7356daa0"
      unitRef="usd">-4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i177c8a1d0d754674a0c18fab88e27143_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctNi0xLTEtMA_8fd95e52-681a-4c09-9a89-364080d4f1cb"
      unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b6bd17fd1a848c39c8365d388aeb423_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzctOC0xLTEtMA_1129814d-84de-4c53-83ec-70ab888b7e2c"
      unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8c191952c6e484ba3dd03915045e4df_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtMi0xLTEtMA_f59cabe5-dc23-420e-9c62-ca0a14a8797e"
      unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5386b3cc1f54a49bc7493b4ef834955_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtNC0xLTEtMA_3a0679e8-f0cd-47b2-a2b8-7da4d5335751"
      unitRef="usd">5600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifc7874f6e244472f9ef1586998fa6bd7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtNi0xLTEtMA_33e2913d-401e-4fce-9f7b-594b53ee24c5"
      unitRef="usd">10200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9dddb0afc8b342b58b72feb818dfc513_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzgtOC0xLTEtMA_6fcfd460-0f39-4af8-8ec5-1716a27ab32c"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTItMS0xLTA_6af9ad71-5efa-438c-9319-f11aff011cc3"
      unitRef="usd">59400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTQtMS0xLTA_576b7490-2cbb-4c42-9622-c720f1c6a669"
      unitRef="usd">45500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTYtMS0xLTA_11311df5-7579-4f2d-8c13-eec6bd577e5e"
      unitRef="usd">137900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEwLTgtMS0xLTA_b8011757-b3c7-421b-a2cd-ccec92fe072a"
      unitRef="usd">121900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTItMS0xLTA_f0fbe86f-9e90-4676-9f52-7f4a9667a93f"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTQtMS0xLTA_b7cf527a-952a-4515-ac96-0e5a774aaa51"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTYtMS0xLTA_9fdfddb8-15ef-4e34-b497-e93f1c24d2da"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzExLTgtMS0xLTA_8f359a50-18d0-4eae-acc5-a200fbc81ddd"
      unitRef="usd">3000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTItMS0xLTA_c4011a09-ce90-493e-914a-b2053dc8c067"
      unitRef="usd">57700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTQtMS0xLTA_9ca557cd-8424-48cc-91c0-b9797ae3748f"
      unitRef="usd">44000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTYtMS0xLTA_7ff1681b-dc89-4c13-9fd8-0cfffde7157c"
      unitRef="usd">133600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDMvZnJhZzo3N2U4ZWE0NjQyOWI0YWVmYjFiYmZlMzJkNWQ0ZWVkZS90YWJsZTphNjFkYzcxNGVkODk0NDYyOWQxNDI0Mzc3ZjdmOTZjOC90YWJsZXJhbmdlOmE2MWRjNzE0ZWQ4OTQ0NjI5ZDE0MjQzNzdmN2Y5NmM4XzEyLTgtMS0xLTA_c82d468b-7d2d-46db-810f-bed77584e67e"
      unitRef="usd">118900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzMzMjI_fc070357-fc43-4a4f-b766-4dcfd73dc536">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Litigation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $1.7 billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1.6 billion. We continue to assess the realizability of these deferred tax assets and have recorded an increase in these deferred tax assets by approximately $92.6&#160;million and an increase in these deferred tax liabilities by approximately $88.7&#160;million for the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate were primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. We recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed above, were primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market. Our 2020 effective tax rate reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2021, our 2021 effective tax rate reflects a decrease related to the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in 2021. The tax effects of this change in value of our equity investments were recorded discretely, as the changes in value of equity investments cannot be forecasted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, we increased our gross unrecognized tax benefits by approximately $375.0&#160;million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM, as discussed above. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset discussed above, and not as a separate liability on our condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $20.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <biib:DeferredTaxAssetsValueReductioninValue
      contextRef="i84f242af2dd048a2bc766c9493467dc0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwNDA_873573e6-64f9-408f-9186-d8e0686af7a8"
      unitRef="usd">1700000000</biib:DeferredTaxAssetsValueReductioninValue>
    <biib:DeferredTaxLiabilitiesValueReductioninValue
      contextRef="i84f242af2dd048a2bc766c9493467dc0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzExODU_e55c84f0-9b35-4d1b-8176-e22d7b620b36"
      unitRef="usd">1600000000</biib:DeferredTaxLiabilitiesValueReductioninValue>
    <biib:DeferredTaxAssetIncreaseDecreaseInValue
      contextRef="i5336835708cc4dc48247e0e9ad7969f9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIwODc_30c1a8ad-8f43-4b68-bda2-134fc7ef9b22"
      unitRef="usd">92600000</biib:DeferredTaxAssetIncreaseDecreaseInValue>
    <biib:DeferredTaxAssetIncreaseDecreaseInValue
      contextRef="ia5082dfd8d8a4569a216ee449ace1886_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIwODc_5e491d23-ff5e-49b4-8645-36c45f35dfb0"
      unitRef="usd">92600000</biib:DeferredTaxAssetIncreaseDecreaseInValue>
    <biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue
      contextRef="idf8d368179dc4c9290de72ce73993e6c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIxMDQ_953c13ae-ef99-405d-9e04-81c6fa774d39"
      unitRef="usd">88700000</biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue>
    <biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue
      contextRef="i3cce66e5d593473eb28168ab00d42bbe_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzEwOTk1MTE2MzIxMDQ_e6d24fc6-573a-4c63-a9f6-4d0b8fb23e21"
      unitRef="usd">88700000</biib:DeferredTaxLiabilitiesIncreaseDecreaseInValue>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzMzMTA_63408395-c798-490c-b6f4-705680d883a7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItMS0xLTEtMA_4b3557cf-9c0a-43e2-80b1-3f6b9b98a25f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItMy0xLTEtMA_2c61841d-c5de-4806-9cb3-dd07b114e7d5"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItNS0xLTEtMA_7c12032a-54ca-46a6-98f4-98a4ae47fde4"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzItNy0xLTEtMA_c7c99ee7-e866-4898-a079-a4cd4d2249df"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtMS0xLTEtMA_1d1f166c-4f58-4e2c-83b2-7dc6768f2756"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtMy0xLTEtMA_2a0b06b7-589c-4942-b9ea-a2789852601f"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtNS0xLTEtMA_cb3b7092-0fbf-4b90-af8f-eb3511a6273a"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzMtNy0xLTEtMA_0c898d1b-35ac-4796-a56c-2ff031354e86"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtMS0xLTEtMA_d9e4dc6c-619e-436b-bb87-617aafc8da4c"
      unitRef="number">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtMy0xLTEtMA_6db91ce1-4a87-435a-bfc9-6f36733311b1"
      unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtNS0xLTEtMA_91ddd6c3-f54e-4a53-873d-a7c3410850ec"
      unitRef="number">-0.091</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzQtNy0xLTEtMA_3040603f-5d04-4679-9be0-50a3ab5f8b92"
      unitRef="number">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtMS0xLTEtMA_368f7ab9-4c3d-4a27-9dd5-124a5c73ddec"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtMy0xLTEtMA_38c84f4a-44b7-4b56-b627-091f6ca46801"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtNS0xLTEtMA_290a73f0-7489-41ad-9223-1a6bb02d9005"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzUtNy0xLTEtMA_275d4998-fce0-4ecc-93ca-4188178c325e"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtMS0xLTEtMA_fe8f595b-65da-4a11-bb33-9536f46aa39b"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtMy0xLTEtMA_9f2ce90e-ea5a-47ef-a597-676ab622eb7e"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtNS0xLTEtMA_2c1d07a4-fb36-4df9-8edf-ab66c4e3a624"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzYtNy0xLTEtMA_f55dc9e3-dfc6-4e5a-9bc3-1dadd7c06558"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktMS0xLTEtMA_2d24904f-d6d9-4bb8-a55b-69f47aac3a0c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktMy0xLTEtMA_89a40df8-44ba-47d3-b7f8-61dc638f81a2"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktNS0xLTEtMA_09f86ed2-18d8-4354-b970-fa7e7bed1f15"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzktNy0xLTEtMA_0540b99e-423b-4477-9c82-1ace175b1d4d"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTEtMS0xLTA_3cb258f4-9173-4dd0-9f0f-014885c5aca5"
      unitRef="number">0.015</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTMtMS0xLTA_b212cf11-af5e-43b7-9475-56daf508a45a"
      unitRef="number">0.015</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTUtMS0xLTA_335ecc42-130d-4518-866e-d81497c7c9f5"
      unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEwLTctMS0xLTA_c056bf33-6663-40bd-b78f-b914abc6c8c6"
      unitRef="number">0.011</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTEtMS0xLTY1ODM_b5adf60d-bc72-476a-8611-34e16d4bc87a"
      unitRef="number">-0.831</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTMtMS0xLTY1ODM_c47915b6-d93e-467e-8a1a-93c68e97bc18"
      unitRef="number">-0.002</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTUtMS0xLTY1ODM_8cdc24d2-9d26-4a92-aad8-c5d6de582952"
      unitRef="number">-0.463</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzEzLTctMS0xLTY1ODM_1578d2c4-d888-402f-bc2a-95794a7e251f"
      unitRef="number">-0.002</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTEtMS0xLTA_81bddba4-a941-498c-ad2e-43b3e5156606"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTMtMS0xLTA_b69e0108-d77b-4d9c-bacd-f5dfcdf9196f"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTUtMS0xLTA_7ec0fc84-2117-4d9e-a088-22ce13fa4f33"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE0LTctMS0xLTA_4e83bb00-e40f-4897-8541-a3e344db8a4f"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTEtMS0xLTA_b1301735-2284-4b35-8415-22848ea99a92"
      unitRef="number">-0.703</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTMtMS0xLTA_3551595a-36c8-4395-8a6d-04b6cd3f313b"
      unitRef="number">0.219</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTUtMS0xLTA_4ee18e89-7faa-4f78-9493-899927dc2c15"
      unitRef="number">-0.348</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90YWJsZTo4NzBlMjBlZGI4Mjg0OGQ3YjE4YWVhM2I0MmFmODJiZi90YWJsZXJhbmdlOjg3MGUyMGVkYjgyODQ4ZDdiMThhZWEzYjQyYWY4MmJmXzE1LTctMS0xLTA_9a4b88d1-1f09-49b6-b738-c092683b1ad1"
      unitRef="number">0.198</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTEzMDE_384f0730-4831-459f-ab5d-524aebc3207b"
      unitRef="usd">500000000.0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTI4NDY_e75e9d52-5135-4b41-9649-8a565ab98922"
      unitRef="usd">875000000.0</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTI4Mjc_8e843464-99ef-430a-8351-4a8adc174b8c"
      unitRef="usd">375000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzE2NDkyNjc0NTM4MTE_8e843464-99ef-430a-8351-4a8adc174b8c"
      unitRef="usd">375000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMDYvZnJhZzo3Y2EzNjI3YjlmNWU0MjczYjJlNTZiYTAzNzQwNDJmZS90ZXh0cmVnaW9uOjdjYTM2MjdiOWY1ZTQyNzNiMmU1NmJhMDM3NDA0MmZlXzMxODU_932ddec4-6e8c-49d9-b65c-717352b03f0b"
      unitRef="usd">20000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyMzg_3259320e-4df1-446e-b5d8-2622fe9cb8fc">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(121.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(410.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June 30, 2021, net unrealized gains and realized gains on our holdings in equity securities were approximately $153.9 million and $0.4 million, respectively, compared to net unrealized gains and realized gains (losses) of $102.9 million and zero, respectively, in the prior year comparative period. The net unrealized gains recognized during the three months ended June 30, 2021, primarily reflect an increase in the fair value of Denali common stock of approximately $263.0&#160;million, partially offset by decreases in the fair value of Ionis, Sangamo and Sage common stock of approximately $105.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $288.4 million and $6.6 million, respectively, compared to net unrealized gains and realized gains (losses) of $42.0 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the six months ended June 30, 2021, primarily reflect decreases in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $284.8&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(281.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(288.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,042.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;760.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,741.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,356.4 million and $1,329.6 million as of June 30, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $652.7 million and $709.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyNTU_80008175-7b16-4d1d-8b04-ac2b5f6e0a53">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(121.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(410.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItMi0xLTEtMA_740c607b-dd31-496c-9c1d-0cfec9aae5a8"
      unitRef="usd">2700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItNC0xLTEtMA_2ba2ce89-887a-40ed-b492-deb3225570cb"
      unitRef="usd">7600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItNi0xLTEtMA_b790a42d-3914-4508-8ede-99655b16e46b"
      unitRef="usd">5600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzItOC0xLTEtMA_701d6068-6b84-44c9-b64f-25ba153cc221"
      unitRef="usd">32000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtMi0xLTEtMA_8b6a20af-05cf-4095-8098-319ec9343893"
      unitRef="usd">56400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtNC0xLTEtMA_1fae6d71-9c7c-4c18-aacf-ca4977ebecde"
      unitRef="usd">66000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtNi0xLTEtMA_c207bf11-c218-4411-9cf4-1e2c2e401484"
      unitRef="usd">121100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzMtOC0xLTEtMA_6a8c94de-1254-490a-a3cc-3ee374a7bf04"
      unitRef="usd">110300000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtMi0xLTEtMA_bdf729ec-071d-4407-926f-06d6efd8d694"
      unitRef="usd">153900000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtNC0xLTEtMA_9f2c9eda-e649-44b5-a813-2152fff740f8"
      unitRef="usd">106800000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtNi0xLTEtMA_72530866-0c9e-49dd-8bbd-1574e2b12ba3"
      unitRef="usd">-282700000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzQtOC0xLTEtMA_95484d21-5c44-4bef-9ff2-5f028fd18fa6"
      unitRef="usd">29500000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtMi0xLTEtMA_5a2d48a6-87a8-44d9-b7f7-ee9b7f50880e"
      unitRef="usd">-800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtNC0xLTEtMA_20601c1a-1b6b-4c77-8619-7dd0486afa4b"
      unitRef="usd">10400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtNi0xLTEtMA_ae57b245-4147-41b9-8462-7dc036b83daa"
      unitRef="usd">-9400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzUtOC0xLTEtMA_5b4a591b-e8cf-48ef-9402-c36d103ef71f"
      unitRef="usd">-8500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtMi0xLTEtMA_70ea0dd3-9a26-4a93-8629-76451db4b28f"
      unitRef="usd">-3000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtNC0xLTEtMA_a0284cf0-3e04-45b4-b34b-38f52e5f9742"
      unitRef="usd">4200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtNi0xLTEtMA_20b17287-5406-4aaf-b788-ec623b511802"
      unitRef="usd">-2900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzYtOC0xLTEtMA_8e1d15ee-b6f9-4fab-89df-0d1c38be1293"
      unitRef="usd">-200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctMi0xLTEtMA_e6765f8a-9349-49a1-92e7-1b7c3a07a117"
      unitRef="usd">96400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctNC0xLTEtMA_5d406f21-20b6-42ec-8bf0-4480b3aeb21a"
      unitRef="usd">63000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctNi0xLTEtMA_66212041-7879-447a-b0aa-327b1dcbd81a"
      unitRef="usd">-410500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTo4YTA4NTk0ODAxOTM0MDVlYjY5ZTc2MTZkNTQzZTlhYy90YWJsZXJhbmdlOjhhMDg1OTQ4MDE5MzQwNWViNjllNzYxNmQ1NDNlOWFjXzctOC0xLTEtMA_b4a8bf06-e470-418e-a887-f1ab3d58b161"
      unitRef="usd">-57500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzUzOA_11d2d361-8662-4107-9d0e-d61b0de0d40b"
      unitRef="usd">153900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzU0NQ_ab01a85f-6060-439d-b87f-606316b98c4a"
      unitRef="usd">400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzYxMw_3e8c81b5-38a9-4340-9c54-c2e639003bb3"
      unitRef="usd">102900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzYyMA_d5719445-f329-40f9-9856-44e1b5698ed1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1d9d0511d58d472bb7e1f483ef7f6e88_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2MzAxOTk_6021e2f4-e316-4e76-9534-ed6538757e75"
      unitRef="usd">263000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i1d9d0511d58d472bb7e1f483ef7f6e88_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzg1Ng_01aae5f0-600f-400c-b3ce-deef2c7e1a56"
      unitRef="usd">105800000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2MjkyMzQ_0554b5da-1b17-4b8d-a1f0-03c09bca1816"
      unitRef="usd">-288400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2MjkyNDI_11af56a1-c993-467c-acc5-f4384c360522"
      unitRef="usd">6600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2Mjk0MTU_b8036358-3df5-4d96-a7a3-72070a1f866d"
      unitRef="usd">42000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2Mjk0MjM_f8b368c1-92fb-4fb6-8fe8-7574d85b0b3e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="ic33fdfdf2e5d4d1b9eed0a03f5eb93d0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEwOTk1MTE2Mjk4NTE_b9e516df-e940-4f77-9c10-1b9676c95637"
      unitRef="usd">284800000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyNjE_627a476f-e6c9-441a-a6b5-efacc99af363">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(281.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) realized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(288.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItMi0xLTEtMA_2b8bec93-9bd0-419a-8586-704342120495"
      unitRef="usd">154300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItNC0xLTEtMA_b0a2b6b4-6d60-4e4f-9d17-4e4f89d15704"
      unitRef="usd">102900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItNi0xLTEtMA_0ba3ae75-314f-4a31-80b8-5cc52de84aeb"
      unitRef="usd">-281800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzItOC0xLTEtMA_98d000d4-3b9c-4369-b576-64a532f45dec"
      unitRef="usd">42000000.0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtMi0xLTEtMA_ab01a85f-6060-439d-b87f-606316b98c4a"
      unitRef="usd">400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtNC0xLTEtMA_d5719445-f329-40f9-9856-44e1b5698ed1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtNi0xLTEtMA_11af56a1-c993-467c-acc5-f4384c360522"
      unitRef="usd">6600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzMtOC0xLTEtMA_f8b368c1-92fb-4fb6-8fe8-7574d85b0b3e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7b0791f187a342618d92225b098c9d17_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtMi0xLTEtMA_11d2d361-8662-4107-9d0e-d61b0de0d40b"
      unitRef="usd">153900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i940e2c7ab2704a5aa80a9dd7334a2b5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtNC0xLTEtMA_3e8c81b5-38a9-4340-9c54-c2e639003bb3"
      unitRef="usd">102900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtNi0xLTEtMA_0554b5da-1b17-4b8d-a1f0-03c09bca1816"
      unitRef="usd">-288400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia751a6a24d634f2ab7a1b398529c3c66_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTpjOTA3ZDBiMTM3NDU0MjIzODk0OThiZDRhMDM2Nzc1MC90YWJsZXJhbmdlOmM5MDdkMGIxMzc0NTQyMjM4OTQ5OGJkNGEwMzY3NzUwXzQtOC0xLTEtMA_b8036358-3df5-4d96-a7a3-72070a1f866d"
      unitRef="usd">42000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyNjI_566ad2bf-f1de-4669-bf0c-df1ccaca9791">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,042.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;760.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,741.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idf361b51f5534b34939b0f745631d54d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzEtMi0xLTEtMA_bd8e9028-48d0-46b9-8d20-4f96a62ea3eb"
      unitRef="usd">1042100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3ad6c76d74374942bcbb4934411ede69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzEtNC0xLTEtMA_3da8fefd-7f97-41c8-bf19-81b530fcb003"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzItMi0xLTEtMA_09b24bf6-ba32-4d92-b7c5-c79d8c7a543d"
      unitRef="usd">383400000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzItNC0xLTEtMA_2d7d202a-8686-4be6-828b-bb1de5ec80af"
      unitRef="usd">389900000</biib:Collaborationexpensesaccrual>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtMi0xLTEtMTI5MzA_2a732740-c94b-43ca-a923-58bbe4039e0c"
      unitRef="usd">242500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtNC0xLTEtMTI5MzA_79aa8aad-7447-45d8-a86c-21e9d3060a72"
      unitRef="usd">333800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtMi0xLTEtMA_8c2879e1-3d21-4ebf-b968-440129721b05"
      unitRef="usd">240300000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzMtNC0xLTEtMA_4dc2768a-176c-4a32-b5dd-8b8112382483"
      unitRef="usd">218500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzUtMi0xLTEtMA_2037efb4-ed2e-44fc-9a10-326c07eaa8d3"
      unitRef="usd">72400000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzUtNC0xLTEtMA_a9b584f8-9bc6-46b1-a861-ca5e9b64009d"
      unitRef="usd">181500000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzYtMi0xLTEtMA_c0ae4542-fa9b-4c4a-94f1-0c2b014f6a94"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzYtNC0xLTEtMA_7083f905-16e1-4129-8b61-46b0eacd0a34"
      unitRef="usd">149600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzctMi0xLTEtMA_55bd8ea7-3396-4341-8ff8-7c7f0eee7e97"
      unitRef="usd">760300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzctNC0xLTEtMA_13b091cc-97c3-4ec7-93b4-2843dce2fc09"
      unitRef="usd">791400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzgtMi0xLTEtMA_9e377ced-20a1-4586-8cb7-9af27f248914"
      unitRef="usd">2741000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90YWJsZTowMjUzYzQ3Mjg1YTM0ZDJlOWMzMjk3ODM2YzFjN2VmYS90YWJsZXJhbmdlOjAyNTNjNDcyODVhMzRkMmU5YzMyOTc4MzZjMWM3ZWZhXzgtNC0xLTEtMA_7e9cc0d6-7c9e-4157-8073-cb90e418e257"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzExMzE_26413be5-1d01-45b7-8e2e-b8203daa0155"
      unitRef="usd">1356400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzExMzg_1c45e206-c774-4c27-8f7c-af45b946d416"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyMTU_a6998a9e-5ffd-4294-9ff2-4edbbd44ac15"
      unitRef="usd">652700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTIvZnJhZzo2MTZiNjczNWZlYWQ0ZTg4ODQ1MDIzOWM4OTkyMTkzMS90ZXh0cmVnaW9uOjYxNmI2NzM1ZmVhZDRlODg4NDUwMjM5Yzg5OTIxOTMxXzEyMjI_6872e155-6607-4a87-bbaa-7d8e098889ef"
      unitRef="usd">709900000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzc5_0b92e0f9-be98-40d5-805a-07d87fb3ef9b">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lecanemab Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In addition, the Lecanemab Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our Lecanemab Collaboration, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ADUHELM Collaboration Agreement, we lead the ongoing development of ADUHELM, and we and Eisai will co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of ADUHELM in patients with early Alzheimer's disease. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the ADUHELM Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019 we and Eisai announced that we planned to pursue regulatory approval for ADUHELM in the U.S. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of ADUHELM to the FDA and made a $75.0 million milestone payment to Neurimmune. We recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that is utilized to co-promote ADUHELM. A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;o-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $40.1&#160;million to reflect Eisai's 45.0% sharing of the net collaboration losses in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the ADUHELM Collaboration Agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we record&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ed $77.2&#160;million as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $9.6&#160;million in the prior year comparative periods&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of June 30, 2021, our ownership percentage remained at approximately 49.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, we recognized net income on our investment of $34.3 million and $16.1 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net income on our investment of $15.1 million and $0.4 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income on our investment for the three and six months ended June 30, 2021, reflects a $31.2&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the current period based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled 691.6 billion South Korean won ($612.8 million) and 673.8 billion South Korean won ($620.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. We may pay Samsung Bioepis up to $195.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2021, we recognized net profit-sharing expense of $69.9&#160;million and $138.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $55.4 million and $127.2 million, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $60.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts payable to Samsung Bioepis related to the agreements discussed above were $158.7&#160;million and $99.0&#160;million as of June 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2020 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:NumberOfProductCandidates
      contextRef="ie30cba3e2edd4bc08f2a74408c366d3b_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzMwNg_26c78e26-2a91-4e39-b4d8-9e0881dc3e93"
      unitRef="product">2</biib:NumberOfProductCandidates>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzc4_0f1d6159-6b73-4757-bbad-3c1dad4970c3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i080d328364f74b708ca4d19448cd3c44_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItMi0xLTEtMA_da991665-fbef-49fa-ace2-4ea4e53bc9ba"
      unitRef="usd">62200000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i60376f76b3314e2bbb38c6fa9587253b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItNC0xLTEtMA_4c7525bf-7188-47cb-83ac-4144c1d9ff1c"
      unitRef="usd">33900000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i9b682df909084551b169517453ffa2c0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItNi0xLTEtMA_9a79a2f7-7490-41ce-9507-533f8921f763"
      unitRef="usd">117700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i1f83a2e2c6a4460c9814ca56bd7798e3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzItOC0xLTEtMA_de67982d-684c-4514-a097-811780f37e30"
      unitRef="usd">77500000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i080d328364f74b708ca4d19448cd3c44_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtMi0xLTEtMA_0026d340-1a6f-4fc7-9057-404d7ba9b972"
      unitRef="usd">31100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i60376f76b3314e2bbb38c6fa9587253b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtNC0xLTEtMA_836f31e4-d9f1-45d7-a157-ea69c7d0588a"
      unitRef="usd">17000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i9b682df909084551b169517453ffa2c0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtNi0xLTEtMA_2b73406d-ee2a-43b7-bd12-c56ed92fed05"
      unitRef="usd">58800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i1f83a2e2c6a4460c9814ca56bd7798e3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzMtOC0xLTEtMA_358fa1e2-e467-4a22-ba2a-cffa021b35d3"
      unitRef="usd">38700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i683dd88ba1804d5d81e60a6e361b15e2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtMi0xLTEtMA_523cca8b-f903-496a-8a65-3d896f06bdd5"
      unitRef="usd">4300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i0cf76ad095d44d08b376319fd02096b7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtNC0xLTEtMA_ad2551ef-a438-4055-9ebb-5274b4fb7278"
      unitRef="usd">1400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i69a1d8eb24644ccdb1958fc8538a767b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtNi0xLTEtMA_6bd683f6-f6ad-4b7f-a8b3-1dc8009e27e8"
      unitRef="usd">10000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i7e917d9b36df462b8f02b672a61e80a6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzQtOC0xLTEtMA_3211ce34-6515-4bbb-9b6f-f4295d829cc7"
      unitRef="usd">6300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i683dd88ba1804d5d81e60a6e361b15e2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtMi0xLTEtMA_fbe9d8f9-59dc-45fc-8a4d-446945d4302f"
      unitRef="usd">2100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i0cf76ad095d44d08b376319fd02096b7_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtNC0xLTEtMA_3bbcb44d-e63e-4c0a-b3fb-95f71ec5fd2f"
      unitRef="usd">700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i69a1d8eb24644ccdb1958fc8538a767b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtNi0xLTEtMA_cfbced61-858e-458b-99ff-d4b843f6eae2"
      unitRef="usd">5000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i7e917d9b36df462b8f02b672a61e80a6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo5ZGNmZjlmNjEwN2U0MzQwYjYwYTMxMThiYzI1NDRkZi90YWJsZXJhbmdlOjlkY2ZmOWY2MTA3ZTQzNDBiNjBhMzExOGJjMjU0NGRmXzUtOC0xLTEtMA_620a19bb-e0af-4a60-a4e2-7924e62511da"
      unitRef="usd">3200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzI0MzM_16a475cc-af74-49b5-ac6a-5e5f2b5821cb"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="i940aec5d7103466d9529cc5b08d8e33a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzMxNjg_15cfedd5-03a2-4394-bf5a-d39dfabfb2b9"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzMyODQ_16a475cc-af74-49b5-ac6a-5e5f2b5821cb"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjU2NjY_3686da28-e9b4-4b11-9de5-22b82cc7867e"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzM2Mjg_d21a2290-7741-4415-9c8b-ecee04197ecc"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzM2NTA_16a475cc-af74-49b5-ac6a-5e5f2b5821cb"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzM2NjY_3686da28-e9b4-4b11-9de5-22b82cc7867e"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjU4MzY_205efa98-18e2-41e6-8cd7-5de5b428b99c"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0MDc_624761d7-d792-4015-829c-30982872aa91"
      unitRef="usd">45000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0MDc_c3a4c490-b0e6-4db6-9587-6b73ba15b698"
      unitRef="usd">45000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0Mjk_16a475cc-af74-49b5-ac6a-5e5f2b5821cb"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0MzI_205efa98-18e2-41e6-8cd7-5de5b428b99c"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzcw_9c450b2d-e26e-40d1-8f65-30e14758a4da">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="ic0e9f1b5c6644324895da8c763579ea1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItMi0xLTEtMA_7115a590-3462-40ce-92f3-44b14fb3b526"
      unitRef="usd">42100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i657a17d9e3ef4c86b23042aa118c1b39_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItNC0xLTEtMA_2dd2ff71-9991-4ba5-bfae-0051121d8e18"
      unitRef="usd">35900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ifa87cc62218145ad8330f96b7227e231_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItNi0xLTEtMA_885cb10d-554c-412b-8cf7-5da721fe6d83"
      unitRef="usd">89100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="if2cbebcfd92341b9a4800299106bcc4f_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzItOC0xLTEtMA_bea988a4-8b24-49e1-a54b-c5f16ee745af"
      unitRef="usd">55000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic0e9f1b5c6644324895da8c763579ea1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtMi0xLTEtMA_27b1ecb8-5aa4-4065-9ee8-ee4e2d195453"
      unitRef="usd">23200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i657a17d9e3ef4c86b23042aa118c1b39_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtNC0xLTEtMA_e0d91a21-be5e-4293-a8b9-d1372b71c504"
      unitRef="usd">19700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ifa87cc62218145ad8330f96b7227e231_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtNi0xLTEtMA_962b1406-59a8-4dec-b657-8d868a3f76d5"
      unitRef="usd">49000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="if2cbebcfd92341b9a4800299106bcc4f_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzMtOC0xLTEtMA_ea492987-549c-4ca9-bf43-56a90efad7ff"
      unitRef="usd">30300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i70a1617e837c46c9af07f92da67420a5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtMi0xLTEtMA_242cecd6-2019-4ada-a630-8b7ece06516d"
      unitRef="usd">125600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ibfb715e3d5a940248b7d9789bde6f8cd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtNC0xLTEtMA_32636f24-bde2-4fb4-b1f9-d840a41dfc3c"
      unitRef="usd">45200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i5bd89562ebcc4af9ab88aabef74b9794_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtNi0xLTEtMA_6f263e46-ba9c-480b-9bca-e8418c7429c3"
      unitRef="usd">237400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i14520938d40f4be7b3788532f0a39e36_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzQtOC0xLTEtMA_f442b233-ae2d-477b-93b8-a20cf1623921"
      unitRef="usd">67900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i70a1617e837c46c9af07f92da67420a5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtMi0xLTEtMA_a13a5d4b-ff9e-4cff-9d6e-0c5426dd0cda"
      unitRef="usd">67600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ibfb715e3d5a940248b7d9789bde6f8cd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtNC0xLTEtMA_5c5e7095-9494-4565-85f6-f509351538ac"
      unitRef="usd">25200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5bd89562ebcc4af9ab88aabef74b9794_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtNi0xLTEtMA_456e1fd3-6391-411c-a696-2bc9a8a5d23b"
      unitRef="usd">127900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i14520938d40f4be7b3788532f0a39e36_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzUtOC0xLTEtMA_8b353af5-408b-411a-98bc-4aec4f9f7273"
      unitRef="usd">37500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtMi0xLTEtMA_04d244a0-45c3-45b5-9268-cd369a19f623"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i9789f6e0bd394724b1766f169596f0eb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtNC0xLTEtMA_091438cc-3395-43c3-ab6f-dde22da1432e"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtNi0xLTEtMA_170e9d53-c198-4b69-8c74-b50ffd7d62ac"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i2b30bd6c2b6a47a09c2ee57818fe9437_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzYtOC0xLTEtMA_a7321de2-4f70-4e46-94f4-ffcc90320b38"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctMi0xLTEtMA_a933855b-b701-4739-80ac-6efef46d0a1b"
      unitRef="usd">45000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i9789f6e0bd394724b1766f169596f0eb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctNC0xLTEtMA_45ad167b-e5fd-4071-a6a6-f8e1d3cedce8"
      unitRef="usd">33800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5bc8a65e75ab42718ed2c1209d844519_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctNi0xLTEtMA_7c2daca0-4cc0-41ef-9243-2c24acd0bab8"
      unitRef="usd">45000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2b30bd6c2b6a47a09c2ee57818fe9437_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTplMjRmNmRiOWJkYTc0NmRiOWE5MGViZjE4MGQ4MWVjZS90YWJsZXJhbmdlOmUyNGY2ZGI5YmRhNzQ2ZGI5YTkwZWJmMTgwZDgxZWNlXzctOC0xLTEtMA_52e0fdf2-be92-4a11-8bc6-bdf3e764514a"
      unitRef="usd">33800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTM0NTc_16a475cc-af74-49b5-ac6a-5e5f2b5821cb"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTE4MDk_3f887941-b559-4c45-8d23-e2860a50b108"
      unitRef="usd">40100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTE4MDk_eda2c27c-88f2-4cc3-8760-564dfe4d9e64"
      unitRef="usd">40100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:Expenseincurredbythecollaboration
      contextRef="i68eaa385cc39449cbea95fc77f8b73e5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItMi0xLTEtMA_bba2bca5-22b9-4aaf-9c0c-e8bb9507517c"
      unitRef="usd">16100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ia53f50175e4b428ba3381dc4cbbabff9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItNC0xLTEtMA_842f5205-c92c-4dfe-b5ef-6e82466d04ef"
      unitRef="usd">6500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i33c297982d9641fcb3a085dda0c1bd2f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItNi0xLTEtMA_fc63383e-e531-417a-96fd-1929e4b98291"
      unitRef="usd">33000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="icf3b63d2e34c47ca90c46007d640803a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzItOC0xLTEtMA_ac1e5514-0e5a-4767-adc9-1495d7111c3a"
      unitRef="usd">25500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i68eaa385cc39449cbea95fc77f8b73e5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtMi0xLTEtMA_eb6efe9e-b6b2-48dc-a96e-617b39b52397"
      unitRef="usd">8100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia53f50175e4b428ba3381dc4cbbabff9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtNC0xLTEtMA_90fe3f1d-3233-48ca-9e5e-de8152087782"
      unitRef="usd">3200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i33c297982d9641fcb3a085dda0c1bd2f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtNi0xLTEtMA_d1a03b0d-1f81-4f5e-92f3-04445cd1a7ba"
      unitRef="usd">16500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="icf3b63d2e34c47ca90c46007d640803a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTo1ZDIyY2VmMjc3MDY0ZjQyYWM2MGYxMTRhZTVlNzc2Ny90YWJsZXJhbmdlOjVkMjJjZWYyNzcwNjRmNDJhYzYwZjExNGFlNWU3NzY3XzMtOC0xLTEtMA_ffeefc25-0af6-41a7-a3fa-b6e63dc45437"
      unitRef="usd">12700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzU4OTY_8c2b9253-da1b-4b85-8411-11d2aa239cf6"
      unitRef="usd">650000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzU5Mzg_3d5ff800-f95d-4f1b-b10f-afbeca036ee5"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzU5NjU_65226e62-f273-4edd-9926-f222bd383de1"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzYyMTk_5b9ba581-a66d-46ae-9d4f-6a5a361cd582"
      unitRef="usd">209000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzYzOTk_2aabd2e1-bb36-453a-a5c9-2d1adf53a6d2"
      unitRef="usd">875000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzY1NjE_1a43e8fd-1b25-45da-9fa1-f402d7768d99"
      unitRef="usd">1600000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:Expenseincurredbythecollaboration
      contextRef="ibb9cc66426f84e3e828a71db655b5ca5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItMi0xLTEtMA_b6a14092-060c-48f1-9f4e-6fee5e81742b"
      unitRef="usd">54000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6d35c0b653e746d894c5a5ff25f40d74_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItNC0xLTEtMA_294c1dd3-cade-4cb3-81cf-e66d7d3911f4"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ice2fcfe4886749c19597e9ee5c80f50d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItNi0xLTEtMTA5NTI_e257eb75-6c1f-42f1-ac90-85ac8d577422"
      unitRef="usd">93800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ie9327f22b43043478937934e403bdec8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzItOC0xLTEtMTA5NTU_a8602630-3623-41b3-af86-9d0741e0d554"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ibb9cc66426f84e3e828a71db655b5ca5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtMi0xLTEtMA_af121b8b-5954-49dd-8756-a907ba35f882"
      unitRef="usd">27000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6d35c0b653e746d894c5a5ff25f40d74_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtNC0xLTEtMA_72aa70da-e427-4d8d-94a1-89b1dddbb5f9"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ice2fcfe4886749c19597e9ee5c80f50d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtNi0xLTEtMTA5NTI_825d9594-c6fc-4641-8eef-2a69c3b18517"
      unitRef="usd">46900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ie9327f22b43043478937934e403bdec8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzMtOC0xLTEtMTA5NTU_141d7556-bdc8-4641-aa4a-1464b92113b8"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i70318dd2805c4be293874a85d342f3a0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtMi0xLTEtMA_80e8ece4-4853-42ac-973e-244890439bcf"
      unitRef="usd">10500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="id6801ccc665a4e8db08e33134390d9c6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtNC0xLTEtMA_85a71523-6ee1-427d-8ed8-78ee197c8454"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i8b163de37ced4db78033769ec4cfd792_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtNi0xLTEtMTA5NTI_1a78c843-2662-4dc1-9201-f8987af5c8fe"
      unitRef="usd">15800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i658f7b7a80934324a5fde431814f9cd9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzQtOC0xLTEtMTA5NTU_8f3db5ca-7c72-4c2e-a5ea-1de84ce01e50"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i70318dd2805c4be293874a85d342f3a0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtMi0xLTEtMA_c3480539-5319-404c-b3a8-0f4f0a0bd62e"
      unitRef="usd">5200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id6801ccc665a4e8db08e33134390d9c6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtNC0xLTEtMA_7a31f20e-5cfa-49a3-b469-c9ddf17c3500"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i8b163de37ced4db78033769ec4cfd792_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtNi0xLTEtMTA5NTI_7f7d7b3e-a2f7-4801-a3bc-cfec47c80a04"
      unitRef="usd">7900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i658f7b7a80934324a5fde431814f9cd9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYzVjYjk0YmQ1NTQ0MzBkOTIxODE1MmU0ZDBjNTNhMy90YWJsZXJhbmdlOmNjNWNiOTRiZDU1NDQzMGQ5MjE4MTUyZTRkMGM1M2EzXzUtOC0xLTEtMTA5NTU_febfba2c-bc9c-4b88-918c-42592af4c38e"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzc4NjM_a394f47a-16cb-4812-9f02-2218c2b15256"
      unitRef="usd">465000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i82cf1cd794bc4e22b1558829c36fdbe6_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzc5MTM_bfcff615-27bd-49b2-906f-e08fbdf8116c"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzc5NDA_8609403c-6638-423d-b748-2def391ed8b1"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzgxOTY_21d87393-f3a5-4cd0-ac72-f1458d8015ad"
      unitRef="usd">41300000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzgzNzg_1313362a-fb5d-4d6d-8a25-677bc100212a"
      unitRef="usd">560000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i75d091ff84b4451fa11780e682c2b5cc_D20210101-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzg1NDI_ba11806b-52d1-4afa-85f2-9cd9a4f816c1"
      unitRef="usd">1100000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzQzOTgwNDY1NDkzNjg_47967d48-4079-426c-a8a5-a31642d1a96e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i7c1ff74fe0d44db0b1983d0c557a90b0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItMi0xLTEtMTE3ODI_070e9a3b-ea6a-4f4a-98b3-63459f4ad693"
      unitRef="usd">10400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ibe0eff84f0a64614b8a69a4c069072af_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItNC0xLTEtMTE3ODI_b0f9bf6e-a7da-4aa0-945f-7c90e57d2b0f"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i94c24d776c67459baefa074ef5ce43e8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItNi0xLTEtMTE3ODI_4b28dfe9-10ac-4a1f-a19c-27dae5e59669"
      unitRef="usd">18700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i0531061801234f06bd21a3e0b235a6a9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzItOC0xLTEtMTE3ODI_32a3eb3b-c011-46fe-8992-d4124c6d9524"
      unitRef="usd">0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i7c1ff74fe0d44db0b1983d0c557a90b0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtMi0xLTEtMTE3ODI_b22ad479-9fac-4fd2-a415-8ee6895cf47b"
      unitRef="usd">6200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ibe0eff84f0a64614b8a69a4c069072af_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtNC0xLTEtMTE3ODI_ad526364-c358-4f5d-b58f-1bcc4605d30c"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i94c24d776c67459baefa074ef5ce43e8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtNi0xLTEtMTE3ODI_0199fcf1-7047-4adf-9997-bfa5b9fac812"
      unitRef="usd">11200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i0531061801234f06bd21a3e0b235a6a9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90YWJsZTpjYWRjODMwN2JlMmI0OTk0ODVlNDM5NzkyOTUyNmRlNy90YWJsZXJhbmdlOmNhZGM4MzA3YmUyYjQ5OTQ4NWU0Mzk3OTI5NTI2ZGU3XzMtOC0xLTEtMTE3ODI_a9f8e1f9-84fb-4847-9b51-a33cd21978b7"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Termofcollaborationagreement
      contextRef="i26e88285d5d8470a8b499ee193fb4bbf_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2Nzkw_52ec4fda-49c5-47f0-8b23-dfff8790dc9b">P5Y</biib:Termofcollaborationagreement>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk1MDE_c5dc7682-1418-4700-b054-184d7b932999"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk1NDY_df30e7d7-e158-4a58-b58b-e1f4302ab1eb"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk1NzM_d645e7cf-6c39-45fb-8a62-d28db742fae9"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i512790f7d615460ab79e03a4291d683a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzQ5NDc4MDIzNTA1NzY_f96858b6-6577-490c-92ea-ca4bb332f32d"
      unitRef="shares">12000000</biib:Investmentincommonstocksharespurchased>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzk4MzA_887f5f13-d2fa-4507-b8de-c8ebd46ddce9"
      unitRef="usd">83000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwMDEz_ff49d322-1a25-4d33-b17d-0b9c3a978d00"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwMjAw_57dde346-016d-4e2f-9d9d-cba6d113057e"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwMzYx_ea86783c-9f10-4023-9501-09d90b71e902"
      unitRef="usd">80000000.0</biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwNDAx_1a033fa5-2871-449f-92db-53386e0bac67"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones
      contextRef="i266a572040e74f2e820d9c7521db5009_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwNTI4_7b2ea598-5699-4da0-bc83-49b6510b0444"
      unitRef="usd">380000000.0</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1453070338d24ee3b7ee1fb21644243d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4NzY_89d997e3-2c5a-4757-ad4e-6749dd8c46c8"
      unitRef="usd">77200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i525a88b3fbd24d928dea67537541252d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4NzY_f34fe3a5-250a-43a6-976d-07ce3a6f256d"
      unitRef="usd">77200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i86a1f935392743a6b8a9a61a8026ab24_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4OTU_661118a2-a1d6-414e-a27b-62e2f2540280"
      unitRef="usd">9600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie24ae1e5faa24314a3a0baafdb89a376_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzcxNDY4MjU2MTY4OTU_a7683289-c6cf-4b89-8b8e-636659cb187a"
      unitRef="usd">9600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="ie35fa105818345dcb7a4da4701cf3007_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMjQx_a2aa4096-e592-45d1-ac71-3e96b4d91014"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMjYx_b9ee3de5-9d24-4d84-b297-7d369e6dc9f1"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i20ee31d08aa74924bcbdee76fb8c552f_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMzU0_131714dc-8eaa-4576-9c1d-eec6100520ce"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie4bbf4a5ff6c4f5085293b4809ad89df_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExMzc1_01b37358-ceaa-4757-b9f4-94c41d159dd4"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzExNDYy_b9ee3de5-9d24-4d84-b297-7d369e6dc9f1"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i11863a558bbf46bca75ffd9f7fafbba7_I20181107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEyNDc3_e88906bd-7038-4b25-aaa7-2e768260e763"
      unitRef="usd">675000000.0</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="ia4f071a5198246d4a5303f52da35079c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEyNjY5_c951be4f-8c5d-4f89-83f7-1339133bf03f">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i8ee4b7c75b03465cb35c3c8b87a54189_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEyODM3_8f630d8d-3ab4-420c-b1a1-102ca44bd90c">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i187bf0ed97484588819f3c772481972a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzMzQ3_060a7fe9-e97a-4960-a91e-c86174054873"
      unitRef="usd">34300000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTU3MDA_395d1a8e-a12e-4d52-94b1-d18993fa62c8"
      unitRef="usd">16100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i4faa3349fe88498e9d027f1467d57c95_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTU3Mjk_92ea47fa-18f4-419f-91ef-100986b12426"
      unitRef="usd">15100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ia27d340d112941fc9280b61618209c41_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NTU3NTE_fc8bdf45-ed69-4740-9200-089f0d855788"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i187bf0ed97484588819f3c772481972a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYyNDE_011d1622-1cc8-4632-bd64-ca8ca6a2aec2"
      unitRef="usd">31200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYyNDE_d09c16d3-7294-4b7e-8d07-c28fabc7b5d0"
      unitRef="usd">31200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EquityMethodInvestments
      contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNTYz_e7c8b34f-dfb2-4599-9ec2-3928a45e8ffd"
      unitRef="krw">691600000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifbe702e233b746d5bf9f5f50fe2879ad_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNTg0_d26b0986-0204-4cec-9866-405c73144f43"
      unitRef="usd">612800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="idcfeec350bdb466ab3c2f0500fc633e2_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNTky_6536ad20-f418-4a4f-a722-a3e17bd5a784"
      unitRef="krw">673800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="idcfeec350bdb466ab3c2f0500fc633e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEzNjEz_9c508e44-1e79-4449-a953-5e1b79064215"
      unitRef="usd">620200000</us-gaap:EquityMethodInvestments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0MzIz_0b94f65b-b58d-4560-94b1-0c41fe204162"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0Mzcx_a07718e6-457c-4597-ade3-7ac9752a720a"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i41b0165e2b7d4f55925670a51aac39ab_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0NDM1_7374409d-026a-4ab9-bc2c-a44bb34a9dcd"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AdditionalMilestonePayment
      contextRef="i22390c69ed8c484a87e99931785d60cd_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0NTU3_de386941-fd4c-4e01-83e0-02970365b137"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i85191396f14a48159b6ea71eb3da36ae_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0NzIz_1c037df3-7fd2-47ff-b84a-6b787af679ea"
      unitRef="usd">195000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm
      contextRef="i85191396f14a48159b6ea71eb3da36ae_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0OTIy_3684c25b-230d-43b0-9d01-532a007e3358">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee
      contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE0OTc0_7041b1c6-7361-4127-9734-2b2ef85fde90"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1NDQ0_1fe9645b-36f4-4694-a4e6-5e2a51bc04cb"
      unitRef="number">0.500</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i187bf0ed97484588819f3c772481972a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1NzEw_df380882-3a87-4adf-be27-1756413c6d69"
      unitRef="usd">69900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYxMjI_d99077fa-4804-4181-8c3e-d0604a5ed513"
      unitRef="usd">138400000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="id18cfe7cc9aa44b0822a1050a7fa7b44_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1NzQx_1fe9645b-36f4-4694-a4e6-5e2a51bc04cb"
      unitRef="number">0.500</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i4faa3349fe88498e9d027f1467d57c95_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1Nzk4_5800ecdf-3ccc-4d39-8443-28ef75a1e094"
      unitRef="usd">55400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ia27d340d112941fc9280b61618209c41_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzEwOTk1MTE2NjYxNTU_4424bb70-483f-43d6-967b-1ad73a4e37bb"
      unitRef="usd">127200000</biib:Collaborationprofitlosssharing>
    <biib:ContractOptionExerciseFee
      contextRef="i11706266e0b64d6b838208836874f7c9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE1OTgz_7041b1c6-7361-4127-9734-2b2ef85fde90"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i8dc20aceecce4ad98ad607135283cd1f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2NDU5_d01f869e-389a-42ed-bd7d-91e64a3d2175"
      unitRef="usd">158700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i1d184845c0fd4540af43215a509def5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMTUvZnJhZzozMmQ4NzkxYTRmNDk0ZmVmYTY5M2E5Njg1ODZhMjk0Yi90ZXh0cmVnaW9uOjMyZDg3OTFhNGY0OTRmZWZhNjkzYTk2ODU4NmEyOTRiXzE2NDY2_b31943c3-1490-4e10-9d5e-cdcc2f7bf325"
      unitRef="usd">99000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzU0OTQ_e22b20bd-6932-45e5-95d0-fa49821a3253">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $100.0&#160;million in additional milestones to Neurimmune, which includes $50.0&#160;million if launched in three or more countries in the European Union (E.U.) and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021 and 2020, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended June 30, 2021, we recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ADUHELM Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on commercial sales of ADUHELM to be shared with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $15.2 million and $12.8 million, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="id238c93aacac4f80a409e4c0cd6eb474_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzc2OA_7968b515-680c-4fef-969e-21f5c6ef66e9">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="id238c93aacac4f80a409e4c0cd6eb474_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzExMTE_339afb17-4df1-4f68-80ad-f20a051f52ff"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i05bc48381d6b4149b19415bd7d37bd95_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEyNzE_32f1dab0-47ec-4cc3-bcdb-e5ef24e1e397"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="i05bc48381d6b4149b19415bd7d37bd95_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEzMTQ_6233ec7d-9b5b-4305-a7a5-9b956c0d10cc"
      unitRef="number">0.150</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i3d03ddf77e1f433eaa830646366273e1_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE1Mzk_84fe6881-16b1-47da-b71c-91a849a4035d"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="i3d03ddf77e1f433eaa830646366273e1_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE3NzQ_ec560caf-40df-4a62-9732-660d7bff1756"
      unitRef="number">0.050</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ifa100d41aa7e425a9482c71b0293c71e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzIzMTQ_839aa02c-12c0-4dac-92ed-443798670c16"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ifa100d41aa7e425a9482c71b0293c71e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI0NDM_839aa02c-12c0-4dac-92ed-443798670c16"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i13a0bb57ef4847dcb84a45d333b9d1da_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI2ODM_9dbf7ec8-3619-49c0-9be6-52c8a9213d7c"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI3MDU_99f7adf8-bb6d-4f0c-ab69-4fc79bdbe23c"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ifa100d41aa7e425a9482c71b0293c71e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI3MjE_839aa02c-12c0-4dac-92ed-443798670c16"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i2a247039a04a4250a57179e383ed799e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzM1OTc_c5f7d652-b503-44cb-a14b-d4026129d500"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i2a247039a04a4250a57179e383ed799e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzcxNDY4MjU1ODc5NjA_c5f7d652-b503-44cb-a14b-d4026129d500"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i95d0e998a1764fefaa1b533582262643_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzU5MzY_d1cdf61d-983d-4bf3-a4f7-8316c23bfe9e"
      unitRef="usd">45000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzcxNDY4MjU1ODgyMDQ_99f7adf8-bb6d-4f0c-ab69-4fc79bdbe23c"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i2a247039a04a4250a57179e383ed799e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzQ5NDc4MDIzMzMxNDk_c5f7d652-b503-44cb-a14b-d4026129d500"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:AdditionalMilestonePayment
      contextRef="i3ddd0476ee7949d8821bb3a65c74d207_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzU5NTY_7a171455-9d19-46c9-b11a-f414f82f03d2"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ib43ae0706b95445a8789a5fcbf8ac563_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzU5NzU_54151986-5d9e-45c2-9f26-0710a7dba899"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i361307437209490a864b62473d1cedf7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzI5NzE_b368d755-8fe1-4a05-bff0-90bd10e70ba7"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE2NDkyNjc0NTIyNTU_384f0730-4831-459f-ab5d-524aebc3207b"
      unitRef="usd">500000000.0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE2NDkyNjc0NTIyNjQ_e75e9d52-5135-4b41-9649-8a565ab98922"
      unitRef="usd">875000000.0</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzE2NDkyNjc0NTIyNzI_8e843464-99ef-430a-8351-4a8adc174b8c"
      unitRef="usd">375000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzEwOTk1MTE2MzMzMDU_74fa802b-cf1c-40d9-a5e7-c7823442625f"
      unitRef="usd">15200000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjEvZnJhZzpjMDk1ZGIwODc2ZGQ0OTA2YTViY2ZkM2JmMDVhNDk2MS90ZXh0cmVnaW9uOmMwOTVkYjA4NzZkZDQ5MDZhNWJjZmQzYmYwNWE0OTYxXzQ2OTA_b6382065-a16c-4413-b803-307c0b75ed7c"
      unitRef="usd">12800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjcvZnJhZzplMTRiZmIyZWE0OWQ0ZmMwODU5OTg1ZDA3MzVhMTQ1Zi90ZXh0cmVnaW9uOmUxNGJmYjJlYTQ5ZDRmYzA4NTk5ODVkMDczNWExNDVmXzExOTk5_feef7698-9e1d-4798-a279-89f1b80bd937">&lt;div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and transferred to the U.S. District Court for the District of Massachusetts in March 2021. The action alleges violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. We have filed a motion to dismiss the action, which is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. The request for preliminary injunction was denied in June 2019 and the decision was affirmed on appeal in February 2021. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#x2019;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#x2019;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#x2019;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing was held in May and June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. The case has been stayed pending proceedings at the European Patent Office (EPO).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Samsung BioLogics Arbitration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. We expect a hearing in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#x2018;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc. A trial date has not yet been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016 the EPO revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. The Polish Patent Office dismissed the action in February 2021. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#x2018;263 Patent in the Polish Patent Office. The action was suspended by the Polish Patent Office in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. A hearing in the Italian action will be held in June 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#x2019;s and Mylan Ireland&#x2019;s respective applications to market a generic version of TECFIDERA. The EMA&#x2019;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i60b121f8efd14872a1e30df2ef86c797_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMjcvZnJhZzplMTRiZmIyZWE0OWQ0ZmMwODU5OTg1ZDA3MzVhMTQ1Zi90ZXh0cmVnaW9uOmUxNGJmYjJlYTQ5ZDRmYzA4NTk5ODVkMDczNWExNDVmXzUzNzM_f5842806-bf0a-4b2a-90c1-83738c236a77"
      unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzAvZnJhZzo4ZDEwNTUyOTc1ZjM0NmNjYjBlM2MzMjBkZDVhYzc0Ni90ZXh0cmVnaW9uOjhkMTA1NTI5NzVmMzQ2Y2NiMGUzYzMyMGRkNWFjNzQ2XzQzOTgwNDY1MTU4MzI_c88ade80-519c-4a6f-88cf-e18caf91360c">Subsequent Events&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#x2019;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the proposed collaboration, we will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;InnoCare will receive a $125.0&#160;million upfront payment and is eligible to receive up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. InnoCare is also eligible to receive tiered royalties in the low to high teens on potential future net sales of any product resulting from the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Closing of the collaboration is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and other customary closing conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i8f888c4ff5e0416ba053664107506cc4_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzAvZnJhZzo4ZDEwNTUyOTc1ZjM0NmNjYjBlM2MzMjBkZDVhYzc0Ni90ZXh0cmVnaW9uOjhkMTA1NTI5NzVmMzQ2Y2NiMGUzYzMyMGRkNWFjNzQ2XzEwOTk1MTE2MzIyODk_7c9b30ae-9856-46b7-8331-8ccc913c6038"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ic0a38fb832714a92860b173e6a8b3564_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzAvZnJhZzo4ZDEwNTUyOTc1ZjM0NmNjYjBlM2MzMjBkZDVhYzc0Ni90ZXh0cmVnaW9uOjhkMTA1NTI5NzVmMzQ2Y2NiMGUzYzMyMGRkNWFjNzQ2XzEwOTk1MTE2MzIzMjE_c98785de-5e1c-4d9d-bcd5-24232f276dec"
      unitRef="usd">812500000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i485215ff9a05477a89ba4c168695e13f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwNGNhNjdiNDhlOTQzOGFhNDVjYzg2MGEzZTk4MTQ2L3NlYzo5MDRjYTY3YjQ4ZTk0MzhhYTQ1Y2M4NjBhM2U5ODE0Nl8xMzYvZnJhZzpjOTg2MTZlM2I5YTc0Y2RlODM5YTNjM2QzZDhlMDNhNi90ZXh0cmVnaW9uOmM5ODYxNmUzYjlhNzRjZGU4MzlhM2MzZDNkOGUwM2E2XzE2NDkyNjc0ODk5MDk_99f7adf8-bb6d-4f0c-ab69-4fc79bdbe23c"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123291368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,033,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605124941272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">459.7<span></span>
</td>
<td class="nump">411.1<span></span>
</td>
<td class="nump">937.8<span></span>
</td>
<td class="nump">865.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">585.1<span></span>
</td>
<td class="nump">647.6<span></span>
</td>
<td class="nump">1,099.3<span></span>
</td>
<td class="nump">1,123.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">637.3<span></span>
</td>
<td class="nump">555.1<span></span>
</td>
<td class="nump">1,232.3<span></span>
</td>
<td class="nump">1,125.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">604.1<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
<td class="nump">702.2<span></span>
</td>
<td class="nump">133.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="num">(33.5)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">2,289.3<span></span>
</td>
<td class="nump">1,707.1<span></span>
</td>
<td class="nump">4,009.4<span></span>
</td>
<td class="nump">3,421.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">485.7<span></span>
</td>
<td class="nump">1,974.5<span></span>
</td>
<td class="nump">1,459.6<span></span>
</td>
<td class="nump">3,794.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="num">(410.5)<span></span>
</td>
<td class="num">(57.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">582.1<span></span>
</td>
<td class="nump">2,037.5<span></span>
</td>
<td class="nump">1,049.1<span></span>
</td>
<td class="nump">3,736.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(409.1)<span></span>
</td>
<td class="nump">446.1<span></span>
</td>
<td class="num">(364.9)<span></span>
</td>
<td class="nump">738.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="num">(34.3)<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,025.5<span></span>
</td>
<td class="nump">1,606.5<span></span>
</td>
<td class="nump">1,430.1<span></span>
</td>
<td class="nump">2,999.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="nump">577.0<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
<td class="nump">571.4<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 858.7<span></span>
</td>
<td class="nump">$ 2,941.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 17.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="nump">$ 17.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">149.7<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">150.8<span></span>
</td>
<td class="nump">166.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">150.1<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">151.2<span></span>
</td>
<td class="nump">167.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,236.0<span></span>
</td>
<td class="nump">$ 2,795.7<span></span>
</td>
<td class="nump">$ 4,447.7<span></span>
</td>
<td class="nump">$ 5,700.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">440.0<span></span>
</td>
<td class="nump">478.3<span></span>
</td>
<td class="nump">829.0<span></span>
</td>
<td class="nump">998.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 192.3<span></span>
</td>
<td class="nump">$ 516.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605124256840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 858.7<span></span>
</td>
<td class="nump">$ 2,941.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(51.2)<span></span>
</td>
<td class="nump">138.6<span></span>
</td>
<td class="num">(17.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">451.0<span></span>
</td>
<td class="nump">1,510.4<span></span>
</td>
<td class="nump">985.9<span></span>
</td>
<td class="nump">2,895.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">576.9<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">572.0<span></span>
</td>
<td class="nump">59.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 1,027.9<span></span>
</td>
<td class="nump">$ 1,575.9<span></span>
</td>
<td class="nump">$ 1,557.9<span></span>
</td>
<td class="nump">$ 2,955.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605122880424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,742.0<span></span>
</td>
<td class="nump">$ 1,331.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,308.8<span></span>
</td>
<td class="nump">1,278.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,688.0<span></span>
</td>
<td class="nump">1,913.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">422.2<span></span>
</td>
<td class="nump">413.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,254.8<span></span>
</td>
<td class="nump">1,068.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">767.9<span></span>
</td>
<td class="nump">881.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,183.7<span></span>
</td>
<td class="nump">6,887.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">915.1<span></span>
</td>
<td class="nump">772.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,442.2<span></span>
</td>
<td class="nump">3,411.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">402.5<span></span>
</td>
<td class="nump">433.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,385.0<span></span>
</td>
<td class="nump">3,084.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,763.9<span></span>
</td>
<td class="nump">5,762.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,849.9<span></span>
</td>
<td class="nump">1,369.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">2,528.1<span></span>
</td>
<td class="nump">2,899.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,470.4<span></span>
</td>
<td class="nump">24,618.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">230.9<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">375.3<span></span>
</td>
<td class="nump">454.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,741.0<span></span>
</td>
<td class="nump">3,145.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,347.2<span></span>
</td>
<td class="nump">3,742.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">7,269.2<span></span>
</td>
<td class="nump">7,426.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">918.9<span></span>
</td>
<td class="nump">1,032.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">363.9<span></span>
</td>
<td class="nump">402.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,356.4<span></span>
</td>
<td class="nump">1,329.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,255.6<span></span>
</td>
<td class="nump">13,932.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(171.8)<span></span>
</td>
<td class="num">(299.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,900.7<span></span>
</td>
<td class="nump">13,976.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,751.9<span></span>
</td>
<td class="nump">10,700.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">462.9<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">11,214.8<span></span>
</td>
<td class="nump">10,686.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 24,470.4<span></span>
</td>
<td class="nump">$ 24,618.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605133099592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123415832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,430.1<span></span>
</td>
<td class="nump">$ 2,999.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">219.8<span></span>
</td>
<td class="nump">232.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">124.1<span></span>
</td>
<td class="nump">115.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(622.8)<span></span>
</td>
<td class="nump">180.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">283.6<span></span>
</td>
<td class="num">(39.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="num">(16.1)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">112.4<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">211.5<span></span>
</td>
<td class="num">(268.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="num">(8.7)<span></span>
</td>
<td class="nump">149.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(193.8)<span></span>
</td>
<td class="num">(188.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(188.4)<span></span>
</td>
<td class="num">(441.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">171.5<span></span>
</td>
<td class="nump">504.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(97.3)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by operating activities</a></td>
<td class="nump">1,996.3<span></span>
</td>
<td class="nump">3,415.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,452.7<span></span>
</td>
<td class="nump">3,879.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(1,626.9)<span></span>
</td>
<td class="num">(3,753.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="num">(254.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(37.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow used in investing activities</a></td>
<td class="num">(217.4)<span></span>
</td>
<td class="num">(389.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,050.0)<span></span>
</td>
<td class="num">(5,029.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of borrowings and premiums paid on debt exchange</a></td>
<td class="num">(170.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2,967.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash proceeds from settlement of swap</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="num">(94.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(20.5)<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow used in financing activities</a></td>
<td class="num">(1,349.5)<span></span>
</td>
<td class="num">(3,558.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">429.4<span></span>
</td>
<td class="num">(532.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,331.2<span></span>
</td>
<td class="nump">2,913.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">1,742.0<span></span>
</td>
<td class="nump">2,384.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of Sangamo Therapeutics, Inc. stock</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (141.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605130260152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="nump">$ 16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,343.2<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,999.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,941.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,941.2<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(44.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,750.0)<span></span>
</td>
<td class="num">$ (3,750.0)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (76.2)<span></span>
</td>
<td class="num">$ (3,673.8)<span></span>
</td>
<td class="nump">$ 3,750.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(48.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">11,289.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="nump">14,466.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,308.7<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(182.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(191.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">12,536.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(149.3)<span></span>
</td>
<td class="nump">15,673.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,546.9<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,606.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(30.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,808.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,808.9)<span></span>
</td>
<td class="num">(2,808.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (60.7)<span></span>
</td>
<td class="num">$ (2,748.2)<span></span>
</td>
<td class="nump">$ 2,808.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">11,289.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="nump">14,466.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,308.7<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(182.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(176.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(299.0)<span></span>
</td>
<td class="nump">13,976.3<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,700.3<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,430.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858.7<span></span>
</td>
<td class="nump">571.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">127.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,050.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,050.0)<span></span>
</td>
<td class="num">$ (1,050.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (163.3)<span></span>
</td>
<td class="num">$ (886.7)<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">11,214.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="nump">13,900.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,751.9<span></span>
</td>
<td class="nump">462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(172.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(174.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">10,663.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(174.3)<span></span>
</td>
<td class="nump">13,833.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,682.2<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,025.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="nump">577.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NoncontrollingInterestIncreaseDecreaseOther', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450.0)<span></span>
</td>
<td class="num">$ (450.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (69.5)<span></span>
</td>
<td class="num">$ (380.5)<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 11,214.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (171.8)<span></span>
</td>
<td class="nump">$ 13,900.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,751.9<span></span>
</td>
<td class="nump">$ 462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(172.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestIncreaseDecreaseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase (Decrease) Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestIncreaseDecreaseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120186888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120483944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson's disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our </span></div>condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121652728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,511.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,074.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,795.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*** </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the United States (U.S.) during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,699.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,291.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">954.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,577.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,012.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,385.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,059.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,304.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,395.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*** </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 30.2% and 9.9% of gross product revenue for the three months ended June 30, 2021, and 30.1% and 9.6% of gross product revenue for the six months ended June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 31.7% and 17.9% of gross product revenue for the three months ended June 30, 2020, and 30.8% and 16.2% of gross product revenue for the six months ended June 30, 2020.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,577.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,960.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(275.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(906.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,182.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(676.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(802.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,042.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120200760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,254.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120537672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,252.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,141.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,637.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,252.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,385.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets totaled $604.1 million and $702.2 million, respectively, compared to $61.5 million and $133.0 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, amortization and impairment of acquired intangible assets reflects a $350.0&#160;million impairment charge related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and a $191.6&#160;million impairment charge related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2020, we had no impairment charges.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of June 30, 2021, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Nightstar Therapeutics plc (NST) and Convergence Pharmaceuticals Holdings Ltd. (Convergence). For additional information on our acquisition of NST, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and now plan to perform an additional clinical trial of vixotrigine before initiating a Phase 3 study of DPN.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021. As of June 30, 2021, the carrying value associated with our remaining vixotrigine IPR&amp;D assets was $136.0&#160;million, all of which is related to DPN.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we recognized an impairment charge of $115.0&#160;million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 did not meet its primary or key secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of $350.0&#160;million during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D asset from $365.0&#160;million to $15.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2021 we announced that our Phase 2/3 XIRIUS study of BIIB112 did not meet its primary endpoint; however, positive trends were observed across several clinically relevant prespecified secondary endpoints. We reassessed the fair value of the program based on the results of this study and recognized an impairment charge of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$191.6&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> during the second quarter of 2021, which resulted in a reduction of the IPR&amp;D asset from </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$220.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$28.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are evaluating the results of our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112, including evaluation of any future development activities we may perform. Our estimates of the current fair values of the BIIB111 and BIIB112 programs were derived by using a discounted, probability-weighted calculation of future estimated cash flows associated with the programs under multiple scenarios, including the possibility that we will cease further development of BIIB111 and/or BIIB112, which could result in further impairment of these assets. The key assumptions in our estimates are the amount and timing of revenue, probability of technical and regulatory success, discount rate and clinical data associated with the programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we have entered into third-party manufacturing agreements related to the BIIB111 and BIIB112 programs and we may incur a financial penalty if these agreements are terminated. Should we decide to terminate either or both of these programs and/or manufacturing agreements, we will likely incur impairment charges related to the remaining book value of the applicable program as well as charges up to, in the aggregate, approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$30.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related to our inventory arrangements and other costs associated with discontinuing these programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,763.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121652728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,052.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,778.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021. In addition, there have been no changes in valuation techniques during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage) and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. The holding period restrictions for a portion of our Sangamo investment expired during the second quarter of 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of this portion of our Sangamo investment was a Level 1 measurement as of June 30, 2021. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Financial Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of June 30, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.68%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.68%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"/><td rowspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td rowspan="2" style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 21.7% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are recorded at fair value on a recurring basis, we record assets and liabilities at fair value on a nonrecurring basis as required by U.S. GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Book Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Book Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB111 intangible asset</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(350.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB112 intangible asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(191.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, we recorded a partial impairment charge of $350.0&#160;million related to BIIB111 and $191.6&#160;million related to BIIB112. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,037.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,945.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,471.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,140.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on April 30, 2020 and September 15, 2015, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, approximately $226.3 million and $110.3 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expense and other.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121613512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">725.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,308.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,308.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of June 30, 2021 and December 31, 2020, was approximately 13 months and 11 months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,490.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,879.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, our strategic investment portfolio was comprised of investments totaling $1,647.8 million and $2,024.6 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our strategic investment portfolio for the three months ended June 30, 2021, was primarily due to an increase in the fair value of our investment in Denali, partially offset by decreases in the fair values of our investments in Ionis Pharmaceuticals, Inc. (Ionis), Sage and Sangamo common stock. The decrease in our strategic investment portfolio for the six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, was primarily due to decreases in the fair values of our investments in Ionis, Sage, Denali and Sangamo common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of June 30, 2021.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121769144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of June 30, 2021 and December 31, 2020, had durations of 1 to 18 months and 1 to 24 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,269.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity as of June 30, 2021, reflected aggregate net unrealized losses of $53.7 million, composed of gross unrealized losses of approximately $67.0&#160;million and gross unrealized gains of approximately $13.3&#160;million, compared to aggregate net unrealized losses of $212.5 million as of December 31, 2020. We expect the net unrealized losses of $53.7 million to be settled over the next 18 months, of which $58.2 million of unrealized losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of June 30, 2021 and December 31, 2020, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our condensed consolidated statements of income during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of June 30, 2021, had a remaining duration of four months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $0.1 million and net losses of $21.2 million as of June 30, 2021 and December 31, 2020, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.1 million and $0.2 million as of June 30, 2021 and December 31, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,205.1 million and $1,158.0 million as of June 30, 2021 and December 31, 2020, respectively. Net gains of $4.8 million and net losses of $12.6 million related to these contracts were recorded as a component of other income (expense), net for the three and six months ended June 30, 2021, respectively, compared to net gains of $8.3 million and $5.9 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121789880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,880.3 million and $1,782.3 million as of June 30, 2021 and December 31, 2020, respectively. For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, depreciation expense totaled $54.7 million and $103.5 million, respectively, compared to $51.3 million and $99.7 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support </span></div>space and 51,000 square feet of administrative space. As of June 30, 2021 and December 31, 2020, we had approximately $618.4 million and $1.8 billion, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.3&#160;billion of fixed assets being placed in service during the second quarter of 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605122260360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indebtedness</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the six months ended June 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the six months ended June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.90% Senior Notes due September 15, 2020</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with our 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes during the second quarter of 2020. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income and reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121613512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million and 3.8 million shares of our common stock at a cost of approximately $450.0 million and $1.1 billion during the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, respectively. Approximately $3.6 billion remained available under our 2020 Share Repurchase Program as of June 30, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 9.0 million and 12.2&#160;million shares of our common stock at a cost of approximately $2.8 billion and $3.7&#160;billion during the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1&#160;million shares of our common stock at a cost of approximately $1.3&#160;billion during the six months ended June 30, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.006%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121767848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120456808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123930616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to have a substantial negative impact on our TECFIDERA revenue for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $1.7 billion and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1.6 billion. We continue to assess the realizability of these deferred tax assets and have recorded an increase in these deferred tax assets by approximately $92.6&#160;million and an increase in these deferred tax liabilities by approximately $88.7&#160;million for the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021, compared to the same periods in 2020, the decreases in our effective tax rate were primarily due to a current year deferred tax benefit in Switzerland resulting from the accelerated approval of ADUHELM by the FDA in the U.S. We recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit discussed below. The deferred tax benefit relates to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc. For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the decreases in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset discussed above, were primarily due to the change in the territorial mix of our profitability, which included the effect of generic competition for TECFIDERA in the U.S. market. Our 2020 effective tax rate reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, our 2021 effective tax rate reflects a decrease related to the non-cash tax effects of changes in the value of our equity investments, where we recorded a reduction of value in 2021. The tax effects of this change in value of our equity investments were recorded discretely, as the changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we increased our gross unrecognized tax benefits by approximately $375.0&#160;million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM, as discussed above. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset discussed above, and not as a separate liability on our condensed consolidated balance sheet.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $20.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121574104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(410.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, net unrealized gains and realized gains on our holdings in equity securities were approximately $153.9 million and $0.4 million, respectively, compared to net unrealized gains and realized gains (losses) of $102.9 million and zero, respectively, in the prior year comparative period. The net unrealized gains recognized during the three months ended June 30, 2021, primarily reflect an increase in the fair value of Denali common stock of approximately $263.0&#160;million, partially offset by decreases in the fair value of Ionis, Sangamo and Sage common stock of approximately $105.8 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2021, net unrealized losses and realized gains on our holdings in equity securities were approximately $288.4 million and $6.6 million, respectively, compared to net unrealized gains and realized gains (losses) of $42.0 million and zero, respectively, in the prior year comparative period. The net unrealized losses recognized during the six months ended June 30, 2021, primarily reflect decreases in the fair value of Ionis, Sangamo, Denali and Sage common stock of approximately $284.8&#160;million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of June 30, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(288.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,042.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,741.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,356.4 million and $1,329.6 million as of June 30, 2021 and December 31, 2020, respectively, and included accrued income taxes totaling $652.7 million and $709.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120223208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for lecanemab and all costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits equally. In addition, the Lecanemab Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, we lead the ongoing development of ADUHELM, and we and Eisai will co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of ADUHELM in patients with early Alzheimer's disease. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we and Eisai announced that we planned to pursue regulatory approval for ADUHELM in the U.S. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE trial met its pre-specified primary and secondary endpoints. In July 2020 we completed the submission of a Biologics License Application (BLA) for the approval of ADUHELM to the FDA and made a $75.0 million milestone payment to Neurimmune. We recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense are shared in proportion to the same region-based profit split that is utilized to co-promote ADUHELM. A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2021, we recognized net profit-sharing income of $40.1&#160;million to reflect Eisai's 45.0% sharing of the net collaboration losses in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, of which approximately 12&#160;million shares remain subject to transfer restrictions as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we record</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed $77.2&#160;million as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to $9.6&#160;million in the prior year comparative periods</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of June 30, 2021, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain officers and affiliates of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, we recognized net income on our investment of $34.3 million and $16.1 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences, net of tax, compared to net income on our investment of $15.1 million and $0.4 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income on our investment for the three and six months ended June 30, 2021, reflects a $31.2&#160;million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the current period based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the carrying value of our investment in Samsung Bioepis totaled 691.6 billion South Korean won ($612.8 million) and 673.8 billion South Korean won ($620.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our condensed consolidated statements of income. We may pay Samsung Bioepis up to $195.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing in our condensed consolidated statements of income. For the three and six months ended June 30, 2021, we recognized net profit-sharing expense of $69.9&#160;million and $138.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $55.4 million and $127.2 million, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $60.0 million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services are reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts payable to Samsung Bioepis related to the agreements discussed above were $158.7&#160;million and $99.0&#160;million as of June 30, 2021 and December 31, 2020, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2020 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121846472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on commercial sales of ADUHELM, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $100.0&#160;million in additional milestones to Neurimmune, which includes $50.0&#160;million if launched in three or more countries in the European Union (E.U.) and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the ADUHELM Collaboration Agreement with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021 and 2020, amounts reimbursed were immaterial.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended June 30, 2021, we recorded a net deferred tax asset of approximately $500.0&#160;million. The net deferred tax asset is comprised of approximately $875.0&#160;million of gross deferred tax asset, reduced by approximately $375.0&#160;million of unrecognized tax benefit. The deferred tax benefit relates to Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM and approval of the Swiss cantonal tax authorities, with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ADUHELM Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on commercial sales of ADUHELM to be shared with Eisai.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 and December 31, 2020, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $15.2 million and $12.8 million, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121926104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2020 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and transferred to the U.S. District Court for the District of Massachusetts in March 2021. The action alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set. We have filed a motion to dismiss the action, which is pending.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. The request for preliminary injunction was denied in June 2019 and the decision was affirmed on appeal in February 2021. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#8217;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing was held in May and June 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. The case has been stayed pending proceedings at the European Patent Office (EPO).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung BioLogics Arbitration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we requested arbitration in the International Chamber of Commerce Court of International Arbitration against Samsung BioLogics seeking interpretation of certain provisions in the Joint Venture Agreement executed on December 6, 2011, as amended, by and between Biogen and Samsung BioLogics (the Joint Venture Agreement). Samsung BioLogics has asserted counterclaims, including breach of the Joint Venture Agreement, and seeks declaratory relief and unspecified damages. An estimate of the possible loss or range of loss cannot be made at this time. We expect a hearing in the fourth quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,699,281, 9,090,558 and 10,080,733) pursuant to the Hatch-Waxman Act in the Delaware Court against Teva Pharmaceuticals Development, Inc. A trial date has not yet been set.</span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the EPO revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. The Polish Patent Office dismissed the action in February 2021. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#8216;263 Patent in the Polish Patent Office. The action was suspended by the Polish Patent Office in April 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. A hearing in the Italian action will be held in June 2022.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#8217;s and Mylan Ireland&#8217;s respective applications to market a generic version of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to a generic application related to TECFIDERA in the E.U. This generic application is now before the EMA, which is reassessing TECFIDERA's regulatory data protection by performing a scientific assessment pursuant to the European General Court's decision. The result of the scientific assessment of the EMA is expected in the fourth quarter of 2021. We have appealed the European General Court's decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121846472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a license and collaboration agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the proposed collaboration, we will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">InnoCare will receive a $125.0&#160;million upfront payment and is eligible to receive up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. InnoCare is also eligible to receive tiered royalties in the low to high teens on potential future net sales of any product resulting from the collaboration. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Closing of the collaboration is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and other customary closing conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605132964808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2020 (2020 Form&#160;10-K).</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2020 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our condensed consolidated financial statements and there may be changes to those estimates in future periods.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt;text-indent:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605116519896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,511.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,074.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,795.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*** </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADUHELM, which became commercially available in the United States (U.S.) during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships - Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,699.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,291.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">954.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,577.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,012.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,385.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,059.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,570.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,447.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,304.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,395.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*** </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Eisai Co., Ltd. - ADUHELM Collaboration Agreement, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,577.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,960.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(275.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(906.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,182.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(676.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(802.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,042.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120554840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:58.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,254.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605125487304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,252.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,141.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,637.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,252.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,385.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,763.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120439352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,052.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,778.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Fair value measurements, nonrecurring</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Book Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Book Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB111 intangible asset</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(350.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB112 intangible asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(191.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,037.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,945.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,471.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051 </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,140.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2021 we completed a private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes), whereby approximately $624.6&#160;million of our 2045 Senior Notes were exchanged for approximately $700.7&#160;million of a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes). For additional information on our Exchange Offer, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605132942360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">725.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available for sale:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,308.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,308.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,490.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,879.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605133070888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,269.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121623528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.006%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120547816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121626808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121638280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605212974248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(410.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of June 30, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) realized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(288.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,042.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,741.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605118605192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121811384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605218713672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 18.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123522136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">578.5<span></span>
</td>
<td class="nump">1,190.3<span></span>
</td>
<td class="nump">1,131.4<span></span>
</td>
<td class="nump">2,291.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">269.1<span></span>
</td>
<td class="nump">921.7<span></span>
</td>
<td class="nump">505.1<span></span>
</td>
<td class="nump">1,699.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">309.4<span></span>
</td>
<td class="nump">268.6<span></span>
</td>
<td class="nump">626.3<span></span>
</td>
<td class="nump">591.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">400.4<span></span>
</td>
<td class="nump">481.4<span></span>
</td>
<td class="nump">800.9<span></span>
</td>
<td class="nump">947.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">257.4<span></span>
</td>
<td class="nump">345.6<span></span>
</td>
<td class="nump">499.2<span></span>
</td>
<td class="nump">638.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="nump">301.7<span></span>
</td>
<td class="nump">309.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">524.2<span></span>
</td>
<td class="nump">432.0<span></span>
</td>
<td class="nump">1,027.5<span></span>
</td>
<td class="nump">954.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">299.8<span></span>
</td>
<td class="nump">244.1<span></span>
</td>
<td class="nump">573.1<span></span>
</td>
<td class="nump">521.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">224.4<span></span>
</td>
<td class="nump">187.9<span></span>
</td>
<td class="nump">454.4<span></span>
</td>
<td class="nump">432.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,529.2<span></span>
</td>
<td class="nump">2,126.7<span></span>
</td>
<td class="nump">3,012.5<span></span>
</td>
<td class="nump">4,244.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">826.3<span></span>
</td>
<td class="nump">1,511.4<span></span>
</td>
<td class="nump">1,577.4<span></span>
</td>
<td class="nump">2,859.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">702.9<span></span>
</td>
<td class="nump">615.3<span></span>
</td>
<td class="nump">1,435.1<span></span>
</td>
<td class="nump">1,385.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">499.7<span></span>
</td>
<td class="nump">494.6<span></span>
</td>
<td class="nump">1,020.2<span></span>
</td>
<td class="nump">1,059.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">149.3<span></span>
</td>
<td class="nump">210.3<span></span>
</td>
<td class="nump">298.0<span></span>
</td>
<td class="nump">445.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">350.4<span></span>
</td>
<td class="nump">284.3<span></span>
</td>
<td class="nump">722.2<span></span>
</td>
<td class="nump">613.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">121.5<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">243.2<span></span>
</td>
<td class="nump">239.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">121.5<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">243.2<span></span>
</td>
<td class="nump">239.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">113.5<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">113.5<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">202.4<span></span>
</td>
<td class="nump">171.6<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
<td class="nump">390.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">202.4<span></span>
</td>
<td class="nump">171.6<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
<td class="nump">390.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,236.0<span></span>
</td>
<td class="nump">2,795.7<span></span>
</td>
<td class="nump">4,447.7<span></span>
</td>
<td class="nump">5,700.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">977.2<span></span>
</td>
<td class="nump">1,721.7<span></span>
</td>
<td class="nump">1,877.0<span></span>
</td>
<td class="nump">3,304.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,258.8<span></span>
</td>
<td class="nump">$ 1,074.0<span></span>
</td>
<td class="nump">$ 2,570.7<span></span>
</td>
<td class="nump">$ 2,395.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605122657016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,960.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(48.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,182.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(802.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,202.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">141.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">375.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(275.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(119.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">123.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">1,093.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,577.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(51.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(906.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(676.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,035.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 43.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605133340632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,202.3<span></span>
</td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">160.2<span></span>
</td>
<td class="nump">195.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,042.1<span></span>
</td>
<td class="nump">$ 1,080.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605214166136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">178.8<span></span>
</td>
<td class="nump">257.5<span></span>
</td>
<td class="nump">352.9<span></span>
</td>
<td class="nump">598.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">261.2<span></span>
</td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">476.1<span></span>
</td>
<td class="nump">399.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 440.0<span></span>
</td>
<td class="nump">$ 478.3<span></span>
</td>
<td class="nump">$ 829.0<span></span>
</td>
<td class="nump">$ 998.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605125302552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">87.1<span></span>
</td>
<td class="nump">395.5<span></span>
</td>
<td class="nump">170.3<span></span>
</td>
<td class="nump">489.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">407.6<span></span>
</td>
<td class="nump">192.3<span></span>
</td>
<td class="nump">516.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123323720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 2,775.0<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 5,469.0<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
<td class="nump">30.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">17.90%<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">16.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="nump">$ 395.5<span></span>
</td>
<td class="nump">$ 170.3<span></span>
</td>
<td class="nump">$ 489.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 192.3<span></span>
</td>
<td class="nump">$ 516.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605120533592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 328.0<span></span>
</td>
<td class="nump">$ 314.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">723.0<span></span>
</td>
<td class="nump">544.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">203.8<span></span>
</td>
<td class="nump">209.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 1,254.8<span></span>
</td>
<td class="nump">$ 1,068.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605211317576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="num">$ (5,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">7,637,700,000<span></span>
</td>
<td class="nump">$ 8,220,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,637,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,252,700,000)<span></span>
</td>
<td class="num">(5,136,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,252,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,385,000,000.0<span></span>
</td>
<td class="nump">3,084,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">604,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,200,000<span></span>
</td>
<td class="nump">133,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">110,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,141,600,000<span></span>
</td>
<td class="nump">2,257,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,252,700,000)<span></span>
</td>
<td class="num">(5,136,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,252,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">179,400,000<span></span>
</td>
<td class="nump">762,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember', window );">Vixotrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">44,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">136,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 191,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member', window );">BIIB111 and BIIB112 | Nightstar | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605122307672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,762.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 5,763.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,763.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 604.1<span></span>
</td>
<td class="nump">$ 61.5<span></span>
</td>
<td class="nump">702.2<span></span>
</td>
<td class="nump">$ 133.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605211995384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,223.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,051.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,180.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,593.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,052.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">226.3<span></span>
</td>
<td class="nump">$ 226.0<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">$ 351.6<span></span>
</td>
<td class="nump">$ 341.6<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">298.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,382.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">688.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">152.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">273.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">273.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,180.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,320.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,703.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,778.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,429.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,382.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">688.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">152.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">226.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">226.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123282120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 226,300,000<span></span>
</td>
<td class="nump">$ 226,300,000<span></span>
</td>
<td class="nump">$ 110,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and Regulatory Success, Probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605128687592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.68<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0068<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123511000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Nonrecurring Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (585.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">$ (350.0)<span></span>
</td>
<td class="num">$ (115.0)<span></span>
</td>
<td class="num">(350.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Ending Book Value</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">(191.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112 | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Ending Book Value</a></td>
<td class="nump">$ 28.4<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605124255736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,269.2<span></span>
</td>
<td class="nump">$ 7,426.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,140.7<span></span>
</td>
<td class="nump">8,515.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,037.8<span></span>
</td>
<td class="nump">1,054.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998.5<span></span>
</td>
<td class="nump">997.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,945.3<span></span>
</td>
<td class="nump">2,003.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742.0<span></span>
</td>
<td class="nump">1,741.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,483.1<span></span>
</td>
<td class="nump">1,557.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099.7<span></span>
</td>
<td class="nump">1,491.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503.3<span></span>
</td>
<td class="nump">2,365.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,491.6<span></span>
</td>
<td class="nump">1,723.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,471.1<span></span>
</td>
<td class="nump">1,536.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472.9<span></span>
</td>
<td class="nump">1,472.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605128817576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="num">$ (10.0)<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
<td class="num">$ (5.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">226.0<span></span>
</td>
<td class="nump">341.6<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 351.6<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 351.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605212018312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,180.2<span></span>
</td>
<td class="nump">$ 626.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">297.8<span></span>
</td>
<td class="nump">37.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">725.9<span></span>
</td>
<td class="nump">505.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 26.5<span></span>
</td>
<td class="nump">$ 23.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605122978616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,223.6<span></span>
</td>
<td class="nump">$ 2,049.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,223.9<span></span>
</td>
<td class="nump">2,051.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">2,223.9<span></span>
</td>
<td class="nump">2,051.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity Securities, FV-NI, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,239.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,072.2<span></span>
</td>
<td class="nump">897.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,072.1<span></span>
</td>
<td class="nump">898.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">309.9<span></span>
</td>
<td class="nump">402.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">310.4<span></span>
</td>
<td class="nump">403.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">236.5<span></span>
</td>
<td class="nump">380.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">236.6<span></span>
</td>
<td class="nump">380.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">452.1<span></span>
</td>
<td class="nump">245.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">452.0<span></span>
</td>
<td class="nump">246.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">152.7<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">152.6<span></span>
</td>
<td class="nump">122.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity Securities, FV-NI, Cost</a></td>
<td class="nump">1,168.9<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">607.6<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="num">(183.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">1,593.5<span></span>
</td>
<td class="nump">86.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity Securities, FV-NI, Cost</a></td>
<td class="nump">1,168.9<span></span>
</td>
<td class="nump">1,168.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</a></td>
<td class="nump">607.6<span></span>
</td>
<td class="nump">733.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</a></td>
<td class="num">(183.0)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">$ 1,593.5<span></span>
</td>
<td class="nump">$ 1,887.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121597128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,308.8<span></span>
</td>
<td class="nump">$ 1,278.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,308.9<span></span>
</td>
<td class="nump">1,278.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">870.9<span></span>
</td>
<td class="nump">722.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">870.5<span></span>
</td>
<td class="nump">721.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,223.6<span></span>
</td>
<td class="nump">2,049.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,223.9<span></span>
</td>
<td class="nump">$ 2,051.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605116524184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 633.5<span></span>
</td>
<td class="nump">$ 1,490.6<span></span>
</td>
<td class="nump">$ 1,452.7<span></span>
</td>
<td class="nump">$ 3,879.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="num">$ (5.2)<span></span>
</td>
<td class="num">$ (1.2)<span></span>
</td>
<td class="num">$ (24.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121726904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">13 months<span></span>
</td>
<td class="text">11 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605128834984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ / shares in Units, shares in Millions, number in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares)</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration agreement, purchase price per share (in usd per share)</a></td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,647.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DividendYieldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DividendYieldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605122733416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (212.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">$ (8.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net losses recognized on the decrease in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,205.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,623.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,623.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,229.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.8)<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605124776936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,880.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,880.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,782.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">54.7<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="nump">$ 103.5<span></span>
</td>
<td class="nump">$ 99.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">618.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605211414120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">$ 151,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,400,000<span></span>
</td>
<td class="nump">$ 66,000,000.0<span></span>
</td>
<td class="nump">$ 121,100,000<span></span>
</td>
<td class="nump">$ 110,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption, Amount</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">624,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="nump">$ 700,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.973%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.174%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts', window );">Payment of early call premium and write off of remaining unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain', window );">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605211460744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000,000.0<span></span>
</td>
<td class="nump">$ 5,029,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="nump">$ 3,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember', window );">October 2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_October2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605212097880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (171.8)<span></span>
</td>
<td class="num">$ (181.0)<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.2<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="num">(44.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(171.8)<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179.0)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(40.4)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="num">(50.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138.6<span></span>
</td>
<td class="num">(17.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(40.4)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="num">(40.4)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(31.9)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(31.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(31.9)<span></span>
</td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(31.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.6)<span></span>
</td>
<td class="num">(139.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(79.2)<span></span>
</td>
<td class="num">(186.5)<span></span>
</td>
<td class="num">(79.2)<span></span>
</td>
<td class="num">(186.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (79.2)<span></span>
</td>
<td class="num">$ (186.5)<span></span>
</td>
<td class="num">$ (79.2)<span></span>
</td>
<td class="num">$ (186.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605127336856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="num">$ (410.5)<span></span>
</td>
<td class="num">$ (57.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(409.1)<span></span>
</td>
<td class="nump">446.1<span></span>
</td>
<td class="num">(364.9)<span></span>
</td>
<td class="nump">738.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,775.0<span></span>
</td>
<td class="nump">3,681.6<span></span>
</td>
<td class="nump">5,469.0<span></span>
</td>
<td class="nump">7,215.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">448.5<span></span>
</td>
<td class="nump">1,542.1<span></span>
</td>
<td class="nump">858.7<span></span>
</td>
<td class="nump">2,941.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(27.6)<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="num">(49.0)<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605125497464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 858.7<span></span>
</td>
<td class="nump">$ 2,941.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">149.7<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">150.8<span></span>
</td>
<td class="nump">166.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">150.1<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">151.2<span></span>
</td>
<td class="nump">167.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605125291720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (55.8)<span></span>
</td>
<td class="num">$ (49.5)<span></span>
</td>
<td class="num">$ (128.4)<span></span>
</td>
<td class="num">$ (118.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">137.9<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">133.6<span></span>
</td>
<td class="nump">118.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(24.9)<span></span>
</td>
<td class="num">(20.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">85.2<span></span>
</td>
<td class="nump">73.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">$ 108.7<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605134461768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (55.8)<span></span>
</td>
<td class="num">$ (49.5)<span></span>
</td>
<td class="num">$ (128.4)<span></span>
</td>
<td class="num">$ (118.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">137.9<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">133.6<span></span>
</td>
<td class="nump">118.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123381016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetsValueReductioninValue', window );">Deferred tax assets, decrease in value</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesValueReductioninValue', window );">Deferred tax liabilities, decrease in value</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetIncreaseDecreaseInValue', window );">Deferred tax asset, increase (decrease) in value</a></td>
<td class="nump">$ 92.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue', window );">Deferred tax liabilities, increase (decrease) in value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetIncreaseDecreaseInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Increase (Decrease) In Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetIncreaseDecreaseInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetsValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetsValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Liabilities, Increase (Decrease) In Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605234973624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(9.10%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">TECFIDERA impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts', window );">Neurimmune tax impacts</a></td>
<td class="num">(0.831)<span></span>
</td>
<td class="num">(0.002)<span></span>
</td>
<td class="num">(0.463)<span></span>
</td>
<td class="num">(0.002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(70.30%)<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
<td class="num">(34.80%)<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605133435496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(56.4)<span></span>
</td>
<td class="num">(66.0)<span></span>
</td>
<td class="num">(121.1)<span></span>
</td>
<td class="num">(110.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="nump">153.9<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
<td class="num">(282.7)<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="num">(410.5)<span></span>
</td>
<td class="num">(57.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">154.3<span></span>
</td>
<td class="nump">102.9<span></span>
</td>
<td class="num">(281.8)<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) realized during the period on equity securities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">153.9<span></span>
</td>
<td class="nump">$ 102.9<span></span>
</td>
<td class="num">(288.4)<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,202.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,202.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,276.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">242.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">240.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">383.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">760.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,741.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,741.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">263.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,042.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,042.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,080.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123333720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 153.9<span></span>
</td>
<td class="nump">$ 102.9<span></span>
</td>
<td class="num">$ (288.4)<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,356.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,329.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">652.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">263.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net losses recognized on the decrease in fair value of equity securities</a></td>
<td class="nump">$ 105.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605123630264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>product </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585.1<span></span>
</td>
<td class="nump">$ 647.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099.3<span></span>
</td>
<td class="nump">$ 1,123.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfProductCandidates', window );">Number of product candidates | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.2<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117.7<span></span>
</td>
<td class="nump">77.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.8<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration agreement, purchase price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration agreement, amount, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration agreement, shares, purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global licensing collaboration agreement, shares purchased per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets', window );">Global Licensing Collaboration Agreement, Payment, Selection of Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.2<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.1<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.1<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237.4<span></span>
</td>
<td class="nump">67.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.6<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.9<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605127322264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16.1)<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (409.1)<span></span>
</td>
<td class="nump">$ 446.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(364.9)<span></span>
</td>
<td class="nump">738.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775.0<span></span>
</td>
<td class="nump">3,681.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469.0<span></span>
</td>
<td class="nump">7,215.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">$ 612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 691.6<span></span>
</td>
<td class="nump">$ 620.2<span></span>
</td>
<td class="nump">&#8361; 673.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
<td class="nump">55.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.4<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.1)<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="nump">$ 158.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605211442360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Neurimmune | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | JAPAN | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Europe | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121918216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140605121876792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - InnoCare Pharma Limited (InnoCare) Agreement - Subsequent Event - Forecast<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 125.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="nump">$ 812.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MDK$>F?A1)(XP' IF;!AHV0!HHPY0@$[-'@STFSQ$E9"XW)2'*^5[&[08RWY
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M!7!^+:4^[9@;%(NHH_\ 4$L#!!0    ( /F!]E*ZG2$;H0<  $$@   8
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MF_/K=R27YASW<%T*')BL_M^X#W0FPUP-^)@&[';N41<O? /.#R>7?J\?J5U
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MLGLWU5THL6U?[]P+I439?MQP!OFK#>#W!P'->W^AWQCMWQ!>_ ]02P,$%
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M!(Q&U], ='=9.\>JQL_[6EFZ/=ZLZ'U#[0)HOU3*'AQWA887,_L/4$L#!!0
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M,QE4AMJ=>9UIZ:#R4)S5'DIY+][?*W=/)=@(T%Y(L2CL3!9BIFV52Q10JNH
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M3&\O;R:C7W<\@1Q&L5S<O1M?76]_HJND?F;RSG?7(^BZ8YF'#Y"752&_UOA
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M<']N0<V;+[1!]X;0Z_\"4$L#!!0    ( /F!]E+GEYNV/ ,  .4&   8
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M\BG;Z!:A6Y(!A"$UB<CT.W =YU_^M] :V %#ZY#!B"'4<QAD'6L8Q^R]0>P
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ML$30$[KYKZ%YJ=22[_<GJJK4@KMS!*#4- '?"9I7+[1 ]X?/T;\ 4$L#!!0
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M2#8"AW4NA7T.VX'BW@#/3,LEGR+;94 *J+@.B4!7W"U6[.#B^NH5!41 2#(
M+>EF-*M\1'IAA)JCE6Z\E(A^O#B#+>;<D)T#< @"M#8:'LN$X3B1O5!$L.G_
M*S1%%<"&3 Q+>'[Q%GE1A@3O(0T4\/N(W%00#G5J!\=\@\.5;RZNKT*0-A0(
M!((X*!>>)H5M@G5]"GELVS]%%QZZ/*)QRA5UX7Q.)G29JX"-NXH(+-ZL,YZH
M*EY@C+PVK9UGTJ"!^E(C_\!U\)T *=G5M/5VH>4NR%OG^IBM+2!<0@'[U$E$
M13>5"J"[A,LNF-Q(/=Z>;?%*7M06DA>1," /)C:E&;Q4N</A)"JB=Y3,D<4:
M3S+Y(67N%:H25<\XDI_GI8$'GV*(5N8:;T+-[=V5BDV5&<+ \"%#&VNWM,GS
M>X([K&A9:*N:U@FC\B*)-6$A+X@\LJM'.J60C#-/%^R1P=K-;N_.;M8!U)+,
M9:@[2CK\D^ RU'TK2K:?Q:HA10.H-BN-:KG-_61HVTH8%4M-(#4YS1^7Y90L
M:#"HUW:1&M@AA;W$A)M]4/Z</GJ-IP6B(8.0A:FNC"+^D>NRF=$E:!W%[D(]
M9>P__ZTUTOZ(_79Y<_GS[6.+I$];I#7 6[;02ZJ+D&@U951@/D! Y50_ #GU
MU IS3XK,C$:I:6ENA(6AI!=P/L>JT C+F<3\_R=;;_:<?ZVMZ>QCT];I23+N
M!KP.J&P6)'1(28\$?#[.2.X7V;_75#Q$I278=%IJQ6:UHV/)C;Z#CC'@!<*7
MCR5?M3DQ89] 4#3';+;50:CN763&[M,N (YJ4T_82'*MZ8I1)T.Y.9<VHP9
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M(PL@L-CW?1;4F[6Q7]U"J4+<+;/<O3U:%,7J]>FI2Q9J*5U@5BK'DQMCE[+
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MH6^+MUR(/A\J+^HJ[W_8[;4@^44'KOW<ZL(05S@IK]ZUTKLB?Z&7 /DX[==
MXR  J Q:B=?BN3884,%2-I>5UGY2I34.W2RM^K2<_> ![APEFM6WE%]56\LK
M>>\E\0B[7%48>PO=US"V0?8"#S<.T^UGZ[Z>T14>44RM);!@]9KKF;"VKGZ5
MSEU5 @?M[A>%KH8E7QB6M%^L;JI?O>8:@&7WBFX)Y&S'MMU\^]A(T1.S!II!
MGNIZRG>DA+$&0RHN=>=%XQ&R\L7FPK0%'4,J1PRU!H,@/D%NC#LGJ3Q]< :]
MTQG$U1F=\:ZBO[._[VWG/$^GSGD>:_7#S52/<#/UA.C#"(0_,&UMV8++S$&W
M$6N&^S>9[S09G%-Y@;=5UQK\/B,S^?P599I./U'%WR.Y;B8S20'![_J=#S'?
M2=)O+SQ ]ROVG2^3Q%*J47?T9J+UCB5X!A9NW9?O5MQA*J/$B[1'B ]FHZ+#
M[X@S>=^05@][]ST1OE%)JZ.'!5L]_58VOM5WIK!Z3N^DX4-S*Y?NR1H)_UB-
M;-'6E#,A#M\U.%$Z+XU5U7G[#NL [BVZK2Z?1?Y#U%\37J$SD[Y; FD5[/H-
MQFGKURU+*A[T&QXG^*+%_]"EF6U^)G3F?QVS6>Y_8_09K1GUP9FZP58@HOA(
M6/^['3\HS(I_*S,S16&6_'6!&JLL+<#S&X-B6PWH@.;'4^_^"U!+ P04
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MX^$!,,/?"/D3IU?\7<Y,.Z<S/HSAO#*T /<7&E$H3TA!_:'6V;\!4$L#!!0
M   ( /F!]E)7G6!HCPP  "LI   9    >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;-5:;7/;N!'^*QC7U[%G=+1$6Y;M2SQC.Y>[7/,V\5WSH=,/$ E)2$A"
M!Y"6W5_?9Q<@14JR;-VE[70FL22\+/;UV5V0+Q;&?G4SI4IQGV>%>[DW*\OY
MQ=&12V8JERXR<U5@9F)L+DO\M-,C-[=*IKPISX[B?O_T*)>ZV+M\P6,?[>4+
M4Y69+M1'*UR5Y](^7*O,+%[N#?;J@4]Z.BMIX.CRQ5Q.U:TJ?YM_M/AUU%!)
M=:X*ITTAK)J\W+L:7%R?T'I>\'>M%J[U79 D8V.^TH\WZ<N]/C&D,I641$'B
MXT[=J"PC0F#C]T!SKSF2-K:_U]1?L^R092R=NC'99YV6LY=[9WLB51-99>4G
ML_A9!7F&1"\QF>._8N'7GF)Q4KG2Y&$S.,AUX3_E?=!#:\-9_Y$-<=@0,]_^
M(.;RE2SEY0MK%L+2:E"C+RPJ[P9SNB"CW)86LQK[RLM7RNH[29H1;PI7V@H*
M+]V+HQ*T:<51$NA<>SKQ(W1.Q3M3E#,G?BQ2E7;W'X&GAK&X9NPZWDKPEZJ(
MQ'&_)^)^/-A"[[@1])CI'>\DJ)!%*GY6Z5074W%%'J)+K9QXI5V2&5=9)?YQ
M-<9R>,\_MW!QTG!QPER<_&EU;Z5#H7KAYC)1+_<0BT[9.[5W"3>%$Q;BIK)6
M%<F#P,!"VE3<P#0D@1/?-\*VE?"J4J(THIPI,<W,6&:BD"7);B;"5%8  JRD
M('(],3>6O]5S5MVI OM)D6$=J*M[H(;#*(A8E1@+IQ"Z@$<S:Z1B@^,LSI0%
M'_Q;=!N)U&29M)'X%0-W,JN8@^TGY$J2F9AZBX83VA%=Q#BT LP9?P$.D)0)
M3ISB?*R?!(4EM<+4O9\5.$2Y"$H2Q+JE?3D\8XIAHHIS YF>6"A1X?<:K4E0
M?M(H'T0RDWRED[L'">F<232^I@C_<B9DK>9:RT0]D:YD.4ME"S8'#+55.9%X
M_317Q,UD0LJ1;%0$GFH"C^F^4HG*Q]#"\8!',3>3J4BKX!2T:T#2#<Y$[E&
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M:7+^.D/!HRPMP/S$H/()/^B YOW(RW\#4$L#!!0    ( /F!]E(5@("?; ,
M /0'   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)U5VV[;.!#]E8'0
M1Z\DRT[B!+:!I!=L%PA@-.CNPV(?:&ED$:5(E1Q6<;]^AY2M.-G$P!;PA1S.
MG#ESX7#9&_O--8@$CZW2;I4T1-U-EKFRP5:XU'2H^:0VMA7$6[O+7&=15-&H
M55F1YY=9*Z1.ULLHV]CUTGA24N/&@O-M*^S^#I7I5\DT.0J^R%U#09"MEYW8
MX0/2UVYC>9>-*)5L43MI-%BL5\GM].9N'O2CPI\2>W>RAA#)UIAO8?.Y6B5Y
M((0*2PH(@O]^X'M4*@ QC>\'S&1T&0Q/UT?T3S%VCF4K'+XWZB]94;-*%@E4
M6 NOZ(OI?\=#/!<!KS3*Q5_H!]W+/('2.S+MP9@9M%(/_^+QD(<3@\5;!L7!
MH(B\!T>1Y0=!8KVTI@<;M!DM+&*HT9K)21V*\D"63R7;T7ICN;Z6]A/8**$)
MA*[@XW<O.TX\P=G3949,(,!DY<'9W>"L>,/9)=P;38V#C[K"ZKE]QL1']L61
M_5UQ%O /KU.8Y1,H\F)Z!F\V9F,6\6:_E(V_;[>.+/?1/V=<S4=7\^AJ_BNN
M7DOM6;AP=V]<)TI<)7PY'=H?F)SXZ$8?.(8C+/*U*HWE6H @:"1WFY6E4% :
M1Q/0/!-,S1>G]*U7@EBM0D8OI0@W*H7;-TZ /]U9W[UP\&XZ62SR=,9MK52\
MH:S"PJM%<2IT@0,7&L="1\4/6&*[10NS:93R&<?=8;SE:I\"7UJ@!OEK$:.)
MDX_0#@V(H0&?HTZ>AX"///<<FQL2BG7?7<S3JQ=4\UEZ<10]=S_A%+8=9[AB
M +:=O@SS^OH)[:6IU)%X9R6'L$=A#V B* !G59K*I?!@E*'&6[9_Z"7]1*L"
M]+W0ON8F]5;J'7P2I522]O"9J\*5MH&/\UUG+!?76Z@]:R+LN'VIB=PJZW><
M"^9BAF)ULL/0;Q/H,7;-UDM5!70!2M@=_N:X:5@LF=%.EHX'U"F'^LB! WN=
M= I?.\Y,"%,AQ900M^.39<^98O-2^8HK=CV;Y'G.$]P'-G5XNRP.;<C1_3]2
M7/SK_#]PW'(];QKC'8?M*:A*=$,;';+WVA#(3B9QB\PBO#>. _.:AJ$\2L<G
M[7:8Y$_JPWMXST%([4!AS:9Y>G61@!W>F&%#IHMS?6N(7XFX;/A91AL4^+PV
MAHZ;X&!\Z-?_ E!+ P04    " #Y@?92P07O ) &  !E$P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6S56-MRVS80_94=->DD,PHE49(OB>T9.TXF
M:2=-)FZ:ATX?('(EH@$!!@ MN5_?7? F6Q?;G3ZT+Q() F=O9Q<+G"R-_>8R
M1 ^K7&EWVLN\+UX.!B[),!<N,@5J^C(W-A>>7NUBX J+(@V+<C6(A\.#02ZD
M[IV=A+%/]NS$E%Y)C9\LN#+/A;VY0&66I[U1KQGX+!>9YX'!V4DA%GB%_DOQ
MR=+;H$5)98[:2:/!XORT=SYZ>3'A^6'";Q*7;NT9V)*9,=_XY7UZVANR0J@P
M\8P@Z.\:7Z-2#$1J?*\Q>ZU(7KC^W*"_#;:3+3/A\+517V7JL]/>40]2G(M2
M^<]F^0YK>Z:,EQCEPB\LJ[GQ80^2TGF3UXM)@USJZE^L:C^L+3@:[E@0UPOB
MH'<E*&AY*;PX.[%F"99G$QH_!%/#:E).:@[*E;?T5=(Z?_9>ISCSF&IT#I[]
M8CRZYR<#3\C\?9#4*!<52KP#Y0 ^&.TS!V\(+KV]?D :M6K%C5H7\5[ GTH=
MP7C8AW@8C_;@C5LSQP%OO /ODHR$2^D295QI$7X_GSEOB1)_[ &?M."3 #YY
M@ ^W^>[AJ^'-*LF$7B!\G,_1PGL-;W%F2TJ7X E8(B0F+Q32 C"EO;O S,.H
M1P*U-"4>3J9PA5H:"R&X0'D<IL3#Z>CV%Z%32(3+^N%): )C2&^@*"U)<?@0
M;$:(X)SR;;&PN! >H;!2)[(0"D1N2NU92U$4UJPDI16J&WAR$$^B ^*W4IRJ
MM16; I;" =86IT&<>*2@P^$P.MP4M,T7'2[;!(6XH6+DW1;0T704'36@$7S<
MC MY#V:(7(42UJS1GB0!AQ]RD\JY3 27JE<\[LJ$(N&S6CI'W6B2WT%1^>+:
M1E ,DZ:2UY+M 2\EK@<7L"72L4.LEW_5DTF/]$\J+FP0!UB21A:=)^=2M>=
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MV.I2IWKQI@@7*3/CO<G#8T;&HN4)]'UNR.KZA06T-VMG?P-02P,$%     @
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M@,<H)+RY"=WT;:^&]U/4?Z [&?X%O 20"T<_,]0RI%=FK6/XH[8/O;">;6!
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MU-=[8M([$76E<Q?4>-),[+H4N;[B#(QAT? ?%".^@H<=??\YZJ PQK740EB
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MI;BG>/2^<I^1H86"G@)"AZ(L2VRJCW8K==B5 5I5?+V$\Q=$/!'UGRAR%&1
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MK11*IFE60J%)L>!Q\=TRP6=6!$L04ZHPR_') ]M#H"Q$R,_].T(5A!O];EC
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M 55V\6D( )UH-T/ I]9[_EI KM+C1U1Y!OVC!I0;GG$GZ&84LT8M_V-@[B0
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M\I^([\?<O!"5G/N!Q'L5Y(1K?1AY_$HS'NN&[(6^I[HB?X!QI_)[3<6#.[U
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M=?I[E7+M0)Y<*P37&8P(PCW7&<P/Z\+!*#$>C3W4'Y!;52E)1(GW>(M_-YC
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M5W&%+/F1//M$H7"<^IUP@MQ,_+D%4K(.*M07TI'ZR\GTUO2Y!%FK&2#1)GQ
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M)PK[^QK[Q60Y_Z9EDAF3+?@C(G.L"AJ ]],,]NF^T +A1TYO_Q]02P,$%
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M== [/>ZT#;@91%>G"WH*J:Y*GR7^K]B+ =9G#L5;#R3 ]H]M_"]02P,$%
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MSB'-/\&6_&47C$B 4_XS4\!.1POP?FHQ?]3_T 'MMY_>_0]02P,$%     @
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MB'U)YL,<^.Y=%7TEM\R)>[;S.66';9N^#W_\\BDDD'CM>=+U^%.([4HN;=R
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MCP/0W=QV!ZMJ/RL;96GR_+:DIPZU"R#_5BF[/[@$P^.Y_ -02P,$%     @
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MTP:.8#I*SR9A2M!Q-DJR))R>$)R,XDD<YE_?QVD>9MU]DDW#&97!::-5@<:
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M+W=O<FMS:&5E=',O<VAE970S,2YX;6RU6&UOXS82_BN$+SUL $.6*,FRTR1
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M*>%$'H&QL(Y>&+Q'5>"VV6J$P9(_L0L1XUF+-&W1W&-K?)<B*,VB$1G<BZQ
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MVM'9WM^F*"@>[D#O9UJ[U0,[J#_/C/\!4$L#!!0    ( /F!]E)YI:,F% 4
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M*T$;9FHCU3T88J.806 B \QS="G:;3_U#/LI3*A._HN$K-431(#KMFKY3\R
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M%QK='(5EZQXN,-[!G==:X]'P!--3F/\%4$L#!!0    ( /F!]E(Q1/UZZ (
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M3W&Z!Q1_?TZ2_/AFW\'IT4$7_P=02P,$%     @ ^8'V4CRO]A]<!   -A0
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M*8"\OJ%4'$]4@&KNG?P$4$L#!!0    ( /F!]E+YKZ,PJ ,  -\.   9
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M E,&\OF&4G&X40[JF7;V'U!+ P04    " #Y@?92=G8T,&("   G!@  &0
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M[FD@K8%YOQ8F1\W$.FAO?O/_ %!+ P04    " #Y@?92W5+>]: "   I"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6S-5E%/VS 0_BM6GC:)-7%2
M2D%I)&B%Q@03 @T>ICVXR;6U<.S.=MKNW^_LI*&P-DSBA9?&9]]W_NX[]<[I
M6NDGLP"P9%,*:4;!PMKE61B:? $E,SVU!(DG,Z5+9M'4\] L-;#"@TH1QE$T
M"$O&99"E?N]69ZFJK. 2;C4Q55DR_><"A%J/ AIL-^[X?&'=1IBE2S:'>[ _
MEK<:K;"-4O 2I.%*$@VS47!.S\8T=@#O\<!A;7;6Q*4R5>K)&5?%*(@<(Q"0
M6Q>"X6<%8Q#"14(>OYN@07NG ^ZNM]$O??*8S)09&"OQR N[& 7#@!0P8Y6P
M=VK]%9J$CEV\7 GC?\FZ\8T"DE?&JK(!(X.2R_K+-HT0.P#:/P"(&T#\OX"D
M 20^T9J93VO"+,M2K=9$.V^,YA9>&X_&;+AT9;RW&D\YXFQVR;@F#TQ40&Z
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MDQT#]XR*'6?JHDH!/LR8I'$B /P(?@/?'V?@P[N/X!V(,W ?)XFZ9&+B2F5
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M8@QMAS/(QL%98FPHBX^B[($8=PD;>EXWQ>4POS',&XB#82NVX_#X (\[7DE
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M831U= B#X\@W6%G4EBIEH>['@QYG"7.JY_Z0AE@K%1CL@HGM(8$J/:)N/3)
M+76VFPAHXTSU;"4:JA2"NA7B.XA EP S$73:M2$KL:!NL3A;].MZ8HQ^W<S'
MV';,0I7LT-ZR\VO"7R\(F<)??V)Q'"=2I7ZT]VFNG0+V3?F=%&"P"P+]Y&O<
M>%NG?%7JEN4;F<.!F-]+1V_DRSG)]V\?[6]$]EB]P+/,A,B2ZG++V9KGI8'\
M_3[+Q+>;\IV@PSM@L_\!4$L#!!0    ( /F!]E*Z?"DA P,  *4)   9
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;*V676_:,!2&_XH5[:*56I(X0$(%
M2"VH6B=5JHJZ7;OA!*PZ-K,=:/?K9SMI&B!05NT&8ON\Q\][$G\,-T*^J"6
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M)#W&Q(>8I$DG.LAXC D"M]N<,*X3QI<EI%S*YNV,CY;VUC_:S090VPT/0C:
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MDP7.$_6);SZ2>D##PE_$$UG^!YOZ76\ HEPJGM9@S2"EK/K%SW4B6@#MIQN
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M 2]W9+FUOR9T!ZO,2A7YPJ'N*6=[HB;2%@C?.NLX^1)K<!@Y&Q-UTGXPC+:
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MKH<[;>G\G/?[G_/^H1\>DDC!82?\H1_^1R2[X&>M<*LI= L^MX,O2+$0@.W
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M84RP*I\V4-=WC,G3B790_>FP_!]02P,$%     @ ^8'V4N5]\J$<!P  /2P
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M6Q))9A/.CH@K-'A3-SK[VAKRE95**$^2P]L,[.3L:4<XO9U#JE/T0'Z!!*1
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M[BA)*5< >+]A3)X&*D#SKXK9_U!+ P04    " #Y@?92CF0ML-@$  "^%P
M&0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6S-6%MOHS@4_BM6- \STA:P
M@4"J--(T8;4[4J5JNK/[L-H'%YR "IBUG:;=7[\V$*X.J3I]2!\:,-\YQ^?B
M\]E>'BA[XC$A KQD:<YO9K$0Q;5I\C F&>8&+4@NOVPIR["0KVQG\H(1')5"
M66HBRYJ;&4[RV6I9CMVSU9+N19KDY)X!OL\RS%YO24H/-S,X.PY\3W:Q4 /F
M:EG@'7D@XD=QS^2;V6B)DHSD/*$Y8&1[,_L*KP/D*X$2\6="#KSS#)0KCY0^
MJ9??HYN9I69$4A(*I0++GV>R)FFJ-,EY_%LKG34VE6#W^:C]U])YZ<PCYF1-
MT[^22,0W,W\&(K+%^U1\IX??2.V0J_2%-.7E?W"HL=8,A'LN:%8+RQED25[]
MXI<Z$!T!J4<O@&H!-!1P3@C8M8#]5@M.+>"\U8);"Y2NFY7O9> V6.#5DM$#
M8 HMM:F',OJEM(Q7DJM">1!,?DVDG%@]Q)B1JUL9Z@C<XU=9 H*#SQLB<))R
M +^ *_#C80,^?_H"/H$D!W=)FLH$\Z4II'6EPPQK2[>5)73"D@WN:"YB#H(\
M(I%&?C,M/Y^0-Z77C>OHZ/HMFE3X;9\;P+9^ <A"4#.?]=O%+9T[/V<]>+?U
M7C#LI@[L4I]]J@ZJ1@'H%G!5$N7JBT!(,]F2."X7-7E1SP1@SFF88"&_'Q(1
M@RC9;@F3E0,*1G<,9QS\_?61"R:[P#\3<W.:N3GEW)S)&CT](5TM5AJ]4J-J
MEL^K*]<U_*7YW,VP!N4L#+>/VFA0$/F&TX<%.ACT.S9[SKN-\^ZT\_M'005.
M=4Y6DG['HKL83FL]!CGNR,4Q"-J>L1AXJ$$AV$'U')PW#LXG'5SC(I'^)?_)
M[/)3F0XI%]J>,Q]-Z0H:WB $6M P!!J08]B#"%0@MPNR]>Y[C?O>3Q6W;+IA
MNI<=3W7?LA*J8 "<1T>,-C+>N#B\462\D3_.H'XV8SW0MHWY(# :E*S]$Z7A
M-['Q)V-SA]F3W"M)$@R?P#Y/AB704[IHE"XNKM-!JZ5CZ\-[7:VR&_R%85O=
M/SC(NT;$&W:.C0:$1CTTT*'FG=75#T1G7P(G _&'W(Y>/1.N8L_D#TM"]?BV
M6H"H-8,NKQI:4H;VQU>#/6[XUH@5-"C;&?5$#<JW#32L 'O413QT(O\MY\-I
MTE]C'@-.A$BE[P5AY9DH#TF5ILGDM]0*W<M+?LN+<)H8WY7\,4%9P\QKB,XR
MX##S9Q4%.D5=[NV[W?(AG";$^TZNSZ[SEDF@?WFI;BD)+CX^U8OSJ3X+V9R'
M!#7D9,'T#U\MTZ%IINOFN=/5FS4OMSOE\-1)KV43!"\N_:@E(80^//VURF[B
M!IO5=0WI,?-HH6M 9S8/@48$H@[#]*/0DAV:)KLW%$0H26$JXBV[(.?RZJ'E
M)73FS/>>>A@?SNP1Z]>@WOEEN.O3*!H=*@,-R#FUVT<MXZ%IQ@NR(J6OY)C^
M8L_"6 8!%"G.IP+;<@OR+B_M+4>AZ>/.N]+NCVX=[.&I=:T!N<,3W$8#@M9H
MKZ=!>:/$FYW[R(RP77D1S*5/^UQ45U+-:'/9_+6\8AV,W\+K-=2,;^!U4%TE
MM^JKFVUY9-PE.0<IV4I3EN')0F7597'U(FA1WH8^4B%H5C[&!$>$*8#\OJ54
M'%^4@>;*?O4_4$L#!!0    ( /F!]E(-,)!77@,  '\,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<R+GAM;+576V_:,!3^*U:TAU;JR(T$6@%2N53KM$I5
M+]O#M >3',"J8S/;*>U^_>PDI*&$ *O& XF=\UW.L9.<]%9</,D%@$(O"66R
M;RV46E[8MHP6D&#9XDM@^LJ,BP0K/11S6RX%X#@#)=3V'">T$TR8->AE<[=B
MT..IHH3!K4 R31(L7H= ^:ION=9ZXH[,%\I,V(/>$L_A'M3C\E;HD5VRQ"0!
M)@EG2,"L;UVZ%U>N;P!9Q'<"*UDY1R:5*>=/9G =]RW'. (*D3(46!^>8024
M&B;MXW=!:I6:!E@]7[-?9<GK9*98PHC3'R16B[[5M5 ,,YQ2=<=77Z!(*#!\
M$:<R^T>K/#;4BE$J%4\*L!XGA.5'_%(4H@+0//4 KP!X[P'M'0"_ /B'*K0+
M0/M0A:  !(<"P@(09K7/BY55>HP5'O0$7R%AHC6;.<F6*T/K A-F=M:]$OHJ
MT3@UN&813P ]X!>0Z&0,"A,JT0.\J!334_09/=Z/T<FG4_0)$89N"*5Z/\B>
MK;2V8;"C0F>8ZW@[='QTPYE:2#1A,<0U^'$S/FS VSKG,G%OG?C0:R3\FK(6
M\ITSY#F>6^-G=#C<J4OG8^J3CZE?-</'$&FX6P??J*5?;B(_X_/W;B(TTJM$
MV!Q8](I^?M-QZ%I!(G\UJ+1+E7:FTM[I>@9"0(R4UL%2@I)GB(&JVXPY4Y@Q
MF8?K\R!P=*;/U15JCMFP&)06@^,MS@67M7=,SA54#'0[P3N3S3$;)L/29'B\
MR90)B/B<D3_%A2DPF)':XH9;GOPMW\TQ&[X[I>_.'M^1?G=*, ^B778E(A*9
M*,[PE+ZBI2X]F5*HNT<Z6^OO[5C^;NFPV^CP83*ZNAY/[BX;=OMYR77^'^\I
MUWE[_CO'[X:X4NIG3-.Z^@T+XNH:NYVMNVQ?U*;MRFO+/=PV)7A**%$$#O;N
M;KL*M[WOB=KT[KUY]XXL^9DV6[@^6?L_;4X@E^A4K)U[K>"\^GN?S3&0S=3>
M7@2N_X_+<F2"HT*HZK;;;74V<YKLB\K3L"O]40)BGG6R$D4\92I_RY6S9;=\
MF?6([^:'[L7(K9D?NQ>3O!=^H\];\QLLYH1)1&&FI9Q61V\FD7>[^4#Q9=:=
M3;G2O5YVNM!?""!,@+X^XURM!T:@_.88_ 502P,$%     @ ^8'V4@>V$AD#
M!   HQ$  !D   !X;"]W;W)K<VAE971S+W-H965T-S,N>&ULI5C;;N,V$/T5
MPL "+M#JZDL<V 826]MZT6V#9+=]IJ6Q3:Q$NB059_OU)2E%L384E;@OMDCQ
MG)DYXI!#SD^,?Q,' (F>BIR*Q> @Y?':]T5Z@ (+CQV!JC<[Q@LL59/O?7'D
M@#,#*G(_"H*)7V!"!\NYZ;OCRSDK94XHW'$DRJ+ _/LMY.RT&(2#YXY[LC](
MW>$OYT>\AP>07X]W7+7\AB4C!5!!&$4<=HO!37B=A+$&F!%_$3B)LV>D0]DR
M]DTW-MEB$&B/((=4:@JL_AYA!7FNF90?_]2D@\:F!IX_/[-_-,&K8+98P(KE
M?Y-,'A:#JP'*8(?+7-ZSTV]0!S36?"G+A?E%IWIL,$!I*20K:K#RH""T^L=/
MM1!G ,5C!T0U(/H1,.H Q#4@?JN%40T8O=7"N :8T/TJ=B/<&DN\G'-V0ER/
M5FSZP:AOT$HO0O5$>9!<O24*)Y<;FK("T!?\! (-UR QR<5/<U\J;CW"3VN>
MVXHGZN")T6=&Y4&@A&:06?!K-W[BP/LJIB:PZ#FPV\A)^*FD'HJ#GU$41*'%
MG]7;X8$MG/]G/;G8>DN,N/G*L>&+._CN(64T)3G!)CNW($\ %,D#H*_>@X=V
MD ''.1(2RU(R_AU)_(0XEH PS1#L=F 2NNEV^#1J?!H9GT8=/CTTMEX35A_8
MC8]"+P@^V+[LA;CUA;CD_;B68.-&L'&O8.8+@+"IY0:'7FP7RPT+O)%=JSYK
MH5VJ/FMCIU*31JF)DZ=:S=1$5QNIVBDH LPIH7NK;FZJX=2;!A]L"^*J!QAK
MZ6S =0]PIL6S 9->BZ]=;>DW;?2;.IE6'#(BA<E]JHH559:H'%4"HIP)@4JI
M5I)_S5)B$]3-/8R\68>@/4"31U9!>X"QGOM602^PV!+TJA'TRLET5_+TH,J9
M#!$J,=V3;:Y65B% 6J>DFVP8>%<="KJ!@1?9D[G77M>$?+>]EGJS1KV9.YV3
MU<?-.KF_0:0X8L)5G2IMLKE9@J[MP@V+=%+91+O,6N*&A3TK8!B\U'6!D^G7
MS>]?-M8ZSHVS>%#)="%NW8NS;TQ)+^[5%M-6ZJP"#IU,?T#)25&4M"IO]!Q+
M[7E9$^E:7C'I,]CC\A>5C;$J\1Y;6MD'!D'4'KCN&#B:Q.V!R1L8V^%'+^%'
MSO#_5%4@MT;KQG65!JM>7$="]>(F'1/EW7ZVE7HIHL/8R93TE,&U;&Z2X33H
MVHY6/5!52<XZI.NQ&8^ZMHRD!QK.--(FGW]VZ"R [\UI7Z"4E516)Y.FM[E1
MN#'GZ!_Z;\/K56CI7^L;"'/(?:&OKB\^8[XG5* <=LJ4FE J*WAU(U U)#N:
M(^^6276 -H\'P.J,HP>H]SO&Y'-#&VCN99;_ 5!+ P04    " #Y@?92C/9R
M,# &   [&@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6RU6=]OVS80
M_E<(8P\)D,@B)<MVD 1(+'O+T'9%LG8/PQX8F;&)RJ0KTDF[OWZG'Y%DD6(U
MM,U#+,O?'?D=CW<?I<L7F7U26\8T^K)+A;H:;;7>7XS'*MFR'56>W#,!OSS)
M;$<U?,TV8[7/&%T71KMT3'P_&N\H%Z/KR^+>^^SZ4AYTR@5[GR%UV.UH]O66
MI?+E:H1'KS?N^6:K\QOCZ\L]W; 'IC_LWV?P;5Q[6?,=$XI+@3+V=#6ZP1<K
M,LL-"L1'SEY4ZQKE5!ZE_)1_N5M?C?Q\1BQEB<Y=4/AX9@N6IKDGF,?GRNFH
M'C,W;%^_>E\5Y(',(U5L(=._^%IOKT:S$5JS)WI(];U\^8U5A":YOT2FJOB/
M7BJL/T+)06FYJXQA!CLNRD_ZI0I$RP#\V U(94"Z!F&/05 9!$-'""N#<.@(
MD\I@,M0@J@RB(O9EL(I(QU33Z\M,OJ L1X.W_*)8KL(: LQ%GED/.H-?.=CI
MZS_TEF5H(862*5]3S=9HQ045":<I>M!P ])(HYAIRE-T4GZJ4W2./CS$Z.27
M4_0+X@*]Y6D*B:(NQQHFE;L>)]4$;LL)D)X)!.BM%'JKT%*LV=IB'[OM(X?]
M&()11X2\1N26.!W^?A >"OPS1'R"+?-9##?W;72^;_3E]XV^<IO'+ %S;#,_
MBF509U=0^ N<V74G$KECZ&3Y!>JA8J=GZ!W3#N]A[3TLO(<]WN^$9AE3&A(P
M'\"6>Z6#:>$@+[+/U\2;7HZ?V^MI8J9>=(R)3<RDBUF6F*B%"4@-.2(XJ0E.
MAA%D9>1L#$L/L]:HYY/("SL<2]2DC8JZ'"V>,,$>[M"TP;#O!7:J44TU<E+]
M%9H@.DFE@MH"#8>+9^"=EQYUAD0W6TKFD3$1/ F\>8>Y!>5'WJS#W42=DYF1
M*DL31N;>Q,Y\6C.?.IE#@X3V)V"-DRT5&X8V$ I5QH*ITU[Z4W/*?I?7P@3!
M4G62([9XFG=!2PMHUD=]5E.?.:D7Y:&7X,S,V:!#;V9,*O1(AYV).2?=+%E:
M0+[7LWOG-;NYD]V?4D,/E44)Y%4)9'4)["$]-R8RA]WLM_XZ^W$Q-\(4=<(4
MFT[/0\B#22<(%MADVK?&V&\4AN]L LO/!ZZ_H@>6'#*N.8,=O?IX_N[N#)6;
M_DV^Z<_030K%3M!<:**_;QZ5SD!U_N-H$[BE<;!S):#=='85B.)$;@3_%_3.
M&J8E-@C6">U9QN4Z+T"LG+2J)VU5-MA2@D*OFZ4VF&_D8&R!01'"W3V]K'#M
M%0][4A63)D3$&:(W3*D+9 T43;\W3,0@9A2A105JL_*[ 3+]1$87=OHY#DZC
M8G#@#,X'44?AIZ11,*B35;#IM]+(] 9I-#,*>H6+AJ11H\APZ-SK-TF2'2 8
ME=13B(HU*LJ\:R,W>@B[!=$]>V;BP,XSEA9'%1!'+ .E@."(C=9<)?( BJ$8
ME*9P:(9S3$_(316#0?-VMVX\$+>J<-$1;AKUA+,11=BMBN"\G-)'F='B%.Y0
M@=BB3$+2K?#Q,-C* @N"H%6(CNDT2@>[I<Z]_$K3?!<4*Y3R)']" 7OFB?6L
MDBDZ2.B;BS0(MK+!<*^&P8V(P6X5,WR13)41S )#C@V#K:RP>:L<'--I5 MV
MRY;%(<OR(_]>9@4A^802.&'#.N5WX5+Q-:O(RL>4;XI+^_J9VL2HZ=^$K+"I
M2W X]WHV%VET"?&=1&.HTL^EWD@Y?>1I;X&N'+5G,"5.51;_?Y.5Q01#^^_)
M3]*H'^)6/Y;R6]$R!<<T,K?7,-C*!IOC5MH>3[]1)L2M3$H93:O&4FVOHH#(
M7F*F!B#3T%BB(:@5,45'@,-)WWF7-**"N$7%G10<I/ #G/GH3IZAF G0& 6Q
M![IAKB=933LF[G;\LZ0W:3HV<7?LGRR=B/E@@T1]2].T7?*MMKO;2Y&7.RA^
MG<Q3?:EW/%;3$\GTQRLFTC0GXFY./TPQ5>,<JT_0#L:N&H9;67$SWRCKX]:S
M[1W+-L5;"(6*>9</(NN[]9N.F^+Y?N?^+;Y88,O]&%\LR_<8C?ORM<I;FFWR
ME$W9$PSE>U-(LZQ\4U%^T7)?/%E_E%K+77&Y912Z8PZ WY^DU*]?\@'J]T77
M_P%02P,$%     @ ^8'V4INQF]E] P  ?0L  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S4N>&ULQ5;;;MLX$/T50NA# B367;8#VT!BQV@72!O4V]UG1AK+
M1"G2):DXW:_OZ!)5EA6M@3ST)29'<V;F'$X&,SM(]5WO  QYR;C0<VMGS/[&
MMG6\@XSJD=R#P"];J3)J\*I26^\5T*0$9=SV'">R,\J$M9B5MD>UF,G<<";@
M41&=9QE5/^^ R\/<<JU7PU>6[DQAL!>S/4UA ^;;_E'AS6ZB)"P#H9D41,%V
M;MVZ-^MIX5\Z_,/@H%MG4C!YDO)[<?F4S"VG* @XQ*:(0/'G&9; >1$(R_A1
MQ[2:E 6P?7Z-OBZY(Y<GJF$I^;\L,;NY-;%( EN:<_-5'CY"S2<LXL62Z_(O
M.=2^CD7B7!N9U6"L(&.B^J4OM0XM ,;I!W@UP.L"@C< ?@WPS\T0U(#@W QA
M#0C/!40U("JUK\0JE5Y10Q<S)0]$%=X8K3B4SU6B46 FBL;:&(5?&>+,XHO9
M@2)+*;3D+*$&$K)F@HJ844XV!@W8189<K,!0QC7Y&UY,3ODEN2;?-BMR\>&2
M?"!,D ?&.7:*GMD&JRIBVW%=P5U5@?=&!3YYD,+L-+D7"20]^-4P/AK VZA&
M(XGW*LF=-QCPKUR,B.]<$<_QW)YZEN?#G3XZ[\M^_[[LZV'X"F*$NWWP(RW]
MIKW\,E[P1KS/.!I3'&\:AU L4\'^PP;#@8)=AUT3XRC4Q8%L*5/DF?(<B-P2
M^)$S\Y-HB'/%#(/>KJH2C\O$Q?A\7KBA/YK.[.?V6_5X.5[7:W7J=>U-)J/@
MV.V^<HM:;H'7N!SI$S3Z!&?J<\&EUJ O42C*2YD2)"_24JH]*"9+X<Z2ILHY
M:=7I=+DL@Q,N3D>4TRC1*.HH,A3E2)"P$20<%*2:1UR*]-J R@AG](GQ-YF&
M)S6Z?AAUR:[.<UN'I\WB>],6Z2-*44,I&J1T&\<JQ_?$?I<9$$-?^KE$IWJ'
MWFC<H7*6USHZ83)VIJVV/R(R;HB,!XE\DH+I*[*A(J69O"(K$-BJA(H$;2D,
MC(M)DV'RI\9%E3AL*>)%?K\>TZ;:Z?]66_W7]I2;P+O*G?;,K7 TZ33#J9<W
M"5I>%2V[M1YDH-)RD=,DEKDPU2AOK,VN>%NN2!W[G7NS='OL*_?FOEH%?X>O
M%M,'JM+B.3EL,94S&N,#J&K9JRY&[LOEY$D:7'7*XP[W8U"% W[?2FE>+T6"
M9N->_ )02P,$%     @ ^8'V4O+8W\C2"@  &D$  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S8N>&ULS5Q;;]NX$OXK1+ +M$!6%DE1DHLT0&([L8NF)ZB;
M/0^+\\#(C"VL+EY)3AJ@/_Y0,FU*(D7;N6"=AR16AL.9X<Q\,R25LZ<T^SM?
M,%: GW&4Y)]/%D6Q_-3KY<&"Q32WTB5+^%\>TBRF!?^8S7OY,F-T5@V*HQZR
M;;<7TS Y.3^KGMUFYV?IJHC"A-UF(%_%,<V>+UF4/GT^@2>;!]_#^:(H'_3.
MSY9TSJ:LN%O>9OQ3;\ME%L8LR<,T 1E[^'QR 3]]\7$YH*+X,V1/>>UW4*IR
MGZ9_EQ\FL\\G=BD1BUA0E"PH__'(!BR*2DY<CG\$TY/MG.7 ^N\;[E>5\ER9
M>YJS01K]-YP5B\\G_@F8L0>ZBHKOZ=.8"85(R2](H[SZ#IX$K7T"@E5>I+$8
MS"6(PV3]D_X4AJ@-0+!C !(#4&L ]CH&8#$ [SO $0.<?44B8@#9=X K!KC[
M#O#$ *^M@]\QP!<#_'UGZ(L!_7T'0'NS<G;E0>LEK_QE2 MZ?I:E3R KZ3F_
M\I?*Z:KQW$W"I(R/:9'QOX9\7''._2JB]VE&2S<%-)F!_Q0+EH'O+**E ^>+
M<)F#/T"-CC\$'X:LH&&4?P2_@1[(%S1C.0@3<)>$17Y:>W 31E$YXI03UCZ>
M]0HN?"E"+Q""7JX%11V"0G"3)L4B!Z-DQF::\2/S>+QK_-@\WC6,[W&C;RV/
M-I:_1$:&7U:)!;!]"I"-X-UT"#[\]E$CUL#,Y5OZN.5B"RYR2=;?-5R'9JY7
M[-X"J'\HU]&;:'RU/Q>[F\NUF<L-S3@7N(O+^'"-EEDZ6P6%-)>&[>1-5/RR
M@PM-=JC8\%N\S1BX8HOWRA@764:3.>.(6539H_YYG4F*!4U <]!?7SE/,"E8
MG/_/()&SE<BI)'(Z)/K.<D:S8%$),&2/'/27E0"CG[R,R!GX,/H91*M9F,S!
M1?#/*LS8K$Q&MUD:<&_FPN6%SKZC];1>-6U9:#R>$Y]8\*SW6'=7E<IU/,MM
M4HU5*FCW^Q9NDDTT9!!AJ[\E:UB(;"U$C!8:A3D-#99VMWS<(UE[;RN19]3L
MVRJ^YQ.E#T#$'0BX*.&,%AQ_?FT>ZB)[S9?4+(WT1O:WHOA&46Y9%G#5>559
MBO.P*E89XZ6:=,> ^UG.BTJ.K-P!BQ1HEF7M>.:)'&+9]N^ZS'GXN(:F_:VF
M?2.CKRF/FJH^K@5>4].DR'CIFX."9;QNJ11^"HM%I\K7ZQG=VG(X1+\>T):U
MC6V4\V(V"\MZA4:\>(H8+Z>XZRWI<RFCSGR"75T(KTN(6H$%=\<>=\7+BV_(
ML6%EJU'$DGO&DT]!"\-Z0"0G04<2F%#B!,1FQ47VG23!*BM3[N5SLXS4%G%8
MS:;(0JV4*ZC\&A6N)TE1T*F\(/0LKY5R-<P\S^I:=PE*T(Q*&_5YOU<V@R(
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MG[Z%>,4JOV"';A+:'#.TO3% #,5TC?V?3M>1,.:88>S?!HBAHSE=<KH PI'
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MP:<'&M,EDY\!?59U<$I-=.0U#76=4=W2BZ:8ZS;\F192PRH8]MW^J.9V4RS
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M>S!=(CNHRRX47Z>G.'.N%(_2GRM* BJT #Q?<.A(?J$=%,>EP_\ 4$L#!!0
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M;GS)9_/?P*_^ %!+ 0(4 Q0    ( /F!]E('04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ^8'V4E(_
MX"'N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ ^8'V4IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #Y@?92TUZ@*R@%  !0
M%0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ ^8'V4KJ=(1NA!P  02   !@              ("!:PT
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /F!]E)LH@T2
MDP0   41   8              " @4(5  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #Y@?92ON[@TL0&   M'   &
M@($+&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ^8'V
M4JB.$,I! @  /04  !@              ("!!2$  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( /F!]E((7RWUB @  $LD   8
M      " @7PC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #Y@?92A)ECH@<-   K5P  &               @($Z+   >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ^8'V4@Z_MKCM#0  +20  !@
M             ("!=SD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4
M Q0    ( /F!]E+GEYNV/ ,  .4&   8              " @9I'  !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #Y@?92D>DWH9X)  #\
M&0  &0              @($,2P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+ 0(4 Q0    ( /F!]E(_"(Z/=@(  #$%   9              " @>%4
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ^8'V4K"!
MU$ ;"P  %!\  !D              ("!CE<  'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"% ,4    " #Y@?92'"?O(\P+  !()0  &0
M    @('@8@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M /F!]E(+R] 0L0H  +0E   9              " @>-N  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ ^8'V4E>=8&B/#   *RD  !D
M             ("!RWD  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #Y@?92%8" GVP#  #T!P  &0              @(&1A@  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /F!]E+!!>\ D 8
M &43   9              " @32*  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ ^8'V4JA[YM%A!@  <10  !D              ("!
M^Y   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #Y@?92
MJ+^ #%D#  !T!P  &0              @(&3EP  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /F!]E(?T!LHC 0  )$+   9
M      " @2.;  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ ^8'V4K%HY$MI"@  ;!L  !D              ("!YI\  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #Y@?92,XS$KE0&  !V$0
M&0              @(&&J@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( /F!]E+_JZI)=QD  ,Y<   9              " @1&Q  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ^8'V4N1;9N10
M"@  :"$  !D              ("!O\H  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #Y@?92!IGD]K$2  #P-   &0
M@(%&U0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /F!
M]E(W5-]!6P0  +T)   9              " @2[H  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ ^8'V4F2Q")#6#0  "24  !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( /F!]E) >@0O%@8  *01   9
M  " @?02 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M^8'V4LV#<F]3!0  JA$  !D              ("!01D! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #Y@?92>:6C)A0%  ";#@  &0
M            @('+'@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( /F!]E+@5UH--0,  "('   9              " @18D 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ^8'V4K!T;XTN!
M< L  !D              ("!@B<! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #Y@?926%O-EA@#  #<!@  &0              @('G
M*P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( /F!]E*F
M-KR5P00  .4+   9              " @38O 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ ^8'V4GE <)&4!   ! \  !D
M     ("!+C0! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /F!]E)[K+278 (  !P&   9              "
M@8I- 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ^8'V
M4OHY/#YV P  EPL  !D              ("!(5 ! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #Y@?92.,RE@;$#   ##P  &0
M        @('.4P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( /F!]E+YKZ,PJ ,  -\.   9              " @;97 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ^8'V4G9V-#!B @  )P8
M !D              ("!E5L! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #Y@?92+*/$A,T'  "U+0  &0              @($N7@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( /F!]E(KEJZD
M+P,  ,X)   9              " @3)F 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ ^8'V4M=EJBY?!P  <#,  !D
M ("!F&D! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #Y
M@?924DW(0X,#   %#@  &0              @($N<0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /F!]E+=4M[UH (  "D)   9
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M970U-RYX;6Q02P$"% ,4    " #Y@?92/L4N^X\&   /)@  &0
M    @(&;AP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M /F!]E*Z?"DA P,  *4)   9              " @6&. 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ ^8'V4G)B,!3? @  @ @  !D
M             ("!FY$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " #Y@?92S)RM3ST"  !_!0  &0              @(&QE $ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( /F!]E(I>L1TK 0
M !L5   9              " @267 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ ^8'V4G>T3KG""P  ^T4  !D              ("!
M")P! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #Y@?92
M K#KMML#  !1#@  &0              @($!J $ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( /F!]E(XW[J\708  +DA   9
M      " @1.L 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ ^8'V4KE#XQ_) P  @!   !D              ("!I[(! 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #Y@?92Y7WRH1P'   ]+
M&0              @(&GM@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( /F!]E(8AU%Q]P0  /(6   9              " @?J] 0!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ ^8'V4G'*80 %
M!   @@\  !D              ("!*,,! 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " #Y@?92[JTP&B,$  "V$   &0
M@(%DQP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( /F!
M]E*.9"VPV 0  +X7   9              " @;[+ 0!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ ^8'V4@TPD%=> P  ?PP  !D
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M=#<V+GAM;%!+ 0(4 Q0    ( /F!]E)K4)-P[@<  $@G   9
M  " @<#M 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
M^8'V4G JX$P-!@  .AT  !D              ("!Y?4! 'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " #Y@?92*E[A&/@!  #\ P  &0
M            @($I_ $ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( /F!]E+8F(:_C (  *$%   9              " @5C^ 0!X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ ^8'V4I_3@OA? P
MV!8   T              ( !&P$" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #Y@?92EXJ[',     3 @  "P              @ &E! ( 7W)E;',O+G)E
M;'-02P$"% ,4    " #Y@?92$96,QLD%  !B-   #P              @ &.
M!0( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ^8'V4K3%"JYH @  1R\
M !H              ( !A L" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ ^8'V4BP!9SL; @  #BX  !,              ( !) X"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %@ 6  ?&   <! "

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>710</ContextCount>
  <ElementCount>450</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>156</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142110 - Disclosure - Indebtedness (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessNotes</Role>
      <ShortName>Indebtedness (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2156114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2160115 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2164116 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168117 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2170118 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2172119 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2345307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350308 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesbyProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails</Role>
      <ShortName>Fair Value Measurements - Nonrecurring Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2436423 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessNotes</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2471440 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2473441 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEvents</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-20210630.htm">biib-20210630.htm</File>
    <File>biib-20210630.xsd</File>
    <File>biib-20210630_cal.xml</File>
    <File>biib-20210630_def.xml</File>
    <File>biib-20210630_lab.xml</File>
    <File>biib-20210630_pre.xml</File>
    <File>biib-2021630xex311.htm</File>
    <File>biib-2021630xex312.htm</File>
    <File>biib-2021630xex321.htm</File>
    <File>exhibit101amendedmanagemen.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20210630_g1.jpg</File>
    <File>biib-20210630_g10.jpg</File>
    <File>biib-20210630_g11.jpg</File>
    <File>biib-20210630_g12.jpg</File>
    <File>biib-20210630_g13.jpg</File>
    <File>biib-20210630_g14.jpg</File>
    <File>biib-20210630_g15.jpg</File>
    <File>biib-20210630_g16.jpg</File>
    <File>biib-20210630_g17.jpg</File>
    <File>biib-20210630_g18.jpg</File>
    <File>biib-20210630_g19.jpg</File>
    <File>biib-20210630_g2.jpg</File>
    <File>biib-20210630_g20.jpg</File>
    <File>biib-20210630_g21.jpg</File>
    <File>biib-20210630_g3.jpg</File>
    <File>biib-20210630_g4.jpg</File>
    <File>biib-20210630_g5.jpg</File>
    <File>biib-20210630_g6.jpg</File>
    <File>biib-20210630_g7.jpg</File>
    <File>biib-20210630_g8.jpg</File>
    <File>biib-20210630_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20210630.htm": {
   "axisCustom": 5,
   "axisStandard": 33,
   "contextCount": 710,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20210630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 712,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 23,
    "http://www.biogenidec.com/20210630": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 31
   },
   "keyCustom": 81,
   "keyStandard": 369,
   "memberCustom": 77,
   "memberStandard": 70,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142110 - Disclosure - Indebtedness (Notes)",
     "role": "http://www.biogenidec.com/role/IndebtednessNotes",
     "shortName": "Indebtedness (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156114 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160115 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164116 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168117 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170118 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172119 - Disclosure - Subsequent Events",
     "role": "http://www.biogenidec.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345307 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350308 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "if6d044336b8f4a9ab994c3824c06a493_D20200301-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesbyProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic3c40ac7856a4709b06d820f5782887c_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i702781d7d4d143c985f549228c64fa29_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i31978ab53c1242d2b851e6c69e47254a_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i49dbdd6ccc5c4f4e8c800f8f4c3db2ed_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i6f98fda190d242ab8aa70b53d46f8e0f_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i8b7d9660d3bf4a90965d36747d39593f_I20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i8b7d9660d3bf4a90965d36747d39593f_I20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Fair Value Measurements - Nonrecurring Assets (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
     "shortName": "Fair Value Measurements - Nonrecurring Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i71f9390e677c4071a7ae6a84252c90f2_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i2688408eb08c4656a8e3ebeb05647de1_D20201101-20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436423 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i6c93ea4397fb4f4cacf7e9b9766c5d11_D20210101-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "biib:DividendYieldPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i43e9a82c06fb46bab58a5f1115cdafbd_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i025174d34d0e4fed9880bf522bf39caf_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ie0d7f325ae73459e825690036a3d6239_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ibeccde350a794ad3a057220538aae69a_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ibeccde350a794ad3a057220538aae69a_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i81326f8c0faf4c82934916df0e7ba73b_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "iaa5fa1b4ae5249e69c9c272bba7781f8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i7b0791f187a342618d92225b098c9d17_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ie30cba3e2edd4bc08f2a74408c366d3b_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i11863a558bbf46bca75ffd9f7fafbba7_I20181107",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471440 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i60b121f8efd14872a1e30df2ef86c797_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i8f888c4ff5e0416ba053664107506cc4_D20210701-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473441 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.biogenidec.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "i8f888c4ff5e0416ba053664107506cc4_D20210701-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20210630.htm",
      "contextRef": "ic893fca259aa47f19e6372cfd49a1d3e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 156,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2.90SeniorNotesDueSept152020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "label": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "terseLabel": "2.90% Senior Notes Due Sept 15, 2020"
       }
      }
     },
     "localname": "A2.90SeniorNotesDueSept152020Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ADUHELMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADUHELM",
        "label": "ADUHELM [Member]",
        "terseLabel": "ADUHELM"
       }
      }
     },
     "localname": "ADUHELMMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]",
        "terseLabel": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20210630",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111AndBIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 and BIIB112",
        "label": "BIIB111 and BIIB112 [Member]",
        "terseLabel": "BIIB111 and BIIB112"
       }
      }
     },
     "localname": "BIIB111AndBIIB112Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB118 [Member]",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Amount",
        "label": "Debt Instrument, Redemption, Amount",
        "terseLabel": "Debt Instrument, Redemption, Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetIncreaseDecreaseInValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Increase (Decrease) In Value",
        "label": "Deferred Tax Asset, Increase (Decrease) In Value",
        "terseLabel": "Deferred tax asset, increase (decrease) in value"
       }
      }
     },
     "localname": "DeferredTaxAssetIncreaseDecreaseInValue",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxAssetsValueReductioninValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Value, Reduction in Value",
        "label": "Deferred Tax Assets, Value, Reduction in Value",
        "terseLabel": "Deferred tax assets, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxAssetsValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesIncreaseDecreaseInValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax Liabilities, Increase (Decrease) In Value",
        "label": "Deferred tax Liabilities, Increase (Decrease) In Value",
        "terseLabel": "Deferred tax liabilities, increase (decrease) in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesIncreaseDecreaseInValue",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesValueReductioninValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Value, Reduction in Value",
        "label": "Deferred Tax Liabilities, Value, Reduction in Value",
        "terseLabel": "Deferred tax liabilities, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DividendYieldPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield Percentage",
        "label": "Dividend Yield Percentage",
        "terseLabel": "Dividend yield percentage"
       }
      }
     },
     "localname": "DividendYieldPercentage",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "label": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "terseLabel": "Payment of early call premium and write off of remaining unamortized debt issuance costs"
       }
      }
     },
     "localname": "EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "label": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "terseLabel": "Neurimmune tax impacts"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNuerImmuneTaxImpacts",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Equity Securities, Current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Equity Securities, Non-Current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation",
        "label": "Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Nonrecurring Basis, Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisReconciliationCalculationRollForward",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global licensing collaboration agreement, amount, shares purchased (in shares)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Selection of Targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionofTargets",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "label": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "terseLabel": "Global licensing collaboration agreement, purchase price per share (in usd per share)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPurchasePricePerShare",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global licensing collaboration agreement, shares, purchased (in shares)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "label": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "terseLabel": "Global licensing collaboration agreement, shares purchased per share (in usd per share)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchasedPerShare",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_InnoCarePharmaLimitedInnoCareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InnoCare Pharma Limited (InnoCare) Agreement",
        "label": "InnoCare Pharma Limited (InnoCare) Agreement [Member]",
        "terseLabel": "InnoCare Pharma Limited (InnoCare) Agreement"
       }
      }
     },
     "localname": "InnoCarePharmaLimitedInnoCareAgreementMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Investmentincommonstocksharespurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in common stock, shares purchased",
        "label": "Investment in common stock, shares purchased",
        "terseLabel": "Investment in common stock, shares purchased"
       }
      }
     },
     "localname": "Investmentincommonstocksharespurchased",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20210630",
     "xbrltype": "stringItemType"
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "terseLabel": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "localname": "IonisSangamoDenaliAndSageMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LongTermDebtExchangedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Exchanged, Amount",
        "label": "Long Term Debt, Exchanged, Amount",
        "terseLabel": "Long Term Debt, Exchanged, Amount"
       }
      }
     },
     "localname": "LongTermDebtExchangedAmount",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "2020 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Capital Contribution",
        "label": "Noncontrolling Interest, Capital Contribution",
        "terseLabel": "Capital contribution by noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestCapitalContribution",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NoncontrollingInterestIncreaseDecreaseOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase (Decrease) Other",
        "label": "Noncontrolling Interest, Increase (Decrease) Other",
        "terseLabel": "Distribution to noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseDecreaseOther",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Product Candidates",
        "label": "Number of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_October2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2020 Share Repurchase Program",
        "label": "October 2020 Share Repurchase Program [Member]",
        "terseLabel": "October 2020 Share Repurchase Program"
       }
      }
     },
     "localname": "October2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20210630",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "terseLabel": "Percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential future milestone payments commitment to third party"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "label": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "terseLabel": "Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain"
       }
      }
     },
     "localname": "PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20210630",
     "xbrltype": "stringItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenue from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics Inc."
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Common Stock [Member]",
        "label": "Sangamo Common Stock [Member]",
        "terseLabel": "Sangamo"
       }
      }
     },
     "localname": "SangamoCommonStockMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN [Member]"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and Regulatory Success, Probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax",
        "label": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized Gross Gains on Foreign Currency Derivatives, Net, before Tax"
       }
      }
     },
     "localname": "UnrealizedGrossGainsOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax",
        "label": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized Gross Losses on Foreign Currency Derivatives, Net, before Tax"
       }
      }
     },
     "localname": "UnrealizedGrossLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VixotrigineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vixotrigine",
        "label": "Vixotrigine [Member]",
        "terseLabel": "Vixotrigine"
       }
      }
     },
     "localname": "VixotrigineMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20210630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r384",
      "r385",
      "r392",
      "r393",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r384",
      "r385",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r192",
      "r296",
      "r300",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r316",
      "r319",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r501",
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r316",
      "r319",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r501",
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r192",
      "r296",
      "r300",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r189",
      "r296",
      "r298",
      "r503",
      "r554",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r189",
      "r296",
      "r298",
      "r503",
      "r554",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r306",
      "r316",
      "r319",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r501",
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r306",
      "r316",
      "r319",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r501",
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r296",
      "r299",
      "r557",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r296",
      "r299",
      "r557",
      "r582",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r262",
      "r317",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r476",
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r18",
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r15",
      "r509",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r61",
      "r66",
      "r68",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r66",
      "r75",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r66",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r64",
      "r65",
      "r66",
      "r536",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r66",
      "r68",
      "r130",
      "r131",
      "r132",
      "r391",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r56",
      "r66",
      "r68",
      "r391",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r332"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r321",
      "r326",
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r208",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r110",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r117",
      "r177",
      "r181",
      "r187",
      "r221",
      "r384",
      "r392",
      "r444",
      "r507",
      "r533"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r52",
      "r117",
      "r221",
      "r384",
      "r392",
      "r444"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r199",
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r203",
      "r206",
      "r530"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r203",
      "r205",
      "r529"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r196",
      "r200",
      "r228",
      "r513"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r198",
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r198",
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r322",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r408",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r315",
      "r318",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r369",
      "r370",
      "r372"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r369",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r369",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r107",
      "r112",
      "r113"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r449"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r375",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r261",
      "r516",
      "r541"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r83",
      "r522",
      "r549"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r82",
      "r382",
      "r383",
      "r401",
      "r521",
      "r548"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r81",
      "r381",
      "r401",
      "r520",
      "r547"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r515",
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r307",
      "r314",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r86",
      "r503"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r508",
      "r510",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r119",
      "r277",
      "r280",
      "r281",
      "r282",
      "r459",
      "r460",
      "r462",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r118",
      "r350",
      "r356",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax assets, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r110",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r110",
      "r174"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r53",
      "r54",
      "r410",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r53",
      "r54",
      "r410",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r409",
      "r411",
      "r418",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r407",
      "r409",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r416",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r121",
      "r465",
      "r514",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r145",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r523",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r145",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r523",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "TECFIDERA impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r339",
      "r359"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r159",
      "r222",
      "r276",
      "r283",
      "r329",
      "r330",
      "r331",
      "r352",
      "r353",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r178",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity Securities, FV-NI"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Equity Securities, FV-NI, Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r216",
      "r551"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "verboseLabel": "Less: Net gains (losses) realized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r216",
      "r551"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net losses recognized on the decrease in fair value of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "auth_ref": [
      "r430",
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "terseLabel": "Fair value measurements, nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r430",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r431",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r430",
      "r431",
      "r434",
      "r435",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r307",
      "r308",
      "r313",
      "r314",
      "r431",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r307",
      "r308",
      "r313",
      "r314",
      "r431",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r431",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r436",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r430",
      "r431",
      "r434",
      "r435",
      "r438",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r408",
      "r413",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r243",
      "r245",
      "r248",
      "r251",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r248",
      "r505"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r243",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r248",
      "r504"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r307",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Gain on interest rate swap",
        "terseLabel": "Derivative, gain on derivative",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r409",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r235",
      "r236",
      "r506"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r407",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r252"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "negatedTerseLabel": "Impairment of intangible assets",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r120",
      "r177",
      "r180",
      "r183",
      "r186",
      "r188"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78",
      "r110",
      "r175",
      "r217",
      "r517",
      "r544"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss on equity method investment",
        "terseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r342",
      "r343",
      "r345",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r340",
      "r344",
      "r349",
      "r354",
      "r360",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r141",
      "r142",
      "r176",
      "r338",
      "r355",
      "r361",
      "r552"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "(Gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure",
        "periodEndLabel": "Ending Book Value",
        "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNonrecurringAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r242",
      "r246"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r173",
      "r458",
      "r461",
      "r524"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r233"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r233"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r233"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r88",
      "r172"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by investments by consolidated and nonconsolidated entities. Includes, but is not limited to, variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.",
        "label": "Investments by Consolidated and Nonconsolidated Entities [Axis]",
        "verboseLabel": "Investments by Consolidated and Nonconsolidated Entities [Axis]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments by consolidated and nonconsolidated entities. Includes, but is not limited to, variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.",
        "label": "Investments by Consolidated and Nonconsolidated Entities [Domain]",
        "verboseLabel": "Investments by Consolidated and Nonconsolidated Entities [Domain]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r117",
      "r182",
      "r221",
      "r385",
      "r392",
      "r393",
      "r444"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r117",
      "r221",
      "r444",
      "r512",
      "r539"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r117",
      "r221",
      "r385",
      "r392",
      "r393",
      "r444"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r269",
      "r510",
      "r535"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r263",
      "r264",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r49",
      "r117",
      "r221",
      "r444",
      "r511",
      "r538"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r79",
      "r111",
      "r117",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r149",
      "r177",
      "r180",
      "r183",
      "r186",
      "r188",
      "r221",
      "r444",
      "r518",
      "r545"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r72",
      "r141",
      "r142",
      "r388",
      "r400"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r283",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r14",
      "r510",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r177",
      "r180",
      "r183",
      "r186",
      "r188"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r58",
      "r59",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r66",
      "r75",
      "r450",
      "r452",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r75",
      "r80",
      "r276",
      "r450",
      "r455",
      "r456",
      "r519",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r70",
      "r73",
      "r381",
      "r382",
      "r390"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r408",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r40"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expense and other",
        "verboseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities",
        "negatedTerseLabel": "Cash proceeds from settlement of swap"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r95",
      "r99",
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r91",
      "r96",
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Purchase of Sangamo Therapeutics, Inc. stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r101",
      "r104",
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r91",
      "r92",
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r93",
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r106",
      "r117",
      "r133",
      "r141",
      "r142",
      "r177",
      "r180",
      "r183",
      "r186",
      "r188",
      "r221",
      "r381",
      "r387",
      "r389",
      "r400",
      "r401",
      "r444",
      "r525"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r258",
      "r540"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r75",
      "r450",
      "r454",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayment of borrowings and premiums paid on debt exchange",
        "terseLabel": "Repayments of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Senior Debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r335",
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r283",
      "r332",
      "r537",
      "r563",
      "r565"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r222",
      "r329",
      "r330",
      "r331",
      "r352",
      "r353",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r77",
      "r117",
      "r170",
      "r171",
      "r179",
      "r184",
      "r185",
      "r189",
      "r190",
      "r192",
      "r221",
      "r444",
      "r525"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r66",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r204",
      "r207",
      "r210",
      "r211",
      "r212",
      "r214",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r409",
      "r418",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r321",
      "r325",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r321",
      "r325",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r117",
      "r220",
      "r221",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r243",
      "r247",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r115",
      "r160",
      "r161",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r384",
      "r385",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r159",
      "r222",
      "r276",
      "r283",
      "r329",
      "r330",
      "r331",
      "r352",
      "r353",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r159",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r276",
      "r283",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r17",
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r276",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r16",
      "r17",
      "r276",
      "r283",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r16",
      "r17",
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r117",
      "r195",
      "r221",
      "r444"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r117",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r221",
      "r222",
      "r283",
      "r329",
      "r330",
      "r331",
      "r352",
      "r353",
      "r379",
      "r380",
      "r399",
      "r444",
      "r450",
      "r451",
      "r456",
      "r561",
      "r562"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r283",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Stockholders' Equity, Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r457",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r457",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r457",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r47",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r17",
      "r276",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r47",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r276",
      "r283",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r307",
      "r526",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r123",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r143",
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3444-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r597": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r599": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r601": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r602": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0000875045-21-000044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-21-000044-xbrl.zip
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M@YB9 ML_54MMQ4OUT^?(I:X1SYLLK$Y"(%9N9$[ #$I@"8C!:^MQ,END7%T
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M<T%/"7)W$<0#EEK'_"@Z&%VCII";-P'[NWF<ZZCKUF0!!T4P[TH!N'.VD2Q
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M9SIJ*Y"W( N\;OCP&&(AX=GAV>GE/A"_5X/>X*B*HQWH3S*!V,EP51L">.^
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MM@,R;$&5,ID3:O&EVB H3E0B)R?)F#S#TB*(M2BPL(PT:SZBP"(#8,IH:8G
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M7HNC&SE8DD&TR&56R4=O(T.C29:5-LZW(>EE6>'1[0Q^$BA$#$(FX\@E%H'
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MRT'JAG(<HU5.:.V\5D9+)X4W1&?N.0>GVN2AMXC4C5CH@,F@28PPME8A0M"
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M59UQ>HF]![E3)LZ<X%5+/?='#^ER6-=['%0?.SN#NC#R2SYI.81>L.^2D06
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M2U:WT+DH67BTM_-\<_=U9W-WJ_-\?V_KY:-#^O;Q]O[V[J/M&Y4M+*&6.T\
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ME+?! 8Z):)AU/%$.2JLV"(1-3*;(LK5-AJX3)F5#I9G*8NXI!05W<\+=3.B
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M>7^F_>VXL_?GWOF'DS\^M5_]?M+^\_UY>[L=]SJ3_99#].6OG%4<N:;@(A;
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M3NK0R6PRBD$\."X5.*8%,&8\*&\D1&HDB=9K%U@RZ82M<"I*L>GSL>D%>_/
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M-#EFWEF0=_:WKYP5)JOZEE&BD4\68'(2;;FH(K8UQ!3GH*3(9X57B:Y6-;K
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MSC[5&AEKD:(MN=18'8(LW1DGATU^A6!MT(0U-F;^^D/CS,!WS,#SI5PR:)
MS8N"7 64[$1G2E%3TJ%*,,KK+LLY<"&7=4,S4R\;BXWUT.OD$M([>)U\H'5R
M+L]#Q>B-3%F0E*ZMDU!%M+(*S+ZF0$IJ[WB=7$LT,_6ND;$6JMW[[2D>3+T/
M0[WSN1Z>4D&9I"A8BVC>2G<&$T%X*9NKDI-4!E:(>A]9EL?+\?$)C:;8@VU"
M1SBCTK74Z<.L(G4E&@<G>-:UX.%B"[Q\L+'86&PL-A8;:Y6-=;]AUQM$](NC
MHW'NY$2?'O5]IR3FQ<;.^^XAL7)>0#GO';Z8S6U:)*P)$$BH6J4 C%$@E"2H
M*NM 6YMSW-BR]AKIS#A>!QPSZ;*QV%AL+#86&VM=C+42L3/6GG>B/?<.?^M2
M^YK^?/&Z.G"*M!)9Z2"@5"O0DA/96U^D#<YGP^)SC8',K+M&QEJ)L!FS[MVP
M[J]['UE760TZN"JJ#2B HF^LJXL(X*&K6EK(Y)5CW4<6,CN8O:4)Q\)X26!C
ML;'86&PL-M8*&VM%CR"^'1\5FDQW_GLZG)WUBH)U\4*Z>&<^$N:,\2EY*8PW
M31;K&D3(V0F5:D#,1KEJ^:CA>@.967>-C'6_)PV9=>^/=?<.+W<C*$BD%$DX
M@R2@YBB"-%)8E7QT"M$J8-I=;R0S[;*QV%CK'RGE-?(^U\C+.*FTP:H<J\!8
MD@ 5C0@5E)!056Y&C2DJ7B/7&\E,NVMDK/L-E3+MWB/MS@5*"T*PB:HHLE@!
MN3$N0H&N#%6LQD1TMJXB[:YMK-1?"[;O\:BK(?UL\'^G(QH8^6S0 >5;@J=I
M/&DX$>=7]MRT:2[CTW1$@^Z"/KPZ&Y\\[RPP'1\-R_DKCX^OKJV$2[DFY[+"
M0!HDV9!<2;9YZ0T-+D-]O?LM3/6RKP/>\]5YT=N#T]ETAJ-N9IFN%J*KW0NJ
MZO>OHVQ+37?RN=T"L;$5%9$:20D34M:>4.H@E\U6RP#2 ^N5!^.*1;GVGJCB
M?Q[B'EC ]BM(HI^+OKMET,^UWNXH'YUVL_G#>-*-[<5L-AFFTQDV.QR.]\>C
M;G23\5&[J#>[;9R-=6?,M8MR[66]"=L5'FWV%-[DI@=CE"*D($6*J*)TEI2,
MS+7?Y!NR1ONB1BM%U:2QN (.E,[!:405L"IOHJWV9H9A-79G#+%_J<9*D,;F
M9$0S25-C)C>&< &%KLHXBB&";@RAO-Z,S ^LQ5B+W9D66Q93LNIZ&$Z=*T2,
MTKMHM#!HJ@ %46"2('Q&7:U.ULC<5?E2S*C,J,RH=\:H$:)VJ7HP)4&L"M&8
M"#[6BE(#$'NW:\BS<YFPWE4K"RCA^TQ8S$5@42"R3*BU+"KGI;?-8JYEKGTR
M7+M0A5HB4VTNU14$5TU*)4:@4IH#655Q-Y/MEPK3,K_>^^[A>4NC/K"<4R8J
MT@L=8Q! ) 5F&X0).12?HHU1=YL#:AD%:YE9F5F?#+,N<F; :)!%YI2JA@@E
MVN"(/$1GJTKA"_L"\RIV='I<QK.+UYEJ5X1JYXH=! J H$6(BAK5ZB1"R5[8
M CY3X]F8^R[PSZ*42^L$_P@HET,U7Z7?KH_5D):RUI*#3>VN"]A&"4[&''.Q
MI#S':AZ$)'Z^3/33M92LO8@(5D#R582:4$0??0T1HC)U8TL;EF,LQUB.W9&C
M^_4L^='196&VZIR;/W*N0ZN:)D,A0VK"S*@D8A<O-]'40-8H**YQ[K/H_34!
M':9=IEVFW66<"BPN@T_> R3(6@;0*&,*%31 29*]X/4EV\L#A,Y2]!*JL"YH
M =*1B#J0R#$:**J9&$OS@N4S;Q4G)#'E,N7>)>6J!D 5K4W2@_$Y6E"R)E]"
M<S2C5)R0M-J\^NME("=*D,E@$:[J*MK2:44BLD(CY%13BBK;C2UPG.7)I,JD
M>I>DBF@KJ@1(5D,DUVT;:*]30N^#JH%U[/KR[64T)R!@<%H*HSJ^17("=3("
M5+,T: K*A:9CU3.M8&GEJQ^2<ONCW'_K;ZCVO0Q_W_I[^_)AR'._*U-W?UV@
M=>OO:?*WK8_7R1_CCUWSL>6>Y5?RSRA==Y3^BFB .8^/VP#.&CH&H_&,IEVW
MX-E;FE*C>&R,VC40;MQ9NEK__:,>5GU?X3H<X2@/\:@-OSW1-Q7>7/:474!7
M=(KAN85V91^>Z3%[_M17_NZ+Z0"]Z;M5\&0\'7;D]+QOG#S\G;Y[-RRSMQ]6
MP+D/7A"0O/P(IC8OI[.;/[)2IH]7IV3^Z]O)Y<R_(9$FA+\)K&W S_'H'9Y-
M-_YVY;J.AR/QR3Q^.@4W7FBM=U>OHEWG^6W1),1XTG>L>-X6%)IT[VKCPI4:
MS^#MI--._V_8W)B,SB<(%,$$1+ Y!R?14 P*W&N_L778K4&#<1V\[&17W\D;
MMZZSZ#?#Z/R988?^V7/C>M_A&ELVUPI]^?J;5M]B\C:VOM\]^,?._F!W_^7F
MX,7^]N#5S]^_VMW>??'3[LZK;V7<^[F"EP?[VSO[KW:V!^W1JX-_[FZ_.&P_
MO#ILW_9V]@]?#0[^=[#SX\^[A[\,Q. OG7F'HU,J?UV/R_O+QQ7CV:#]WO9G
MCMI=/EU\]%^QBO:Z[)*>>R'8+OX(3Z;T_,.#[\IP>G*$9\^'HW[T_8>^.\;)
MFT9B%YS>$=@G.K#_>^<O7W!;C)O.VX[>+FK[7/SA"^;;[)GO$U%[\5K[I DW
MOBPWU<T?_<*O-9O&WOS)+_W6+[]F0-_!6)WW:S-6GM>[&&MS"?VZS*O?=!'6
M9*QVTVJS)F,UFS[8-1DK;#J[+O> VPS:K<E8_:8-ZS)6NZGD[>[7BZI_G[B9
M"GK]_#@J 5Z_?_?QPN)M+NS"QUBU2_NAN6(TF5!GX''^[<9K_-QX-V9NK_-T
MG*<Z+V\NVELGXW>?9K2OW[R\: /NO'@\ZKV5$QR6YBGWCS.>#&?M>9ZMR]G*
M^?3X]*C;-^RG:-QW7>PG:WQ\,J&W-)H.?Z?^F:/Q=,IS=SEW/]$,VY/G$T<X
M&;7A+V6"UIF6#B>$T]/)&1/39S,SGEUPTO?#\1L:#79'>;/_N3\2<Q$V[6L&
M^._.[ZD^A,IS>#F'5P/&_20-+Z+&3$W7WFO7W$/7RV MGXX,GDO-N2DV?4UX
M>@WL?G[H;5G7_268/,[Y>W$\/AW-EL0DCW.*^!9;O5OLP=_ZR&S$]_CCN\<?
M:\N/;<ITG&@R,*IO^R&7T/;CS^_#M2I&L%@M@A2D5#*$J*P##3(ZYRL%+1%\
MB4GW>;)2::.XM\>UB:__^>W@'_]WM/_O?[W=^_6-^<^O/]KVW>[I'?6??_]G
MN'_XK^'^<1O[]IMWGR6^'O\(OQS_W-ZW<W:P78[WMW]KWW_[XY?#?QW]YWA7
M[?][5_^B=^3!]O=U;WA1C>^5U'O;;UX''1+E L*!D0**,R(!16&DS5BL<>;.
MFGO<BK;7X#S!5\+^D1T:N,4LK#7I?7XRX&X9CP\%/ 0W_O&!&_</?WP=R:I4
MBQ?>Y2P@H1.H,@F#N9#/$!3=53..E>=&ED<+RJ,(A50-C2LT6*VB2@6JM1YM
M@:+"S63!0NBNP*XNA="/KZL+5AGKA$/=A%#C<A&*T4(96:6/M5D/NM*9;E,_
M,:BS#&(9]"49M"1F8\'S$!QHY@5/U259#2!B=5WI))L$ J0F?< !($&%< =]
M,)@!5Y$"F %O77?#:T6H-!2#D%0,N?CB,R)HGRU5=@37CQ?M/"_*[ ,!@LC!
MJZ8-,8K@97M4<FRT&&6-^:DZ@LR-3X\;%ZF^J5.0N:AHG97@DXF0I/$0? DF
MN>AO)D=N,[%"?/C^0T/P_5]_EJ\#H.G:A0@7,#<:]$6@IBH(-*125"Z &ULZ
MQDVYM J;S(2K2 5/G D7:6[F29=JO$S1@0P)M3=96K*69*;Z!2+D0D(K3HUG
M<]08LVE46+S0.86N_# (C":*5#/H$@WX>-$7PKM-\\3$(D<-%NSP((..4KF,
M+AE0:"-Z'WTHH?&$-#5QV. !\+X_+X6\)J^D1U&3C )L5"+E7 74&ET*&DN
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M46EWE">$4]JF\^_]IC'O"B^R*SQ?&NYPYX^#'U]#TEI: *$+>0&2G C11>'
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MB]EL,DRG,VQV.!SOCT?=Z";CHW91;W;;.!LC<I^(A7GP\C1L] ZMP]I%8*V
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M,7D3?%*!IB1IR([1**RR)J!?X=)-K+#*5_?/5R>7@M'&*>ZI!@(LH[.8I"0
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M^ISZH3VH&G)&#;E].6&(%@T36D8B#7H TJ&J]#(XXIW(*J=D)9,E82BJ%[
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M#NRG 5XSC+7IV457R^L)^N'PJ\L?]WL?^G T:-[PIPIE^A.]9J@EMGU3Y;F
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MO]J>_:TU..R-.F@:3=1<HUV['T?=<5E>,^S9#.JB?LK@KZ@JN6QK7V$EC^.
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MI'&>8YSRG#7-.<E<# H'E/HD^!-9]G3F5EL?1_'#>1H.V6MT=#QFD(9:"XU
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M8+?N/?UZ$HW;Z,;-\TC:=A>=_K)I8%&:2L]=?>!GO[P7PEHN9"994$XD99Y
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M=.GC%PD@IDBU2H%+J10PQ:AB,D>>C..QQB_F0C'[4QD:JA,UD"QAG#=I&D$
M1""1E3VSBEIO+)HBRCS$@&E%YX7H8DPN<(/F030RED;J8!W->!U0C"=1T3DG
M=)ZG,\H1NT9 (%9H3F2FDMC@$:R!)?02K,7W2G,=<<4._HK.!X5.B>:YYCHY
M XA0I<'C)=!F=S9$:B:6>T7GCT?G>>P_49<%VC)$.H[&N3%HG"<;"3>>4I5I
M4,JOK./,+X'NG &$=X^U1?.254S2:>? <R]3YD[1)*,+V4:<TFAJT&Q.6#N/
MH*-1XG3*FEB>(Y&6H9V:F2>>>=2(T3I7NBH)J18_9/8H(95$=DJ L5XSF;CS
M+C(>DD!+QJ*R@@JI.4%J.@XM@@47-",NYT0DT$@<IX&$K(HSH*2R#LU+H=9L
M!=4"@LI;:;(P@<9$982,#(ENO(A<Z1 UHQ54<P/5><C6JLBRRAX-0G37I-2!
M^, M$=1R@  L\V(56C:K55@#MM^"S<';_8WGK[=KK/:NJNFS\,@AJ*D]E4$R
MQ[E//H?26,N;6&.U\^&6]E2L5CFAD,4MH0&07H0TJ*ZY)LP%8UW466>ZLLY+
M@Z>%]S=K-.C[8K7).8[NJ/;HJF;+/#AK,Q40*:J=FDF9&SK/8[7&!I!,6F)2
MI$0&KX@U"HAP(FO%<D /%M')Y1)$@RHZOPN=#ETF03T-!JC4EH+%=4%!&!.#
M4<E5=,X)G>>Q6K#60<R*(&]J='63)1Z8(B6+DI02^%]:65>(3K[PZ*P^\'1>
M))=*YVRS\5K*P$ #.L,B!<7 R\"K#SPGK)W':GTVZ"D81WS6#CU@88D#)TE@
MROD@&!4YHR:4<M9=GQ52\X%4R,ID$;.E7AK(/F1A<BK'*DJ@J<9JYP6IZ5@M
M!"N\<Y9PCAZ@-#P3FYPB- ,+NAPTP6!EG5FSYBJH%A!4:!$F(9 9*5(A9=P'
MR2U+T5@3G%*R@FINH#J/U>9R'@0UENC0-#?/C#@/GG!F<P;@AD6T"J7@L];7
MU%CM-]NY;.S\^O;U1HW5WM6./QR.+$>Z&)JE%@X <D37,SJ1LK/I!O[F=%7_
ME]3O11@<5L:Y"\8YF8K@!IFS%Y(2ZY@N]7R!@*2::):T-51)'7+I,FTYX\\6
MW@^M4:+O0FVT5C*?57+>RA@<),-Q%2B:,O>>YAHEFA,^SV.XHARWP[PAT85
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MJOA\V/AT(CD'#$PRIIQH;9G*H,%P7 ."Z[I)?_YYQ8WW*6B>$[4D*U7:*<=
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M%Q4L>PU"!&DQ!Y(YI6:"3H5@>C>C]U,(D2@QS*(8H,)3[;R&3)#@ #Z0,<4
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M$J$?Q5ANNNS]P?"ZR]=FL#%A9B8K+'*2:X;$@65) "J$8"C>49=M<)L*W$Q
MX%YXB$Y!J-7=#,I$+AN1 J?4?%-3 M9-IR\7D:0$8H@B%FA%9#7]GSF?18B8
MLT%7Y)L8M]!>P]64LJ<%)DS*V0"@54$7%T9RS;4L"!.JX6IJN+KI\]6*%UU"
M,-#:%\41!',F$M.:A ,' $D_%+#NX/(5<E'.@\_WS7$XJIT9GG?6WW0.BU)V
M'(\Z_;--/25'\,B-'AZG*:N<,C:JG'PFT*;(D"C*7C?!V1B,'==+W**8)LU6
M&Y<EOJN5^Z5;M(#@I0V4F)>0&)#(#'E1M8W5MIA)03CC:A23MF.G(?P\3.;(
M4?7$H2^43)ZKG&/* %+ZI 6AH:1M-E+8!OV'ASZ_ 7WC4!JA HMH:QU*TBQH
M4PQL[HV5/B+ $/J@)E?AOT'_T4'?:!6\3TF8+"$J<JAB<!A<30(*:90R3@WZ
M]PQ]>0/ZPCJN$Q%+R14[15K%G+*&\:2E3JJ8CRDM+*EGO"C_DXI=?B#HCX/P
MZ0)YUCP*(D>NN:VGPQ:L3$YK;5)A_Y2I)I&UDI /#V2X"N3U#]N ''.RDG'M
M<P%R(N9! I.HA?-:*)%]K0CI]/CEVAI>9QNOG(J-IK7EW(;A*8G)5J"G@"BL
M5KSA]>'Q>NET'SH'U[:#L#(J\$PD8QB8H%A9,LNBTD 1HB505>E63B_R!MA'
M!=B(43O(VF,V8)4.9)7,B-Z5OP*,4H:] ?;> 7O#FQ\)$82+K'!JL9*Y0.8X
M))8Y3R&+5#@X+"S!,PDP<Q+VW-M_\7WG^U8-8?K3;4Y_K@?MB.9WN\9T5VHV
MWSK>J=7LGU0=]O9QM[-^/(C'N]CO+!_U#PYW3NZ_A?;<;O99N<93>NOCS0YZ
M\\=:]_7R^Y8>-#'%EBM;<X((C %G=% VHPA>"&U,]"V&>2K:ZWK56B^TUS(?
M&Z^VG3(YU;:%Z @8N,A90%M,3E=SKX/UWM'"DO1N;%NSY1G,&4:]EHBU"F[4
M'!RG@!(HELLH7TM;C-)ZM&%T(ACMOKB&40G1BNB003 %HXEGYLA89HA(I)P]
M15Q8LE*V?AN/'J,4:WEXY5(B2! \ B2TICSG@?M1^FTT!]&]P_=<Q'97WO+N
MJVUM U%1<U@6M92KEJ%(5ZZ8TA05<6-,#F=EH/@< +B%6%^!(SK4/+ODC+=@
MG?!! X6039*8C6WU:J:&N8TK(G-]>1M)8"X3SJ+U6"LGUYKD6;&80FUK6K1;
MX@M+ 'K<W+P&K.GDO$I9D_"2%-J#H[)>TJB8=:V * *U^FK3LQ<WEX?A!+]O
MKI7[*\B"$$7.P QR6Y51SAS8P%2AOB+1@*RS"TM&J-EO2/LDD9438EDO)766
M@,($0DX49?DM$' 4D=4TR/L'W=HYZ%Z)[N;:=E0Q.8[$M"?# '-1(;W(M1&
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M0L2J@RJA?21P6 M]/"M4^HC)\Z\X<E:H<"HNCN]2X8,SWJQY1ZMY)DC:J+R
M[*1SFJ2HM:<4& (QYC%?8[S[8+QK:8JG6]LN%UW1&LN*]"0&61OF03JF3= 8
MK54<:C[4L_)[[&/W1FR-V!X#L670+B'*8&6&D- 7@BLFL3$9A(X>&['- +%=
MS_1<E]M:9R.S]BPHJ:HNYYEW%&JF)R^:G+)42Z3(9\KK.Z:5-69KS#;?S):R
M0HQ96VXE9.\#IN (>5(HO;+C5D]NS'8_S';CK!NT)8!D&!E=:YF#94Z;VF^
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M;40?-92EE\8&!F")H8?$BKXH*20K4^*%.,RM_K2?LY+X#2OI[/)%T2NV2YR
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M:*!^"%!?.AY,4,)SRDQ& @8N".9S(@8VJA2D44FI NKF8GS,D)YL<$.#]$-
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M3\"B<A9S=H609%'WM+VEBOK#AK W=:FI2Y.I;0L62:$1"GTM"HZ$(A-J:T&
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M(;+Z!R>X>W3RU75RL-\)O8-!K]P.]FN,<.WA?NY'?X-[@^-RK5][!W38N\_
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M!<\Q6[1).6P6ZI2@=FFAQFRM 0G,*RI0,U6.HR 6%+>91R$);6T ,W;&T4Q
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M6X/C"EZ1FQA@/LZ(YT@=&M5F)WM>-0NM)IUSMFT['C3(]J!MX>NP7U.%<RH
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MK3^"D1FM/]YMDV%)YKD-I]NCS?4OPFEAM+:(,>,05QH\$QQ"/FJ*6R-D4DD
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M.E\\9NH^2GZ[0--_'B+-['TF+V9MG->:WW+ZPO'VCLYQE8:#82^>3[C/E5/
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MK-1:]:;5L1V?W:7-"35;>W#:FYD/L(]^71,EQ$Z_/MZI4P<\P+\+53IK=W\
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M<4F_+..79?PE+N,_OL&8;_'02\^E4BZRY+CRRI&DA">!DEQ\5%Q3]+HL'JX
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MS02QVG!+I>6*!VVUY=X:K36WUG@[HX=Q$GO=8/O[Q5 N51\GKCW105)P"U'
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MY?<,7H"%R>D]2PDL$3Q3[W?W8Y5LJU=]SZ'I&HVB]?NGEFV"49?-6P"6W3N
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M]GI$L%:(7R%^A?C]6D XB8>*J&.0&I#/N1P_$1A9QCS*!QXF8'V1!5J(WVH
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M"$52,W UK*T/04/ P@61W'(AE5A9UW+Q^T&]D$Q.IU0EWKL-G0\A.*\52#3
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MM41&L4 @BM#.VI5U1>GB-W4HZOB,ZEA,YCU5<1S0<T&<2B(@J@-#G&>V8J+
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M/B(NG$5:88]PU,1[8H6.(0.446;M>C'5W0#UV#@TW[CN>?W&M[F[1O^P.LZ
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M6JNF60=S91WN$CY!-6'\,87OYH6Y+'R[>8XO)'!)96V[D\6D$P<FK.Y%77>
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MXV#5&68)GR/ '$:"?WLS-"%SQX-S\D[Y3<"!3D;8/X+S^0S$S9M]7%/P(#.
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MB<-ZP*$R3GQJ6#."QQ^Q#E9HT)_]D5GWMUA<N6<1*%77%V3RSZ/NV*@<1N3
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M5BZWSP_R8 ')E4(>$XZ K$JDO;; 74G$@<OL+JZL48-_+"N=5)S!7XXZ@QX
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MGMXR@JM9FACSAZ253A[ CR,2[ZV/-V(1SYTC\_0X]?UL>_U 1H.9,@0)X8'
M8TV0I<XB00QW$G.E$LD$?DIZZ2@EYE^WE.&W,JFZU^R5252C7*Y.J]4YRWV^
M[JLJP[Y@*'?G?,MN*@^Z&Q>>0GORL"LJ?W_F)AC7UTE5BS)77$=BH;D2BC'!
MDTDNY.I5BH6@0B;G:_U['/TCC?4#3SFCB6I$@*LB#LXTRE5Z*"E6CN-*D>66
M0]-:'8ST[VX@GBD'[3+7?G&B<-=^C\CA9[C+W4P?PL?8S54@]G#,%!%]?2+
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M)P6&1VLDP T'@+(<:4,IBA:</J*=U_F$?.Z,E24K2'LE:KH< ?%:81>OL.-
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MZ?!@2DG92'*6=LT03]$B&VE 03@&@V14(FQM@ZH9>:/O6^UM 3A91CFX5>'
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MW(N]KRT?)U(ZW<3--HAI_6DWO0--"(;>.<@Q-*T[$NY?6)1Q\^TG[AW/18S
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M]/1VVG^./GFC&$<BL(0XUSD3&^8HQA1\%!3&"HQV84JBV<<"\ZK9& O/G%;
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M[W=]*]-H==H:'%71^J.JFZKNL'?[Q2>][F'/'O=?7@*\AM"MG08=-&[9%0*
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M)45$4^U%5%PRL[;!\<)*!Y?$ T\#1>:2, 9C;B5GBEJK.-%*!AL3%N/8< G
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M$_-9O]=Q!O#+3\:J-)_=SE9Q#M. TW4"]M#9Q"K.EX_B6V/=7H?,03'U6W4
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M#*20TE'$=?#(&AF1),HQXP1E1JUMZJ75MVH\D.=;SJD5<=F*.%75,3A%EDA
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MO,^S]UK?#D3SCN^WWA]J3YVA@J%@B4/<:8$T)P01$JBUE!F?Y-JF%#=SF$S
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M69JX-%L[APD2Y9"X0#%(@S@X261@A1#6)D$R)X328 +Q(MRG&RS@G4YD/M/
MO'F;C4V+HO;&;8'KV%F Z5_QJ+1EOXS//+^,W9C:/_/AYBD=^OC^O+F]<X@)
M"41FD$/O->*24>1"9K&SVEMIJ8V>WNN$^^.'E/4"W[;  ;P8D8$A!?X-<:<B
MT@$KY*E.UGGE1,"05BQB0?O*\757S?9TG;7:5>Y49U,3F(9<R1CCVV4$O8(C
M#+_,; Z,M\*FZ$#FC^GFJ+/:.EATOPI=LSPT3"SXN @UP1^Y1#>Q9=<97&O_
M,DRM4%(R2,CGRO)UXU%E[V/QP3Y.<_)4H#J#82^7<L%!=$LQZGJ0_$R=Q()3
M.15J3O35-C(CY:]X_=:MS]OJ9F5W,M[KV."WG=JYUVG!^G#@];)$L_7^XA!,
MN7:,)Q22RT>,C4$&? )B$"A;+J).*:QM2D,6G0%;SN' ;US^^WB2^@C@HN4_
MPH>!2I>3+P0Z#^[#1X_@-XDX%EXQPGGB>2>9T U]RQ'  K5P=WT/$$%$SP1V
MP7$IK6.>)H@A</*2L4BK3H-KAT!K??_>!?]T?B@%DS90C%(A%K*@^59!?&A9
M),H%894N9S[9H@5?CKY_X_+7^OZ=R_]QY^+0>(%UY!R1J""GYMP@:P1#(A*G
M#):<$@'+3_&">/%2W^?3ZLL#A+X#4=Z84W!0@K&3TUYW7.1;&D7%TN$+GZIM
MKYPOG.K=+=/R:HJ"L@IBOZ^?CV^HIV_HNXPO)T<JKUI1[&R;RH+48,Q/"3'_
M>!<WYN;F00[A"\5K.;XTR]PY/.M-02/V3H^'Q[9S4IT+6=#!M]XX>$D@\K6%
M\["7Y0_&U';MB]&)==-7]&-5[<Y!\9MWKW::K=V#ZI *W$',W,&F3MOED^*G
MPYONL//^S<Y6*4N=V(^7!U0&5R"E\ZG)NXV#C?7&*]NUP:XW=D;P+/C.'S8O
M;1[$UF@ L]EIVXUKDS@YZI)5-^=(&<$NEX7"G/R5[PU&IZ<=F"H0@:O#,C#+
MHQK:\>O0CJ:&=ERI\=30CC6TXTJ\WG=".WX5JG$.VC%XD8Q5*3&%N8Q)2\(2
MU8%:#B*/R8W0CJL90UQGRYVEQQVC<2^%NXD0A265&4D?9E@Z#1$BUII)K7A2
MWLSO&K)OR%5J[J9O26-@/+L7A]@9GJ1PF=DT(- +7)V.P)Z3%"GF1-*U3?"2
MMW(W]:X%22"R?]CN)</\%-OEJDE/35;W=4'Q7PXM5HKH*'/;L\_ES8Q@%QE2
MUALEJ%446\AW;V.KNS>]5Y:BDN?<]ZP")PX3*2)U*O DA*%"*FP%L=8S8]T8
M@8-\3W-T/^:F_K%\@- 4B-RMDH3_U-+2W-XCAXHISK$)*&.V(6Z=0<Y3C_).
MIV/<FN #!/CJ/M)B<S_;T':/2L9U2=B9!03"M,MFQ%Q'"54[9+51W^Z'V5[$
M;(XFF S7,N3[,:I09K"7)F8(1\VM5M$8PXC2(DCLEX+"6+S;U>O->[>?6]9:
M[]@A6"$M#2<H!0Z6*<)D:Q8QB)Y1F(%O(TR5PU#796UVGW;: ETR/TR*<ED:
MQWP19?/T ? 6"W'F%0O*7"?SO8G-M""&,",3X99K(B#&C5:1Z%BP3-JXC ,&
M50O-I*-G"H5H''KE+M0IAI_]-.5:MQ:R]?WDQC/'9,1CID("WYH"11SR#N3
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MJ%)KK^[6H#FE44SA %3]U&<1#0 &@O$0]%UI!HER[*1Y_ 7L@30(?9$2O;I
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MW#>+DW,6R1- T&(4.D:>#M%6C&+U1 '655B[P/2=7+"(Y#*>XRF&L?.2(>F
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MFII[-E2N9<)]/_?;.,ZP[329T0:.L0VKV>_H5M/275_ONPZGECS#7-&2UU@
M_K9T'LX/"O]FU/!O.[6>&OZMAG_;B=>[)_Q;5>'<2N/4"(QHQ+Z%H^D(2SIH
MI VZ0!C@F9^RN6HZ1ZH-PU%8:/]::Y57-0R4S:.8&XFZUB,37JMR15:0,ZOZ
M70B]KFY0FFF1>:K*T5S\K28"B?G8J@V4^*!G#2QPK9Y%".$WB$2OY;)"?+J
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MC?O3B<A^9"_9QI(&PQ##S$<$&=J@*H@(BX$G5ZC=I7.%'\VO<&_%(Y^U%OR
M,A,D;JDKB*R7K,(QJP\N'[LE]V\4#!Y59(##$91##U^"43<&>3K !)&T@!Z\
M6@"..;8]H6F6^64K)LO?T"V[31' MDJF!+*/[&=X,G+M+9\(0#74 W1J,<>.
M;L()OPSY565%FW*B.EKO>HAQ#+"41LSGTTD(5D/:()0^;8^^?)85N(P5.40B
MLS!ILN@HR9C(&7D'>/)D?E3D2_?>GG5?/"."[F E/TE7*FC,\8ZV5Z*?$).I
MWM<B<3'@U&E8GM=P##NKEK!5M81PP0J?Y!,ZI%5+1=X4J 3Q.E$1K]ZI<#;L
MCJZ-SJGJ"N3:Y.)ZJ VF(Q2J(!\YAD^O44UDG9@#ZA*A59X=[K\\.C@\Z8)/
MVL=DXE$YKRXRZ<@$*CC&J!9VJ%TE.)HF]PNUZ1AM=]6B(B(Y,T7%610U>U$1
M)P.>2\"UI><)#I<\7$SW9QR;*6;!J6GFW+^4GO=^F/C3<"((/?/ALP6E77<K
M%]U%"?@GF_@7S0_L&T9!,>90:)<K!KOS;7]#^K*)BX&+R5H26U-='Y70#^$E
M1<GGE:KX&ZNCM231L)X^0T$?51H_GB;I5 )^4FPIF9YK;Y.0;,=1)GV1Q960
MY<D(=%$ZR1 H123*\#IV@R+E<022_FL47T6RK5J;VU+BZ@-8[!76QW8%G".P
MM3)&L7\))/>?<#0F%SY>@]JAH76'7_E(>RTZU:E_0WL]"?"+481';$:I"%]]
M/QP/F:HI:V 5&T:^YJY]>SEIR;O]B?! L?;NM-N0#WX]'>,1G\"YGL"I^U-(
MB53#*WK,'_(X2.=5FKA;[_2XO.3"D\1/@!J1=MKJX@<)$B">U8]R&:>P$?%W
M]8^+<#AF6@_VGDB4O>'ID%WW$21.W$-0X72ZX)[!-*7)-VJI:RZ2S\TNTEX-
MXSZ&"3\=-K2S6%1!S^T!W?GLPQS%U?T^P,$; J<4=CNC$''>IVM8PMQ]]V![
MGDFK >$+%$:$*#O,F.L@J[E^=I/2Z6)P-;M'F5WI!Z(&6?&K$/@WN/UQ3%U8
M4>DY'[#(ZGV($BEDXF'EC\03*YI0>:.*FLPB!-Z"%\R@*;Y,@W,2;4@U05HR
M_Q2BL?#>LEC9$JTL&IFP28CN0ZB)B*Z=Z7Q,RHPSR.%"P1K/5R#%XJQ65A5^
M2K,O*[&N\:WF2Y2LND1II]93ERC5)4H[\7KW+%%Z0B5'9W/FQF+=N,30T6)A
MB)PG,1SS-%>>V8^EUERDA$&E#<.\V7;62)?)!_!U(Q_L:@&?3NA1$]*0Z!B
M4ASFO4H+%6MZ8Q7Z WBR[]_U#D^.SC[>TY&=I<GV^?BHV!M8#.6C'Y?@W#/I
M1QPA.>!SU?AS>V]W(0UGG-V]<CPKQ8!6V_,:9L=H:%Y#]_2&XXA"*4-OZ!V]
MX5K6LSD?>6Y;5=%7^<0JW^",7[(YY^4@ARV3D<_N;'$#QORO^20O<K@+#WB[
M=B:65 ^^&6<P"]7T<D3,IBTJ)-^^R5IS,$"YJ';/U S+U1PKJ]VC\*@(E]PZ
M0'K3P.B\2!8<?89 R>3M4\0\+;0824V!KT0.;Y9DFBO"H2?_Q2(5=C6KBI=1
MD%I&9VY#7\8)]0=+R=7][?17;:_\X;,E.][1#<UR'+7C"XLQ3:<U^PA";YF)
M)=]CX^;VK%@GNH'\X+8DS=G'T^Z+DZQ)^"3K0+M-SG GN;-8CNY2W^S_M%>]
M%W\VJ,EP.#/-YVT\',MH'=B#XX;6)]R=20%_0"HPA(K*FPVE9%95 (06BD=@
MYC)B;<,QVY:(7,EO?\4/9CII\[JG#-)KT4$Q0-8YFF&ZXH8X?5O[%?\I;R=K
M DE<LF $MFLZR3O\(X8,\IT:CO<D#SRC\X)2%<2IR%3-+[-X'HOI(ZOT@S)Q
M9->]-&YS:LZW=7:GYU,P!B@]Q#*@6D*VO&X4]@AV<RAJ%40\F"!XYG=L?E<*
MM)?!L,*KK=C@4M$H)EC3:3H6XUMEBG7AFQ<37E4M]19C\I0)6JZ0>25)?Z,3
M):6S])"4.5B. $MY_"<[G_*&=LPQ#(PV+YBEN=(TVL\:Q28 :?W+6^QE:JG]
M+/.?"FV8V8-.:%)?24P\*[*,C(LR61MV, 6#MJ&>B3<^PC-4;D)(&UH1B;F1
M*9B9XZD..U&/3NE=#FFA6V')>:1%TV7S#1.I:'E.9&<PO:R:V"@SO6J3Q%UR
M[E_0IJTHK>@C/LW4*+)%D+"KJ-@:H2JT)!W5 Q \K<^S_E;5UVH^'9^W&T73
M(=FN;\L(8Z]X)$+HQ=.0B?]WT=+T;C5ERTP6[4.<?$T+@N.TJ^UE_Q*'620Z
M,D\8DU][I<^>:526)H4-AFE41[WDMIN0.']JV>Z4#4+E180E6\/42T*$X4YG
M!RJ=>Q[E)1&C3.M2T;"V=]CK/H,]'B!T&=TBDT+9HK)6\[G%9-_D4JA,!+@?
M-JMSK(0[1TK /J*-($5.QD]"$,!:"G>$):%73E)C4? L]Z3D*$.PR)-X!+\\
MGPY%W1^\!RM@I[6*X8X275!@@]XA>8#/4P5-0XZN&4EGT;) DD]"&V;4[775
M;E/?GK(,0%5G-&QI;T3KO*,&KY>>7^82VD45G8.[_XJ!AZ@I=Z;8-#$WM#$G
M<V$?BAC\.=7DDDE7G&'QXJ)?AOCH*Z#P()9X%;">0JD+J 9$!23FR6[]:[IB
M$Y L8YY@F3NAZFFI'Z+)-< GT[U$3&DFP+.85+^FA?X1@1!"6'YR9Q;?NKAM
MJ:S45&@52RLT%X=.UZYJ;OF9'/@+3$\TVI;'7/-.T )'E87!3(OHD_$3WTHH
MHM>AJO3*YT829'91DU53&4GP9@GGF>,V*Q2F8?;J!9Q0 =<QCQ9Z+MB/(*!]
M!%N=B'@$NG,1-I0,<W#*XHR'#Q?A4!QK!9=)J"#+X#*SHF?F^]-$3&8?)ZA3
M*$&4#TCL8\'UI;@SCHJFRFHXFY@3E[*_]!3^#4Q1% <*@?J*D#EGX385MB<?
M#/ABV,T<3Q,G35#PLD[_KTW_V\O3_[>8$&#I/]5% W710%TT4!<-W+1H8+&R
M-NPMCPGQEHX)V? XD--I/\7NLFARB/W1NS,"Y'M7=F_&]J>#PZOCLW?7;\Y\
MX].7GGX\.O[R\<N+80_'F'YY\?73P?N+C]]]_7BV>_/+Q=?>6=<X/CMRCK^_
M'_6^_VU^-(_#WJMWWS]^[UWW7IU\/?[P\LLQ?/[/=UC_V?G5\<%'HW?VSNY]
M/_KL=SHLX!V]Z1B>W[19>]#L=/Q!DQL=GPT\PVKK_BSDC<><@>?K5M#Q3)O[
MG3[O,*/3\0PS&/2M3GMV&DA.?TULP!R<V>QLF/F:E[7/?! ;E>'_-F@8&&:I
M1<@TT+I3!2\TIXQE.. B]K]P6)EP4(_ ;MRG&F)9_"Q+"O;4%Z(3*$9+JY^
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MK,H^F\K>%=T8:2-#I$"W1_3V%>X@JQS0]\+Q)$"#0IM'H8E 5G[2PO$.X6"
M>)$3N;<8X2FE_%/*R"KK$ZO)B]6/]$P,[1 <+5?)]^))*&"&R[P]55#+3@=9
MST_Y^\)/RG :&2_E-@_(&$PMB5PQ_DU5-<M88J'.6<[Z4#4$LH>CHC:0A!8>
MQ1$VW*H$%YP% ?Y9;G"8S8,%4Y7&)^[#_'Q^OJX$R$S*J::878N$W 3<!<)X
MQS8"54A"_26JTB80:;^+.!VC_,2:*9+]\ID%^%[%GQ''P"-BCE+S@ZAI0[S4
M<JMLUK6 K(*_P]<K2 "QF.([YN^MJJN+^+8*OK:1KR1_N)I0.+ZX3D,0!(C
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MFTX^ O]9VGD,[13R-5EL)J5]D,&9<8R'&W<16"V9CNGLH9D+MFZ8P*ZC Y?
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MMI;/L'XT&78S@O>AA_MHID1OFP]W\H[GIV?-BW5FJ6^/W2IKC953]"I*N$T
M4PFA58/W--.M%TF%IQ]?O1,Y>+:2_=9YX;T-&Z_HT/!6N]7L+25[?;!+++Z%
M8:T=G?''Z=C#% #=LWZS?12&4-E.[G;#=G(,^N?]9K>V&)Z0HIQZ^#%9&$'?
MOE\I(^ =V)!AE&$\7;VZM9DEWSXOS_-)J'3X(KEU=MX\?Y1(?@I"[<-[/9AC
M< C^[?ZY?2=4@".UPA8^ *8FC?<3)2WK_L\%_9^]NO^S[O_<4O]G77M0UQ[4
MM0=U[<'BVH,;_WM=>5!7'M25![O@N[KRH*X\J"L/-HSN-%JGO54>;T5"[G7M
M095K#UJ-\_/^JBJ8.I=05Q]LCP/!+]ZP"NL@\HL532&V^^<KJC[JDUV7'^Q$
M EST.JNRV16QA9Y)^4&KT4< [=IH> X%"'7UP9.2Z/#%<0<,L@WK09^*2H=3
M=U 7'>R<R7="@M[%ROJ:/?-R2;E!>5ZT>W!(0+N9]"+GN/ F3DL"L@\?Z&)0
M+G(-\SQ3YERBIYV6C"PKQ4B+0H0U@XOG)@],<"+%%'$J#$27&D109="B;6QZ
MZ<[2Y)18C *&_LJ-7)$ )+GQ9[B#YPK_#O$6CV1:RLY.6A[.Q8L2.>Q&AK@6
M'#6>8(*_IN$Y#-P;+H9/J0;1<=P>3N^YEX9Z@N-;$#&:(&P,:LTD O;,X)W+
MAT/K$]]@X+Y;]P[1:##=!Q0<"!%*,&I$I<:1)[&>80+W(9BO>10/);>B$$DR
MGEG8.FI0GG,=.K_!72<#@?,-6A<-Y[_<,$-@$0+WPRNL#UIE2V;4'!%Z-@H0
M\4#@9J%W:_!X-, /+G\@>(X27@N?I+D1-S@BR4]RPO+63>#_XVB>!!2D/P)E
M&:8*^T\C3X82:3 ?FX&-60<I30,VT9AP/A%!7A70QJC3,,2)0TF*NTS@E?9Y
M@O= P"$^3',C:2PR'A4,X3Z/HLTL<T/D]9Q+WMA$&/;UW"F.\K%1]OAX2/<;
M&98VC1"CZ,[$!:L8D3GN!)XSB6A19?@[\&^>).3,A!NOI_ ?!'ZV+_PF!=7W
MI+!O!Z@ /CT8JPS1 ?V$I5(<S=P@G>GKH]"('#D8E:5V&9Y3*7/1"BS#]<H-
MW:%;V7E@I4;- R$?O_IHS_\F[ITOT<0-*S!Y:>D*GAH/&J<;/9B)RVT\YEV)
M[6I8N F$S_,YF#81R$[$ZBMC^=&#3=DT L$$'[_$]H%3501'E[[L]OO-3@Y7
MN.BRV61[V3X];[;S=^B<G:H*C05W\)7A@5H?1;F\)V.7*C.@HH=0;4M16H$Z
M') 9)+6=2%*"<I92")X>#PG;FTU/J56!<$ ?[]89NJEK[[ID P\!PFEZHL&>
M]J(8Z1V%9#<S.9O..W_$EJ= Q.GTGLQD+\U @Y,_(I<SG%NX&ACI#O_,$@)I
MA5U36Z@'PS.Z-'R&%CALIW"^A=%]J&"GX>UQ)&%,IA\;=\Q! X:[-N!]$GFZ
MJMO_> ABR[ VWH]]GUB,W7BH=CMOOI^@XJ/!NO#S+'!YL"K:4=K4DB;4 P18
M)5"06>*TSJL(A?RXV7H;XR#W6B]^6=Z099VU5G>_H,@Y&[ERDYE*S%\0B18*
M+[A:+ .3M?!$V7W<;0>/U:OTT!:>3K]YT=JL\V7Y=[W.XH=NVA5SWNQU+^JU
MUFO=PEH[YYLULAW16GO]+32<4:;PC+M=#SV+_'2]9YVURG8.M ^F!K[5[6<-
M'.\D@(O!G\+=<L?B:5K2+NJ6M*=M2;MX'BUI=2O?6G3[P;FBH6PU[1Y.NY=E
MM'M.K9"Y=(\W%[-0868K9E$W2M:-DNN6Z56L2?)QZZD;0XJ[WS^\W=\7,7YX
M K%9]^@^L1#<R3OJ":W[:K5YA!7S7#ND]M@=M:]W?HR >@A;5)8G3C<]Q\^1
M(Q[/!<>AKZJFK$[7 _)\>B:O=G"UG)@RTRHK6="=]J)XBNZU+GRHP266MI9W
M-G4@]^ C/N=]ZFZ* ' 03?X5M4BZI^T5'G9-W4?P]*H.TYJXFQ/WU5F_>3Z7
M6ZP)^WC"=DXOFJUM4G:#BHA6F[I=#MY>^XH5Z?G*^@.9&_+<LR%/0:0*F%$7
MJT(,VR=3A8SE+1^@P^01*G^M()-4/^]R*(+Z$ )=>Y?'.W*PSE:E, ]4[CX\
M4'\P4G1'P?PUH_D'(RQW0I;MY(!68S =1X;HU5FO>;;(]7H*6CP33MHV]QR/
MPEV7"H?/+Z\ZI^?-_H$=GH<!N=7-<-5KA*K76J^U;H9;MQFN7(TK619&-$"Q
M_N7:OZR;"Y])<^%ZD^WVSV('Q%<5;5<LL3J?0<>B_=:/:5I\<NKMA"GKOL6Z
M;W'7M"OM6SP2NZ?NK]QRR4%=47 L!0,5&[Q4]U<^:7KRD7->ZCQ_W5]Y!%GZ
M58,0Z_[*@]NR5O.L[J^L^RL?AA90I\@WI,D1JZNJZ:K]ME=6)3Y0E5]6-KA>
MMZMNQZPYWWCT9D5+\"NZ41>]>F;]'BR\T_,51;<U=1_5K]JIB;NM\L1^MWE:
M]ZMNH^ZSW=MNOVI5C,FJ_++N_WW:9-S^Z]L/.D^WQ\+WW?@,%^T5>GNK%*J0
MKW$XW425;O3=::]1Q5)_^Y?%AQ!F/?9>HUZKOU[*\( D:]UUN:56WKKULF:G
MO*??7HQ,57-2K5AKQ;HLF-,]S";>J@17JO++!S9%,S\,XI]^63A5=*Z?V?JN
MT"T]""+OVUQO=#25/='=?K-[P4V+Q8>4WFCB?C_A*\^:IZVS']Y,8.W\09\_
MF'_4VC=?OLJV6>7<[>3)ZK:YXV\:)33-^6>N%;\3I@.\0"UYP$[-)>X CE.6
M+KYDKM]A*T)DS?FTO7Z>2>S_OHV-WAD#C6/A?CMQ1[#BG]W@WITE+W[*<R)L
M98&011HL?-/1:'L]'/"B+,&&PI,SN'\&/U[$^"M8EWM0ZW%N8S'ZSQ=_6SW,
M^>S%+U\) "$:.5?P0!P<_1\_N;^4[>B6#W^1O>7\Y5:+8M$+PQ6=@?L$#$ZW
M+9L<7CY5.M<D<K7.X/"*SJ5_>#>,,XU]G$X=S-0 \D27J*@9UE'H#'P0=K!J
M-\9Y\</,2Q-^R(T[2;)P[+SU(S'UDY(QY94@''82HQV$='$#(,4HBB=$)7Q[
M'N">HV8<8WL83VZ_]]/;(B$:SC00;H*5/>[0V<48^H5GHOR-?XM2X;3ZC?7.
M0V,7;[!TO4X:R7U IDD$VE(AF;%N"G^,_- -/1_V+DGA ]X8R=%#^(<#RP#.
M%M,H3C=BTH,4;'*GK)*R*UU2]J6085/O^LM_^).QD\0>F#*^/SC!YN33?N?T
M_XW/FW].QR\<N->BKPJVT^GI]/LFL#J=UMGT.YH2%9,2?^!Q]@2>$Y:1OI!B
M,!3@4[D!_ GB0DM(DK3 ?L"Z4Y>4-;"AFSKWPKEUX291EI[ 1C,[X^[=TP/
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M%;)@R 8<4%?  Y!Z(;$-K#-A;T.9&;3_=#]<>%7/44X/:C'?R'.$?DO>Y%B
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MW?9G/X75>BLWPL!4WC!,Y7L-4SG7MG>=:]O36;UKT[9WF6_;,^+>GXR=)/9
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M8'Z?WKJI,Q"AP*[V20:6US00UD5)AL]+G*H:5Z7,M$_. 4\)]*'AAP92]U[
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M*L81ZE>'#M#5N^[IK_C9C,7E!_@%Q4K65=>_7[UMK#()DEF2B@F\<)!-P4L
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MIC;/S4XRG,+M2^F7P&V3T2S/Z(UBD+P!8@"7,X;M@,/HNS3W=4Z<-LI.HCP
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MVG5195;!+;;/2]E)*6V-<QD/)Y58C-@-FA&D#\_>M@FK\GW*2==]&\K%SS_
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MALDT Q\K$>8>Y/K0\$G@$1#G?G++!XI%N?PY^@:NAU*"&P\CH'[>^;9#W"3
MT4'A:C*96X>#$B5RF?!BNH>Y 1+HKPS.=PI"@[OC*24&;^"GEG_&)2<@!+ S
M>L02;6@7U))+E*,7>466B49Q%=)9ZE080O M*5""+RZA#[EETL.R\T=T'I\?
M>.?Q;^+>N?0H782[>Y.BI(Z'53U&Y#<ARJ:7)8DT"[#JW#6OF*A7K(3[ ZKH
MQAAI-U;0S]JUS\#DWC.(<:]YZ%JM S]T5VCM8KS6VL/W*E14T9/WE42G8+@(
M>_[RVHR@;!O3S,SW8\[ $QP/2>V0*K1.-$ALN-<4^QQ,B!J^QZGD0Q5:^KUY
MTT0[E5 C$VQV4$7..DC7</[,AF/38PX^1#:9RF@EZB$,6+FC$87OR)5!/A5#
M;5&B#4T@,XT\UB$^%%5<C+70LD1/1<&YO)>M7I1;093(D(Y58E8.H@@6+9KD
M.ITP<!.?O#6J%B:W#'9@G=<C;3F@P)M]!5KE<"#!<"=NQ26#(8Y;0#@")EG!
MD )S]+K'?0RP($8V2;E)%'+20+J""GR1=QZ#7/0-OPF:(K!#^&K6R@=1EDIT
MY3BFUAFJC5Y$?28V;0#]TW@ >$')CC01EP:]8+4\W'4&IM20/HG%-:5QG+KP
M3Q?^M>K"O[KP;WN%?X>F!\LL4%*$2N=;BLL2S0=NBWYVXY3C']?7!V!E'B"%
MKL&*80J=-9V/;NBR1XS NZVS-XGSSG $*IO+T UFJ.2 /3YH8^A*Y<CH-U^,
M?ORDLS;[)WXQF\%O32D-9QTX&N4B+#L0$I1FT7,V=PVZ&[L&+:_GG@VW[1H8
M-NHT^7_G__O_9"Z&+DQ%'GP0J+_?:1LR<2[)5OK(@94O?O*MHKZ%1(I)LL&?
M,G6N@OD8(YHWSI%M2I&]&Q:B'HW1T.UWEODXCU5NNG;N(C37,(U.8'PR^,SI
M?F]F&KMCENHZUD2-W)/H3ACS&[P6C[T7D?!VF1YN"YO22J6#,@^C"5#4I-*5
M=\/!,_J33>E[!19&-W-5GEWF::X^_>OZW4GKPH$='0JXI>P91*G%B?C)%(N%
M,/BW_!WI57*OB=L11]GX5GL'QMG#('><26_/4)4&9S#[6K_0LQKFE@ ?W+NQ
M:=29HS1:%78!3G&-3G+O3LT/N(1"EF?@[QBPH'3='""-75JX#*]F@81(Y)AI
MHLJH,KR7:GIC2,7$+J^B GCWSR@N/,I/,X53QAX+EZR ,,U5?44AFO?&WZ8P
M*X$!D(,<SB@-82UCUG2<HZD<_""YXDIQA<:67%?2%5'Z#T#2?5HDN8H"</FQ
M! F'F0!YJ0T(&D0#8++0M>M&S%,H?*^$16-9F8/R1AN+EDO3@)2L!7[%7!>+
M9Z[*D^'^W$+7$:D&/9&X7"8>U?N]S^*HX;Q%TP('(.&P.MA'<GS&#><*!-S0
MA[4,L1 Z;C@W]WZ"Z7!XJ0;W/> !G0FVOVY >]XZ_PTK<A$U9K.NYP-@JC]N
M_8#%NMD_>]=@ER5?6)BR'+"1 2Y8#<;/)-T2#M^,LM"3]4FV9.;R5'G?LCPN
MBC*XWH_M6@"0V-9]FLZ' E^H 5++5)%4;KG>%ZT-0;SK4C1*E%JV@H'5E&1I
MR 0;WL"=20,#*8)Q(-]#30H,-\4\E9=2GQ%)>50$<4,A2EL4P]2<",?P*;P-
M%K'IF)E\%S(S\"(]^@+_0/A/NHL*4]'"P:G'/>:Y)HNVB%605..P5FL$5<$>
M<*W%(0GL99LDM<+ZG0!W,%H?G.'<@O5B91Q-A7.9V$$2K;OPRWGRW0OWVR-)
M9\=<:4FZUG#Y<JIZYA7JD)7:M4EA6%X1!7XQ5NWH^00O)6(GVJ75#>I\!J(4
MCY&+4YO@W%L&LJDJ50?WJ"K>]KF[6@+FW1G+5[" 1:AIG\[K@[R7JG+^.ZYS
MI?)T])B&SE\9%LL0_#D6R]!7U!_$^#^@=SZC/>[CU*FO+O ZF):>EB17[!&@
M9KO,L"Z!O6VD?2K&44S ,)>(L /'R67IRBI(FBA4??VGK!3"+DTNZ)'%3NST
MC ()583&FT)MI[F/%$;]P32$@L9A8 -42?JQ/R;2.YRA=L6Q!,',W!9+&$ ?
MP#=ZS?RXH3^T:DY,J$:Y?^%B5]K)>2W*'%Q03(7^5V)5OW,MR-,]51D(ZT^5
MK )LY!=+7IN1D^^EO/ZGE->?61I7-+3SR3(2M2!2JD@J&IZM29!T#$TE;9 &
MU\EAA2'"1%J@>%8(@]D([T;)N[P(S#M-2GP29-@254GA @1"61V8D"""[KCD
MQZA6&Z8PE@(!4F]*T[EPKTS64"%YA Z!X7U!#:0K%7QN,![L?S1! #0Y5B*_
M.*MQ/ 1^<4!H\GR+?*0$ZZ^H/TJ]D@Z&8.\79T*H'7TH8*G!7(:;C_DZ1HGD
MA(//DU#-SCGV7NB(UK45\]I_\/X)ZW/6"B4=J,B1O5"V-'E0W'.1K+#<K"&.
MM$3#FVKH[<#=0V(W'/9)\*1CCR'*.Z FHZ7*'B<2>" #Y_S0H:P#(:$8YY8
M!Q(O-K'#E6'>HO.KR<;1\F]8)DU^YMCE,G!%2U69+8.B^2G:91%14U:3E(\;
M>PBDKG[>T5@%^=)GC'5:Z<8CL0HPX8,1 ZED2W2J?6A+>%<&PFT4,*DN\ZXM
M#85FSE1UOQ'%6%%R2PVUEC-,0:W"NO0RRLZ7K8!1:H!^!26)*#2E22C['NX(
M,6?(1\,CSV>(^@=P<*[LFJ62. K99&CO_%LLL5),)S3I=8FBS&:&E9U5I>$%
M@D@:6Z0\[$-^@/S^E;A8H5'_9>=W[=9/#0>45U5Z8TV",0H7V8]^:)M=C1*;
M:SX 5+#"YMNTZA*XI25P[;H$KBZ!.T[LNV6=AZYS.YMBK%[6^<CV_18&M+2L
M6B,2.3>6T$X-N%X<):!3@@ #26JHYCUU#!EP@<)2[#F+\U/'YR7G?'-DYQSV
M13>?4E]DMW?>;*N/\BV1K!95==,P%YWE%[VGB60XR(WGM8$PAP6:4*:1]OA7
M[F7RWH.F*X714NIVD<J[J/31$<H2H?$5)B*]C89R4D(DU=!H9A68L/6#LRTR
M"D::J@@_L;/3=B4X3VJEBFKY$MS.-1"V1Q*H&FO$AB-J+=2"7 %N+P@>'O"X
M$ 3")8Q:'WR<2'#,,<4J?QY!P<8,<<L<TQE-:$=*UG-SJ^ X_ ;D,G!9Y"F(
MBOL)R,'L<NO76C-V:%G#MKNM)C'-21G9.5 L"2@F4PF /R<INA?-BQ^<Z#X$
MV7?K3TT=$M#A!FRI#-;ZUH_$U&<S/#<RY4$!QE)7B,Z'G@VP,J9H$DB4/P$I
M(V?>W$E81PH'CB)"H>* X -:T==3" ^0W7FY71#1O6[S(B^A>WWSR=H"^A&2
MV=!O?:E\-/59&H'O"Q*@PM6G*&0L 8-^*_AJ?F3<,?(_L<<(.$;7=R:W\$,>
MS6JNE@YRGF_I-)7/!L]I5:GF"R+'(/!;IU=JQWQAIHQS%'Y?.$?HY!=J)06!
M%Q2*,V_=A$N\,5Z12 "TPE$%^U>V<DTC']6N//#Z-)0:;P\2*?<6" FE1,DR
M>=@J5@B< )>X2MBTNLU^7MB ";# &M000FO0N<@ONF++XBENXK=D%*-^T<R%
M$QY"I8J-X0C<49X;)SU1%8UJNQ_@5\1_0S=UCT<,?99O_EF665>T,/0?J(%#
MC7.JHIE^KHQA614XA?= 5S$>#S ):S$ABXRQ>CZ713>_I0;Z/!Z9N18XF8#:
M,%7G!@C,Q],1$C9-R"RGNT8$?0FG"9'JD(G'^HURT(W$\'@ZY2.PBGQ&L^5E
M3859+4G?!G9SPOX>3VW1GCF-Q0*BV""H^11XBR4U0MRC&$MCB8B.,SL2#!ER
M849(0L9@^%&M;J0+/*GE 22ICR(F%FD<N?P%7Z71_A)K1CE"AV93TS)A!N19
M@$)^XLGN:[Q@P%7">.6=B&7@?.HF:7%U=$-5:0.\#LI:)\.&<3:6*%E!!,+U
MA$8ZZKK2 K"\1KS7=:>)D(]+D'$)I86ZIF7X0GZ%D5@N9-07,L8\BG<).JEZ
M!/!<BR&[['YH92^C 3V;#P5( _IC"+8(GGGS(-=*#.J3A*<(_>,H! UF3JK*
M9VJ4,+T6"6ZD,%GH)H-,MMY@OD:JUB#7B6.MEDP;(7OS2=F8)6KP5.849:2@
M\)%RS<:-Y.5*Y36.H_OTUH#7^B$!72D!IO=5:4%5!"$;53"<@(7C4V'>), "
M _2+X&3 %I'4DKR$8DP$U .R6:W1 :B3:QL4822&!$M,5FM*_3-B["<!-0D
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MSWUP/<QS/GG9P.EI]^)L<ZTUQS_E[_F%A@=],=ER3 6_E3FX343003H0II#
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M:UHYO&V_44T?Q9W-C5]:Y#,H,W@B]#A<VAZ4,@\ =ZU"9.EZ5 RSB=1*F^$
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MP?-T1T8IFNL8KP[M&-@+2>_2O8/?;LX2@0:.N4PF-Y3O:R5,NZ6UF*Q%+(I
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M5,<7;;AI%0%P(B+B,&V_3%?%5^5^ 8*/"B/\S,8L5\)0G^Z6SF=?.HF%3Y(
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MCL1.7NO>[)2P(-T;WWW5-M2^(? @L1Z#RJX]F%=$/DD_1P<(>WGSB%3:(W<
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M1@G&?(PK)CEE-/*!5#2KB5RD)<?I9/N3JN, U4^8H2LJDK:4V*DC[@S@+1C
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M:6.9K87?;X12F-:G^"DX!S8P#N+R10U'?^'2\$G-]*V66=.J%*>64^AC4V5
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MDYP ,/E4NMBS65YE7"BA.:@HT9FB%29$$G<AV78\DK*<*_L@<Y3YRQ6:TV(
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M.0-BFP(=W %AM2'U98_:RWG=T/,9?R%@AU9V9)K!DH\"P/G%JX(:CW?4JVU
MUT,K-:F-DV'^O"B%/[HP5EPGDG?RERY:VM,%8O@)KP)F+I"W2P&:$@1RZ75J
M#'*T$IBT%*I.BC#%'5&;3C7QRLEW9@QR$86:6ZV#I'W"IH,\3]10XBAIX%/[
MH^A]B,[D3'!N#')^5;97#;KEM:,^F:/2=$',)>[< Y]&",(:1DP64F[.7.CY
M?-\8A08X0CG<X96O:\.4P$N-E9/^,!^3S5.ABQ9)=CEK2[XR!%)I=J(;PYQ'
M6T20#HHF,7/^N(<U0>N:YQ4%L%+Q=#+0\_GM DE/8-%B-%U;_\OT&M854:48
MY$)J.,Q'3D-:7&[1HHMB*K^DN[E.A2CDHLHPAODZG85DZ:JP*EK4&HE>$AQR
MRIP8PYQM):5,M[*\0BO_&;W7"TTG0'+5<:KG;\9$CH4 [^9*UZ]$D 65*XFS
M8=%10++J750.J37<-0>K'(5<!)T;PX)"$&ER=#CC*K^H^Q"D@A(7QE JCCJI
MGJ.P4_)<Q"9';/-$1+@J->O)*:&4JH_3OIZ_8!?'JE+/6R1);<E#%R'^3S+F
MU[RN]JF+6*J;3O5A_NBN%DF[J+R42;!;Y<<ZF*4"]I0G&N])W4\)7$Z$^C9+
M?=1R @^-82['09' 7;9RKJCCH!EE(E<1N594<#4<EK<@JQI;5@&77*L:>O[V
M\Q92D;@5%W--X?TD6&HQZJI198QR_7DRS)\5*1&OBWJS>LU3+>"3VNISUP[D
M0O;4&.92,=1HO-4./NRD.JTF2I@K=H_]!;5X+5//WRU<O'=/<CXX,X:Y$TE5
M/HA>^0M[UE)==Y(E4O,G[F^($2X*QZZ/85;^C>M#/W5K%U>CDVOA<SU?WB)-
M)N)J,68M1JW%N#])M[W6.Q5!5L8JWZ47QK"P0+(2(3NY&^\ T5R,09U@*1CI
MOCKKZ_FR"PEP)U>Y]N[(@TJWP)EN&+D#AP1')WE\&LP\_&< $[AYK9F?D864
M\_M S]>Q2%!H(8X.+WS]'( 2!/(M,#2,@I<Z,V3X;]\)OQR_>U_1:D5<F_)/
MPK]=EX9C%Q_!)]@)(T*<7#-"9O^\QC,_N<#YA"V\7'& T9(_WG2DH1E\ATS_
MVY&-' \?:2Y:8GXG50[F$FXK.] 2F@#4^XPYY.L*,T(M/NAO1U; (CT4?C<+
MG[V'+_",  8/* B*.N!MOC,:K+X=A0V)CY='FB^0A)\LJ0NT9>LQ?,.1'QV7
M3O=E93/J^B/7NB?@D?L &:<AW",+/],M(W^"F.]B5KH*.V)KZ^(\8[:DMIEV
M8]&<X>BE]9(UD /5F6J-2<5 "I,:64O84'SHG ;3%3+Q/5[.MJD:#BZ<D 3@
MX+-QJ>L&RZ\672*B,ID)9B871W/.3*(8WZ,]!2E*673%L81(E7#5,R.PVY&K
MRGM\5JNP4Y5=Z3*,'/)O;'V'=>!I[]A[=&\IPV3N7@6,8==<)S?.O0?L7V*;
M\NSB]_+-N1?2&@N2V:(FP];'[='?R#OU&9D3MX*-"QHVSKZQ#S9VN7XF%D'\
M?:@2^A4W/OP<:G'JA &AWJ\6B,UC44_M&\2<]15R'/AV28(E<JT?#/J@MDWM
M)\P7A[CS%Y@693YG2*$]/2_@#'-%/9_S'K437N0,6[Z7_X-#:*NFFB)W#E-)
MO4'HC5WSRRA6//*MH0K=^'X)(XE+$4@DF[C&#'G$LXAM8R["<$12,8YP;*6L
MLS.^YM7X-8;A@60%X7Q'T(PX(H8C5!E8GX')T?!PDL.'5VJTUL"QNP+X4,Z_
M'(\O=5V7,WBF4>-\G%+%#/0PERT'U>\[(&VK?N?E.\(*Y3"3F&'Y]4#L>H)$
MF[K.B;];KBIV0M92SK]%)M^QZSL:WJ8<O1.O; ,4MSW /K#\KQ99\GN:H=3:
MG@T,!;2LBOX*EDN8-;^#"KP) Q5G2-CRZ0CD$(+-A69;QXGB )EG;UPZU/RC
ME.![X_TH4>''72@LCCA58ZEWC5'TKK&?*.Q5].)PZ4K40[*'G?.QXN"*LA4G
M%>;VVI2_82!T5BC>*LP<-=C&E4,BHN^1S\>XOA:@9=,J;]_X5!XPC&>Y#*I\
MLWR[QH?.J^6(R".^@Y6ULD_#O7C8#IP[8I<KFQH8#C[;P.OQ7[R-13E5E<3)
M/?];$!(E.0-@.CS:,END)I;6BIM[Q/[ _M0'0?T"E/3D;%S6NG%FOEFN'+K&
M6 QM$E50X<:0?#Z58(U/[#M]Q<SEG]74!0J C4_NY>IRLD!LB:9?1E_DTREL
MVO@$1B9L?$\<WGBC:-RE4>;"MA_D9RO;I0\!7\I'^\>".MA##F;E%E9AVP^:
M '%]/,=,80;9FBN/-2J]5-'L,+B;IG%Q% 1&"NZT![9B^'.\4RRE%$M; XF7
M-P\WD]'=N"*>DFG5N*0IMC >WUS8A NR2HY[PHC'R+*$I$%.K-6>&7(]9(9#
ME$8+#]5)LR=,X5P2W3=Z140,YY:R*<BNU"X6T:0DN,0W;W4PZF#X6QY\X<WD
M[EE1R\;WRW>'PCK=$9.+97>^%0+9A/U%;0(O9EYKLJD]54+S_9!^U$&60*]B
MK R^7/139\#7 9[BE:^?#/J#?L4)N0IHXS2_L6W,HV!\7SW!Q@/M35W.FZ+3
M[^.[Y[$OV]&*X T?2"HQX1/V, (.O,:OV*&K\*,Y%T>4K9'+0\)+Z)$@)Y?'
MLA_W[]5Q6VV&:YX<0F9@_+''JDA/<=O&]\8#F2]\4".L(DZ5;=;XP/E+O7R<
MCR+;[.:=,X^';W&YE)9 M)7!ICSW",^)F5A=$\I\FSJ$EH?^I4 M-2MNWOE1
M%'>3>"S"NEQOB9%RV5P!UEK"4H?ZBX"YTS?B_QLSZ-.J2%600+1@,Z96'8<T
M 7O?9.*>=.E^E &U]5CV^?N#G%"I!HW3Y7XZ893G,SQ%YU\58=RRYHU/9/2*
M&?B7\3G/HQU&G/F8$E>KE-,4H9O/;8DC:1$9KF"/B\O\U;&W HC&(W B"F;&
M9X],B07E,,WSX?7+_][<W5=X1=N-&A]TZN1I7'K/KBKD61-)T['-E%/Z_$8G
M%+CV@8!/$;I3X*<^O\'/=?A_A>;=!57C1']>>VC&2"07*E168=O&IY ].+YY
M-YW  OI_I]1Z@]$IYL+4QM.&W)<DB)IUB,O5G 2DM0?-MP$H9<Q],R (/X2,
MA\[AO(H(HQ)LXWS\I)9\I,C-.V)K T\_4-?D3C@8_ER*;]+ZMX^*A E0;O#4
MP=%:KD_KE 7#6&B5*7D'!7/++X@5ZA;X4EU3[8*U\9TR&GP9G*1F805@M*_U
M07]8'8BN FQ\<DGYY'3B;1+! )W$DZ7$'8R1:T5?E)O^.^-K:U!D*U-341I*
M8=H@\VX&I_T+\,HN1P\#HU^1KE_2N''6W5KE*D^AI'&+/ (A#+ELY/9\1BC>
M4@;_\9Q255%;"UOCI(2A[9I)K0+:TO!RDJ) ;5M8C59R$&5R"<GB_/@;XB&B
M<']6%5'#QX)CUZ57H"C"++D[L@145ORAXC6Y>C@:9_&" Y"*J),,HO'II!*L
M0O]UY[MN4O"V!MRCY-0)HZ^$7[;QGNEVE)H?+3,@6UA]S9T_4YYGXXVCJU_^
M[QB5NQ,'PMY:1^,>%- <I-4H*HPG6. 2F7]@*PE]@T^EE#N\([+&=] -H%QR
MH9S*3(N2"UY6U!V9"P+$%CEM=BI!8528EE"N'P_=35OM=!'M7?\@%DZTX:,=
M[1=^[>$>_8NR5,*#9,EV0-6P0@6/BYA LVOB!$#K^#&T.)^KRCI6!F_:7A;F
M2X6[DF[2^"Y/<4EEI*2X;>-32'L5-&#"J_@'9I+H33U/I3[.QI<DEJ!/&(QM
MUQNM5@X!"3OGE[S]*E6M8@$<KH.VRNO;T?WD]Z>1G$TRC1JG>YPPB%PKY6$A
M;G'([GM7@K7GZO>CZ5-8:YXJFWDM?!*ZTQ4GY:K@C9-R"DH]4V*EJBQ+*4#C
MDTEGM:L4'DC:M8?SBL]0KM"*^,@1:9)<-<KR[FI@:*UK=!EX!.QL[_$5A#K!
M;Q/J$'-='7*NA&M#V'DT')QD,O-O\8P%L#0\._^D(A"M#-[X?E3R20_GW;;-
MM;U"WF**?=\1-TILRI9\ZX1W32J*0BA -CZ]2T(]LB0.8A6S*6C8^.#WLBPG
M,$SV<89K"GU;S=:P=M5 I<#5H#4TS]8;4KLBEVW=^#2V<K-7C-K$=ZCG>2 =
M@'W44KH+P-K*:L_87+C4H7-B(@?D?W(U:1J8)NAZV$ZS\&YS>9G*>D@:CF*5
MUX?*G$$?MOA4'>1M,*.>;ZYNQ]<W5<YSKEGC&S@YR!J[H!O]F#?7/%<$N81G
M""%_Q/ U!MM]"0:M]4PO\0LWZS=/R)4_TE*::?FAO;;T<%D,U,:,5E25R;=K
MG$UVOZW.JRQ^Y&WX#/ZVGDY>@WRSL&O]3K!C)6<8Y:>Q9>W;H0\>LR+[F5YC
M%RB2#L?LH1+VQ]\&K1"5#>:G=KS &  IE1DN:-^X (@OQ09@LEC_"I2R)>0P
MC4]IN@!'GJL7*ZD/*"=/.4#CDU&Z7!]Y@JD#9FK?$N;YR;DR%[8*1]@?U5U;
M#?]\"4E93+>L=7LBNZFT'D;7R/'7/+%IA=9\>#QF&Q.(E^DJ9X.Z:!I67L5L
MRM\C4?-4,R#-WP,%VUGXD=X]<@.;BUI._\H(F 2F<4$V&O3U\UW.N10 &Y]<
MXO<0L3G F^%:WA/!U'C0Y=7X5<$/73DK$BZB&_4L\.2 E7@FKR99<7^R$JQQ
M\FV*GX<)DO<8\?KGUJ/[0,$?X:4E8"?QQ!UON_;/5?*TUQ/($_!IWA"SRH-]
MA^VEZ02A\?W3Z.ZZHF!>IE'CI%8S<#9B!MH=IOI7"<JF:W^-0<5[D7L2.F(C
MU^+'[Q54K0)KG,XIQT0YHW=S)B*I)+$GVK;:P9?B#4:A"?@3;BM&ES2)X7N4
M.>+5K/(S<57XIL,<D_'#T^@?%>'<;*O&N?DQ\$/Y@JT)&.*5'GIY^\:GLO_[
M5.7!Q@.@;NL&S09.DY JGT3DCO( J^UCQA,XA<#9F!R2TCA[XFUI3#ZNBS/]
M,P"9=(MQ>=F$HJ8?(J8 .SJ4B9*I)GK0TJ0?9UJJ>AJ2+$[Y@;H"8.,2D"?>
MV Y]\RAT*DR%N/A9=<*.'*[QJ4W1T@O B=DDXRB_PU<%U_C41F#EKL$W>[3#
MEXWAIVM= :/-,3?QBBQ!Q:.1 V!NPZ%(MBZ):15>$98S0DTDC7-%]+X>$*Q&
MME)!\\8G<D?!8\%LR;7^S;LIN,^J>/I;"M/:M-_1\(M>6"KDI*K&2#5@XV2,
MBGR0J![J; V;QZQ3254&V5;;^(F:"RS0?<<N?(/-1864*0=HG(+)W5%VF+.<
MW1$V[:O'*0/%.C!=X29)'KH,.6ZZ #->50$?OJ,VZ.-1ZO5>4#CCY0J<MO#R
ML7ARB.5?9BOGH5UPM55<I+/=-R^619GP1"6=HP:"QL5)/KNF\O:5%*3Q"?UC
M_'#Y]/MS100OVZKQ8>\69QG%D2H>G3IP#">#NZ5QG&SUDCU>IY+#M]9>%<&9
M1_N*'S>$0?5)&%27%X8KAFCM++.)HDHWMBJ &M_TJ3?' X_K!E@.LCGK7V!K
M#N:G3VT?O>/WT,@ (VQ%W3 30#"H%3&JA,,/V4EK&>0'\/2"P@Q?_.B).7[D
M&*Q6(,6F*V16G%@J@S?.-&.WUE%/:?/&)U(GEW *T,(UH?8S8G.9+;HOVK::
MI<EUH21QLBI85@[1./5+WAQ7+36E#-[X1)_)$O\&JX\M<!A]1DSX3?7=9#78
MQJ>X.7F(JGHJGE-D6C<^C2C$Q;#-I0*VWHB_$$:M+QIZ8".)5UJK8F0*"-HJ
M9&[OQG\?75;D;&4:-4^WC)FG*D.JX1J?&K@A8BB#OGZQ2W*L.GSC4[WGY[*[
MSE,1N/%)1C%#FS(N!:]YIFM0:<)5 #4^*?D#F \!9N/E,G#YUSPR:,I2='9
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MD/@5VC/3ZC_'RK\<PZ@]<X&7Z->?_@]02P,$%     @ ^8'V4LIH# Z])0
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M+EB)G.NLR4_,$I26]6_<4OR8;8Q)JW#Y,JU6"9HS$,-+Q+18[@^>YAY1V<F
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M+9-2QY_7/V)8X-__]/\!4$L#!!0    ( /F!]E(@J+EN-+   %N:!P 5
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M?(RJW[:E;_^:WT:X?0?"?/P^A3@9+L M=B%57 !Z*1,RT9)60[-#K> :>'3
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MM6*:M)^]CNA:,\TNN%I>JVX"=IAKT5T5=R</=I3Z/EFA(ZW"/%K&0=N+W/(
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M%[#?W<)6Q6B3+,O:UPN90I1-H;#,30'Z@3/K%</;HCS/QG J1#F0%IH' X?
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MVT9L6XVCQAD=OXXSQCGF,<YF>R1Q;/J8)GD;3^);2]7@@MP00<:LK84\9*:
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MEIV$8ISCF;MA&\?!,'_;Q'O)"FZ8Y[%8YOXK.H^A".X22;<V=-;%9N9C-=N
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MFDP6'IPIZVD,V[3]U*-.0MM-Y=GAW0[\#KJ?KO ]?IX+4S??U4"XX+/&F%@
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ML?6 U \DWO^%,S+#_Z _IZ-4#?(Z8?Y/TMA-48LJ:#5$IGCMC9-<9 $UL%)
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M3-HKK(/WM E6_7**JZK'(0![WN,_B? X=_E-]#F (_LKXRBLD;4>5M8*V0A
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MI6 9:.8,?>(/_G303,,6 0N0-U&[BO#=U31](M%4"5QCBVAI6U1DLUM)U(;
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MM/"4F(QU;&,L@HSO6GR=Z<P4M)$5F9^U)VQYX"D2H9F &P98'B'K-J2V%"V
MC"1'!A+39#(QB$HPAT%E])C)'MMC7_B."-%8V!U&##XXTNY ?H/S<\,#&.6K
MA5Q9*\ PC[I4@UER(K(P7/>PD9[ =0IDZ:&"#JGR#^#]<SJ9S<[)!0O<6,-
M*>)MA+IV(QE*KK(S,:@^3>LWPSEI/NPN\ X=$#?:OC?)2'_5\,RYT2%J<)8A
MCXYI0TR-@G8U+RU9/TH8)\-!./$0VTD39$]5; UT[,.6U2GWYWAZDZ!VV^9S
M]NOL#_KY9 SQXNL[HO>HYJMQ$WD4M,DEQ$7V16'@43&$.I@J6NMTESKM9Z$]
M+4;U5M=#CKDV#=_NB^-Z>&A&M%Q)5K2K<Z)5(@?< LO!9,.%E61P'2JP<]!:
MJGX,:2/L8U<WS:;S\W?3277/WTZO,VP7>5\"M3 2ZEBT&G"V,K,HO6=Z(1D1
MK5P/A6QD#'W^';;0O]:9L@W L?*.&ZEUTE"\#0,@=_#4XM-K1+-5XZD!H';(
M_]U%]P_1'#9QMXVB'FJ]D90/1@&N J1LR+4J1&WM4F*@I6;%&@&01(YQ2+..
MEZCZ+6FO!]3\+L)M/DWVY]>__/K3SW^<K9)3("0+5K,(N18%%\>"*X'9(A%5
M,5*LIQ%M2TZ\_\&',P(;RGK22%!;[RX:7Y"^G7_"*1U0L\G%*-=>!@]G%2QO
M#?>8&[GS,YI<I^ZWLK5;5HDIJPQ.J(+:QNQ3Y$$'9ZS7R@&>[_RT/>L=;AH^
MWEB@+G@OC#$,HRU,<RM9$"J2[V!\O1N);CW[JE&UP@,H^SL?<YSB;+XTH&[;
M!MUTU+!(;XHF8]L &5$Z23*[P1(X<+Z #S*O-[YKY8,\#NP(&2+[\>"A)])0
M\AVJ&G\=?R%T=;U+A"N\YQR2%-D%QD,D7#%P<K\<[=%1D%OF$.^,;F_+B,V
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M?.8U#1%2Z!*Q>QS6J7&EH1(Z5&$MT&V 905"-B 9*L6K0T:^6%90V]>"3 J
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MZ>3OT27,\>+KN3,19+3(/)>9'%>24^0Y,"^SM:9$KG"8F]\ S.&3)SIQZ?[
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MQ%#AF2%#CIU&^?L^A(F;<^KXY@EO[V'8L1>(KC\NOWBW2O_U'_\/4$L#!!0
M   ( /F!]E*D,L/2H[X  *+T   4    8FEI8BTR,#(Q,#8S,%]G,2YJ<&?L
MO >XXU:9/^P[?6YR2260 ,DPJ41,9,F6+0]IJI9LR[:*+=O @KIE-5N6+<FT
MI2^!77KHL 06"+"PE"3 LI30R]([+)O LM2%! @$ N0[OI,R"6$I_^?[/]_W
M/)R9:Q\=O><]Y[SU]_I>^=:OW'I=X?@&R[.%C8V-PN7@7^'6_RD\N#N.DF@^
MCJ8'2A<4"SC)"SO_I[!NQZ\I"AN%C=O?;[U>.FN<)-/#,!S.+]#,2+<N,*(
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M5Z&F@N'E%45LM&4/510SZS1ZV$*)S2[!U$"]H&#M;JE/A#V.%1<(4^_U22E
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M93&(C<ZR6N7UA+%0H^I.%DFG1E3Q5:IV:1\?M#(8;@IX%JZFL%BL"2VDUQV
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MF0>^8*Z0T1JYEZ&*9*J0IX4S8^8/02'3[)3B)&<7'"9T=;^A5(3,0N:.,.8
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M5OW, A_R?81?Z<7P@IA<#47? *.[F&2KE]Q-D#N:?=V8UV?JW-R.*V#84 :
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M<,LO:"B\+- 4J>A@A:GOA'I.?&\&V4PA@F)I_A)0%[R]\/Z/S6!/'^1BMF&
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M1Z@.)_N0JWF\C8\GO^CH:@3:D@ ?R) ZG*9?'V0 2KH8@#0$ ^!GR@!<6&4
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M6KGN4SZMK!Z[= \3_*N--Q"IB/-TKH#&Q96?L1U!9PI*#FKZ+]L^U::/E7^
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M[B!\'V4 '("3:Q;X%UL\0^7R%,[8E\N+N_BV6UG>E0 G#X3DQ8\/D"^1G0P
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M!:_LVL<77/7O29(]=?&MM>;5'-28S7K<"5OP=(_UA065D^LJ_EEOPZ,:%N:
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ML*AU'2:2#<- F4E("G@RD;H(!@/!;-A*-T U!!R?LF%K()Q^ FA'Y%&A?Y,
M^G["3TJYU"AB8I!XBC 7!UT0"[H"04WFU:N3 RR(2@78,"*4BI RP*$V-FR6
MB: HLV$?@2>0Z,]"%T81!B*W(?K??:+_7CKC0,N>=>>EE4-6PZ^K#"[6RO(1
M5N37SU9W[RP:C8?B=C$M&=? -I49[*0N[UK]=NILB*Q<<G$93.N1@X56_;A
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M%3D+I]S'#X40:3JL.%5UDGJ9EGM;1D3"UR;,>DE^YM[KZV%[WJ^3+JE$HD)
M7E:YVB6OO9+S@ #39;\+ZT]JWTRI_ZMU;>$/[M>JKG&ZHRCWB<,5QJPR-9FT
M+X\2[E+2@DX1;_58YG>)\)?;N30GB@LI3]S\'C9>X,4)W*( W#TUXU=<WNMG
M7K..OS<:UX9/L!E'FS4*7BQ=?BXZ\NC V1Y[%K$S/4JSSXH7>H;=X&\K07>&
M9L@ZZ^4Y:M#&@5-_=K;^@V;5R$F8F(4Q*,%X^P844Y=6W":\0<-SM-KS,O*4
M%*/NW(,MK(8W;.^WIDBM@=7?H:&N8]H$,%W$HK1/F586PJH*XQJZ#O<][C:+
MM@X6OZ:U:56$).U3/YV;O7CF9\8C^\=Y1[W$#H^%QK+B*APMNDX,JGDGFC34
M\]RL3(C6,>E8V*@.ML<,>;VDK>A3:#@7P+98:.!(5XN+?;ZWW]#-+Y6/*$J.
MCS5>R$>\3;5*#@&?1U>4L?A."G[Z;ZWW6ORG]=ZW_V&]]Q]2H(E7C!3P !U*
M0-JH2JQ@3]2VY2,KX"@T2AP_".\[.0*AED@8@H[]L[,P]!$Y?_KO3<%_6<PM
M5_BG5&D=SP-,.1B 5026)-<L1ASXF8O[NY=)YZ>=MI%S3%4&#[C7@0V36(04
M[<\1!AMVW9SU'=^(HI_!,W&Y.#;LH<4*:Y<#[3L!A[X+W0O$0[L!10QYHID9
M@J)/;^VDD6L]*_\WU=[^VV<98;,RV-R$*N+"?J',^JT[A)MOW]S?O:MXK%6^
M7_L;0MKVRM2J5LWN][Q&608I7/I9>B%])<DH^3N7;8SM$R^/) 7+6/ -=M)\
MJ4+D&]2WFA3G $<F^99A]&S,ARW%^Q'623=5SLI)E"GKQ9Z&SPF,PVNO"='<
MZ8@O7G+UE*U75F_M9;I"7J]5ZVA+3=)'VZ[ZY.'E6*^AYXDX -;C>#&=SE,+
M2;)](@;9BV(7NI.J[YI-GS'X[?Y824F99YT3N.92(@C8#QB^8,-J XAC0 >(
M4J,A7HV/'07;DQ=-0.E-<($, A39UBTBN*_^;_B.@\S.>&=)G-.7_Q^7=1/^
M0QGMNAF1&9H''\>!49VUY9!U96&G*?A_:5]$5_J';CEK<H>AF&>A U;+L<0U
MY\:$(8-M2J?#P1B!N1!HJ+T()[4=11T$ZUXRK2F[@<.5%Y\]I4J\(X>]*JK4
M62/^.2\S ^.2XS6KFI09L ]AAN+G\SZHC*_RZ2VBH@@4(R1=C'.ECOS$D!Y)
M&=!54N,O%9\U[B+?+XR7@C+QO-/3.2UM!Q%]UM0?:-P/+Y_&W^^.&(7%$"()
M+"BE(1,\GZPZJ4Z8_4+*UT'.\"L._$! $<JV&%#2M10X%<"&U2-"QD3I\J0,
M=P+W8GEZ8)'M#:/RO%);:TF7F.?P3_?V&$Z=&A_H4^. ;F*>Z4'Q]:OW57J'
MOM=Z<=8^7D^;;V"I^R;B#GTL9,UE4)'KV$I(JG U68K%2(K@4FH:7Z\W^F!B
M/5I-QA8R#2"WG*%/D'C$0[J':[9/A)4*F,[K5X;X7D^R$T($2,T@PHF%."S"
MEN7BSG?"*]V8*MA@_3&6]."&<U+U \G=+K,L?^'<LR&=')%/Z5=<)VR;Y,KO
ML&&8Z4GY;(RLZL?X_*BE,9Q'K?IAR15E^$4GV,G%?M4?^)X5^EE/ID"WHUA.
MM;Q7:WU;K&DG\VR_ ;X]HR:@^NFU2]RF:W\*)C\.E0%T<24F__9F8WDLCLI!
M&HOM?R4J^L NZ42%;H']_@O&%A]4OXEDA/_HQ'[<#:F:(2GX8?"3<"-^F)'1
MT7U<USDQB.;/=ES<3S]R6VW?TW%P#V&AVJH(IN-)?/&?74^X.3H^$JIBPSZ!
MH;-#*Y"[4@LVZJ%\Q1X8++G)RL9P.YS:1_TKIJ3WX+6B[@R[RXR8F2L]UWHW
MX VI<2G'F *L;P@;^&%,*QLFN '?2\_MR%G)MKCPZW6"#QT[&G_DM),&/.B*
M/L=?7,N!9(#A2(?39"A*M/00Y\K1.U0+AI)F\<.!\E#L,I[2Q#<6^2.K)_8,
M<M*&W C-"A<5('>2CIL,2*]72=SJ?NI]N4JQ7]"S:+16YD7;S-6#0JK?3WYY
M=Q3_1U7>[-N5'#C-V_V5S^@DL6!^UMUF"Q'4*1,G,PW^+I=Q(\N.#J"DKN+W
M[%2&W%K]SUT/_FJ*S+*D X8EU3_*2_.J"B*?^9'&;IWX4?XYP%A_WP]5/UYU
M3 %0*PF,9^6C/2L+Z"[4LPMB5 ^BG%;?\-[RGT9LF)'<(Y?76B+!*B\F9YF1
MF855^K.W>\DKSY?%BRH+8FS\O!Y\>__SVZ7\'U,73A_4/!U"47X;2!DL%N[*
MKEHID,UDP^+<!_K;-R^=8/#'D 3MY489>G,#6S3?:[+8^?C*+%H;*]8-.\PW
M+IXS/GH_IW)MEVN:E>"(&Z.!J^T#[V14]M64'^.?P^3H$@!9CPT[X,.0L<6<
M*[<EE#CJV,5W:\!XO ]:=KSYK146M>N/=D3?LA&S3YGT<ND)ME[_<_4,;GHK
M95OR4/W,476YD$0MUCQ^L0O7@6_$^ZMLUJP$'VM^Q]1](IZ0:^NY9VR&:V-!
M&*FAH2]L^J*U)F)OK@<!R@;&4PB4>S)"-"+E,<JTJCI\DGSLB.55/>LMV9XH
MF=R]PA=C&3DM-[5A?JW$$-R1ZH/TZ'$3K#-3GM1Q=D6]OW!F6*9RL=?#[5%]
MBOO^;UF\-Q18 G4C!H$=<W;+?3ICV(6*=/IS)ANVB^0DC(\Q69@O66Y;]XUG
M>EH]&'U F0UVAW,Y%)>G10/>J0O&E[AS<LGBML_>-&MHZN^+7#A@D%R=IJ=O
M[ ._*'QY&5M8#2E?K5OU!;1\?D!;P_TYC$I!T),.PKOAL<D?:X_K<%D:[3[Q
MM+V(\4GN([L/H>'&[\^-M)%ROB-?<OWYQ56LBWG6A9(+&O\<5;FU\*B/^3F%
MKO[-5Q8>YAI_<<K?T_ER*KU%$?-ZIV?"V[=H7_R0-I\_6F "?^#3+CT%<D/Y
MASSWV@=[HT58J8^:[]"')TO(,I/XH2<-H=_IDPU#<4&RR:-3HK^.C/6>2C[W
M8>\D%\=50QN.*[FG0M8OC9UJ^\&7P*VNOCG*6EZA*LOO9UQHEGU@9"(V_'13
M2J[F7'(YGS]A7Z4Z%=]$4SM.R8WTSEDT?^L8T#^H=''CV35!3?WVFV]:SE:%
MQ(CL+>L8E+'P$6E-OV<0]4YP>/ LH7X%Y@ 75'5,I7O6;_LV9>8X*/$XV#CL
MW4KU4/6!71$+WG5=]/TN!48?8P^F.=YFR8RRK[Y>D7Q@K,@-,YBSL)= W7*K
ML;%3W;*]$,2K+'Q:7A&] G+G04C2T0T\QD/8Y;1XZ58V^E:?XSL33[N.Z@3A
M6@<?]*HWAUM@;$V-7NUV.6'79)*LV0<P_1U0'MK'ALFS86(]%0-Y#!SGBY2V
MB8U*?=92;.B6R59U5?'RSGJKA^_6?XL +?\3 0+__R? RE!:$2MM SGXMEYQ
MNR,=@A%^KV&=B/[E38.R'K&(R]UG2@Q?KJY<$]:)Q&[-C/5-#  4D_7N:@Z)
M!M];$W)AS]%RWJX'BG&>,KVGK)*[A0VWK &WAL&?^ ]UULI+NN?ZO_(TW6L;
MBV!ECZZL#EMB,QIM/DHK:-XI7"+EL@8=Q^;-B=?61Q@J(5NW)G%,P:Q:%"?F
M+[0*=8"FEIFC23TVNNSX7"8M_%FAJ5]P91-"5E^3_[/[0Y??799>3OP=U(.T
M#[:*N?WS]HE)*RFZ)THC)%LSD%$YUHG1@TM]_6W?/=7PD*S/(K_\MUZ?"=F+
M7YV7CC&U>0E.\E52[U$X\.1^_&IM2E%^L4_P9YE>Z_=!W,JPZ.8;.[V)VH@"
MB+E$.F01NY503"="BJ34LK)S^,+T41-_?S'1J6F/H5&QX9_TZC/C0V:Y8H]M
MC!HS4JVC!TN([: K,!%7+0YT7:4.@'N="/11^#\--X<@23U&S)T$QI%,+!=X
MQI]O"V3#*(*@S5H"&[:_BBH/!A,C")1;[FQ8TQP;%F"UTZ;E]DHS9 @[;5K<
M6<)ZFDSUYYHL#CR3FPU[#S1<^,J&(8C@7X3_XC6<8\."<G;ZNKCOO)5]E8\>
M<!@Q"QE<C<D6[I<S\])F0^>V!$9EI[ID@ T[GJ[.D&;>2S**0 2JJ7J^%#1R
MX\DW37K-)TM(V?<_A_*"0@.2"3'MP;I 2+\!^C[(I[<6NP@/.\/C-SICN.J
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M\'.Q\J3.\[MM\K-^M-SG6Y1KX*.+#=2@@A4OUGM3B+?R;)_P-\O&S-AUG^.
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MP1Z'95UU[[\+M.PQ(?]GWK?GR89Q'9[OD0C"'+8DLV&:442#("7&G?YOV);
M =PM5$8,E< \LD8#2NFU#+AB5?KUG@6K757'"B1SS7+V?5R^N/3EVSLVS$,
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M=_>ZCW_Y#XI:4KEJ5(I3A [AXA3.C@VSSF\"AH++J98K9 BL.'NH7(W7CNP
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M<ZV!KFB>@YI2_U?U/@5=@NBMMS0O^=:&XU'WA'_NGMR7M8C:!8FF'">F?>R
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M\J3N-#UM7*@4_BJ&P,)>PZDGP,NOTLT8K[$!((L%$ZE)QRGFK&,"&+)2B//
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M3[5^-U:=EPN#>*5S=@6 +H6>H+Y1 *O1%\#>HWE$ :P ::9"^OI010"[0IF
M4-=$ .L7XIU'KT!V##J1>VYA.(Q7GT)8U &ALT<H_$_ _]:+29!@=<8L:].V
M #TQ MAX#TE5NP'(^\3*FCZ1,UU8JCW /C6#&"9-_[CZGBMG=FV0U_,KEBSQ
M8T%&)86,71GZ.T-8]=^G/N;.+V*X<HM$_GZMF=B_1@W_RRM5?__A=;*4>1$H
M 6R1JP$&N<7:__$0WP5_C&BQ1(;PSX:I?-CSEHX1X6 JY>0*F,2G1TT\M"_F
MANB[.+ELBE*YDM-E\657UXI*6K1Q@\=GG4\I8?M#?G\GOAP' W'T[&D![),:
M"0RUH7Y$0SUGSFP!SEU+A5HN-OL#[WHQ*_U7Z\0N;6[!*:D1B>4E+O0Z&N^S
M4/R@=Q#;9BULI^@)8+<HR^K)!Z!R.FDK$OZ&FP#R50$,_HL0Q!("]1> ^A7-
M\)0PU=G6QJJLB8<Y\3FN+#>J4CK&U_6DYY-?W<[1)Z2ZK(W6^X4MI[*9_!1P
M/Q;.0%>9]Q73:;4>FO0*2DUB]J5?1#%OCV.RI$_9KP^7VO2G-\[I+B><?M3X
M&E=F&5IK :&V TZ#,T\'GLAM8<6'0*ZNF;B=HWV)^5P2#^_457/>/+&TT7*_
M NK9>I_367OV[[D]*W2G/Z F-^Q:\=G#GOT51_N6R"WW%\A%"\EV]/B/%T=C
MV38#69 Y<6#Y^WND@VF=WI'*AI'.78LF[I8/J)%>)]\XC6N+Q5B=V;)N_WJQ
M2HFYXNEX+J3X*P\6H'>9LACLP3:<CB1IV+^(Y>:@TJ/>=5.2N6_34*CSIL1+
M^W7$M]LJ*_1 /+4^K-U[6J>2*(ZF1X[F*U<V\FY,,T]SGH\YL<6DMQ?L VB;
MD=HN\64QP4AL[O[KOP[:I"H4DMO+K+JGK:V1J.SG&(WT@Q7#COM=,6''PCWZ
MWC>_&B#IIV!,KG%%&*AV#XWK'9Z%.M@<%P', J/PBZ3,_6!F3K=2G7."7/GJ
M$LFD.$A:"F#A,:"(Z_U&[CE1DZMZ1_44*LID9JE?V_U#"[JN<&L.\9-2#@6=
M-??^0KK"J6?,4CN&>GABJI7'B%(X^VRL3UUIRVC26PZI1NIRWB\9LUBO]Q>R
M%*+PMWY*)I\W:PG>T*^ U&HV/U9QPLRB3;_9\$%VNXTZ:FF*N[OPWE:;W R1
MJ!DWJ;MY/I0*(9\6"8^%P5.MW_OMKUPDER2T-UL\<?7H]ZBQN/BQ#6$ ^VG>
MG4'ZULI1T9BJX&H#E=J RRDI=@D_IOPX>2N+]*3<,/T=$7#),D/77#(YDEX;
M.[BT[Z=S."[R.7$@>I.TQ,J.MY.2R7O;#B[R=6,V+'[TV2:Y4V?WN2W@>I3'
MEO._+&,/A.[75TXMS:\H56_-&/4M*=]]\NI>AXC7;Y45/^27>_BK+^1;^<R4
M[K"WM^GMK_@Y_?5.K<Q,M+7=@?>+"LP-:H4MA2/"WJYWHFOW!45=^''DTZG*
M76)H2=YMIF<H%P-4FO6S'3C5NU8(U>@@Y%;'GMGR_>Q,^:(N[ZS,JIJE?4?(
MUPTWK_U@OB7C_8,-M/S6IPM +PD4P7P &R@B-GZK:Q>WZ<D 5:A4K#-)[MI1
M?YO-14^\BZQWOF3$:;GN7/>D__27TQO1#O&%'/]OGK8TVQ5;]XD*7N2@-=R1
M!<['$..H]P2P,.X<M]]FP-,_ ^T'-M'F,.2= AA)&2(6$GH]:E  RROF)<X&
M(2<A8%UP[PFOI<UL$\"DQEO3F5S0H!#X GW]/CE 7QPUEC'Y^.\FC_\F.J?Z
M-SCZXG]FZN:?4SC+F</FRSM) M@D&\W?TG6@[(^'_ ^(M<B$#X#82J"XQ=73
M?U?"OQ+9J?U'9*?]^'^/[/R57,<5\?Y@&S!GKVLI@#EF4A8.K$1!K8;+!!%=
M"-%A."]\7  C++A(0<U&(\8D2T'NWHH?SCN<YDH117I0MMK883'VUBX%Y![>
M8:V95UM8$G:Z$[+9'WN?Q=[<_[Q,-%EUF,A1$B4]/8C7XR',>\-M64=7M@R*
M=Z'9C_.-9A68_'+0?&7-%>1,'"M#7E7XN,5WN"8RT[*9)\&Q3.5MXUB^Y2DQ
MP50O'^>WUIO=_1);R+?#A$]XO-DRWRLR[S[D8BLMDIVEH>%GD$3"%_D?\_#^
M/.WH=1)[NS1]?=J/@OSXL@_1%+5BE*E[J7DZ82\'HMH-, AY'V)=ZJBM54@"
M(%&NXY2-]1RI?N\JI]*6KG2D0?8^_H:BHI7!KCK;4W!Y"0:1:9HH>J5F4(6?
M1E8!FQUDRYAC541)-RL"\PEUUMQ/YX2W>&ZLAD:VQXCEW%#T4$VUB/@C*5C=
M5?_"CYPK5:!\]'[<.7K99O:CT8T5^4877;I\UA&J2 <^J)R_!-L)VQJ;]JG0
M[;K\Y;385#]KZU\)70,+_H4/_+<X156W51G'JNBT*"RGO;[OAK+X:5-46GR#
MVKV$//R/Q8L$!-,4'HC.C1VK1O<;&GT_B)>W,<E4KE7;43>(<%UL,;_D'FK]
M\I6\JZ=T6XR3ZN[R>VDW*PALM7;<*3J!H[ A,I@G#C<L10N)'IGE&IJS] OF
M6UU33DWZ1SI?ZVPJVU;3<-4S\OP-C]YC?((?';/EETW:R=%4>O/F\/[;_LES
M?D=]K]<OV460AMSF/Y2^\-YPH7+]'7W'X.8,@YYH7.Y=AYFEHKP>^_)B_V^O
MK>Z:B^&O-9XP->4NY:/:Y6;+R"M39>[+BJS)H?JI4UP#K-<%?BSR-P$L)%F#
MDS$,80:::C-1+%,<6JAVQ8CCG_JQK:+K5RA+E#*3.G=Z.>W 3]3Z1[0TXC;@
M%N(I1 ?%$7JRO*VL/9V7E^I1A%2.A4?V^>>SQ:'"VXL,*@OC7^^:MY^)I+?"
ML?=.[&.R YQ_B]%;MFKJVK=U,$U%6F\TI_OE[<W5)XS5]AOW&S0UIY/*RKKY
MI:K23EX7&.)[M90WS9]R]M56K)B*C8T+]>F>&:M%2N,\WN!K*,RK-Z&.<<2N
M.9UW@I/!'-XM D@TKBM\]RK;QDSF>([U&;&#SS2:6B+RY1I&D$/P\/L:_8:@
M2. '?!=%^(:_(;VUFA0$,,,F!E5L;YKXVUXK*7,=Y6J6R%TWW'%$<VMDP5R.
M,%?;HN/^M$.3J;;5IZ!?5.=^K8J:,VWU;ZW6BRVFYW[*;9]B="STJV1/T^US
MSZQW%!-Z8_%%'$S5<&?YO?[1752\2.[I<5\.';US7P\^>,]/AV9F3W)WX)%G
MV)/NT3U_P<Y*B27*5+8 IL2E$U;F +[,XC#+A_L46;NB.8&#Q-/S;#03R3^@
M_*9-7V)Y8F7H_]TI:KP;-@8T4!7 5OCQ M@Y+>,<SA^/*6[!7PBC'X@U^+?Z
MXI;;_K8, DX; D:?-T"O9(\ =C[;PTJC&EA6?BC$?^P!+!AW=^$/VW+:%UT6
MHF3Y5+GP.1$>EY\"H6TI-@NLO@*,6ZX(HXE  9H7;RX!]+IA^"+DU*=(V@$@
M>-&P&@MIEGTK2 9?NA9JL:6Q$?K?YE#^*[36]&\O8E;WWWT1OL'3&#J%VE.'
M%$%5$7.)-21AK':M35#F%JED-=:#<*6T!(-D2]YDN+N^LTGBF_/7C[Z*4[]6
M=$?\T4-_B65N)E!9@=Z@=_@S2V@ZB^L.?A? I+6XA.2Y,3M.K'I21OW>7VJW
M#UH=GW9JW:=U4"C;N@WB28A:I" G$PK05S=_\ 0J3?#J'"7VCUE")6+'(L Q
MX2G[$9:OL^/W*A73EFQNI<^+__:^863=;((J@L[@K)C#;F%8-KOW(<6/$6[C
MC.0>S14^H2V;L!_?=EY[;E,\OFKHL'W9YY;;EX1:T9_005-:F("$PJZO/2+5
M]3)-P_N;(OS3RT38-,Z9!<+R,@3T7XI(\G^3;+81R=NS8LCC06T[9 NI\$UZ
MSP4PI#:%(]F5JP]S$L"JX&E :\LLN*$0P0R80,S/0R4\]K 5_[]7_A]X)=Z5
M$WC6?:E!\[&OBC2D;+I._A>4EAASOC+A*@C[/NJ7^ EM6'1=<N+1J&(VX7==
M[1WO3P""8DA0(C6L@ MTRL#;<8H\ MSF+P_B,0!3+0NR,=2U5!UD)%ZY,/3E
MQX<U3>G]RK,^IR87]OWGS.G?33Z31_@O><KO:#PAYL!(C]29Y)90X7M-R&[*
M&;3H7['^[P'%UH6N=JQN0IU>4JHFZWSN1RXB)-M8A=1JWO.'.>XF\S" >7E
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M'JR-Z5HC2Z51)*_6V9R<&0>C#,?/34'W,BN* G]X%3)3V8;\9/(FG ?G.=<
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M(7;^8+OVM^G(WIVP-7/D5*@B ] HDEGT<-4US,0W/2SO81V-%&7P'%CH5V(
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MN3+?]/E+XQOXQW&(2O^2//0 *#3G)<Y"F#W9B%QP0TE#-+D$R5OE+*!WZ:,
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M?O//KYQ[C:_],$X]45)<&+LXWV7;PT2>5RW@)R%'2K$HL/H2!%:6M3VNW)-
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MY'J>J\>HEF)3@<P*&<+G/+:#\,/P)WN_Y7[J_:;>UKL1&\T12:02VXA[./)
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ML(4&3-SM,O_;JP('2FQF,!Q1-.LAL,8VP88!X^Q#D%NL(3#J6PF".GZ;VO,
M\XDS%01;YH.ZF.<N6EZ;[)O:]U:G31\NV_?YLD$+OYAOL;RX;5U#X;@JY>'
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MP^1-1L$EGP2/)%%-[5[4G-KW?BURRW9%/#6=4H7B["EJ]D$L#K*/@"-'.:9
M[K3^XV3O#MS!H9\3M-= Y05;LGWBVYF<W:]?/_]@1-KVEC] JY*[8(0>*0B[
M.'Y+>ZJD4!5C4>J8Y7UO9DJ02\0)AZRR7C/S%P.>U>3S8-M3PW]:R-DXB=AM
MJ6:?)!>=F>E^LWSCV/NF=BPT+S>O ?WLC=P*"D@M7#^I$K/T<%H%%4ONJ&=Z
ML=M!8>8!DN>1FR&/6[,T.GR,&N:3*@UV'(#OUH_*J"MP1B *?IUQ9!!C#"[*
M:D#79$HGV'=_-:QE>1Y-YL$:GC<WK\H.#;0-Y&^_Z(^M,&?=G0Q\]^YV[4=X
M'(D: R)&JI-EIF>7E%^&('FP5A &U#([+S$1K3YZ5N6A-F\''0Y#!.[(#KYX
MM6V;-PFLD[XO*?\4:4+\..%)^ 40>LJ;8%=W\/4)CC$$."G9[ER<\DK)H='U
M#E?!S.H91,M[^&UHROX*/QP2"1KJ47[-JH/AWK/SZP)MB!]\C9#+/H[_R8]!
MV;0R@YF>=U%]&_8JE?\'&Q0T8VOBQA"5B#9T,J8:W438$6+2"6X'/I6&R,^V
MK>L2BQJ?EGI*QSPJL#OEO;/X8_*.FL%C1OKO-1[=VJJX'VSFQN)])R58]<-8
M?\8"!,"W!$)PG+ 'E/42SR3M-A"@F\38%6=_/9 ^$E*Z;[_:U4QMY_0=U]7\
MJW+U4J"!^ WO2IC 8!B(1*P-PX;5-TQHO4N);T#=1$K/XW>65!/*/M2]RFET
M??KQEI&_K%6#\\PT7N-F^HYGSJVC*%?,F(4-][$-'=-6$LP*'\:Z,P/H]<WJ
M":#2?)UJ@Z!2=4UHJ&AM6=R:U2G?4O/VMXG78VX=E1@KN1#ML(F5?BY4)0!C
M)%::.7"8'&@^.@3?*$>7AAL&]9@=Q,"-0MC<!!^%T4;-$+91.J7M1/A:,9;O
M^6?E+&0A7H$'*[K?ON_'-?;BQ^3(WP<P+_"NJ/&)%D2%WN($M7>\MEEBT&$.
MMZ-O[^#S=W4PL]OOM92^"P@.F#J^E]TT)BL(=+(VEM&1((54X>"T/XLZRA$C
M6-0.85U+NXI#*IV&\>Z/5;@FU@U8\$?HXV2S+S<U)R[JVP3LYG-3IO!@GO"Q
M:58V]R7^:CUA7-V)6_MJH,&UN$D5:\4\8\90.J^;Y^$6E+FE/&%N2UV7L*GM
MR_'#)4]B5>Q&;2]OL\J_? MCX^G$@WT</=Q_([V>W<1 )X%*$/R(Z $'I!%-
M\(C'D&4"SDP7^;A#LK7M_&Y@4S*^I\\CV_MGMJC;I,'"CY]DD^\?:U'4DEO>
MR)/<"I([(@I1L51D"_8'U9([:JE^4DX8I2N8V-O^OHI#*<]%SAQJ2*#OUS@B
M'!7VP33M^!X_SD;-](W2WZ8H=W0L* ><8D# M9#V5+D%*563,(KNNX%R>ZJK
MO7M?MQIDE#>U4[ZJ*OH&N;D[?S1#9K$#<$VX_=Q7R/TA_!#HW<[\.DW+:B?$
MH(-R9)A'^R]>J*ROK#.L''<DUS]+UX6%-]^S_&ZHE.1;1"MTOIJKTR6FU*A*
MGK))>#<UYVAO60O/_BF'8B7\1U7.8$"/"#7K7. DO*.N-IYSLN0;#[;)P(0!
MZI8/&)PL"'MJ;Y7RM>62Y\>5I@_Q_K-UL*"UL"OJ Z\!-@W-$2&RXIFI2QMI
M[2:$6*O<(NWE..G.UD2+,5 >L&C!P:6-TUY^=C2908>P7V5:Q%\Q@,GPF1_:
M3!5<A6_![@;J:21R40=!+G"9;')QQ$".?G)/1^\IP%TW^\*HX9M[ERP#9:<"
M[B1K7#!?,TN>O/+6OS+7KF/ )NGN@8S@N_M]M(-#52B-S^DDACV&S-].V,J#
M77MZD5;;DCP @85I<:(W8[6I)@VIE+ERT65'TLM;>3Z<'[)AHQH_WQ/#()(#
M>71!W =2958$WAVUY?!3_>9&V>I!A=\/#-YB=FRN+ -_IONED<@!#O!.Q-AM
M;!BW!KD'',;I  22(7#&M:#[><AFC[<6R<Y+!J0E*37L\IJ[=&>%^L&'MS\C
MOJHXK=D.%UE>NV8.;\A;J, HD<3_VT42S/^W%TG^*4O(G]:]B+N)?H#[!O9Y
M"F$?-!CE/1^"YJ[C:=SS,E561F' /R4H_8?(T[\BJ ]_C3R=Y\%$4%^,AO +
M<1"LB[[EPH-]AJQ+#":#OPW";)RX?VQKC<$?V-B"_)\_YF\!U] <BQ7#_]AC
M)MZ[^!<_TH?<NR'55>Z=;DBJTFOKC8A$4J)%/Q@.(4ULR#_U3,3S#X.+7<G'
MOS\-7U\D?;3I&V9]5F18_TJ=AP;,9IQOI>>/HSM$3N5$*4,J\HGSZ0PFJ7=Z
M ]N:_F-N5T/@CWEA+OT95'-34ADNW\)56CCXC7Y"6 &3REF8_,OGK\=JN0,$
M@&2H\>U% G#T'[,8_O>KG7^(H?;=2,!/_2<H_@_9]S!T=^@>J5Q_Q/INHB#
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M"N<BYWDQ#R:%_S#:* )!M[T9/-@%;_(O-*!$6LQEKK)<H>EA T1.X\-)Y4?
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MF^7->;HJDATMM\E<RZ06W'\F.59>1@N7)2XQ&;F@8"W;#!I78V>F>KL?<.!
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MDTG5V"W%W_R*/>M663X?Y0/3MZJJIVE[:E(5L<7WWLP-A.M_4.DVD&#[X#Z
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M,2I2YQZP,BS.1&JW7VJ:&?87';@596\S<8XM36",(RKQ7%$_SDLG/#,;1:M
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MH]0/C8GWW.JV9/M<"V2]W!94EI2<TY#76Q=2Q5GJ5\7E3PTHD(JV']28G"/
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M#)V\[W\6_[$]/#QC'-8DU]4?%@?/Q]?I,&4TV8(#C!M((>H.184!0W<)OFW
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MJY\CI@M.CB6H'C0W/H@# 4[JT*NI*Y2C91Y 2E>K:$R[0%@HT<7@:.&X0>#
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M!TUDBI.B86='Q]9"3CC6U34^613;?-C2WCRM?N!5[II&];N6(D* D?R%[)I
M@Z^OH0$-R217J[#Q!W'/1VZ/\@W &D=VFWPZP&*$@WJ9SLJ&!3/LXMA'J4T]
M+YD'#[8#]GQ)$LMS@2W'O+)V=MX7278X*>Q/>RGRF<^7<1PUA*$ZP!*@LMHF
M;HQ+Z"[[[?1DE$3R6'@K-;J\\PRL9]/D[:,+!]MCZ4ZV:0ES8@G] M+;%"DN
M(O2]SB[!$3X%<IHJ]K%TIAJ4V@SS$Q5GVG(@3]5G\+6P!M0(!P*RD=];K.)/
M#-A?#N3K)H%=K3LB346S!0RHT]TP ;0__B%F/_(>6X\Z0-&EV?1Z:$_=)H_!
MZKY](4W>3-#S/U 0CKO]](5Y:;_*GT:,]KU?OTNEN/Y@R1P(H.++E+(!WVP\
M?X/N.F-Z MUUC?*.+6Y)ZO^R'?C5B'3%DFP\Z%<\[QE2X9[W-;.+6Y773+XD
MQUK<,H,G-7">#9K>=;A=G=9&5P.,&2?0W3^GD 9+Z3%_[SWB0$1,CR$B+UEM
MZG>X_5/[9%+'=%"EU>3$XY&7 9\=GSW$:\CC6D!"?AZP9!BBNVYDD6$)FV!%
MA@%'G1[J(-5>K[V_OO;7*98M:.D=34:HW.E?))/)/QWK7703CENVR4%2E^O0
M?G#@\#1%KAPU.S=-607GV1:KLCX]P>,X;2K.NP1I3UU):3\042W9.^A39FP\
M=;Y [F!K@L[7A&N'GG)M?6>.U/F]%GT"NP$#U"+389Z$N4TREH*A>=)Q$Z9'
M@28R.[%T'I'K;MX=NMJMV7;N3R94@S2I3=]/3EXXN%4<;Y9IG@WS_'(!(F7_
MGS.D_Y# /J+/@3Q;0G>=PF\<HEF"LT#&\2\47@"E.MC]N63$E,QC=T.ET-M=
MWF>A5DB!7>5#BF 3H$KHFYN (V$60RT)!P'U%=UMQVI:00>A;SM_C&C:6#P'
MZJ$MNN]0%BKL4?\1P( 1!M:O!; ^Q"+]6&"V2$YH7_ _A;NW&@U@P$5T(Y-
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M9Q]%7LVUL1,.9!]N>EZ/%IJM*HF4[UO)?C+.C^P[ND>S[OW':T(UG29Q]%"
MCQI'E^= XN+"\;.!;('6IE;U& -TG&SK],!(XH/@JM"(8K^F6[:MWHL?2T*#
M(C7W6W2:W[=KAM0VAB/UJ$(D.%-&<O=>DJ4_K-$G85$/N,DP,GL-.)$(/8.,
MU9Q_Y/-_OVV23RC5USV==(R[_XNF(?K>)_ZA $L;,$#NK H8\0D.,G&+]0+O
MG3[O0R /](\D&>7(3Z>;>%?YGTY>5]*;](RU24EYZ5VPUYG\Q.!%'R^KYO5!
MF7N1J, N*!0%]JTN91BQ%E:?P:HSL8/&FBJBQF3^BJ:@%,#P7VO,"&_!;E1[
M-4V$KP9+7[0,7;;RNGK+],*52]YG.Q6-F!)-EACZU5VVSYZ 4ZTPPD"34Q8I
M,7Z[6K:/(!#.J+YF_=-$[V:EVRUZMX"WUKIP6+N/M.I&EV=V1E(/JP%LH?%P
MJ@5\-H4N!Z33\OKQ^S:WM7U[E*3:)[/([/*E( NT6%_E@+CAM$VH6K]J2V#Z
M$56S<U8;%9++>QKPQ.P"S3$.)$ '..)+<0"S&?WEK<YMG-CZ:8MTDFA"@<J$
M_NH-]N+[L>JF@-//[%N3Y!>&Y>\'RRXKY' 5>T-5T3UD-/$5E'H5,X>S2X%2
M+^/GVFRHEIW0!"657Z;22*$)_<$_I;2$0H%/@7^)30^7_')@+;5:9U<0_1R(
M"?</G2?XQFD*EBK+%D%3TP=T% ",PS@X1WNZ6M43-Y!F:!7+:*G<YVMNYE$J
MF/S@)P6+(2]0H;K[4#<"A=B"=F &G^\^E9*-I]IQ,\)0W7^]-^-1)Y&"61>G
M+7O#IX[E_NKSI633 G0#\DHUPZ0_#6JERRG<W2-\R-L4E+1[[X_JHP&-'7"&
M]:(ET#?2W$T0YQM1FE2AU48'4<I]_7PKA<>W$LY;RY][ZFZ15"\;X7@YDMM#
M%CQ2#\Q8 WL(3G4@ .K\K!3838P4+ 5GP(S.LAZ]C3K@MKH##:;.&WQO;WV4
M^T+W8:!B[04-D]1[*_O:BH4[N7^'D$+203F9C!9N/T4SMGXT$$@^PSMRM3&U
M.:AFX5QFQ8?UF*7<Q;?0^ +N]X 3=: '(ZS_)C4;IS!Z>[O-7Y"BK=A^5.+5
MO0]F?2&7N2Y(_9\9<&GF,=#/0-18P8G=]2H_D(N&S.?0B[Z8>!KU1"GZ7@(,
MB.D"B']6IQY(G4[X4=K:\O);9$MSH(^XT:>JI_N5]DS//;O,BWZ,/$H*D74=
M\";C1?S_EAP?.IR@:#&L?O5I^)T#8ON]B$\"ST)X(?]^N_1C2B>*+ZX7NW02
M*5=2]GZ]X;?W>)&LEFZJW+V?)E%3#5*7>>'))I+$$85Y2^\E._[5!^VZNGZ%
MDUHJS5=-7UN5<+O*9&=GR]3,.L];"A]_;568M*?RR'X(5R?W6$E1C%[#"#_"
MKO?7W *0T_WW7K%:*BXH-6?*?FAJ"QTM%%?3?"!52?,5JXB]%V%$+P#$R839
M>;+:S_(04/_+_S Z;=C\]\S*[$_7SR3A,&7KAL9-"R]UO@2#.?NS<B@^JE.\
MJ0)"QPJ((-H*$FQ&MT6.$2Y]J1\\/R]=^E;\K?VYN-I*C0JEV(8C13&"5=5^
M#]23PEOJ[<3]Z$UT)Z'&*./YB.RCO&$)%CQ*9TV2&RY S,I6<X/3;NY[7N)/
M=76=[Y<0"O1[%-I?7%19P75V6_K,O^?I*M*<E"X"M/T3)-E7H%0SJ94?=Z:L
MV"^KM_= K'T73WJI1U&,7%!0D'>08GY^ZP5A*XDC16<KDWGWQ)R$[-.U X.N
M:3K2[2$UWK".D5IE[Q\G3NJ(J2V7BCP+-%G3C=GB:HGI)!9,%O[[6HAEK\=^
MZG3*=O\7I MI7?'*\(S>7(!ADLD_EN<<_^O50D)"?$,42TL$I.P/6A6EG?NW
M%$#NE7\!3Y!?CC#O?F#1$$FV5>_^&_&N&,4WOTG9*+;^&3H^%,&%H1VN]WN]
M)_G(_^.#IC.C<G7B-SK.M?IS=<5(A#) <+Z02?:Y)WC,2BA;/>;TODE*/<3^
M@M1_PG"<^#TL>R'*^7>:Q]07;'#VW,?@8!F]4.,]UU07+'8..<?+J1Y=2H8T
M_-O4S[3*4+'1C'?DJ=/MY)X8W?/%L?Y__IN6PS7O_ J4ZF7_LFL"/;GNQ 8.
MQB<)*:5D'_1:*H6X%L680SZ9\=RYX(AQ_Z(=X1RNF>\S9KS^2&?OJQQ!M0R+
MNXX"'P\HG:6<E:DHRK1623#,=I&VOYKM R*S)!?BJE&01@9I[+WA^R3*W<]L
MJ>@T[>>?+A9V"%RQB*[\_A_K<^85:Z=1Z>4C50'3U+DYU^YQ=_?KGR1.>EYV
MR7_Y7OHL3R8"XE =7!U2[8FK:7GBYY-JHG>>]'PB-8'GCMF!6,U?HKL, LX>
M-3W$JF1:[SYW356G'"UBRE K44.YTT\:SJ 8Y^O:)MI#3!EY\ U-&=S0<6R.
M9%M[P/@2JG//)M0)W67$YF=/0OEPLG.VM!7Z:!M00V*Y=;?JXR3>3[:+E/L[
M%4![A;V3WFF=T_YV&\M_A595_NSN,#Y&M*0".X &=#!,R71Z.&!7S31@-8?/
MX_<'$,20=HQK" NY$*39DN9@F^WI.?*:9>;<V%!S+'^=Q T>K=<WC-1A-6""
MK_M21*BP'G0]I@LMAA2F)3YFFI6LHE3K9)KF$N,;$L<WR>D/6K:"5?X4J0>/
M61J[)#Y@?@5KNB7[$YH7?8L '#.B>#-@3)XOOX5T]JUB]IG(ADH$M$Y^+@S3
M&N\<MU7-6FC[L/%YX_Y)N4X(Y CW[W/TOX/_U&==G@A1;HJ5TM;Z]4%<W/**
M-5$P.._-:FO?LP<%&15F$4%'AIQDQA(MY?K-CQ[<TNS$WTX'U#8WT& 'A= &
M$MK=&=<1>M=HT3GQ6LN)%ZDEBZIMC6/R+HK."\-!0:HH9+&?XPF9RR7,EF6<
M%NL9;B_SR.YC(<04S*P#6^ CG:5"RM_L.AJ!?X(6W3!P^;GMSG?-2"%\=<)6
M)27PH],GUNC!/Y><1=[>X?J;\Q9([UD\D'R*:?YNUED56ZO>T6H5U_1:R\*N
MP>V:T^4?G;$G^$W$X;SH+FM0L0$'.9 $W)'K[$D,]:JH",*4T&MZ:M8WI!JQ
MWB<?J]99UY!\2.2MP,DG)VHJ)93/#@TY9]K>Q5.#W\6]^X'C >:-NL^8]TFR
MAW;@DK,<B \:L/%I\4?7]-YNLO6GXPDIW,?-]C%];Z=:T.^>A5E6OGWP,\D0
M>_BA3)W?-,U"-?MCL-30X]"$H_F==T\-//BSQ!;BIHV3\1N@?.;I V9I \2(
M;XT%FJ"\?'BL[ N6LO15+?7)-97P.)[@>,52GEBN5,E.@S^;M!6V@#MC+Y,+
MS+0*J*DZ<?L6%_VA<DP#ZKL>,F\2XZPKHG)CW37]L0?_N_:59O_D3TT.5C>W
M7DCW$KF:>5^+SN9J?D#?$)U3L6=5XV^)/B+4]S>%2)U.3V-#5UUQU<("C2<W
MU1HMFJ\J/K-=YMK8^^#W_W0)'0%G2A+85@75'(CG8AT'4GJX8ZQ=ART \C!5
MNVL<2,VF"P<REN6Q>G:OE/W__D#I 8/T9-8[/+$$5K]<7N**6I3!\Q?MKF[9
M$*'\2$WJ]*/ZJFKX/S::-I,IO4Y85.:@GFV2]"U!;>IU[Y=W\772P"0(4Z_=
M/8\ JP2E@W#$^V-$_$T/ /$ER.N)-D"6:0M)V^$L3=+_VJA'[Q:K:/'(<GOB
MT).9/BV=8V:I1[]50U#%3#7 F)8]0 _*(6(IN@SSZ\!.;U/VZ?B$-TLLZ+G$
MLZTML9'/;V4<;/1YLH@@A;O3B++I",?/7_[44"7I(KN+9#?L@),[I)$84ZXN
M\E&5:1!.T8%7IQOLI("BS6L=$SJP^E2/VYD+'WH5,RKF'CK%AF;:1O.!1N^?
M-CV!"*0KTK"/489 UH 1;-_V2++IH3SBDVK:&77V AK2JVPHZ2[P[!_+P3L?
MEX\$Y=V+*7#&IK-5T5T!:&+.W#13%D\:H/B7LJ?F3 C[MN&S\U>I]#?DF\5K
M>XX8G(I0SS6^E4 8TO(\5"N%Q?EQTS_A3X**I/K.5]0,AFH_,HMA"YB1,>(!
M,ACA=F__=\ X>3FK+."$*_[Q[? ? K7CI8B7\(W-TQ^77ZO<T>@1D<_X#:/L
MBDH9ULO=6P&S43WH1FA:1(?#5:I1RL]Z!/)4-(FB79X+!#QT_7PAZ=-Q)Z=K
M*\)<WWR3_SBP!2>1A!HL4ZJ*[@GBO0J8MNC((:'CM0T(W$SGJ8W;JBVFB@T3
M-Y3[V5>37/I:%TQB+?NE]MIG9YA!OK?;@E+2B2F^N;N><7(55E.0L"@,>#*L
MNK ()[)ZSZ#0GSR;T_EI;YWD4>7"$FW\/X4^*-^[CDP^*Y>1] G@9AQC[MU=
M:4!W.>(#HPB@G$K((?,QCX)\"B4-!%)_7<?GAW,@HOX2\R8)?XVO1HBHS0^T
M?^K$/'\?VB2/,P)8U!RV( 5T_2DKSV[#E^S,#*%NTN_$>=!">C&/Y6W;TTI[
MT%&!BKC\\@MW/DG8I)_05='(VM(3"Y-\6 H>9H@'+R_NSX$T*F')Z7-U]$::
M:)=.VIQE8I R3:F-*"J];JHX\3OM*%G"3*K6I?\*Z]X1^SIDC'*ARJT*R J8
MM6P.!-I@-YN^)$L9WEU!!M3)F@0IA T=$?H.*3<>H7W.W:R^>65\)3M:Q.N>
MO[Q"8'.FZKF^A_YFI][QL05^@\>TLN+P001 517>A*<XW@\E8U/8IM2?#62,
M-#)\PL0FO/5=8J79F<^S0=^M'8.N?>B,L:B4W%$]\=PX<!)&7 R95>\ND 7R
M:9MT&N!"M7,$T-0!<G9IR0\.A+=>5$QUO8+@=_KV"=7<R9$YEW*?"?6G"\$O
M4U,CFS0^#*QLIB\>YD#B@IGJGDMG0HBP/K0B N,\]3OO#=_&&RJC3TFE<0SI
M1H8?KYP=+K2HK,3>27Z7>/N0$]=%RCFNG1&FF"R]"TADA**[CIK*,$. CFJ;
M-T"CL<VP;*_K*TJKS>I&\/<&FR0%H"1S/SECOJTMEXZ>3Z';L;(XD$!"K"@1
M/V_7[?\6$.W)6>I]$)__N2'2\W9U( ^AHSG0Q=-?^7RFY9'>0@T!/C_LBW_=
MU5#XLJO>.1"J.5H4**8/-'34YW7->2T> N+]"^?4>NF1K@4E\(V/\K55^K"
M!)FY^3#)YZJW< FL8CRQ&%:3L]%&3>G"R.+!K"?9D.#\2"NKPB\&MG"+YH+9
MW"AXO:K3X?W?Q((?%WAU>TEK9W)!F!^ $"(64'?$,J5MZ%%9;)&=267V1/W4
M3R]6H2QI\0T:EL"!D$2WWJ/K77T#PW2?UG96V+P\;K50(\Z P],(#? !#F0F
MD+X,@NTAZM,<FBF^-6)-@_9A^)%>X[\QCTUA0!#IC;:V/II'V:KU>6,QXNG
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M7Z#@MA)X?FBC /%2K Q3T :MC5B_*@2#%R"& SH%B$FV /%\^4Y^^P>V>9,
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MEEID>:1EE(P4)1<RN@,3Y>3E-9(DSO^+,;P(1"VNL1(@G)XNID6]_8OI\ZX
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M!Z!./R6EW$K7Q"<6YL&;="]W"G%EN,ZX1J (Q1QEO47?1I40ZGY@,72/$H_
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MR%@X@[O%!,GB[+973L'W1LUXZ7LZ,1$F$Q%M?ZLSSYY*Y![ ]5:O;??QK=Z
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M__P5?G[7>OI4'MWHU&B_D><="5+ ;8DP*C.>ZPAF<G!LF7KJ'4"D>I,CV,%
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M8M^K&\);\I_@<9YYOR> Q@:%2A=N_Z,< 6HVV3.=S/=JW8N;73JC3!R)+,U
MQV?IF<V^@=FZ[0V0^!O35(K)^F2#-3BW(0LZ;S+NRXH=JU%GXE9IMJ)[D@&G
MMX_J(N*;0]LGW73NJW _QN?SJQ9"AE!-4$RPR6H)KX5 XPKB-W(%T152%EA#
MS!I:8RBS7WI7HO#^(XSL_8T4U^3B\(3$1)J#\V?N .HCYJK"-R:O2>]JFYYS
M&<W&G&OJE!G@5>,3X%-85Y,!B4RN(-3O,I#<!\1)RH]JYW_ZUSOV#LA\Y,8*
MXN+[6+ZNKO/J0XU!S17$NRC4\FWUR4;80WU_#L6%_]>2%7<MSL)8UW@%X8D"
M->58:YBQH%I%8^PZO%@'1D0[AN'[\$[SPUNF>L^K@_(*4V0:Y"PN+T6@2H[H
M'$Y(>VP2ZWX[\>@;W"FHE83 TDN414!66B")4[C:\@!OP*:&:A%Z^%1&B #C
MJ$=R0%7!U9.8JKAM>Z=?I3UAS^_VIC8Z!W /KR!J=:CT+,,*UO@8>1#%V;?:
M$S70CV%#&O/2,OS*K2O&JU5TQ\]H'CP?I5^MTUK\P]_7X&I38^)E_^B@X];*
M#[G:A"\K",#.-W)4J10MMUJ$!5@1A7A' :4L&K4"C\K$RY5TNG4;T#X_\:EZ
M?+3#^U7:4SJ^3J=&(=2(^M<MM/[AC720R;^$RH6GB=P8'- Z=S%P]:59',*V
MA0A8P5L9V4@%=UI$8=:$,*BT.90 2/Q8&<E) R(R <ZA (L>?[WKERH_1)F]
ME[)4&#]^;O?#>0.4KL#BN$R9Z.+U'NM3U]J"U)>&D*^P;K$#79"H(C#+C(E]
MN()P1X([H62V=%TO<#HY5;H,W.&2?JBUU+OH757$S(E8ET3\^H/EK+$#A1:0
MZ!$8T2[S<ZF^N U3*PAAO!XW: !$,D@/;T5[F3O6Q@(O!JU?V%]^=MI5KBU(
M/.]#)_;)FIA79\9PCAT.)O(.,HEV Z8^,\US9>0)K[O,T2+21R(MF8Z*\.6A
MN2>AOG*BS&O'8$VB>(I%I"R$,CR])R,C+\A .B0K<._-!IFY6*=F.$1<;0]=
M02A"ZWD2-: /VXJ3T4W9 2:%G()^M#=5-L5\;_5.*-IS['OI7*1=H("VP)H.
MK][L_ GG-X,U964+9K[&6:V$UP3"KU'@%+SRP@JNN0>V;&8U1MSH'&V^HQZN
M!OQXE1,[0&LP42;M;G)[5*>'UGIX\\R<P8;GY,IJ^4RP_@BP(3$=I#:>!>\U
MR#I@)#U?3/3+?CUTBKW=.GZLY6C=^OC#[>,Y%^^6A]UPW&1MVVC3H)+EHU]Z
MF:H2"N &ZCG;NPB*^,WLB?M&^F 25@ZL8,ZD98_BS[,QLJQK>@95,:\= ZV?
MOU#T"L9ICVS^+1GU_%>;LRU@ HFDL,?JG57 0PQ?F"Z5*<>-(2.Q):QFFI&"
M^QW?>\[UEI1439.2HN3S'[QRI*P\?'=L%[[\X$ ]]CKA:WJ.RUZQ%"=>LI?'
MH/F^G_\RH?O6N_]BWMX%4C/V'DUHM95JY6AMNXP7;>1YEA<G?62.6W\G;\"Y
M*:4G-M$0WY%0X;'CU9O'BP":)RW&\0(MN*K$VDM4#W(8=OVMO"ES(0M [G[6
M0W\M9^9RD-H+V21[9:_(@,M?O_QQ5-\-I_/N5GDGWBP5[,RC#>9EUO"X>["F
MV60I/FQ<])?4(B)K(/OGG0J6$RQKN0N!U^09'5=2["EE7)W3EID(A_;-/DW[
MN --(WO;\)K<-81:7+%-'*P(56#X6/L FKY8$<Z3X&(";90$VLIZT-K)9]G.
M:9O2Q^N'VK;Q&_,3!BO%UU_/0NF;=]0S?G4\?4F[84OX5<XYQ>OK*?N&[+E#
MSOE%LWGH2HLHR1FD.>:LR:I\[G+8]./Z9W=M--F>K9P8?CC1ATIS8U*;8"P6
M$3U&C+I73S'L+D6&P]:%44WSK"S+"J_&7CRNE3_L:'=I>](O\Z6@9Z3A\F_G
M-8X)W4O2?#[E/GLUH)#F1+A(Z*C?9R"9V5B=IW(M+:ZC>+/RD77^,C(1.6\]
M\W9,OG@DIRE>L.FM2&+=_E]90A%*S0X\'EAP Q PAWVD'-Z\CTJ/I<5\ VIZ
MHX,"WAHS\@8_:9<N!#][G+?%ZV83DW:EG&LF_+CS?MCKM66?H?:1??R[!!'"
MJ+(R>Y8GW=YH)--%D9I$E8P4Y/)N4 '__I#MG31YGS>=,^C/4GG9O(J@>6SG
M*=\A8;72QP(OI.*O39:Y5JGP6;>N<<P<:Q!\;1\3"[/%3MKRQEML>:G^SYBF
MP]?MT.?6;'7+TM/#DU9[X'S3PSYP1O=AZ:]1I6M-WH!C8UJE-P*%ZI;?_$QV
M5@:NK/MTZ7)1PGMS_;'@ZW*0PYG<PW-%.#M;I3NG8LZ8C8R2<!\FKZO]N8Q@
M:>+O,LZF TU@N(OJ7J4DQ0(3K_Z4(YU3]J>$,ZH\J>FCYDOP ]N70?U(C'C1
MUX2.'D&7?,/K,0:%JGOUO"8&E:K-1A\E7;Z>&R6FJY,;=E(H@WR0GTV\B@K%
ME1/K@B AJ),B8*0"E+5-&_A-NEA7E0SOTZK4G]>Z&G5&Y*O!Q=^"L)]FR952
MT8Z^OEN-SO!)% 6>U>K!;_C;0 6+Q34#S\S78P6K9;*)'KRUH%..VN KAPG(
M/C#Y_.DG!;$O:,JWPQ3WJV;A!J7,B!%$X$+[@ N3'%U(:4T#,VI3U8%7X0L%
M#ZRLYAX5'?T2:)O<=OQ(3PK"3;#J%1H2-OVCLP#99U%"EQ/<FY[4>3Y^: 51
MU\W>*_SY".[IK^.2PELV1OV.I?EQK,#U7!?\W@2&$$L.F!MM<)"O>CQ'.Z">
M)#(]D]&>?,,7L[NX=M?,1:7-6W0U/A<)=27IBN=E"2YI[:1]LM?S.3014##,
M"@"%/J, 2Y%M8 )L?3[\:$@RT.9[>WX@T9IM$+78[S/ZXUV72_%#*7MB9?RG
M+7$:&%T-YT4./SD&KY@-OIW_N$R,OO5IL<!P4\K9#@8UIK# Y;HH)DYP).KC
M(RG$ 69U).?<ZC,QZ#.UB/Q@,589OP5P34-'^7.OE/=BG)A$2:=?M,RV2DD;
M9*E3RW3<VMS;:CVJF]ZI'E$BP9;HBKI+$>>_KK;D6@5Z?83_9D\\6L@S-VBH
MG.6\:N47TP:L+\:V!)W>RQ+-N+F]J%FE3^].Z:X3>Z)OW_=^E53PJ2+DE@.%
MJTW'P^AV_>(*(B$ /+2"<-M+G^4K'0I)8:,9%7<)>_%&O009_!F@L;",,2LY
M66+G96C-3%#JJ<ZU_D8/TT&NDSQ2NTY2 O^;/0@)P\1F'9.?":G^HLI!^KQU
MU%[>D0*<ZH^,@!6$F(!S><S$^?.V=ELI)S.VG7>YC":?\^J%YXT=.$;'3OL!
MG#$&;GJ6SBV0/OJAYTIW5DD5>SWG39N?RHVFV1\C[?M"9:+VENIW/ H54>EQ
MZ \(SQ(^=:'#9SJ^=S@HI7.80C?2!9>X*)XF:,DV.,J/AD.R1$#C;Y0TA 9O
ME!(W!HXUC.A2>LD\$8!&LS9H]5 =BE?<EQA%<TR_2_$(D%63-%%GKG97*BV/
M!DPXC\$)[B&H4YJG"[1/IS'%J*(\ ]#BK?L+?*7>^..'6;2VG=W5H +3[W;Q
MYK&Y\>C6NL2AAA=\0<!V>A%H_4B4QUQB<TVZKKFR<8^W%]]S[/$E*[LZ>IT<
MT&)=M&$*VP9_.([0;?DZX/)B'OL("YBU]T^,935J63&I#4@!+Z0?4S/Z ,\E
M;7)$JWOW E&ZU:-BNM/31O)T^>\"Y49$2^2VPS[U43\S8S-OY0X7Z'D<K,K[
MN>P(P]SU=Z>I8ACW%824T6;0CZE2:=6O3WT]\$O+1:/5\3G#%%\R4U4$VBRJ
MW'ASLNCX7>O#HKE[$ N;RKZ7IWS[]VJ/&O]?UAZAGL& ]2QU"8.$@=(0_&5S
M3@]SD7O$F.AX?;0SF>_,&%*VYL>U+]XY/^D7XI*<,E![[,5(+8U34\@J&YF8
MOQV\$ S1OK+M(SG)ZN4YAB\I3;SJN9ME_-P:LM< KA@K-T7#TE-)<X'*DBN(
M]Y%0RHS7 C-J?\*D&?0.F-'=!;5\7V[<]?0#I:BME;65T>9[D>PUTF=+F[K>
M0HDE]G\8D=L#=4YP]+99)?</IL2?LJ&6W:XI"#YX^Q(,'.9,^=O_.(3[']-E
M \/_CI;@K.J(LUTK".2OT.'T?ZSEH$/[H.[1$M3TH%+^:*D%2YZ.163^2BHA
M*H"4UE/2H==/*3ZW"A0JU+TP6C<*(^II,79S\VVL&$&4,(05XEUBAEBU05^
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M+L85U^GJ+;*&7F>^*KXU+W_FQ[HUX9>IQVW'B<TX!-2)52#2F>;!#-\ZWY@
M[(;.,<[M$MBE;[:;?.+D>?N%%"[#W#<KY/6^LY_TIA\4:)S8E7XTX]"-CV<S
M'?)?F3GL]74</,/IF^E&5F"OC,:@*H0:+#;^&E'D%\(10PG-J-8OWSODH< )
M9TN-.I9W;Z'T5>Q]8_E)X'7]->\\@=H6/29-G2=#9BKGO'$?+2UHGJ[Q0DXO
M,E$/INA\-!/!3F)=D.UV-(^U33#G[C$N"BZ;^RC]/"Q.K4[8(8^KSSN[2G?0
MH 8,\\*"\'[\-#ULM#.23:Y_6.U(QTJ#24TT+3?3U!%Z_:'$AJ2?T3<4=Y6&
M'7U]K^RP@+\?2II()T&J_!=8M\'8B!6$W&KC5V0_])DD@7=#-XC<N@J\S&.B
MBFNSC?)D'_21//9\NJ;=+W/UOH7Z)P562_,%=X:UXWFSD7'/H5Z/$<Y46[#]
M(30A-,2:3>5D=V.$N"=X!OQ$:'.@#DHJL**II"W'J\CLSJ7H>HI".7/B_+/<
MO2J?.QSKY6FJ24<-LD_H32<N-0/JS%'6$0;V\<,\=VP)%,-$TK"<>T#WR(&^
M?;,*@8^==,U!(CU%X]R@66>J74%68N:P8>3C_<G^7^8Q]]?)P+A_VI1K,P#U
M4]>.@9GHNS,8=,'D\DS&Z\"JNC[;Z)O+)\B7;G)^VXS<#+=_:GC-%G'-Y-S1
MEW<_1=5]?B1M9EQ%88UF^2A8%)"[D4[_;M4@!_PW\MI)+"+,8C0Y:#YID4Q#
M,U'WJJW)DX9;RG/\,@,UCQL^SMR;^N.@_][#\@&AG7D&.T0W<\BGR7OX!00-
MZ!M1D""3U8 =:.;X867T')7.2><'&@TVG)VL*)G,Q'U-^FI:&V5VW\AQM_;9
MDP+9%QO=!>;%F%2># H2MF8/,@4SV+@Q6][&%*9M-,8BK]0G%[S7@"OFOQH?
M'SC9JZ)COOO1C,V^X_+JHJ&W9"9QP!DJK1X2;F2C.<T ,8QX9194:7]H),\[
M7 -]@SZR:^ =G7=+._9VNFOF"LE_P=L!J3.L=M]E]OE1Y2U]V1XP$KZ)XDG-
MUB\_!")9.\:(6WB;V-['^+JU)%DC>4\:(<W;Y&S39K7[\T,G_6C/X0T50A"^
MXE#DE%HB8&X1NH* M](#*=7"W$ED2 $QO7%I Y^#1W]5OKG>Z(:ZS+WR_9'
M"P2W-ZH)# @:>V7"@,*S\18=N_>U2[5G.'QB*ATTJ_**=G3\\? T^YCFKN<[
M[,5R/R"*0T_*-WI_^XN37WH@-6)+=/8*HF\C+$+1N=A_:.MRA]K0OK31'[7,
MQ"YLNP #_=\*5$;R]X]L&*=1M_]E=6E!+(+8,OF6V,<D&C;_^8_)6B(%9A%2
MO&_*DW!HFJ*?__MJO07D ^QW@9 5A//-%<1/00J!',F<978N$%^OMA51_JLJ
M^G6TOWN9B9G\4U ,J1#FR=2X+*\V'.$<QL__^76F_I]C8M^8+M@/#W'NKT;X
M[ZL<6:7W,)I?051060+LJ3JLLAX9W)64XA$$3#0X1.0!G ["&OO]G4;=%/N8
M?D]1[?*&C08GJQ.'0\U#)HQ]CTG;2JCONETUD\#K$FC FP,&G)8>."J:(<-I
M6%:51&2CHV9B*C'J'<^@= ZM/U2=:C5YPO6A9=K54.91 F[/I<="86 *)!+.
M=2'T.JL#PY&\36Z<B2Z,&QR#%!84J#Q-L@ H>$AYU*GR;L51WT+Q]AW'-_B)
MQA2\#,L7L!W>9-W59)M),%.O67+Q)WREX<LG+V*JQI)KD=%4:8H63Y?]NWZ6
M9F(%N$;3:Z[]F&],E2OJ.MT16#YRLN-<K]M\PJ?S5UTERD_/8D3GVP?5.4AV
M5A,U1EF27TATQ3UV860UCJZ?#% P+J_Q3U/+RIHR/-Y6LS UY7H+O?E)24:>
MX(G;%T5HMI.G=FDP=W5Y-$Z_&/#^;4'A7Q-J)17'3@NPT8P5!$LS'QHDE?UF
MB<@UM$?=B8U(KG^!H;E%VI[JQ!]X(X+_45Y:,:_BZI;PP^-5Q9:XQW8505PK
M0JL#E64QYAOY AM=[>@C5T\4!1\%WFLD2.OGSP4F<08ELHYH?M]9%D5<B'QX
M+XB\Y3!=H[VDXXQ=;F<>2[%'4TOVU3Y']'S?=:, ?A;Q"O8100?&JWNY%Z'/
MU,VE:&'>X6]XC6"&SRF4+'C-R>I4[ZW@YV/O-YIM,9 TVQ)GL3E1"15_ZMW6
M/ENN%.&S#;%H]&,#Z(B.F<%8%OPRG,D@@U6-<OI>UY8I9.+-WW*V1J>2[)Y6
ML<ZO8QT_:[8E8:KT7-+V_.Q<GY_5R6:#3@M5_X%J;^U_N]I[O99O/4&)K5?I
M ,8>+N[>'O-;): W9U?>K19Q8<%\NWZ[R:2XR66?ES8<H+#_==B>!_>^[:2+
M)OV-%?]3DZB_\R;.EO]NH64""H)]MP[OF?*VU>2ZPW_5-NC_5@O_[Z\6_I]5
MP__+7SS^U63_S02@6_3_:@+0/W5 \?FS2%-O_5T[H,'[!-&1(OZJY+A;_W_?
M7?1_=F-YCG'DZD&#1@BVS(\$+HH7"+A%X)7\KO^^=YIM$/F&4BD77Q0T]!E[
MOX@1+-K<#0G#(.."7K3(OC833A%HKR*MK6(!'E65EV\_>X2<_S-S9].-&_&5
M%_&78(6#H]]Z&)!D/ /M8886W@<OQX2G8\O;]!N"0X ;)"6'XSF%D(QOK"!<
MQT?G?Z! 43CX&NU9042<6JT"6T%T?,'OAEGUT:D51'0&)*\)B<)LQ60O .N:
MB!@9TJ:TI\=.#U5!>-BRUN"^"S6A@$\XP&IT^4!L. D\Z41DWR+6JQ)K+8@_
M?QC)$AG;_&'3Z1M8L.2G)!/;GQ'IFKQ0'A?, /(@45M@L,E9''@URY(&1CPP
M3@7E)%_5BOMO1:2%6V<2_*1L8QFUA7U_,8F:>DXL@(ZNMF>[,-0J&&V"P57F
MR"8I)\^NNC6.=J?%TP93GS-K"/_EB8+U?S%X+'B%#&K,\K<TU[7S5+2I8"77
M* I;<G-V:1[)6T]\@MK\S_?MIA&GX>O7G^R<O=SMC?68#8]K$XN(@9GTA@_[
M=U#$+E,^I;^\.4W1,;>,\N+F\4*7+" 9F+G!8AN#Q299#!N$: (DRH5G<F-U
M)L+VFK\^:[Y#/M4VVD"L==8N&.DETOH8+BH/K/L@28\31S;ON'=A!?%7LK_D
M*!;1L.]7[:GA3N*SOYILQU\K$LZMP^Z_46W\6WF>H.H?N5Y'@+P+X/-LJ(,J
MH;VU(]^\X1TM\-2-':&'ZY(O?YAX3ZZ9^HKUHHH&QC9C2RP>X7<PE+8[\N&)
MF+CG3],1U>0/9SI2>7^6XU)>/:Y$CK=IK,%H2]<B2/3 A?],[K6\L-V4(?;J
MLY( XCK8?BAW]I]WRQ=8;IHU S9$OO6496WB+!\JM6K@6_:JBF<-21I[_[>H
MRK^]^R:<:TXK""/8SD/)<P)C.U<0,)O2X)W;701UX<0$--=F09+<5-A=W.T[
M]I?J<F>_MY$R]%G48#K^/ZIA%XUT$CBP>PLCM>XP4V?I >]*]NXF,I ?OI-
M)8._%O1[:LG-B16$]O\S4>0_[0*6$4^E9U$7_%!B6.!)Y0J".36]O!-J:Z5.
M?,$",M#A_Y0S0PU\". M14)KJ2W(,",]_&HKG6?XK:!U(?YT-]%]-")9TKU7
MC6GG@U'='_=QZR6SH@OS0S:C$517-*C1_ !_(&L*@#JI8AWH_/3WQQ/JY X^
M-11$,-BIP;:=U++1<(S)&&D@J\EH(_ X3@O*)&:4VMR^CG"V'<IR;R=HDL$0
MEX!,4.A8EY[8[:C@$&6:!I.0/245834CO/WO=/[3_TD/]!]5JW$QXCT28!OM
M>*OL'J<,M,M16&\,?UG!*E00\;T+=ECGB+4XXL^9U1N+J8;8&]]6B2\6&,>"
MY^&K1I</KB[MZ"<[A\B_^;L>]-5N7YB!SX;'F^LFQ?WA\.35*0*K#J^D(#+M
M@:EU6/R\*?2?"U]^_Z?#E\0?X8M=45OAO+MS!>%.BN!T#'H%O @V"69H1">%
M'0V/:!+P:%;B>Y7]]=S(U_E1>#'F;.2HR**6=-,+\67_H9$]/=H9871$FWA"
MD@E]84><,_4?3/Y_IR4]^HM;^YT&5X]^NMXQO:-KWRRMF7'E^M'W,5B&\%.Z
MVR%3-4I)>EG&_3K&>-NIEY=Y\;@GJ .\W: '?(5!)V';I$)R8SO-D3%2P,B^
M5N]E>"V9(;+U_?M((<TMD?>OO>SK>&KI]"_/?9,YT]I 4.XN4XQ!G>GS+M1F
M(9>M\^5.SAW[:N0OI GV34SP9"V8Q";L8U09;AH&=>L>@%IL"WO@4%:S)M_1
M&LQ@MDL,I82<0DIXW(;PY;>[Q)\Y3'D7/1?:FJXA_OA7)_[V"N*>'_6B(_+N
M;U^N)%ZG&CS"]JU_X9V,VT!1!8\UT.X;OGJ;HR![?^C4?-&'QR9KKDA=2;Q-
M.T\/17ZKS'H3&'F8O=9,^VZA_>ANJ<T_O X^?7IB!3'L\X;.50#5.5NZ,:N=
M'E:;T(8=XNUF^[)B^$7[J=58('62H-#[H].E=W9AH-#[C5E$V15BR="E:PZ;
M!P1_'!86BUI:07!F^!'$JTA0+9*5PE7U' 7,<((6P.R87 RDY[&L368@Q;P,
M;CJ"";5I3F5!:%9F8D]:^/$KK;5K3:[9RXPA^&'I44LN,(F?9K!)QU=;?>%-
M^+F+%H)+SFOZ*.L"B?659VKX&=XCA$R?'.?V?<J'GWRI<DG2'VF1G/EX^0A"
M8+***OE35N&E@A;G@YO$^#>UWD['I_:N MSL,XY9EVPUY\?&J#Q),TBXEMY^
MCX(!J[C&O+U50>'AG HF.=I9G4W)T"ZZ\IFLZ9Q92_(VEQ78OGV=ZOE-WD_\
MJ?0'<3P\/V_U]94(,,'R&T/+:N>-886]#(\K[X0ZX@>=DH^G>N4%*_:\'Q][
MS]UQHL-B?J_8I@^7 R21U>[D3[A^'$<5W,B%][;V<^I6\" 7.S#E]?87JNC*
MBZ\Y 4SLQF'/Y.2*.3#WJWJJ::%3BNK6A[<+>Q1U-DF9\CW_ :)K,H@@6HAU
MC#W*$/H(6R^I1&ZZ9,P>CV:+<:+ DDR\42?>T1OYZK7]<)%< /#D9O'VZ</U
MXF$V_KM^OD&$O,>8,,8*4!(QMUNYQTVJ^T-R,/3W7UG/AQ\%-%X@AZG!*N9%
MI2<*,>0!O=A:_N7!QJDU2>CH#K"8"TDE=K-)+(ORH/>Z2Z3JP8K/[<K.(YHP
MA0^S 2N82-ZF#$B$S7;C;.!_@%2]:*1H(RF\58^1'#C5.*+<DUIOV7>Q2SLM
M<,:\(<C?P]IAQ$0('ZU8Y-,I]QK9H8B2_*GPBM^4^'8J*4#.QDWN]K<+&9_6
M+,"FTU5S@=P4"^[^S9/>P1& 1W,GM-!0+#'8@CC@C6"@@A/^CMT;^18O6PWX
M/O =[^8=R[4($37+^K1E_A.G(=CEX+OKIG,?52)A2%)4N>-7IWMYO!?0J#3O
MT.3K$CHNZY,1"&/1#=-CM% MZT.V#8:"][^I?2BT'TAYCJFZ%' S[CF.F_<^
MICGN(_FYT0'"5Y0\#Z;HZ[U!,>Z90+]:J@> #8,4P>93;/T*6$-)+E44?>S5
MV$\>ZSI]YZXLQ<G;^GZQW;%_M?2 'HX#S'QC2%+5'FPN)P640S^N/L9L_33K
M'^/79(3NWF)W](B1>>X;=K/;.J]753+VA\<?KWF-+/+,7_X1[9-[+&UH2K9H
M9&A;<+#!>\O=N;KQV6?LQ)4/LW#/4,#Q=II<$U602'^.*XUM],+)3A'T06,@
MDHF,&0?7%P;&SYA.]& T,@>?7SS^G.+A4]^X?<?R<\GUPAL#1_NC(>%Z0(@#
MP+M[H9_01RK-?)O'Q-*.C:E'S%1?135IE V^7W12//]>Q_RMHMKCP^5LQ^QR
M,5$)DJ:XS[;S HLS44M82/@&UP&<Y8S"-['FH?CI% U/WQ!FB,FQ]UW5QX@[
MEV:UI]'7=BN/<^62I^MLFA7?'#*T[?TS^;\Q6JK^T2*<5*9>BY*&VK&*F+VR
M10R<W,^YR<I>$GH]\\;ON,HW#VJ=MMQ\'%6__LCK#4U1O-O +&]3,R=OM<<@
M7H6-Y6V<:H*4NGG^7%.0>+8(:)_^D&]^L1WY>)_6X4_**;D7/JR7XQ[:$7<M
MX,F'BN.[3R99SHX*4>DT,JCV#%1BQ(I#?:3UV\ \]H9>S>A9!?R1;OR1'-JP
M%ZWM^ULFY]<Q'S]9H+/HO+:8<,<:E>]/8->JR1:"1&!>O^X@/ =[0B=6FNBE
M)3"&FTYS*W3 '^!G+<+@%=26QUCFU?-3WC@^J$XY>ZGJV%:GYHDG)2_GFJIP
M-"PDTL?=C ^"S2\2DB4TX>0(@O9>)'&>(E=LP!'TJJMP2&0V7U6*J GV<E^7
ML^<Y[[WI8:?^E^,/,=^$ILUEEE8#GSK__BT+<#ON(VS%84^)M;OP]LS1M29
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M^[K.ZSR?N>[K)IT,.TSA]["H\18&-.9)KF:GALKPWW+['X(OKR=+9)9/.8Q
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MJX7^;Q.2<ALP8)N= U(JT5ZVC4:> >ZW"ZH6SBX<+X8N2I;,WH3.)&4$_$,
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M;$)Z\)-EC$I28DBE!L?.($RIYD-=VU!0L7)D9+E=XE!D!&0>631]PK,KGV6
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MT0ETZF<1& [%-)0"SO]JXNG1.[FF!9].9CQ3U+X 5YY_B) !'7,?R+-*B;I
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M???UU=9*3>+^R6,S:^(+>4_SO?*^$E8X,FV5C=@_6R+D5C)!%R%#M&9B, F
MK5^&:33;Q96\=S[^LTR;45+Q,.E"9&9 KYV]ZS.K?7U%H8QD$ZHTR"[!YN*9
M_WWE\/^'"UQZ]S=02P,$%     @ ^8'V4DT=Y.?$P0$ 62D" !4   !B:6EB
M+3(P,C$P-C,P7V<Q,BYJ<&?LO&=4%%&[+EAD2;9($A!:R1F1I(*T*!)$1$6)
M0HMD$1 !06F[$00D* ("BD)+EBPYVBU9102) D('3(26;L2FI-,MOGON?.?'
M-V?-G+ES[YI9IUB[5D%5[7K3?M_GV;4+SF<.$=AURLK6"N#BY@(N0S\ YQ>P
MT\(G](HOX M &Q=G#C@!<'-M;]M[[NV-EV=[S\?+R\/+S\?/_X\F(+@#:@+\
M_#N$=P@*;6_0D8BPD,CV+]N=_/=;N?EX>/B$!/@%A/YO;YPW@-@./B;W;1XN
M18!;C(M'C(O3!\ A&?G^(1X7\&\;%S</+Q^_ "2&,'1!\RY(?!X>2&@^2&+H
M[!WH/, KQK=[O[X%O_@Y+P'%,(F#=S,*=R@=K^^6//^)JFQPY4:<H)"4]!X9
M6155-74-34,C8Y-#AX^<L#QI96UC>\KQPD4G9Q=7-V\?7S__@,"KX1&1-Z.B
M;]V.OY>0F'0_.24SZW%V3NZ3IWE%Q26E9>4O*RH;&IN:6UK;VCMZ>OOZ!P;?
MOGL_-CXQ.37]>6:61%[\^NW[CY]+R[3UWQM_Z)O@WZUMO;@ 'J[_L?U+O<0@
MO;BW?2"PK1<7=]3V!6*\?/OU^7=;G!/P"A-7/'AWA\3QC,+Z;D$E@_-4R2LW
M/@E)*1N25&C;JOU#L_]KBL7]IS3[/Q3[IUZS@ @/%^0\'C$  ;"812GJP/]'
M&P^<+)W" 4@\U)WMB^FO[M0QY*S;<0R]9]_^+IRV5QW^;!K>*M,]$!Z/S,<W
MZC&EM-A"@XS+*&'J)D6)@<!T"U4WUPE$E\W:;AP]CYS-M6X.NK^89^/RI'Q\
MS+(OHZU7?:G@GBQCC7Z/ V0*+*8SQ/\@6"J9>'4,,0FS T^L7U#D '$740I3
M&#\.,*=&)"1VB9L_N!TA"NO#"OVJ6ZOQEGTP&IE#TA/S43VVNN-<[)N;PP"Z
MC6E*$TB-Y ")L](I:!50%R&TTMHA7T.X;V;*JI)?7I(.%>JBXP./51Q*'BK/
M>Z&U^@7@;]K(][:9KLYU'/WC'C3GKZS27[*BJ"\@(%(2/XP.QW3;,U4Y0$L=
M4_($/0(2R@?E/UT'6>;\507!:;,HFD"O6TBASG-/O;8F13D[K<3D[.&N&SP:
M:<9[]$<TJ[L&'W( ?W@"@FJ+ ;755@>#&"(@VH$O6HV>B!&+]B:']GIHTKU+
M%H9\O>6'"\HE.QNU3<0Z8W^]\#/2U/]NX\+S1_C\Q,:\PGM[!^>)?<TM]_W<
M4Y\>5Q195'D2>]A(V^!DV.X1WLJ?RS+R<OOO?MUE?0Z9@6UP9HI7T0-9[7AB
M%:95JI[A"KIA9*.C>C'B&RX;H3R$96>Q):T8W4R1W-\6$BFMXO<GE=+>9>QN
M*K5"*OW)ZF;OIJ[%HE1*0>D>V2NN@4=T\_D2<WWE#'1>=^E7APT([[:Y<%%&
MN>"P(==7?*,#I9V(GPU:_#%0%ZL@1PVI*$<R=]-.YB37()&V,DEG<[Y/4[24
MN00O%T:;QAZN=2#644;(=<EPZGE$.K;>_SY3IWB)K0!:D# B5SO0N,:VMHXC
M^4U9I]6^S$EZ:R3LVVF0!ZJQ!0<Y &\J9/Y0IB>T3V3/F,N#60PU,,:I ;Q%
M\[=*ZKZY*3[/-Y89?.C2VWK*8_&.T.>_1LR_.%\L0?=B>/#!'  \I$>OH?Z@
M:)1Y@JG=';#8+L'P,**KD4;AN%'0X/C[[J-?KW<\N\M=O7 IY%3(\_;S;^\!
MZ#H7PN?EG+!EV>"OSE*_]T7[QQW[N7Q[5V_<T?Z3,;4_\X(IN&<O5XQS-DW2
MG,868A*LGS\LE'A>O^7\W615KCPZE"WXFG&'/4MHJ'LCJK@.3R@0 N^\8%I2
MDV+=M@(I33%+38RG>E[-NPT.JO1E%$N.R%T0X4*JL7MQ7*SGB&OPF?-S]!Q6
M!P<@/N( 31R (D:S(Q<M7"W8#^++ECHBIKI]VA];[$Q56GET-/MU!Y]-STD9
M)RNB^L6S,,*1OQAZ*ZL"0RQ#[$#KP'>PWR.IIYXYI)E+L#\D>BT*XLR6//=Z
MW^CO&L(T>+C;JKU+8'U?-?XE()D/V?H\HKDYB2G. 7K1.UE-J,/D.9@4&.H\
MT?1,$!4MSO#;M$[YQ@$:OW?I=U;9T_T>&E\>;NO/_&#K_><!@/9!#R&I;G6@
M9A0EGSJU2/ZQN@)U>;!QVE#8X_:F50$=.9MJTZ1U*U MVRQ&U_#K#4GP"__X
MQ&ZMI?295CJ5UCH  ]4%*##&_NC?W;+&\24HR=$N>4Q@I?7M8;.1JJ4&CR\J
MO?7K]+ZE9M=CO#YY-!AH[, ^-UF'F;E.2V(_%[V%B$-X(>]B6V%,Z37Z\"@'
M"+RCNM97($+E $DX>0?$7=6)\J33DZ$EGW:TMG>F2#LTR47:]@5\?1&4<Z,T
M6R@6_6H&Z7KUYK_TN_7+(%FKS%'5JLHY=[FG]XQ[R)$GM).*=!T^#+[:._T#
M"G]'TD@BWAN*.$UI2@R#FPESKS$E62?MHT:EH.1),J&E!81CG1/5JC$_*5T#
M5^J'%(LI'Z6OW%TCXZDATLS='(!^"IQD $PS5BTB0(_;;A&[YW,TP:63:C3U
MNO)2E_GNAX.>[0%%KQ)\7 J')\Y[F"9\6=,7.57Y$F"A)ILI,(N'AR.'_<;>
MJ3ZR%O?XHNWU9>.L2QKV:BLR'G(9_#Y:!--]C!E*"Z<WLEYCB-F8)FF*3NU5
M@OB?U[">J#S^K/*%Z)@>-]&2A9.X7&^)K?Z*1-_N0)_U>(-7E^=2#:+*Z<FL
M=@3Q.8)J"9NM\V@"O6DGWK@AX[J\)--7?W( B;30VI]H^<E?JQ2EA)*',;'H
MGFF#6[H^*+A.>"P L)[:1UEF.6-@98T!TTN[,E83>IYF([H<36-_U&I.HB51
M)UAIYL ,^GV4F_7J-!0X7JQZ0X=9GC.?'A83.4!ZZTVWJRLWHDN5?BM-A*PY
M]NVV^61_'7&[4-[RAOG;=6EX([)A^CY.)QI/]P'#R2/I./D[\,';Y7<-4_&R
M2P<M7TZY=>6<._J5SSE!P]2F;:]HUUD!_\JKLTY)/ELYS15S,W/6Z0?)R[X/
MI,U$&G?QV09&!6*"Y2D//H2?T.1/"7A^L*/@GEBWY%\"!^ [U<9*Q!F@9] R
M+"S*'Q+U!PU)L:7EGJ(BZ#5U\4VO3YG>4>K-,\L]$_=KW6ZN3;LPQS5*,\?Y
MT3T>]=*H6^5,,?3: +RQE2GIL.B_:EV,_F"N",*).M:DF]F+^7I$>OOBLZ-H
M4>&S)HEC,:F'K_T*46I-^6HC7TAX](FG^8*5.L\?=Z>IIF#^"<^5O.::QZK'
MXH+:IXRT;^NZW,U:<@JB<0"VH!HD5PWK$3X8RXN* 3,8?JBCF/OU:I3#B\,F
M/;/\S97SNM@7[L+,894F,9N47(-3'SP7GQH/"E6IGXG&\K"G$7"\3RAH(D!/
MAXO@5*\.5S'AX' M4Q^\0PX^Q2KX?6K,W:/Q5>*)ZVC?Z/VXQU:++%>;..*^
M-P++"*:$,+V^DY6!O[(&H8FF\ECMC0<QE\ PDE:^JZ'=4)%WH+?'T-X>XYVQ
M;/[7 D2!/H\39 [P!L/+=)ML H-UF>=(\B;.'<TMRH,BN<;U']Z6ML\*/S+X
MR(=VX0#=%Z"T>!]1+[#Z%-+P%IBU6#>SUK.I( ,F$4< 6_-"FN*<:[ML>@J/
MA,=Q'=NTA) QFMNE 6*1S<]/"9^+\':8*WI_#W* >PBZW0:,96)Q3,&4$87I
MMC/S91QBHJG.J\X,;?8':0ZPAVT4O6;9/JV-TBY0BK<:W\A7$-#'%=Z).=B6
M8K OTO*"RJSQI2H)6"E#BSV.I9Z'RS#]TTG.E >07*1Q-OQG[I%+FTZ874PU
MFM.TY_@'&J6_I(6\HSSAL_[^M^JG,J;:"*!Z%%-<;W%D$#,;U(UOW5S58SBZ
M,S7!26*=T)=H?\J1'TE9%\:,6+*V!9A7\Y;H@)XAY8?*9[^&D$YH=OSE *LL
M*!REH-+XD/V1T.K<NP:J;3(ETXEKO<[/R-_*2CF 4"^YM4=KI;X<.?^Y1S5O
M;'GV]V;R?BN+KAT3AADOK44^QL*]4+MHN10[,B(5*[ZA]Q KL('9"2*LIFN\
M0/?:P-F&2PYDT:,UFPY'^X*TGLBK_N5N*%1ZKM"\].?O/*3I,#4JP5P138!3
MS\$ <*UWZC8NN8;I\*G:Z([6V;N^<>NS'B*#V@>5KK]]^Z%$88<J3IT&2T'K
M,H^R*NL0Q.DZ+O3D[>#6'I@8B.-M!--5Z_=/,4U)[JF!=?Y4D[RWY^I\=NQ/
M&,KZ:O^J8D$QC6>S""<)Z8N# B&H&HJ$+(P$>A<HY\3*"V%&E3%/R;[^V%CE
M$OUD9HC$0M@SM'.C[$)T5!F>0[>^/2D#VUJ5HH:S&4HDO1Y,$I(;O><G@A\G
M!IX:/TX=3#1\&4&!V=3;U[O-6=X]QW_+;*<+5-J4,VWK/D))7<ND!\^/VL:"
M$^Q>/!]:*3!N\Q@MZIZYWL_9^<+!M> 0E*97]JV?ITPOTPVYZ.F41H8O$\%*
M17@C9-$SM_\T!.4Y)S /LPI+/[LNW).=_%"JU-#\\&RM-$5\B/<4":D0$%R3
MIJ#%%D1 +A6:@%0KPS=<18_+3K^9!B.C<1H3379XX2$RG&+<FO/QG)P^=I7J
MDX7-'5J4MT??8+_'[,(IHF<*C%C/\<1D#B"E0&:XL)Z8[U^>31^<*4G.,:7H
M]80K*\B]O9;\HBNFBO^R[3S]QI>-:E@LLAG>C_B\R!9%@QR ]H-84!]>%ETV
M1)Z^WS2OYMQDZCN>QP'ZG*9@-](.VRH]_#:S]T8#K])4+"+L\G2$78U3L-"<
M:U/FUCS/B+]\SU-OQS2I8S<$E#)-)RN9SUE=D#3X>ORJ,Q0J S1K"IQA^/FJ
M@B1(H(;W.)!9\,7(Q-<11L-V3HT686%&'X8UQ&NF9BX67?96B'I?##@A*8RR
M2YAN"PX00 !5YJ?[=,(O4JE@.8D#[%Y14#.7F?!I>-X=3KIS9'W]_>%B19O,
M@ \M']Z^)Q]^%J31#<!K9D.:BX-4PTJN3K5:S7J+OFW)]UDOD3_7DM6<5/B]
M*XI(V :R:826]('0S^76$)#UKV9*U5,I'QNK+[V3:9Z0=FZ*>6FYW_:Z]P7-
MN=BOM#PPBFRR&LDPQ73K8HCUB ;C&H8PR(566$+L(?072("YI!JI+<RKH)RI
M#K?YF2'M\S:]PRDWD-'?7K6;[:4B&S$04& +#M%^L(6#&5=1!N!KA@:(\1A%
MZ0<3/1PMQD-^M OZWZH,;)5V_JUA:Z%CR &ZKF4:C'+U W<8I+HYYWZW0::D
MW #R56(Q*5B3T(N3!O7*P"F]73(ET@Y'!PJ-&GN(^7$J-KT\:5^?/W<>G0TI
M+ULQUE^^;5[,-]_TXDFM3IFKV$!8K\:^]1U,K74">6W5@YI+?\\!XN^C?*GX
MQ9K7OTJ)HFITM]%0HU ^BXKA8/_:#WG#/>[6,5\;FNBTW>NW1.9D3R8_,?Z@
MD$4'0!VBPV='MC"&5D579N6NJE()/2.[F"*?NF[!XLZONU8;UO@S+*I]<J8.
MRW=E9YC[G[4B2UQ_>?<8PKJVRXXTI.,FS_T;V9#()OHMO'<O<2W=N_[RS/>?
MMW=.WL3SL650.UEI>!\X5Y "!$OCMC#=FCCEH 63=IIN<=@B=K8D4!JM-/JG
MT.AK'1_CJK$!J]C^G'!/ZFZK:K.N1W79\':L2#.<=P4NRD14H0RG+D^@#D<6
MSMJ36,=G?X[(3V8=?\!;L5_Y;8V,$RRK;>_7[['F)UGM&.)+0E/=ZAHC#+2C
M[V0]QE_>@S,$Z_H1.\MHT8$X;3<P,+BFJ#-SUI(#G&K*,1GHO_8WY0R3;]%H
M#OT.WJS'E!@D;_87DN"SK6Q!QT!J3 ]V)NLTR@LVF*_5=TWW0EUN*-W./>#K
MWW5"UWS"W-OO.&M(M_AH;WHY+92YUYZ::\M*1VN"SMT+!R!:ZS7Q)4A!G_HU
MKQ0[8U5G\@R>L;?>F*YR?>[5@>C#=8T8'V0BGNJXQL^TQ4%Y(Q@YFT3"/.C2
M4DW2=D-G$^N2<F7M)]SNYNW.,AN;/R6[?_?'4N,X-\O#?VWVP2V6.P:R"EU;
MBFN6<Z9N+K\QW'2L#A \!#3N.FQV8?G]LOR>7586 G%:M$VVH-?V$&9E0D_@
M "GPEJAT#A"$Y[9?I)C:LUK1^Y8*X-2'S967'FB=>O:Q-9.\I15=<M+$4?M5
MWUB+Z_FI PDW&*]P,/0X80_""P8J^E/>D1#W%(RF_#$S(XMU*5T\U-QSN,Z8
M9S7BUC'YY@L?M!_:&;@]6_*QNG:W/GJV,X#GCSA]EE5:RGH"*9R*:1*(WS_V
MYT$4J;5WWKGOP,_<*(1RYNS,.[.P#[N2+&_$^EPFTMRQ#?X#HDAZ(BN;+<-$
MT_BS@KTPB]BD+9/[>M>NS:09CWM^[KU!*[SB4MET3^0Y463ZNQZE&%+S!"L9
MQX_IEF+&T+Q)Z4EK&_B4#H'N&%;,1;"5OSTB,EWL4DN!WX3WZ^Q21;+PA$$?
MM4T_ :O)HYEQEQ'&#*--;9,I!N33*';_EG42>O\R6QS\1*2(HA4#D$(^#X_&
M],F:/R6M"'[]1%FP2[V>>L-?P4_E0=KU-I$;%V,1WANOHRRGS:"!Z3?V>W5\
M3ZWYT/6&6^=WOIRSG>T=_6U7N7+$/"&(3@F]V-(8V^9P9#GR@8E"O/:Q=QMU
M _?9_#/,_:PR\QVHR]NS*5"AW(L(P-Y54/R$4UJZ'=7WK 9I,[ZZH1/3W=B>
M>C:.M6]*-VUL0$;UH5-:0X.!E+:X0B<1(F00YF9*QK.%11GV@] X. L2NB$:
M,0:&]G  $;1"D E$6'Q=7O^YE^O<\3AG>3GKDITB2?ERF Q/?D8VL-5+7*.T
M+R*2D53'NC3LJ]I"(D67< (,(F)VKN2%M/)FRE6]BY0,5[[!?9//HSAD%&8V
M/1;Y-Q0R6R4K#R7/4(+D#D=<7;N+%36J.8,16L**HN3U$@WGG1US:!M!&CFN
MS@X/79\^[Q8VJ#[5]_C^P-/]%G43*8!ZT7^N#8()) ?0P8RG-AI.X0 ^[)E/
MOZZA)[_=*G#(%[?&AUBMAGP\:)#FX_P8TVV"]T:"42.K=D3XYQ]L*013A4"-
M7]J4PE,S.( W*YZ""_ZR*8<;^6'_;?'C7+I^8^MAF3?T+76>[W!0'<$4;W5A
MU:*\J3_HR: D;?8'"3D0>L\M87[P+BJ2/U6A.&1J,VQ'[09CSCI"VGA<,=:*
M^M96:_.I>SHK'T/,0S9);E*RBM@$! 2X9JOLP<)%+.]/D]L.O7JP:,<>^.<.
MZ81,"JISZ.5B8%DF^7L ![CI<U/N0D9B'QHY,W%6(!;]#O]JD'EPDZ)&8] 3
M.$!",:N= P@/#<BB(=#.2J:'KCHTNK*>O?N-^FL^WKD6.B-U)/AH$.%G4:RY
M+@W)%(?1\Z@(2A9-FE[/2L807^@S]9K ]ENE2)0%U:^=6C3==W/:.<>8/./?
MDF?7&=7\6U$@NO?;YY;KDLX3.%%T+YSZ$H(W+["RB) 1T TQ"Z>V=B%(PP9L
M,>C)6@PUAN8\Z;?Y^(]6[/>U^=;WZ7[ZN2N>'. D@/I+G:;O;*;"F!)R9 )E
M_ Y-\>AY> I.>)2),(DO'3U>$[?T<]G'A-]///G$>J+RW,.:/*I#(I9JES[W
MFZ[4-($6@[R'(+[PW L5*;G7;M\9O6P ?$8=7<F,/D$1-QP_X14E^45/6<&[
M4]N1IU7MNY^?]^8?":YN]C!\)\X I06:E$7KT>- EEX?!Y"VT/G0@4_[2IW'
M/=)S<_V:(::C,V3-&Z:D?8I'7VN/]H>^K(5SD-00'^-]QXK#D[X0&B%(_@8.
MNA&H3UB=@[*#]_'-^%?XQI8[..+PUUN>J)F9_,[-!_,WZT[54]7H>R#G:#!0
MJ%NL-@P)<F0@!^CY-<[4"^( .P;I:EFL5%:ZMTKM6M-?"AUK^H&0KGOTR0#R
M<!VF*-:,ASB]J@_A_W2VD""MF+[Z#S\70GZ.Z67O'4>0I-A]Z_@&3$/- MR
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M3[.&1H'4Q2TXL@!.=73X>\:$*?Z,W0.7P&QT^QZ#VZ $MYD/*9)-@"M@O-;
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MBU%I@LI2Z^/^6M##VUD5^&"')$)+!))ZVF%VFMR:@--T4UO]6X8Z24WO@\'
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M\-C5+M>T[-*#)'V.,**9)0/3X&'VT8%&R5XPK,I!3M>ZD]VE)']12")>O7,
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M9J!Q43H7N<3&C3AD?Y<'&#3<F1?16*W#S-PM'C$4;9YGX3!2 ESZB2 ,6/\
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M_8<B-&G$+%:$C;_XJMCS]X^#^.$>]Q++2',P7GL\OBQZ<Q+_P5%!,-:C):!
MN,US%+0/F7,5UP B9PPIWQ/K>CJ,<9C$P+EPJT\S4$MR3WWVS9M3X<=VD],O
M6_=9/;M<?DQ/Z\:LGECAAY]3[K8'?Y4.1MS!28<,01;S!FA9NA->R5K+[TRZ
M3YP_Y-TK5-XGNJ-JUOY31KUBP^?)3!M;8@RF_OZNM]$;+Y0A+&#8A;RA <".
M["-)]AD8@<(3LFO+5"0A/XTU+EBI0L:QEU="'LFT-32=47CHK29XU^#=%_P
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M8",?R50CC=)ZY5++U*93$>BXO<)BQ<?$@]=V[)<4T=_UT&CP%[?;G!B<DT8
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MLI08BO02ADG1FW&?31%OT^W#>YP*BPM]E9Z$3^>:NY^EY9H,$"[]'834D^$
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MD!#I%1=HJL82?O-O0]/W8>KCU(J;6/+D"+=M*J'B%B5O():@^%\K&)$"5;B
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MTMSNDV[@%A)C:)P+[!Z0I:!V0;V(')UJD15L%]""M1=C"*:\QNCF@_@;;[F
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M&B'%>^G,"BJ/F]N*6FD?X9DWI4XXW8.1WL[WCGU\L/Y"$;[K.G,UO*SOLC>
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MU"3<RF(GQL*QD&K+RU_'0DQR6J:F!B-HW[94RP5*G(D8YAW9+#QC[!<$B/=
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MZW?]?M?U^R/->WCOS]?S^7@\URQO!/W16),EQC"P>C2:'$["4A#P#="2K%N
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MH$%AD)[HMX>Q9<+C#CD=OFOS+*0*<B*%BX"[BRO);HIY,"P7C9(@.3<,OV!
M]3TMBOM11P8.E5(=#Q^VB? 6.24%:2YY-Q1*9D(H!V-HF6<(%?1 1=A*[7!U
MENE V^3ZBRSVVG*75Z,(,3O7]$G_I8S7G\\8WSK5\"(AX6T&8>K]2NK\MR0_
M!<\N\HCR RD0IFZY2LDCM,:-7_(Q\'(SSH@Z8U \^/%AB# D19SE7@<JB.B(
M'7\!+8//$V!N<![T()FQJT^M7;/ IIX)X3Y8#76X_:+110P;C[BME>N<D'61
MX7)F2]KE/:@JO4]0GE(WE29@JRJ,!W''Y;8C@#="^%?YLK4?-+F1.QL0'@<3
M71><(IO2<V&;,]&GFN <6FI4A(^##D7DQ2=X)[VBP.?2)$DP)$O?WL"M8)+O
MX&YMB7X9KX,B+?W"%A+"919OVG*.W:I:JM*<<5JU1GZIS(Q13MB:O960>USA
MMM[38W.>B0?+:BKM"OBF-VJL&)Q>(J!9O#C,&!L6"B[X.KBJ>%13$\KC&*EG
MB\ 4"1>EMLBD:#UYYQ3F]V7R+30J:8W&ST/FI%B]8 PR(8* :RQ)R+"W3(R%
M9%17XF/X?F!@N&?R.CYV9?V9Q2/5W8:Y56$[M>^("\!@V :8".H$>"X6'_5F
MZ]H0;U$7[>/%I*B/:>^MS7NAEDC%!W7O#AOQ#S'FG"/% S8SEL-)B_?5H!39
MT BA4_W[^JZ1*ETT@.")XH?'^YW?UE3$R81"YSBB[$]%Y[Y\<Z+,[XV+18YL
MEJAI7 EBS-6X_/&:BP+L7';>Z@TEJ!BGZN4LCL$4B1[TK(>![")"=K0_W68Z
MX(JS+^*5M0[@J-&^@Y3_\'WHWO[[IR2;1-=A$R;-P+ 1.8C^!K2V5[%#U(DM
MM*/=*+%Q:H!W"_I@:7?!8IE86Z$M^\&%GG%5CST7)%[47[UU3 (=20P9"R(.
M-DCR4P((6(&+-J[&+VT^73KEBPI3G.]J""?L:1*QB7SX+ W1C+W.\VEY0@*W
MH(BD7F:\PPJM(+DH \B=2J&$ *EFC3-C+M9?X]IJ91^>G3EX(7,'VX5; GKO
M69&K1:X%AJ9?:N>>RCF[YVABE*HDM]L25XKXR%'*7DO'%5J3-H[F;]@IBI[K
M?)Y(/4"[3?DZ#A]>;,:^UEN0(\GB6H8?I^*-  $?Y98@@_"&22;$V/?L[GJO
M'<=B.J(O;"EFJ3ES> 5Z87 J<3Z;.$)X60*^BB<DJQCMO32[$E)Y"1X9 O*!
M**LSO>CVER[641T-$0'[QDY\.YU5*<)Q1ZES4K">@#WC>FLXX8!IHMK*H[BJ
MJN( ^XKRD9J(CZ]ZLL)"93#R.E4*"F4%"0GQW?,50_\D)O#HUY@ =4",/BP9
ML<1)FZ)G8;_44JK^-9CQ\ ]FEY=4PCC[!+FQSH24EP0=9>P(."<9+H^9;*S_
M^;3&'WS_)Q#?FSMZ3+W)NCP)NCH# J:;)W[)IBRMT$VG^TQU@%_23_[#D>8.
M!"O:@^$8N@=T8Q=&[H?H?S[*<+,ZP90)*00!ZVE^%H+GWTU(Q(S#UL5+.S=H
M)E.7_KQQ4G+B_[FD)C4M\!%)"3 A='3[9I.!+"O4=U_ R\Z,ZRU;F!!@YS''
M*:M4&70GO/1SDN-@2V<HK^N:M?)3>NRK1N"VH[?CI-O8OC=E<<?/'^U_MX.E
M#J.;\6BF-T_RTHM!YU<S%GFG73V_$ ;-YQDKJ'4J!Z.."6$'K@%;7/Q*83L]
MWU0#LM'EZ#TD4?M.?]6@.[]X&-_\T-UT$[MOZP5S5+5EQ0(;B'GGZ#%85T 8
M&Z.M23M8.:AV_$9&:9P.R2G'A>^,B Q_H]MM<>>M:7>^K,EMJ2D/;[Y,S W,
M?)=BI9M0$W#NJ=.QF:MI>\WCDF>337K6:JIC5.@I@,/BT!S9J+P_G\%"D9W3
MB; Y)&&@A-(!@$G?O4W^Z"&M6ONM,6M'I[2F6"5=@?%8W.LFA@)\]VPZ=YF;
M;K\::P T5 TFY*JN<>&SD!)\/NZ<PY4W\47WSGE4B%OU])GY:$D_RYAI:7=T
M=)R6GSQ&,4_0[T]4K4!]_#9BA[,1V<"%:*D03';8^<@U24)+JKL7\^T_+AN]
M+;>J2!I]F'FV.[;T^07SPL/1"@T,(:!>"7" !FO#>FKW4:SP \]/#(866D\T
MD$4[PY"8?$\#@X]4&Y>OUR<N^[)MS8'D;&6%GS:U,.,YG?\HFW]X>,Y!XV*U
M!;LA_R0AJ](X;R,%V82\"V5G'*3@&J"\C#T^1M0SEXB2F8IK(<K:. ^A3^[2
M%E8!L>]RE$Z_:KIWMQ5B)4/58S3"2]86C D2L!8HO^KH+46'7XH1FL9F)TDZ
MWU+ERY5L&W#."1:#'G*36R.).GYT_JG0YZ9J\MD!*Y_W$TCFCB*GW8Y-YX^%
M?4N\MIC3B.YD0DJ0]<I#R#HLL1"]S8=S\%3/,+Y0R7*_Y*7"[,NLQJH])08J
M#R&?Y\]!6"$L=AW\%@V[L@6$\V2Z1<QS+I1^GAQ!WEF]09?\'M;GP[]'_C37
M"E+6;.?TO#JU](30EQ^""RM7?^+VE9IPIH4=PJTN,R%NSMO=:,(;*2?X3>$=
MH8$_'WHJ0)4&U<%;BM5O(TY/H/T&O_>S4J&!Z4NF!-A<+XB&Q_V>FI"^SFQD
M=F]ZBI]JW_U'78K]6ILPZ[QET T";&6OO<G_Q@7E69LV:WH4Q@&*O!6-/WG"
M\64-B8OL18]@<-K/::0WGC!I***=)-$'(Z[VN*GZI^J=+T6X:6];RGJ\,!55
M_=8PY&*<I701BPE.8!V$#=NLZ/=HBCDN:5KTUTR(4\RP51.:A82NPOA8_4()
MRIJ^;0.?WNCXK%$0+'A[;,CP!5>RA_2%'4>^L;/ QS0/L0T!)= FW# ?P3MH
M58P)&38CNYK<UUB]GS_P>L:2<:AB8&%QH<FT<K31@U,OV,G;.&[?F\,ID;M,
MFIF0W=KR3$B]&1/BS$.1UYM?'P>B8>70D#(,&\J65(O)'J- &P >-[=G%:5E
M9<N9W+XWBVVKH(=57K<&AL;M5/@$&T].+X,N*(*H/ H'GML!/IS=5"M&\@[3
MYG!-4MU/XFGP<RFN&%1<%;NDQ"M;L:-M6Y_]I4L"[.=MW+6-.UN!>A/85^GT
MUYWT1_#=P$RY*&2CD1Q# 4C9!.\&Q"+;ICB7[DC?H67JH<7M."%<K8C(+\N0
MSNV1&W)G0CRI74>N+545']^"U0#%*02T'37H]V@-R@EB3#V.:#77*4S!3K U
M"7MRRYU!WF6(%@F2#U0ME@D^U-N_WSU*[$CP%X,44N>L%XJ+>AQ*<>ND*,HU
M0X?=;Y/3MS,^BNZF:1(UXY^\(&W[.*.&>+02)Z/L^GDI1F0#$J!,O>S#1AZ@
MA&5,)PG-(TA,2 -NI[.Z&70WHG8O,9O<1)#(^\IU7>3QB?H*P>6=AR.],: =
M#93=3.J0!%QC/AF94'*H!JBS3$AP7O.9YLJ!5*\"X)KUIW62C;W68<;DP+$)
MVP/1$>D7_ 8'5HD8FE@.$R(_ H*!X@@"DG[<Z"34RVH*7L\C"+Z^D[#Q+)PP
MX]@<@XO^=E&;C>* =VX.,*H;$R4B[]-X7N)&VV0>_#(KM.@7.2^SS/_@4:ZC
M+4_58SI+,:DB2 W*/^8#-2&Y/]6NR#X=[RJJI4XJZ\]W9]&+VS/2?9$W\"2;
MEM77P7E'*O17M%KF,S*1O>!%6B,X1Z!D""(,&=<T+B0G37D@OG'J7._\T59(
MG_70UJ20WH/!3Y6,(N4MSC^3AVQ@&1P\U(LH-WH>*&LF?)\978,:EID$3&@Z
MOQIFJZND7-?"64&T%*/SL(-IN-JZZ;7E.P^?7.@N8CDUK%U'A-*BK9WI:+EE
M3"!L_#YTEY<OFI-F3$_\L'$T^SF*BU*5YR/7D";?M>+O+UP6I;W]DM3CBPNQ
M5Q /KVE?>\#VY***^]6/3(C_#XX7LR;H$DLM$X(Y#JRPVF^SIQ)XUB$X8# %
MN\&"V?*W8Q(X\F$3&SP;\]@/5ET6RPNA-. 4$V*7N!Z^P?E?8(",\ ,/?H;
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M _%%+IA0A=$?8>79(2N=VQD]VMNK!ST7)&EC,\1+E$33WAVW'\E?K(EJ4II
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M"HB;/\[%-SRZ-%XH;/B6]:&.![P(,S]!ND\E!Y*@"T54/1JLAR:4/VLO$M3
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MWR6-EBVZ>Y.7Y5ZJ&EJQ6.5+&NG16XU(Y\[]8^WSLR])QE[B*0G+VF$I)=C
MH5W:X@P_FD>:OPW-%*>=3F)>E7+56)MU+#K\>!R-7;V;<NZ3Y]6E U\/']ZB
MUH%4LK:X:1&K\=3CN8V1VHWXMK3DC/12Z;2D5WZU\,7#4T,K3#XP6&'EM\:_
MSE&U,&Q?X02::WUX2\*VL!MV\+Y:,9-)>N!IR.OWW !OO,DH_%-!""^*;:B"
M%/+);Y/$!V06C''_%C#S59D)LRC-^,7VZ>+PX<8VV#_IY:%>_E<O#P+Q?U;7
M7!_8A8 \".0]<% P;\NX[/AKWUP9@I@.Y=]03%L9PZZK*>0KLV! *G@ O+FT
MY+XF= U1C6!*8S=!QD7?P)C_Z2B1QT?XPC "9$(=P.>OV.48ZX42( Y==G)^
MSRU8L..5SU$THO(\[YZE*23#912UA7&,G/QF%"]!BR*<:RM(0)9T%FJ=]MAS
ME'*@R=N^"DY(-='TZG%EE,;-3ON5NA<G%W5,OLG0\9\9AM/D";-J%'B#&#)0
MU20<Z9WOLFKH3IIANM>L1V$=,@T:N9]\_W[RJ8K]_0U7/SW9K"\T!11PS1G2
MM<%F$%Y(T9OCH!@:D^LAPQ**B.OOF[<]J9C;*)9? GMXDNO]!_NPFJ\)B3<2
M+>>G6SI_)'.(&W]P,GC^/#5OW <31DQB"M4S-C#?@'R83M2V;/ @@YL"4"=#
MW.9E'@Y=  F?"H>DSILVQGGL<3M4*ZH0V*]&M/R6**]C<'!JMHU@EF1@?CO>
M*5OLGBKCFZG=/LHH>W--$OPJ<2*.A*TCA*K#^XN\PWTRITIE'OAE:+]RJ^)7
M(O1=>W*R[-RMX[P7@SDVB:V8A"#X&5LI/E7K[G6X8#OY_.YE\6N])FG3+W8N
MA'E*103V/N2./29?]7##IHNG*[AC]TA*C14CN\0NUHPXF45:5;]ON=&AOW[$
MK<RDKP,*5D' K!H?&'39UAN;G\Z(,^&&LDQG.)/[[;]\L5H+?NRJ'L.#T;:^
M%0HHHX[+5W\ER3@\L]SQ*TF&0\]2<20+MM"K3"8LA9(F(&>NS0["I) H'7]E
MZP:'CF2U3RKJ3]H?7M#6-NN=%&UP6817E?K,QI+@H9BMY!Z&X"0IK225MNA(
MV>]O1)&MVZTPM;=;60*][1&U^.D+DWWVW]^W"9Z=Q+X\@BG_;TBDD75P46U%
MD(B1I"V0Z2<I<;,;TE N6'(D[=E7<:W*?4X=/]9+6\3#6N2<8+'[C#*MY?8/
MUIS,^O10[SO93CY;%)DJ_.R9:Y-%I%S.I8O%"C'=&@-9JO$1227&7Z3B2YFW
MJ$#/B!-0?5'3A13]"$$V"(^4' X)[:6AS(O:5<41EAU>DO=:W^E+.3<<[^O]
M*C' Z_<J:GA2-K$33N[&0[E[$!E1.\0/[L74B8D$@UR]M8XWJ&*RH6!;-MK/
MZ/F[V]\O]_LJ""26ND?N^NBTY<97(U<(AF[JI&QFDW]CPZE;*(B(#VF4/1J7
MXX2)>:+;LBM3J9.546I2;HM"_4T#Q2<.5Y\ZX1)/6P!8,,Z-S#QM&&+6"X=I
MS$<KF%,V$B_1^AO7L:$?<E03#&^F1DY\*CB7V'(\IF7-ODH.OXGRZ=XGD9CN
M6KW-X]P%HX_?3QO?O1V3MK8S2X@@(M,>8VV4[N".:6_?'A,M$REWHF@N#<K
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M",D/]F/CCQ8KE:8#H53UFREA>CW_M/>70,U@(T,*@NDK"T8:C"+^0YW8]A5
M9RI3]);TL G YRQ^$$K!IQ1I^\,.X'KY)ME;XQN#5H/\U3-HP;7U\<&AKD?3
M4^LUK5V7GP0JY1E]-/C+6!@%J:/][&VB:_^%-.<0CB9K!Y.%V*?.$>M"'EY$
MS%<L!(\A+''U/; L/]D E%YDP7@845_*0%U!H!'>"G_]W%0'<Q30W87?B1A+
MFF'!J)RET*TJH1+5UK4HDJ#^()[-U(=C[NQ:JT7Y5+-@55G3>!F,%107OL+;
M4?'0E2OK&#]^!Z;+2/BU71\0,]2?5/:V&&>T.ZBKP+?._(/W'HGB:X"+P^E^
MRP@3\@(-C;T$S%7K""+KL>^PFM/_WELT^G/E@O8%/+I!1_#B_=_1S2[S_;7A
MM,ODKWD$KO<'"[99^_'&<F4H)BQJ_&O&<T7[7U]7VH<# W(L6/@R!YM6,/"W
M;;2_Z)A+G4(_"&4SG\/3@1XH%KT16T^&_L-@:<#%S7,01,?\=NX! ?71MCA4
MFG8\ZVA,ADV]"$-6[*OE)<,]S-225F]$P3@N;)3&-Z*'[W*]_L@J9_G<%BG?
MC&\]B+^S>AG3&M\Y$5=KM5#GNK(9_;YS70[1OK:U]Y(S3XG+3UUS&L[4XU?]
M?J4SJ3BOJ]_5\[A'IVQHM<5;\7%1Z8"<#KU)5Z%E/H8</ B*_HK V"P+QK"%
MD]]A(*7_E@OI>#X+1O&: ^JL2(2U%20+M@$2M")"G@5[#"2R8(1FP!^_QC$Y
MK? #3C-#\$!6" &>ICX6C%:*()UC*$/R@!9%%A+8"+0"C_-KL4O3.)"##[P$
MI_ M8=?63!;B(-?FS]0)@&R<6X\$,'G@:R>@YQ31^_6N*,+HNV  Y*"JKK)@
M+1S@/O N"X:08RY"2\^'?8][#?S]BD&29#P8%,U(PD*K^A;<3]@.$#+Q-%[$
MVA6@#O$5F!Q'5*(8#Y96_K,4/'\1 A\M9(W 8*2OMD"^6AN34OG@;Y<3C*Z!
M<DEAQ*(W !Z,IH5K'F?!M#-9L.%#+-@X]/8=+!CT$^QS< U8Y")T]6((,W>@
ME(AQJ.A.IH'78_]BK\]</AYV;W^1C UDRAA^AE8;N/\F,2T!RJ(.^OG1!N6T
M>U2(5>3;EP-IG81Z"7C]J;8@^>(7892@G.6>(8U#B3P)W^K-L^1JVI[YM;S%
M+V)/!OQ/Y\NC0Z8GX93MA ;#X6VW"1^(A[=)3-[+SMT4+9<_B->:6?8;T6/$
M5 !@53%J73IK*;AR(9 %>X#LPIQGY-<A5A,1[_"J@J8Z :%KWWYGLW=KJZ/P
MUW;<Q_0);UT95%@V_S,G#.XK81MD4_702J-RV5R5!C,D6NTH) EW3,@4*,Z"
M\0G,\#$__76N^\V_3GF_%D;+7XZ9#!^NH5X9$Y@H.K?2JO./>Q?\+,,=1V7:
MLGG%6E/>%$5?*\R5VO96?+KGSQ0Z2/]?XK+]S[BL M:/ NO;^H!A",F*41;$
ME)K1N LV31;C(DH3&@<W')]5&'2I80 0S$U+AQXPFC$S<:R8V8ZEX4^J_$@)
MHQWZ+6'!"@%&I.68</56!&>Y[)&1S)78>&YWM+F=GMT0F0">M?UC&G=/)QE+
MA\!E[?IKQ3XBNO#@TX5"%^1C]05^I<]2?F*=*6%T\C\L5=CA*$>@S_V#E!OY
M_-="11<H WP.9T\ZYH>,CGL,\J2?NE@P7KP,UV-(JFL[?LM#>@O- >H9_<$C
MK_6G%SW&/,Q%+"UNXOZJ 83N41PBOZ@77J]2"F@ZT0/A9AXO%BS%&G_,99Z&
MH D%(,<(+9IG6##?VG7#I5-0(.G%)G$BL1;M<UX\ 3*39L51\W/BV:YV#CO/
M9T2."R9^M&UYIN$F.F."+W%1$,7M).K''WA5I\);_HAWSO1[\D.\FO8FQEEF
M.L*=+Q3.4WG4&B2^&!3H\>I7%BZ,#M94(=D>G?(7>[%DW4C5;Q^WLQJ\R%_V
MRB"1L^^^OINFI<K5U%T'2@QLA8I*3;S+<#27_+:J\<6&TUY[.NW%^\NZVUVN
M#_7Y -DQS$/OE;R,#J^/N!@JZ6Y-+78MYM<YG'\V8!='+,)Z31GDCALE1,(Y
M\</)'YU:*9;GU ;,S=O\$2,+XE/>V&LW7R=;1,TOJEKN[\=LJ;+_:'#R>/5/
M_IY L 6?#S $?*@>;8 +T'>B-GQX08RF4'?/VHD8E)Q]'. _I=@<)XST2PQ_
M_D)I\:@NX'W[I)3EL0C_]\W>P4\,S,KR\RN;OR[H=7EK'/*]J**2EF1H\"[Q
MJH,GL2B[*-YXYFV ]<*ZI-33VMU&JF&/PPR/[(%QF1GII$-H.?N6LFKV:9Z7
M^GL-W0]X27F)<@FQIRANUSK2 ,K3!$9,(N],X\E?.Z:+XQ""8*W4S,8FZ0+7
MU,+5ITOA[IIS-^AO/;Z?DKL<-SM.PO8-$D!N4Q(45&@R:G5Z53MHYF;PW0B2
M<&F\+9<2#W!CVY?SNK.$KSOFMSP:]E\S_[+'0[M5QWK*?>%$O\5NY]@5GQ_T
M[2],Q5XJWYI8:)'SUYX>=[W3C&PW)BIX10<@3COSM)J?[Q@/WLW4W2)!HIZ,
M.9]YW5UGTV) D D*@G,?)V=Q9 &0>]L;__/,-\ M$VZ@QG5482A4K#)42BSM
M+00M:]0=;TU_O-0OY89W)&:7W:X5KYH\+IO.;Y>J\23=6*X9.=!GY9Z-Q33*
M"&PU*!2+S6QJ.%34/+]84>"J<'-^80W[1A#Y&4_60T26]M3A'FBKT% Y:.)D
M71:Y=D0[G90D@*KXM)2&;[_FX*(O%4/[VNW 17\?N])E)U;NH2IIJ74^]Y/5
M<*[Y&UD?D54JH&I+'F)$6,)7Z#^Y?'/P:IKJ;,:^$":F_B>?O0(N:I0O*II9
ML0Y/H?DP-$T^(*C#*6$*(X1VD_^]!W_^DI;83?WE)4JE'C__G 6K7]\0#=EN
M]>\ '@Q9S#C"@CT5,6;!<B E/ZTV(C0'N1KH8CH=^)E0*$Q'!IA H!IOPD!D
M<GBSCPO]ME'V[RT=TRR8 &),Y[^8D/3^QH2$&G%D/"[]@PDIYSQ CT216Q:O
MH(,@;/?T]T,*&N\CQCS_F$I@W_VG%Y[#^"$(7H9B;O)Y0G)?(:M@_N;2_A?"
M:IL0L_=C;OS:ZQ>FO$;[PC9]7[AO+.@CNX?/FE'&S"CW@\!B(*V+?HIFTG@O
M!1&RPE.A8)M0[TJ:XS-M8^@(9Q5U]KT(/O ,6;K$2])'(F_-*Y;W3!O= :5H
M%F]I"2.X(%!Q8%I=99!FV6)6E%\4[1Y[>'#+IJ#%([%TC=%- :.)E,O'&(J4
MBYU(I9QBY'1Y#T.@LSFWDZR6.-[JIV5_T"Y:[VUE4;'KBK8/C<-K/U!]8#D!
M2Y-;R6ZM3T"[F8Y>'0D_GE9*Y[#3(%:T-XA=/?:H_\@AYLBA[^>\I/R#* O#
M/;/'Z3JTN^>8L8@K$'K$'*2EC_+M0!&MI^XZ5\IT%AK)DJA1^;JKR$S9NJ.C
MS=%-'!,Q+D\^26UFWG) FD6]?GCHE+AS<B2)P(>^<WP_F1KH<"5&>\VRN6O_
M]L%W!T2U)S[B7L@OCQH;J::D]"-C[(IG?LRN:'PLZ:_I3KJ9]FYL[%GLZP0B
MI9!HESFC]X8"9P@::?*3\ZG93&RY%5WO1X<M@XO,+'KC]'YWBTAIARK3\3-_
MGTF 6-;F741)1S/!$$D.KVO*=8B^F5$40W!R>+X86A*JT=%%(P%C*%*2W&B!
MU?=\GJ85Q4B7AMOXE4CJ1#DNQ19M-\@U.56\O'&ZFT@E&I[H1T\$7U10-'OM
MX*5UBNNA5N:VW2>_E1]W9&))<\+M-4,>[ON;^ZZ=3TYWOG_$0K/2[,/8NY++
M;Y4JQEM<!2K#C0=0=^0FR,$2*K?=3"/>4/RR#1.0NYU[U .L3=+*38( )R X
M6869XF]!/W1S#L(D6_4"EQ.T]"[M)+H6+[I96&L]<UN+VG7]RK5*#?;94IKD
MUU!*7*.V)/0%NY.&J,]^K^].X:BQXZ)LSDY#/':+"]S3732=0GHW$$D9/OXD
M]]8+9^;F3'5M4?+ ?+9PA2^)+NK^>M=#JLU9)WOX;(DH_$%V[B[GV*G%2F36
MO0:JK4:V:P_./H$K,C4HJU5(-5Y_\6O//;N%V!^#&3;&\XTM6/(Y>%^_+6T?
M'4$+;TB6IGG[PQ%UP.Y!6K01.; Q=UGKX,FG?5:ER18OI 8"EV##1W<=PGVX
MF5)4>R%8[)&3WO6[]BH6*I\R>I(7 7++6#B;H?1I6"V(O_9SU&5LST1Z,.17
MKGV$G%HO>WINJA?E^U5*&PM6C#^S[+Z=!0L)70D!OT,VZ&^UKK_T]<];ZIW$
M/_7)HB((HU>@MYW[[=#<DS0 /'D4L3(I MZ7'[CXU^8Y9E0TV?['?86_HL0!
MA?\I:M0<I<8R<Q".J#Z.&DN,*C,%(VN-]B:850I;G]],=,FJT!V+>.R:[=JN
M/P^'UXJIB(K6^ZHS!$9![J=D$>KD-U5W[JGUY7B@SI>A2OR:2SK.4,^P4KR@
MF+&[95/Q[93+NF*7@G\,K'E<1 R_QN?YS,E2>$9[JH?ZSU -L37QN(C*[4T?
M&I)Y*%\6JZ]^L':VG-K4H/ X-K*P61&0%"+Z;*OC)()0OK,I&D(I#Z8MM?EH
M:G1A-IUPOF[)\#:?.I"O+($$A%WOG"L45ZB_350PO)-K*"Q&=(B>/%3Z3)#W
MH^*#BG-7;Q)@TZ?N&N9DV(Q,N11>3R@FW>!ZQY[4A1]^#T@@KA[S-QIQA]:C
M6M/??!2_!7W&N*"\Q]_'8Z3?"&Z@D_1T8QUA3_O7YL7]A\Y]W;6^T64&Q4&+
M P40G#?!0W21/GQA09D?(7\M@8$[JA:0\%'=WOO(@T1/H44L0X0 FFZCX, J
M;\3ZW7R<YT=:*@GU )_[!2'&\)*:24$C2/$S]VJMZR<,E%Q5H53/+)QAE'>T
M:A[]P=$XD>PYOL7:V%C+*R^R&!.@R 6E#-47@>$LB5V0.)QILL85[97\EQDZ
M%%MF>6E$LE!N=U!(KRK:5C+!K 3;E-#TV$AQ1YKYZC/#0I/FWE43<<:M'H8"
M_5@39:@&OT4-+SPM>[*H\Q9#E%2D[^XN<55TQUE"H;[$#<,]VS*-3R!'9>=$
MZ<Z8S_C=P' \"U; UQ@=BBHH?K1B0N083<9>I:(V]PV6=Z!=SA1WNHY]_'9%
M>F.@X+[)Q)R!I;*89_=[9D5F=>@G&;N8D+;?&-I&ZQAVK#,Z44>T"$YP31U$
M.>58[2L/)L*/"CS1=OA>LMYCJ<RYYZ#8SML^9LY&@X1S^#++&!LB^& ,PE7%
M#,' D<8Y)-V H<M\6:F&:>@9VJJV$+(N\RK3T#4#W3YT,7EB][?6'9[%068<
M'Q6NG)N<J.;6";!'\6":H=B=S&ZQ;!IZ""6KSRJG<C0]Y6KRQB)C(FP+9P0'
M5Z_X%]*M@>K3F/V,@\QT3WAO(-6$&3\T$EVOY%B3ATXPS:^@J-[3?O7FYHS*
M?=O+W\OO""L=Z)6T('Q)1QP.5)\-8,$X.2BK#29$Y7I$KL_<&?JQ%C)^!!_$
M4.=['&-82-ESKS+IPX]V@X_,HNXIR0B2@Z=N9-S>HL/GKE1NHZ-J*>8CZ0QA
MY9/D28; R)()F=" VLR01I#S&!XCKQX1!6AN([/Z[JFMUW)%W7)XQV6L))^)
MA^E.8#::T/GJ*6=([@RACD8['F:E; %%!$K(1?SE'RY5@1KDNA0M3H8LY[Q4
MQY5\%<6BNTKM:[B))L2KXGTQ'*WSZ,N(+N7FDI+CQ?X]E52\LE*E=R=?FQB5
M!0L&%O=/#:W408FQ;OGI"CP)"Z$9'Z8'8IT_!_P'E:J_=[S_DO@M1O_*A8RO
M(ZSQ>_W!A7SY)0NV*H8GQ8U54=C;-OMAF:4-Q6_1/B:N-G5B%=F1F1J2WP<O
M*YIFG7BDHU@'LWIU<?OX_3WQA:A8@&R*(")')^?$*:NCCK/IZ9AV(E"SL-W_
M0%<YCW <2<%U>W. ?8/9M%A01.O[K>X<@@^[]2(RJT(\+BYMX;4H_8BVNC:]
MF'Z]&(,T3%W'+W&LF(4M 7TQI+@Y3G)Z]7IT,/ZF.]$*E!LZ^J'#26+O)W)L
MVE,/SJ=AAY0FHCKX#6;V?QZ\>5'J&"?F,I: (B*IW#0^NB3 YIJ_CGB,V)93
M;IZ!#FD ^!DG_4]ET_+K?>X]7\J\M'6GVLZ2*&G+6#(_\N$&V8U9?,&IUN]>
M3V8:92FD7Q^R42MV?P+/O(B4I1"&J0\H$ XX6$R^6V]-+4YS(C+?%Y=7D@<S
MJ<C<M!7[<6.LZO4YXKE))\D*?R@1VE3#C <%P"84^9([T64XNMI6?KWC5 >#
MDR0W8FN(_%29K)\6E/I"+YXTT)N?+V&\^39LS\6V-\;98C$3!2DX%[><%ZM+
MLU5,F91R'RJ>&0QR8[Y;'PPEH:*((6$VNFUN:8E3$A(4HZ^O-K^^;F%6C+CA
MX'N1<TV7]- DVQ_"[)M'IHJL$0P!A?/MJKW^97XH"=JSW>A5@4(1T]B+UY\9
MP_8DW[QT[TZ-1K-U6HSE J9X<99K$-(L&#B (!N8T"33JY4#49#2N<(CL'E'
ML8!7ZM1Z].-"IU2*6RY_I_N8TMZ(3>7<V5JUF;#7L'883.C8/<],P@O7-&J>
M\<+D@0>K*W\N&=3!R:?P?0=1?2+@UNSA;!ZK]LKZ'%IOTRA\!_%^U1FM==VK
MX2X[+S8ZB7^XM?7SS7XUR!S^C<;=#1(/3'@\<O!,BZ568+_\ <F?_-^#Y+^M
M=/G4 HLJEX">6?8(L?921N=?\[1*>(2V!H*Z^@.#)0V1*=H0\.A_"&4PX0C]
M_]U\36@4%(O'/#LA] +I89)?ZB\_\&\49L%*S=E'9#:S1UQLYHH&.U ;\4[*
MH>L3H2.$OC)J0Z>VR-"4Y5)U@#TB<$ZM5=E"7W27Z%SZS8'KIT-<ZN6/BC_X
MK+8DR]A)![<.4;;WGZ0=IU_$="-VK^ %7/!\Y=*^3N2AJB6:I9)81PW*]<RV
MCJ9=-^*GQT=V:S99G;0D'1:,KOR1\]Y>P?SUE"YQ):^BL+0"ETV?2_O"]PPQ
M_ Y.-L$1LZ@KY'D\F_^D. E['Q2EQ9TK*N@JAP+KUNQ"J]07<H\:KOKW/&DN
M2Y)<@^WJZYQ7FP)R)V?I=&/_'>3@]&$<T8]:V $>M-)*2DH/20DA91<]+'4H
M-VW:\_13V(A[X5;!NL.T_O'DLJ]:>6$F(M87A43<+)B]0^GL)HK2!R1$,7)6
M81CH/T(UIL3-MJ3:3MEM_T1Q>"Y,H;T8JC6UU0J-FI!;W1)8A]J__].2R()C
MXI55=?P6!I*TT#=O\@BUR3_ @;0- ^=+C7HZ\H[<B?0@VDH9[BIS.>JE7SEO
M<"1B><!V3@A;G/7Y38  GF"R:'?2?\,P0).&,A)$%:(@)!SAG,T'<O>D1N]"
M3YITS&J:WAO*;PTUS')1Z]NHZ&@JQ\]3[7#!Q#Q^O6PTKIHO'"]0J<0X0EFM
M72#JF9-OA ]7N$TLU2>+Y':<;T,7#9YK,^MV7(IINNAP8UO1^05-[A4Q!>N7
MS2LW4A5L%?Q5K*T'1%S+/#G&X<1H<.L,Q:<>7^@:-]=&%P7;OS'4:) *;?E(
MG@QU+<3QYN#>H<.-K?Q[V]'^GP?E^'-#34-K]F[P55*>?<ON^J2E#O,1HY',
M$N 6'_&4MHR_"9Z<1W/7 9O)1"<-DY "W+'S5.JWK5*.-YX('R[;7/NI\8M1
M@+D.W+;.3]DQ0,DU=HY(K:C$V/R3$H$?0Q9D(LC@^VU$=B?8/^1OS6*<9W_N
M?_&WCL-_H6\%0K&+^Z?_H&\M46'!YM6 6N6F!R.02\"<W8!Z!9"M<1$HL@'A
M,;B'(E)#@((8T2BZGH_7Q5HZ+>$]^FU-G+>/C]C=Z:-FWPNC4G(?:.'['#XU
M-\K)GPUQ_K@9;Z002:.3;4XQ7X.[;/T5*4>S?!T<?=Y/]41[V.>W\CD&<(YL
M*.</]O,R;QRPC]@C-E.-#(;SBS:OJ^47H_16-U!Z&/RZ6G;]#8@]MRIY7$!U
MR+QO?/)B[L-L&D1/+4CHLF!G[V8JA=L].''IP\0^T:L%P\,OEK9"&0GM )25
M"$E2MU!$&(+*5+N>913QB%$R@82H,^$':FJ2//N_J;IVA[JI!VY1IG=Z,@?G
M]=+5U@DZ[GN\E+.;RX<'N@J<W"4L^\=]W/VF<E[[1@71'3!?!J69+U'4UF^@
M@O5E_\/11I\ZX?7A3K?W"7\S(+?(OK#?2;H>V;/[R")Y"ZX5UT< N0ELWC-R
M#T.8BWJ?!JT#ID/#%A_(<!D>XIX"1;K[#2OE@+NN[GGHKK.<G6]O&Q[@RE5;
MG]1Q.,,?_%8L[(+[*YL1@^8I%DRAK"- "[:X0$R@MC-?(JY%\TPEJS+?@TI6
M-+WSW<JM+Q)\?!T]#B7?#CY]_]3N)]X9Q_=N5Q@>HJF?H4XS8W+PCN(B5*W
M4>D8?_TN38<1V].U-37-DZWQO=\)WE([?>TN2)S.'_YT;%<#&M>I(6=>=R%X
MY\5$FSM.@],]R*+$RGLSJQO&![F9. P_>I6:24F?O?NZ*)U]DOW^LJ$XTD[
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MJWC*)<)^E<49.@"E=:]+\;3#J F_QK\]>N<OPK'CTX%/H[B ;\5L+CBGGXP
M^&1(C6Q1#%'E)<0[Y0?WNM-'3!YJ;Z<(%]Z=M$/1D"8E90G7<*\4^G6_]%Z
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M/Y=5@--@)C)L2)\ 1_Q&G8.YW'DT=4/>K3]TWEE ^OUO'A;DHH0R<SZ=AIT
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M1M.]^P%/P8HICE_^5FGOF\^7.UOCJV,EGB6WI(Y3'[;W7?P .,>BG3$Q#GP
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M6LUV+R^%Z)^%?D&^?N*]?.-L4T9=9EK\_$3Z9%>$K!GN)!7[Q9YQ\ "?U9M
M8\I-8'LF.RQX@2B$3XQ.&0]4;DX1K SU6SL>*^%=+G[=Z*B1][P,LO*^YWQ.
M9;!@8+[EY1,5J3@K+R>,59^?4BK;T.R0W!>U5_XFOZJ#?>UO+FQ:N9-4*0%
M.]40>._%0A,FF>/J)TH*OS2D?']Z2&'ZF%.&ZTW'V-#1J.##6?(W9MI7DLC+
M%(_R@<K$N*S#AFKU]B_5ZKU,!DO6BCWM?;X<#0GPY3R%TA?_+"LH5)SWM-&
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M4-A15#"8]_@1U>B6ZWL%J_Y#WD]F3[&>>T!G3YZO84^>;R&/?T=@%\+)NJ>
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MGGXLI[S\T?[UACDM_1"R/;IY6:1>^>LYL9<%MA4WQGY1^DQYMPRLGZMD/[C
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MO.%YU^2\CI?>%W#')TUJPP%DSLP@S4KNIOJ"N7H!R-_6=="C>J-^[D+*35=
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M.]QR>!A!\DEO#='2\HT3Q-[M.2(1)\56D&OUY #D 43TSB,=@QE-HBN8JA^
M=J)M F]4!J0%HFD&>"BG6_HUUVJ;WG9CXV-6+90?'5W5&E6%KB=M8RT")$SE
M'@H]Y",;$1(!!:YF?]#U]):A)$O3R&RVK6/N)OUJ0LI*VNS%;I(F=5$4$;RC
MGZ-VSHD(93["A=KN6XW[F YSH()H3$ WF ?6@2^N9*VV*9(-%TZ3X)E+U5V$
M\VS5JZ##6<F\+37VK1'&OMWYKC5'4]Z-V]+?2L=W_;P&^YVN,+Y:G/BH@PQZ
M?-8N1+C?A"U4,=V:?-Q#90F?E_9C%]*D"UVU'T_S1]3<C)5ZDN7"M);-A1J#
M5J&)H23>5O21M5W(K0(:.\FX%7K(K\3@ CD]1AO-G#'4#WLIE;91]?Q9^&%>
MY]DIV9<?<S_)$(KFLS^.T/A,OV:7Y=..[$(HUH SWFN_&YR'<3IP&9^5S=*<
M&#XI^/G28.67_<<&>B0/VHH(DGH49W.[$\QB.,U+0A,(@7= BP^[[W;J D^.
M[-?%U","^\[W=4#V_;":_4WCY<+GMZP!4B,K0Z1R!ELKWI39GF8*F)!5\3+1
M[N0FE@JJ5RQMGY?G*RNS_KGCG1K)N>YV-YFH9<(=V).H%:;-(LJ7/56<P!F*
M&6FD:2W*D>*$%F'\@ KDI8TT(5B0XH3!$!^=.@GWT?=#GAYXZ^*2OBAJVB,>
MZSLZ;U\&385EDZY[X;2:L96("+CC%""'7O%R)N4Z .E.(<K-RGR!CNW>0+C^
M\&J)Q$:I[Z(4MZYT7K_>1H'?":5#EM_W;5LQV+9=2;GM4Y5>*YU[.FU?@&XR
M$T.HR?30$HXEKN$$C8MLLI4Y$L5#"JH*3NG-1[]3?)=\- H9VJOLGC!F5H,8
M'=G#Q7(T!WHYC >'/ W^)YUF"^#)4+V1]\,PZ*]S"VWV/JW^_@*G;2ZOCU\N
M9Q6O%+M<DY:4*Y5Z(;G1D$6>RL,8F2)9&((TXAVT2BQU&OM3H[M=G^L8\%#1
MM#D#2^3@3ZV.X*6J1QB[]?^\G!(?LPM!$=1C))'Y0=M%RQB<,H/-A)P#Q55;
MT:/AMZ"CY^#Q4]S:XKFC2V@>/T7WMM._S@E$W*ZSISP;MZM0-=(9[$L\?2M!
M=>[9MI:=<D_V0;B'Z6@Z@W5/MSV(_JDB<2R>@$1SIA/0,<ACQ32=AA&U;LRG
M94K2XD'6+)P+X:Z/:+'D \/FNX>)]X.LVM!1B'W8N[L00 ':3D<PV+BH9D@7
M0!),&@GIPLHQ,'Z:/HFEI1[1''RT@G0S2"##CT91D+0M$+UW^K3@D[*N[1A1
MIDTNBC+8<<F]Y)$6! ^#%34XQ3P'J).MIK=*ZG<A3VGRH81#E?)'^_-C\\(M
M/C4D'/%4O.D8.B51<47C\_<]V?^]!?U;6'?P;Z<.^O6.0?$(&J_JM4'XO5\Y
M#2'* MTS@#A9/S_WZUVCK5<>_&^V"6:B3Q1Q?FEZ5]X3+$P5J:=1O6B2"1KG
M.4)YLF?O*,;/*6[8*=H5LN;7L36F988*&9.XA> >L[&=:GZ@,&V[/"0W=^\P
MU3'IF]LW0WL:'O5U%T*RFAH5F8;2>)J;X9^R6XVW*_9F$@_7\6BS%-*8/_?+
MPL0'*Y<-A8=%K!7W\Y[YXI1 &_KF)B,]ZE\%T<$P.-+_"."']@)X]5X UZ^7
M9; 5@L.B!L+RL%L $Q[;(M+[: ?3<HB&)E]M;FR__*-2_ #QRY>P>3/U.OT3
M!\9'JP^ES>5P]G--*LGW8*='T6">^)I(95E&[Z 'W:-V(>%)#>*:3:8<J$XX
MOU5C37J,0=1>H= ES-M?PU$AW7/55=C4M]4Q/E+?N",N=&O\./>#)1A+LC#%
M]4X+M"M'HT :$!;'^'H4RT8[0G9O^0CX-,'.@0/0TJ%]X6AJB=U^#U_Z]3-$
M K?VV.581^<G*EDW=<]-T/.QTR6[D*,H'G"<=)7@>P6]0'M;T2J@F9*'III#
M$/R!J-6QMH^+54^D:M*$&L8W;%,_545*C#MSR7=*)5UZEO:@>0$#G#0@ME.5
MP&=8;IJ&37WT6ME'OC-&,'U"LR>G-.,8&,TH\9<C339BV6<_UPYZ93X+3<H5
M,=>3&66]H[':5/V1IEW]&#N] (T),&%[R4O1Z3>3DN\J).^38OIU&3,+DI%"
M $Q]!_3H.0SF12@KVGG"E'(RO"6[DJ7U;:'Q;5)T<X-VQ&*P2>KK?E9U^7I[
M_-BQZN2R#KC?EQ=UMPY>=+>EV(+=\P)L#92(1-^"CV$IYJ81<-Y*4XYN#'!T
MQH#\T#U#-OZ^^!TE6,_#CTU]=GIA/4SOB3&]SS2BR&#XTFPY)D#AV%OHVA-/
M#XMG_#B:KH%@\0/'[5QZLXY/6[>C B6+?\C6C!I:,1*E[GC89Y5;X<57\6YN
MOHSF&F";U,Q@RP0_H9V>R9!@M,+$Q4Z1H"N]^$0!-P0W0\KE(Y9RP\'=DM71
M/4_OH;G"!D?8]0+K("\93@O2ON7@:!J_%@4#+%#/T_2 VV":6Z"'*<). E9X
MEIAWI-\)-&\"//9!8/ DU2Y2UVXQV*V^8M+WXZR\L;AA\S-.OEQL&+I19!?B
M'HB$DP08;"Q4SU92K>6C7VA1I#UAM(X7TZ& R4D;,(B;-SF'3[W+?5E,)O(G
M"]O79X*'!<!!5<5Z8$>C&:QZ14@T/1KMM0N)HV YD!:Y-"\R5WR=3@CA1=Y3
MZ%$7X>>QZGGTYX\/U22%?:HPJCG_58G]H$4CV&%6\%CT?>PH.X/M8M9^TM'\
M=V[9?#!%8$F9*Q!M6ZY17=99X!*75C9^"3CU;?*^4]]'BQ?A VK[=MBGN<:<
M&;S9@$S67N]Q[T(BG2F(:IJ &'P7$@&G.J-!W^0I1U.4*[<E=;2Q6EW0R5&:
M^CQL+]XW(\\!/F!GC0*V5&0@=II2YEV*O%/>YT%C(N4VIQ>%%BSAYO/%ED.5
M6#/.A"=M''V>@[_V+#(N%^E*2F&P;5 %7;"D\[_@3HKP=BN0" BKF8[.;WRM
MQAXJV0S)+1U;HF1<JM(4"\6FOU DG*Y;OPH8XO6E5D7<TI\@Y6>P+.A&2?AT
M)KQ:,[H!ZI8E3UKXRK[&#J00CB:\_5DY-"LLFA$8-7,MCG\[3V-*/I7I^.F'
M%F8O(*%S5&W4 )QDH2R M/A1!Z=>03>JU&E.8UF72>/UO3%(.+EJQ.HS:276
M7>U':Y 'Q;!N3<-P)CRT]K-^JG78%\D94T#:E C"S0-7A[%NV3B$$?KGU=X6
MB@_JQSWH4;T/C!_>)P.Y?+E9[Q-YC 4$^@R$5,(%DDNO_GBS@?!&@E$NK'%/
M+!GNNA8[R0^<INHP1L1$R.BX.B?^E@RQR!SIEI$#XI5I2Y:92,SF^;*+"[\9
MB)X(J.K)["3X[;4Q38H[/0P^G;,+J<Q?V850;R,O(R! $0%!W'>PDK33;->_
MFJI]P2G4E=ER'=>5I/:0288;WV!YYLSQ::8Q/R_@1#0QC]Q.>0QDDN(9K$3J
M(1>8]@\8%U!(4R6L"04N$.)<3D^ZFS4E]SHY>U:E=#2=EBC,N/BA];.@$-P&
MR4).;X7'0 ]MF@HB/0"0Q1UBB5OS>%G9R[(+\6K^P*'BE)3>;?N9WS'3\!I^
MR"I:"#)K-3="? P&P49.#-S5- XMJ"T.]IT).7^ED5QT9;CT?H.DT31<</)7
M3^&2_Y4?V^DVYJ0*FQ=:^^A-A-L;G@JM12N]@,1(.Q273P'32I@G30O 4IVL
MQY43M@R5M2<N;A@(^^Y4/@GP,7!&*Q9 +FZ,%5^_!1$\]0#R0(YI*?C_%)O^
M1JX.1VJ2!1HSL,UK0J[8^_WJ$RHS5X<\M!<2>ZNR-)Y:_WYK:=_Q3>7=D==A
M7.KY>N9.<D:7E7K8S)X09J1]>U_"\=\1I*O0'4TXK78KD6&<RQ"= ]T)OPO)
M!=VJ&VN]"YFMV?&,V]J%#"L=WX6\Z<("*NCY(/A/(0'Z_NM@CWKO0B3;L<Y3
M/Z&4*_0TI+,/F64:WI2XHNBP<27TW/P:U9^Q'%K>*9H@UAT[:Y8>I?I,=7WF
MC!3T=D[<1MF9.DL-3$6+^?.Y29/JW[7E/YKQ#WZ>0WV/X)/$G9#^?3PG3O[U
M^'\<7__^JDF,YPN9S^'49U)#I@R&65_.S^#3D_&VU[2B$R*/9DF<9]5S_UWJ
M/]E M*_B>EOQDW<J'SN.;S%;.D<AN:8Q!Z3Z C4;=QR2J[D:\+X],"UO^>"J
M5I'$+R67Y2 ?,M:B-Z%\KLDN6=)]BNHB)QYME"B7I+EDLTC*38<#<=5Z$(L^
M7QW>YN"[-LK1OB&V[&<$[A]-LUSF,TO4LX!P?367;7+@ATF*G8()#7PO%5_7
M+[B?2S5,I&9Y:GI0OLM?C(/(S_<"<HDK!C.F8ZHM"(@ZA@7H-N[GQ;,0F=XB
MSP^E7'^JKSF<=N(!QH/SJ[=\4/.!CW6B&3M7XR"]_4A9O#W+M;JA33B'*\4J
M^$F8R<6E_D[)Y,6V!_TJC^S6@\XNV_"9G>>>6J0(ESRON5?HQ-%307Z>-4DX
MOBB1%%:<'\;UMD"-BS,PI"GCCDN#P(_[%6-G.D_CK&W>G1;7>5  @:;:YSQ2
MW4*S K8M E7!:=C_C[;WC&HB^MM%8T$$Q-!!$*)T*48IH@C$1A,UHG2$J$@7
M$ $)&A.0WD1 05$)J A*DZZ B701$0%I"1 2K$!D0@DC288[_,]=Z[YKW;/.
MA[/>]\,L9A:99/;>O_(\LW^%66ZQ^NM,;N_@7[3>@',]T<)O+$8;OS--!1Z)
M]B:+P59/F<'EV0Q9%[P7-M:A.4UCLDC\?F"H:=HESR,F^Z:N80.^PJO6\Q6>
M>*J8IT> A0*0D%M\P;-^MGO."&1&?0G+O7+VPJ\1XU>6,ANRR_%B'R;5A_3K
MJ))X0UOJ^YI=-$_//_UV>IMWIM_]='*Q;TM=R?_@>ZDOG Q^BFFE(-9W#=$?
MY&;\=!KU3R8"Q]O2MX9X1GO3OH9HPO9#1_ :,O:XC TTON@:(K/Q%]12"6N*
M6J5SI38H"RM"1)\@%K>&L++VK,0]!_KX*;FE"%B&?Q_1;<5,O237]_$//^?N
MY/QBPYY.M ^21H''@N:\83<7PO/E8=A4/VI]31?-[%'S>ZH? RJOJ=GIJS8Q
MRT2"AYY#9\,X#*AE50LB+\T@>*36F_-\#1790;/37)P:SQJ;,/N1T=2S*&$Q
M/N6[H_.:X9]SLXI0//.WW"QNF*UW.7)KEN>%LI.?;VKK'=&B55.D2=VZ0)\@
ME8M;W:V[&,@=@PGP12KM,7>1,Q_-7X\ 2.?@V.X<NU8YQ8B,=GWO.IZ[LG3;
M,?>+P]S]V->XXU=SMZ G33_$5(_YZA4Y;%IBM.>QJ0E\8Q++G^5_^4U5SI\!
M X.9I LQ^09'*M&".VN(J\BM$ -7C8%/ _LVXK'GOBZ1%4?[PKR+ N:5+M#+
MG W=[_TT<,CZFMWRVY((.[<6+0CERG<2Y%.O4D$M-%L<L'8>H"CA-W7N[V+V
MQ4&&G'"W\4F%FL;!X7_AA;<#S5ZI2_2)VBJ6E3>$;K,++B4#(:2YXSQY/HR+
M[K@1UFE.]F]23? #=$<3:L/L:OQ(RE0.J=YC+A_2S%"Y=*I96Y5I>NNK\$P'
MM^F9?^2-56)Q&<V]#\_3WY7/M/\5<F+SCPRUF%FG4@#-E0$2YV9Y?L2>;MYY
MXB09L,F@>7'303+',U!@[0F6%_VY2>!*GA@)4Y=KU.VN.,)UXOY^G21U<,SC
MPNVOKS%G8,:95 4--UK/R;X Y;G=0%=:^+PD'M=^\V5V03='N >B-W_U>E+_
MU)B9/N%V:5/9J>/UA"<Y7CF[4.X7QNFN]/<3/UHM96P\7:]<>YVRQ58=0"R7
M&-T..\$1?_@M7/SR\.IXE;WYT]9/CY2M?JC[4-:Y QOZ@MD)F1X'L!T6*,%3
MF-BDD[;RY:</LX]/8UI"M@6V?EIIS^GSDVJ-.*Y^F1WD.[&[?N*16$GGQ.<G
M77SIP#8J<&+^+E7"0AOJ(R-(E\LCIWYE+#,2YU\2SH,FTVL(,09X$UII6S3M
M_,*U\FG(,O\BT2LFK^(G%)UY?</RKSD17C >9LR; '$( XJU-+Z,OYBO/11^
MW*NT6^F4]YO&6[[9^[.:7.]E?KD658FC<.03E]X?8]A^6Z8?OE5:DVKG_S=3
M_<DO!4LM_;XBXFE80.IAXG>:-!K XP8,P%)%IX[U69*2+93 <M;CV\B.EX$9
MM6Z6(27C[L=>F_4^M"$>?6 6T?WS#3\2@$GW(B^2<!(LG,:.94-;/:8S:'(,
M>TY^N3^K,FW%\_";?E7*4 XSOGN@HL[CS*%3]C8=D@4NT^<>6NH8',%XZ=3=
MK7L>$.E\P"VX/##4^$G,7N:=B!LQ&9;7MCL >(L'8#$S@U[)?0VKU=3P8_*.
MHQP3]S><<:)!-K.\,KU.&=OW+;Q)F",QV+XPWDGT?U83AGBJ(/$I2S<8D5\#
MB=G!"N@JB"-=08)J?>T92=3J^6@?P#JU69E9:MG$"<JI">52I=V[HX)DA^I+
MW$XWE%HL:BH3;7,T,X*_UF[@2=F<=4U";+=]W6C5] Q_9ZS22-EG8%7VWG,[
MWVO5)9>&;,]9W2Y=<(=$6SBQ[9Y[P7C>3N('VAJB#9M,- *]ILE;/,%4%BZ:
M*-4M%:BR+Q8[6-Y;_[31KM2>>U3-J&&KIM!S1,8CF31&[!I">-Y"G-1RA"A"
M@ 'T'3]X632I?LCHF_J,I"_QG$]=[7EGR-[,7M^VFE;[O;X)#,?&WMXRNJ;M
MQCV[*#^#-R $\:]I]77/?Q\@AXP8!P9JF\0M5OQR&0S];="^C7RR!G>7!&L7
MJ(F>>\R[BB_FUH&Y/!PHA4[*.8"I6\DP"A''8R]0G]:RM_T#>L(B91M-GTV,
M1WTM/74TTZLN3FVOBP1R],/1'5M*L67^<K3[IL9?2H.4?WRJ<:>9S:C?U^Z1
M/7?]0V3727XDZ/\:_YP9PI>&Z=-ZI.H:(K?S9FZ2V6Y@>U>'(K;MUH2GX&^%
MGM'AWNV!#XWJ'W7[RXTF'''),@F:THF9Q;WIF]/G[8<ZJ8 = ^8%9\H@Q894
MZ!#>G7M5!5W'F4^JTRTMG3>!)!/"WR09-:G6WIWH>'%--<ZE_XS)CY)-2_6W
M(T_4#5WZ6A'QV&:^0J)9[OH%[1S+'=T.6NK7HC;5N55V5XYN@K:^@E>*3@9.
MA6PC#I!J_^:6@#73D9T8,5*K:QDA\%L=_7F%?U[YJ'_YR[I'5S9.!(5)N-S?
MVI>]N&=SRD(@FB[&35B/#TO'50G#%""%*FO\U"*$IC3M06V#+R?UWWQS4Q+@
M3KRA4!MR)*^]O:0_?N->LOH7C^8/]-@WNU#UC4YUSP/KV9&%,\,-F>HO37(&
M(C(=NQPU;!%I"SK=NX_Z[$(<TJ0J8:;J4( =:726JP.Z H:LD+DH8 &5 #-\
M/X;0;TCU:[BYU90+F#(Z<;AU1,)63:_A;+?$E;>8YJV+KWR072](+988[PP$
M-$H%KJ$_P&)%E5L6=P"/37/Q(\'-]L_\;[X8]O*L2[7_^.9MEK"MQ9>!A_DG
MG%0NIGIYN\8@!)A:SO884E'].Z\*U]XK,:F3EM?3I>(_7GU[4*&ES^PR^<6L
MHM7[*XWYB:_IGO1#N_?J:[E*)AT\Z*VN$KC8LVZ@,)"(.V\O81]XFB?2Q]LT
MBY'Z:W::]1Y[#G0&D$S!YV[EY;EK_W)'1C;:O;UHYY=U^K/O#4N#8)=NIRL
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MQ#M; J)_&G=5OZ_*HBG=TN"YOZ]*_IGOKYG;=^O.;VJC2PZ%_2S:;!/77Y"
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M"^<#M?-07 SM<@JFZN_B=YX50]<B6.W+_-O]?0^AKU3@U!HB(R^$3:J )E'
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M$.&"L%U(#]*Y7L1-E4)8>*(%#\/[0$V+>/C<ZNV;$4V@.#F\U/=K\WZO@)J
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M1OH!BAZGG;*U/O<$9^\KIO;>O>QLCYJ$4;V<D6=C!6^Q>NA/O?MH==]F5E#
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MP@_"NHDZ:]-J_I W(/(C\_K<M<MV_CULJW7WXNV/UY%J% 8953/7I03J\2H
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M[MR4CBG5KE68EDC3+]:BVZ;QD!NF8Q2WQ<W3S!K[I(L<NMG55E(ZUN''4+I
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M+[!*SN@+\_;NY=U_V#-D;C.S.="V\C=5:1YA-*0_@'4M]KUL?4UIFH;R,QU
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M:]Y7OL+2KV];RZ-C9O_(VX;TC!X.6.+C!%+"0@HCG0XXYV03&C0$JH\9R8^
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MDIQ*$2:4R@;\4X3:<C?_X'7^$S-9K^?,]>Q"S*:*96Z\?=CZM4;DHP0""RN
M4]7 [A?I%HP";##(8L%$:HXYQIQS2P9#5@9Q"K@KG-SE*/CS@>)DB;3#XM"Q
ML0#%MQ%MK58>29PM7_IO'=,?'9VF)AKZE[:E5!4[G3VG^9L4]^*.M>J+%\)\
MX,@H9#^.W(L3H@?A=0!7-/D)&)2>%,]^!0,:G&KT!?F!\3+L)R,GI$BGX'LL
MSD@#^WI@Y;HO.9_)\X?<U(=J0 _I?,E9AO?+=/D2T(^@HEV6Q#J;'[-6LN'S
M<&KY9SL)!Q__ON$@3=WW.0>XPB]Y0D20[1,&W=+]4F<NC4?$N*]%WJP)];T-
MDM#JK^7IJ3D7I\(9BA_M;)VP23-+DHM: _TEHMPO;YYBCX,9F6FB>F1!OY;^
MXS;J.AI%XT:"5-UI6,N>4'OBQ)65J'G5WO $]^FNN,KWJTTM%/$A_B&)S /7
MW;_JVV*NNT?]$NZ!)K$@Y$HF/W"&($P=H^;3%3'2DULH$K1I!Q9 ,VB^?1=S
M_<=<IP^I\YG,X 6]:RIUTW5_FZ-:770_"50KJ-V\_7'U+J=HC\+?ZW_Z3W"A
M7[K_FMW]_EPZ_RY-JWSV2.,G)C$GC[X/@B#1/)@CN+;M?EC:B9!!Z)<J)A\W
M=]_99O*N?T=57)<]F2H8<W;:R[HR-SC%OZQPYI:-:+%BE*85#[%K%@^GBTU2
MTRDZ)#0!NC#&Y#.A>;O1+U-\^X).,&<)R0_H&OCF\2T=(>L8:&Y$1--HGNW+
M8E/MGTK!4S##]]18+)BEALAA3%X69'DC#BJ.]:]/QX'.]GMF A=#H&:U6H*$
M5L% @OLE][I<O")G-5=*NPD>CON2S_GN^/P=XWJC)C TQ)BC=6"N6Y]"W0P1
M =:<IDP]:];JE@7ME],6UF<K*.UAZD#&%2M7%5<SIW1;M*JN#*_/8\:'<Y [
M(.<UU:48]<!Y$28$X72<N!;"EUBD9Y.T<)7B79S R"OL^M7I]G.]U/^! "#P
ML5'RZY7JBZ<S#S)>L" WT !8'<@7H7,;U%]@FJMCY()Y3P$WX(#JU6(D_F1!
M@E&W5DJ'8?Y_)M>7+IB._;VT@X[Z1IO>.BG!-AP=A8_J@?,@SL\B]0%[ G=B
M,W8_4+K_)L4H37]#>,'\Y2JE]U66RO3$P3R"@Y/3V?2>TW%'(?5/8;[V@%)F
M+Q8LH.0+]5!4SW&D(>+,LZ%B:2"Q?JWPT<N7"W[+MH5? Z1A?NEGD_S?Y2V=
ML[3F/=@58./YO;Y1O;6AUE]!84*[RYPH>&E^L'=P[K=.2(CJE9*V1(FF][_[
MU=6KE1L.0GCUV78FB5! :98NH;$<TG-2CRK'V"N?+Z68RH#@C2"MB,!KXH17
M_DPUBG;NK5_C*VWW4CK",T(/!/PI][%F1^PL36_E#T$!U<I$BCNUAE&(\AOC
MC]Z$"JR@FQ+6UJJB+7#F?\JF#TZ%O]T""*Y=6S3U=PU)T,[\Z!WD^>#Z%\V"
MJ-,4YQ1_8@C_FG-AWK-J=Y6!I!*/.TWF8?S57MG&(KD1-\P%>#D/I!9O4L<N
MM&33+G:F\BB>GOBD?]]!(D*Y&/)"F)/Q$@86%'_X_! UEE$-VZME8/CTIE"X
M6EZR(""QN!E;10NCG7[G=A<958SVV:1@(S]$A??^K3\&S($1-<0HLR=5+,,6
M0J@*C&X7@E G1:=OU_D9A=]R!B,U#Q2/.<8:&J9.$ ]I37>Z=_0/\.Q+\"JF
MQZ95!A3ZM'@K5)6M'KVV8*,G.= \K'A\]+BWLH)_1VM#N9^AW<NUPKJ6W$81
M!>+OB R)G/MY-R$_XDR->J$-!YA@[HQ/ _*9?!QAE//7/A!A#PI#XKW(;\;I
M#?QN2\/A(2!(*5H8>8:H/Q(T&/6<6+,"??.DPY(N43, )3OP(#5;61!1NEP+
M63;:+MQ4[HP@[5H:(>IGT<[HF,:'_8-1Q;E;$G>4JU52^C0@3D^^B:XY*5.$
M[@N]*5;(O]KDON.(B-2Z$^]['7FCX*LE]_/(%\+QS"/@+#3!XNM9$'F,<""V
M,7D0!:ACXPU"DI?4)U0_TQV()O#[HFX 2-/.%PFX2"U[;\\IWE7T31]I^!X5
MS%^L0<J,A_%T06EF=&ER\CMX<I8]-)DN2HB%G1J?6 TYYM34U/IH263C?GO7
MVUG5 \\+5]7K7K>7X@*,9,_E-00:++Z !K2D$MRLPB;O)>2.W1KG'H*UCNT5
M^4R 00L'^3*5D0<+IMDG,-7(;7T%](,'NP '[A2Q'_.![=I>.=O;;TK%NUWD
M]F<4"(YR^]*.(D?09$=8$E1:R]2==@'5X["5F8H42YT([R#'5KT[">O;,*U]
M<.Y@5SS5Q2XC:5XD:9!7<HLDP8:'OM'9 S@"QB"FJ6%J9])5H.2W,#]A4;H=
M"_)8]0NV$=:"'&-!0#3R=Y-1]I$&VV5!%C=PS#K=,4DRBLEK0)[MA?&B_+'W
MT?L1D4P]\A!)EV+;?UUKYA9Q M;T[3-AVB-)S_] <3CFUN.G9RH&E79:T5J1
M?_Y62+#MU!-9$$#)ERYA"WY8SWV)ZCEI=@S5XTQZS12U) Q^W@I<-")<LB2:
M#/N5+7B&5%][MIC=PZ',92Y;GF\M:IG%F1ZXP 1%[SG<I4KII*H )K1CJ-[?
M,PB#Y<RXW<@'+(B@F79TU 6K#?UN]_.-CZ9US(:5.DR//1PK"!AU>G(?JRZ+
M:0<!^5G DF:(ZKF10X0E;8 9&0:HN=S70:B\6'US=777)9[)9^D=2XQ6NCVX
M1"02?SLUN^HF';7LE(&D_VA"^<&!P[,DF2KDW/PL:06<9YN,5\V92=>/4F82
MO,L1#N2?:5T'(NK$^X=]*DU,9LX6RQSL2-)93'(^])AM\SM]K,GOA? CV T8
MH!*5"?/$S6\0ZTEHBB<5,V6F!K01F<D5"]&%U\[TAJ[T:G2>WLF&JA.FM:C[
MB:E?#VZ6)9IGG\F#>7X^!Y%P^!_3)'<(8!W19T&>+*-ZC+'KARB6X"R0<MJ%
MPHNA9$?[G0M&=/%GS%ZH!&JKQ_L4U K!N\=\"!%,'%0!Y;$!..'FT.3R<#"@
M%E&]]HRVGZ@@U*TK'R+:UI=.@WQHD^H[DH,,>S!X!#"@A8'YZRN8'^(1?@S0
M6P07E"_X2\G>4J,!#+!!M=)QI!"2>]2S89K18XQE;E/PAJ'=SJAX!0*);5%]
MEPD<QM*EPZ@9%#BI:GD!!0$"E]OZ<%RK:&&Z>_TYY7O>?U:DLN>NS<>^4#M7
MY-IWZZ;05U2LD0Y=+(J:2O8EN8":-C :,,<1!I,15[IT:Z)UWMD2ADEPN[Q1
MNTNC&K8/LW>/5SI%Q-^LI>A!KBMFW^!FCS/ ^M8#6I8D$BV4+M(-3-/$4#V'
ML81#S61J0_4*4RE$#'&];?+%V_:6XG-2'8'=3V,^N!T2;VH.'9#[J"BHI)&[
M';(/U7,3Z\V"B*!ZM/:>UJ@#7HU=&:?+*V1I%F8F5R1Z3^&GECL#I28^'RNU
MGJ<@GJC>;/T>^:4\ZP>,?*OC%1CPJG2STW'V_5!I\?NS3-6V7-!B\5@?>!H+
MT@*ERUD2,X40PN0?]:_7EB08)1%8"4M"-SN!B)D.JD58ZN=+44?01Y^>'5/G
MW!GN+S&_^2(NMFT9"FCL*64,B U12QDM*'R>6+0XOGP[KP:LQ)8#_+'N<')1
M;G_* 9?YI*=Y+Y\(*B-OA5I-G'G[3?>2\*]]&7_S7GH*554N#IWL[K?5ZB*_
M]<K:[^UJA8_G.4B;)>)2S)1!N2$8?017D9D6JL<#Y2_H8C6[;C961]>C6 Z-
M25Q?O=3^+M;LIZ695_;[ [=T=X)K^^+[N+!>&&BT[QDR/*X9QAU]TSC__$1X
M6J"6<?#^ D[1LR_WW[RKU6)AO7$*NC>^'=83!R@%MQ,UH O23+Y\ EH JCVS
MT+OKW+Z,$L.9>T@;&>DN#'&&U9H%^D3JO.GD'%P_(HG'DLU1@H".U=ZB<9$E
ME7TJ8@[EF?+,.I/0N^IBE%D)%:WU6D7-L?_9QOHX^[C*_=;;\;#EW+^;0 6I
M:#R()'JTF)STZU,H'^$%I65T$L*$**^X-.L0!!WLD/@Q[U>9&>[8H_%NW.;V
M2%6@]*7](B;T&C!3I,]@]B-N[[D.<>\?>*08(X"V9!08P)-E@W.K ]RBDK]/
M--N+1T^8E/MT-]R?,/"4?U-L?$U))NHK:J;F.+<).,@,(Q'E P.T7!X@M5$]
M9T&NPV1'/9RORC13#2R$]M&";*]T6)FJ$)[)(,<"@VX\_EC*:\0K7W%5[Z@S
MH6"8 :)53C9@@.+8CVN*ZA^;"UN&/8J BJ^AFNJ'8*((@Q:*0H-NWH;CI*9R
M^MPGO>)K#^X\O6_Z)/'$WWHT%O\4W@9;[P:'""##!L!DKII,EQ G7H4*1M0G
MP\1;%D-Z[JPYBS_L<B*DK2 G_>_>^" CK7WE8Z7R\,OYMU]E7&91^%3GZX<9
M:)1'_2,<^2)N_DQ/X5C23:";XCX(W5\Q7D_BPZWL<J:JW%>04A+R:,MVNF1Q
MZ<KN1>Y?1=%1I#TC4A@%H.5*I!1DR+,DQ]+ >]O)"+W8D\1HY\G^?&=99(5^
M:FI==-YHYFVEN2>7".8^[V\1.Z%S<&H.$$6[P1R[+L&HQ(@MK&8!@8-N5Z;T
MG69JD9_NW-#\6$OY1AK]^LA*W5P^\*<]H)5/E\SI@Y-M=.8J^P8-[QE@*I:Q
M!U;M2^EFS5/3LW;Q&WXZ,;&*FZWC&C6-]6.'U&OB7,<Y?@BZ4*\PT'N^A9.O
MV<\-X7_N47O+3G(ZTX2\\5 ;8T8W'F\)+-C*(?S2.M4P]?I%GJ749FS5B-57
MS[#!!$B#&!4JAY2(UF#R58'IZA,E9#V#9G_&Z*&9(',4Q[?5[<B4',8-2R;5
M$X.<'C0L+2E?J R5K"&=#9:,4TJ^#8#(VE)X?IO)*TW>&()_D0T!'60+#-$N
M(H*GB"B%Z-6-,U/9/Z]-\>79\NMIO5*I>P"12!5MB'RA+*!^>&@0FLKD  /4
M#=4327>G.2*GW KV*OZ\">%"?N4\_4Q[4U8SR:B_P_I*WN#ORY<._M$2O]>)
MUSTHW/']E#[*0X?''TZ^@ *T?/MU@,.6/9TU"SH)Q2<!M4"*Y3NFT%ML'G&A
M[T1J@.6%KM:F/ZZ%1ZHTE$D*5OLD!/A6, :H'@X8/OVZ.&"WC$Z#->?WR0VW
M8WIB:L&R.)36%58]7.-*<BG8./?AJ?)AS6 GJU[$"XE;C^^&?/$<G(?2)7R9
M_!$4<2:? ]DZN 66@!5B\KHCM,C)Z<6C5K?HUJ\^O)2WV S44WR9=]S(FO_X
M?I7Q>',NC NC!(5O0)'M<8"Z, GUBJ[(>(,*=+=/AC8.]3(BV %98M]%V>2!
MHNO<[_-HZ^/M"=:)4Y)M-^O5^$8X;IQBVY:FB_0P3R G0<N?17/]@K<892!<
MM7ZFTDWJ_&5#4H-UKB]<19OGQ3R+D1N#J4R@FB3\*K^GUE[R3OF*$*=:,)(Q
M[,AW./*=*2@OS'=!*R*< :<>15^="4%8$]V[G3=9D(LY ^S<Q=:ORR,Y!X+X
M2->J#;V.:/8SD\& : U93Z"L47V>4;,9SS&J*_>J^N39)U:-9IH_&<;$N!_7
M]!QY_Z;+:K5!D3%]_H9'&#S7K8HN5<7DC871#VA5(;\X(&?F31"&R=2S(;RV
M1/1Z[)F/UP*98J[!S*'O#/2GQ6]'<R(_/3V^6'R$@SK:=8:* 3[3 NAZF+V:
MC?+,_#)L!Y1%U R%[PXV$(4?SC"AD\VB,@\ME!<%)J\V=^("!A0D3@\\]3;_
MN\$-M/5A8.2\_&4L3X!_3/G:O7#IW6NK2NI?W>UD/QR(.\K)9>$8S_8S"UZ
M);O8IRYQMX&16$S7 $1I2.8XYBC@2=->@_)N;) BY#GZMSN$BH@Z,G7,OJH
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MXF]J(KA?1>O9Q]NI?QNI-/; ME[.MNJM?>69ZVYVXU#25^@Y$'@E(@+ /1*
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MO,XSP5MP'X!J.>]"&("21X&7XZ&B!AG[SD*5U<=E9.P_V\5WR(@VU*JMIJ0
M0X,9[#+^;JLA)8])WPLVU]5X1][TN!ET8ST&'F&ZYBJ*Z'K50'4>\2+<*D;@
M;I]#618J.SFF;(;_M""6YS;IV\HEM!IP6A#$J'_F/*LA%-L6":J1:BB@>G*-
MDW8U6H=C7L3 K,);.4=BP2 .LF9F:8F-U 3[86.@*"#S$,%)%$4LW3J60!8%
MJBT -QMPVUIJ#6X9?PO(XIWPPBI5B4T^6G_=#&SQ82LP"(XV"=JZ6RZ2U,.M
M:UJ4 QX9G<EXLB['G%7V8S@&,6?PEPM1O%MYL.2MWE6\(.OH4TF<Z=DA@W!S
M\MDLJ3SM6AEGR\WARS3SGAIK7_+9*;&'U.)VTVAQP,WMMZJ'J.XX<#/LC!I<
MOX]\%+N]FLZV(TN<PHO7F'\:1(J-HPI+DUQEQ]GER266=K9N4>5BQ[:M+MOM
M_ZJ(7#'VU]W>[\DP2=F/ =4;IY@<RK :4XJ=#DEI9%J,H*+[7E5R;*+Y>WAZ
M]A,I<6VBO!R]ER\[5Z>5QBV16G965=E.<M$S[$MH*4%3D&V\DF?D1# ":3P[
M!W!R>,T+K!:E+A:(+)T_=,3X2=5[V%<*;#;B/G_Q6W;]/>U#?W=VFRDJY290
MK809>J9/+UU,+SL/BYN6-03+ER#>>.6V B%B66W6G(690D[(YU RSZY)>O09
M3L>7?^GA)6RZ,[*]TBP=M++Z9(P=WM\5Z.UDN#30^JSFR4Y<_DD]![45V6=7
M!"VCB:P/.B,;UQ7_:\?;W89HY +@#8LF1'!QW4($#)%]4N8O7WT,[+!(^%9S
M5N[K_2!9W+7IOJ/(9%U?T2WKLE>?/&GNBBXP0Q"/$FF80A9_S5H>&GIK2 Y'
MBP/5IE3&13QP($'9VEP:R>C01ZV@!&R@;9/_-/,^93<K447>.M;XAL+)F8MY
M/U UK3W[:AQM^#*'V[E:@FO&_B/(J_+SH]?OKE6N-YR-<%V(T@=2OIK=_38\
MW6=7=A-K67[>3TE'V;)\PQ-5T<D8==&9(*[#@O7_Y;+(<_1K*393LSP]^,F%
MK\&@2'DP^@:;D+U65HF6F?[EEJ-WK6TS'KG[.EJ<:[SZ$"$^UA#N_=Q^[.YE
MQZ^Y9;,O^AJ2DYM]UROL#!?YO/+:7M\+J8]OZL1Q3CY[O(BZFQ (0[RSX"4.
M,_2X:M?"[:3\A<6%>9Y]J&C^8=)91H^Q)7M1*_9V3<JVKSO&2W?V3QQ\\5@Z
M$C\<G[GI_JN@@7D],P2>/I7*MN(^![V'M/QKR*61S$M/^3ZO.[4E"CO6@2[>
MC)=Y%_K6D;RX;!O##ZO+=EQ6C:#%28+3C=#2'-X%PB9PS[!-CPO7$?[PO:P;
M&'>4K!,V0V5U!WIM(S"L+>T9],DX^8I31$;WUF4V7]_+.ZC.J,HD[JSU)]YN
M,UWC/L5D(QGDJ2*V=@U0E%7=LFH<4F"[A>,R/4H_\/KWR2Q!JI[!W?K@1%_M
M[N;R+O_#'X]=1L;3V394\#3 /HJZAF4?P8&G@%XZ.\L80QDGLV&Y?&:.#FO@
MOLL4W-?0G%9LT5S(K,]T!CW.]4IWV_>%.\:(U4+$"QO^#NTXR!!? <F7\3?2
MV>5$7:]'&!Z&J]!#+:CJ61$:&T36[M._($0X1<VZ?Y.<IM#4( DLSXK@NP#_
M'E2V+:[7ALLK!C'#H6J,#7A)*V7ZC;O01DLF4.Q+R4@.F/V8)N_9=GGN/.5V
MJA"Q6Y39I"[*6*L!+6WEZ(PDU[,D"0LM^!@VUDH;WIY3H*P]R8Z='/:$[40*
MY^M(\X.G\WTO:"D=PX]9;CU_NT+#U_P\)FAA"\'<$_8LM#3I+X.I>KS#_(."
M7$@6J#Y;7(%5Y!_N5'%R<>(@IQ@N.71:3^1F:4/EV-0C]WS2CL1LB';9]^6)
MQO0Z[*=Y==%FC+MV.+E$K99\38&X5)!&]9K$1#L;I(0\+>9T4FIIH<N- @(6
M+=9?T;H5<^=-P:8&_M"(' >]L-'=8Z'@$^22+C+/SQFV<V_=RR I$Y2W$>^=
M&.&>;:^SS'C=5NYQ2/3$=&QP[JE@IYZ1791/Y>JB*,8@:02))& ^5F(X4@V7
M0!*VH(WI\Z-U1?U3K<2)Y&B9W.Z] ZOO]ENN<U^IL=V:MF>=6^G/@UISM=SO
M\,=A(ER+@PF#%$<4DJ?S55'L#/1V3\B0I\9%TH#2JJ8]/!4A JU=Y-LXWV])
M^J8TCXY!:(R2KE+ACM]" M5QC1A:.]SUW&3^MGA4[644.P8X&XR!T;]7'W"C
M<RDF56U?!5/!ME/CR9/8?3 THN!Z'ER(N8""$.%#)0&+A A/( PH789:6HEE
M;QNMDQTKF\4L3^/(.*.SI1]J'CHZ0$N[8.6N>'8SRPBSY3!!B&C$L,U)??[<
M<F\4#%+6U*'G: WP%?M;ZY&(Z4E&UG5H;0]>Q[I+1<WN &OPD\/3\DB_[.G9
M?,EKF8IN5%/UQY+E*I'I>)?]16SZ_UB[R>IJ7GO_K7VW#AV[)"@3]N'80B$3
M5P:M50T,,@P,JT. "7WN?(G]#WKV;YO?L__!HGEJP&#K^J,%:BQE_I/[R+<X
M^>_T!W^MC\QG7&OC9*.\]"W#S1LGBU<JN>YXKZ]3Z/;^F=VC\GWO5]<GOV^6
MWR9_R)8Y]G)]3OQM9_\?%\M7Q!RY9?IT_J'7\3SK9G.X";E<O'W'1\]\TO)B
MT=O;)2S7IRUJL+?( 5N^_<!^IA^'OWG_!;:8'BPIN\__CZ'B<M 5]>Y#5<L/
M3[FR=3['[?C=ID^G3:W]-H5;>*;JC7.S'QJ)!<4;F=^^OVG[FXL?UG^S^#MW
MC^)O@QKA2TLV?]C?]"7CRUL]ZW9^G85%YTW6,/#J;#(^]8:!]4ERXYSP!93?
M04A/+/__)@!02P,$%     @ ^8'V4L5<6PXB@0  OK   !4   !B:6EB+3(P
M,C$P-C,P7V<Q-"YJ<&?LO =8%%V;)ER(Y)R3T$H0)8A(4D%:#$01$04!I44R
M"(A$I>E&$%! $1!0$%HR@HADB2U9103)0>B BH26;L"FH-,6[\S^WS??SK6[
M,__NSA^FN$Y=5535J2>=Y[GO4U7-FF3A 6%+4PM3@&T7&W =^@-8OP%!$_?
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M;?N0ZB(7ZVC/M5SK176.J'2G%DH,REWB9T.H,KO:V1@OX#=A4Q=GJ)F,9A:
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MH;!R*7,\;.F][J;=:V^>HT"M\#&C2TN?EN2EA4U-N&+4*9M,'M>=(<Q(@^[
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MJP&C&;;^IUB<;:N*R ) )2^ZN!6TL9+Q"MUQPO@(NL.>](8I8D;H_;KA-VM
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M-FJLL0S?I:?%,T>7BC5_=WPNY=6A%)7*M5FG9UTF_IZ2=XISJ7T_G*L%TCB
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MEA6SR#?]T=+#>+05R_>^25GNOL3S<L8&K+(/!;X"9@GK![OL)4/V"!G;-6%
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MB-?$8<-:CMU].=:NFI'1<7^WTMB@TY4?Y=?/ '7[^2A/JQ@L:"T!Z2]TLZL
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MP>OAQD[\_'50%.X;EE=2EUW+V9XVRME&PFBGQ)?Z#C4/]0ATM2\>N(5T7=4
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M$4>3&K]Y8M@B<!A')?)1]]+T@WL[E/:S2.R^Q?QZIBS7)B5I7C) OV/!!%9
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MFG&$WL%]<'=9$* SZ7R-1VJC5>&25+FN&KTU\8M[Y$?8$KP0@!%%\&!U-]'
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MV)HA9OBOG'\^WT"Z,I?MZ(CG^S;MS9#[.%&[MSZ=90%^B Q,0^00+@U35UA
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MM.Z:U\(I"V<8)5W<48:#DH5'R#_FL76_]!#WYQOI_-04YT#/1<Z!OL'MY-O
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M.EK:%[D_F.K=W))L2]'O_I:9CH[,6V1.P>K6Z>)]3'Y%FB&XQ.3%':44S/2
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M<2B@(032+I?P[/X@$>"G^4T!*([( 0UG,1+HT.XZ@ 5%LP8?!-D?5&^B(D<
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M <0K2%PC+_\+Z]W_Z)-89Q@"[*@@XD(GD@,;[/JR)'X7\6T]1%7=KT$5V4C
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M 2PX33R_S^%:299OOE?".4T3O9]:W3P8N1HR:F!5UU6<PP6XZE&'W!-^8L%
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MM#^J_4VS_W>*Q?R[-/NOBOU=KVE A)L+=AZW.( $6,S")$W@?]/!C2#+)G$
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MC^1#N0%[VP%$U71075' GAO%_A,-EM,>HN_K\SS7BI4<ZS/J$@H66L*)A#]
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MG%;E?R4JD_>,DTMER2IJK8',7^]X4OH]ESN!.L0^X6;*?HME"4S>=VY@&G"
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MV9+NA;=M%K==6G)OM3LAO""T+_B;0]CH-^D;T(1P-ODYMM2I\1P8BR\Q&9<
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M4]2B!MU5+OLT;_1G!X(+?BR>IR#W9+;2"S,IOE,=&(D 68(&5XW32SK$,Q6
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M:^6;#J4]GY CS7#P#J*L-3CA%E=(Y3#%B9<6F<5SHT2)3!5%X5\?!P<:+SY
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M<ON5%SRJXW'(L/,3$?8U9X*%IET;<C9FN(?\E+KN>SFGRQZ^PJ^:8SI6Q7S
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M)W/_0%\0[R_2ZKFD>ZHV/Y1N[^[_Y?<JH6,F<?KU-YPU[%M"M!>]DA;*W.Y
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MJCD."BU@1=%*>DF&,R[.>;2UH-UYKBZ.F:[W'W0*&SRUZ[ESJ^_^3HO:T51
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M\,U/]&_SD?:5T$G9@\&'@@C?2^+,=6DHII0XO8"*I.32Y.AUK!20^%"?J=<
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M7&!/ZUAUN/UHHY'(LQWZU=%ZK^Q) Q240]Z@P\E!+?M;.1O[*TY'QE]\2C,
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M:1<E'*HH]<_MZ=D>[]3)DU7N61(G'QP<[!.L5%34=DS$1E*SY'!5*M^6N/V
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MZ-]E+'[GSG%SISCQ8:'-NOX_&&9Z;$&8=J@YGN$ =2NN'& XUW-ADT[PK'.
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MUFZC'W?^<X1-(NP]V]K!D8U'_)YH^]>[;VBAC'(D#1/G]?&8#/7\7][_IW
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M18EJVCF[MX'FF&P^QLH/JV):C=4240UN T&[ONOJ*IN\<W[-]W6_VMY.8&(
M13VK%T>@'D8E(1MCT"$L'$XKFCY-7DFGE!3W=^,$:)Z-YJ5T[T2=N^3ZD?78
M'-FS!YOS7NRSL?HFZH:G6M<F(JF6XJFHA@B$+'C>,1,OT8A(40::6UM:J%&9
M'4'/K".#17L[\G+L=V$?WY63N-G:MR96U]YG>T;K,.+)VC])\3^2X@$.$(1,
M0340NH:29<UWLNZ OFFH5)QJ88_L>#-.J9U6U)34-!63_+.6M[?K16OZ3>43
MBH4@?\)A!$^T.[V!!5,ZXGV0ZN(X9>T&H^*6ASA/$%(N=,W#G83JS8BQ*O!
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M",V5&"\6+<%E<)D(M<A@S*OPTG@:?:Q(1D$F;L(E5 >WJ7FB>C[-J4J9D-T
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M])J:(3YT!>()OA4!QGOZV,90/Q+"]OT6+G?:_&P1SE9(!%^NCIF=1&#(9I5
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M3==V .2-0[KV0@TQ=Q=5*0)O,A0>*E!"NGX#Z7JU3 =LC,^]-.6E,DD16%?
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M4T&:B);7[D!DF.AZSA9UF@ZVBE!%.*%ZTR4 3$9R)O:!_W-O$LOY.%@\G,7
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M1U9 JYCJ,SV-+RL=3<=C.5XAB8&2!^9G:^LMF]/I6O*K+W:AUM)C;!0@:^:
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M]Q5,W) ^K A >N+21,?HD*NFO6 E16:*J@;4.@L+*CCX@,KR4K[A0&52D<_
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MK*'Q<9M*\3&]@YY2:H,O]JAL%3:!VY@^'$<&>6#P&Y/>2!]\V=&$7_0Q<B:
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M@YAN\&L\>]),"4IG:$*1%ZN@VS1OBX2V6^M2,[Q#:0&'+G^HI#R1:@IZ_FO
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MJAW9IEEG8GZMVDPWZ+S,= K?F^GXZ!Z/5E'X[1*F!&:E&U%=SY2QF_->MBS
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M5/02#&UJ:=85G^&FKFW<CN=#;W'!$78'GA>CZANS?HP6?L],[^?4S,N>E8!
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M A>E.\V]4]F(@:(;3V ^LEZ%S+/2@W+UGGV/(AAKX]]V+;AY4[/8VW]3JSO
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M2: $45S"<WH9QH]PEAG5@2L';3<^2Q6A,?A:S?>ID :>*1="?T!#44KFID$
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M)TNFU^D8%EQL[D[(0"4[IX9Q-"*D<'(6NN[S3A;KZM\?\UDQ]$9):/%)QOL
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MT(7S\R"_ \N9K U%#Z_EG+ +WW7-_#?-B;TDF+!%[R=\P?P\2=@F0C :JDB
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M"PC_3U_<=X"$(._Y;;=Y>=2 ;1(\O!(\W!X !LFX_1_B\0#_>O%LX^7;SB\
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M3^WE_>/F.%$?S#_FL9S?4/-PS['XH.8)8]W;^LYW<A8=@^A<@".D!<E5PWZ
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MIOR^4BF6:TD:,_=K\FGV25B:;>;,;X9Z_1A: O(>@O3<0QDJ4DKMKM^9W1P
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MCKT;_E8_=>JL$E]/>\KYYK!S:D2P@BX2RN1VHGF#V<T(*2UK"(S&P&HBEPJ
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MD75"2=$'!)XDT6R4YOEUC Z,6;6-[7CY<*ST8]PVM8GTKKLH%>B,+Y@?"1(
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MD!43^F,1/)30UN8^=$5IQ*X>CYO+F2!(^PA0\\D)+6N!-0!YK6G25$*ZXD"
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MO'J^Y@U7D9%GXMSQPP)5LKM^1#*@).'@!C-RZ9J]*R9/<25O(]^T4?HF1$=
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MW8RB\16*]BN+#WT?4M@3GZ0!B_'=7\HTJ0#9FZH>BFRNB+TU<9D%,XOM:-0
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M-\MKR#-@C*!BRFX<WB3A7B^J<?(^_L30H\&I;+KJ8B,<O.L.VD;C,70Y!#D
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MD3-$Z$-QK!$1<&FA(J$))4MT:UN!\QG#1A(OL64+MR+A8.=97U]\0/JY:<X
M[8CV<S.37Y?J)P]W$MCJ1[3&9=%3Q =XM72^&>0,Z3(R:X@%/_2WT=!Y\[3K
M"SOJ\EXQ'\05'4%?=RH4X32R9@#4V&P=.3I5L8--I >2.(W'PDXZFEDR9Y4N
MNRH7JR@EO)O1S[#WW?XK]G9$1*;8>;_1LV[BKP71*/>V&)H$BOX.4QS&1C"7
M8*+W@JI1BD2&"[&&VKL$*V2["WN$S>U9196"EFN%[;=/[<V:C=V_T.1W+FG9
M<H/I]  6C7>2OP&RN,G"0511?5;U%+80\]!U'0?#WU;\ 9#.L ,C;3M_^#ST
M*/;--RZ.,%#9'15W)%WF8P#L./XE9"'7@)(\"V(U&JDRS-_>0:4'.J"DD";?
M2C/CJH%&%P =EA96<[+QIGP^9DMV5A,6$?AVMVR:>\DJ":MZ0BUD+E.()4HL
M!,^"OTOP 2\'=;@%5."93<$+]:HY16:B@!LCE>KO[GWWC;/%58/SO3<6$ =+
M>">MSII=:7+:(6MXR0-C)X@JOPU8CF$:]9QG**"F!E^:TYKP[+I6ZG[ Y.4+
MBS>2^2OT<RI24R\E^V0CIY]U'(K^X#M\+^P_<>O (8G0O=A7CU[#-\&JX/7^
M1WM?&@]E&\8[)3O9LB^C*$E(62K,Z"TA"2EKC"798EYES9B1?1="\=:40O(B
MNZ09NTJRDW466V+R3#(>YIEQQGL^G=_Y<KZ<W^]\.!^>Y]OU>^[KOJ[[NO[_
MY[[NZZ9+.%F5?(';)MRE%/4W&4FQJ/H""DHZO_/57E0_05)JD7XB.\=)V^9U
MN[!Y/=KBMI3&Z9<TOVOZ'_^=;H%D-\XU'2+?N^OPKOI:>,/(%?V +[_=BN"A
MMBAA1_8$KGZN).K@,X_YI<*H%/NS1ZSDOM9]4.#F^OS38C]A&' M2-%=%_!C
M8$^-(^OU;C2@:((UXLHYUT]_O['/Y #9/83+:-PIWSKYR[RTO2UF6I7##0YE
MIA<E__UTH?3-7WYFX:HY$Z4Y#PI#;$TCU5K_IVY+:JFM/AQ#7695$\GOX/4^
M:]G,\WL]H8(0@A$:E&,)%(U9^-4X\J\X*OQ<@Z;.L2>RVBI.#N(5Q*_K[#K8
M<1N-%>TX)456&=$=GD0X#^XU9]B#:T]^HF1;U3S*7"SW)9&C\W.UXJ4N.ZF:
MAY@O/@<^W4X)N^OYW,UD,0,6;6>*U<*U:_VW7<R'T%MUSJ*-,;UQ[1;L<YU4
M30/4Q'H)J/,B0L0NMSW_/'SJ]KO:E.*Z(>^ ]RHNR=[<6I@AY8M'<A6>THCD
MA[C&QTC !B[)0:GUR)Z]L@E43R"*NE0)3]9S19$QSD+C;MS#(:,?"X?GSBZR
M^QPY_N\\9W/]#X'16:%[SX9W-5"27O6>HP$GU,;:^2J=^0 T]-(T];X]*_/O
MM!R% LLB#.U;@-EGE,!B=;V(2N>O^[M$3EWQDEULXX6;84)9;W ^Q,DB<LDZ
M399.HC)2*,0#CLZ]P08IVE7M32&Y2C9I=^8-+;)K5(2^F0L<].5J+28X@GLM
M88M8,;LP/[B<0>=Z$EX48X=^^_GE7,#YP*9D@NQJB_N8+M,Q?63&6:^_4+/-
ML8>6>C4^Q YE]-]_##)Y[Z*#^HDNZV2B ,$0LFRQNK?.R!Z#U '_"7/P)O5
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M_Z=RN3?OQ[1:)PN=#B(\A]]]ODLQ481)<H ^#.F.GM1FN+.*0N&3&N2"#HU
MZ;:IL8\+#QC/%#>["N0J7'L\WQ<NK2R<Z=--#GOJ;$7F%KAQXN$T1A"$ Q\8
M_B"20HK!'X!T6&D4)/]*\,H<?!@[;3PP&?A*QAR:G%W$X"(GGVSI[MM6XSC1
M+NP'";@1C6+S5[^T8FI"UJRGFG>7Z(B]D_<E^"R(FRI(%-=J">5GC^I%!FZ>
MO6Z98]1Z1P]Q(48T./?/UEH"4YRCI>4NS!WY/8R3RQW6.ND2Y(,?YZ/PZ0^J
M6O,):B.;1=9"/QXH[AAWM80^UJ_:$K-0G.?)<$WE*\'D?%<;1NCCVB4X\MH9
M1.D&?.8P".]6.DBW3ED2!^MLP8!YED-G7Q51]>.,OH%8MT;.5V>KE]]K3G;]
M,_$>^Q5?2VHC?E^E*.+;!B8GVGE-@/Z\KULZ3HB2^Y$J T:)%J4Y4>6J^4Z*
MW^O.O%<MA$%TCN/_[&7Z?^:H_@N#04V7(&0,TGNJ*1N^"+$,\Q7\9&>7LWHZ
MD9&TCF&QL6N8HC"O9V,,;4C2@3&-WKMVBC-43G!M8.>1BU 2LV#0M\^Z&<=^
M!S8V28<7-#+":&<R'_U;P*]"CKW))\1_($JM!QY'$D+ZBB3*+;?C,I3XW]'A
M":T6[@SGN93R;H)\L_S;=^18O@.G#N?%N%^ 3:3\=P;;=&_+F@.F5.@3;>A]
M&*X\2)&N<;5Q!/*FD$3!7L?QP&K-RB["7Y=;$F8X+'=R^;U]7)][N_RYS-,O
MX$5[Y58&<43R:Z0(DIS[7 4L9W+X<OL%Q"%_GGDW )HRB,$H B&3=?Z=MDUY
MTE9CRZ-NWKY>%DL;1K$#0J?+IQ2R&6J0@B$..&@-JK%ZXQ$J*W)5971Y%[IF
M!G%MNRSBNFOA1L0\#K*\\\YCX[+7_18'&=;G[/OO!Q4-D:!!$9O?Y3ZYB)3D
MA@0UJ-9ROA/G,0^P>.]Y9$HA#1RZ.TR53XBSOM,J[/F!G"P5_ZI6/>-I]JS+
MBH@,^Q.RKJD+/F7706P@92*4</Z0"8#(#BT%+SH1QJH6DLP3EQ%1+I-/L7T*
MPUP-50?<@DTDL(,P&!C %E[,))F-LL]'^#"JV</(1EW$N=/806FW8_G2'P@-
MRKNPV_WNGON0M82O-R[5Q+Q=;.8;3&5I5^M-$&^+3$YTX1H.)C%]_>$'(6(*
M00GXLR.9E/IO:, 'IZ,C=XX^'UXZ[FV./B(4_G9&-=:@LW0<-E%BPTO.?+H+
M.W$-;&)W<"CMSCO3Z'8.Q/P%N@!;[3@ '=Y5G30G#61DY&=1T-Q@M)&Q!SKH
M36%$TVC(9GP7[\P)GGTRY.R9B6%.*CE%]&C&>4810;4;N ,Z0!#;0FF]G03D
M_,09(EZRBGMI.#^F33]I/>()+OP7IH'$'B35&;3#IZK)B ;F&4P48,W8BC4R
M]1&NJBG&^=V:8A7+E&3>0)V?,E^Z:F1^KXI_.M9<550D%N=742F_UT%B =L5
M3JS770FF]&7%SQUI!E1^@OHY$6V=@H89)/7FWT;%3Y>__F9@OE</HC+[J)N@
M 76;+7>8P[?+,4?+183K+VX5;ZS1%A+6V?6F(\U*8Y^QHZAWQ+4*I@]&M@'D
MY]".(W5TM<0_DQY%9JDN3U^VC*@EA'4;5XYJU4U_J>CY\W>7N,PC<Z.RM2P.
M=^A@Y1$]27 2Y 1:\Z9O(@_]E-/P_0W&]>S"1!M<[U$UC?H.E8X?C@P^<BG1
MW-.KYB)<\YZYS L1/)$\MXJ<;">2$Y BKR+JCP$0&SZ>U2U"LX7G;Y7^7/#'
M32GYV-6+SJ&A&D[6XYF"F-%2&]UXP&\K#M*A1F@'&:GCZ+_&!SIL?YZD.NGR
MT@->G[#$M-T_CF($9^J@WN E.5$M#@Y<74]'BH7NPI*=.4N)=O^JM?1/,QMZ
M=2)&>[[?Y<H0YF+(M:7"7QWCB\IA7GV2-V<L-',L$/-T-.,(*X]P%K-_&.E-
M3,;SWCT&XE[<\JO[09 :_A6D.QUP[%VV:IT8*]/\J;A^!I])V*-3%Q1L>'M)
M0#"I/2M128L5BY6%#,<@60]6FC>=V<:0.H^1*E>P;QQVB\XH3KGAJ<<TJE:2
MAJGW7OFX"^/=_V/J<AP0Q?":T#76FONVWDELY(TYF&!<?R*Q*W*C]/L[A.D4
M; IQ:U\O%_P.=I#XGQ-5M.^$QV"-035FE,4PQL*C>H6!GW+0)]B_\CY5.!4X
M_OMR?ZV)O,=1^5<:!T\@I^",6Z $T_X'0@D8Z!W@PJ$=08<>.5QJB R2DZ^Q
M?15.9XPKOP66I!-Z[B!<\C/J-C1L>)>(W=^)=S.LV0>MZ0UE;5E2T)%AHYO2
M:_37N[".%ESZG,)H*%_)$'NX!_*+_?+K^VN2_^GMI)-7/9H%Y @/67BB!VIZ
M?(0M<+\4UVZ"]*].1W%;36$T6X&P\F+,":"QHO3SOU/R;WYYY,_3F@J4 B[J
M#\JK"+1':Y"0=W&@VMZ=VP_\ID["Z\LZUFG&9IT&FL$4G/B*<^6WIQ6^PXT&
M>@VTU]G],H8W'L_6I):?,)?I8N40R06H6H,U#[K2+FP>V>$JV'T^*R/46,I*
M::-[3H_^JZ(*I?]\P]1P6L-MQCS[93[?/VLW57O>JQW:]T?O_U+5Z/]__M][
MX+N3_P-02P,$%     @ ^8'V4C'6[\MC\   ?AH! !0   !B:6EB+3(P,C$P
M-C,P7V<R+FIP9]2[=U@3T?<F'GHW]"I$*=)!$40!B8@T41$+':,B-4)$18+$
M1$%Z$T00$"(@(BH@-?1(5Q$1Z4%( HI2(HEH&$G;X;/?_>WS>Y[]8W?_V\LS
MDQDR<^\YYY[SGO/.W/"F>12(]'%'%T<('S\?Y"+X!^']@NRPNX*Z' @)A("-
MCS<+L8?P\VVW[3W_=A,4V-X+"0H*" H+"0O_9Q,1$P4W$6%A40E1,?'M!AY)
M2HA+;I]L=_+?;^47$A 0$A<1%A'_/VZ\MQ 94?[C_+<%^#0A_#)\ C)\O#X(
M#)11Z#_B\4'^J_'Q"P@*"8N 8DB %S1)@^(+"(!""X$2@]_> ;^'",H(R>[>
M9R<LYWY)1#-2WNQ>=JFHUM&Z;H4SHW3M_9>OQXF)*RHIJZCJ[-'5TS<PMSA@
M>?"0E?TQ!T<G9Y?C9\^=]_#T\O8)N!(8%!P2&G;C9M2M:'3,[?C["8E)R2FI
M.0]S'^7E/RXH+"M_5O&\\D75R_J&QJ9F0DMK6T]O7__ X+OW'[Z,C4],3DW/
MD*@+B]^^+_WXN;S"^+WQYR]S$_BWM:T7'T2 [W^T_Z5>,J!>_-MS(+*M%Q]_
M]/8%,H)"N_<)R]JYBUR*E-,TNR<J?S2[M*Y;3&O_&;K"Y>NCXHK:YE0=QK9J
M_]'L?T^QN/\KS?X_Q?ZG7B2(I  ?.'D",A XA,,N2]6#_+^RU=ZS-<!U^^+"
MA_"SY$7HVB&6"@_2;53--76E!QWF=Y,&<G"9>1KJ\VW-!0I_!'WG9@[L]?'B
MNL XIQ8):/?-.>Q1M,A;(H&0@:,0882CV%X<#"- \0Y_W:4&DR5F8I0.O#$]
MWW&@Y,A]ATBEW-,IA.!;M-4QU"Y8.;FN=@!*&EQTZNUT[<,UBZQ%0KOATKY(
MM_!*= 0TF8G=HY1W6;D@@CL6*A^J8F93]^^8HH;'&O6N1B6RYF=^6^Z614E#
MJ,7W%\(K7PP30B^)//\N8HB/1)3 Z1YN&0C"R!J2!Q'T80RT,@P7)^^]P'A/
M-K5#H;[HS;=MDFT.7?FA+U:D?<U'^\:<&1\?V+S4V2'>7EXCGOI[!-"O9<NL
M,VUXD+@87+=ETSJ)S#2@_^5![F+W8V3':#;V3S$>;R8C3E6_G'.(%&U3C6],
MB)A<]CG-:%O[2A$2R]T%JX[R/3%IGA&FKSOZUQ?9F!J4ZME<?$5,D_--QZ57
M\K=5*AL/]I["MAW#49["Z.[K@*['/8;(V8E&==T%6.^Z6EB)?B.=6V7Q9&/F
M?:F7_]?0'G1!8*;^N%J,>'U=J@MDUY.I99&U5M8N[C"BSJUWMC8!5D_L,=[?
M?6%GYP3^7.L7\X>ZN9LH^=,=T]F/$_4%CU H:Y_,7'8IXU3A5]=%, J<6JXX
M=O#VR'T+ZV'$XDV-/?D.$]47]H572BE^4&N]3TT.6#):J6K<*7WCGE\6K9,5
M@1YC>G/*X,&F\;;*](C\JAEV*/#(,K&I:.B?MNPR7:?\E,[]W9 N3]@!1\-O
M",!@?4T!E.XS#T+W)4XO#2ZZO>W4[9/!'!_%[O9%+YOJ/):Z;&SHT%CDYGW
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M<<F[WJ6TON(3CC;!6/9BQ*%/D:[/PPJ#F@(U*LM7]OK/'M^OT-\XI'GPT\%
M;0TD@\C\,\95#H/1SY(%<-U[F_#3JPN$/M0,F?+C[3N,:R5[!V"3;>.366G[
M]&+BC].N12PWVP'2KI<I2[8S1<K3ORH_$REXO"0&2??DBF>7A9'K@MER18NH
MMZA[M@?HIRK"&<&@_:3-6=;^.XR#A#8::<<_2(0[KME;)R"#9[]7>2!R<YPA
MG.,3433H4>EBE'=C ^M8F2&NR<\(BRQ);4_^.M];2$#$D>NX370GKKA, $.
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MA<Q5MY:0]*KPZ,J:X9^R)[L"#-9G.Y.'8XEL&5>N.XQU"#<# YG8GVQ#$,<
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MH]M )#7$S\RJY+Y,M\9?N54?&Y^7(6?")H?N:#LZKY&B9-MVO)8[I$56KOU
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M+#4X0$R?8EJ:^860_/MD/K8%9>V4<1[!10J^+XH3O*;]9!_F'\X;U[T'%XH
M=-PRL5#3-0(XP4U ?MG*O#H0^MQ7@K;?90RU&ZUXZV%XWV^_7I62T&>9'C%F
M'X=S;J="@!]<L1CP!BXG'T=I@C<0,W@0RC,B_32"WQ_-@_3Q(,J8R)I^JD2Q
MDU=;,F#?.TFX[CWC'?IJ9VKSP)Y4IPW(UX]V5XO[.V]PQ50"%]QF-[ABT0PY
MYBY.C:TV4.G; B 8P?[ V053A6GD]9F5MJ;G#Z/#;1Q^/?AWKU#L,B%:Y,9
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M&=;9A9&Q8Y4\0&BRZW=RQ(6N"ZF?M#Z$GKN9LTOF\4T<?WF^]%Z^SSS <W;
MLQ952ISF%D!M*#%=FS$U98J3TMQN)C]'0:K#WF'T4M:D:K*Y:KQIZ8ZZP O3
M@C^U_6P<?GX4,ORZ@!5V2R;(,&92L,[9DTN%0[:7[$XI1(UL[]Y].DK'R@H
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M?OS(NE5G(_'SZ_Y)XF\??:<=<<3Q,+4WW_N-Q\$&98[RL5;O6U_T.[_UE?&
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M'SO_YT?*_J5$:D,,1D/GD(VH)>0''O U=Z3Y$)K^^=1D\+ES5L&#7.]A>:7
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M7:>(# DTD8$^?E1L7*3^+E2<OJ*M:3ZW@//M=W+&KZ%GSY\_WO)RQ?E=#14
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M8]G<ARGD53G"*QJ&$YO+ V!%\3'^F0:W67-!.*R!2[VX!IB5EB.C_XJ5;B3
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M_XC[Y!)27[AEL\*/<6(:2$WF 8PS&FMA$8K4XQESXVNF<1P,M3Z6EO/FMSZ
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M[__P43T?19^XB&<EY.123FA5ZFK(V^>/W>UT<8Q!\4A;IEWWNG+TQUF:9.3
MH"_&B%Y^^N'&O^>$7#[^*2=4N9,3.G_!0K+R4N/?S$Q5KSS#[86?IDG04W5:
MP2&DBC]EA);Y(B^RG8'4G>,3V".9HJTM?;;+J+!+];)[T*G/'D6N/H5;7I2L
MY;&".FLW]4:K+)G+Y\+B=*56-:VTLJK*AIUMELKB:/6/4%J48R1^<G#?L:3)
MN8:"Q>^;Y^J6R-6V;Z&*+Z7S'GS-JGC*"IKZ,)6(Z6.(+2*XCI+<(FF2+FY\
M2:FSY&6IS!_M!V.46[7VQ)P-=S?5V$64F0H.]]Q+0C?#V,>ML&7=KD-"+KT'
MC@P)FMQL?#HM,L4Z6!_,;\IB\C+C3K.^C$&7E/E/10+J5F-3;VM?H:"1T>#.
M'H,3V;MRU(<)*I=;KH0TH0\TDU*$C2F1IW.<^T3<PY!+>(@7&2DS,VJ@_.+;
MKF7S6K&ZQ:G"A)!:":J"KW\#3DA) MGV&J]ZVG/1(JP\91FC?^:-D?;>.(Z3
M E(7SD">/ILH?Z73N<&7X2RE-TBQ0DTR5FPI=5VE2?3'RYLSD4P07R>>L8EH
M!^?AV-#3"10W1@,?8ON8S)-/<%Y$NSP11W\JRP2M7S;9@ N',$&^R ):]_ C
M)J@A.)WV_!<!P7CF_%NMT:<A VB)<@010?A"6VS!;?%^9X+ #&RW .HV/118
MMQ$J9%-Z9NT%$LJ<.%I=&)E$?B=/D+,]TCU]UZ)]3ZVL[QU>&]FJ$^+6)U3%
M3"U5FB#"OK<FF:"("1)_!$/ L?Y,[\MSS?ZI3@D*ET3FYTUE9&51W'G'XOJG
M#ZL-$02P9UKN+1A]\'N;WJ<[7#;P,7D@:<,J9XJBUM>,_SGPLNJN3:*+Y<GD
MY8%DPCR=\U. ,_5H@! ]B\%#4R6N+,52M74U*_F#-VJ0;+Y7VJKUAQ>$OLH@
M/!3G*X_$O_SZ\EK2^7%NN+'NB<D$$^U3"U?V/-\_+415,:%7U.^G<5)LB2L8
M6"EB:<8VB]+$R;G(M[TOK< 7:VE8*S-G-8HY=GC+\+7$H^7Y7OK &XZ/JFZ)
MC'V^*Q-1SY46"3I3J(8")/C.J/G+TI(7K7V.'&[*$]>SKZ6_:8^.+GLVI(IB
ME_!+9E-*-C.X>6,U9VEK9 ZIG)<[XFPY3AM3A;JIWO%ZTA^GVG;.T4.I^TN"
MN*JG8P=UJ=#5JO)" 8/] !,DF02AO]Z69$3KP.2&>F$5$$(>D9U<JK_"TTH]
M<9?BT^:C'.]=40_$J:#72J/>Q)&EF]E#2ST9L5QOVX]&C%0=KP*_KD8U6,J0
M-2@>$SBVG^:6<RW"!%/#@5K3C^:2*TN%5U$<A6]1-*VW@A5,T/YA^L*(9(H,
M2]SDIXW<#@63%U:+Y>DC<5-2IRWE"@S(?;>MDYHYPK^2SH<J99Q:5*3/^+>?
MMM"5["I<KZZT%-RPI_'P3X&7J,3+*Y-RY4-+N#0*$W2KGG(I79&+DD*>-ONY
MK5>0>0;;O">52_WCUUYE_+Z&?>=DNC1/:!$]R'+T?,8!^ _$_EI)?\<)--]\
M!5S2C:W3TSY)G[-:IL8A\\WLQ?SARYCXJ:,//L,X&#_ >VK]B1E-Z(-,D#-Z
MF'J3%-3]3+8K*HBFE>J;7#:2D?-J-%[E:-NBN(.OJ8"M%:M$V&-PF1O!6)X@
M2()=(GE7$F<QUXDY09[4"S+-]:S%M6\N.6=95&BADI\N?6/?EP!:/;/O.VMT
MPC2E6N.S8U- WNT([3G?;^>J0T-GO9_DP,U&C .]-MRWZOE*XX]S1REXSNQ-
M<[RL-SK:'6?I6AFW[MT'S8*STCCH\??HM;4JI,5&7 7@IG3NVR2:6O K#9GL
M'U:BWLY5RU<NN6A N3)/Q9Q?.VF_Q^:A]_,?/+ ITP8<*P.+*QMJE ^%2[BP
M M2;QTWIAFBMH;/#$'L6+*NO6E_<<4U1^]91E]HYUT?GFKMKE:@.\ [D;M1)
MRFNJ+!RS^80_LJNLV%%M[C7-]F2>6YIBB&%6Y;-T0]EG9D&.G**/'E\B05YJ
M:E"LTVG:R%9P&7^S?K?(3Y_O7^4?XDE[*_@A#M$OV*/5"O@>/?;^=*Q29,"H
MXZSO>^."$&-5X_--4E0E];:[[46F[9Z]I;&;R<LQY0-WA]B#(]0\137M5?5N
M^.NPZVD4:MIVY;LNR&@YJX_CG!E-,!; *)S$[C8*DAQ)'(I24F>"7IBW5P4W
MG1W5M;;.EK7^&H/WR]!:2\8JF;WEVEUU$JU1, ]]#:D -XT)3\R6$OG)VA1N
ME6>*4;RZ1TBO*O.=NW(7GI2=C>D9\0OBO??R;/MM*IW(OF_MQ@F\3_,8A!PX
MP."&!0@65Y/DF*"0X_4EI+YQ/+YC^(AQ(9^\[++)T0K"E'#]3Y2^5+,U<:/@
M@;.VD9<MB]U$8JC)K)-\G%>/\E*"J?6WKK,"(EK2YYV,0F]/27I]ZW/!Q:F>
MMN\SB:D)Y.V"#KN1K4A( F3*K\SEY#9.FTB.<"/C^"DUM]1ER]1YV_VR'ER4
MO>@2/<U_HN25+;V?'ND5]4IM:*EUHKV>G5Y<*^6<R2ZZVYGT.J>BPKM2]\.]
M>U^.XY[OVMK:DP6_3.$D;]&1ZYS#L&OTN%I'JK"E4[5E8?>(TDB=)/XZ%D:>
MF=7E'OUH$H1TZ^ 5'#9],+5<!#&#3*1LSSW7T*4*43CO4MPF=#44TD8='RLC
MT_0++E#OY& E6*XOY_?:/E.55ILJA_O@-=:$* [=1PQN/L]S<&;E^TB?<U3U
MT,.>C GM\^ZN)VX+!HI<3PO.$VQO6NO5S?%*K[WM9[SA6"E9U"[6J<5C.FV_
MD/:;6PJL03O5/)F@Z=<+./*%1<BVD?.8S&^$Y-M_U(;;L@;DAL;.,]>.B2J1
MK 1'*@=\V$J2XHSG#$&7J3R7H]FG.18/+\)%$EJL825EP28Q3>Y!M95)-C':
MXL9QZ3\6:MXA$<#_&\*'866<!/Z<@,<4%JK- IQ[L!9*E,'SC/,,T! 3%*$^
M?1)'50775I?P6;[-(\\[S\FP7+X(NA<;2_5!- *@8HW$^K<\"C BVC=T7E!H
M4\.U$/:8DY9SLBD8TYZI045*N;Y?N7*\C,S+4(L\N?A[,6^Y#@B<^Q(1#-:A
M*="#T3:X%[!2JQP@6,E0A#,<P(>4ZLZ1F^\0O[TKN9KP??SJ]]'W61QS^N+1
MQ29Q'[YH:[KN VF> CK^!M'(BYAX@]R+GDA!'JD_X7N+_(2(::J[U2#&5C\8
M($GB;-[TN..4:)7GLD?7_FC-FL9(L..@^)$OWVSDR^'>1IH%.Z,/,*-4DH88
M!PJ)$#P3A'$LDB2YA<"%'7T2!PA8O,5/(9813X"_7W]V4O+I]9=/9=K*(!05
M2<8!_:S%1)?E8J)_J^:QGG7GLJI>#5$\ZO63P:QT[!>D!Y\/__684^W"XN.9
M7/N/1L-<D_FO6W(SCHQ8P$J&PV"E.ARQ[S1R*PCL@N%Y47N>WG[^6:"-!03?
M.<6IA)Y2WWFR$5:&H/%T V)-GYC3W,X]@6D<'G6-2"MQ=_]HV0+=J^O9862\
M$/NE:F)0DL9#;<3Z$-8 EWA-D6>"]C904/A@8O"S=510)9+;A::3>H4%'>)E
M>4<^J]Q2'=J?&9'U:5@4C950;K6).=,8N;N$3J+*,CI@(,@#U/-J>X#IGJ5I
MA#4Q.'M/5B5B] "=4,$%5>B6J=TTTE7\V'L-XU%S^$P&6^HA??+WG9JJ\"^(
MRF5DFA;U>H!\H/XM8F'?*.562[4VRBO;":N(JO2P&#?7%<D5=HH)"N7*UXM)
M?<H9#-]%$R"NT+B:&>Q9$ZAAGPG[R VH\#RB#-H<87&+E$$AXR]8M,#!2/W7
MF1550@5':_Q5OVKS5B9CSQ[UOE4#@J<XI&@2)5\':!7X7FE.4>KUXK"XZ)M@
MV;OD=2JKJB_16.YPBM*#[PG&#VH:1GFB/YB^@F-@1+V5'Z5D05)]*<EZ M&<
M?!DA[/O\ZYU%3562SVLWK\('LS]XCW.6C7>>T.$S/'"-_.I44&FY^SR$#6*#
M&%Z<"&[#O0:7V0/+,A@WG'*.4N6>W4UBO\,8K$%23?3WV[SZOG5+K^?2#$8Q
M+,3HS$C)2,A>4 "!A&+LWWF)V)GR@CC5IGF*$D:5]CW7AFO11Q0M,D&'C<C7
M4(3I#^WNRNG585_,Y3X23JG7ID7>3ATQ0Q-=6=O< %$H@IZ(A;.0=-K _$Y6
MXDD& QL1X.;Q4P.;2<G6UTK1B>RZT_9;[_*/!;M/AVCKJDH ;C Q@J-('$KS
M)'L$B)-"*8^=,]PAS_KP%77T,-F@S0\CPE^M$>J7V#'7W6&.M L4OPG8R_I]
MO7#!@+/$R.147__+GR([M7L\D[2>8SO&E=BB=81 O!=%64 />_Z]0&4KHQ>\
MZLH 0*M8'J#)O;K.6QC4_-2O.0GXT*0.-5N&9DA[3UD)!:^8N1$[URX!6+@H
M.?,[+-S7_=>MD5\W2\(IQ;2[DIE,$+EO8X4='12Z$<P8Y3'4@E^&?X0;^A8P
MM /U&>A9)NA[U\T"QI_W3&2VE9'$H30*!S1B.XC'T$2W8 K!9^4[UYHP?KI?
M+OV5_];7$JU#WE(- H+BY(]4]<4Q37>/^WZR7+N>B9_CO4\)#0T-:3K\_*5)
M&#3:Z$.6BO+&D\@8W9/168G:/M;Q=JKBV[$WTD-++F<G&/7;E^D?6)GU/:X:
MR?_V+33U&\L5K9.QHEBV1(Q1OV?[=:P+;7!9F[U1ZK).O]"K4*$;=YZ[J*?U
M=LJN*O9]^;;T^!LA!IJGB#V5?>+_JRW=/Q2ON !O?-)*#V[L,F=WV8V?04R>
M'X2^/R+0C;6(=!Y!3$H,,$'S-^N8H/KXVJA?]CXM=0@1.Q70\+AM(I0N*NIY
MWR'0GM<@@M ECL(NMPDDXDR;#0I1'4F5Z5581),^8(+O:8"5 N7 Q)@%0#.>
MLF*"</JP.$_3^3^6Y=U)L_^AM.X E*+KA=CFD4>L9&4PN"QAC"!V'/6G\VK1
MOZZWF_^??L[P#_6#(4.H[6! C#)!U%L;M_[9O ,3]#+!%)C2RYN,;7-:07H4
M)1BWP<T$Q2#(DXPZ1#^$ 66"L,A\Y!\;UZ&)5Z/I;/SHS=ZA&4L>1(LF$Y2+
MI,4R096<?ZA3?/M/C4/^:&>T]+\L8+R0\\_6>YB@ Z=13-#EH!7Z>OF6J>7*
M4LU.R=B)%2KG"-"8<>2)IPQ4<#+L(RQ.Q=6@@PGZZAP\!7.SXJ$'527"^'W<
M9B!:3- ?OQSU3S,7ALJL]2UW*]'3:5KY[51-WV458A9V']$UE[WT-#^=R\IY
M:^R_!XPPS14RI#V7[V5&?\2^846,%R)T_F10V#?)OP5..Z?/_]6,6P"\4'(!
M,\/Y^D?E:Z]]TI=4^K@XW3X,"*'QJ"W!#?EM)BB)";JB=!F=X0A P!/PTWX*
M+M=0B]?FMVLFFPDZJ*&5CR$.-??D!)T>/1WLL.?5797E6XEC?YK6X%\@Q72M
MZ 0=#T>M09XT,T&[Q<)6S_YY"OYQUI);UYWJ2C-,L?!^C6PS#<J %ZRM*]'W
M_O;.;O:?[^P._<T[N]5,$%&_SL>HG/ZL7FBD>3(I;\#3\6*<X"/<SUN>J*;0
MWUP+.4>",JZ^12P"3*[7!AXUB:1%.B-V7KK)NDH>N>!O5%5][22QJU^ZZU7<
M\*/ZV?)?KX3\Q\]O3E'\%4D> _W[TX;. N2AVY8R@@_ N.>(^?E%]$[,R>(D
M80"$T^&S98*.+^ F$J:[N[:![Z9"FW=GEI?5U'^PN&.AJ_B2Z\1K]K,@+@/6
MU+UT%AV8-HV#R/F<=F "?2! !]G 30EE@EKBL<UWG1Y;Z<57&S7N[3@ZPG=N
M]=0]_91=ZGZ"(JJOU 38- B6-9EE YGCA*P21-;PR+-&?6&+:'4)N_%JF:P>
MS4)XA<XW8^D?X^7%M1:JUX].=)Q0O[2]7H@,$3M*A+Y6NB9/.S)Q9/*'UB>+
M O'^F6J=! ^NA5Y:QWYIY1CW\+G$3<X7:"XFR 4=\J3B/9[CY )^I3G"\T2-
M?YBP0]FD:_C>?"9(.O=FZHNHI$C5W-8IF?O$!92LT6+W:0MO<ZF3XW7PU4^?
M]<Q"EQ,4D:[7U@(VW!WEK\P)Q>A;Y*;IOW;)-)ONCE]ZN6];;&.9L8?HUN06
M@JR(SZX']TU4$2.1[EYY[&;6]*_M!_U#\]=7OXZQ7J[U5/*9",8@A>#?P7RP
M2?G6I,\;G(=\BX23O/HX2O:OSQY1;R+>VQW$%L1Z8?6QMG-BD8O1$8\@F=Q&
M Q]O1_4:"7L_\22GQ?3Z:D^C3JEO>N?R/F9/"LMD#Y2[+K17?-Q8V 9K'->(
M/!&AKR B_2SFAIJ_'\'VS-T&4O6&+L]SR!ZK2:*+?#UWP"$2,#O BC-O"3#.
M7"!C;ZN]N%BBF<1>/RQQL2%(%F[9XOYLQ>26$<F4P$Z5]2UM@W&),[X/! CG
MCNAF+,9>3+</U=[M[.VUYW'N,>+C2R>P^7X%$:;+\G8Y BJ!;J<ME(1=5D[G
M+1-L/S;+&F76S7W#S\:5E;GYUZPLU\</PRPU#H7*C$+LQJ2;)Z_,0_AJM>QB
MG!C'!R?[ L"V:G,V-Z0Q'@&7EO+;%)D@Q]>-(XF$-GS\H1?)163]&D:Y6_J-
M#^^N*[2:W*Q+,!U&F$L,E$5Q%FV2+7>*I!-]Z,$$ *2D?0@W .CFG@)3#W71
M?J)+5F@?("_02Q @?*>9"(3BS-KG3 9GL\?JK#T>7I"_GW0Y>:53L?ZG&5T^
M/52&R+VY)XR>"9D>HP'(]\ *@(;,F*&U*%@/AG ,6%,K4S@JUP:4+AZ/_O"$
MCFJ*VKQN2LG84B#A>"#CGW"3";//0T^A!J&=T *T#>P'9C*Y+6X2' XI2VBI
M<5'&M%6H+5+TFQXY<.;>=3HSC+TK._0X>3Y^D;MH?6]Q=,9=T*%)_+@&18?8
M$'"3N/F4L3O@H9A2*8G=HEDLPVOR9UF5[++=AY:C\5*"6^ 3KMJVQ]H.7=J#
M@]P#0F?-W9(Z(FJ)0"J8J(_ =W,ZFIO4^$_*$(Q4"[U$E0_(GI[Y'(J=/7?@
MU8,8J8X*=B[.+ZGNX')4$^0E *H:1XA(<C[]@R?=HXD,.7RLOJ:26%_YY+1]
MS_+'T]917U\]2,L*ZMRG?4]WY -MQ'3Z$^5CH.RR9[%"W)P7^V,U-TJDC-:W
MQ'"O>H(>H>AVH'& \K[L&VR??;6_#_K,WC*_932VJM0E)U?BU*YI]T2R-8O^
ME FR0T;ED*\.(6Q?TXRM,\8L'%.D*2]\\ 6=@086[X]H+";Y6KN=5 I!=PKN
M56XZ,*<T@^:%L]'$__'TF#Q7@ 2%/GG#H@TN2%R*)*O!D7GL4EZG9H+LRM;L
M#-^U#7-_/75N_SV6)[9H@@)5F='/!(EZRH=J'J6_J=4JH-GVKSQ,8V!Z-:Y%
M.ZA]RQ&X-O4YA9O[AM",88KBO<QCHQA9C"2#S4<,1=5#-.I[,4&[ D3[8"U"
MI5WWTT::<TY!'&M?817?ZYR_&>,7VAK)W_G@&BAQNG,N-"O\E? 1PO%D0;6B
M6^@Z?I8NOLPMDY*!Q]F%MLL_!Z(BA;*YS,(AXHD%O#>T^3;-8V=BW.]V7YO?
M2O2IV2S_09%(@V/ E39B,A2M2<2PH:8 )4&/&+%</HGBFH=+U]:'*)6\.F.)
M>:3W]F%X>[.W@+C]'&IXKA51"GVQ<0%ZFYY1S^U<?S;DDD!/6>$)*\:WD/;/
M*PH=^3!7Y2FW"\Y833E*7P/B$Z*IRX=L1)'$LP>ZX2&O7>#-)&N,\HUWLH"'
MQR=*A%E+>+3TNG]^_KF[D[_#>&'&USXDZT[>C9M)=Q,^;'VLC(D-Z#'REUE"
MY9R=F34+"L[3/=\X&+1%$%@=(_#%S+C*^+B,E<]H E/\_!U-F&),E"%GUQ E
M&Y&L3-!]!\F+?6Y'^Q!EDM6K*<ZVT4R0GWI-I605)I5WC1X(4$\6P!]CNY",
M%CH0G*]EH!)/!RC@U2\<&FG9A(/KPZ[7QF64]=N4>3WW@=7F'1,V"Q=YZEM4
M^ZILP>:=8W_LX[<G"GQ<1FH&2A,TLH3\OAWGF7+(Z[SZ,09MFZ[3 V:K5X"W
M,DY6$7'-9HB)]^3MS9!RUM(^OJ4 B\&C+MH;'5JS?@[*;39OYIR(-9_.\P+=
M8Y$GZBQM$6O(A0-P7O@WL0-15WIH2M9NUOE:APH\?&,7+BK&?O9_+]J&.WM?
MYHW"@?-[/ZPCB/KH@_,I I0@?#>6BA%ZTIU*$R:6;7=@Y$>K!FQ-7K7A+KS_
M4".UU%,8,()'<CO#E4B:&5-@+ES=8%8!K,LO]V[[9G:*Z>GEP,ZSD CWR3.D
M.P2HK>KJK8C,9-UVU6[+K),)LD9/)$A;HKZU5U-T.9WW>_3']=U\:?Y2<?SL
MC37=\@($ZWOG20SM[0561K,)>EO5>?L6:K;TK[_I#C!CG.;N15 =-^OY$>R\
MBYSTSZ?20VDOZ6:,)_5'X7UH$9=:O\*12U.!>6*HQ[GHX0H,2*\!T:GVA0EZ
ME4D!$/?*$..6'((RX $^ I#LM$4<60@@1#U=9@-T+WV.8++A)E]G.B3.">\N
MUFM%'=NP3_VE\"7%"1J)6[^ F#D'Z+$(4V2/>: %!RUL61MQ!PA6ZM3A>3"Q
M'RF*GG_"!'78 CQ=*.,O-2WGU@TW'JJLRE>Q#KI#OC'(3UC_4B?SK[WUH_/\
MVS<N;7R KJ'K4IX!,*A+&F$$HVC9YDP0*1_RY\*;5@@ML$DSXCCU3: ]-VUE
MY>\,0V?@$^Y+_33X?W<4"!UTZ<;&8 Z1OU$H;KUF[C/Q59)L=QG'U\'BF$?G
M15(&AH;XJ2J W*JAL#-:ZN29(-WC1;WH&/<G#_(1KQGV&YK\=Q7_"](Z[D_2
M&O[_D+3^S4L(11GD-@ J[$EN=%])1F1D%>(O=WZ]P!4JM"1(&&*Q$;+NZ86+
M0WSI#:9, 1S[1!C0I6@O-Z+^JOTL'?CJ=\G)9["+\'8&'SU#49@*/D*[T.]J
M1R2G.?K(M0AY9XD49^(/F)Q59'FML\9[YH[?EM_Q>D0AC(52LM:H>2RJQ9NO
M1U_V)O1PY$/"<3.KX[Y'B2+1RRR/[,R<WM6*YUW&YF3&]?4-W,&A##"NL)"<
MH%;MS)4,"W4E5$;UZN+HAALV$2NG-]+HS9 HZ2$PCMX=&94,2^\-R+IX/5\N
M?-ST2TG<J(5()$582_(9VIYSA+5)4Z84RCF/S0XC.[^9,A1*E\N4/F2N;?NF
MX*3J4?M'7QJ_R;0Z-0YL6-O2WWGI1Y4BNM$I(Y"5#_A/D7NX]0\(\<P).\,=
M*LI=YJOB8NIB?'H[MH4U7,6*I ;S!&'ZC]LETRM0<6,UEN4NKDN!W,XDR*1W
M%-7/"3L;EV?>.-EUKSU[=(%O:>]Q79<XL9LZPM>G)+8?6YS/1^]F[/&=FY!O
M_:DI'7"G3SMI$K>_V>/1=L;7%,LU@>3CUP[!'\\\ P4>.K"[WC<OI]^+O<!A
M:=EM-D8 T=^R&I.WSOJ,8J+0/IOG+VTL)WA9<<;+N]^U*'D@Z48.8"W'HIZN
M>PM4O;<KI[J^*7OKUJ@KV7LF0G.,AZ#Z%,Y\^'?SJ-<;=)^)BEAZ^J94#:QW
M_'SV*[R4Z"<Q0>C*/EW!/2<D4R4UHTD0C)4F!4'5<(9S4\KY$C(7K:3CQSGX
MF]2T/IXYF>PHDF)3*<^C(?6&ACXK^^C"?K"2^;CECV^G'Q9EOM*BEER=,8,?
MC\'C\<MVGZN3IZ._6>D*E)[=E"QT#.E("VEMRWSK=RNL5W.SQBY!B5Q-\'<L
M3C[XS2Q )D?,U2Z14H?S1WB/C'P;ZL<-U M0D-H4]ZP HUJ^G>+Z7:.#@[8G
MOR;AQ95G,'M>1#H/R]:KTO92DDANS2I#R'WE!?XU_F.:F&MFM7HL=6_=OX1Q
M?7P@7\WY5=M/?*TK8$W+\\$Y"GYHQ68K02G15=GH9\;0U;J (NLKHK*R:"]>
M^T[/WCCL8GZ?Q;;?CPW8R'%@T0XA1;V^:"A-+A:H?U92'3))\<<IN6:-GIFO
MT8E7(\6:[=22^ -]-F7Y)3&2?%>MR:8O/7GKW@". O.GCRF?CO,)[9HT+O"X
MH1XPE$,3[>[=49%[(*[GT=@KC!LX#)HLL8#<UI5#G-^@B\!_DY?%T@"(\&Q%
MA$)B(:*D*_1%#H8@W $(2W0;6MDV)_G6/\JW.%,X?+)\(6:4%Q[N$UVG.V_J
M7S@^I56*5H[I=#D?UJYRI/1JO7_&&6U01,.KO7FK4>$(4?AI^'=-:9@0S9HT
MMER7BW']=$FNQUC?]Y*X%H\#[_&+NNJ&MVUB(YUCTS\[VGYF$ZAZX-@7^B$N
M25>RQLW":GE[LZ]XQ/0LQJ0)PZ$6\RBRO=(E!DLNJ4@NUWP!)MZ&C)P&'T1R
M_D0?]NQDCR_F<T/]'.?_5-G_==?EO=3KCX)OE>VJ/4RS]_9#G:9(42\%P.C)
MC./RK5$O&&==9%ID]O9PZ.F?.OTN,X/+UO5(?^R"=N!B1'JHGY6%]H>?3>$\
M]B0)7D<_)1?36+;W\=8FF=(&91_2B/7V7K/)ZW"';2XJ@PU)]7 RZ3.WHEGV
M6:F'#)\$$Y\[//UT_\67TB^+0X5^.0THK,X4>&FHR(H2-=$=*K=>TZ7]W<*R
MTSU]>#PXY,R]W6-:QU%'17)9<;S-AGHIQG&]6=(WTU@$ W2UI=1=O)S5_2*S
M[=\;%PC%HE1.+8UF8NO)/M7H: )$$#V1!BO'$5@GDKJ#$?SUIT:<M@U2[U/O
M@HEACO&KD+CC[6(2SX?%;PKR3)SY=N;Q =Z&1:2(YBG?V$FQ8**,.0F2/ GC
MP(U:.52;_DB%E7:KGC1=,]X;];EX\MVS%%"146BU*GP/!PN;HC4/\IR>E(2,
M^4*GCHM\7=GQ"HAH2%*R>4FL4U>5,K9N:9E<7X'=3K:+)C7C(U\0$2:4 QF4
MC"4&SY#7-2\.:_W(#I#K\O$]G?+*W8KYA+TZ:#MM[[G$Z?GTZOMZ<2J2^[-\
M?&QKL"LU)>9;(FMY1NEZ-VID9-8MAKW-2^W_UWP*H_$??&H;%X1K:MW)3+GN
MG%X\!C&!)':',$&K-S=6J!R6B/G9CT[#E"@F2(+3"HB/ T.,2*<VU!(;I"DJ
M'1*;SP3Q67T$7/[[T_2<_K(N?>WZ!/V!]2V"ZSV74HO1%NL8A?F.AL/P<A;Q
M/M.+?09?3Z5G!QOTGY:SK:\L3KQV#)-\[JJ>3DI2R 1<<43_D6Y=B,,?+NDR
M(B%V3-"6"F(7XD="%A!,Q8VQIK]C$F](B!4O",!>%+9+V1F+4)K,*AL#CIY(
M1ZP&X'@A2YYU3-#WQ6T6U-PB@TT2 (8NTBT&1A]'/X36(Z(8V@, QC!!E2?6
MNKD1TZ97: BJL\8#0""/1K4^_]U5GM^=$V_4^Z_ES[;W 1]HXARY_)L/</[R
M=A* 6J?LPQ&3('IXK?\4Y])*.3U8/X+1->?GO^;.->5]2&U;*.L7[I$/(QJ#
MMW3F6G#4W< ,9]TTS8EIU5=MUEI:N+*30TO^H(N1:M%U38/0)9 Q2.(8>$,?
MO0IT#[MS 7^>"<JW9(+BT(P>&*0'UH\<_@&9H<&VD%T0[/GN61K_%O@BHMD3
M,7 :((HX)L@A@R&<P<CS89@P052M ";HUD^L75;!6!B')#1EP=O$]M7X\>7+
M>7;G;QKL?@Y-W4O.7*5QF;H#+3[_>K9P6)\(F_;OIJGHT(U6:(4 FPN%3%9#
M%A(0,P"FEYEV;ZC]?))D)FKL^;,KOV*PZG!E/&?VDK6B!GIO911^)]-]IJTN
MBR*_>F'NC]T _V%0,G/;'QS_HXW<P.SIR^-F;C=^M 7F^L$/N($!LO=.MEF(
MG#"!_K*)I+A&;6?AMBR8( +/GT:)VA4J)1E]_Y6RCS=;2(;$ZWG0"K2VI+9O
M6:C[9EG\@5LKK8JV=^"IJU),D/T$RA6VTRRZ[&P%6F6G7?2_;A<YGT%59Z6A
MPYB@,XR>-L3.WV_O^>-@GB0LZ5/O(YKLJ18T#6(.309=BG#PS1[D+$,XKZQN
M:BI4M@MNVYBVEB\Q042#[BU-MR $6>T.8MZK,7'B3'3'8CFX^#1J"_9^+-Z:
M]/AKKJ1\I5C85D(T?7>/%B^M"''] ^S7]!&P"ATY@44HQ@3]2,A'_!0OITT-
M$> \B.H'Z%9P.S*2DL;8>,4$'40K[FP6EL#-?U=>^2'M/.":P:E (TX Y=:1
M0^AYT08#?OTEI3L,W-KT!,H$N4"LB#44,Y09@M"H]6_9_+4[)#!#3PQ8SO<+
M4'21@0@+R"]J[ID.Q7!=9]4+AN\<" KDI_+1]E'<IF O(3P0!TZQ ,7^  2D
MF>JB0E5I>&*7IH0>$5JPUZE*+L0D3S?EFH604A[?/CCT+6X)5R+9#,6.M)AG
MIY%8R9"AHM2A=;M(X8(+W"V&YD[GFH_:=32L'JL*.[5'.KAQ)&[EKB!&A1Q0
M:'QK4'/-57JTXV?['<Q[_TKS@C'1K1OU=<)]7HI/)+Z2O9WD=3KHBQ=$/W[#
M,-B42,(3J!#&6=_*ID36)8+;Y J?&25#Q4JZF"0Q6A (BGB!D<ALC18I#@^^
M_/F'=M^'J#2$/8*',5!M3^-&3RI'4,5I[D3,2R]5K[K \G?E=.L;%<Z9*B\O
M%A?BBZT_ZV^R]J_G(2;2AS2E:RD2)$,FZ*$<N/G[XDU*T@WHLR$WCLPGT\0M
M],^TVJAQI=R7X,2;YS!YFE::.D0HC1M#;J<D3-3QXR6;T<_YMV=?X]D1*M?[
M%4=J_(XD^%T6\7O:<D5J[WFK]S^[ EX)WE,0"7WIW!]TOB]Q,(/\)HGL+ZE<
M5$>H_YK>:WYW^^,5C.W6F./-E]D+6C]9EN9X"6JYDO;+*^0,\9'!5ARV6YM>
MO//PKJ,5"[W$#B!O+P=G9-=K9)(*]&UURF*\CVC<<"K@Z5F)@29[?+O]H8CU
M,V,06;'2"OLQ1<YV&^XC>U17]L!% \[S/7$@)OYHNC<8',T]5C<[?=+T??+
MAP\3^P0>Z,XQ06X(OLI&!">\&\Q*NX)WEG/#2S8E'W>LM2(G=+J3=9QS3Y9_
M\KO]QHKG]9NG!KOV/FI69X+*<4M72/YD-!W0G).I$/L+Q[Q6@M'<+/%9+O@O
MK@^HRC'9^WMG7-OOW?=]+_I^_[<S&;)L$<<L=H5$ I-Y65%5.K/0*:##4,\0
MJM6U=X:E+JETX>I/ZUQ];I&#.=*CZTD^=?KG*_!87+R+MIMSEH=U,V(_C96J
M"00E]P!(AN])K*A\,[]/L'G?T8=:O)G\:K=+U0X20TH$0:*\%T7ST&7!H>B)
M(@#@]M?>SU] "GDB!"A'"D\7UD+=)F6Z^&_ZRPCND7D]. Y1XK]_[+U'V6Y=
MD%UM);FK#)"T;F#**<X0FCSUS!T=O'C)IRB#[WSJE S^[S_,\_5([2>DS\N6
ME$S0%I\KO)'I^;=+8CH8MQ^5>*M*JCYC0%,PH5$,U!,@EVOA_,@YH5C;:S">
MJ_@'9O_C/@7-P3T"$B"1-S(Q95(WFVZV/9 P\ WIR:Y+OI9G<,.RR*+>5DK%
M.9,^4_1U(4.MO-CXDZ]O?\0!XUQZENKY1DF;K8\?IWA0=H-15R86MKG)N^D%
M<.F 0Y2<250P^%#J]\)4DGRDXH^-"P:+EY[CJ>TQONF^&8G&UD*\DLM/+XD_
MY_#+:0+4RB*>OQ4'\AW!F[XT:?E9OZOO&'JH:^!;^UZC&NDMYQ>U,X>TM7QP
MGTR7&DE34VYM;AP!%RD6Q.4YTQZ:W-0-:1?XMO [PX??[XJ__!0]D#2M#3EU
M06;)PZG*Y6Y][5FNL'#CK*\#L4XD@VW+,:6%J-B./#O%XG7[X/"WF>LS!@1)
M>V=G%U&&K3SEU! -"6V%4$5<=W+_)//MA!T:?([F2?&B7O/%3>5$:(J-FOE"
M6^J54BYPWHF9Y=//]O([S&)Z^EQTU=;;0.R64\%QE'8]]/+MS,RWQ\L<%]*+
MRA:JHY,-"Z\HHX2BW5T?/REP&"D=RIA'Z(!+$;0D]%/TDGXO\+48:8),&!T@
M*=-C-):=S8($)B@SVM01UGD>O5F-Q"/>T\\&,4%>.0S>K;]?-SCKSWN0<_\7
MWU#XST[\.270>'48AELD%4;#)X 2W>;U^64?\C9Z(A\"<+G7:#)+,$"+4E&F
M)YB@Z'%^1OT_6-+[9,07)#!\*P ^,DN)1@!O6UC;\I59!L(6=:*R*>H%X@!#
MD.972Y'QF4JVQU2(2<5084FWJ\(,B-/>\0F&89?C9Z[HJ\D\[_W4(/?)QB;@
M&.PAT%%%ABA\C,$QJ(@0I7$.N2W7<A8Y5B>W$K*#42.C(\V^%3Y2^ZM+[4]*
M!:P'LTP)/S.X]@65A$_Z6(AV2BVO?NQ^:]-V>4WN5EUF?&5Y8JG]=V('5$%_
M6+5.MO]V5> \=11UHPC5NVGP$WR&9DJ)(B);QE5Z:V%$CPE;]/-"@AS>F<Y1
MWAEA,(C_*6%W3NHS'=_667S=-FDY1GBV85N=#,SM\U#&.%H(X1BUGZ;1%V#L
M5O S<;"2):+[^5'B1KJC2T[I,PUM\;#IU_?']><>Y\?H-GX$:&K1VW'),HIN
M)J7S$K$+C;FA]VT5_%I9DX\JZ]1[H?<DDASM&A!7[="YTOCERS?^>V(C".H!
M^ "N>+,11C'!E>0T6N .!UPAO8JMQ""X"$6$#$OI808Y(7NKI*#(G=I.9'>/
M] ZI_>"M+ED8;V@\R>FHZ=N,U=6545==ZS05Y0ZC9%:YU*=DL[,D&7[-K^9&
MBJO:0NSY^99C;TY'AIJ7#?8$#(W 1"D^5(4 -LHPX-F.0YJ'*08=4O6B/^$2
M_6[+LHJC98]'S$_HD8OW+@I?K[_)!I_<@NJMHT(!BD'CS6:";I#$TB;&+)H3
M38)R?MY2PC5QLH__Y!YU,+\B!3MYX\*>:\IM#6(ENWU!X9S\]*<:A@CJ06"^
MKY;=.$$.+A83<?8[V4.[*F\7'K;'RXV:XV-T^Y3WRU)[MJS7&D+K@%-MDJ_2
M<]!VL!%WA ,RRK#^V03NP*B36L+K  0B%T.6T\->.[D+_^8L]5)RIA&/;;WK
MQ?NATU^Q:2&/\]2\3AB$BT(<JN@9=X>F!T=[RUQ[8P>5^W0&XG,L#F48<+_,
M,7?**0VH[]*T\' DMJV6N,A)!'H#B]A:SGQSPF?I LF'_)%BF6.ATL(A:=Z[
M;JEN$3,@F7"Q^//]V=&K1?NUWU0FU$:>.3LJ^F5CY36XDI_&'84W;85%W0(4
MI&_4I$E53O>D&_^8N7:"T8C!Y.DEJ]LW;2)XXV\*BRN@SK=IK)"O#**="3KX
MJ$@:E'K$5W&A0L5_I,6*-W%P<!8[!TUTU,B=+?M B#.5>/PT;E3[HC72BY[&
M.!O@1#E!/>A;,YE#4'"9Q''X5N(O=,4A7S($*-8&9:5AE_J.)757H>/'AV8B
M<A[JK,7,.4T%W:NQGCQOAZRY&><XD"6^A?;?3_W0,U/>?_MVTH!._(V5>C/!
M)C][=+>089:1W&/&LM%FE6V7OZKJ^:R,A'.6RC0JJ@8]D0@I=VN%"OT<EZ,G
M+T]\_U@KGT'C&Q+7#U2X]%QP.3N4QSC>KVDK1E.T= WD\67"M-U*@IY2?\SW
MU@0$8,4.7<8/$9,B)),<K_M9 LL^T-F14MFD/O"IC@\B'X8& 3B$#'.3(X)O
MD23;5.'\8YP'@1!WNNI^JA/:Z87M3$LCU_F!@*Z..]&OS'9A3M99 4YOTNYD
M\#%]R\*PQOR&NB**'(=,[%\[[QIIJW\^A\T]IMK !#KA]+,F,,%KIIB8[ ^A
M<9<RH$F3,'ID/&Q;U!TB7 ^BP>@?-&#\3QG*OB<#]YBF-,H_*/F<(B68ZN-I
M^M6@F27#/7QNIFB$<6!X1RP#$AFC+T\_5/>PK5!Z2\GI[706OX&)XQC$:ZEG
M9F8]_WO7?%\>OZ!4V\\"I16Y/DBJ^:ET=&SW O=_RQ;U[P0R!S(8O'IS'4SE
M, =BU SJIP$ZL?N77PF2K"F?H;J TLI9'/_KMI&S)@#R[5>&T$M*7DQ01F)Q
M@3T>0GM[P9_1; K;5BT00G\"1#";9@C#H(!VY\FG]%"9RX>B\"LMA:93G"V%
M]GCOJOMNSCZ%5L*O"005/X>674&CNAC1+IN?5A(DL2">BFW)$/F'4^\>V)37
M^+:\R/G*$\Y0T@O]QI/7E)C#NYP98Z5OK6N<IQ:9\:3.8F.WKNK)0O/%ZK'X
M9.5H^X^65QP?>[@[\S;+/D:2WXJH3!D[%#@JY1TH_U3<+FXD6ZQJ8L16\N&P
MCKO)!N*([XN6?<I#Y2.=?6R$D+$QC236U%$#EEOIP0*5_BQ8$[93Z>]VLAB<
M\U-DMYVC6T1^^NLG,$:,EF66.^(7JK#%R<_8O$6#KD$*SJ"7RYB@)O31W^1-
M4LU_3;"LH]B V.L"HX&ICR$:0,C5\H3LE+0J;=M)BGZAF?WV^?C?%9[E08VC
M*1(^M(RUR03Z,SL@2N<MKLGS *WKZC#JY>DG=>89@DS0E]E*NC]B^S8TU>'7
M$F__\?-+?7PC(+#E J(;HGD2 %L^,%WZ>6D]!-$H![$'8V7PQD.M8#[?J+9J
M8\+H61TYY*M:+;+ZI6+WJ@='W@AL6(_&/$G$ SK@"ZS$C<[C%HJ@6( 92I9F
M(M#^XK)B/K1XAHR+OR(AT,5?Y,<H9.B,URFK49)[/;G:B0SA<T!AW2B/^9<
M-J8EC$<R^ #S1 "B[-!E>BQB/B,  -&F'SN[>G1KQO%N^B4F: ;*F(4#YCE<
MR4AG@E:1 ,K"98=TB$B\20$Q"G/8=^7JI\JJSY6EM95FKI4/9=R=Y4JYRUZ\
M*2D6V=A3#F]D@IK?H&UPVZ=P@/6(%9"=_;^_=N#V;9()K^-G*(OG ')%#4)]
M5 T7^/:V?RJ\U&!Q,]"47@^7[8&5X8C3\L,JC%"55@A-+NH?VX(B053 A#W:
M%("M!>W4@C1&D/@0"YQ,D#1B\QP$S\<$]<,8MW9.=[8F5GJ@G!,2'ZI=F"WU
MD4NN^LI7<E=!!YA$6]T&FLR&RE0EC<N9_)CB3SHQF1-4!A&C:?N[\?HF+RF=
MK";YJV=>YIIHNVKM;.-U="@'\=<QQ9+N7R#"MH O547X6@W^Z*8!/1I!A@MY
MY^0Y;#KG.@J%DTMS1E.P=CJP#*F]M]S<W+QD\N3+A:M<)>,J]15[^7TT,U-T
M45CPWYH="%Y6!K< X,Q0-V,63&(?*]SX]R^&*9H25&BJ[.0;3%!Z! G*!+%;
M_]N^;O Q>#MZW;!>"O"=APC* (02!ME@98+B(-1WZ#];BHR@2-K3D"I-:*JH
M+'I=C0[Y]=_!?YV-H@!8*,R\J3]C0]]#JX!ZHZ@0\13'/IDS4'Q[,="55F(P
MWNT/:%E5LA(OJ?MO]1"N!\\.E*!>0[374#89+75 [W0E4'-B:$?T7[Q?Y]?V
M"@B^M\(A Z%*]Y<NY*A#\3/E*/HPS&/J<\9+)FA0KRR'4(<\[CPY6T>@S_R@
MW4G_>XTN(O"R@*7 C-M,T+)])Z)%C@G*1?]730_^IY.>88)"+)@@0\06\/>5
M_V*!FK)3;R :CT'LD$'@71JW2/S-5A!*K 0C.JN,G.<_Q>?[_L6NM5/A7*H;
M/(@60%+D0FA M!MM9AQSHVL!2QC"&*7%IJ-M:("(V&M&CRM?V><H-+/2 @UE
M5UI^[Z91P!^Q_V:W4''#ZF=!I9S?^]O_'/7]OV#!WUR9M_]ES_ZF[0$[AI0R
M03<1_UAEP;3+N.TP $01]"K*#'&*H2?V8B<I!Z.+E-.EAC"0OP,6I ]W6A&+
M5^<[?U A]EWD*I0_PENYO+8;-0D78(),TDPTA[ >(TNKV"'&6OW<CW[3O]?L
M*NL ,A+VU[P@]<;O#/N7<<,^76F%7SM%A[IM^S%!6'!L9Q/#464#B&X_<?\5
M:QO#_H"#B#^O;AERTN^FYU>8_B<^_-7/%^T)2H KO:0GPGD"]I*@+3 .7R8(
M?SUA6SN^#YNU$GX';W>0]6OZF6MS_:;0"23E.&:I$.6K<&U('GX\X.8=E&>G
MWXQ9K</E5[X#D:QQ#>T9?X@V )XA%N29(&"UD.>F;'G_EN%T:%K(;< #.I#T
MKY#_]O'^GZYKS9C?Y3]$_DYL-)U6RO<W+TDN],:-PPOUQ#K>WA^6V 1;F_XN
M*0+T]^\XQWJM3 MZX=OI+(0M036CT]75PBF9'+U6"VU&+XKQ\02B2F?B5CJ[
M N7&P']_\('=?Y@""IH2A-[@9X+>,D%4#Y)=*#W[;X20?^D%^*[_<R_8L"8#
MO7]^ _X-)L 0QE%R6JTN4")XN]"O-X3W#S:W$H0$TMZE<QVTGVV8GDM<7_E=
M(#YBST@%@ \PI ?G_VL#_'7WKW;Q[_A]O77HYQ&Z7>,5S@V$?>=IY[4U3Z?!
MF2B/>8K]"_3 5QN2& Z9J%$Q,[.0O/*5"K8VA,G1)(!/Z<"[$/OJ)>:1O!KR
M4ZB02J'(%[D2,Q^$$L+"*U:.BSP[[F?]9#M\#69DV@1V_4\?OS25)R5-F3;!
MAG&3*86DA"EDRPW)IA3>[X4TNH7EX H?N[^GN/1,4H$"K[%AO)VM\=XW,C,P
M$!/4V+CS- IGB.;I7@TI5H*H?[H67B;-;;+[L"^Z =L6D>D4P_WT>'U=>22(
M\\'RT^WOK-C;IDGP 7#YYM((E8MV(F&JDJ!/LFIN$N,-75:'$2R^V"5U?7ZC
M('ZV=;=&S)=&D9=:#RZGG$<)T=\A)BH01&"&L%-3+,@&SB"(Z.E"#?O\RWT.
M<#&2S\L-.:Y <R6CUL(;&[6ZJ@W6Q0)5;!C778J["&@!QL$%!'> _P0G_X_%
MF^:8B97#]1D>!WN*G8/.\OS(]%15G:W;%SJYCL)")MHJJ5><P279"5/R*A@L
M9Q!!0ZO  3(\)#/M6*F@NU=A:_8LNVN,%/^#*O=*B8M'WQS"AU(2V@ KN(-I
M7%<:K,[T!TCDPWN'AJ+G$\/,%K'DB E1ITV]OM.\%3SQJ^S:P:\FXNP,4VX$
MWG$DK4UD,4$-9'K61TTI!P\:!'I(%X4.O]=ON$[*PK ;;,(?J0=D1=SIM =)
M=>N!%G-120B;;HH,AL:-)/^D#!7 N\$E]@1YZRD8WWSBP>K!K/LY#N;ACS#6
M(L2+:W+]@^UN1[E&&VJ,M*W11P\+1&7F_J6B:3<)%DJ3GX >=!)3(J%#ECP#
MA75+XM>,![S4RYYCOXTKR8OW?IF6=<AGYWL  L5>%.(Q;3D+3'HKDGAM6.F9
M*\+Q@I:B2;]F4[UR["2CHGI7U5BI/?E9Z>K9FB@%GP2<MRHJCR$![T7L@A\.
M.%!+SX$?IYGV>*X$#PI=-T_&A#%^2!0K/UXZ<CU&Z_.U2)L;02INXS4>T1=%
MZ]QQ9?S-ZBOA:!::%A%]O1]?\GEP?;8B=,%3-CKF4ON>F/.H]YJ'@:XT@(EZ
MB @$=QGTY<Z)N.4R^I56?F>727T<#T7&M&=)*<\LZ'9E35UY*)=9')O@VV);
M]IB+J-)3>R!-YHKU(L3L]Y,_9^^(-4-?C4U?>CISPEC<7\0DZ!'C)#V#<=!7
M?:H["&T'.4+I7!H_3\J.RG6J%^R!E!;!"/'QFJ;8S+5XA8/^&O,,4R^[L=57
MC9AN2!F8QF_/.!!%5:"9#6GN#[A*6<FSI"0UE;ZKO9-#L6[ UG^L/@;V)QAA
MS=M%?.=D/G]J_)+*B<HMDB3[ I_<!Q^$'/!$1>)*HUH(\JT,KL'H).A@V?LP
M[1F#(6V37?AH,UZ',>/^\#/[ZKTH<4#XV7G*YT[ 24II/NTH*8H@K344O!&=
MZ9M@U4>3R1MW2%3:>H2TJ^Y/K? WNZO*-AR[_[%('BL(?,_PIN.3[/=%CO';
M@V&YC7[V?KNACC[.Y]IY2&JO3+6-KDCM/7RI<>^16]__F5SG;:=Y4L:((V07
MRB4\. HL4!Y6J-XTSML'NSFT(2PGM'+37_\VYKU*M"-/J5KJUKM\Y8&#&+;,
MIX=*0ALH%B2=R<VV[E=8_C;.($W9LB$-!;R+-(?^Y4'9N^^*"'8725^J0.%Y
M(H?WJ^[=O1\54PO$.%9.1".XEE5!/H0)<A9.XR3'$<+YR1". %T?1Q^ES/KK
ML^-X#E7\YPB;CJUB];86T8\_4CG+3Z%> -1A8A9'.:XT<JT"76$\_4I2ZE34
M)#0TLDWT]I3^!-4TE;;S.N<4HO$,Q+Y0I[%:IQ6%5=LTJ*$\(U*A)/3+0A>X
M*.4Y69^PC_)%SHT-^^/:_?$'CQXDV.15SFE]^<+Z'?*_\L^BX'_M8*;/X1U@
MHDDW11),J,/W$:ED6_K' !4\^$@(]BIQH..N8_6'_ R/MV7UH8+3;*HNN=Z1
M!BR!_!=9>)LQ5!V:0!(Y)HE\-:KM#B78;<*W]KY*,+JT"&[)I]\N&[/8O4I[
MD122K%$L^4YY6:KL%>0L#0#-%R_1$[%H-@W_CS1-$B=!--<*.EFH;<')LV#.
M^;2\4 ?:4W0B,#*!WX0<=5AZF-59^8Q'*(AJ%#I%DZ1>##A"PC4*(!PA^VBW
MOV] 0*,.CYV/^%9WW]0I5CZ;H1'[_E+#[=N!PXU&X0*[]XN=I<HC&@&),I&$
MJ$C .*.&"\@6]%Q%)DB0TM%]+>D6TJ!W_<+52^1K*8HQ6C4QPRY(#NF#LD&1
M2T\O*NY:K_OC<5I>_99$1O(D]!# %4PM8AVSA_6]/&4_VE:_PPCQNYT6,)Y^
M3SQT(N+.CPGIF(M%$,",N9I[X$#89EF/PO*3G2AASG@DZV**0U^YO[-?ZFC/
MM9YK43SS,4T+\QU&5TT$IA^?VE.77J]+ 9@]2^_.2F)\JS]/ C>CPR!E_>0G
MR)>UE^A!>.YLRAY8?V&ATMG#<4N,/EMK6<YS4EL]HN'V,X&%K8\ 5M+8A29>
M=72U*0TC=]0ZIH,ZN6A2)$,;UFP=LI6VPYX5-9EIM!BBT0,RD0 [R. ,.$_9
MF()B]9;[FG#\AXHTQ6 ZQ,T6[LX"T=.3+JAB%]X74,XXF7S&MN+XH>G1*B4?
ML@_0N6%$HRS:"1'BC3Z@R<'XD0)&MO*OA7CNE-!] :W_OB(O(;G[U(/^B4I'
M&\GTH[+^;""RVS!JXEL.4:'!M/[P@%>N_'0UB8.<7FK1UI%?VG'W).>C0QQ/
M.'B;*3AR%.4L<6K*[1G"'B((P!W\'"7!K0 ZD2Q,59N%$@36OSQ(I&P5M_5<
MF<%HW'AMR;[<Y'KTZ:Y10Y@XHQ="O NCG*Q<0I%\3"GL))6I5UE>>(!*Q>U<
MB[Q"K'SNY7)_/<CFD-#,$B$S4O[MB[**"4Z]3<0PDIQ%3V&"'D:]] :+,D%V
M\J';IN&U4GD*616%6==^W.$7GHQ781?G*M*>SS3V&CV7<?RI^K;,-"0<0;2,
MHDBL-$2%57<W(D+ 93891L2VS&J?L/(+)YK,L].R'/@?CNSE3R!7]%HT'D5$
MOT4O_SA,W7]^N[F9<?1[@$6J&:6@"3N0G97MY.UN^;,Z(JBIBZ6?ZZCO3.15
M"4O!:[;WKAU]KO:=I>/OO)BI #C[1Z%]251 G#=:(ZPY?RC@6TM@ 0J?$5R^
MBRTI(C5;A5Z+!.7V\3:I#(AL.W?+3,8]XQB_/;LY H>HM^%?P?O1SMW#F%9$
MJ62;/-NPDY@023M8&7FAEKS0-!!ZA'='MYO*RE=<&WMD&'WM:.C6(H,-0]U'
M\Z*GE:\$@2M,ETR+YLE@44T0Y=7<;:(+,L3&89T).OS#4KO824BK)>R%0(HX
M6XD]>\+=U+=?D.?@XS"B&8QRRN ]<>0B/7YCA2(9GT55HV"F3J<'"-J2G/%N
M$4O+M7*3!9WO.C3R?'(^IM]1CE^]_ORHF5MSR)C#GA_HB5'PZR<Y!$M @SZD
MR.,1D8EWQ8X-!(!] K-_FL>7.U4>0@YO)O -^AQ1?!H7H_[@TX%=8R]=_92^
M(!IO;T Y&3@T\>;*<!_Y #U),=<K2H0F0JG,"KA.R9E*XCV8LKOGX6I3AWX0
M-4'E:\]2Y3=H+'<)H1F5'G"+GH!^B*:<[*8=&6E&%Z-I7-R3Y>A(^ D'\P!S
MN92</*=X-;]RY_B4P"L6QG4IY\UAFKI"Y\TO\^9<OAHF:++*!%%.1@33>/:0
M.2D^&;0#Q&[:X<[6L\HU11A_D@P^'DW5HIALWA[<.# -=AZ4U]/K'3T_NGQ\
M[YO4X].K%R'0@A8-*:H0H T 'L3"3D(09@ Y!NX&'!TU"8^; )K70A23Z0E+
MI@DJ$"<J](//"E4;)]]A6:-05_J,L'Z3M1M9F4!0IYY&-&I K,><6W'<-,%L
MW;2[(^T9OFZ3;7%9VK!6M8C>ZM9,<^SQ(S*C9VUM]U\T6FYVL+9R!XQ]@1X*
M/PYO1Q)UHX*9H!(<X4HJ=M1I2,T56'(0-EA;I?+@82=3'WY)_6CPX\_7EI7U
M@A\G.&K?\8,<I5QI A/O!"+(]$&(&^<(*V/_8D$ =%!#U>M"0@/NT)T /V)A
MY.L)%Z7(P<^OQBW>"P5>OK?+/P?;G)[_- S\$]7(&<8$E44!*LK>&?4:)X"P
MD>D&^:X*R*?@)B,P$>L$O3OC1W'VT$IL<04,PO[<X 1NS5-Q%PGUE*8PB09T
M?6-O8G!PK<0D550>6DE_$>>RY+EX];E ,$V"2,Q]*AV5BNK!TMZ4U )8UV6.
M:#1?@4QD [U,^Z@4,=2PBSCAJ\,08FV".W4HO>V'CY"CRB:*N#M7R?:2ZC6F
M"YLO-F[X6Q#C$PI]"YHYTYT2$CVY%\QE$Z)'E8*:VPHEJN(A,4;A>FZPN(KI
M1PY[M/]TF%,%/8$?*=3'NP91S_V/]LX]&JK___=3*H24>V[3A22D<DMDE(H(
ME4(&T\4UE^F&D3$[<K]3$<I4B(AQ5\@TKD7R";D,FAE#P@Q[4F/77)SM^SUK
MG=_YG=\ZZZSS]^^/M[5FK;'?K_V^O%[/Q^SW?KV$[2-_*_IR8BQ,A0-NF^YS
M-E94*N^.*++>D66WJ^>8^K6Z0+/%V,B%7W&M[K"AC0 %A8=Y<J.8(+=N%2'.
MU^5,J\M"^2",Z,I JH4<[N6,>%R[9[6/GSG[66,68U+IWKCX:6-R]M9[$>Q^
M2GI,&%$<2=?L;S\JWK+UKQ;7#&<S=Q/P!7S_$%S&"/V-EY-]>VN5NN7_P'"Y
M:6GN;@1?5/ "N-RO/*J5R)<%=;@%'/V8%D7LE-+&Z=/%:(^B87#;WLM=VE^^
M;Q ,9]ITK7N-I98+)=9*P>L(4@&?7",8H4R$XEJED%-G=5]0X23?*J=K.*=5
MM.K=FYN2=Q\.4+<'7ZW]=B).Z^PIY]U[?20C [@G!)EDOR5H#Y$O$]'!I=4\
M;4WD=#.74K1:./7<%R$XO;I^.5S^!5Q*SFGS@9,J:&O%[!Z[[EF]UF,IO;$(
M!D"'M0UTC5L&63T#*#L($KCK_9U$%<+^A;\>WQ.]5:]:T9_N&^":+N*M0A?Z
MBNQ4;UE6//+?,+ OOEU;@/QB^.=.JL*@+?%L-IL=="UQL<0T/*ET(QSF<4RM
MB9%I(E^VI)T&7EP:#3O%079(JP$4&?.+G-U,DPX/RWF4'$%W 0/SP>Z68=_^
MC]C-X7U<]%X7<?FFAJ\21$MR19[\]^)2O^RPOY_3J)'3W.J/89<'7[^D.I]U
MV[7PLW7 =E%5U>NL:"K^##QZC*O";X $$-0/N:ZN%;Z+#8"W_%8_#)@"7/M#
MI**H<4-_:/[+.1]_MO:MF#?2R$O[3>>$9GP?P1, ED31ZGJ"%X3]\WDF]_&:
M1>(A6)GKYZ@:&/\WF??TZA$!R;E/RO8B6M)Z"C62?B7Q'PBJ+)0 RB4A"J#8
M3D,D3J-0W/\5W@-2 TO<#/#;0/5''&+[78><4DQ7AU:"T>'*Q3.-3LS'E[,,
M7:TNO[*XDB'R#.[3#Y)FQK/6TJSG"LJ!()W^^!7DEOT66@'J9E MR&1,?_ES
M"(=V>. 0?N=7U@Y$G//6W0\1&X\I;KY5OD #K3%C+@SI1!0]FBPI7!]@H5)#
M/ %E@@5HHGQ%QSY:,-$Y[72E=VZ")LV ?O#C>D.1=:>.#M)]DP@HX1AR/3Z(
MCAKWY>XB0P?5ZP-N/S>)7Q3N\+_+F\\+Z7N5YI\==#1WURK"=:Y>&&SPST@[
ML'X5P5A&59%9Y\)A>VM!?9;T;28\PA"A_2PXV]:?UA26^FO<8]VO5],YK*;8
M7P:V^_6*Z]/<56[$D#/*BF8C$!'I?)63'+-.E#R9GDC>$-*O-"_CX>G?%/JJ
MT-J<]"8?K>?V<WC,](?,M[V%(E\V1HY[[H1[H@I2?\%R?)9E ..-Q6!(Z6\M
MT"6^0SF[<+-\VJ+0W^MM2ZY<2DQ$[G=OT8PBWR<CC?^+B\[.*T?&55RQ>%0V
M9G4[X+;$R=M!-[?B9E*C)%-*XLZ+;U 7,S*26P?E<@H99#:))TOXQX4&6NJ/
MJ71DS*TB)%<1_GUN3!?(CGGIMP&7'->J=M-<J#6X(X4_$'CB=N"A-XJ25KGN
M=0")6(ME+8%$[AE(EH$=:Z>'Q5T;,->A"W8=15G7.*"O3M=EF7!Z=V=G3OQ<
M9'5G!<"1B9K#M18\M]@-4 +)WOW460I1NG4,7&;TW^=CKC'U88 .<+,6$(^R
M8ZK=2C(URLV;)Q_Z[)W8?ZO3VHC[#D'  138;4_7""=1W'"AMO#L,)!"G@F@
MB:\BQC).KR)>&;'OEO!E,-QS$(]WB']&4,X_QB&_QXQF S+P?;T#.@O$\WGG
MAV=YUM9OMX6;'&Y\],FL@3C9(W,L[8++ P*5++KV.L9F6#\UML)1-3J>T M4
MI=*ZL&)CPKYR>L2/P%8-OSR)]M+6^HA0IG"/;'F539YLYG:G[W3CB_<0U3 C
M&N'7@_(TOFQ^![*A.]YPW$-ZJIMR%'.*H]B^BD"ZME5?-Y:M?!4@<5Q+).+4
M1X-MVS7QG:G5C^17^BE+RIYX&^@T YN0%YLW/A'P3;5ZR+?QS)16P:2F]_99
M1#4REA J'$35DOCR&*'$P2N%A#Y,O2]KD+$T5DM7AJ)[ST.I)28=$5@9W(/.
M*NJGVLYK$OX+W #7O!.G?'QU7R?0&P95"(]=72_Y.Q^8RPLJNH%&GZA&4V0V
MVGRQW%PFBD @1*CWS)W'N48\%%\N;46X>=N:GD %0,@@<%FX#<D"WDXOR,YC
M@GDN3S_C5Q$Z'W^^&6_^9$I5X?G EM7 -T[BGA\1ZO+=O]3U2DM:9HV[0HYV
M@U>7S:U*)Y:T2]#H?5/AB^Y5.G4IBF%MY54KRGQ"*XCB*^AW(\%S%2[<KVM'
M6ND9>:1.M+[(_&VJL+]5M@J:8T2B3H#%E3]1]5(M*_M7CJ3TE'[#1TD";4G.
M.[>*?D6"QTBC(U.^+!*\>QI &@5#=:)D^/_-2<2&!&'/@VK3QUT-=8[:,F;L
MM;]0-N@ZF'\8O?'S0_QAT^6GCFV>\J U7W69+BT%Z;<?(626H(6=*VT24OM[
MS'#7D&!F;UO1Y;W\C9&Y/%,\1E!$V(O?VLQ91723QS8O,X"4G05S>OAU(<Q(
M,Y<LQF[+*S?#?;HV+KL^0CQY>6A"F<\<@85#K=L(7SX"#LS1623^-BO7M.Y3
MT&[4O?PV7VX4F)M]26/HVPK[*I-]>+-(X$^N;.;3R5*1WZU)W5!8):Z\@R;]
M2U\&MT21P?FZ#QE&H)_ZMM^:W^;1\"!,PW;9;3MCCVF*@YO!+K7TVEO@R<#_
M<+@QG=RX0!BF@:>6J(67!@!ZP=T]C\(9F'$7#WO%ME:U(?WA;^/O:3*5Q4DB
MY<=3-@L*IK:K^Z2L;[TC$CITPEH034I"T2M@78=BB_,<^-<%F7PT:,98X7XG
M@MW<C"]\)V9^.CO #LN:W+->LM$L6/-4/I:_G& >7Y.'X)(@+2+K*+@@%%_@
MZ?HA:^/O836'*H/":%!MQTBNB>>NX9+V;]=-)#MJS6ON3+B6[=MC<PRS7]@.
M_*P:8?>M(JX"[8# 8.1')-Z?MX_0@T(25 "*URKB>C^UMJMU/4_Q'D$3AZ48
MMVX>(=?K>0F_Y+7;_PP>^9#FG(?<[YASZ,6F^>)XPW4S 'B1],>>Q)>-%W9)
M)]#^^@^64^$UUD"L,:&@J,U"\69.,&V*&&,X]QLCSD=]Y1]C2&^S#WRQ=&+H
M=9!&4S1.JPN*@QZY:ZLP?9TH)!UX$BF$?EI#?^(J(CA]3);;)L@ O,6%>N-X
MN2'\M9"I=YO'NZC."?3K"G<CW]4DAH@7BMY,"^W18?:T!TT4T0E#H400C8&T
M1]J"7+CF#[BZX B+0D]71JL93(FFMSAQSK=W4)_DG7B#+@^0.*HK)V.WW>]C
MGN7KM(7''Z4MD0X 99?P,&Z!FPE;XL7? HUPS,YG\SK<9MLK3']7' _=8S?^
MF/G3D_%Q_J?2IY1(]^'9KJ71$:&B%KL>U%][]S<V?>WITV:T(\>;Q-]-'!6&
M<?NYD\7%K4MUX;U<0(O57#WS\3NVRRG8\1D!IHD->'&>(5\2C&?]!F$. J1Q
M6NVA;GM253\K.]:.'Z_>;88P,95XFX\TD(D8P5BJ*G9))])JEUA1(+&35F?2
MZ>%B!6+C#-\4?>5?JJRO.:Z)W_<G*]!C\-.TQO4# V9R)S=DZ-"1D$9ZC(4>
M7DZ0#%PG0WNM^3KH]'@JMLM1 <J9<FR71F#0"44#O^IJ,MG[7\9(5?7>N&!S
M5C+0=?3&^RTN7 @Z!VM*M* (GMK"@[B<J4:^K.PYZ!WO"%Y_Z%HSY$%7V\U4
MC#>,1'4<*=OW:#C$;VG_F48S\9ORY5T)3[P.' JGX82?B+(H?T=J.H.6C#?E
M^0HIC>1-5PKT60N1*F>A^&+<?=[U 9R'[^6_MP^UR:G%8C8L??CA)S)+@G:$
ML9;!9C=X0K;S#X.B27R3H')7O@/8\*H4M\S.3$2B\YW>ON79N1MX]709NS8:
M.XP.A<HK\E5V,AUEH1*A&(^.E,:57XH\Y2@6T+02'TCRCNS3+*Y\=:-J/]"4
M6=-56'/J14L^US=>*+$.GI!VP:,0?6A/?!MY5&%EJGXD;M'(3CH:V/ZK7WDN
M.\]J;L1%IB_(HERJ(]FHI:'"3"%!6T:L;6>7)K8>17^TBJB6!$ 'XJ@68Y:5
M:D%6J'@%!9S)QFR='^:U-+]SF)]"-S<>?W\PQ=Z@3&%=PRXOD4Y$I.A_=7KZ
M/S=7I"Q!#J\'C3#$A>I\+RC@&:[1LBG+I.D?OGWA,<#78+?H*3]?YU/[WA_0
MN&&YJ_'',['7NKIWRI7NO-O?HQ,0X)>M$Q&!:[.6NXZX<%%UWST$X@;BE=__
M_?<.@Q8,K'K%^,? =VN5X",806;N7T+0+@U?#5,]N\SRT1]4K[S(UEYW>FO:
MYJH=:2_RZ?T;( -&=VR@N3BXW';$Y_[S.>=>[$L_JEY,:$/V#9+-5)SFA51K
M[[.(BB/_1]6U_V[_H0)=K. 9V1\33:SIOZ_7NH./XY1P%3+#7[U\&A0FR+\=
MTCK#S#J9[MURZT"/U<Z/2G]N/LF03@?:F0#]">K73>(?OP D/]'3&U9-(JN(
MCWDX7V%/2(XPOUZ9'T'Z>M@NZN<3GI9KRXGO1=,C35/9!=58#NK@5(%AWR'S
M,8;?\2W:6DO:)J2BG&G"CU7$?[YJ.\]".$#>B+J.W>3./P8SAR-[<E>_4^21
M[TL\X^\CWCW6JJGJO0G,:S%Y!AD'EZ^9;I">-29?0=%IZ7\,'&6!,0=X-0V&
M/K56 (V=,J:7%..?3#S,6GGB-C*@+=S-\#3L,_@T=B6@;;.>R>(KK9+7Q.G(
M+R?E7&9\Y_[]&@ ^BN<M' +46N4 BBOY*JQ0"]^KF_)$HPFZJXBV3M@'1[T
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M&-9.]1X+3P&D,\D 5I^ ZR/0\1+P^#9SKT,H!NT><0/_H""9@1*?NSGW#3E
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MTRFX*-$6V+QGY^)6EM8BD;(P?YF6SOC*!:(?H#UHA,F2CW_R22(:#.?N *.
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M>HG;D=?$(&4OZA<R\KZ2T8 7.-PU69K0P$M+=\#7A[\HD;0*SS2?^*;]R-;
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M*W3?6*[W%J3J*#;LV?;RSF>+UH#3/,>E_GL&2IJE"^OIB^G)VK?1K[H.<]&
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M19[:R$^DK/[L?^F%6+5<V4X;3%QN^X&^2)Y3/-,Y9##B8QQO=M+JR+G_N5I
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MBPP.?&M?V[4*GPGCH #4B"DG^2?,</<?1,#V=N "(G-,*[#'K '.[''\1[G
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MO+\O I!ZK)QQ9!-JB$+++6%ECN-:CFLTY<I^*>'RW-S[Y[:*A=]0V_TMI]A
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M/5;[^%RB1CVKBOT\!*U329)!YYQ!)V;:F?=8*;K9R&5TVK=/ZC0>3.R*AM$
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MCHCP.4%!1=<B>2*N'<XY,W(K)4#[<)!4+I?PR5=2U^YHUUE8KQY#;,]OB_/
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M^?8T<%T><SO7[0NU$MF"!-<) &8IV[V-X9" DZ'XJE!C++1=?3X<.^F?:?!
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MY8\1_7V3A_R7V=]PD_L>>0!]IDPG&"PJ8 EO0\WD\@.9< *E"C?KK1[L!L;
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MKQG1TU IBP;GYX3]O0$/7A)?QCY\6?DBP>Q\\^LXZR,-&Y9=12Q3R4P"> ?
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MQ_:TC$3SR9+[*R5&11JG!^<YNT 'QC1%E5%<\  T;5 Y>=@/TNL_,;A&EJ2
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MSGO[O-^OU^=\#LY7#A'8?>:TS6F :P<7< W^ SB_@5T6'D$W/ %/ -ZX.#.
M);"#:WO;_MRQO?%P;W_R\O!P\_#Q\O']J_$+[(0;/Q_?3J&= H+;&_Q-6$A0
M>'MG^R+_I>L.7FYN7D%^/G[!_^Z-\PX0V[GCS(Y[W%S*P XQ+FXQ+DX/@(!E
MY/V7>%S OVU<.[AY>/GX83&$X!,:=L/B<W/#0O/"$L-'H^#C (\8K_@^?0L^
M"8?K_,K!DH?NIQ?L5#E1TREU_@M5U>#&[1@!06D963EY-76-_0<T#8V,30X?
M.6IY\M1I*VN;,Q<N7KKL>,7)V=W#T\O;Q]<O)#3L3GC$W7NQ#^+B$QXF)CW)
M>)J9E?WL>4YA47%):5GYJ]>U=?4-C4W-+:U=W3V]??WO/WP<&1T;GYC\.C5-
M(L]___%SX=?B$FWMS_I?^@:TN;6M%Q? S?5?M_]0+S%8KQW;/N#?UHMK1_CV
M"6(\O/OT^<0M'/BO!TLH'[J_4_)$>D%-IX"*P7FJU(W;7P2E50U):K1MU?ZE
MV?\]Q6+^AS3[7Q7[W_2:!H2YN6#G<8L!2(#%+$S:#_Q/VK@19)DD#D#BINYJ
MF4][&U7-4+!JP3'T7OS8G/O'3GWPJVE(DUQG7T@L*A=?I\>4UF(+]C.NH86H
M&Q05!A+L%*QLJ.:/*)VV63]V'C6=;=7@_W ^Q_K*L[+1D9,]Z<W=^Q?S'L@S
M5ND/., 3_ODTAL1?)$OM"7X_2$P =^*)-7/*'"#F$EII O3B #,:1$)\NX3Y
MHWNA(J(]6,'?U:M5[O*/AL.R2'IB'NK'5W8Z1+^[,PA@FIFF-/[D, X0/RV3
MA%&#=)&"RTVMBE6$AV:FK K%I469(,%V.M[W^*O#B0-E.?E:*]\ OOKU7'?K
MR<KL"\-_7?QGO%75>HN7E?7Y^86+8P<Q(6"G'5.= S16,Z4LZ:&P4!YH[\EJ
MV#+G_90$)LW":?S=SH$%.B_=])KKE15LM>(3,P?;;W,?2#&6U1_2K&SO3^4
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MXV^LPFBBOBQ:>_U1Y%4HF*25ZV1H.U#H[NON.K"GRWA7-)NO@Y_(W^-J2>8
M[T >IO-X/12@RW0@*9HXMC8TJO8+9QO7?'I?TC(M]-C@,R_F"@?HO BGQ8?(
M&OZ5Y["&=Z&,^>JIU:X-)3DH@3@$V)@7T)1GG%KDTY*X)5U/Z-BDQ 6.T)RO
M]A$+K7]]B?M:B+<%;^AM'N( #Y!TVW51EHG%<2531CC8:6OFR3C,Q% =5QP9
MVNQ/,AQ EFT4L7JR95(;K9VG$GMZ=#U7B5\?5Q 5>:@YR6!OV,F+:M/&5RLD
M14L86NQ1+/4\0H[IG49RI#R"Y2*-LA&_LH]>W;@,[F9JT"Y/NHU^HE%ZBQO)
M.\OBONKO>[__3/I$,P':'\Z4T)L?Z@>G_3OQ31LK>HP++DQ-:)Q8+?@MPIMR
M="$AX^*($4O>)@]\.WL2X],UH)JJ>NY[(,E2LW63 ZRPX'"4ADMC*OLSH<FQ
M>Q72V&!*I1%7NQU?D'^4EG  P6YR4Y?6<DT9:O9KEWK.R-+TGXW$?:<MVG>.
M&::76PE_CD9<1^^F95-LR<ADK,2Z7BJ6?QW<!2%/3U9=AUS>^$[77K4GBQRK
MVK _UN.O]4Q1?7-';8'*2Z6&Q;^;L["F@]3P.'-E# %!=1 %H-7NB7NXQ"JF
M_9=*HRBM<_<]8]:F787[M0^IW'K__E.QTDYUW'Z::!)&EWF,];H:29RLYL*,
MWPMHZA(5@W \=5":>LV^":8IR279M]J;:I+SWJ':8^>^N(&,[W9O7\TIIW!O
M%.*D8'UQ<"#X5\*1D %*8G9#"I=9.8',\%+F&?F.SW455R*>30V06$@[AG9V
MN&V@CCK#;>#NCV>E4'.32OA@)D.%I-<%)J!V8&1_(?EP8M"9T1/4_GC#\E"*
MJ'6-78WSS,G[#GQWS79=@4N;ZA.;ZL]P4M<RZ<+SH;>QX!B[&\^+4?&-V3A.
M"W]@KO=K>K:@?S4@$*UY/?/NKS.FU^B&7/0T2AW#DXED)2/=D?*8J7M_:_US
M'..81U@%)5^=YA[(CW\J4:EM2#WW1H8B,<!SAH12\@FH2E'28@L@89<*CL&J
ME>)K_3"C\I/O)J&P"-R!L7I;O-  &4$Q;LKZ[*"@CUVA>F1@LP?F%>TPM]D?
MP=TX9<Q4GA'K)9Z8R &DE<B,*ZQGYON6IM/ZIXH3LTPI>ETAJDH*[V\FYK='
M5O!=LYFEW_ZV7BD:C6I ]"*_SK-%,! 'H"T0\VI"2B-*!\B3#^MG-1SK33U'
M<SA S^4)T=LI1VQ44G],[;E=RZ,R$8T,OC89:EMU.4!PQJG^R=8L]Y"W8M=S
M]PLITL=O\ZL\,1U_S7S):H>EP=?@5QSA4.FC65$0#,.O?DI2$($:TF5/9B'F
MP^([0HT&;2_7600'&WT:/"!1-3%UJ?":NU+XQR+@,HK"*+T*=EIP !\"I#8[
MV:,3<HE*A<I('$!\64G#7&[,H_9E9P@IZNC:VL<C1<K63WP^-7YZ_Y%\Y(7_
M@4X 434=V%#DKQY<[#?1='K:7>1]8Z['6K&B0V-&0T+!S_9P(F$;R*80&M/Z
M@KZ66<% UKN2*5U#I7RNJ[SZ0:YA3,:Q/K+\Y#Z;6^X7-6>BO]-RH'"RR4H8
MPQ3LU 6)-<A:XRJ&$,2%45I$RA)Z\R2A;%*5]!;XUC]KHM5Y=FI ^[QU]V#2
M;53$C[<M9GNHJ#H0!@IL@0': ELH@.&'-H Z& <@T'48K1] =+U@,1JXT"+@
M??>U;Y.,XY\#-A8ZAAR@_>83@V&N7B"*0:J><>QU[F=**?2AWL87D0(T"=TX
M&4BO%)K0VRU7+&-_K*_ J*Z+F!NC9MW-G?+]Y4O'X>G LM)E8_VE>^9%O+/U
M^<_>Z)0ZB?4%=Q_8N[:3J;5&(*^NN%*SZ1\Y0.Q#M"<5/U_5\;N$**)!=QX.
M,@KBM7@U&.#]YE/.8)>+5>3WVGHZ37SMKO",_*G$9\:?E#+H *1#M/]Z@2T$
MTBKHJJSL%74JH6MH-U/X2_M=T9CS:TZ5AE7>#(M*CZR)(XKMF>GFWN=.DR5O
ME=\_CK1ZTVY+&M!Q5MSQ!U4;SR9ZS7UT*78JV;-6?O;GKWN[QN_@>=ERZ%VL
M%+P'@LM?"8:E,5M@IR9.U7_.I(6F6Q0\CYTN]I7!J S_+3#Z7LW+\#,V8!79
M.0AU)8N?KC1K?UR=B6C!"C<@>)81(DQD!=IPXMH8^DA8P;0=B75B^M>0XGC&
MB4<\K_:IOJ^2NRR:T;SG^\]H\U.L%I!83JBO7EEE!$.V]%VLI_AKLCA#J+H7
MN:N4%N&+TW:&? .J"MN>3)_D &?JLTSZ>F]N)IUE\LX;S6 ^(!KTF)+]Y(W>
M A)BNHDM<,&7&MF%G<KX!WU=M#]7J^>F[L7J[""ZK8O/]\TU0OMLW,S[GS@K
M6+?8"'=Z&2V(N<>.FFW#2L-H0HZ=<P=A6GM][)N_DC[U>TX)=NITM<D+1/J>
M&F.ZVJV9MP<CCE37@1ZH>#SUPBH?TP8'YXT U'0""7S4KJ6>H.V,R216)V3+
MVXTYW\\1SS ;F3TCOT_\<XEQC//)(YO6>Q$62ZU]&05.C4552UD3=Y;>&6Y<
MJ/01. S4[3YB=G'IXY*B[.[3%OPQ6K0-ML#U[2',>@+?@0,D(1K#TSB /WZ'
MW3S%U([5A-F[F(>@IC:\OOI(Z\R+STU/R%M:$<6G3"YHO^T9:70Z/W$P[C;C
M+4X4,TJ015X7A92]*1](R =*1A/>X-30?'52.S<UVP'7%OFB2L(J,M=\[I-V
MJJV!\XM%C],W[]=$3+?Y</^5H$^S2DI8SV"%D\%Z_MA](W\?A9.:NF<=>P[^
MR@Y'JCZ9GOI@%OQI=\+)V]$>UX@T%VRM=Y\(BA[/RF3+,3$TOHR Z^ \-F'+
MY*'>S9M3*<:C;E^[;],*;EQY7?] ^"51>/*G'J4(5M.2E8CC SNEF9$T=U):
MPNHZ/JF5OS.2%7D):N)K"0U+$[O:F.<UYMZ16:),%AHSZ*$VZ\=A-;DUT^\S
M@IG!M(EM,L6 ?1K.[MVR2L#L6V)+0%^(%!&,L@]*T"/U6&2/O/ESTK+ ]R^4
M.=OD6\FWO96\U!ZEW&H6OGTI&NF^WA%^<M(,'IA>(W]61F7?F _<JKU[?E?Y
MC,UT]_ ?V]?+1\WC_.F4H$N-=='-]D>7PAZ9*,5J'_^P7MWWD,TWQ=S'*C7?
MB;ZV/9L"%\H]2!_L?27E+SB5Q7OA/2^J4-:C*^LZD9UU+<GG8EA[)W131OKD
MU%,OI]36&DAK2RBU$6%"!F-NIE0L6TB$8=</CX-S$*$3IA$C4% 7!Q#&*/F;
MP(3%\TK'WP?9CJU/LY:6,J[:*I-4KP7+<>>F9P);W<152LL\,A%%O5"=@GW[
MIH!(T2580OY$<-=R3F 3SQ.%B@]A4B&JMW?<X74M"AP6-9L<"=L,@LWVFI6#
M5F2HP'*'(/U6[V-%C*K.@H*+6!&THEZ\X:SCA2S:NO^!+"='^U2GYR\[A0PJ
MS_0\?=CW?)]%]5@2L+_P?ZSU0W$D>\C>C/M-!(+" 3S84U]^W\2,_[B;9Y\K
M884//+T2^/F008J'XU.PTP3OCH+"AU9LB8BO"VQI)%.-0(U=W)#&4],Y@#LK
MEH(+^+:A@!M:L/LQ_WDF3;^NZ8C<._K6?NZ?"&@_DBG1=(7U!NU.7: G0E*T
MZ042JB_H@7/<;/]]=!A?LE)1X,1&\,XWZXP9JU 9XU'EZ-/4]S9:&\]=TEBY
M(#$'52^U0<DH9!.0,.":KK"#"N:Q/+],[MEWZXE&7.A"?&V5B7M"0;<-E,_[
MECXA__3A '<\[BA<3(_OP:"FQL[Q1V,^X-_V,P]M4#1H#'H<!X@K8K5P *&!
M/GD,#-I9B?2@%?LZ)]:+#W_0F^:C;:M!4])' X[Y$WX51IOKTE!,"5%Z#A5)
MR:#)T&M8B2 Q7Y^I5P^UW"U!H2VH7BW4PLF>.Y..6<;D*>_&'-NV\(8_ROP1
MW3^^-MZ2<AS#B6"Z$=1R&-[D8^61@4.0,W(:06UJ1Y(&#=AB\)VU&!H,S5G2
M'_/1A2;LS]79IH]I7OK9RVX<X!2 WJ1.TG<U4$69D@ID F4TBJ9\[#PB"2<T
MS$2:Q)8,GZB*6?RUY&'"YR61:+D6KSJ36I5#M8_'4FW39O[05>K',&*P]Y#$
M?+<]<)%2Z'#^R>AF ] +ZO#RDPA+BH3AJ.7U<*EO>JI*[FW:%[B;-'YZ>;EO
M_)7DZF0/(G;A#-!:D$EIA!X]!F+I]7  &0N=3ZWXE._46=QC/6>G[^EB.CH#
M5CS!*MIGN/6U9+4_]63,.<!2PWR,YP,K!D_Z1JB#(?D[!.1,H#YCM?7+]S_$
M-^#?XNL:HW#$P>]WW=!34[EM&X]F[U2?J:%JT&5AYQQ@H-%W6<T@"7:D+P?H
M^CW*U//G #O[Z1H9K&16FKO:F]7Z30H=:_J)D*9[[%D?ZD@U6!AMQDV<7-&'
M\7\:6U" 5D1?^9>?"V _1W:S]XPB2=+LGC5\+5A;-8<PH)A'WF4'LF;0Y71W
M.4P]V'D0?ST-"N=?<2=53TFPI=.8ZBAJFI]\U213%?D5.T7P8006!4<VO?_S
M<ZJ.HF#P4W'&Y'I(?21+DHO:L/&OJ8PV5@[&).(/&<N4X*>/#K,1D#\9?/B3
M)I.,DV%:4&7H/].#JCX#S6/:JDED@:I_VBZV(P])<S]^_3"OB;3Z%23K]>E]
MW>C'UC8Q)9/IL0GSUE"BT<>EUO@7)"%0M+/4R4980*KDY<'V$G3B=1.Q(97V
M//_OU-=%O^S<KWXQ.^85I@A>::AI$I8<NGNK1MW>HN6AW"O*FX!JG9'?GTEJ
M21=%)6N:/<-4]L8<WKLUS-^EQ,V*A6.R#K'33,:=*DHJ8TJU==V&]*SJ;!6%
M>I7V0XJ["LB16OLG/<ZUO1AO;$W?K;DYTM_R\;>GZF,,D1KXJ"(BI$O>,:&!
M TC85Z&N^+YUF5LV<5"]3?B4_KJC^S7P^O.[%L&#0KL/5\BGMA3ZK,UT5OA+
M-U:'ZV7[99L(QGNSE_A4@NE[QE\#$(%>""?N4,S(5C:E$0Y6Y%MORJ5"M"FM
MM(;X#'U@OD.HSTWHZ$3ZFRD+ [L@\[$\N6O-#QN_5>S^*(G&(Y^CZ ?@[N>8
MIUG/\8$PBX43J07N$'O*.0$.63GT<>BN:$+[!9&%!\JC!3(.L_V'AOR4F\.:
M&JVOQ_,T?.VY><CP\^=Q>IRQ;V%38EG>I9.GM']3HO-OVVCDYXL*PE<&,3T$
M:A=A%S. J <Y8:E/X:!TI[GW*!DQ4'23KY@/K%<A"ZR,H%R]YS^B""9:^#>]
MBV[>U&SVSC_4NFZP!MNO]S5C'M4CU^Y-PJ8BQ-JMR%5G?DY:RX=.H^C%7^PD
M';Q\NP<"M/7?9^SA"SWO#NS&M(P8=<CT2%N>'PZ+=%F^<Z,BV/L63$++OQ6G
M)&6<&PME*7^TL[V$CY^8DYK5Z>TI$.-_=>/XCFBDB;DVV"D/^[7P7].H*UB0
MP8^!J?JE 1U[4N71HU<6PZ<UND)C7<;;HTO?+]4UT"3ZA?HET_:XN7PSM,6Y
MN83_$NU$Q', :BE;"+(DB=*'Z-E,99S,Z#I(0=1M(OT81O6W[N+<?DZU>5':
M7LCUG35P5:L:K_I;'][HJ#\H7*YTX,:MCTMW><0ZE?ZZ_>DYRH=]Y?)K<NO'
M2YGLNPR=XLG]M8-L<D86DQ= 4QC7V9\(31L]R.2C07V(KV5L07[^[I/UU"W?
MUK+H=GLJ723RY+B'36EF8*)O4<[$S3-B><KAVM8[R>V31!13?)2>0M.C8$F(
MF2&VH"G#TYEYD>;='7"4/4E*>,#4(M8/K^OMLHE$9(:%U7W.LGV59Z:[H!(X
MAC1^3X_"PUFJGQK"%N  \ZO1" F\;W4* 7:VSPM3E#@:G-1I"-BU! <2RB>A
MR_'<%07KJ4+&#?AP]-=LGG>'IV\?J3:I@T-#G/VY"LYU*V/@C:#=T/*E,3/W
MBN6J>1'[^>29E<D26DN()O3HBK63FI/YI11;K(:^G(#78]:'4\!MF/.:Z=-,
M.E$":%.2: I!0@?M3<XU.!,_<Y7FF1?+RLII_]7FO+!2Z/M &!+^6"OU[4KY
MN1-I>UGY'. :%H*K _4<8FJ5_@M.<U6L3#CO*1%Z'< N'5;< @<(!&\N%@X@
M??^,KLR=-1OZ>WX3&_Z=,;Y^3))K("*<&-Z)VHG^9Q)C"-F3^./J\;)0H>P-
MFDFRX:KHC,6K)5K7ZW2U\9&]622'2Y=.IG2>B#X(5#]#>MM#*FE=>+B 4L]6
M(\#.PQACM.6+_CP9**YZ.2?UU:L9GWG;G&]^,DB?E)/QON^RYDY9V0CL;?<[
MX_ZCNE:SL:;25TEI1+?=@BQR?KJOJV_JMUY0D,:5@J8XR;KWOWLT-<M5:_8"
M H9<FZ-D!*0RR934F@_J/&9 5V!ME\]7TFQ52.1:@$Z8OZL$Z;4O^P!--_/F
MK^'%IGN)K:&/@O?X_2GVLMF!WIP;7\_N1T :I7$T%WH%*P?T&1**6$,(+V+K
M8I>7RR).$RS^%(WO'0MM7H=(3NWK#,UW-?&(MNR(3<P_@=7Y]2+@"=KE1%]R
MD-#RY9RL%^4N:KWQ!==OUUF$")5[/#FR.S/LFH6P ,^>I+PU^M#9AB>,<VU)
M.Y5/C P:WG>0#%/- _)%>5BOD'!!\45-]].C6.7([5H&AT]7(HVOX14'@(G%
MC:@R1@CCQ#OGNYCP/*S7&@U_YT-X:-??ZD/0%!Q1_:PB>TK)/'(FB*[$ZG D
M[6JCZ75O77Y!$[*:P$E/0WE#%Z*,C9-&R/MTQMM<6GMZ=_+&>N0QHY)+_7*\
M&CR5RHJ6#KK.G#&0ZJT?4#[\^;"GJI)O:V--L8^QW:OEG*J&S-K=2N3?88\D
M,^YGW0!^1IN9="%J]K#AW!F3#&6S!;E#:/^X?B C'^0$Q7A0WPXS:X2<YP9"
M@V"0DCOSZ06Z>G] 7_A+<L4BXNW35BNF9$4O@NJP$Z/=R '$F H-5/D(NU S
M!4L1AFLR*7PA=_/SD-8'V;[PO,QUR=NJY6J)W5K I:??Q98OJ=)VW=_U-D\I
M^VJ=R^8%]!V=VS'>;IAKS[]9\;^\DR\:P]X/CT)3/+&: RCB1/WQM0E](*2)
MCS$*2IC3'-'XPG0@FZ+NBSE#,$W[)U?847K><V-*^:ZR=\JGFA_A@4)Y6I2T
M&.3.=@3#G"E#37B'2DBW1R0PQ4A1R./#(TM!AR[5U36FSNU>O=_2WCRIL>=E
MSI)FU9N60H*?B?RIK!I_H]E\A%]#$LG9.F3T7FSFT,UA_GYDX]!VD4^#6(Q0
MF"_365G(0(9]+/L M:G[.7/OWG;(@3]1_.>T?XNN1\;&QMM"B0Y'!=E'ST4^
M\WLS#F(^8:D7D/$(&1TS%\99L--A/2T)(YXT$MI*C2I[=PS9O6I6^>#4WO88
MNJ/=H_CIW?%] E+K%$DN(N*MWC; $3X"8YH*MFX:4PU!;4;ZB(HQ[3C 8XVO
M^%ID V:( \!HY.\:J^@C [G% 697">PJ_2$I*L@6,*).=B$%0%_\?:PL^@[;
M@-I/T:?9]KCI3-PDCR#KOG\AC5^/-_#=DQ>*N_GXF65)G\IF(U;GSI^_)9)<
MF]5D#@"I>#,E;>$O*YFOP,YCYH? SLN4-VPQ*U+?EW7_61/2>2NRZ8!/T8Q[
M4+GKB]DGG=RJ?!;RQ=DV8E;I/"G^,VQ8]$[U=@U:&UT-,F4< KM^3Z"-YM.B
MM^X\X  BYKH1X6>M5PT[7/ZI31W7,Q]0:34[]'#HN=_G2T_OXS7E<2TP(#\)
M63&,P<YK&61D_"J<D9'0 <?[>FBU_*6W5Y>V'&/8@E:>4>0(E5M]<V0R^?>E
M>B?]^(-6;7) RL\ZT <%J4]2Y,HP4].3E$5XG*VQ7M>GQ;L=I$W$>A:C':@+
MR>U[PJHD>@:\2DU-)T[FR>UMC=>;C;^\[S'7V@_F4)U/OF@J\AH24@M/0[H3
MIE?)U10LS9V.&S,_ #61V0DE,Q$YKI9=P8M=6FTG-I\@-$GC.G19<M*WO6M%
M<19/++.0[E]. 9(._SE-:I,$UQ%##O!T'NP\@E_91[."1X'TI2T$*@]!O6"_
M>=:$*?&"W860!-<[/8\CK-$"V\R'%,8F()3 ZZO0)<(4EEH<"@?4+-AESVI:
M  / FU<^A#6MS)V ^= :W?M3!B;D0=]^R(@1 N>O;W!^B$'[L&!OD1Q!;_B7
M@NU'C49(Z S8R"10@B@NX2\&&":/<5:9=8&KQG:;GR5*T!A\@\:[-$@=SY0)
MH3^BH2AE\S,@ /G/-W43^):PHDR7ZE.J]SS_+$H_F7*=CLH_<"K7J?OFC5W?
MP"@3/:9X.#V)ZDUQA#6M8=7@#J.-1L.NM.M71.B]LR4-4%!V69_MSG_6LGWX
M9.MPZ:6PF!N5- / 3?G)-?X=T49X[VI(QXI"800S=W= XPQQL%,=3]I73Z77
ME"^R58+$T6Y-H_G-+0UYIZ1;_3N>17YPWB=15Q_<J_!1641%*W,CB!?LO('W
MY "[P4Z=[=4:5=#KH2O#3$6E=.V<M(22.,\QXMA\F[_TR)=#A3;3-/13C1N-
M/^Y\+4[_B:3>;'T-![P&T_Q$M'T/0D;B_B1;HRD3ME@,W@N5S $:$$P%*W+:
M+K0H]6?UF^4Y259!&%[2BM2Q@T3&C0=4HJT,LZ7IG[ 'GYT<TN39'.@IL+B1
M'QW5-(^ M+:5.@*)]],+60T@,4L\0H)8O)%5 5=BJUZA*!<4-3>S)W&/XW3\
MLZQ73T54,3>#K4<LF[_KGQ?]Q?OH;]8K]UUEI;/]QSIZ;'7:J<T>Z;*>3M;$
MF)U[&9-D0J*Y*BPW@#-$\^6:ZX"=UT%?$4?KR17SH2JF <VJ?TC2;>E\R[LH
M\P4K<X\G[_?<U-\,K.R.Z>;#>^ 0$=Z65%1T/9(_XL:1[']&0I/]=8X$RC[G
M$3OY2O;&79V&TS:KQQ';U[?#NQ,@E< 6LA9B1H8MF$W""B-T)V:ZMBZWS(/B
M!(OK,B8F^C/]/"&5YOY>=_3>MO'TK>R7(N*I%J (I&>]_= XUXJ^8RQL"G1/
M?&&31NI:<C1)*T6(57HL@5,[_FS@O2Y[.2G\-MB\;LLCNQ5+AZEH#(PD.G78
M/$RW,=!+=$9E'AN/-B4K*L]-.@0@^EHE?T[[E*:%7NC4>C=\YM:G,G^9\[*[
M39D5<*9(F<#)HF]MNPY][U]X) \GC+5B/3=")<@'9I;[.8<G_!BIMY>(&#$M
M]NJHN3]BY*[X-N^(JXI<^#=PHN(PORE\D0E6'.B%A'0<'V!TP<Z3,-=A[P ?
M3I>EF6OXYR"Z&0&V5UJMS=1(+^0P0_X!UQY_+!0P$5 LN6IP\#+I^0 +1JL\
M7% O[4(/H2Z\9V@J9!Z9&H:06 ;KJON18FBC!II2C7[6ZH51;=64J4&#/-<'
MMY_=-WL:=_1O-19/?(9J0JYTP)?PHR)[X62ND<"4E"!?18B$52<@)1IF@SIO
M+U^6>-A^B92\B!GUO7OM@YR,[I6/I:H#KZ:;O\DY3H+$I,MNZBPL>+TZE4 ]
M1YBV[,P9BK\!==!<^A"R)</5%$'"XA9/DMI])6F57=>;GEPZ?_K\E:US_+]R
M(\(IVT:DL9[#EBN05I*C3E(N%/K?VTA &T0=(T=<'NW)OBR/*3%,2JJ*R/J<
M=DMEZNEYDH77^YOD-L04BIX!A3.NL8?<)%FE./&9I73(O\_YRICAI8E*S.#M
M:]H?*VG?*9^_I5IK6BCZ+]A#.ME,J8QN%/6,WE1I=Y_Q/2-<R3Q^SY)](=.\
M?FQ\TBYFU4<O,DIYK7%8JZ*V>FB?9D6TTS#W3Q%'^A46=MNW**JK_50_<6&;
MVENU45/8IM35A[HX<^:1X0;_Y^L9I%\ZQVO&WN1G64FO195]LO[F'M(7"]2(
MTQ$*&,D(+;9@&9RN!FE!*X\8]I8F#\U%V)\)@NL=%]A2 X0!J?AJ<L"E!S5S
M<ZIG2X.E*B@G Z6B51)N03"RMA*=WF +R%!7^U%?Y8-@!]E"_8QSZ, Q,J@4
ML;1J.?9DP75,,,M6R$#GM5K5 T R2:SF3KZJL*9Z?Q\BB<T-!Z@SV'F'Z<*X
M@!ES?KY=\:=-26>S2Z>9EBUUZ?44DYY6FRM9?;\OGM_[1T?B7AM1?Z]HZX_C
MAN!UO9V^*.I9$-+Q[M&#U*TZVRIF]&+SCD$'_&E6[]B[FO%9Y)GNHTE^5F?;
M&^O^..7L+]-2I2A9\TH*"R[BC,!.;B0QQ4T"LIO')B/KL[L5!EIPG9&5<%GL
M3VX/*1^H<*(X/E\]]>&9JKIVX"7K+G2^Y,W'=X.^NO=-(YB2WFRA,)H$6]"!
M:A/8@(S%[V(+N*!UJ DI>9^M;S)M7G]XI7AZS=] ^57681,;H<.R:L,Q%GPX
M1U8!2*P!J?8$2%.4 KYF*K/>@OXN]@F(VOXN5M@.2)[<?4X^H3?7C?]]%F-E
MN"76)FY,JNE&]0'!3]S7CG-MR#!W=[*/8D9ARY_$\OU"-9@\0COI+"0Q3:M\
MY8.2 O7<9JYB+;(B7T0J#"'51L Z29_2'TF5YST3OZ$EZ*=9";@=F'<$ZNTQ
MA #2>T8G+)2%HA_$7IT(0MN073HNKW& <QF]._CS;-X4W^'I#1"DN)8;>^S7
M[F$GP '1&+022UNF>[V@/V&]Q&DLWBOK5MPQLF0R43]H'!GI<EC;_=/[M^W6
M2S7*K/%_KET/064ZES&ER]@"44CF'ITRS%<'S,2T*=HX@7XR2,"6C%V)LOSH
MZL\6=PID]_]@80=GOQ_,N#/X[/!LWGYN^N=V2SH.^L+P8QK@MFLVZ)[V=< .
M*@JKZ _=ZJLABSZ<8"-&Z\7D'IY6G14>O5K?1O#K59(\T?O,T^+O*C_4U(U#
M4K.RY_$[_7PCBY?OA<ILN2ZI:'YSL9/_L"?Z( _?Z0LQ7 OIJ.=XJJ-]TAQ_
M$QR)>4PM2(R!80_C#D+N#-UEA,#J*B5,D;MGHW57+EE/KHK=7>;G')>AFBQ\
M9Y_7R4/*JYX+/[]S+P9];6,+JM$NS",H6N2TKR'T+E:V @G1NRH"G1>5<O+-
M,M=*=AEI/Y7_(9A^H=QI5C7XH$#PP[P#NP]E[<$^TWL"F;*%!!C7,",$:7,#
M-"\K"4]\X4O&[T;+0F6O(7O7":85S5Q1[_23Z?&>6U>UAWP[WKR1@]',R4=7
M3Z1K?4"NBKG\'(+4'Q!J2@C,/0?4""L"A1&9;#D.T*V]%.S+UIIDVE0M9;%5
M.NPP[Z]^^VI?>=5..RL]-XLQKZR>)9#TNV]^?9*Y.\]0"<EJ\MQI@IB)[#O>
M>&3O*<_[6]C/T<?LZ3:P==Z@]:$_##FT):N"?3A"D$$*6.A\Y.WR!:,/65WL
ML%U$F[[RM59MC5-[=-'UP&E+!<U'*S/'54/6L!07.+D@6:WF< W19Q_ #(.[
M\<3L#9PLI#+/ 1[D_, ED/>;*[O,0<EG:_"C7O']%SM&+O,*!:C8";U7>5X<
MHW%(*NR$O1@1-;5,UJ X,F R?X'-A5:K\<=+1,32$VB'AU=VDU8#KS?5-MMZ
M4EHOR#QM>3>00O1JM4_#4IT)7V/)(%/,JA?/SQ0EWQDSUUY&[C#2$YACRL1:
M-Q^=2WNEFZ96M3;K_*S;(L!+^FY)+KW_ATN-R!->(*H-K@(1,& ]AQG$TRV9
M,)\I';C7P?""R[(^Z(&"]FLDH_7(HM.$+GE\LB%AY\RWTN<D$YK:;&F&89WA
MS4!='4IQ&D5<[^F.H!OY!NBR(Y(@,0VQEB0ZU<1^#\8CUZ>"W-1@\WR%#=SG
MBZ7^0P B4"29[EGW,Z/L ^B+.;;VPOYL]:;,>E!HJJ(X7+YW(2MU=">Z]\ .
MK;JW'RX+U;PSBZ4'0_S46+H\!XB-#<5/^;,%6IM:-:*-P%B9ULG^H81[@17!
M844^33?L6CWG/A0'!X1KR9Y^9WG7OAFH;0Q%&U"%2"BFM,3VLR0K7V2C5_R<
M 72=86*1#SF2"-T#C,7L?^1S_U8VR<>7&.H?3=3E[ONB90S>^;CSDY^5+6P@
M5U8YDIB* \9NL)[A/=-FO CD_KZA1)-L^<DT,\\*WZ-)RTH&X^XQMLG)SSWS
M>*^04XV>]?*Q:O+W2M\)Q_AW(A 8N&YU*B.)M<CZ=%:=F3TBQEP1,R*])9J,
M48#-?[DQ/;2E>J7*HVDL=#%0ZHQ5\$]KCXLWS$^=/^MY_)VB"5.\R0I+O[B-
M]MEC**HU5AAJ<LP@)<2M5\GT$@1"&567;7Z;&5Q_[7*#WB7@J;TL'-+N):6Z
MTNF>E9[8S6J 2V@<BGH:-95,EX/2:"_Z\+M6UW6\NY4DV\<SR.RR^8#3X.[>
MU_UBQI.VP6I]JBW^:?M5+4Y8KY1+_-S1@"=FY6F-<  _/6B_-^4"[,VH+Y5Z
M-W&[EX^>3B.)QN>IC!DN7F//O1VI:O([^M2A-5'^VZ#\W4"9GPK97$6>"%6P
MFPP27R*H%['3./MD!/4<?KK-EFKU#A&OI/+'7 HM-&8XL%E"BR\0^.B_16RZ
M/^^3C6RIU3Z^$-'' <RX?^FEXALG*=54&;8(2$WKUU. L!=&X3':W=FJD;""
MM@!5K*(D<S*77"PC5;"Y@:EY<T'/,,'ZNS#7_(78@O:P!S.W5Z5DX:GVW(P0
M3->6YVH<YC!:,./,I%5/Z(1NSI]>;TH6S4_?[T6)5HC4QP'M-#F%VSN$]WF:
MPY26]^ZP(0AI;L CK <4!Z\]<C6+.-F(T:(*+39>$*7<-<RU5GAX(_ZDC?R)
MQZZG$^MEPBZ="^=VDX%[&L >:V!_0E$O$""-G:QDY'6L)#(99\2,RK 9OHG9
MX[*X@0BDSAC]:&]]D/-,_[Z_8NTI3;.4.PN[VHJ$WW'_#2(%I<%T,@D4;C]"
M,[5YT.]//L8W=+$QI3F@YMN))^7OEZ/G<^8J$7%YW&\A1VI_-U;8\%5*%DYA
M^.9ZFZ\@14>Q_8#XRSOO+7J#SG&=DOQ_IJ&DF+JPGOZ8D;Q#V_-5/C 6#9K)
MIA=^,7,WZ8Y4]#X+&1'3!"+^69RX)WDT_E=):\OS[^$MS?Y>8B8?*Q[+*NV8
MG'YZC@]\B#Y "I)Q[O<DXT5\MXH/?E*/5SP]J''Q<>BM/;ME/8BI_L<!/N#?
M'I=^2'Z'X8_MJ9X_C)8K+GV[W/#7<[101EL_1>[.;[/(B0;)<WRH)#,)XI#"
MC)7GO/W.Q7OM^OH^!>/:*LT7S?.MB[F=I;.RLJ1KIJ[,6 D?S+<N2-SQ>K\L
MP/6.>Z2X,-J@86AGA'W/G^EO4';7UITBM11<0$KVA,.GB34P2BBVIGE/BI+6
M2U8AFS?"A)X'B9$)4S-DM=]E03#_E_]E<M2X>>O8PM1OY\\DX1!EFX;&U=,>
M&OSQ1M,.Q^4P_%3'.'.%"#UK*(QH)TBP'5X7T26<_5(_<')&JJ12K-+A1&SM
M:\URI9B&_871@A55/O<T$D-;ZNW%?.A-=$>AQDC3F;"L WPA\:=YE(Z;)36<
M BQ*%W,"'UW?E5GL2W5VGND3%_+W>1#<5U3XNISK^+K4L7_STT6T)2E-!&K[
M)T"B-T^I9EP[-_98:9%/1D_/GAB'3IZT$K?":+F @ #/ ,7<W-93PM;B^PN/
MOT[BVQ%]&-BE;P\;7<M\J,M-<K1A&2NYR)8=)8[K[5;[62+RU-]L23]ZC:LE
M^ATQ;[S@W^9"K'K<9*F3R>M]7]!.I&7%\X-?#:;]C!/-_K$Z<>F_WBTH*,@[
M2+&D6$#28:]UX:,3_\4%P)VR+_ %<LLB++ONG6X()]MI=&V%O2G"\,^L4E:*
M;'X'CWX*X\+2U.M]\G<D[?^?K,V;2S(C()"6W6-^F(J/>?-&:96TD?RB&Z-L
M^S FH,-%R[;[!S'WPP^WDR;!?_AE-_U36+4P,475.JZ(DCI4>E -,KT1ZQHT
MJ64GR-^J;C0P3,3V2C,0F#K]>>2(Q@N%QP8\TR63(2+=>Y4&3T64K03!>6@7
M*QT?%&#BTLIZCCO  ?Q1$3=^Z##M211[F]91(SME*Y[\YKKVU"-%E[D:<;./
M&J)O7+P_AXZ$_E(3Z"C(E"R:Q@&4F"&^I&I^R,7>?S;<N</1H_'![L/6XWE6
M7IK)\EJF=9JOZP[R<%<7MC>1$)02AB'Z#NOI/*O)7!)M'>!">M"J6U!A1;[T
M)>BZCK?''[5/,=-7+B]\][\;3] *N;EIZ1GRAX= #4$RQ0Y-2S<WLVJ"BAY)
MUK4Q]]/."?*?MQF!)+DV'DE]0/-#B]0F^G/(E$1(P_.TG]D:>M#N6*I>0&)=
M6F<D6X;=W)S1R S9<SO_\/M=2<&?#YX*JP<<W+2H16Q!#1C;A; JT-X,,;0:
M1/!]PSP+1;FK$5+,CGB7S-T<+4JU5GZLT/C ^?VB6H_UEWZMHS6>GKQ[]!K^
M+U)@1/:*V&N_>_C.JLL+E\>\6]/1097*'X(-3'EE5'D')-XI\OO1I_^'UX7\
M]S:M^2!(=S46[[NZ!X8<2",=(?KU8;1+Y0<.(."59I*V+IJPH;>KHR+"2=?2
M[W*6B-PN[XBN1^7A1^\FQW^[R,IP\V5<@B;I!5 D=8[0BZKU?L<2(NL]#/C[
M$*QOUZB"RGU*5^T/:+R@^Y>E6H\0D4\OGFD37.6)C3V.R(!9FW4YGAB-TV"]
M;7<LCM#H.AK479VTY=@7V@X=(:V*EU:0*(%"7$6+UED>9W\U_3/IBY&?<,R<
MS7WA.U<9U4:?A+*I\W0DC//B,9+L"4)C8 E?(K7L*BLOB+F/:+_'_]J;3#C%
M2HF<M4U\4"=6.V%S\WF1>(MKUU5O/V,S'\P0H8F?*25#MD]C"R]C:_ARJ=4V
MHTC_6=.^O(-0&CE-<?%>:A')YF:]W<X/I;[#7PVK=<9J3@FQ\H^^$R?N4XN]
MR=I>VWN?Z0]M4*O_&5[72P"I=I$<8%JER_F;B2VYS<Z@Q_GJ(=_;?=>-/TXX
MQ_-.V[:>=Q+]G:*R=U46@/0L62TX;O0=6/XB<RE_?$UU\DVF%6E(@BDU@5:9
MKY:/"%\8^3M08?TF[%2\Z0,EUYF9![6SRM+3ZB=GUXB1V?TS-?!@=615MMM1
MIWM[%U88#'V[X!#R*\<707),RZ39/!&S])[&UO.U@YH+(F&JUA^[S)*Q;X-6
MPAFVZ*NLEB&F9!J]G95;KQ<S[1W+%-"(Q?"CQ;_\U7*9"C4]\M/ S2_[B5-Y
MDVUBD^250D9-FU;T>[GU=E\.P+<&=II]'S&S+X<TNO'BVD8B7JZ6#M)''?MT
M;H],N#!BUNKN'KA3H[OIHGIMUUURM"+<98 #?-R%X0&_(F'Z,\HN<D)1;S7U
MH&0B!HC\W1P 4L=WLEPIZ #&>>:).NJ#$/BLRIIAY2>FC]PV%.=3Q>2M]=EO
MPM<KX* )2F-*:+C]:[5:CY)2[+Q5K!%A%_/*I.$FB?8[,6K^\KAVU3_.F<O3
MR1$%S3DC(L.V"OI-*L%!V)_\"C@15CH'\$$E8ZDN! GV-RR"C0 ]T6:0$W6$
MT(7EFHYR'@EY-8<*S+XT?EG6\ZY.KL63R8T!!9L]#X^;G@7,.R!OZG(7<J?Y
M'A^$ !NQ>.!Z/N1^JF$DU$663>DH:=<2UD_S/.D .0YAJ1>&IA?(B'=I"6Q%
M%A;IM3-@E7V4Z3N.[08%US>C/49GO)9G;Y/N]E;%M?A^(]T'#^S<]_D8-WT!
MNL] ,?59+XU 6787GJL>FX@2#_A-D;&FIC9569;-N)[\4_C-U-Z06OCT85NT
MAYPF\.'P&ZOM%;$QE]GO$4T)/: HTQGB /E0;KLE*4H]RN#TN)G!?)2559:"
M4[&XC9QQB%6S 7 V9"3:7 ON%<G^B!!%W@B"#HM>9+W$*=@&A_L7L'LF E[Y
M.ZXXKSJ/>=$,;\\NF>C:Z)G]:7_2HDK$?5DKY_X;@S^ D0 [ ;-]5 );2,ND
M[P6")^*ON; /7J">D;8K(F=YGG=EXSQ4*^)V #>@NSQZ5Z?YOI!LR86;/>'N
M22SG_]/2)RJT+1D'^" QCE^)G #7BR=;'>/@)'6, WQ/7"+0CRTCM\[[S_Z_
M];;I)I:<QI2T9TLU]=AYOT-1RW SK Q0K6F: Y#VKC%GRQ0:6;F-"Z,:RZZ0
M<)UBSL5;7=W/2\)?.Z.G#]=,I8KJQ.2I7WW5IJ/ S#!_5HBSX0 ))> XK.0
ME@.TE/_[W8IQ#G Q(H&-AG4=AEN: <OW/;BPP;;58Y_<BNU6XJ:B8JH;JFR[
MW&1J1]^8G:I0O."6\WG6H7KUG]WO M545C_\L!".3#.]X?#U<@,:3K6B9SC
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M4L=2@AAGK!BN:)BDQ5S#3*,D#%>5(A9(:HW959 [V2@^4?JY1N*Z$'1I_'?
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MC +] C9>0/S"QM 51#?M9$X!>'IK$H#3?6ANHH/*1;GZ8DI5=W-U#8#1#$2
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MB%?<R$93$[-5!%MC[B4A>_9//80PQ*^Q,2,^4?.#\.-2^ZVE8-7?Y+Y$4&(
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MPJ9"5':Z_CVN]\;^[R,QX-7?!1T9T3DTE7D4B]D4"G0B%G%_C.[D!/S5M38
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MN%$1%,8+]HY5".7X4?G)UIY?'M+!-3SG+O>P):,;C'&WL</^C .9)!AACB:
M9K!O3^352R C"7HQ99HP$?T[A;^K@;:F2E]V-S_GW,+/YW[7)$736D7?K-QY
M48;=+21XI5;E#M@75M#V.@.D=A5"@,U/K(<V#^!&$%QM@85I\Y;^E*H,;1&&
M>KIKM_8M-[=W'SR7T34SO7_<"_,&F[3[=B^<I_&P+8-3G21,&*+Q1S+8Z601
M6+B$-- P1>18;>YQ$?$&2#FA[@I\BQ2JB<)SF[<4W7I;PJ]$"'^96@ZX\0.L
M/Z(;M'$394S( =Q$#N:(?/$#% ]02MBWU8@3 UI%CYRH('7-C8[>+/E2LS:0
M?#XG-I'WQ &$?.5MKHM*J,,!QTE0&E\D@S.!A*?8TQ.*=E]HHSAB2VBM4EEM
M"L/.)!GU:^EE7O5XE>XB%C5^*6X@H-*"$'[7ZR7[CC_B+8P;I4@#MUE0/L@Y
M42*H7LSG1! PV8T;,<-)A/H:B2*RR(_!2]EX9*1UV$BTZ@C\IHQCN:?*NW.9
M!]F/V.'O =R4;X SU9AF!RQ1H31>LE!1%I(Z02P/#@W;-"!*H[J<?/.MN^7?
M]/"U$?>PGNX\8&_.Y741BH&2[+HED#D,CB.D3-")?HT)D9"L*0<TJ<H I^E@
M_2DWFX LL^8TU5>]V?UEK#Z$R9+V<3N([1;>.3SA^BSN,GKB'6(MNGMXG?$-
M_9()V>AV0[S#E,O0^,T8')Y4=G!Q).K/!IPLI]<SQ-P0W,HX"/#"C&S_%L<V
M;6C;?.CAYV[_TR,ODWX0O90T[_D>U&N'-#[7WM78,H !Y34)2^-/(C@P>O"'
MO16%6G(#+I"(0T'].J0VBDN?\KT^>:W(4]TI,B/W+J7VTVI*MW0@SYS^!=GW
M<[<@MJ494KO)17.,L*>T$NS/U0C<F@%-?S>]J)O.L[GM@,A!HAFKB$%8/$QC
M"C/5LY$T&Q1Q$ML3\_)/QPL4 3A#]YD: T=@0GI:4,5#,\+!Z&GG?O02 TH_
M"%\DHEPFV<AG&* W'37N 40!'[K#3K" "2(5^A2M@N$%831]"4\1J0;%7I?5
M0"D9RK@N4<>$W"G TL4&HA&_!-#!T*MH&0O&Z3HK$QW!]#\FO&P\HJJ!(%T#
M<#*:ZQ29$/WCQ7U?<,,XAB'^*X(BO8#>T1=\DD +C61"_/,8,MN8@;>(+1LT
M ?$:_B=WW"/_CYY[!QZ,7E/%,KCI5= T)"@ CU=#0>,8M9X"E2QJ&G7ZCZ$Z
MZNX+&(M!KH(*. ?.^FG\CL4%% =\%4'CJV&8;),Z&%]+T0OFF]M)$>@UJ4R0
M!@HSXB4WT ?!>?&R9=3AZ+(R/<I@ SRHD;^]<8 >U13=P(:[9SS21,D=P#TP
M/HSJQ4G4:DZ)FP[*6>$;$/RV1I7]Q+C#4VOR%K?O!9TX&WY$L*+LU;*N327:
MJ1N01#1Z#AM,5023MYI@%5 B=+* R$:TUWTQA8_L7TPV',*XR9>L$^W/2(^4
M"M_ )%[598@,T8MW7^V ^*2V;$$.ASG'1$+Y5%*-VW!W7JVM-DIPD!(HY<^<
M/(_N5U<0ZI.Q\MUOR;$L5E#@/O(U&5.J1A/RI5RF%VJ#GABB+8Q$3&;5UV#I
M.<M*R'B"94'VL&*LNWS'=I(:3^$CVNLO=LT>=_/5;Y]D6=+X9PZQW"$G106H
M3W ?' /:6D9BAI5'#S>-W=I6/-%R6D \EU/BVOPA\V.R<281-4^EJN-/Z?(^
MCO]L6VH4L68,>&"&$8R()(:)(@YH@9+&8)]Q=$%%6@8"38[8@)64QNRP@0;R
MW( &LOL'!8R@8TQ(8!OM1^@N0AASH7K&Q7JT5";=[U':%;F!I4MDP[+$?6KZ
M7EFN9Q!-_)ZF6I5Q^RQ;N?H>7FHH7JR-9XCF4$#.EP$R_S<&JXRS>C0UXV50
M>.B  N)D$IYV-V;YP10C<!$]P<>$'&4,MN/FCT,!,73G9K7<=QBA&NV$WI%%
M;%^M!PFM +K)F]$. HTY;BW\&<B"3S):?\#F)7(8>Q37N/^FL]W7>P..$10/
MC=LM:HN3ZE/O/,HUF$5T.SF)&3^FT?K./;^UYJ>N-5!WQ:A_T^U(69=EJVB*
M6UBGU^COJQ+J/%&"3EH\>@[VH&(YU$^5 S>L*1/2+@VNP.',?Q@.1?41$W)Q
M$T9B1X.TV@FQP<M-XX+-/@T)_7#?_G#?9*^62L:(R^#-O<?*2BJL[D;QQY?S
M0-0W!#W^NZ;&-N,?6X;3%*EW&#]0RF1!3+"6"IF?J!&2_O"3C2T3XF@O\TY2
M;$\5@4/[8^!U:UWW U4&W,I)6]*,*Z]<$HVNG\7NQV]E,IRS0<R:$Y_]/P/>
M"YB)F*^>[ ;.&<BYR<K(X^650\1-H5YEJXW6JL3%\\=>:_WPE6WE#9EAC6O1
M/?L^1A4(!.&8%4";!T'W(#> H!]N=R1O:2=28CA7;M]U?/S[^9YO4N)XFTWC
MX8XIU4S/1YD!BN2MYX4JJ0H_NDV^]"HH\EWS*'+P=TDSC[#0:J5:27"Q3] ^
M<#E/M35U0^;K^4@Q+;!05>$=I]!(]Y6W\T\3VI(I,:P1+S,GA*,KG?3GHK:^
M;M,N!!AJC9B3^5"4V$I%R4%W^:KX&;NG.455)BOP]-"\Q%,]$5L^"=M5B:^-
ML7*WNE?<#,92=8,)J\-#;6A6FGL!<(6 RG3)1SI?*T^31Y@.3L>.6TN-_ H_
M$,7%;3?F?[<6W? 4$Z+LR6^SB#I':EK2>" =_>-M4M$##VU=#JV6?:\]1O3%
M)GC'Z]0HX,K'<9/1C*^6T)V; ]/L8G&.;:*J QVWG5D&JQ^><2T^$?GFO7D<
M/-[=GM?CQY9-Q49Y]6&'>ZFG+U@<SIX<C]77--*WL^F^6HG/6P&M7UZ;E=$K
M;(-Y7J3-+A.L>+O70_&!2I>:39I/Y?VD\^^DI:VYCWC4A;!_:Z"G:(F3J#8D
MWU<!=Z8PH=R3X5HP)R<%3'9;[F];I;)2Y0<LEQ\C&Z8ETC:'&5UXP5H#<K_M
M%V#?E/S^1GE.>-\]X9%7H?=.WROEO6HM'4N0E3+\>LIZ#^N7[G0R8E_ 32":
M5*^Y": G:^K.JNR-';ME3;"Q2XEX#K33)Q\>6.IVG0@6L]-#'&(__]U?-?Y]
M6I+O%D.Z,Z/?3FWQR8]BH>3TL#A3^QW/.#E;.7\,YXR[\@ZQ9P@HF42'V"2\
MM%%\B7,>(CW)%/P6YQ_N0ZW)B9,OU"H5F]CW77:TFO9E]9:T_\Q61*TQ.9YR
MD2P<J:V@3Z'BN98L'P$.MZK#V&?.51>2/"'">[A6O$9AW@Z-,WT^5LKSY7X;
M'2_+4MLO>9,^O=(5OUQQYMK*OJ=^3N8+U]\GO)>:7)71K)'YF%702^P=\]9:
M;DVQD#31S-/1]\]7A;M9B L5H/*[\XCV"OW:'+2])-S+!^6(E[S(FIMDX9")
M@=5-6[H]\J[%6\SOR\>/[JTQLII>XP[@,J:D .X$Q1"&>O\4Z:HOCTOU7&B1
M"E*9^EVMPV%N?^?!MCC=W^L_#CM?,/X88 %@BAA=-L8OM8\@E2[V^VA*];AO
MFN0"(3WCX7,ITK3 8Z,';[\2TI)X;.2GY4E$9]@J1M!@9$ZG@;JY*"TE]P)7
M&Y^9_L[!TO-'\\M>?HF9V3:G_^8Y V'YWN$ZA,PWBW^"T2XV7'?S61GO^3PR
M_JHMYZU9QJ>!8P)8+D,!TYF^[O%QN#]^X-:Z(@<3\JT[FPD9HL%V#F,'1F@9
M(/F+VO&DHYN8D/0(NATVE<P"O$7KHXDYN*_X)NP2].?)C C:/+5_NQ"(84*D
MN4'N\FE@B/'*M;4($\:$K-W<7*4>LD//SQ:Z,KYFTD[N2&YK8,E.BXT1)XL.
M_(G@P3)C_LJC6AB@K%[S8.P%G;$B",I]UPK*L--:".J8,1G6R2@$96YU/Q/"
M\4\$ZOMJ_R90O_[?&JC/B%A'C_1/JA%Y29D3JJ53V&$SRN.8R;97#Z;+1?0"
MI<E.%2'5077-+DK//B]MF?@]+(LCU&\EE3UN? X[#VHEX&3W_ZB&_F6W9B;J
M)XH7^#YA#'7MH5T?]!8/0'8T(;@5/9F0TA7)OJ,1AK)^?%H=(D'QETG;8?4!
M)?6M-RI_XC_/T82HE.-T+$/S/J(4VRAJ',XYJ<A#+Z"JES,A(4\3,?>U(JT]
M/JXKR(0[Q&P]K%?CK:K(G8Y8 UM'JM'$6,!1;[F %V_&1<%UV# >UJ,T@]WY
M2C,'J!^0G)2/X(6Z-4V6),V$C. J _R%V\;X;=T5G0K[KD3*F<QVS1K%7EFC
M=VOZ$0PASY+^?)0BEUZ"FQZF@<[0'M0TF9G%B'\@:79ZNR]Q/M$]B=\A&=/%
MQ7UG$&O*Z8SSX,1?F^S$3=O9TOAH[[9Q.@+P#7;@]A_SMOVI"J"Q- &:C"8*
M$[(C^-!BG-&!6WO(X-H]?HUC!-_RBZ%%+J%#$/$:).CJ3UP+M N:M6&B@[Z
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M&(:]J'@W7\+5,J-OYZI_A]R8AFA8EA.K'._Q][SQ/:_*99HQ,1B!>KE?ES(
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MZOMJUJHR\\Z]*A7#'J2N+^;4_ZV=5VYE69D049%W/7O1(C[*DE0KN3CRR[3
MX7V.L:)ID$3QU-=95]Q#1C'F%B9BJG2^*'>IZI&I/7!.P=6-X(?G+W/VZI$3
M/]]VRJZCB_UES(-%O,\P&TV;SDF1)G%1S!" R\S8UWOQ#R5;BPKM*9Y9UI>S
M5I2D-"#ZHK=>@PHKHW'KQD"9* <*.I1A<M[-OGS50W'U?D'^^,^"Y%E7(K-
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M=R G40A&$)89W].P6]"AH.?']!\/DL'GA?AAVM=1<KNAE,[=4(K@GR["S^U
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M?.DO>O[L58XD[]M,S0ED0*L6SD.RH#Y5N0,E29.GHR@]#=K>U"AR6U/[BI;
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MG)62DI"\AGN)'O7G@MX,='QT&#IJ5%M0Y=HV<7_-[Y&;\T1Y,<Y[N-UKY$Y
MC[.&2F):?!VV+C&^9MBNOEW-Q1WZMC))('FXURW)#R?9W%=H<JD@R45ZSX5-
MZ8AM(<ST*TR53;_1**"Q=Y+=\4&-2$ R@MGK^KC]EL?"5AH\3.1SV0T<*;R
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M "?(;% +3D/OMDK NR!&I*GW^C*&M+S)WL3)1(HR$1MSS_QL +MN62>[K*+
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MKG'!V40]2.7 GF+%.UZY[_:N:9Z*BI?KDUM#4+\ NYUD7'9/BO;+)1#QK5.
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MU7B1VC+/R)[2BG@>M\/W1C_1MLS"MF18-NY$;"&I(-D+Z05%T,3<X8H@5#7
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MT5DL.E_TF&Z6C:W1^!D1(Z=]"_D'U/]3RIS_*__[ @@G_@M02P,$%     @
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M+,H0^M)V4R3AW,:E-X:5?G2+-]YYDX<5VAYFF_N=M2))7G]Y^QC2^FV;'7%
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MNUD ](0RLIH38TF6,!RS](R6^JJGHNC5JNW$U:B^Y.OKM?5'DJ.3-8C8W6&
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M!NE7 [$4VW4)UB26\H(E'1/'B49#]W5TARK><DHVIAAF<Q\T/'[BNGK+%9F
MJ,LO#R#71%+0^L2J70'IQ9!#]^01]P)][[JQ2O%=#PI+- $.Y*GV8P@3L-,
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M.[^V*HCA]%Q,Q; \JLT#!>HHW"2>F=YN7[6RD2?H_1;/'V5$IS%X69;58'E
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M]:1#;A2Q%$,/*=@HJG^=SI$/00WYW!)6M7)X]62]$T!*J--$=*F[YXR3W&K
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MK $-^_9/&[8,ZM+?)VB!GT0>=JLS(,E1=-F'0%.6OG<$16UH\DFBUR=H6W[
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M29M  A4G#-I_;ZF!=K65"]YUI_)IFT2OC_IRW:1X9_^W_!6_FS="-%*?/MC
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M\'N1S+=R6X/I^B.^Y*ME.6+%I1WZ2HJ@*73>7P4BPOM :QTVMV=,.!@8=>@
MIB D9XOIY S&]!'R4RU3CXMPT:P-((;"0.0M#/!7VI8S%LQ_H@&6J)^) B=
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M3)/ TZQ;OZNSM- S+4PIX[,<_I[CX:Y<\YY>G_\A_%XJTM&U!E[EZ_85X:N
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M)487CBHYC]G6DT6I;C!$_RZRCM!/[T"\.U!1L$28&.4J8X&3*81T.IT=Q7A
MK_R[S&'#NQOI);FT=N,0EAEGS7RUL%7TUS(*1@ 6_7P=PQQ!-I+\R&5VI3N0
MT1!0)GTR'$#/5/SSN?UJI#@(Z5?QN$4ET%@Y:66%M+UH<LYO]/0\KB.E$(R)
ME<?_KB[,.-A?9X\%_[K+"O>2@EKQ@;7O0!2V*SB8"X9TZ=6#?Y5,VZS8V07F
M0:D=B-17B@FS2Y_ .(R[0<8R=09 $KL#J1%?Z^5%35M<I:-HKAKWP<:,H3O^
M+EOQ7EP 2,R3"*OHWG XE16,=S?RL2TW_F;%7YYBR+SV"K4P"?;' R2:A*''
MN:+P-6!?7MO>#[Z@E6OT;[/(_25AV%]FA,^N_#E/8P&JQ13U"XKA12UR<#&3
MM.Q*=$$.VB#'0$0P7Z$5U$"?TI1B-O:"-G,DYH*C9&!VE;(,*_=;/$,)I;[Y
M:,@SZO]PLJ>%Y'XRL3U%97#P9=47\_)/\=?PY[*-'URS&!*YGRQ;N5>7FV)#
M]0(*R')=:H[!R/-.@R.2@\7[+)3]I$QK:JL#'9-R>".+I_V[]^M^YNSLAYLB
M.V$B*$=T[,01P)DL/IE7.PD*\W124^JDO_<E?</^P37]G[)RQ><<,O6F#DG$
M.?VLX,R*6*6\^<BQAEN"T61<X!7C$6%T^[=T_3Z$*Q$K9'W'D"3'[]0CX3'V
M0H)=P_!0EB)/3NFA"%79F.GST O/OY15?',,;]>[^L[^L^RCV8?Y2/,QXT3S
MQI*B6AN47E1/Z9/N$R_:\C7+4^3[K]NJVJ1*GIK,V*RHG]$+@(?C[-V'(CJ:
M9"H![2Q4R]5[=93'.9[5R;SY;0NY?1(-]E7':?HW#@\B3J<\GM!J69D]QL:(
M0LH#>"H60X79!*K+<0^Y^ F,%(^WSRXF/VGFZ/'NC7G]W#[@C4/-:1;9J$64
M/2P8*43NQ+ MU=#TQ_1R$:KDS+Q$)VI$-%; )5X9*'([PEB?"/V:N!Q<)']^
M,07G"!N-OE;):%3"C1A.#<24.DVH&]QH:T<-N]BN+]A\HE<Y=:JHOCC0=:7#
M]"7'7='<%U_/Z/.*RNJ93X<.WE SFSNZVJG2;Z5KHVD66.TJ+.1@2?H5F?=^
M[:O3FZK\0>,9S^KZ2^=*EAZ$=]&.(/8"!?:37%S(;FA5-##:J2G<-_M3@LQ\
M2YSS_KWQ^KA0:M%#^:9-H^[.9D&VX\'L)5#J?<8K-TT5P+X#)J@I@;A90S8$
M8915>P^%+5*J?V+9///A*&=Q8YU\:J[7\MYIWI\L&R@ZKSCU*<!.=J<.?Z<;
MOF4.9@I3!@:^-KWE"E/$'!RQ%1H6'C21[-A,%\[](+&':?!%O^Y9/X:?D:DI
M26>EI+3(18$0AVMW?U$]P5%-T8W,PFOP3Q;6.TN6Z4<_/4"[U)7,<5+CWI6F
M\_+MJ_PV\0\_+N!SKKR;R5G$J(?EY5Q44M>-AR?I+(S[^OT8Z3+I.6^>8UUY
M@DW.I99O1?!TAZK=G66\9\5FTD"516T'W9&10&?+0?#!*E,61RFY#7Y$VJ5[
MBCANV>7GVV[,:)^3,W+* GY<?!G[/@R-79FZV!6&)Z! D$4( ^I@M.EG9".D
M<Q N/^A>!08"D<I5[X$ H1U(^=*="=;RD#-YUQ2^W%&O-6N=N3#8M _K*MYE
MVGF6_.I-TL75 CW/ZC?VLF8Y],'&I &,2=>W4E-R7,P4OZ"QZ+<+?GH%-]34
M<;^:EK\MO%UO979 ]R#Y$3!R1"3*%3Z2,-LJC(_S/EU5+-*6!@W-'9"L[,_K
M3?3RG#3EJ&?;=.'@?/?@Y>4UPY$VJ@,>Y0"/)/OS&E,,XAKS7>IDJZM(N"/.
MW>9BA@8?QZ>_<9??3H@[F/#$E!@?@GS+R*IR'\XAX8.9W'1-1A-":E+N*+"F
M1Y9]9H-FO57-9OA]J,+:TE9/NK0N[?R#K1S+4A'6(?IL-X[X?E!3O!YH(QE"
M.0-:0;QM.@$$YAF2?RC2V*IL.#G-DCE4(J?CDRT_![77/Y:+KU$7[.E6D E"
M^"B9>WI@*L>UM59Q?L.5KZKQ$P'%9IN79/KE6FZWF'J3^$][/IJ>*6E<<4KW
M(!CZ.>:4K2D%PNB\%4S#=!*<$9<,WQ;S[_AS2=!A-S!N%^D"8#AX5]'2C9MV
MODH'PUQ?/&/O#VU^>C+*^ U\Z<2N:IDBT'@V#!D2R;@W 6!(<N8"(](QD ND
M?$#-2531I_!+2#Y4W7U<!_0S)@YXR]P(WX$<^K?EF7*D-9_I=G)J@1.^;RZ@
M"7.I^ MGM6O@ZQA/G2 AR[U<@]%B<B8#8CG]BG/+0H)>14<JDH[ELSS33U-N
M7(=*-Q87@+3EIM8_K*CO[VU#;YT.X&*$%Z/6/?'K^?"OCG\NB0'*Z'>DWNU
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M$8KPJ,%RUTS19*JJA)O E%7YTQ/A&T9Z#ZM]5S,&V&>_F!$A&C944V"WRK<
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M(?U!//T3M4[;5>XAKHP^6':JNO(:E1+)B P#G!LI=4U^=</^AUYVZ,\'G'=
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MXA >\RUO\+_SGH](XOBLGS@,\I>;):NP$@_,=FQ1OOY*VBHLL%=]:HBR8XB
M6%H<3A\A81ZLPJ[ZF^>:I/DQ0S["NE6OP:1?5!3P6\=?4E=4Q\75XX!@>>4T
MO,O&=?>F^(2_LWV<"E=A*DLE!*6>W4-_?&8',L?\L" ZV1ZV"GL?Q4>OI _C
M) ^=L*5?ODN0_ZE1(730?T<?!;&D.7QC),HS8JU&:Y+)55U$Z$F'-M@U!]FF
M&K>:; Y^2N$QIM16)=O=U?XR";NCMXS]L4CM#[=R^1[K'?DDWH],=T>-.=G^
MM5VXR%0J__ ,:( 1J[4))Z&6/1#\>IRG)-H3'71:X)2R,*[&& $Y"C+)WF1&
MA9^C8JW?,UU_?<UP9VSFNJI7LLV@>;F$7M"($:O6"(NAXI;B"P*5+\ 58MPM
MRYF$2\T44O>#CEN7C@;U+2A]<A+''M%N]<L@?,O6>1>ZD _1QH&57,E.@(:<
M006X*K0!#9IB#9R0!)[F*BFT62V;MZ,3\DU6GMJY/AN9(/.95=:>NTHW=[^5
M?Y&^W?.TEN-;&X=Y@*?+7Y1L=&<!7^.%8:""R%'L-60GRWI5?V^!R.!VO<XH
MK0C6[LRNR#PY:U9<6WGN1/_887SEX[MQQ,QZE/F$I(AE+AVR+-;;_:5%JW@T
M)*=)9%7R>^G1Q4W<9PPM%W-6R!CYR03!D&[8CW<J@J ?H>@:?#O\?Z._V!%&
MN S0H,AX!:WWJX#OCM:5?$35D7E,+GH8)[S6;Z_95D%N1^L<?_VP*QGO-C2I
M';RKRL0=>A]7;[H7N<<7MG&G: *@45=AC:73W:(#>!7Z/VLD=0A&76Q<QFM<
M!TK#ZSU_[AS=[&E+GK.E2V79\+[^J]%CF\>>(]9+8\N&-9/GD0J361/YVOVF
M%E,['6;#3,)RMCPP,MIX1PJ4)Q_2BQ"=%^\8DM@3WJ/4*3+1'@+3!;2VV&9P
M7M>*@QFN]?7W<L4AU+YNR-0187Y:3R/_F>])@;Q^%08:$A,ITH1^RG:<O/@R
M>)#U!S^)RG<ZV__3]:;(ZV7J=+]/6^B+W(Y^KZ_'BY_,26[Z6J$P4U93-,HF
MBD!1SY3"?_;(JC+DD6F#S=5+H2FD@H?_X:'%)_!..%1%G5$'FB$M4?("3_/-
MN8%9-YZ!^;U=_EL^WW#=-J]!.F4MV><RWQAIU[7-Z?K]B9ASTO$9\<+.^SNE
MY\@29>20)8I1P";3D."NQ:1(.=P,$(1.R[%-:M"@K,\&@3/'Z U;-(BCP2=S
MRN2X!H&4W2N%D9 BYKM@04/2=#EDI\U /3.5B/29&#-%IZB^;39ZU2+XE!M3
M1K-\+^$]+VX\.&MU9Y\K8:[_$#)[O&%\6DK@PRH0(SKXUFQ,:T'2XO(J+,5^
M0XC])L'B?;QNR2'_GV>RQR)N5[:IQ_HED*/VAW4>3V%M?FL)L&JP_-,U7T42
M^;7U#T*2<!.$%@!_G R6"-#<3T6%P6.Z_*3T2S:O^CE$CX:6II;/69FQ2;^I
MCLSL>[B[W4K>>,]*1-6H$2T?WF?I\R;J,-2P ;%E5E.B;I<MW)QO/VVR/J_[
M:5_<)_L6V%)OR5^%B76,17NOJ/HB<NC4()3Z6[*J^<?O!HG6B[3MJ-QJ.&BR
M*'Z</&T$Y04.D#XK5AL:_^PF^\/LH>@H?COT;[X +9QZ95R#,"PQ2:;Y*ZV4
MV!U@*P6QN]I-KQNYFOFD(]#9K7,N.5,RVW)=EBHRSFP4?OO>9P4%DB+A$S!&
MA 5HK4@]@@4>^;*9U*J)K),D![-K-HU,#C"=.(CH&S+'J'=.5/1*N_YTU&EJ
M3X4%?,@,79!=HXFAU/J9::(&>*OK=/V<AJ2[;-A \+=_>@--2Y<8\DK=W4&U
M33$DY;Z&RK%U=_NDOKI)E_W+]O3_?_[OSRKC?P!02P,$%     @ ^8'V4G--
MGK$%Y   #@P! !0   !B:6EB+3(P,C$P-C,P7V<U+FIP9]2[9U13T?LN&(KT
M7J5&J4H5 5%!(J(4$1%4$! BTD% ! 0EY% $I @""HI"!&E21&JD2 Q5143I
M14A!14HD40Q'TN;PN_][Y\O,K)D[=S[,R=I9"<G9><NSW_=Y]CEP9CA$F,1I
M&WL;&!<W%^P*](!Q?L'$K/PBKOK#_&'0P<69AUG#N+EVCIUG[IV#EV?G>1<O
M+P\OWRX^OO\,?D$!:/#S\0D("P@*[1S0*Q%A(9&=-SN3_+=3N7?Q\.P2XN?C
M%_I_?'#>PB0%N$]SW^;A4H-Q2W+Q2')Q^F%PR,9=_S&/"_9?!Q<W#^\N/G[(
M#&'H"VT2D/D\/)#1NR"+H4\3H,]AO)*[I/8:6?%)._OPJT7*'$S**Q-0/]&$
MEW7Y0M4POGHC65!(3GZW@J*FEO:^_3HFIH?,#A\Y:GWRE(VMG?WI\Q<NNKI=
M<O?P]?,/" P*#HF*CKD9&W?K=LJ=U+3TNQF9^04/'A86/7I<7/Z\HK*JNN9%
M;7-+:UL[]G5'9V]?_\#@T+OW'\;&)R:GIF=FYTCDI6_??RS_7%FE_?ZS^9>^
M!?[;WO&+"\;#]=^/_T._)"&_N'=RP+_C%Q=W[,X7)'EW[37BD[)RYO>)E%8[
MF"0@<R*OK DOJ&[L0I6]>N.+D)R&"4F3MN/:?SS[O^=8\O^49__#L?_=KSF8
M" \7E#P>21@"QF*69^Z#_?]T\,#)\ID<&(F'*M:QE/LJH9&A9-O1PS!\\OW?
MXAE'K9$9\RBL GXP*@59@FLQ9,KILH6&&%=0PM0MBCH# >"%ZML:^>.JYNPW
MC[D@YXILVT+O+A7;77I4/3YVLC_O==^^E=([BHP-^AT.+)]_*9<A_1?!TLS'
M[0.(Z8  CMBTJ,:!)5]$J4X! 1S8O#:1D-8M;7GO=K2H>#]&Z%?C1H.OXKW/
M,84D0TD_K>/K LZ);V^.P-"OF>8T_JP8#BQM3CX3K0D:((36L)TJ#82[%N:L
M.I75%?D(H6XZ+OCXB\,9P]7%SW37O\+X6C=+?.VFZXO.?_[K&3H?J*$Y4+&F
M9L3/+U*1,H*. O".3"T.K+V1*6M-CX:,\D,%3C="D7$)416<MHBE\?=YA)?I
M/_4V?-VJIN2@FY;Q<*3[!L_^[$.[C49UZKN'<CBP0'@J@FH/@'K:ZT.A#!$0
M[;0K3IN>!DC&^9(C^KQTZ+X5B\/^OBHCI=6R72UZ9I)=B;^>!9CJ&/VPN\3S
M5]AE8G-!]8.CD]O$GK;VNP&>68]/J(DL:3Y*/&*J9WPJ4FJ4M_;GJH**TMZD
M;Q*VSL@\3+,;4[J.'LSJP!'K *Q<$\,=]  4XV+[ .G-2YL1/(15-\D5W7B#
M?)&B/U8RF5CINY/JV>_SI%HK;9#J?POP;"GJ1B)*LQ*4[U6\ZAY\U*!D5UJ1
MOY*Q_IMNH_K(06$INPL7%31*CYAP?<.U.%$ZB+BYT*7EP<9$525J^(MJ)%.*
M=JHPHP&)M%=(/U?X8YJBJ\$E>*4LSCSQR$LG8B-EE-R8 :>Z('(Q38%WF?K/
M5]BJH!4)$ GI1/>TO'[=>;2DM>",]M=Y6=_]J7O$C(M!;;;@$ ?&FP6%/X+I
M#3VGL6<M5< "AC88[]H,WJ(%VJ3C;VY)+^P:RP\[?/E=$^6!=&?$TU^CEE_=
M+E:@^P >7!@'!AXVI#=0ERG[J[S!+'RG>&*W8%0DT=UT?]FX:>C0^ ?\L6_7
M.Y\D<=<O7@X_'?ZTP^7='1BZ\1)A9K4P<E4Q[)N;W)\]<8')QW^NWI;H2SXV
M<"K^Y<_B,$K/DYJU0X5;9MFN8XOQJ;9/<\IDGC9MN_TP6U>JCHM@"[YA)+#G
M",V-;T75?L-32X7 A&?,D]3T1(_M8$IK_$HKX[&A3YN4\4'-_KSGLJ-*%T2X
MD-KLOAXNUE/$-?BLRSR]D-7)@1'O<V"M'!A%DN9 +E\,*=T+XJI6.J.G\'X=
M#ZS$LM37[A][^*9SEUWO*057&^*^B^?$"4?_ 70LZP5 K$((H/7A NP/2.KI
M)T[9EC+LCVD^2X(]%BO>RKXW!KJ'@68O3WOM]ZFL'^N'?O'+ED"Q=D&TM:4S
MI3FP/K08JQ5UA#PO+@=&N$VT/A%$Q4DS K9L,[]S8"T_NHVZZASI 3F'KHR\
M'LC_:._[]QX,[8<>1E(]&D&=6$H)=6J)O+R^!DUYL&7:1-CK]I9-*1TYEV77
MJGLK6/NA1;R!R;<;LN!7OO$)*=V5W%DLG4K##HJ#^_@IXHR]<7_PBH=2*E"R
MG[M5@.!:V]LC%J-U*\U>7S7[FG[3^U?:W(_S^A73Q,%#3FSGR49@]CHMG?U4
M]!8B&>&#3,)@Q9GR&_21SQQ8<(+61G^I")4#2^]1<4(D:4U4IY^9C*CX(H#M
MZ,J4=VI5BK'O#_KV++3P1N5#H43TJUFD>\C-_\.\V]:$*MKD?]:JJYWW5'I\
MYU O.<9:+[W<P.GCT"OEZ64(_N=)HVDX7PAQ.O*4> 8W4]RSP9QDF[Z'&IN)
M4B$I1%26$HYW3=1KQ?^D= ]>;1I6>T[Y)'\U:8.,HX;+,Z4X,/II<)(!8UJP
M7B*"#+D=EC"[9^((E[JHIE-O:B]W6TKE#'EW!)6_2O6[5#8RX>)EGOIUPTCD
M=&T-C(6:;*.(6^4<B1D)&'NO==]6VNNKGL_7S7.7LC$A6&0*E#+X7;0(@#_.
MC*!%T5M8;P#B0Z!5GJ+_,H0@_?>->&]L,5]!]6)<?*^':,7BJ9XB7YGM@1=I
M_OA@O]\IQJ^NS&<9QU;3,U@=".)3!/6D^%RC5ROH2[-^ZX%,[O:1S5W_R8')
M9$>\_(E6F?RU3E%/K<B)3T3W3AO?,O!#P?6C$F$PUF/'V),%;H!X54O0](I$
MWGIJ[^.'B.[SYHG++W4FT;(H:U:V)6P6_2'6PW9]&@*.#ZO)Q&F.Y^R7G.=$
M#BP7>],C9.U&7*7Z'_6)\(WS_5)V7QRO(VZ7J9R\8?GNMSR\!=D\?;='/PY'
M]P.CR*.Y/2H)\*';U4DF63C%E8,G:Z8\N@N=CWW;Y9:ZW]SNM;)H]SG^P-J0
M.==TO^W"MA?SL_.VN0?)J_[WY"U$6B1VV0?'!@-A*I1['Z.L=?@R@YX>["R]
M(XF7_4?@P':=?LU*ZS%&SZ(56!A4(&3J,@U)L:<5G:8BZ V-*:UO3ILGJ/<5
M6Q2=3?[UVV'^M5Y9H7NL3J';_3L\^RIC;U4S)=$;@_ 6+%/6:2EPW?8Y^J.E
M&@@GZMN2;CY<*C$DTCN6GAQ#BPJ?,TL;B\\Z<NU7N#HV\YN=2AGA_A>>M@LV
M^WC^>KI.M8;Q37BO%;<U/- ZGAS:,66J=]O@4E+!BFLHC0-C"VI#=C6P[N/"
M,+RH>#"/$8 Z!MQMTJ8<61HQZYWC:ZM=,, \\Q1FCFBV2MIE%AF?_NB]]/C0
MD%#=OK-Q&![V- *.\XL S?CIN7"1'JV0D3HF'!QYR30"$\AAIUFE?TZ/>7JU
MO$JSOH[VC]O;\\!FB>5NETS<\Y9_%<&4$:8W=;'R<%<W(#;16IVHMWDO_C(8
M2=(M<3=Q&"[W#?;U&E;N/226R.9[PT_D[_>R)G-@;P%>IL=D*QAFP'0FJ9BY
M=;:U:PR)%!UJ^OBNLF-.^+[QIUWH2QP8_@)4%N\BFOC7'T,>W@(+EAIG-WJW
M5!7 =.(HS-ZRC*8V[]ZAF)O)(^-U0M\^.S5\C.9Q>9!8;O?S2^I,.<X!N&KX
M[R '=@=!=]@49YE9'5<U9\0"> <+?\9A)IKJMN[&T&-_E.? =K--XS9.=DSK
MH?1*U5-LQC=+5/F->LH2X@^^SC3>$W/R@N;<H<MU,N*5#%WV.(;J E=@!N:2
MW"CW(+M(XVSXSZ*CE[=< 0FF-LUUVGO\(XTR4-%.%JA.G3':^V[?Z;RIUP1P
M7RQ3VG!I= B8"\7CL%OKAHSSGDP=<)+8*/0U+I!R=#F]X,*8*4O1OA1XM7 2
M'=0[K)&C<>Y;.,E:I_,?![;.@N H![7&'/8G M:M;P/4WF+*YA(W^MR>D+]7
M57)@0GUD;*_N6E,U<F&F5ZMX;'7NSU;&7ANK;H$)D[P:6Y%/B7 ?E 2MB.)
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MF'Y8[4Q[0A(&Q/%5[O8B@K*53P]T5Z(R?,PD1]6[2T._46N?_W3TO?S%XEA
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M'C6<H.K;M.'.@8T5>*_L[+WP;G%@^=IUP,Q6/0>V8M\8_;]&QN%,.; (Q!S
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M;/Q0R(W*:%=SY8'2,OKWC@4+CC:Y1FM%#IA[Z<-#-/R"(3@1A!7V!!$Z[P6
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M,F=)Y, >3YE@077QG:<?\_\1"&98TFU8L+%[>->0#_J:HM$Y8V [1K<XBM[
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MGHF=9UO/,-,"=L6ZNE[J]:KYH1\M=H/M.KUZ )7,=)WN8 X<!P>RX56R(GL
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MQG1.WW6ZU7?9PRN:B%GPG#^EFAJYT%9$&_*!3M@0%A=5H$<>>7:]J.\Z,!5
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M*S6L?R_C$__)0Y1DUGE3%&DF'S&NC>C"S.D?R'K\]OXF#VW\6K/1%HR0[X;
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M)HGZ[Y[QL?_O/>,Z8" 'LA =->'&E $K<KA!FU$4'09RE0BF(M0P0.9N(?G
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M;E2B#\J[7HN%0MP0B-5[-)[2+-$[USCIVHPJ_#1%0QK];=1W.[^']*N%_OB
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M_'<VL RR ?/F1"-&;-@RK(D>.L\7@%^8#JK\G2"HH_^-'Q"V^<$V&?#[#S*
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M#D6IV.GG%XMF8F-:? ]^"-ZC"UG0BK5<YY,KJ#"5/!<_$U5]P27JAP9_X!W
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MRTCZYI&S)NY",,A+^YA*G%D2QRV^G]E+RP&K08GTM&I:VNIY64Z/_=EL982
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MUD8\49?G_^Z#'ZE\WJ7VPO/P71W[*#;_HW$A9_=&-8>I>]JJT$ZR( WWP-;
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M#PZ9 =A"OP?S ;#'=6+O@=5)*W'>^A%7\2)/[IK*4\I;3^IW;B#*(S1O[!"
M]R%#H((LB#,4ROPRA.2M.\G\9)X.H4R?1%[ -XEB1.=&$DMK+M5]P7J4V]^K
M0PFRO=3&__CIM&L*N0-P;$*!;QN:K<+#XZ??1#UGB_6@L1\?_38W&,FFQ /H
M3TX:06Y +R$SRS<E'?S!:)=6!HY/^3BZX1KXEE<L7$5QP;LFZ\D8NC+/$_I
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MNQJ(@,46P0)Y;@?<)PJMRV67G?K>XE@3N<_P=4RAUO7/0EM#BY$T*50/@6P
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M#M2UM=I*,@?+,#2-@%$.NW+$$5TS?]_J8Y^-/EC/1#US)3V"T+>7],"8W>[
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MY3FW)L^:HIV!E>Z/]G9R1YDC#?3H_EH;Q9RC9]6/NFB(2@3[B+V % WO='L
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M?L<L=<]$=*C:Z3BO'E%ET]2PK&>T"O,F),HR1T4-\';"U=H^C J4WN7XMN?
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M=S\ P+NBVUEH?N[4X,JOVT8C[[2L2+\VCW.&NW$5ZMP7 JV?1'VPECL(!CB
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M]+;TIXW'C:_&9[TCY%!.374M?*)C]^[6';,U;4N6>D-\%UBK,?'K"UXY]9J
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MT>R33MIB9 &:H/!0[WTXT9G4/,O@'B6@9;&((SF4D(9\2E8#IGW*A]25GU'
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M^GCXV[-*=B7(H]L]N0]9Q?[ :$*U3I,H?P'@1"7Q%FBI%+T((?;&%\O:?70
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M+2SH8X?#OVS,1RHD2NNO>:*MJQ8^509@KTTN!KIGR"=<1'HQ^N5!C1B7@EQ
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MCSWVCS#68&1FEC7OZ[ZN.>][3MUG:01=71TPDL5M#(F .5 KG34,%V7#7/M
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M/A3@H:V1>7^U!MY9O.6Y\KV1#8VDP-1BI0SD?M/3JJA-@>)W":T/_9.V"OC
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M^R]S:NGP[1,=V+!7BA0^9C!D =UO7:GUV^?<CJ?@5AQ2=T!=M"!LF2MA-@2
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MJIE/'X0O',X>H'TOP=G6]Q;80N<%!2=)S8>N)#>W3RQ$'^NP#G"(F$1V6XD
M9XS?/WXB<_U)X4CJ)\--_RJ5*!*<I8SM%!^MK:':-ZNZ/+2NO_TYZ/++.F>X
MV,VT:,L#A_>]/.T3]>K)+3=%);'KF=^7JGQ0"C6)[ZGQY.?Y[8=J!*I&AVR6
M!_IP%:2=P-1S/PU6D[$6&V:87O"Q OT$L7)9^Q ;=B<KA0W+Z!JP1+^S9"G6
M6&^5PLD&71Q8)=8P&[;B"_ C%EVK(%JS0(LC'/SS\-Q-+<)S'$U]%'(%WLL4
M$OT'$V'^RP_/[,:!!/W'MI"(N8,Y\1M1E%W7L=,/3\8UPJ,E3U*$-Z)^46X=
M1-RF^. "%.$N&@*5:JMJB)J5-(N1B_;:4T&J5@1WC\.,$P-8.;_$AB2-NKV/
M3 5L_((.Q?#;N):?5IJZ>%I,NNQU49[ ]="+7XCZYR83F6\9''3#!?_HY6C@
MGLZ]"0E'H[L1$P.& U)EM7$G3C\L5,U-U<X2.^_N&3M6^X;Y98;*.U //(^F
MF\PE2=N4^*\',Z0JG/)?(1-45)ER&O&KR9X'M+^=L^]->;,BWTM['%R-#U3,
MZ$%.H^X/(*>Q+17ZN-(V<;/ILG)/8RTO1.2C+14M7T<<4*?*ACEU/$^2;>'C
M8.SMNM.U],B(>75V7M4@_:*'\I-@ZS/5BYD4,?TSL5^;,!N?G#0D3X"MWN1(
M Q[ES G'TO#G/\6-@H-8]VH66%QOZ0C,G0%=!(B83(T?#_]%R4KY.-(2\.D3
M=7=X4TG$A1OT#N7TD&4[-RJ>S->,'L)-+"5&L:1!<3>%)>R1Y.M=&/KS-[:*
M&CQ'I=KNM8R9?*'W9<A</!=RI<?U;9-/WQAR\ZU%Z+'';N<L3.,-UWS,2MQ6
MEGX%J"S)T*T9>LQ$P,F+HC7N]D,3^83!K73?(+3_I]3^C]IOQJ8+BC*^=2=Z
M*YIXAHK>,3;*Q7XC[/?&@2?2,8JE75'8?:DRU$-S#_3UW7ASOKC>M9Q2,'Y3
MC[]\]O"3Z]@>>!&ZD43TH+U@PT*Z*!K&MO9U=CH'RRE^<><F5]0Z;T<K'YQ*
M^&$LJ!"7_0Z3KKCWD*;CTFW*@#&$^[D&U(,26#[P\NUHC(9D0??3 ^%NEW<&
M,K4))?N6YS[__JD0JMQK_H$:<,X+A753 I;MZ L5LX9V53=Q3XDM"?2'"P&
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M;9L)<3ZTZB10G+>!CH$Z;896@RC1^>T ^C\[#E&G?^JY".*?.@ZP- P&G'V
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MDT>6]D U!*,PCYE)6$G,K9[M6.2A2-9>,^H&#5M$O8VCHUITY4'$_L2L%EJ
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MN(MON1W/&8 2[^R_'*(N<6S!1 3K6>;X@K8W4C%X[/YI=WC5N2/4[9CI?VW
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M_0),.ZLER#P*HRB[RHJ>V[5QK%\3BX)"EZ\=E#YOF;@[Z)LU,YL&*;+@0-8
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M<P-.D[;G]E<^DCW@U_3EXJ#XR#0(KK$I175"&+(,AQP-3L_3$R?S6L=;<'M
MTR&/7<DQ09YM6UE1!+> N-1;[0W[VY,^P&=%[^46%U<3.]+223\+[\J:]AQ%
M17QH9:P%O"-NX?P3<O$_?KY+M!KW@@2?MDB;2(W3UR?J>WEE0(R;CC&ZJ\&5
M/DO3KVD[Z*]IGH6>]25+6+S" $U;+UV+\NV+EZK+M;M?VM0>V$DC=XR)Q@ZW
M86N&ESRI:LB6)B5 :MIGA+.E#S@TS5-&MC#O4^>6:0LIZ4?O=W_317P[T29=
M*EUM-7(S,;*[=N]);WV?J15B,ODLA66='^@$P2A)],8W&O2SG7;>3TB9:E=L
M1+*R%6O\E#.XNX\?T[;#O5=M>.[2=HAKJI"T,N)*6=GNTF5&9D5+MUE!LQ:E
MEP42'AMH!Y6/>JD3E<=-!^PM2$9HN4WU3#TACD>;98J;1T?><IV&IV6(VJNT
MR]])R;EL&=.0?ODA?&*QY^O186CV8!K^YP6UXLMZ_7GLY_7>FG?>'7?)5^ZI
MKBZW(Q)Q),L1;X@[=CQRRIAVH*)=9X)8<P]AX5D,Y!.,,JZ'4(@E8[;GD-TW
M5X2YOU=^9-P(?R\1JRI7"G< M$D_&>S9VS,;@2/YR$\BEB3L/:3VZ3=!H9U-
MG!7U3T9$J6;^Z1^W9'-OL9]PY:M0-C"4*JX. 0.R,WCZ,X@W9CL5@Q-TA]X-
MVM4V]*[F(4/28R@U 4(YVKADO)26I'CM[<,+G\7)J_?8%!=X(82$6!@K2-B^
M+KJ"O=]#/;Y(!C MD%TEZPG\0=.=.OX\8PAX6B"YS<59[%.VD]</:1<'VL,G
M?J(@* 5E6Q@:ZN/.XT1KFIT(]NI!H@6['E&P5_(\J;PN5]";P73ZEA\L.76+
M%9F=\ES=V4VY1V=IVVW4F (!U0D>GS8FI[6WO 3Z+WUAB"+D2*4QA0NI32)?
M;E\]%Q":$2HF?=?A U;IA,QWKY<%E[&OFWCIQ0:"0=.4##)J*2V[>GLX@L\#
M=4\E"_L#MA'5J\HI=BK*YCC=ZX^,]BK@F: 1LVFVI7&6%R@&L-13C%Y8%39&
M28^M:!$F@$% \1;[/5/+<P]+DNCM[I3KNS_FGB>]?:I^+957[1X[=WSLYSLE
MEY-F$RH:GKZH2E"U.U::NH'#9,8[9+T@K14WF>HTE/E:!J8IA%0N30Z-.DV:
MHQVWFT;=H,=!\.GJB]N]-)='&>*3"X>T-#6'AN&JG&:1UUPCDN9CWQ[WOF >
M5U\+XG/"P010+4+^XLXV?4TG&5_&H ]7*E5V(:X O85!X?AE-.H6I<<O_ZTU
M-:2U66CH[HY=N^BPUWW(88RQ2L'"5+:R5>6H@LJQM',;3L8IZ7U6?AQ/9N\.
M!RXO#X[Y%%L845]]9H401V(LMC99T> 904HFPC8']?Y&/Z.)A1R^1(3EPPYU
M@<5Y35'$_!\&K""8]\ B+[V6Y?@ M;6*_Q_E_1+EN03AFIO8@0R\^-EF,!\-
MG >$GQDL2<=9?0THWK=<HG+$NZQ;H.B#9-9"<_3@JWL&;&0X331NNS8RV>[=
M$)8%4PXAK@-2E/DQSV[><+2@BG^QJ;3S3SX?E4PQUG8#-:S%[Y764$)9>^5
MM6@Q=@);PP1&':G?'LB>-CO$[4SHC44>JR.+#Y:Q'<F)_T[/%-/Z)'9._.*^
MZ_=A+E]/@4!<?V7=?FM>YH&C"5@P+E1TX2@<,4S0^1M%Z'\WK9._A[%I03/[
M::RL2_^( 5PVU<BMT;*8OMX/9W*K:CW-"I93U?T$[K>:U-FT?-ZW+*^3U.?K
M&2#XX?Y1OO=OG)^ZP-A.2M6J[_Q&/=N>)4G/0-WVV1?TDZ!+NSJ 8'L3%$\]
M);*.C?+O][ON"A?PZ^ W5%=*Y"3Z/&\>K9$&G3K,E_T-6*3PT-],-Y"S[GL5
M+CKQ- 2&7EVY>C9@=OQXO&&RNR['QU*#2R931'U='!L"L2U5^,M FVTM/451
MJ=3>JL\%W48&9O%>&NQG'5+\HYZ\3^PT51*IVVV2(\]FX%* _)(.:T<G;*5U
MXL8.X=L/*X1?_:92J6MN9*XO9<G?L2_Z'->'&7D)ASE=Y(V[YL%"(=;.O>8=
MJW9#@4T?/ZA38?!QQUZ? W9/!W6B/<><:!_.CW^H[G=<6G-<JTJ  5*^)#;*
M)-EPHWGB+"6P3T^4X&5VL;Z.U!6%.!'J^WCY55S>J*]8:>NY:_F*P=.[]H3S
M'J5G0=SM?>XQA,GPB"K>B#%8M)>>HX\[]^#K,C_)4\6[$R2^E>'1BA^1J],^
MB&'77,80=E<3U[Q(7N]2(U5_XH?3L<'*>44L7I;,%B6RY6@@O%?Z('FW-8^Q
ML8R4^+[W&#W@Q#1FE EJLW-AQ)'KI\)6HGIZ6DU="N>SI$.%EY[N%-[Y\.93
M+;;9[\[QKRLCY.[VG.?_'ECI4S)$]'PU;K9VRZ]$4,=;0^IS'4;ZS9NA*.J[
MQO4:ZY$UK"AP92J-N(NJ "10(@!?4A'OKJ"$YO2\V,,2_?[U'US>#GB5?N<S
MEO:4.R8GV"LA=OVB7ZW7YL?&'$(OT7B*",7O0O9B04B^!+8@FT5+,Z*W68GU
M"J;*O?^P;:J1];[H,T_N\:7LYGNOI]RX/7UR <WFKQ*9#F_M-E/R,QM0EAE
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M5,;8\#BB,-FX#<U=A1O!:X3B=IR>&I=5IUJP>R#M1CPXD^\H']2Z7.$M49F
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M[&+XCA>Y=XQX3V)FYW[I93$/(!MD^POR)L!2[2,>*0O]OI[GF*"S\QX*LVC
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M(707,+P&T!-^]#Z@$'[5?3Q%;:.#6O_D<$,8(4T9OE\Y]@UASFV ]$\+]]>
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M*_P&F FZ4+<#C785:V56);#)#OM3%:[7(?.[ _@VX,GFZ=SH/T*YIM3:3]"
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M2BJ=<+Q:AT?9R<OO+!QVG$NN5G:YJW[?:AH2?[J*T!D74M L$HA919S@52Q
M9:L(W0M^:-X5^!KYA,$A&AS&X5QMKZOBRRJD7OMZ=ZMG@N;IHUQRZ]N\5QXZ
M(N<;$#<1)6\(2OS-Q$XJLM["%UU>]:!^FW55HL"84T-G#L47=Y1@O_3@_96A
M7M78I(NTW6)I,XL3VX)Z/MG+K^,8"!1U&]W5X(PQ2.Q]!-]M&]J'[>STKM=F
MAVMN M%,<+RZ7Y%K=8 XU*^=G-V8F69L\H_#X:>>FPY>C3TE%%EC*L+W>I :
ML6.)6I;6CI+RLUD'9O'-6E%1];KXXQ.RM&&,ZWZS,?]3.NN./OU:YW[;XCY%
M+X)X_@+:EOB54HIDL?GJ?I!V/\R1YDF4$5(;4:>:BXJ;OQ$<\/'P_(7!O6)&
MX]U!H7IEQ]JWK^<[9[SRFLT$846[85Y(KC<07.3ZM*.W$W2>"\Y/4TF/\2IM
M%I5I4^&8DQ9M43IJ;)^DOAF=;X&Y_EW.74<E"M2C$0CBVF9FEFC?;E"GN]7@
M(14%,-ZL(L2I#'(8J8TN2>S+U$LQD (II\#.5V"XZ(,_W98G2]\I.B\_D\XW
M>-:B_OF8VK%UY$*@<3-14W 6#.%O@7H S@D*S9S)GH\4!//1E?D\I)A_^D1]
MUJVKS(]7^@*/G#P2<N.K:N\1S9\S=L>C%TB=C[+^=#-R&\DQZ++<)O1F@CAH
MP-2Y8R ..AZ+<N1 R1OZCE56OGMUSFFAS$'#PZNVS%+VXO-G*:&.\R,E/)\!
MM"^PA3B8AI*. Y=:U_9]?X!N"1O?-LARS/,=6XH/U>_S%-FOL1XPZ#J_;!N!
M?X7\W UJP"%9QIB'%KY',Q)7$=(V:@0/D,*]=X+26J\T %1>[8'T_!73[XC5
M1(][Y3RVO/0V,$&V2/EPB**H=CG@0Z8IM5)5 <9(-RVH*5,]4'$) Y[]!S_6
MX"[/W44J=PRWZ&ZQL(Y^8UHDN.FJ?C@B-4C9,._"OM0#5UJ$%_U6$9N&@4:E
MPCLMO?I4KT!;EYT-_6-3[7'IX\6WS[4$&R5D_STC=N";<_]98ANJ=)KX>8GZ
M7HO4F+C+"73.PQ/#9><::W8]][PQ9!PC9[=M-,769Y+5IRLN:6P8V)*.F(6#
M_7/L0F+WZ"+T"7BPBOC3'>!.=P&DZE5  \9L,PY)4 =O90$^^)"F&M5_R*]^
MPGPJ!5<ZZGKX4:/2<UWC^I%>YZ RPS8'S<>N3_[OSP#___:?M76KH_\-4$L#
M!!0    ( /F!]E)&E#W;*"\! *U= 0 4    8FEI8BTR,#(Q,#8S,%]G-RYJ
M<&?LO =4$]_;+CI(D]Y!0(A21*DB3:5$+!01$141$*+204 $!"5D* )2%!4!
M12&"%!61WB&1K@(BO9."C1))$,-(VAW^WW?.O>N>WSWKGF^=<]:Z=WW#VEEA
MRIZW[?=]GCVSPYGD$ 'QDU:V5@#7-B[@,OP'<'X!HI9>(5>] 6\ WK@X,\ Q
M8!O7UK;UN6UKX^'>^N3EX>'FX>/EX_M7XQ?8#C=^/K[M0ML%!+<V^)NPD*#P
MUC];G?S;I=MXN;EY!?GY^ 7_AS?.>T!B^[;:;;>YN52 ;1)<W!)<G"X  <O(
M^R_QN(!_W[BV<?/P\O'#8@C!)]2)P^)S<\-"\\(2PT=CX., CP2OY&Y]2SXI
MQRO\*J'2!^(>%FQ7/5K5+G-VB*IF</5&O("@K-P.>07U/1I[]VD:&AF;'#QT
M^-CQ$U;6-K8GSYUWNN!\T<75T\O;Q]?//R L/.)F9-2MVPEW$I.2[Z:D/LI\
MG)6=\^1I;N'+HN*2TE>OWU37U-;5-S0V-7=T=G7W]'[X^&EX9'1L?&)R:II$
M7OCZ[?N/GXM+M+7?ZW_H&]#?S2V]N !NKO^R_:->$K!>V[9\P+^E%]>VR*T3
M)'AX=^OS25HZ\E\)E5(Y$+==^NC#@JIV 56#LU29JS>&!&75#$GJM"W5_J79
M_SO%XO]#FOU7Q?Y/O:8!86XNV'G<$@ 28#$+4_<"_Q]MW BR7"H'('%319L6
M,BIC*AB*UDTXAMZS;W_G3]GO&9@T#6N0;^\)2T#EX6OTF+):;,%>QF6T$'6#
MHLI @NV";^LJ^*-*IFW7S<^BIG.LZP+O+N3:7'Q2.C)\O.MA8^?>Q?P["HQ5
M^AT.\(A_(8,A]0?)4G^$WPL2D\'M>&+5O H'B'="*X^#/AQ@1H-(2&J5LKAW
M.UQ$K LK^*MBM=Q3X=Z7B&R2GH37GB,KVQUCW]\< #"-3%,:?UH$!TB:EDO%
MJ$.Z2,'EAF:E<L)=,U-6F=+2HER(8"L=[W_D]<&4OM+<%UHKLP!?[7J>I\W$
MVYQS7_ZX!<[XJJEW%RVKZ//S"Q<E#&#"P'9[YAX.4%_!E#E&#X>%\D+[3E3
MECD;H"PP819)X^]T#2[0>>ZAUUBKHFBGE922-=!Z@WM?NO$._4'-MZV]]SF
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MI!U[[XJ*;[TBD['RDP-(IX>\^XE1&ONU0E%-++H?'8OIF#"XI>N%1NB$Q0(
MZZE]Y/%,9U"LI,9O8E'\X4IBQ],L9.LYT]@?[S3',#+H8ZQT"V *\RG2U7IE
M @Z<*ZPJ0X=I[M-#]U\2.4!&PTW7@.4;4<6JOU5'@U?/=4G:#-E?1]XN4#I^
MP^+#FARB!E4]<1>G$X6G>T%AY,$,G%(,HO=V:9QA&EYA\<#Q5^.NK=F.YE]Y
MG1/WF=HT[A1I/</O^R9@^D*RUV9VW>N9J1GKC /D)>][<F;"->*\MOZ1_F"0
M$N5>?]@Q3;Y4O^<'FO/O2+3+_"5P -Z3C:PDG %F"B//PJ)]85%_T% 46UK.
M22J27EZ14-MVTC1&M3/7+.=T_*\UNYE&[8)LETC-;.<'=[CW%D?>*F5*8%9[
M$#4-3!F'!=\5ZY>8?@L5"$'4L2;=S%K(TR/2FQ:>F6-$A,Z8) U'IQVZ]BM8
MM2'UJXU2 >'!$'?=>:N]W'_<+HS7!O&->BSGUI4_WG,D/K!IW$C[MN[%N,S%
M"X$T#L 6T(#E*F<]P =A>=#1T$.&#]H<O%NE03FT,&#2,<U7]V9.%_O"38@Y
MH%XK89.:8W"RWV/AJ7&O8-G>TU%8;O8$$H'W"H%,^.D9"&'<GH"!,B8"&GC'
MU(=BR$$G6?F_3PZ[N==4)AV[CO&.VHU[;+7 <K&))^YZS[^$9$H+T:M:6 _Q
M5U=A-%%;&JN]?B_Z$A1*TLIS,;3K*_3T]W3OV]EA+!K+YFOC)_)WN1\C<X#W
M( _3=:P6"M)E.I*43)R;Z^K5>H5SC*OZ/Q0W30L],/C,B[G( =K/PVGQ+K**
M?^4IK.$M*'.A8FJU8T-9'DHF#@*V%@4TE1F7)H6,5&YI]Z,ZMNF)P<,TUTL]
MQ$*;GT.)DX5X._"JWM\#'. .DFZW+L8RL3RB;,J(!-OMS+P9!YD8JO.*,T.;
MW2_' 7:PC:)6CS=-:*.U\U43K$;6\Y3Y]7$%,=$'&E,-=D4</Z\^;7RI3%JL
MF*'%'L%2SR+DF;X9)&?*/5@NT@@;\3/G\*6-"Z X4X-V8<)CI)]&Z2ZJ)V\O
M39S4W_UA[\F'XXT$:&\D4TIO8; 7G YLQS=LK.@QSKDQ-:$Q8H7@;)0OY?"/
MY,SSPT8L!=M\L'+N.,:OHT_MOMJ9K\&D8YK-?SG "@L.1UFX--YG?R8T.'>N
M0AH;3)D,XFJG\S/RMY)B#B#826[HT%JN*D7-37;LR1U>FOZ]D;+;RK)U^ZCA
MPU?6PI]C$5?0XK0<BAT9F8:56M>[C^5?!T4AI-5$^17([9W_=/4E![*(>?F&
M@WE7H-83I3U_MU47J#Y7KEO\\W<.UG2 &IEHH8(A(*B.8@"TVCE^&Y=2SG08
M>FL4HW4FSCM^;=I=N%?[@.KU#Q_ZBY2W[\'MI8FE8G29YJPW%4CB1 479NQV
M4$.'F 2$XZF!,O94[1YGFI+<TOPK?*DFN1\<*[RV[T[LR_QJ7_EZ7B6=>Z,0
M)P/KBX,#(? M' F9H#1&'%*\P,H-9D:6,$\JM'VN*;L8]62JC\1"VC.T<R+M
M@G7V,#SZ;GU[4@(U-JA&#F0Q5$EZ'6 R:AMFQT\D'TX".CERE-J;9/@JG")F
M4V5?Y3IS/,Z1[Y:9Z$6XM*D]LJWX#"=U+9,./!]Z"PN.LCOQO!A5__B-([3(
M.Q9Z/Z?G"GI7@X+1FE>R;OT\:7J9;LA%SZ#4,+R92%8:TA.I@)FZ_:<Z,-<Y
MD7F(55 \Z3)_1V&LOUBUNN[^F7=R%*D^GI,DE+)?4'FZLA9;  F[5' 45JT$
M7QV &5&8>#\!143A]HW6VN&%^L@(BG%#]F='17WL"M4K$YO3MZ!DC[G!_@2*
MXU0P4_E&K.=X8@H'D%4F,RZRGECL7IK.Z)TJ2LDVI>AUA*DI*WZXEO*B-;J,
M[[+M'/W&[/I;L5A4':(;.;G %L% '(#V@YA?%5825=)'GKA;.Z?A7&OJ/9++
M ;HNC(O=2#]DJWK_V]3.&]4\JN.QR-#+$^%VY1>"!&=<:A]MSG$/^BIU//4\
MERY[Y :_ZB/3L3?,YZQ66!I\%7[%&0Z5'IHU!<$PG Q0EH$(U+ .!S(+L1"1
MU!9N-&!WH<8R--2H?V"?5/GXE%/A94_ER$\O@0LH"J/D$MANR0'\")#ZW$27
M3I@3E0J5DCB Y+*RAH7\J%?U\_8P4LSAM;5/AUZJV#SRZZ_O__")?.A9X+YV
M %$^'5SW,G!/:%' >(/5M*?(A_H\K[4B)<?ZS+KD@N^MD43"%I!-)]1G](1,
MEEK#0-;W+5.VBDKY7//VTD?YNE$YY]KH5\=WVU[W/*\Y$_N5E@M%DDU6(ABF
M8+LN2*Q"5AN7,X0@+HSR(G('H3M?&LHAE<MN@I6!V>/-KG-3?=IG;3H'4F^@
MHKY5-IGMI*)J0!@HL 7Z:#_80D&, +0!U,;8!X'N7]#Z043W<Y8CP3^:!'QO
MO?%OD'/^O<_64L>0 [1>>V3PA:L;B&&0*F:<NUU[F3**/:C*I)>D($U")TX.
MTBN!QO7$Y8OD',Q["HQJ.HAY\>HVG=SI7Y\_=_XR'5Q:LFRLOW3;XB7O7.V+
M)^]T2EPD>D([]^U:V\[46B.05U?<J3GT3QP@X2[:FXI?*&_[54P4T:"[?@DQ
M"N&U?#T0Y/NN/W>@P\TZ^FMU+9TFN79+>$;A1,H3XW[E3#H Z1 =)L^QA4!:
M&5V-E;.RATKH&!1G"@^UWA*+/[OF\M:PW)=A^=8K>_R04FO60PO?,U9DZ>NO
MXHX@K=^UVI'Z=%R5MOU&52>QB3[SG]R*7(IWKKTZ_?WG;=&QFWA>MCQ:E)6.
M]T)P!2K#L#1^$VS7Q*D%SILTT71?ABY@IXO\Y3"J7_X4&'VMX&4$&!NP7MH[
M"G6D25J]-6M]4)&%:,(*UR%XEA$B3&09VG#\\BCZ4$3!M#V)=73ZYZ#26.;1
M>SRO=ZM]*)>_();9N//K]UB+$ZPFD/B*4%NQLLH(A>SHHJS'^,L[<(9013=2
MM(06Y8_3=H7\@\H+6QY-'^< )VNS37JZK_U-/<WD73":P7Q$U.DQI7O)&]T%
M),1T UO@G#\UN@,[E7D*?46L-T^KZYKN^8J<$+J=F]_7OVN$UKG$F0_?<=:P
M;@E1GO126@ASISTUQY:5@=&$G-OG]\.T]LKH;*"R/O5K;C%VRJK"Y!GBX<XJ
M8[KZ]9G*_5&'*FI +U02GGINE8]IBX/S1A!J.ID$WFO5VI.L[8K)(E8DYRC8
MC[K&Y4IFF@W/G538+?FYV#C>]?BAOS:[$)9+S3V9!2[U+\N7LL=O+KTWW#CW
MUD_@(% C?LCL_-*G):4=XE:6_/%:M VVP)6M(<QZ!-^! Z0BZB,S.$ @?IO]
M L74GM6 V;68CZ#>KWMSZ9[6R6>?&QZ1-[6BBDZ8G-.N[!JN=SD[OC_Q!J,2
M)X89(>Q 7A&#5'PI'TG(.\I&X[[@U.!"16HK-S7'$=<2_:Q<RCHZSV*^7_N^
MG8'KLT4OJVMQ55'3+7[<?Z3HTZSB8M836.$TL)8_8??PGWN1I(;..>>N_3]S
M(I%JCZ:G/IJ%]HLG'[\1ZW692'/#5OOVB*#H2:PLMCP30^/+#+H"+F"3-TWN
MZEV[-I5N/.(QV7F#5G#UXIO:.\+/B<(3W_4H+V$UC[%2<'Q@NRPSFN9)RDA>
M7<>G-O.W1[.BG: &OJ;PB R)2_7Y/J.>;5G%*F2A48,N:J-^(E:36_-A'".4
M&4H;WR)3#-BGD>SN3>MDS.XEMA0T1*2(8%3\4()>]\VCNQ0LGI*6!;X.4>;M
MTJZGW?!5]E&_EWZ]4?B&4RS2<[TM\OB$&3PP?89_KXSL>&?1=[WZUEG15S.V
MTYU??MN]63YLD1A(IX0XU=?$-CH<7HJX9Z*<H'WDXWI%SUTVWQ1S-ZO$8COZ
M\M9L"EPH=R+]L''**D,XU<7;D5W/RE$V(ROK.M'M-4UI9^)9N\9UTX=[Y/?<
MOY!>76T@JRVEW$*$"1F,N9DR"6PA$89]+SP.SD"$=IA&#$,A'1Q &*,<: (3
M%N^+;7_NY#@W/\Y>6LJ\9*="4KL<*L^=]S +V.PDKE*:%I I*.JYBG1LY;L"
M(D67< P*)(*BR[G!#3R/%,L^1LB$J=W8=I/7_67P%S&SB>&(OR&PV=ZP<M%*
M#%58[C!DP&H<5L2H_#0HN(@502OI)1G..9_+IJT'[LMV<7:X[_+T>;N0P=N3
M78_O]CS=;5DQF@KL+?R/M5XHD>0 .9AQOXM"4#B %WMJZ-<US-BW6_D.>5+6
M^&"KE>#/!PS2O9P?@^TF>$\4%#FX8D=$3/Y@RR*9Z@1JPN*&+)[ZD -XLA(H
MN*#9#47<X _[;PN?9S+T:QH.R;^G;^[E_HZ ]B*94@T76>_0GM0?]!1(AC;]
M@X3J";GCFCC7&X>.X$M3?AD\OA&Z_=TZ8\8Z7,YX1"76BOK!5FOCJ5L&*P\D
MYJ)J938HF85L A(&7--E]E#! I;GI\EMATX]L:AS'8C)9KG$1Q1T2]^K!?^2
M1^3O?AS@IM=-Q?,/D[HPJ*G1,_RQF(_XRE[F@0V*!HU!3^0 B2]931Q J*]'
M 0.#=E8*/63%H<:%]>SC;_1?BY&6U9 IV<-!YH&$GX6Q%KHT%%-*C)Y+15(R
M:7+T*E8*2'RAS]2KA9IN%:/0EE2?)FKA1-?-">=L8_*4;WVN74MDW6\5_JC.
M;Y/UUV6<1W$BF$X$]14,;UY@%9#!@Y K<AI!;6A%D@8,V!+PG;48&@S-.=)O
MBY$?#=COJW,-GS)\]'.6/3C "0#]ESI!%ZVCBC&E%<D$RD@,3<7\+"(5)_2%
MB31)*/YRM#Q^\>>2EPF?CU3*L;4DM9G[Y;E4AR0LU2YCYC==M784(P%[#TE\
MX;$3+E**;:[?&9UL 'I&_;+\*.H81<IPY-B52)E9/35ESQ;M<]P-&M]]?#PW
M_DASM;,'$*(X [069%(2I4>/AUAZ71Q SE*GOQF?_I4ZAWN@Y^KR]:&$CDZ?
M-4^HJO9);GVM'=K]79GSCK#4,!_C^<B*QY-F"34P)'^/@%P)U">LEEZ%WKOX
M.GPEOJ8^!D<<^'K+ STUE=>R<6_N9L7)*JH&?0?LG'T,-/H6JQ$DP8[TYP =
MOT:8>H$<8'LO72.3E<;*\%1_MUK[ET+'FO83,G3-G_2@#E6 A;%FW,2)%7T8
M_V>P!05H+^DK__)S >SGZ$[VSA$D29;=M8:O!JO+YQ$&%(OH6^Q@U@SZ%=U3
M'E,+MN_'7\F (OE7/$D54U)LV0SF'A0U(T"A?(*IAIS$3A'\&,$O0Z,;/OS^
M/E5#433XKC1C<B6L-IHES46MV_C75$8+*Q=C$O6;C&5*\=-'OK 14" 9O/N=
M)I>&DV-:4N7HWQ^&E'\&&D>UU5+) N6G6LZW(@_(<C]X<S>_@;0Z"9+U>O0F
M-WJQU0U,Z31Z0O*"#91B]&FI.>D920@4:R]QL146D"E^OK^U&)URQ41B4+4U
M/_ K]<W+G_:>EX;,S'TBE,"+=54-PM*#MZY7[7&P;+HK_YKR+JA"9_C79Y)Z
MZGDQZ:I&[PC57?$'=VU^X>]0YF8EP#%9@]AN)N=)%2.5,F5:.FY >M8U=DI"
MW<I[(271 G*TUMX)KS,MS\;JFQ^*:_X=[FWZ],M;[0&&2 V^5Q85UJ'@G%S'
M :0<RE$7_2O=YI=-'-5N$/H?OFGK? .\^?R^27"_D/C!,H7[385^:S/M98&R
M]161>CD!.2:"2;[L)3[54/K.L3< 1* 7PHD['#.\F4.IAX,56>E+<2I$F])*
MJHA/T/L6VH1Z/(0.CS]\-V5I8!]B,9HO?[GQ;OULF?@G:30>^11%WP=??H9I
MQ7J*#X99+)Q(+7$'V%.NR7#(RJ./0+?$DEO/B?RXHS)2(.<XUWM@,$"E,:*A
MWN9*$D_=9->U X:?/X_1$XW]"QM22O.=CI_0_D6)?7'#5N/%"S%!N&<0TT6@
M=A!$F4%$/<@%2WT,!Z4GS;-+V8B!HIM,8CZR7H?]8&6&Y.D]_19#,-'"O^M>
M]/"EYK"W_Z;6=()5V%Z]R<P%5)=\JR\)>Q\AT6I-+C_Y?<)&(7P:12\:LI=V
M]/'O[ O2UO^0N9,O_*PG((YI&C9JD^N2/7;V2T2TV_+-JV6AOM=A$OIJMB@]
M-?/,:#A+Y9.]G1,^:7Q>9DZGNZM @O_UU2/;8I$F%MI@NP+LU\)_3:.N8$$&
M/P:FZDY].@ZDMX</7UR,G-;H"$]P&VN-+?FP5%-'D^H5ZI7.V.GA-FMHA_-P
MB_PIUHY(X@#4$K80=(PD1A^DYS!5<'(CZR %4?,7&< PJKU^"^?Q?:K%A]+R
M3+[GM(&[>OE8^9_:R'IG_0'A5\K[KE[_M'2+1Z)=^8_'[Z[#?-C7;C\G-K\]
ME\NYQ= IFMA;/< F9V8S>0$TA7&%W4]HV.A"IAT.Z4%,EK(%^?D[C]=2-_V;
M2V-;':ATD>CC8UZV)5G!*?XO<\>OG93(5XG4MME.;IT@HIB2(_1TFAX%2T+,
M#+(%31G>KLSS--_.H,/L"5+R':86L?;+NIZH;30B*R*BYG.VW>M\,]T?JL&C
M2.,/]!@\G*5ZJ6%L 0ZPL!J+D,+[5Z038&?[/3-%2:+!"9VZ(-$E.)!0?LD=
MSF<N*MI,%3*NPH=C)W-XWA^<OG&HPJ0&#@U)]N=R.->MC()70\2A9:=1,\^R
MY?(%$8>%M)F5B6):4Y@F=.^BC8NZBX53NAU60U]>P.<!Z^,)X ;,><WT:2;M
M* &T*4DLG2"E@_8EYQF<3)JY1//.3V!EY[;^;'']L5+H?T<8$OY4+3-[\=69
MHQF[6"\XP&4L!%<'ZAG$U"K])YSFREE9<-Y3)G0[@ATZK,0?'" 8O+98V(?T
M_SVR,G_:;/#/V;_8R*^,L75S::Z^J$AB9#MJ._K4!,80<B#Q)];B=T"%.Z[2
M3-(,5\5F+%\OT3K>/%0?&]Z537)T<CJ>WGXT=C]0\03IZP"I9G3@X0)*/5V!
M -L/8HS1QY[UYLM!B17+N?=?OY[Q6[#+G0V00_JE'T_R?Y\]?\+:5F!7:\!)
MSV\5U9KU56_]E96'=5LMR2)GIWLZ>J9^Z86$:%PL:$B4KOGPJTM3\Y5:U2Y
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MY9$X_GK'U5LZ=5:VJT<06_W;XST)D&IP$UD+,2/'%LPA8841NN,S'9L7FA9
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M&%X+UM6A%&50)/4>;PNY^L( 77I(&B1F(-92Q:8:V!_ ).3Z5(B'.FR>2=C
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MD;K*%J@ &<>C[-R2%M'._B51:79)]KH7^_=,N?:=>=]B&WG2;C=KZ(Z7T@*
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M2R3[+(SZ/@V.!&C]UF"K<-&0+,53",@9W%!"T,3%4CC S^G+<&YLX0"-/SG
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M5!I9C*)$_4WZ0^C$WL6(#'G MMWHRC/MN?UTHIAFPFQ\D6^7[9\?'?]J@3_
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M&.MMSZ*%D"8Z!D794X1ZL5C#-N=.1+5.Z3T?FDG'W:]#[W16AC_U.>0'W>
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MQ?K!DN$ZG$69MYYR[>(>?HQ"U&E@M^6K8??(% G=9/P=#[&_I9B34&W+!VW
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MFXD@.?VU1Z\R$T;6*R:B>P[V+V-Z$XT%CJ)O+ %P%_#Y%V'2%88O* @>NZP
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M#[ AP"1H7Q31K7:[TEEJ;QW;_%9GXNLBC AE(YRN21%N76\\E>+'G^_E/:]
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MI6,]8J".+\6"8[8>#NQ=Q/+-V].N0\/4\H7%[QMYLIN5[PBP)X;!=F8ROFG
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MB\4>DJL)''I2>Q+5#KVZVDA[>/U&W(.XU$W+2F-?E8CYPEX;FIE5PK1@@=^
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M]H?X6&;ZBN7?Z]_B_J'0Y"=V,O3WU@C4RH3^W]^:TK]R<&)<L_N']7@UF.?
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M7-$OU0FT?]D8;=$_>Z54ZX/.W?#=>@=D=U"KL@X89W.K+4%W;Z3%?G+AK'2
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M(LG95:Y5Z2(OKWI,R[@4^SNK*5I"RMK-+J8-[8YM$Q=@!T*38>B5R3JLF!P
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MC#:7EB)!:[89T-WJ:/M0S*1')?KZ'./G]9C5< &\W';K-\G?>Q$PU-!;/,U
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MB30SW*IF0@.>"8/F8F;\<AOPARJ2R5"?ZH%OIZKEUF&]V^%LN;*"[Q4<S3U
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M@^-T'JFV**?APYPPYQRIT^1=#KLG5=LK32PR2EU*5_A>*TD^<_82/@.+4>O
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M[**VMW5_[[>&JV4[[^SX_/XH7,TQTS48*$;5H, C7(VZ@AP>L;6XU[Z#Z1E
M;2IM)=(3@3*TME$+4C7=%_UE5O+82.&\^O8;+#=OK+_%+VNS@:9'=]TE3UZF
MI,5+RWRI2]WJ!J_2RW=<FP]51!6K:^3_(@\X\XX/#A03GOQTN7U=-B8+?:;'
MS<#$+:)TA2!Z/YG1468Z,)N9>#%%_/@#3%M$6M6\9P[:5-2ABSG5[J\\RS)E
M*F&NT5QGQBEH$L[<&L7A!X2G>A*]HFY7R#\<MSPIES3<OU!@-#0R5CW!+N#
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M_0UF_/LT,&6T!(H6:V^L%IB0YH 7!AQ<@RW* H<Z^9=_G=2EU811QWH1R1+
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M 2 T(DOH*2,5G*<]'0+J]/K"&>;TO&HA,)"I@3%OKT;8(^5+N7[\E)OK#:\
MKYPQY_<Z>"OH@NS9. \#Y 3A&30G*M=A15I-KF'HK=7"G$YHW%:>C---<2@[
M5'BB:;TH? =ILXLRD]<$Y508>+[Y:O.'VHBBO.MA^_LNP')46:+6D)&\1>UH
M?9*'A4_O&U0TV_D!8X-K2"#37A1D1T!FYU_44H/_SA[[56WBL\"@6[6R!,H:
MB+N!H4P$30\7CGKO/=M*E[7I9)G38JDI.31BDXT"C9''$(FJV/[*D[?)S46B
M.??JN^Z%TVHC9K_"79Y7>79 *NH+1!BU/<'C2&D2]J=A*Z'JXQ7LOJ8WUD#M
MC;7H5<U7#(3BX:%OE\U;XRKP)UU;;/RA=O:Y[H:.E"$.O2*+$H<RH FFN,T!
M*4H7JB>'E),;@/T^FM\ZO_IG*J2KV]MG.:D]/*EVK&YV@33ME*2B\A.^L2EN
M*U"CA+J) H\$ST2F<GX2:7JNP4)$7N"^)?S ?5^[&L?6[6 0QUJO_FS&RL^,
M<DQTJSK>2:OT9 775KS<YBMN.*9H&C+_2+C]$>).?;)RWCW&:3[]>R35P%;:
MW(]SN70N!D1] @J@JV"5.3^YUV';SD&?TSD#2"'$GKUV3RFJM2\]J@RF=4#S
MC"\/2WA(PN.=8U;["X(>/L\MAN4P_5,=?=&A'CHH_@GO\(=WWUHTN=L]>'<^
M_M@>I>-;-RMEB#\:>XR\#8YN( ,=Q]I;-*0X>X;2NIV=_9G#"[H.'Y"M)Y$9
MD87^47-@+SL>)94AJ$W\&CMV^:XU\815Q! +#35G+U C7ZV"N4K/;IHGN0Y9
M59^EP\,5I:NZE5N%0>*-A[>XMZZJO(MM.O":O\!KQOCNEOC3VZL;" WK,%!&
ME;5O"^,6.X?HA-L-U"A@9;%=T:Q](&+(_SR)Y4&_7%J6;DJOJG>[K<<W64N2
M=O2S_F9 '2U]M7WT6O;:$'PC.?0(]F>U,G@2NJ'?V!E860NPS))>5JOX#+4;
MXZKX6=Z]/L%-#YE#T548:-XLV;*HXR)^C!_1^>7QT?/AC9QZ-$T3\1A5%LP2
M&*MC5+(SY971_)QVQ'YU5<_AHYP3N@6_FMY-D#)K8IR/]YURVU86]DOCO=D-
MIU4S6WL>XAT,#QC+W +47 :&\-5(=B)J*!G%O\1+W%PS%'GI\X.F-_:J*EZ)
MQ\H[4H2IW*?T2_<>X;O"=48R1IN 0]V"Q!'7S#!SUX81Y@%WR20]FW):TRP_
MS;#.&[DK:>C7X*L'GI&&IB5*%[*:[$0.,:]Y\SB'Q'%?J(SI/W][$T.5M7N8
M44(GSQ*AON>"*&B.&W0.,NO7HH(?9OL$<?07!ZU[;0;,SC4S%!7[GN5'J5[Q
M]2#DR8ZT@H=P,TG#K;VQ'&X]FA_#%\S)U+Y%]=O%-VQ WXX_P1Y-[D[U>XCM
M_G&6*\0JY"7?%DW?993YWS:$W63E/<M-$Z38S6K3M" *4=3:V+I3(\_'M&%-
MO=RE)+NYQN>U_XA+SN'CIEIBZ6GO:VXX?DA[C#I0J089\(F-]'AHRG&KZT'-
M]J43@SU1![#M6$2G'.8D4\%1T.QDW7 D[PTEK:RI!(4+&IS6*R.6R2,*SFV\
M E(O_%9JYD&57 YW%I++Q[8.53)><P4KP[I4$D9E-N)W>R)V.WB563"*'AW[
M6%7^O-^JH?)4GC%O0.VI\]IGI&49 U&0G7 =QM87V!H %#3(C#DSK(-GZ8VC
M,_9L I]"#8*T> "D_&ODB/:(4&))_!,Z@7&CJ$<>*<;I6%N'!6*$=J8<[:)P
M6MKEZVUTWQ[_E?I<87CQB_F/1[;6A%D$=(9I=@12'3H#)*!X4;:*X<0M<B6M
M0=A=[,"9?)8RQ3+_*MVV,*K.IJJD>+/1RVL<*\DW"C/7W>I3' >)0U 3%LP!
M%SP3.L,>2 8Y?B&Z;-2^LV<'0:,V1N9BW6?G(F5(/FIU IS&=%V<257QQU>[
M.JLE.\5/E]:(5E]M'#_=U-R3"5/E\.@Q=TS@:9>)CS>B#B'%%F $%C54;\51
M"DJR!GP6*7*#2L3.2E5JBXC?%V>[,!W+OJR%>X9*Q^.$G2X<NH%PA'<1MOI4
M:-.A(Y=PXO=WCC59ML_.ST2$!QUO$?GRZD!4]]Z-0OS;Y-G5&(B?;LL'MRFR
M!%$<;JT,'QQ5CBQ0DJ_2WX3?,TR+8^.#U1'I-7Z[.A=UO;WW7#2W_&+,_\9Y
MZH[Q$=VW@ EF%V67-&4EP /8=/\0IR[-WF3-/^%EGZN,</>IKW->;]_ DYR(
M=O (&C2NSIXHTIS>]F'*:-/,!]LA$'.)G>Z\Z*@/QLPMSV)P)UN%R^(0WT^L
MVGG]9#[1'\/O)PX%X&E:1RN/#<]'(HJ)M=HE.E4:R@?<&\@"K%O#D1KS,WOF
M4W2>O?Z1X_ \XL6.L'>[[ZB>87XC0A/340^44YR1@OHFR?Y0@NM+8A2RW\UP
MA#B0V.6IU!J=Y@A5%':B2K!RT_N*^$?U&&96I,G=WUXM],5KAQB<EQ1] "\D
M#CU) $3_LG^/A$)@*J?-1HWN/')VR9>#H^CM0Y.UMW]RIY2F./K)$L\43AZ/
M*(L[])5;[)K2<;U SG?@/?XSJA?.X=.AM=8A'M_P>3+K2>P[J=^MW*+5('ZD
MO,O5=3[)>L'"_L@GKX,OAR*<=7,7QEVTI9<,&49LB.#<@9/4&!X($>*=^9#$
MZ_FT_CIZ2W8#D#[I;F%AEOE"IWI/(#4R^C#N/D_.8QAOQ]Y58^H\**_'$F#J
MK\.>/F9),:W[L-TD=3S?J758G]=\G5#*41%DZJA&+K),JI;T0H5C;\L/_WAD
M0,Q._0;7;/)>'&V^B0.'1.HZ["*835NQQ!G^5-=))TV5BV?N<<KUMGLHT+(S
MU6K[IG3/F\*;3W[97OJWZ(C-":'J9][X--65<?CI-I'..?:^^2]*?>.3_7B^
M[NJJ?&MP)4/SB\?=VYEZ6P5D%RPUV$7*BJ"JEA7XA,G-LJ?-AZA;TTB+U\KI
MBC-^RI6"UE93!JT/<J2?VFCL'+RC:LI?['*)?VO$R&AZ"+;"=&P=QA(J.$UF
M1+$#PALS<*1U6!T(L0A[X#/6:!-B!O).6[>P7V-/8W;'4B'R64:1PM>3H] "
MZA>DPSF''&(=A4J?ZE2F2%TI3O(J^HACB_S8_?[=OCL[Q0C-Q?!7P%TX>(C,
M$FBF*K+VN3/>LQ,P=LRCYH,@G-(35,GO.=2RJ5(_-VVRD&Q?[=G/;3"C(_U*
MNB7T0,"2%9\L8XVHCKI%7#5S9$#-_("B$#FO)K9\A@ @&Z(YUX'>BCIR&8HE
M&,SAGLY@[2K6>XKO1PD>0G+'&E?%'([I[T67OQJT/=/244R</BV]A0=&N,K^
M1!P*![:C;B/Z<(U "=1Y <?ZZN/@?KHL)2%XCJ5_UY%"%'%0M= D[GVAZZX<
M.!LXLWA)27N/F\Q;GHIO+CO?A&W$L_>";-I3AB4$".\V @&02 R&7BPN1@L.
M5L:'N#M:='T7^!;_=LTK0>"#6=S Z(C&JA%[_BJ1Z;'Q[*1Z$X<$%"$@%FA+
M!J7V!H=6JV$,P&1*/Y&W5SI0_=#;2UD3_.C+W>UD,MKZPI[CDOI7Y_BH6YZ1
M2[0=8,P$!A<[JVDVB;D/H\C.&6FW??^1WA.0IVQ]L7;S-:\>M\O(-@$![:-%
MW'NU1]YN[4G$=A*+@AN!$&C$C( ^K?^+NG</ARIZ_X:G5')J<@YERKG0I!Q2
MFJD42=))<IR$G$W*,=-LD800*I4R#J&0R;F$R5E)SJ=QF(.B,-E#IETSL[W;
M]_WC>:_K^;W7[W==SU_/'VM<+O;LM=9]K\_]^>R]UGWS[H->,>11)N/N,WR+
MCED HCN]QRR%+[0*"WW D91=5@H.=9^V/[HAL]_F_:WLZ%O:/!'A4Q6>@3"!
MK$CN5%2NM/_CN@&TN_OH%:.1LGN:HX;Q?K0&=<?G_OWL1;DHO^%7(M]L[]-
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M?FTNUWG*Z$RPVNC9UO.R1W3PM_WW;H','"P>5AI.@\6Q87S1U?4@VT/SQ8A
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M4>CAU;W7<;1* B</67MJB#%,(%U>C3"Q+L(-7)A2J&>]"_F@NS.XV+H>>V%
M7S--I7ZW75VRN?R;+P\^%ZOMM5;XD=G5](ZH!HDBU]L)7P',$H(*K$H2$296
MO@ACK2.+V@W2_/";_525HR,I4I/FAM7M31<3@76I1BU+YON4>(')<A>WA*3M
M0@GWYR8(FD%,*Q[:A>:LYAW "5^OEO.)0Z)-NL  L@?3G7MP[:7>L%@?U>B)
MU*]G&C8'>G]MUU$/<XK_GN5F6%R^94JGM"T*;ZM#C480 4MOYE6#*>UHNBPL
MUL]W(YVKX XGP9O";W:WD#=".3[9C86=;/U-_^B6\:5OKJB>=![['&V\*\=C
MHH>S&_9#6%;@()Y9@@?/HD>)+$5.%]\2:#Q: /)2M0J\5$5!1G.])L#2+:L<
M\$R.,#J8LO.4S36UQQK6%^+=XZ\ 61;NAS&%@XE<#%L[FBQ-P@WC=@E.<C6K
M4U@,*1]%Y8(/Q:X&T@ZCC2K6AMU1IP>/7]V_CMM*#B!_:D!">G0FT'C%3)K-
M&/-BB0KD5.>8^.9.JOSL,T(C?F.X%PO.*'HS^"*IV4G*^L+C?R9I-PS+WNVQ
M^)SXEF/&KNOF/1>^7D'Y(@1/6[!9=&JH:FHA@4LZ!"6"UHY<?#3.U"=+N4<_
ML*3./BB_33UK5*JO8K1Y;_>Z) U-YP.UKS>&]HB.*!,$BFB>RP#@!6R!AQ0)
M(K#I3P!MALD=F>UDUX>Q-)=CLV@^$6%2)3(_TYS]G3YVF1%CM]_[NN#[SZ^%
M42G:2%D/S34"DF;N7-E3?0)+[N8)]+H?8<-K=H?<K8YR=M;;*;BZ_\G!31^'
MI]O;L$HP P.>QD,F<ZV4*H4X?J0O69^K7]A,7.=",GV\@F*UQ7IGH:.M$[=H
M5B>I5^^\25W?D7+K\P?LPRUN3Y[%P.)38";O(80(JO7!PMA?.&7R"+WP=BG)
M"GU_.]C52HD.+EYB98X$&SY>Y!G<D)4HJ(WO4T@.^+3YGJ&;0WPV>O"?[I(E
M+&[-MX!'\6_MHVE>U%$&6UL@=\!&]#3T:"K MYE-Y-B7"HS[>BLW[J@Q,38^
M^G5+;%)=AE[;A%?PWW52.WYT$5:3_9K5J7 /#,S2-MO#XM5X'R+*-]1*(:$K
MS_M4\%CKK6ZU6>63N5]+[J!W#G ^;E^M+"C"M65CX^#-) ,NII6JD-_IXZK8
M0S2Z9>//6M(RYO74]6WL5[_!,8_M^/2QA#8Z,T6)!GRHM[-DA3DXE5;R,]'[
MOU4"")8VY_H[WBLL90?+6*:7@1;VVAO* 7] %:I@V<_'<\^SXZ*JB&_]&E0@
M8JGO,_T_J5MI7A]JWF9Y>XRJE>.&CQ]T./G\<O1>W:4EWI/5?,+P1(,8\E.)
MW$6H&F["QH>F"5R@^-)PY7ZG@64IA8]'2JQ>Q<PT:UB,MP:FXWJZ);T[Q'0N
M1N'/(3*#0B]N7<W:#FGA[Y-ER ,$.8"9H\N]T=2P%_J0&XYGVS=',N*40S,*
MZ6.S:89'ITZFH0+5C.=QQQY;[I4JL/#?0^SW17T3F'+[$:F9V* 'I3,M[Y+5
M?,(F#<#8_!?#\0)3XG7EN5-W.1)C9J\%:L?/7?BS]GVD[1B:*5S@%(;QUQ^E
M%PJTJPE2>=POS)&4,L#ST)\1"ZV)=.P+@0IYP91#>(K(3_Q5[%AD.PUTH8Z)
M'(/.(KZS;U@@^GK,FRS=4#\T#RM P)G(3HDGVFF=M@8NASL2O11V.#P4TQ()
MSL]\]I-L!J%Y-5R:8*L_0P*X2DL><I48HM*N<' 81=+).G!<\4^HL324?%ZC
M.O3ZE?$)F_VW19\H[^^S<E:7L_N/QS$I(^Y3)IQ44!$6!Z92(,UNCB?_Y"=N
M<B.\R9%T"HJ<2K)MOOCL:GZ 1\B^ N>1"?UG)>?8-]YOC1H[,G^4V@5(X9D%
M.$W$3/=F7?= /XN QC"<(OS95::">S4GG[0'(DHQ8AGV65_[SLO=K*8*RW8\
M?#IJ_:9(+^AOY GW#T$H80+51%@(^*6,+O",P<!4K@@O=?4%W<;I5&IX;F=S
MK0V#9S,Q0WGM\E@!]*]*L'#YKC)S63IH:4\'=2-R7RS,P.T1UN&],/(V7.O6
M!GFN]GV<(LEJ$($NC"*DRC8U!.1N/3BNV5#F]7W?]KO38GG^NO+CI1=V/<CK
MP#-GL'_W$>\0>,&J4BNHGE^O1'[KML'[P.'FE/6S*ZC- J_7MU(L>X(_)%E>
MK%MTM56C;Z0[>(QNN1KPJB3TE5Y0E!C[+8P2W(1L^6<$RN ?C@B(;07&LJ2Y
M%[-JZ!NH/"5.P^ :3?._]F);7W_.VB;'[7N+#V#\W8LX%8-GO;R"$IK8NJZ^
M343&\M 8[@9XMJP55&]?C^@[>(A0[37?RI<4Z!'O(^&5V":UKW%2E7^./C9!
MT$OKC+CV\5'TY*1\1*GF#H>Z=ZF9OF5M:]3; 2\*I$\1R'[@/8$^Y9*[L]9"
MA6RI@VUD+>2F34;94 UKNB*OH4@]/O_&NHS0U[(L^4R5QH]F]D^!1J\5U%4"
MO;F5L(UVM7NLG>< *7EQKQ-'_[0>:,LI%6B]'V259UR*_D??^/C7Z/0&?*73
M%HGL'<\/JJNEO=R&'>V&)>+YIH(@838B)G3@ 4KY3"L^BB9;-58'F1R#/C&[
MRQUGAQ/$.?T+:SS3;)\4E5WZ\WAC_M.F!^C:'_]%+I+_;]/]1H-V$P6YG>P4
M82/^]U\W@N-9)Y;?+2=9\2&:[NF)^5\WW/>LH)R:+N1$WFAMX]-GA_%I_W3_
M]>0VM MOK* *,:L%M'U)VO\0YSJ+_ZN]@O(G(6"]#IF5APZDW2NH=PR8@OT)
M,-\S*DS:%L8483%[KA<O4/B<)+NZ%S_)S,8KOR N=P7EX^0@S,\9G"_54 T9
M2&UYDJ"D,A/R=5PR;<V_KPG0O!VQA.WE.#0=,%8UT?VAD06_OE-X],^WA"1>
M_:-2LC<I D($Q_IRX4N\![ 9;LM"OCW:B ZIS;0UB%*:3,@'N"GM"^A)GW\V
M55UYCK:AO"%]C<54E?<7SEQKD=DBE?2:?V(UV1Y\"'+BK1/>IWE@HP]$<+M6
M4!\9R9.H(9+7ZR2+R2[[4_VX'N+" Y>3F7F6Z=]B)3K?OK+S5Q:JY+X]8!M%
M\[6]#52+SL<C/3'+A,6#^%IPMZS@"DA+:=CJ!%FR:<U"=>>JLB'_@DK*E\I!
M_Z1^#7O4]LV5*LTA;L^_;^.KPMV8JAK.ZNE7W6$:\Q7"D"P_JH,4RSZR(M"T
M!BQF%>25.A%F4WST1VL_#"R+5EU-4 S55SZZY4&I.>J,&>56[V',4UI9=S,
MZ2(:\ /+.!\Q!A_2YTM#D>SAJ+I#I;[723N@FC#NQ>83E?W!G6.O2Z<2+U4\
M46GSB_"ZSO%/J2<?:^N9::4QGQ+>[OZ ]&03PE]ODO7)7PZLH%H^F!KA[Q$4
MS6Q>0W[M?OY-0XMP_\6[)[!-42>BG8J-I6J"I#_<3C,@!))\$ /L(G\!MM;Y
ML0$9*'$JK/T%UI);^OH&P&:L#;\Q=97JR1)>](O#7M,HLPK==<*A1DV>\(0I
M_L^=V=Y(B:55T)KJ)9@IC?AUER!B4Y92?U^[>:_AC\^M?FM_BVA4&&A4')3Y
M^N5+2YE&%#D2TF87<A)9W:*C)&,H$Y&>[)^(1FQ)U#U6W3"$C#K\-*-9N>3'
M!T<N5@OG67E.>CK"1M9J2\"[*Z;+5'H&[QP2='?"#-K;F79@@V!'>0W8WF3,
M#:9(W\TLHEL&L!@UWGOH8^9R@=Q/09BL-S)_I:M[LM\>;Z16>6>CT_$!U-',
MJ;!6!J13,P]P&:R9:*#2;"=8TY*%K>5.%@OS Q1Y'B:U2E55Q%T."E8U7T*O
M:%ZOO[1KB6 C.#H@<,N%1)V'<*KA5[?YM2@\._2%KI!TXZ9^'JWNTM.<&I\G
MTC)UM\^\7Z?CSWN3H"/"78+%Y4&3U7(DT2](^@V0M:A@LS(0!Z@898X1*DB^
MPW7VK($:\.6G(-GZ?[,\F<S.CT5)]_K,&H[03[22WX5K6PP*3)E=ZLV3V[GK
MGE4)[SXE$F\5?<ETY7DDV4V[I4?/2T@O. :?$6TFU(BV,!(;]*$8-CH&V(9G
MW@FCJ-:A_?:G-.)VE@\*3(J<9G=J&%145M?>3^TLJ/WL($$:76Q^/2/R?6%U
M>Y@F+;"8")F83&'GC1 $OE,]U0[CH80&=1#=I()7&G,^SI)2LY7VR7B=NSLG
M1"]T@1<>4*JIIT'O4E^OU]4];R2W9M%+H'B0=Q6:X%]9W>H#Z\%=C(J4:("E
MSBV,+_E=V?.;P-'UPU=6'JA_U!+SM39M?[JTN3KIU_NQVVF'<:L;+#8*L_ ^
MM'4P@[)F!<7,IJ#Q'H40EP6@()'S8-L'\%_[N;*4<SW8W:XF-E?;#@Y?*G@0
MN[A5=X-X=O*F[T*IW"B\,5F&M!69[32X%P\Z8N((X!EB"K[\IL (<LLA[1P2
MF.9[AY'W]!.K]/7SKW&[2 ].!1WJ-&VY)G9.AWG_8)R>: 72][V 9W<RHV*8
M(\:_!$U-B=ZFE1O2XBFJVES%Z-VT2DX@,HBAR@0#W(AF:-ST117-C0*O0-VY
M?SHB2X2I%=3\;>X*BG=T55@+3@IK8!ERTS\3S@Z0,45^^I*69+:]1MG_YI]8
MHZ0#XV/Z$VFS^Y/9D^%ETQ;)F"^F+'<7QC&X$='+F5,,)2BF97(7\CWV='*W
MXU9'C[/>M=5YKW]0B^=.+UZ]]+*Z/^S6,XV1N#]I,O,6<@&?_I$34%P*I!,V
MG^[)#X5;*#(TC\CZD.#W9D&L^)(2(]/-Y8ZN.QT"\D.VENMQ6[Z(:AX163?<
MC-G<H 8T^I"-R(U_,. I/@72>M06QT430'O!]@9MJ!V8FMAM*V9>:$7DZ;ZX
M@MUM'KR@^3[,*4CQJ<JGYP8V<<O&"8B)>,C410>2+O7A1.%F?$7W_"@KWNQL
M/KF;L(TD_0JBGLL\4U49'FRSZVOX[A %A^^V!HE[WR?H+\KNH+_<A%M!(5%.
M4"IL(+GQ3ZW6KH^);Y"#D'ET@:S]ICCVEL*,JIW+"^NL2EH+Q^<.G!UZF>S]
M9K=VR\[KR>#7Z(L7@D0L'*QC7#- 2Q:6$\</ QK/FJU6UQ 1(L#J.6')K(G"
MB8;C+_7!2I!3JW+7H\GW;WS_E5R97/SG49%V@I/MY/:]:-]C/?G;.S*)0XXU
M\Q$@X"@LKTP9*U\.L85.5]JBG,,/=.2#"L!HA8M$X<2F28\E4?2'VVVZ@SHB
MW]"0QL+\>^X8SYM+Y%B_%@0@RU[C/QN0 =GPYL848:'?#6%>[D2[K_ZO,J+N
MD[ GC#_7YU-#!1U[][%H\G@/? JC#-&9HNQNSEEPF"?2A_>QC06VENH9!1"/
M5F9:I[3@I(8XS#U=&M*S!\_]&OKF]CDO[F*[N.Q>\A,DENB16WFP!O33;RH2
MF\0 K;HDF'%WC ZI2>$^M[<H'MBV/),0,+T4.Z[X.%2<V[SVU;V(&P?_9KE[
M'G:]Y=Z(*8N;+P3C;(=W0%+\_>$B'TT:MO=I]E=)V38VB)?U>ST6%?T>6A,O
MF: B5?G<0_SWJJ,WPV)2X!0L;L#7A+^JRB&F]R*%"1.N]E1B-_YTG'R*;F>@
M!2?[=O_^>R?=9=QQO+4P(I%4TK5W^\7[\F[OJ^_?_K:">FL;_?]N]B@SF3^S
M@@)MT''(IW6'/[S#0>MU?DIR+]1\,J7IS]R-H(-:]=>:;&ML=[TL(G]QW_L^
MZ<*3V[J8N4-R:_ZV\@U(JQNVL\EM 'B4<!=?3OB(C=I\G+LT?QXBS]I8MOPC
MC-3)U-Q,&D\I<3ZY6VGWXXV:#@JZP"&ZQ6'WRZ55Z2 -%C/A(A\&W#@6I9T&
M:<MGU7"UQBY5QS33*A?N&*7(-*X?OO_H6]H-]A,/VKL3YV"Q[X_N6QQIV+GN
MI(7+V.^O"$%;E.!=AVA\5W(W!70@CN6QB1]31D/Y4^B84I(#ZR!V2[A[L^/W
M_*R:PO'2Q(8^WB!6=7_@E1VE:H\-U#HDCLYNT4T0WJ+J0MI\51(&6L_M9]=P
MT$SY0=%[Y+V^M:$Y4[*1)(VH+D_?@.Q%6>_%N,<12J9FW,,8?;AQ!54^S/&:
M8B2OH"I-!'(W>.\@2W24&8$;T_R8K 0J-J\?RJY_WU.IJ^)UJ6NBY5A+X.ZK
MGJD/C-7I1]0/GA\ F/'_V4,RJ@*+!8&)O!O"G#H51(+\N5^'S9L\4OJ#03<>
M!JZF+JN\?AA1W6<E.VTJ79[</-WX;3.N$ %=+."1A BHU;=B@2 F@>:V@HK#
M@Z<GB%/4J)(ZIZ)98%V=&Y.A[//8(#]IN7F\]$619<0N*U^NM?JO%W:]-2^R
M8S_5LS"09CN'P,1#:MH<:5"QI38PDVV;0JM4S6$#RN&%EKU5.E<JE>'27DJ9
M>="UGZH#)W+/_6*9+#3+-V/Z3^J(L-#03MMY+[Z5 $"<0706*",TV=Y=0=$9
MLKMQ*I"M=5PS84SA6N"'BMI^C?<I'-E3CZ>NC'T)4S*N[GZ89A$(--H J^S?
M">KE[R;3,>741B?"O<GMD"A[FTL5-:Z;G>BB-G6^;-"PJOQI=NT'-11W2[/;
M2.!$XQPA"%F!VP5>PE= 0#$U&B<S5(>0JG5>0V;N[FSWHD:N-JL'2F1-'.4?
M3E9R4\!^-RL8/F_]:)_IB6]2BH]OW]8+8M/ 4]@1*IMR%\_,SSH@?%^GR1<_
MSM<7Z SCY)M9.> '_NGF;N[N<J/U[Y6_5"O[IP2X?V]21KW?%*:P]<3RO[/'
M41$T3@H3JT"R$Z;B=I&PH$(Z3QC60I%:[L(>+UN:2N0HABG(-DM&?O,\-OXK
M[\:>L\_3-MB0U+DQL!B'3X *X8W=_)WDSP?035A\^PI*BN0&_N.WU8KRX"S:
M:(]/LM3<7\ZU[9F=VW+#L((UQ;_I":B_(K"$.7\W*5180O.BQ66)"BEU4D):
MD3=!U4R;K7]QF']Z:+BCW[^4;OWTCW.G<G7K]OES+K6[RJC4'XC?X'#:I)W"
M!L!]=8=T32M^S)KG)TQ MZ-%!9X@.JY2>'3X!)28[VU?JYJ77_(@:N[U)^6N
MK:E[+KMKQ#2*;/TS*2%\NH+R]D$TBR)"P'_5@_65"W'_,N9?>+*,!RD.%0^;
MJ5*1G/)+6]+.[Y.[\VOI#OELFTAZZZWTXRC2[164)(+7,.8G,M8WB+>;")RP
MD <:.@JPM.#^JA74@P6!)I[(UQX5,"J!]IH%,P;V,[R-W^#X]P;ONC #[PU
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MRT/<VLOGW[\&1,;'Q '?)2B5HL)X+O SI H5!( GN^E./'>P9KY["J!GMF'
M\Y1$BJQAEXIYWR^<AA]>9=ZK[S=-RB7BG)4V+]A>V?.IF&['>=]#'XF[Y2Z.
M6R".(7R!!-MJ"G@:30?8#?&@/8O:QN?;;@XOTLIH?!M>T?BL-!X=+WVSZLXP
MK]?RNNV6XP&<++DE@B%BY^N*IS-6<4)K3& QNH(2;[.E2[#*!:Y+W?_P O7)
M"UD _<:BD (\^A"F4E<[BV=._ZC310MD*YH5<4K6(5 BD9O>9,G,J1#?G>$"
M]Z1<KFKO^C#/\&;=$LW.1K_"^W1#NQ3G-?DJ FMB#*62TCY&D RGP)N7N6;*
MAO_T!8L3/F\B>7+>DIL/C)\:QGQP\NX\/:*GODL"?7@5 WPP=_%5U,;Z?5.T
MQI]&H3U&/J57*N&)GL#@SFS0V6K=;4YIJF;*3%+9>PN+C<P$*(-M'T7:,86'
M#CBQ>!7L6^*3O)EF?%GKK^*<3V9N2?DLKMQ0PW6OO B3\P66^Q\,_ZA'D1%&
M>02')4].&B&^_TZ@)8RF>6+'?.>8C#B! QAGQ]4J [S /Q;#64X?G J/_PW9
MZ/!0KDE0FNV^7RN=YX_$!N+"J#LL_B$':#2@!0!T17-H(I=T#/(+8U/7"8Y6
M@(=H<<LVN$@'#1GZQ)A#>F"O7,*I_:C'.SO^/HA8$,BE,+WNX[U3H/VZ3'PS
M($+NQ>V%7 #L/)\ZCDT0B.G7^DJ7A)6>VCY^?)<_B=7@S&V4I_#WDI2' .93
M#.BLB]E$'@5DEBGW36B5BK>G^W&2@IO<KO$W13XFQJ<T:\$O\;3Y,HW$<N]O
M=_=W'BQ"3?K%HOXD$7CQPE*R#M!XA;R/_!%>*\P9:\*I5 J?!(1TKY_0OO.;
M/X7HQ<W.DXDA TV=FR-S;]_FFY5O<0H4OS_=$"2L#>Z&]+OG?;C63$QS(A':
M+3]SSW[*J_6#[7KK".UY%LOI?%Y)1Q<O.]=DJ:/-K*X J-,=PR&\^7,W00&1
M4OV_B<*#[98"131\&N!M6D%5O.VC_;;N$<7SKR%1:OVEU6(\0*-)PT%X &>\
M>HC(67">NRF)E60&Z<] ZBSA%F][FR+'=OV/FU^^OM&@I'HH+<?N*ZMCW2TA
M_Q!4Z,+M_H@5@89;31B^ \LIHC\SZ$G=#U_/V.J77#_!/[/>N4(V%B4)HJA/
M 29S!;4A/*:=!EK@Z2)'P*\4_<$!5TDG7L*63I-4GPABR+[+H9=R4N/GY9[Q
M4D8JV-W-*?+D1HH$O-='U:!_K%F&I-\7(CKD47L\6B7X;5)^Q-;GEM\YU_CW
M1L[&7(XYC-D%-.ZB>1/&,F#Q'0A]:(=RV/JVO.STXU 11<;L;#:DW?Z)Y:)3
MFJ:OF3)OK5DX:E/7*[)HZOW,PM)_SZT2TVVRL$07VW8UM]JA9>\&30'."O!;
MD(3*\7<5":([DLB]11#=N=7GAJ2.Q9S8@ K-($AU,,WP>N@^1P1R @6>+,(=
MA'^?H,B2^_ R5>\J\>L9@I/<C$3UX1"S5AD?L>#/PS991U,J.E=0I&=_=2_U
M(2N/(BT(CX$WU;Z#=GB91/^FRND9XR5>@O,$^@+8JT^PQ6EB_R1!EB:[T"=0
M..*#(AT1GA//',S@2( TWF6P.I'O+B"FM..E]8-O!TT1Y;<9?VV:*&7LM=YZ
MEFXN:;W.=/'1YPV>]P]>;Z.9 LP7>/#B"FILWY2M0,[$G(OGK&%GA@DSD7[8
MG&]3]IH?\Q+&^07^(]'E/^O9ZC<=K3#]$'TP3<8'L_?R#M25^DY8(HA/S(\3
MR#QQ)G?<_$;6YMIR=.A>M^%-U2G7<ZH<0EI'IX]^L7?C[WA2G):CX?U'GAH/
M!! W 8T7!*:(388A(MC<2 ./U5NS.H2/M7K-W%GH>U;<A>:;E<]N>)\EOGOW
M^/- R;":]_IFJZW^#A/-;AVHJ%M)*RA127@07U,X/PA2F86KAUQ>T&3=P.X4
MQ$Q7*\'\#^/>M;?FPQC>E>\,G/8T1'O<-^Q4_)IS"8A4*GT#, OH,QPD>*W;
MS9T1R&&9%PO,#*;JT4R8%A'I/134J7VW[FRAPZG=^I,2L2$XNR_''VF9-^Q3
MV<OBNAH@B\02XC.I]+QFVBKV6[*^\'_;;B4/JHH-57[?K91K?4\C_3,I.%CO
M;-Q5BVW%'7AFR>=5&8;>1NXG2S=6((K$BZ3"=8$?BBK0T2V)M]0 W([1#?F;
M,-I/M>E%:]N\199M>8I0ZI3M?: ,V\A(I$DO4S@8Z?!B%B&N*BGR#-_LFK"(
M-V-3\RR"].[169,3\V-G[2RNH5#B>8A>FJ25_YG?5^ =AJ@78C+Q]ZC@;- A
MVMW*-RK-!^Y2;Q59BQ>??# VTF@8YQVL>4_<1#+UV>JS4J2/#P,1L<4S%VBO
MH HB';D+8U.\>N&KWXB#W&!9(L&'9U /XN^:>7(EFFK;[U41[V7A^K0&=O09
M?MB;X%9>F7"IH?^&1HRFZ^&$U%_;9W:MF2.4(=-+X1T0?C"RB6QB5-!:E7X)
MCK/<5,+3FQSAVY%YL_3K^/$TZX,_KCQLNXX/+_KT&/566[Y=L%KHMA=9=_L;
MQ*!BA-*@S5RXT],SK:[27!5OQ^$[P7A1W^%_V0TG+OHHZ'KK.\PDJ0=[9>WI
M*5B^>.U+$?D(%)%+N@5YK1[:$NB!1(X4WP5R8L?=+P6\WMP*2:1(D(Q3FL\Y
M^'1=3QMSG- (J[%@*EU)NS!^_NH:U-T-]7AXXS*3('8<L;66L*%!:W=L8,@H
M;#CBD_2Z\O"7ZOC+FIN+0^RP.ZZ(2AZ=.6B!PK4+T_'^*:,5O"G(!-U.&XUD
MQQ8FF!GHCU>GNQXGZM=59YP-V#LV?N2 QMN3.0\?IE[@>+H]\M2>!A(!T 71
MQ\;UK)1M ASDP#_E#/@[_GQ6D)X+M8TU'TCSQI9J5F;9E1QHK%&P,4CW/JI)
MG[^@;N I.FV+;IPB;H*L8?$E%BWZ@:W?K?4<#ISNF5\Z9-U)D>S4_-*[:VGF
MQ!%_ZA?GM::MD0O-NMA1#+R#TA_P2[T78%VBC#HWY+^S_"XLY&^O:M[*Y=%J
M(NY,S?!M;2ER:^89(#+\A!64#,YT]5Q;PT:!,T2;.KB"D@[/= 4OV#M^K2FR
MF79V/>7Y0#'TT&G4#/TMP"Q>0=7\::6.[NUG9<S/\;4A72LN(D"285T +3"M
MX$KL[P_^%G]V(<2Z3&D3.&:IX7_V]&G!XN;77H+-ZO"9,?ZA%=0H/FX%96GM
MNGI\*GZH!+A*@791YHWXD:333_5@E7!""ZP-IB0L\U.KQX[7#@5WEX_:F,5]
M3U;KTE7TWW5/3+M'I"[F/PGDUB>5]V:T]@"-P54. J^:KK2F!69@-,ELX7XF
M4%$4_UA/D.6=_D5DNBV<2H4E)@7.?;!H.'D%Q<NJ \=QAI4]:D05EW"?ES8Z
MKB^!GS)C3[\N1[V]ZB*(-?M-14)J]%.!'"3DWF"^AZA\4WB"O <R1X2/9>SR
M&\?O9ML*+TT<9V-_>T]'G1K6X5_$[^ ];#O>G/Y<'-)E8P1RBKRGW R!BC;X
M%;:5G\7M@_[P3RE -U@.ST[DU@TL+&\[O3ADL<[_Q.=12S4QG)VE=[S;4-0!
M&J35+9"G\GH@A&NO7]^#Z"JZ2:O"#"]<6%!*(A#YAB/5<7X!NU]HQ84K&!C^
M%#\U/3VH=4TK;$*K5U54_H\]IYA_@#Q.V69DBYZ .S#@V4S*;6-Z0'V37_4#
MDG:?F;7P[:_>)\^KLV^(/I9OD[V[M)?\@_IY82S&"AGPJW!W6&P0[&\DHU=/
MT,[BI=R%#P,-"5L@Z_8Y[E+SS8J?GW(..TY;^7-.=EVO<"IINS2E^>+)ME(+
M] \"QQ[I<0QD#MKR)$$,QPVD',YH(^M!_?F7M!O1<<92TX3P%/N&6%65*_%+
M>M<J$WEQ4U>-;_TYOAVC (_BMB-WG"!M$A8V;%T]85]!$"BT+;#CVK"8;MX8
M8Y/)_!PK -?=-*EZ]-B_KWG7'WQUN[>'GCJOOW,=MJN,,,M(64%597#P"-+]
M$C8(UD?R;4E.N)W"3+*!@P/DN"UT[G!YA2J*F[;]4I;/&[:%L>/=(=,7WQ;S
M]>\F[P>%%($,!19CL8%1E297-6$VWF<%)=<ZA:%KLY?IOBLH!8'OQST)1]<D
MGJA0OS?_QEZZJ%0^P0.5J&PY#C3:-2@(\-"GU;/CT P3B,]2K!K\70TYO9E,
M=*KLL,YTVAD84'!^T-64G7S<K<-C0Y29_25A$<V'.A8#B]L7D3L)9?@VASIY
M,(\9\+Q7$ C%%/RX2<[1JF";3JF--?,"(M?UYE2W9U[[8;)66>T,1[\>N=5)
M81E\@#Q J$A)Q"F3A^$=<6>A8="=;4%E4N(S@GQ 1XE1SB\E#O7<1FGU$]]N
M]]JE'GU_>V23#PTD%C;C14BKO/RP0":CD8RY^YDH&W[6[ A;Y9%F_D#(P>J]
MSBZGYJVMU+=*IEU[E;"G*)O$YSN1KH%A NE,6$*S%!XFXQZ."+2%^3@I1A<[
M(*G<@(UH0WHE")2KLCLW6[R;T/LC=?]YCVB=P%CX!F%I](.PA-\4;;299=N"
M*2/)0Q(@_3/^WC.2LLW+9@=N8(&CD[=49TN_Q0/ZKRMO.YX\7ENZ14;T-@)-
MWD@XI]6D-&+I3V$,\CMN^8-[#MS-V+0#RN";^RSDT5T ?Y^TV= RK0<:64K*
M0[9E;R;Z#2U,]E3LN=:16T^$-YX%N\\(LVC,S-H,3A[?9E;:!\9"8\6^#,4&
M+=\_EXOHC3>5V9NM_C[6F4_;:8QYY_%@S1QW6" ;.845R.6QL;$X4WB$KBB0
M]CH#?<J&A[+TZ@;Q+ T:Q&()U]FRO-GIMF_[DO)'?5JN-<YDAXY-ZV6_&JMZ
M(L*+8U%:"!L%!"@HFW0) HHUX1CV+87AB[W$/'Z-0L;FDIZ.0T^WV4XYA?SM
M0MCRJ, 1*LR'/TWN1&Q#(O?A%.O A1;::$UK"HMCWUR;5;C^^V!U2FC!DK57
MUOB3_+4FC]>'?VVS]E"/(>09_O\EF?D_:O:*?'.XFR"Z@O)E1$]N%V:1<9 Y
M/[(1WEFA4,M+$>8$^?%>'4O<3C"FG_AN^U3N^S;;;4'/.#K9F_:Q3>:YH"WB
M%Q_G&*-4=D9STL$6U0T#P1Y]5))IL<75:*<+=M(Y>M:!+O<^_YTL26B,0?G-
M+(PNP1M7*[N R-+5^X%7KE,!VPE#(=VB=PDB&)7PN0O#^G5[7JY)W(@-U$A>
MBW*A5M9RUE]2]9L[J2/2_0OP[+YM E1)U7!>!#$#&#)OS#;!Z!JN-N]%SVAN
M%6-,>7B>3:AXWKWT]RY^7[6PSCY[]5$@XQ[>$QOENE-88(@>0[N BA2N2A.L
M\K['$"L-^+I@1ROGXK"&>"^'8^CW\0<GC8-&8\WY)^$.0@6-$YD?[G5"F(-3
M74$%%L:8.?FP ?'Q(\4N(\X_;U:5+JC-*LU_3[#S' ^?J'HWOFG#H5T)J*5Z
M==XY:'TVW/^/QLG(#Y?X#*670J<QDK,-&O! +1%OG>!F&+J"\MJ;&=(29;Q\
MW_3'I60=:(J_D[16^))TEHE7$GB#BKRO^6!G:VIXYL<_>'H&PO-':U_ZVNTV
M;MRE-[).D!9G/F%S4U-NS::\0I]_#11<>O&EYA"_$ GS&P%!F\._)]V6O%^X
MXV'T$=%H*=+Q8J"Q%@!/OK ]4Q\]S%Q(,.R6G+6?7CH'W<H56 ^5" [=, CX
M8G/'WEKY=6"HUL"VM;=;;[4C,V?2NH(:<>==@'[R#9KY2@)SR#*0K'@DP"M
M,?KWH9,+5I4*O%+J.LP/F:8V>0_S[PHCK1;?]U-/V(I"I_%B:)3V74-NSNX7
MPBQ#MZL43X4L0@8/T%4Q>T/1^A(PUF;@:'A&]"L%C6>FT]YBFSK("J.0+C.@
M18&VWNB-]47(Q3UL2O_*K['#=0W;QS_)F2@25:*;K^LES$DH>-_QC,<?];T9
M2"GY6:.,H[K+=^6/HZ4&*[EQ5NZ7[5(?@D?61://^-[4$9FAK::OUETM\K=>
ML MR JV;*>NTXI @M)[DFZ4/N>=WLCF.;CFS<X85;YH^:?9;[8W7>G1GGV$J
MZ9O_1U0HH5ITWIZ_!YY$Z*@')(H Y<X:;ERLQD#VP(:GQCDWO'LGS"F[+\U4
M/=Z9=UEI6&=JUWSAKA;,N=RH/; 2R00D-';?G52%CH-3%O!7<"$V^* -YD@_
MW*O!\"ROCMT1C=U[T>M666[IS%7W^VE66G7%O&X$'D+(GX&:*EJ<MC"') L8
MES''/NVNV\&F;IH;OGF:FF>]_2QV]!='PTK>>=?=HR=?% 4].G>H+0'UMY,7
MNGH2%!':Y=TM79BIL"9T=+\3-'6\BA:-5YK-TAF@+NLRJN_%]D]T!5U;0?FG
MMAA$+8D:%*U/N<)US00!GC,D"\JVDP]!&6#F1\;H 4;+PF:MFJE$!N?@:T23
M4(=VR'25^[CL:$(9M[RJYV;Y]>ADHW&0/5]7L![:R55DHUM3[I+7NAPD0*^+
MC[R&>'^K=#-O%TV8BZ:J/)E^-'5G(^Q2MFOG[!&SX:\\#'B8 6G^>L&>$]YD
M,$\7&-J8G\\XE\Y:$&C17X$M]GT>55]NGGBGT,%,^W1G3&6]09'\.=RGW*C]
M*Z@H_!JR+-S)V%!WB(\G28"%/,P=DF[AF^3;+V_51E+*/XI=S@IH_J2[V)X1
M:K9<3%%L0)/T("'(N @=XE:PX'0V16*NFN8U^%L_\--N_=*\CLM*6Z0?-#I<
MNEY2]#%ZS39D<8&M*0*5%PA<597=#R>13+GC#7*6XUEK*.P_]S#F9Y]S^#OK
MFK4QU])>7CNRU;['A #:$D:^SK10Q.IL13\&[/Y,N)T4RA#W#R[.3#R(1M=_
M\=OZ]?&9$X_[WMNM,RO[H.XY4"S3/OHJ6YS>EIH/Q9RH[3'JW%@Z3WV3-;DX
M%"R9?FS6KO?VK'C:QM]&BXH(;#*C5C/>,%3#T1\I4F9V_#T,YQ\TR1*BGD#"
MER(CL)3]N=G%N7Z ^[)L5E=]PS-+XHM,[X/VXFM3REYEH^_AV5NID#I#J(*]
MAP>7PC^LH!Y7+5?G@TZLTC+P]!0O=$!P8 DZ,-?4S>I,TER8T==Z,M0VF+UO
M8:G<39/4!7O=&GM?6I" ^@:O%Z A%[X1"0,N?+2-)F^!6T'*G=_O?B^@?^(#
MLF;FJWOO:Y#]?RTVX.OFOT0^8],"\".*/$O$,^,$1OWP9GB$)IK-S8C[_<;'
M*.# 5QO'Q5;.@LQ.-1F]H1OFNXVMU1XRJLKWBMFUO^T]O#6LE1:%%\.9DJ2&
M:%<9\3A9$U<Q[J8[_W:_R1DAC%_2HT=J/Q[JU"Q)[526^[O1POFU;D^J(R"!
MVP*AF91F/)JT#7)BO0L&I,+MCU?UD?#Y3A_V.HR.M929;_;2?+)+[7Z97E":
ME<;0LMR:&54%81K@U;T.[G?5$9:9[62*N',5VVKE"U+8;\C;'!>NYOOX53J5
M/"X@5"C>WU7T65UF_=\PC@;&\G_X+/Q_WNH09;B/&\G6_@B,#+?AY1ODH#B^
M+J&/5@$W KP37HMU$Q9TQ;]:EA9?KA]8+%3J:$0-7Q05.[^GK:^IW^?DRSSY
M6U2MM'IJ0>V/KY+]>_(>>C[B#J9?RQ<[;>7(.;K[]+"/:Z=U)750=>PX66,%
MU3Q!8^8P?E\#_OK\Q OB+06'QF#Q;8B20ZC!XZST%53'HW]XP5%7]144I9(&
M(@QFL8)+@9[@)%=0V21+>(TM\G^4Z@'[>*#1M %+.@9Q^<K0079-ZVJ^)=^Y
M?U1>W-@"_$E2E?CHU7@314/GWKMD0U<Y+R53C6>\Q+FY;;O; FS/UR70Z9-:
MC]GLB+4:)_+TOK3'HM9:F:%TE^Z'RA00DHIC7_4_,CVY>\Q5O]!OS,:P%U/A
M&1&[E:&7DYS[+/:21=#IX9-!Y^PK?'DW1ZO()8\3H/06 ABD+9"Q;*X5\I[A
M?:R%MM9]U(;V(JCY"*A0]<K[8KI7X-" /D=U(D.#]&.>LN=@61J.VM-@1MK"
MM6T,$>8*#+CFY@-U&_]M??8YO,9VX)S?AK?)QFG6M_?*Y,N?C3>=\A%]X/=P
MX<!GW2Q0NY401Y,C*_G0E' JX:7]+F!;Q<N"PI=^!SP:/$RJDS/[+HU!CS(>
M1 YK\I7A(888$$@;+6[&5!$_5@]TQYJYR']Y=F1(+[;^Z\CN@JI;W+L!M+K;
MW$\=C0N'55_\MV>%(V@<=[X#24H83Q;UI57B.6CV>T.*U,^]YA+U50]K[!7M
M]YTH.Q*P3EK7K.^3^JZB5[^LFJ*;J/.9_ L_$'G5'D5LV/Z#LHZL#<FH;',H
M 2K(NN&;YIK_#&L<WYI%VN,<U7?X6,ZQF.B.N4$;U,U'_UMF>7MMDW;;&-X*
M2B5'F'D5BL^GI@2:[9U4BVFZ^^U6U>]\ROPT:#G\69:\$/;G7?:F\H3%%10&
M'L:(DU7( P":YF$K?:0$HT"R[EOV6T%MLO(K)%9<JOSQV"GE0$#SYX 2X_O;
MVOOJCT:)ZS;3_*G03C02EU&C/N?@06#KO)GI+:J!B\CAFHIW T8VIV)J]C@X
M6NHM[F;+O;.)>B A.6S WX7P  )P&3.&8=^#Y,'(J>-=M.2LP5_9("&QSN#5
M#\='7W1*YL'CP#J"]QKIY_<2']E=W8XZ@?IW)0&:85,$BE.PF GHQ"Z,;Y @
M60H+%_Q)ELR)P #U%MXUDA%WV\!%Q53<)[7(>X9_[K#B)NUUQ[?><&7P=\+C
MC')%3BO+CZ)$_D2IQ-XEA7AZ=!C)]1(;WY7IOXAF3S1U;9C?&G'O?6/;-6^1
MP1_4=)H/!=+O%LB&\4Y#]46DM5 A]\.9]]RL.Z_H*ZBX.EUFO?VE3&O+)(^+
M[_P.^J@G?@OQWQ?8+)+ 8XS>X%4(G],""'>, 63]>E(3'0GWZW1OZ38KO"[8
M]SK!HS'\:L)QA\N/S'<:=!0Q]Z;M^?@ ?2RWP0*:0AA1#P+15\A?5U"*RY1H
M0 ;PCJ!5U6'#J[/VU/>:J1?YW@R+*]W"D7:=I#M9K?_PZZ^#]?<MF_DGC);M
M8^O.LZA;(:_37(0F'_$J]OY7?]^^]N+K0N>2H3^/^[+#IQ..:;HH;=G[5F/S
M$;DUY(1OL"XI&,*#)K T#7)B2!O2-JV@FMS8G7C)< +_W#=D@DM<%OA&]TWY
M_5;?&P87*A$3NL$CJV+%K3OF)[=Y*L8WQOP6<+JWL4_O> O#I_Z=4SCY:.?B
M0E!ZENA^PS6SP?]%N42YL\Z4IH5DBBAL[!+^K)UETF*#;9$--VD9QFWC7KCI
MV?'@Y\TW[\X;/1_AEV<'?^:-ZXB4Y-;1F.V<(+!PJJ9M(0&/,I/>\+;V3].V
M\[9ON>Z$GY-V'ZPC_ /=^&:9*<\;+OU-WH"6G_T?:*\N&FA/_&N9TH+EWUE!
M_:1_;4BC9@+,4L9B"N8>X8_8"JJ_ZD4D:=\*2E-5 F[H7T'UL4GM*L GI:?
MR"&BT$2=JY6@0YWK%_S"!]"8J7CDNCC:'X75Z[Z'8P5;Q[CH-EAI]9W0_]/>
M=W8UT47A1A%1BE&J@! %%)6F5 5,;#1Y,2#22U0Z$2/2@H9$:D"0IL@KB!$5
M41%"CP(22@ +"$@/)07% D@"&$93N)/W_H&[;OEV/\S*REJ9F7/.WF?OYSG9
M95*PCX-*_U4?#5"X=ITBR3$S1^V,W4.8X+Q?D&,%HXP/%P?S;5T[U=;(@ Y2
M\*2'M23LHJXNQGN F.,YM3J$"'X^I=:@,A%!":ZTRD<_O?/;$UBH'8^5+<]6
MHG<7C<Y*G]![&WL$=CC;CGZB'?;.UTD\:@M1ZS XZB^$Q]8*ZQ"=8)]UR(55
MPNH4T@WPX,!84NVH9#6[A17.$(M76 :8G![T<*CFK)J'\2Z&*ER\/9#ET"+O
MV^AX[]*$OH.  $@Q$;MPA\6G=))B*!$ESI]7OM*BPNQ/]2BGP:70Q\QG1,<.
M=KH/&9')JZ%:;]SMF=A*.8I$M/^-=RD.*Q[##^6$+0AF TE6I.XCT #((++#
M#@LBN79.]3Y;<!@6)J/)6E-Y;,ZE.MS8P333+/^H9L#)]Z^O;>Z]":*EZG*!
M/)5-Z4",S\]6Y?'_P9WZW("ZS:B?G_<FT18)]G:B_J%?F,I]%$I-X[NI45Z%
M"7/V5?;F\WNQQ*$'1,%V!A.Z&,1" ;IK';!,?ROAV]\D10%B&+Z57J+-.M;3
M.:WV>?*,O%=IBF'I)KTXB_Q'SXV/,AXTVHN5(@-1AQ H:<_V"'84LRB9K1L(
M[2?O,.>*G_QHHN-,.<^2F1I6YYS.V?_VF;-0:^A:;B89?_^X,VU[>N[CHRL:
MZ; +A/;]KB)I=0Z*%\L)6=#@GQ4G; 9SGMWGK$-8*Z$N M=JH.1)N&5LY=Y7
ME]0)AI]4\6.P!_]>?G=SCVNSJM(4^'-90C#F-J-F3"!/9EDL3//ML+JB'?UJ
MV.#^\TY1-J+/C2U\$Z>*F2E;ZWDOG8P5Q4'*N\7;XT=VW]RPTBB.<O\$$)^"
MC]G<"FIHN\WF3)8/,H.D9*:'D@KM)T\)[YRHYTJ@_,;["=&]L^_KLSS]_+9[
M0EXJ5JM>_$+8164^0>T U8= =(<U](CUD9F30JT?^911\6.1J\)\98(]IUT5
MMC)E)_DQM.+9>]YSW<1 XY=WM&IM>_],-C0M)3,XMB1Z>3>,@['H@(U7]+1J
M#+9H</M9L-M5H.A+U&F%]YJRB\S0A.WA<;&C:^>\'4S/G3I6QCKG]N^!?Z_
M] RN8XAX(_Q0D?!M85+@.B3YLOZ"]07_(S'H/D<:7B&SL[$R5^=U]F_']];H
MCRF><=4;KC^X*4.BA"R*RZ1)<74%2G=8L(6C?"7\ !V9U&+ E6&.EE4!R5[#
M@KTA+PE!\1:!A#"?'F.I>TS;%[*1IDER0\1\BRTG^!8\/\"!&\ L[ BUEN ^
MX>6.XO70N0S??T2'QE9O.*J_>)RWIN.D]/B5Y_'8),7  #,F:@<U").MUB]0
M9K (BYA'6$D?%C5-M'$>KCX2\V6XTMG[IPGC:?5D9M3NDL0LA;<!^P\GM7%1
M%P:DON4L"OFG".VGR51F%4H:<8$T/CL[5\@D0+$KK&TO7F&+W4:LQ<,-:'@[
M*_'B9/ZC^"L;M=IW.>U.QK&^V&U-[L-/(QH8XCEO6OH,EQ&U>5 Y+D;;;+@2
MLRKI#<4EKKP<X'U9F+ORS/8!?;9#62S%0.[!V#^?]<T_[MLQ>?!C?M6Q(7:(
M.'J4AN#X]*<A&GAY3(P5BT%LE9CWUQBU/B4L#Z>&#)=3'2XEOPL[O?1F@]6H
M<7+I!6Q5E$AZC"^+0P.=W&0F=7&2?PBGQZ'2$.HX>>J(UC!<!=O$EKF!W/F]
M*$M&J>\E\FJEHH7+7?F3RY#$^_<SZ"_;-.4X=2)I&!L#>M%QP(23>4;<S!8K
MP7O-4>E&*I"DT==MRKX142C.PPI]?5Y1BJ[MA<"Z?+?E0(<[EWT*T<H746?P
M[8P&9$]S_^0L[ZXPD1">HTG H#5EQQ:M_3CD<\6.#?4WR)M_1N8<G'"G[Z=U
M?(@Y9/WIF6T\/OAR9"+_J, 9Z.+"9@FIJ\508/='G-%GUG RD,.6ROR-D/,N
MD=4RV:K/JC/NC]]S]669=;7%%?W#R=W@=KJ,"&!,SOH!;YFHR631U@@.#[H=
M=ZZ6@T@7:0 49 3^HU-\O<'9S[8-S2OD?:E;:UHWLK1EO9[FP<^5ID-*.<DB
MZ;?<ZPQ>M+ &P7R!VBXX25]J)VP JI9.@S3J^V6#"[>6CQDH?W(<C-OECZMA
M_)3OMK#_I;6%?WY#8XN*F_#-.B3TK17O0C&O%PD<F6<J]715$&1)\J2;SG[8
M?X"(B8O\4]B8XP\8];3@#8CBN?N'CDAI_Y+) 708B1@$,W,>5)=[M6-/A@PF
M62G7U='5)[U4/'>^N;&<+%G0  D)?*>O6JA]E$P2R6++>>^! QSR:6 KMUDD
M]VL(%\^5ZFP*5',%/K8W45/O=,YHASK;4N;F%O-]D!:AL0Y:^F7%B1T#DOV3
M1B+I,#Y*< IPX6\3. N3<'9E6/=U".\NUZ"AE?P4R'%,$GW:^:M^I.#)Z^"<
MO@-H/>O;7TR1^Y-#@^2ZRV]9A_S/O)(D#'X:!;$^RNWAK;0 WSCSL_V952W:
M; UM&GSCD&GF;:@;VOWAYU]="R[V&25GZL]Z'CSP]7ZR;@+?7_0!44\ 002C
M!DI#2@HDADQO$-(0VUW]@.+2[TTC^72L]P'3NEUY)_T>\\]'?NI3^[/%$:)^
M87,3$CA ^2^D.E58B@A<V@5R;PM>:R&G?Y:FJ<5].\8KJ:3RKA0UYG>'3%H_
M'\+U/@D\P7BPV 6!01#AB&QQ+9VD7OP JC8G0Q#%(T.PVBQJRF^DS'?8Q+T7
M/+UF6N[4^V]/3\9;%,#TLS^\_G.\7* O?(4W] >5RU<$QW^:L022REF4F_@=
MV!":&CSW;T2M')S]M>KVU%QT.G)W4 ;>(]9M<CGQ#LD(X#-ADTB>^)B;#-3Q
M5H"M?%@X0UT@R8UB/2MXA"UVY)2GZU_^38#^;(K.WI-K$Z\39M:2=VA31>#A
M2UTGG^<3QHUXH<(W G$)2RWA(P*:,1G%(PSAU%FD3(*<->(I0#A5S?5[]DQ_
M#V5E]L[9^ZR$)<ON#H? +7M6=(,ROIR?.@Z_ JB#=VN+TP<EI3GP<KX[MDXD
ML\0A\;PH([_1OX$P3K@5>6M?W)/Q]JN<R2ETP/F[4T[6'8C#I2B#C<:U>=1P
MX1BHE1'"YA;Q?U^;A9F5(GV<7>'QUUQ,FL#M)1;9U41*J=I$/_LBX>)^),7K
MB(ZI HW3^U2>VK('[ZSW!3%AQ\,)RT%750#2F4!A9NMN0OMN<0TZJ@P6X]FZ
M#DF-X&+:D:R5^!<_"E6,?6TP+WU^RBE6^YZ:NVN<-%A K\C37!-N$V;N X@)
M''.&.U#*UPEE;#)#]YV9\P 2'L\K>\R'*0MK'/5'[:M-/VM5'')JOZ82%=$'
M$:-&J2,X$V""G9-$VH)S96+HWB#-5Y/'7>,\*]9-710878S;5?1@[-L"G4RR
M#G;F"=@0W N3E1>5.<!^0A<! ,6WL(<SQ(L!7#G%O'=$M@>-D$&M-Z.F&>&0
MLU#(#W/EL5B+V*@_[F/*/&=)^ST%RL'Y4,.X\T';3/P'P14K%1;"K?"CJ#I&
M9[^$J']FLX@Q8FJ4HZG 5:Y "\O1Z"]AC1X1>WOY54&W?2[EQAXPG%;R'.D'
M#A 7^KC-O"2@CZ\'D%G0)$+#ZCHD;1U2KY&3@0N+%)9%8(0E93T!<0I3$46G
MPZJ7'TULC[.J58'D;IBE-L*Z<B8_BK9Z\0\B*U"BL3&$9JL!+ARXSV)LP!W
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M>#)2CB@=4)*//],Z4GDHZA>YK?=V3;]"$?FKU.W[:R0<Q5^*(<H&:!? 43K
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MQU[8OI)OU60^_-(V5[+R?7E)12&7I@R;JZ97[;<O\_S*BP@G[QB1RGP.6:Y
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MH8PA6<;BC88S]FN4H2:NH,:F#)#'$VGG G@M29C5:)//3KXLT1O^K+Z?3,S
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MG_L$T0<D# \\^TI5+P^ZO<&])+N6W]>)J1M,@ =8@P<28Q@<.[^MH80.)C3
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MJ7FQX>ZF4Z3H0L9.-@%?;M:(Q[SEK2?&8JF&;>+('=219W0<1?,NV"LQ+0_
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M 2_LQZW>=LTY&HDZ[-K]_"W%J2YQ.C]R[;6GX%V)QJ.X]4Q9%FB%74%KZ].
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MOCQTM*QRZDY]UXTU67)=.JTV,0_8$R5ADZ"(?=@) Z)A9'_D61 %L"#A3N=
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M-RD"9>R*9XBN&6!5?!R@[EN#R:/4WE;=,"179V=U]0]-N$^E1D[^KG+[PXA
M,K1/WW&:FXM>CN8,_5@*.NWRWQ3"4)E FIG;0B189@W&PT.\]EEV(?ID )R)
M.FS-YT>SP0J1QU_\1=9@7E+WTD+Y]=.0HX\+#X#_=(+>M$%0;69D]2XV2?VT
M/628LU70B9A_F,#V@W4O@-F/T#>IV7X5A:3_UE/UI/^M)#-Z%K6:VPFLS$ T
M#1I 5;PN?H*BC-C'#07?L;S8$57@B@^38PF&O0"/'D9V7/$WJ5K$:Z:QV1^<
M6B4]-^N(-U=M>_UR\NCR+J5B!G#S_ 9PD#G?(=<DT3V0JL?:RJI53S\Q6LR<
MJGML[E2T?Z/PF8GM;]LZZA_)7%7<>. =BP#J5MQ<WSUPC>R<B)#B#Z.WA_>;
MT5-CC%LE/[2U.#._<U!YOU%9IZJB$X*,=__PF$CR+]^9>=#V3)J/X^O 01(U
MB52926(I=",5<JA974BY*7S_*IY4T,&$"*_IX+)E@#?YX BBO;Z\FA=[D%N3
M/*$]>=]>6#PJ/*R%F'GH;.Y)[U7.:J!Z>G)941+*/8#QG8[U-:G(M,X]I&V8
MPN)--UF9%.5^)U\=ZT<?+_Z!ZB%\_D:%['A]\9H8+]L\D&J?NHWR#:_%&JV)
M*'/OQ*LTDC)][/=^350-?O#"T&2CY@QL?B.1S'N*WP!*L3-!#+(=2(B4?S%H
MH/\LDT\Y/N)='5V0_#O*0/48,O-SA^"N!]U6N%+H[-+KA82IN9DDR)<N40*?
M\2>S39[[,CET>/PN, N?)_=I.\ZX;OS"9BNMQ]6&AR[I?=;)>S(V#M3\[AX8
M=V;?@ #ZE2E(6QQP6BP.7RIUP^2QB\R$0?.#YGKE%(4$/:_ZLT8Z1XJP!4X/
MQD0JJV$] 76/@B@JA=J#5^TD _HRG0(S-(9;?^_MOO);:BQ6.4#\TUTW3)XI
M*L\AL'_0.# (MX$3PG\'5/<LG:43[DSOY<6U:&C<0>@$4"3#>0;'AKC(EY.-
M8_O97NRWY1?3K"7=2X(,5+::PGK$>[X6XBPX0K@P2,0+@7E[ZW@50!!$/[3E
M[AH0#X+$(;- M 09:^/4\)II5= S.Z3K_FZ+1XBH[HS9D]=B;VK2^$G\CWD;
M02N.(=<?1#'EZ+Y=_4<"*3M_<<K@;7=0S)>94F$8Q:NV\R2RT,-F;P]%DY/^
MU.I7V?>*$1&"ZF4R<H4UQ,2Q&\&SNGVQ#4E2(N=X$)C-_3*G4/>KJJ7"[R?)
M_2=R+Y*:#R@19;@6O/KPU'%3=B(KMCZ0V=&!ETAU'S-7H14V12_+?Y,S^G.M
M"9/A9[Z0?_S6HQ*JMPE][ZO#@7SAF>#UY]8($Y8'I;+BYG><$KW4_D"P^46:
M@]/0&@S5>GO;!#U*]_N$$FJU$]XIH'RDO)K]CO=@W7-M^@,-3!=HRN[@O3#'
M[:^(02! -#+6"\Q%QOED]W3@55-H)T(]_P11+KN6.??9NMP\D78GQN;"&FS\
M.75] 3=F&=03[.G&?.ZC7P6S:(2.Y3M7_?+V@Q47GSK(9KT,6)G>N7N(>NV"
M_O2!WEY/6T<1&V^]/M3!-S;2W^Q",817/A%*Z:C"9G>24Z0C[?TH=@?MV<G3
M=MFMQ3)RA\FAQ'K GSBU??F3\] _1Z;4?T:DYP?^P\G@YO_)R]S8SJ3P;:<A
M42^XHWF2M;4>E#CNP1D' 8NJC_DLP2=)/OZ*(E\^)K=)ZX?F'7(<^(=R2J1]
M)9]*;,N7>'5W?43V)4VI_5&0^?.;8P51V'"6,R^V" H=I=__L46+40_I=5'9
M#&GG(MZP$21LD@QPQIBU[[_=)JHX@_ ;F#L/D5JOUPUB)^;/>[PL#:*@50<>
MSBA6P+.I"\/M'8]?>BYF9MX@(\[D$S/_U0U_ OX%F4$H]U>J^AJ,0/JC2WK+
M_<T[24?^8:W!TB'"G(;PK^@#0"WUC*=8@)T YM!)$X&TU$1CPM;S]K109G0G
MX4)3*Y/_X%*6[!J,_+JIW<XB3&,YK-7^P%N/S9Z4YG\>;N(62$U><$5Y),0V
M4+1K&I[$/EO#2NWXQ3*(0\5QHVD5"@OLH=?!SJAQ\:F8GY6VTLE7<!G8['-_
M!G,NQ:K$[?UP%7<>GN$XXEEQS>&P?+73RG!U]6$/0APVSJ!KI3<VY5WM@:(L
MPT@'TPE/8V=/.\KK<@)'S@VGT4+BQ?Q*UIYI/Y3R^K>STRKBI3G+;>K1<R>4
M=J1!@-T>N,Z6@U/U7U3!WXQZ&E($M&1/\=*"S#5HN4C[6]S(\N:V8E?5+>^#
MO-3BCVPXJ$&XODKA"T/A?E,HKX"[CP6G+S/L.59D,)*64LI".P_[5(/^3SW4
M7S0=DW5:ELL-"Q50-8@P._Z!KM?W('?))>;/-W8C+Q&@5JS!9) !) AF2^&V
M0Z<CCNC_1-\];S!2_K09D\27N_>-/6R]*]%E</F.^_=SDL%77#:WP>ZXGALP
M['VDMM6[H*#FM+^K@UG9_B;G6FZ]26''SBG=#XX'%?-G]#SRI^8<2@]'!* R
MV=642\M<&<(;96EPO5P:%TR@879RS[YF!B=4UC4>^O[RBX)WIFC#Y10M637_
M'<>_5MY,[&\<"ZC<@.HEU&DP#"#4WL<^ST2_0=]#5A61F*B.\UIC-=A?\ 2$
M;F7$T'Z9Q'/A)L1SUL>SCQ#/!1^:R']UUTCS'3R?4"?!E;1D-_!:D-2<HFFT
MA"O.'*RJ?QUX#2W>8OER GTTZYKS*Z^:;/X'WUN='Y]&^/26VB7.7:M4AG-L
M\+W(]8HVFL@V$]X]"!F0>SKL!V0\7=VQW[KY^UE.Z29)S]R[PJ2'^@-&QPP=
M\)''-MZ]IZC(N5<YWNUY/L)#VX^:T8AN99F9E9G6CM13'$S[#D2;M@\]DW\8
M,F*CLV(SV93XQ0F_,L2.!(.#/?GIF[;?ORIAB5:#0KH0$)2$F9B'>&G-[Z5^
MYD#[ZJ^B'&851F*2E-AR+.BIZQS)_^U&M2B7F&/\;:06SN1V=#C.B7<7"#2(
M(2)!"^8\52)N/0<5UNCT)]5AOCHV?Q6KI\[LO[O7>E?3<>\FFR9_!:R.?*/"
MU2/]5Y"UJ1W(B7KV-;!9(Y8ORV\GJH.-U,?A#>K5K-0[YI:%'0>:+[6[NP;I
MEY]Q%([9<\JNCNNE'?BQ(L^[X9%F;ZF3_]?"IC58O>OL12PZ86^$XDS<F::
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MIS='I/&(H(S3O,=@4*WF_L#^2Z,Z?4\=RE[5BU2=$/(L.>FNQ/I_EGK]]X?
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MP?^YLL9ZFCN+_SO-W9[UW2A/\DF'_[&.1W3]K0@SAF_[-;>\0N1C\\%T%8:
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MB'O\KRL_GPD.#@>$71?E-L =29H>[D>1*4=+3AX6C,CX T51P8)AA"%^"*E
MND!)H@BNP?S[G=]<]TU!J"_X=CCMPZ).DH*E3C=69L\97QC;5YGM&&L5M_3C
M,CSKVE3/>B*9^GE&* <"T&TZ@'?J9NX!5CWC^3/L,KVB:R#Q/M:K Y E:H+1
M=DQ^.LU,:T8<\2Q*/+LCA$FV46C0NSUPZ/OTR]<W\7&GT:G$?>MKWL!F]G86
MJ8.0V"3$E0NC%3-<:5- CYMO'%^=:\)!Q8R=B1U=Q:@NDNT6).9MV)$^E^LO
M[I'6T-WW@"/XEU7)_],!5P;:+(#9:G\"6Q=BMH5RQC3'U5"K&Y=%$Q'%=V/@
M7GC'P!5WB!LBA(RH $/QQ@G4Z,&H*<:[:-R?K%F\U]C7U#;D'Q7$]G62T+$&
MLYTISTND?3 B,=Q"XZKGYB*GUV#YAQ'*M-0E^>&7C*@_:6CQL@KPT6DK&2K!
M:7VY \Z?HXWO1<+Q"D";]QHL8(!<W4W<R)&[B5?#8MI,B")CI%H];_Y@=H?#
MCY"QMRE.V7!]5)9A_N;%PCCCQ_GX'DJ-P1(T[X)9+>O[;B^3XBS/@L:LW^UE
M$CVB.@YN0^,X)-U^FT->3=V*O<( ^ZZ7:+P,):Q?Y[;=/&-14V#%B'V#N<R5
MUN!O68/-()/@&Q$*_+9#OWM(,41#,+T$VT?#Q+=(T:=,/GRSNV&5:1N>:ZTP
MOCW_^*Q'6:_0F9TIPF92DY"ZIY(J4WLPXSFT^D[2/:"VY9 CJ0N30I&JE5#$
M#E@.AL1T%=W6WUA(S%+LV!,J%G"5FO$^QO+ *09;\"I)@2A-QH6"CF4X32*+
MDMBR3[8^8->-Z#9Y;I-3Z66!4DQ=<]Q\#-\CY/R5X\M'X \ Y@G4Y_HN!G35
M.:SYI=^A='M/--5FR8N>BW$%SQ:[:^WU)_<DSL0N'CY<=>T=>T?VSZVB5EI"
MR;]^UD. E^K+V,<<YHL\6W^Q92ZSD0T@C]HO13->OKW,E2M8--FWF"?WR?L3
M8K1IZHGSAP=]J@\>!$WL,'P:='\O:@2HC%NR8(JRQ4#/*&8U5?W!R_C:Y&OS
M[BSU9KKX>4_+<V,19K?-OTWTO4R(^G*AQ%113/.-XOR8G\#*'788J 8)O0L<
MA%XKATC4?$)-\5*S1 <ASIXI#S'TZYL3^7N'?XDR=G\H5&2I_6C34E_$]>_;
M]NJ!%3Q#P<Y;3*>6EPA<Q*02MP\!P11!G >S"1LP,9/5C99:/+_Y4\$GO?+,
M;_:DX>=UL<S"EO)!\8G4K%VVB//GO)VGSIT2ZD S;0(!4%-H:9EI_P;Y.HMA
MP1%PH'DJT,;N*MBMP6(J+[),;3[5,!P9.4'J.@>\.=[XJTJ4EGO!VI9>>X@V
MO"+2)8(L#F*VM]=@5IRM6)5.IW2N#)C[P@^H$>J&"[\IX*5QCG,<'R1:P0W2
M7WB6I?<J9%W:$;P]F5)U?3JSZ4MR9'[KKY&2:;=W&QJKGG3MM_A4#DY>33&Z
MWW'_B#&-4)G%E8IF7^?%F]O0!^(!B0C,3K"T.^^ 21^= ,?9LFY\:"ZC=(04
M7J@/+$US.7;SB?:M/-,0<@/L-_D?T_6NH%()+%[1&FQL)S)[K'#0XV"**,=2
M6%MQLKZNCOB!]Q%^<!!M?1IMQ'\!0"&4F[4&JQ,0I65QX[/_EHE+P8DA[3QV
M<2%:9%MQ](\"XMP%Z+1UL(J;0. :;%R%_8[W&-+Y? V^2#44LU9 WR+<<4(7
M<=N=#J0"0@(=..CO?(C16HFN"K@F%\:?"\D_EF*8=D$Z*6"VMPO/S[^)W$L*
MA$-TL<T.H-;F*0P!7L!.?)=;S]("TV0-=KZ2"-;320K8NO9O;F.Z9;[VMPK]
MV9FHW?$ME=W=45O0#U#,FJO725SI"K8KKUB7Y \)A6)_XB7Q-[APCR&K6^<3
MEC#\G5WT) ?9Z'XSUZ&+PR.,<@.1-T53%S_T7'#7%KJ*^))_$[&#5XC?SO],
MJD/>(WE5I)![E@JCJ#?LWP *^A E2T!(D5B9&3=,X_;/UK76)E[.$^:6DO;N
M\!8.\8Z0@O6*U!U*!;7JEQI9$^P8WC.D][(B#LXT91.SF ,SG<I[6*UC[-PR
M$CLDNRZMVW?"_,4P[OUS;PO*$T;7#< *A@_D?P0JEQD;.!"5:;,AJN(G25N
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M7D H:3@-JQ %[7]0_E O&2>W<NQ<Q91+1[;MZ:]['...G+)HV2_<<9G7]TW
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M^DL$ZX@>&_)L&=UY K=^D&H.C@)I^QTHH@!*L;/Y>\F0(9''ZH)*HK<ZO<]
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M<OLH_^W'!4?V'LO>CWD.RP!.L03YZ==18WAI8UWD'F82CI#G3\+M1>X#RM\
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M/&P=^(KNM$,3<N%-AHS_C;WW#FMJ6_M%)X)TC'2I42F"@%%IHDA4! 1$;(B
M$A5I(L2&H(0$07I3$ L(01$1$:-4D1)Z$2G2"4H*(BA$$DJ8D'8GZSO?7FOM
MM?R>L\\YSSGWW+O_R/,D,W...<I;?K\QWO$.N:L-ZIJ@%A42YO[H!L)MGMXG
M _U2PBID7<CI<[Z>48&9SY4C4'NW!P33=@' 1?/,9LAP@RJ%%Q20@ACIU<3H
MUP''@W<=M+AX<!L?4'_+[,"L+/6Z566Q>>(KN&0ABU9O[[6RC8OV9-S.&O=5
M7L3<N9?XYL'T!!O%Z^#)]F$VL(]C1ZXCE0Q2!NH'Z[VZJ/Z$J*3$U557-&-&
MK3Y^FVR5-*\XFF4[534V/D-"\43GH!? N;E$GRXAB&E P$E!PZZH!CQ-2[0_
M"7IZ$8L#;T?L9Y];LM9==\%G"ZO^1<8S=[N?M=H0N?C*5'^9LAUQF[!.>/U6
MS[K%E\N$Y'D^(#DY.*K+?'7$YZ;% T^#;P6O+@S>K?/W1BLKIKAHGENU\3_V
M-&@*N%N.X8;QK$HF'YA6P;%-+O"!\LC^Z*8"MJP$YAJ##]PZUSL>A2H7&S@Y
M/Q00;FWU3N&K_IAYA9F67P>1\@+%.(A(Q#&.$(8WU<.+DE+9E]Q!A2Z[]\7X
MEIWQP89L!XPG*_B>?M 1B9$K;XW:)XRP'@4FG\./G 2"B?5N9$5<'<2)T$A!
M[)>;SE'&4GHL;VZ6\:ZE&IG3HZY&IC@9C.U&;I;#B1UD*?5,_^+%@Y=.]TV8
MI>P@6A&I6OU\8/)P-1^HN5_CP,WZ;?<"N#FHCJP8;$UNPC-.$"7]LE8QOG0\
M"\*NZD%ZJ>E9Q\TX1%_@1BE1B!X^SXU%7\5<ESP;W!2:MF<='_BCB;3YW;0.
M-,D))/_1O);@_JC1%YTG@N@:09?PZIB3!9L$3^%583,G^CSV'<4.." T\1,Z
MC\'8<SGRTQN4D#.V+;,)1,W0N5^7AO4)+9O@0>,_]C2Y[#,?Z$)QKCG;%+?C
M)KY"%5S-!]K7./H]AJZGX\#M*,X++N)/GA[YQSXA&EF,7.4#NW',3S8C ;@)
M F^G#NL&FL/!\P#BTIF04Q.\%3)4E\('QFV^XW[E3):>L$;P2U-\("GN]_+^
M6"-!T@1R[AN>)_F #VQ&0A;_CY5(!FT#<<MR"-Q,+J$#]I]-.O*/(G=G05P4
MN8D/A"%X)]4'S?@ 'C("C//$I2/+J'^MGXY,SY*7EI < =QL+:NBB[.4QP<B
MM/C A^0>2"[^48T<GLQI%"]2@LS^[C=G22]'S@WR 36YW\OSO@^5UP:9*0D^
M<%^DM!,WT8'D*"%XQ[$/_@NGBDJ'^U?P@2PB.$GH1@X;DQR'1^H[)S2'+1RY
M93>;2R[=3?Z9I\VA/1C7Q5J#-\;&30IZ$YP7O;[.3%+A75^O*]QDY5Z]=L>!
MFO'"*4-*KX@:VG'AB-75S%O_YV>L4.)3>(@\RGL7NKN,@(L7+Y\^<)? .OVD
M/FK]FK,OB8P15$DT5P[&R77A \QT^G(A;(D/P-[C.+>^F6,W\X&?I1;+*,X;
M=D\<B."I^+'N\(&GM_C O0(DS]"&8S)(A]R@E2 ?T#V!XWCA^W5PW?LM?N Y
M8:$X>3ZP)^U?>#CYY6$^D!T3VH]< I9Y>KQ;FT/GB4MG%W/E&:B_W OZ$TB6
MO#@1WM%7D'QTP(\_X0-[U[)?XF8%%CC.W%7'V=]QLPTS=GH4XC_?^D]-MLBW
MY(5O6#P.C8C@%$A8%LI?A$1N/'KTGG,=[I_N15++B+ZP91WXDETQ)&Y&H4>C
MN4*6/R''VBHRR$3-BQV;R864"E:M0PB'5.G/-^,:_+$]\/G#R-DT",@W^RSG
MPI9%H[] WND.C$ C3LKDD2']NP^_><0%*]PW8TP0FEQNSD$\NAR4Z]:QBRYX
MM>3"QTN 8,K-RZYIC?/>SS+[ZXD[B;[()006XLAO((U>EL?&#4XXTR&-U)II
M(K)4\9#^/3.,65DX>&&\V]G^T\61(P/&>B'V@8$GLKYY)@H:KC[L$J.D7V>3
MOSXH?VIND#4$3C&CQX*:X7'$XJ8'+7X(P >W9@$NVI('7I'2'CCMV#CK/NIZ
M8/"I_9VFL^77]RG(FVT(NK.F1V!9WNH26:!*A)E!G8@B7$,D(M7<:%(C%PRT
M,UYU4-O]37P*#_H(;<\MT[@;$8W>NOGK#J'+J4Q<"VH(ZBC8]!?(A:[F9IA[
M4WPY>T,+@W-:E-L& E'2P7&T99<T \&G.G?+K+-;AT1S$@0?BP-<L1?K^^9'
M"O(O^I>*:F9)WF"TZ"#4;P8 7['&<T2./'H,E<03Q3;O_)G#J'0--6S,VMCW
M"H/,N7"Y]0A=LRK3XX93].9ZA*G?&J>8LZT$*6X)Y("Z(HAO@J8)BG0GMIZO
MLS*L$1&Y>#.4#=X-5$K@K8]]_23JIQZ]\X3G0[O.VH3S_NN.6@'8L![#S;I!
M9P ES2S@I?NZP5<<)VHULDGY.K8K_V13H+#C+LT]4\O2*&%(Z2TMS#@&X"VV
MWW=DT0.Z%(T>,$A]$&V^0;W\=;!]@]^UQ1K#@2W>L_1KY,V]B[W[[T9L<ZIM
M]6\\>Q((G<O[D>Y%0+.J-QT)_V'0A!FYD3:H\:)5\_C"+)$C2QOAB0UA_&CY
M1 _"JL\@LLGD_B422*Q_GYO+C9S>)OQ%MLW[^E"SXW(CO%%0?0_AI0Y Z,8-
MZ_$<>NO)"S1(<';:<<"_7 +F75=B=_[F8X[@B<WP 4W'$WS@[0RD&CVI[M]7
M0L6$%OE RJ8"W- BI&O?;0G7_I=$C\ ^PF5QK2TO<(/SQ&6EE\8AC>39;3_@
M"UP$+^I"XG_0:F<!MB/ODX4D-\U"U ^GRKGA?2/((^>9W7WE:V=_(K9HIVV(
M$JU;'W!#\TC*)0%-AEYMS6I>+[S\>C5SL7FG=SP?.']@Q!KRQ\G697TE0S7:
M;@[(VY2LYN%' R:WCG[UOVH>KQ*^KNCUK,!ZN/L1U';L$%&EQOP"O@3?T#64
MP;K"S"V/6$ I^9:3NF(X_A:/U*;?>V5<W%9$4KJJ8J\1=?KCFD[1J;O)$"*C
M$>@2; />\*@,-[4&R4$CI3F[F+LLB16,H)@%-9G1EL.]I1*:,@Y^B.'P%B-'
MI<^O]_A_+.B^(K"0*>?<["[$C*;?8(<&0P69QO.D>+VS'#W&IG#,Z4!JLEC#
M,]"]ZW"&2U6)Q 3Y5'5/RMDM/V2,2.(I:Y1LS\"*?0B0&(9C>#U9N[E/+62G
MTE'-;GJ[<.H8"R9$%6]SO(SF=5<WC><(L![V<?ON*CFJ!L#"A('%]-]BU;A;
M08B8:HXTD%F"D+I\TG5+BV:T\&S+HXG3(KZ093]:#LE5)X'DR+,GQ^.FS9"\
M2-33TJ5^MBT?: MAHKG1D&'J?B'XFSTB1! I^619'"5K=$?W C&:##='YKE"
MS=K3;U00HM*!:RA7*#=T,::_2LVP[]^C'=V:@KE])VT#[_ EOQGE;Q;;,/J?
M>(:@\!CU9_6+SZ214Z/#ITI8&9C:@<%+7]:KW%IG(![1LN]R1 > :8?DDN!@
M!Y/EG"P%W5X%OX:<[2G7YG2BZ$^,ZZ+^!%>I,[LL\9I0AX_6;+W"NAT[M,I3
M(6M:#N/(";(L!OB /RQL9W,:LZS9#QWM;C) I!JE70P(ZYF[^"9Q*1[!;O1<
M,KTV_XUH[9,-2R%2L@?NX\H6.;*O9VC>TV^#S5TO!DJ@9(+/N(RTKGEV$2&:
M;F3C=&7DZ"7% )=[P!JJNQ_;G_<9MQH9@!O>"1N.8)UDR@;'TT2:_*IW.48W
M'!YN9R7*; N4'#PZ&IZ]Y\ZK@Z\:QS9=^A!N0UXXVMZPO";CQ:D+I.NQWNC
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MAT'_A9AK!N?-[U_Y4JNZOW??.JUZQ,.6#_?,SU/2M/:J+<@)?"6+(WVZAF/
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M^9Y7$DE7::]J^)ZQ= 8,U)1#,APSG>M)IC%8 93/ %'.OVKS '9+KW_ 3_\
MSX0/"3-:SW*/GGYUE[=TI.QG\TR&2#>.\D9=CE%:SI$=HPW&T3G&>2TO3TT.
MV%[.UTJ7B'5"%X87'!#^!EP2,!<'ED-L^R\:=VP><>O)F_-'&_2$^%Y/(ZN\
M\-RQ7OJ.C9!7 5C>M!-VJTHO'QQI@NB,9Z]1J(4?W6[J@_?LF5C)%(N^U1GB
MSZA[-ZFN\D-233DI1$FH>2M[VI[*0)C!!R4^5;,3%!S#"X'N[?2=6<44[J&6
M0V5S\N;#XZ4I.WJOKBVX?V;[ 4'SNWO4X=Y0WS]:.9X55>7KS=[[N6UBJ[0\
M8TM%5-<A;%/<(CX!J<13X  @+H1I/[8I\>*\E(BC!*MPWT*2X+;ZIR_#>W:I
MKUJO[[C';RQY%0?-K212,HG%IK?IO-W8#^KJ_3QXL,:^HMZJO?D@LNG;F%,O
M/<<I]O6H2()F=J!.8AAL"V#@AF,<(\J"04=Z^( WGA1TM/R!"W@LFV/S9M#\
M2"#ZPER#U#-&A"]._XS,N7V-7Y.7?!2%W@@)CM0(8LGXHD&ZVI@UB&:,M SJ
MTN!O,]X9.03MJ^S=$E#8XG+6_D7.W#W =C@%T PS*T23-%@MW$RH0Z-[]6L,
M@Q>G=R:5?33R5V@X]*ZFIGID,>$ZJW56'CZZ?DMP9S AD4C)P9=%3T,>F9R
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M"_\FB$ZOP\(<LX^;:Z'^@^2T6.<X_*V+MB;5:/OK4F_%.$K/@H3+7D<#&OO
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M&@;+GF0N3N=X,)RIZ :"3%Z<2/37]\4I?*#Q_6>[$\.C>GN+UIW3;WS0;G%
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MV<M]:8Q6 MUHJT?O(L*Q<+*OM0I:,/>9K,U559FEF8GX!W<U/<:;2AJ%5<P
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MZ0DI76.OTB3Q!_&FM[^8W-^&'#=\;O;I2M1;[^7846T2D2$F33O"3*KVI".
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MQ53N0'DQ%1.BAKKJY499.X,UH4;G.=$NZYQQJW6%?TW@OF>@<N- ":];([.
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M%7&I>TP,+!T<XLJG"F62;:JLMQCCN@2!O=B%MW29S7 ,OR5@0=O/+$===9R
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MS7H/*>]M=/E"37T^<71&WY#>*U@5 ;()[K'>S?-U#^'<90((UC9\X4RR+<^
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M.>G<DD@"P419E:5:PHUO X:MUN^O1<J)USB#MYH&?VF,N8F-QE NJ,BJT*X
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MO,ZFGBLY'^UN#PR^LUAQWBQ2%4S#.".! T/S6G0EE$DJB;=I*=("28F_-EQ
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M=UJ8,;$4NYD E7H&9C-R@HP8&<N8&_OE\_=C%<Q>+(#7/SR3$0$<XIM$<5%
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MPL EN3IV;AA^8BE*I-[8FF%@N0%KNJ$I2$/S3O0C+@62+(%M\EI80+C!0B<
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MQS,C@8;KPBB!N2Q,.Q*!]4Q\.O"[IOH!^\"S>U*O^JY?L+;?>M5M[/H[!!(
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M\7K!=-(;FUUT<?]I"4_,OKS=\LH_G4F[ZW3>%W2WDL%]W6R;(B*M15R8NH;
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M$E6'<$9C G]A!E!41:G_6;.2;NAS- ]G/.+X4DY?M^J7PMT3J/*'KIUK"$6
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M?EG=S6$A+[>\7XR"$0R6HLI\#X*!L S-:*&H$<T%>O7#VIR+V-?$%+6[9*]
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ME9!,JZFFC^> BJY#$V2C-J"] 3U?M8;X^G8-,:6XJN1:Z(LGM!3LS];3JAW
M%J$UJ$>PQ[O\ELL=BO$]4^8!Y$^NYC[D?E0,\-.2H+F&N-R9 &5U>RNN(:1A
M'W_1O8;(@55LF&N_N3AG3J ^O77 3)-'A76\;^ M'A#PDQ?9<B$HO^X+^]/D
MC/;V^>!>EAE5)*/XO*'VA\&(_I>%@6I+F[\\>N:<5&[F;.ZLE3FB3\[R*U!P
MP&H1[ZQOOR6>#H )4D8'E98+26\45M? \ZDNH8,4&QH *7!$)KT$IGD?/9U^
M&5Z0J-\X*WZSZN'N4VSTL2N_N\/7*R9P7D#MV/H$-AR1-W&$3_UP,@2_D2^U
MW-E\;JE+8T.6/5C K-?;ZDCE)5WY.5O]8%I$X8S5+_-A<T_K-40TJ,IS $4Y
M$[QX+I7MSB!OB$[IILM5_)[ JBS0:;F.0$#[)6160,N9S)J#?VX(&I)DZEUT
M(Y\3-:#WV->43H F^8Y4BTDW5Q,6L\3:W7"7.+BDRO#@)IN*)TT9?6_B1L0=
MCSTON&G6,&+A]>'"Q@_68E_K!;(M?9!$> 66.!"!?9W;01ZGG^<>$I:L\QS)
M U16;JQ1TY)L"?C/%L)WW>5M\HN%]AT2FK1#!QV)04O$O5 ;4&.R& 5W]X6P
M)1R71I$U$ZN8$CCU&ZTAMILD0"H!*[=,O=,B#SQL6RZ.F0_T,J/O/XKY=%O^
MG[^0+]&!)! >XT4COI, 2^+=XV;<K5U#2($\7K^>$7:;X!CW63&3SSXKNL'E
MV+.J/*.&MA?/ Q7_V?\B_MW&)LIX-T]4^!#PQ<2:J\-6BV42J5OQ+?.S<YV\
MPEW#/Y8CC7I>Z@W0(IKR5MVOY'^(-TS+SK_6?P?!NF.6>R9) #.$3;(UL2>P
M=<?A1XA/\:NCH_^A,O^2.6#ZY4%&963&8BY7YYVWRK]Y \=FV,&=.0<#5B,6
M*V](3?$GR3E95D_[1#K_^;7KT3E/T]P_)ZB*O]&+6?!-7PGC*)> ;4%J1X4Y
M+=)8O-^*TX#6P(_'@&JP:5P>S:S_0[]58%2D4;,F(>!DNM&NC8_C+B/SP"AH
MR[K7U'!&DY:EO-L9!YZNZ@FG.L<XN[O3EETY7TN&F+&3)Y\)2]\GGVQXM 4[
M93R2J*FAB !/\Q(Y=7=G2*!Q%D^?@TG^_7XI[*T/[ #Y.\]^NO2P<-KSD6:F
M,<_W,G*D!:;;L;$55\-@CA/176EP[G4RC49OM;? X39=DM/RG+!_\>*(/0*Q
MX=W&MZ6N_[Z+Z#9=6IQCX,;UG<'CLP)S,.1%8%Y&C  -L^#-CRGCHZ91N:^S
MJ,H;(YOKM-@Y5B[0KN&)]=>ZKT=;UQ"T>D9](MJ?E-$B TUS@.2KG2_?PIHK
MX**'\(6LQGOECW691YUF+8Y:.75?]+MCK@6W6"'8"]Y@4D'CA2ZZM"%Z<R"/
MIA;'L;6)UCP7/^RBXUJOE'GJV^._#C>67UMH*GPZ0N]&C^7S'@J?/EYG#M?H
MXV*\6 XU#C(@&(#7=B4/=J_*SWN8-_B^<)M(FFF0-:5>ZRR^:J?D%N^[@KI(
M\!(^:MDBB! 6+J/'/5GU,4 M0;3B6V#QO >2E_U!+3Q35%*9M#7I,$-#T,M\
MLS#2W,Y;?_WN0NRBUZKB3]MSUQ!Q!+N2^>F-GUTM. F)9CMGICRM*(,UW-?"
M'7:!-^.=_\C,>LWI_//EGSO74:^0[#_\\P2,L*)%'6B%37B->A="<NB=N 1(
M^15W"U>L/<0O:DKLXL"/IS]'K'.^6G265]PC_G!TO^OS,TZTI9<L)TQ?+Z:(
MKLY8U)9^&\X_3D WUHT0W,V<\*\[;T,-$>7!*GU=6S+8RKF9-CHO-MYZ_%=*
MYJD8&_.)_V,!Y/]>_R&@KHW_%U!+ P04    " #Z@?92P5&[@L18 0 >$@X
M%0   &)I:6(M,C R,3 V,S!?;&%B+GAM;.2]>7/D.)(O^/]\"FR_??:JS(0J
M'N"!MIEYIKRJ99N5F9.IZIZ>LK4PG!*G0J2:C,A,S:=?@$=<BF  #)#BSC.;
MZ4I)).'^ _F#N\/A_L__^_O#$GP59945^;_\R?_)^Q,0.2MXEM_]RY]^NWT'
MTS_][W_]IW_ZY_\+PG]_]?D]>%.P]8/(5^!U*<A*</ M6]V#OW%1_0%D63R
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MRW+OJ5I*K*7T8RWE_S@UV,\7B.](WM5S61T(5ZO[P96,?9A^<";NK>(',;[
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MSN\RNA375256U=OO;+G6FS*_% 7_EBV7MT3][59\7[U2:ORQD"D77H!\*))
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M8_::5/<Z]5S]1P>,OY*E3M!I=GR3B*$PYA$,,4<0Z1)7. DIQ-(/ AXQ+.7
M7?>>4>=F,^P>[]+R-B<G]#]V)+]TZ[UO%LQHQ#FV([.*&U@OV'PW@&F<G?>^
M@5]HV]T B]-[[B8W#X@IW>1Y\9J4XM,]*1_(^^PA6PG>_?+ZKA1U@X6V<AR3
MV(M%FD(B0F6Y1%X 4TX$C)(H2E J AP9,97UR'-CJTY,T @/6NG!#]T??@0;
M#2QB)5:381!Y&@OBD4G+!MTAI>6M8+:(3HT%]T2!*B<OM5V(:@ABO=$JJP=.
M%[@:HN=>#&O0 X96QUZ1+!?\+2ESW;UOI_CK&R$SEJT6A 4!H\IY#7G((-*5
M\$D<$X@1(IX(:1(R2P_V_*#S\V8[F8%HA;8M7GT69S.;U"UVHV\PM*!UTH(?
M=NM/MP([[&!FCH[;0M)G1YVX6+0I"L\+0AO?.<#\?'5S\\KW?678-O\*VE4W
MI&$2<=^'3$H,$9,,IE[$H,0L%#$/! V-#DGW#3(WH[(5LW;16D$MC)I32!J8
MB0[P&9DUCD SQ/ [A9&%C>< JXG,.9O7R<YJ.X-!KX%VZM[I;+$STN^97>>N
MO;"QZWM!*O$YN[M??92_5:(^]+,(4^[QV",PH@&%*$$Q))*$4(0\32*/RE!8
MA0-[1YL;!VX;FBZUM,VV^-!FKT?A-;.IG($V,C%N\:H%O0*UJ+"04 D+:FE'
M: ;;!\HH;6&/#O@R#6+[=#_9*K;WIF$D\HNRRJKW=17-C_G;[WJ4=5;=ZX7E
MHZR[I,LH3GR4^I"DB2X"X"&(_81!P14I8]VKR"P9S'C$N9&)%KCMB R*'.R+
MK"/BO0W5!Z)NQB].L1R98RZ#T9IEC*%QR33G!YV4;8PQ.&0<\QL=M*IN.G[4
MM?A*P1=!$B?(YP)Z011!Q$,*"5,_$LYBAG'@L^CB#M7[0QI])"_1F/I4N9%-
MS^FKIIN'I673A[[T)(DH]6 0>B%$5,80TQ1#'&*6$%UR)[ J*W8I[)/F_;X
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MW0O%'+]B0("%B9R46:&+%3!2=6>=_913&D0!%$PHDX+["*:>3R!"OA!12FC
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M+HA=AFC8JV%GQGWA2V&7D;A^':SGV1O+%+[Z4=\<K.FOSGN%A$$%RP)P*"3
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MK*O%P^OEW/QJV>23;8N#W3_:'M*-)_*IK1PF9ZG '&6VC!1%$&"8(< YA(#
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MU,F7':;-CP/*][F#Z^';#@+R2"YO/+#]W&%OS'J]9/>WC><\>VMXX%/[/QW
M]G6%5JU6RT47'4 :(<X1*$J. =:2 99Q 337I,PE+ N/;@3';Y\:=^_D\R"0
M$\@<2/@6( ;FVIUH(6QZ H8':=X"RDC<Z/ %\2.]2SKW<MO)0^-1V"5Y#YCJ
MXH="F^EM(Z3?U7Z&O[%T/QB9+_SZJ_G;F@G[A=CK7%WD@J8RY4 7B@!<9A@P
M+3D@*<^E9"5BRNGF]Q#"38T.#W3;OX=3.XG[_VX*-FR^L45R^- -+<ACSKJ;
M5_]2<SDPHX\UC0$][N+C';<G7D3Y1NZA%Q_9TYY[ XP1MD.\6ZY4];!X_;RR
M#5)^=.73S/L9K^;5YL<[5JWL48G:]1R8Y6D*(3(33TID;\7GQK(MM>VSI<VN
MH$@A,N9W>S9$#!^>&.>^[%YA!]%IX$?=0=/A1M%#0SPP%;?B)YW\VVJ+Z[MD
MJ\)=8I6H3V?57L.3>+Q["X@Q^35(CE%Y]!:DCOGRIG?=TKOTB_&*FJ3"KJ4F
MI$0*::Q>8P/;4#GF@*9% ;(":TPU,\3H%8&Z,,[4[-FV[-A6SAO;E9[BZL9A
M$= :_ S 'ZC #J4788C?G?1TJ!?H3'I1W_-=22]_/.!P[_5R]60-,O5&\<TN
M#FZ,M8:4NL*FC+%4ED*"@MAZ05J5@*6*V[;&&N:,9Y 6;I:1S[#3LX2V@B?2
M2+Z7(),8V8%HA/<X''/%W^$ <0!,!_=".S"MR'N),Q;,UB!R*#X;CJK'2>0
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MC489Z\'+I;F!,M!MR!<O@>:F?<^-QGAES>H3"'O;Z?W"V"GU&=)G)=7C4]T
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MKZI^:[3R\@"CA2NOZK@?K[S^8;]5+E4U^TT]L'D=_/Q1!](U+V!!10F*4DJ
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M X]J/'EA<6Q7^3T<(T>DN8#^;,SCCT_MY?/U*Z67JUU!>[7^O5HL5]7F1V=
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M(;$^*50WZ&!AN\O]=U;-[7MLPRECL>T.] ^/]V=:R!)AG0(E,@UP63! E2Z
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M(=2YS"" ' J &9* %B4&5%"N&.2*<*="N/W#3(U\]R5-.E$]K;8KP%[WN^+
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M7\H:6ZE[<Y&7BB3A,?1]*B'B3,!4I@+Z*%'<J?X/A5;ET"WG7QJC[M7%^2[
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MH"5OJB_J*V]#UKI^!0V\[\E791ZFVZFQ5[%,5+_IU>F4Z>ON/.]5\FVK^]Z
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M$ I=3H$)?9O&J3(=A;Y-(S*1!/O8-S(8+T^UM,^_D13L1 6=K.!/+:UE5O4
MPH:'RTYPF_I<>21D]B?*%]%P>IA\?K9YSY$O:GUTA'SYB;%F E,>;R7>B/9_
MW^=]V]>O@HFLJ;^^0HPA3RC&8%% (,)(0D(0A0%7[('B-(W]P*Z;C\FTRSL3
MWC8N+K="VMH2!FB;FA:.$)S+TFC%!'_I!?Y-G[UM$?UZ&=$1IH<Y1&XM$8-Y
M9S9,S)$XME,LGG51'/)#EHOWM7BL5K''0AE[RE'1O<-0ZB604!9!G["8H@BE
MC-#Q!2*W\RS-8'E1VA#\J24%C:A7E83< 6M&,0[@FIA51B%U92'((QRF*P:Y
MF^H7%H0\TG>X*.3QST>Z,GL5P-KZ7RNJ= E02J%$U(/(HP%,8Q)#P8D?RP1[
MDGBKNJCIVM"%.9K"B@FV$TWW?M_I.<"KK+@7>1L=6VE#L)/Y?_RW)/#C_PE$
M([NE'W,,KZ'_<A5H4_LM)F7COM#!Q&9['^8L(DY]E^-9YO59SFIYY*N<_^58
M*E"VO>:6S[*M8WV;\Q/5K;?E-WR>1BP1?F<VQ"2%22HI] -?\I03SK!16Z:1
M\R_-G-B*KZ\*3A:B'UMBSG9A3!EF,K@GIQ\'2(_@GU%XN24G.Q%F9JY1^!S3
MVKAA1D0#_+W9XS>5^*/67>UT,96<?]L\/15E_4V_>WVAD\#S>4PEQ(KP(.*^
MA F+"0Q)E,K0DR+P/>,@ ,-)E\9N6[%OP%;P)A*V$QTTLEO</)N"/TQF4T$Z
M,8.9H3DF^<T45HM[_ G@G>GZ_LJ7UNZVWA*FP4MZT['FNYNWU.[@2M[VV1%4
MKG-*OHFZ7@O^192R*!]UY'=SG-\G)6#"J*>/TT.LZX&@)(0D":CN(HAX[$4Q
MXT9M4 SG6QJ!-^E652LR>-K)W+JZ-J'4!E@;D+9;!"?FZPO@C2%J Q0M.-HM
MFC/1\]6HVA&T.4:#W&PPS'RT;*[3 2-;/#:"C&_# 'O?1)X5Y:>B%M6;C7@G
MTG)#RV<?!Q[VN_=;)(P)&:90F="^8N20PQ3[&#(4192DDM(T,F9DPTF71LOA
M7Y78_QVT@H-&\AN@9 >]\,#'-T#+;\$MI@M@0-,3P#HQ5YLC.H:V3:&UX.X)
M()Z)P!V\O'84;@G5((^;CC4?F5MJ=\#HML^..R+^D-%TSX0_OMSP2(1CCW.8
M""8@BN(8$I8(*%(I$Y&$(DRYS=W1I0F7>9.TWDG=N)MC;HXN0FUVRNL2P(F)
M^\,+U-X.HV9]@&L*A<L3VXMSSGI$:XK RS-9X^?&L<KM+C.PJ3%ZXKA7IXCU
M;557:<P1$XI:>((3B+PX@M1+(B@\YGF^<O&Q9]EPQ%("FX]FGFHUMQ>2*W4V
MJ!W_V"X*)BA$?J!60<:ZC@9+(46(P2@,F!^%7/*(KI23EQ7J!:)E_<L7YJ4L
MOVYQ#KJ.[S<3!ZFXS_)<I]6F=*U=M&G7D,><^!112&@H=8ZC@!1SY9#I1CY1
MX'&1^C8WNA.NWAR^V:L6\QOPOVC>6K/:F/63:1?!\Q+LT3"!DNH:BQ'&D J2
MP# )1!!Z1":\_Y#>YH9QP)-_1KTD2_R(1,YG^X+,C+()EV-B&VU_%=IZ[B?O
MWYNR$;^UW6/5*@S5@[ VXT:"Y]*JLQ5A5B-O)#XO;;ZQPXS.CU #JG%.M323
M:EL*/4%A$F-E6O@>@@1%:I?"/)*4RF9;LNQ3?7ZZY1EWW4>EQ+5O43T JQE7
MN8)J8F+:831]+S@32!PG.IR?;^X$AXN:GTALN/R,'6MPD:W>YK7R/&\Y5V]1
M]5K]\7-Y5_S(5\KYPR@,!.1(>LH/25*8RD3G-A 9)0PK4\JHGM_ '$NS4ULQ
M02?G#="2*AR!EM6,+X8 ':8)1S!-S ZC$#+F!0,,=G10]7Q0"?;7^^+[OZBG
M6RI0?WC) $,CS_+A&ZC6?^\F/QW9ME$?:'^ASTW:7ISB()8L5"@Q90Q$20!3
MX>G^C"G&) @("RR-@?WAE[?Y-]*!IU:\&\!H63YK=Z:IW6798G$?1[/=?RPV
M$W_/+2B=7 Z[')[0UFG_POWQY^U,>$*SHYZ#IWXS[HM]^_BT+IZ%^-J66MD[
M/^[Z5:S")/8"&410<I) 1 2"2:*^95\FU)>!GTAF57;WXHQ+V[3WNMX6.1!C
M2J9<1MGL(W>*W=0[>2<K[&LN[4E[TS<Z<L<(QM"XI(G+D\[*'<88O"04\P?'
ML<P[FI5_T]O@J^?M'_\M$Z4:Z.'Y@Z[ZU!0,X5@D?D)\B.(FGS'F,*7*@ C3
MB*;29]*75B59S*9=&M]H44$C*]@*VURS?KK]VZ@2+8;HFU&0>TPGYJ%KX+1F
M(3MT7%*1X<RS\I$=&B])R?+I<<S4M_2Z*V[9/S=9*=[GM7I[,F59-0TTJU4D
M0I*FH8211X6.1A>0Q&$"DU!0SF(?Q6Q;%/S.G)LN3FST"1U6>[F;@9T:::M,
MVT*5OC'(MF*WW9,MSSTOXV]&2V[@G+E59%V 3EJP$[?MNWL>1FM.,H;&)1U=
MGG16)C+&X"4)F3\X(OSZ]W61TO6'C.F[FOS^P-'8MIOJ)+AE#YGB//W'0K[+
MRJI^73P^BE(W/M+]%#YF:U'512ZJ%251A"/MI_F,*3-*%T4.I*=LJ1B'/@LB
MQ!/C:.UI9%R:S=5J";9J@D.G;ZOH#>A4O0%[RFH>;-0%.WV;?KQ@I[%%Y/)$
MK\4PD2YDL2>FWO\;UMDBH/W7K_=,\>^_<-WMXN:G79'!,/N)IIXO*G]:[ Z"
M^">>:F1>K>ZZ415/HFQ:#G<GE7V.HA?&/ BYA&DJ(XAX1"&-O!2&7BQBR3P1
M<&F553LTV]+V]]=]4Y+J!FQ%[L]R;5-J!V$VV&5=@C?Q?CF,V]ALVD$ +7-I
M70$Y9R;M%8#:)]*: '0QC79PD'F3:$WT.4JA-7IH[ F2/B#O>U0*0A.!&90Q
M(A A79$O49P;$ADD82P#$6";$^S]P9?&J1?*QET&RTMXPEF80D%##99'8:KV
M)4@Q"@EC!/'4LPL0& O7/ $";<I9DS*O?/%*\"8P6KV)!S>+^Q'15X!K>FPV
M#K#)3\A*X;3?^9"^;H^]]L:?^83K6+/CPZP3OQE;H;AO^;77=+MO$?;J^=_:
M'G/-?:(^*7[(GIH[)BD2/]4U!*1B28A$J/F1$$A$0'R!"$)Q:%? >(P82V/2
M3DRP+^>HF[Z1JV+&%=-C/3&KC(%Y1&WD:U!R6SIYE"0S5U:^!JWCPLM7C38R
MMB'+::Y]^=V<S4>%I4\B#_LPBKG05,<AD5)1'0](DN+0)ZE5W-29>9;&95LQ
M#\J0CXE:.(.K&5DY0&MB-AH#E'T\PC ,3@,0SDPU;\3!L+Y'(087?CZR/#-[
M$'RS%I_EJTV5Y:*J]B_-7SWO_>UUD3<.:5ZK/U49%^T1XET;0(T%C5CD0Y^E
M 42>]""A1/V5>T$4>Y$?)<2J;+,;N9;&.+U:VF?J%0,'80KI\_[?;\!..W"@
M'OBS4="VZ+.CY38CME^PB!,3X8SK9U]*VBW:3DM,.Q)MWM+3;O$\*DGM>/@1
M]S!OA!1E*?@=_;D71GO<,Z@)9UMQ(GP6L0!*SXL@\N,44B\2,!1>&.+$8XKC
MC2]EK*9>&HOWPC>% -;[H>+9ME,6W^^499%6,V)A#*YQ)H-[8KX]0/H@*/]4
M3[+W>1L\.QG2%O<]DR$^T^6/8^3M[H)&@3=X,60WXGRW1*,T/;@R&C?"J-V"
M-:>Q@>>3TRTMN^-\B4G,="1?F 88HL@/E"_ E5? 4"0X#H,P,N]L8#KK\O:(
M5FY=VX> <SU9K9C*$'ZC[< ]J)/O!"9XCKGE-P;6BOW= SP;\;L!VI;Q[0"[
M0/:&@\W)\W;ZO:!XRX?'G04U%7D^*65H]=#6U^C:FZ\\*E"(!=8!6$B?[B20
M\A!!/PP\27'$:,A&Y)6<G=#HLY@_GZ21U^[ Y3RF9D<HUT$T#S6W);LZ(;?%
MNCHY?W-WP'$1"Y='%N<GF_40XJ+.+X\5+C\P,G2H+/B&]1$;.(J""*4A3'7O
M$Q0RK!/-$)1!(#P:XD#Z1FU/3HZ^-%.N$ZX)=K&,<CD S>R+'PW%Q%]Y)]<4
M@2ZG-'8:Z7(PP;RA+J=T.XIU.?FCL37ON)!9GM7B0_9=\)<I8*^>/]+_+,K7
M:UI5[=5OFD9$, 0]X8<0H8A *@F#NG,1X6I_%]*JWZ;E_$O[UG?BP[66_SC9
M<=0%L>VJF%'%A%A/3";7PSRBOMXHL-R6W+,38>8J?*/P.2[,-VZ8,1V!OM-L
MK>] WA6E3D[Y)MBF;$Z_=%?SC[3N_G8K%7.\4]+\AZ!EM<W/7WD^\R/=B%SZ
M)%9&#)<P(3KIQ \]%,H8R4"8Q?2Z$,?FZYPG!ECW7*%:6"!U%=YG+>X-$%6=
M/39%<J2N5F%[M7'MHAF<;LVX$!/3Y%83H%1IL_AVR@"M#=BI QI]@%8(-!J!
M73F1&1?(ID?1? LUT^'9W4-6 <5]CZ 43VK@MG3"@]C[5G3H -<K5VVUO0$_
M'C+V /11FXZL9_KKJ@OPJ!$X_@:!)N]FU*[Z.*@>A*@!5U]E4RUF-YK:%,5]
M46;_I0;,1=8XZK0"#V+-85W QQ;B9Y"KUZLN:5/2?"?77UTU6'*SSL.-EZZ<
M8\:&3&[0.&S4Y&C,T6&E9_;[/RHA-^L/F10K&> T1,K1X"G#$&&>0,)"##GG
M81SC$(G4LK^*R;3+VU7?;O?/M9+O!OPER]O/^OQ)V7C0S?P(UT!.O"NVXL(/
M)QV'&]#*#+303H-3C2%R'*EZ>=ZYPU:-D3@1PVK^[,@BH4WO*-U7H,C5[ONF
M>*19OHI1XODTPC"0H8 H\$.8A$D"9<BQ-O8105:Y/"=G6=I91BLDV$H)_FSE
MM#R[.(VH&;-<C=/$5&(/D7VQSR$(G!;X/#G1O$4]AW0]*N0Y^.-Q7_]797+K
MFGNW.7^CJ^X53]KH?Y]_*0LFJFH5D1C[6# H211")#F%"2,^3%#@<1I1Q%E@
MPP,7YEL:(W1UP3C(<OC4B@C*3H7&<^ [)>Q(XA+P9G3A$,Z)B>/K/FI[LNIH
MSTY:=Q1B"(M+,KDTY:RT8JC_2X(Q?>R*:(DS_8O.NV.W_#\W5:WEV';W"KPP
M"@(A8(R9XB02<)@FO@]]Z2=(Q @31NP<(U>B+<]Y^B,O!5TWQQGW:K>HVLYL
MHOH-%/G>P06@VX,S692@HNLK2A4X6V@S#OP5BS<Q67Y^_?ZF/:W\MG?FM54&
MJC6"WYHUT@FPVSYO[;G73K.&:YUV?7.-M?, %!>RS1^OXA#1D^$M+L<?6U)B
M&W3=WFOI8[2VHMIZ7?S0A[(K)CQ,XT!"/TX01"R-(=4Q=%$H!"61I%YLE51M
M,.?2[,V#)(*VY/(-V"@.9\5]WK!XVX\V%S*S-#A-5L",<!WC.C&7;B'53>EN
M.TBW$H.MR"ZK1!CCX[8DQ.5I9Z[_8(S#<;$'\T='7(1_%3I\2(V6Y67Q3-?U
M<TEKT75W*C0_=B4<M2%4K=((Q2)FL4(<,8B24$(:1!%$:9@RCGW*B7E^AMW<
M2R.HK?3:;^OD!UJ!OC>6MBMW.C26I$T)1LN5&2:LB?&>W&->%-06U]3303[3
MK;1;Z.WN?L>!-WC5:SGD?#>[XW0]N,@=.<2UQ3_.F\YMO8<(\SB.? &3. X@
MPI[:,M1F 7D21Y' A&(O&E?>X\+,2]LP]@M '#JPU8OHG"OK<UQ:$3/;=A*<
M)]XHW$%\10D-0[BF*9)Q:?)?5 ;#$)/SA2Y,!Q@5"RI*>B^Z2)?GS_(C+?\A
M:CWL;I:52,(HBAB%*=;![B%!,&%,0-TW*18TQG%L%_%I,.GR#E$[L<$V^DM]
M:(];R0_BTAZ+O'ZPL<+,UL' SG6.[<2LU8/:"PP^2[ 3>8^UG(-I%7#I&-29
M#-@>W%+H.V(=I%AGCV(;(GG\#A\%6-+CC62*.$<+>"]$,YJ,-&?,HH5F+R(3
M;9X<G9OX),KZ^8MZ:>K;G.O(@J?NM'<51SS!$0HAEPF'2"08IE(D,!8>3C$/
M:>3'EI6[!Z9;'MOWTMZ )RUO<XDB>HG'Y32>!]O,*G4%X,24OD/NRQ:YMSOD
M/@T@-R8'\B(DCE,BS\\W=X;D1<U/)$Q>?L9U+'-U^UB4=?9?S5[7)57K,.H[
MM2YB%8><Q7',H Q313,IPI"B4$#J<10&/$F(93_@<7(LS5]^VZ<SR$V;R[ G
M^ZZ+@'I) U?1S\/+9$90,X _,7==B)'>+LN^.C=-VA!H5)DC<MH(RWF"J8=%
M64A\M1%>YB'79L/9L2@7V>IM7BM#[X[^?,\5(V<R8\T,GS9MY0B/ICQ%R@7G
M20P1Q2E,DRB"GA#20SQ($K-"P1=G6AP3-L(VU[:'XH)67C/^NPSP,,,YA6UB
M#AN-F#%'&:.Q8Z&JIR'E/O[UOOC^+VJ,EH'4'UX2S^7Q9Z$68S5[\C!_X-J+
MAT^%'I2N%1=M\KKZ+#]OZDK1E,Y$W+5(^%)T97&;<\([\;-^I?3ZQXI%'&&/
M1)#)A"G?SJ.0T%C]E<8^PX*3,$[L?#M'DBW/#7Q7E"*[SX%RN4N1LV<=&/F#
MEKJO4UZ7E#5YJK0&/X1.0LT5(S9AXG6A3UD4)O=-**5@M-)F0RF^B]PTK=CU
MJMM>?<RVDC->C/0Z@4XI_>_VU ([O<!6L>Z^!&C=0*/<)%<G3N">YF+E.M%^
MT;6+$SS/7\JX&7Y,%]BB?-)M:(6.#-Z=!;YN"*JOF86('W,O#:%@2$ D$Q\F
MH;890^X)F6 9(<.L8>,YE\?=6ZE?GFN#3G";GJ8FJ!O<S[A&<F+NW$'X(@Z]
MAW!4?U@3+&UZQ#K&=*X^L9=>3U?W*S;X#+>)-1EHQE:Q%GH=MHNU>7!DI'M6
ML751;4JU5;S>:P':="83_'51U553D_:5[A+:M1&O=L8:#KR8X#2 -!$>1(E@
MD 1"UX_5U^U<,ID&=B;ZE1(MC]Z_[759[<6U#(:_<I',+.H9@9_:DCY&'-R6
MI?J):%N;36(B.\+/:9#]E2+-&X#O!K^CX'Q'PX[CUT^BWF4PK9( QP&)*(RI
M9!"EE"K>E B&$E,1QHF06*QJW9O9C"L/1K<Z$=W.,=U7J(33#7-TM6A:UV66
M;MK@C;H K[+B7N2ZEO1YV\$ 3AKPU.<>@4D4QQ!Y1,($!P2RE".!"/,)-VI9
M=#V<,QPP3P^GV38Q&J2)25_CTQ<G;S),P>T+F"YTB;<F_)-(N*3OPPEF)>.3
MNKVDUM,_&G%6T-8*.>=B$9HD08(1I#1.(,(Z@YZS /I8R#"5B> ,&2<T#4ZU
MM&^^JU^SGU9M?R0P#*[!68 SR*:^4#J+UACO?Q@V"[??&7PS^?LC7CH[/]\(
MD$$'?WB$^3Q[(TT.7'JS)\;6AG_9%.SS4]-+,K]_39\R9?'=IE5S&;3R<) H
M(PE!&2D;%(DH@"1,).01]F..)(VI;^>VFT^^/ _]]8-V#2N=/E?T0G?Y[$U4
MX$$/R%S4_VI;'=YX7<Q,L&FPGIB=3_455(!O)0>=Z.#/7GBGU>%M$7-;&-YX
M]IEKPMNB<EP.WGJ$*\HQ[35 ['ASA7Q$ R*468B4'XU0+&&:)@AZ+!4T\3P9
MA6Q$=:7CF9;'6K>,E1O!^S#+AJF*D2VL3B#K>4(B7W#U/H<*7DF4_2T]"E,J
M8A)'H12>D=7M$-<Y3.X[?3("Z+38FM&\ \0FYO2V-=A!^UAGIJ(A"LYK,IV8
M:OX22^?U/5DQ:>#GUT9P_8V6F3Y >=_$#%5U$S>V35/V_-CS,14PY,IZ1+Y,
M8.*'#))4^%X0QX0+J[!XPWF71AK[H3N]X*"7'/2B7YLS/KP49IPR <!37^:X
MP?:*B"<CI*:):!J>^A=%+!GA<3XBR>SQD:F"_?5-\3'+"YV1V%SM/!1K-4:U
M$E&:T)@+R*FOK$4>I/I,,8#8ER&-,$Y#1D8T.AV>U>A;FK_;J3XOYUG5'I'K
MJ.NZ +DN09+72I2U]LBR;H4L,PB'UR!,2.*3-%(F)?,@TAV9:*IL=P_Y5'@\
MH3*RNK1Q /Z<S28[:37:GP[1[K\'R^" "W";;0ON0)QX-[@*/_NT32-8G"9N
M#L\X;^JFD?9'R9MF3XT]XORNQB[*Y]VM_B[,)6*2-@G@H51V*.**V(E $<3Z
M/#/ ./0CRU3PH>F6=R"PE=;V>'( 4],#23<X37X$V8D)=G).% QD@HC;(\:!
M^68^5+RL^?$QHL$S(^Z57VVJ+!=5]5E]@-\S\>-+L<[8\^[MC@4+HC!!,(U1
MPQBZAJ]'8!3[(18^9RE*+<+/+TRW/,;H!;6X%KT$J<%]LD.8)B:,7E+0BPK^
M;(4U2K*Q!\_B5MDAB#/=*[\1%5/.AB[?GX.B!U27['\0NCSE$\V?FX/63.<[
MM=<(1>ZL>H\A8(/WSI?&F._FV5";@[MGTV?<-\S8]DA &*-01!QRF2KG3Z88
MICADD+-0V6>A#!)AU:#'9-*EN8#MH3G;%[H/[&O:7?PV32\+AWTJEMB#H@'U
M0-[#:,"FH(\&=;8.$[^J>\3R.D-<T_7ARHX.55EW,3<?1?U0<&UI5K40G]2[
MU+6Z2XA( RP(Y*%NT(-Q *D,E1$8\D0D#'D(81-.NCS5TIBHE; K=Z5^9]E!
MT #;8:YQB]@,SJ,=6,9L8H[# (>H0?;X0_WM)7<8S#(+8YAKV_.$Q1,CG,1O
MF\='6CX7\I;5V7<U29<94A=O@\@CRB)]=?LI0)[_NEBKAXK6+GU1M""A/DDD
M]B%E*(4HHBDD(8YAJ+B%1)$?$B&-8Y1=2+0TKNET:JH^=UJ!3JTFA:%5J"W"
MMQ9Y*IA:8EJ# Q4M7"TGJVK@S,Z]5E/?M@XO4Z-3LTC]@AVH95."8J(ELW"A
MYUZZF?SLXS5HNN0Y65D'FYUSZ <]=B<3S>?6N\3EP/=W.O#(F*)MDN5^&J;N
MD-26GKK-^>LUK:IM+:KW^;LLI[ENA_%-?31-[FZU#94.@BCQPR"%$D>T#?^D
M@L>0"((B+@CG2619',JI@,L[[=U/B][7$'35 ?4IQ'K#F\)0NFY45:PSWO!#
MM=5.TT=[6&$9Q>1V\<W.,'[=@DZ]2P\GN-_T*\H;0N\BL75#OINNH-0D0?;3
MP.TTL,JMA//&7TV"[E&8UC2SC-LQSC<4T051NIKSNO^G[B3[.1=W#V6QN7]X
MEWUO*IWV%5#;)/^5"!E-0H] 3S*=\^1Q2"3V8!S'-,&,>%@:=@>91+[E[1=O
M-J)KTEOD CSKXL%UJP&0^GQ5_QO=>Z'70NT9MK%B;E?8;%?X9:LV\:9@U(%Y
M*SS0TM]L^YG<@.X;[_:,;UE^O]YK=_)&_9>^97-31EH! SID@(;&W38RR?JX
MW$7<"CCK)C()MB_WD&DF&;>%?"CR>S7+HY[Y3@UQ^S.K5CXE/)#<@Z$,0X@"
MQ&#J)<IU(!3Y'*54IL+F%O+4)$L[?],R0BUD4R'O!F@YE16H)+7,1SB)J!GS
M7HO3Q 0Z!B)K=AO"P"5)G9QG5JX9TO0E90S^=J3QV.1O]QEW+$I"9>=Q2'6N
M.PIB!)/ TTWBH@1AD>*$)C:5EPY&M_K69ZB\U.8PLJ[V19O(;FF7'8!G:%>-
MA63BS[KOHNX\,_&DPDX-C8,)YC443NEVM-&?_)%]2XENA'=9Q>A:FP!O<ZX-
MSI4GA9 ,89@&GH[/] *8DIC 2&<F(\'BB!EWDS@WR=(VZKYD32MH:VPK41L+
MW+R)Q%E(A[]E5T!-_$F/PLBJ;<0E$*[H&'%VZ-F:15Q2;K]/Q,7?CNGFRGG6
M5B7_F*U%51>YZ$XQ5UR&&!.L-N88-REBH?KV.=8E_7A(,$W4?S>^1S\_S](^
M^IVDX+$757=O?[0K]34 [/!W[Q"NJ7?S'5);*?LS<#=(V31<=8+87%U6!]XQ
M9RU2+P(RW!?U_.,S-D.]J,-A!]3+/Q]!D9]97:2BU-M'<R3_53RI]^"!5N)+
M6=R7]+&O0^<1P;P$09G&#"*L#[49B2$6,N4"R3#V4V.^-)QT:>39B:W;#'J@
M$1SL) >=Z!;<8(J] :5.@.C$_&H$YIAZBL9OM#G]3H#N3%Q\W2MKQ\F6* T2
MM.E8\[&UI78'U&W[[+B#J!.![7U0^WZ%XKOB,)^]3V=?A3SAF*4Q9 SK*M=,
MPM27D?*$$Y^BF(A8&E&\(WF6QOZOSR?2'!7*/E/?HAJ?<7/MXIH=K<VX9%-[
M[F89.C='Q;O/%'MP=YKG"&.7YW_7BC3KB:$C_%Z>,;H:=AQWOZ5EKD:KOHBR
MV2&V 6C8\WE($88X";7=34)().+ZC#))= U=[&&[8))S4RTO+F2O$\&3LF$J
M+:UE2=RSN/JAAV/B8Y@B@J'R7QA,!,?0$SJNDV".(ZO-S@6JLU1Z[^0$2M#.
M(#0(T;/#UFRO<8'8Q)O(.+"L=X1+2+BD^K-SS<KAES1^2<X7?S_F</C-'__V
M]L/'SAO$##,D!(6^(!Y$L>]!*F2B8"0D0 D7?FS>^^%@Z*4Q0"><S1GF 5(F
M![QC]9_Z3+>5:\RIPB$&-D>W8[&8Z[3VPNM@>2Y[2MOAH]B#)V8\?3TEZ>&!
MZ\E?C P2R>N,9^N-[H&["U-[^[/-@WBG1-/VYZ9=[,_R)=]]R'+QOA:/U2KV
MI114*M><-/=6RF1)<!+ U N9'V+U_T1D8[>X$FQQ++>GUWZ;UEXSH%\'L*>;
M=@A/[?=:0]"H:&D>.5MR,W/J5RSDU'0]YQK:1^4X!MQI0(\KV>:-!7*,Z%$8
MD>OQ1_KZBL%U<F1WRG!'?WZEM?@J-$K9.FMF;U)<;G/^0;V&Z^WO1+6B<>1Q
MQ 1D1/>AB"F!"0D2*!+! @\G*&6&C<Q=B+.\,X-&4GV\*BPC$:]:%4./=R:D
MI_:*>S7Z8U4E(-":@$-5;D"[&#K-HU%G[_<Z;41]5\QIG*0+?)WZVM?(,Z\_
M[@"Y(Y_=Q9AC_'J;K) S"5Y2=Y[A'E.+BGR(D"[5Q!B&&.&$1I1ZG!AV&W<E
MTO*8=I>U=VV2GK-E,SF:F'<IIK:0>VW .UUY0^FS;R<WB7H[E4"C4Y-$UT2R
M5B^2]&9>+)LSE'D7;::3E[N'K *9,BA!*9[4P$W9 Z[7K-I+KJ1U\R5M;XXI
M_\]-6QZL H^4BZ;FBFXC)=H]M_L NQVXZ24%ZP>:0S714U'JRBS9XQ/-RF:(
MFV9W?A#\7EFZ-R!3X^?/-^#'0\8>@/:==&,JUI5N>=1 'W_TK1NFBZNF5"G(
M!*@>A&[ZT&_^N]%TWN=]43:O7"ZRII8BK=3\:P[K C[V6:"YTJDN*=<WL#LP
MG 4/NGN=AH^V',PSXX&8.U0.C]$<CCO"'+C[_5-W:.N1 $<1X1!+)B%*> (I
MIQ(F2/E2D2_")#9*\C@<=FD'7TJP,>?;.Y@,-M%1RD^\%5ZMM\5^-$K_N7:5
MWS\YHLDC+0?);O?K^2CK2,(#XCG^KV,ZQK<%;I1OHO-3^*OG@[I5JU &J="M
MA7#*/:@SQ2 ):0"#_[^Z+VMN',>R?I]?@;>ICC!ZN( $. \3X5RJOHS(JLS)
MS.J>B7I08+4Y+4MN4<I*SZ__ "X294L40 $T)Z*CVFF+P+T'XL&]P%U2G!6*
M"E)DD7W+^,&YYD8T73&G3ESPYFET$<4+*%M0DC_L0I^>3 >;2^]X;_!-17-U
MZK$\%!1KP&1/VEKN2>[+9+3#9[B7_/ 0$S:3M]+EN)N\W2,C^/6+O-LM#?)/
M^ZR6JK/7!,^X2C)(,,XABC,$:4$XC!01"<I4A*1]2,;Y>>;&JP=)#XEGEF?9
MEQ"UX%$_. 7FT),0C;'^!K!R($\_F$U$G".Q<Z/+RX@,4N7 X]/1Y&4=CBC2
MXN,C0T>X_E[LZB*J[Z0J5YI^Y4K_L/VLU[6ZW1\'M=_;%*<HR4D$9:XP1$FA
M+5(429BB3$22,44SJP+AXZ:?&YG^OE*[E6@KB^[JJJ*/ZVIK#LLV=0E!P!IM
MP*-1QS'"PVUEAMDW/-ZASZ(/@H-6<M"*#FK9P4'X%UD7GVE=9\$?#5T'I]=8
M##<)IHVX&(7.B[B*<:.,L!;?E=]+(5?BOTNY%.W],;V3"R0HPHFV$ADAIN0F
MS;71J 14V@5'1"54VK56&9ID;M36B0F>C)PF0Z(5U,'^.8>GA:'H :7 A+0'
MJ!81?/8)D(-UZ &HJ1KG.0/F9A5>0&+0)#SW['3VX 7ICXS!2Y\=9PF^DYOR
M.S4A%5^D:493KNZZNJGQ@DE&"B4$1%0F$*$DA442)Y D*D5%E/-".C8E'IIN
M?N$(7TQ1<F/?B5W;T-'\0ZTWLKQ;M37J^)/YQ9]T8Z(35G4&B:/)-[@$=@:>
M+UA#L^=>S!NP%W1?I]>?@68#AT]S;'"^28TO&\V?FUI6SXQLF[%=\W^TW=.;
M)EB'9$FI*&81@3$7"*(HT[1"N?8NLR1!2J9)'B''%AAG)YL?L[PIUW=R!3X(
MR<VI_5^;1-16^'\%LA;?L4O%>:SM2,0/?H$II"_DOX)&S+.>7X@^$1=!\MKS
MX?QLT_9ON*CUBUX,EY^X^NAJJ/7FQWVJ2TY8*C+MQYD#?H@$HI#$B?ZGR)C(
M"XX0YB,/KZP$F)N/US]3N=AY]II<)=>%<C[+\@[_A*=9GI"_YNS*";Y IU=V
M,KS6^9430@,G6&[CC'7DOLOE^E&*;Y+?K];+]=W3E_+N?MO=/5$B,Z[)#BI3
MA DI7,"B2&,8QZFVP](L5;G3&?Z%^>;&>GMQP78OKZN;-@RPK:?F#;;@SEJ'
MV$%4T,@:X$S=$A>_7MOPE!,[;E;ZO_3=[!X;QRD_:V=P*S]JOA(?5EO]Y2BU
M@=T43K_MA82WD1PFQM;$VBX*'LL\R3E,$\TRJ) 8,I->2+@I^993%./8A6K&
MB3$W!GK?1;VK71/RWA.]"SJZ,445D1LOC5PD.[H*#WU@%FL4@+4&X* "J'5H
M>@W6BW)[E.)0%V7WVQGJ.B1]\MY(22:EP^O0>LZ25X[FWA3B77NYTE2>_RPW
MY5K\K']7+7":""299L14FE"*1.F?,#&A%$KPQ#1W26R[0IR=96[4UPG:]3QH
M1 6UK/9M(<Z#.LQEWJ *;7"-0<FI,<1%%*[H#'%^[,E:0UQ4K]\;XO*'W5[[
M[C9H\?[W+PN:4"V[U*]UEDN(B(I@H=)<_X>(.,V3A%'+7-_^L/,[QGZ_VZSM
M7N C>(;?U[$J!WX]C:Z@,:O!6].'>%/G4@Y"8/UVGM)YX&7L/MZ\D=V_GK^6
M1X-.\A:>4J-[Z4[^S>T=JS;;Q=_H<M=U\_W/'5V6ZJE<W=UR;I:D>J??YN6Z
MTO9UW?Y]H;"D."H*B$G&(<I-2Y:(Q)#H%Y1B1GB2IC;;K?/,<]N"O[Y_"[[R
M>REVII-JG,"HN %[C>J4VH-.H%,*'+0"?]1Z61X"NZ_4,"<$Q3_TE55PZ*UI
M9C2, _Z''K/G>^A_/:<A]TDGX:K16'2$-GZ $5&*ORS7C"X_EMR<'Z_NCG)E
M;N\VL@X\;GNW?)5+4R5EO5JK;W1SI[V<14RIR(AQ.PJ6:[<C*V"!,P)QG%"$
M\XA%F%H',UXGR]R8L=$&[-4YSIP#>X5NNDY--V"O5%/QO5;+(0#PRK4<9LJ)
M5R@P=_Z?6QR'(,[I%FFB6,_0B^46&>H'WL$ TBNGF"[.U \61^&HGH8<=S'Q
M9J?GE%5UR_^Y*ZNZA5G]HY[VW=K$L)G"''&DI#9"TH1"I-UQR+BD>L,3M(AY
MFM/8:L.SGG%NVUHG,.A)? ,ZF<$?C=2.,1V7<;>[5O"*9N MZ%H@G6\*K,'Q
M>2EP>=))S_^M,7A^U&__H,]"JV_7JVVYVFD>_/0HVU#QD\4)]R&9*548J22&
M-*][A0@."<$<Y@IK$UV;ZS$N?-1<=99L?H>,QW(")K=_2KFJBX/]_M>O?P5*
MZN73=D>=CEDG(6_I#[#I*H7)?6G1[M<^BKBZK[@=,[["*H8^-[4N[=HFM83I
MA^(7U_ E7=U%FT%UU]%XVA5Z'3_\B!.7#RMA$D_/71S_7DFUT_:ODHL("80S
M'D/$,P%185@]I03FLD@R$4<XB>V+P%E/.S>#\R X6-;1%N4AVH+6LH-=+;S^
MLW+)E[1?"(N3D2#P!F;0'K*GXU@JT,@-/H9"UN%8(PC"$YU@N'V'?16"<D9L
M\%#"?K3ISA^<-3PZ:G!_>IQM;\*QFRWFSEQ4OJ^VY8/>6CZIS_H/9C[S@07&
M28&9XC!CF;;<HX) FI 49G$:I2DC"<).@=16L\Z-[(U,H"?U#>CD-@=YG>3
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M:Y$529%([;[+B&HC3U!8)(G)^,XI+Y#*9&S57":\J'/C*:-IT[^CZI6(J6Y
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MKS'WR@QIH),4%C)2$!,E8NTI%3BG;A9 .-"G:H,T >QV>THX*$-[.D9>R(S
M)K*YSKOJY?O<=,W6;@!5VK#PVRYS'&H^]Q)'"2;=2<:A\WP?&3G*M;E=/Y_?
MNIH<)$QIBE@DH,Q5H3DMRR"3J818Q#S-:2:%6\-'^ZGG9DOW,Y@:V>'',\;=
ME9E@%Q?%\F0G"-2AB<X?RE?DC=D"%B:-[.+LKY159HO*^20SZQ'&AN(JN=F8
ML4\W6969-L4X2:%$,H6(1Q*2)$(PBXJ(2YZ((G.Z=;\PW]P8K!/7M)-L^P2[
MIIA=0MB.F3SB%IB.]I!-T]?6$AB_L<##4TX<'FRE_\N(8;O'KJUTM,\^^*0.
MO^PR$9X6!!'*%,4P)@I#)%0""RXB* H>)T04<<3B<66-AB>>'\^\R&5]N@%J
MG_TUMD#1!?AMN<<_J,%):(_GQP.>_9RL7S;K.D"Y_6.(0D-V:(6I*G1A[E<J
M(62'R/EZ09;/CPA]?E]6M.P"GPFAB"<("IE3T^2O[L*8PI@1EI TR3"Q<N">
M#SPWTJE%<PCX[6,TS!S7:!Z8&6JIQH0[][5W"'8>B<)$H<Z6:+@%.I]0>3#,
MN?_YZ8*<3TAY%.)\ZN\C;R!,_(HI.%37NN)1% F""IB23+,+YSDD1.F?:$YD
MGL=)3IU,GJ/1YT8QM7# 2#>J6M@Q<I8'UF/Q"$P\]E"XGS:?4MGK8?+1!-.>
M%9_2[<51\,D/C3 #?EFN&5U^++GVA<K57:\XVWIU>[>1]=5!?=Y<?=Z9-E\F
M:JQ@<91)%IE2/+%V8N(,LHA@J(2,(X033E*K#.;1$LSMK6]TT)Y,JP3@?2T
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MW#UH)^[OFW(KUTJMU1=IS"WM1/RNO\9U7K@4[R3;=@U%30>]:L%B5!11H:!
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M>Y%J;JYC7ZD;<*16?1K;5\S$X.Y5 P?=G)/Q_:ZS'0%.OGJ!:7*JA7-F5*]
M^^1=/X)-RLY>L7S.X7X''\?TO1JRK?NZ?ZW3(J5<"0XSH<U()"6&5,4*1HE,
M<Y'1E&!'1_/\9/,S'KLSJ.5!YG]W(]<!:.T8TP]<@6FP)Z1FP>[@+@"M74;#
M)U<-S#8I 5W6^CFK6#PQXOS_5HC2<!%=;J38<?-CN=JLG^AR^V3"N%LORW2-
M>WB0&\-5%5W*:I&3),X1-1%:IHLMRA5D*<<PU^1"599'L; *P;Y*BKD9?0<]
MP%X14V*U5:7NB](YKJ9F_$$=4.OC<" ^>N$L;AJF6([ ]/5_824<KBRF6)&)
MKC*"K8S;9<>UB Y>@HP>?+K+D6OU/[HTN7HPGYVZCELEW6Y_EGK$QL0V70*?
MCCZ\$*C(HH06,(EYH?>QE$/"!(:1*(HD51G*$LMN[!ZEFI_9O)?36V\OMV6R
MO,:9%OK0%S[6W<#H%K1*@<-"/7MHLIYAH^ .WTS,3:P9=!D;A:-=^[%Q0[MG
M;;Y?;<UE^KU<+DWH-5T]+2)9<(JR N9YQB'*HP)2C".8$)%PS*(\D](V=?/E
M\'-S"!H)02TB:&6TS^(\ =\P#UX/2FA*<\'#*:OSO-I7I':>&'2R_,[S"O63
M/ <^-;;Y<27U0_>F=*K\+I?K.K+X_0]3.UN^_\&7.U&W/?CGKMR83@B?-VLN
MJ\J4BE@424X(U\83*B2"B"4%+! G4.2""4EEG&72S9:Z0IKYV5"=,DUMX(,Z
MKAV5QR\0BD66(II B7.]2G$D(54T@SQB,HWB1'#IE'<RT?),T^>ZMS@]94"K
M#?AIKP_H%#)N:ZM271_G?":K]Y6TLX<G6I_ FT;8I1G1D/MJ4/UV[1XOSL2M
MO:_&[67_[^N'O++;;MNAL;Z[V_=H;&.2:93ED< <<EEHND69IMM8$8A9IDB6
M%84DS&T_M)EV?AM?OY-J7_";0]/4D6UNA]"WHTC?B ;FPCZ4AXZS_@L?N< 2
MI%OLT+ROTP36 HFSO5UMGAUQ>_=.;LKOU+CWE>GF5ZY6<EONBY#?2W$G]6_6
M:DM_R)H-I="._>-Z)4U3QJ;*@^CJCG!)DHQ%#**4F !T352$T@C&*2XT5<4L
M5O:52WU*-C=3\1=:KBKPTW)=5;+ZB[FCT*J @W:@5N\&=(J!O68.MTI>E];B
MSN^U%BPP7_;4VC>\/+U:YK=K!;1^IU8.E/NZ->)BW9K J^EP;_A:JSK17>*K
MK*[;/6.(%1B\>_0ZX73WD2%P.KJC##+!V*Y![?'ZVW7='%FN^%-3:B<A3&89
M22$W5Y(H2Q5D<2Y@$;,LBE0BD'(J@W1VIKGMJ;W+JIZHXXH;G8?7SB7P EK@
M?6TD7B-: EW PF\GH'.33=P Z(+.+_O^7'I@;)/S/WL=U#?KE?Z1-TY$W4_]
MJ?GO(=D1IR+%1#%8*(X@BH6$1<K,/PGC*8LHEDZ%&%T%F!NK:/D!W2L 'H\T
M<.UQ[K@6=EP3$N' %&3 /<@.CH6_ 8W@X(_V_X-DJHY%SV_O<T<9)NZ /@ZA
MEWW01XXSCOEZYR4?5H^[NK*1F=S$([3'>U)0R23!D J)31VB'!(<8Q@+HLTT
M)5'.L0O779YR;NS623@B),L"7SO^\HM:8,;J"0MJ:6_ 'L,ZKLK_.:H]/CXY
MR6+625G('H7GO./PY#BFV6=>];*Q/J^K.ISUD/&*(I+%L80J0;'A&@29=@9A
MCM(L$<8I8U;)#BZ3SHUM]C(?)SUV8H_.5;5: #LR\@UK8#KR@*@S'[E Y).1
MK.:=E)-<D'C.2D[/CKC7^2*_R]5.5D9JJDTN+I)H>VA_I_V8NPU]Z-J[J AG
M@A<YI-AX?:F(8(&T810CH:(L):(HA/7%C=/4<^.H5GA@A =&>OCV71*!GOR@
M4\#A\-YM-2SN6H)A')BP.KE[^!K13^([ILB;&] .UR#! )_HGL,%>$_W%J,@
M&[R8<!MQNIN'49H>72V,&^'<OM!?P(_ZI__XE^XW^C^,5O(__N7_ U!+ P04
M    " #Z@?92,<+"[YW?  !$ 0H %0   &)I:6(M,C R,3 V,S!?<')E+GAM
M;.R]67=;27(N^NY?4;?.Z\VNG(=>ML^BANJC=:22+*G<ME^P<H@DX08!&0!5
MDG_]C=P$.(+D!K"3.]6^W:LD#M#>,7P9&1$9&?&/__O;^>RGK[!<31?S?_J9
M_8G^_!/,XR)-YZ?_]//OGW\E]N?__<__\ __^/\0\F\O/K[]Z=4B7IS#?/W3
MRR7X-:2?_IBNSW[Z:X+5WW[*R\7Y3W]=+/\V_>H)^>?N'[U<?/F^G)Z>K7_B
ME+.[OUW^F=(D?5"",,$]D9I%XJD$(ARET8%CAOO_]_3/7-L4F0I$NBR)C)X1
M%[,B ,'&2'GFP70/G4WG?_MS^2/X%?R$S,U7W;?_]//9>OWES[_\\L<??_SI
M6UC._K18GO["*16_;#_]\^;CW^Y]_@_1?9HYYW[I?GOUT=5TUP?QL>R7?WOW
M]E,\@W-/IO/5VL]C><%J^N=5]\.WB^C7G<R?I.NG!S]1OB/;CY'R(\(X$>Q/
MWU;IYW_^AY]^NA3'<C&#CY!_*G___O'-K5>&Z>(4YM,$\4]Q<?Y+^<@O+Q<(
MB _^M!#</6#]_0O\T\^KZ?F7V=7/SI:0_^GG,)T&4C1+M:#EM?_K^A__<DW!
MER6L$#0=QV_Q!YMGE+<=2@U\6\,\P26?V_?,%O'6AV9%RHOE]E_.?(!9]]-)
M@NFD>_))6*V7/JXGW''O0W#$%2Q),(9X[B4Q7#-CM# TJ-O,%\)72'FGE!72
M?+KX^@L^&)7#:?FB2(82RC8J^5_W7GHIH\.HWZ[$S_C9"96X6KS3)&0/1!KN
M2+#(@65>4R&25)P.0/S-=]ZF_::&3Y;QI\4RP1(-RO:E?AGO:?LVF#>?^.6+
M7^*#2#R;SM+V7Q?+,H3>UHL!Y'>I'"3WYY^0ZPS+):2WE[IYD+F.LS6:6>@^
M.83>_^7"+_&)L^\?X<MBN9Z(A!PH)-QFJM!.:DK09J(<LM0Q:I<M3P-"X,[K
M>Z&!MX^&8Z3:"# ^P'*Z2*_GZ15NT!.AG<T:R<XZ<B)5]B1$QPE(RFS&739Q
M/R L;KV\%RA$^Z X7**-0.+STL]7TR+X#:Q]<HKJ9$B@&7D((J _1?$/'0)+
M-BIC\I#[Q9WW]P*&;!\81\EU9&R\GJ^GZ^^_3F?PV\5Y@.5$\!!$$I$PY7 /
M!+#$2= $(@\T)*[1V1X $W??VPL+JETL'"7')C#P$4ZG10CS]6_^'":&,\$\
M!E<>="222D\LAET(::%BRMG0: ?#P>UW]\*";AT+1\BS"3R\1%DM_>P-AE??
M_B]\GP"3PBH7B9"T )HQ8E7P1.>48Y31<#&<8;CS\EZ(,*TCXAB)C@R)EQ?+
M(JE?IZOH9_\.?KEU@WSPZ !E24IP1*3U&"T%CEN=<@(R-=RD(>*-A][?"QBV
M76 ,(M=&W,MK)G[%GZPFUED1F4AH\91 #]D$XI6U&%<SB)1%+OP0!N.!U_="
MAFL7&4-(M2E@7(9/ETP8JKDUQA-N!$-T9\#(6E@2;$R<1Q:R'S+PN$= OZP5
M_5'0<:AH1\;'"7*0.BYF_G2";A&'K#S2;"61,J*KA(XRX4(FRASNAV&(G>36
M2_OAH.'TY>$B;,+'?#./BR6&S)W(/Z'DX>7B IVD[R\7"28Q22]EMB1KBSP)
M0*,7%24Z.4<#M3P+.9C'^2@I_7#2<&)S:'$W@9[/_MN;A.*;YNGE,=HF]+;,
M@0F"$@M&$:DYFL"2QD_)61.I=%ZXP7#S !']$--PUG,X$3>!E9.44 >KS5]O
MIW-@$VZC,-P&PF+&D)S)<MSC/.+?T8A?)<9A,)SL(* ?1AI.@ XCVI;P\1*_
M?+_\O/AC/@F9Y0B@"<T4([!<S*%DEGAA+(TZ $O#69%[K^^'C>83HL>)M25D
M=-OE^^6'Y>+K=!YA I1R\$R0# [C,*O0Q<X,@S$(B@*@L/(0A0*/T= /(\TG
M2@<0<$M ^;!8K?WL/Z9?.J<*S5UT#(,P&3!2ER@6@CP)8@-83[UQ<I#\V,,4
M] -)\[G3HX4[=@*U\+ $W]$M,J<A2D:0<Z3;:D."5XYHE[U/OLACD"*C&^_L
M!X.6,Z6'"G!DQ9<2O]F'L\5\>S"($7KV,E "6:!KE&@FWN%6:/!;PPS+(@R1
M^[K[WGX :#@A>I0@1P;!)X@72P0PX^'S=#W#S<TD'J26Q!I)21=U6R,TX5);
M*Q"].0ZQ+=Q];[_ZK(;SGD<)<F00?%[Z4E#]Z?MY6,PFAG, H8 D5FH-(TW$
M:0'$R2B%2T)1.D2MYJV7]E-_P^G.PT78B %X_2V>^?DI="4!(BH3E,XDN<B(
MI)Z1()0DF5MF.0-E'1O0"-Q\=S\D-)S0/%J@380,F^/?R[*Q FS4P<5JDB-E
M@EE-G#(([&PR<8#HEE1Y"MI(>ZV:XTLM=M+0#R#-YR\'$' 30'DSQZ>A.*9?
MX95?^PU;$^E$M.CF$)ZY)E(P3JP 3GQ.WFG/&:5#GI#LHJ$?4)I/8@X@X":
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MH#<B990!LO:Q3['\(?6(&Q+&#2H'MC@'2K:!_0DA?0W]D_5Z.0T7ZY+=^[Q
MYS7B5HXOG'7NZ^5&/3$)@QLF%0%E2IMQ%XEEN?14L-3%1(6057:NO2D=9X)(
MK4BBJIX:R'[=8G"28LI41X/44DID%(Z$B/Y>U-D)%[0Q=$<'I8%!-M*4D>=
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M-AG-5/4,@XF[^\P1,F\B&7-)_V7>Z7KG#8D+EZTB4I765T9)8JGT!&CD7N<
M.E=)L>RD9EP$':/@G5@Y1M9-0.:E7YV5_TI'A*]^5K;/C^@B+:<1+7OYQ<D\
MW?[!C4].L@K2*Y,(BP$##!XI"3$(8@0#196PLDXC]Z.H;@&"1^'FKG?\;"IL
M K$/5^B\@K"^_FXCXHEFT@@4(:YJA8N<9=P08M)$2,$22$OIW6[( YF__>@<
MMSYE>%365%,#N8J3&!<7W4J+,.W:Y6)$NN5%:)Z,9T""X);(S$NLBRY)Q!]F
M;1-H6>5NWV-$C5L#4@%?0RE@_$Y0KRY@.S'QY:N=$Q,G:*"E",X1!Z7K3(:
M5KJTJ!?XEV="QKOU%@^T?WKZ7>/60@P'E!JB;6(#+ 5+<_S(=P3\)%"?&'.X
M7P=3NI5F0:QWC.0$U,I(<Z@SM>DF$>-6 PQO6@X6<!/PZ!*VMX0RX=H9ST,@
MN,F&<@Y B=.XMP*G+$3C# JEVB'[+5+&/3<?'BI'"KL)P-PFGP5IG;*<9.2<
M2)M0&L"+3:08(.C@F:KC+N\-DVK'UQ6<E8-%W,#Q<U]/OARV;#CT7*.:T?5B
M+G6S[*#,:\V$EOZ)$ITRGJOL2ON3VD+8-4P^JJZ6&@BY/BQ+K^WU]U)J6OH)
MERS&ETWUW"1IFKE$T1DC*)&>&[2Z DBDB0G!<G*TRE' 8T2U$'(-@JW!)-_$
M?G?5[_]MJ>C_6/H9O,^_KRX'@4VR#YQE5#3SAJ&<HB,A)XMZ3]QF:T2$.K[2
M8U2U$),-@J3A9-^ 0;H[0PY7P]78S#+B]8_I;#9QT9B4HB<B=#4X49>9F;Y<
M'>$Q<W0#=)46!'V(:R%P&P16@VNB"4-U17E03KI2'.L]+XW-@R NBTB2!!!6
M^.13E>'O>^&D<M0V"$X.DN@1UU+6@^#@U>:E5WWOKT ^24XRJPTE'$H5M186
MA0&!B!BLMEI%E:M<QWV8I!9"MT&P,I#4&]BG;B0I;GC_B:8,P(%PEPV1(7+B
M@C5H$S6C25 A?)6-:2<UX];Z#NG@'"WK)K:>S5!<!TH[E= X2AN0;L^(YZQ4
MRSOF&=K) '7B^/YCB:L5O@Y>*[*7-!O(^VRG>Y;>%_/T:;V(?SM;S%#HJ\OQ
M&3<']7%/)26:LG*"XCQNIN!)8KBE.HP"3:I2F]:7P&:Z^]2I6JNBIR:LT W.
M[F9C(1A#(7@2LRVAHG+$=DTIM&79ZXA^7&W,-5795@<$#R/M&'TT@:UN2MD'
M_[VD3+>)>>IY=&5>0HK,8EPH&7' 2PV*U\QXL)Q6.?O804LS:#I*T7>[<!PI
M\R: LRT\N<-'TAQ &EQ(8'!="0 2@#.BK$:QY$0#K3*==3<YXVYYE> S@.2;
M0% 7(]R7T41Y= E]5X#IT E( 1F1#CU.@8O!.O0VZT#H 7K&/;ZHA*$A9-\$
MB';PD'5V,CBTHN  XXO$B06'?P@#P68?G*@2K1T(G6KG%96@<Z3$6XCH%O/3
MS[ \+R?"$W0"M<E2$<YLN9!9$$]%( P0[$%):F*5I/)-(IK9IBKZS(?*O DK
M<R\)>D-F)1-J$>!<@B ^,E<*;4OCX\@(==I;C&!Y\E7F1SQ!5S-;5SU<#:F9
M)J!V^VAXR\WW&UE4KL Z:Q-QJ9C<J!1QWBIB%..&.5>Z>=0_FM]!63/;73VX
M#:N=5@Y%;JZ9:TX4MS%(JI'TC$N'F4R\C\@)Y\B5,2HX^1Q^^)X JW90_SP
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MGK>R>C./&SZ\L9X'!<3D<I^K1+<N4$L,!0,Z2R[ ]L+$(R\9)Z*K"8NA)-K
MW<NK_1M#'WB#7ZXF0FKM(7H2O$&Q&$:)+3>W@+IRVI8T#97NE=PEI9%<P.&N
MS4!2;@ G9:(71A4?EHNO& *G%]]_7Y4+[U=WD4_B>OKU\D3AJDUCXIE2[0C/
M&F,.$7 E,..)H$&5/(FEJ4J2:7]2&W&A#P3'XEDUU0 6D;4\79>RR@D'REU*
MEMB2().EG4Q(X(BF)GEE!>>L2F[CFH1QL5-;V?>G3QPB^2;RXB?I/R\N(XC5
MY\5'B(MYG':3"J^K=#\O]A4F9]H;F10)1@/&&^4.:N"1"/0FHLK) -09Z%R!
MF7%WVV=&\NAH:&)-O )\=YQV2L:O9]!I>YY.SDMARG]W/Y_XE'$;"JR(61$9
M?2"6XMZD LC <RR30FI@O ]Q(P^0'AU$]SH1#:S/)E#ZYOR+GRXO4]MWQXN\
MF2?(T_ET#;/I5TCW1XV@IY1SDHY$2TLW00.X8W%)4E991>6CLU6.!HXA>N1)
M:*VA^MGTWX!O^Q%UC0240?&OX"O,%MUPKS=SE'4$=+M2YMKY:$MSPU!&'Y8>
MO:D4!3*:P4EK<I696$_0-?)\M=80.Z06&P!E5Y;PPG?GW.=?8+ZZW$A<XM)#
MR"3F4I?MK,0H-95+1](!-59%7>>NQ4YR1A[,UAH$!]!9$YO_7_QT7J3W'AV:
MY?0K<E'N5:* +CIAHX0_+&'MOTT<38RE3$GBCA,9F"8.XU"4G45!L>B3J5),
MUY? D2>\M8;/*GH]]E;:Y\%,YJ_HL7157>^Z:W9=?N^OT_79[_-%6,'R:TDI
MOYE_N5BOMLJX]-H_ENFP2Q0W+MWIZJJYXU9:ES<'BEZVMS\G24CF$_,D)A5Q
M1>=$@L %;L$HCPH"':NTXGPV#D<>>=?:PFD36>VLO'O=>%]_*]L?O( Y1@IE
MY'=0V8E,5"P3Q*..Q)5MD*;H41O4Z5@IG?$H72,/ZVL-Y4-JL0$/&MDH]ZWA
M%5S^C:NL.YN^'@;^Z]??IA-<7H8Q28GC6A*IH\.O."/6LZ"E=A'JW$7M1][(
MDP%;@V@%G39QJ_Y:GK^B$G878:TF"A0$B,49BXQ(A=&$<UH0D143*AGA9)6I
M7[VH&WE<88-('5BC[6SW7=>=<F46Y7G)YV:GF#C- D\)MPBA'9'<N3+ITY.D
MN'<F94BV3P'OW@A]D*)^AQ7T?PPLAU%=.U"\OR%<26[3B^Q*;-9)H1BCQ;7&
MM=95G3$GB:4R )/9Z%@EC=N?Q'Y@_9]SM%9)N4WDV.[SMIWOAI*':1=23ESP
M ,A8&>8&92YJ*6P,BKB,/\=?1!6JW-?O0]RXQ\"UH/$D H_44BO>YAVN7EU
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M3S]T(,.T)_5'6JO+:4HW;.$5W'*RR5AJ"!->$<D91DI.8^2>@7,$A0P\]]K
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M.-/>$S<S,8>(]403\_-\G,*L#>TWH0#F!Q5G]]%!K0N_8"5*G1V""<(2<SE
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MF!LXG@:[P.G+Z]5LCJL5N1UQ-E_KKW)*>YRT0%^M9J3(VPX3MWS7,0&E%!T
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M->YS\(K;(6V(!NG]NY4GUOPQ>EN,(<1)8\,UZ>&O!Z1S'[B148 .AL(-"C'
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M;SU$E!R8Y$QI4Y"8;<'G#EHZB=I.1</3+44/EWH'P=2.2396>>[K-*[D%7'
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M=#8X;%;#P 6G3<9U#;>3=#,]XOZYH(^:5P'MVT'DS93@B MCG:BI382HBH-
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MZH!9A,"8 1X\4Y:X4;S)#=8^@GKIH-70GQA5)YUB:]-0U$:/7B'D^J!86<_
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MY^LSIZ3AWF1PNEZP2$F;V'L!)>N<? [9BR83EAJM9]H<LZ/=T ->IA^*LNF
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M.P><H[-4<Q R([>IU*O\J8#^,^&G?61Y*8 ?%0(O!O@U'R;9*$D]*\'$(HJ
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M%Y0G1VYL'6DMP >5():8HW-( 4F3F'&70-/"[!@C+QIHO%/D;'GH+&F L^C
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MTCXCVQMR2S=%SN$:[Z(]]P^\&B%\NP7J$_1JVT*&Y)<I; L092#5&"TAD*Z
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M3N;EACPXKX;ABG$;G D/8[E=C]8_^=+$''6G0OVH"I\:^K7_^6G@9YX4CRR
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MQ4AUQ6ME;79!N"?&/XWA&P=(-VWLV25(Q[=J!U"MV>''<J<,9!,.I:*#DDX
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M=]R>D93S>6F, 8.V5M()!;YLYH@D3+66!?V0&[QAY/)W/CQ-UC,^!(Y2Z,1
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MO#E4X&//X _XE?*=[6]6#OAK$>J^N>'QXL[IH&0&BB]\W04<@J>M8',,)K"
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M*(..AB]RWH-(+7@M= &X ?TL>Z9@@":8? Q@@5ERSA2U9NMYX'-D ?NZI[J
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MV?5#6F.-:YD:=R[ PE1HEW,<[]XO^ZFH_@TJ^X)T2O2$$O9$*.D";"R\;><
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MW+6K^6,Z;4QVPHK^1%D;3%),H<2Y<Q )$U-&Q:]/FUJ;+!4IO7,WT8;ZS,T
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M     &)I:6(M,C R,3 V,S N:'1M4$L! A0#%     @ ^8'V4F$1'X%8&P
MBCD! !$              ( !Y6P$ &)I:6(M,C R,3 V,S N>'-D4$L! A0#
M%     @ ^8'V4LIH# Z])0  2G@! !4              ( !;(@$ &)I:6(M
M,C R,3 V,S!?8V%L+GAM;%!+ 0(4 Q0    ( /F!]E(@J+EN-+   %N:!P 5
M              "  5RN! !B:6EB+3(P,C$P-C,P7V1E9BYX;6Q02P$"% ,4
M    " #Y@?92I#+#TJ.^  "B]   %               @ '#7@4 8FEI8BTR
M,#(Q,#8S,%]G,2YJ<&=02P$"% ,4    " #Y@?927Y4A1-K-  #C\@  %0
M            @ &8'08 8FEI8BTR,#(Q,#8S,%]G,3 N:G!G4$L! A0#%
M  @ ^8'V4IQ[RX@]$0$ LC\! !4              ( !I>L& &)I:6(M,C R
M,3 V,S!?9S$Q+FIP9U!+ 0(4 Q0    ( /F!]E)-'>3GQ,$! %DI @ 5
M          "  17]!P!B:6EB+3(P,C$P-C,P7V<Q,BYJ<&=02P$"% ,4
M" #Y@?92-29I 0"'  #8M@  %0              @ $,OPD 8FEI8BTR,#(Q
M,#8S,%]G,3,N:G!G4$L! A0#%     @ ^8'V4L5<6PXB@0  OK   !4
M         ( !/T8* &)I:6(M,C R,3 V,S!?9S$T+FIP9U!+ 0(4 Q0    (
M /F!]E*O9$EZ)WT  -6I   5              "  93'"@!B:6EB+3(P,C$P
M-C,P7V<Q-2YJ<&=02P$"% ,4    " #Y@?92/?.5C0E]   "L@  %0
M        @ 'N1 L 8FEI8BTR,#(Q,#8S,%]G,38N:G!G4$L! A0#%     @
M^8'V4L;?=? N=P  K*4  !4              ( !*L(+ &)I:6(M,C R,3 V
M,S!?9S$W+FIP9U!+ 0(4 Q0    ( /F!]E+-V_B'\G\  #ZL   5
M      "  8LY# !B:6EB+3(P,C$P-C,P7V<Q."YJ<&=02P$"% ,4    " #Y
M@?92L^\9-R;I  #R) $ %0              @ &PN0P 8FEI8BTR,#(Q,#8S
M,%]G,3DN:G!G4$L! A0#%     @ ^8'V4C'6[\MC\   ?AH! !0
M     ( !":,- &)I:6(M,C R,3 V,S!?9S(N:G!G4$L! A0#%     @ ^8'V
M4BN0Y,%0?@  ?J0  !4              ( !GI,. &)I:6(M,C R,3 V,S!?
M9S(P+FIP9U!+ 0(4 Q0    ( /F!]E(@C<QOSWL  (6D   5
M  "  2$2#P!B:6EB+3(P,C$P-C,P7V<R,2YJ<&=02P$"% ,4    " #Y@?92
M&3[/WG#=  !(" $ %               @ $CC@\ 8FEI8BTR,#(Q,#8S,%]G
M,RYJ<&=02P$"% ,4    " #Y@?92RBE=Q(+;  !=# $ %
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M2P$"% ,4    " #Y@?92ITX%M>3%  !H_P  %               @ &>310
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M+3(P,C$V,S!X97@S,3$N:'1M4$L! A0#%     @ ^H'V4MWUH7H\"   $2D
M !8              ( !L%$8 &)I:6(M,C R,38S,'AE>#,Q,BYH=&U02P$"
M% ,4    " #Z@?92^<U8EI %   0(0  %@              @ $@6A@ 8FEI
M8BTR,#(Q-C,P>&5X,S(Q+FAT;5!+ 0(4 Q0    ( /J!]E)&6Y=';QD  ):"
M   >              "  >1?& !E>&AI8FET,3 Q86UE;F1E9&UA;F%G96UE
;;BYH=&U02P4&     !\ 'P 8"   CWD8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
